{
  "source": "2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
  "overview": {
    "source_file": "2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
    "counts": {
      "parents": 415,
      "children": 730,
      "table_groups": 361,
      "pages": [
        [
          1,
          1
        ],
        [
          3,
          54
        ],
        [
          56,
          203
        ]
      ],
      "page_count": 201
    },
    "quality": {
      "high": 145,
      "medium": 619,
      "low": 381
    },
    "avg_child_per_parent": 1.76,
    "parent_previews": [
      {
        "chunk_id": "e563af48",
        "chars": 4027,
        "preview": "（4）其他长期职工福利的会计处理方法\n向职工提供的其他长期福利，符合设定提存计划条件的，按照设定提存计划的有关规定进行会计处理；\n除此之外的其他长期福利，按照设定受益计划的有关规定进行会计处理，为简化相关会计处理，将其产生\n的职工薪酬成本确...",
        "page_numbers": [
          111,
          112,
          113,
          114
        ],
        "child_count": 4
      },
      {
        "chunk_id": "17399413",
        "chars": 4021,
        "preview": "2、出售重大股权情况\n□ 适用 √ 不适用\n七、主要控股参股公司分析\n√ 适用 □ 不适用\n主要子公司及对公司净利润影响达10%以上的参股公司情况\n24。\n\n单位：元\n公司名称 公司类型 主要业务 注册资本 总资产 净资产 营业收入 营业利...",
        "page_numbers": [
          24,
          25,
          26,
          27,
          28
        ],
        "child_count": 5
      },
      {
        "chunk_id": "3d922d70",
        "chars": 4005,
        "preview": "对国内药企而言，无论是仿制药“集采”，还是创新药医保谈判，其最终结果都是\n企业以较低价格来换取竞争机会。“集采”使得仿制药竞争聚焦于成本端，而原料药是生产成\n本的核心，拥有质优价廉原料药的“中间体+原料药+制剂”一体化企业竞争优势较为明显，...",
        "page_numbers": [
          11,
          12,
          13,
          14
        ],
        "child_count": 4
      },
      {
        "chunk_id": "42eff880",
        "chars": 3993,
        "preview": "2006-2016年就职于天健会计师事务所（特\n殊普通合伙），历任审计员、项目经理、部门经理等职，2016年10月17日起担任公司副总经\n60。\n\n理、财务总监。5、毛文华先生,中国国籍,无境外永久居留权,生于1967年8月,大学文化,工程...",
        "page_numbers": [
          60,
          61,
          62,
          63,
          64,
          65
        ],
        "child_count": 5
      },
      {
        "chunk_id": "55ff37e1",
        "chars": 3986,
        "preview": "（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n往来款 459,656,754.37 320,145,265.41\n押金保证金 5,000.00 5,000.00\n应收暂付款 6,339...",
        "page_numbers": [
          198,
          199,
          200,
          201,
          202,
          203
        ],
        "child_count": 6
      }
    ],
    "accounting_standards": {
      "revenue": "new",
      "financial_instruments": "new",
      "lease": "new",
      "decided_by": "table_keywords"
    }
  },
  "parents": [
    {
      "chunk_id": "7e0484a5",
      "content": "归属于上市公司股东的净资产\n5,724,462,095.55 5,390,549,932.23 6.19% 5,142,008,176.75\n（元）\n七、境内外会计准则下会计数据差异\n1、同时按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。2、同时按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。八、分季度主要财务指标\n单位：元\n第一季度 第二季度 第三季度 第四季度\n营业收入 831,903,896.72 900,629,910.88 643,422,185.88 565,456,776.82\n归属于上市公司股东的净利润 202,484,692.73 293,308,368.91 194,299,384.33 80,689,739.12\n归属于上市公司股东的扣除非经\n193,305,262.65 289,682,381.16 190,626,850.03 77,595,366.39\n常性损益的净利润\n经营活动产生的现金流量净额 121,163,063.50 182,750,885.24 145,547,827.28 162,937,319.29\n上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异\n□ 是 √ 否\n九、非经常性损益项目及金额\n√ 适用 □ 不适用\n单位：元\n项目 2019年金额 2018年金额 2017年金额 说明\n非流动资产处置损益（包括已计提资产减\n-4,150,774.97 -102,273.45 23,519,733.42\n值准备的冲销部分）\n越权审批或无正式批准文件的税收返还、\n1,828,299.60 1,237,210.17 760,878.00\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27 10,554,527.86 8,815,813.87\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70 3,024,312.63 11,532,098.63\n| 2019年 | 2018年 | 本年比上年增减 | 2017年\n--------------------------------------------------\n营业收入（元） | 2,941,412,770.30 | 2,718,608,796.51 | 8.20% | 2,308,922,170.29\n归属于上市公司股东的净利润 | \n| 770,782,185.09 | 605,003,820.78 | 27.40% | 342,217,155.60\n（元） | \n| \n归属于上市公司股东的扣除非经 | \n| 751,209,860.23 | 604,944,470.09 | 24.18% | 301,310,316.13\n常性损益的净利润（元） | \n| \n经营活动产生的现金流量净额 | \n| 612,399,095.31 | 791,449,237.66 | -22.62% | 118,141,514.53\n（元） | \n| \n基本每股收益（元/股） | 0.48 | 0.38 | 26.32% | 0.22\n稀释每股收益（元/股） | 0.48 | 0.38 | 26.32% | 0.21\n加权平均净资产收益率 | 14.07% | 11.35% | 2.72% | 6.90%\n| 2019年末 | 2018年末 | 本年末比上年末增减 | 2017年末\n总资产（元） | 6,747,198,664.47 | 7,035,373,344.57 | -4.10% | 7,466,927,438.54",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "27342050",
        "7b39e477",
        "6462a9db",
        "9b736d33",
        "a3a23618",
        "eadd823a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1669,
      "page_number": 7,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "49x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 49,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "经营活动产生的现金流量",
          "收入",
          "每股收益",
          "现金",
          "资产",
          "基本每股收益",
          "利润",
          "稀释每股收益",
          "净利润"
        ],
        "time_periods": [
          "一",
          "三",
          "二",
          "四"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.181248",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1669,
        "word_count": 181,
        "sentence_count": 66,
        "chinese_char_count": 570,
        "readability_score": 0.0,
        "information_density": 0.16177351707609347,
        "coherence_score": 0.97,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7349189155827124,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "每股收益"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "基本每股收益"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "稀释每股收益"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "经营活动产生的现金流量",
        "收入",
        "每股收益",
        "现金",
        "资产",
        "基本每股收益",
        "利润",
        "稀释每股收益",
        "净利润"
      ]
    },
    {
      "chunk_id": "91815ffb",
      "content": "| 第一季度 | 第二季度 | 第三季度 | 第四季度\n--------------------------------------------------\n营业收入 | 831,903,896.72 | 900,629,910.88 | 643,422,185.88 | 565,456,776.82\n归属于上市公司股东的净利润 | 202,484,692.73 | 293,308,368.91 | 194,299,384.33 | 80,689,739.12\n归属于上市公司股东的扣除非经 | \n| 193,305,262.65 | 289,682,381.16 | 190,626,850.03 | 77,595,366.39\n常性损益的净利润 | \n| \n经营活动产生的现金流量净额 | 121,163,063.50 | 182,750,885.24 | 145,547,827.28 | 162,937,319.29",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2896b2fb",
        "29bf3e0a",
        "1b17b8c5",
        "48a0e5eb"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 414,
      "page_number": 8,
      "bbox": [
        47.5,
        80.0,
        547.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "经营活动产生的现金流量",
          "收入",
          "现金",
          "利润",
          "净利润"
        ],
        "time_periods": [
          "一",
          "三",
          "二",
          "四"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.181839",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 414,
        "word_count": 49,
        "sentence_count": 16,
        "chinese_char_count": 68,
        "readability_score": 0.0,
        "information_density": 0.38647342995169087,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5367729729729729,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "利润",
        "现金流",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "经营活动产生的现金流量",
        "收入",
        "现金",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "ed68d6a9",
      "content": "除同公司正常经营业务相关的有效套期保 | \n--------------------------------------------------\n值业务外，持有交易性金融资产、衍生金 | \n融资产、交易性金融负债、衍生金融负债 | \n产生的公允价值变动损益，以及处置交易 |  | -449,486.55 | -5,010,265.70 |\n性金融资产、衍生金融资产、交易性金融 | \n负债、衍生金融负债和其他债权投资取得 | \n的投资收益 | \n除上述各项之外的其他营业外收入和支出 | -1,973,019.24 | -12,795,318.78 | 2,111,133.99 |\n减：所得税影响额 | 3,519,880.50 | 1,409,621.19 | 822,552.74 |\n合计 | 19,572,324.86 | 59,350.69 | 40,906,839.47 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "45a8a636",
        "c916a52a",
        "f2d60fb1",
        "3ef4156f",
        "7f771917",
        "f69a06b2",
        "ab8914d9",
        "b1986928",
        "36df5def"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 398,
      "page_number": 9,
      "bbox": [
        47.5,
        80.0,
        547.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "10x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "负债",
          "公允价值变动损益",
          "投资收益",
          "衍生金融资产",
          "所得税",
          "资产",
          "交易性金融负债",
          "交易性金融资产",
          "衍生金融负债",
          "营业外收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          9
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.182073",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 398,
        "word_count": 45,
        "sentence_count": 11,
        "chinese_char_count": 132,
        "readability_score": 0.0,
        "information_density": 0.678391959798995,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6345164835164835,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "公允价值变动损益"
        },
        {
          "type": "accounting_item",
          "value": "投资收益"
        },
        {
          "type": "accounting_item",
          "value": "衍生金融资产"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "交易性金融负债"
        },
        {
          "type": "accounting_item",
          "value": "交易性金融资产"
        },
        {
          "type": "accounting_item",
          "value": "衍生金融负债"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "负债",
        "公允价值变动损益",
        "投资收益",
        "衍生金融资产",
        "所得税",
        "资产",
        "交易性金融负债",
        "交易性金融资产",
        "衍生金融负债",
        "营业外收入"
      ]
    },
    {
      "chunk_id": "accb05d8",
      "content": "2、收入与成本\n（1）营业收入构成\n单位：元\n2019年 2018年\n同比增减\n金额 占营业收入比重 金额 占营业收入比重\n营业收入合计 2,941,412,770.30 100% 2,718,608,796.51 100% 8.20%\n分行业\n医药 1,608,858,743.47 54.70% 1,441,591,423.51 53.03% 11.60%\n染料 1,316,830,162.67 44.77% 1,249,940,574.56 45.98% 5.35%\n其他 15,723,864.16 0.53% 27,076,798.44 1.00% -41.93%\n分产品\n原料药 1,020,477,644.34 34.69% 1,033,340,734.78 38.01% -1.24%\n医药中间体 583,792,425.63 19.85% 405,506,789.40 14.92% 43.97%\n制剂 4,588,673.50 0.16% 2,743,899.33 0.10% 67.23%\n| 2019年 |  | 2018年  |\n--------------------------------------------------\n| 同比增减\n| 金额 | 占营业收入比重 | 金额 | 占营业收入比重 |\n| \n营业收入合计 | 2,941,412,770.30 | 100% | 2,718,608,796.51 | 100% | 8.20%\n分行业 | \n医药 | 1,608,858,743.47 | 54.70% | 1,441,591,423.51 | 53.03% | 11.60%\n染料 | 1,316,830,162.67 | 44.77% | 1,249,940,574.56 | 45.98% | 5.35%\n其他 | 15,723,864.16 | 0.53% | 27,076,798.44 | 1.00% | -41.93%\n分产品 | \n原料药 | 1,020,477,644.34 | 34.69% | 1,033,340,734.78 | 38.01% | -1.24%\n医药中间体 | 583,792,425.63 | 19.85% | 405,506,789.40 | 14.92% | 43.97%\n制剂 | 4,588,673.50 | 0.16% | 2,743,899.33 | 0.10% | 67.23%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "9e4cb574",
        "0608ba8a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1042,
      "page_number": 15,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "27x6",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          15
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.182304",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1042,
        "word_count": 154,
        "sentence_count": 66,
        "chinese_char_count": 118,
        "readability_score": 0.0,
        "information_density": 0.05758157389635317,
        "coherence_score": 0.31665671641791043,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5475771823916435,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入"
      ]
    },
    {
      "chunk_id": "9ce1abc4",
      "content": "| 营业收入比上年 | 营业成本比上年 | 毛利率比上年同\n--------------------------------------------------\n| 营业收入 | 营业成本 | 毛利率 | \n| 同期增减 | 同期增减 | 期增减\n| \n分行业 | \n医药 | 1,608,858,743.47 | 983,149,430.95 | 38.89% | 11.60% | 1.30% | 6.23%\n染料 | 1,316,830,162.67 | 465,697,259.49 | 64.63% | 5.40% | -10.70% | 6.34%\n其他 | 15,723,864.16 | 14,312,670.59 | 8.97% | -41.90% | -27.90% | -17.67%\n分产品 | \n原料药 | 1,020,477,644.34 | 652,198,278.33 | 36.09% | -1.20% | -6.10% | 3.30%\n医药中间体 | 583,792,425.63 | 328,224,382.60 | 43.78% | 44.00% | 20.30% | 11.06%\n制剂 | 4,588,673.50 | 2,726,770.03 | 40.58% | 67.20% | -20.50% | 65.65%\n染料 | 973,070,914.24 | 312,738,811.13 | 67.86% | 15.20% | -1.80% | 5.56%\n染料中间体 | 343,759,248.43 | 152,958,448.36 | 55.50% | -15.20% | -24.60% | 5.56%\n其他 | 15,723,864.16 | 14,312,670.59 | 8.97% | -41.90% | -27.90% | -17.67%\n分地区 | \n国内 | 1,512,860,024.18 | 745,641,007.79 | 50.71% | 8.80% | -8.00% | 8.96%\n国外 | 1,428,552,746.12 | 717,518,353.25 | 49.77% | 7.60% | 2.20% | 2.63%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "475c8be5"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 955,
      "page_number": 16,
      "bbox": [
        47.5,
        80.0,
        547.5,
        480.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x7",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "营业收入",
          "营业成本",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          16
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.182625",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 955,
        "word_count": 170,
        "sentence_count": 66,
        "chinese_char_count": 81,
        "readability_score": 0.0,
        "information_density": 0.10471204188481675,
        "coherence_score": 0.3127611940298507,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5033157558325344,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "营业成本"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "营业收入",
        "营业成本",
        "收入"
      ]
    },
    {
      "chunk_id": "2aa37234",
      "content": "项目 2019年 2018年 同比增减\n经营活动现金流入小计 2,374,777,732.18 2,809,734,855.49 -15.48%\n经营活动现金流出小计 1,762,378,636.87 2,018,285,617.83 -12.68%\n经营活动产生的现金流量净\n612,399,095.31 791,449,237.66 -22.62%\n额\n投资活动现金流入小计 1,177,235,296.80 963,819,628.62 22.14%\n投资活动现金流出小计 440,639,977.78 2,061,240,331.20 -78.62%\n投资活动产生的现金流量净\n736,595,319.02 -1,097,420,702.58 -167.10%\n额\n筹资活动现金流入小计 285,000,000.00 1,388,743,300.00 -79.48%\n筹资活动现金流出小计 1,187,336,603.58 2,295,021,451.90 -48.26%\n筹资活动产生的现金流量净\n-902,336,603.58 -906,278,151.90 -0.43%\n额\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61 -138.81%\n相关数据同比发生重大变动的主要影响因素说明\n√ 适用 □ 不适用\n经营活动产生的现金流量净额减少主要系收回银行承兑汇票、信用证保证金等减少所致。投资活动产生的现金流量净额增加主要系去年同期购买银行理财产品及结构性存款较多所致。报告期内公司经营活动产生的现金净流量与本年度净利润存在重大差异的原因说明\n□ 适用 √ 不适用\n三、非主营业务分析\n□ 适用 √ 不适用\n四、资产及负债状况分析\n1、资产构成重大变动情况\n单位：元\n2019年末 2019年初\n比重增减 重大变动说明\n金额 占总资产比例 金额 占总资产比例\n货币资金 1,556,575,372.45 23.07% 1,956,089,124.33 27.80% -4.73%\n应收账款 459,781,564.19 6.81% 479,537,782.06 6.82% -0.01%\n存货 842,985,260.60 12.49% 905,418,218.49 12.87% -0.38%\n投资性房地产 11,206,951.46 0.17% 12,338,615.29 0.18% -0.01%\n长期股权投资 47,879,382.43 0.71% 66,088,139.79 0.94% -0.23%\n固定资产 1,724,407,333.34 25.56% 1,215,120,643.61 17.27% 8.29%\n| 2019年 | 2018年 | 变动比例\n--------------------------------------------------\n研发人员数量（人） | 443 | 405 | 9.38%\n研发人员数量占比 | 13.45% | 12.75% | 0.70%\n研发投入金额（元） | 122,548,224.53 | 111,304,662.07 | 10.10%\n研发投入占营业收入比例 | 4.17% | 4.09% | 0.08%\n研发投入资本化的金额（元） | 0.00 | 0.00 | 0.00%\n资本化研发投入占研发投入 | \n| 0.00% | 0.00% | 0.00%\n的比例 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8c52a050",
        "488c5f96"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1455,
      "page_number": 19,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "44x4",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 44,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.182946",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1455,
        "word_count": 162,
        "sentence_count": 78,
        "chinese_char_count": 420,
        "readability_score": 0.0,
        "information_density": 0.07560137457044673,
        "coherence_score": 0.391253164556962,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6335044372792876,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入"
      ]
    },
    {
      "chunk_id": "e04e42bf",
      "content": "项目 | 2019年 | 2018年 | 同比增减\n--------------------------------------------------\n经营活动现金流入小计 | 2,374,777,732.18 | 2,809,734,855.49 | -15.48%\n经营活动现金流出小计 | 1,762,378,636.87 | 2,018,285,617.83 | -12.68%\n经营活动产生的现金流量净 | \n| 612,399,095.31 | 791,449,237.66 | -22.62%\n额 | \n| \n投资活动现金流入小计 | 1,177,235,296.80 | 963,819,628.62 | 22.14%\n投资活动现金流出小计 | 440,639,977.78 | 2,061,240,331.20 | -78.62%\n投资活动产生的现金流量净 | 736,595,319.02 | -1,097,420,702.58 |\n| -167.10%\n额 | \n| \n筹资活动现金流入小计 | 285,000,000.00 | 1,388,743,300.00 | -79.48%\n筹资活动现金流出小计 | 1,187,336,603.58 | 2,295,021,451.90 | -48.26%\n筹资活动产生的现金流量净 | -902,336,603.58 | -906,278,151.90 |\n| -0.43%\n额 | \n| \n现金及现金等价物净增加额 | 456,569,632.85 | -1,176,569,020.61 | -138.81%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5d5682df",
        "865437d0",
        "65258f3e",
        "e787af75",
        "2e6ffc4c",
        "96eb2483",
        "766f0e4d",
        "e4783ee0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 691,
      "page_number": 20,
      "bbox": [
        57.5,
        80.0,
        537.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x4",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "经营活动产生的现金流量",
          "投资活动产生的现金流量",
          "筹资活动产生的现金流量",
          "现金及现金等价物",
          "经营活动现金流",
          "现金",
          "现金等价物",
          "现金及现金等价物净增加额",
          "投资活动现金流",
          "筹资活动现金流"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.183366",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 691,
        "word_count": 90,
        "sentence_count": 30,
        "chinese_char_count": 119,
        "readability_score": 0.0,
        "information_density": 0.33285094066570187,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48203851261620184,
      "relevance_score": 1.0,
      "keywords": [
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "投资活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "筹资活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "经营活动现金流"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物净增加额"
        },
        {
          "type": "accounting_item",
          "value": "投资活动现金流"
        },
        {
          "type": "accounting_item",
          "value": "筹资活动现金流"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营活动产生的现金流量",
        "投资活动产生的现金流量",
        "筹资活动产生的现金流量",
        "现金及现金等价物",
        "经营活动现金流",
        "现金",
        "现金等价物",
        "现金及现金等价物净增加额",
        "投资活动现金流",
        "筹资活动现金流"
      ]
    },
    {
      "chunk_id": "2287f5cd",
      "content": "公司名称 | 公司类型 | 主要业务 | 注册资本 | 总资产 | 净资产 | 营业收入 | 营业利润 | 净利润\n--------------------------------------------------\n浙江海翔药 | \n|  | 货物及技术 | 30,000,000.0 | 69,541,379.7 | 69,007,694.1 |  | -1,190,555.1 | -1,177,557.0\n业销售有限 | 子公司 | 6,399,758.49  |\n|  | 进出口 | 0 | 5 | 3 |  | 0 | 5\n公司 | \n| \n浙江海翔川 | \n|  | 医药制造及 |  | 1,905,943,80 | 1,307,615,66 | 1,278,861,76 | 204,310,101. | 183,572,535.\n南药业有限 | 子公司 |  | 740000000 | \n|  | 货物进出口 |  | 5.66 | 6.90 | 2.53 | 35 | 16\n公司 | \n| \n上海海翔医 | \n|  | 医药化工技 | 16,566,791.9  |\n药科技发展 | 子公司 |  | 5,000,000.00 | 7,712,899.66 | 5,961,858.15 |  | 1,609,827.17 | 1,416,778.77\n|  | 术开发 | 9  |\n有限公司 | \n| \n|  | 工原料、化 | \n台州港翔科 |  | 工机械及配 | \n| 子公司 |  | 5,000,000.00 | 5,444,685.96 | 5,116,968.43 | 0.00 | -143,703.23 | -145,514.30\n技有限公司 |  | 件、五金批 | \n| \n|  | 发、零售 | \n|  | 主要产品染 | \n|  | 料、染料中 | \n台州市前进 | \n|  | 间体、溴盐 | 304,000,000. | 1,540,527,12 | 1,254,548,70 | 1,202,406,88 | 485,937,936. | 418,599,011.\n化工有限公 | 子公司 | \n|  | 制造、销售 | 00 | 2.83 | 0.45 | 0.92 | 39 | 39\n司 | \n|  | 货物及技术 | \n| \n|  | 进出口 | \n|  | 医药中间体 | \n台州市振港 |  | 及化工产品 | \n| 110,000,000. | 933,575,895. | 617,871,041. | 783,594,897. | 128,045,956. | 89,296,052.8\n染料化工有 | 子公司 | 制造，销售 | \n| 00 | 73 | 59 | 92 | 93 | 4\n限公司 |  | 货物及技术 | \n| \n|  | 进出口 | \n盐城市瓯华 | \n|  | DCB、1-氨基 | 19,778,647.3 | 203,873,894. | 186,550,175. | 65,214,784.2 | -48,941,877. | -48,959,944.\n化学工业有 | 子公司 | \n|  | 蒽醌生产 | 7 | 28 | 49 | 5 | 12 | 21\n限公司 | \n| \n盐城市瓯华 |  | 化工产品研 | \n化工研究院 | 子公司 | 发及其技术 | 1,080,000.00 | 1,071,232.47 | 1,071,232.47 |  | -724.90 | -724.90\n有限公司 |  | 转让 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "332682b7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1518,
      "page_number": 25,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "45x9",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 45,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入",
          "资产",
          "利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          25
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.183688",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1518,
        "word_count": 332,
        "sentence_count": 46,
        "chinese_char_count": 263,
        "readability_score": 0.0,
        "information_density": 0.08563899868247694,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6177064631956912,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入",
        "资产",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "f1774b12",
      "content": "| 产\n--------------------------------------------------\n应收票据 | 贷款和应收款项 | 107,399,476.04 | 以公允价值计量且其变动\n计入其他综合收益的金融\n资产\n应收账款 | 贷款和应收款项 | 479,537,782.06 | 以摊余成本计量的金融资\n产\n其他应收款 | 贷款和应收款项 | 10,817,853.96 | 以摊余成本计量的金融资\n产\n其他流动资产-银\n行理财产品 | 可供出售金融资产 | 150,000,000.00 | 以公允价值计量且其变动\n计入当期损益\n可供出售金融资\n产 | 可供出售金融资产 | 1,800,000.00 | 以公允价值计量且其变动\n计入其他综合收益\n应付票据 | 其他金融负债 | 490,006,533.85 | 以摊余成本计量的金融负\n债\n应付账款 | 其他金融负债 | 301,908,929.93 | 以摊余成本计量的金融负\n债\n其他应付款 | 其他金融负债 | 24,723,304.20 | 以摊余成本计量的金融负\n债",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c25307aa",
        "faa8af50",
        "5a247d55",
        "0afef70c",
        "42cad80f",
        "e5f31e7e",
        "34209814",
        "b7b9da4a",
        "e7723898",
        "cfb442fa"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 475,
      "page_number": 33,
      "bbox": [
        97.5,
        80.0,
        497.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "20x4",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 20,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收款项",
          "其他综合收益",
          "其他应付款",
          "负债",
          "其他流动资产",
          "应收",
          "应收账款",
          "应收款",
          "应付款",
          "成本",
          "应付账款",
          "其他应收款",
          "应付票据",
          "资产",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.184218",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 475,
        "word_count": 70,
        "sentence_count": 8,
        "chinese_char_count": 222,
        "readability_score": 0.0,
        "information_density": 0.631578947368421,
        "coherence_score": 0.5729920079920079,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5904871369294606,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "成本",
        "融资"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "应收票据"
        },
        {
          "type": "accounting_item",
          "value": "应收款项"
        },
        {
          "type": "accounting_item",
          "value": "其他综合收益"
        },
        {
          "type": "accounting_item",
          "value": "其他应付款"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "其他流动资产"
        },
        {
          "type": "accounting_item",
          "value": "应收"
        },
        {
          "type": "accounting_item",
          "value": "应收账款"
        },
        {
          "type": "accounting_item",
          "value": "应收款"
        },
        {
          "type": "accounting_item",
          "value": "应付款"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收款项",
        "其他综合收益",
        "其他应付款",
        "负债",
        "其他流动资产",
        "应收",
        "应收账款",
        "应收款",
        "应付款",
        "成本",
        "应付账款",
        "其他应收款",
        "应付票据",
        "资产",
        "应付"
      ]
    },
    {
      "chunk_id": "e15d3ec9",
      "content": "公司董事会薪酬与考核委员会根据实际情况对公司董事、监事及高级管理人员进\n行考核后，一致认为：公司2019年度董事、高管薪酬方案严格执行董事及高级管理人员薪酬\n和考核管理制度，与公司经营业绩挂钩，董事、高管薪酬方案合理，薪酬发放的程序符合有\n关法律、法规及《公司章程》的规定。九、内部控制评价报告\n1、报告期内发现的内部控制重大缺陷的具体情况\n□ 是 √ 否\n2、内控自我评价报告\n内部控制评价报告全文披露日期 2020年01月23日\n详见本公司于2020年1月23日在巨潮资讯网披露的《2019年度内部控制自我评\n内部控制评价报告全文披露索引\n价报告》\n纳入评价范围单位资产总额占公司合并\n100.00%\n财务报表资产总额的比例\n纳入评价范围单位营业收入占公司合并\n100.00%\n财务报表营业收入的比例\n缺陷认定标准\n类别 财务报告 非财务报告\n内部控制评价报告全文披露日期 | 2020年01月23日 |\n--------------------------------------------------\n| 详见本公司于2020年1月23日在巨潮资讯网披露的《2019年度内部控制自我评 |\n内部控制评价报告全文披露索引  |\n| 价报告》 |\n |\n纳入评价范围单位资产总额占公司合并  |\n| 100.00% |\n财务报表资产总额的比例  |\n |\n纳入评价范围单位营业收入占公司合并  |\n| 100.00% |\n财务报表营业收入的比例  |\n |\n缺陷认定标准  |\n类别 | 财务报告 | 非财务报告",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ae85be09",
        "07817199",
        "83f9d57c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 659,
      "page_number": 70,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "31x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 31,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入",
          "资产"
        ],
        "time_periods": [
          "2019",
          "2020-01",
          "2020-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          70
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.184478",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 659,
        "word_count": 62,
        "sentence_count": 5,
        "chinese_char_count": 425,
        "readability_score": 0.0,
        "information_density": 0.1669195751138088,
        "coherence_score": 0.47566153846153847,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7483100343845173,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入",
        "资产"
      ]
    },
    {
      "chunk_id": "8a13ff51",
      "content": "| 重大缺陷 1、利润总额潜在错报：错报≥ |\n--------------------------------------------------\n| 利润总额的10%或4000万元 2、资产总额 |\n| 潜在错报：错报≥资产总额的1% 3、经营 |\n| 收入潜在错报：错报≥营业收入的3 % 4、 |\n| 所有者权益潜在错报：错报≥所有者权益的 |\n| 2%； 重要缺陷 1、利润总额潜在错报： |\n| 错报≥利润总额的5%<利润总额的10%或 | 重大缺陷非财务报告内部控制缺陷导\n| 利润总额2000万元≤错报<利润总额4000 | 致的直接财产损失金额≥利润总额的\n| 万元 2、资产总额潜在错报：资产总额的 | 10%；重要缺陷利润总额的10%＞非财\n定量标准 | 0.5%≤错报<资产总额的1% 3、经营收 | 务报告内部控制缺陷导致的直接财产\n| 入潜在错报：营业收入的1.5%≤错报<经营 | 损失金额≥利润总额的5%。一般缺陷非\n| 收入的3% 4、所有者权益潜在错报：所 | 财务报告内部控制缺陷导致的直接财\n| 有者权益1%≤错报<所有者权益的2%； 一 | 产损失金额＜利润总额的5%。\n| 般缺陷 1、利润总额潜在错报：错报<利润 |\n| 总额的5%或错报<利润总额的2000万元 |\n| 2、资产总额潜在错报：错报<资产总额的 |\n| 0.5% 3、经营收入潜在错报：错报<营 |\n| 业收入的1.5% 4、所有者权益潜在错 |\n| 报：错报<所有者权益的1% |\n财务报告重大缺陷数量（个） | 0 |\n非财务报告重大缺陷数量（个） | 0 |\n财务报告重要缺陷数量（个） | 0 |\n非财务报告重要缺陷数量（个） | 0 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e421143b",
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "e4f55902",
        "d9ee5f38"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 729,
      "page_number": 72,
      "bbox": [
        97.5,
        80.0,
        497.5,
        580.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "23x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入",
          "所有者权益",
          "资产",
          "利润",
          "利润总额"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.184700",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 729,
        "word_count": 96,
        "sentence_count": 6,
        "chinese_char_count": 394,
        "readability_score": 0.0,
        "information_density": 0.28806584362139914,
        "coherence_score": 0.8276262626262626,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6774574049803408,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "利润",
        "经营",
        "财务",
        "4000万元",
        "2000万元",
        "2000万元"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "所有者权益"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "利润总额"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入",
        "所有者权益",
        "资产",
        "利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "08411be3",
      "content": "开发支出\n商誉 757,736,770.14 757,736,770.14\n长期待摊费用 1,618,771.89 1,842,423.21\n递延所得税资产 27,339,683.56 32,487,223.69\n其他非流动资产 450,000.00 515,993.37\n非流动资产合计 3,684,768,846.71 3,301,778,337.96\n资产总计 6,747,198,664.47 7,035,373,344.57\n流动负债：\n短期借款 200,267,029.59 598,700,000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其变动计入当\n期损益的金融负债\n衍生金融负债\n应付票据 238,306,005.00 490,006,533.85\n应付账款 363,440,583.96 301,908,929.93\n预收款项 12,919,749.09 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n代理承销证券款\n应付职工薪酬 52,367,142.28 45,234,354.42\n应交税费 44,781,205.55 54,890,661.34\n其他应付款 28,200,073.22 24,723,304.20\n其中：应付利息 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 940,281,788.69 1,579,026,351.68\n开发支出  |\n--------------------------------------------------\n商誉 | 757,736,770.14 | 757,736,770.14\n长期待摊费用 | 1,618,771.89 | 1,842,423.21\n递延所得税资产 | 27,339,683.56 | 32,487,223.69\n其他非流动资产 | 450,000.00 | 515,993.37\n非流动资产合计 | 3,684,768,846.71 | 3,301,778,337.96\n资产总计 | 6,747,198,664.47 | 7,035,373,344.57\n流动负债：  |\n短期借款 | 200,267,029.59 | 598,700,000.00\n向中央银行借款  |\n拆入资金  |\n交易性金融负债  |\n以公允价值计量且其变动计入当  |\n |\n期损益的金融负债  |\n |\n衍生金融负债  |\n应付票据 | 238,306,005.00 | 490,006,533.85\n应付账款 | 363,440,583.96 | 301,908,929.93\n预收款项 | 12,919,749.09 | 19,196,692.94\n合同负债  |\n卖出回购金融资产款  |\n吸收存款及同业存放  |\n代理买卖证券款  |\n代理承销证券款  |\n应付职工薪酬 | 52,367,142.28 | 45,234,354.42\n应交税费 | 44,781,205.55 | 54,890,661.34\n其他应付款 | 28,200,073.22 | 24,723,304.20\n其中：应付利息 |  | 1,088,752.57\n应付股利 | 2,051,370.43 | 2,051,370.43\n应付手续费及佣金  |\n应付分保账款  |\n持有待售负债  |\n一年内到期的非流动负债 |  | 44,365,875.00\n其他流动负债  |\n流动负债合计 | 940,281,788.69 | 1,579,026,351.68",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "422979b4",
        "9a967750",
        "b021e7e4",
        "d356db58",
        "0919af1d",
        "169be968",
        "4c91af4a",
        "3356d636",
        "1d4b50ae",
        "be63768c",
        "ffaa3b3e",
        "2d287494",
        "a8cf2b7e",
        "fbee28a0",
        "77a903d4",
        "38b0374e",
        "1d727939",
        "d12a39d9",
        "9600fe13",
        "f24174d7",
        "2c473c1f",
        "d091fc89",
        "3822210b",
        "50e7b266"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1585,
      "page_number": 79,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "68x3",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 68,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付职工薪酬",
          "应付股利",
          "其他应付款",
          "短期借款",
          "拆入资金",
          "吸收存款",
          "衍生金融负债",
          "负债",
          "商誉",
          "交易性金融负债",
          "预收款项",
          "应交税费",
          "短期",
          "应付手续费及佣金",
          "长期待摊费用",
          "合同负债",
          "应付利息",
          "应付票据",
          "应付",
          "递延所得税资产",
          "应付分保账款",
          "长期",
          "应付款",
          "应付账款",
          "所得税",
          "资产",
          "开发支出",
          "一年内到期的非流动负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          79
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.185025",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1585,
        "word_count": 186,
        "sentence_count": 64,
        "chinese_char_count": 414,
        "readability_score": 0.0,
        "information_density": 0.2586750788643533,
        "coherence_score": 0.31999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6899151798274976,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "应付职工薪酬"
        },
        {
          "type": "accounting_item",
          "value": "应付股利"
        },
        {
          "type": "accounting_item",
          "value": "其他应付款"
        },
        {
          "type": "accounting_item",
          "value": "短期借款"
        },
        {
          "type": "accounting_item",
          "value": "拆入资金"
        },
        {
          "type": "accounting_item",
          "value": "吸收存款"
        },
        {
          "type": "accounting_item",
          "value": "衍生金融负债"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "商誉"
        },
        {
          "type": "accounting_item",
          "value": "交易性金融负债"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付职工薪酬",
        "应付股利",
        "其他应付款",
        "短期借款",
        "拆入资金",
        "吸收存款",
        "衍生金融负债",
        "负债",
        "商誉",
        "交易性金融负债",
        "预收款项",
        "应交税费",
        "短期",
        "应付手续费及佣金",
        "长期待摊费用",
        "合同负债",
        "应付利息",
        "应付票据",
        "应付",
        "递延所得税资产",
        "应付分保账款",
        "长期",
        "应付款",
        "应付账款",
        "所得税",
        "资产",
        "开发支出",
        "一年内到期的非流动负债"
      ]
    },
    {
      "chunk_id": "7c85b643",
      "content": "生产性生物资产\n油气资产\n使用权资产\n无形资产 15,682,148.91 17,059,632.32\n开发支出\n商誉\n长期待摊费用\n递延所得税资产 6,054,576.79 9,371,365.80\n其他非流动资产 450,000.00\n非流动资产合计 3,523,330,465.50 3,519,853,167.02\n资产总计 5,422,728,523.57 5,912,436,388.49\n流动负债：\n短期借款 200,267,029.59 287,000,000.00\n交易性金融负债\n以公允价值计量且其变动计入当\n期损益的金融负债\n衍生金融负债\n应付票据 178,855,770.00 202,286,262.85\n应付账款 21,476,176.18 25,423,635.65\n预收款项 4,099,111.19 7,777,982.57\n合同负债\n应付职工薪酬 7,965,755.58 6,439,699.82\n应交税费 12,495,191.97 948,517.30\n其他应付款 98,040,880.51 104,178,588.96\n其中：应付利息 805,795.63\n应付股利 2,051,370.43 2,051,370.43\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 523,199,915.02 678,420,562.15\n非流动负债：\n长期借款\n应付债券\n其中：优先股\n生产性生物资产  |\n--------------------------------------------------\n油气资产  |\n使用权资产  |\n无形资产 | 15,682,148.91 | 17,059,632.32\n开发支出  |\n商誉  |\n长期待摊费用  |\n递延所得税资产 | 6,054,576.79 | 9,371,365.80\n其他非流动资产 | 450,000.00 |\n非流动资产合计 | 3,523,330,465.50 | 3,519,853,167.02\n资产总计 | 5,422,728,523.57 | 5,912,436,388.49\n流动负债：  |\n短期借款 | 200,267,029.59 | 287,000,000.00\n交易性金融负债  |\n以公允价值计量且其变动计入当  |\n |\n期损益的金融负债  |\n |\n衍生金融负债  |\n应付票据 | 178,855,770.00 | 202,286,262.85\n应付账款 | 21,476,176.18 | 25,423,635.65\n预收款项 | 4,099,111.19 | 7,777,982.57\n合同负债  |\n应付职工薪酬 | 7,965,755.58 | 6,439,699.82\n应交税费 | 12,495,191.97 | 948,517.30\n其他应付款 | 98,040,880.51 | 104,178,588.96\n其中：应付利息 |  | 805,795.63\n应付股利 | 2,051,370.43 | 2,051,370.43\n持有待售负债  |\n一年内到期的非流动负债 |  | 44,365,875.00\n其他流动负债  |\n流动负债合计 | 523,199,915.02 | 678,420,562.15\n非流动负债：  |\n长期借款  |\n应付债券  |\n其中：优先股  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7ac61d68",
        "9de73d53",
        "907221bb",
        "a8fcf491",
        "767b11d3",
        "a55c326b",
        "82a55dac",
        "f7177951",
        "13ad63e8",
        "c7639c8e",
        "7a673bc3",
        "533a69ef",
        "93473c62",
        "965996cf",
        "2a87f808",
        "a5608201",
        "7252d4d0",
        "67004a9a",
        "e88ea4ef",
        "8ec2e77d",
        "bb59ac4b",
        "4d5e3ca8",
        "8fa3423d",
        "bcac073e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1444,
      "page_number": 82,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "68x3",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 68,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付职工薪酬",
          "应付股利",
          "其他应付款",
          "短期借款",
          "衍生金融负债",
          "负债",
          "商誉",
          "交易性金融负债",
          "预收款项",
          "应交税费",
          "使用权资产",
          "短期",
          "应付债券",
          "长期待摊费用",
          "长期借款",
          "合同负债",
          "应付利息",
          "应付票据",
          "应付",
          "递延所得税资产",
          "长期",
          "无形资产",
          "应付款",
          "应付账款",
          "所得税",
          "资产",
          "开发支出",
          "一年内到期的非流动负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          82
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.185694",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1444,
        "word_count": 179,
        "sentence_count": 58,
        "chinese_char_count": 376,
        "readability_score": 0.0,
        "information_density": 0.2770083102493075,
        "coherence_score": 0.31999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6894254513883474,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "应付职工薪酬"
        },
        {
          "type": "accounting_item",
          "value": "应付股利"
        },
        {
          "type": "accounting_item",
          "value": "其他应付款"
        },
        {
          "type": "accounting_item",
          "value": "短期借款"
        },
        {
          "type": "accounting_item",
          "value": "衍生金融负债"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "商誉"
        },
        {
          "type": "accounting_item",
          "value": "交易性金融负债"
        },
        {
          "type": "accounting_item",
          "value": "预收款项"
        },
        {
          "type": "accounting_item",
          "value": "应交税费"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付职工薪酬",
        "应付股利",
        "其他应付款",
        "短期借款",
        "衍生金融负债",
        "负债",
        "商誉",
        "交易性金融负债",
        "预收款项",
        "应交税费",
        "使用权资产",
        "短期",
        "应付债券",
        "长期待摊费用",
        "长期借款",
        "合同负债",
        "应付利息",
        "应付票据",
        "应付",
        "递延所得税资产",
        "长期",
        "无形资产",
        "应付款",
        "应付账款",
        "所得税",
        "资产",
        "开发支出",
        "一年内到期的非流动负债"
      ]
    },
    {
      "chunk_id": "d3af29f9",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------\n一、营业总收入 | 2,941,412,770.30 | 2,718,608,796.51\n其中：营业收入 | 2,941,412,770.30 | 2,718,608,796.51\n利息收入  |\n已赚保费  |\n手续费及佣金收入  |\n二、营业总成本 | 2,020,492,002.44 | 1,996,990,314.89\n其中：营业成本 | 1,463,159,361.04 | 1,511,944,676.18",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "db858b50",
        "fc6b5a20",
        "94a06612",
        "2c574e95",
        "db111d14",
        "04864a44"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 283,
      "page_number": 83,
      "bbox": [
        97.5,
        80.0,
        497.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入",
          "营业成本",
          "成本",
          "营业总收入"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.186875",
        "report_type": "财务报表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 283,
        "word_count": 32,
        "sentence_count": 8,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.42402826855123676,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.548696803652968,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "营业成本"
        },
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "营业总收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入",
        "营业成本",
        "成本",
        "营业总收入"
      ]
    },
    {
      "chunk_id": "e09f3121",
      "content": "四、利润总额（亏损总额以“－”号填列） 912,452,980.27 697,295,611.05\n减：所得税费用 141,670,795.18 92,291,790.27\n五、净利润（净亏损以“－”号填列） 770,782,185.09 605,003,820.78\n（一）按经营持续性分类\n1.持续经营净利润（净亏损以“－”\n770,782,185.09 605,003,820.78\n号填列）\n2.终止经营净利润（净亏损以“－”\n号填列）\n（二）按所有权归属分类\n1.归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n2.少数股东损益\n六、其他综合收益的税后净额 -1,438,409.58 16,560.46\n归属母公司所有者的其他综合收益\n-1,438,409.58 16,560.46\n的税后净额\n（一）不能重分类进损益的其他综\n-1,800,000.00\n合收益\n1.重新计量设定受益计划变\n动额\n2.权益法下不能转损益的其\n他综合收益\n3.其他权益工具投资公允价\n-1,800,000.00\n值变动\n4.企业自身信用风险公允价\n值变动\n5.其他\n（二）将重分类进损益的其他综合\n361,590.42 16,560.46\n收益\n1.权益法下可转损益的其他\n综合收益\n2.其他债权投资公允价值变\n动\n3.可供出售金融资产公允价\n值变动损益\n4.金融资产重分类计入其他\n综合收益的金额\n5.持有至到期投资重分类为\n可供出售金融资产损益\n利息支出  |\n--------------------------------------------------\n手续费及佣金支出  |\n退保金  |\n赔付支出净额  |\n提取保险责任合同准备金  |\n |\n净额  |\n |\n保单红利支出  |\n分保费用  |\n税金及附加 | 26,841,009.21 | 32,182,923.43\n销售费用 | 59,623,024.88 | 43,781,054.42\n管理费用 | 386,185,538.84 | 349,284,396.57\n研发费用 | 122,548,224.53 | 111,304,662.07\n财务费用 | -37,865,156.06 | -51,507,397.78\n其中：利息费用 | 15,506,676.74 | 42,594,267.08\n利息收入 | 41,773,975.28 | 44,371,159.00\n加：其他收益 | 27,136,924.87 | 11,791,738.03\n投资收益（损失以“－”号填  |\n| -15,240,062.55 | -9,359,378.55\n列）  |\n |\n其中：对联营企业和合营企业  |\n| -16,759,549.80 | -6,923,938.93\n的投资收益  |\n |\n以摊余成本计量的金融  |\n |\n资产终止确认收益  |\n |\n汇兑收益（损失以“-”号填列）  |\n净敞口套期收益（损失以“－”  |\n |\n号填列）  |\n |\n公允价值变动收益（损失以  |\n|  | 5,010,265.70\n“－”号填列）  |\n |\n信用减值损失（损失以“-”号填  |\n| -2,502,149.00 |\n列）  |\n |\n资产减值损失（损失以“-”号填  |\n| -11,738,706.70 | -18,867,903.52\n列）  |\n |\n资产处置收益（损失以“-”号填  |\n| 244,580.94 | 659,231.88\n列）  |\n |\n三、营业利润（亏损以“－”号填列） | 918,821,355.42 | 710,852,435.16\n加：营业外收入 | 1,125,654.53 | 1,713,286.09\n减：营业外支出 | 7,494,029.68 | 15,270,110.20",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "491fafbc",
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "e9246c2f",
        "c3518769",
        "e7f7d9ff",
        "205d22fd",
        "f2a16e4f",
        "0eef19f9",
        "37ca6157",
        "24bfa4f7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1625,
      "page_number": 84,
      "bbox": [
        85.5,
        80.0,
        509.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "84x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 84,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "利润",
          "管理费用",
          "投资收益",
          "销售费用",
          "成本",
          "资产",
          "财务费用",
          "研发费用",
          "营业外收入",
          "营业外支出"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.187049",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1625,
        "word_count": 195,
        "sentence_count": 64,
        "chinese_char_count": 520,
        "readability_score": 0.0,
        "information_density": 0.18461538461538463,
        "coherence_score": 0.4027109974424552,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7433045459490167,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "管理费用"
        },
        {
          "type": "accounting_item",
          "value": "投资收益"
        },
        {
          "type": "accounting_item",
          "value": "销售费用"
        },
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "财务费用"
        },
        {
          "type": "accounting_item",
          "value": "研发费用"
        },
        {
          "type": "accounting_item",
          "value": "营业外收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "利润",
        "管理费用",
        "投资收益",
        "销售费用",
        "成本",
        "资产",
        "财务费用",
        "研发费用",
        "营业外收入",
        "营业外支出"
      ]
    },
    {
      "chunk_id": "55f8b4ec",
      "content": "6.其他债权投资信用减值准  |\n--------------------------------------------------\n |\n备  |\n |\n7.现金流量套期储备  |\n8.外币财务报表折算差额 | 361,590.42 | 16,560.46\n9.其他  |\n归属于少数股东的其他综合收益的  |\n |\n税后净额  |\n |\n七、综合收益总额 | 769,343,775.51 | 605,020,381.24\n归属于母公司所有者的综合收益 | 769,343,775.51 |\n|  | 605,020,381.24\n总额  |\n |\n归属于少数股东的综合收益总额  |\n八、每股收益：  |\n（一）基本每股收益 | 0.48 | 0.38\n（二）稀释每股收益 | 0.48 | 0.38",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "48eafba5",
        "40640f87",
        "7a2c9711",
        "3f25670a",
        "c72adac8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 354,
      "page_number": 86,
      "bbox": [
        97.5,
        80.0,
        497.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "其他综合收益",
          "综合收益总额",
          "每股收益",
          "现金",
          "基本每股收益",
          "稀释每股收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.187628",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 354,
        "word_count": 51,
        "sentence_count": 14,
        "chinese_char_count": 107,
        "readability_score": 0.0,
        "information_density": 0.4519774011299435,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6204263027295285,
      "relevance_score": 1.0,
      "keywords": [
        "现金流",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "其他综合收益"
        },
        {
          "type": "accounting_item",
          "value": "综合收益总额"
        },
        {
          "type": "accounting_item",
          "value": "每股收益"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "基本每股收益"
        },
        {
          "type": "accounting_item",
          "value": "稀释每股收益"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他综合收益",
        "综合收益总额",
        "每股收益",
        "现金",
        "基本每股收益",
        "稀释每股收益"
      ]
    },
    {
      "chunk_id": "ed0abeaa",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------\n一、营业收入 | 812,259,638.86 | 825,098,603.87\n减：营业成本 | 587,096,405.03 | 619,846,906.93\n税金及附加 | 5,519,793.76 | 6,987,907.49\n销售费用 | 16,512,217.50 | 13,811,113.34\n管理费用 | 54,148,420.30 | 76,492,418.62\n研发费用 | 34,026,076.54 | 27,532,948.31\n财务费用 | -13,410,251.73 | -18,322,346.97\n其中：利息费用 | 9,198,148.55 | 23,746,817.96\n利息收入 | 15,402,930.57 | 21,054,583.18\n加：其他收益 | 8,727,855.85 | 2,788,654.20\n投资收益（损失以“－”号填\n列）  |\n| -4,635,510.82 | 996,151,682.18\n |\n其中：对联营企业和合营企\n业的投资收益  |\n| -5,766,425.53 | -4,216,789.49\n |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e01edfba",
        "591d46ad",
        "adb7ea04",
        "42f94a42",
        "7aee31d9",
        "8da49c66",
        "7b94c12b",
        "a101424a",
        "3ce461b0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 566,
      "page_number": 86,
      "bbox": [
        97.5,
        80.0,
        497.5,
        500.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入",
          "营业成本",
          "管理费用",
          "销售费用",
          "投资收益",
          "成本",
          "财务费用",
          "研发费用"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.187802",
        "report_type": "财务报表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 566,
        "word_count": 72,
        "sentence_count": 24,
        "chinese_char_count": 79,
        "readability_score": 0.0,
        "information_density": 0.38869257950530034,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6203608247422681,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "投资",
        "财务"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "营业成本"
        },
        {
          "type": "accounting_item",
          "value": "管理费用"
        },
        {
          "type": "accounting_item",
          "value": "销售费用"
        },
        {
          "type": "accounting_item",
          "value": "投资收益"
        },
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "财务费用"
        },
        {
          "type": "accounting_item",
          "value": "研发费用"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入",
        "营业成本",
        "管理费用",
        "销售费用",
        "投资收益",
        "成本",
        "财务费用",
        "研发费用"
      ]
    },
    {
      "chunk_id": "66ea691f",
      "content": "1.权益法下可转损益的其\n他综合收益\n2.其他债权投资公允价值\n变动\n3.可供出售金融资产公允\n价值变动损益\n4.金融资产重分类计入其\n他综合收益的金额\n5.持有至到期投资重分类\n为可供出售金融资产损益\n6.其他债权投资信用减值\n准备\n7.现金流量套期储备\n8.外币财务报表折算差额\n9.其他\n六、综合收益总额 112,575,451.35 1,086,145,333.95\n七、每股收益：\n（一）基本每股收益\n（二）稀释每股收益\n5、合并现金流量表\n单位：元\n项目 2019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 2,018,927,512.97 1,988,078,802.41\n客户存款和同业存放款项净增加\n额\n向中央银行借款净增加额\n向其他金融机构拆入资金净增加\n额\n收到原保险合同保费取得的现金\n收到再保业务现金净额\n保户储金及投资款净增加额\n收取利息、手续费及佣金的现金\n拆入资金净增加额\n回购业务资金净增加额\n88\n以摊余成本计量的金融  |\n--------------------------------------------------\n资产终止确认收益（损失以“-”号填  |\n列）  |\n净敞口套期收益（损失以  |\n |\n“－”号填列）  |\n |\n公允价值变动收益（损失以  |\n|  | 1,406,950.55\n“－”号填列）  |\n |\n信用减值损失（损失以“-”号  |\n| 961,136.35 |\n填列）  |\n |\n资产减值损失（损失以“-”号  |\n| -4,457,462.80 | -4,264,339.86\n填列）  |\n |\n资产处置收益（损失以“-”号  |\n| 187,029.94 | 278,081.30\n填列）  |\n |\n二、营业利润（亏损以“－”号填列） | 129,150,025.98 | 1,095,110,684.52\n加：营业外收入 | 56,093.96 | 1,807,586.73\n减：营业外支出 | 2,735,128.50 | 12,741,122.39\n三、利润总额（亏损总额以“－”号填  |\n| 126,470,991.44 | 1,084,177,148.86\n列）  |\n |\n减：所得税费用 | 13,895,540.09 | -1,968,185.09\n四、净利润（净亏损以“－”号填列） | 112,575,451.35 | 1,086,145,333.95\n（一）持续经营净利润（净亏损  |\n| 112,575,451.35 | 1,086,145,333.95\n以“－”号填列）  |\n |\n（二）终止经营净利润（净亏损  |\n |\n以“－”号填列）  |\n |\n五、其他综合收益的税后净额  |\n（一）不能重分类进损益的其他  |\n |\n综合收益  |\n |\n1.重新计量设定受益计划  |\n |\n变动额  |\n |\n2.权益法下不能转损益的  |\n |\n其他综合收益  |\n |\n3.其他权益工具投资公允  |\n |\n价值变动  |\n |\n4.企业自身信用风险公允  |\n |\n价值变动  |\n |\n5.其他  |\n（二）将重分类进损益的其他综  |\n |\n合收益  |\n |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c5dce1fe",
        "9cf7f8f3",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "2411be7e",
        "69274b47",
        "d9948b3e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1365,
      "page_number": 87,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "79x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 79,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "其他综合收益",
          "收入",
          "其他权益工具",
          "成本",
          "所得税",
          "资产",
          "所得税费用",
          "利润",
          "营业外收入",
          "利润总额",
          "营业外支出",
          "净利润"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.188097",
        "report_type": "财务报表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1365,
        "word_count": 178,
        "sentence_count": 38,
        "chinese_char_count": 561,
        "readability_score": 0.0,
        "information_density": 0.23443223443223443,
        "coherence_score": 0.3930623306233062,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7582882773625076,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "其他综合收益"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "其他权益工具"
        },
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "所得税费用"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "营业外收入"
        },
        {
          "type": "accounting_item",
          "value": "利润总额"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他综合收益",
        "收入",
        "其他权益工具",
        "成本",
        "所得税",
        "资产",
        "所得税费用",
        "利润",
        "营业外收入",
        "利润总额",
        "营业外支出",
        "净利润"
      ]
    },
    {
      "chunk_id": "eb6da782",
      "content": "1.权益法下可转损益的其  |\n--------------------------------------------------\n |\n他综合收益  |\n |\n2.其他债权投资公允价值  |\n |\n变动  |\n |\n3.可供出售金融资产公允  |\n |\n价值变动损益  |\n |\n4.金融资产重分类计入其  |\n |\n他综合收益的金额  |\n |\n5.持有至到期投资重分类  |\n |\n为可供出售金融资产损益  |\n |\n6.其他债权投资信用减值  |\n |\n准备  |\n |\n7.现金流量套期储备  |\n8.外币财务报表折算差额  |\n9.其他  |\n六、综合收益总额 | 112,575,451.35 | 1,086,145,333.95\n七、每股收益：  |\n（一）基本每股收益  |\n（二）稀释每股收益  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "642cd972",
        "dce24ef3",
        "2821f176",
        "2284b8b8",
        "6174ec2f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 360,
      "page_number": 88,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "19x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 19,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "综合收益总额",
          "每股收益",
          "现金",
          "资产",
          "基本每股收益",
          "稀释每股收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.188596",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 360,
        "word_count": 54,
        "sentence_count": 11,
        "chinese_char_count": 140,
        "readability_score": 0.0,
        "information_density": 0.5277777777777778,
        "coherence_score": 0.31666666666666665,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6378545454545455,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "现金流",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "综合收益总额"
        },
        {
          "type": "accounting_item",
          "value": "每股收益"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "基本每股收益"
        },
        {
          "type": "accounting_item",
          "value": "稀释每股收益"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "综合收益总额",
        "每股收益",
        "现金",
        "资产",
        "基本每股收益",
        "稀释每股收益"
      ]
    },
    {
      "chunk_id": "281add89",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------\n一、经营活动产生的现金流量：  |\n销售商品、提供劳务收到的现金 | 2,018,927,512.97 | 1,988,078,802.41\n客户存款和同业存放款项净增加  |\n |\n额  |\n |\n向中央银行借款净增加额  |\n向其他金融机构拆入资金净增加  |\n |\n额  |\n |\n收到原保险合同保费取得的现金  |\n收到再保业务现金净额  |\n保户储金及投资款净增加额  |\n收取利息、手续费及佣金的现金  |\n拆入资金净增加额  |\n回购业务资金净增加额  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "36d9ef06",
        "23216a95",
        "c0d70b4e",
        "146173a4",
        "acaa180d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 307,
      "page_number": 88,
      "bbox": [
        89.5,
        80.0,
        505.5,
        480.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "14x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "拆入资金",
          "经营活动产生的现金流量"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.188812",
        "report_type": "财务报表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 307,
        "word_count": 39,
        "sentence_count": 2,
        "chinese_char_count": 139,
        "readability_score": 0.0,
        "information_density": 0.2931596091205212,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5632113277623026,
      "relevance_score": 1.0,
      "keywords": [
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "拆入资金"
        },
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "拆入资金",
        "经营活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "0049f295",
      "content": "三、筹资活动产生的现金流量：\n吸收投资收到的现金\n其中：子公司吸收少数股东投资\n收到的现金\n取得借款收到的现金 285,000,000.00 755,700,000.00\n收到其他与筹资活动有关的现金 633,043,300.00\n筹资活动现金流入小计 285,000,000.00 1,388,743,300.00\n偿还债务支付的现金 683,700,000.00 1,500,000,000.00\n分配股利、利润或偿付利息支付\n483,358,140.11 204,568,679.00\n的现金\n其中：子公司支付给少数股东的\n股利、利润\n支付其他与筹资活动有关的现金 20,278,463.47 590,452,772.90\n筹资活动现金流出小计 1,187,336,603.58 2,295,021,451.90\n筹资活动产生的现金流量净额 -902,336,603.58 -906,278,151.90\n四、汇率变动对现金及现金等价物的\n9,911,822.10 35,680,596.21\n影响\n五、现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n加：期初现金及现金等价物余额 1,069,208,275.60 2,245,777,296.21\n六、期末现金及现金等价物余额 1,525,777,908.45 1,069,208,275.60\n6、母公司现金流量表\n单位：元\n项目 2019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 794,479,241.27 765,335,887.08\n收到的税费返还 63,235,140.24 46,673,265.97\n收到其他与经营活动有关的现金 2,428,120,879.18 2,178,495,326.41\n经营活动现金流入小计 3,285,835,260.69 2,990,504,479.46\n购买商品、接受劳务支付的现金 576,564,206.12 485,651,890.91\n支付给职工以及为职工支付的现\n43,273,656.13 44,578,456.58\n金\n支付的各项税费 4,696,293.04 11,167,793.85\n支付其他与经营活动有关的现金 2,653,901,946.32 1,818,361,700.45\n经营活动现金流出小计 3,278,436,101.61 2,359,759,841.79\n代理买卖证券收到的现金净额  |\n--------------------------------------------------\n收到的税费返还 | 105,999,603.44 | 49,705,278.88\n收到其他与经营活动有关的现金 | 249,850,615.77 | 771,950,774.20\n经营活动现金流入小计 | 2,374,777,732.18 | 2,809,734,855.49\n购买商品、接受劳务支付的现金 | 897,240,432.80 | 913,013,009.11\n客户贷款及垫款净增加额  |\n存放中央银行和同业款项净增加  |\n |\n额  |\n |\n支付原保险合同赔付款项的现金  |\n拆出资金净增加额  |\n支付利息、手续费及佣金的现金  |\n支付保单红利的现金  |\n支付给职工以及为职工支付的现  |\n| 311,715,734.86 | 280,419,788.03\n金  |\n |\n支付的各项税费 | 269,810,257.63 | 208,588,464.73\n支付其他与经营活动有关的现金 | 283,612,211.58 | 616,264,355.96\n经营活动现金流出小计 | 1,762,378,636.87 | 2,018,285,617.83\n经营活动产生的现金流量净额 | 612,399,095.31 | 791,449,237.66\n二、投资活动产生的现金流量：  |\n收回投资收到的现金  |\n取得投资收益收到的现金  |\n处置固定资产、无形资产和其他  |\n| 5,019,341.20 | 4,418,098.64\n长期资产收回的现金净额  |\n |\n处置子公司及其他营业单位收到  |\n |\n的现金净额  |\n |\n收到其他与投资活动有关的现金 | 1,172,215,955.60 | 959,401,529.98\n投资活动现金流入小计 | 1,177,235,296.80 | 963,819,628.62\n购建固定资产、无形资产和其他  |\n| 160,639,977.78 | 255,780,578.95\n长期资产支付的现金  |\n |\n投资支付的现金 | 20,000,000.00 |\n质押贷款净增加额  |\n取得子公司及其他营业单位支付  |\n |\n的现金净额  |\n |\n支付其他与投资活动有关的现金 | 260,000,000.00 | 1,805,459,752.25\n投资活动现金流出小计 | 440,639,977.78 | 2,061,240,331.20\n投资活动产生的现金流量净额 | 736,595,319.02 | -1,097,420,702.58",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "ce402e4b",
        "6cab59eb",
        "0ab8d664",
        "7bf63e9b",
        "a48459e9",
        "895bc68f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2180,
      "page_number": 89,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "76x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 76,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "无形资产",
          "投资活动产生的现金流量",
          "经营活动产生的现金流量",
          "固定资产",
          "投资收益",
          "长期资产",
          "现金",
          "经营活动现金流",
          "资产",
          "投资活动现金流"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.188985",
        "report_type": "财务报表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 2180,
        "word_count": 212,
        "sentence_count": 74,
        "chinese_char_count": 717,
        "readability_score": 0.0,
        "information_density": 0.11926605504587155,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7173211948919274,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "长期"
        },
        {
          "type": "accounting_item",
          "value": "无形资产"
        },
        {
          "type": "accounting_item",
          "value": "投资活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "固定资产"
        },
        {
          "type": "accounting_item",
          "value": "投资收益"
        },
        {
          "type": "accounting_item",
          "value": "长期资产"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "经营活动现金流"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "无形资产",
        "投资活动产生的现金流量",
        "经营活动产生的现金流量",
        "固定资产",
        "投资收益",
        "长期资产",
        "现金",
        "经营活动现金流",
        "资产",
        "投资活动现金流"
      ]
    },
    {
      "chunk_id": "842634b6",
      "content": "三、筹资活动产生的现金流量：  |\n--------------------------------------------------\n吸收投资收到的现金  |\n其中：子公司吸收少数股东投资  |\n |\n收到的现金  |\n |\n取得借款收到的现金 | 285,000,000.00 | 755,700,000.00\n收到其他与筹资活动有关的现金 |  | 633,043,300.00\n筹资活动现金流入小计 | 285,000,000.00 | 1,388,743,300.00\n偿还债务支付的现金 | 683,700,000.00 | 1,500,000,000.00\n分配股利、利润或偿付利息支付  |\n| 483,358,140.11 | 204,568,679.00\n的现金  |\n |\n其中：子公司支付给少数股东的  |\n |\n股利、利润  |\n |\n支付其他与筹资活动有关的现金 | 20,278,463.47 | 590,452,772.90\n筹资活动现金流出小计 | 1,187,336,603.58 | 2,295,021,451.90\n筹资活动产生的现金流量净额 | -902,336,603.58 | -906,278,151.90\n四、汇率变动对现金及现金等价物的  |\n| 9,911,822.10 | 35,680,596.21\n影响  |\n |\n五、现金及现金等价物净增加额 | 456,569,632.85 | -1,176,569,020.61\n加：期初现金及现金等价物余额 | 1,069,208,275.60 | 2,245,777,296.21\n六、期末现金及现金等价物余额 | 1,525,777,908.45 | 1,069,208,275.60",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3e602bb9",
        "2ee55a88",
        "f084e5ef",
        "8b547886",
        "f6e6b5f8",
        "c9ee37e0",
        "aed89698",
        "98be7b42"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 746,
      "page_number": 90,
      "bbox": [
        89.5,
        80.0,
        505.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "22x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "筹资活动产生的现金流量",
          "现金及现金等价物",
          "现金及现金等价物净增加额",
          "现金",
          "现金等价物",
          "筹资活动现金流",
          "利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.189700",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 746,
        "word_count": 84,
        "sentence_count": 23,
        "chinese_char_count": 207,
        "readability_score": 0.0,
        "information_density": 0.22788203753351208,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.638715710723192,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "现金流",
        "投资"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "筹资活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物净增加额"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "筹资活动现金流"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "筹资活动产生的现金流量",
        "现金及现金等价物",
        "现金及现金等价物净增加额",
        "现金",
        "现金等价物",
        "筹资活动现金流",
        "利润"
      ]
    },
    {
      "chunk_id": "6e3f4d62",
      "content": "经营活动产生的现金流量净额 7,399,159.08 630,744,637.67\n二、投资活动产生的现金流量：\n收回投资收到的现金\n取得投资收益收到的现金 722,088,153.34 160,759,162.54\n处置固定资产、无形资产和其他\n1,169,750.39 337,155.52\n长期资产收回的现金净额\n处置子公司及其他营业单位收到\n的现金净额\n收到其他与投资活动有关的现金 475,265,164.50 811,296,572.90\n投资活动现金流入小计 1,198,523,068.23 972,392,890.96\n购建固定资产、无形资产和其他\n984,040.99 10,199,423.26\n长期资产支付的现金\n投资支付的现金 20,000,000.00 156,121,497.07\n取得子公司及其他营业单位支付\n的现金净额\n支付其他与投资活动有关的现金 20,000,000.00 1,255,559,950.55\n投资活动现金流出小计 40,984,040.99 1,421,880,870.88\n投资活动产生的现金流量净额 1,157,539,027.24 -449,487,979.92\n三、筹资活动产生的现金流量：\n吸收投资收到的现金\n取得借款收到的现金 235,000,000.00 389,000,000.00\n收到其他与筹资活动有关的现金\n筹资活动现金流入小计 235,000,000.00 389,000,000.00\n偿还债务支付的现金 322,000,000.00 772,000,000.00\n分配股利、利润或偿付利息支付\n476,237,693.27 185,312,985.94\n的现金\n支付其他与筹资活动有关的现金 20,278,463.47 295,075,572.90\n筹资活动现金流出小计 818,516,156.74 1,252,388,558.84\n筹资活动产生的现金流量净额 -583,516,156.74 -863,388,558.84\n四、汇率变动对现金及现金等价物的\n4,468,592.83 11,626,754.25\n影响\n五、现金及现金等价物净增加额 585,890,622.41 -670,505,146.84\n加：期初现金及现金等价物余额 593,590,172.62 1,264,095,319.46\n六、期末现金及现金等价物余额 1,179,480,795.03 593,590,172.62\n项目 | 2019年度 | 2018年度\n--------------------------------------------------\n一、经营活动产生的现金流量：  |\n销售商品、提供劳务收到的现金 | 794,479,241.27 | 765,335,887.08\n收到的税费返还 | 63,235,140.24 | 46,673,265.97\n收到其他与经营活动有关的现金 | 2,428,120,879.18 | 2,178,495,326.41\n经营活动现金流入小计 | 3,285,835,260.69 | 2,990,504,479.46\n购买商品、接受劳务支付的现金 | 576,564,206.12 | 485,651,890.91\n支付给职工以及为职工支付的现  |\n| 43,273,656.13 | 44,578,456.58\n金  |\n |\n支付的各项税费 | 4,696,293.04 | 11,167,793.85\n支付其他与经营活动有关的现金 | 2,653,901,946.32 | 1,818,361,700.45\n经营活动现金流出小计 | 3,278,436,101.61 | 2,359,759,841.79",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cc670f44",
        "4cf5cc5f",
        "34506370",
        "969d05a9",
        "82c8adbf",
        "746e7ab2"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1570,
      "page_number": 90,
      "bbox": [
        89.5,
        80.0,
        505.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "51x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 51,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "经营活动现金流",
          "经营活动产生的现金流量",
          "现金"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.190030",
        "report_type": "财务报表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1570,
        "word_count": 133,
        "sentence_count": 60,
        "chinese_char_count": 490,
        "readability_score": 0.0,
        "information_density": 0.07006369426751594,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.673597780224762,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "经营活动现金流"
        },
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营活动现金流",
        "经营活动产生的现金流量",
        "现金"
      ]
    },
    {
      "chunk_id": "062a4bb5",
      "content": "7、合并所有者权益变动表\n本期金额\n单位：元\n2019年度\n归属于母公司所有者权益\n所有\n少数\n项目 其他权益工具 其他 一般 未分 者权\n资本 减：库 专项 盈余 股东\n股本 优先 永续 综合 风险 配利 其他 小计 益合\n股 债\n其他 公积 存股\n收益\n储备 公积\n准备 润\n权益\n计\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,\n一、上年期末余 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 549,93\n额 253.0 9.23\n2.47 68 17 8.50 2.23 2.23\n0\n加：会计政\n策变更\n前期\n差错更正\n同一\n控制下企业合\n并\n其他\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,\n二、本年期初余 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 549,93\n额 253.0 9.23\n2.47 68 17 8.50 2.23 2.23\n0\n三、本期增减变 -105, -24,36 11,257 292,84 333,91 333,91\n6,982, -1,438,\n动金额（减少以 000.0 9,047. ,545.1 6,480. 2,163. 2,163.\n499.53 409.58\n“－”号填列） 0 78 4 45 32 32\n770,78 769,34 769,34\n（一）综合收益 -1,438,\n2,185. 3,775. 3,775.\n总额 409.58\n09 51 51\n-105, -24,36 31,246 31,246\n（二）所有者投 6,982,\n000.0 9,047. ,547.3 ,547.3\n入和减少资本 499.53\n0 78 1 1\n-105, 19,996 -20,23 -20,23\n1．所有者投入 -131,2\n000.0 ,827.2 3,077. 3,077.\n的普通股 50.00\n0 2 22 22\n2．其他权益工\n具持有者投入\n资本\n经营活动产生的现金流量净额 | 7,399,159.08 | 630,744,637.67\n--------------------------------------------------\n二、投资活动产生的现金流量：  |\n收回投资收到的现金  |\n取得投资收益收到的现金 | 722,088,153.34 | 160,759,162.54\n处置固定资产、无形资产和其他  |\n| 1,169,750.39 | 337,155.52\n长期资产收回的现金净额  |\n |\n处置子公司及其他营业单位收到  |\n |\n的现金净额  |\n |\n收到其他与投资活动有关的现金 | 475,265,164.50 | 811,296,572.90\n投资活动现金流入小计 | 1,198,523,068.23 | 972,392,890.96\n购建固定资产、无形资产和其他  |\n| 984,040.99 | 10,199,423.26\n长期资产支付的现金  |\n |\n投资支付的现金 | 20,000,000.00 | 156,121,497.07\n取得子公司及其他营业单位支付  |\n |\n的现金净额  |\n |\n支付其他与投资活动有关的现金 | 20,000,000.00 | 1,255,559,950.55\n投资活动现金流出小计 | 40,984,040.99 | 1,421,880,870.88\n投资活动产生的现金流量净额 | 1,157,539,027.24 | -449,487,979.92\n三、筹资活动产生的现金流量：  |\n吸收投资收到的现金  |\n取得借款收到的现金 | 235,000,000.00 | 389,000,000.00\n收到其他与筹资活动有关的现金  |\n筹资活动现金流入小计 | 235,000,000.00 | 389,000,000.00\n偿还债务支付的现金 | 322,000,000.00 | 772,000,000.00\n分配股利、利润或偿付利息支付  |\n| 476,237,693.27 | 185,312,985.94\n的现金  |\n |\n支付其他与筹资活动有关的现金 | 20,278,463.47 | 295,075,572.90\n筹资活动现金流出小计 | 818,516,156.74 | 1,252,388,558.84\n筹资活动产生的现金流量净额 | -583,516,156.74 | -863,388,558.84\n四、汇率变动对现金及现金等价物的  |\n| 4,468,592.83 | 11,626,754.25\n影响  |\n |\n五、现金及现金等价物净增加额 | 585,890,622.41 | -670,505,146.84\n加：期初现金及现金等价物余额 | 593,590,172.62 | 1,264,095,319.46\n六、期末现金及现金等价物余额 | 1,179,480,795.03 | 593,590,172.62",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2161,
      "page_number": 91,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "100x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 100,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "经营活动产生的现金流量",
          "投资活动产生的现金流量",
          "无形资产",
          "筹资活动产生的现金流量",
          "固定资产",
          "现金及现金等价物",
          "投资收益",
          "长期资产",
          "现金及现金等价物净增加额",
          "现金等价物",
          "现金",
          "投资活动现金流",
          "资产",
          "筹资活动现金流",
          "利润"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.190463",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 2161,
        "word_count": 316,
        "sentence_count": 80,
        "chinese_char_count": 560,
        "readability_score": 0.0,
        "information_density": 0.14807959278111987,
        "coherence_score": 0.4950994909763998,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7398148848294577,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "长期"
        },
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "投资活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "无形资产"
        },
        {
          "type": "accounting_item",
          "value": "筹资活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "固定资产"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "投资收益"
        },
        {
          "type": "accounting_item",
          "value": "长期资产"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物净增加额"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "经营活动产生的现金流量",
        "投资活动产生的现金流量",
        "无形资产",
        "筹资活动产生的现金流量",
        "固定资产",
        "现金及现金等价物",
        "投资收益",
        "长期资产",
        "现金及现金等价物净增加额",
        "现金等价物",
        "现金",
        "投资活动现金流",
        "资产",
        "筹资活动现金流",
        "利润"
      ]
    },
    {
      "chunk_id": "93f482b7",
      "content": "税种 | 计税依据 | 税率\n--------------------------------------------------\n增值税 | 销售货物或提供应税劳务 | 19%、16%、13%、6%\n城市维护建设税 | 应缴流转税税额 | 7%、5%\n企业所得税 | 应纳税所得额 | 15%、16.5%、17%、20%、25%\n| 从价计征的，按房产原值一次减除30% |\n房产税 | 后余值的1.2%计缴；从租计征的，按租 | 1.2%、12%\n| 金收入的12%计缴 |\n教育费附加 | 应缴流转税税额 | 3%\n地方教育附加 | 应缴流转税税额 | 2%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4ededcee",
        "d4fb6b72",
        "f4fab038"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 282,
      "page_number": 122,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "9x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.191210",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 282,
        "word_count": 42,
        "sentence_count": 3,
        "chinese_char_count": 108,
        "readability_score": 0.0,
        "information_density": 0.1773049645390071,
        "coherence_score": 0.34444444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.54717668997669,
      "relevance_score": 1.0,
      "keywords": [
        "收入"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "所得税"
      ]
    },
    {
      "chunk_id": "e5b3f018",
      "content": "| 指定为以公允价 |\n--------------------------------------------------\n| 其他综合收益转 |  | 其他综合收益转\n| 值计量且其变动 |\n项目名称 | 确认的股利收入 | 累计利得 | 累计损失 | 入留存收益的金 |  | 入留存收益的原\n| 计入其他综合收 |\n| 额 |  | 因\n| 益的原因 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "67e3bdd0",
        "01d7eaf6",
        "a1cc7685"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 183,
      "page_number": 137,
      "bbox": [
        97.5,
        80.0,
        497.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x6",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "其他综合收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          137
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.191328",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 183,
        "word_count": 36,
        "sentence_count": 0,
        "chinese_char_count": 74,
        "readability_score": 0.0,
        "information_density": 0.27322404371584696,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4537507246376811,
      "relevance_score": 1.0,
      "keywords": [
        "收入"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "其他综合收益"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "其他综合收益"
      ]
    },
    {
      "chunk_id": "f3f7ee61",
      "content": "应纳税暂时性差异 递延所得税负债 应纳税暂时性差异 递延所得税负债\n单位价值500万元以下\n固定资产一次性税前抵 179,410,105.32 30,527,355.71 44,259,216.46 8,175,428.28\n扣\n合计 179,410,105.32 30,527,355.71 44,259,216.46 8,175,428.28\n（3）以抵销后净额列示的递延所得税资产或负债\n单位： 元\n递延所得税资产和负债 抵销后递延所得税资产 递延所得税资产和负债 抵销后递延所得税资产\n项目\n期末互抵金额 或负债期末余额 期初互抵金额 或负债期初余额\n递延所得税资产 27,339,683.56 32,487,223.69\n递延所得税负债 30,527,355.71 8,175,428.28\n（4）未确认递延所得税资产明细\n单位： 元\n项目 期末余额 期初余额\n可抵扣暂时性差异 34,056.67 42,122.21\n可抵扣亏损 54,023,245.91 120,721,788.89\n合计 54,057,302.58 120,763,911.10\n（5）未确认递延所得税资产的可抵扣亏损将于以下年度到期\n单位： 元\n年份 期末金额 期初金额 备注\n2021年 106,844,539.90\n2022年 13,876,526.38 13,876,526.38\n2023年 722.61 722.61\n2024年 40,145,996.92\n合计 54,023,245.91 120,721,788.89 --\n其他说明：\n31、其他非流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n| 期末余额 |  | 期初余额 |\n--------------------------------------------------\n项目 | \n| 可抵扣暂时性差异 | 递延所得税资产 | 可抵扣暂时性差异 | 递延所得税资产\n| \n资产减值准备 | 70,299,465.99 | 14,376,262.42 | 68,698,671.21 | 14,236,323.65\n内部交易未实现利润 | 39,421,112.05 | 6,246,640.41 | 62,503,070.92 | 9,773,506.85\n与资产相关的政府补助 | \n| 43,621,205.16 | 6,716,780.73 | 36,278,025.15 | 5,567,975.82\n分摊 | \n| \n预计负债 | 11,637,669.47 | 2,909,417.37\n合计 | 153,341,783.20 | 27,339,683.56 | 179,117,436.75 | 32,487,223.69",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5fb301c2",
        "0760ebd6",
        "cef61d74",
        "6aa9fbfc",
        "52d2bac7",
        "834ad36c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1170,
      "page_number": 148,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x5",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "所得税",
          "递延所得税资产",
          "资产",
          "利润",
          "预计负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.191441",
        "report_type": "财务报表",
        "fiscal_year": 2021,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1170,
        "word_count": 145,
        "sentence_count": 44,
        "chinese_char_count": 349,
        "readability_score": 0.0,
        "information_density": 0.1452991452991453,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6552289774970391,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "利润",
        "500万元"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "递延所得税资产"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "预计负债"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "所得税",
        "递延所得税资产",
        "资产",
        "利润",
        "预计负债"
      ]
    },
    {
      "chunk_id": "f1babdf9",
      "content": "| 应纳税暂时性差异 | 递延所得税负债 | 应纳税暂时性差异 | 递延所得税负债\n--------------------------------------------------\n单位价值500万元以下 | \n固定资产一次性税前抵 | 179,410,105.32 | 30,527,355.71 | 44,259,216.46 | 8,175,428.28\n扣 | \n合计 | 179,410,105.32 | 30,527,355.71 | 44,259,216.46 | 8,175,428.28",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "150f7c93",
        "bf3005b7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 254,
      "page_number": 149,
      "bbox": [
        47.5,
        80.0,
        547.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x5",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "固定资产",
          "递延所得税负债",
          "所得税",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.191805",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 254,
        "word_count": 31,
        "sentence_count": 8,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.5118110236220472,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4742886446886446,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "500万元"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "固定资产"
        },
        {
          "type": "accounting_item",
          "value": "递延所得税负债"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "固定资产",
        "递延所得税负债",
        "所得税",
        "资产"
      ]
    },
    {
      "chunk_id": "d8e68070",
      "content": "| 递延所得税资产和负债 | 抵销后递延所得税资产 | 递延所得税资产和负债 | 抵销后递延所得税资产\n--------------------------------------------------\n项目 | \n| 期末互抵金额 | 或负债期末余额 | 期初互抵金额 | 或负债期初余额\n| \n递延所得税资产 |  | 27,339,683.56 |  | 32,487,223.69\n递延所得税负债 |  | 30,527,355.71 |  | 8,175,428.28\n\n> 注：预付软件款 450,000.00 515,993.37\n合计 450,000.00 515,993.37\n其他说明：\n32、短期借款\n（1）短期借款分类\n单位： 元\n项目 期末余额 期初余额\n质押借款 76,700,000.00\n抵押借款 50,066,500.00 143,000,000.00\n保证借款 20,000,000.00\n信用借款 150,200,529.59 359,000,000.00\n合计 200,267,029.59 598,700,000.00\n短期借款分类的说明：\n（2）已逾期未偿还的短期借款情况\n本期末已逾期未偿还的短期借款总额为元，其中重要的已逾期未偿还的短期借款情况如下：\n单位： 元\n借款单位 期末余额 借款利率 逾期时间 逾期利率\n其他说明：\n33、交易性金融负债\n单位： 元\n项目 期末余额 期初余额\n其中：\n其中：\n其他说明：\n34、衍生金融负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n150",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fe98a5ac",
        "98d96670",
        "2b75fe3f",
        "9de02a5e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 670,
      "page_number": 149,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "33x4",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 33,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "递延所得税资产和负债",
          "负债",
          "递延所得税负债",
          "所得税",
          "资产",
          "递延所得税资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.191914",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 670,
        "word_count": 90,
        "sentence_count": 16,
        "chinese_char_count": 273,
        "readability_score": 0.0,
        "information_density": 0.208955223880597,
        "coherence_score": 0.6085074626865672,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5731575082101806,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "递延所得税资产和负债"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "递延所得税负债"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "递延所得税资产"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "递延所得税资产和负债",
        "负债",
        "递延所得税负债",
        "所得税",
        "资产",
        "递延所得税资产"
      ]
    },
    {
      "chunk_id": "dcd3c20c",
      "content": "催化净化处\n理塔建设项 140,000.00 30,000.00 110,000.00 与资产相关\n目\n年产50吨培\n南类产品及\n132,000.00 48,000.00 84,000.00 与资产相关\n扩建厂房技\n改项目\n企业技术中\n心创新能力 133,333.33 40,000.00 93,333.33 与资产相关\n建设项目\n年产8亿元\n(粒)口服固 7,065,200.00 997,440.00 6,067,760.00 与资产相关\n体制剂项目\n临海市创新\n驱动加快推\n进工业经济 1,042,718.40 208,543.68 834,174.72 与资产相关\n转型升级政\n策\n省级工业与\n信息化专项\n资金回收溶 632,766.12 92,599.92 540,166.20 与资产相关\n剂循环化技\n改项目\n省工业化和\n信息化深度\n融合示范试 457,675.28 66,169.92 391,505.36 与资产相关\n点区财政补\n助\n浙江省化学\n原料药基地\n椒江区块循 263,333.33 40,000.00 223,333.33 与资产相关\n环化改造项\n目补助资金\n| 本期计入营\n业外收入金\n额 |  | 本期冲减成\n本费用金额 | \n--------------------------------------------------\n|  | 本期新增补 |  | 本期计入其 | 与资产相关/\n负债项目 | 期初余额 | 其他变动 | 期末余额 |\n|  | 助金额 |  | 他收益金额 | 与收益相关\n| \n| \n年产400吨 | 1,423,820.2\n8 | 4,271,460.84 |\n碳青霉烯类 | \n抗生素关键 | 5,695,281.12 | 与资产相关\n中间体 | \n4-AA项目 | \n年产1吨瑞 | 117,931.20 | 117,931.20 |\n格列奈、10 | \n吨卡洛芬、 | \n10吨阿托伐 | \n醌、50吨 | \nT1620、300 | \n| 235,862.40 | 与资产相关\n吨聚卡波菲 | \n| \n钙、300吨 | \n4,4'-二氟二 | \n苯甲酮、100 | \n吨奈韦拉平 | \n产业化项目 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0bced6b7",
        "cba2f31b",
        "50e685fa",
        "7102ff5b",
        "7ba8d1b4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 935,
      "page_number": 158,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "60x4",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 60,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "资产",
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          158
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.192141",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 935,
        "word_count": 152,
        "sentence_count": 30,
        "chinese_char_count": 318,
        "readability_score": 0.0,
        "information_density": 0.10695187165775402,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7035586416268363,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "8亿元"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "资产",
        "负债"
      ]
    },
    {
      "chunk_id": "37cd38cd",
      "content": "62、税金及附加\n单位： 元\n项目 本期发生额 上期发生额\n城市维护建设税 8,979,337.87 11,136,827.27\n教育费附加 4,206,609.84 5,294,134.87\n房产税 5,843,558.13 6,064,374.46\n土地使用税 2,733,446.70 4,311,794.23\n车船使用税 92,034.56 91,578.70\n印花税 2,055,976.68 1,234,528.45\n环境保护税 125,638.87 520,262.21\n地方教育附加 2,804,406.56 3,529,423.24\n合计 26,841,009.21 32,182,923.43\n其他说明：\n63、销售费用\n单位： 元\n项目 本期发生额 上期发生额\n佣 金 23,106,866.17 4,449,906.56\n运输费 15,855,838.29 18,776,797.69\n职工薪酬 11,454,758.67 9,017,672.93\n宣传展览费 2,730,663.11 3,083,947.22\n保险费 2,384,650.11 1,684,252.56\n业务招待费 1,327,567.15 3,743,333.54\n差旅费 930,856.80 1,475,970.50\n邮寄费 306,320.89 564,905.56\n其 他 1,525,503.69 984,267.86\n合计 59,623,024.88 43,781,054.42\n其他说明：\n64、管理费用\n单位： 元\n项目 本期发生额 上期发生额\n职工薪酬 135,254,390.92 119,986,220.11\n折旧费 71,414,444.32 59,647,789.49\n| 本期发生额 |  | 上期发生额 |\n--------------------------------------------------\n项目 | \n| 收入 | 成本 | 收入 | 成本\n| \n主营业务 | 2,925,688,906.14 | 1,449,500,049.29 | 2,691,787,601.50 | 1,492,180,658.53\n其他业务 | 15,723,864.16 | 13,659,311.75 | 26,821,195.01 | 19,764,017.65\n合计 | 2,941,412,770.30 | 1,463,159,361.04 | 2,718,608,796.51 | 1,511,944,676.18",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d0e9e900",
        "fc51fc41"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1075,
      "page_number": 164,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "38x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 38,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.192514",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1075,
        "word_count": 130,
        "sentence_count": 54,
        "chinese_char_count": 176,
        "readability_score": 0.0,
        "information_density": 0.05581395348837209,
        "coherence_score": 0.3286363636363636,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5324778771615981,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "收入"
      ]
    },
    {
      "chunk_id": "ef05b1b6",
      "content": "其他说明：\n67、其他收益\n单位： 元\n产生其他收益的来源 本期发生额 上期发生额\n与资产相关的政府补助 6,554,259.99 5,071,751.21\n与收益相关的政府补助 20,582,664.88 6,719,986.82\n合 计 27,136,924.87 11,791,738.03\n68、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n权益法核算的长期股权投资收益 -16,759,549.80 -6,923,938.93\n银行理财产品收益 2,079,074.70 3,024,312.63\n处置金融工具取得的投资收益 -559,587.45 -5,459,752.25\n合计 -15,240,062.55 -9,359,378.55\n其他说明：\n69、净敞口套期收益\n单位： 元\n项目 本期发生额 上期发生额\n其他说明：\n70、公允价值变动收益\n单位： 元\n产生公允价值变动收益的来源 本期发生额 上期发生额\n交易性金融负债 5,010,265.70\n合计 5,010,265.70\n其他说明：\n71、信用减值损失\n单位： 元\n项目 本期发生额 上期发生额\n坏账损失 -2,502,149.00\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n利息支出 | 15,506,676.74 | 42,594,267.08\n利息收入 | -41,773,975.28 | -44,371,159.00\n汇兑净损益 | -12,759,207.59 | -50,821,750.14\n金融机构手续费 | 1,161,350.07 | 1,091,244.28\n合计 | -37,865,156.06 | -51,507,397.78",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3b9c020d",
        "8321dc03"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 770,
      "page_number": 166,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.192815",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 770,
        "word_count": 93,
        "sentence_count": 27,
        "chinese_char_count": 244,
        "readability_score": 0.0,
        "information_density": 0.09090909090909091,
        "coherence_score": 0.42666666666666664,
        "standards_profile_summary": {}
      },
      "quality_score": 0.540487751405967,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "投资"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "3ca1f2fe",
      "content": "| 计入当期非经常性损益的金\n--------------------------------------------------\n项目 | 本期发生额 | 上期发生额 |\n| 额\n| \n非货币性资产交换利得 | 56,093.96 | 126,221.82 | 56,093.96\n无法支付款项 |  | 370,069.55 |\n违约及赔款收入 | 896,839.67 | 972,312.09 | 896,839.67\n其 他 | 172,720.90 | 244,682.63 | 172,720.90\n合计 | 1,125,654.53 | 1,713,286.09 | 1,125,654.53",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "748dfed3",
        "83671f89",
        "165a680c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 304,
      "page_number": 168,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x4",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.193056",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 304,
        "word_count": 46,
        "sentence_count": 13,
        "chinese_char_count": 52,
        "readability_score": 0.0,
        "information_density": 0.19736842105263158,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48091987767584093,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "资产"
      ]
    },
    {
      "chunk_id": "a22bec99",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n收回银行承兑汇票、信用证保证金等 | 146,000,576.25 | 268,324,454.49\n收到银行存款利息收入 | 31,637,094.38 | 37,993,941.65\n收到政府补助 | 31,594,591.50 | 17,182,776.65\n支取为开立承兑汇票质押的定期存款 | 33,903,500.00 | 442,038,662.00\n收到房租收入 | 923,003.40 | 2,147,867.09\n其 他 | 5,791,850.24 | 4,263,072.32\n合计 | 249,850,615.77 | 771,950,774.20",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7c0576a5",
        "6ed7d700",
        "1ab6814d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 358,
      "page_number": 170,
      "bbox": [
        97.5,
        80.0,
        497.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "银行存款",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.193197",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 358,
        "word_count": 42,
        "sentence_count": 14,
        "chinese_char_count": 69,
        "readability_score": 0.0,
        "information_density": 0.13966480446927373,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.533843947858473,
      "relevance_score": 1.0,
      "keywords": [
        "收入"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "银行存款"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "银行存款",
        "收入"
      ]
    },
    {
      "chunk_id": "ac8833fb",
      "content": "（2）本期支付的取得子公司的现金净额\n单位： 元\n金额\n其中： --\n其中： --\n其中： --\n其他说明：\n（3）本期收到的处置子公司的现金净额\n单位： 元\n金额\n其中： --\n其中： --\n其中： --\n其他说明：\n（4）现金和现金等价物的构成\n单位： 元\n项目 期末余额 期初余额\n一、现金 1,525,777,908.45 1,069,208,275.60\n其中：库存现金 131,545.99 195,522.60\n可随时用于支付的银行存款 1,525,298,726.49 1,068,623,694.25\n可随时用于支付的其他货币资金 347,635.97 389,058.75\n三、期末现金及现金等价物余额 1,525,777,908.45 1,069,208,275.60\n其他说明：\n(1) 不涉及现金收支的商业汇票背书转让金额\n项 目 本期数 上期数\n背书转让的商业汇票金额 1,203,398,004.56 1,019,486,370.21\n其中：支付货款 763,162,260.55 663,084,419.99\n支付固定资产等长期资产购置款 440,235,744.01 356,401,950.22\n(2) 不属于现金及现金等价物的货币资金情况的说明\n项 目 期末数 期初数\n质押的定期存款 34,316,000.00\n结构性存款 750,000,000.00\n银行承兑汇票保证金 30,797,464.00 102,564,848.73\n补充资料 | 本期金额 | 上期金额\n--------------------------------------------------\n1．将净利润调节为经营活动现金流量： | -- | --\n净利润 | 770,782,185.09 | 605,003,820.78\n加：资产减值准备 | 14,240,855.70 | 18,867,903.52\n固定资产折旧、油气资产折耗、生产性生  |\n| 172,822,169.17 | 161,268,842.88\n物资产折旧  |\n |\n无形资产摊销 | 30,277,923.13 | 31,103,003.79\n长期待摊费用摊销 | 223,651.32 | 162,421.24\n处置固定资产、无形资产和其他长期资产  |\n| -244,580.94 | -659,231.88\n的损失（收益以“－”号填列）  |\n |\n固定资产报废损失（收益以“－”号填列） | 4,395,355.91 | 761,505.33\n公允价值变动损失（收益以“－”号填列） |  | -5,010,265.70\n财务费用（收益以“－”号填列） | -7,552,032.06 | -14,604,700.41\n投资损失（收益以“－”号填列） | 15,240,062.55 | 9,359,378.55\n递延所得税资产减少（增加以“－”号填列） | 5,147,540.13 | -4,649,984.56\n递延所得税负债增加（减少以“－”号填列） | 22,351,927.43 | 8,175,428.28\n存货的减少（增加以“－”号填列） | 52,643,000.47 | -99,308,067.53\n经营性应收项目的减少（增加以“－”号填  |\n| -276,602,622.13 | -71,443,627.33\n列）  |\n |\n经营性应付项目的增加（减少以“－”号填  |\n| -191,326,340.46 | 152,422,810.70\n列）  |\n |\n经营活动产生的现金流量净额 | 612,399,095.31 | 791,449,237.66\n2．不涉及现金收支的重大投资和筹资活  |\n| -- | --\n动：  |\n |\n3．现金及现金等价物净变动情况： | -- | --\n现金的期末余额 | 1,525,777,908.45 | 1,069,208,275.60\n减：现金的期初余额 | 1,069,208,275.60 | 2,245,777,296.21\n现金及现金等价物净增加额 | 456,569,632.85 | -1,176,569,020.61",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1757,
      "page_number": 172,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "65x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 65,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "经营活动产生的现金流量",
          "递延所得税负债",
          "现金及现金等价物净增加额",
          "现金等价物",
          "负债",
          "应收",
          "经营活动现金流",
          "利润",
          "长期待摊费用",
          "财务费用",
          "应付",
          "递延所得税资产",
          "净利润",
          "长期",
          "无形资产",
          "存货",
          "固定资产",
          "现金及现金等价物",
          "现金",
          "所得税",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.193376",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1757,
        "word_count": 207,
        "sentence_count": 57,
        "chinese_char_count": 532,
        "readability_score": 0.0,
        "information_density": 0.21627774615822423,
        "coherence_score": 0.43999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7188702770264732,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "经营活动产生的现金流量"
        },
        {
          "type": "accounting_item",
          "value": "递延所得税负债"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物净增加额"
        },
        {
          "type": "accounting_item",
          "value": "现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "应收"
        },
        {
          "type": "accounting_item",
          "value": "经营活动现金流"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "长期待摊费用"
        },
        {
          "type": "accounting_item",
          "value": "财务费用"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营活动产生的现金流量",
        "递延所得税负债",
        "现金及现金等价物净增加额",
        "现金等价物",
        "负债",
        "应收",
        "经营活动现金流",
        "利润",
        "长期待摊费用",
        "财务费用",
        "应付",
        "递延所得税资产",
        "净利润",
        "长期",
        "无形资产",
        "存货",
        "固定资产",
        "现金及现金等价物",
        "现金",
        "所得税",
        "资产"
      ]
    },
    {
      "chunk_id": "5b532a7c",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n一、现金 | 1,525,777,908.45 | 1,069,208,275.60\n其中：库存现金 | 131,545.99 | 195,522.60\n可随时用于支付的银行存款 | 1,525,298,726.49 | 1,068,623,694.25\n可随时用于支付的其他货币资金 | 347,635.97 | 389,058.75\n三、期末现金及现金等价物余额 | 1,525,777,908.45 | 1,069,208,275.60",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "bfdba451",
        "cf5f0183",
        "7c06d640",
        "0469ff6c",
        "40ceb3a0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 289,
      "page_number": 173,
      "bbox": [
        89.5,
        80.0,
        505.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "货币资金",
          "现金及现金等价物",
          "现金",
          "现金等价物",
          "库存现金",
          "银行存款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.194067",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 289,
        "word_count": 31,
        "sentence_count": 10,
        "chinese_char_count": 58,
        "readability_score": 0.0,
        "information_density": 0.41522491349480967,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4879038062283737,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [
        {
          "type": "accounting_item",
          "value": "货币资金"
        },
        {
          "type": "accounting_item",
          "value": "现金及现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "现金"
        },
        {
          "type": "accounting_item",
          "value": "现金等价物"
        },
        {
          "type": "accounting_item",
          "value": "库存现金"
        },
        {
          "type": "accounting_item",
          "value": "银行存款"
        }
      ],
      "topics": [
        "cash_flow"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "货币资金",
        "现金及现金等价物",
        "现金",
        "现金等价物",
        "库存现金",
        "银行存款"
      ]
    },
    {
      "chunk_id": "1d6ad1e5",
      "content": "| 购买日至期 | 购买日至期\n--------------------------------------------------\n被购买方名 | 股权取得时 | 股权取得成 | 股权取得比 | 股权取得方 |  | 购买日的确  |\n| 购买日 |  | 末被购买方 | 末被购买方\n称 | 点 | 本 | 例 | 式 |  | 定依据  |\n| 的收入 | 的净利润\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "203916cb",
        "58408333"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 188,
      "page_number": 177,
      "bbox": [
        89.5,
        80.0,
        505.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x6",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "收入",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.194290",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 188,
        "word_count": 43,
        "sentence_count": 0,
        "chinese_char_count": 68,
        "readability_score": 0.0,
        "information_density": 0.425531914893617,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48332636815920405,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "利润"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "收入",
        "净利润"
      ]
    },
    {
      "chunk_id": "8bcaa04f",
      "content": "（3）合并日被合并方资产、负债的账面价值\n单位： 元\n合并日 上期期末\n企业合并中承担的被合并方的或有负债：\n其他说明：\n3、反向购买\n交易基本信息、交易构成反向购买的依据、上市公司保留的资产、负债是否构成业务及其依据、合并成本的确定、按照权益\n性交易处理时调整权益的金额及其计算：\n4、处置子公司\n是否存在单次处置对子公司投资即丧失控制权的情形\n□ 是 √ 否\n是否存在通过多次交易分步处置对子公司投资且在本期丧失控制权的情形\n□ 是 √ 否\n5、其他原因的合并范围变动\n说明其他原因导致的合并范围变动（如，新设子公司、清算子公司等）及其相关情况：\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n6、其他\n九、在其他主体中的权益\n1、在子公司中的权益\n（1）企业集团的构成\n持股比例\n子公司名称 主要经营地 注册地 业务性质 取得方式\n直接 间接\n川南药业公司 台州市 台州市 医药制造 100.00% 设立\n海翔销售公司 台州市 台州市 医药销售 100.00% 设立\n上海海翔公司 上海市 上海市 技术研发 100.00% 设立\n| 合并当期期 | 合并当期期  |\n--------------------------------------------------\n| 企业合并中 | 构成同一控 | 比较期间被 | 比较期间被\n被合并方名 | 合并日的确 | 初至合并日 | 初至合并日  |\n| 取得的权益 | 制下企业合 | 合并日 | 合并方的收 | 合并方的净\n称 | 定依据 | 被合并方的 | 被合并方的  |\n| 比例 | 并的依据 | 入 | 利润\n| 收入 | 净利润  |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4412cc96",
        "d08862ef"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 741,
      "page_number": 178,
      "bbox": [
        81.5,
        80.0,
        513.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "收入",
          "净利润"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          178
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.194385",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 741,
        "word_count": 117,
        "sentence_count": 3,
        "chinese_char_count": 473,
        "readability_score": 0.0,
        "information_density": 0.18893387314439947,
        "coherence_score": 0.8262337662337662,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6673774025432563,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "收入",
        "净利润"
      ]
    },
    {
      "chunk_id": "86e8cb96",
      "content": "| 期末余额 | 期初余额 | \n--------------------------------------------------\n子公司 | \n| 流动资 | 非流动 | 资产合 | 流动负 | 非流动 | 负债合 | 流动资 | 非流动 | 资产合 | 流动负 | 非流动 | 负债合\n名称 | \n| 产 | 资产 | 计 | 债 | 负债 | 计 | 产 | 资产 | 计 | 债 | 负债 | 计\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8403be42",
        "634e9580"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 206,
      "page_number": 180,
      "bbox": [
        47.5,
        80.0,
        547.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x12",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 12,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.194594",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 206,
        "word_count": 59,
        "sentence_count": 0,
        "chinese_char_count": 65,
        "readability_score": 0.0,
        "information_density": 0.2912621359223301,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48799841740850647,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债"
      ]
    },
    {
      "chunk_id": "ed58cd38",
      "content": "| 本期发生额 | 上期发生额 | \n--------------------------------------------------\n子公司名称 | 综合收益总 | 经营活动现 | 综合收益总 | 经营活动现\n| 营业收入 | 净利润 | 营业收入 | 净利润  |\n| 额 | 金流量 | 额 | 金流量\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e7fc2e51",
        "f5e40715"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 158,
      "page_number": 181,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "利润",
          "收入",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.194720",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 158,
        "word_count": 33,
        "sentence_count": 0,
        "chinese_char_count": 57,
        "readability_score": 0.0,
        "information_density": 0.6962025316455696,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4749201149425287,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "利润",
        "经营"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "利润",
        "收入",
        "净利润"
      ]
    },
    {
      "chunk_id": "1101ee7d",
      "content": "| 期末余额/本期发生额 | 期初余额/上期发生额\n--------------------------------------------------\n| 苏州第四制药厂有限公司 | 苏州第四制药厂有限公司\n流动资产 | 29,519,105.76 | 25,072,727.50\n非流动资产 | 84,757,893.18 | 93,352,602.90\n资产合计 | 114,276,998.94 | 118,425,330.40\n流动负债 | 36,442,141.82 | 25,462,418.24\n非流动负债 | 21,400,000.00 | 22,000,000.00\n负债合计 | 57,842,141.82 | 47,462,418.24\n归属于母公司股东权益 | 56,434,857.12 | 71,167,909.30\n按持股比例计算的净资产份额 | 18,431,624.34 | 23,243,439.18\n--其他 | -297,151.93 | -297,151.93\n对联营企业权益投资的账面价值 | 18,134,472.41 | 22,946,287.25\n营业收入 | 57,010,459.03 | 39,434,028.51\n净利润 | -14,733,052.18 | -10,672,428.70\n综合收益总额 | -14,733,052.18 | -10,672,428.70",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "062f6755",
        "ab714458",
        "a6ff97aa",
        "c41a1d06",
        "e9596674",
        "427af33f",
        "b0eb8b3b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 615,
      "page_number": 182,
      "bbox": [
        97.5,
        80.0,
        497.5,
        420.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x3",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "营业收入",
          "收入",
          "负债",
          "综合收益总额",
          "资产",
          "利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.194805",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 615,
        "word_count": 74,
        "sentence_count": 26,
        "chinese_char_count": 118,
        "readability_score": 0.0,
        "information_density": 0.3252032520325203,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5536871961102108,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "投资"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业收入"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "综合收益总额"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业收入",
        "收入",
        "负债",
        "综合收益总额",
        "资产",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "9ae69cb2",
      "content": "十六、其他重要事项\n1、前期会计差错更正\n（1）追溯重述法\n单位： 元\n受影响的各个比较期间报表\n会计差错更正的内容 处理程序 累积影响数\n项目名称\n（2）未来适用法\n会计差错更正的内容 批准程序 采用未来适用法的原因\n2、债务重组\n3、资产置换\n（1）非货币性资产交换\n（2）其他资产置换\n4、年金计划\n5、终止经营\n单位： 元\n归属于母公司所\n项目 收入 费用 利润总额 所得税费用 净利润 有者的终止经营\n利润\n其他说明\n6、分部信息\n（1）报告分部的确定依据与会计政策\n公司以内部组织结构、管理要求、内部报告制度等为依据确定报告分部，并以行业分部为基础确定报\n告分部。分别对医药业务、染料业务的经营业绩进行考核。与各分部共同使用的资产、负债按照规模比例\n在不同的分部之间分配。\n（2）报告分部的财务信息\n单位： 元\n193\n|  | 对财务状况和经营成果的影 |\n--------------------------------------------------\n项目 | 内容 |  | 无法估计影响数的原因\n|  | 响数 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fb9ab767"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 472,
      "page_number": 192,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "30x3",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.195100",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 472,
        "word_count": 57,
        "sentence_count": 3,
        "chinese_char_count": 308,
        "readability_score": 0.0,
        "information_density": 0.1483050847457627,
        "coherence_score": 0.67,
        "standards_profile_summary": {}
      },
      "quality_score": 0.539764805600337,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "利润",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "balance_sheet"
      ],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f17a2761",
      "content": "项目 医药行业 染料行业 分部间抵销 合计\n主营业务收入 1,604,117,711.02 1,546,764,954.54 225,193,759.42 2,925,688,906.14\n主营业务成本 6,064,447,216.11 657,131,007.06 211,204,035.55 6,747,198,664.47\n资产总额 1,003,573,077.78 2,269,859,610.07 1,587,108,161.71 1,449,500,049.29\n负债总额 798,878,476.78 525,463,301.92 301,605,209.78 1,022,736,568.72\n（3）公司无报告分部的，或者不能披露各报告分部的资产总额和负债总额的，应说明原因\n（4）其他说明\n7、其他对投资者决策有影响的重要交易和事项\n根据江苏省盐城市委市政府于2019年6月14日发布的《盐城市化工产业安全环保整治提升实施方案》(盐\n办〔2019〕71号)(以下简称《方案》)，要求对盐城市化工园区内所有化工生产企业进行安全环保整治提升。盐城瓯华公司配合有关部门已按照《方案》要求进行停产并做好安全环保排查评估，同时根据评估结果制\n定并实施了“一企一策”整治方案。截至本财务报表批准报出日，盐城瓯华公司为达到恢复生产的标准仍在\n对环保及安全设施进行改造，相关闲置固定资产账面价值为6,057.05万元，已计提减值准备49.95万元。\n| 归属于母公司所\n--------------------------------------------------\n项目 | 收入 | 费用 | 利润总额 | 所得税费用 | 净利润 | 有者的终止经营\n| 利润",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5c608dba",
        "9ca8f631",
        "83bd0fb6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 736,
      "page_number": 193,
      "bbox": [
        47.5,
        80.0,
        547.5,
        420.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "14x7",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "所得税",
          "所得税费用",
          "利润",
          "利润总额",
          "净利润"
        ],
        "time_periods": [
          "2019-6"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          193
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.195220",
        "report_type": "财务报表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 736,
        "word_count": 50,
        "sentence_count": 21,
        "chinese_char_count": 327,
        "readability_score": 0.0,
        "information_density": 0.29891304347826086,
        "coherence_score": 0.5995169082125604,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5698368794326242,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表",
        "057.05万元"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "所得税费用"
        },
        {
          "type": "accounting_item",
          "value": "利润"
        },
        {
          "type": "accounting_item",
          "value": "利润总额"
        },
        {
          "type": "accounting_item",
          "value": "净利润"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "所得税",
        "所得税费用",
        "利润",
        "利润总额",
        "净利润"
      ]
    },
    {
      "chunk_id": "59a01941",
      "content": "8、其他\n十七、母公司财务报表主要项目注释\n1、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按组合计提坏账准 130,720, 7,187,81 123,532,2157,389,6 8,184,787 149,204,89\n100.00% 5.50% 100.00% 5.20%\n备的应收账款 059.44 5.25 44.19 87.72 .74 9.98\n其中：\n130,720, 7,187,81 123,532,2157,389,6 8,184,787 149,204,89\n合计 100.00% 5.50% 100.00% 5.20%\n059.44 5.25 44.19 87.72 .74 9.98\n按单项计提坏账准备：\n单位： 元\n项目 | 医药行业 | 染料行业 | 分部间抵销 | 合计\n--------------------------------------------------\n主营业务收入 | 1,604,117,711.02 | 1,546,764,954.54 | 225,193,759.42 | 2,925,688,906.14\n主营业务成本 | 6,064,447,216.11 | 657,131,007.06 | 211,204,035.55 | 6,747,198,664.47\n资产总额 | 1,003,573,077.78 | 2,269,859,610.07 | 1,587,108,161.71 | 1,449,500,049.29\n负债总额 | 798,878,476.78 | 525,463,301.92 | 301,605,209.78 | 1,022,736,568.72",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a03350b4",
        "ac4533d6",
        "6b9e1608",
        "e7187c14",
        "7344d42d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 797,
      "page_number": 194,
      "bbox": [
        47.5,
        80.0,
        547.5,
        660.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "26x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "主营业务收入",
          "负债",
          "主营业务成本",
          "成本",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.195441",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 797,
        "word_count": 108,
        "sentence_count": 36,
        "chinese_char_count": 155,
        "readability_score": 0.0,
        "information_density": 0.22584692597239647,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5997632996632997,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "财务",
        "报表"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "主营业务收入"
        },
        {
          "type": "accounting_item",
          "value": "负债"
        },
        {
          "type": "accounting_item",
          "value": "主营业务成本"
        },
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "主营业务收入",
        "负债",
        "主营业务成本",
        "成本",
        "资产"
      ]
    },
    {
      "chunk_id": "0ec4b075",
      "content": "| 本期发生额 |  | 上期发生额 |\n--------------------------------------------------\n项目 | \n| 收入 | 成本 | 收入 | 成本\n| \n主营业务 | 797,912,055.33 | 574,154,902.09 | 805,112,431.82 | 606,077,442.30\n其他业务 | 14,347,583.53 | 12,941,502.94 | 19,986,172.05 | 13,769,464.63\n合计 | 812,259,638.86 | 587,096,405.03 | 825,098,603.87 | 619,846,906.93",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4d0b6259",
        "71e222aa"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 313,
      "page_number": 201,
      "bbox": [
        47.5,
        80.0,
        547.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x5",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.195720",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 313,
        "word_count": 45,
        "sentence_count": 12,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.19169329073482427,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47209950248756216,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "成本"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "收入"
      ]
    },
    {
      "chunk_id": "be6ff6d4",
      "content": "项目 | 金额 | 说明\n--------------------------------------------------\n非流动资产处置损益 | -4,150,774.97 |\n越权审批或无正式批准文件的税收返还、  |\n| 1,828,299.60 |\n减免  |\n |\n计入当期损益的政府补助（与企业业务密  |\n切相关，按照国家统一标准定额或定量享 | 25,308,625.27 |\n受的政府补助除外）  |\n委托他人投资或管理资产的损益 | 2,079,074.70 |\n除上述各项之外的其他营业外收入和支出 | -1,973,019.24 |\n减：所得税影响额 | 3,519,880.50 |\n合计 | 19,572,324.86 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5393cac1",
        "1a5b3dc8",
        "86e633ff",
        "76de9d35"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 330,
      "page_number": 202,
      "bbox": [
        97.5,
        80.0,
        497.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "12x3",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 12,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "营业外收入",
          "所得税",
          "收入",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.195858",
        "report_type": "财务报表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 330,
        "word_count": 43,
        "sentence_count": 7,
        "chinese_char_count": 117,
        "readability_score": 0.0,
        "information_density": 0.33333333333333337,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5869833805476865,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "投资"
      ],
      "entities": [
        {
          "type": "accounting_item",
          "value": "营业外收入"
        },
        {
          "type": "accounting_item",
          "value": "所得税"
        },
        {
          "type": "accounting_item",
          "value": "收入"
        },
        {
          "type": "accounting_item",
          "value": "资产"
        }
      ],
      "topics": [
        "income_statement"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业外收入",
        "所得税",
        "收入",
        "资产"
      ]
    },
    {
      "chunk_id": "23b40e2e",
      "content": "释义\n释义项 指 释义内容\n中国证监会、证监会 指 中国证券监督管理委员会\n深交所、交易所 指 深圳证券交易所\n本公司、公司、海翔药业 指 浙江海翔药业股份有限公司\n川南公司、川南药业 指 浙江海翔川南药业有限公司，公司全资子公司\n销售公司 指 浙江海翔药业销售有限公司，公司全资子公司\n上海海翔 指 上海海翔医药科技发展有限公司，公司全资子公司\n台州前进、前进公司 指 台州市前进化工有限公司，公司全资子公司\n盐城瓯华、瓯华化工 指 盐城市瓯华化学工业有限公司，公司合并报表范围内子公司\n振港染料 指 台州市振港染料化工有限公司，公司合并报表范围内子公司\n盛嘉环保 指 浙江盛嘉环保科技有限公司，公司合并报表范围内子公司\n苏州四药 指 苏州第四制药厂有限公司，公司参股公司\n高盛钢结构 指 浙江高盛钢结构有限公司，公司参股公司\n北华环保 指 江苏北华环保科技有限公司，盐城瓯华参股公司\n东港投资 指 浙江东港投资有限公司，公司控股股东\n报告期 指 2019年1-12月的会计区间\n《公司章程》 指 浙江海翔药业股份有限公司章程\nActive Pharmaceutical Ingredients(API)，即药物活性成分，具有药理活\n原料药、API 指\n性可用于药品生产的化学物质\nGMP 指 Good Manufacturing Practice，药品生产质量管理规范\n药品监督管理部门对药品研制、生产、经营、使用单位合乎相应质量\n药品认证 指\n管理规范的情况进行检查、评价并决定是否发给相应认证证书的过程\n药品监督管理部门依照法定程序，对拟上市销售药品的安全性、有效\n性、质量可控性等进行系统评价，并作出是否同意进行药物临床研究、\n药品注册 指\n生产药品或者进口药品的审批过程，包括对申请变更药品批准证明文\n件及其附件中载明内容的审批\nFDA 指 U.S.Food and Drug Administration，美国食品和药品监督管理局\nBI 指 德国勃林格殷格翰公司\nThe European Directorate for the Quality of Medicines & HealthCare，欧\nEDQM 指\n洲药品质量管理局\nUSP 指 U.S. Pharmacopeia，美国药典\n释义项 | 指 | 释义内容\n--------------------------------------------------\n中国证监会、证监会 | 指 | 中国证券监督管理委员会\n深交所、交易所 | 指 | 深圳证券交易所\n本公司、公司、海翔药业 | 指 | 浙江海翔药业股份有限公司\n川南公司、川南药业 | 指 | 浙江海翔川南药业有限公司，公司全资子公司\n销售公司 | 指 | 浙江海翔药业销售有限公司，公司全资子公司\n上海海翔 | 指 | 上海海翔医药科技发展有限公司，公司全资子公司\n台州前进、前进公司 | 指 | 台州市前进化工有限公司，公司全资子公司\n盐城瓯华、瓯华化工 | 指 | 盐城市瓯华化学工业有限公司，公司合并报表范围内子公司\n振港染料 | 指 | 台州市振港染料化工有限公司，公司合并报表范围内子公司\n盛嘉环保 | 指 | 浙江盛嘉环保科技有限公司，公司合并报表范围内子公司\n苏州四药 | 指 | 苏州第四制药厂有限公司，公司参股公司\n高盛钢结构 | 指 | 浙江高盛钢结构有限公司，公司参股公司\n北华环保 | 指 | 江苏北华环保科技有限公司，盐城瓯华参股公司\n东港投资 | 指 | 浙江东港投资有限公司，公司控股股东\n报告期 | 指 | 2019年1-12月的会计区间\n《公司章程》 | 指 | 浙江海翔药业股份有限公司章程\n|  | Active Pharmaceutical Ingredients(API)，即药物活性成分，具有药理活\n原料药、API | 指 |\n|  | 性可用于药品生产的化学物质\n |\nGMP | 指 | Good Manufacturing Practice，药品生产质量管理规范\n|  | 药品监督管理部门对药品研制、生产、经营、使用单位合乎相应质量\n药品认证 | 指 |\n|  | 管理规范的情况进行检查、评价并决定是否发给相应认证证书的过程\n |\n|  | 药品监督管理部门依照法定程序，对拟上市销售药品的安全性、有效\n|  | 性、质量可控性等进行系统评价，并作出是否同意进行药物临床研究、\n药品注册 | 指 |\n|  | 生产药品或者进口药品的审批过程，包括对申请变更药品批准证明文\n |\n|  | 件及其附件中载明内容的审批\nFDA | 指 | U.S.Food and Drug Administration，美国食品和药品监督管理局\nBI | 指 | 德国勃林格殷格翰公司\n|  | The European Directorate for the Quality of Medicines & HealthCare，欧\nEDQM | 指 |\n|  | 洲药品质量管理局\n |\nUSP | 指 | U.S. Pharmacopeia，美国药典",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c7b90b54"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2115,
      "page_number": 4,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "71x3",
        "has_header": false,
        "table_type": "financial_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 71,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          4
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.198799",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 2115,
        "word_count": 272,
        "sentence_count": 8,
        "chinese_char_count": 1254,
        "readability_score": 0.0,
        "information_density": 0.014184397163120569,
        "coherence_score": 0.5063833600244033,
        "standards_profile_summary": {}
      },
      "quality_score": 0.803427874628953,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "eef800c4",
      "content": "第二节公司简介和主要财务指标\n一、公司信息\n股票简称 海翔药业 股票代码 002099\n股票上市证券交易所 深圳证券交易所\n公司的中文名称 浙江海翔药业股份有限公司\n公司的中文简称 海翔药业\n公司的外文名称（如有） ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD.\n公司的外文名称缩写（如有） HISOAR\n公司的法定代表人 杨思卫\n注册地址 浙江省台州市椒江区外沙支路100号\n注册地址的邮政编码 318000\n办公地址 浙江省台州市椒江区外沙支路100号\n办公地址的邮政编码 318000\n公司网址 http://www.hisoar.com\n电子信箱 stock@hisoar.com\n二、联系人和联系方式\n董事会秘书 证券事务代表\n姓名 许华青 蒋如东\n联系地址 浙江省台州市椒江区外沙支路100号 浙江省台州市椒江区外沙支路100号\n电话 0576-89088166 0576-89088166\n传真 0576-89088128 0576-89088128\n电子信箱 stock@hisoar.com stock@hisoar.com\n三、信息披露及备置地点\n公司选定的信息披露媒体的名称 《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n登载年度报告的中国证监会指定网站的网址 http://www.cninfo.com.cn\n公司年度报告备置地点 公司投资发展部\n辉瑞、辉瑞公司 | 指 | Pfizer Inc.是目前全球顶尖的以研发为基础的生物制药公司\n--------------------------------------------------\n|  | Eco-passport，由TESTEX瑞士纺织检定有限公司于1993年创立的针\nECO认证 | 指 |\n|  | 对纺织品染料、助剂化学品等产品开展的生态环保认证。\n |\n|  | 天祥认证，天祥集团是世界上规模最大的消费品测试、检验和认证公\nIntertek认证 | 指 |\n|  | 司之一\n |\nEHS | 指 | Environment-Health-Safety，环境、健康、安全生产体系\n|  | 一种染料类型，染色时与纤维反应，二者之间形成共价键，成为整体，\n|  | 使耐洗和耐摩擦牢度高。用于棉等纤维素纤维、蛋白质纤维、锦纶、\n活性染料 | 指 |\n|  | 粘胶等合成纤维的染色，色泽鲜艳，色谱齐全，匀染性好，湿处理牢\n |\n|  | 度优良\n|  | 一种水溶性较低的非离子型染料，在染色过程中呈分散状态进行染\n分散染料 | 指 | 色，主要用于涤纶及其混纺织物的印染，也可用于醋酸纤维、锦纶、\n|  | 丙纶、氯纶、腈纶等合成纤维的印染\n|  | 分子式为C22H16N2Na2O11S3，一种常温型蒽醌系列活性染料，拥有\nKN-R，活性艳蓝KN-R | 指 | 鲜艳色光、优良匀染性、高亲和力、高日晒牢度等优点，主要用于对\n|  | 棉、麻、毛、丝的染色，是国家产业政策鼓励发展的一类染料\n氨基油 | 指 | 间-(β-羟乙基砜)苯胺，用于合成乙烯基砜染料，染料的关键中间体\n溴氨酸 | 指 | 一种红色针状结晶，重要的染料中间体，用于蒽醌型染料\n|  | 深蓝色粉末，易溶于水。该染料用于棉和黏胶纤维的染色，及其织物\nP-3R | 指 |\n|  | 的印花，各项染色坚牢度优良，是重要的蓝色染料。\n |\n|  | 一种高温型活性染料，色泽鲜艳，光牢度优异，因具有极好的耐盐碱\nKE-GN | 指 |\n|  | 性能，广泛应用于连续染色、蜡染等\n |\n|  | 一种中温型活性染料，色泽鲜艳，具有极好的耐盐碱性能，广泛应用\nDK-ER | 指 |\n|  | 于浸染和连续染色的冷轧堆工艺\n |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ad8a07e1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1572,
      "page_number": 5,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "56x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 56,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          5
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.199262",
        "report_type": "financial_report",
        "fiscal_year": 1993,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1572,
        "word_count": 174,
        "sentence_count": 15,
        "chinese_char_count": 853,
        "readability_score": 0.0,
        "information_density": 0.01272264631043257,
        "coherence_score": 0.6692324202531892,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6696604671448709,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8d0a05c3",
      "content": "股票简称 | 海翔药业 | 股票代码 | 002099\n--------------------------------------------------\n股票上市证券交易所 | 深圳证券交易所  |\n公司的中文名称 | 浙江海翔药业股份有限公司  |\n公司的中文简称 | 海翔药业  |\n公司的外文名称（如有） | ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD.  |\n公司的外文名称缩写（如有） | HISOAR  |\n公司的法定代表人 | 杨思卫  |\n注册地址 | 浙江省台州市椒江区外沙支路100号  |\n注册地址的邮政编码 | 318000  |\n办公地址 | 浙江省台州市椒江区外沙支路100号  |\n办公地址的邮政编码 | 318000  |\n公司网址 | http://www.hisoar.com  |\n电子信箱 | stock@hisoar.com  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f6d5642b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 405,
      "page_number": 6,
      "bbox": [
        65.5,
        80.0,
        529.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "13x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 13,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          6
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.199725",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 405,
        "word_count": 59,
        "sentence_count": 5,
        "chinese_char_count": 151,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.8361538461538462,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5395605442176871,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6a80a320",
      "content": "| 董事会秘书 | 证券事务代表\n--------------------------------------------------\n姓名 | 许华青 | 蒋如东\n联系地址 | 浙江省台州市椒江区外沙支路100号 | 浙江省台州市椒江区外沙支路100号\n电话 | 0576-89088166 | 0576-89088166\n传真 | 0576-89088128 | 0576-89088128\n电子信箱 | stock@hisoar.com | stock@hisoar.com",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a5d961f9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 240,
      "page_number": 6,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          6
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.199887",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 240,
        "word_count": 30,
        "sentence_count": 2,
        "chinese_char_count": 59,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4099219917012448,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "120612aa",
      "content": "四、注册变更情况\n组织机构代码 913300001482332737\n公司上市以来主营业务的变化情况（如\n无变更\n有）\n2010年9月，原控股股东罗邦鹏先生向其子罗煜竑先生转让其所持有的3,480万\n股（占总股本的21.68%）股份，使其成为公司控股股东。2014年4月，原控股股\n历次控股股东的变更情况（如有）\n东罗煜竑先生向王云富先生转让其所持有的5,940万股（占总股本的18.31%）股\n份，使其成为公司控股股东。五、其他有关资料\n公司聘请的会计师事务所\n会计师事务所名称 天健会计师事务所（特殊普通合伙）\n会计师事务所办公地址 浙江省杭州市江干区钱江路1366 号华润大厦B座\n签字会计师姓名 沈维华 汪兢\n公司聘请的报告期内履行持续督导职责的保荐机构\n□ 适用 √ 不适用\n公司聘请的报告期内履行持续督导职责的财务顾问\n□ 适用 √ 不适用\n六、主要会计数据和财务指标\n公司是否需追溯调整或重述以前年度会计数据\n□ 是 √ 否\n2019年 2018年 本年比上年增减 2017年\n营业收入（元） 2,941,412,770.30 2,718,608,796.51 8.20% 2,308,922,170.29\n归属于上市公司股东的净利润\n770,782,185.09 605,003,820.78 27.40% 342,217,155.60\n（元）\n归属于上市公司股东的扣除非经\n751,209,860.23 604,944,470.09 24.18% 301,310,316.13\n常性损益的净利润（元）\n经营活动产生的现金流量净额\n612,399,095.31 791,449,237.66 -22.62% 118,141,514.53\n（元）\n基本每股收益（元/股） 0.48 0.38 26.32% 0.22\n稀释每股收益（元/股） 0.48 0.38 26.32% 0.21\n加权平均净资产收益率 14.07% 11.35% 2.72% 6.90%\n2019年末 2018年末 本年末比上年末增减 2017年末\n总资产（元） 6,747,198,664.47 7,035,373,344.57 -4.10% 7,466,927,438.54\n公司选定的信息披露媒体的名称 | 《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n\n--------------------------------------------------\n登载年度报告的中国证监会指定网站的网址 | http://www.cninfo.com.cn\n公司年度报告备置地点 | 公司投资发展部",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "adf35dfb"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1098,
      "page_number": 6,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "40x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2010-9",
          "2014-4"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          6
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.199986",
        "report_type": "financial_report",
        "fiscal_year": 2010,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1098,
        "word_count": 97,
        "sentence_count": 39,
        "chinese_char_count": 483,
        "readability_score": 0.0,
        "information_density": 0.06375227686703097,
        "coherence_score": 0.7933333333333332,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6069998102106663,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "3de1bf48",
      "content": "组织机构代码 | 913300001482332737\n| 股（占总股本的21.68%）股份，使其成为公司控股股东。2014年4月，原控股股\n| 份，使其成为公司控股股东。\n\n--------------------------------------------------\n公司上市以来主营业务的变化情况（如 |\n| 无变更\n有） |\n|\n| 2010年9月，原控股股东罗邦鹏先生向其子罗煜竑先生转让其所持有的3,480万\n历次控股股东的变更情况（如有） |\n| 东罗煜竑先生向王云富先生转让其所持有的5,940万股（占总股本的18.31%）股\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d6a3fe5e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 276,
      "page_number": 7,
      "bbox": [
        97.5,
        80.0,
        497.5,
        340.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "9x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "股本"
        ],
        "time_periods": [
          "2010-9",
          "2014-4"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200352",
        "report_type": "financial_report",
        "fiscal_year": 2010,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 276,
        "word_count": 22,
        "sentence_count": 4,
        "chinese_char_count": 129,
        "readability_score": 0.0,
        "information_density": 0.03623188405797102,
        "coherence_score": 0.9179999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5581549361207897,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股本"
      ]
    },
    {
      "chunk_id": "e19d656c",
      "content": "会计师事务所名称 | 天健会计师事务所（特殊普通合伙）\n\n--------------------------------------------------\n会计师事务所办公地址 | 浙江省杭州市江干区钱江路1366 号华润大厦B座\n签字会计师姓名 | 沈维华 汪兢",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "64c35536"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 134,
      "page_number": 7,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200483",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 134,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 62,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5298581453634085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b66c6c60",
      "content": "归属于上市公司股东的净资产 | \n--------------------------------------------------\n| 5,724,462,095.55 | 5,390,549,932.23 | 6.19% | 5,142,008,176.75\n（元） | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "eaf1984a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 141,
      "page_number": 8,
      "bbox": [
        47.5,
        80.0,
        547.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200554",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 141,
        "word_count": 14,
        "sentence_count": 4,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.14184397163120568,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5131473684210526,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "73ae1737",
      "content": "项目 | 2019年金额 | 2018年金额 | 2017年金额 | 说明\n--------------------------------------------------\n非流动资产处置损益（包括已计提资产减 | -4,150,774.97 | \n|  | -102,273.45 | 23,519,733.42 |\n值准备的冲销部分） | \n| \n越权审批或无正式批准文件的税收返还、 | 1,828,299.60 | \n|  | 1,237,210.17 | 760,878.00 |\n减免 | \n| \n计入当期损益的政府补助（与企业业务密 | 25,308,625.27 | \n切相关，按照国家统一标准定额或定量享 |  | 10,554,527.86 | 8,815,813.87 |\n受的政府补助除外） | \n委托他人投资或管理资产的损益 | 2,079,074.70 | 3,024,312.63 | 11,532,098.63 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "69fb08ea"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 425,
      "page_number": 8,
      "bbox": [
        49.5,
        80.0,
        545.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "11x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200620",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 425,
        "word_count": 57,
        "sentence_count": 12,
        "chinese_char_count": 113,
        "readability_score": 0.0,
        "information_density": 0.07058823529411765,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5667067204301075,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "d63f4959",
      "content": "多重耐药菌感染、产酶菌感染。 | 原料药、中间体\n菌联合感染和需氧菌及厌氧菌的混合感染。 | 中间体\n\n应用领域 | 产品名 | 适用症 | 类别\n--------------------------------------------------\n抗感染 | 美罗培南系列（4-AA、MAP、\n美罗培南粗品、美罗培南侧\n链） | 用于重症感染以及以G-菌为主的混合性感染、\n| 替比培南酯 | 全球首个口服碳青霉烯类新广谱抗生素，主要用\n于治疗儿童肺炎、中耳炎、鼻窦炎等 | 原料药\n| 亚胺培南的关键中间体\nKETO | 用于敏感菌所致的各种感染，特别适用于多种细\n| 西司他汀酸中间体 | 西司他汀酸与亚安培南共同使用 | 中间体\n| 盐酸克林霉素胶囊、盐酸克\n林霉素 | 用于由链球菌属、葡萄球菌属及厌氧菌等敏感菌\n株所致的下述感染：中耳炎、鼻窦炎、化脓性扁\n桃体炎、肺炎；皮肤软组织感染 | 制剂、原料药\n| 克林霉素磷酸酯 | 用于敏感细菌引起的各种感染、败血症、骨髓炎\n等 | 原料药\n| 盐酸克林霉素棕榈酸酯 | 用于革兰阳性菌引起的各种感染性疾病以及厌\n氧菌引起的各种感染性疾病 | 原料药\n| 盐酸阿莫罗芬 | 用于真菌引起的指（趾）甲感染 | 原料药\n| 联苯双酯 | 用于治疗病毒性肝炎和药物性肝损伤引起转氨\n酶升高 | 原料药\n降糖类 | 伏格列波糖 | 改善糖尿病餐后高血糖 | 原料药\n| 瑞格列奈 | 用于饮食控制、降低体重与运动不能有效控制高\n血糖的2型糖尿病 | 原料药\n| 阿卡波糖片 | 用于胰岛素依赖型或非胰岛素依赖型的糖尿病 | 制剂\n心血管类 | 达比加群酯的关键中间体\nOA、MD | 新一代口服抗凝药物直接凝血酶抑制剂(DTIs)，\n用于预防非瓣膜性房颤患者的卒中和全身性栓 | 中间体",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8a33bf30"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 768,
      "page_number": 10,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "29x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 29,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          10
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200772",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 768,
        "word_count": 104,
        "sentence_count": 2,
        "chinese_char_count": 519,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.28016949152542375,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6001930501930502,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "c23f5de2",
      "content": "鸡肠道感染及支原体引起的慢性呼吸道病。 | 原料药\n系统、肝胆系统、泌尿系统和消化系统的感染。 | 原料药\n\n|  | 塞 |\n--------------------------------------------------\n| 琥珀酸美托洛尔 | 用于高血压、心绞痛的治疗 | 原料药\n兽药 | 氟苯尼考 | 用于鸡大肠杆菌病及鸭浆膜炎及鱼的杀鲑产生\n单胞菌、鳗弧菌等，用于敏感细菌所致牛、猪、\n| 氟尼辛葡甲胺 | 用于缓解马的内脏绞痛、肌肉与骨骼紊乱引起的\n疼痛及抗炎；牛的各种疾病感染引起的急性炎症\n的控制；另外也可用于母猪乳房炎、子宫炎及无\n乳综合征的辅助治疗 | 原料药\n| 甲砜霉素 | 用于流感杆菌、大肠杆菌、沙门菌属所致的呼吸\n精神类 | 富马酸喹硫平 | 用于治疗精神分裂症 | 原料药",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "afd729e5"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 355,
      "page_number": 11,
      "bbox": [
        97.5,
        80.0,
        497.5,
        360.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "12x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 12,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201047",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 355,
        "word_count": 43,
        "sentence_count": 2,
        "chinese_char_count": 228,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.6813207547169812,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5670646239554318,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8fb6ba79",
      "content": "高的日晒牢度和优良的匀染性，适用于连续染色、冷轧堆等印染工艺。\n型染料、蒽醌型染料。\n\n主要类别 |  | 主要产品及用途\n--------------------------------------------------\n染料 |  | 主要生产蓝色系列产品，包括活性艳蓝KN-R（HG）、KN-R（SR）、\nKN-R（SP），P-3R, KE-GN、KN-BB、ME-BP，活性翠蓝KN-G以及\n酸性蒽醌蓝等，主要用于棉、麻、丝等天然纤维织物的染色，具有较\n染颜料中间体 | 染料中间体 | 主要生产氨基油、溴氨酸、间位酯等染料中间体，用于合成乙烯基砜\n| 颜料中间体 | 主要生产DCB等颜料中间体，主要用于颜料黄12，13，14，17，35，\n55，颜料橙13，颜料红38等中高档双芳胺类偶氮颜料",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6df6da27"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 353,
      "page_number": 11,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "9x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201187",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 353,
        "word_count": 24,
        "sentence_count": 2,
        "chinese_char_count": 175,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5449626062322946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "d69b547b",
      "content": "### 二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。\n\n|\n固定资产 | 主要系川南、前进、振港在建工程转固所致。\n\n--------------------------------------------------\n主要资产 | 重大变化说明\n|\n股权资产 | 无重大变化\n无形资产 | 无重大变化\n在建工程 | 无重大变化",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "473b1f0f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 241,
      "page_number": 12,
      "bbox": [
        97.5,
        80.0,
        497.5,
        400.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "11x2",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "无形资产",
          "在建工程",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          12
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201330",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 241,
        "word_count": 31,
        "sentence_count": 3,
        "chinese_char_count": 137,
        "readability_score": 0.0,
        "information_density": 0.20746887966804978,
        "coherence_score": 0.32857142857142857,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6128553826030085,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "无形资产",
        "在建工程",
        "资产"
      ]
    },
    {
      "chunk_id": "5aa8bf83",
      "content": "染料 973,070,914.24 33.08% 844,776,715.53 31.07% 15.19%\n染料中间体 343,759,248.43 11.69% 405,163,859.03 14.90% -15.16%\n其他 15,723,864.16 0.53% 27,076,798.44 1.00% -41.93%\n分地区\n国内 1,512,860,024.18 51.43% 1,390,967,219.07 51.16% 8.76%\n国外 1,428,552,746.12 48.57% 1,327,641,577.44 48.84% 7.60%\n（2）占公司营业收入或营业利润10%以上的行业、产品或地区情况\n√ 适用 □ 不适用\n单位：元\n营业收入比上年 营业成本比上年 毛利率比上年同\n营业收入 营业成本 毛利率\n同期增减 同期增减 期增减\n分行业\n医药 1,608,858,743.47 983,149,430.95 38.89% 11.60% 1.30% 6.23%\n染料 1,316,830,162.67 465,697,259.49 64.63% 5.40% -10.70% 6.34%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分产品\n原料药 1,020,477,644.34 652,198,278.33 36.09% -1.20% -6.10% 3.30%\n医药中间体 583,792,425.63 328,224,382.60 43.78% 44.00% 20.30% 11.06%\n制剂 4,588,673.50 2,726,770.03 40.58% 67.20% -20.50% 65.65%\n染料 973,070,914.24 312,738,811.13 67.86% 15.20% -1.80% 5.56%\n染料中间体 343,759,248.43 152,958,448.36 55.50% -15.20% -24.60% 5.56%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分地区\n国内 1,512,860,024.18 745,641,007.79 50.71% 8.80% -8.00% 8.96%\n国外 1,428,552,746.12 717,518,353.25 49.77% 7.60% 2.20% 2.63%\n公司主营业务数据统计口径在报告期发生调整的情况下，公司最近1年按报告期末口径调整后的主营业务数据\n□ 适用 √ 不适用\n（3）公司实物销售收入是否大于劳务收入\n√ 是 □ 否\n行业分类 项目 单位 2019年 2018年 同比增减\n医药行业 销售量 千克 1,495,834.8 1,352,154.98 10.63%\n染料 | 973,070,914.24 | 33.08% | 844,776,715.53 | 31.07% | 15.19%\n--------------------------------------------------\n染料中间体 | 343,759,248.43 | 11.69% | 405,163,859.03 | 14.90% | -15.16%\n其他 | 15,723,864.16 | 0.53% | 27,076,798.44 | 1.00% | -41.93%\n分地区 | \n国内 | 1,512,860,024.18 | 51.43% | 1,390,967,219.07 | 51.16% | 8.76%\n国外 | 1,428,552,746.12 | 48.57% | 1,327,641,577.44 | 48.84% | 7.60%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ec6e87ae"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1613,
      "page_number": 16,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "38x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 38,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          16
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201425",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1613,
        "word_count": 206,
        "sentence_count": 119,
        "chinese_char_count": 237,
        "readability_score": 0.0,
        "information_density": 0.018598884066955985,
        "coherence_score": 0.310325,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5067255742134723,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f625037a",
      "content": "生产量 千克 1,578,601.92 1,380,545.9 14.35%\n库存量 千克 415,819.13 333,052.01 24.85%\n销售量 吨 12,857.65 13,393.7 -4.00%\n染料行业 生产量 吨 12,911.47 13,832.98 -6.66%\n库存量 吨 1,868.83 1,815.01 2.97%\n相关数据同比发生变动30%以上的原因说明\n□ 适用 √ 不适用\n（4）公司已签订的重大销售合同截至本报告期的履行情况\n□ 适用 √ 不适用\n（5）营业成本构成\n行业和产品分类\n单位：元\n2019年 2018年\n行业分类 项目 同比增减\n金额 占营业成本比重 金额 占营业成本比重\n医药行业 原料成本 788,091,701.93 80.16% 778,035,997.89 80.14% 0.02%\n医药行业 人工成本 53,109,659.74 5.40% 53,601,426.45 5.52% -0.12%\n医药行业 能源成本 47,606,219.00 4.84% 45,369,217.29 4.67% 0.17%\n医药行业 制造费用 94,341,850.29 9.60% 93,792,389.85 9.66% -0.07%\n染料行业 原料成本 337,976,777.23 72.57% 383,594,259.37 73.59% -1.01%\n染料行业 人工成本 33,802,565.03 7.26% 28,163,412.97 5.40% 1.86%\n染料行业 能源成本 34,241,371.69 7.35% 37,944,159.74 7.28% 0.07%\n染料行业 制造费用 59,676,545.54 12.81% 71,581,678.92 13.73% -0.92%\n其他业务 14,312,670.59 100.00% 19,862,133.71 100.00% 0.00%\n单位：元\n2019年 2018年\n产品分类 项目 同比增减\n金额 占营业成本比重 金额 占营业成本比重\n原料药 652,198,278.33 44.57% 694,525,290.09 45.94%\n医药中间体 328,224,382.60 22.43% 272,841,947.14 18.05%\n制剂 2,726,770.03 0.19% 3,431,794.24 0.23%\n染料 312,738,811.13 21.37% 318,486,635.33 21.06%\n染料中间体 152,958,448.36 10.45% 202,796,875.67 13.41%\n其他 14,312,670.59 0.98% 19,862,133.71 1.31%\n说明\n行业分类 | 项目 | 单位 | 2019年 | 2018年 | 同比增减\n--------------------------------------------------\n医药行业 | 销售量 | 千克 | 1,495,834.8 | 1,352,154.98 | 10.63%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f2b96b94"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1308,
      "page_number": 16,
      "bbox": [
        57.5,
        80.0,
        537.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "37x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          16
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.202002",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1308,
        "word_count": 174,
        "sentence_count": 87,
        "chinese_char_count": 267,
        "readability_score": 0.0,
        "information_density": 0.00764525993883792,
        "coherence_score": 0.31459090909090903,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44925626640536154,
      "relevance_score": 1.0,
      "keywords": [
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b7065e21",
      "content": "| 生产量 | 千克 | 1,578,601.92 | 1,380,545.9 | 14.35%\n--------------------------------------------------\n| 库存量 | 千克 | 415,819.13 | 333,052.01 | 24.85%\n| 销售量 | 吨 | 12,857.65 | 13,393.7 | -4.00%\n染料行业 | 生产量 | 吨 | 12,911.47 | 13,832.98 | -6.66%\n| 库存量 | 吨 | 1,868.83 | 1,815.01 | 2.97%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "af3574f9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 275,
      "page_number": 17,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          17
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.202342",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 275,
        "word_count": 52,
        "sentence_count": 15,
        "chinese_char_count": 26,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3215625,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39477849462365594,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f1c78b02",
      "content": "|  | 2019年 |  | 2018年  |\n--------------------------------------------------\n行业分类 | 项目 | 同比增减\n|  | 金额 | 占营业成本比重 | 金额 | 占营业成本比重 |\n| \n医药行业 | 原料成本 | 788,091,701.93 | 80.16% | 778,035,997.89 | 80.14% | 0.02%\n医药行业 | 人工成本 | 53,109,659.74 | 5.40% | 53,601,426.45 | 5.52% | -0.12%\n医药行业 | 能源成本 | 47,606,219.00 | 4.84% | 45,369,217.29 | 4.67% | 0.17%\n医药行业 | 制造费用 | 94,341,850.29 | 9.60% | 93,792,389.85 | 9.66% | -0.07%\n染料行业 | 原料成本 | 337,976,777.23 | 72.57% | 383,594,259.37 | 73.59% | -1.01%\n染料行业 | 人工成本 | 33,802,565.03 | 7.26% | 28,163,412.97 | 5.40% | 1.86%\n染料行业 | 能源成本 | 34,241,371.69 | 7.35% | 37,944,159.74 | 7.28% | 0.07%\n染料行业 | 制造费用 | 59,676,545.54 | 12.81% | 71,581,678.92 | 13.73% | -0.92%\n其他业务 |  | 14,312,670.59 | 100.00% | 19,862,133.71 | 100.00% | 0.00%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8817494b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 756,
      "page_number": 17,
      "bbox": [
        47.5,
        80.0,
        547.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "12x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 12,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "营业成本"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          17
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.202538",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 756,
        "word_count": 140,
        "sentence_count": 45,
        "chinese_char_count": 98,
        "readability_score": 0.0,
        "information_density": 0.03968253968253969,
        "coherence_score": 0.31930434782608696,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4769409282700422,
      "relevance_score": 1.0,
      "keywords": [
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "营业成本"
      ]
    },
    {
      "chunk_id": "fdff3777",
      "content": "（6）报告期内合并范围是否发生变动\n√ 是 □ 否\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n（7）公司报告期内业务、产品或服务发生重大变化或调整有关情况\n□ 适用 √ 不适用\n（8）主要销售客户和主要供应商情况\n公司主要销售客户情况\n前五名客户合计销售金额（元） 649,326,403.37\n前五名客户合计销售金额占年度销售总额比例 22.08%\n前五名客户销售额中关联方销售额占年度销售总额比\n0.00%\n例\n公司前5大客户资料\n序号 客户名称 销售额（元） 占年度销售总额比例\n1 客户1 212,211,696.91 7.21%\n2 客户2 149,494,409.10 5.08%\n3 客户3 105,676,622.82 3.59%\n4 客户4 93,657,620.14 3.18%\n5 客户5 88,286,054.40 3.00%\n合计 -- 649,326,403.37 22.08%\n主要客户其他情况说明\n□ 适用 √ 不适用\n公司主要供应商情况\n前五名供应商合计采购金额（元） 328,471,523.80\n前五名供应商合计采购金额占年度采购总额比例 20.82%\n前五名供应商采购额中关联方采购额占年度采购总额\n0.00%\n比例\n公司前5名供应商资料\n序号 供应商名称 采购额（元） 占年度采购总额比例\n1 供应商1 144,631,621.96 9.17%\n2 供应商2 56,660,417.02 3.59%\n3 供应商3 52,856,752.15 3.35%\n|  | 2019年 |  | 2018年  |\n--------------------------------------------------\n产品分类 | 项目 | 同比增减\n|  | 金额 | 占营业成本比重 | 金额 | 占营业成本比重 |\n| \n原料药 |  | 652,198,278.33 | 44.57% | 694,525,290.09 | 45.94% |\n医药中间体 |  | 328,224,382.60 | 22.43% | 272,841,947.14 | 18.05% |\n制剂 |  | 2,726,770.03 | 0.19% | 3,431,794.24 | 0.23% |\n染料 |  | 312,738,811.13 | 21.37% | 318,486,635.33 | 21.06% |\n染料中间体 |  | 152,958,448.36 | 10.45% | 202,796,875.67 | 13.41% |\n其他 |  | 14,312,670.59 | 0.98% | 19,862,133.71 | 1.31% |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ce8601f7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1174,
      "page_number": 17,
      "bbox": [
        49.5,
        80.0,
        545.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "44x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 44,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "营业成本"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          17
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.202771",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1174,
        "word_count": 178,
        "sentence_count": 48,
        "chinese_char_count": 373,
        "readability_score": 0.0,
        "information_density": 0.02555366269165247,
        "coherence_score": 0.561797385620915,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5594370651486401,
      "relevance_score": 1.0,
      "keywords": [
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "营业成本"
      ]
    },
    {
      "chunk_id": "fcb8e670",
      "content": "公司名称 | 股权取得方式 | 股权取得时点 | 出资额\n--------------------------------------------------\n盛嘉环保公司 | 设立 | 2019/4/29 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b38a66b8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 105,
      "page_number": 18,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203073",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 105,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3844075471698113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9d8c041f",
      "content": "前五名客户合计销售金额（元） | 649,326,403.37\n\n--------------------------------------------------\n前五名客户合计销售金额占年度销售总额比例 | 22.08%\n前五名客户销售额中关联方销售额占年度销售总额比 |\n| 0.00%\n例 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "26c74f3c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 153,
      "page_number": 18,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203123",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 153,
        "word_count": 14,
        "sentence_count": 3,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5566666666666666,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48490318471337573,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "2e7d222d",
      "content": "序号 | 客户名称 | 销售额（元） | 占年度销售总额比例\n--------------------------------------------------\n1 | 客户1 | 212,211,696.91 | 7.21%\n2 | 客户2 | 149,494,409.10 | 5.08%\n3 | 客户3 | 105,676,622.82 | 3.59%\n4 | 客户4 | 93,657,620.14 | 3.18%\n5 | 客户5 | 88,286,054.40 | 3.00%\n合计 | -- | 649,326,403.37 | 22.08%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8faec516"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 278,
      "page_number": 18,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203217",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 278,
        "word_count": 50,
        "sentence_count": 12,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.472326618705036,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "a9803204",
      "content": "前五名供应商合计采购金额（元） | 328,471,523.80\n\n--------------------------------------------------\n前五名供应商合计采购金额占年度采购总额比例 | 20.82%\n前五名供应商采购额中关联方采购额占年度采购总额 |\n| 0.00%\n比例 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "56c6cb8e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 156,
      "page_number": 18,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203425",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 156,
        "word_count": 14,
        "sentence_count": 3,
        "chinese_char_count": 59,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5544444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4873125,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6c4890fc",
      "content": "4 供应商4 38,420,130.22 2.44%\n5 供应商5 35,902,602.45 2.28%\n合计 -- 328,471,523.80 20.82%\n主要供应商其他情况说明\n□ 适用 √ 不适用\n3、费用\n单位：元\n2019年 2018年 同比增减 重大变动说明\n销售费用 59,623,024.88 43,781,054.42 36.18%主要系佣金增加所致\n管理费用 386,185,538.84 349,284,396.57 10.56%\n财务费用 -37,865,156.06 -51,507,397.78 -26.49%\n研发费用 122,548,224.53 111,304,662.07 10.10%\n4、研发投入\n√ 适用 □ 不适用\n公司注重技术研发，坚持技术创新。报告期内，公司在新设备、新产品、新工艺、新材\n料、新应用技术等方面，开展了有针对性的研究创新。在提升公司产品质量与性能方面，取\n得了突出的成果，提高了公司产品综合竞争力。\n序号 | 供应商名称 | 采购额（元） | 占年度采购总额比例\n--------------------------------------------------\n1 | 供应商1 | 144,631,621.96 | 9.17%\n2 | 供应商2 | 56,660,417.02 | 3.59%\n3 | 供应商3 | 52,856,752.15 | 3.35%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "60c07ce0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 617,
      "page_number": 18,
      "bbox": [
        97.5,
        80.0,
        497.5,
        540.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "20x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 20,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203519",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 617,
        "word_count": 76,
        "sentence_count": 27,
        "chinese_char_count": 191,
        "readability_score": 0.0,
        "information_density": 0.01620745542949757,
        "coherence_score": 0.45999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5389862226274453,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "4cf6f8bd",
      "content": "公司研发投入情况\n2019年 2018年 变动比例\n研发人员数量（人） 443 405 9.38%\n研发人员数量占比 13.45% 12.75% 0.70%\n研发投入金额（元） 122,548,224.53 111,304,662.07 10.10%\n研发投入占营业收入比例 4.17% 4.09% 0.08%\n研发投入资本化的金额（元） 0.00 0.00 0.00%\n资本化研发投入占研发投入\n0.00% 0.00% 0.00%\n的比例\n研发投入总额占营业收入的比重较上年发生显著变化的原因\n□ 适用 √ 不适用\n研发投入资本化率大幅变动的原因及其合理性说明\n□ 适用 √ 不适用\n5、现金流\n单位：元\n4 | 供应商4 | 38,420,130.22 | 2.44%\n--------------------------------------------------\n5 | 供应商5 | 35,902,602.45 | 2.28%\n合计 | -- | 328,471,523.80 | 20.82%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4ff3b3da"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 454,
      "page_number": 19,
      "bbox": [
        97.5,
        80.0,
        497.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "19x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 19,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203723",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 454,
        "word_count": 63,
        "sentence_count": 22,
        "chinese_char_count": 145,
        "readability_score": 0.0,
        "information_density": 0.04405286343612334,
        "coherence_score": 0.4217173913043478,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4460019109663409,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "现金流"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "56e887d3",
      "content": "| 2019年 | 2018年 | 同比增减 | 重大变动说明\n--------------------------------------------------\n销售费用 | 59,623,024.88 | 43,781,054.42 | 36.18% | 主要系佣金增加所致\n管理费用 | 386,185,538.84 | 349,284,396.57 | 10.56% |\n财务费用 | -37,865,156.06 | -51,507,397.78 | -26.49% |\n研发费用 | 122,548,224.53 | 111,304,662.07 | 10.10% |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3d540ab4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 291,
      "page_number": 19,
      "bbox": [
        69.5,
        80.0,
        525.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "研发费用",
          "管理费用",
          "销售费用",
          "财务费用"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203888",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 291,
        "word_count": 42,
        "sentence_count": 12,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.1718213058419244,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4361468926553672,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "研发费用",
        "管理费用",
        "销售费用",
        "财务费用"
      ]
    },
    {
      "chunk_id": "548081b0",
      "content": "在建工程 560,674,634.43 8.31% 674,333,677.99 9.58% -1.27%\n短期借款 200,267,029.59 2.97% 598,700,000.00 8.51% -5.54%\n2、以公允价值计量的资产和负债\n□ 适用 √ 不适用\n3、截至报告期末的资产权利受限情况\n项 目 期末账面价值 受限原因\n货币资金 30,797,464.00 开立银行承兑汇票\n固定资产 22,554,937.46 银行融资抵押\n无形资产 10,291,182.19 银行融资抵押\n合 计 63,643,583.65\n五、投资状况分析\n1、总体情况\n√ 适用 □ 不适用\n报告期投资额（元） 上年同期投资额（元） 变动幅度\n593,621,971.72 606,637,800.32 -2.15%\n2、报告期内获取的重大的股权投资情况\n□ 适用 √ 不适用\n3、报告期内正在进行的重大的非股权投资情况\n□ 适用 √ 不适用\n4、以公允价值计量的金融资产\n□ 适用 √ 不适用\n5、募集资金使用情况\n√ 适用 □ 不适用\n（1）募集资金总体使用情况\n√ 适用 □ 不适用\n单位：万元\n| 2019年末 |  | 2019年初 | \n--------------------------------------------------\n| 比重增减 | 重大变动说明\n| 金额 | 占总资产比例 | 金额 | 占总资产比例  |\n| \n货币资金 | 1,556,575,372.45 | 23.07% | 1,956,089,124.33 | 27.80% | -4.73% |\n应收账款 | 459,781,564.19 | 6.81% | 479,537,782.06 | 6.82% | -0.01% |\n存货 | 842,985,260.60 | 12.49% | 905,418,218.49 | 12.87% | -0.38% |\n投资性房地产 | 11,206,951.46 | 0.17% | 12,338,615.29 | 0.18% | -0.01% |\n长期股权投资 | 47,879,382.43 | 0.71% | 66,088,139.79 | 0.94% | -0.23% |\n固定资产 | 1,724,407,333.34 | 25.56% | 1,215,120,643.61 | 17.27% | 8.29% |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ee851b7f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1030,
      "page_number": 20,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "长期股权投资",
          "货币资金",
          "存货",
          "固定资产",
          "应收",
          "应收账款",
          "资产",
          "投资性房地产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203997",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1030,
        "word_count": 165,
        "sentence_count": 47,
        "chinese_char_count": 272,
        "readability_score": 0.0,
        "information_density": 0.1262135922330097,
        "coherence_score": 0.45999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5713641425756668,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "长期股权投资",
        "货币资金",
        "存货",
        "固定资产",
        "应收",
        "应收账款",
        "资产",
        "投资性房地产"
      ]
    },
    {
      "chunk_id": "885eeb58",
      "content": "在建工程 | 560,674,634.43 | 8.31% | 674,333,677.99 | 9.58% | -1.27% |\n--------------------------------------------------\n短期借款 | 200,267,029.59 | 2.97% | 598,700,000.00 | 8.51% | -5.54% |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6be31084"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 182,
      "page_number": 21,
      "bbox": [
        47.5,
        80.0,
        547.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "短期借款",
          "在建工程",
          "短期"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          21
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204324",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 182,
        "word_count": 25,
        "sentence_count": 10,
        "chinese_char_count": 8,
        "readability_score": 0.0,
        "information_density": 0.16483516483516483,
        "coherence_score": 0.34963636363636363,
        "standards_profile_summary": {}
      },
      "quality_score": 0.36832173913043476,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "短期借款",
        "在建工程",
        "短期"
      ]
    },
    {
      "chunk_id": "948753c7",
      "content": "项 目 | 期末账面价值 | 受限原因\n--------------------------------------------------\n货币资金 | 30,797,464.00 | 开立银行承兑汇票\n固定资产 | 22,554,937.46 | 银行融资抵押\n无形资产 | 10,291,182.19 | 银行融资抵押\n合 计 | 63,643,583.65 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6e3edbe8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 184,
      "page_number": 21,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "无形资产",
          "货币资金",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          21
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204398",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 184,
        "word_count": 27,
        "sentence_count": 4,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.32608695652173914,
        "coherence_score": 0.5233333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4326306306306306,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "无形资产",
        "货币资金",
        "资产"
      ]
    },
    {
      "chunk_id": "aa891f1c",
      "content": "报告期内 累计变更 累计变更 尚未使用\n本期已使 已累计使 尚未使用 闲置两年\n募集资金 变更用途 用途的募 用途的募 募集资金\n募集年份 募集方式 用募集资 用募集资 募集资金 以上募集\n总额 的募集资 集资金总 集资金总 用途及去\n金总额 金总额 总额 资金金额\n金总额 额 额比例 向\n非公开发\n2016年 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 存放银行 0\n行股票\n合计 -- 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 -- 0\n募集资金总体使用情况说明\n1、经中国证券监督管理委员会证监许可〔2016〕765号文核准，并经深圳证券交易所同意，本公司由主承销商国泰君安证\n券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币普通股（A股）股票99,890,023股，发行价为每股人\n民币10.28元，共计募集资金1,026,869,436.44元，坐扣承销费和保荐费等10,000,000.00元（含税）后的募集资金为\n1,016,869,436.44元，已由主承销商国泰君安证券股份有限公司于2016年9月1日汇入本公司募集资金监管账户。扣除承\n销费及保荐费、律师费、会计师费用、登记费等发行费用12,465,829.73元后，本公司本次募集资金净额1,014,403,606.71\n元。上述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验证，并由其出具《验资报告》（天健验〔2016〕358号）。\n报告期投资额（元） | 上年同期投资额（元） | 变动幅度\n--------------------------------------------------\n593,621,971.72 | 606,637,800.32 | -2.15%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4186d45a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 829,
      "page_number": 21,
      "bbox": [
        47.5,
        80.0,
        547.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "19x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 19,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2016-9"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          21
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204474",
        "report_type": "financial_report",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "券股份有限公司",
        "industry": null,
        "char_count": 829,
        "word_count": 73,
        "sentence_count": 26,
        "chinese_char_count": 392,
        "readability_score": 0.0,
        "information_density": 0.048250904704463214,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.538262154940777,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "10.28元",
        "436.44元",
        "000.00元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0b0dde60",
      "content": "2、本公司以前年度已使用募集资金337,797,729.53元，以前年度收到的银行存款利息扣除银行手续费等的净额为\n16,576,229.98元，以前年度收到的理财产品收益金额为20,933,628.61元；2019年度实际使用募集资金480,021,367.74元（含\n永久性补充流动资金370,616,060.66 元），2019年度收到的银行存款利息扣除银行手续费等的净额为4,244,642.08元，2019\n年度收到的理财产品收益金额为8,695,157.17元；累计已使用募集资金817,819,097.27元，累计收到的银行存款利息扣除\n银行手续费等的净额为20,820,872.06元，累计收到的理财产品收益金额为29,628,785.78元。截至2019年12月31日，募\n集资金余额为人民币247,034,167.28元。（2）募集资金承诺项目情况\n√ 适用 □ 不适用\n单位：万元\n是否已变 截至期末项目达到 项目可行\n募集资金调整后投 截至期末 本报告期\n承诺投资项目和超募 更项目 本报告期 投资进度预定可使 是否达到性是否发\n承诺投资 资总额 累计投入 实现的效\n资金投向 (含部分 投入金额 (3)＝ 用状态日 预计效益生重大变\n总额 (1) 金额(2) 益\n变更) (2)/(1) 期 化\n承诺投资项目\n原料药及中间体CMO 2019年7\n否 40,000 28,440.36 4,548.29 28,796.95 101.25% 0.00[注] 否 否\n中心扩建项目 月[注]\n年产30亿片（粒）固\n是 35,000 不适用 是\n体制剂技改项目\n医药综合研发中心 否 15,000 15,000 2,521.91 2,611.91 17.41% 不适用 否\n医药中试车间技改项\n否 9,000 9,000 1,436.42 4,730.88 52.57% 不适用 否\n目\n环保设施改造项目 否 14,000 14,000 2,433.91 8,580.56 61.29% 不适用 否\n承诺投资项目小计 -- 113,000 66,440.3610,940.53 44,720.3 -- -- -- --\n超募资金投向\n| 本期已使\n用募集资\n金总额 |  | 报告期内 | 累计变更 | 累计变更 |  | 尚未使用\n募集资金\n用途及去\n向 |\n--------------------------------------------------\n| 已累计使 | 尚未使用 |  | 闲置两年\n|  | 募集资金 | 变更用途 | 用途的募 | 用途的募 | \n募集年份 | 募集方式 | 用募集资 | 募集资金 |  | 以上募集\n|  | 总额 | 的募集资 | 集资金总 | 集资金总 | \n| 金总额 | 总额 |  | 资金金额\n| 金总额 | 额 | 额比例 | \n| \n| 非公开发 | \n2016年 |  | 101,440.36 | 48,002.14 | 81,781.91 | 37,061.61 | 37,061.61 | 36.54% | 24,703.42 | 存放银行 | 0\n| 行股票 | \n| \n合计 | -- | 101,440.36 | 48,002.14 | 81,781.91 | 37,061.61 | 37,061.61 | 36.54% | 24,703.42 | -- | 0\n募集资金总体使用情况说明 | \n1、经中国证券监督管理委员会证监许可〔2016〕765号文核准，并经深圳证券交易所同意，本公司由主承销商国泰君安证 | \n券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币普通股（A股）股票99,890,023股，发行价为每股人 | \n民币10.28元，共计募集资金1,026,869,436.44元，坐扣承销费和保荐费等10,000,000.00元（含税）后的募集资金为 | \n1,016,869,436.44元，已由主承销商国泰君安证券股份有限公司于2016年9月1日汇入本公司募集资金监管账户。扣除承 | \n销费及保荐费、律师费、会计师费用、登记费等发行费用12,465,829.73元后，本公司本次募集资金净额1,014,403,606.71 | \n元。上述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验证，并由其出具《验资报告》（天健验〔2016〕358号）。 | \n2、本公司以前年度已使用募集资金337,797,729.53元，以前年度收到的银行存款利息扣除银行手续费等的净额为 | \n16,576,229.98元，以前年度收到的理财产品收益金额为20,933,628.61元；2019年度实际使用募集资金480,021,367.74元（含 | \n永久性补充流动资金370,616,060.66 元），2019年度收到的银行存款利息扣除银行手续费等的净额为4,244,642.08元，2019 | \n年度收到的理财产品收益金额为8,695,157.17元；累计已使用募集资金817,819,097.27元，累计收到的银行存款利息扣除 | \n银行手续费等的净额为20,820,872.06元，累计收到的理财产品收益金额为29,628,785.78元。截至2019年12月31日，募 | \n集资金余额为人民币247,034,167.28元。 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "901a9a1f",
        "27b5491e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2235,
      "page_number": 22,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "58x11",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 58,
        "column_count": 11,
        "contains_financial_data": true,
        "accounting_items": [
          "银行存款"
        ],
        "time_periods": [
          "2019",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204732",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "券股份有限公司",
        "industry": "financial",
        "char_count": 2235,
        "word_count": 245,
        "sentence_count": 66,
        "chinese_char_count": 970,
        "readability_score": 0.0,
        "information_density": 0.022371364653243846,
        "coherence_score": 0.7104761904761905,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6496147575952801,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "729.53元",
        "229.98元",
        "628.61元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "银行存款"
      ]
    },
    {
      "chunk_id": "43d67af9",
      "content": "| 是否已变 | 截至期末 | 项目达到 | 项目可行\n--------------------------------------------------\n|  | 募集资金 | 调整后投 |  | 截至期末 | 本报告期  |\n承诺投资项目和超募 | 更项目 | 本报告期 |  | 投资进度 | 预定可使 |  | 是否达到 | 性是否发\n|  | 承诺投资 | 资总额 |  | 累计投入 | 实现的效  |\n资金投向 | (含部分 | 投入金额 |  | (3)＝ | 用状态日 |  | 预计效益 | 生重大变\n|  | 总额 | (1) |  | 金额(2) | 益  |\n| 变更) | (2)/(1) | 期 | 化\n| \n承诺投资项目 | \n原料药及中间体CMO | 2019年7 | \n| 否 | 40,000 | 28,440.36 | 4,548.29 | 28,796.95 | 101.25% |  | 0.00[注] | 否 | 否\n中心扩建项目 | 月[注] | \n| \n年产30亿片（粒）固 | \n| 是 | 35,000 | 不适用 | 是\n体制剂技改项目 | \n| \n医药综合研发中心 | 否 | 15,000 | 15,000 | 2,521.91 | 2,611.91 | 17.41% | 不适用 | 否\n医药中试车间技改项 | \n| 否 | 9,000 | 9,000 | 1,436.42 | 4,730.88 | 52.57% | 不适用 | 否\n目 | \n| \n环保设施改造项目 | 否 | 14,000 | 14,000 | 2,433.91 | 8,580.56 | 61.29% | 不适用 | 否\n承诺投资项目小计 | -- | 113,000 | 66,440.36 | 10,940.53 | 44,720.3 | -- | -- |  | -- | --\n超募资金投向 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b9be9d4b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 820,
      "page_number": 22,
      "bbox": [
        47.5,
        80.0,
        547.5,
        620.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "21x10",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 21,
        "column_count": 10,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.205388",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 820,
        "word_count": 201,
        "sentence_count": 17,
        "chinese_char_count": 210,
        "readability_score": 0.0,
        "information_density": 0.012195121951219513,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.524960380348653,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "830ca2b4",
      "content": "募集资金使用及披露\n中存在的问题或其他 不存在重大问题\n情况\n[注]：该项目已于2019年7月部分投产，但生产的相关产品尚未实现销售，故本期未产生效益。（3）募集资金变更项目情况\n√ 适用 □ 不适用\n单位：万元\n变更后项目 变更后的项\n截至期末实截至期末投项目达到预\n变更后的项对应的原承拟投入募集本报告期实 本报告期实是否达到预目可行性是\n际累计投入 资进度 定可使用状\n目 诺项目 资金总额 际投入金额 现的效益 计效益 否发生重大\n金额(2) (3)=(2)/(1) 态日期\n(1) 变化\n年产30亿\n永久补充流片（粒）固\n37,061.61 37,061.61 37,061.61 100.00% 0 不适用 否\n动资金 体制剂技改\n项目\n合计 -- 37,061.61 37,061.61 37,061.61 -- -- 0 -- --\n根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分\n变更原因、决策程序及信息披露情况募集资金投资项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿\n说明(分具体项目) 片（粒）固体制剂技改项目的市场环境已发生较大变化，公司终止实施该项目并将结\n余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。未达到计划进度或预计收益的情况\n不适用\n和原因(分具体项目)\n变更后的项目可行性发生重大变化\n不适用\n的情况说明\n六、重大资产和股权出售\n1、出售重大资产情况\n□ 适用 √ 不适用\n公司报告期未出售重大资产。\n无 | \n--------------------------------------------------\n归还银行贷款（如有） | -- | -- | -- | -- | --\n补充流动资金（如有） | -- | -- | -- | -- | --\n超募资金投向小计 | -- | -- | -- |  | -- | --\n合计 | -- | 113,000 | 66,440.36 | 10,940.53 | 44,720.3 | -- | -- | 0 | -- | --\n| “医药综合研发中心项目”原实施地点为公司椒江区外沙厂区，考虑各子公司所在园区的长远发展规 | \n| 划，对子公司职能定位进行调整，公司将项目的实施主体由公司变更为全资子公司川南药业，实施 | \n| 地点变更为浙江省临海市，因此导致投资进度有所延缓。 | \n未达到计划进度或预 | “医药中试车间技改项目” 主要是通过实施原料药和关键中间体产品的中试生产，为产品的中试开发 | \n计收益的情况和原因 | 提供工艺验证和数据收集，为开发大规模生产的产品提供必要的研发支持。该项目计划建设用地位 | \n（分具体项目） | 于公司外沙厂区，需要拆除原有车间，在原址上新建厂房。由于原车间为药证体系注册车间，需要 | \n| 办理相关药证转移变更程序，故导致医药中试车间技改项目进度低于规划进度。 | \n| “环保设施改造项目”为配合厂区产能整体规划、协同活性染料产业升级及配套项目建设规划需要， | \n| 投入与实施计划有所延缓。 | \n| 根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资 | \n项目可行性发生重大 | 项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目 | \n变化的情况说明 | 的市场环境已发生较大变化，公司终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普 | \n| 通账户，用于永久补充公司流动资金。 | \n超募资金的金额、用途 | 不适用 | \n及使用进展情况 | \n| 适用 | \n| 以前年度发生 | \n募集资金投资项目实 | \n| 根据公司2018年8月28日第五届董事会第十八次会议审议通过的《关于变更部分募集资金投资项\n目实施主体和地点的议案》，公司将募集资金投资项目“医药综合研发中心”实施主体由公司变更为全\n资子公司浙江海翔川南药业有限公司，实施地点变更为浙江省临海市。 | \n施地点变更情况 | \n| \n| 不适用 | \n募集资金投资项目实 | \n| \n施方式调整情况 | \n| \n| \n募集资金投资项目先 | 不适用 | \n期投入及置换情况 | \n用闲置募集资金暂时 | 不适用 | \n补充流动资金情况 | \n项目实施出现募集资 | 不适用 | \n金结余的金额及原因 | \n尚未使用的募集资金 | \n| 存放银行 | \n用途及去向 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2eb363c1",
        "13925b03"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1907,
      "page_number": 23,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "70x11",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 70,
        "column_count": 11,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-3",
          "2019-7"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          23
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.205673",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1907,
        "word_count": 238,
        "sentence_count": 22,
        "chinese_char_count": 1185,
        "readability_score": 0.0,
        "information_density": 0.01048767697954903,
        "coherence_score": 0.6514795918367347,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6942309594745377,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "5860c420",
      "content": "### 2、出售重大股权情况\n□ 适用 √ 不适用\n七、主要控股参股公司分析\n√ 适用 □ 不适用\n主要子公司及对公司净利润影响达10%以上的参股公司情况\n24。\n\n募集资金使用及披露 |\n\n--------------------------------------------------\n中存在的问题或其他 | 不存在重大问题\n情况 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3ff19b8c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 171,
      "page_number": 24,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x2",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.206275",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 171,
        "word_count": 21,
        "sentence_count": 1,
        "chinese_char_count": 80,
        "readability_score": 0.0,
        "information_density": 0.05847953216374269,
        "coherence_score": 0.21,
        "standards_profile_summary": {}
      },
      "quality_score": 0.46909765260956277,
      "relevance_score": 1.0,
      "keywords": [
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "047f2ae0",
      "content": "单位：元\n公司名称 公司类型 主要业务 注册资本 总资产 净资产 营业收入 营业利润 净利润\n浙江海翔药\n货物及技术 30,000,000.0 69,541,379.7 69,007,694.1 -1,190,555.1 -1,177,557.0\n业销售有限 子公司 6,399,758.49\n进出口 0 5 3 0 5\n公司\n浙江海翔川\n医药制造及 1,905,943,80 1,307,615,66 1,278,861,76 204,310,101. 183,572,535.\n南药业有限 子公司 740000000\n货物进出口 5.66 6.90 2.53 35 16\n公司\n上海海翔医\n医药化工技 16,566,791.9\n药科技发展 子公司 5,000,000.00 7,712,899.66 5,961,858.15 1,609,827.17 1,416,778.77\n术开发 9\n有限公司\n工原料、化\n台州港翔科 工机械及配\n子公司 5,000,000.00 5,444,685.96 5,116,968.43 0.00 -143,703.23 -145,514.30\n技有限公司 件、五金批\n发、零售\n主要产品染\n料、染料中\n台州市前进\n间体、溴盐 304,000,000. 1,540,527,12 1,254,548,70 1,202,406,88 485,937,936. 418,599,011.\n化工有限公 子公司\n制造、销售 00 2.83 0.45 0.92 39 39\n司\n货物及技术\n进出口\n医药中间体\n台州市振港 及化工产品\n110,000,000. 933,575,895. 617,871,041. 783,594,897. 128,045,956. 89,296,052.8\n染料化工有 子公司 制造，销售\n00 73 59 92 93 4\n限公司 货物及技术\n进出口\n盐城市瓯华\nDCB、1-氨基19,778,647.3 203,873,894. 186,550,175. 65,214,784.2 -48,941,877. -48,959,944.\n化学工业有 子公司\n蒽醌生产 7 28 49 5 12 21\n限公司\n盐城市瓯华 化工产品研\n化工研究院 子公司 发及其技术 1,080,000.00 1,071,232.47 1,071,232.47 -724.90 -724.90\n有限公司 转让\n报告期内取得和处置子公司的情况\n√ 适用 □ 不适用\n公司名称 报告期内取得和处置子公司方式 对整体生产经营和业绩的影响\n浙江盛嘉环保有限公司 设立 无\n主要控股参股公司情况说明\n八、公司控制的结构化主体情况\n□ 适用 √ 不适用\n|  | 变更后项目 | 变更后的项\n--------------------------------------------------\n| 截至期末实 | 截至期末投 | 项目达到预 | \n变更后的项 | 对应的原承 | 拟投入募集 | 本报告期实 | 本报告期实 | 是否达到预 | 目可行性是\n| 际累计投入 | 资进度 | 定可使用状 | \n目 | 诺项目 | 资金总额 | 际投入金额 | 现的效益 | 计效益 | 否发生重大\n| 金额(2) | (3)=(2)/(1) | 态日期 | \n|  | (1) | 变化\n| \n| 年产30亿 | \n永久补充流 | 片（粒）固 | \n|  | 37,061.61 | 37,061.61 | 37,061.61 | 100.00% |  | 0 | 不适用 | 否\n动资金 | 体制剂技改 | \n| \n| 项目 | \n合计 | -- | 37,061.61 | 37,061.61 | 37,061.61 | -- | -- | 0 | -- | --\n| 根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分 | \n变更原因、决策程序及信息披露情况 | 募集资金投资项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿 | \n说明(分具体项目) | 片（粒）固体制剂技改项目的市场环境已发生较大变化，公司终止实施该项目并将结 | \n| 余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。 | \n未达到计划进度或预计收益的情况 | \n| 不适用 | \n和原因(分具体项目) | \n| \n变更后的项目可行性发生重大变化 | \n| 不适用 | \n的情况说明 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b2df5fb0",
        "dda86cc4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1891,
      "page_number": 24,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "76x10",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 76,
        "column_count": 10,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.206349",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1891,
        "word_count": 302,
        "sentence_count": 55,
        "chinese_char_count": 685,
        "readability_score": 0.0,
        "information_density": 0.026441036488630353,
        "coherence_score": 0.676060606060606,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6762352701659708,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "c37746c0",
      "content": "公司名称 | 报告期内取得和处置子公司方式 | 对整体生产经营和业绩的影响\n--------------------------------------------------\n浙江盛嘉环保有限公司 | 设立 | 无",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "57f538e0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 25,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          25
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.206890",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 11,
        "sentence_count": 0,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.09259259259259259,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4077111111111111,
      "relevance_score": 1.0,
      "keywords": [
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6c614835",
      "content": "第五节重要事项\n一、公司普通股利润分配及资本公积金转增股本情况\n报告期内普通股利润分配政策，特别是现金分红政策的制定、执行或调整情况\n√ 适用 □ 不适用\n公司第五届董事会第五次会议及2017年第一次临时股东大会审议通过了《公司未来三年（2017年-2019年）股东回报规划》。具体内容详见公司2016年12月19日于巨潮资讯网（http://www.cninfo.com.cn）刊登的《浙江海翔药业股份有限公司未来三年\n股东分红回报规划(2017-2019年) 》。现金分红政策的专项说明\n是否符合公司章程的规定或股东大会决议的要求： 是\n分红标准和比例是否明确和清晰： 是\n相关的决策程序和机制是否完备： 是\n独立董事是否履职尽责并发挥了应有的作用： 是\n中小股东是否有充分表达意见和诉求的机会，其合法权益是\n是\n否得到了充分保护：\n现金分红政策进行调整或变更的，条件及程序是否合规、透\n是\n明：\n公司近3年（包括本报告期）的普通股股利分配方案（预案）、资本公积金转增股本方案（预案）情况\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购\n专用证券账户的63,005,888股）为基数，向全体股东每10股派发现金红利3元（含税），预计\n派发现金股利466,712,809.50元(含税)。\n接待时间 | 接待方式 | 接待对象类型 | 调研的基本情况索引\n--------------------------------------------------\n| 具体内容详见互动易平台2019年3月\n2019年03月11日 | 实地调研 | 机构 |\n| 12日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年4月\n2019年04月09日 | 实地调研 | 机构 |\n| 10日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年4月\n2019年04月25日 | 实地调研 | 机构 |\n| 26日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年5月\n2019年05月14日 | 实地调研 | 机构 |\n| 17日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年5月\n2019年05月15日 | 实地调研 | 机构 |\n| 17日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年6月\n2019年06月04日 | 实地调研 | 机构 |\n| 6日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年6月\n2019年06月05日 | 实地调研 | 机构 |\n| 6日的投资者活动关系表\n| \n| 具体内容详见互动易平台2019年9月\n2019年09月16日 | 实地调研 | 机构 |\n| 16日的投资者活动关系表\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ced0c1a8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1174,
      "page_number": 27,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "44x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 44,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2016-12",
          "2019",
          "2019-03",
          "2019-04",
          "2019-05",
          "2019-12",
          "2019-3",
          "2019-4",
          "2019-5"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          27
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.206939",
        "report_type": "financial_report",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1174,
        "word_count": 124,
        "sentence_count": 7,
        "chinese_char_count": 676,
        "readability_score": 0.0,
        "information_density": 0.04258943781942078,
        "coherence_score": 0.6748387096774193,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6056700490871346,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润",
        "投资",
        "3元",
        "809.50元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ba3a345e",
      "content": "公司近三年（包括本报告期）普通股现金分红情况表\n单位：元\n现金分红总额\n现金分红金额 以其他方式现\n分红年度合并 （含其他方\n占合并报表中 以其他方式 金分红金额占\n报表中归属于 现金分红总额 式）占合并报\n现金分红金额 归属于上市公 （如回购股 合并报表中归\n分红年度 上市公司普通 （含其他方 表中归属于上\n（含税） 司普通股股东 份）现金分红 属于上市公司\n股股东的净利 式） 市公司普通股\n的净利润的比 的金额 普通股股东的\n润 股东的净利润\n率 净利润的比例\n的比率\n2019年 466,712,809.50 770,782,185.09 60.55% 19,996,827.22 2.59% 486,709,636.72 63.14%\n现金分红政策的专项说明 |\n\n--------------------------------------------------\n是否符合公司章程的规定或股东大会决议的要求： | 是\n分红标准和比例是否明确和清晰： | 是\n相关的决策程序和机制是否完备： | 是\n独立董事是否履职尽责并发挥了应有的作用： | 是\n中小股东是否有充分表达意见和诉求的机会，其合法权益是 |\n| 是\n否得到了充分保护： |\n|\n现金分红政策进行调整或变更的，条件及程序是否合规、透 |\n| 是\n明： |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3764960c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 568,
      "page_number": 28,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "27x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "现金"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.207260",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 568,
        "word_count": 73,
        "sentence_count": 7,
        "chinese_char_count": 336,
        "readability_score": 0.0,
        "information_density": 0.07042253521126761,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7084883296010017,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金"
      ]
    },
    {
      "chunk_id": "b68c66aa",
      "content": "2018年 466,744,309.50 605,003,820.78 77.15% 281,514,686.68 46.53% 748,258,996.18 123.68%\n2017年 162,161,025.30 342,217,155.60 47.39% 0.00 0.00% 162,161,025.30 47.39%\n公司报告期内盈利且母公司可供普通股股东分配利润为正但未提出普通股现金红利分配预案\n□ 适用 √ 不适用\n二、本报告期利润分配及资本公积金转增股本情况\n√ 适用 □ 不适用\n每10股送红股数（股） 0\n每10股派息数（元）（含税） 3\n每10股转增数（股） 0\n分配预案的股本基数（股） 1,555,709,365\n现金分红金额（元）（含税） 466,712,809.50\n以其他方式（如回购股份）现金分红金额（元） 19,996,827.22\n现金分红总额（含其他方式）（元） 486,709,636.72\n可分配利润（元） 1,525,328,398.95\n现金分红总额（含其他方式）占利润分配总额的\n100%\n比例\n本次现金分红情况\n公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20％\n利润分配或资本公积金转增预案的详细情况说明\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购专用证券账户的63,005,888股）\n为基数，向全体股东每10股派发现金红利3元（含税），预计派发现金股利466,712,809.50元(含税)。本年度不送红股，\n不以资本公积转增股本。三、承诺事项履行情况\n1、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末\n尚未履行完毕的承诺事项\n√ 适用 □ 不适用\n承 履\n承诺类 承诺 诺 行\n承诺事由 承诺方 承诺内容\n型 时间 期 情\n限 况\n股改承诺\n收购报告书或权\n益变动报告书中\n所作承诺\n| 现金分红总额\n--------------------------------------------------\n| 现金分红金额 |  | 以其他方式现  |\n|  | 分红年度合并 | （含其他方\n| 占合并报表中 | 以其他方式 | 金分红金额占  |\n|  | 报表中归属于 | 现金分红总额 | 式）占合并报\n| 现金分红金额 |  | 归属于上市公 | （如回购股 | 合并报表中归  |\n分红年度 |  | 上市公司普通 | （含其他方 | 表中归属于上\n| （含税） |  | 司普通股股东 | 份）现金分红 | 属于上市公司  |\n|  | 股股东的净利 | 式） | 市公司普通股\n| 的净利润的比 | 的金额 | 普通股股东的  |\n|  | 润 | 股东的净利润\n| 率 |  | 净利润的比例  |\n| 的比率\n| \n2019年 | 466,712,809.50 | 770,782,185.09 | 60.55% | 19,996,827.22 | 2.59% | 486,709,636.72 | 63.14%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a9c20f8d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1327,
      "page_number": 28,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "49x8",
        "has_header": false,
        "table_type": "financial_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 49,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "利润",
          "净利润"
        ],
        "time_periods": [
          "2019",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.207451",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1327,
        "word_count": 175,
        "sentence_count": 28,
        "chinese_char_count": 611,
        "readability_score": 0.0,
        "information_density": 0.05275056518462699,
        "coherence_score": 0.6575856472088575,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7431102007807443,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "报表",
        "3元",
        "809.50元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "f3ebfbfb",
      "content": "2018年 | 466,744,309.50 | 605,003,820.78 | 77.15% | 281,514,686.68 | 46.53% | 748,258,996.18 | 123.68%\n--------------------------------------------------\n2017年 | 162,161,025.30 | 342,217,155.60 | 47.39% | 0.00 | 0.00% | 162,161,025.30 | 47.39%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f73c7fb6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 242,
      "page_number": 29,
      "bbox": [
        47.5,
        80.0,
        547.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          29
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.207784",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 242,
        "word_count": 31,
        "sentence_count": 14,
        "chinese_char_count": 2,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.34839999999999993,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37463966942148763,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b99c9734",
      "content": "每10股送红股数（股） | 0\n公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20％ |\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购专用证券账户的63,005,888股） |\n为基数，向全体股东每10股派发现金红利3元（含税），预计派发现金股利466,712,809.50元(含税)。本年度不送红股， |\n不以资本公积转增股本。 |\n\n--------------------------------------------------\n每10股派息数（元）（含税） | 3\n每10股转增数（股） | 0\n分配预案的股本基数（股） | 1,555,709,365\n现金分红金额（元）（含税） | 466,712,809.50\n以其他方式（如回购股份）现金分红金额（元） | 19,996,827.22\n现金分红总额（含其他方式）（元） | 486,709,636.72\n可分配利润（元） | 1,525,328,398.95\n现金分红总额（含其他方式）占利润分配总额的 |\n| 100%\n比例 |\n|\n本次现金分红情况 |\n利润分配或资本公积金转增预案的详细情况说明 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "db4ce2aa"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 543,
      "page_number": 29,
      "bbox": [
        47.5,
        80.0,
        547.5,
        480.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "股本",
          "现金",
          "资本公积",
          "利润"
        ],
        "time_periods": [
          "2019",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          29
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.208013",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 543,
        "word_count": 44,
        "sentence_count": 7,
        "chinese_char_count": 254,
        "readability_score": 0.0,
        "information_density": 0.14732965009208104,
        "coherence_score": 0.8263945578231293,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6355635925256178,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "3元",
        "809.50元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "股本",
        "现金",
        "资本公积",
        "利润"
      ]
    },
    {
      "chunk_id": "ec00a3a4",
      "content": "（一）本承诺人及本承诺人直接或间接控制的除海翔药业、台州前进\n及其子公司以外的企业目前不存在自营、与他人共同经营、为他人经\n营或以其他任何方式直接或间接从事与海翔药业、台州前进及其子公\n司相同、相似或构成实质竞争业务的情形；（二）在直接或间接持有海\n翔药业股份期间，本承诺人将不会采取参股、控股、自营、联营、合\n营、合作或者其他任何方式直接或间接从事与海翔药业、台州前进及\n其子公司现在和将来业务范围相同、相似或构成实质竞争的业务，也\n不会协助、促使或代表任何第三方以任何方式直接或间接从事与海翔\n药业、台州前进及其子公司现在和将来业务范围相同、相似或构成实\n质竞争的业务；（三）在直接或间接持有海翔药业股份期间，对于本承\n诺人直接或间接控制的其他企业，本承诺人将通过派出机构和人员（包\n括但不限于董事、总经理等）以及本承诺人在该等企业中的控制地位，\n王云富、\n关于同 保证该等企业比照前款规定履行与本承诺人相同的不竞争义务；（四）2014 严\n浙江东\n资产重组时所作 业竞争 如因国家政策调整等不可抗力原因导致本承诺人或本承诺人直接或间 年05 长 格\n港投资\n承诺 方面承 接控制的其他企业将来从事的业务与海翔药业、台州前进及其子公司 月05 期 履\n有限公\n诺 现在或将来从事的业务之间构成同业竞争时，则本承诺人将在海翔药 日 行\n司\n业、台州前进及其子公司提出异议后及时转让或终止该等业务或促使\n本承诺人直接或间接控制的其他企业及时转让或终止该等业务；如海\n翔药业、台州前进及其子公司进一步要求，海翔药业、台州前进及其\n子公司享有该等业务在同等条件下的优先受让权；（五）如从第三方获\n得任何与海翔药业经营的业务存在竞争或潜在竞争的商业机会，本承\n诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并\n尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上\n述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其\n子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述\n承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东\n因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归\n海翔药业所有。| 承 | 履\n--------------------------------------------------\n|  | 承诺类 |  | 承诺 | 诺 | 行\n承诺事由 | 承诺方 |  | 承诺内容 | \n|  | 型 |  | 时间 | 期 | 情\n| \n| 限 | 况\n股改承诺 | \n收购报告书或权 | \n益变动报告书中 | \n所作承诺 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e6815786"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1099,
      "page_number": 29,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "41x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 41,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          29
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.208193",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1099,
        "word_count": 92,
        "sentence_count": 1,
        "chinese_char_count": 857,
        "readability_score": 0.0,
        "information_density": 0.0272975432211101,
        "coherence_score": 0.6166298342541436,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5322409647701225,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "cf537023",
      "content": "（一）本承诺人将采取措施尽量避免或减少本承诺人及本承诺人直接\n或间接控制的除海翔药业、台州前进及其子公司以外的其他企业与台\n州前进、海翔药业及其子公司之间发生关联交易；（二）对于无法避免\n的关联交易，将按照\"等价有偿、平等互利\"的原则，依法签订关联交易\n合同，参照市场同行的标准，公允确定关联交易的价格，并严格按照\n海翔药业的公司章程及有关法律法规履行批准关联交易的法定程序和\n信息披露义务；（三）本承诺人及本承诺人直接或间接控制的除海翔药\n王云富、 业、台州前进及其子公司以外的其他企业不通过关联交易损害海翔药\n关于关 2014 严\n浙江东 业、台州前进及其子公司及相关公司股东的合法权益；（四）本承诺人\n联交易、 年05 长 格\n港投资 及本承诺人直接或间接控制的除海翔药业、台州前进及其子公司以外\n资金方 月05 期 履\n有限公 的其他企业不通过向海翔药业、台州前进及其子公司借款或由海翔药\n面承诺 日 行\n司 业、台州前进及其子公司提供担保、代偿债务、代垫款项等各种名目\n侵占海翔药业、台州前进及其子公司的资金；（五）不利用股东地位及\n影响谋求与海翔药业、台州前进及其子公司在业务合作等方面给予本\n承诺人及本承诺人直接或间接控制的除海翔药业、台州前进及其子公\n司以外的其他企业优于市场第三方的权利；不利用股东地位及影响谋\n求与海翔药业、台州前进及其子公司达成交易的优先权利；（六）本承\n诺人愿意承担由于违反上述承诺给海翔药业、台州前进及其子公司造\n成的直接、间接的经济损失、索赔责任及额外的费用支出。首次公开发行或\n再融资时所作承\n诺\n股权激励承诺\n其他对公司中小\n股东所作承诺\n承诺是否按时履\n是\n行\n如承诺超期未履\n行完毕的，应当详\n细说明未完成履\n不适用\n行的具体原因及\n下一步的工作计\n划\n2、公司资产或项目存在盈利预测，且报告期仍处在盈利预测期间，公司就资产或项目达到原盈利预测及\n其原因做出说明\n□ 适用 √ 不适用\n四、控股股东及其关联方对上市公司的非经营性占用资金情况\n□ 适用 √ 不适用\n公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。| （一）本承诺人及本承诺人直接或间接控制的除海翔药业、台州前进 | \n--------------------------------------------------\n| 及其子公司以外的企业目前不存在自营、与他人共同经营、为他人经 | \n| 营或以其他任何方式直接或间接从事与海翔药业、台州前进及其子公 | \n| 司相同、相似或构成实质竞争业务的情形；（二）在直接或间接持有海 | \n| 翔药业股份期间，本承诺人将不会采取参股、控股、自营、联营、合 | \n| 营、合作或者其他任何方式直接或间接从事与海翔药业、台州前进及 | \n| 其子公司现在和将来业务范围相同、相似或构成实质竞争的业务，也 | \n| 不会协助、促使或代表任何第三方以任何方式直接或间接从事与海翔 | \n| 药业、台州前进及其子公司现在和将来业务范围相同、相似或构成实 | \n| 质竞争的业务；（三）在直接或间接持有海翔药业股份期间，对于本承 | \n| 诺人直接或间接控制的其他企业，本承诺人将通过派出机构和人员（包 | \n| 括但不限于董事、总经理等）以及本承诺人在该等企业中的控制地位， | \n| 王云富、 | \n|  | 关于同 | 保证该等企业比照前款规定履行与本承诺人相同的不竞争义务；（四） | 2014 |  | 严\n| 浙江东 | \n资产重组时所作 |  | 业竞争 | 如因国家政策调整等不可抗力原因导致本承诺人或本承诺人直接或间 | 年05 | 长 | 格\n| 港投资 | \n承诺 |  | 方面承 | 接控制的其他企业将来从事的业务与海翔药业、台州前进及其子公司 | 月05 | 期 | 履\n| 有限公 | \n|  | 诺 | 现在或将来从事的业务之间构成同业竞争时，则本承诺人将在海翔药 | 日 |  | 行\n| 司 | \n| 业、台州前进及其子公司提出异议后及时转让或终止该等业务或促使 | \n| \n| 本承诺人直接或间接控制的其他企业及时转让或终止该等业务；如海 | \n| 翔药业、台州前进及其子公司进一步要求，海翔药业、台州前进及其 | \n| 子公司享有该等业务在同等条件下的优先受让权；（五）如从第三方获 | \n| 得任何与海翔药业经营的业务存在竞争或潜在竞争的商业机会，本承 | \n| 诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并 | \n| 尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上 | \n| 述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其 | \n| 子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述 | \n| 承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东 | \n| 因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归 | \n| 海翔药业所有。 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "def42295",
        "dd1acf3c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2064,
      "page_number": 30,
      "bbox": [
        49.5,
        80.0,
        545.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "76x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 76,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          30
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.208522",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 2064,
        "word_count": 197,
        "sentence_count": 3,
        "chinese_char_count": 1570,
        "readability_score": 0.0,
        "information_density": 0.029069767441860468,
        "coherence_score": 0.6728169014084507,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7799655365622692,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "c4fe433b",
      "content": "| （一）本承诺人将采取措施尽量避免或减少本承诺人及本承诺人直接 | \n--------------------------------------------------\n| 或间接控制的除海翔药业、台州前进及其子公司以外的其他企业与台 | \n| 州前进、海翔药业及其子公司之间发生关联交易；（二）对于无法避免 | \n| 的关联交易，将按照\"等价有偿、平等互利\"的原则，依法签订关联交易 | \n| 合同，参照市场同行的标准，公允确定关联交易的价格，并严格按照 | \n| 海翔药业的公司章程及有关法律法规履行批准关联交易的法定程序和 | \n| 信息披露义务；（三）本承诺人及本承诺人直接或间接控制的除海翔药 | \n| 王云富、 |  | 业、台州前进及其子公司以外的其他企业不通过关联交易损害海翔药 | \n|  | 关于关 |  | 2014 |  | 严\n| 浙江东 |  | 业、台州前进及其子公司及相关公司股东的合法权益；（四）本承诺人 | \n|  | 联交易、 |  | 年05 | 长 | 格\n| 港投资 |  | 及本承诺人直接或间接控制的除海翔药业、台州前进及其子公司以外 | \n|  | 资金方 |  | 月05 | 期 | 履\n| 有限公 |  | 的其他企业不通过向海翔药业、台州前进及其子公司借款或由海翔药 | \n|  | 面承诺 |  | 日 |  | 行\n| 司 |  | 业、台州前进及其子公司提供担保、代偿债务、代垫款项等各种名目 | \n| \n| 侵占海翔药业、台州前进及其子公司的资金；（五）不利用股东地位及 | \n| 影响谋求与海翔药业、台州前进及其子公司在业务合作等方面给予本 | \n| 承诺人及本承诺人直接或间接控制的除海翔药业、台州前进及其子公 | \n| 司以外的其他企业优于市场第三方的权利；不利用股东地位及影响谋 | \n| 求与海翔药业、台州前进及其子公司达成交易的优先权利；（六）本承 | \n| 诺人愿意承担由于违反上述承诺给海翔药业、台州前进及其子公司造 | \n| 成的直接、间接的经济损失、索赔责任及额外的费用支出。 | \n首次公开发行或 | \n再融资时所作承 | \n诺 | \n股权激励承诺 | \n其他对公司中小 | \n| \n股东所作承诺 | \n| \n承诺是否按时履 | \n| 是 | \n行 | \n| \n如承诺超期未履 | \n行完毕的，应当详 | \n细说明未完成履 | \n| 不适用 | \n行的具体原因及 | \n| \n下一步的工作计 | \n划 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "acfa7db5",
        "b0ee4083"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1048,
      "page_number": 31,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "39x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 39,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          31
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209061",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1048,
        "word_count": 150,
        "sentence_count": 1,
        "chinese_char_count": 646,
        "readability_score": 0.0,
        "information_density": 0.02862595419847328,
        "coherence_score": 0.61,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6277637662883564,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "3709ff15",
      "content": "原列报报表项目及金额  |\n--------------------------------------------------\n应收票据及应收账款 | 586,937,258.10 | 应收票据\n|  | 应收账款\n应付票据及应付账款 | 791,915,463.78 | 应付票据\n|  | 应付账款",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7b5b7c37"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 152,
      "page_number": 32,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应付票据及应付账款",
          "应收",
          "应收账款",
          "应付账款",
          "应付票据",
          "应收票据及应收账款",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209432",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 152,
        "word_count": 19,
        "sentence_count": 2,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.5921052631578947,
        "coherence_score": 0.4875,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43177154989384287,
      "relevance_score": 1.0,
      "keywords": [
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应付票据及应付账款",
        "应收",
        "应收账款",
        "应付账款",
        "应付票据",
        "应收票据及应收账款",
        "应付"
      ]
    },
    {
      "chunk_id": "45e2b9f4",
      "content": "项 目  |\n--------------------------------------------------\n| 2018年12月31日 | 新金融工具准则\n调整影响\n可供出售金融资产 | 1,800,000.00 | -1,800,000.00\n其他权益工具投资 |  | 1,800,000.00\n应收票据 | 107,399,476.04 | -107,399,476.04\n应收款项融资 |  | 107,399,476.04\n其他流动资产 | 227,882,993.23 | -150,000,000.00\n交易性金融资产 |  | 150,000,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "bc005c17"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 290,
      "page_number": 32,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "9x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收款项融资",
          "其他流动资产",
          "应收",
          "其他权益工具",
          "资产",
          "交易性金融资产"
        ],
        "time_periods": [
          "2018-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209504",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 290,
        "word_count": 36,
        "sentence_count": 9,
        "chinese_char_count": 55,
        "readability_score": 0.0,
        "information_density": 0.3793103448275862,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47852789115646255,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收款项融资",
        "其他流动资产",
        "应收",
        "其他权益工具",
        "资产",
        "交易性金融资产"
      ]
    },
    {
      "chunk_id": "63d75739",
      "content": "项 目 | 原金融工具准则  |\n--------------------------------------------------\n| 计量类别 | 账面价值 | 计量类别\n货币资金 | 贷款和应收款项 | 1,956,089,124.33 | 以摊余成本计量的金融资",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "72d82696"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 136,
      "page_number": 32,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "应收",
          "货币资金",
          "应收款项"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209618",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 136,
        "word_count": 19,
        "sentence_count": 1,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.4411764705882352,
        "coherence_score": 0.24,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43240476190476196,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "应收",
        "货币资金",
        "应收款项"
      ]
    },
    {
      "chunk_id": "d7c1acbd",
      "content": "货币资金 | \n--------------------------------------------------\n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 1,956,089,124.33  |\n| \n应收票据 | \n按原CAS22 列示的余额 | 107,399,476.04  |\n减：转出至公允价值计量\n且其变动计入其他综合\n收益(新CAS22) |  | -107,399,476.04 |\n按新CAS22 列示的余额 | \n| \n应收账款 | \n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 479,537,782.06  |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b023f503"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 292,
      "page_number": 33,
      "bbox": [
        97.5,
        80.0,
        497.5,
        460.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "14x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收",
          "货币资金",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209680",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 292,
        "word_count": 41,
        "sentence_count": 4,
        "chinese_char_count": 79,
        "readability_score": 0.0,
        "information_density": 0.136986301369863,
        "coherence_score": 0.47,
        "standards_profile_summary": {}
      },
      "quality_score": 0.503651724137931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收",
        "货币资金",
        "应收账款"
      ]
    },
    {
      "chunk_id": "e0b47cf2",
      "content": "其他应收款 | \n--------------------------------------------------\n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 10,817,853.96  |\n以摊余成本计量的总金\n融资产 | 2,553,844,236.39 | -107,399,476.04 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3f946eab"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 162,
      "page_number": 34,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收款",
          "成本",
          "其他应收款",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          34
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209801",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 162,
        "word_count": 18,
        "sentence_count": 3,
        "chinese_char_count": 33,
        "readability_score": 0.0,
        "information_density": 0.49382716049382713,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4548457364341085,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收款",
        "成本",
        "其他应收款",
        "资产"
      ]
    },
    {
      "chunk_id": "b48e3113",
      "content": "其他流动资产-银行理财\n\n产品 | \n--------------------------------------------------\n按原CAS22 列示的余额 | 150,000,000.00  |\n减：转出至公允价值计量\n且其变动计入当期损益\n(新CAS22) |  | -150,000,000.00 |\n按新CAS22 列示的余额 | \n| \n交易性金融资产-银行理\n财产品 | \n按原CAS22 列示的余额 | \n加：自可供出售金融资产\n(原CAS22)转入 |  | 150,000,000.00 |\n按新CAS22 列示的余额 | \n以公允价值计量且其变\n动计入当期损益 | 150,000,000.00  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "132ff8c7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 315,
      "page_number": 34,
      "bbox": [
        97.5,
        80.0,
        497.5,
        440.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "其他流动资产",
          "交易性金融资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          34
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209874",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 315,
        "word_count": 40,
        "sentence_count": 4,
        "chinese_char_count": 104,
        "readability_score": 0.0,
        "information_density": 0.15873015873015875,
        "coherence_score": 0.35333333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5485873723305477,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他流动资产",
        "交易性金融资产",
        "资产"
      ]
    },
    {
      "chunk_id": "8d03083b",
      "content": "应收款项融资 | \n--------------------------------------------------\n按原CAS22 列示的余额 | \n加：自应收票据(原\nCAS22)转入 |  | 107,399,476.04 |\n按新CAS22 列示的余额 | \n| \n可供出售金融资产 | \n按原CAS22 列示的余额 | 1,800,000.00  |\n减：转出至公允价值计量\n且其变动计入其他综合\n收益(新CAS22) |  | -1,800,000.00 |\n按新CAS22 列示的余额 | \n| \n其他权益工具投资 | \n按原CAS22 列示的余额 | \n加：自可供出售金融资产\n(原CAS22)转入 |  | 1,800,000.00 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "23ee8b82"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 329,
      "page_number": 34,
      "bbox": [
        97.5,
        80.0,
        497.5,
        460.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收款项融资",
          "其他权益工具",
          "应收",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          34
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209994",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 329,
        "word_count": 45,
        "sentence_count": 4,
        "chinese_char_count": 102,
        "readability_score": 0.0,
        "information_density": 0.2735562310030395,
        "coherence_score": 0.4344444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5839971014492754,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收款项融资",
        "其他权益工具",
        "应收",
        "资产"
      ]
    },
    {
      "chunk_id": "9236ce33",
      "content": "### 八、与上年度财务报告相比，合并报表范围发生变化的情况说明\n√ 适用 □ 不适用\n35。\n\n按新CAS22 列示的余额 | \n--------------------------------------------------\n以公允价值计量且其变\n动计入其他综合收益的\n总金融资产 | 1,800,000.00 | 107,399,476.04 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1e7afd2b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 178,
      "page_number": 35,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": true,
        "table_type": "financial_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "其他综合收益",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          35
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210126",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 178,
        "word_count": 19,
        "sentence_count": 3,
        "chinese_char_count": 63,
        "readability_score": 0.0,
        "information_density": 0.33707865168539325,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5275232649338806,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他综合收益",
        "资产"
      ]
    },
    {
      "chunk_id": "167c568d",
      "content": "应付票据 | \n--------------------------------------------------\n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 490,006,533.85  |\n| \n应付账款 | \n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 301,908,929.93  |\n| \n其他应付款 | \n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 24,723,304.20  |\n以摊余成本计量的总金\n融负债 | 816,638,767.98  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1d974035"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 265,
      "page_number": 35,
      "bbox": [
        97.5,
        80.0,
        497.5,
        440.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "14x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "其他应付款",
          "负债",
          "应付款",
          "应付账款",
          "成本",
          "应付票据",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          35
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210204",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 265,
        "word_count": 38,
        "sentence_count": 4,
        "chinese_char_count": 71,
        "readability_score": 0.0,
        "information_density": 0.339622641509434,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4879326860841424,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他应付款",
        "负债",
        "应付款",
        "应付账款",
        "成本",
        "应付票据",
        "应付"
      ]
    },
    {
      "chunk_id": "774224ca",
      "content": "合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n九、聘任、解聘会计师事务所情况\n现聘任的会计师事务所\n境内会计师事务所名称 天健会计师事务所（特殊普通合伙）\n境内会计师事务所报酬（万元） 170\n境内会计师事务所审计服务的连续年限 17年\n境内会计师事务所注册会计师姓名 沈维华 汪兢\n境内会计师事务所注册会计师审计服务的连续年限 沈维华1年 汪兢4年\n当期是否改聘会计师事务所\n□ 是 √ 否\n聘请内部控制审计会计师事务所、财务顾问或保荐人情况\n□ 适用 √ 不适用\n十、年度报告披露后面临暂停上市和终止上市情况\n□ 适用 √ 不适用\n十一、破产重整相关事项\n□ 适用 √ 不适用\n公司报告期未发生破产重整相关事项。十二、重大诉讼、仲裁事项\n√ 适用 □ 不适用\n披 披\n是否形 诉讼(仲\n涉案金额 诉讼(仲裁)进 露 露\n诉讼(仲裁)基本情况 成预计 诉讼(仲裁)审理结果及影响 裁)判决\n（万元） 展 日 索\n负债 执行情况\n期 引\n上海合契投资管理有限公司诉公 上海合契投资案件受理费由上海合契投资管理\n司、东港投资缔约过失责任纠纷一 2,500 否 管理有限公司有限公司负担，此前因诉讼被冻结/ / /\n案 已撤诉 的公司存款已经全部解除冻结。黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 204.01 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n应收账款 | 39,520,283.30  |\n--------------------------------------------------\n其他应收款 | 17,101,274.23  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3fd02199"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 740,
      "page_number": 35,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "34x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "其他应收款",
          "应收账款",
          "应收款"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          35
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210314",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 740,
        "word_count": 97,
        "sentence_count": 5,
        "chinese_char_count": 488,
        "readability_score": 0.0,
        "information_density": 0.0945945945945946,
        "coherence_score": 0.28785714285714287,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4885876817792986,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "其他应收款",
        "应收账款",
        "应收款"
      ]
    },
    {
      "chunk_id": "953275f2",
      "content": "公司名称 | 股权取得方式 | 股权取得时点 | 出资额\n--------------------------------------------------\n盛嘉环保公司 | 设立 | 2019/4/29 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7ef72279"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 105,
      "page_number": 36,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          36
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210573",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 105,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3844075471698113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8326dc32",
      "content": "境内会计师事务所名称 | 天健会计师事务所（特殊普通合伙）\n\n--------------------------------------------------\n境内会计师事务所报酬（万元） | 170\n境内会计师事务所审计服务的连续年限 | 17年\n境内会计师事务所注册会计师姓名 | 沈维华 汪兢\n境内会计师事务所注册会计师审计服务的连续年限 | 沈维华1年 汪兢4年",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8ded8675"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 187,
      "page_number": 36,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          36
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210646",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 187,
        "word_count": 18,
        "sentence_count": 0,
        "chinese_char_count": 103,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5869311827956989,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f7d0299a",
      "content": "黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 747.56 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n十三、处罚及整改情况\n□ 适用 √ 不适用\n公司报告期不存在处罚及整改情况。十四、公司及其控股股东、实际控制人的诚信状况\n□ 适用 √ 不适用\n十五、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况\n√ 适用 □ 不适用\n1、限制性股票激励计划简介\n（1）公司于2015年1月20日召开第四届董事会第十二次会议审议通过了《浙江海翔药业股\n份有限公司限制性股票激励计划（草案）》及其摘要等相关议案。随后公司向中国证监会上\n报了申请备案材料。\n| 披 | 披\n--------------------------------------------------\n|  | 是否形 | 诉讼(仲  |\n| 涉案金额 |  | 诉讼(仲裁)进 | 露 | 露\n诉讼(仲裁)基本情况 |  | 成预计 |  | 诉讼(仲裁)审理结果及影响 | 裁)判决  |\n| （万元） |  | 展 | 日 | 索\n|  | 负债 | 执行情况  |\n| 期 | 引\n| \n上海合契投资管理有限公司诉公 | 上海合契投资 | 案件受理费由上海合契投资管理 | \n司、东港投资缔约过失责任纠纷一 | 2,500 | 否 | 管理有限公司 | 有限公司负担，此前因诉讼被冻结 | / | / | /\n案 | 已撤诉 | 的公司存款已经全部解除冻结。 | \n黄小留、张伟诉江苏天腾建设集团 | \n有限公司、江苏海阔生物医药有限 | 204.01 | 否 | 败诉，已结案 | 已支付全部款项 | 已执行 | / | /\n公司建设工程施工合同纠纷一案 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0c17f621"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 745,
      "page_number": 36,
      "bbox": [
        47.5,
        80.0,
        547.5,
        660.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "25x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 25,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [
          "负债"
        ],
        "time_periods": [
          "2015-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          36
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210722",
        "report_type": "financial_report",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 745,
        "word_count": 124,
        "sentence_count": 6,
        "chinese_char_count": 435,
        "readability_score": 0.0,
        "information_density": 0.040268456375838924,
        "coherence_score": 0.5917897091722595,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6753263122709767,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债"
      ]
    },
    {
      "chunk_id": "6b94f7dd",
      "content": "### 5、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于回购注销已离职激\n37。\n\n励对象所持已获授但尚未解锁的限制性股票的议案》。由于原激励对象林宇峰、丁春明已经\n离职，根据相关规定及股东大会授权，公司董事会对林宇峰、丁春明已离职激励对象所持已\n获授但尚未解锁的限制性股票共计24万股进行回购注销。2016年5月完成上述股票回购注销。\n黄小留、张伟诉江苏天腾建设集团 | \n--------------------------------------------------\n有限公司、江苏海阔生物医药有限 | 747.56 | 否 | 败诉，已结案 | 已支付全部款项 | 已执行 | / | /\n公司建设工程施工合同纠纷一案 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "707eee20"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 352,
      "page_number": 37,
      "bbox": [
        53.5,
        80.0,
        541.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x8",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2016-3",
          "2016-5"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210967",
        "report_type": "financial_report",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 352,
        "word_count": 27,
        "sentence_count": 5,
        "chinese_char_count": 223,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6137956655246796,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "679f44cc",
      "content": "十六、重大关联交易\n1、与日常经营相关的关联交易\n√ 适用 □ 不适用\n关 是\n关 关 联 否\n可获\n联 联 交 占同类 获批的 超 关联\n关联 关联交易 得的\n关联关 交 交 易 关联交易 交易金 交易额 过 交易 披露\n交易 金额（万 同类 披露索引\n系 易 易 定 价格 额的比 度（万 获 结算 日期\n方 元） 交易\n类 内 价 例 元） 批 方式\n市价\n型 容 原 额\n则 度\n浙江 原 市 《2019年度日常关联交易预\n采 不同规格， 银行\n荣兴 控股股 料 场 2019 计的公告》公告编号\n购 单价从 存款 未偏\n活性 东持有 材 公 年02 2019-012，内容详见巨潮资讯\n活 5500元/吨 278.51 28.94% 2,800否 或承 离市\n炭有 其50%料 允 月18 网及《证券时报》、《上海证\n性 至15500元 兑汇 场价\n限公 股权 采 价 日 券报》、《中国证券报》、《证\n炭 /吨不等 票\n司 购 格 券日报》\n采\n原 购 市 《2019年度日常关联交易预\n江西 银行\n料 原 场 2019 计的公告》公告编号\n华邦 控股股 400元/千克 存款 未偏\n材 料 公 年02 2019-012，内容详见巨潮资讯\n药业 东控制 至420元/ 2,730.75 1.06% 5,000否 或承 离市\n料 药 允 月18 网及《证券时报》、《上海证\n有限 企业 千克 兑汇 场价\n采 中 价 日 券报》、《中国证券报》、《证\n公司 票\n购 间 格 券日报》\n体\n销 销\n售 售 市\n江西 银行\n原 原 场\n华邦 控股股 存款 未偏\n料 料 公 市场公允 不适\n药业 东控制 5 0.01% 不适用否 或承 离市 不适用\n药 药 允 价格 用\n有限 企业 兑汇 场价\n中 中 价\n公司 票\n间 间 格\n体 体\n台州\n市\n市东 采 采 银行\n场\n港包 控股股 购 购 存款 未偏\n公 市场公允 不适\n装用 东控制 原 原 0.44 0.00% 不适用否 或承 离市 不适用\n允 价格 用\n品有 企业 材 材 兑汇 场价\n价\n限公 料 料 票\n格\n司\n| 关 | 是 | \n--------------------------------------------------\n|  | 关 | 关 | 联 | 否 | \n| 可获  |\n|  | 联 | 联 | 交 | 占同类 | 获批的 | 超 | 关联 | \n关联 | 关联交易 | 得的  |\n| 关联关 | 交 | 交 | 易 | 关联交易 |  | 交易金 | 交易额 | 过 | 交易 |  | 披露 |\n交易 | 金额（万 | 同类 |  | 披露索引\n| 系 | 易 | 易 | 定 | 价格 |  | 额的比 | 度（万 | 获 | 结算 |  | 日期 |\n方 | 元） | 交易  |\n|  | 类 | 内 | 价 | 例 | 元） | 批 | 方式 | \n| 市价  |\n|  | 型 | 容 | 原 | 额 | \n| \n| 则 | 度 | \n浙江 |  | 原 |  | 市 | 《2019年度日常关联交易预\n| 采 |  | 不同规格， | 银行 | \n荣兴 | 控股股 | 料 |  | 场 | 2019 | 计的公告》公告编号\n| 购 |  | 单价从 | 存款 | 未偏  |\n活性 | 东持有 | 材 |  | 公 | 年02 | 2019-012，内容详见巨潮资讯\n| 活 |  | 5500元/吨 | 278.51 | 28.94% | 2,800 | 否 | 或承 | 离市  |\n炭有 | 其50% | 料 |  | 允 | 月18 | 网及《证券时报》、《上海证\n| 性 |  | 至15500元 | 兑汇 | 场价  |\n限公 | 股权 | 采 |  | 价 | 日 | 券报》、《中国证券报》、《证\n| 炭 |  | /吨不等 | 票 | \n司 |  | 购 |  | 格 | 券日报》\n| \n| 采 | \n|  | 原 | 购 | 市 | 《2019年度日常关联交易预\n江西 | 银行 | \n|  | 料 | 原 | 场 | 2019 | 计的公告》公告编号\n华邦 | 控股股 | 400元/千克 | 存款 | 未偏  |\n|  | 材 | 料 | 公 | 年02 | 2019-012，内容详见巨潮资讯\n药业 | 东控制 | 至420元/ | 2,730.75 | 1.06% | 5,000 | 否 | 或承 | 离市  |\n|  | 料 | 药 | 允 | 月18 | 网及《证券时报》、《上海证\n有限 | 企业 | 千克 | 兑汇 | 场价  |\n|  | 采 | 中 | 价 | 日 | 券报》、《中国证券报》、《证\n公司 | 票 | \n|  | 购 | 间 | 格 | 券日报》\n| \n| 体 | \n|  | 销 | 销 | \n|  | 售 | 售 | 市 | \n江西 | 银行 | \n|  | 原 | 原 | 场 | \n华邦 | 控股股 | 存款 | 未偏  |\n|  | 料 | 料 | 公 | 市场公允 | 不适 |\n药业 | 东控制 | 5 | 0.01% | 不适用 | 否 | 或承 | 离市 |  | 不适用\n|  | 药 | 药 | 允 | 价格 | 用 |\n有限 | 企业 | 兑汇 | 场价  |\n|  | 中 | 中 | 价 | \n公司 | 票 | \n|  | 间 | 间 | 格 | \n| \n|  | 体 | 体 | \n台州 | \n| 市 | \n市东 |  | 采 | 采 | 银行 | \n| 场 | \n港包 | 控股股 | 购 | 购 | 存款 | 未偏  |\n| 公 | 市场公允 | 不适 |\n装用 | 东控制 | 原 | 原 | 0.44 | 0.00% | 不适用 | 否 | 或承 | 离市 |  | 不适用\n| 允 | 价格 | 用 |\n品有 | 企业 | 材 | 材 | 兑汇 | 场价  |\n| 价 | \n限公 |  | 料 | 料 | 票 | \n| 格 | \n司 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2dc4bb41",
        "f29accbc",
        "c251d22b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2529,
      "page_number": 39,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "129x11",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 129,
        "column_count": 11,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          39
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.211089",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2529,
        "word_count": 834,
        "sentence_count": 14,
        "chinese_char_count": 943,
        "readability_score": 0.0,
        "information_density": 0.015816528272044286,
        "coherence_score": 0.5700000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5983177147201093,
      "relevance_score": 1.0,
      "keywords": [
        "经营",
        "5500元",
        "15500元",
        "400元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b922751c",
      "content": "台州艾斐科技有限公司和台州市振港染料化工有限公司电费由台州市振港染料化工有限公司\n统一向供电公司支付，台州市振港染料化工有限公司完成电费支付后再向台州艾斐科技有限公司收取相关电费。2019年度上\n述关联交易总金额为45.66万元。十七、重大合同及其履行情况\n1、托管、承包、租赁事项情况\n（1）托管情况\n□ 适用 √ 不适用\n公司报告期不存在托管情况。\n合计 | -- | -- | 3,014.7 | -- | 7,800 | -- | -- | -- | -- | --\n--------------------------------------------------\n大额销货退回的详细情 | \n| 不适用 | \n况 | \n| \n按类别对本期将发生的 | \n| 2019年度，公司与上述关联方日常关联交易的实际发生总金额未超过预计总金额。实际发生情况 | \n日常关联交易进行总金 | \n| 与预计存在较大差异的原因为：公司与关联方的年度日常关联交易预计是基于公司业务开展进行的 | \n额预计的，在报告期内 | \n| 初步判断，较难实现准确预计，因此与实际发生情况存在一定的差异。 | \n的实际履行情况（如有） | \n| \n交易价格与市场参考价 | \n格差异较大的原因（如 | 不适用 | \n适用） |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f764b28b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 555,
      "page_number": 40,
      "bbox": [
        47.5,
        80.0,
        547.5,
        580.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "20x11",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 20,
        "column_count": 11,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          40
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.212035",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司和台州市振港染料化工有限公司电费由台州市振港染料化工有限公司",
        "industry": null,
        "char_count": 555,
        "word_count": 66,
        "sentence_count": 7,
        "chinese_char_count": 330,
        "readability_score": 0.0,
        "information_density": 0.01801801801801802,
        "coherence_score": 0.7051282051282051,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6041709090909092,
      "relevance_score": 1.0,
      "keywords": [
        "45.66万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9794f116",
      "content": "（2）承包情况\n□ 适用 √ 不适用\n公司报告期不存在承包情况。（3）租赁情况\n□ 适用 √ 不适用\n公司报告期不存在租赁情况。2、重大担保\n√ 适用 □ 不适用\n（1）担保情况\n单位：万元\n公司及其子公司对外担保情况（不包括对子公司的担保）\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n报告期内审批的对外担保额度合 报告期内对外担保实际发\n0 0\n计（A1） 生额合计（A2）\n报告期末已审批的对外担保额度 报告期末实际对外担保余\n0 0\n合计（A3） 额合计（A4）\n公司对子公司的担保情况\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n浙江海翔川南药业有 2018年04 2019年02月27 连带责任保 2019-02-27~\n20,000 5,000 是 否\n限公司 月04日 日 证 2019-05-17\n浙江海翔川南药业有 2018年04 2019年12月24 连带责任保 2019-12-24~\n20,000 42.4 否 否\n限公司 月04日 日 证 2020-12-24\n报告期内审批对子公司担保额度 报告期内对子公司担保实\n0 5,042.4\n合计（B1） 际发生额合计（B2）\n报告期末已审批的对子公司担保 报告期末对子公司实际担\n20,000 42.4\n额度合计（B3） 保余额合计（B4）\n子公司对子公司的担保情况\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n公司及其子公司对外担保情况（不包括对子公司的担保） | \n--------------------------------------------------\n| 担保额度 | \n| 实际担保金 | 是否履行 | 是否为关\n担保对象名称 | 相关公告 | 担保额度 | 实际发生日期 |  | 担保类型 | 担保期  |\n| 额 | 完毕 | 联方担保\n| 披露日期 | \n| \n报告期内审批的对外担保额度合 | 报告期内对外担保实际发 | \n|  | 0 | 0  |\n计（A1） | 生额合计（A2） | \n| \n报告期末已审批的对外担保额度 | 报告期末实际对外担保余 | \n|  | 0 | 0  |\n合计（A3） | 额合计（A4） | \n| \n公司对子公司的担保情况 | \n| 担保额度 | \n| 实际担保金 | 是否履行 | 是否为关\n担保对象名称 | 相关公告 | 担保额度 | 实际发生日期 |  | 担保类型 | 担保期  |\n| 额 | 完毕 | 联方担保\n| 披露日期 | \n| \n浙江海翔川南药业有 | 2018年04 |  | 2019年02月27 |  | 连带责任保 | 2019-02-27~  |\n|  | 20,000 |  | 5,000 | 是 | 否\n限公司 | 月04日 |  | 日 |  | 证 | 2019-05-17  |\n| \n浙江海翔川南药业有 | 2018年04 |  | 2019年12月24 |  | 连带责任保 | 2019-12-24~  |\n|  | 20,000 |  | 42.4 | 否 | 否\n限公司 | 月04日 |  | 日 |  | 证 | 2020-12-24  |\n| \n报告期内审批对子公司担保额度 | 报告期内对子公司担保实 | \n|  | 0 | 5,042.4  |\n合计（B1） | 际发生额合计（B2） | \n| \n报告期末已审批的对子公司担保 | 报告期末对子公司实际担 | \n|  | 20,000 | 42.4  |\n额度合计（B3） | 保余额合计（B4） | \n| \n子公司对子公司的担保情况 | \n| 担保额度 | \n| 实际担保金 | 是否履行 | 是否为关\n担保对象名称 | 相关公告 | 担保额度 | 实际发生日期 |  | 担保类型 | 担保期  |\n| 额 | 完毕 | 联方担保\n| 披露日期 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2c0675db",
        "8a399f08"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1747,
      "page_number": 41,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "80x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 80,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-02",
          "2019-02-27",
          "2019-05-17",
          "2019-12",
          "2019-12-24",
          "2020-12-24"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          41
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.212252",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1747,
        "word_count": 347,
        "sentence_count": 8,
        "chinese_char_count": 839,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.44002070496774814,
        "standards_profile_summary": {}
      },
      "quality_score": 0.615989726436507,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "19342b54",
      "content": "台州市振港染料化工 2017年04 2019年01月15 连带责任保 2019-01-15~\n6,000 240 否 否\n有限公司 月21日 日 证 2020-01-15\n台州市振港染料化工 2017年04 2019年01月23 连带责任保 2019-01-23~\n6,000 172 否 否\n有限公司 月21日 日 证 2020-01-23\n台州市振港染料化工 2017年04 2019年03月22 连带责任保 2019-03-22~\n6,000 523.52 否 否\n有限公司 月21日 日 证 2020-03-22\n报告期内审批对子公司担保额度 报告期内对子公司担保实\n0 935.52\n合计（C1） 际发生额合计（C2）\n报告期末已审批的对子公司担保 报告期末对子公司实际担\n0 935.52\n额度合计（C3） 保余额合计（C4）\n公司担保总额（即前三大项的合计）\n报告期内审批担保额度合计 报告期内担保实际发生额\n0 5,977.92\n（A1+B1+C1） 合计（A2+B2+C2）\n报告期末已审批的担保额度合计 报告期末实际担保余额合\n20,000 977.92\n（A3+B3+C3） 计（A4+B4+C4）\n实际担保总额（即A4+B4+C4）占公司净资产的比例 0.17%\n其中：\n为股东、实际控制人及其关联方提供担保的余额（D） 0\n直接或间接为资产负债率超过70%的被担保对象提供的债务\n0\n担保余额（E）\n担保总额超过净资产50%部分的金额（F） 0\n上述三项担保金额合计（D+E+F） 0\n对未到期担保，报告期内已发生担保责任或可能承担连带清偿\n不适用\n责任的情况说明（如有）\n违反规定程序对外提供担保的说明（如有） 不适用\n采用复合方式担保的具体情况说明\n不适用\n（2）违规对外担保情况\n□ 适用 √ 不适用\n公司报告期无违规对外担保情况。3、委托他人进行现金资产管理情况\n（1）委托理财情况\n√ 适用 □ 不适用\n报告期内委托理财概况\n台州市振港染料化工 | 2017年04 |  | 2019年01月15 |  | 连带责任保 | 2019-01-15~  |\n--------------------------------------------------\n|  | 6,000 |  | 240 | 否 | 否\n有限公司 | 月21日 |  | 日 |  | 证 | 2020-01-15  |\n| \n台州市振港染料化工 | 2017年04 |  | 2019年01月23 |  | 连带责任保 | 2019-01-23~  |\n|  | 6,000 |  | 172 | 否 | 否\n有限公司 | 月21日 |  | 日 |  | 证 | 2020-01-23  |\n| \n台州市振港染料化工 | 2017年04 |  | 2019年03月22 |  | 连带责任保 | 2019-03-22~  |\n|  | 6,000 |  | 523.52 | 否 | 否\n有限公司 | 月21日 |  | 日 |  | 证 | 2020-03-22  |\n| \n报告期内审批对子公司担保额度 | 报告期内对子公司担保实 | \n|  | 0 | 935.52  |\n合计（C1） | 际发生额合计（C2） | \n| \n报告期末已审批的对子公司担保 | 报告期末对子公司实际担 | \n|  | 0 | 935.52  |\n额度合计（C3） | 保余额合计（C4） | \n| \n公司担保总额（即前三大项的合计） | \n报告期内审批担保额度合计 | 报告期内担保实际发生额 | \n|  | 0 | 5,977.92  |\n（A1+B1+C1） | 合计（A2+B2+C2） | \n| \n报告期末已审批的担保额度合计 | 报告期末实际担保余额合 | \n|  | 20,000 | 977.92  |\n（A3+B3+C3） | 计（A4+B4+C4） | \n| \n实际担保总额（即A4+B4+C4）占公司净资产的比例 | 0.17% | \n其中： | \n为股东、实际控制人及其关联方提供担保的余额（D） | 0 | \n直接或间接为资产负债率超过70%的被担保对象提供的债务 | \n| 0 | \n担保余额（E） | \n| \n担保总额超过净资产50%部分的金额（F） | 0 | \n上述三项担保金额合计（D+E+F） | 0 | \n对未到期担保，报告期内已发生担保责任或可能承担连带清偿 | \n| 不适用 | \n责任的情况说明（如有） | \n| \n违反规定程序对外提供担保的说明（如有） | 不适用 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f8e16881",
        "e7a7cab9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1908,
      "page_number": 42,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "76x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 76,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债"
        ],
        "time_periods": [
          "2019-01",
          "2019-01-15",
          "2019-01-23",
          "2019-03",
          "2019-03-22",
          "2020-01-15",
          "2020-01-23",
          "2020-03-22"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.212838",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1908,
        "word_count": 304,
        "sentence_count": 13,
        "chinese_char_count": 802,
        "readability_score": 0.0,
        "information_density": 0.020964360587002098,
        "coherence_score": 0.7905839008596629,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7478477188533846,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债"
      ]
    },
    {
      "chunk_id": "a16cbec0",
      "content": "截止2019年2月25日公司\n回购方案实施完成，公司通过集中竞价方式累计回购股份数量63,005,888股，占公司总股本的\n3.8921%，支付总金额301,511,513.90元（含交易费用）。维护了广大投资者利益，增强投资\n者对公司的投资信心。（2）员工权益保护\n公司多年以来一直将员工视为公司发展前进道路上最为宝贵的财富和动力源泉。\n具体类型 | 委托理财的资金来源 | 委托理财发生额 | 未到期余额 | 逾期未收回的金额\n--------------------------------------------------\n银行理财产品 | 暂时闲置自有资金 | 10,000 | 0 | 0\n银行理财产品 | 暂时闲置募集资金 | 21,000 | 0 | 0\n合计 |  | 31,000 | 0 | 0",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5f05445a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 359,
      "page_number": 43,
      "bbox": [
        93.5,
        80.0,
        501.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-2"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          43
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.213433",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 359,
        "word_count": 41,
        "sentence_count": 5,
        "chinese_char_count": 178,
        "readability_score": 0.0,
        "information_density": 0.08356545961002786,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4854817357001972,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资",
        "513.90元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b2325fc5",
      "content": "（5）促进地方教育事业发展\n为积极履行社会责任、促进地方教育事业的发展，公司向台州职业技术学院涌泉奖助基\n金会捐赠人民币132万元，用于促进台州职业技术学院的发展，奖励优秀学生和教师，资助贫\n困学生顺利完成学业，为社会培养更多更好的优秀人才。2、履行精准扶贫社会责任情况\n公司报告年度暂未开展精准扶贫工作，也暂无后续精准扶贫计划。3、环境保护相关的情况\n上市公司及其子公司是否属于环境保护部门公布的重点排污单位\n是\n主要污染物\n公司或子公 排放口分布 执行的污染 核定的排放超标排放情\n及特征污染 排放方式 排放口数量 排放浓度 排放总量\n司名称 情况 物排放标准 总量 况\n物的名称\n| 主要污染物 | \n--------------------------------------------------\n公司或子公 | 排放口分布 |  | 执行的污染 |  | 核定的排放 | 超标排放情\n| 及特征污染 | 排放方式 | 排放口数量 |  | 排放浓度 |  | 排放总量  |\n司名称 | 情况 |  | 物排放标准 |  | 总量 | 况\n| 物的名称 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ff694486"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 488,
      "page_number": 44,
      "bbox": [
        97.5,
        80.0,
        497.5,
        500.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          44
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.213568",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 488,
        "word_count": 66,
        "sentence_count": 2,
        "chinese_char_count": 320,
        "readability_score": 0.0,
        "information_density": 0.020491803278688527,
        "coherence_score": 0.67,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4980210961484132,
      "relevance_score": 1.0,
      "keywords": [
        "132万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e734f6ff",
      "content": "COD:66.45\nCOD≤500m 污水综合排COD：18.9\n浙江海翔药 吨/年(纳管\nCOD、氨 g/L；氨氮 放标准 吨(纳管量);\n业股份有限 间歇 1 厂界内 量)；氨氮：无\n氮、PH ≤35mg/L； （GB8978- 氨氮：1.32\n公司 4.65吨/年\nPH 6-9 1996） 吨(纳管量)\n(纳管量)\n化学合成类\n制药工业大\n浙江海翔药\nVOCs≤150 气污染物排未超过核定VOCs≤12.4\n业股份有限VOCs 连续 1 厂界内 无\n（mg/m3） 放标准 排放总量 2（吨/年）\n公司\nDB33/2015-\n2016\nCOD纳管\n195.45吨/\nCOD≤500/ 污水综合排COD纳管 年(排环境\n浙江海翔川\nCOD、氨 L；氨氮 放标准 190.84吨；量39.09\n南药业有限 间歇 1 厂界内 无\n氮、PH ≤35mg/L； （GB8978- 氨氮纳管 吨)；氨氮纳\n公司\nPH6-9 1996） 13.35吨 管13.68吨/\n年(排环境\n量5.91吨)\nVOCs≤150\n（mg/m3）； VOCs 22.13\n二氧化硫 污水综合排 吨/年；二氧\n浙江海翔川VOCs、二\n≤200 放标准 未超过核定化硫15.2吨\n南药业有限氧化硫、氮间歇 2 厂界内 无\n（mg/m3）；（GB8978- 排放总量 /年；氮氧化\n公司 氧化物\n氮氧化物 1996） 物36.78吨/\n≤400 年\n（mg/m3）\n浙江海翔川\n委托有资质 按照环评核\n南药业有限固废 / / / 3762.85吨 5129吨/年 无\n单位处置 实标准\n公司\n台州市前进\n污水综合排 COD：\n化工有限公 COD<500m COD：8.321\nCOD、氨 放标准 27.164吨/\n司、台州市 间歇 1 厂界内 g/L；氨氮 吨：氨氮： 无\n氮、PH （GB8978- 年；氨氮：\n振港染料化 <35mg/L 1.248吨\n1996） 3.551吨/年\n工有限公司\n| COD:66.45 |\n--------------------------------------------------\n| COD≤500m | 污水综合排 | COD：18.9  |\n浙江海翔药 | 吨/年(纳管 |\n| COD、氨 | g/L；氨氮 | 放标准 | 吨(纳管量);  |\n业股份有限 |  | 间歇 | 1 | 厂界内 | 量)；氨氮： | 无\n| 氮、PH | ≤35mg/L； | （GB8978- | 氨氮：1.32  |\n公司 | 4.65吨/年 |\n| PH 6-9 | 1996） | 吨(纳管量)  |\n| (纳管量) |\n| \n| 化学合成类 | \n| 制药工业大 | \n浙江海翔药 | \n| VOCs≤150 | 气污染物排 | 未超过核定 | VOCs≤12.4 |\n业股份有限 | VOCs | 连续 | 1 | 厂界内 | 无\n| （mg/m3） | 放标准 | 排放总量 | 2（吨/年） |\n公司 | \n| DB33/2015- | \n| \n| 2016 | \n| COD纳管 |\n| 195.45吨/ |\n| COD≤500/ | 污水综合排 | COD纳管 | 年(排环境 |\n浙江海翔川 | \n| COD、氨 | L；氨氮 | 放标准 | 190.84吨； | 量39.09 |\n南药业有限 |  | 间歇 | 1 | 厂界内 | 无\n| 氮、PH | ≤35mg/L； | （GB8978- | 氨氮纳管 | 吨)；氨氮纳 |\n公司 | \n| PH6-9 | 1996） | 13.35吨 | 管13.68吨/ |\n| \n| 年(排环境 |\n| 量5.91吨) |\n| VOCs≤150 | \n| （mg/m3）； | VOCs 22.13 |\n| 二氧化硫 | 污水综合排 |  | 吨/年；二氧 |\n浙江海翔川 | VOCs、二 | \n| ≤200 | 放标准 | 未超过核定 | 化硫15.2吨 |\n南药业有限 | 氧化硫、氮 | 间歇 | 2 | 厂界内 | 无\n| （mg/m3）； | （GB8978- | 排放总量 | /年；氮氧化 |\n公司 | 氧化物 | \n| 氮氧化物 | 1996） |  | 物36.78吨/ |\n| \n| ≤400 | 年 |\n| （mg/m3） | \n浙江海翔川 | \n|  | 委托有资质 | 按照环评核 | \n南药业有限 | 固废 |  | / | / | / |  | 3762.85吨 | 5129吨/年 | 无\n|  | 单位处置 | 实标准 | \n公司 | \n| \n台州市前进 | \n| 污水综合排 |  | COD： |\n化工有限公 | COD<500m |  | COD：8.321  |\n| COD、氨 | 放标准 |  | 27.164吨/ |\n司、台州市 |  | 间歇 | 1 | 厂界内 | g/L；氨氮 |  | 吨：氨氮： |  | 无\n| 氮、PH | （GB8978- |  | 年；氨氮： |\n振港染料化 | <35mg/L |  | 1.248吨  |\n| 1996） |  | 3.551吨/年 |\n工有限公司 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ef03799f",
        "bcef109b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2171,
      "page_number": 45,
      "bbox": [
        85.5,
        80.0,
        509.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "108x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 108,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          45
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.213737",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2171,
        "word_count": 475,
        "sentence_count": 38,
        "chinese_char_count": 618,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.2995704295704295,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5868390790923216,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "c3867489",
      "content": "2019年8月，瓯华化工收到盐城市生态环境局出具的《行政处罚决定书》：2019年5月，盐城\n市生态环境局在现场检查中发现瓯华化工存在危废管理不规范情况，鉴于瓯华化工已主动整\n改到位，符合《盐城市生态环境局行政案件办理程序规定》第七条“主动消除或者减轻环境违\n法行为危害后果的”等从轻处罚的适用条款，对瓯华化工从轻处罚，处罚款人民币四万元。2019年10月，台州前进收到台州市生态环境局出具的《行政处罚决定书》： 2019年5月台州\n前进存在排放不符合大气污染物排放标准废气的情形，后果轻微，处罚款人民币十万元。其他环保相关信息\n无\n十九、其他重大事项的说明\n□ 适用 √ 不适用\n公司报告期不存在需要说明的其他重大事项。\n| VOCs≤120 | \n--------------------------------------------------\n| VOCs： |\n| （mg/m3）； | \n| 32.337吨/ |\n| 二氧化硫 | 大气污染综 | \n台州市前进 | VOCs、二 | 年；二氧化 | 见其他应公\n| <550 | 合排放标准 | 未超过核定  |\n化工有限公 | 氧化硫、氮 | 连续 | 2 | 厂界内 | 硫：2.286 | 开的环境信\n| （mg/m3）； | （GB16297 | 排放总量  |\n司 | 氧化物 | 吨/年；氮氧 | 息\n| 氮氧化物 | -1996） | \n| 化物17.562 |\n| <240 | \n| 吨/年 |\n| （mg/m3） | \n| \n台州市前进 | \n化工有限公 | \n|  | 委托有资质 | 按照环评核 | \n司、台州市 | 危险固废 |  | / | / | / |  | 661.46吨 | 2384吨/年 | 无\n|  | 单位处置 | 实标准 | \n振港染料化 | \n| \n工有限公司 | \n| VOCs≤80 | \n| VOCs： |\n| （mg/m3）； | \n| 大气污染物 |  | 9.553吨/ |\n| 二氧化硫 | \n盐城市瓯华 | VOCs、二 | 综合排放标 |  | 年；二氧化 |\n| ≤550 |  | 未超过核定  |\n化学工业有 | 氧化硫、氮 | 间歇 | 8 | 厂界内 |  | 准 |  | 硫 10.875 | 无\n| （mg/m3）； |  | 排放总量  |\n限公司 | 氧化物 | （GB16297 |  | 吨/年；氮氧 |\n| 氮氧化物 | \n| -1996） |  | 化物11.986 |\n| ≤240 | \n| 吨/年 |\n| （mg/m3） | \n| \n盐城市瓯华 |  | 自行焚烧、 | \n| 按照环评核 |  | 6017.333吨 |\n化学工业有 | 固废 | 委托资质单 | / | / | / |  | 2410.811吨 |  | 无\n| 实标准 |  | /年 |\n限公司 |  | 位处置 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fd685657",
        "1e8432dd"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1229,
      "page_number": 46,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "50x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 50,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-10",
          "2019-5",
          "2019-8"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.214594",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1229,
        "word_count": 253,
        "sentence_count": 12,
        "chinese_char_count": 485,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.28276595744680855,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6000154293433335,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "43c42095",
      "content": "内容详见公司于《中国证券报》、《上海证券报》、《证券时报》、\n《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《回购报告书》（公告编\n| 本次变动前 |  | 本次变动增减（＋，－） | 本次变动后 |\n--------------------------------------------------\n| \n| 数量 | 比例 | 发行新股 | 送股 | 公积金转股 | 其他 | 小计 | 数量 | 比例\n| \n一、有限售条件股份 | 27,076,100 | 1.68% | -12,801,500 | -12,801,500 | 14,274,600 | 0.88%\n3、其他内资持股 | 27,076,100 | 1.68% | -12,801,500 | -12,801,500 | 14,274,600 | 0.88%\n境内自然人持股 | 27,076,100 | 1.68% | -12,801,500 | -12,801,500 | 14,274,600 | 0.88%\n二、无限售条件股份 | 1,591,744,153 | 98.33% | 12,696,500 | 12,696,500 | 1,604,440,653 | 99.12%\n1、人民币普通股 | 1,591,744,153 | 98.33% | 12,696,500 | 12,696,500 | 1,604,440,653 | 99.12%\n三、股份总数 | 1,618,820,253 | 100.00% | -105,000 | -105,000 | 1,618,715,253 | 100.00%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2df7644f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 714,
      "page_number": 48,
      "bbox": [
        47.5,
        80.0,
        547.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "10x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          48
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.215231",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 714,
        "word_count": 109,
        "sentence_count": 15,
        "chinese_char_count": 121,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5567466120344366,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b6968622",
      "content": "具体内容详见公司于《中国证券报》、《上海证券报》、\n《证券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于回购公\n司股份实施完成的公告》（公告编号:2019-019）。采用集中竞价方式减持回购股份的实施进展情况\n□ 适用 √ 不适用\n股份变动对最近一年和最近一期基本每股收益和稀释每股收益、归属于公司普通股股东的每股净资产等财务指标的影响\n□ 适用 √ 不适用\n公司认为必要或证券监管机构要求披露的其他内容\n□ 适用 √ 不适用\n2、限售股份变动情况\n√ 适用 □ 不适用\n单位：股\n本期增加限售股 本期解除限售股\n股东名称 期初限售股数 期末限售股数 限售原因 解除限售日期\n数 数\n299名限制性股 限制性股票激励\n12,696,500 0 12,696,500 0 2019年4月4日\n票激励对象 计划第四期解锁\n回购离职激励对\n回购5人限制性\n105,000 0 105,000 0象持有的尚未解 2019年6月24日\n股票\n禁的限制性股票\n合计 12,801,500 0 12,801,500 0 -- --\n|  | 本期增加限售股 | 本期解除限售股 | \n--------------------------------------------------\n股东名称 | 期初限售股数 | 期末限售股数 | 限售原因 | 解除限售日期\n|  | 数 | 数 | \n| \n299名限制性股 | 限制性股票激励 |\n| 12,696,500 | 0 | 12,696,500 | 0 |  | 2019年4月4日\n票激励对象 | 计划第四期解锁 |\n| \n| 回购离职激励对 |\n回购5人限制性 | \n| 105,000 | 0 | 105,000 | 0 | 象持有的尚未解 | 2019年6月24日\n股票 | \n| 禁的限制性股票 |\n| \n合计 | 12,801,500 | 0 | 12,801,500 | 0 | -- | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6196e0a2"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 849,
      "page_number": 49,
      "bbox": [
        81.5,
        80.0,
        513.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-4",
          "2019-6"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.215461",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 849,
        "word_count": 136,
        "sentence_count": 4,
        "chinese_char_count": 386,
        "readability_score": 0.0,
        "information_density": 0.02355712603062426,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6069286492346283,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "091a1209",
      "content": "二、证券发行与上市情况\n1、报告期内证券发行（不含优先股）情况\n□ 适用 √ 不适用\n2、公司股份总数及股东结构的变动、公司资产和负债结构的变动情况说明\n√ 适用 □ 不适用\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。3、现存的内部职工股情况\n□ 适用 √ 不适用\n三、股东和实际控制人情况\n1、公司股东数量及持股情况\n单位：股\n年度报告披露\n报告期末表决\n年度报告披露 日前上一月末\n权恢复的优先\n报告期末普通 日前上一月末 表决权恢复的\n71,441 71,441股股东总数 0 0\n股股东总数 普通股股东总 优先股股东总\n（如有）（参见\n数 数（如有）（参\n注8）\n见注8）\n持股5%以上的股东或前10名股东持股情况\n报告期内 持有有限 持有无限 质押或冻结情况\n报告期末\n股东名称 股东性质 持股比例 增减变动 售条件的 售条件的\n持股数量 股份状态 数量\n情况 股份数量 股份数量\n浙江东港投资有 553,982,5-2201741 553,982,5\n境内非国有法人 34.22% 0 质押 241,382,587\n限公司 873 87\n118,800,0 118,800,0\n王云富 境内自然人 7.34% 0 0\n00 00\n新昌勤进投资有 49,650,00-1435000 49,650,00\n境内非国有法人 3.07% 0\n限公司 00 0\n香港中央结算有 21,438,17 21,438,17\n境外法人 1.32% 18018169 0\n限公司 8 8\n14,350,00 14,350,00\n王丽英 境内自然人 0.89% 14350000 0\n0 0\n| 年度报告披露\n日前上一月末\n普通股股东总\n数 | 年度报告披露  |\n--------------------------------------------------\n| 报告期末表决 | \n| 日前上一月末  |\n| 权恢复的优先 | \n报告期末普通 | 表决权恢复的  |\n| 71,441 | 71,441 |  | 股股东总数 |  | 0 | 0\n股股东总数 | 优先股股东总  |\n| （如有）（参见 | \n| 数（如有）（参  |\n| 注8） | \n| 见注8）  |\n| \n持股5%以上的股东或前10名股东持股情况 | \n| 报告期内 |  | 持有有限 | 持有无限 | 质押或冻结情况 | \n| 报告期末 | \n股东名称 |  | 股东性质 |  | 持股比例 |  | 增减变动 |  | 售条件的 | 售条件的 | \n| 持股数量 | 股份状态 |  | 数量 |\n| 情况 |  | 股份数量 | 股份数量 | \n| \n浙江东港投资有\n限公司 |  | 境内非国有法人 |  | 34.22% | 553,982,5\n87 | -2201741\n3 |  | 0 | 553,982,5\n87 | \n| 质押 |  | 241,382,587 |\n| \n王云富 |  | 境内自然人 |  | 7.34% | 118,800,0\n00 | 0 |  | 0 | 118,800,0\n00 | \n| \n| \n新昌勤进投资有\n限公司 |  | 境内非国有法人 |  | 3.07% | 49,650,00\n0 | -1435000\n0 |  | 0 | 49,650,00\n0 | \n| \n| \n香港中央结算有\n限公司 |  | 境外法人 |  | 1.32% | 21,438,17\n8 | 18018169 |  | 0 | 21,438,17\n8 | \n| \n| \n王丽英 |  | 境内自然人 |  | 0.89% | 14,350,00\n0 | 14350000 |  | 0 | 14,350,00\n0 | \n| \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "db21cf29",
        "65d546e8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1654,
      "page_number": 50,
      "bbox": [
        73.5,
        80.0,
        521.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "85x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 85,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          50
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.215746",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1654,
        "word_count": 321,
        "sentence_count": 13,
        "chinese_char_count": 651,
        "readability_score": 0.0,
        "information_density": 0.018137847642079808,
        "coherence_score": 0.7042424242424243,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6697664789997514,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "7e819619",
      "content": "前10名无限售条件股东持股情况\n股份种类\n股东名称 报告期末持有无限售条件股份数量\n股份种类 数量\n浙江东港投资有限公司 553,982,587人民币普通股 553,982,587\n王云富 118,800,000人民币普通股 118,800,000\n新昌勤进投资有限公司 49,650,000人民币普通股 49,650,000\n香港中央结算有限公司 21,438,178人民币普通股 21,438,178\n王丽英 14,350,000人民币普通股 14,350,000\n中央汇金资产管理有限责任公司 10,540,400人民币普通股 10,540,400\n全国社保基金一一七组合 10,000,000人民币普通股 10,000,000\n中国工商银行股份有限公司－国泰\n8,595,000人民币普通股 8,595,000\n鑫睿混合型证券投资基金\n招商银行股份有限公司－汇添富医\n疗服务灵活配置混合型证券投资基 6,100,049人民币普通股 6,100,049\n金\n叶小青 5,796,235人民币普通股 5,796,235\n中央汇金资产管\n\n理有限责任公司 | 国有法人 | 0.65% | 10,540,40\n0 | 0 | 0 | 10,540,40\n0  |\n--------------------------------------------------\n| \n| \n全国社保基金一\n一七组合 | 其他 | 0.62% | 10,000,00\n0 | 10000000 | 0 | 10,000,00\n0  |\n| \n| \n中国工商银行股\n份有限公司－国\n泰鑫睿混合型证\n券投资基金 | 其他 | 0.53% | 8,595,000 | 8595000 | 0 | 8,595,000  |\n| \n| \n招商银行股份有\n限公司－汇添富\n医疗服务灵活配\n置混合型证券投\n资基金 | 其他 | 0.38% | 6,100,049 | 6100049 | 0 | 6,100,049  |\n| \n| \n叶小青 | 境内自然人 | 0.36% | 5,796,235 | -1618820\n0 | 0 | 5,796,235  |\n| \n| \n战略投资者或一般法人因配售新股 | \n成为前10名股东的情况（如有）（参 |  | 无 | \n见注3） | \n|  | 1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00% | \n上述股东关联关系或一致行动的说 |  | 的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司 | \n明 |  | 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制 | \n|  | 人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。 | \n前10名无限售条件股东持股情况 | \n| 股份种类 |\n股东名称 |  | 报告期末持有无限售条件股份数量 | \n| 股份种类 | 数量\n| \n浙江东港投资有限公司 |  | 553,982,587 | 人民币普通股 | 553,982,587\n王云富 |  | 118,800,000 | 人民币普通股 | 118,800,000\n新昌勤进投资有限公司 |  | 49,650,000 | 人民币普通股 | 49,650,000\n香港中央结算有限公司 |  | 21,438,178 | 人民币普通股 | 21,438,178\n王丽英 |  | 14,350,000 | 人民币普通股 | 14,350,000\n中央汇金资产管理有限责任公司 |  | 10,540,400 | 人民币普通股 | 10,540,400\n全国社保基金一一七组合 |  | 10,000,000 | 人民币普通股 | 10,000,000\n中国工商银行股份有限公司－国泰\n鑫睿混合型证券投资基金 |  | 8,595,000 | \n| 人民币普通股 | 8,595,000\n| \n招商银行股份有限公司－汇添富医\n疗服务灵活配置混合型证券投资基\n金 |  | 6,100,049 | \n| 人民币普通股 | 6,100,049\n| \n叶小青 |  | 5,796,235 | 人民币普通股 | 5,796,235",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0a00d7d6",
        "4a471fe8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1794,
      "page_number": 51,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "63x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 63,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          51
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.216313",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江东港投资有限公司",
        "industry": "financial",
        "char_count": 1794,
        "word_count": 263,
        "sentence_count": 10,
        "chinese_char_count": 699,
        "readability_score": 0.0,
        "information_density": 0.016722408026755852,
        "coherence_score": 0.4584827201783724,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7000796131193603,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "42ab74e4",
      "content": "### 3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。\n\n前10名无限售流通股股东之间，以 | 1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n及前10名无限售流通股股东和前10 | 的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司\n名股东之间关联关系或一致行动的 | 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制\n说明 | 人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n| 股。2、王丽英通过信用账户持股1435万股。3、其他股东不存在通过信用账户持股\n| 的情况。\n\n--------------------------------------------------\n| 1、新昌勤进投资有限公司通过普通账户持股1465万股，通过信用账户持股3500万\n前10名普通股股东参与融资融券业 |\n务情况说明（如有）（参见注4） |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ab4d61a4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 466,
      "page_number": 52,
      "bbox": [
        47.5,
        80.0,
        547.5,
        400.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "12x2",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 12,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.216910",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "新昌勤进投资有限公司",
        "industry": null,
        "char_count": 466,
        "word_count": 29,
        "sentence_count": 9,
        "chinese_char_count": 277,
        "readability_score": 0.0,
        "information_density": 0.04291845493562232,
        "coherence_score": 0.8208035714285715,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6740412836438924,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "199fb6e6",
      "content": "是否取得其他国家或地区居\n实际控制人姓名 与实际控制人关系 国籍\n留权\n王云富 本人 中国 否\n一致行动（含协议、亲属、同\n王扬超 中国 否\n一控制）\n王云富先生自2003年3月起一直在东港集团任职，曾担任东港集团副董事长、总裁、党委\n副书记、工会主席等职务，2012年9月至今担任东港工贸集团有限公司执行董事、东港投\n资执行董事。王云富先生持有东港工贸集团有限公司73.20%的股权。王扬超先生系公司实际控制人王云富先生之子，2008年参加工作，曾担任东港工贸集团有\n主要职业及职务\n限公司销售经理、总裁助理，台州市振港染料化工有限公司常务副总、台州市前进化工有限\n公司总经理等职务。\n| 法定 | \n--------------------------------------------------\n| 代表 | \n控股股东名 |  | 成立日  |\n| 人/单 |  | 组织机构代码 | 主要经营业务\n称 |  | 期  |\n| 位负 | \n| \n| 责人 | \n| 国家法律、法规和政策允许的投资业务；股权投资、资产管理（未经金融\n|  | 1998 |  | 等监管部门批准，不得从事向公众融资存款、融资担保、代客理财等金融\n浙江东港投 | 王云 | 年07 |  | 服务）；机械设备、电子产品、工艺品、服装、家用电器、日用品、针纺织\n| 913310027046766827 |\n资有限公司 | 富 | 月09 |  | 品、金属材料、建材销售；黄金饰品加工、销售；房地产开发；市场摊位\n| \n|  | 日 |  | 租赁；塑料原料销售；企业管理咨询服务；货物及技术进出口（国家法律、\n| 法规禁止或限制经营的项目除外）。\n控股股东报 | \n告期内控股 | \n和参股的其 | \n| 无 | \n他境内外上 | \n| \n市公司的股 | \n权情况 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3b329931"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 781,
      "page_number": 52,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "33x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 33,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [
          "2003-3",
          "2012-9"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.217063",
        "report_type": "financial_report",
        "fiscal_year": 2003,
        "fiscal_quarter": null,
        "company_code": "月至今担任东港工贸集团有限公司",
        "industry": "financial",
        "char_count": 781,
        "word_count": 103,
        "sentence_count": 5,
        "chinese_char_count": 463,
        "readability_score": 0.0,
        "information_density": 0.06402048655569784,
        "coherence_score": 0.28013793103448276,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6981643217012494,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "301e7560",
      "content": "公司与实际控制人之间的产权及控制关系的方框图\n实际控制人通过信托或其他资产管理方式控制公司\n□ 适用 √ 不适用\n4、其他持股在10%以上的法人股东\n□ 适用 √ 不适用\n| 是否取得其他国家或地区居\n--------------------------------------------------\n实际控制人姓名 | 与实际控制人关系 | 国籍 |\n| 留权\n| \n王云富 | 本人 | 中国 | 否\n| 一致行动（含协议、亲属、同  |\n王扬超 |  | 中国 | 否\n| 一控制）  |\n| \n| 王云富先生自2003年3月起一直在东港集团任职，曾担任东港集团副董事长、总裁、党委  |\n| 副书记、工会主席等职务，2012年9月至今担任东港工贸集团有限公司执行董事、东港投  |\n| 资执行董事。王云富先生持有东港工贸集团有限公司73.20%的股权。  |\n| 王扬超先生系公司实际控制人王云富先生之子，2008年参加工作，曾担任东港工贸集团有  |\n主要职业及职务 | \n| 限公司销售经理、总裁助理，台州市振港染料化工有限公司常务副总、台州市前进化工有限  |\n| \n| 公司总经理等职务。现担任台州市椒江区第十届政协委员会常委、台州市椒江区工商业联合  |\n| 会副会长、上海海翔医药科技发展有限公司执行董事等。王扬超先生未直接持有公司股票，  |\n| 持有东港工贸集团有限公司26.80%的股权，故王扬超先生间接持有公司股份。  |\n过去10年曾控股的境内外上 | \n| 无  |\n市公司情况 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e0e86f1c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 661,
      "page_number": 53,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "24x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2003-3",
          "2012-9"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          53
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.217345",
        "report_type": "financial_report",
        "fiscal_year": 2003,
        "fiscal_quarter": null,
        "company_code": "月至今担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 661,
        "word_count": 78,
        "sentence_count": 7,
        "chinese_char_count": 415,
        "readability_score": 0.0,
        "information_density": 0.0151285930408472,
        "coherence_score": 0.6312175008911556,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6601532953851739,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "610aa661",
      "content": "### 5、控股股东、实际控制人、重组方及其他承诺主体股份限制减持情况\n□ 适用 √ 不适用\n54 第七节优先股相关情况\n□ 适用 √ 不适用\n报告期公司不存在优先股。\n55\n第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。\n56 第九节董事、监事、高级管理人员和员工情况\n一、董事、监事和高级管理人员持股变动\n本期增持 本期减持\n任期起始 任期终止 期初持股 其他增减 期末持股\n姓名 职务 任职状态 性别 年龄 股份数量 股份数量\n日期 日期 数（股） 变动（股）数（股）\n（股） （股）\n2015年 2022年\n孙杨 董事长 现任 男 5308月25 11月12 4,400,000 0 0 0 4,400,000\n日 日\n2019年 2022年\n王扬超 副董事长 现任 男 3311月13 11月12 0 0 0 0 0\n日 日\n2014年 2022年\n董事、总\n杨思卫 现任 男 4612月08 11月12 4,857,800 0 0 0 4,857,800\n经理\n日 日\n2017年 2022年\n洪鸣 董事 现任 男 3705月31 11月12 315,000 0 78,750 0 236,250\n日 日\n2016年 2022年\n朱建伟 董事 现任 男 6410月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n姚冰 董事 现任 男 3811月13 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n苏为科 独立董事 现任 男 5910月17 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n毛美英 独立董事 现任 女 5710月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n张克坚 独立董事 现任 男 6411月13 11月12 0 0 0 0 0\n日 日\n监事会主 2019年 2022年\n陈敏杰 席、职工 现任 男 5211月13 11月12 0 0 0 0 0\n监事 日 日\n57。\n\n第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。\n56 第九节董事、监事、高级管理人员和员工情况\n一、董事、监事和高级管理人员持股变动\n本期增持 本期减持\n任期起始 任期终止 期初持股 其他增减 期末持股\n姓名 职务 任职状态 性别 年龄 股份数量 股份数量\n日期 日期 数（股） 变动（股）数（股）\n（股） （股）\n2015年 2022年\n孙杨 董事长 现任 男 5308月25 11月12 4,400,000 0 0 0 4,400,000\n日 日\n2019年 2022年\n王扬超 副董事长 现任 男 3311月13 11月12 0 0 0 0 0\n日 日\n2014年 2022年\n董事、总\n杨思卫 现任 男 4612月08 11月12 4,857,800 0 0 0 4,857,800\n经理\n日 日\n2017年 2022年\n洪鸣 董事 现任 男 3705月31 11月12 315,000 0 78,750 0 236,250\n日 日\n2016年 2022年\n朱建伟 董事 现任 男 6410月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n姚冰 董事 现任 男 3811月13 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n苏为科 独立董事 现任 男 5910月17 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n毛美英 独立董事 现任 女 5710月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n张克坚 独立董事 现任 男 6411月13 11月12 0 0 0 0 0\n日 日\n监事会主 2019年 2022年\n陈敏杰 席、职工 现任 男 5211月13 11月12 0 0 0 0 0\n监事 日 日\n| 本期增持 | 本期减持  |\n--------------------------------------------------\n| 任期起始 | 任期终止 | 期初持股 | 其他增减 | 期末持股\n姓名 | 职务 | 任职状态 | 性别 | 年龄 | 股份数量 | 股份数量  |\n| 日期 | 日期 | 数（股） | 变动（股） | 数（股）\n| （股） | （股）  |\n| \n| 2015年 | 2022年 | \n孙杨 | 董事长 | 现任 | 男 | 53 | 08月25 | 11月12 | 4,400,000 | 0 | 0 | 0 | 4,400,000\n| 日 | 日 | \n| 2019年 | 2022年 | \n王扬超 | 副董事长 | 现任 | 男 | 33 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2014年 | 2022年 | \n| 董事、总 | \n杨思卫 |  | 现任 | 男 | 46 | 12月08 | 11月12 | 4,857,800 | 0 | 0 | 0 | 4,857,800\n| 经理 | \n| 日 | 日 | \n| \n| 2017年 | 2022年 | \n洪鸣 | 董事 | 现任 | 男 | 37 | 05月31 | 11月12 | 315,000 | 0 | 78,750 | 0 | 236,250\n| 日 | 日 | \n| 2016年 | 2022年 | \n朱建伟 | 董事 | 现任 | 男 | 64 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2019年 | 2022年 | \n姚冰 | 董事 | 现任 | 男 | 38 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2016年 | 2022年 | \n苏为科 | 独立董事 | 现任 | 男 | 59 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2016年 | 2022年 | \n毛美英 | 独立董事 | 现任 | 女 | 57 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2019年 | 2022年 | \n张克坚 | 独立董事 | 现任 | 男 | 64 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 监事会主 | 2019年 | 2022年 | \n陈敏杰 | 席、职工 | 现任 | 男 | 52 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 监事 | 日 | 日 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c92f906a",
        "3bb68113"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2798,
      "page_number": 57,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "127x12",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 127,
        "column_count": 12,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          57
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.217561",
        "report_type": "financial_report",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2798,
        "word_count": 765,
        "sentence_count": 4,
        "chinese_char_count": 845,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3994736842105263,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6396811280347088,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b4aa5502",
      "content": "| 2014年 | 2022年 | \n--------------------------------------------------\n汪启华 | 监事 | 现任 | 男 | 56 | 05月15 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2012年 | 2022年 | \n龚伟中 | 监事 | 现任 | 男 | 55 | 10月11 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 日 | 日 | \n| 2017年 | 2022年 | \n| 常务副总 | \n李洪明 |  | 现任 | 男 | 51 | 05月13 | 11月12 | 600,000 | 0 | 20,000 |  | 580,000\n| 经理 | \n| 日 | 日 | \n| \n| 2011年 | 2022年 | \n沈利华 | 副总经理 | 现任 | 男 | 54 | 02月23 | 11月12 | 1,200,000 | 0 | 0 | 0 | 1,200,000\n| 日 | 日 | \n| 副总经 | 2012年 | 2022年 | \n许华青 | 理、董事 | 现任 | 女 | 39 | 09月19 | 11月12 | 1,260,000 | 0 | 315,000 | 0 | 945,000\n| 会秘书 | 日 | 日 | \n| 副总经 | 2016年 | 2022年 | \n李进 | 理、财务 | 现任 | 男 | 36 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 总监 | 日 | 日 | \n| 2013年 | 2022年 | \n毛文华 | 副总经理 | 现任 | 男 | 53 | 07月19 | 11月12 | 1,800,000 | 0 | 450,000 | 0 | 1,350,000\n| 日 | 日 | \n| 2014年 | 2022年 | \n许国睿 | 副总经理 | 现任 | 男 | 43 | 11月21 | 11月12 | 600,000 |  | 150,000 | 0 | 450,000\n| 日 | 日 | \n| 2015年 | 2019年 | \n| 原副董事 | \n郭敏龙 |  | 离任 | 男 | 56 | 08月25 | 11月12 | 4,000,000 |  | 1,000,000 | 0 | 3,000,000\n| 长 | \n| 日 | 日 | \n| \n| 2015年 | 2019年 | \n| 原独立董 | \n田利明 |  | 离任 | 男 | 66 | 05月06 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 事 | \n| 日 | 日 | \n| \n| 原监事会 | 2004年 | 2019年 | \n郭世华 | 主席、职 | 离任 | 男 | 60 | 04月01 | 11月12 | 0 | 0 | 0 | 0 | 0\n| 工监事 | 日 | 日 | \n| 19,032,80 | 17,019,05\n合计 | -- | -- | -- | -- | -- | -- |  | 0 | 2,013,750 | 0 |\n| 0 | 0\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "632ba9ca",
        "ce6df800"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1337,
      "page_number": 58,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x12",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 12,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          58
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.218451",
        "report_type": "financial_report",
        "fiscal_year": 2014,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1337,
        "word_count": 421,
        "sentence_count": 0,
        "chinese_char_count": 192,
        "readability_score": 0.0,
        "information_density": 0.007479431563201197,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5463121526213008,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "41b949b7",
      "content": "7、苏为科先生，中国国籍，无境外永久居留权，生于1961年2月，理学博士。历任浙江工\n学院有机化学教研室助教，浙江工业大学有机化工教研室讲师，副教授，现任浙江工业大学\n教授，兼任浙江省制药工程重点实验室主任，浙江省新药创制科技服务平台负责人，浙江省\n制药重中之重学科负责人，长三角绿色制药协同创新中心执行主任，国家化学原料药合成工\n程技术研究中心常务副主任。现担任兄弟科技股份有限公司、浙江花园生物高科股份有限公\n司的独立董事。\n姓名 | 担任的职务 | 类型 | 日期 | 原因\n--------------------------------------------------\n| 原董事、副董事 |  | 2019年11月12 |\n郭敏龙 |  | 任期满离任 |  | 换届离任\n| 长 |  | 日 |\n| \n| 2019年11月12 |\n田利明 | 独立董事 | 任期满离任 |  | 换届离任\n| 日 |\n| \n| 原监事会主席、 |  | 2019年11月12 |\n郭世华 |  | 任期满离任 |  | 换届离任\n| 职工监事 |  | 日 |\n| \n| 原董事，现任副 |  | 2019年11月12 |\n沈利华 |  | 任免 |  | 董事职务换届离任，仍继续担任公司副总经理\n| 总经理 |  | 日 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "656edd5d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 568,
      "page_number": 59,
      "bbox": [
        97.5,
        80.0,
        497.5,
        580.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "18x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "1961-2",
          "2019-11"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          59
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.219373",
        "report_type": "financial_report",
        "fiscal_year": 1961,
        "fiscal_quarter": null,
        "company_code": "现担任兄弟科技股份有限公司",
        "industry": null,
        "char_count": 568,
        "word_count": 91,
        "sentence_count": 3,
        "chinese_char_count": 301,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6009974495200925,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "335e623e",
      "content": "在股东单位任职情况\n√ 适用 □ 不适用\n在股东单位 在股东单位是否\n任职人员姓名 股东单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n王扬超 东港工贸集团有限公司 监事 否\n在股东单位任\n无\n职情况的说明\n在其他单位任职情况\n√ 适用 □ 不适用\n在其他单位 在其他单位是否\n任职人员姓名 其他单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n朱建伟 上海交通大学药学院 院长 是\n朱建伟 浙江医药股份有限公司 独立董事 是\n苏为科 浙江工业大学 教授 是\n苏为科 浙江花园生物高科股份有限公司 独立董事 是\n苏为科 兄弟科技股份有限公司 独立董事 是\n执行董事兼\n苏为科 浙江天诺医药科技有限公司 是\n总经理\n毛美英 台州市沿海高速公路建设管理中心 职员 是\n毛美英 浙江万盛股份有限公司 独立董事 是\n毛美英 浙江伟星实业发展股份有限公司 独立董事 是\n毛美英 永高股份有限公司 独立董事 是\n毛美英 浙江永强集团股份有限公司 独立董事 是\n张克坚 亿帆医药股份有限公司 独立董事 是\n张克坚 湖南方盛制药股份有限公司 独立董事 是\n独立非执行\n张克坚 华润医药集团有限公司 是\n董事\n张克坚 广东华南新药创制中心 首席科学家 是\n孙杨 浙江海翔川南药业有限公司 执行董事 否\n| 股东单位名称 | 在股东单位\n担任的职务 |  | 任期终止日期 | 在股东单位是否\n--------------------------------------------------\n任职人员姓名 | 任期起始日期  |\n| 领取报酬津贴\n| \n王扬超 | 东港工贸集团有限公司 | 监事 | 否\n在股东单位任 | \n| 无 | \n职情况的说明 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a837499d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 738,
      "page_number": 61,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          61
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.219584",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "东港工贸集团有限公司",
        "industry": null,
        "char_count": 738,
        "word_count": 132,
        "sentence_count": 0,
        "chinese_char_count": 530,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5615759444737305,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b3b29d6c",
      "content": "杨思卫 盐城市瓯华化学工业有限公司 董事长 否\n王扬超 上海海翔医药科技发展有限公司 执行董事 否\n台州市椒江民营企业联合投资股份有限\n王扬超 董事 否\n公司\n李洪明 上海海翔医药科技发展有限公司 总经理 否\n汪启华 上海海翔医药科技发展有限公司 监事 否\n汪启华 浙江海翔药业销售有限公司执行董事 执行董事 否\n汪启华 台州港翔化工有限公司 监事 否\n公司现任及报告期内离任董事、监事和高级管理人员近三年证券监管机构处罚的情况\n□ 适用 √ 不适用\n四、董事、监事、高级管理人员报酬情况\n董事、监事、高级管理人员报酬的决策程序、确定依据、实际支付情况\n决策程序:公司按照《董事、监事、高级管理人员薪酬管理制度》，建立了高级管理人员的\n薪酬与公司业绩挂钩的绩效考核与激励约束机制，公司高级管理人员实行基本年薪和年终绩\n效考核相结合的薪酬制度。确定依据:年末根据公司年度经营目标完成情况以及高级管理人员的工作业绩，由董事会\n薪酬与考核委员会对高级管理人员进行年度绩效考核，并监督薪酬制度执行情况。公司则根\n据绩效考核结果兑现其绩效年薪，并进行奖惩。\n|  | 在其他单位 | 在其他单位是否\n--------------------------------------------------\n任职人员姓名 | 其他单位名称 |  | 任期起始日期 | 任期终止日期 |\n|  | 担任的职务 | 领取报酬津贴\n| \n朱建伟 | 上海交通大学药学院 | 院长 | 是\n朱建伟 | 浙江医药股份有限公司 | 独立董事 | 是\n苏为科 | 浙江工业大学 | 教授 | 是\n苏为科 | 浙江花园生物高科股份有限公司 | 独立董事 | 是\n苏为科 | 兄弟科技股份有限公司 | 独立董事 | 是\n|  | 执行董事兼 | \n苏为科 | 浙江天诺医药科技有限公司 | 是\n|  | 总经理 | \n| \n毛美英 | 台州市沿海高速公路建设管理中心 | 职员 | 是\n毛美英 | 浙江万盛股份有限公司 | 独立董事 | 是\n毛美英 | 浙江伟星实业发展股份有限公司 | 独立董事 | 是\n毛美英 | 永高股份有限公司 | 独立董事 | 是\n毛美英 | 浙江永强集团股份有限公司 | 独立董事 | 是\n张克坚 | 亿帆医药股份有限公司 | 独立董事 | 是\n张克坚 | 湖南方盛制药股份有限公司 | 独立董事 | 是\n|  | 独立非执行 | \n张克坚 | 华润医药集团有限公司 | 是\n|  | 董事 | \n| \n张克坚 | 广东华南新药创制中心 | 首席科学家 | 是\n孙杨 | 浙江海翔川南药业有限公司 | 执行董事 | 否",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5673cb33"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1106,
      "page_number": 61,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "40x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          61
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.219833",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 1106,
        "word_count": 188,
        "sentence_count": 3,
        "chinese_char_count": 759,
        "readability_score": 0.0,
        "information_density": 0.018083182640144666,
        "coherence_score": 0.2803896103896104,
        "standards_profile_summary": {}
      },
      "quality_score": 0.585768255414842,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "4feccbad",
      "content": "实际支付情况：报告期内，公司董事、监事、高管的薪酬根据薪酬计划按月发放。公司报告期内董事、监事和高级管理人员报酬情况\n单位：万元\n从公司获得的税 是否在公司关联\n姓名 职务 性别 年龄 任职状态\n前报酬总额 方获取报酬\n孙杨 董事、董事长 男 53现任 80.08 否\n王扬超 董事、副董事长 男 33现任 60.08 否\n杨思卫 董事、总经理 男 46现任 70.08 否\n洪鸣 董事 男 37现任 35.08 否\n朱建伟 董事 男 64现任 8 否\n姚冰 董事 男 38现任 13.98 否\n苏为科 独立董事 男 59现任 8 否\n毛美英 独立董事 女 57现任 8 否\n张克坚 独立董事 男 64现任 2 否\n监事会主席、职\n陈敏杰 男 52现任 10.94 否\n工监事\n汪启华 监事 男 56现任 45.08 否\n龚伟中 监事 男 55现任 26.54 否\n杨思卫 | 盐城市瓯华化学工业有限公司 | 董事长 | 否\n--------------------------------------------------\n王扬超 | 上海海翔医药科技发展有限公司 | 执行董事 | 否\n| 台州市椒江民营企业联合投资股份有限 | \n王扬超 |  | 董事 | 否\n| 公司 | \n| \n李洪明 | 上海海翔医药科技发展有限公司 | 总经理 | 否\n汪启华 | 上海海翔医药科技发展有限公司 | 监事 | 否\n汪启华 | 浙江海翔药业销售有限公司执行董事 | 执行董事 | 否\n汪启华 | 台州港翔化工有限公司 | 监事 | 否",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f7656261"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 666,
      "page_number": 62,
      "bbox": [
        49.5,
        80.0,
        545.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "28x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 28,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          62
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.220121",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 666,
        "word_count": 140,
        "sentence_count": 9,
        "chinese_char_count": 368,
        "readability_score": 0.0,
        "information_density": 0.015015015015015015,
        "coherence_score": 0.5135802469135802,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5286880643760674,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "baf5727d",
      "content": "李洪明 常务副总经理 男 51现任 60.14 否\n沈利华 副总经理 男 54现任 60.08 否\n副总经理、董事\n许华青 女 39现任 60.08 否\n会秘书\n副总经理、财务\n李进 男 36现任 60.08 否\n总监\n毛文华 副总经理 男 53现任 60.08 否\n许国睿 副总经理 男 43现任 60.08 否\n原董事、副董事\n郭敏龙 男 56离任 68.08 否\n长\n田利明 原独立董事 男 66离任 6 否\n原监事会主席、\n郭世华 男 60离任 12.8 否\n职工监事\n合计 -- -- -- -- 815.28 --\n公司董事、高级管理人员报告期内被授予的股权激励情况\n√ 适用 □ 不适用\n单位：股\n报告期内 报告期新 限制性股\n报告期内 报告期内 报告期末 期初持有 本期已解 期末持有\n已行权股 授予限制 票的授予\n姓名 职务 可行权股 已行权股 市价（元/ 限制性股 锁股份数 限制性股\n数行权价 性股票数 价格（元/\n数 数 股） 票数量 量 票数量\n格（元/股） 量 股）\n孙杨 董事长 1,100,000 1,100,000 2.25 0\n董事，总经\n杨思卫 1,100,000 1,100,000 2.25 0\n理\n原副董事\n郭敏龙 1,600,000 1,600,000 4.3125 0\n长\n毛文华 副总经理 600,000 600,000 2.25 0\n副总经理，\n许华青 董事会秘 300,000 300,000 2.25 0\n书\n沈利华 副总经理 300,000 300,000 2.25 0\n洪鸣 董事 150,000 150,000 2.25 0\n李洪明 副总经理 150,000 150,000 2.25 0\n许国睿 副总经理 150,000 150,000 2.25 0\n合计 -- 0 0 -- -- 5,450,000 5,450,000 0 -- 0\n| 从公司获得的税 | 是否在公司关联\n--------------------------------------------------\n姓名 | 职务 | 性别 | 年龄 | 任职状态  |\n| 前报酬总额 | 方获取报酬\n| \n孙杨 | 董事、董事长 | 男 | 53 | 现任 | 80.08 | 否\n王扬超 | 董事、副董事长 | 男 | 33 | 现任 | 60.08 | 否\n杨思卫 | 董事、总经理 | 男 | 46 | 现任 | 70.08 | 否\n洪鸣 | 董事 | 男 | 37 | 现任 | 35.08 | 否\n朱建伟 | 董事 | 男 | 64 | 现任 | 8 | 否\n姚冰 | 董事 | 男 | 38 | 现任 | 13.98 | 否\n苏为科 | 独立董事 | 男 | 59 | 现任 | 8 | 否\n毛美英 | 独立董事 | 女 | 57 | 现任 | 8 | 否\n张克坚 | 独立董事 | 男 | 64 | 现任 | 2 | 否\n| 监事会主席、职 | \n陈敏杰 |  | 男 | 52 | 现任 | 10.94 | 否\n| 工监事 | \n| \n汪启华 | 监事 | 男 | 56 | 现任 | 45.08 | 否\n龚伟中 | 监事 | 男 | 55 | 现任 | 26.54 | 否",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "405a67ee"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1361,
      "page_number": 62,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "61x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 61,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          62
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.220347",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1361,
        "word_count": 354,
        "sentence_count": 26,
        "chinese_char_count": 485,
        "readability_score": 0.0,
        "information_density": 0.0073475385745775165,
        "coherence_score": 0.463847619047619,
        "standards_profile_summary": {}
      },
      "quality_score": 0.620992652823511,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ec0353f7",
      "content": "李洪明 | 常务副总经理 | 男 | 51 | 现任 | 60.14 | 否\n--------------------------------------------------\n沈利华 | 副总经理 | 男 | 54 | 现任 | 60.08 | 否\n| 副总经理、董事 | \n许华青 |  | 女 | 39 | 现任 | 60.08 | 否\n| 会秘书 | \n| \n| 副总经理、财务 | \n李进 |  | 男 | 36 | 现任 | 60.08 | 否\n| 总监 | \n| \n毛文华 | 副总经理 | 男 | 53 | 现任 | 60.08 | 否\n许国睿 | 副总经理 | 男 | 43 | 现任 | 60.08 | 否\n| 原董事、副董事 | \n郭敏龙 |  | 男 | 56 | 离任 | 68.08 | 否\n| 长 | \n| \n田利明 | 原独立董事 | 男 | 66 | 离任 | 6 | 否\n| 原监事会主席、 | \n郭世华 |  | 男 | 60 | 离任 | 12.8 | 否\n| 职工监事 | \n| \n合计 | -- | -- | -- | -- | 815.28 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0efc4530"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 499,
      "page_number": 63,
      "bbox": [
        97.5,
        80.0,
        497.5,
        560.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "18x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          63
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.220793",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 499,
        "word_count": 155,
        "sentence_count": 9,
        "chinese_char_count": 121,
        "readability_score": 0.0,
        "information_density": 0.02004008016032064,
        "coherence_score": 0.5136904761904761,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5605447276361819,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "13b0b0b4",
      "content": "| 报告期内 | 报告期新 | 限制性股 |\n--------------------------------------------------\n|  | 报告期内 | 报告期内 |  | 报告期末 | 期初持有 | 本期已解 | 期末持有\n| 已行权股 | 授予限制 | 票的授予 |\n姓名 | 职务 | 可行权股 | 已行权股 |  | 市价（元/ | 限制性股 | 锁股份数 | 限制性股\n| 数行权价 | 性股票数 | 价格（元/ |\n|  | 数 | 数 |  | 股） | 票数量 | 量 | 票数量\n| 格（元/股） | 量 | 股） |\n| \n孙杨 | 董事长 | 1,100,000 | 1,100,000 |  | 2.25 | 0\n| 董事，总经 | \n杨思卫 | 1,100,000 | 1,100,000 |  | 2.25 | 0\n| 理 | \n| \n| 原副董事 | \n郭敏龙 | 1,600,000 | 1,600,000 |  | 4.3125 | 0\n| 长 | \n| \n毛文华 | 副总经理 | 600,000 | 600,000 |  | 2.25 | 0\n| 副总经理， | \n许华青 | 董事会秘 | 300,000 | 300,000 |  | 2.25 | 0\n| 书 | \n沈利华 | 副总经理 | 300,000 | 300,000 |  | 2.25 | 0\n洪鸣 | 董事 | 150,000 | 150,000 |  | 2.25 | 0\n李洪明 | 副总经理 | 150,000 | 150,000 |  | 2.25 | 0\n许国睿 | 副总经理 | 150,000 | 150,000 |  | 2.25 | 0\n合计 | -- | 0 | 0 | -- | -- | 5,450,000 | 5,450,000 | 0 | -- | 0",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "58e6c0b0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 802,
      "page_number": 63,
      "bbox": [
        49.5,
        80.0,
        545.5,
        640.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "23x11",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 11,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          63
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.221055",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 802,
        "word_count": 219,
        "sentence_count": 9,
        "chinese_char_count": 168,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.41555555555555557,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5201600000000001,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "87f8cb8f",
      "content": "4、劳务外包情况\n□ 适用 √ 不适用\n65 第十节公司治理\n一、公司治理的基本状况\n报告期内，公司严格按照《公司法》、《证券法》、《上市公司治理准则》、《深圳证\n券交易所股票上市规则》等有关法律法规的要求，不断地完善公司治理结构，建立健全内部\n控制制度，并进一步规范公司运作，努力提高公司治理水平。目前，公司整体运作比较规范、\n独立性强、信息披露规范，公司治理实际状况基本符合中国证监会发布的有关上市公司治理\n的规范性文件。公司本报告期内经过股东大会或董事会审议通过正在执行的制度及最新披露时间表如\n下：\n序号 制度名称 披露时间\n1 股东大会议事规则 2007年4月\n2 监事会议事规则 2007年4月\n3 董事会战略委员会议事规则 2007年6月\n4 董事会提名委员会议事规则 2007年6月\n5 董事会审计委员会议事规则 2007年6月\n6 董事会薪酬与考核委员会议事规则 2007年6月\n7 信息披露管理制度（2007年6月修订） 2007年6月\n8 股东大会累计投票制实施细则 2007年6月\n9 独立董事年报工作制度 2008年4月\n10 审计委员会年报工作规程 2008年4月\n11 内部信息保密制度 2008年8月\n12 防范控股股东及关联方资金占用管理办法 2008年8月\n13 董事、监事及高级管理人员薪酬管理制度 2009年4月\n14 突发事件处理制度 2009年10月\n15 首期股票期权激励实施考核办法 2009年12月\n16 年报信息披露重大差错责任追究制度 2010年3月\n17 建设工程招投标管理办法 2011年8月\n18 投资者关系管理制度（2011年9月修订） 2011年9月\n19 重大事项内部报告制度 2011年9月\n20 大股东、实际控制人行为规范及信息问询制度 2011年9月\n21 公司章程（2011年3月修订） 2011年3月\n母公司在职员工的数量（人） | 482\n\n--------------------------------------------------\n主要子公司在职员工的数量（人） | 2,812\n在职员工的数量合计（人） | 3,294\n当期领取薪酬员工总人数（人） | 3,294\n母公司及主要子公司需承担费用的离退休职工人数（人） | 0\n专业构成 |\n专业构成类别 | 专业构成人数（人）\n生产人员 | 1,769\n销售人员 | 77\n技术人员 | 659\n财务人员 | 53\n行政人员 | 736\n合计 | 3,294\n教育程度 |\n教育程度类别 | 数量（人）\n硕士及以上 | 50\n本科 | 484\n大专 | 541\n其他学历 | 2,219\n合计 | 3,294",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c12c1774"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1125,
      "page_number": 64,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "52x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 52,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2007-4",
          "2007-6",
          "2008-4",
          "2008-8",
          "2009-10",
          "2009-12",
          "2009-4",
          "2010-3",
          "2011-3",
          "2011-8",
          "2011-9"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          64
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.221335",
        "report_type": "financial_report",
        "fiscal_year": 2007,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1125,
        "word_count": 139,
        "sentence_count": 2,
        "chinese_char_count": 652,
        "readability_score": 0.0,
        "information_density": 0.017777777777777778,
        "coherence_score": 0.506468253968254,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6090778927450221,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8dbb1dcc",
      "content": "22 外部信息使用人管理制度 2012年4月\n23 内幕信息知情人登记管理制度 2012年4月\n24 董事会议事规则(2013年3月修订) 2013年3月\n25 控股子公司管理制度(2013年3月修订) 2013年3月\n26 对外提供财务资助管理制度 2013年3月\n27 募集资金管理制度（2014年4月修订） 2014年4月\n28 公司章程（2015年9月修订） 2015年9月\n29 授权管理制度 2015年12月\n30 风险投资管理制度 2016年1月\n31 公司章程（2016年3月修订） 2016年3月\n32 债务融资工具信息披露事务管理制度 2016年3月\n33 公司章程（2016年10月修订） 2016年10月\n34 衍生品投资管理制度 2017年1月\n35 公司章程（2017年4月修订） 2017年4月\n36 董事、监事和高级管理人员所持公司股份及其变动管理制度（2017 2017年8月\n年8月修订）\n37 公司章程（2018年4月修订） 2018年4月\n38 内部控制缺陷认定标准 2018年4月\n39 公司章程（2019年2月修订） 2019年2月\n40 内部审计制度（2019年2月修订） 2019年2月\n41 公司章程（2019年3月修订） 2019年3月\n公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件是否存在重大差异\n□ 是 √ 否\n公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件不存在重大差异。二、公司相对于控股股东在业务、人员、资产、机构、财务等方面的独立情况\n（一）业务方面：公司拥有独立完整的业务体系和自主经营能力，控股股东按照承诺未\n从事与公司业务相同或相近的业务活动。（二）人员方面：公司拥有独立的人事和劳资管理体系，公司总经理、副总经理、财务\n负责人和董事会秘书等高级管理人员均在本公司领取报酬。\n序号 | 制度名称 | 披露时间\n--------------------------------------------------\n1 | 股东大会议事规则 | 2007年4月\n2 | 监事会议事规则 | 2007年4月\n3 | 董事会战略委员会议事规则 | 2007年6月\n4 | 董事会提名委员会议事规则 | 2007年6月\n5 | 董事会审计委员会议事规则 | 2007年6月\n6 | 董事会薪酬与考核委员会议事规则 | 2007年6月\n7 | 信息披露管理制度（2007年6月修订） | 2007年6月\n8 | 股东大会累计投票制实施细则 | 2007年6月\n9 | 独立董事年报工作制度 | 2008年4月\n10 | 审计委员会年报工作规程 | 2008年4月\n11 | 内部信息保密制度 | 2008年8月\n12 | 防范控股股东及关联方资金占用管理办法 | 2008年8月\n13 | 董事、监事及高级管理人员薪酬管理制度 | 2009年4月\n14 | 突发事件处理制度 | 2009年10月\n15 | 首期股票期权激励实施考核办法 | 2009年12月\n16 | 年报信息披露重大差错责任追究制度 | 2010年3月\n17 | 建设工程招投标管理办法 | 2011年8月\n18 | 投资者关系管理制度（2011年9月修订） | 2011年9月\n19 | 重大事项内部报告制度 | 2011年9月\n20 | 大股东、实际控制人行为规范及信息问询制度 | 2011年9月\n21 | 公司章程（2011年3月修订） | 2011年3月",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d42e3989"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1465,
      "page_number": 66,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "48x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 48,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2007-4",
          "2007-6",
          "2008-4",
          "2008-8",
          "2009-10",
          "2009-12",
          "2009-4",
          "2012-4",
          "2013-3",
          "2014-4",
          "2015-12",
          "2015-9",
          "2016-1",
          "2016-10",
          "2016-3",
          "2017-1",
          "2017-4",
          "2017-8",
          "2018-4",
          "2019-2",
          "2019-3"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          66
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.221709",
        "report_type": "financial_report",
        "fiscal_year": 2007,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1465,
        "word_count": 181,
        "sentence_count": 3,
        "chinese_char_count": 780,
        "readability_score": 0.0,
        "information_density": 0.0341296928327645,
        "coherence_score": 0.281764705882353,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7561632254320155,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "92b7b3eb",
      "content": "（三）资产方面：公司拥有独立的生产系统、辅助生产系统和配套设施，产、供、销系\n统完整独立。工业产权、商标、非专利技术、房屋所有权、土地所有权等无形资产和有形资\n产均由本公司拥有，产权界定清晰。（四）机构方面：公司设有健全的组织机构体系，股东大会、董事会、监事会及董事会\n下属专业委员会等内部机构独立运作，不受其他单位或个人的干涉。\n22 | 外部信息使用人管理制度 | 2012年4月\n--------------------------------------------------\n23 | 内幕信息知情人登记管理制度 | 2012年4月\n24 | 董事会议事规则(2013年3月修订) | 2013年3月\n25 | 控股子公司管理制度(2013年3月修订) | 2013年3月\n26 | 对外提供财务资助管理制度 | 2013年3月\n27 | 募集资金管理制度（2014年4月修订） | 2014年4月\n28 | 公司章程（2015年9月修订） | 2015年9月\n29 | 授权管理制度 | 2015年12月\n30 | 风险投资管理制度 | 2016年1月\n31 | 公司章程（2016年3月修订） | 2016年3月\n32 | 债务融资工具信息披露事务管理制度 | 2016年3月\n33 | 公司章程（2016年10月修订） | 2016年10月\n34 | 衍生品投资管理制度 | 2017年1月\n35 | 公司章程（2017年4月修订） | 2017年4月\n36 | 董事、监事和高级管理人员所持公司股份及其变动管理制度（2017\n年8月修订） | 2017年8月\n37 | 公司章程（2018年4月修订） | 2018年4月\n38 | 内部控制缺陷认定标准 | 2018年4月\n39 | 公司章程（2019年2月修订） | 2019年2月\n40 | 内部审计制度（2019年2月修订） | 2019年2月\n41 | 公司章程（2019年3月修订） | 2019年3月",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "bcee98c0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 841,
      "page_number": 67,
      "bbox": [
        81.5,
        80.0,
        513.5,
        620.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "24x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2012-4",
          "2013-3",
          "2014-4",
          "2015-12",
          "2015-9",
          "2016-1",
          "2016-10",
          "2016-3",
          "2017-1",
          "2017-4"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.222088",
        "report_type": "financial_report",
        "fiscal_year": 2012,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 841,
        "word_count": 106,
        "sentence_count": 3,
        "chinese_char_count": 396,
        "readability_score": 0.0,
        "information_density": 0.04756242568370987,
        "coherence_score": 0.29000000000000004,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7193313131313132,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e82aa735",
      "content": "（五）财务方面：公司设有完整、独立的财务机构，配备了充足的专职财务会计人员，\n建立了独立的会计核算体系和财务管理制度，并独立开设银行账户、独立纳税、独立做出财\n务决策。公司与控股股东在业务、人员、资产、机构、财务等方面完全分开，具有独立完整\n的业务及自主经营能力。三、同业竞争情况\n□ 适用 √ 不适用\n四、报告期内召开的年度股东大会和临时股东大会的有关情况\n1、本报告期股东大会情况\n会议 投资者参\n会议届次 召开日期 披露日期 披露索引\n类型 与比例\n年度 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2018年年度 2019年032019年03\n股东 45.19% 及巨潮资讯网披露的《2018年年度股东大会决议公告》（公告编号：\n股东大会 月11日 月12日\n大会 2019-020）\n2019年第一 临时 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2019年032019年04\n次临时股东大 股东 45.07% 及巨潮资讯网披露的《2019年第一次临时股东大会决议公告》（公\n月29日 月01日\n会 大会 告编号：2019-027）\n2019年第二 临时 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2019年112019年11\n次临时股东大 股东 44.40% 及巨潮资讯网披露的《2019年第二次临时股东大会决议公告》（公\n月13日 月14日\n会 大会 告编号：2019-059）\n2、表决权恢复的优先股股东请求召开临时股东大会\n□ 适用 √ 不适用\n五、报告期内独立董事履行职责的情况\n1、独立董事出席董事会及股东大会的情况\n独立董事出席董事会及股东大会的情况\n是否连续两次\n本报告期应参 现场出席董事 以通讯方式参 委托出席董事 缺席董事会次 出席股东大会\n独立董事姓名 未亲自参加董\n加董事会次数 会次数 加董事会次数 会次数 数 次数\n事会会议\n田利明 5 0 3 2 0否 0\n毛美英 6 3 3 0 0否 3\n苏为科 6 2 3 1 0否 0\n张克坚 1 1 0 0 0否 0\n连续两次未亲自出席董事会的说明\n| 会议 | 投资者参 | \n--------------------------------------------------\n会议届次 | 召开日期 | 披露日期 | 披露索引\n| 类型 | 与比例 | \n| \n| 年度 | 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2018年年度 | 2019年03 | 2019年03 |\n| 股东 | 45.19% | 及巨潮资讯网披露的《2018年年度股东大会决议公告》（公告编号：\n股东大会 | 月11日 | 月12日 |\n| 大会 | 2019-020）\n| \n2019年第一 | 临时 | 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n| 2019年03 | 2019年04 |\n次临时股东大 | 股东 | 45.07% | 及巨潮资讯网披露的《2019年第一次临时股东大会决议公告》（公\n| 月29日 | 月01日 |\n会 | 大会 | 告编号：2019-027）\n| \n2019年第二 | 临时 | 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n| 2019年11 | 2019年11 |\n次临时股东大 | 股东 | 44.40% | 及巨潮资讯网披露的《2019年第二次临时股东大会决议公告》（公\n| 月13日 | 月14日 |\n会 | 大会 | 告编号：2019-059）\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7d24f3af"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1503,
      "page_number": 68,
      "bbox": [
        65.5,
        80.0,
        529.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "58x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 58,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          68
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.222350",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1503,
        "word_count": 211,
        "sentence_count": 8,
        "chinese_char_count": 809,
        "readability_score": 0.0,
        "information_density": 0.026613439787092484,
        "coherence_score": 0.9044975614712457,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7004758277988775,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f79a9af7",
      "content": "不适用\n2、独立董事对公司有关事项提出异议的情况\n独立董事对公司有关事项是否提出异议\n□ 是 √ 否\n报告期内独立董事对公司有关事项未提出异议。3、独立董事履行职责的其他说明\n独立董事对公司有关建议是否被采纳\n√ 是 □ 否\n独立董事对公司有关建议被采纳或未被采纳的说明\n公司独立董事勤勉尽责，严格按照中国证监会的相关规定及《公司章程》、《董事会议\n事规则》和《独立董事制度》开展工作，关注公司运作,独立履行职责,对公司内部控制建设、\n管理体系建设、人才梯队建设和重大决策等方面提出了很多宝贵的专业性建议，对公司财务\n及生产经营活动进行了有效监督，提高了公司决策的科学性，为完善公司监督机制，维护公\n司和全体股东的合法权益发挥了应有的作用。六、董事会下设专门委员会在报告期内履行职责情况\n（一）董事会下设审计委员会的履职情况\n董事会审计委员会在报告期内主要负责公司内部会计控制, 财务报表和公司其他财务事\n项实施监督工作。\n独立董事出席董事会及股东大会的情况 | \n--------------------------------------------------\n| 是否连续两次 |\n| 本报告期应参 | 现场出席董事 | 以通讯方式参 | 委托出席董事 | 缺席董事会次 |  | 出席股东大会\n独立董事姓名 | 未亲自参加董 |\n| 加董事会次数 | 会次数 | 加董事会次数 | 会次数 | 数 |  | 次数\n| 事会会议 |\n| \n田利明 | 5 | 0 | 3 | 2 | 0 | 否 | 0\n毛美英 | 6 | 3 | 3 | 0 | 0 | 否 | 3\n苏为科 | 6 | 2 | 3 | 1 | 0 | 否 | 0\n张克坚 | 1 | 1 | 0 | 0 | 0 | 否 | 0",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0fc20f73"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 751,
      "page_number": 68,
      "bbox": [
        73.5,
        80.0,
        521.5,
        660.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "25x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 25,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          68
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.222727",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 751,
        "word_count": 123,
        "sentence_count": 3,
        "chinese_char_count": 469,
        "readability_score": 0.0,
        "information_density": 0.053262316910785625,
        "coherence_score": 0.2829032258064516,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6148477387474488,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "99fda42c",
      "content": "重大缺陷 1、利润总额潜在错报：错报≥\n利润总额的10%或4000万元 2、资产总额\n潜在错报：错报≥资产总额的1% 3、经营\n收入潜在错报：错报≥营业收入的3 % 4、\n所有者权益潜在错报：错报≥所有者权益的\n2%； 重要缺陷 1、利润总额潜在错报：\n错报≥利润总额的5%<利润总额的10%或 重大缺陷非财务报告内部控制缺陷导\n利润总额2000万元≤错报<利润总额4000 致的直接财产损失金额≥利润总额的\n万元 2、资产总额潜在错报：资产总额的10%；重要缺陷利润总额的10%＞非财\n定量标准 0.5%≤错报<资产总额的1% 3、经营收 务报告内部控制缺陷导致的直接财产\n入潜在错报：营业收入的1.5%≤错报<经营损失金额≥利润总额的5%。一般缺陷非\n收入的3% 4、所有者权益潜在错报：所 财务报告内部控制缺陷导致的直接财\n有者权益1%≤错报<所有者权益的2%； 一产损失金额＜利润总额的5%。般缺陷 1、利润总额潜在错报：错报<利润\n总额的5%或错报<利润总额的2000万元\n2、资产总额潜在错报：错报<资产总额的\n0.5% 3、经营收入潜在错报：错报<营\n业收入的1.5% 4、所有者权益潜在错\n报：错报<所有者权益的1%\n财务报告重大缺陷数量（个） 0\n非财务报告重大缺陷数量（个） 0\n财务报告重要缺陷数量（个） 0\n非财务报告重要缺陷数量（个） 0\n十、内部控制审计报告或鉴证报告\n内部控制鉴证报告\n内部控制鉴证报告中的审议意见段\n我们认为，海翔药业公司按照深圳证券交易所《中小企业板上市公司规范运作指引(2015年修订)》规定于2019年12月31\n日在所有重大方面保持了有效的财务报告内部控制。\n|  | 重大缺陷：1、公司董事、监事或高级\n--------------------------------------------------\n|  | 管理人员缺乏应有的胜任能力，或高级\n|  | 管理人员流失严重； 2、公司组织架构、\n|  | 业务流程存在重大缺陷，权责分配严重\n|  | 不合理，缺乏科学决策、良性运行机制\n|  | 和执行力； 3、公司对外担保业务未根\n|  | 据相关法律法规经过适当审批； 4、公\n|  | 司资产管理制度存在重大缺陷，大量长\n|  | 期资产使用效能低下，维护不当，存货\n|  | 严重积压或短缺； 5、公司核心技术管\n|  | 理存在缺陷，核心技术人员流失严重，\n|  | 核心技术已经出现严重过时的迹象；\n|  | 6、公司信息系统存在重大漏洞，导致\n|  | 内部相关数据收集、处理或传递错误或\n|  | 严重延误，或重要商业机密被泄露； 7、\n|  | 公司的安全生产管理、环保管理存在重\n| 重大缺陷：1、公司董事、监事或高级管理 | 大缺陷，安全、环保事故频发，引起政\n| 人员舞弊；2、公司更正已公告的财务报告； | 府或监管机构调查或处罚； 8、公司的\n| 3、注册会计师发现未被公司内部控制识别 | 质量管理存在重大缺陷，出现重大质量\n| 的当期财务报告重大错报；4、公司对重大 | 问题引起政府或监管机构调查或引发\n| 经济业务的会计处理违反会计法律法规或 | 诉讼； 9、已向管理层汇报但经过合理\n| 《企业会计准则》； 5、公司随意变更会计 | 期限后，管理层仍然没有对非财务报告\n| 政策或会计估计，导致相关财务信息严重 | 内部控制重大缺陷进行整改。重要缺\n| 失真； 6、公司缺乏对外提供财务报告的 | 陷：1、公司关键岗位人员缺乏应有的\n| 流程、审批权限等正式制度，或制度完全 | 胜任能力，或关键岗位人员流失严重；\n| 未得到执行；7、因财务报告相关的信息披 | 2、公司组织架构、业务流程存在重要\n| 露差错导致监管机构处罚；8、公司凭证、 | 缺陷，重要机构设计不合理，职能交叉\n| 账簿、报表等会计资料管理混乱，未按照 | 或缺失，运行效率低下；3、公司对外\n| 相关法律法规整理、归档或保存；9、已向 | 担保业务虽经过适当审批，但存在重要\n| 管理层汇报但经过合理期限后，管理层仍 | 潜在经济损失风险；4、公司资产管理\n| 然没有对财务报告内部控制重大缺陷进行 | 制度存在重要缺陷，部分长期资产使用\n| 整改。重大缺陷：1、公司关键岗位人员舞 | 效能低下，维护不当，大量存货积压或\n| 弊；2、注册会计师发现未被公司内部控制 | 短缺；5、公司重要技术管理存在缺陷，\n| 识别的当期财务报告重要错报；3、对重要 | 重要技术人员流失严重，关键技术出现\n定性标准  |\n| 经济业务的会计处理违反会计法律法规或 | 过时的迹象；6、公司信息系统的关键\n |\n| 《企业会计准则》；4、公司频繁变更会计 | 环节存在漏洞，导致部分环节内部相关\n| 政策或会计估计，导致相关财务信息不具 | 数据收集、处理或传递错误或不及时，\n| 有可比性；5、公司虽有对外提供财务报告 | 或商业机密存在被泄露的风险；7、公\n| 的正式制度，但制度未得到完全执行，对 | 司的安全生产管理、环保管理存在重要\n| 外信息披露未经适当审批或授权；6、公司 | 缺陷，出现重要的安全、环保事故，引\n| 凭证、账簿、报表等会计资料管理部分环 | 起政府或监管机构关注；8、公司的质\n| 节存在漏洞，相关资料存在丢失、毁损或 | 量管理存在重要缺陷，出现重要质量问\n| 被未授权人员接触的风险； 7、已向管理 | 题引起大宗产品退货；9、已向管理层\n| 层汇报但经过合理期限后，管理层仍然没 | 汇报但经过合理期限后，管理层仍然没\n| 有对财务报告内部控制重要缺陷进行整 | 有对非财务报告内部控制。一般缺陷：\n| 改。 一般缺陷：1、公司一般岗位人员舞 | 1、公司一般岗位人员缺乏应有的胜任\n7\n| 弊；2、注册会计师发现未被公司内部控制 | 能力，或普通岗位人员流失严重；2、\n| 识别的当期财务报告一般错报；3、已向管 | 公司组织架构、业务流程存在一般缺\n| 理层汇报但经过合理期限后，管理层仍然 | 陷，部分机构设计不合理，职能重叠，",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "05bf3860",
        "7052d525"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2518,
      "page_number": 71,
      "bbox": [
        61.5,
        80.0,
        533.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "76x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": true,
        "extraction_confidence": 0.8,
        "row_count": 76,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "资产",
          "存货"
        ],
        "time_periods": [
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.222960",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 2518,
        "word_count": 246,
        "sentence_count": 11,
        "chinese_char_count": 1753,
        "readability_score": 0.0,
        "information_density": 0.051628276409849086,
        "coherence_score": 0.8091053307868896,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8283141844190005,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "利润",
        "经营",
        "财务",
        "报表",
        "4000万元",
        "2000万元",
        "2000万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "资产",
        "存货"
      ]
    },
    {
      "chunk_id": "b90b744c",
      "content": "第十一节公司债券相关情况\n公司是否存在公开发行并在证券交易所上市，且在年度报告批准报出日未到期或到期未能全额兑付的公司债券\n否\n73 第十二节 财务报告\n一、审计报告\n审计意见类型 标准的无保留意见\n审计报告签署日期 2020年01月22日\n审计机构名称 天健会计师事务所（特殊普通合伙）\n审计报告文号 天健审〔2020〕58号\n注册会计师姓名 沈维华 汪兢\n审计报告正文\n审 计 报 告\n天健审〔2020〕58号\n浙江海翔药业股份有限公司全体股东：\n一、审计意见\n我们审计了浙江海翔药业股份有限公司（以下简称海翔药业公司）财务报表，包括 2019\n年12月31日的合并及母公司资产负债表，2019年度的合并及母公司利润表、合并及母公司\n现金流量表、合并及母公司所有者权益变动表，以及相关财务报表附注。我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了\n海翔药业公司 2019 年 12 月 31 日的合并及母公司财务状况，以及 2019 年度的合并及母公司\n经营成果和现金流量。二、形成审计意见的基础\n我们按照中国注册会计师审计准则的规定执行了审计工作。\n内部控制鉴证报告中的审议意见段 |\n我们认为，海翔药业公司按照深圳证券交易所《中小企业板上市公司规范运作指引(2015年修订)》规定于2019年12月31 |\n日在所有重大方面保持了有效的财务报告内部控制。 |\n\n--------------------------------------------------\n内控鉴证报告披露情况 | 披露\n内部控制鉴证报告全文披露日期 | 2020年01月23日\n内部控制鉴证报告全文披露索引 | 巨潮资讯网\n内控鉴证报告意见类型 | 标准无保留意见\n非财务报告是否存在重大缺陷 | 否",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "512ca336"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 756,
      "page_number": 72,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "28x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 28,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019",
          "2019-12",
          "2020-01"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.223568",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 756,
        "word_count": 63,
        "sentence_count": 4,
        "chinese_char_count": 539,
        "readability_score": 0.0,
        "information_density": 0.10582010582010584,
        "coherence_score": 0.31099099099099103,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6404977443609022,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金流",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "971f53cf",
      "content": "年度，海翔药业公司财务报表所示营业收入项目金额为人民币 2,941,412,770.30 元(合并财\n务报表口径，下同)，其中主营业务收入为人民币2,925,688,906.14元，占营业收入的99.47%。如财务报表附注重要会计政策及会计估计所示，海翔药业公司产品销售区域分为国内和国外，\n且需要根据不同的手续进行收入确认。由于营业收入是海翔药业公司关键业绩指标之一，可能存在海翔药业公司管理层（以下\n简称管理层）通过不恰当的收入确认以达到特定目标或预期的固有风险。\n审计意见类型 | 标准的无保留意见\n\n--------------------------------------------------\n审计报告签署日期 | 2020年01月22日\n审计机构名称 | 天健会计师事务所（特殊普通合伙）\n审计报告文号 | 天健审〔2020〕58号\n注册会计师姓名 | 沈维华 汪兢",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "42a335da"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 392,
      "page_number": 74,
      "bbox": [
        47.5,
        80.0,
        547.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2020-01"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          74
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.223798",
        "report_type": "financial_report",
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 392,
        "word_count": 23,
        "sentence_count": 6,
        "chinese_char_count": 244,
        "readability_score": 0.0,
        "information_density": 0.10204081632653061,
        "coherence_score": 0.7282758620689656,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6735111389385808,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "财务",
        "报表",
        "906.14元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "df939867",
      "content": "天健会计师事务所（特殊普通合伙） 中国注册会计师：沈维华\n（项目合伙人）\n中国·杭州 中国注册会计师：汪兢\n二〇二〇年一月二十二日\n二、财务报表\n财务附注中报表的单位为：元\n1、合并资产负债表\n编制单位：浙江海翔药业股份有限公司\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,556,575,372.45 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n项目 | 2019年12月31日 | 2018年12月31日\n--------------------------------------------------\n流动资产：  |\n货币资金 | 1,556,575,372.45 | 1,956,089,124.33\n结算备付金  |\n拆出资金  |\n交易性金融资产  |\n以公允价值计量且其变动计入当  |\n |\n期损益的金融资产  |\n |\n衍生金融资产  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4f5a50b1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 449,
      "page_number": 77,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "27x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "交易性金融资产",
          "衍生金融资产",
          "货币资金",
          "资产"
        ],
        "time_periods": [
          "2018-12",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.223927",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": "financial",
        "char_count": 449,
        "word_count": 51,
        "sentence_count": 4,
        "chinese_char_count": 214,
        "readability_score": 0.0,
        "information_density": 0.20044543429844097,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.620983212267958,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "交易性金融资产",
        "衍生金融资产",
        "货币资金",
        "资产"
      ]
    },
    {
      "chunk_id": "4fe8d535",
      "content": "应收票据 107,399,476.04\n应收账款 459,781,564.19 479,537,782.06\n应收款项融资 74,531,666.41\n预付款项 33,851,486.79 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 18,297,536.18 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 842,985,260.60 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动资产\n其他流动资产 76,406,931.14 227,882,993.23\n流动资产合计 3,062,429,817.76 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 47,879,382.43 66,088,139.79\n其他权益工具投资 20,000,000.00\n其他非流动金融资产\n投资性房地产 11,206,951.46 12,338,615.29\n固定资产 1,724,407,333.34 1,215,120,643.61\n在建工程 560,674,634.43 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 533,455,319.46 539,514,850.87\n应收票据 |  | 107,399,476.04\n--------------------------------------------------\n应收账款 | 459,781,564.19 | 479,537,782.06\n应收款项融资 | 74,531,666.41 |\n预付款项 | 33,851,486.79 | 46,449,558.50\n应收保费  |\n应收分保账款  |\n应收分保合同准备金  |\n其他应收款 | 18,297,536.18 | 10,817,853.96\n其中：应收利息  |\n应收股利  |\n买入返售金融资产  |\n存货 | 842,985,260.60 | 905,418,218.49\n合同资产  |\n持有待售资产  |\n一年内到期的非流动资产  |\n其他流动资产 | 76,406,931.14 | 227,882,993.23\n流动资产合计 | 3,062,429,817.76 | 3,733,595,006.61\n非流动资产：  |\n发放贷款和垫款  |\n债权投资  |\n可供出售金融资产 |  | 1,800,000.00\n其他债权投资  |\n持有至到期投资  |\n长期应收款  |\n长期股权投资 | 47,879,382.43 | 66,088,139.79\n其他权益工具投资 | 20,000,000.00 |\n其他非流动金融资产  |\n投资性房地产 | 11,206,951.46 | 12,338,615.29\n固定资产 | 1,724,407,333.34 | 1,215,120,643.61\n在建工程 | 560,674,634.43 | 674,333,677.99\n生产性生物资产  |\n油气资产  |\n使用权资产  |\n无形资产 | 533,455,319.46 | 539,514,850.87",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "99420158"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1399,
      "page_number": 78,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "68x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 68,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期股权投资",
          "预付款项",
          "应收款",
          "其他应收款",
          "应收分保账款",
          "长期应收款",
          "在建工程",
          "应收",
          "应收账款",
          "应收利息",
          "使用权资产",
          "应收款项融资",
          "其他流动资产",
          "其他权益工具",
          "合同资产",
          "应收保费",
          "投资性房地产",
          "长期",
          "应收票据",
          "应收分保合同准备金",
          "无形资产",
          "应收股利",
          "存货",
          "固定资产",
          "持有待售资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          78
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.224096",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1399,
        "word_count": 170,
        "sentence_count": 52,
        "chinese_char_count": 388,
        "readability_score": 0.0,
        "information_density": 0.21443888491779842,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6927594483431446,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期股权投资",
        "预付款项",
        "应收款",
        "其他应收款",
        "应收分保账款",
        "长期应收款",
        "在建工程",
        "应收",
        "应收账款",
        "应收利息",
        "使用权资产",
        "应收款项融资",
        "其他流动资产",
        "其他权益工具",
        "合同资产",
        "应收保费",
        "投资性房地产",
        "长期",
        "应收票据",
        "应收分保合同准备金",
        "无形资产",
        "应收股利",
        "存货",
        "固定资产",
        "持有待售资产",
        "资产"
      ]
    },
    {
      "chunk_id": "c17679af",
      "content": "非流动负债：\n保险合同准备金\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 1,333,333.00 12,971,002.47\n递延收益 50,594,091.52 44,650,629.91\n递延所得税负债 30,527,355.71 8,175,428.28\n其他非流动负债\n非流动负债合计 82,454,780.23 65,797,060.66\n负债合计 1,022,736,568.92 1,644,823,412.34\n所有者权益：\n股本 1,618,715,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,670,350,322.00 2,663,367,822.47\n减：库存股 301,511,513.90 325,880,561.68\n其他综合收益 -1,490,188.81 -51,779.23\n专项储备\n盈余公积 213,069,824.31 201,812,279.17\n一般风险准备\n未分配利润 1,525,328,398.95 1,232,481,918.50\n归属于母公司所有者权益合计 5,724,462,095.55 5,390,549,932.23\n少数股东权益\n所有者权益合计 5,724,462,095.55 5,390,549,932.23\n负债和所有者权益总计 6,747,198,664.47 7,035,373,344.57\n法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n非流动负债：  |\n--------------------------------------------------\n保险合同准备金  |\n长期借款  |\n应付债券  |\n其中：优先股  |\n永续债  |\n租赁负债  |\n长期应付款  |\n长期应付职工薪酬  |\n预计负债 | 1,333,333.00 | 12,971,002.47\n递延收益 | 50,594,091.52 | 44,650,629.91\n递延所得税负债 | 30,527,355.71 | 8,175,428.28\n其他非流动负债  |\n非流动负债合计 | 82,454,780.23 | 65,797,060.66\n负债合计 | 1,022,736,568.92 | 1,644,823,412.34\n所有者权益：  |\n股本 | 1,618,715,253.00 | 1,618,820,253.00\n其他权益工具  |\n其中：优先股  |\n永续债  |\n资本公积 | 2,670,350,322.00 | 2,663,367,822.47\n减：库存股 | 301,511,513.90 | 325,880,561.68\n其他综合收益 | -1,490,188.81 | -51,779.23\n专项储备  |\n盈余公积 | 213,069,824.31 | 201,812,279.17\n一般风险准备  |\n未分配利润 | 1,525,328,398.95 | 1,232,481,918.50\n归属于母公司所有者权益合计 | 5,724,462,095.55 | 5,390,549,932.23\n少数股东权益  |\n所有者权益合计 | 5,724,462,095.55 | 5,390,549,932.23\n负债和所有者权益总计 | 6,747,198,664.47 | 7,035,373,344.57",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0e829aa5"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1465,
      "page_number": 80,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "63x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 63,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付职工薪酬",
          "递延所得税负债",
          "盈余公积",
          "少数股东权益",
          "未分配利润",
          "递延收益",
          "负债",
          "利润",
          "应付债券",
          "股本",
          "长期借款",
          "其他权益工具",
          "租赁负债",
          "所有者权益",
          "长期应付款",
          "应付",
          "长期",
          "其他综合收益",
          "库存股",
          "应付款",
          "所得税",
          "资本公积",
          "预计负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          80
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.224512",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1465,
        "word_count": 167,
        "sentence_count": 56,
        "chinese_char_count": 364,
        "readability_score": 0.0,
        "information_density": 0.17747440273037543,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7333038605652668,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付职工薪酬",
        "递延所得税负债",
        "盈余公积",
        "少数股东权益",
        "未分配利润",
        "递延收益",
        "负债",
        "利润",
        "应付债券",
        "股本",
        "长期借款",
        "其他权益工具",
        "租赁负债",
        "所有者权益",
        "长期应付款",
        "应付",
        "长期",
        "其他综合收益",
        "库存股",
        "应付款",
        "所得税",
        "资本公积",
        "预计负债"
      ]
    },
    {
      "chunk_id": "4f31ed89",
      "content": "2、母公司资产负债表\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,200,455,459.03 983,565,710.16\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n应收票据 20,885,763.88\n应收账款 123,532,244.19 149,204,899.98\n应收款项融资 6,422,715.29\n预付款项 2,178,567.27 5,554,458.78\n其他应收款 467,513,480.14 1,043,055,918.72\n其中：应收利息\n应收股利 7,222,088,153.34\n存货 96,708,887.42 84,396,333.98\n合同资产\n持有待售资产\n一年内到期的非流动资产\n其他流动资产 2,586,704.73 105,920,135.97\n流动资产合计 1,899,398,058.07 2,392,583,221.47\n非流动资产：\n债权投资\n可供出售金融资产 23,017,502.51\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,247,420,801.54 3,250,556,852.85\n其他权益工具投资 43,017,502.51\n其他非流动金融资产\n投资性房地产 15,051,583.93 16,409,402.65\n固定资产 190,528,741.25 182,948,202.54\n在建工程 5,125,110.57 20,490,208.35\n项目 | 2019年12月31日 | 2018年12月31日\n--------------------------------------------------\n流动资产：  |\n货币资金 | 1,200,455,459.03 | 983,565,710.16\n交易性金融资产  |\n以公允价值计量且其变动计入当  |\n |\n期损益的金融资产  |\n |\n衍生金融资产  |\n应收票据 |  | 20,885,763.88\n应收账款 | 123,532,244.19 | 149,204,899.98\n应收款项融资 | 6,422,715.29 |\n预付款项 | 2,178,567.27 | 5,554,458.78\n其他应收款 | 467,513,480.14 | 1,043,055,918.72\n其中：应收利息  |\n应收股利 |  | 7,222,088,153.34\n存货 | 96,708,887.42 | 84,396,333.98\n合同资产  |\n持有待售资产  |\n一年内到期的非流动资产  |\n其他流动资产 | 2,586,704.73 | 105,920,135.97\n流动资产合计 | 1,899,398,058.07 | 2,392,583,221.47\n非流动资产：  |\n债权投资  |\n可供出售金融资产 |  | 23,017,502.51\n其他债权投资  |\n持有至到期投资  |\n长期应收款  |\n长期股权投资 | 3,247,420,801.54 | 3,250,556,852.85\n其他权益工具投资 | 43,017,502.51 |\n其他非流动金融资产  |\n投资性房地产 | 15,051,583.93 | 16,409,402.65\n固定资产 | 190,528,741.25 | 182,948,202.54\n在建工程 | 5,125,110.57 | 20,490,208.35",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c110ad36"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1478,
      "page_number": 81,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "66x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 66,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期股权投资",
          "预付款项",
          "应收款",
          "衍生金融资产",
          "其他应收款",
          "长期应收款",
          "在建工程",
          "应收",
          "应收账款",
          "应收利息",
          "应收款项融资",
          "其他流动资产",
          "其他权益工具",
          "合同资产",
          "投资性房地产",
          "长期",
          "应收票据",
          "应收股利",
          "货币资金",
          "存货",
          "固定资产",
          "持有待售资产",
          "资产",
          "交易性金融资产"
        ],
        "time_periods": [
          "2018-12",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          81
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.224935",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1478,
        "word_count": 176,
        "sentence_count": 54,
        "chinese_char_count": 393,
        "readability_score": 0.0,
        "information_density": 0.19621109607577808,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7037954270677762,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期股权投资",
        "预付款项",
        "应收款",
        "衍生金融资产",
        "其他应收款",
        "长期应收款",
        "在建工程",
        "应收",
        "应收账款",
        "应收利息",
        "应收款项融资",
        "其他流动资产",
        "其他权益工具",
        "合同资产",
        "投资性房地产",
        "长期",
        "应收票据",
        "应收股利",
        "货币资金",
        "存货",
        "固定资产",
        "持有待售资产",
        "资产",
        "交易性金融资产"
      ]
    },
    {
      "chunk_id": "821f4587",
      "content": "永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 1,333,333.00 12,971,002.47\n递延收益 1,269,332.86 1,262,720.34\n递延所得税负债\n其他非流动负债\n非流动负债合计 2,602,665.86 14,233,722.81\n负债合计 525,802,580.88 692,654,284.96\n所有者权益：\n股本 1,618,715,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,669,212,269.41 2,662,229,769.88\n减：库存股 301,511,513.90 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 213,069,824.31 201,812,279.17\n未分配利润 697,440,109.87 1,062,800,363.16\n所有者权益合计 4,896,925,942.69 5,219,782,103.53\n负债和所有者权益总计 5,422,728,523.57 5,912,436,388.49\n3、合并利润表\n单位：元\n项目 2019年度 2018年度\n一、营业总收入 2,941,412,770.30 2,718,608,796.51\n其中：营业收入 2,941,412,770.30 2,718,608,796.51\n利息收入\n已赚保费\n手续费及佣金收入\n二、营业总成本 2,020,492,002.44 1,996,990,314.89\n其中：营业成本 1,463,159,361.04 1,511,944,676.18\n永续债  |\n--------------------------------------------------\n租赁负债  |\n长期应付款  |\n长期应付职工薪酬  |\n预计负债 | 1,333,333.00 | 12,971,002.47\n递延收益 | 1,269,332.86 | 1,262,720.34\n递延所得税负债  |\n其他非流动负债  |\n非流动负债合计 | 2,602,665.86 | 14,233,722.81\n负债合计 | 525,802,580.88 | 692,654,284.96\n所有者权益：  |\n股本 | 1,618,715,253.00 | 1,618,820,253.00\n其他权益工具  |\n其中：优先股  |\n永续债  |\n资本公积 | 2,669,212,269.41 | 2,662,229,769.88\n减：库存股 | 301,511,513.90 | 325,880,561.68\n其他综合收益  |\n专项储备  |\n盈余公积 | 213,069,824.31 | 201,812,279.17\n未分配利润 | 697,440,109.87 | 1,062,800,363.16\n所有者权益合计 | 4,896,925,942.69 | 5,219,782,103.53\n负债和所有者权益总计 | 5,422,728,523.57 | 5,912,436,388.49",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d9eae77e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1311,
      "page_number": 83,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "56x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 56,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付职工薪酬",
          "递延所得税负债",
          "盈余公积",
          "未分配利润",
          "递延收益",
          "负债",
          "利润",
          "股本",
          "其他权益工具",
          "租赁负债",
          "所有者权益",
          "长期应付款",
          "应付",
          "长期",
          "其他综合收益",
          "库存股",
          "应付款",
          "所得税",
          "资本公积",
          "预计负债"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.225365",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1311,
        "word_count": 145,
        "sentence_count": 52,
        "chinese_char_count": 290,
        "readability_score": 0.0,
        "information_density": 0.19069412662090007,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.728099938781757,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "收入",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付职工薪酬",
        "递延所得税负债",
        "盈余公积",
        "未分配利润",
        "递延收益",
        "负债",
        "利润",
        "股本",
        "其他权益工具",
        "租赁负债",
        "所有者权益",
        "长期应付款",
        "应付",
        "长期",
        "其他综合收益",
        "库存股",
        "应付款",
        "所得税",
        "资本公积",
        "预计负债"
      ]
    },
    {
      "chunk_id": "643035c4",
      "content": "6.其他债权投资信用减值准\n备\n7.现金流量套期储备\n8.外币财务报表折算差额 361,590.42 16,560.46\n9.其他\n归属于少数股东的其他综合收益的\n税后净额\n七、综合收益总额 769,343,775.51 605,020,381.24\n归属于母公司所有者的综合收益\n769,343,775.51 605,020,381.24\n总额\n归属于少数股东的综合收益总额\n八、每股收益：\n（一）基本每股收益 0.48 0.38\n（二）稀释每股收益 0.48 0.38\n本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0.00元，上期被合并方实现的净利润为：0.00元。法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n4、母公司利润表\n单位：元\n项目 2019年度 2018年度\n一、营业收入 812,259,638.86 825,098,603.87\n减：营业成本 587,096,405.03 619,846,906.93\n税金及附加 5,519,793.76 6,987,907.49\n销售费用 16,512,217.50 13,811,113.34\n管理费用 54,148,420.30 76,492,418.62\n研发费用 34,026,076.54 27,532,948.31\n财务费用 -13,410,251.73 -18,322,346.97\n其中：利息费用 9,198,148.55 23,746,817.96\n利息收入 15,402,930.57 21,054,583.18\n加：其他收益 8,727,855.85 2,788,654.20\n投资收益（损失以“－”号填\n-4,635,510.82 996,151,682.18\n列）\n其中：对联营企业和合营企\n-5,766,425.53 -4,216,789.49\n业的投资收益\n四、利润总额（亏损总额以“－”号填列） | 912,452,980.27 | 697,295,611.05\n--------------------------------------------------\n减：所得税费用 | 141,670,795.18 | 92,291,790.27\n五、净利润（净亏损以“－”号填列） | 770,782,185.09 | 605,003,820.78\n（一）按经营持续性分类  |\n1.持续经营净利润（净亏损以“－”  |\n| 770,782,185.09 | 605,003,820.78\n号填列）  |\n |\n2.终止经营净利润（净亏损以“－”  |\n |\n号填列）  |\n |\n（二）按所有权归属分类  |\n1.归属于母公司所有者的净利润 | 770,782,185.09 | 605,003,820.78\n2.少数股东损益  |\n六、其他综合收益的税后净额 | -1,438,409.58 | 16,560.46\n归属母公司所有者的其他综合收益  |\n| -1,438,409.58 | 16,560.46\n的税后净额  |\n |\n（一）不能重分类进损益的其他综  |\n| -1,800,000.00 |\n合收益  |\n |\n1.重新计量设定受益计划变  |\n |\n动额  |\n |\n2.权益法下不能转损益的其  |\n |\n他综合收益  |\n |\n3.其他权益工具投资公允价  |\n| -1,800,000.00 |\n值变动  |\n |\n4.企业自身信用风险公允价  |\n |\n值变动  |\n |\n5.其他  |\n（二）将重分类进损益的其他综合  |\n| 361,590.42 | 16,560.46\n收益  |\n |\n1.权益法下可转损益的其他  |\n |\n综合收益  |\n |\n2.其他债权投资公允价值变  |\n |\n动  |\n |\n3.可供出售金融资产公允价  |\n |\n值变动损益  |\n |\n4.金融资产重分类计入其他  |\n |\n综合收益的金额  |\n |\n5.持有至到期投资重分类为  |\n |\n可供出售金融资产损益  |\n |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4c6d2722"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1691,
      "page_number": 85,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "77x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 77,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "其他综合收益",
          "少数股东损益",
          "其他权益工具",
          "所得税",
          "资产",
          "所得税费用",
          "归属于母公司所有者的净利润",
          "利润",
          "利润总额",
          "净利润"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          85
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.225738",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1691,
        "word_count": 201,
        "sentence_count": 73,
        "chinese_char_count": 566,
        "readability_score": 0.0,
        "information_density": 0.11827321111768185,
        "coherence_score": 0.31380952380952376,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7469727684009049,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他综合收益",
        "少数股东损益",
        "其他权益工具",
        "所得税",
        "资产",
        "所得税费用",
        "归属于母公司所有者的净利润",
        "利润",
        "利润总额",
        "净利润"
      ]
    },
    {
      "chunk_id": "07ab5c41",
      "content": "3．股份支付计 -44,36 51,479 51,479\n7,113,\n入所有者权益 5,875. ,624.5 ,624.5\n749.53\n的金额 00 3 3\n4．其他\n11,257 -477,9 -466,6 -466,6\n（三）利润分配 ,545.1 35,704 78,159 78,159\n4 .64 .50 .50\n11,257 -11,25\n1．提取盈余公\n,545.1 7,545.\n积\n4 14\n2．提取一般风\n险准备\n-466,6 -466,6 -466,6\n3．对所有者（或\n78,159 78,159 78,159\n股东）的分配\n.50 .50 .50\n4．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储备\n18,997 18,997 18,997\n1．本期提取 ,055.9 ,055.9 ,055.9\n7 7 7\n93\n| 2019年度 | \n--------------------------------------------------\n| 归属于母公司所有者权益 | \n| 所有\n| 少数 |\n项目 |  | 其他权益工具 | 其他 | 一般 | 未分 | 者权\n| 资本 | 减：库 |  | 专项 | 盈余 | 股东 |\n| 股本 | 优先 | 永续 | 综合 | 风险 | 配利 | 其他 | 小计 |  | 益合\n| 其他 | 公积 | 存股 |  | 储备 | 公积 | 权益 |\n|  | 股 | 债 | 收益 | 准备 | 润 | 计\n| \n| 1,618 | \n| 2,663, | 325,88 | 201,81 |  | 1,232, |  | 5,390, |  | 5,390,\n一、上年期末余 | ,820, | -51,77 | \n| 367,82 | 0,561. | 2,279. |  | 481,91 |  | 549,93 |  | 549,93\n额 | 253.0 | 9.23 | \n| 2.47 | 68 | 17 |  | 8.50 |  | 2.23 |  | 2.23\n| 0 | \n| \n加：会计政 | \n| \n策变更 | \n| \n前期 | \n| \n差错更正 | \n| \n同一 | \n控制下企业合 | \n并 | \n其他 | \n| 1,618 | \n| 2,663, | 325,88 | 201,81 |  | 1,232, |  | 5,390, |  | 5,390,\n二、本年期初余 | ,820, | -51,77 | \n| 367,82 | 0,561. | 2,279. |  | 481,91 |  | 549,93 |  | 549,93\n额 | 253.0 | 9.23 | \n| 2.47 | 68 | 17 |  | 8.50 |  | 2.23 |  | 2.23\n| 0 | \n| \n三、本期增减变 | -105, | -24,36 | 11,257 |  | 292,84 |  | 333,91 |  | 333,91\n| 6,982, |  | -1,438, | \n动金额（减少以 | 000.0 | 9,047. | ,545.1 |  | 6,480. |  | 2,163. |  | 2,163.\n| 499.53 |  | 409.58 | \n“－”号填列） | 0 | 78 | 4 |  | 45 |  | 32 |  | 32\n| \n| 770,78 |  | 769,34 |  | 769,34\n（一）综合收益 | -1,438, | \n| 2,185. |  | 3,775. |  | 3,775.\n总额 | 409.58 | \n| 09 |  | 51 |  | 51\n| \n| -105, | -24,36 | 31,246 |  | 31,246\n（二）所有者投 | 6,982, | \n| 000.0 | 9,047. | ,547.3 |  | ,547.3\n入和减少资本 | 499.53 | \n| 0 | 78 | 1 |  | 1\n| \n| -105, | 19,996 | -20,23 |  | -20,23\n1．所有者投入 | -131,2 | \n| 000.0 | ,827.2 | 3,077. |  | 3,077.\n的普通股 | 50.00 | \n| 0 | 2 | 22 |  | 22\n| \n2．其他权益工 | \n具持有者投入 | \n资本 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d9a4d167",
        "317f4c1f",
        "0c2beaf7",
        "2ab2c3ac"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1953,
      "page_number": 92,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "97x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 97,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具",
          "所有者权益",
          "股本"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.226216",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1953,
        "word_count": 482,
        "sentence_count": 54,
        "chinese_char_count": 299,
        "readability_score": 0.0,
        "information_density": 0.02560163850486431,
        "coherence_score": 0.5148131080389144,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7086901016410893,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具",
        "所有者权益",
        "股本"
      ]
    },
    {
      "chunk_id": "ec3ee607",
      "content": "-18,99 -18,99 -18,99\n2．本期使用 7,055. 7,055. 7,055.\n97 97 97\n（六）其他\n1,618\n2,670, 301,51 213,06 1,525, 5,724, 5,724,\n四、本期期末余 ,715, -1,490,\n350,32 1,513. 9,824. 328,39 462,09 462,09\n额 253.0 188.81\n2.00 90 31 8.95 5.55 5.55\n0\n上期金额\n单位：元\n2018年年度\n归属于母公司所有者权益\n所有者\n项目 其他权益工具 其他 一般 未分 少数股\n资本 减：库 专项 盈余 权益合\n股本 优先 永续 综合 风险 配利 其他 小计 东权益\n其他 公积 存股 储备 公积 计\n股 债 收益 准备 润\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n一、上年期末 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.75 75\n0\n加：会计\n政策变更\n前期\n差错更正\n同一\n控制下企业合\n并\n其他\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n二、本年期初 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.75 75\n0\n三、本期增减\n-2,79 33,533 225,47 108,61 334,64 248,54\n变动金额（减 16,560 248,541\n0,000 ,011.2 7,311. 4,533. 4,962. 1,755.\n少以“－”号填 .46 ,755.48\n.00 2 68 40 08 48\n列）\n605,00 605,02\n（一）综合收 16,560 605,020\n3,820. 0,381.\n益总额 .46 ,381.24\n78 24\n3．股份支付计 | -44,36 | 51,479 |  | 51,479\n--------------------------------------------------\n| 7,113, | \n入所有者权益 | 5,875. | ,624.5 |  | ,624.5\n| 749.53 | \n的金额 | 00 | 3 |  | 3\n| \n4．其他 | \n| 11,257 |  | -477,9 |  | -466,6 |  | -466,6\n（三）利润分配 | ,545.1 |  | 35,704 |  | 78,159 |  | 78,159\n| 4 |  | .64 |  | .50 |  | .50\n| 11,257 |  | -11,25 | \n1．提取盈余公 | \n| ,545.1 |  | 7,545. | \n积 | \n| 4 |  | 14 | \n| \n2．提取一般风 | \n| \n险准备 | \n| \n| -466,6 |  | -466,6 |  | -466,6\n3．对所有者（或 | \n| 78,159 |  | 78,159 |  | 78,159\n股东）的分配 | \n| .50 |  | .50 |  | .50\n| \n4．其他 | \n（四）所有者权 | \n| \n益内部结转 | \n| \n1．资本公积转 | \n增资本（或股 | \n本） | \n2．盈余公积转 | \n增资本（或股 | \n本） | \n3．盈余公积弥 | \n| \n补亏损 | \n| \n4．设定受益计 | \n划变动额结转 | \n留存收益 | \n5．其他综合收 | \n益结转留存收 | \n益 | \n6．其他 | \n（五）专项储备 | \n| 18,997 | 18,997 |  | 18,997\n1．本期提取 | ,055.9 | ,055.9 |  | ,055.9\n| 7 | 7 |  | 7",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2185a88a",
        "fff15a46",
        "0080fa2a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1703,
      "page_number": 93,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "98x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 98,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "所有者权益",
          "利润",
          "资本公积",
          "盈余公积"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          93
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.227480",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1703,
        "word_count": 361,
        "sentence_count": 55,
        "chinese_char_count": 288,
        "readability_score": 0.0,
        "information_density": 0.03523194362889019,
        "coherence_score": 0.5448796241926013,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6900182243970003,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所有者权益",
        "利润",
        "资本公积",
        "盈余公积"
      ]
    },
    {
      "chunk_id": "434db5fd",
      "content": "| -18,99 | -18,99 |  | -18,99\n--------------------------------------------------\n2．本期使用 | 7,055 | . | 7,055. |  | 7,055.\n| 97 | 97 |  | 97\n（六）其他 | \n| 1,618 | 2,670, |  | -1,490\n.\n188.81 | , | 213,0 | 6 | 1,525 | , | 5,724, |  | 5,724,\n462,09\n5.55\n| 301,51 | \n四、本期期末余 | ,715, | \n| 350,32 | 1,513 | 9,824 | . | 328,3 | 9 | 462,09  |\n额 | 253.0 | \n| 2.00 | 90 | 31 |  | 8.9 | 5 | 5.55  |\n| 0 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cea3cc32"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 392,
      "page_number": 94,
      "bbox": [
        47.5,
        80.0,
        547.5,
        440.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          94
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.228300",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 392,
        "word_count": 97,
        "sentence_count": 11,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5026649746192894,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "98f5d356",
      "content": "（二）所有者 -2,79 33,533 225,47 -194,7 -194,73\n投入和减少资 0,000 ,011.2 7,311. 34,300 4,300.4\n本 .00 2 68 .46 6\n-2,79 -10,60 281,51 -294,9 -294,91\n1．所有者投入\n0,000 6,500. 4,686. 11,186 1,186.6\n的普通股\n.00 00 68 .68 8\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计 44,139 -56,03 100,17\n100,176\n入所有者权益 ,511.2 7,375. 6,886.\n,886.22\n的金额 2 00 22\n4．其他\n108,61 -270,3 -161,7 -161,74\n（三）利润分\n4,533. 58,858 44,325 4,325.3\n配\n40 .70 .30 0\n108,61 -108,6\n1．提取盈余公\n4,533. 14,533\n积\n40 .40\n2．提取一般风\n险准备\n3．对所有者 -161,7 -161,7 -161,74\n（或股东）的 44,325 44,325 4,325.3\n分配 .30 .30 0\n4．其他\n（四）所有者\n权益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n| 2018年年度 | \n--------------------------------------------------\n| 归属于母公司所有者权益 | \n| 所有者\n项目 |  | 其他权益工具 | 其他 | 一般 | 未分 | 少数股 |\n| 资本 | 减：库 |  | 专项 | 盈余 | 权益合\n| 股本 | 优先 | 永续 | 综合 | 风险 | 配利 | 其他 | 小计 | 东权益 |\n| 其他 | 公积 | 存股 |  | 储备 | 公积 | 计\n|  | 股 | 债 | 收益 | 准备 | 润 | \n| \n| 1,621 | \n| 2,629, | 100,40 | 93,197 |  | 897,83 |  | 5,142, |  | 5,142,0\n一、上年期末 | ,610, | -68,33 | \n| 834,81 | 3,250. | ,745.7 |  | 6,956. |  | 008,17 |  | 08,176.\n余额 | 253.0 | 9.69 | \n| 1.25 | 00 | 7 |  | 42 |  | 6.75 |  | 75\n| 0 | \n| \n加：会计 | \n| \n政策变更 | \n| \n前期 | \n| \n差错更正 | \n| \n同一 | \n控制下企业合 | \n并 | \n其他 | \n| 1,621 | \n| 2,629, | 100,40 | 93,197 |  | 897,83 |  | 5,142, |  | 5,142,0\n二、本年期初 | ,610, | -68,33 | \n| 834,81 | 3,250. | ,745.7 |  | 6,956. |  | 008,17 |  | 08,176.\n余额 | 253.0 | 9.69 | \n| 1.25 | 00 | 7 |  | 42 |  | 6.75 |  | 75\n| 0 | \n| \n三、本期增减 | \n| -2,79 | 33,533 | 225,47 | 108,61 |  | 334,64 |  | 248,54  |\n变动金额（减 | 16,560 | 248,541\n| 0,000 | ,011.2 | 7,311. | 4,533. |  | 4,962. |  | 1,755.  |\n少以“－”号填 | .46 | ,755.48\n| .00 | 2 | 68 | 40 |  | 08 |  | 48  |\n列） | \n| \n| 605,00 |  | 605,02  |\n（一）综合收 | 16,560 | 605,020\n| 3,820. |  | 0,381.  |\n益总额 | .46 | ,381.24\n| 78 |  | 24  |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fee5306c",
        "d4077427",
        "5a7cf280"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1759,
      "page_number": 94,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "88x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 88,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具",
          "所有者权益",
          "股本"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          94
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.228640",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1759,
        "word_count": 418,
        "sentence_count": 51,
        "chinese_char_count": 277,
        "readability_score": 0.0,
        "information_density": 0.028425241614553724,
        "coherence_score": 0.5374019329164298,
        "standards_profile_summary": {}
      },
      "quality_score": 0.673578231292517,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具",
        "所有者权益",
        "股本"
      ]
    },
    {
      "chunk_id": "910ad1a2",
      "content": "5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储\n备\n19,301 19,301\n19,301,\n1．本期提取 ,110.5 ,110.5\n110.51\n1 1\n-19,30 -19,30\n-19,301\n2．本期使用 1,110. 1,110.\n,110.51\n51 51\n（六）其他\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,5\n四、本期期末 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 49,932.\n余额 253.0 9.23\n2.47 68 17 8.50 2.23 23\n0\n8、母公司所有者权益变动表\n本期金额\n单位：元\n2019年度\n项目 其他权益工具 资本公 减：库存 其他综 专项储 盈余公 未分配 所有者权\n股本 其他\n优先股 永续债 其他 积 股 合收益 备 积 利润 益合计\n1,618,8 1,062,8\n一、上年期末余 2,662,22 325,880, 201,812, 5,219,782,\n20,253. 00,363.\n额 9,769.88 561.68 279.17 103.53\n00 16\n加：会计政\n策变更\n前期\n差错更正\n其他\n1,618,8 1,062,8\n二、本年期初余 2,662,22 325,880, 201,812, 5,219,782,\n20,253. 00,363.\n额 9,769.88 561.68 279.17 103.53\n00 16\n三、本期增减变 -365,36\n-105,00 6,982,49 -24,369, 11,257,5 -322,856,1\n动金额（减少以 0,253.2\n0.00 9.53 047.78 45.14 60.84\n“－”号填列） 9\n（二）所有者 | -2,79 | 33,533 | 225,47 | -194,7 |  | -194,73\n--------------------------------------------------\n投入和减少资 | 0,000 | ,011.2 | 7,311. | 34,300 |  | 4,300.4\n本 | .00 | 2 | 68 | .46 |  | 6\n| -2,79 | -10,60 | 281,51 | -294,9 |  | -294,91\n1．所有者投入 | \n| 0,000 | 6,500. | 4,686. | 11,186 |  | 1,186.6\n的普通股 | \n| .00 | 00 | 68 | .68 |  | 8\n| \n2．其他权益工 | \n具持有者投入 | \n资本 | \n3．股份支付计 | 44,139 | -56,03 | 100,17  |\n| 100,176\n入所有者权益 | ,511.2 | 7,375. | 6,886.  |\n| ,886.22\n的金额 | 2 | 00 | 22  |\n| \n4．其他 | \n| 108,61 |  | -270,3 |  | -161,7 |  | -161,74\n（三）利润分 | \n| 4,533. |  | 58,858 |  | 44,325 |  | 4,325.3\n配 | \n| 40 |  | .70 |  | .30 |  | 0\n| \n| 108,61 |  | -108,6 | \n1．提取盈余公 | \n| 4,533. |  | 14,533 | \n积 | \n| 40 |  | .40 | \n| \n2．提取一般风 | \n| \n险准备 | \n| \n3．对所有者 | -161,7 |  | -161,7 |  | -161,74\n（或股东）的 | 44,325 |  | 44,325 |  | 4,325.3\n分配 | .30 |  | .30 |  | 0\n4．其他 | \n（四）所有者 | \n| \n权益内部结转 | \n| \n1．资本公积转 | \n增资本（或股 | \n本） | \n2．盈余公积转 | \n增资本（或股 | \n本） | \n3．盈余公积弥 | \n| \n补亏损 | \n| \n4．设定受益计 | \n划变动额结转 | \n留存收益 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d083741b",
        "e528d8e6",
        "86e612fb"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1763,
      "page_number": 95,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "97x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 97,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "所有者权益",
          "利润",
          "资本公积",
          "盈余公积"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          95
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.229694",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1763,
        "word_count": 367,
        "sentence_count": 55,
        "chinese_char_count": 290,
        "readability_score": 0.0,
        "information_density": 0.034032898468519576,
        "coherence_score": 0.5368859897901305,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7044630016902055,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所有者权益",
        "利润",
        "资本公积",
        "盈余公积"
      ]
    },
    {
      "chunk_id": "86748755",
      "content": "5．其他综合收 | \n--------------------------------------------------\n益结转留存收 | \n益 | \n6．其他 | \n（五）专项储\n备 | \n| \n| \n| 19,301 | 19,301  |\n| 19,301,\n1．本期提取 | ,110.5 | ,110.5  |\n| 110.51\n| 1 | 1  |\n| \n| -19,30 | -19,30  |\n| -19,301\n2．本期使用 | 1,110. | 1,110.  |\n| ,110.51\n| 51 | 51  |\n| \n（六）其他 | \n| 1,618 | \n| 2,663, | 325,88 | 201,81 |  | 1,232, |  | 5,390, |  | 5,390,5\n四、本期期末 | ,820, | -51,77 | \n| 367,82 | 0,561. | 2,279. |  | 481,91 |  | 549,93 |  | 49,932.\n余额 | 253.0 | 9.23 | \n| 2.47 | 68 | 17 |  | 8.50 |  | 2.23 |  | 23\n| 0 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f34ce0f1",
        "1ed9d086"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 519,
      "page_number": 96,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "24x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          96
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.230680",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 519,
        "word_count": 122,
        "sentence_count": 14,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5034949622166247,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "c81c55e4",
      "content": "112,57\n（一）综合收益 112,575,45\n5,451.3\n总额 1.35\n5\n（二）所有者投 -105,00 6,982,49 -24,369, 31,246,54\n入和减少资本 0.00 9.53 047.78 7.31\n1．所有者投入 -105,00 -131,250 19,996,8 -20,233,07\n的普通股 0.00 .00 27.22 7.22\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计\n7,113,74 -44,365, 51,479,62\n入所有者权益\n9.53 875.00 4.53\n的金额\n4．其他\n-477,93\n11,257,5 -466,678,1\n（三）利润分配 5,704.6\n45.14 59.50\n4\n1．提取盈余公 11,257,5 -11,257\n积 45.14 ,545.14\n-466,67\n2．对所有者（或 -466,678,1\n8,159.5\n股东）的分配 59.50\n0\n3．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n| 2019年度 | \n--------------------------------------------------\n项目 | 股本 | 其他权益工具 | 资本公 | 减：库存 | 其他综 | 专项储 | 盈余公 | 未分配 |  | 所有者权\n| 其他 |\n|  | 优先股 | 永续债 | 其他 | 积 | 股 | 合收益 | 备 | 积 | 利润 |  | 益合计\n| \n| 1,618,8\n20,253.\n00 | 2,662,22\n9,769.88 | 201,812,\n279.17 | 1,062,8  |\n一、上年期末余 | 325,880, | 5,219,782,\n| 00,363.  |\n额 | 561.68 | 103.53\n| 16  |\n| \n加：会计政 | \n| \n策变更 | \n| \n前期 | \n| \n差错更正 | \n| \n其他 | \n| 1,618,8\n20,253.\n00 | 2,662,22\n9,769.88 | 201,812,\n279.17 | 1,062,8  |\n二、本年期初余 | 325,880, | 5,219,782,\n| 00,363.  |\n额 | 561.68 | 103.53\n| 16  |\n| \n三、本期增减变 | -105,00\n0.00 | 6,982,49\n9.53 | 11,257,5\n45.14 | -365,36  |\n| -24,369, | -322,856,1\n动金额（减少以 | 0,253.2  |\n| 047.78 | 60.84\n“－”号填列） | 9  |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4c60e0d4",
        "cc606c36"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1212,
      "page_number": 96,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "82x10",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 82,
        "column_count": 10,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具",
          "股本",
          "利润"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          96
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.231276",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1212,
        "word_count": 232,
        "sentence_count": 38,
        "chinese_char_count": 246,
        "readability_score": 0.0,
        "information_density": 0.04125412541254126,
        "coherence_score": 0.6400330033003301,
        "standards_profile_summary": {}
      },
      "quality_score": 0.712079982015287,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具",
        "股本",
        "利润"
      ]
    },
    {
      "chunk_id": "c2bff2eb",
      "content": "6．其他\n（五）专项储备\n6,960,83 6,960,833.\n1．本期提取\n3.11 11\n-6,960,8 -6,960,833\n2．本期使用\n33.11 .11\n（六）其他\n1,618,7 697,44\n四、本期期末余 2,669,21 301,511, 213,069, 4,896,925,\n15,253. 0,109.8\n额 2,269.41 513.90 824.31 942.69\n00 7\n上期金额\n单位：元\n2018年年度\n其他权益工具\n项目 资本公 减：库存 其他综 盈余公 未分配利 所有者权\n股本 优先 永续 专项储备 其他\n其他 积 股 合收益 积 润 益合计\n股 债\n1,621, 2,628,6\n一、上年期末余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n加：会计政\n策变更\n前期\n差错更正\n其他\n1,621, 2,628,6\n二、本年期初余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n三、本期增减变\n-2,790, 33,533,225,477, 108,614 815,786,4 729,666,70\n动金额（减少以\n000.00 011.22 311.68 ,533.40 75.25 8.19\n“－”号填列）\n（一）综合收益 1,086,145 1,086,145,3\n总额 ,333.95 33.95\n（二）所有者投 -2,790, 33,533,225,477, -194,734,30\n入和减少资本 000.00 011.22 311.68 0.46\n1．所有者投入 -2,790, -10,606,281,514, -294,911,18\n的普通股 000.00 500.00 686.68 6.68\n| 112,57  |\n--------------------------------------------------\n（一）综合收益 | 112,575,45\n| 5,451.3  |\n总额 | 1.35\n| 5  |\n| \n（二）所有者投 | -105,00 | 6,982,49 | -24,369, | 31,246,54\n| \n入和减少资本 | 0.00 | 9.53 | 047.78 | 7.31\n| \n1．所有者投入 | -105,00 | -131,250 | 19,996,8 | -20,233,07\n| \n的普通股 | 0.00 | .00 | 27.22 | 7.22\n| \n2．其他权益工 | \n具持有者投入 | \n资本 | \n3．股份支付计 | \n| 7,113,74 | -44,365, | 51,479,62\n入所有者权益 | \n| 9.53 | 875.00 | 4.53\n的金额 | \n| \n4．其他 | \n| -477,93  |\n| 11,257,5 | -466,678,1\n（三）利润分配 | 5,704.6  |\n| 45.14 | 59.50\n| 4  |\n| \n1．提取盈余公 | 11,257,5 | -11,257  |\n| \n积 | 45.14 | ,545.14  |\n| \n| -466,67  |\n2．对所有者（或 | -466,678,1\n| 8,159.5  |\n股东）的分配 | 59.50\n| 0  |\n| \n3．其他 | \n（四）所有者权 | \n| \n益内部结转 | \n| \n1．资本公积转 | \n增资本（或股 | \n本） | \n2．盈余公积转 | \n增资本（或股 | \n本） | \n3．盈余公积弥 | \n| \n补亏损 | \n| \n4．设定受益计 | \n划变动额结转 | \n留存收益 | \n5．其他综合收 | \n益结转留存收 | \n益 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fc0e4285",
        "7bcc853a",
        "b8f3f381"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1674,
      "page_number": 97,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "95x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 95,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "所有者权益",
          "利润",
          "资本公积",
          "盈余公积"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.231832",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1674,
        "word_count": 300,
        "sentence_count": 58,
        "chinese_char_count": 306,
        "readability_score": 0.0,
        "information_density": 0.03584229390681004,
        "coherence_score": 0.5489486260454002,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6916639554778837,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所有者权益",
        "利润",
        "资本公积",
        "盈余公积"
      ]
    },
    {
      "chunk_id": "dafb8c7e",
      "content": "6．其他 | \n--------------------------------------------------\n（五）专项储备 | \n| 6,960,83 | 6,960,833.\n11\n1．本期提取 | \n| 3.11 | \n| \n| -6,960,8 | -6,960,833\n.11\n2．本期使用 | \n| 33.11 | \n| \n（六）其他 | \n| 1,618,\n15,253\n0 | 7 | 697,44 |  | 4,896,925,\n942.69\n四、本期期末余 | 2,669,21 | 301,511, | 213,069, | \n|  | . | 0,109.8  |\n额 | 2,269.41 | 513.90 | 824.31 | \n|  | 0 | 7  |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0de0f855"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 348,
      "page_number": 98,
      "bbox": [
        61.5,
        80.0,
        533.5,
        540.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "18x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          98
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.232559",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 348,
        "word_count": 70,
        "sentence_count": 10,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.504360465116279,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "1eef0e46",
      "content": "2．其他权益工\n具持有者投入\n资本\n3．股份支付计\n44,139, -56,037, 100,176,88\n入所有者权益\n511.22 375.00 6.22\n的金额\n4．其他\n108,614 -270,358, -161,744,32\n（三）利润分配\n,533.40 858.70 5.30\n1．提取盈余公 108,614 -108,614,\n积 ,533.40 533.40\n2．对所有者（或 -161,744, -161,744,32\n股东）的分配 325.30 5.30\n3．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储备\n4,736,183 4,736,183.5\n1．本期提取\n.53 3\n-4,736,18 -4,736,183.\n2．本期使用\n3.53 53\n（六）其他\n99\n| 2018年年度 | \n--------------------------------------------------\n|  | 其他权益工具 | \n项目 | 资本公 | 减：库存 | 其他综 |  | 盈余公 | 未分配利 |  | 所有者权\n| 股本 | 优先 | 永续 | 专项储备 | 其他 |\n| 其他 | 积 | 股 | 合收益 |  | 积 | 润 |  | 益合计\n|  | 股 | 债 | \n| \n| 1,621, | 2,628,6 | \n一、上年期末余 | 100,403, | 93,197, | 247,013,8 |  | 4,490,115,3\n| 610,25 | 96,758. | \n额 | 250.00 | 745.77 | 87.91 |  | 95.34\n| 3.00 | 66 | \n| \n加：会计政 | \n| \n策变更 | \n| \n前期 | \n| \n差错更正 | \n| \n其他 | \n| 1,621, | 2,628,6 | \n二、本年期初余 | 100,403, | 93,197, | 247,013,8 |  | 4,490,115,3\n| 610,25 | 96,758. | \n额 | 250.00 | 745.77 | 87.91 |  | 95.34\n| 3.00 | 66 | \n| \n三、本期增减变 | -2,790,\n000.00 | \n| 33,533, | 225,477, | 108,614 | 815,786,4 |  | 729,666,70\n动金额（减少以 | \n| 011.22 | 311.68 | ,533.40 | 75.25 |  | 8.19\n“－”号填列） | \n| \n（一）综合收益 | 1,086,145 |  | 1,086,145,3\n| \n总额 | ,333.95 |  | 33.95\n| \n（二）所有者投 | -2,790,\n000.00 | 33,533, | 225,477, | -194,734,30\n| \n入和减少资本 | 011.22 | 311.68 | 0.46\n| \n1．所有者投入 | -2,790,\n000.00 | -10,606, | 281,514, | -294,911,18\n| \n的普通股 | 500.00 | 686.68 | 6.68\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8d49a5f0",
        "00b24f32"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1434,
      "page_number": 98,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "77x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 77,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具",
          "股本"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          98
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.232860",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1434,
        "word_count": 290,
        "sentence_count": 42,
        "chinese_char_count": 265,
        "readability_score": 0.0,
        "information_density": 0.02789400278940028,
        "coherence_score": 0.5889400278940028,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6771764601131696,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具",
        "股本"
      ]
    },
    {
      "chunk_id": "65f83155",
      "content": "1,618, 2,662,2\n四、本期期末余 325,880, 201,812 1,062,800 5,219,782,1\n820,25 29,769.\n额 561.68 ,279.17 ,363.16 03.53\n3.00 88\n三、公司基本情况\n浙江海翔药业股份有限公司（以下简称公司或本公司）系经浙江省人民政府企业上市工作领导小组浙\n上市〔2004〕16号文批准，由罗邦鹏、上海复星化工医药投资有限公司、张志敏、张智岳、罗煜竑、郑志\n国、李维金、中化宁波(集团)有限公司、重庆医药工业研究院有限责任公司和浙江美阳国际石化医药工程\n设计有限公司共同发起，在原浙江海翔医药化工有限公司基础上整体变更设立的股份有限公司，于2004年\n5月13日在浙江省工商行政管理局登记注册，总部位于浙江省台州市。公司现持有统一社会信用代码为\n913300001482332737的营业执照，注册资本1,618,715,253.00元，股份总数1,618,715,253股(每股面值1元)。其中，有限售条件的流通股份A股14,274,600股；无限售条件的流通股份A股1,604,440,653股。\n2．其他权益工 | \n--------------------------------------------------\n具持有者投入 | \n资本 | \n3．股份支付计 | \n| 44,139, | -56,037, | 100,176,88\n入所有者权益 | \n| 511.22 | 375.00 | 6.22\n的金额 | \n| \n4．其他 | \n| 108,614 | -270,358, |  | -161,744,32\n（三）利润分配 | \n| ,533.40 | 858.70 |  | 5.30\n| \n1．提取盈余公 | 108,614 | -108,614,  |\n| \n积 | ,533.40 | 533.40  |\n| \n2．对所有者（或 | -161,744, |  | -161,744,32\n| \n股东）的分配 | 325.30 |  | 5.30\n| \n3．其他 | \n（四）所有者权 | \n| \n益内部结转 | \n| \n1．资本公积转 | \n增资本（或股 | \n本） | \n2．盈余公积转 | \n增资本（或股 | \n本） | \n3．盈余公积弥 | \n| \n补亏损 | \n| \n4．设定受益计 | \n划变动额结转 | \n留存收益 | \n5．其他综合收 | \n益结转留存收 | \n益 | \n6．其他 | \n（五）专项储备 | \n| 4,736,183 | 4,736,183.5\n1．本期提取 | \n| .53 | 3\n| \n| -4,736,18 | -4,736,183.\n2．本期使用 | \n| 3.53 | 53\n| \n（六）其他 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f47a5d13",
        "d4fff770"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1176,
      "page_number": 99,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "53x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 53,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "所有者权益",
          "利润",
          "资本公积",
          "盈余公积"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          99
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.233657",
        "report_type": "financial_report",
        "fiscal_year": 2004,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": "financial",
        "char_count": 1176,
        "word_count": 162,
        "sentence_count": 24,
        "chinese_char_count": 399,
        "readability_score": 0.0,
        "information_density": 0.07653061224489796,
        "coherence_score": 0.4800680272108843,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6862260920826266,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润",
        "投资",
        "253.00元",
        "1元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所有者权益",
        "利润",
        "资本公积",
        "盈余公积"
      ]
    },
    {
      "chunk_id": "bd43d7b2",
      "content": "公司本期将以下15家子公司纳入合并财务报表范围，情况详见本财务报表附注合并范围变更和其他主\n体中的权益之说明。序号 子公司名称 公司简称\n1 浙江海翔川南药业有限公司 川南药业公司\n2 浙江海翔药业销售有限公司 海翔销售公司\n3 上海海翔医药科技发展有限公司 上海海翔公司\n4 台州港翔科技有限公司 港翔科技公司\n5 港翔国际控股(香港)有限公司 香港港翔公司\n6 GeneVida GmbH GeneVida GmbH\n7 GANGXIANG INTERNATIONAL HOLDINGSGANGXIANG(SINGAPORE)\n（SINGAPORE）PTE.LTD\n8 台州港翔化工有限公司 港翔化工公司\n9 台州市前进化工有限公司 台州前进公司\n10 台州市振港染料化工有限公司 台州振港公司\n11 盐城市瓯华化学工业有限公司 盐城瓯华公司\n12 台州市东旭医化设备有限公司 台州东旭公司\n13 盐城市瓯华化工研究院有限公司 瓯华研究院\n14 盐城市瓯华环保科技有限公司 瓯华环保公司\n15 浙江盛嘉环保有限公司 盛嘉环保公司\n| 1,618, | 2,662,2 | \n--------------------------------------------------\n四、本期期末余 | 325,880, | 201,812 | 1,062,800 |  | 5,219,782,1\n| 820,25 | 29,769. | \n额 | 561.68 | ,279.17 | ,363.16 |  | 03.53\n| 3.00 | 88 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c063642c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 678,
      "page_number": 100,
      "bbox": [
        47.5,
        80.0,
        547.5,
        620.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "23x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          100
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234207",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 678,
        "word_count": 90,
        "sentence_count": 8,
        "chinese_char_count": 302,
        "readability_score": 0.0,
        "information_density": 0.04424778761061947,
        "coherence_score": 0.6605171656310801,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5974821984795563,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "22971add",
      "content": "序号 | 子公司名称\n\n--------------------------------------------------\n1 | 浙江海翔川南药业有限公司\n2 | 浙江海翔药业销售有限公司\n3 | 上海海翔医药科技发展有限公司\n4 | 台州港翔科技有限公司\n5 | 港翔国际控股(香港)有限公司\n6 | GeneVida GmbH\n7 | GANGXIANG INTERNATIONAL HOLDINGS\n（SINGAPORE）PTE.LTD\n8 | 台州港翔化工有限公司\n9 | 台州市前进化工有限公司\n10 | 台州市振港染料化工有限公司\n11 | 盐城市瓯华化学工业有限公司\n12 | 台州市东旭医化设备有限公司\n13 | 盐城市瓯华化工研究院有限公司\n14 | 盐城市瓯华环保科技有限公司\n15 | 浙江盛嘉环保有限公司",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "62975253"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 366,
      "page_number": 100,
      "bbox": [
        97.5,
        80.0,
        497.5,
        460.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          100
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234429",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 366,
        "word_count": 53,
        "sentence_count": 1,
        "chinese_char_count": 164,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3352941176470588,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5403972602739726,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "34128b8a",
      "content": "公司在每个资产负债表日重新计量预期信用损失，由此形成的损失准备的增加或转回金额，作为减值\n损失或利得计入当期损益。对于以摊余成本计量的金融资产，损失准备抵减该金融资产在资产负债表中列\n示的账面价值；对于以公允价值计量且其变动计入其他综合收益的债权投资，公司在其他综合收益中确认\n其损失准备，不抵减该金融资产的账面价值。(2) 按组合评估预期信用风险和计量预期信用损失的金融工具\n项 目 确定组合的依据 计量预期信用损失的方法\n其他应收款——应收出口退税组合 款项性质 参考历史信用损失经验，结合当前\n其他应收款——应收押金保证金组 状况以及对未来经济状况的预测，\n合 通过违约风险敞口和未来12个月\n内或整个存续期预期信用损失率，\n其他应收款——合并范围内关联往\n来组合\n计算预期信用损失\n其他应收款——应收拆借款组合\n其他应收款——应收暂付款等组合\n(3) 按组合计量预期信用损失的应收款项\n1) 具体组合及计量预期信用损失的方法\n项 目 确定组合的依据 计量预期信用损失的方法\n应收银行承兑汇票 票据类型 参考历史信用损失经验，结合当前状\n况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，计算预期信用损失\n应收账款——信用风险特征组账龄组合 参考历史信用损失经验，结合当前状\n合 况以及对未来经济状况的预测，编制\n应收账款账龄与整个存续期预期信用\n损失率对照表，计算预期信用损失\n应收账款——合并范围内关联合并范围内关联方 参考历史信用损失经验，结合当前状\n往来组合 况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，该组合预期信用损失率为0%\n2) 应收账款——信用风险特征组合的账龄与整个存续期预期信用损失率对照表\n账 龄 应收账款\n预期信用损失率(%)\n1年以内（含，下同） 5\n1-2年 30\n确定组合的依据 | 计量预期信用损失的方法\n\n--------------------------------------------------\n款项性质 | 参考历史信用损失经验，结合当前\n状况以及对未来经济状况的预测，\n通过违约风险敞口和未来12个月\n内或整个存续期预期信用损失率，\n计算预期信用损失",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "19e461f3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 933,
      "page_number": 105,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "40x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234580",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 933,
        "word_count": 69,
        "sentence_count": 2,
        "chinese_char_count": 744,
        "readability_score": 0.0,
        "information_density": 0.05359056806002144,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6497152524167562,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "成本",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "d20de2c8",
      "content": "项 目 | 确定组合的依据\n\n--------------------------------------------------\n应收银行承兑汇票 | 票据类型\n应收账款——信用风险特征组\n合 | 账龄组合\n应收账款——合并范围内关联\n往来组合 | 合并范围内关联方",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "611d289d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 134,
      "page_number": 105,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "应收账款——信用风险",
          "应收",
          "应收银行承兑汇票",
          "应收账款",
          "应收账款——合并范围"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234852",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 134,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 60,
        "readability_score": 0.0,
        "information_density": 0.3731343283582089,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5276025062656642,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收账款——信用风险",
        "应收",
        "应收银行承兑汇票",
        "应收账款",
        "应收账款——合并范围"
      ]
    },
    {
      "chunk_id": "5e01f864",
      "content": "账 龄\n\n--------------------------------------------------\n1年以内（含，下同）\n1-2年",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2caef8b7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 71,
      "page_number": 105,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234925",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 5,
        "sentence_count": 0,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43328571428571433,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "3cac7f61",
      "content": "### (2) 包装物\n按照一次转销法进行摊销。106。\n\n16、合同资产\n17、合同成本\n18、持有待售资产\n19、债权投资\n20、其他债权投资\n21、长期应收款\n22、长期股权投资\n1. 共同控制、重要影响的判断\n按照相关约定对某项安排存在共有的控制，并且该安排的相关活动必须经过分享控制权的参与方一致\n同意后才能决策，认定为共同控制。对被投资单位的财务和经营政策有参与决策的权力，但并不能够控制\n或者与其他方一起共同控制这些政策的制定，认定为重大影响。2. 投资成本的确定\n(1) 同一控制下的企业合并形成的，合并方以支付现金、转让非现金资产、承担债务或发行权益性证\n券作为合并对价的，在合并日按照取得被合并方所有者权益在最终控制方合并财务报表中的账面价值的份\n额作为其初始投资成本。\n2-3年\n\n--------------------------------------------------\n3年以上",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0b263586"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 407,
      "page_number": 106,
      "bbox": [
        97.5,
        80.0,
        497.5,
        480.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "16x0",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 16,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          106
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234971",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 407,
        "word_count": 24,
        "sentence_count": 7,
        "chinese_char_count": 277,
        "readability_score": 0.0,
        "information_density": 0.17199017199017197,
        "coherence_score": 0.7075,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48862176991150447,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "成本",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "7b74e087",
      "content": "（3）融资租入固定资产的认定依据、计价和折旧方法\n符合下列一项或数项标准的，认定为融资租赁：(1) 在租赁期届满时，租赁资产的所有权转移给承租人；(2) 承租人有购买\n租赁资产的选择权，所订立的购买价款预计将远低于行使选择权时租赁资产的公允价值，因而在租赁开始日就可以合理确定\n承租人将会行使这种选择权；(3) 即使资产的所有权不转移，但租赁期占租赁资产使用寿命的大部分 [ 通常占租赁资产使用\n寿命的75%以上（含75%）]；(4) 承租人在租赁开始日的最低租赁付款额现值，几乎相当于租赁开始日租赁资产公允价值\n[ 90%以上（含90%）]；出租人在租赁开始日的最低租赁收款额现值，几乎相当于租赁开始日租赁资产公允价值 [ 90%以上\n（含90%）]；(5) 租赁资产性质特殊，如果不作较大改造，只有承租人才能使用。融资租入的固定资产，按租赁开始日租\n赁资产的公允价值与最低租赁付款额的现值中较低者入账，按自有固定资产的折旧政策计提折旧。25、在建工程\n1. 在建工程同时满足经济利益很可能流入、成本能够可靠计量则予以确认。\n类别 | 折旧方法 | 折旧年限 | 残值率 | 年折旧率\n--------------------------------------------------\n房屋及建筑物 | 年限平均法 | 5-20 | 0、3、5或10 | 4.50-20.00\n通用设备 | 年限平均法 | 3-5 | 0、3、5或10 | 18.00-33.33\n专用设备 | 年限平均法 | 3-10 | 3、5或10 | 9.00-32.33\n运输工具 | 年限平均法 | 4-5 | 3、5或10 | 18.00-24.25",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cba70c57"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 718,
      "page_number": 108,
      "bbox": [
        53.5,
        80.0,
        541.5,
        400.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "13x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 13,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          108
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235116",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 718,
        "word_count": 66,
        "sentence_count": 12,
        "chinese_char_count": 428,
        "readability_score": 0.0,
        "information_density": 0.04178272980501393,
        "coherence_score": 0.8701020408163265,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6040720610950325,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "46562e7e",
      "content": "项 目\n\n--------------------------------------------------\n土地使用权\n专利权\n非专利技术\n排污权\n软件\n特许使用权\n特许经营权",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4763f525"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 90,
      "page_number": 110,
      "bbox": [
        97.5,
        80.0,
        497.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          110
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235332",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 90,
        "word_count": 10,
        "sentence_count": 0,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.11111111111111112,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.393361797752809,
      "relevance_score": 1.0,
      "keywords": [
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "1269de41",
      "content": "会计政策变更的内容和原因 | 审批程序 | 备注\n--------------------------------------------------\n| 本次会计政策变更已经公司第五届董事 |\n执行《关于修订印发2019年度一般企业  |\n| 会第二十三次会议及第五届监事第十九 |\n财务报表格式的通知》  |\n| 次会议审议通过 |\n |\n财政部于2017年颁布了修订后的《企业  |\n会计准则第22号--金融工具确认和计  |\n量》、《企业会计准则第23号--金融资产  |\n| 本次会计政策变更已经公司第五届董事 | 公司根据新准则，已于2019年1月1日\n转移》、《企业会计准则第37号--金融工  |\n| 会第二十次会议及第五届监事第十六次 | 起将前期划分为可供出售金融资产的股\n具列报》三项会计准则，并要求单独在  |\n| 会议审议通过 | 权投资重分类至其他权益工具投资\n境内上市的企业自2019年1月1日起施  |\n |\n行，根据新旧准则衔接规定，公司无需  |\n重述前期可比数。  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a42cfe49"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 453,
      "page_number": 115,
      "bbox": [
        97.5,
        80.0,
        497.5,
        500.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x3",
        "has_header": false,
        "table_type": "financial_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具",
          "资产"
        ],
        "time_periods": [
          "2019",
          "2019-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235393",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 453,
        "word_count": 49,
        "sentence_count": 1,
        "chinese_char_count": 270,
        "readability_score": 0.0,
        "information_density": 0.17660044150110374,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6809999999999999,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具",
        "资产"
      ]
    },
    {
      "chunk_id": "45f07711",
      "content": "合并资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 1,956,089,124.33 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产 150,000,000.00 150,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 107,399,476.04 -107,399,476.04\n应收账款 479,537,782.06 479,537,782.06\n应收款项融资 107,399,476.04 107,399,476.04\n预付款项 46,449,558.50 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 10,817,853.96 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 905,418,218.49 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 227,882,993.23 77,882,993.23 -150,000,000.00\n流动资产合计 3,733,595,006.61 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00 0.00 -1,800,000.00\n其他债权投资\n原列报报表项目及金额  |\n--------------------------------------------------\n应收票据及应收账款 | 586,937,258.10 | 应收票据\n|  | 应收账款\n应付票据及应付账款 | 791,915,463.78 | 应付票据\n|  | 应付账款",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f54c2ca2"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 760,
      "page_number": 115,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "40x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应付票据及应付账款",
          "应收",
          "应收账款",
          "应付账款",
          "应付票据",
          "应收票据及应收账款",
          "应付"
        ],
        "time_periods": [
          "2018-12",
          "2019-01"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235545",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 760,
        "word_count": 81,
        "sentence_count": 26,
        "chinese_char_count": 242,
        "readability_score": 0.0,
        "information_density": 0.17105263157894737,
        "coherence_score": 0.44999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5372432480070505,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应付票据及应付账款",
        "应收",
        "应收账款",
        "应付账款",
        "应付票据",
        "应收票据及应收账款",
        "应付"
      ]
    },
    {
      "chunk_id": "cc714fbb",
      "content": "持有至到期投资\n长期应收款\n长期股权投资 66,088,139.79 66,088,139.79\n其他权益工具投资 1,800,000.00 1,800,000.00\n其他非流动金融资产\n投资性房地产 12,338,615.29 12,338,615.29\n固定资产 1,215,120,643.61 1,215,120,643.61\n在建工程 674,333,677.99 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 539,514,850.87 539,514,850.87\n开发支出\n商誉 757,736,770.14 757,736,770.14\n长期待摊费用 1,842,423.21 1,842,423.21\n递延所得税资产 32,487,223.69 32,487,223.69\n其他非流动资产 515,993.37 515,993.37\n非流动资产合计 3,301,778,337.96 3,301,778,337.96\n资产总计 7,035,373,344.57 7,035,373,344.57\n流动负债：\n短期借款 598,700,000.00 598,700,000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 490,006,533.85 490,006,533.85\n应付账款 301,908,929.93 301,908,929.93\n预收款项 19,196,692.94 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n项目 | 2018年12月31日 | 2019年01月01日 | 调整数\n--------------------------------------------------\n流动资产： | \n货币资金 | 1,956,089,124.33 | 1,956,089,124.33 |\n结算备付金 | \n拆出资金 | \n交易性金融资产 |  | 150,000,000.00 | 150,000,000.00\n以公允价值计量且其 | \n变动计入当期损益的金融 | \n资产 | \n衍生金融资产 | \n应收票据 | 107,399,476.04 |  | -107,399,476.04\n应收账款 | 479,537,782.06 | 479,537,782.06 |\n应收款项融资 |  | 107,399,476.04 | 107,399,476.04\n预付款项 | 46,449,558.50 | 46,449,558.50 |\n应收保费 | \n应收分保账款 | \n应收分保合同准备金 | \n其他应收款 | 10,817,853.96 | 10,817,853.96 |\n其中：应收利息 | \n应收股利 | \n买入返售金融资产 | \n存货 | 905,418,218.49 | 905,418,218.49 |\n合同资产 | \n持有待售资产 | \n一年内到期的非流动 | \n| \n资产 | \n| \n其他流动资产 | 227,882,993.23 | 77,882,993.23 | -150,000,000.00\n流动资产合计 | 3,733,595,006.61 | 3,733,595,006.61 |\n非流动资产： | \n发放贷款和垫款 | \n债权投资 | \n可供出售金融资产 | 1,800,000.00 | 0.00 | -1,800,000.00\n其他债权投资 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4d7f3d73"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1493,
      "page_number": 116,
      "bbox": [
        69.5,
        80.0,
        525.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "68x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 68,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "预付款项",
          "应收款",
          "衍生金融资产",
          "其他应收款",
          "应收分保账款",
          "应收",
          "应收账款",
          "应收利息",
          "应收款项融资",
          "其他流动资产",
          "合同资产",
          "应收保费",
          "应收票据",
          "应收分保合同准备金",
          "应收股利",
          "货币资金",
          "存货",
          "持有待售资产",
          "资产",
          "交易性金融资产"
        ],
        "time_periods": [
          "2018-12",
          "2019-01"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          116
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235809",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1493,
        "word_count": 187,
        "sentence_count": 56,
        "chinese_char_count": 389,
        "readability_score": 0.0,
        "information_density": 0.16744809109176156,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6665019466797013,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "预付款项",
        "应收款",
        "衍生金融资产",
        "其他应收款",
        "应收分保账款",
        "应收",
        "应收账款",
        "应收利息",
        "应收款项融资",
        "其他流动资产",
        "合同资产",
        "应收保费",
        "应收票据",
        "应收分保合同准备金",
        "应收股利",
        "货币资金",
        "存货",
        "持有待售资产",
        "资产",
        "交易性金融资产"
      ]
    },
    {
      "chunk_id": "dfcc4d26",
      "content": "代理承销证券款\n应付职工薪酬 45,234,354.42 45,234,354.42\n应交税费 54,890,661.34 54,890,661.34\n其他应付款 24,723,304.20 24,723,304.20\n其中：应付利息 1,088,752.57 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动\n44,365,875.00 44,365,875.00\n负债\n其他流动负债\n流动负债合计 1,579,026,351.68 1,579,026,351.68\n非流动负债：\n保险合同准备金\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 12,971,002.47 12,971,002.47\n递延收益 44,650,629.91 44,650,629.91\n递延所得税负债 8,175,428.28 8,175,428.28\n其他非流动负债\n非流动负债合计 65,797,060.66 65,797,060.66\n负债合计 1,644,823,412.34 1,644,823,412.34\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,663,367,822.47 2,663,367,822.47\n持有至到期投资 | \n--------------------------------------------------\n长期应收款 | \n长期股权投资 | 66,088,139.79 | 66,088,139.79 |\n其他权益工具投资 |  | 1,800,000.00 | 1,800,000.00\n其他非流动金融资产 | \n投资性房地产 | 12,338,615.29 | 12,338,615.29 |\n固定资产 | 1,215,120,643.61 | 1,215,120,643.61 |\n在建工程 | 674,333,677.99 | 674,333,677.99 |\n生产性生物资产 | \n油气资产 | \n使用权资产 | \n无形资产 | 539,514,850.87 | 539,514,850.87 |\n开发支出 | \n商誉 | 757,736,770.14 | 757,736,770.14 |\n长期待摊费用 | 1,842,423.21 | 1,842,423.21 |\n递延所得税资产 | 32,487,223.69 | 32,487,223.69 |\n其他非流动资产 | 515,993.37 | 515,993.37 |\n非流动资产合计 | 3,301,778,337.96 | 3,301,778,337.96 |\n资产总计 | 7,035,373,344.57 | 7,035,373,344.57 |\n流动负债： | \n短期借款 | 598,700,000.00 | 598,700,000.00 |\n向中央银行借款 | \n拆入资金 | \n交易性金融负债 | \n以公允价值计量且其 | \n变动计入当期损益的金融 | \n负债 | \n衍生金融负债 | \n应付票据 | 490,006,533.85 | 490,006,533.85 |\n应付账款 | 301,908,929.93 | 301,908,929.93 |\n预收款项 | 19,196,692.94 | 19,196,692.94 |\n合同负债 | \n卖出回购金融资产款 | \n吸收存款及同业存放 | \n代理买卖证券款 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e2e56250"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1535,
      "page_number": 117,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "70x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 70,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期股权投资",
          "短期借款",
          "拆入资金",
          "应收款",
          "吸收存款",
          "衍生金融负债",
          "长期应收款",
          "在建工程",
          "负债",
          "应收",
          "商誉",
          "交易性金融负债",
          "预收款项",
          "使用权资产",
          "短期",
          "长期待摊费用",
          "其他权益工具",
          "合同负债",
          "应付票据",
          "应付",
          "递延所得税资产",
          "投资性房地产",
          "长期",
          "无形资产",
          "固定资产",
          "应付账款",
          "所得税",
          "资产",
          "开发支出"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          117
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.236249",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1535,
        "word_count": 197,
        "sentence_count": 60,
        "chinese_char_count": 379,
        "readability_score": 0.0,
        "information_density": 0.2214983713355049,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7187587109679506,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期股权投资",
        "短期借款",
        "拆入资金",
        "应收款",
        "吸收存款",
        "衍生金融负债",
        "长期应收款",
        "在建工程",
        "负债",
        "应收",
        "商誉",
        "交易性金融负债",
        "预收款项",
        "使用权资产",
        "短期",
        "长期待摊费用",
        "其他权益工具",
        "合同负债",
        "应付票据",
        "应付",
        "递延所得税资产",
        "投资性房地产",
        "长期",
        "无形资产",
        "固定资产",
        "应付账款",
        "所得税",
        "资产",
        "开发支出"
      ]
    },
    {
      "chunk_id": "e9e275e1",
      "content": "减：库存股 325,880,561.68 325,880,561.68\n其他综合收益 -51,779.23 -51,779.23\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n一般风险准备\n未分配利润 1,232,481,918.50 1,232,481,918.50\n归属于母公司所有者权益\n5,390,549,932.23 5,390,549,932.23\n合计\n少数股东权益\n所有者权益合计 5,390,549,932.23 5,390,549,932.23\n负债和所有者权益总计 7,035,373,344.57 7,035,373,344.57\n调整情况说明\n母公司资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 983,565,710.16 983,565,710.16\n交易性金融资产 100,000,000.00 100,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 20,885,763.88 20,885,763.88\n应收账款 149,204,899.98 149,204,899.98 -149,204,899.98\n应收款项融资 149,204,899.98 149,204,899.98\n预付款项 5,554,458.78 5,554,458.78\n其他应收款 1,043,055,918.72 1,043,055,918.72\n其中：应收利息\n应收股利 7,222,088,153.34 722,088,153.34\n存货 84,396,333.98 84,396,333.98\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 105,920,135.97 5,920,135.97 -100,000,000.00\n代理承销证券款 | \n--------------------------------------------------\n应付职工薪酬 | 45,234,354.42 | 45,234,354.42 |\n应交税费 | 54,890,661.34 | 54,890,661.34 |\n其他应付款 | 24,723,304.20 | 24,723,304.20 |\n其中：应付利息 | 1,088,752.57 | 1,088,752.57 |\n应付股利 | 2,051,370.43 | 2,051,370.43 |\n应付手续费及佣金 | \n应付分保账款 | \n持有待售负债 | \n一年内到期的非流动 | \n| 44,365,875.00 | 44,365,875.00 |\n负债 | \n| \n其他流动负债 | \n流动负债合计 | 1,579,026,351.68 | 1,579,026,351.68 |\n非流动负债： | \n保险合同准备金 | \n长期借款 | \n应付债券 | \n其中：优先股 | \n永续债 | \n租赁负债 | \n长期应付款 | \n长期应付职工薪酬 | \n预计负债 | 12,971,002.47 | 12,971,002.47 |\n递延收益 | 44,650,629.91 | 44,650,629.91 |\n递延所得税负债 | 8,175,428.28 | 8,175,428.28 |\n其他非流动负债 | \n非流动负债合计 | 65,797,060.66 | 65,797,060.66 |\n负债合计 | 1,644,823,412.34 | 1,644,823,412.34 |\n所有者权益： | \n股本 | 1,618,820,253.00 | 1,618,820,253.00 |\n其他权益工具 | \n其中：优先股 | \n永续债 | \n资本公积 | 2,663,367,822.47 | 2,663,367,822.47 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a339f62a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1629,
      "page_number": 118,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "71x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 71,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付职工薪酬",
          "应付股利",
          "其他应付款",
          "递延所得税负债",
          "递延收益",
          "负债",
          "应交税费",
          "应付手续费及佣金",
          "应付债券",
          "股本",
          "长期借款",
          "其他权益工具",
          "租赁负债",
          "所有者权益",
          "应付利息",
          "长期应付款",
          "应付",
          "应付分保账款",
          "长期",
          "应付款",
          "所得税",
          "资本公积",
          "预计负债"
        ],
        "time_periods": [
          "2018-12",
          "2019-01"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          118
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.236710",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1629,
        "word_count": 201,
        "sentence_count": 64,
        "chinese_char_count": 376,
        "readability_score": 0.0,
        "information_density": 0.17188459177409454,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.694738029039234,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付职工薪酬",
        "应付股利",
        "其他应付款",
        "递延所得税负债",
        "递延收益",
        "负债",
        "应交税费",
        "应付手续费及佣金",
        "应付债券",
        "股本",
        "长期借款",
        "其他权益工具",
        "租赁负债",
        "所有者权益",
        "应付利息",
        "长期应付款",
        "应付",
        "应付分保账款",
        "长期",
        "应付款",
        "所得税",
        "资本公积",
        "预计负债"
      ]
    },
    {
      "chunk_id": "62549ae5",
      "content": "减：库存股 | 325,880,561.68 | 325,880,561.68 |\n--------------------------------------------------\n其他综合收益 | -51,779.23 | -51,779.23 |\n专项储备 | \n盈余公积 | 201,812,279.17 | 201,812,279.17 |\n一般风险准备 | \n未分配利润 | 1,232,481,918.50 | 1,232,481,918.50 |\n归属于母公司所有者权益 | \n| 5,390,549,932.23 | 5,390,549,932.23 |\n合计 | \n| \n少数股东权益 | \n所有者权益合计 | 5,390,549,932.23 | 5,390,549,932.23 |\n负债和所有者权益总计 | 7,035,373,344.57 | 7,035,373,344.57 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "733ffe1d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 405,
      "page_number": 119,
      "bbox": [
        97.5,
        80.0,
        497.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "12x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 12,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "其他综合收益",
          "负债",
          "库存股",
          "盈余公积",
          "所有者权益",
          "少数股东权益",
          "利润",
          "未分配利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          119
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.237238",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 405,
        "word_count": 53,
        "sentence_count": 14,
        "chinese_char_count": 65,
        "readability_score": 0.0,
        "information_density": 0.2716049382716049,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6116666666666667,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他综合收益",
        "负债",
        "库存股",
        "盈余公积",
        "所有者权益",
        "少数股东权益",
        "利润",
        "未分配利润"
      ]
    },
    {
      "chunk_id": "856c451f",
      "content": "流动资产合计 2,392,583,221.47 2,392,583,221.47\n非流动资产：\n债权投资\n可供出售金融资产 23,017,502.51 -23,017,502.51\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,250,556,852.85 3,250,556,852.85\n其他权益工具投资 23,017,502.51 23,017,502.51\n其他非流动金融资产\n投资性房地产 16,409,402.65 16,409,402.65\n固定资产 182,948,202.54 182,948,202.54\n在建工程 20,490,208.35 20,490,208.35\n生产性生物资产\n油气资产\n使用权资产\n无形资产 17,059,632.32 17,059,632.32\n开发支出\n商誉\n长期待摊费用\n递延所得税资产 9,371,365.80 9,371,365.80\n其他非流动资产\n非流动资产合计 3,519,853,167.02 3,519,853,167.02\n资产总计 5,912,436,388.49 5,912,436,388.49\n流动负债：\n短期借款 287,000,000.00 287,000,000.00\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 202,286,262.85 202,286,262.85\n应付账款 25,423,635.65 25,423,635.65\n预收款项 7,777,982.57 7,777,982.57\n合同负债\n项目 | 2018年12月31日 | 2019年01月01日 | 调整数\n--------------------------------------------------\n流动资产： | \n货币资金 | 983,565,710.16 | 983,565,710.16 |\n交易性金融资产 |  | 100,000,000.00 | 100,000,000.00\n以公允价值计量且其 | \n变动计入当期损益的金融 | \n资产 | \n衍生金融资产 | \n应收票据 | 20,885,763.88 | 20,885,763.88 |\n应收账款 | 149,204,899.98 | 149,204,899.98 | -149,204,899.98\n应收款项融资 |  | 149,204,899.98 | 149,204,899.98\n预付款项 | 5,554,458.78 | 5,554,458.78 |\n其他应收款 | 1,043,055,918.72 | 1,043,055,918.72 |\n其中：应收利息 | \n应收股利 | 7,222,088,153.34 | 722,088,153.34 |\n存货 | 84,396,333.98 | 84,396,333.98 |\n合同资产 | \n持有待售资产 | \n一年内到期的非流动 | \n| \n资产 | \n| \n其他流动资产 | 105,920,135.97 | 5,920,135.97 | -100,000,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "14e57db4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1318,
      "page_number": 119,
      "bbox": [
        73.5,
        80.0,
        521.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "56x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 56,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收股利",
          "货币资金",
          "存货",
          "预付款项",
          "应收款项融资",
          "应收",
          "其他流动资产",
          "持有待售资产",
          "应收账款",
          "合同资产",
          "应收款",
          "应收利息",
          "衍生金融资产",
          "其他应收款",
          "资产",
          "交易性金融资产"
        ],
        "time_periods": [
          "2018-12",
          "2019-01"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          119
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.237421",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1318,
        "word_count": 157,
        "sentence_count": 52,
        "chinese_char_count": 310,
        "readability_score": 0.0,
        "information_density": 0.1669195751138088,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6606019830028329,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收股利",
        "货币资金",
        "存货",
        "预付款项",
        "应收款项融资",
        "应收",
        "其他流动资产",
        "持有待售资产",
        "应收账款",
        "合同资产",
        "应收款",
        "应收利息",
        "衍生金融资产",
        "其他应收款",
        "资产",
        "交易性金融资产"
      ]
    },
    {
      "chunk_id": "b91ec86e",
      "content": "应付职工薪酬 6,439,699.82 6,439,699.82\n应交税费 948,517.30 948,517.30\n其他应付款 104,178,588.96 104,178,588.96\n其中：应付利息 805,795.63 805,795.63\n应付股利 2,051,370.43 2,051,370.43\n持有待售负债\n一年内到期的非流动\n44,365,875.00 44,365,875.00\n负债\n其他流动负债\n流动负债合计 678,420,562.15 678,420,562.15\n非流动负债：\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 12,971,002.47 12,971,002.47\n递延收益 1,262,720.34 1,262,720.34\n递延所得税负债\n其他非流动负债\n非流动负债合计 14,233,722.81 14,233,722.81\n负债合计 692,654,284.96 692,654,284.96\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,662,229,769.88 2,662,229,769.88\n减：库存股 325,880,561.68 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n流动资产合计 | 2,392,583,221.47 | 2,392,583,221.47 |\n--------------------------------------------------\n非流动资产： | \n债权投资 | \n可供出售金融资产 | 23,017,502.51 |  | -23,017,502.51\n其他债权投资 | \n持有至到期投资 | \n长期应收款 | \n长期股权投资 | 3,250,556,852.85 | 3,250,556,852.85 |\n其他权益工具投资 |  | 23,017,502.51 | 23,017,502.51\n其他非流动金融资产 | \n投资性房地产 | 16,409,402.65 | 16,409,402.65 |\n固定资产 | 182,948,202.54 | 182,948,202.54 |\n在建工程 | 20,490,208.35 | 20,490,208.35 |\n生产性生物资产 | \n油气资产 | \n使用权资产 | \n无形资产 | 17,059,632.32 | 17,059,632.32 |\n开发支出 | \n商誉 | \n长期待摊费用 | \n递延所得税资产 | 9,371,365.80 | 9,371,365.80 |\n其他非流动资产 | \n非流动资产合计 | 3,519,853,167.02 | 3,519,853,167.02 |\n资产总计 | 5,912,436,388.49 | 5,912,436,388.49 |\n流动负债： | \n短期借款 | 287,000,000.00 | 287,000,000.00 |\n交易性金融负债 | \n以公允价值计量且其 | \n变动计入当期损益的金融 | \n负债 | \n衍生金融负债 | \n应付票据 | 202,286,262.85 | 202,286,262.85 |\n应付账款 | 25,423,635.65 | 25,423,635.65 |\n预收款项 | 7,777,982.57 | 7,777,982.57 |\n合同负债 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f18aab49"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1511,
      "page_number": 120,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "70x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 70,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期股权投资",
          "短期借款",
          "应收款",
          "衍生金融负债",
          "长期应收款",
          "在建工程",
          "负债",
          "应收",
          "商誉",
          "交易性金融负债",
          "预收款项",
          "使用权资产",
          "短期",
          "长期待摊费用",
          "其他权益工具",
          "合同负债",
          "应付票据",
          "应付",
          "递延所得税资产",
          "投资性房地产",
          "长期",
          "无形资产",
          "固定资产",
          "应付账款",
          "所得税",
          "资产",
          "开发支出"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.237804",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1511,
        "word_count": 195,
        "sentence_count": 60,
        "chinese_char_count": 362,
        "readability_score": 0.0,
        "information_density": 0.21178027796161483,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7173932214544257,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期股权投资",
        "短期借款",
        "应收款",
        "衍生金融负债",
        "长期应收款",
        "在建工程",
        "负债",
        "应收",
        "商誉",
        "交易性金融负债",
        "预收款项",
        "使用权资产",
        "短期",
        "长期待摊费用",
        "其他权益工具",
        "合同负债",
        "应付票据",
        "应付",
        "递延所得税资产",
        "投资性房地产",
        "长期",
        "无形资产",
        "固定资产",
        "应付账款",
        "所得税",
        "资产",
        "开发支出"
      ]
    },
    {
      "chunk_id": "2b9e08d0",
      "content": "未分配利润 1,062,800,363.16 1,062,800,363.16\n所有者权益合计 5,219,782,103.53 5,219,782,103.53\n负债和所有者权益总计 5,912,436,388.49 5,912,436,388.49\n调整情况说明\n（4）2019年起执行新金融工具准则或新租赁准则追溯调整前期比较数据说明\n□ 适用 √ 不适用\n45、其他\n六、税项\n1、主要税种及税率\n税种 计税依据 税率\n增值税 销售货物或提供应税劳务 19%、16%、13%、6%\n城市维护建设税 应缴流转税税额 7%、5%\n企业所得税 应纳税所得额 15%、16.5%、17%、20%、25%\n从价计征的，按房产原值一次减除30%\n房产税 后余值的1.2%计缴；从租计征的，按租 1.2%、12%\n金收入的12%计缴\n教育费附加 应缴流转税税额 3%\n地方教育附加 应缴流转税税额 2%\n存在不同企业所得税税率纳税主体的，披露情况说明\n纳税主体名称 所得税税率\n川南药业公司、台州前进公司、盐城瓯华\n公司、GeneVida GmbH 15%\n香港港翔公司 16.5%\nGANGXIANG（SINGAPORE） 17%\n上海海翔公司、东旭医化公司 20%\n除上述以外的其他纳税主体 25%\n2、税收优惠\n(二) 税收优惠\n1. 根据科学技术部火炬高科技产业开发中心国科火字〔2017〕201号文批复，川南药业公司通过高新\n技术企业复审备案，自2017年起减按15%的税率计缴企业所得税，认定有效期3年。2. 根据科学技术部火炬高科技产业开发中心国科火字〔2016〕149号文批复，台州前进公司通过高新\n应付职工薪酬 | 6,439,699.82 | 6,439,699.82 |\n--------------------------------------------------\n应交税费 | 948,517.30 | 948,517.30 |\n其他应付款 | 104,178,588.96 | 104,178,588.96 |\n其中：应付利息 | 805,795.63 | 805,795.63 |\n应付股利 | 2,051,370.43 | 2,051,370.43 |\n持有待售负债 | \n一年内到期的非流动 | \n| 44,365,875.00 | 44,365,875.00 |\n负债 | \n| \n其他流动负债 | \n流动负债合计 | 678,420,562.15 | 678,420,562.15 |\n非流动负债： | \n长期借款 | \n应付债券 | \n其中：优先股 | \n永续债 | \n租赁负债 | \n长期应付款 | \n长期应付职工薪酬 | \n预计负债 | 12,971,002.47 | 12,971,002.47 |\n递延收益 | 1,262,720.34 | 1,262,720.34 |\n递延所得税负债 | \n其他非流动负债 | \n非流动负债合计 | 14,233,722.81 | 14,233,722.81 |\n负债合计 | 692,654,284.96 | 692,654,284.96 |\n所有者权益： | \n股本 | 1,618,820,253.00 | 1,618,820,253.00 |\n其他权益工具 | \n其中：优先股 | \n永续债 | \n资本公积 | 2,662,229,769.88 | 2,662,229,769.88 |\n减：库存股 | 325,880,561.68 | 325,880,561.68 |\n其他综合收益 | \n专项储备 | \n盈余公积 | 201,812,279.17 | 201,812,279.17 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b1221aa3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1540,
      "page_number": 121,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "65x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 65,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付职工薪酬",
          "应付股利",
          "其他应付款",
          "递延所得税负债",
          "盈余公积",
          "递延收益",
          "负债",
          "应交税费",
          "应付债券",
          "股本",
          "长期借款",
          "其他权益工具",
          "租赁负债",
          "所有者权益",
          "应付利息",
          "长期应付款",
          "应付",
          "长期",
          "其他综合收益",
          "库存股",
          "应付款",
          "所得税",
          "资本公积",
          "预计负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          121
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.238244",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1540,
        "word_count": 194,
        "sentence_count": 43,
        "chinese_char_count": 541,
        "readability_score": 0.0,
        "information_density": 0.18181818181818182,
        "coherence_score": 0.4170401337792642,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7095208502470447,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "收入",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付职工薪酬",
        "应付股利",
        "其他应付款",
        "递延所得税负债",
        "盈余公积",
        "递延收益",
        "负债",
        "应交税费",
        "应付债券",
        "股本",
        "长期借款",
        "其他权益工具",
        "租赁负债",
        "所有者权益",
        "应付利息",
        "长期应付款",
        "应付",
        "长期",
        "其他综合收益",
        "库存股",
        "应付款",
        "所得税",
        "资本公积",
        "预计负债"
      ]
    },
    {
      "chunk_id": "9820a769",
      "content": "未分配利润 | 1,062,800,363.16 | 1,062,800,363.16 |\n--------------------------------------------------\n所有者权益合计 | 5,219,782,103.53 | 5,219,782,103.53 |\n负债和所有者权益总计 | 5,912,436,388.49 | 5,912,436,388.49 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5ddbe025"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 195,
      "page_number": 122,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "所有者权益",
          "利润",
          "未分配利润",
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.238661",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 195,
        "word_count": 19,
        "sentence_count": 6,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.358974358974359,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4812666666666667,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所有者权益",
        "利润",
        "未分配利润",
        "负债"
      ]
    },
    {
      "chunk_id": "57e6dfab",
      "content": "技术企业复审备案，自2016年起减按15%的税率计缴企业所得税，认定有效期3年。认定资格有效期届满后，\n公司重新申请了高新技术企业资格认定，截至本财务报表批准报出日尚处于审核阶段，2019年度暂按15%\n的税率计缴。3. 根据江苏省科学技术厅、江苏省财政厅、江苏省国家税务局、江苏省地方税务局联合颁发的《高新\n技术企业证书》，盐城瓯华公司被认定为高新技术企业，自2017年起减按15%的税率计缴企业所得税，认\n定有效期3年。\n纳税主体名称 | 所得税税率\n\n--------------------------------------------------\n川南药业公司、台州前进公司、盐城瓯华 |\n公司、GeneVida GmbH | 15%\n香港港翔公司 | 16.5%\nGANGXIANG（SINGAPORE） | 17%\n上海海翔公司、东旭医化公司 | 20%\n除上述以外的其他纳税主体 | 25%",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "16938d13"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 404,
      "page_number": 122,
      "bbox": [
        77.5,
        80.0,
        517.5,
        360.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "11x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.238742",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "公司重新申请了高新技术企业",
        "industry": "financial",
        "char_count": 404,
        "word_count": 28,
        "sentence_count": 5,
        "chinese_char_count": 225,
        "readability_score": 0.0,
        "information_density": 0.07425742574257425,
        "coherence_score": 0.43226890756302516,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5821156435057828,
      "relevance_score": 1.0,
      "keywords": [
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税"
      ]
    },
    {
      "chunk_id": "d86aeed2",
      "content": "4. 根据国家税务总局下发的《关于实施小型微利企业普惠性所得税减免政策有关问题的公告》（国家\n税务总局公告2019年第2号），上海海翔公司、东旭医化公司享受小型微利企业的税收优惠政策，减按20%\n的税率计缴企业所得税；对港翔科技公司所得减按25%计入应纳税所得额，按20%的税率缴纳企业所得税。3、其他\n七、合并财务报表项目注释\n1、货币资金\n单位： 元\n项目 期末余额 期初余额\n库存现金 131,545.99 195,522.60\n银行存款 1,525,298,726.49 1,852,939,694.25\n其他货币资金 31,145,099.97 102,953,907.48\n合计 1,556,575,372.45 1,956,089,124.33\n其中：存放在境外的款项总额 649,218.69 2,180,766.37\n因抵押、质押或冻结等对使用\n30,797,464.00 136,880,848.73\n有限制的款项总额\n其他说明\n[注]:期末银行定期存款116,083,968.00元。2、交易性金融资产\n单位： 元\n项目 期末余额 期初余额\n其中：\n指定以公允价值计量且其变动计入当期\n150,000,000.00\n损益的金融资产\n其中：\n银行理财产品 150,000,000.00\n合计 150,000,000.00\n其他说明：\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n库存现金 | 131,545.99 | 195,522.60\n银行存款 | 1,525,298,726.49 | 1,852,939,694.25\n其他货币资金 | 31,145,099.97 | 102,953,907.48\n合计 | 1,556,575,372.45 | 1,956,089,124.33\n其中：存放在境外的款项总额 | 649,218.69 | 2,180,766.37\n因抵押、质押或冻结等对使用  |\n| 30,797,464.00 | 136,880,848.73\n有限制的款项总额  |\n |\n\n> 注：3、衍生金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n4、应收票据\n（1）应收票据分类列示\n单位： 元\n项目 期末余额 期初余额\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n其中：\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收票据坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备收回或转回金额重要的：\n124",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6f39363b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1323,
      "page_number": 123,
      "bbox": [
        85.5,
        80.0,
        509.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "73x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 73,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "银行存款",
          "货币资金",
          "库存现金"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          123
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.238874",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "对港翔科技公司",
        "industry": "financial",
        "char_count": 1323,
        "word_count": 160,
        "sentence_count": 31,
        "chinese_char_count": 637,
        "readability_score": 0.0,
        "information_density": 0.06802721088435373,
        "coherence_score": 0.49545729402872263,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6441481063052558,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资",
        "财务",
        "报表",
        "968.00元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "银行存款",
        "货币资金",
        "库存现金"
      ]
    },
    {
      "chunk_id": "e605b08c",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n其中：  |\n指定以公允价值计量且其变动计入当期  |\n|  | 150,000,000.00\n损益的金融资产  |\n |\n其中：  |\n银行理财产品 |  | 150,000,000.00\n合计 |  | 150,000,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2e317a4e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 186,
      "page_number": 123,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          123
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239197",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 186,
        "word_count": 26,
        "sentence_count": 3,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.16129032258064516,
        "coherence_score": 0.35,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5079234811165846,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "9eda933c",
      "content": "| 期末余额 | 期初余额 | \n--------------------------------------------------\n| 账面余额 |  | 坏账准备 | 账面余额 |  | 坏账准备  |\n类别 | \n| 计提比 | 账面价值 | 账面价值\n| 金额 | 比例 | 金额 | 金额 | 比例 | 金额 | 计提比例 |\n| 例 | \n| \n其中： | \n其中： |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5cee8e4b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 192,
      "page_number": 124,
      "bbox": [
        97.5,
        80.0,
        497.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239279",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 192,
        "word_count": 48,
        "sentence_count": 0,
        "chinese_char_count": 58,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5001650385604113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "92c0c488",
      "content": "| 期末余额 | \n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例 | 计提理由\n| \n\n> 注：□ 适用 √ 不适用\n（3）期末公司已质押的应收票据\n单位： 元\n项目 期末已质押金额\n（4）期末公司已背书或贴现且在资产负债表日尚未到期的应收票据\n单位： 元\n项目 期末终止确认金额 期末未终止确认金额\n（5）期末公司因出票人未履约而将其转应收账款的票据\n单位： 元\n项目 期末转应收账款金额\n其他说明\n（6）本期实际核销的应收票据情况\n单位： 元\n项目 核销金额\n其中重要的应收票据核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收票据性质 核销金额 核销原因 履行的核销程序\n易产生\n应收票据核销说明：\n5、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按信用风险特征组\n合计提坏账准备\n125",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a07c7192"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 482,
      "page_number": 124,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239381",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 482,
        "word_count": 79,
        "sentence_count": 0,
        "chinese_char_count": 309,
        "readability_score": 0.0,
        "information_density": 0.04149377593360996,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4857289991728701,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "76a51acb",
      "content": "| 期末余额  |\n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6f871627"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 89,
      "page_number": 124,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239547",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 89,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37160000000000004,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f840dc22",
      "content": "|  | 本期变动金额 | \n--------------------------------------------------\n类别 | 期初余额 | 期末余额\n|  | 计提 | 收回或转回 | 核销 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "471e6c9b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 107,
      "page_number": 124,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239601",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 107,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.379778417266187,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ee5ba752",
      "content": "| 款项是否由关联交\n--------------------------------------------------\n单位名称 | 应收票据性质 | 核销金额 | 核销原因 | 履行的核销程序 |\n| 易产生\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4b593500"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 109,
      "page_number": 125,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收",
          "应收票据性质"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          125
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239670",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 109,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.27522935779816515,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.391,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收",
        "应收票据性质"
      ]
    },
    {
      "chunk_id": "d5d0b5ef",
      "content": "按组合计提坏账准 500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n100.00% 8.19% 100.00% 7.61%\n备的应收账款 838.93 74.74 64.19 65.36 3.30 2.06\n其中：\n500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n合计 100.00% 8.19% 100.00% 7.61%\n838.93 74.74 64.19 65.36 3.30 2.06\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n账龄组合 500,776,838.93 40,995,274.74 8.19%\n合计 500,776,838.93 40,995,274.74 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 481,295,912.96\n1至2年 2,351,572.07\n2至3年 4,521,732.29\n3年以上 12,607,621.61\n3至4年 8,370,022.99\n5年以上 4,237,598.62\n合计 500,776,838.93\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n| 期末余额 | 期初余额 | \n--------------------------------------------------\n| 账面余额 |  | 坏账准备 | 账面余额 |  | 坏账准备  |\n类别 | \n| 计提比 | 账面价值 | 账面价值\n| 金额 | 比例 | 金额 | 金额 | 比例 | 金额 | 计提比例 |\n| 例 | \n| \n其中： | \n按信用风险特征组 | \n| \n合计提坏账准备 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "04a6eb64"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 952,
      "page_number": 125,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "49x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 49,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          125
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239726",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 952,
        "word_count": 147,
        "sentence_count": 32,
        "chinese_char_count": 321,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5200840336134454,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5864292005369922,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "4e458774",
      "content": "按组合计提坏账准 | 500,776, |  | 40,995,2 | 8.19% | 459,781,5 | 519,058,0 |  | 39,520,28 |  | 479,537,78\n--------------------------------------------------\n|  | 100.00% | 100.00% |  | 7.61% |\n备的应收账款 | 838.93 |  | 74.74 |  | 64.19 | 65.36 |  | 3.30 |  | 2.06\n| \n其中： | \n| 500,776, |  | 40,995,2 | 8.19% | 459,781,5\n64.19 | 519,058,0 |  | 39,520,28 |  | 479,537,78\n合计 |  | 100.00% | 100.00% |  | 7.61% |\n| 838.93 |  | 74.74 | 65.36 |  | 3.30 |  | 2.06\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3decfc2e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 442,
      "page_number": 126,
      "bbox": [
        47.5,
        80.0,
        547.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240067",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 442,
        "word_count": 90,
        "sentence_count": 20,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.04524886877828054,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5048128342245989,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收账款"
      ]
    },
    {
      "chunk_id": "7fd72e76",
      "content": "| 期末余额 | \n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例 | 计提理由\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c7be2afe"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 96,
      "page_number": 126,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240220",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3764129032258064,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "c70de7f9",
      "content": "| 期末余额  |\n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例\n| \n账龄组合 | 500,776,838.93 | 40,995,274.74 | 8.19%\n合计 | 500,776,838.93 | 40,995,274.74 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f65cd186"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 177,
      "page_number": 126,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240277",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 177,
        "word_count": 27,
        "sentence_count": 5,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3824615384615385,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "92604267",
      "content": "| 期末余额  |\n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "77491d95"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 89,
      "page_number": 126,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240551",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 89,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37160000000000004,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6df6959c",
      "content": "单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n39,520,283.30 1,474,991.44 40,995,274.74\n备\n合计 39,520,283.30 1,474,991.44 40,995,274.74\n其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数的\n单位名称 应收账款期末余额 坏账准备期末余额\n比例\n重庆天地药业有限责任\n85,994,787.83 17.17% 4,299,739.39\n公司\nACS DOBFAR S.P.A 30,318,565.17 6.05% 1,515,928.26\nFIS-FABBRICA\nITALIANA SINTETICI 23,576,101.39 4.71% 1,178,805.07\nS.P.A\nPFIZER ASIA\nMANUFACTURING 19,767,647.40 3.95% 988,382.37\nPTE LTD\n绍兴舜德进出口有限公\n18,868,983.58 3.77% 943,449.18\n司\n合计 178,526,085.37 35.65%\n账龄 | 账面余额\n\n--------------------------------------------------\n1年以内（含1年） | 481,295,912.96\n1至2年 | 2,351,572.07\n2至3年 | 4,521,732.29\n3年以上 | 12,607,621.61\n3至4年 | 8,370,022.99\n5年以上 | 4,237,598.62\n合计 | 500,776,838.93",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f3fa2d23"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 866,
      "page_number": 126,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "47x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 47,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240618",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 866,
        "word_count": 107,
        "sentence_count": 34,
        "chinese_char_count": 266,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5274025687815834,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "40e41f6f",
      "content": "|  | 本期变动金额 | \n--------------------------------------------------\n类别 | 期初余额 | 期末余额\n|  | 计提 | 收回或转回 | 核销 |\n| \n按组合计提坏账准 | \n| 39,520,283.30 | 1,474,991.44 | 40,995,274.74\n备 | \n| \n合计 | 39,520,283.30 | 1,474,991.44 | 40,995,274.74",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3294b9a8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 225,
      "page_number": 127,
      "bbox": [
        85.5,
        80.0,
        509.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          127
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240942",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 225,
        "word_count": 37,
        "sentence_count": 6,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4038470588235294,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "d2292020",
      "content": "| 款项是否由关联交\n--------------------------------------------------\n单位名称 | 应收账款性质 | 核销金额 | 核销原因 | 履行的核销程序 |\n| 易产生\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f3ed3dbc"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 109,
      "page_number": 127,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收账款性质",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          127
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241140",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 109,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.27522935779816515,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.391,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收账款性质",
        "应收账款"
      ]
    },
    {
      "chunk_id": "06e6f574",
      "content": "（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n6、应收款项融资\n单位： 元\n项目 期末余额 期初余额\n应收票据 74,531,666.41 107,399,476.04\n合计 74,531,666.41 107,399,476.04\n应收款项融资本期增减变动及公允价值变动情况\n□ 适用 √ 不适用\n如是按照预期信用损失一般模型计提应收款项融资减值准备，请参照其他应收款的披露方式披露减值准备的相关信息：\n□ 适用 √ 不适用\n其他说明：\n7、预付款项\n（1）预付款项按账龄列示\n单位： 元\n期末余额 期初余额\n账龄\n金额 比例 金额 比例\n1年以内 29,093,214.59 85.94% 37,487,264.60 80.71%\n1至2年 2,278,425.47 6.73% 6,488,949.11 13.97%\n2至3年 683,976.07 2.02% 1,208,687.98 2.60%\n3年以上 1,795,870.66 5.31% 1,264,656.81 2.72%\n合计 33,851,486.79 -- 46,449,558.50 --\n账龄超过1年且金额重要的预付款项未及时结算原因的说明：\n（2）按预付对象归集的期末余额前五名的预付款情况\n期末余额前5名的预付款项合计数为9,950,421.65元，占预付款项期末余额合计数的比例为29.39%。其他说明：\n8、其他应收款\n单位： 元\n|  | 占应收账款期末余额合计数的 |\n--------------------------------------------------\n单位名称 | 应收账款期末余额 |  | 坏账准备期末余额\n|  | 比例 |\n| \n重庆天地药业有限责任 | \n| 85,994,787.83 | 17.17% | 4,299,739.39\n公司 | \n| \nACS DOBFAR S.P.A | 30,318,565.17 | 6.05% | 1,515,928.26\nFIS-FABBRICA | \nITALIANA SINTETICI | 23,576,101.39 | 4.71% | 1,178,805.07\nS.P.A | \nPFIZER ASIA | \nMANUFACTURING | 19,767,647.40 | 3.95% | 988,382.37\nPTE LTD | \n绍兴舜德进出口有限公 | \n| 18,868,983.58 | 3.77% | 943,449.18\n司 | \n| \n合计 | 178,526,085.37 | 35.65% |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "10c035aa"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1121,
      "page_number": 127,
      "bbox": [
        65.5,
        80.0,
        529.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "46x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 46,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "应收账款期末余额",
          "应收账款期末余额合计",
          "应收",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          127
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241201",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1121,
        "word_count": 146,
        "sentence_count": 46,
        "chinese_char_count": 347,
        "readability_score": 0.0,
        "information_density": 0.07136485280999108,
        "coherence_score": 0.5237062496720365,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5403344131251108,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资",
        "421.65元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收账款期末余额",
        "应收账款期末余额合计",
        "应收",
        "应收账款"
      ]
    },
    {
      "chunk_id": "62c3fafa",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应收票据 | 74,531,666.41 | 107,399,476.04\n合计 | 74,531,666.41 | 107,399,476.04\n\n> 注：项目 期末余额 期初余额\n其他应收款 18,297,536.18 10,817,853.96\n合计 18,297,536.18 10,817,853.96\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n单位： 元\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n129",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "667e8c6b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 476,
      "page_number": 128,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "30x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收票据",
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          128
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241576",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 476,
        "word_count": 71,
        "sentence_count": 8,
        "chinese_char_count": 205,
        "readability_score": 0.0,
        "information_density": 0.06302521008403361,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4386454125730818,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收票据",
        "应收"
      ]
    },
    {
      "chunk_id": "80a2bcba",
      "content": "| 期末余额 |  | 期初余额 |\n--------------------------------------------------\n账龄 | \n| 金额 | 比例 | 金额 | 比例\n| \n1年以内 | 29,093,214.59 | 85.94% | 37,487,264.60 | 80.71%\n1至2年 | 2,278,425.47 | 6.73% | 6,488,949.11 | 13.97%\n2至3年 | 683,976.07 | 2.02% | 1,208,687.98 | 2.60%\n3年以上 | 1,795,870.66 | 5.31% | 1,264,656.81 | 2.72%\n合计 | 33,851,486.79 | -- | 46,449,558.50 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "dbb80de0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 350,
      "page_number": 128,
      "bbox": [
        81.5,
        80.0,
        513.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          128
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241782",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 350,
        "word_count": 63,
        "sentence_count": 18,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3252631578947368,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4114967741935484,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "11b7be59",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n其他应收款 | 18,297,536.18 | 10,817,853.96\n合计 | 18,297,536.18 | 10,817,853.96",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8ac56729"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 140,
      "page_number": 129,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "其他应收款",
          "应收款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          129
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242067",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 140,
        "word_count": 16,
        "sentence_count": 4,
        "chinese_char_count": 17,
        "readability_score": 0.0,
        "information_density": 0.21428571428571427,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3712142857142858,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "其他应收款",
        "应收款"
      ]
    },
    {
      "chunk_id": "6ed50665",
      "content": "| 是否发生减值及其判断\n--------------------------------------------------\n借款单位 | 期末余额 | 逾期时间 | 逾期原因 |\n| 依据\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "170d3530"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 98,
      "page_number": 129,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          129
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242136",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 98,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3833076923076923,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "3f2dddf6",
      "content": "（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n应收暂付款 19,403,087.81 21,023,388.15\n押金保证金 8,079,470.25 4,971,398.75\n应收出口退税 6,994,977.96\n拆借款 1,250,962.00 1,797,563.33\n其 他 697,469.95 126,777.96\n合计 36,425,967.97 27,919,128.19\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 17,101,274.23 17,101,274.23\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 1,027,157.56 1,027,157.56\n2019年12月31日余额 18,128,431.79 18,128,431.79\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 12,618,376.33\n1至2年 8,167,903.05\n2至3年 1,213,988.18\n3年以上 14,425,700.41\n3至4年 2,214,569.77\n4至5年 510,000.00\n5年以上 11,701,130.64\n合计 36,425,967.97\n| 是否发生减值及其判断\n--------------------------------------------------\n项目(或被投资单位) | 期末余额 | 账龄 | 未收回的原因 |\n| 依据\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "796d8dad"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 769,
      "page_number": 129,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "37x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          129
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242189",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 769,
        "word_count": 94,
        "sentence_count": 25,
        "chinese_char_count": 251,
        "readability_score": 0.0,
        "information_density": 0.013003901170351103,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45310017825311943,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "3c144538",
      "content": "款项性质 | 期末账面余额 | 期初账面余额\n--------------------------------------------------\n应收暂付款 | 19,403,087.81 | 21,023,388.15\n押金保证金 | 8,079,470.25 | 4,971,398.75\n应收出口退税 | 6,994,977.96 |\n拆借款 | 1,250,962.00 | 1,797,563.33\n其 他 | 697,469.95 | 126,777.96\n合计 | 36,425,967.97 | 27,919,128.19",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4fa471fc"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 270,
      "page_number": 130,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收暂付款",
          "应收",
          "应收出口退税"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          130
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242502",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 270,
        "word_count": 36,
        "sentence_count": 11,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.11111111111111109,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4007867158671587,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收暂付款",
        "应收",
        "应收出口退税"
      ]
    },
    {
      "chunk_id": "818facd7",
      "content": "| 第一阶段 | 第二阶段 | 第三阶段 |\n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n| 用损失 | (未发生信用减值) | (已发生信用减值) |\n2019年1月1日余额 | 17,101,274.23 | 17,101,274.23\n2019年1月1日余额在 | \n| —— | —— | —— | ——\n本期 | \n| \n本期计提 | 1,027,157.56 | 1,027,157.56\n2019年12月31日余额 | 18,128,431.79 | 18,128,431.79",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fccaf255"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 325,
      "page_number": 130,
      "bbox": [
        97.5,
        80.0,
        497.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          130
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242616",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 325,
        "word_count": 52,
        "sentence_count": 6,
        "chinese_char_count": 86,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5095085106382979,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6f306362",
      "content": "3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n台州市椒江朝晖建\n押金保证金 2,950,000.001年以内 8.10% 147,500.00\n设投资有限公司\n台州市椒江朝晖建\n押金保证金 3,850,000.001-2年 10.57% 1,155,000.00\n设投资有限公司\n应收出口退税 应收出口退税 6,584,960.261年以内 18.08%\nPFIZER ASIA\nMANUFACTURIN 应收暂付款 5,000,000.003年以上 13.73% 5,000,000.00\nG PTE LTD\n浙江福仁瑞生物科\n应收暂付款 3,222,047.103年以上 8.85% 3,222,047.10\n技有限公司\n台州市中荣化工有\n应收暂付款 2,160,572.193年以上 5.93% 2,160,572.19\n限公司\n合计 -- 23,767,579.55 -- 65.26% 11,685,119.29\n账龄 | 账面余额\n\n--------------------------------------------------\n1年以内（含1年） | 12,618,376.33\n1至2年 | 8,167,903.05\n2至3年 | 1,213,988.18\n3年以上 | 14,425,700.41\n3至4年 | 2,214,569.77\n4至5年 | 510,000.00\n5年以上 | 11,701,130.64\n合计 | 36,425,967.97",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8178e0c1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 914,
      "page_number": 130,
      "bbox": [
        77.5,
        80.0,
        517.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "49x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 49,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          130
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242733",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "设投资有限公司",
        "industry": null,
        "char_count": 914,
        "word_count": 115,
        "sentence_count": 28,
        "chinese_char_count": 376,
        "readability_score": 0.0,
        "information_density": 0.010940919037199124,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5388379888268156,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "4941a7e6",
      "content": "|  | 本期变动金额 | \n--------------------------------------------------\n类别 | 期初余额 | 期末余额\n|  | 计提 | 收回或转回 | 核销 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ed522f98"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 107,
      "page_number": 131,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          131
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243052",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 107,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.379778417266187,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "bf066a71",
      "content": "| 款项是否由关联交\n--------------------------------------------------\n单位名称 | 其他应收款性质 | 核销金额 | 核销原因 | 履行的核销程序 |\n| 易产生\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c56297c7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 110,
      "page_number": 131,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收款性质",
          "其他应收款",
          "其他应收款性质"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          131
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243124",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 110,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.36363636363636365,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3919549668874172,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收款性质",
        "其他应收款",
        "其他应收款性质"
      ]
    },
    {
      "chunk_id": "4fd37fe5",
      "content": "6）涉及政府补助的应收款项\n单位： 元\n预计收取的时间、金额\n单位名称 政府补助项目名称 期末余额 期末账龄\n及依据\n7）因金融资产转移而终止确认的其他应收款\n8）转移其他应收款且继续涉入形成的资产、负债金额\n其他说明：\n9、存货\n是否已执行新收入准则\n□ 是 √ 否\n（1）存货分类\n单位： 元\n期末余额 期初余额\n项目\n账面余额 跌价准备 账面价值 账面余额 跌价准备 账面价值\n原材料 209,787,752.67 2,975,404.23 206,812,348.44 243,008,744.60 2,867,227.10 240,141,517.50\n在产品 164,776,116.17 4,244,871.82 160,531,244.35 214,182,041.63 3,023,716.71 211,158,324.92\n库存商品 493,928,178.91 22,117,971.87 471,810,207.04 477,155,579.50 23,329,566.31 453,826,013.19\n委托加工物资 3,831,460.77 3,831,460.77 292,362.88 292,362.88\n合计 872,323,508.52 29,338,247.92 842,985,260.60 934,638,728.61 29,220,510.12 905,418,218.49\n（2）存货跌价准备\n单位： 元\n本期增加金额 本期减少金额\n项目 期初余额 期末余额\n计提 其他 转回或转销 其他\n原材料 2,867,227.10 2,011,138.75 1,902,961.62 2,975,404.23\n在产品 3,023,716.71 2,237,971.32 1,016,816.21 4,244,871.82\n库存商品 23,329,566.31 5,540,847.35 6,752,441.79 22,117,971.87\n合计 29,220,510.12 9,789,957.42 9,672,219.62 29,338,247.92\n| 占其他应收款期末 |\n--------------------------------------------------\n单位名称 | 款项的性质 | 期末余额 | 账龄 |  | 坏账准备期末余额\n| 余额合计数的比例 |\n| \n台州市椒江朝晖建 | \n| 押金保证金 | 2,950,000.00 | 1年以内 | 8.10% | 147,500.00\n设投资有限公司 | \n| \n台州市椒江朝晖建 | \n| 押金保证金 | 3,850,000.00 | 1-2年 | 10.57% | 1,155,000.00\n设投资有限公司 | \n| \n应收出口退税 | 应收出口退税 | 6,584,960.26 | 1年以内 | 18.08% |\nPFIZER ASIA | \nMANUFACTURIN | 应收暂付款 | 5,000,000.00 | 3年以上 | 13.73% | 5,000,000.00\nG PTE LTD | \n浙江福仁瑞生物科 | \n| 应收暂付款 | 3,222,047.10 | 3年以上 | 8.85% | 3,222,047.10\n技有限公司 | \n| \n台州市中荣化工有 | \n| 应收暂付款 | 2,160,572.19 | 3年以上 | 5.93% | 2,160,572.19\n限公司 | \n| \n合计 | -- | 23,767,579.55 | -- | 65.26% | 11,685,119.29",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "55798439"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1522,
      "page_number": 131,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "50x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 50,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "应收暂付款",
          "应收",
          "应收款期末",
          "其他应收款",
          "应收出口退税",
          "其他应收款期末"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          131
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243210",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "设投资有限公司",
        "industry": "financial",
        "char_count": 1522,
        "word_count": 212,
        "sentence_count": 64,
        "chinese_char_count": 364,
        "readability_score": 0.0,
        "information_density": 0.07227332457293036,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5517665407342827,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收暂付款",
        "应收",
        "应收款期末",
        "其他应收款",
        "应收出口退税",
        "其他应收款期末"
      ]
    },
    {
      "chunk_id": "bcbe60b0",
      "content": "| 预计收取的时间、金额\n--------------------------------------------------\n单位名称 | 政府补助项目名称 | 期末余额 | 期末账龄 |\n| 及依据\n| \n\n> 注：（3）存货期末余额含有借款费用资本化金额的说明\n（4）期末建造合同形成的已完工未结算资产情况\n单位： 元\n项目 金额\n其他说明：\n10、合同资产\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n合同资产的账面价值在本期内发生的重大变动金额和原因：\n单位： 元\n项目 变动金额 变动原因\n如是按照预期信用损失一般模型计提合同资产坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n本期合同资产计提减值准备情况\n单位： 元\n项目 本期计提 本期转回 本期转销/核销 原因\n其他说明：\n11、持有待售资产\n单位： 元\n项目 期末账面余额 减值准备 期末账面价值 公允价值 预计处置费用 预计处置时间\n其他说明：\n12、一年内到期的非流动资产\n单位： 元\n项目 期末余额 期初余额\n重要的债权投资/其他债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n其他说明：\n133",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "dfe87941"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 567,
      "page_number": 132,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243668",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 567,
        "word_count": 87,
        "sentence_count": 0,
        "chinese_char_count": 383,
        "readability_score": 0.0,
        "information_density": 0.03527336860670194,
        "coherence_score": 0.7227336860670195,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5653979949179949,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f2c97ddb",
      "content": "| 期末余额 | 期初余额  |\n--------------------------------------------------\n项目 | \n| 账面余额 | 跌价准备 | 账面价值 | 账面余额 | 跌价准备 | 账面价值\n| \n原材料 | 209,787,752.67 | 2,975,404.23 | 206,812,348.44 | 243,008,744.60 | 2,867,227.10 | 240,141,517.50\n在产品 | 164,776,116.17 | 4,244,871.82 | 160,531,244.35 | 214,182,041.63 | 3,023,716.71 | 211,158,324.92\n库存商品 | 493,928,178.91 | 22,117,971.87 | 471,810,207.04 | 477,155,579.50 | 23,329,566.31 | 453,826,013.19\n委托加工物资 | 3,831,460.77 |  | 3,831,460.77 | 292,362.88 |  | 292,362.88\n合计 | 872,323,508.52 | 29,338,247.92 | 842,985,260.60 | 934,638,728.61 | 29,220,510.12 | 905,418,218.49",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8d6452d8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 599,
      "page_number": 132,
      "bbox": [
        47.5,
        80.0,
        547.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243877",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 599,
        "word_count": 84,
        "sentence_count": 28,
        "chinese_char_count": 52,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4371684867394696,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9efc9393",
      "content": "|  | 本期增加金额 |  | 本期减少金额  |\n--------------------------------------------------\n项目 | 期初余额 | 期末余额\n|  | 计提 | 其他 | 转回或转销 | 其他 |\n| \n原材料 | 2,867,227.10 | 2,011,138.75 |  | 1,902,961.62 |  | 2,975,404.23\n在产品 | 3,023,716.71 | 2,237,971.32 |  | 1,016,816.21 |  | 4,244,871.82\n库存商品 | 23,329,566.31 | 5,540,847.35 |  | 6,752,441.79 |  | 22,117,971.87\n合计 | 29,220,510.12 | 9,789,957.42 |  | 9,672,219.62 |  | 29,338,247.92",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5a55afa7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 409,
      "page_number": 132,
      "bbox": [
        47.5,
        80.0,
        547.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244074",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 409,
        "word_count": 68,
        "sentence_count": 16,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42883702031602705,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ad9182dd",
      "content": "| 期末余额 | 期初余额  |\n--------------------------------------------------\n项目 | \n| 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n| \n\n> 注：13、其他流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n待抵扣增值税进项税额 67,707,757.62 76,026,728.13\n员工购房借款 118,571.44\n预缴企业所得税 8,699,173.52 1,737,693.66\n银行理财产品\n合计 76,406,931.14 77,882,993.23\n其他说明：\n14、债权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n重要的债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n15、其他债权投资\n单位： 元\n134。",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fdaab395"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 610,
      "page_number": 133,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "37x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          133
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244445",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 610,
        "word_count": 102,
        "sentence_count": 8,
        "chinese_char_count": 312,
        "readability_score": 0.0,
        "information_density": 0.049180327868852465,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4953651960784313,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "961a27dc",
      "content": "| 期末余额 | 期初余额 | \n--------------------------------------------------\n债权项目 | \n| 面值 | 票面利率 | 实际利率 | 到期日 | 面值 | 票面利率 | 实际利率 | 到期日\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8a9232d4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 127,
      "page_number": 133,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          133
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244658",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 127,
        "word_count": 25,
        "sentence_count": 0,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39291914893617014,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "916258d4",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n待抵扣增值税进项税额 | 67,707,757.62 | 76,026,728.13\n员工购房借款 |  | 118,571.44\n预缴企业所得税 | 8,699,173.52 | 1,737,693.66\n银行理财产品  |\n合计 | 76,406,931.14 | 77,882,993.23",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "50169758"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 216,
      "page_number": 134,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244733",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 216,
        "word_count": 27,
        "sentence_count": 7,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.046296296296296294,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3968821917808219,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税"
      ]
    },
    {
      "chunk_id": "52bc0594",
      "content": "| 期末余额 | 期初余额  |\n--------------------------------------------------\n项目 | \n| 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "abafbf69"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 117,
      "page_number": 134,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244817",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 117,
        "word_count": 21,
        "sentence_count": 0,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38887499999999997,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9ba4ae64",
      "content": "| 期末余额 | 期初余额 | \n--------------------------------------------------\n债权项目 | \n| 面值 | 票面利率 | 实际利率 | 到期日 | 面值 | 票面利率 | 实际利率 | 到期日\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c9331500"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 127,
      "page_number": 134,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244871",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 127,
        "word_count": 25,
        "sentence_count": 0,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39291914893617014,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6a87a989",
      "content": "累计在其他\n本期公允价 累计公允价 综合收益中\n项目 期初余额 应计利息 期末余额 成本 备注\n值变动 值变动 确认的损失\n准备\n重要的其他债权投资\n单位： 元\n期末余额 期初余额\n其他债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n16、长期应收款\n（1）长期应收款情况\n单位： 元\n期末余额 期初余额\n项目 折现率区间\n账面余额 坏账准备 账面价值 账面余额 坏账准备 账面价值\n坏账准备减值情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n| 第一阶段 | 第二阶段 | 第三阶段 |\n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n| 用损失 | (未发生信用减值) | (已发生信用减值) |\n2019年1月1日余额在 | \n| —— | —— | —— | ——\n本期 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cc74da56"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 726,
      "page_number": 134,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244956",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 726,
        "word_count": 130,
        "sentence_count": 0,
        "chinese_char_count": 451,
        "readability_score": 0.0,
        "information_density": 0.027548209366391185,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5943122916908324,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "a7809248",
      "content": "| 累计在其他 |\n--------------------------------------------------\n| 本期公允价 | 累计公允价 | 综合收益中 |\n项目 | 期初余额 | 应计利息 |  | 期末余额 | 成本 | 备注\n| 值变动 | 值变动 | 确认的损失 |\n| \n| 准备 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2044b463"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 155,
      "page_number": 135,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "成本"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245215",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 155,
        "word_count": 34,
        "sentence_count": 0,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.12903225806451613,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4390114209827357,
      "relevance_score": 1.0,
      "keywords": [
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本"
      ]
    },
    {
      "chunk_id": "774ce348",
      "content": "| 期末余额 | 期初余额 | \n--------------------------------------------------\n其他债权项目 | \n| 面值 | 票面利率 | 实际利率 | 到期日 | 面值 | 票面利率 | 实际利率 | 到期日\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cf87435a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 129,
      "page_number": 135,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245294",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 129,
        "word_count": 25,
        "sentence_count": 0,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.394578947368421,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "30113caf",
      "content": "| 第一阶段 | 第二阶段 | 第三阶段 |\n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n| 用损失 | (未发生信用减值) | (已发生信用减值) |\n2019年1月1日余额在 | \n| —— | —— | —— | ——\n本期 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ddbe9e32"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 199,
      "page_number": 135,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245362",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 199,
        "word_count": 37,
        "sentence_count": 0,
        "chinese_char_count": 72,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4929519313304721,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "56967ec5",
      "content": "| 期末余额 | 期初余额 | \n--------------------------------------------------\n项目 | 折现率区间\n| 账面余额 | 坏账准备 | 账面价值 | 账面余额 | 坏账准备 | 账面价值 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "54060f52"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 124,
      "page_number": 135,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245438",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 124,
        "word_count": 23,
        "sentence_count": 0,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3934508474576271,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ca5cf851",
      "content": "（2）因金融资产转移而终止确认的长期应收款\n（3）转移长期应收款且继续涉入形成的资产、负债金额\n其他说明\n17、长期股权投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n被投资单 权益法下 宣告发放 减值准备\n(账面价 其他综合 其他权益 计提减值 (账面价\n位 追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n22,946,28 -4,811,81 18,134,47\n制药厂有\n7.25 4.84 2.41\n限公司\n江苏北华\n17,617,12 -4,471,33 13,145,79\n环保科技\n7.70 1.54 6.16\n有限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n滨海临海\n11,676,63 -6,521,79 1,449,207 3,705,631 7,730,979\n资产管理\n2.15 2.73 .56 .86 .27\n有限公司\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n小计\n9.79 49.80 .56 2.43 .27\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n合计\n9.79 49.80 .56 2.43 .27\n其他说明\n18、其他权益工具投资\n单位： 元\n项目 期末余额 期初余额\n杭州寓鑫创业投资合伙企业（有限合伙） 20,000,000.00\n滨海宏博环境技术服务股份有限公司 1,800,000.00\n合计 20,000,000.00 1,800,000.00\n| 第一阶段 | 第二阶段 | 第三阶段 |\n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n| 用损失 | (未发生信用减值) | (已发生信用减值) |\n2019年1月1日余额在 | \n| —— | —— | —— | ——\n本期 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "695140ea"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 945,
      "page_number": 135,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "52x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 52,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245502",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 945,
        "word_count": 147,
        "sentence_count": 28,
        "chinese_char_count": 330,
        "readability_score": 0.0,
        "information_density": 0.0634920634920635,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5994247995475264,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0bbccb4b",
      "content": "|  | 本期增减变动 | \n--------------------------------------------------\n| 期初余额 | 期末余额 |\n被投资单 | 权益法下 | 宣告发放 | 减值准备\n| (账面价 | 其他综合 | 其他权益 |  | 计提减值 |  | (账面价 |\n位 |  | 追加投资 | 减少投资 | 确认的投 | 现金股利 |  | 其他 |  | 期末余额\n| 值) | 收益调整 | 变动 |  | 准备 |  | 值) |\n| 资损益 | 或利润 | \n| \n一、合营企业 | \n二、联营企业 | \n苏州第四 | \n| 22,946,28 | -4,811,81 | 18,134,47 |\n制药厂有 | \n| 7.25 | 4.84 | 2.41 |\n限公司 | \n| \n江苏北华 | \n| 17,617,12 | -4,471,33 | 13,145,79 |\n环保科技 | \n| 7.70 | 1.54 | 6.16 |\n有限公司 | \n| \n浙江高盛 | \n| 13,848,09 | -954,610. | 12,893,48 |\n钢结构有 | \n| 2.69 | 69 | 2.00 |\n限公司 | \n| \n滨海临海 | \n| 11,676,63 | -6,521,79 | 1,449,207 |  | 3,705,631 | 7,730,979\n资产管理 | \n| 2.15 | 2.73 | .56 |  | .86 | .27\n有限公司 | \n| \n| 66,088,13 | -16,759,5 | 1,449,207 |  | 47,879,38 | 7,730,979\n小计 | \n| 9.79 | 49.80 | .56 |  | 2.43 | .27\n| \n| 66,088,13 | -16,759,5 | 1,449,207 |  | 47,879,38 | 7,730,979\n合计 | \n| 9.79 | 49.80 | .56 |  | 2.43 | .27\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e6a9a1a9",
        "0efedd64"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 876,
      "page_number": 136,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "利润",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          136
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245836",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 876,
        "word_count": 211,
        "sentence_count": 24,
        "chinese_char_count": 147,
        "readability_score": 0.0,
        "information_density": 0.07990867579908675,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6113894628099174,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "利润",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "利润",
        "资产"
      ]
    },
    {
      "chunk_id": "da27651d",
      "content": "分项披露本期非交易性权益工具投资\n单位： 元\n指定为以公允价\n其他综合收益转 其他综合收益转\n值计量且其变动\n项目名称 确认的股利收入 累计利得 累计损失 入留存收益的金 入留存收益的原\n计入其他综合收\n额 因\n益的原因\n其他说明：\n(2) 指定为以公允价值计量且其变动计入其他综合收益的权益工具投资的原因\n公司持有对杭州寓鑫创业投资合伙企业（有限合伙）、滨海宏博环境技术服务股份有限公司的股权投\n资属于非交易性权益工具投资，因此公司将其指定为以公允价值计量且其变动计入其他综合收益的权益工\n具投资。19、其他非流动金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n20、投资性房地产\n（1）采用成本计量模式的投资性房地产\n√ 适用 □ 不适用\n单位： 元\n项目 房屋、建筑物 土地使用权 在建工程 合计\n一、账面原值\n1.期初余额 26,022,834.98 26,022,834.98\n2.本期增加金额\n（1）外购\n（2）存货\\固定资产\n\\在建工程转入\n（3）企业合并增加\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 26,022,834.98 26,022,834.98\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n杭州寓鑫创业投资合伙企业（有限合伙） | 20,000,000.00 |\n滨海宏博环境技术服务股份有限公司 |  | 1,800,000.00\n合计 | 20,000,000.00 | 1,800,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2174e9de"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 675,
      "page_number": 136,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "37x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          136
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.246255",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 675,
        "word_count": 76,
        "sentence_count": 13,
        "chinese_char_count": 386,
        "readability_score": 0.0,
        "information_density": 0.08888888888888888,
        "coherence_score": 0.6683691254279489,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5985989590110605,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "93b03853",
      "content": "二、累计折旧和累计摊\n销\n1.期初余额 13,684,219.69 13,684,219.69\n2.本期增加金额 1,131,663.83 1,131,663.83\n（1）计提或摊销 1,131,663.83 1,131,663.83\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 14,815,883.52 14,815,883.52\n三、减值准备\n1.期初余额\n2.本期增加金额\n（1）计提\n3、本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额\n四、账面价值\n1.期末账面价值 11,206,951.46 11,206,951.46\n2.期初账面价值 12,338,615.29 12,338,615.29\n（2）采用公允价值计量模式的投资性房地产\n□ 适用 √ 不适用\n（3）未办妥产权证书的投资性房地产情况\n单位： 元\n项目 账面价值 未办妥产权证书原因\n其他说明\n138\n项目 | 房屋、建筑物 | 土地使用权 | 在建工程 | 合计\n--------------------------------------------------\n一、账面原值 | \n1.期初余额 | 26,022,834.98 | 26,022,834.98\n2.本期增加金额 | \n（1）外购 | \n（2）存货\\固定资产 | \n| \n\\在建工程转入 | \n| \n（3）企业合并增加 | \n| \n3.本期减少金额 | \n（1）处置 | \n（2）其他转出 | \n| \n4.期末余额 | 26,022,834.98 | 26,022,834.98",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1fc8fd8f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 674,
      "page_number": 137,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "38x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 38,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "资产",
          "在建工程",
          "存货"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          137
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.246490",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 674,
        "word_count": 87,
        "sentence_count": 29,
        "chinese_char_count": 220,
        "readability_score": 0.0,
        "information_density": 0.08902077151335311,
        "coherence_score": 0.2811111111111111,
        "standards_profile_summary": {}
      },
      "quality_score": 0.63633588127769,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "资产",
        "在建工程",
        "存货"
      ]
    },
    {
      "chunk_id": "4ec83b43",
      "content": "21、固定资产\n单位： 元\n项目 期末余额 期初余额\n固定资产 1,724,407,333.34 1,215,120,643.61\n合计 1,724,407,333.34 1,215,120,643.61\n（1）固定资产情况\n单位： 元\n项目 房屋及建筑物 通用设备 专用设备 运输工具 合计\n一、账面原值：\n1.期初余额 942,004,302.57 151,282,471.21 1,160,756,948.05 56,927,137.86 2,310,970,859.69\n2.本期增加金额 127,058,302.67 26,510,821.36 531,882,141.44 4,549,773.50 690,001,038.97\n（1）购置 363,159.41 320,013.97 4,549,773.50 5,232,946.88\n（2）在建工程\n127,058,302.67 26,147,661.95 531,562,127.47 684,768,092.09\n转入\n（3）企业合并\n增加\n3.本期减少金额 13,603,089.42 4,778,065.53 40,235,121.09 1,713,041.92 60,329,317.96\n（1）处置或报\n13,603,089.42 4,778,065.53 40,235,121.09 1,713,041.92 60,329,317.96\n废\n4.期末余额 1,055,459,515.82 173,015,227.04 1,652,403,968.40 59,763,869.44 2,940,642,580.70\n二、累计折旧\n1.期初余额 353,145,143.22 114,199,096.34 571,568,602.36 44,658,442.31 1,083,571,284.23\n2.本期增加金额 52,644,012.36 14,146,453.54 99,289,757.27 5,610,282.17 171,690,505.34\n（1）计提 52,644,012.36 14,146,453.54 99,289,757.27 5,610,282.17 171,690,505.34\n3.本期减少金额 9,335,681.39 4,537,067.86 35,777,262.22 1,569,383.59 51,219,395.06\n（1）处置或报\n9,335,681.39 4,537,067.86 35,777,262.22 1,569,383.59 51,219,395.06\n废\n4.期末余额 396,453,474.19 123,808,482.02 635,081,097.41 48,699,340.89 1,204,042,394.51\n三、减值准备\n1.期初余额 717,598.43 44,323.56 11,517,009.86 12,278,931.85\n二、累计折旧和累计摊 | \n--------------------------------------------------\n| \n销 | \n| \n1.期初余额 | 13,684,219.69 | 13,684,219.69\n2.本期增加金额 | 1,131,663.83 | 1,131,663.83\n（1）计提或摊销 | 1,131,663.83 | 1,131,663.83\n| \n3.本期减少金额 | \n（1）处置 | \n（2）其他转出 | \n| \n4.期末余额 | 14,815,883.52 | 14,815,883.52\n三、减值准备 | \n1.期初余额 | \n2.本期增加金额 | \n（1）计提 | \n| \n3、本期减少金额 | \n（1）处置 | \n（2）其他转出 | \n| \n4.期末余额 | \n四、账面价值 | \n1.期末账面价值 | 11,206,951.46 | 11,206,951.46\n2.期初账面价值 | 12,338,615.29 | 12,338,615.29",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "42f45e7d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1692,
      "page_number": 138,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "53x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 53,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          138
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.246762",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1692,
        "word_count": 175,
        "sentence_count": 101,
        "chinese_char_count": 230,
        "readability_score": 0.0,
        "information_density": 0.00591016548463357,
        "coherence_score": 0.22976470588235293,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5994437335958005,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "564244f7",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n固定资产 | 1,724,407,333.34 | 1,215,120,643.61\n合计 | 1,724,407,333.34 | 1,215,120,643.61",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4ded2c59"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 151,
      "page_number": 139,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          139
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.247242",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 151,
        "word_count": 16,
        "sentence_count": 4,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.1986754966887417,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40442737306843274,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "资产"
      ]
    },
    {
      "chunk_id": "e47e440f",
      "content": "2.本期增加金额 103,473.25 396,068.47 499,541.72\n（1）计提 103,473.25 396,068.47 499,541.72\n3.本期减少金额 585,620.72 585,620.72\n（1）处置或报\n585,620.72 585,620.72\n废\n4.期末余额 131,977.71 147,796.81 11,913,078.33 12,192,852.85\n四、账面价值\n1.期末账面价值 658,874,063.92 49,058,948.21 1,005,409,792.66 11,064,528.55 1,724,407,333.34\n2.期初账面价值 588,141,560.92 37,039,051.31 577,671,335.83 12,268,695.55 1,215,120,643.61\n（2）暂时闲置的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值 备注\n房屋及建筑物 96,021,538.73 24,413,427.38 71,608,111.35\n通用设备 6,855,762.41 5,595,164.87 143,649.07 1,116,948.47\n专用设备 145,417,971.06 110,109,458.33 732,234.31 34,576,278.42\n（3）通过融资租赁租入的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值\n（4）通过经营租赁租出的固定资产\n单位： 元\n项目 期末账面价值\n（5）未办妥产权证书的固定资产情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n公司及子公司房屋建筑物 136,044,964.45公司正在办理产权证书\n其他说明\n项目 | 房屋及建筑物 | 通用设备 | 专用设备 | 运输工具 | 合计\n--------------------------------------------------\n一、账面原值： | \n1.期初余额 | 942,004,302.57 | 151,282,471.21 | 1,160,756,948.05 | 56,927,137.86 | 2,310,970,859.69\n2.本期增加金额 | 127,058,302.67 | 26,510,821.36 | 531,882,141.44 | 4,549,773.50 | 690,001,038.97\n（1）购置 |  | 363,159.41 | 320,013.97 | 4,549,773.50 | 5,232,946.88\n（2）在建工程 | \n| 127,058,302.67 | 26,147,661.95 | 531,562,127.47 |  | 684,768,092.09\n转入 | \n| \n（3）企业合并 | \n| \n增加 | \n| \n| \n3.本期减少金额 | 13,603,089.42 | 4,778,065.53 | 40,235,121.09 | 1,713,041.92 | 60,329,317.96\n（1）处置或报 | \n| 13,603,089.42 | 4,778,065.53 | 40,235,121.09 | 1,713,041.92 | 60,329,317.96\n废 | \n| \n| \n4.期末余额 | 1,055,459,515.82 | 173,015,227.04 | 1,652,403,968.40 | 59,763,869.44 | 2,940,642,580.70\n二、累计折旧 | \n1.期初余额 | 353,145,143.22 | 114,199,096.34 | 571,568,602.36 | 44,658,442.31 | 1,083,571,284.23\n2.本期增加金额 | 52,644,012.36 | 14,146,453.54 | 99,289,757.27 | 5,610,282.17 | 171,690,505.34\n（1）计提 | 52,644,012.36 | 14,146,453.54 | 99,289,757.27 | 5,610,282.17 | 171,690,505.34\n| \n3.本期减少金额 | 9,335,681.39 | 4,537,067.86 | 35,777,262.22 | 1,569,383.59 | 51,219,395.06\n（1）处置或报 | \n| 9,335,681.39 | 4,537,067.86 | 35,777,262.22 | 1,569,383.59 | 51,219,395.06\n废 | \n| \n| \n4.期末余额 | 396,453,474.19 | 123,808,482.02 | 635,081,097.41 | 48,699,340.89 | 1,204,042,394.51\n三、减值准备 | \n1.期初余额 | 717,598.43 | 44,323.56 | 11,517,009.86 |  | 12,278,931.85",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e0e8bfe4",
        "129a0eb4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2141,
      "page_number": 139,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "53x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 53,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "在建工程"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          139
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.247308",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 2141,
        "word_count": 269,
        "sentence_count": 117,
        "chinese_char_count": 313,
        "readability_score": 0.0,
        "information_density": 0.018682858477347034,
        "coherence_score": 0.2469322033898305,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6187065807755463,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "在建工程"
      ]
    },
    {
      "chunk_id": "aea48e63",
      "content": "2.本期增加金额 |  | 103,473.25 | 396,068.47 |  | 499,541.72\n--------------------------------------------------\n（1）计提 |  | 103,473.25 | 396,068.47 |  | 499,541.72\n| \n3.本期减少金额 | 585,620.72 | 585,620.72\n（1）处置或报 | \n| 585,620.72 | 585,620.72\n废 | \n| \n| \n4.期末余额 | 131,977.71 | 147,796.81 | 11,913,078.33 |  | 12,192,852.85\n四、账面价值 | \n1.期末账面价值 | 658,874,063.92 | 49,058,948.21 | 1,005,409,792.66 | 11,064,528.55 | 1,724,407,333.34\n2.期初账面价值 | 588,141,560.92 | 37,039,051.31 | 577,671,335.83 | 12,268,695.55 | 1,215,120,643.61",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ccd4c167"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 509,
      "page_number": 140,
      "bbox": [
        47.5,
        80.0,
        547.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "10x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          140
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248328",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 509,
        "word_count": 69,
        "sentence_count": 29,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.2309,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5099502487562189,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "5afa9890",
      "content": "项目 | 账面原值 | 累计折旧 | 减值准备 | 账面价值 | 备注\n--------------------------------------------------\n房屋及建筑物 | 96,021,538.73 | 24,413,427.38 |  | 71,608,111.35 |\n通用设备 | 6,855,762.41 | 5,595,164.87 | 143,649.07 | 1,116,948.47 |\n专用设备 | 145,417,971.06 | 110,109,458.33 | 732,234.31 | 34,576,278.42 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f5a142a1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 281,
      "page_number": 140,
      "bbox": [
        47.5,
        80.0,
        547.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          140
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248517",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 281,
        "word_count": 41,
        "sentence_count": 11,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39975774647887324,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "68338bb8",
      "content": "（6）固定资产清理\n单位： 元\n项目 期末余额 期初余额\n其他说明\n22、在建工程\n单位： 元\n项目 期末余额 期初余额\n在建工程 535,836,082.97 653,154,180.21\n工程物资 24,838,551.46 21,179,497.78\n合计 560,674,634.43 674,333,677.99\n（1）在建工程情况\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n公司及子公司房\n2,107,384.23 2,107,384.23 6,025,551.57 6,025,551.57\n屋建设工程\n原料药及中间体\nCMO中心扩建 198,852,943.52 198,852,943.52 165,628,666.75 165,628,666.75\n项目\n川南药业公司设\n9,204,900.26 9,204,900.26 7,184,188.76 7,184,188.76\n备安装工程\n环保设施改造项\n41,262,820.03 41,262,820.03 80,121,501.45 80,121,501.45\n目\n台州前进公司\n15500吨活性染\n36,676,707.08 36,676,707.08 147,592,362.30 147,592,362.30\n料产业升级及配\n套项目\n台州振港公司年\n产2500吨关健中\n6,050,304.05 6,050,304.05 42,843,192.74 42,843,192.74\n间体产业一体化\n项目\n台州振港公司年\n产700吨M-562\n285,309.30 285,309.30 93,276,176.18 93,276,176.18\n关键中间体产业\n一体化项目\n项目 | 账面价值 | 未办妥产权证书的原因\n--------------------------------------------------\n公司及子公司房屋建筑物 | 136,044,964.45 | 公司正在办理产权证书",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2c5feb35"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 866,
      "page_number": 140,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "44x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 44,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          140
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248619",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 866,
        "word_count": 94,
        "sentence_count": 35,
        "chinese_char_count": 237,
        "readability_score": 0.0,
        "information_density": 0.011547344110854504,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47146198210265855,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "7642bc9c",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n在建工程 | 535,836,082.97 | 653,154,180.21\n工程物资 | 24,838,551.46 | 21,179,497.78\n合计 | 560,674,634.43 | 674,333,677.99",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "39cb9e76"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 180,
      "page_number": 141,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "工程物资",
          "在建工程"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          141
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248932",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 180,
        "word_count": 21,
        "sentence_count": 6,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.11111111111111112,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37766666666666665,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "工程物资",
        "在建工程"
      ]
    },
    {
      "chunk_id": "09512d7a",
      "content": "台州振港公司年\n产18500吨染料 68,227,065.54 68,227,065.54 5,450,450.43 5,450,450.43\n产业升级项目\n盐城瓯华公司设\n26,608,200.30 26,608,200.30 22,261,730.30 22,261,730.30\n备安装工程\n医药中试车间技\n17,149,684.37 17,149,684.37\n改项目\n医药综合研发中\n15,253,236.88 15,253,236.88 775,995.69 775,995.69\n心\n台州振港公司\n250吨美罗培南 44,267,447.48 44,267,447.48\n侧链项目\n零星工程 87,039,764.30 87,039,764.30 64,844,679.67 64,844,679.67\n合计 535,836,082.97 535,836,082.97 653,154,180.21 653,154,180.21\n（2）重要在建工程项目本期变动情况\n单位： 元\n本期转 工程累 其中：本\n本期其 利息资 本期利\n项目名 期初余 本期增 入固定 期末余 计投入 工程进 期利息 资金来\n预算数 他减少 本化累 息资本\n称 额 加金额 资产金 额 占预算 度 资本化 源\n金额 计金额 化率\n额 比例 金额\n公司及\n子公司 1,816,86 4,597,40 4,306,88 2,107,38 金融机\n房屋建 9.49 0.47 5.73 4.23 构贷款\n设工程\n原料药\n及中间\n46,034.5 165,628, 94,079,7 60,855,5 198,852, 募股资\n体CMO 70.92%70.00\n8 666.75 99.70 22.93 943.52 金\n中心扩\n建项目\n川南药\n业公司 7,184,18 31,205,6 29,184,9 9,204,90 金融机\n设备安 8.76 20.68 09.18 0.26 构贷款\n装工程\n环保设\n15,502.0 80,121,5 35,646,6 74,505,3 41,262,8 募股资\n施改造 75.01%75.00\n0 01.45 30.19 11.61 20.03 金\n项目\n| 期末余额 | 期初余额  |\n--------------------------------------------------\n项目 | \n| 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n| \n公司及子公司房 | \n| 2,107,384.23 |  | 2,107,384.23 | 6,025,551.57 |  | 6,025,551.57\n屋建设工程 | \n| \n原料药及中间体 | \nCMO中心扩建 | 198,852,943.52 |  | 198,852,943.52 | 165,628,666.75 |  | 165,628,666.75\n项目 | \n川南药业公司设 | \n| 9,204,900.26 |  | 9,204,900.26 | 7,184,188.76 |  | 7,184,188.76\n备安装工程 | \n| \n环保设施改造项 | \n| 41,262,820.03 |  | 41,262,820.03 | 80,121,501.45 |  | 80,121,501.45\n目 | \n| \n台州前进公司 | \n15500吨活性染 | \n| 36,676,707.08 |  | 36,676,707.08 | 147,592,362.30 |  | 147,592,362.30\n料产业升级及配 | \n| \n套项目 | \n台州振港公司年 | \n产2500吨关健中 | \n| 6,050,304.05 |  | 6,050,304.05 | 42,843,192.74 |  | 42,843,192.74\n间体产业一体化 | \n| \n项目 | \n台州振港公司年 | \n产700吨M-562 | \n| 285,309.30 |  | 285,309.30 | 93,276,176.18 |  | 93,276,176.18\n关键中间体产业 | \n| \n一体化项目 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "dd39912f",
        "e7e585cf"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1764,
      "page_number": 141,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "76x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 76,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          141
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.249103",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1764,
        "word_count": 275,
        "sentence_count": 74,
        "chinese_char_count": 377,
        "readability_score": 0.0,
        "information_density": 0.005668934240362812,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5158026177430959,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "c2e28c5c",
      "content": "台州振港公司年 | \n--------------------------------------------------\n产18500吨染料 | 68,227,065.54 |  | 68,227,065.54 | 5,450,450.43 |  | 5,450,450.43\n产业升级项目 | \n盐城瓯华公司设\n备安装工程 | \n| 26,608,200.30 |  | 26,608,200.30 | 22,261,730.30 |  | 22,261,730.30\n| \n医药中试车间技\n改项目 | \n| 17,149,684.37 |  | 17,149,684.37\n| \n医药综合研发中\n心 | \n| 15,253,236.88 |  | 15,253,236.88 | 775,995.69 |  | 775,995.69\n| \n台州振港公司 | \n250吨美罗培南 | 44,267,447.48 |  | 44,267,447.48 | \n侧链项目 | \n零星工程 | 87,039,764.30 |  | 87,039,764.30 | 64,844,679.67 |  | 64,844,679.67\n合计 | 535,836,082.97 |  | 535,836,082.97 | 653,154,180.21 |  | 653,154,180.21",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "60340a56"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 589,
      "page_number": 142,
      "bbox": [
        47.5,
        80.0,
        547.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.249645",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 589,
        "word_count": 86,
        "sentence_count": 24,
        "chinese_char_count": 68,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4384210526315789,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b3bfd3b2",
      "content": "台州前\n进公司\n15500吨\n活性染 40,160.0 147,592, 154,147, 265,062, 36,676,7 金融机\n75.13%75.00\n料产业 0 362.30 165.63 820.85 07.08 构贷款\n升级及\n配套项\n目\n台州振\n港公司\n产2500\n吨关健 42,843,1 12,166,1 48,959,0 6,050,30 金融机\n7,850.00 102.09%95.00\n中间体 92.74 71.56 60.25 4.05 构贷款\n产业一\n体化项\n目\n台州振\n港公司\n年产700\n吨\n10,000.0 93,276,1 10,517,0 103,507, 285,309. 金融机\nM-562 106.83%99.00\n0 76.18 68.25 935.13 30 构贷款\n关键中\n间体产\n业一体\n化项目\n台州振\n港公司\n年产\n80,000.0 5,450,45 82,575,2 19,798,6 68,227,0 金融机\n18500吨 13.86%15.00\n0 0.43 81.47 66.36 65.54 构贷款\n染料产\n业升级\n项目\n盐城瓯\n华公司 26,470,4 5,218,03 5,080,24 26,608,2 金融机\n设备安 12.38 4.21 6.29 00.30 构贷款\n装工程\n医药中\n试车间 17,149,6 6,878,35 24,028,0 募股资\n9,256.00 43.31%45.00\n技改项 84.37 9.38 43.75 金\n目\n|  | 期初余\n额 |  | 本期转 | 工程累 | 其中：本\n期利息\n资本化\n金额  |\n--------------------------------------------------\n| 本期其 | 利息资 |  | 本期利 |\n项目名 | 本期增 | 入固定 |  | 期末余 | 计投入 | 工程进 | 资金来\n| 预算数 | 他减少 | 本化累 |  | 息资本 |\n称 | 加金额 | 资产金 |  | 额 | 占预算 | 度 | 源\n| 金额 | 计金额 |  | 化率 |\n| 额 | 比例 | \n| \n公司及 |  | 1,816,86\n9.49 | \n子公司 | 4,597,40 | 4,306,88 |  | 2,107,38 | 金融机\n| \n房屋建 | 0.47 | 5.73 |  | 4.23 | 构贷款\n| \n设工程 | \n原料药 | \n及中间 | \n| 46,034.5 | 165,628, | 94,079,7 | 60,855,5 |  | 198,852, | 募股资\n体CMO | 70.92% | 70.00 | \n| 8 | 666.75 | 99.70 | 22.93 |  | 943.52 | 金\n中心扩 | \n| \n建项目 | \n川南药 |  | 7,184,18\n8.76 | \n业公司 | 31,205,6 | 29,184,9 |  | 9,204,90 | 金融机\n| \n设备安 | 20.68 | 09.18 |  | 0.26 | 构贷款\n| \n装工程 | \n环保设 | \n| 15,502.0 | 80,121,5 | 35,646,6 | 74,505,3 |  | 41,262,8 | 募股资\n施改造 | 75.01% | 75.00 | \n| 0 | 01.45 | 30.19 | 11.61 |  | 20.03 | 金\n项目 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e3c77ac7",
        "0a52b103"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1476,
      "page_number": 142,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "80x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 80,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.250170",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1476,
        "word_count": 325,
        "sentence_count": 60,
        "chinese_char_count": 285,
        "readability_score": 0.0,
        "information_density": 0.013550135501355014,
        "coherence_score": 0.27909090909090906,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6048600979720298,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "98785df3",
      "content": "医药综\n15,073.0 775,995. 35,025,9 20,548,7 15,253,2 募股资\n合研发 23.75%25\n0 69 51.78 10.59 36.88 金\n中心\n台州振\n港公司\n250吨美 16,000.0 44,267,4 44,267,4 金融机\n27.67%30\n罗培南 0 47.48 47.48 构贷款\n侧链项\n目\n零星工 64,844,6 51,125,0 28,929,9 87,039,7 金融机\n程 79.67 64.05 79.42 64.30 构贷款\n239,875. 653,154, 567,449, 684,768, 535,836,\n合计 -- -- --\n58 180.21 994.85 092.09 082.97\n（3）本期计提在建工程减值准备情况\n单位： 元\n项目 本期计提金额 计提原因\n其他说明\n（4）工程物资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n专用材料 9,806,701.25 9,806,701.25 7,121,142.67 7,121,142.67\n专用设备 15,031,850.21 15,031,850.21 14,058,355.11 14,058,355.11\n合计 24,838,551.46 24,838,551.46 21,179,497.78 21,179,497.78\n其他说明：\n23、生产性生物资产\n（1）采用成本计量模式的生产性生物资产\n□ 适用 √ 不适用\n（2）采用公允价值计量模式的生产性生物资产\n□ 适用 √ 不适用\n台州前 | \n--------------------------------------------------\n进公司 | \n15500吨 | \n活性染 | 40,160.0 | 147,592, | 154,147, | 265,062, |  | 36,676,7 | 金融机\n| 75.13% | 75.00 | \n料产业 | 0 | 362.30 | 165.63 | 820.85 |  | 07.08 | 构贷款\n| \n升级及 | \n配套项 | \n目 | \n台州振 | \n港公司 | \n产2500 | \n吨关健 |  | 42,843,1 | 12,166,1 | 48,959,0 |  | 6,050,30 | 金融机\n| 7,850.00 | 102.09% | 95.00 | \n中间体 |  | 92.74 | 71.56 | 60.25 |  | 4.05 | 构贷款\n| \n产业一 | \n体化项 | \n目 | \n台州振 | \n港公司 | \n年产700 | \n吨 | \n| 10,000.0 | 93,276,1 | 10,517,0 | 103,507, |  | 285,309. | 金融机\nM-562 | 106.83% | 99.00 | \n| 0 | 76.18 | 68.25 | 935.13 |  | 30 | 构贷款\n关键中 | \n| \n间体产 | \n业一体 | \n化项目 | \n台州振 | \n港公司 | \n年产 | \n| 80,000.0 | 5,450,45 | 82,575,2 | 19,798,6 |  | 68,227,0 | 金融机\n18500吨 | 13.86% | 15.00 | \n| 0 | 0.43 | 81.47 | 66.36 |  | 65.54 | 构贷款\n染料产 | \n| \n业升级 | \n项目 | \n盐城瓯 | \n华公司 |  | 26,470,4 | 5,218,03 | 5,080,24 |  | 26,608,2 | 金融机\n| \n设备安 |  | 12.38 | 4.21 | 6.29 |  | 00.30 | 构贷款\n| \n装工程 | \n医药中 | \n试车间 |  | 17,149,6 | 6,878,35 | 24,028,0 | 募股资\n| 9,256.00 | 43.31% | 45.00 | \n技改项 |  | 84.37 | 9.38 | 43.75 | 金\n| \n目 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1ad06896",
        "1cae9046",
        "ef0642dd"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1739,
      "page_number": 143,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "82x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 82,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          143
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.250796",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1739,
        "word_count": 354,
        "sentence_count": 69,
        "chinese_char_count": 318,
        "readability_score": 0.0,
        "information_density": 0.011500862564692352,
        "coherence_score": 0.31285714285714283,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5212004104142619,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "15c04e0d",
      "content": "医药综 | \n--------------------------------------------------\n| 15,073.0 | 775,995. | 35,025,9 | 20,548,7 |  | 15,253,2 | 募股资\n合研发 | 23.75% | 25 | \n| 0 | 69 | 51.78 | 10.59 |  | 36.88 | 金\n中心 | \n| \n台州振 | 44,267,4\n47.48 | \n港公司 | \n250吨美 | 16,000.0 | 44,267,4 | 金融机\n| 27.67% | 30 | \n罗培南 | 0 | 47.48 | 构贷款\n| \n侧链项 | \n目 | \n零星工 |  | 64,844,6 | 51,125,0 | 28,929,9 |  | 87,039,7 | 金融机\n| \n程 |  | 79.67 | 64.05 | 79.42 |  | 64.30 | 构贷款\n| \n| 239,875. | 653,154, | 567,449, | 684,768, |  | 535,836, | \n合计 | -- | -- | --\n| 58 | 180.21 | 994.85 | 092.09 |  | 082.97 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "59bc02e6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 550,
      "page_number": 144,
      "bbox": [
        47.5,
        80.0,
        547.5,
        580.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "18x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          144
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.251922",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 550,
        "word_count": 129,
        "sentence_count": 19,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.430890052356021,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "034e7683",
      "content": "24、油气资产\n□ 适用 √ 不适用\n25、使用权资产\n单位： 元\n项目 合计\n其他说明：\n26、无形资产\n（1）无形资产情况\n单位： 元\n项目 土地使用权 专利权 非专利技术 排污权 特许使用权 特许经营权 软件 合计\n一、账面原值\n1.期初 505,413,741. 162,305,608. 11,915,094.3 688,369,268.\n3,072,760.00 3,143,452.96 1,168,163.69 1,350,447.87\n余额 33 72 7 94\n2.本期 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n增加金额 6 0\n（1） 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n购置 6 0\n（2）\n内部研发\n（3）\n企业合并增\n加\n3.本期减 11,116,461.1\n9,433,962.30 1,682,498.83\n少金额 3\n（1） 11,116,461.1\n9,433,962.30 1,682,498.83\n处置 3\n4.期末 527,186,739. 163,203,423. 701,568,832.\n2,481,132.07 4,011,789.99 1,460,954.13 1,168,163.69 2,056,629.92\n余额 19 12 11\n二、累计摊销\n1.期初 55,429,191.3 77,337,200.9 143,036,807.\n4,014,069.57 1,700,580.26 2,061,454.24 1,168,163.69 1,326,147.82\n余额 9 3 90\n项目 | 期末余额 | 期初余额  |\n--------------------------------------------------\n| 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n专用材料 | 9,806,701.25 |  | 9,806,701.25 | 7,121,142.67 |  | 7,121,142.67\n专用设备 | 15,031,850.21 |  | 15,031,850.21 | 14,058,355.11 |  | 14,058,355.11\n合计 | 24,838,551.46 |  | 24,838,551.46 | 21,179,497.78 |  | 21,179,497.78",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cbe94e99"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1082,
      "page_number": 144,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "43x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 43,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          144
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.252345",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1082,
        "word_count": 153,
        "sentence_count": 57,
        "chinese_char_count": 162,
        "readability_score": 0.0,
        "information_density": 0.018484288354898338,
        "coherence_score": 0.23596551724137926,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4947734951067677,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "87c1e09d",
      "content": "2.本期 11,263,080.3 17,674,391.8 30,277,923.1\n563,042.72 517,839.30 205,844.64 53,724.30\n增加金额 6 1 3\n（1） 11,263,080.3 17,674,391.8 30,277,923.1\n563,042.72 517,839.30 205,844.64 53,724.30\n计提 6 1 3\n3.本期\n3,616,352.13 1,584,866.25 5,201,218.38\n减少金额\n（1）\n3,616,352.13 1,584,866.25 5,201,218.38\n处置\n4.期末 66,692,271.7 95,011,592.7 168,113,512.\n960,760.16 2,218,419.56 682,432.63 1,168,163.69 1,379,872.12\n余额 5 4 65\n三、减值准备\n1.期初\n5,817,610.17 5,817,610.17\n余额\n2.本期\n增加金额\n（1）\n计提\n3.本期\n5,817,610.17 5,817,610.17\n减少金额\n（1）处\n置\n4.期末\n余额\n四、账面价值\n1.期末 460,494,467. 68,191,830.3 533,455,319.\n1,520,371.91 1,793,370.43 778,521.50 676,757.80\n账面价值 44 8 46\n2.期初 449,984,549. 84,968,407.7 539,514,850.\n2,083,414.63 1,372,179.74 1,081,998.72 24,300.05\n账面价值 94 9 87\n本期末通过公司内部研发形成的无形资产占无形资产余额的比例。（2）未办妥产权证书的土地使用权情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n项目 | 土地使用权 | 专利权 | 非专利技术 | 排污权 | 特许使用权 | 特许经营权 | 软件 | 合计\n--------------------------------------------------\n一、账面原值 | \n1.期初 | 505,413,741. | 162,305,608. | 11,915,094.3 | 688,369,268.\n| 3,072,760.00 | 3,143,452.96 | 1,168,163.69 | 1,350,447.87 |\n余额 | 33 | 72 | 7 | 94\n| \n2.本期 | 21,772,997.8 | 24,316,024.3\n|  | 897,814.40 |  | 939,029.99 | 706,182.05 |\n增加金额 | 6 | 0\n| \n（1） | 21,772,997.8 | 24,316,024.3\n|  | 897,814.40 |  | 939,029.99 | 706,182.05 |\n购置 | 6 | 0\n| \n（2） | \n| \n内部研发 | \n| \n（3） | \n企业合并增 | \n加 | \n| \n3.本期减 | 11,116,461.1\n| 9,433,962.30 |  | 1,682,498.83 | \n少金额 | 3\n| \n（1） | 11,116,461.1\n| 9,433,962.30 |  | 1,682,498.83 | \n处置 | 3\n| \n| \n4.期末 | 527,186,739. | 163,203,423. | 701,568,832.\n| 2,481,132.07 | 4,011,789.99 | 1,460,954.13 | 1,168,163.69 | 2,056,629.92 |\n余额 | 19 | 12 | 11\n| \n二、累计摊销 | \n1.期初 | 55,429,191.3 | 77,337,200.9 | 143,036,807.\n| 4,014,069.57 | 1,700,580.26 | 2,061,454.24 | 1,168,163.69 | 1,326,147.82 |\n余额 | 9 | 3 | 90\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e0ec1ad9",
        "b2be2f03"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1749,
      "page_number": 145,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "69x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 69,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          145
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.252733",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1749,
        "word_count": 277,
        "sentence_count": 101,
        "chinese_char_count": 208,
        "readability_score": 0.0,
        "information_density": 0.011435105774728418,
        "coherence_score": 0.3518759590792839,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6095752179049667,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "91d0cb27",
      "content": "台州市枫南东路以北、东港大道以东 4,679,700.00公司正在办理产权证书\n其他说明：\n27、开发支出\n单位： 元\n本期增加金额 本期减少金额\n项目 期初余额 内部开发支 确认为无形 转入当期损 期末余额\n其他\n出 资产 益\n合计\n其他说明\n28、商誉\n（1）商誉账面原值\n单位： 元\n被投资单位名称 本期增加 本期减少\n或形成商誉的事 期初余额 期末余额\n企业合并形成的 处置\n项\n台州前进公司 757,736,770.14 757,736,770.14\n合计 757,736,770.14 757,736,770.14\n（2）商誉减值准备\n单位： 元\n被投资单位名称 本期增加 本期减少\n或形成商誉的事 期初余额 期末余额\n计提 处置\n项\n合计\n商誉所在资产组或资产组组合的相关信息\n资产组或资产组组合的构成 台州前进公司资产组\n资产组或资产组组合的账面价值 1,726,678,155.03\n分摊至本资产组或资产组组合的商誉账面价值及分摊 全部分摊至台州前进公司资产组\n方法\n包含商誉的资产组或资产组组合的账面价值 2,484,414,925.17\n资产组或资产组组合是否与购买日、以前年度商誉减 是\n值测试时所确定的资产组或资产组组合一致\n2.本期 | 11,263,080.3 | 17,674,391.8 | 30,277,923.1\n--------------------------------------------------\n| 563,042.72 | 517,839.30 | 205,844.64 |  | 53,724.30 |\n增加金额 | 6 | 1 | 3\n| \n（1） | 11,263,080.3 | 17,674,391.8 | 30,277,923.1\n| 563,042.72 | 517,839.30 | 205,844.64 |  | 53,724.30 |\n计提 | 6 | 1 | 3\n| \n| \n3.本期 | \n| 3,616,352.13 |  | 1,584,866.25 | 5,201,218.38\n减少金额 | \n| \n（1） | \n| 3,616,352.13 |  | 1,584,866.25 | 5,201,218.38\n处置 | \n| \n| \n4.期末 | 66,692,271.7 | 95,011,592.7 | 168,113,512.\n| 960,760.16 | 2,218,419.56 | 682,432.63 | 1,168,163.69 | 1,379,872.12 |\n余额 | 5 | 4 | 65\n| \n三、减值准备 | \n1.期初 | \n| 5,817,610.17 | 5,817,610.17\n余额 | \n| \n2.本期 | \n| \n增加金额 | \n| \n（1） | \n| \n计提 | \n| \n| \n3.本期 | \n| 5,817,610.17 | 5,817,610.17\n减少金额 | \n| \n（1）处 | \n| \n置 | \n| \n| \n4.期末 | \n| \n余额 | \n| \n四、账面价值 | \n1.期末 | 460,494,467. | 68,191,830.3 | 533,455,319.\n| 1,520,371.91 | 1,793,370.43 | 778,521.50 |  | 676,757.80 |\n账面价值 | 44 | 8 | 46\n| \n2.期初 | 449,984,549. | 84,968,407.7 | 539,514,850.\n| 2,083,414.63 | 1,372,179.74 | 1,081,998.72 |  | 24,300.05 |\n账面价值 | 94 | 9 | 87\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1d942764",
        "adbb5ccf"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1572,
      "page_number": 146,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "71x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 71,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          146
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.253359",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1572,
        "word_count": 266,
        "sentence_count": 62,
        "chinese_char_count": 409,
        "readability_score": 0.0,
        "information_density": 0.01272264631043257,
        "coherence_score": 0.40031273836765824,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6154964503130953,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "5ae6fa07",
      "content": "|  | 本期增加金额 | 本期减少金额 | \n--------------------------------------------------\n项目 | 期初余额 | 内部开发支 | 确认为无形 | 转入当期损 |  | 期末余额\n| 其他 | \n|  | 出 | 资产 | 益  |\n| \n| \n合计 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "93baef37"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 156,
      "page_number": 147,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.253979",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 156,
        "word_count": 34,
        "sentence_count": 0,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.1282051282051282,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4373333333333334,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "be16f134",
      "content": "被投资单位名称 |  | 本期增加 |  | 本期减少  |\n--------------------------------------------------\n或形成商誉的事 | 期初余额 | 期末余额\n|  | 企业合并形成的 |  | 处置  |\n项 | \n| \n台州前进公司 | 757,736,770.14 | 757,736,770.14\n合计 | 757,736,770.14 | 757,736,770.14",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0ae5ddf1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 213,
      "page_number": 147,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "商誉"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254056",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 213,
        "word_count": 34,
        "sentence_count": 4,
        "chinese_char_count": 48,
        "readability_score": 0.0,
        "information_density": 0.09389671361502347,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4408204413472706,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "商誉"
      ]
    },
    {
      "chunk_id": "71305218",
      "content": "被投资单位名称 |  | 本期增加 |  | 本期减少  |\n--------------------------------------------------\n或形成商誉的事 | 期初余额 | 期末余额\n|  | 计提 |  | 处置  |\n项 | \n| \n| \n合计 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a7a854b1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 138,
      "page_number": 147,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "商誉"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254158",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 138,
        "word_count": 27,
        "sentence_count": 0,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.1449275362318841,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39422727272727276,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "商誉"
      ]
    },
    {
      "chunk_id": "9b2a270d",
      "content": "说明商誉减值测试过程、关键参数（如预计未来现金流量现值时的预测期增长率、稳定期增长率、利润率、折现率、预测期\n等）及商誉减值损失的确认方法：\n商誉的可收回金额按照预计未来现金流量的现值计算，其预计现金流量根据公司批准的5年期现金流\n量预测为基础，现金流量预测使用的折现率14.16%(2018年：13.00%)，公司根据历史实际经营数据、行业\n发展趋势、预期收入增长率、毛利率等指标编制预测未来5年现金流量，预测期以后的现金流量维持不变。减值测试中采用的其他关键数据包括：产品预计售价、销量、生产成本及其他相关费用。公司根据历史经验及对市场发展的预测确定上述关键数据。\n资产组或资产组组合的构成\n\n--------------------------------------------------\n资产组或资产组组合的账面价值\n分摊至本资产组或资产组组合的商誉账面价值及分摊\n方法\n包含商誉的资产组或资产组组合的账面价值\n资产组或资产组组合是否与购买日、以前年度商誉减\n值测试时所确定的资产组或资产组组合一致",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "056217dc"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 455,
      "page_number": 147,
      "bbox": [
        47.5,
        80.0,
        547.5,
        360.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "11x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "商誉",
          "资产",
          "资产组或资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254224",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 455,
        "word_count": 13,
        "sentence_count": 5,
        "chinese_char_count": 349,
        "readability_score": 0.0,
        "information_density": 0.19780219780219782,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6853589784574399,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "成本",
        "利润",
        "现金流",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "商誉",
        "资产",
        "资产组或资产"
      ]
    },
    {
      "chunk_id": "7efd13f7",
      "content": "公司采用的折现率是反映当前市场货币时间价\n值和相关资产组特定风险的税前利率。上述对可收回金额的预计表明商誉并未出现减值损失。商誉减值测试的影响\n其他说明\n29、长期待摊费用\n单位： 元\n项目 期初余额 本期增加金额 本期摊销金额 其他减少金额 期末余额\n经营租入固定资产\n1,842,423.21 223,651.32 1,618,771.89\n改良支出\n合计 1,842,423.21 223,651.32 1,618,771.89\n其他说明\n30、递延所得税资产/递延所得税负债\n（1）未经抵销的递延所得税资产\n单位： 元\n期末余额 期初余额\n项目\n可抵扣暂时性差异 递延所得税资产 可抵扣暂时性差异 递延所得税资产\n资产减值准备 70,299,465.99 14,376,262.42 68,698,671.21 14,236,323.65\n内部交易未实现利润 39,421,112.05 6,246,640.41 62,503,070.92 9,773,506.85\n与资产相关的政府补助\n43,621,205.16 6,716,780.73 36,278,025.15 5,567,975.82\n分摊\n预计负债 11,637,669.47 2,909,417.37\n合计 153,341,783.20 27,339,683.56 179,117,436.75 32,487,223.69\n（2）未经抵销的递延所得税负债\n单位： 元\n项目 期末余额 期初余额\n项目 | 期初余额 | 本期增加金额 | 本期摊销金额 | 其他减少金额 | 期末余额\n--------------------------------------------------\n经营租入固定资产 | \n| 1,842,423.21 |  | 223,651.32 |  | 1,618,771.89\n改良支出 | \n| \n合计 | 1,842,423.21 |  | 223,651.32 |  | 1,618,771.89",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a42f3396"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 852,
      "page_number": 148,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "32x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254370",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 852,
        "word_count": 97,
        "sentence_count": 32,
        "chinese_char_count": 296,
        "readability_score": 0.0,
        "information_density": 0.07042253521126761,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5430298556687565,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "利润",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "资产"
      ]
    },
    {
      "chunk_id": "07731e98",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n可抵扣暂时性差异 | 34,056.67 | 42,122.21\n可抵扣亏损 | 54,023,245.91 | 120,721,788.89\n合计 | 54,057,302.58 | 120,763,911.10",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "168321ea"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 175,
      "page_number": 149,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254652",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 175,
        "word_count": 21,
        "sentence_count": 6,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38142857142857145,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e2f8b0da",
      "content": "年份 | 期末金额 | 期初金额 | 备注\n--------------------------------------------------\n2021年 |  | 106,844,539.90 |\n2022年 | 13,876,526.38 | 13,876,526.38 |\n2023年 | 722.61 | 722.61 |\n2024年 | 40,145,996.92  |\n合计 | 54,023,245.91 | 120,721,788.89 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1e6a7e94"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 232,
      "page_number": 149,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254804",
        "report_type": "financial_report",
        "fiscal_year": 2021,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 232,
        "word_count": 36,
        "sentence_count": 8,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38394453781512605,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "7799ef07",
      "content": "预付软件款 | 450,000.00 | 515,993.37\n--------------------------------------------------\n合计 | 450,000.00 | 515,993.37\n\n> 注：35、应付票据\n单位： 元\n种类 期末余额 期初余额\n银行承兑汇票 238,306,005.00 490,006,533.85\n合计 238,306,005.00 490,006,533.85\n本期末已到期未支付的应付票据总额为元。36、应付账款\n（1）应付账款列示\n单位： 元\n项目 期末余额 期初余额\n货 款 139,912,212.13 157,970,026.94\n工程设备款 212,622,391.34 137,429,777.27\n其 他 10,905,980.49 6,509,125.72\n合计 363,440,583.96 301,908,929.93\n（2）账龄超过1年的重要应付账款\n单位： 元\n项目 期末余额 未偿还或结转的原因\n其他说明：\n37、预收款项\n是否已执行新收入准则\n□ 是 √ 否\n（1）预收款项列示\n单位： 元\n项目 期末余额 期初余额\n货 款 12,919,749.09 19,196,692.94\n合计 12,919,749.09 19,196,692.94\n（2）账龄超过1年的重要预收款项\n单位： 元\n151。",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "cb92d055"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 597,
      "page_number": 150,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "29x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 29,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "预付软件款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          150
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255034",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 597,
        "word_count": 75,
        "sentence_count": 22,
        "chinese_char_count": 173,
        "readability_score": 0.0,
        "information_density": 0.03350083752093803,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43689755469755465,
      "relevance_score": 1.0,
      "keywords": [
        "收入"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "预付软件款"
      ]
    },
    {
      "chunk_id": "40da044a",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n质押借款 |  | 76,700,000.00\n抵押借款 | 50,066,500.00 | 143,000,000.00\n保证借款 |  | 20,000,000.00\n信用借款 | 150,200,529.59 | 359,000,000.00\n合计 | 200,267,029.59 | 598,700,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4fb988a9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 229,
      "page_number": 150,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          150
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255251",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 229,
        "word_count": 29,
        "sentence_count": 8,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38914061135371175,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "5f4b1f72",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n其中：  |\n其中：  |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1f625329"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 81,
      "page_number": 150,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          150
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255341",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 81,
        "word_count": 10,
        "sentence_count": 0,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4415379310344828,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "2c5a3e91",
      "content": "种类 | 期末余额 | 期初余额\n--------------------------------------------------\n银行承兑汇票 | 238,306,005.00 | 490,006,533.85\n合计 | 238,306,005.00 | 490,006,533.85",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a7dda85d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 145,
      "page_number": 151,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          151
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255389",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 145,
        "word_count": 16,
        "sentence_count": 4,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37262068965517237,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f4b11d2c",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n货 款 | 139,912,212.13 | 157,970,026.94\n工程设备款 | 212,622,391.34 | 137,429,777.27\n其 他 | 10,905,980.49 | 6,509,125.72\n合计 | 363,440,583.96 | 301,908,929.93",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "18281271"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 217,
      "page_number": 151,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          151
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255540",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 217,
        "word_count": 28,
        "sentence_count": 8,
        "chinese_char_count": 21,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3829161290322581,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9a2bd5e2",
      "content": "项目 期末余额 未偿还或结转的原因\n（3）期末建造合同形成的已结算未完工项目情况\n单位： 元\n项目 金额\n其他说明：\n38、合同负债\n单位： 元\n项目 期末余额 期初余额\n报告期内账面价值发生重大变动的金额和原因\n单位： 元\n项目 变动金额 变动原因\n39、应付职工薪酬\n（1）应付职工薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n一、短期薪酬 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n二、离职后福利-设定提\n3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n存计划\n三、辞退福利 26,656.73 26,656.73\n合计 45,234,354.42 326,240,321.13 319,107,533.27 52,367,142.28\n（2）短期薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、工资、奖金、津贴和\n38,780,553.62 273,368,159.46 267,353,757.95 44,794,955.13\n补贴\n2、职工福利费 15,919,594.19 15,919,594.19\n3、社会保险费 2,440,565.13 8,976,976.99 8,845,418.72 2,572,123.40\n其中：医疗保险费 1,731,912.00 7,358,904.85 7,221,509.07 1,869,307.78\n工伤保险费 518,490.75 1,058,240.23 1,071,709.37 505,021.61\n生育保险费 190,162.38 559,831.91 552,200.28 197,794.01\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n货 款 | 12,919,749.09 | 19,196,692.94\n合计 | 12,919,749.09 | 19,196,692.94",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ab736b15"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 911,
      "page_number": 151,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          151
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255762",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 911,
        "word_count": 103,
        "sentence_count": 40,
        "chinese_char_count": 231,
        "readability_score": 0.0,
        "information_density": 0.010976948408342482,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44382862725940403,
      "relevance_score": 1.0,
      "keywords": [
        "负债"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9c43f18f",
      "content": "项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n一、短期薪酬 | 41,640,169.44 | 309,866,403.94 | 302,996,468.43 | 48,510,104.95\n二、离职后福利-设定提 | \n| 3,594,184.98 | 16,347,260.46 | 16,084,408.11 | 3,857,037.33\n存计划 | \n| \n三、辞退福利 |  | 26,656.73 | 26,656.73 |\n合计 | 45,234,354.42 | 326,240,321.13 | 319,107,533.27 | 52,367,142.28",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d99c8e22"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 346,
      "page_number": 152,
      "bbox": [
        47.5,
        80.0,
        547.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "短期"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          152
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.256064",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 346,
        "word_count": 48,
        "sentence_count": 14,
        "chinese_char_count": 42,
        "readability_score": 0.0,
        "information_density": 0.028901734104046246,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4919553191489362,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "短期"
      ]
    },
    {
      "chunk_id": "a25a699c",
      "content": "4、住房公积金 286,968.00 9,072,162.00 9,110,730.00 248,400.00\n5、工会经费和职工教育\n132,082.69 2,529,511.30 1,766,967.57 894,626.42\n经费\n合计 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n（3）设定提存计划列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、基本养老保险 3,311,287.25 15,768,975.90 15,505,552.02 3,574,711.13\n2、失业保险费 282,897.73 578,284.56 578,856.09 282,326.20\n合计 3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n其他说明：\n40、应交税费\n单位： 元\n项目 期末余额 期初余额\n增值税 9,523,602.71 9,931,701.18\n企业所得税 28,390,504.27 37,886,210.59\n个人所得税 764,210.55 778,807.41\n城市维护建设税 501,005.62 756,017.40\n房产税 3,435,584.90 2,902,210.71\n土地使用税 1,583,236.07 1,592,945.01\n教育费附加 214,716.69 435,378.81\n地方教育附加 143,144.46 290,252.54\n印花税 123,171.95 107,074.83\n残疾人就业保障金 73,107.05 60,062.86\n环境保护税 28,921.28 150,000.00\n合计 44,781,205.55 54,890,661.34\n其他说明：\n41、其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付利息 1,088,752.57\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n1、工资、奖金、津贴和 | \n| 38,780,553.62 | 273,368,159.46 | 267,353,757.95 | 44,794,955.13\n补贴 | \n| \n2、职工福利费 |  | 15,919,594.19 | 15,919,594.19 |\n3、社会保险费 | 2,440,565.13 | 8,976,976.99 | 8,845,418.72 | 2,572,123.40\n其中：医疗保险费 | 1,731,912.00 | 7,358,904.85 | 7,221,509.07 | 1,869,307.78\n工伤保险费 | 518,490.75 | 1,058,240.23 | 1,071,709.37 | 505,021.61\n生育保险费 | 190,162.38 | 559,831.91 | 552,200.28 | 197,794.01",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "44b387ce"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1305,
      "page_number": 152,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "41x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 41,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          152
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.256377",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1305,
        "word_count": 157,
        "sentence_count": 71,
        "chinese_char_count": 218,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.474375,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5738708215821351,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e87f6766",
      "content": "4、住房公积金 | 286,968.00 | 9,072,162.00 | 9,110,730.00 | 248,400.00\n--------------------------------------------------\n5、工会经费和职工教育 | \n| 132,082.69 | 2,529,511.30 | 1,766,967.57 | 894,626.42\n经费 | \n| \n合计 | 41,640,169.44 | 309,866,403.94 | 302,996,468.43 | 48,510,104.95",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d0ed0b6c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 263,
      "page_number": 153,
      "bbox": [
        47.5,
        80.0,
        547.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.256996",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 263,
        "word_count": 32,
        "sentence_count": 12,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.46764657534246573,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f042c2ec",
      "content": "项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n1、基本养老保险 | 3,311,287.25 | 15,768,975.90 | 15,505,552.02 | 3,574,711.13\n2、失业保险费 | 282,897.73 | 578,284.56 | 578,856.09 | 282,326.20\n合计 | 3,594,184.98 | 16,347,260.46 | 16,084,408.11 | 3,857,037.33",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fc78e6fe"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 277,
      "page_number": 153,
      "bbox": [
        47.5,
        80.0,
        547.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257242",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 277,
        "word_count": 37,
        "sentence_count": 12,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4721870036101083,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6e37a4e6",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n增值税 | 9,523,602.71 | 9,931,701.18\n企业所得税 | 28,390,504.27 | 37,886,210.59\n个人所得税 | 764,210.55 | 778,807.41\n城市维护建设税 | 501,005.62 | 756,017.40\n房产税 | 3,435,584.90 | 2,902,210.71\n土地使用税 | 1,583,236.07 | 1,592,945.01\n教育费附加 | 214,716.69 | 435,378.81\n地方教育附加 | 143,144.46 | 290,252.54\n印花税 | 123,171.95 | 107,074.83\n残疾人就业保障金 | 73,107.05 | 60,062.86\n环境保护税 | 28,921.28 | 150,000.00\n合计 | 44,781,205.55 | 54,890,661.34",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "860b5a23"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 469,
      "page_number": 153,
      "bbox": [
        97.5,
        80.0,
        497.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "13x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 13,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257476",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 469,
        "word_count": 66,
        "sentence_count": 24,
        "chinese_char_count": 67,
        "readability_score": 0.0,
        "information_density": 0.021321961620469083,
        "coherence_score": 0.32628,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4402285714285714,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税"
      ]
    },
    {
      "chunk_id": "09935bed",
      "content": "应付股利 2,051,370.43 2,051,370.43\n其他应付款 26,148,702.79 21,583,181.20\n合计 28,200,073.22 24,723,304.20\n（1）应付利息\n单位： 元\n项目 期末余额 期初余额\n短期借款应付利息 1,088,752.57\n合计 1,088,752.57\n重要的已逾期未支付的利息情况：\n单位： 元\n借款单位 逾期金额 逾期原因\n其他说明：\n（2）应付股利\n单位： 元\n项目 期末余额 期初余额\n发起人股东 2,051,370.43 2,051,370.43\n合计 2,051,370.43 2,051,370.43\n其他说明，包括重要的超过1年未支付的应付股利，应披露未支付原因：\n（3）其他应付款\n1）按款项性质列示其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付暂收款 14,988,518.12 11,511,834.54\n出口货物运保费及佣金 8,226,443.88 3,988,336.40\n押金保证金 920,310.00 2,476,025.00\n暂借款 350,000.00 1,345,413.90\n其 他 1,663,430.79 2,261,571.36\n合计 26,148,702.79 21,583,181.20\n2）账龄超过1年的重要其他应付款\n单位： 元\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应付利息 |  | 1,088,752.57",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a3e95421"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 671,
      "page_number": 153,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "32x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付利息",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257633",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 671,
        "word_count": 78,
        "sentence_count": 25,
        "chinese_char_count": 210,
        "readability_score": 0.0,
        "information_density": 0.029806259314456036,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4458489326765189,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付利息",
        "应付"
      ]
    },
    {
      "chunk_id": "f70d23f8",
      "content": "应付股利 | 2,051,370.43 | 2,051,370.43\n--------------------------------------------------\n其他应付款 | 26,148,702.79 | 21,583,181.20\n合计 | 28,200,073.22 | 24,723,304.20",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f598936f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 158,
      "page_number": 154,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付",
          "应付股利",
          "其他应付款",
          "应付款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257861",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 158,
        "word_count": 16,
        "sentence_count": 6,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.2531645569620253,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3670430379746836,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "应付股利",
        "其他应付款",
        "应付款"
      ]
    },
    {
      "chunk_id": "a24bfdfc",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n短期借款应付利息 |  | 1,088,752.57\n合计 |  | 1,088,752.57\n\n> 注：项目 期末余额 未偿还或结转的原因\n其他说明\n42、持有待售负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n43、一年内到期的非流动负债\n单位： 元\n项目 期末余额 期初余额\n一年内到期的长期应付款 44,365,875.00\n合计 44,365,875.00\n其他说明：\n44、其他流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n短期应付债券的增减变动：\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n其他说明：\n45、长期借款\n（1）长期借款分类\n单位： 元\n项目 期末余额 期初余额\n长期借款分类的说明：\n其他说明，包括利率区间：\n155",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c29d556d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 458,
      "page_number": 154,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "32x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付利息",
          "短期借款",
          "应付",
          "短期"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257928",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 458,
        "word_count": 75,
        "sentence_count": 4,
        "chinese_char_count": 241,
        "readability_score": 0.0,
        "information_density": 0.13100436681222707,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4743566148781565,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "收入"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付利息",
        "短期借款",
        "应付",
        "短期"
      ]
    },
    {
      "chunk_id": "befa82f6",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n发起人股东 | 2,051,370.43 | 2,051,370.43\n合计 | 2,051,370.43 | 2,051,370.43",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d296142a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 136,
      "page_number": 154,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258088",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 136,
        "word_count": 16,
        "sentence_count": 4,
        "chinese_char_count": 17,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4042833333333334,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "45381ec9",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应付暂收款 | 14,988,518.12 | 11,511,834.54\n出口货物运保费及佣金 | 8,226,443.88 | 3,988,336.40\n押金保证金 | 920,310.00 | 2,476,025.00\n暂借款 | 350,000.00 | 1,345,413.90\n其 他 | 1,663,430.79 | 2,261,571.36\n合计 | 26,148,702.79 | 21,583,181.20",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c95ddaab"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 281,
      "page_number": 154,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应付",
          "应付暂收款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258145",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 281,
        "word_count": 37,
        "sentence_count": 12,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.0711743772241993,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4009508896797153,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "应付暂收款"
      ]
    },
    {
      "chunk_id": "f555640d",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n一年内到期的长期应付款 |  | 44,365,875.00\n合计 |  | 44,365,875.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0b856f40"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 120,
      "page_number": 155,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "应付",
          "长期应付款",
          "应付款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          155
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258247",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 120,
        "word_count": 14,
        "sentence_count": 2,
        "chinese_char_count": 23,
        "readability_score": 0.0,
        "information_density": 0.33333333333333337,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37775000000000003,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "应付",
        "长期应付款",
        "应付款"
      ]
    },
    {
      "chunk_id": "13742204",
      "content": "46、应付债券\n（1）应付债券\n单位： 元\n项目 期末余额 期初余额\n（2）应付债券的增减变动（不包括划分为金融负债的优先股、永续债等其他金融工具）\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n合计 -- -- --\n（3）可转换公司债券的转股条件、转股时间说明\n（4）划分为金融负债的其他金融工具说明\n期末发行在外的优先股、永续债等其他金融工具基本情况\n期末发行在外的优先股、永续债等金融工具变动情况表\n单位： 元\n发行在外的 期初 本期增加 本期减少 期末\n金融工具 数量 账面价值 数量 账面价值 数量 账面价值 数量 账面价值\n其他金融工具划分为金融负债的依据说明\n其他说明\n47、租赁负债\n单位：\n项目 期末余额 期初余额\n其他说明\n48、长期应付款\n单位： 元\n项目 期末余额 期初余额\n（1）按款项性质列示长期应付款\n单位： 元\n156\n| 按面值计 | 溢折价摊 | \n--------------------------------------------------\n债券名称 | 面值 | 发行日期 | 债券期限 | 发行金额 | 期初余额 | 本期发行 | 本期偿还 |  | 期末余额\n| 提利息 | 销 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7ae98d0c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 563,
      "page_number": 155,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "31x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 31,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          155
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258301",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 563,
        "word_count": 95,
        "sentence_count": 0,
        "chinese_char_count": 355,
        "readability_score": 0.0,
        "information_density": 0.017761989342806393,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4993595995215062,
      "relevance_score": 1.0,
      "keywords": [
        "负债"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ee79cb68",
      "content": "| 按面值计 | 溢折价摊 | \n--------------------------------------------------\n债券名称 | 面值 | 发行日期 | 债券期限 | 发行金额 | 期初余额 | 本期发行 | 本期偿还 |  | 期末余额\n| 提利息 | 销 | \n| \n| \n合计 | -- | -- | -- | \n\n> 注：项目 期末余额 期初余额\n其他说明：\n（2）专项应付款\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n其他说明：\n49、长期应付职工薪酬\n（1）长期应付职工薪酬表\n单位： 元\n项目 期末余额 期初余额\n（2）设定受益计划变动情况\n设定受益计划义务现值：\n单位： 元\n项目 本期发生额 上期发生额\n计划资产：\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划净负债（净资产）\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划的内容及与之相关风险、对公司未来现金流量、时间和不确定性的影响说明：\n设定受益计划重大精算假设及敏感性分析结果说明：\n其他说明：\n50、预计负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额 形成原因\n未支付合同义务及诉讼费 11,637,669.47\n未支付担保损失 1,333,333.00 1,333,333.00[注]\n157",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5667550f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 585,
      "page_number": 156,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "34x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          156
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258489",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 585,
        "word_count": 101,
        "sentence_count": 3,
        "chinese_char_count": 323,
        "readability_score": 0.0,
        "information_density": 0.06837606837606838,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5302035358190197,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "现金流"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e4c44824",
      "content": "发行在外的 | 期初 |  | 本期增加 |  | 本期减少 |  | 期末 |\n--------------------------------------------------\n金融工具 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8efe9dd1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 144,
      "page_number": 156,
      "bbox": [
        89.5,
        80.0,
        505.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          156
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258703",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 144,
        "word_count": 31,
        "sentence_count": 0,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.400551724137931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "95e48eb4",
      "content": "合计 1,333,333.00 12,971,002.47 --\n其他说明，包括重要预计负债的相关重要假设、估计说明：\n[注]：根据2000年12月16日浙江省台州市中级人民法院〔2000〕台经初字第204号《民事判决书》，公\n司为台州市染料化工(集团)公司向台州市椒江区财政局的4,000,000.00元借款提供保证，因该公司未按合同\n约定如期归还，本公司需承担三分之一的到期还款连带责任，并赔偿台州市椒江区财政局相应的损失，截\n至2019年12月31日该项判决尚未执行。对上述诉讼事项，公司已按应承担的连带责任计提预计负债\n1,333,333.00元。51、递延收益\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n政府补助 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n未实现售后租回损\n1,307,404.76 402,278.40 905,126.36\n益\n合计 44,650,629.91 12,900,000.00 6,956,538.39 50,594,091.52 --\n涉及政府补助的项目：\n单位： 元\n本期计入营\n本期新增补 本期计入其 本期冲减成 与资产相关/\n负债项目 期初余额 业外收入金 其他变动 期末余额\n助金额 他收益金额 本费用金额 与收益相关\n额\n年产400吨\n碳青霉烯类\n1,423,820.2\n抗生素关键 5,695,281.12 4,271,460.84 与资产相关\n8\n中间体\n4-AA项目\n年产1吨瑞\n格列奈、10\n吨卡洛芬、\n10吨阿托伐\n醌、50吨\nT1620、300\n235,862.40 117,931.20 117,931.20 与资产相关\n吨聚卡波菲\n钙、300吨\n4,4'-二氟二\n苯甲酮、100\n吨奈韦拉平\n产业化项目\n项目 | 期末余额 | 期初余额 | 形成原因\n--------------------------------------------------\n未支付合同义务及诉讼费 |  | 11,637,669.47 |\n未支付担保损失 | 1,333,333.00 | 1,333,333.00 | [注]",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "41c2d9b2"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 935,
      "page_number": 157,
      "bbox": [
        57.5,
        80.0,
        537.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "44x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 44,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2000-12",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          157
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258767",
        "report_type": "financial_report",
        "fiscal_year": 2000,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 935,
        "word_count": 98,
        "sentence_count": 26,
        "chinese_char_count": 397,
        "readability_score": 0.0,
        "information_density": 0.05347593582887701,
        "coherence_score": 0.5389037433155079,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5012662820845216,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "000.00元",
        "333.00元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b4947f33",
      "content": "项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额 | 形成原因\n--------------------------------------------------\n政府补助 | 43,343,225.15 | 12,900,000.00 | 6,554,259.99 | 49,688,965.16 |\n未实现售后租回损 | \n| 1,307,404.76 |  | 402,278.40 | 905,126.36 |\n益 | \n| \n合计 | 44,650,629.91 | 12,900,000.00 | 6,956,538.39 | 50,594,091.52 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "24cfd0ab"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 295,
      "page_number": 158,
      "bbox": [
        47.5,
        80.0,
        547.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          158
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.259096",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 295,
        "word_count": 46,
        "sentence_count": 11,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4085671641791045,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e7572896",
      "content": "催化净化处 | 30,000.00 | 110,000.00 |\n--------------------------------------------------\n理塔建设项 | 140,000.00 | 与资产相关\n目 | \n年产50吨培 | 48,000.00 | 84,000.00 |\n南类产品及 | \n| 132,000.00 | 与资产相关\n扩建厂房技 | \n| \n改项目 | \n企业技术中 | 40,000.00 | 93,333.33 |\n心创新能力 | 133,333.33 | 与资产相关\n建设项目 | \n年产8亿元 | 997,440.00 | 6,067,760.00 |\n(粒)口服固 | 7,065,200.00 | 与资产相关\n体制剂项目 | \n临海市创新 | 208,543.68 | 834,174.72 |\n驱动加快推 | \n进工业经济 | 1,042,718.40 | 与资产相关\n转型升级政 | \n策 | \n省级工业与 | 92,599.92 | 540,166.20 |\n信息化专项 | \n资金回收溶 | 632,766.12 | 与资产相关\n剂循环化技 | \n改项目 | \n省工业化和 | 66,169.92 | 391,505.36 |\n信息化深度 | \n融合示范试 | 457,675.28 | 与资产相关\n点区财政补 | \n助 | \n浙江省化学 | 40,000.00 | 223,333.33 |\n原料药基地 | \n椒江区块循 | 263,333.33 | 与资产相关\n环化改造项 | \n目补助资金 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0c2b20e3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 679,
      "page_number": 159,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "34x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          159
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.259391",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 679,
        "word_count": 125,
        "sentence_count": 24,
        "chinese_char_count": 185,
        "readability_score": 0.0,
        "information_density": 0.04418262150220913,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47884331116038437,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "8亿元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "b29f2ee7",
      "content": "清洁生产循\n环利用及三\n4,800,000.00 600,000.00 4,200,000.00 与资产相关\n废综合治理\n提升项目\n年产15500\n吨活性染料\n1,296,000.00 1,296,000.00 与资产相关\n产业升级及\n配套项目\n孵化器车间\n793,220.34 81,355.92 711,864.42 与资产相关\n技改项目\n浙江省化学\n原料药基地\n椒江区块循\n400,000.00 10,000.00 390,000.00 与资产相关\n环化改造项\n目补助资金\n项目补助\n年产700吨\nM-562关键\n500,000.00 33,333.33 466,666.67 与资产相关\n中间体产业\n一体化项目\n6,554,259.9\n12,900,000.0\n小 计 43,343,225.15 49,688,965.16\n0\n9\n其他说明：\n52、其他非流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n53、股本\n单位：元\n本次变动增减（+、-）\n期初余额 期末余额\n发行新股 送股 公积金转股 其他 小计\n1,618,820,253. 1,618,715,253.\n股份总数 -105,000.00 -105,000.00\n00 00\n其他说明：\n年产2吨盐 | 281,889.96 | 1,808,793.91 |\n--------------------------------------------------\n酸阿莫罗 | \n芬、20吨阿 | \n特来马来酸 | \n盐、5吨多尼 | \n培南、20吨 | 2,090,683.87 | 与资产相关\n美罗培南、5 | \n吨比阿培 | \n南、60吨 | \nPHE产业化 | \n项目(续建) | \n年产15000 | 100,000.00 | 750,000.00 |\n吨环保型活 | \n性艳蓝 | \n| 850,000.00 | 与资产相关\nKN-R商品 | \n| \n染料技改项 | \n目 | \n大品种药物 | 291,265.91 | 2,569,150.76 |\n的生产技术 | \n改造-美罗 | \n| 860,416.67 | 2,000,000.00 | 与资产相关\n培南原料药 | \n| \n绿色合成技 | \n术改造 | \n临海医化园 | 105,000.00 | 385,000.00 |\n区循环化改 | 490,000.00 | 与资产相关\n造项目 | \n南洋涂-固 | 246,999.96 | 2,039,833.02 |\n废减量化处 | 2,286,832.98 | 与资产相关\n置项目 | \n年产400吨 | 1,490,999.9\n1 | 20,471,166.40 |\nMAP、100 | \n吨OA、200 | \n吨DA、100 |  | 10,000,000.0 | \n| 11,962,166.31 | 与资产相关\n吨甲砜霉 |  | 0 | \n| \n素、10吨联 | \n苯双酯产业 | \n化新项目 | \n年产580吨 | 248,910.00 | 1,866,825.00 |\n柳氮磺胺吡 | \n| 2,115,735.00 | 与资产相关\n啶产业化项 | \n| \n目 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e0bfd64a",
        "c4aadda2"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1360,
      "page_number": 160,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "92x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 92,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.259688",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1360,
        "word_count": 227,
        "sentence_count": 45,
        "chinese_char_count": 377,
        "readability_score": 0.0,
        "information_density": 0.029411764705882353,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6557707380965273,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "67470ee5",
      "content": "清洁生产循 | 600,000.00 | 4,200,000.00 |\n--------------------------------------------------\n环利用及三 | \n| 4,800,000.00 | 与资产相关\n废综合治理 | \n| \n提升项目 | \n年产15500 | 1,296,000.00 |\n吨活性染料 | \n| 1,296,000.00 | 与资产相关\n产业升级及 | \n| \n配套项目 | \n孵化器车间 | 81,355.92 | 711,864.42 |\n| 793,220.34 | 与资产相关\n技改项目 | \n| \n浙江省化学 | 10,000.00 | 390,000.00 |\n原料药基地 | \n椒江区块循 | \n|  | 400,000.00 | 与资产相关\n环化改造项 | \n| \n目补助资金 | \n项目补助 | \n年产700吨 | 33,333.33 | 466,666.67 |\nM-562关键 | \n|  | 500,000.00 | 与资产相关\n中间体产业 | \n| \n一体化项目 | \n| 6,554,259.9\n9 | 49,688,965.16 |\n|  | 12,900,000.0 | \n小 计 | 43,343,225.15 | \n|  | 0 | \n| \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a61e6174"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 567,
      "page_number": 161,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "30x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          161
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260215",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 567,
        "word_count": 107,
        "sentence_count": 18,
        "chinese_char_count": 115,
        "readability_score": 0.0,
        "information_density": 0.03527336860670194,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47185214211076276,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "3e727022",
      "content": "根据公司2019年第一次临时股东大会决议，公司按照每股人民币2.25元向赵敏蔚等5人回购其所持有的\n已获授但尚未解锁的限制性股票105,000股，并扣回原已现金分红的可撤销现金股利66,150.00元，实际于\n2019年5月20日归还激励对象出资170,100.00元，其中，减少实收资本105,000元，减少资本公积131,250.00\n元。上述减资业经天健会计师事务所(特殊普通合伙)审验，并由其出具《验资报告》(天健验〔2019〕158\n号)。上述事项公司已于2019年7月1日办妥工商变更登记手续。\n|  | 本次变动增减（+、-） | \n--------------------------------------------------\n| 期初余额 | 期末余额\n|  | 发行新股 | 送股 | 公积金转股 | 其他 | 小计 |\n| \n| 1,618,820,253. | 1,618,715,253.\n00\n股份总数 | -105,000.00 | -105,000.00 |\n| 00 | \n| \n\n> 注：56、库存股\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n限制性人民币普通股 44,365,875.00 44,365,875.00\n股份回购 281,514,686.68 19,996,827.22 301,511,513.90\n合计 325,880,561.68 19,996,827.22 44,365,875.00 301,511,513.90\n其他说明，包括本期增减变动情况、变动原因说明：\n162。",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4995afe1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 677,
      "page_number": 161,
      "bbox": [
        47.5,
        80.0,
        547.5,
        540.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "17x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-5",
          "2019-7"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          161
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260484",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 677,
        "word_count": 65,
        "sentence_count": 21,
        "chinese_char_count": 252,
        "readability_score": 0.0,
        "information_density": 0.044313146233382575,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5898376096557675,
      "relevance_score": 1.0,
      "keywords": [
        "2.25元",
        "150.00元",
        "100.00元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e4c64bb1",
      "content": "发行在外的 | 期初 |  | 本期增加 |  | 本期减少 |  | 期末 |\n--------------------------------------------------\n金融工具 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "dfb9874f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 144,
      "page_number": 162,
      "bbox": [
        89.5,
        80.0,
        505.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x9",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 9,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          162
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260724",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 144,
        "word_count": 31,
        "sentence_count": 0,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.400551724137931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "aa94d04e",
      "content": "项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n资本溢价（股本溢价） | 2,612,188,669.80 | 43,566,610.03 | 131,250.00 | 2,655,624,029.83\n其他资本公积 | 51,179,152.67 | 7,113,749.53 | 43,566,610.03 | 14,726,292.17\n合计 | 2,663,367,822.47 | 50,680,359.56 | 43,697,860.03 | 2,670,350,322.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "43ff81ff"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 302,
      "page_number": 162,
      "bbox": [
        47.5,
        80.0,
        547.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "资本公积",
          "股本"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          162
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260791",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 302,
        "word_count": 37,
        "sentence_count": 12,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.06622516556291391,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.477287417218543,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资本公积",
        "股本"
      ]
    },
    {
      "chunk_id": "ab7f3107",
      "content": "1）本期库存股减少44,365,875.00元，其中：①回购并注销赵敏蔚等5人已获授但尚未解锁的限制性股\n票105,000股，按回购价计算减少236,250.00元；②本期解锁减少库存股16,546,500股，每股授予价格2.25元，\n减少37,229,625.00元；③预留授予的限制性股票第一期解锁1,600,000股，每股授予价格4.3125元，减少\n6,900,000.00元。2）本期库存股增加19,996,827.22元，系本期回购股份增加的库存股，公司以集中竞价交易方式回购公\n司股份，回购价格不超过6.9元/股，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，回\n购股份拟用作员工持股计划、股权激励计划或注销以减少公司注册资本。本期公司回购股份4,528,000股，\n回购总成本19,996,827.22元，公司回购股份计划已实施完毕。\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n限制性人民币普通股 | 44,365,875.00 |  | 44,365,875.00 |\n股份回购 | 281,514,686.68 | 19,996,827.22 |  | 301,511,513.90\n合计 | 325,880,561.68 | 19,996,827.22 | 44,365,875.00 | 301,511,513.90",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "98b6ece3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 641,
      "page_number": 162,
      "bbox": [
        47.5,
        80.0,
        547.5,
        340.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "10x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          162
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260950",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 641,
        "word_count": 45,
        "sentence_count": 21,
        "chinese_char_count": 254,
        "readability_score": 0.0,
        "information_density": 0.062402496099843996,
        "coherence_score": 0.6284295927986852,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4817970947942135,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "875.00元",
        "250.00元",
        "2.25元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "a0fed92a",
      "content": "57、其他综合收益\n单位： 元\n本期发生额\n减：前期\n减：前期计入\n本期所得 计入其他 税后归属 期末余\n项目 期初余额 其他综合收 减：所得 税后归属\n税前发生 综合收益 于少数股 额\n益当期转入 税费用 于母公司\n额 当期转入 东\n损益\n留存收益\n一、不能重分类进损益的其他综 -1,800,000 -1,800,000 -1,800,0\n合收益 .00 .00 00.00\n其他权益工具投资公允 -1,800,000 -1,800,000 -1,800,0\n价值变动 .00 .00 00.00\n二、将重分类进损益的其他综合 361,590.4 361,590.4 309,811.\n-51,779.23\n收益 2 2 19\n361,590.4 361,590.4 309,811.\n外币财务报表折算差额 -51,779.23\n2 2 19\n-1,438,409 -1,438,409 -1,490,1\n其他综合收益合计 -51,779.23\n.58 .58 88.81\n其他说明，包括对现金流量套期损益的有效部分转为被套期项目初始确认金额调整：\n58、专项储备\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n安全生产费 18,997,055.97 18,997,055.97\n合计 18,997,055.97 18,997,055.97\n其他说明，包括本期增减变动情况、变动原因说明：\n根据财政部、国家安监总局联合发布的《企业安全生产费用提取和使用管理办法》(财企〔2012〕16\n号)和财政部《关于印发企业会计准则解释第3号的通知》(财会〔2009〕8号)要求，公司、川南药业公司、\n台州前进公司、台州振港公司和盐城瓯华公司作为危险品生产企业本期提取并实际使用安全生产费用\n|  | 本期发生额 | \n--------------------------------------------------\n| 减：前期 | \n| 减：前期计入 | \n|  | 本期所得 |  | 计入其他 | 税后归属 | 期末余\n项目 | 期初余额 |  | 其他综合收 |  | 减：所得 | 税后归属  |\n|  | 税前发生 |  | 综合收益 | 于少数股 | 额\n| 益当期转入 |  | 税费用 | 于母公司  |\n|  | 额 |  | 当期转入 | 东 |\n| 损益 | \n| 留存收益 | \n| \n一、不能重分类进损益的其他综 |  | -1,800,000 | -1,800,000\n.00 |  | -1,800,0\n| \n合收益 |  | .00 | 00.00\n| \n其他权益工具投资公允 |  | -1,800,000 | -1,800,000\n.00 |  | -1,800,0\n| \n价值变动 |  | .00 | 00.00\n| \n二、将重分类进损益的其他综合 |  | 361,590.4 | 361,590.4\n2 |  | 309,811.\n| -51,779.23 | \n收益 |  | 2 | 19\n| \n|  | 361,590.4 | 361,590.4\n2 |  | 309,811.\n外币财务报表折算差额 | -51,779.23 | \n|  | 2 | 19\n| \n|  | -1,438,409 | -1,438,409\n.58 |  | -1,490,1\n88.81\n其他综合收益合计 | -51,779.23 | \n|  | .58 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "eade4ff5"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1454,
      "page_number": 163,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "64x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 64,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具",
          "其他综合收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          163
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.261201",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1454,
        "word_count": 248,
        "sentence_count": 40,
        "chinese_char_count": 501,
        "readability_score": 0.0,
        "information_density": 0.04814305364511692,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7317433074459139,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "现金流",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具",
        "其他综合收益"
      ]
    },
    {
      "chunk_id": "0d680efd",
      "content": "18,997,055.97元。59、盈余公积\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n法定盈余公积 201,812,279.17 11,257,545.14 213,069,824.31\n合计 201,812,279.17 11,257,545.14 213,069,824.31\n盈余公积说明，包括本期增减变动情况、变动原因说明：\n60、未分配利润\n单位： 元\n项目 本期 上期\n调整前上期末未分配利润 1,232,481,918.50 897,836,956.42\n调整后期初未分配利润 1,232,481,918.50 897,836,956.42\n加：本期归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n减：提取法定盈余公积 11,257,545.14 108,614,533.40\n应付普通股股利 466,678,159.50 161,744,325.30\n期末未分配利润 1,525,328,398.95 1,232,481,918.50\n调整期初未分配利润明细：\n1)、由于《企业会计准则》及其相关新规定进行追溯调整，影响期初未分配利润0.00元。2)、由于会计政策变更，影响期初未分配利润0.00元。\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n安全生产费 |  | 18,997,055.97 | 18,997,055.97 |\n合计 |  | 18,997,055.97 | 18,997,055.97 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6d1b49b9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 702,
      "page_number": 163,
      "bbox": [
        47.5,
        80.0,
        547.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "19x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 19,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          163
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.261675",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 702,
        "word_count": 67,
        "sentence_count": 28,
        "chinese_char_count": 215,
        "readability_score": 0.0,
        "information_density": 0.05698005698005698,
        "coherence_score": 0.8145454545454545,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4748099692889204,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "055.97元",
        "0.00元",
        "0.00元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ab8b3ddf",
      "content": "61、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 2,925,688,906.14 1,449,500,049.29 2,691,787,601.50 1,492,180,658.53\n其他业务 15,723,864.16 13,659,311.75 26,821,195.01 19,764,017.65\n合计 2,941,412,770.30 1,463,159,361.04 2,718,608,796.51 1,511,944,676.18\n是否已执行新收入准则\n□ 是 √ 否\n其他说明\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n法定盈余公积 | 201,812,279.17 | 11,257,545.14 |  | 213,069,824.31\n合计 | 201,812,279.17 | 11,257,545.14 |  | 213,069,824.31",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "db7dce5c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 472,
      "page_number": 164,
      "bbox": [
        47.5,
        80.0,
        547.5,
        420.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "14x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "盈余公积"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.261920",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 472,
        "word_count": 57,
        "sentence_count": 18,
        "chinese_char_count": 84,
        "readability_score": 0.0,
        "information_density": 0.06355932203389832,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4506567392609574,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "盈余公积"
      ]
    },
    {
      "chunk_id": "bfa62e7a",
      "content": "项目 | 本期 | 上期\n--------------------------------------------------\n调整前上期末未分配利润 | 1,232,481,918.50 | 897,836,956.42\n调整后期初未分配利润 | 1,232,481,918.50 | 897,836,956.42\n加：本期归属于母公司所有者的净利润 | 770,782,185.09 | 605,003,820.78\n减：提取法定盈余公积 | 11,257,545.14 | 108,614,533.40\n应付普通股股利 | 466,678,159.50 | 161,744,325.30\n期末未分配利润 | 1,525,328,398.95 | 1,232,481,918.50",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5abcdc1d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 342,
      "page_number": 164,
      "bbox": [
        93.5,
        80.0,
        501.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "盈余公积",
          "应付普通股股利",
          "应付",
          "归属于母公司所有者的净利润",
          "利润",
          "未分配利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262093",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 342,
        "word_count": 36,
        "sentence_count": 12,
        "chinese_char_count": 66,
        "readability_score": 0.0,
        "information_density": 0.23391812865497075,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.530680701754386,
      "relevance_score": 1.0,
      "keywords": [
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "盈余公积",
        "应付普通股股利",
        "应付",
        "归属于母公司所有者的净利润",
        "利润",
        "未分配利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "eda47e53",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n城市维护建设税 | 8,979,337.87 | 11,136,827.27\n教育费附加 | 4,206,609.84 | 5,294,134.87\n房产税 | 5,843,558.13 | 6,064,374.46\n土地使用税 | 2,733,446.70 | 4,311,794.23\n车船使用税 | 92,034.56 | 91,578.70\n印花税 | 2,055,976.68 | 1,234,528.45\n环境保护税 | 125,638.87 | 520,262.21\n地方教育附加 | 2,804,406.56 | 3,529,423.24\n合计 | 26,841,009.21 | 32,182,923.43",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4a32deda"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 382,
      "page_number": 165,
      "bbox": [
        97.5,
        80.0,
        497.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "10x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          165
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262230",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 382,
        "word_count": 51,
        "sentence_count": 18,
        "chinese_char_count": 53,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42221151832460735,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e082340d",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n佣 金 | 23,106,866.17 | 4,449,906.56\n运输费 | 15,855,838.29 | 18,776,797.69\n职工薪酬 | 11,454,758.67 | 9,017,672.93\n宣传展览费 | 2,730,663.11 | 3,083,947.22\n保险费 | 2,384,650.11 | 1,684,252.56\n业务招待费 | 1,327,567.15 | 3,743,333.54\n差旅费 | 930,856.80 | 1,475,970.50\n邮寄费 | 306,320.89 | 564,905.56\n其 他 | 1,525,503.69 | 984,267.86\n合计 | 59,623,024.88 | 43,781,054.42",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "510b2bd4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 411,
      "page_number": 165,
      "bbox": [
        97.5,
        80.0,
        497.5,
        340.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "11x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          165
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262577",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 411,
        "word_count": 58,
        "sentence_count": 20,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.32871428571428574,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42325839416058386,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "55f40b49",
      "content": "修理费 54,078,791.78 25,798,829.44\n办公费 33,101,653.33 21,185,949.02\n无形资产摊销 29,011,624.85 28,842,167.28\n排污及废物处理费 15,278,838.29 7,077,717.42\n中介及咨询服务费 12,874,898.20 27,576,302.13\n业务招待费 10,763,238.07 6,012,227.78\n以股份支付换取的职工服务 6,036,351.55 37,421,812.71\n保险费 3,790,087.45 2,996,910.69\n差旅费 2,464,786.84 3,670,795.30\n实验检验费 1,934,413.09 1,767,427.11\n劳动保护费 1,919,068.07 2,136,408.20\n其 他 8,262,952.08 5,163,839.89\n合计 386,185,538.84 349,284,396.57\n其他说明：\n65、研发费用\n单位： 元\n项目 本期发生额 上期发生额\n直接材料 24,329,506.93 26,831,622.01\n职工薪酬 53,798,685.12 47,193,153.47\n直接费用 27,647,391.51 19,395,798.61\n委托外部研究开发费 15,764,779.23 11,166,389.47\n以股份支付换取的职工服务 1,007,861.74 6,717,698.51\n合计 122,548,224.53 111,304,662.07\n其他说明：\n66、财务费用\n单位： 元\n项目 本期发生额 上期发生额\n利息支出 15,506,676.74 42,594,267.08\n利息收入 -41,773,975.28 -44,371,159.00\n汇兑净损益 -12,759,207.59 -50,821,750.14\n金融机构手续费 1,161,350.07 1,091,244.28\n合计 -37,865,156.06 -51,507,397.78\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n职工薪酬 | 135,254,390.92 | 119,986,220.11\n折旧费 | 71,414,444.32 | 59,647,789.49",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "9da15536"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1026,
      "page_number": 165,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "35x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          165
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262967",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1026,
        "word_count": 103,
        "sentence_count": 52,
        "chinese_char_count": 187,
        "readability_score": 0.0,
        "information_density": 0.029239766081871343,
        "coherence_score": 0.32807547169811324,
        "standards_profile_summary": {}
      },
      "quality_score": 0.470921336996337,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "a1e7abbe",
      "content": "修理费 | 54,078,791.78 | 25,798,829.44\n--------------------------------------------------\n办公费 | 33,101,653.33 | 21,185,949.02\n无形资产摊销 | 29,011,624.85 | 28,842,167.28\n排污及废物处理费 | 15,278,838.29 | 7,077,717.42\n中介及咨询服务费 | 12,874,898.20 | 27,576,302.13\n业务招待费 | 10,763,238.07 | 6,012,227.78\n以股份支付换取的职工服务 | 6,036,351.55 | 37,421,812.71\n保险费 | 3,790,087.45 | 2,996,910.69\n差旅费 | 2,464,786.84 | 3,670,795.30\n实验检验费 | 1,934,413.09 | 1,767,427.11\n劳动保护费 | 1,919,068.07 | 2,136,408.20\n其 他 | 8,262,952.08 | 5,163,839.89\n合计 | 386,185,538.84 | 349,284,396.57",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "69e46533"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 534,
      "page_number": 166,
      "bbox": [
        97.5,
        80.0,
        497.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "13x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 13,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "无形资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263306",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 534,
        "word_count": 67,
        "sentence_count": 26,
        "chinese_char_count": 65,
        "readability_score": 0.0,
        "information_density": 0.05617977528089888,
        "coherence_score": 0.32933333333333326,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4765917602996254,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "无形资产",
        "资产"
      ]
    },
    {
      "chunk_id": "13e24905",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n直接材料 | 24,329,506.93 | 26,831,622.01\n职工薪酬 | 53,798,685.12 | 47,193,153.47\n直接费用 | 27,647,391.51 | 19,395,798.61\n委托外部研究开发费 | 15,764,779.23 | 11,166,389.47\n以股份支付换取的职工服务 | 1,007,861.74 | 6,717,698.51\n合计 | 122,548,224.53 | 111,304,662.07",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4b2c8f8f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 302,
      "page_number": 166,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263504",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 302,
        "word_count": 36,
        "sentence_count": 12,
        "chinese_char_count": 47,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4087443708609271,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "78d5e183",
      "content": "产生其他收益的来源 | 本期发生额 | 上期发生额\n--------------------------------------------------\n与资产相关的政府补助 | 6,554,259.99 | 5,071,751.21\n与收益相关的政府补助 | 20,582,664.88 | 6,719,986.82\n合 计 | 27,136,924.87 | 11,791,738.03",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4f77682b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 195,
      "page_number": 167,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263618",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 195,
        "word_count": 22,
        "sentence_count": 6,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.10256410256410257,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42887179487179494,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "2c0ee58e",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n权益法核算的长期股权投资收益 | -16,759,549.80 | -6,923,938.93\n银行理财产品收益 | 2,079,074.70 | 3,024,312.63\n处置金融工具取得的投资收益 | -559,587.45 | -5,459,752.25\n合计 | -15,240,062.55 | -9,359,378.55",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8ebd7ded"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 236,
      "page_number": 167,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "长期股权投资",
          "投资收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263698",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 236,
        "word_count": 26,
        "sentence_count": 8,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.21186440677966104,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43667740112994347,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "长期股权投资",
        "投资收益"
      ]
    },
    {
      "chunk_id": "19cda2ae",
      "content": "产生公允价值变动收益的来源 | 本期发生额 | 上期发生额\n--------------------------------------------------\n交易性金融负债 |  | 5,010,265.70\n合计 |  | 5,010,265.70",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6c562208"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 127,
      "page_number": 167,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "交易性金融负债",
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263786",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 127,
        "word_count": 14,
        "sentence_count": 2,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.23622047244094485,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4215286089238845,
      "relevance_score": 1.0,
      "keywords": [
        "负债"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "交易性金融负债",
        "负债"
      ]
    },
    {
      "chunk_id": "3478e7a5",
      "content": "合计 -2,502,149.00\n其他说明：\n72、资产减值损失\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 本期发生额 上期发生额\n一、坏账损失 -3,669,712.21\n二、存货跌价损失 -9,789,957.42 -3,098,809.43\n五、长期股权投资减值损失 -1,449,207.56 -6,281,771.71\n七、固定资产减值损失 -499,541.72\n十二、无形资产减值损失 -5,817,610.17\n合计 -11,738,706.70 -18,867,903.52\n其他说明：\n73、资产处置收益\n单位： 元\n资产处置收益的来源 本期发生额 上期发生额\n固定资产处置收益 244,580.94 659,231.88\n合 计 244,580.94 659,231.88\n74、营业外收入\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换利得 56,093.96 126,221.82 56,093.96\n无法支付款项 370,069.55\n违约及赔款收入 896,839.67 972,312.09 896,839.67\n其 他 172,720.90 244,682.63 172,720.90\n合计 1,125,654.53 1,713,286.09 1,125,654.53\n计入当期损益的政府补助：\n单位： 元\n补贴是否影 是否特殊补 本期发生金 上期发生金 与资产相关/\n补助项目 发放主体 发放原因 性质类型\n响当年盈亏 贴 额 额 与收益相关\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n坏账损失 | -2,502,149.00 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8b94aabc"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 760,
      "page_number": 167,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "36x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263855",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 760,
        "word_count": 97,
        "sentence_count": 28,
        "chinese_char_count": 269,
        "readability_score": 0.0,
        "information_density": 0.039473684210526314,
        "coherence_score": 0.39999999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4645213941416389,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9e7090bd",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n一、坏账损失 |  | -3,669,712.21\n二、存货跌价损失 | -9,789,957.42 | -3,098,809.43\n五、长期股权投资减值损失 | -1,449,207.56 | -6,281,771.71\n七、固定资产减值损失 | -499,541.72 |\n十二、无形资产减值损失 |  | -5,817,610.17\n合计 | -11,738,706.70 | -18,867,903.52",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "be0d5055"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 276,
      "page_number": 168,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "长期股权投资",
          "无形资产",
          "存货",
          "固定资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264153",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 276,
        "word_count": 33,
        "sentence_count": 9,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.2898550724637682,
        "coherence_score": 0.43999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5190582430806258,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "长期股权投资",
        "无形资产",
        "存货",
        "固定资产",
        "资产"
      ]
    },
    {
      "chunk_id": "d6525bee",
      "content": "资产处置收益的来源 | 本期发生额 | 上期发生额\n--------------------------------------------------\n固定资产处置收益 | 244,580.94 | 659,231.88\n合 计 | 244,580.94 | 659,231.88",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1b99bbcd"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 141,
      "page_number": 168,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264258",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 141,
        "word_count": 17,
        "sentence_count": 4,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.2127659574468085,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4173843971631206,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "资产"
      ]
    },
    {
      "chunk_id": "4ce09e01",
      "content": "其他说明：\n75、营业外支出\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换损失 4,451,449.87 887,727.15 4,451,449.87\n对外捐赠 1,464,708.00 998,689.50 1,464,708.00\n罚款支出 81,087.21 781,984.81 81,087.21\n滞纳金 425,031.19 3,252.32 425,031.19\n合同义务损失 885,370.12 12,597,010.47 885,370.12\n其 他 186,383.29 1,445.95 186,383.29\n合计 7,494,029.68 15,270,110.20 7,494,029.68\n其他说明：\n76、所得税费用\n（1）所得税费用表\n单位： 元\n项目 本期发生额 上期发生额\n当期所得税费用 114,171,327.62 88,766,346.55\n递延所得税费用 27,499,467.56 3,525,443.72\n合计 141,670,795.18 92,291,790.27\n（2）会计利润与所得税费用调整过程\n单位： 元\n项目 本期发生额\n利润总额 912,452,980.27\n按法定/适用税率计算的所得税费用 228,113,245.07\n子公司适用不同税率的影响 -66,145,071.59\n调整以前期间所得税的影响 -5,756,005.36\n不可抵扣的成本、费用和损失的影响 9,475,292.73\n使用前期未确认递延所得税资产的可抵扣亏损的影响 -15,816,251.10\n本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏\n6,148,624.85\n损的影响\n| 补贴是否影 | 是否特殊补 | 本期发生金 | 上期发生金 | 与资产相关/\n--------------------------------------------------\n补助项目 | 发放主体 | 发放原因 | 性质类型 | \n| 响当年盈亏 | 贴 | 额 | 额 | 与收益相关\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d5913a39"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 887,
      "page_number": 168,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "36x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264319",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 887,
        "word_count": 105,
        "sentence_count": 34,
        "chinese_char_count": 303,
        "readability_score": 0.0,
        "information_density": 0.04509582863585119,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5448651362984218,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "270a4035",
      "content": "| 计入当期非经常性损益的金\n--------------------------------------------------\n项目 | 本期发生额 | 上期发生额 |\n| 额\n| \n非货币性资产交换损失 | 4,451,449.87 | 887,727.15 | 4,451,449.87\n对外捐赠 | 1,464,708.00 | 998,689.50 | 1,464,708.00\n罚款支出 | 81,087.21 | 781,984.81 | 81,087.21\n滞纳金 | 425,031.19 | 3,252.32 | 425,031.19\n合同义务损失 | 885,370.12 | 12,597,010.47 | 885,370.12\n其 他 | 186,383.29 | 1,445.95 | 186,383.29\n合计 | 7,494,029.68 | 15,270,110.20 | 7,494,029.68",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ba0d923c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 417,
      "page_number": 169,
      "bbox": [
        85.5,
        80.0,
        509.5,
        340.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "10x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          169
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264625",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 417,
        "word_count": 62,
        "sentence_count": 21,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.047961630695443645,
        "coherence_score": 0.32686363636363636,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4652677296886864,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "911c12fe",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n当期所得税费用 | 114,171,327.62 | 88,766,346.55\n递延所得税费用 | 27,499,467.56 | 3,525,443.72\n合计 | 141,670,795.18 | 92,291,790.27",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "6dca7ea4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 185,
      "page_number": 169,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税",
          "所得税费用"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          169
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264786",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 185,
        "word_count": 21,
        "sentence_count": 6,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.10810810810810809,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38470270270270274,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税",
        "所得税费用"
      ]
    },
    {
      "chunk_id": "5ca46c40",
      "content": "购置节能环保设备抵减应纳税额的影响 -1,818,754.37\n研发费用加计扣除 -15,620,860.07\n权益法核算投资收益 3,090,575.02\n所得税费用 141,670,795.18\n其他说明\n77、其他综合收益\n详见附注合并资产负债表项目注释之其他综合收益说明。78、现金流量表项目\n（1）收到的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n收回银行承兑汇票、信用证保证金等 146,000,576.25 268,324,454.49\n收到银行存款利息收入 31,637,094.38 37,993,941.65\n收到政府补助 31,594,591.50 17,182,776.65\n支取为开立承兑汇票质押的定期存款 33,903,500.00 442,038,662.00\n收到房租收入 923,003.40 2,147,867.09\n其 他 5,791,850.24 4,263,072.32\n合计 249,850,615.77 771,950,774.20\n收到的其他与经营活动有关的现金说明：\n（2）支付的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n管理费用中付现支出 121,586,061.34 90,307,710.88\n支付银行承兑汇票、信用证保证金等 74,233,191.52 261,266,253.31\n销售费用中付现支出 43,113,653.73 30,879,918.69\n研发费用中付现支出 31,990,487.21 24,535,117.38\n财务费用中付现支出 1,161,350.07 1,091,244.28\n存入为开立承兑汇票质押的定期存款 189,843,512.00\n支付履约保证金 3,850,000.00\n其 他 11,527,467.71 14,490,599.42\n合计 283,612,211.58 616,264,355.96\n项目 | 本期发生额\n\n--------------------------------------------------\n利润总额 | 912,452,980.27\n按法定/适用税率计算的所得税费用 | 228,113,245.07\n子公司适用不同税率的影响 | -66,145,071.59\n调整以前期间所得税的影响 | -5,756,005.36\n不可抵扣的成本、费用和损失的影响 | 9,475,292.73\n使用前期未确认递延所得税资产的可抵扣亏损的影响 | -15,816,251.10\n本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏 |\n| 6,148,624.85\n损的影响 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "128ee669"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1129,
      "page_number": 169,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "40x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "成本",
          "所得税",
          "所得税费用",
          "资产",
          "递延所得税资产",
          "利润总额"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          169
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264863",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1129,
        "word_count": 101,
        "sentence_count": 42,
        "chinese_char_count": 410,
        "readability_score": 0.0,
        "information_density": 0.1505757307351639,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7259048402230546,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "成本",
        "所得税",
        "所得税费用",
        "资产",
        "递延所得税资产",
        "利润总额"
      ]
    },
    {
      "chunk_id": "dc66fe96",
      "content": "购置节能环保设备抵减应纳税额的影响 | -1,818,754.37\n\n--------------------------------------------------\n研发费用加计扣除 | -15,620,860.07\n权益法核算投资收益 | 3,090,575.02\n所得税费用 | 141,670,795.18",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "2b49fe8d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 159,
      "page_number": 170,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税费用",
          "研发费用",
          "所得税",
          "投资收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265258",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 159,
        "word_count": 13,
        "sentence_count": 4,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.3773584905660377,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4269586497890295,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税费用",
        "研发费用",
        "所得税",
        "投资收益"
      ]
    },
    {
      "chunk_id": "b5a18281",
      "content": "支付的其他与经营活动有关的现金说明：\n（3）收到的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n银行理财产品及结构性存款到期收回 1,160,000,000.00 550,000,000.00\n收到银行理财产品及结构性存款利息 12,215,955.60 9,401,529.98\n收回股权竞拍保证金 400,000,000.00\n合计 1,172,215,955.60 959,401,529.98\n收到的其他与投资活动有关的现金说明：\n（4）支付的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n购买银行理财产品及结构性存款 260,000,000.00 1,400,000,000.00\n支付股权竞拍保证金 400,000,000.00\n支付人民币外汇货币掉期交易损失 5,459,752.25\n合计 260,000,000.00 1,805,459,752.25\n支付的其他与投资活动有关的现金说明：\n（5）收到的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支取因银行借款质押的定期存款 632,143,300.00\n收回银行借款保证金 900,000.00\n合计 633,043,300.00\n收到的其他与筹资活动有关的现金说明：\n（6）支付的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支付公司股份回购款 19,996,827.22 281,514,686.68\n支付限制性股票回购款及利息 281,636.25 13,560,886.22\n存入因银行借款质押的定期存款 294,477,200.00\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n管理费用中付现支出 | 121,586,061.34 | 90,307,710.88\n支付银行承兑汇票、信用证保证金等 | 74,233,191.52 | 261,266,253.31\n销售费用中付现支出 | 43,113,653.73 | 30,879,918.69\n研发费用中付现支出 | 31,990,487.21 | 24,535,117.38\n财务费用中付现支出 | 1,161,350.07 | 1,091,244.28\n存入为开立承兑汇票质押的定期存款 |  | 189,843,512.00\n支付履约保证金 |  | 3,850,000.00\n其 他 | 11,527,467.71 | 14,490,599.42\n合计 | 283,612,211.58 | 616,264,355.96",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ca144f34"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1124,
      "page_number": 170,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "40x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "研发费用",
          "管理费用",
          "销售费用",
          "财务费用"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265328",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1124,
        "word_count": 113,
        "sentence_count": 37,
        "chinese_char_count": 422,
        "readability_score": 0.0,
        "information_density": 0.06227758007117438,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6235731697288407,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "研发费用",
        "管理费用",
        "销售费用",
        "财务费用"
      ]
    },
    {
      "chunk_id": "e29eb8bf",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n银行理财产品及结构性存款到期收回 | 1,160,000,000.00 | 550,000,000.00\n收到银行理财产品及结构性存款利息 | 12,215,955.60 | 9,401,529.98\n收回股权竞拍保证金 |  | 400,000,000.00\n合计 | 1,172,215,955.60 | 959,401,529.98",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "41da8c21"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 239,
      "page_number": 171,
      "bbox": [
        89.5,
        80.0,
        505.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265717",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 239,
        "word_count": 25,
        "sentence_count": 7,
        "chinese_char_count": 55,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40731882845188283,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0e72e9ae",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n购买银行理财产品及结构性存款 | 260,000,000.00 | 1,400,000,000.00\n支付股权竞拍保证金 |  | 400,000,000.00\n支付人民币外汇货币掉期交易损失 |  | 5,459,752.25\n合计 | 260,000,000.00 | 1,805,459,752.25",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "eec1f644"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 223,
      "page_number": 171,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265809",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 223,
        "word_count": 24,
        "sentence_count": 6,
        "chinese_char_count": 52,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4045775784753363,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "95b073b4",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n支取因银行借款质押的定期存款 |  | 632,143,300.00\n收回银行借款保证金 |  | 900,000.00\n合计 |  | 633,043,300.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "29b71a62"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 153,
      "page_number": 171,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265898",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 153,
        "word_count": 18,
        "sentence_count": 3,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39187450980392163,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "a8fed66b",
      "content": "支付银行借款保证金 900,000.00\n合计 20,278,463.47 590,452,772.90\n支付的其他与筹资活动有关的现金说明：\n79、现金流量表补充资料\n（1）现金流量表补充资料\n单位： 元\n补充资料 本期金额 上期金额\n1．将净利润调节为经营活动现金流量： -- --\n净利润 770,782,185.09 605,003,820.78\n加：资产减值准备 14,240,855.70 18,867,903.52\n固定资产折旧、油气资产折耗、生产性生\n172,822,169.17 161,268,842.88\n物资产折旧\n无形资产摊销 30,277,923.13 31,103,003.79\n长期待摊费用摊销 223,651.32 162,421.24\n处置固定资产、无形资产和其他长期资产\n-244,580.94 -659,231.88\n的损失（收益以“－”号填列）\n固定资产报废损失（收益以“－”号填列） 4,395,355.91 761,505.33\n公允价值变动损失（收益以“－”号填列） -5,010,265.70\n财务费用（收益以“－”号填列） -7,552,032.06 -14,604,700.41\n投资损失（收益以“－”号填列） 15,240,062.55 9,359,378.55\n递延所得税资产减少（增加以“－”号填列） 5,147,540.13 -4,649,984.56\n递延所得税负债增加（减少以“－”号填列） 22,351,927.43 8,175,428.28\n存货的减少（增加以“－”号填列） 52,643,000.47 -99,308,067.53\n经营性应收项目的减少（增加以“－”号填\n-276,602,622.13 -71,443,627.33\n列）\n经营性应付项目的增加（减少以“－”号填\n-191,326,340.46 152,422,810.70\n列）\n经营活动产生的现金流量净额 612,399,095.31 791,449,237.66\n2．不涉及现金收支的重大投资和筹资活\n-- --\n动：\n3．现金及现金等价物净变动情况： -- --\n现金的期末余额 1,525,777,908.45 1,069,208,275.60\n减：现金的期初余额 1,069,208,275.60 2,245,777,296.21\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n支付公司股份回购款 | 19,996,827.22 | 281,514,686.68\n支付限制性股票回购款及利息 | 281,636.25 | 13,560,886.22\n存入因银行借款质押的定期存款 |  | 294,477,200.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d7bc52bd"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1227,
      "page_number": 171,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265960",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1227,
        "word_count": 103,
        "sentence_count": 45,
        "chinese_char_count": 386,
        "readability_score": 0.0,
        "information_density": 0.05704971475142625,
        "coherence_score": 0.48,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5060074128984433,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "f20bfb40",
      "content": "支付银行借款保证金 |  | 900,000.00\n--------------------------------------------------\n合计 | 20,278,463.47 | 590,452,772.90",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "92f9d5e9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 112,
      "page_number": 172,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266256",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 10,
        "sentence_count": 3,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.36213214285714285,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "977bf425",
      "content": "| 金额\n\n--------------------------------------------------\n其中： | --\n其中： | --\n其中： | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1e1054c7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 83,
      "page_number": 173,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266309",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 83,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 8,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43105783132530123,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8543c023",
      "content": "| 金额\n\n--------------------------------------------------\n其中： | --\n其中： | --\n其中： | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "625fd629"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 83,
      "page_number": 173,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266360",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 83,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 8,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43105783132530123,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "d4cca396",
      "content": "项 目 | 本期数\n\n--------------------------------------------------\n背书转让的商业汇票金额 | 1,203,398,004.56\n其中：支付货款 | 763,162,260.55\n支付固定资产等长期资产购置款 | 440,235,744.01",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d5570ea4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 149,
      "page_number": 173,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "固定资产",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266436",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 149,
        "word_count": 14,
        "sentence_count": 3,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.2684563758389262,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4994198198198198,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "固定资产",
        "资产"
      ]
    },
    {
      "chunk_id": "26cf3279",
      "content": "小 计 30,797,464.00 886,880,848.73\n80、所有者权益变动表项目注释\n说明对上年期末余额进行调整的“其他”项目名称及调整金额等事项：\n81、所有权或使用权受到限制的资产\n单位： 元\n项目 期末账面价值 受限原因\n货币资金 30,797,464.00开立银行承兑汇票\n固定资产 22,554,937.46银行融资抵押\n无形资产 10,291,182.19银行融资抵押\n合计 63,643,583.65 --\n其他说明：\n82、外币货币性项目\n（1）外币货币性项目\n单位： 元\n项目 期末外币余额 折算汇率 期末折算人民币余额\n货币资金 -- -- 214,734,480.07\n其中：美元 30,636,838.136.9762 213,728,710.16\n欧元 40,660.307.8155 317,780.57\n港币\n英镑 75,189.279.1501 687,989.34\n应收账款 -- -- 146,207,835.41\n其中：美元 20,665,705.866.9762 144,168,097.22\n欧元 260,986.277.8155 2,039,738.19\n港币\n其他应收款 2,859.22\n其中：欧元 365.847.8155 2,859.22\n应付账款 5,296,661.70\n其中：美元 663,385.606.9762 4,627,910.62\n欧元 85,567.287.8155 668,751.08\n其他应付款 8,199,889.22\n项 目 | 期末数\n\n--------------------------------------------------\n质押的定期存款 |\n结构性存款 |\n银行承兑汇票保证金 | 30,797,464.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5d5d5d29"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 760,
      "page_number": 173,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "34x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266501",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 760,
        "word_count": 82,
        "sentence_count": 36,
        "chinese_char_count": 223,
        "readability_score": 0.0,
        "information_density": 0.039473684210526314,
        "coherence_score": 0.3933333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47363422930651855,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "1c414f7a",
      "content": "项目 | 期末账面价值 | 受限原因\n--------------------------------------------------\n货币资金 | 30,797,464.00 | 开立银行承兑汇票\n固定资产 | 22,554,937.46 | 银行融资抵押\n无形资产 | 10,291,182.19 | 银行融资抵押\n合计 | 63,643,583.65 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "801f5cd5"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 185,
      "page_number": 174,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "固定资产",
          "无形资产",
          "货币资金",
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          174
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266760",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 185,
        "word_count": 26,
        "sentence_count": 4,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.3243243243243243,
        "coherence_score": 0.49,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4326306306306306,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "固定资产",
        "无形资产",
        "货币资金",
        "资产"
      ]
    },
    {
      "chunk_id": "392168dd",
      "content": "其中：美元 789,910.036.9762 5,510,570.35\n欧元 342,262.847.8155 2,674,955.23\n英镑 1,569.789.1501 14,363.64\n长期借款 -- --\n其中：美元\n欧元\n港币\n其他说明：\n（2）境外经营实体说明，包括对于重要的境外经营实体，应披露其境外主要经营地、记账本位币及选择\n依据，记账本位币发生变化的还应披露原因。√ 适用 □ 不适用\n子公司 子公司类型 境外主要经营地 记账 选择依据\n本位币\nGeneVida GmbH 全资子公司 德国 欧元 根据公司经营所处经济环境选择\nGANGXIANG（SINGAPORE） 全资子公司 新加坡 人民币 根据公司经营所处经济环境选择\n香港港翔公司 全资子公司 香港 人民币 根据公司经营所处经济环境选择\n83、套期\n按照套期类别披露套期项目及相关套期工具、被套期风险的定性和定量信息：\n84、政府补助\n（1）政府补助基本情况\n单位： 元\n种类 金额 列报项目 计入当期损益的金额\n（2）政府补助退回情况\n□ 适用 √ 不适用\n其他说明：\n(1) 明细情况\n1) 与资产相关的政府补助\n项 目 期初递延收益 本期新增补助 本期摊销 期末递延收益 本期摊销 说明\n列报项目\n项目 | 期末外币余额 | 折算汇率 | 期末折算人民币余额\n--------------------------------------------------\n货币资金 | -- | -- | 214,734,480.07\n其中：美元 | 30,636,838.13 | 6.9762 | 213,728,710.16\n欧元 | 40,660.30 | 7.8155 | 317,780.57\n港币 | \n英镑 | 75,189.27 | 9.1501 | 687,989.34\n应收账款 | -- | -- | 146,207,835.41\n其中：美元 | 20,665,705.86 | 6.9762 | 144,168,097.22\n欧元 | 260,986.27 | 7.8155 | 2,039,738.19\n港币 | \n其他应收款 | 2,859.22\n其中：欧元 | 365.84 | 7.8155 | 2,859.22\n应付账款 | 5,296,661.70\n其中：美元 | 663,385.60 | 6.9762 | 4,627,910.62\n欧元 | 85,567.28 | 7.8155 | 668,751.08\n其他应付款 | 8,199,889.22",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "22082417"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1083,
      "page_number": 174,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "44x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 44,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "货币资金",
          "其他应付款",
          "应收",
          "应收账款",
          "应收款",
          "应付账款",
          "应付款",
          "其他应收款",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          174
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266838",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1083,
        "word_count": 163,
        "sentence_count": 39,
        "chinese_char_count": 391,
        "readability_score": 0.0,
        "information_density": 0.10156971375807941,
        "coherence_score": 0.2831506849315068,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6126392601468647,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "货币资金",
        "其他应付款",
        "应收",
        "应收账款",
        "应收款",
        "应付账款",
        "应付款",
        "其他应收款",
        "应付"
      ]
    },
    {
      "chunk_id": "1ebfd7a0",
      "content": "其中：美元 | 789,910.03 | 6.9762 | 5,510,570.35\n--------------------------------------------------\n欧元 | 342,262.84 | 7.8155 | 2,674,955.23\n英镑 | 1,569.78 | 9.1501 | 14,363.64\n长期借款 | -- | -- |\n其中：美元 | \n欧元 | \n港币 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "fff0881e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 208,
      "page_number": 175,
      "bbox": [
        97.5,
        80.0,
        497.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "长期借款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          175
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.267187",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 208,
        "word_count": 35,
        "sentence_count": 9,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.09615384615384615,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4597659574468085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "长期借款"
      ]
    },
    {
      "chunk_id": "05f162c2",
      "content": "年产400吨碳青霉烯类抗生 5,695,281.12 1,423,820.28 4,271,460.84 其他收益\n素关键中间体4-AA项目\n年产1吨瑞格列奈、10吨卡洛 235,862.40 117,931.20 117,931.20 其他收益\n芬、10吨阿托伐醌、50吨\nT1620、300吨聚卡波菲钙、\n300吨4,4'-二氟二苯甲酮、100\n吨奈韦拉平产业化项目\n催化净化处理塔建设项目 140,000.00 30,000.00 110,000.00 其他收益\n年产50吨培南类产品及扩建 132,000.00 48,000.00 84,000.00 其他收益\n厂房技改项目\n企业技术中心创新能力建设 133,333.33 40,000.00 93,333.33 其他收益\n项目\n年产8亿元(粒)口服固体制剂 7,065,200.00 997,440.00 6,067,760.00 其他收益\n项目\n临海市创新驱动加快推进工 1,042,718.40 208,543.68 834,174.72 其他收益\n业经济转型升级政策\n省级工业与信息化专项资金 632,766.12 92,599.92 540,166.20 其他收益\n回收溶剂循环化技改项目\n省工业化和信息化深度融合 457,675.28 66,169.92 391,505.36 其他收益\n示范试点区财政补助\n浙江省化学原料药基地椒江 263,333.33 40,000.00 223,333.33 其他收益\n区块循环化改造项目补助资\n金\n年产2吨盐酸阿莫罗芬、20吨 2,090,683.87 281,889.96 1,808,793.91 其他收益\n阿特来马来酸盐、5吨多尼培\n南、20吨美罗培南、5吨比阿\n培南、60吨PHE产业化项目\n(续建)\n年产15000吨环保型活性艳 850,000.00 100,000.00 750,000.00 其他收益\n蓝KN-R商品染料技改项目\n大品种药物的生产技术改造- 860,416.67 2,000,000.00 291,265.91 2,569,150.76 其他收益\n美罗培南原料药绿色合成技\n术改造\n临海医化园区循环化改造项 490,000.00 105,000.00 385,000.00 其他收益\n目\n南洋涂—固废减量化处置项 2,286,832.98 246,999.96 2,039,833.02 其他收益\n目\n年产400吨MAP、100吨OA、 11,962,166.31 10,000,000.00 1,490,999.91 20,471,166.40 其他收益\n200吨DA、100吨甲砜霉素、\n10吨联苯双酯产业化新项目\n年产580吨柳氮磺胺吡啶产 2,115,735.00 248,910.00 1,866,825.00 其他收益\n业化项目\n子公司 | 子公司类型 | 境外主要经营地 | 记账\n本位币\n--------------------------------------------------\nGeneVida GmbH | 全资子公司 | 德国 | 欧元\nGANGXIANG（SINGAPORE） | 全资子公司 | 新加坡 | 人民币\n香港港翔公司 | 全资子公司 | 香港 | 人民币",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7d13e027"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1371,
      "page_number": 175,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "47x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 47,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          175
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.267279",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1371,
        "word_count": 143,
        "sentence_count": 53,
        "chinese_char_count": 472,
        "readability_score": 0.0,
        "information_density": 0.014587892049598834,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5490776592835658,
      "relevance_score": 1.0,
      "keywords": [
        "经营",
        "8亿元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "09a1705a",
      "content": "清洁生产循环利用及三废综 4,800,000.00 600,000.00 4,200,000.00 其他收益\n合治理提升项目\n年产15500吨活性染料产业 1,296,000.00 1,296,000.00 其他收益\n升级及配套项目\n孵化器车间技改项目 793,220.34 81,355.92 711,864.42 其他收益\n浙江省化学原料药基地椒江 400,000.00 10,000.00 390,000.00 其他收益\n区块循环化改造项目补助资\n金项目补助\n年产700吨M-562关键中间体 500,000.00 33,333.33 466,666.67 其他收益\n产业一体化项目\n小 计 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n2) 与收益相关，且用于补偿公司已发生的相关成本费用或损失的政府补助\n项 目 金额 列报项目 说明\n税费返还 1,828,299.60 其他收益 临政办发〔2018〕166号\n财政专项基金 4,150,682.78 其他收益 台财企发〔2019〕34号、临财企〔2018〕\n55号、台财企发〔2018〕27号、椒区\n委发〔2019〕18号等\n政府奖励 14,486,841.50 其他收益 椒商务〔2018〕59号、椒商务〔2019〕\n51号、台政办函[2019]14号、椒江委\n发〔2019〕18号等\n科技补助 116,841.00 其他收益 台科〔2019〕87号等\n小 计 20,582,664.88\n(2) 本期计入当期损益的政府补助金额为27,136,924.87元。85、其他\n八、合并范围的变更\n1、非同一控制下企业合并\n（1）本期发生的非同一控制下企业合并\n单位： 元\n购买日至期 购买日至期\n被购买方名 股权取得时 股权取得成 股权取得比 股权取得方 购买日的确\n购买日 末被购买方 末被购买方\n称 点 本 例 式 定依据\n的收入 的净利润\n其他说明：\n（2）合并成本及商誉\n单位： 元\n年产400吨碳青霉烯类抗生\n\n素关键中间体4-AA项目 | 5,695,281.12 |  | 1,423,820.28 | 4,271,460.84 | 其他收益\n--------------------------------------------------\n年产1吨瑞格列奈、10吨卡洛\n芬、10吨阿托伐醌、50吨\nT1620、300吨聚卡波菲钙、\n300吨4,4'-二氟二苯甲酮、100\n吨奈韦拉平产业化项目 | 235,862.40 |  | 117,931.20 | 117,931.20 | 其他收益\n催化净化处理塔建设项目 | 140,000.00 |  | 30,000.00 | 110,000.00 | 其他收益\n年产50吨培南类产品及扩建\n厂房技改项目 | 132,000.00 |  | 48,000.00 | 84,000.00 | 其他收益\n企业技术中心创新能力建设\n项目 | 133,333.33 |  | 40,000.00 | 93,333.33 | 其他收益\n年产8亿元(粒)口服固体制剂\n项目 | 7,065,200.00 |  | 997,440.00 | 6,067,760.00 | 其他收益\n临海市创新驱动加快推进工\n业经济转型升级政策 | 1,042,718.40 |  | 208,543.68 | 834,174.72 | 其他收益\n省级工业与信息化专项资金\n回收溶剂循环化技改项目 | 632,766.12 |  | 92,599.92 | 540,166.20 | 其他收益\n省工业化和信息化深度融合\n示范试点区财政补助 | 457,675.28 |  | 66,169.92 | 391,505.36 | 其他收益\n浙江省化学原料药基地椒江\n区块循环化改造项目补助资\n金 | 263,333.33 |  | 40,000.00 | 223,333.33 | 其他收益\n年产2吨盐酸阿莫罗芬、20吨\n阿特来马来酸盐、5吨多尼培\n南、20吨美罗培南、5吨比阿\n培南、60吨PHE产业化项目\n(续建) | 2,090,683.87 |  | 281,889.96 | 1,808,793.91 | 其他收益\n年产15000吨环保型活性艳\n蓝KN-R商品染料技改项目 | 850,000.00 |  | 100,000.00 | 750,000.00 | 其他收益\n大品种药物的生产技术改造-\n美罗培南原料药绿色合成技\n术改造 | 860,416.67 | 2,000,000.00 | 291,265.91 | 2,569,150.76 | 其他收益\n临海医化园区循环化改造项\n目 | 490,000.00 |  | 105,000.00 | 385,000.00 | 其他收益\n南洋涂—固废减量化处置项\n目 | 2,286,832.98 |  | 246,999.96 | 2,039,833.02 | 其他收益\n年产400吨MAP、100吨OA、\n200吨DA、100吨甲砜霉素、\n10吨联苯双酯产业化新项目 | 11,962,166.31 | 10,000,000.00 | 1,490,999.91 | 20,471,166.40 | 其他收益\n年产580吨柳氮磺胺吡啶产\n业化项目 | 2,115,735.00 |  | 248,910.00 | 1,866,825.00 | 其他收益",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e2770d93",
        "b00332c9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2284,
      "page_number": 176,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "77x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 77,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.267604",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2284,
        "word_count": 293,
        "sentence_count": 78,
        "chinese_char_count": 787,
        "readability_score": 0.0,
        "information_density": 0.021891418563922942,
        "coherence_score": 0.5443189210089385,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6551994437445028,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润",
        "924.87元",
        "8亿元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "2cea3f80",
      "content": "清洁生产循环利用及三废综\n\n合治理提升项目 | 4,800,000.00 |  | 600,000.00 | 4,200,000.00 | 其他收益\n--------------------------------------------------\n年产15500吨活性染料产业\n升级及配套项目 | 1,296,000.00 | 1,296,000.00 | 其他收益\n孵化器车间技改项目 | 793,220.34 |  | 81,355.92 | 711,864.42 | 其他收益\n浙江省化学原料药基地椒江\n区块循环化改造项目补助资\n金项目补助 |  | 400,000.00 | 10,000.00 | 390,000.00 | 其他收益\n年产700吨M-562关键中间体\n产业一体化项目 |  | 500,000.00 | 33,333.33 | 466,666.67 | 其他收益\n小 计 | 43,343,225.15 | 12,900,000.00 | 6,554,259.99 | 49,688,965.16 |\n\n> 注：合并成本\n合并成本公允价值的确定方法、或有对价及其变动的说明：\n大额商誉形成的主要原因：\n其他说明：\n（3）被购买方于购买日可辨认资产、负债\n单位： 元\n购买日公允价值 购买日账面价值\n可辨认资产、负债公允价值的确定方法：\n企业合并中承担的被购买方的或有负债：\n其他说明：\n（4）购买日之前持有的股权按照公允价值重新计量产生的利得或损失\n是否存在通过多次交易分步实现企业合并且在报告期内取得控制权的交易\n□ 是 √ 否\n（5）购买日或合并当期期末无法合理确定合并对价或被购买方可辨认资产、负债公允价值的相关说明\n（6）其他说明\n2、同一控制下企业合并\n（1）本期发生的同一控制下企业合并\n单位： 元\n合并当期期 合并当期期\n企业合并中 构成同一控 比较期间被 比较期间被\n被合并方名 合并日的确 初至合并日 初至合并日\n取得的权益 制下企业合 合并日 合并方的收 合并方的净\n称 定依据 被合并方的 被合并方的\n比例 并的依据 入 利润\n收入 净利润\n其他说明：\n（2）合并成本\n单位： 元\n合并成本\n或有对价及其变动的说明：\n其他说明：\n178",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "719472c5"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 944,
      "page_number": 177,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268486",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 944,
        "word_count": 122,
        "sentence_count": 18,
        "chinese_char_count": 487,
        "readability_score": 0.0,
        "information_density": 0.06355932203389832,
        "coherence_score": 0.611864406779661,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5866779638339592,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "350dd579",
      "content": "项 目 | 金额 | 列报项目\n--------------------------------------------------\n税费返还 | 1,828,299.60 | 其他收益\n财政专项基金 | 4,150,682.78 | 其他收益\n政府奖励 | 14,486,841.50 | 其他收益\n科技补助 | 116,841.00 | 其他收益\n小 计 | 20,582,664.88 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8a86ed82"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 197,
      "page_number": 177,
      "bbox": [
        97.5,
        80.0,
        497.5,
        240.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268836",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 197,
        "word_count": 32,
        "sentence_count": 5,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5525,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3979333333333333,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ef357d95",
      "content": "|\n--------------------------------------------------\n| 购买日公允价值 | 购买日账面价值",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "758b4b06"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 72,
      "page_number": 178,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "1x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          178
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268923",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 72,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.36752307692307695,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9b623bc7",
      "content": "|\n--------------------------------------------------\n| 合并日 | 上期期末",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ec4d95b6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 65,
      "page_number": 179,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "1x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          179
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268962",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 65,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 7,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3873220657276995,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "bdd781a2",
      "content": "公司名称 | 股权取得方式 | 股权取得时点 | 出资额\n--------------------------------------------------\n盛嘉环保公司 | 设立 | 2019/4/29 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c4abb088"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 105,
      "page_number": 179,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          179
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269003",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 105,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3844075471698113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "2dda88e1",
      "content": "台州东旭公司 台州市 台州市 设备制造 100.00% 设立\nGeneVida GmbH 德国多特蒙德 德国多特蒙德 医药销售 100.00% 设立\nGANGXIANG\n新加坡 新加坡 贸易 100.00% 设立\n（SINGAPORE）\n港翔化工公司 台州市 台州市 化工销售 100.00% 设立\n瓯华环保公司 盐城市 盐城市 技术研发 100.00% 设立\n盛嘉环保公司 台州市 台州市 技术研发 100.00% 设立\n非同一控制下企\n香港港翔公司 香港 香港 贸易 100.00%\n业合并\n非同一控制下企\n港翔科技公司 台州市 台州市 化工销售 100.00%\n业合并\n非同一控制下企\n台州前进公司 台州市 台州市 化工制造 100.00%\n业合并\n非同一控制下企\n台州振港公司 台州市 台州市 化工制造 9.27% 90.73%\n业合并\n非同一控制下企\n盐城瓯华公司 盐城市 盐城市 化工制造 100.00%\n业合并\n非同一控制下企\n瓯华研究院 盐城市 盐城市 技术研发 100.00%\n业合并\n在子公司的持股比例不同于表决权比例的说明：\n持有半数或以下表决权但仍控制被投资单位、以及持有半数以上表决权但不控制被投资单位的依据：\n对于纳入合并范围的重要的结构化主体，控制的依据：\n确定公司是代理人还是委托人的依据：\n其他说明：\n（2）重要的非全资子公司\n单位： 元\n本期归属于少数股东的 本期向少数股东宣告分\n子公司名称 少数股东持股比例 期末少数股东权益余额\n损益 派的股利\n子公司少数股东的持股比例不同于表决权比例的说明：\n其他说明：\n（3）重要非全资子公司的主要财务信息\n单位： 元\n期末余额 期初余额\n子公司\n流动资 非流动 资产合 流动负 非流动 负债合 流动资 非流动 资产合 流动负 非流动 负债合\n名称\n产 资产 计 债 负债 计 产 资产 计 债 负债 计\n| 持股比例  |\n--------------------------------------------------\n子公司名称 | 主要经营地 | 注册地 | 业务性质 | 取得方式\n| 直接 | 间接 |\n| \n川南药业公司 | 台州市 | 台州市 | 医药制造 | 100.00% |  | 设立\n海翔销售公司 | 台州市 | 台州市 | 医药销售 | 100.00% |  | 设立\n上海海翔公司 | 上海市 | 上海市 | 技术研发 | 100.00% |  | 设立",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "05deb6f7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1033,
      "page_number": 179,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "51x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 51,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          179
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269052",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔化工公司",
        "industry": null,
        "char_count": 1033,
        "word_count": 184,
        "sentence_count": 16,
        "chinese_char_count": 609,
        "readability_score": 0.0,
        "information_density": 0.058083252662149074,
        "coherence_score": 0.518548061341913,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5506578397212544,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "b8ea5f10",
      "content": "台州东旭公司 | 台州市 | 台州市 | 设备制造 | 100.00% |  | 设立\n--------------------------------------------------\nGeneVida GmbH | 德国多特蒙德 | 德国多特蒙德 | 医药销售 | 100.00% |  | 设立\nGANGXIANG | \n| 新加坡 | 新加坡 | 贸易 | 100.00% |  | 设立\n（SINGAPORE） | \n| \n港翔化工公司 | 台州市 | 台州市 | 化工销售 | 100.00% |  | 设立\n瓯华环保公司 | 盐城市 | 盐城市 | 技术研发 |  | 100.00% | 设立\n盛嘉环保公司 | 台州市 | 台州市 | 技术研发 |  | 100.00% | 设立\n| 非同一控制下企\n香港港翔公司 | 香港 | 香港 | 贸易 | 100.00%  |\n| 业合并\n| \n| 非同一控制下企\n港翔科技公司 | 台州市 | 台州市 | 化工销售 | 100.00%  |\n| 业合并\n| \n| 非同一控制下企\n台州前进公司 | 台州市 | 台州市 | 化工制造 | 100.00%  |\n| 业合并\n| \n| 非同一控制下企\n台州振港公司 | 台州市 | 台州市 | 化工制造 | 9.27% | 90.73% |\n| 业合并\n| \n| 非同一控制下企\n盐城瓯华公司 | 盐城市 | 盐城市 | 化工制造 |  | 100.00% |\n| 业合并\n| \n| 非同一控制下企\n瓯华研究院 | 盐城市 | 盐城市 | 技术研发 |  | 100.00% |\n| 业合并\n| \n\n> 注：单位： 元\n本期发生额 上期发生额\n子公司名称 综合收益总 经营活动现 综合收益总 经营活动现\n营业收入 净利润 营业收入 净利润\n额 金流量 额 金流量\n其他说明：\n（4）使用企业集团资产和清偿企业集团债务的重大限制\n（5）向纳入合并财务报表范围的结构化主体提供的财务支持或其他支持\n其他说明：\n2、在子公司的所有者权益份额发生变化且仍控制子公司的交易\n（1）在子公司所有者权益份额发生变化的情况说明\n（2）交易对于少数股东权益及归属于母公司所有者权益的影响\n单位： 元\n其他说明\n3、在合营安排或联营企业中的权益\n（1）重要的合营企业或联营企业\n持股比例 对合营企业或联\n合营企业或联营\n主要经营地 注册地 业务性质 营企业投资的会\n企业名称 直接 间接\n计处理方法\n苏州第四制药厂\n常熟 常熟 医药制造 32.66% 权益法核算\n有限公司\n在合营企业或联营企业的持股比例不同于表决权比例的说明：\n持有20%以下表决权但具有重大影响，或者持有20%或以上表决权但不具有重大影响的依据：\n（2）重要合营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n其他说明\n181。",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "781f7d04"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1207,
      "page_number": 180,
      "bbox": [
        77.5,
        80.0,
        517.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "56x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 56,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269412",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔化工公司",
        "industry": null,
        "char_count": 1207,
        "word_count": 229,
        "sentence_count": 15,
        "chinese_char_count": 648,
        "readability_score": 0.0,
        "information_density": 0.06628003314001657,
        "coherence_score": 0.5234925419044743,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7018346010434534,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "4a538d8b",
      "content": "|  | 本期归属于少数股东的 | 本期向少数股东宣告分 |\n--------------------------------------------------\n子公司名称 | 少数股东持股比例 | 期末少数股东权益余额\n|  | 损益 | 派的股利 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1a5f2524"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 130,
      "page_number": 180,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "少数股东权益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269753",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 130,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.15384615384615383,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4705421633554083,
      "relevance_score": 1.0,
      "keywords": [
        "权益"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "少数股东权益"
      ]
    },
    {
      "chunk_id": "e31580aa",
      "content": "| 持股比例 |  | 对合营企业或联\n--------------------------------------------------\n合营企业或联营 | \n| 主要经营地 | 注册地 | 业务性质 | 营企业投资的会\n企业名称 | 直接 | 间接 |\n| 计处理方法\n| \n苏州第四制药厂 | \n| 常熟 | 常熟 | 医药制造 | 32.66% |  | 权益法核算\n有限公司 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "57cc9dd7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 198,
      "page_number": 181,
      "bbox": [
        97.5,
        80.0,
        497.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269812",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 198,
        "word_count": 41,
        "sentence_count": 1,
        "chinese_char_count": 74,
        "readability_score": 0.0,
        "information_density": 0.15151515151515152,
        "coherence_score": 0.21,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45702083333333327,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "84e81b0a",
      "content": "（3）重要联营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n苏州第四制药厂有限公司 苏州第四制药厂有限公司\n流动资产 29,519,105.76 25,072,727.50\n非流动资产 84,757,893.18 93,352,602.90\n资产合计 114,276,998.94 118,425,330.40\n流动负债 36,442,141.82 25,462,418.24\n非流动负债 21,400,000.00 22,000,000.00\n负债合计 57,842,141.82 47,462,418.24\n归属于母公司股东权益 56,434,857.12 71,167,909.30\n按持股比例计算的净资产份额 18,431,624.34 23,243,439.18\n--其他 -297,151.93 -297,151.93\n对联营企业权益投资的账面价值 18,134,472.41 22,946,287.25\n营业收入 57,010,459.03 39,434,028.51\n净利润 -14,733,052.18 -10,672,428.70\n综合收益总额 -14,733,052.18 -10,672,428.70\n其他说明\n（4）不重要的合营企业和联营企业的汇总财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n合营企业： -- --\n投资账面价值合计 29,744,910.02 43,141,852.54\n下列各项按持股比例计算的合计数 -- --\n--净利润 -11,947,734.96 -3,438,323.72\n--综合收益总额 -11,947,734.96 -3,438,323.72\n联营企业： -- --\n下列各项按持股比例计算的合计数 -- --\n其他说明\n| 期末余额/本期发生额 | 期初余额/上期发生额\n--------------------------------------------------\n |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "dc030c73"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 847,
      "page_number": 181,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "30x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269901",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 847,
        "word_count": 80,
        "sentence_count": 32,
        "chinese_char_count": 256,
        "readability_score": 0.0,
        "information_density": 0.08264462809917354,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47831471643933954,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "74e314a6",
      "content": "（5）合营企业或联营企业向本公司转移资金的能力存在重大限制的说明\n（6）合营企业或联营企业发生的超额亏损\n单位： 元\n累积未确认前期累计认的损 本期未确认的损失（或本期分\n合营企业或联营企业名称 本期末累积未确认的损失\n失 享的净利润）\n其他说明\n（7）与合营企业投资相关的未确认承诺\n（8）与合营企业或联营企业投资相关的或有负债\n4、重要的共同经营\n持股比例/享有的份额\n共同经营名称 主要经营地 注册地 业务性质\n直接 间接\n在共同经营中的持股比例或享有的份额不同于表决权比例的说明：\n共同经营为单独主体的，分类为共同经营的依据：\n其他说明\n5、在未纳入合并财务报表范围的结构化主体中的权益\n未纳入合并财务报表范围的结构化主体的相关说明：\n6、其他\n十、与金融工具相关的风险\n本公司从事风险管理的目标是在风险和收益之间取得平衡，将风险对本公司经营业绩的负面影响降至\n最低水平，使股东和其他权益投资者的利益最大化。基于该风险管理目标，本公司风险管理的基本策略是\n确认和分析本公司面临的各种风险，建立适当的风险承受底线和进行风险管理，并及时可靠地对各种风险\n进行监督，将风险控制在限定的范围内。本公司在日常活动中面临各种与金融工具相关的风险，主要包括信用风险、流动性风险及市场风险。\n| 期末余额/本期发生额 | 期初余额/上期发生额\n--------------------------------------------------\n合营企业： | -- | --\n投资账面价值合计 | 29,744,910.02 | 43,141,852.54\n下列各项按持股比例计算的合计数 | -- | --\n--净利润 | -11,947,734.96 | -3,438,323.72\n--综合收益总额 | -11,947,734.96 | -3,438,323.72\n联营企业： | -- | --\n下列各项按持股比例计算的合计数 | -- | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "33f4de73"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 824,
      "page_number": 182,
      "bbox": [
        49.5,
        80.0,
        545.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "31x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 31,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "综合收益总额",
          "利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270170",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 824,
        "word_count": 72,
        "sentence_count": 9,
        "chinese_char_count": 545,
        "readability_score": 0.0,
        "information_density": 0.12135922330097086,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6657675057589877,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "综合收益总额",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "402f0cfd",
      "content": "| 累积未确认前期累计认的损 | 本期未确认的损失（或本期分 |\n--------------------------------------------------\n合营企业或联营企业名称 | 本期末累积未确认的损失\n| 失 | 享的净利润） |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "baeabad9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 126,
      "page_number": 183,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          183
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270423",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 126,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 52,
        "readability_score": 0.0,
        "information_density": 0.23809523809523808,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5163,
      "relevance_score": 1.0,
      "keywords": [
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "31fc7687",
      "content": "| 持股比例/享有的份额 |\n--------------------------------------------------\n共同经营名称 | 主要经营地 | 注册地 | 业务性质  |\n| 直接 | 间接\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a3b8e576"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 183,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          183
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270495",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 17,
        "sentence_count": 0,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.09259259259259259,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3860493150684931,
      "relevance_score": 1.0,
      "keywords": [
        "经营"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "d54ccfbe",
      "content": "项 目 | \n--------------------------------------------------\n| 账面价值 | 未折现合同金额 | 1年以内 | 1-3年\n银行借款 | 200,267,029.59 | 205,600,371.26 | 205,600,371.26 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5b4ab087"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 146,
      "page_number": 184,
      "bbox": [
        69.5,
        80.0,
        525.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          184
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270550",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 146,
        "word_count": 20,
        "sentence_count": 3,
        "chinese_char_count": 21,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3764636942675159,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "64017ac5",
      "content": "对于外币资产和负债，如果出现短期的失衡\n情况，本公司会在必要时按市场汇率买卖外币，以确保将净风险敞口维持在可接受的水平。本公司期末外币货币性资产和负债情况详见本财务报表附注合并财务报表项目注释其他之外币货币\n性项目说明。十一、公允价值的披露\n1、以公允价值计量的资产和负债的期末公允价值\n单位： 元\n期末公允价值\n项目 第一层次公允价值计\n第二层次公允价值计量 第三层次公允价值计量 合计\n量\n一、持续的公允价值计量 -- -- -- --\n（2）权益工具投资 20,000,000.00 20,000,000.00\n应付票据 | 238,306,005.00 | 238,306,005.00 | 238,306,005.00 |\n--------------------------------------------------\n应付账款 | 363,440,583.96 | 363,440,583.96 | 324,802,966.15 | 27,710,697.69\n其他应付款 | 28,200,073.22 | 28,200,073.22 | 15,005,415.27 | 6,245,135.70\n小 计 | 830,213,691.77 | 835,547,033.44 | 783,714,757.68 | 33,955,833.39",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "15fecc71"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 579,
      "page_number": 185,
      "bbox": [
        47.5,
        80.0,
        547.5,
        440.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "其他应付款",
          "应付款",
          "应付账款",
          "应付票据",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270612",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 579,
        "word_count": 58,
        "sentence_count": 19,
        "chinese_char_count": 206,
        "readability_score": 0.0,
        "information_density": 0.18998272884283246,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5058234902810846,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他应付款",
        "应付款",
        "应付账款",
        "应付票据",
        "应付"
      ]
    },
    {
      "chunk_id": "429f3daa",
      "content": "项 目 | \n--------------------------------------------------\n| 账面价值 | 未折现合同金额 | 1年以内 | 1-3年\n银行借款 | 598,700,000.00 | 611,954,988.49 | 611,954,988.49 |\n应付票据 | 490,006,533.85 | 490,006,533.85 | 490,006,533.85 |\n应付账款 | 301,908,929.93 | 301,908,929.93 | 279,305,463.32 | 13,367,311.11\n其他应付款 | 24,723,304.20 | 24,723,304.20 | 15,643,774.56 | 638,021.29\n一年内到期的非流\n动负债 | 44,365,875.00 | 44,365,875.00 | 44,365,875.00 |\n小 计 | 1,459,704,642.98 | 1,472,959,631.47 | 1,441,276,635.22 | 14,005,332.40",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "91bdcafd"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 483,
      "page_number": 185,
      "bbox": [
        47.5,
        80.0,
        547.5,
        300.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "9x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "其他应付款",
          "负债",
          "应付款",
          "应付账款",
          "应付票据",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270821",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 483,
        "word_count": 65,
        "sentence_count": 21,
        "chinese_char_count": 47,
        "readability_score": 0.0,
        "information_density": 0.14492753623188406,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47174704301075265,
      "relevance_score": 1.0,
      "keywords": [
        "负债"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他应付款",
        "负债",
        "应付款",
        "应付账款",
        "应付票据",
        "应付"
      ]
    },
    {
      "chunk_id": "98cf114b",
      "content": "（八）应收款项融资 74,531,666.41 74,531,666.41\n持续以公允价值计量的\n94,531,666.41 94,531,666.41\n负债总额\n二、非持续的公允价值计\n-- -- -- --\n量\n2、持续和非持续第一层次公允价值计量项目市价的确定依据\n3、持续和非持续第二层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n4、持续和非持续第三层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n5、持续的第三层次公允价值计量项目，期初与期末账面价值间的调节信息及不可观察参数敏感性分析\n1. 对于持有的应收票据，采用票面金额确定其公允价值；\n2.因被投资企业杭州寓鑫创业投资合伙企业（有限合伙）的经营环境和经营情况、财务状况未发生重\n大变化，所以公司按投资成本作为公允价值的合理估计进行计量；\n3.因被投资企业滨海宏博环境技术服务股份有限公司的经营环境和经营情况、财务状况恶化，所以公\n司以零元作为公允价值的合理估计进行计量。6、持续的公允价值计量项目，本期内发生各层级之间转换的，转换的原因及确定转换时点的政策\n7、本期内发生的估值技术变更及变更原因\n8、不以公允价值计量的金融资产和金融负债的公允价值情况\n9、其他\n十二、关联方及关联交易\n1、本企业的母公司情况\n母公司对本企业的 母公司对本企业的\n母公司名称 注册地 业务性质 注册资本\n持股比例 表决权比例\n浙江东港投资有限\n台州 投资 11,800万元 34.22% 34.22%\n公司\n本企业的母公司情况的说明\n浙江东港投资有限公司(以下简称东港投资公司)系由东港工贸集团有限公司100%持股的公司，于1998\n年7月9日在台州市工商行政管理局椒江分局登记注册，现持有统一社会信用代码为913310027046766827的\n营业执照，注册资本11,800万元。本企业最终控制方是王云富，间接通过东港投资公司持有本公司股份55,398.2587万股，直接持有本公司股份11,880万股，\n| 期末公允价值 | \n--------------------------------------------------\n项目 | 第一层次公允价值计 | \n|  | 第二层次公允价值计量 | 第三层次公允价值计量 | 合计\n| 量 | \n| \n一、持续的公允价值计量 | -- | -- | -- | --\n（2）权益工具投资 | 20,000,000.00 | 20,000,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c1fef151"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1046,
      "page_number": 185,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "36x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271000",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "因被投资企业",
        "industry": null,
        "char_count": 1046,
        "word_count": 80,
        "sentence_count": 14,
        "chinese_char_count": 676,
        "readability_score": 0.0,
        "information_density": 0.09560229445506692,
        "coherence_score": 0.7284874608150471,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6448451374720684,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "经营",
        "财务",
        "800万元",
        "800万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "808d2ee0",
      "content": "（八）应收款项融资 | 74,531,666.41 | 74,531,666.41\n--------------------------------------------------\n持续以公允价值计量的 | \n| 94,531,666.41 | 94,531,666.41\n负债总额 | \n| \n二、非持续的公允价值计 | \n| -- | -- | -- | --\n量 | \n| \n\n> 注：合计持股比例41.56%。其他说明：\n2、本企业的子公司情况\n本企业子公司的情况详见附注在其他主体中的权益之说明。3、本企业合营和联营企业情况\n本企业重要的合营或联营企业详见附注在其他主体中的权益之说明。",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d14fcaf9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 300,
      "page_number": 186,
      "bbox": [
        97.5,
        80.0,
        497.5,
        380.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "9x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收款项融资",
          "应收",
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          186
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271352",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 300,
        "word_count": 33,
        "sentence_count": 8,
        "chinese_char_count": 118,
        "readability_score": 0.0,
        "information_density": 0.2,
        "coherence_score": 0.44625,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5953244202108324,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收款项融资",
        "应收",
        "负债"
      ]
    },
    {
      "chunk_id": "0d9d1efa",
      "content": "| 母公司对本企业的 | 母公司对本企业的\n--------------------------------------------------\n母公司名称 | 注册地 | 业务性质 | 注册资本  |\n| 持股比例 | 表决权比例\n| \n浙江东港投资有限 | \n| 台州 | 投资 | 11,800万元 | 34.22% | 34.22%\n公司 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "47afde7e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 178,
      "page_number": 186,
      "bbox": [
        97.5,
        80.0,
        497.5,
        280.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          186
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271476",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 178,
        "word_count": 33,
        "sentence_count": 2,
        "chinese_char_count": 57,
        "readability_score": 0.0,
        "information_density": 0.11235955056179776,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4093944664031621,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "800万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "9afae774",
      "content": "本期与本公司发生关联方交易，或前期与本公司发生关联方交易形成余额的其他合营或联营企业情况如下：\n合营或联营企业名称 与本企业关系\n苏州第四制药厂有限公司 联营企业\n浙江高盛钢结构有限公司 联营企业\n其他说明\n4、其他关联方情况\n其他关联方名称 其他关联方与本企业关系\n浙江荣兴活性炭有限公司 控股股东之联营企业\n江西华邦药业有限公司 控股股东之联营企业\n台州艾斐科技有限公司 控股股东之联营企业\n台州市东港包装用品有限公司 控股股东之子公司\n其他说明\n5、关联交易情况\n（1）购销商品、提供和接受劳务的关联交易\n采购商品/接受劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 获批的交易额度 是否超过交易额度 上期发生额\n浙江高盛钢结构有\n工程建造 1,275,826.79\n限公司\n浙江荣兴活性炭有\n原材料 2,423,957.10 28,000,000.00否 3,914,565.88\n限公司\n江西华邦药业有限 原料药及医药中\n23,998,498.62 50,000,000.00否 809,858.52\n公司 间体\n台州市东港包装用\n原材料 4,393.37\n品有限公司\n合营或联营企业名称 | 与本企业关系\n\n--------------------------------------------------\n苏州第四制药厂有限公司 | 联营企业\n浙江高盛钢结构有限公司 | 联营企业",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "0adffc87"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 603,
      "page_number": 187,
      "bbox": [
        93.5,
        80.0,
        501.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "32x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          187
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271576",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 603,
        "word_count": 62,
        "sentence_count": 8,
        "chinese_char_count": 383,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.702709441299251,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5083787280479963,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8b179ad9",
      "content": "其他关联方名称 | 其他关联方与本企业关系\n\n--------------------------------------------------\n浙江荣兴活性炭有限公司 | 控股股东之联营企业\n江西华邦药业有限公司 | 控股股东之联营企业\n台州艾斐科技有限公司 | 控股股东之联营企业\n台州市东港包装用品有限公司 | 控股股东之子公司",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "4421c7df"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 168,
      "page_number": 187,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          187
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271793",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 168,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 97,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4788590818363273,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6d55126a",
      "content": "出售商品/提供劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n苏州第四制药厂有限公司 原料药及医药中间体 261,061.95 504,310.34\n台州艾斐科技有限公司 电费 404,095.99 678,615.69\n江西华邦药业有限公司 设备销售 255,603.43\n江西华邦药业有限公司 原料药及医药中间体 44,247.79\n购销商品、提供和接受劳务的关联交易说明\n（2）关联受托管理/承包及委托管理/出包情况\n本公司受托管理/承包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名受托/承包资产类 托管收益/承包收 本期确认的托管\n受托/承包起始日受托/承包终止日\n称 称 型 益定价依据 收益/承包收益\n关联托管/承包情况说明\n本公司委托管理/出包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名委托/出包资产类 托管费/出包费定 本期确认的托管\n委托/出包起始日委托/出包终止日\n称 称 型 价依据 费/出包费\n关联管理/出包情况说明\n（3）关联租赁情况\n本公司作为出租方：\n单位： 元\n承租方名称 租赁资产种类 本期确认的租赁收入 上期确认的租赁收入\n本公司作为承租方：\n单位： 元\n出租方名称 租赁资产种类 本期确认的租赁费 上期确认的租赁费\n关联租赁情况说明\n（4）关联担保情况\n本公司作为担保方\n单位： 元\n被担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n本公司作为被担保方\n单位： 元\n关联方 | 关联交易内容 | 本期发生额 | 获批的交易额度 | 是否超过交易额度 | 上期发生额\n--------------------------------------------------\n浙江高盛钢结构有 | \n| 工程建造 | 1,275,826.79\n限公司 | \n| \n浙江荣兴活性炭有 | \n| 原材料 | 2,423,957.10 | 28,000,000.00 | 否 | 3,914,565.88\n限公司 | \n| \n江西华邦药业有限 | 原料药及医药中 | \n|  | 23,998,498.62 | 50,000,000.00 | 否 | 809,858.52\n公司 | 间体 | \n| \n台州市东港包装用 | \n| 原材料 | 4,393.37 | \n品有限公司 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "10633d78"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 985,
      "page_number": 187,
      "bbox": [
        73.5,
        80.0,
        521.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "48x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 48,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          187
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271858",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 985,
        "word_count": 141,
        "sentence_count": 14,
        "chinese_char_count": 554,
        "readability_score": 0.0,
        "information_density": 0.02030456852791878,
        "coherence_score": 0.46499999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5687928802588997,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "429f915d",
      "content": "关联方 | 关联交易内容 | 本期发生额 | 上期发生额\n--------------------------------------------------\n苏州第四制药厂有限公司 | 原料药及医药中间体 | 261,061.95 | 504,310.34\n台州艾斐科技有限公司 | 电费 | 404,095.99 | 678,615.69\n江西华邦药业有限公司 | 设备销售 |  | 255,603.43\n江西华邦药业有限公司 | 原料药及医药中间体 | 44,247.79 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3b58924c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 242,
      "page_number": 188,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          188
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272200",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 242,
        "word_count": 34,
        "sentence_count": 6,
        "chinese_char_count": 84,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42545185185185186,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "59aa1ded",
      "content": "委托方/出包方名 | 受托方/承包方名 | 受托/承包资产类 |  | 受托/承包终止日 | 托管收益/承包收 | 本期确认的托管\n--------------------------------------------------\n| 受托/承包起始日 | \n称 | 称 | 型 | 益定价依据 | 收益/承包收益\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "53a4ccb9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 160,
      "page_number": 188,
      "bbox": [
        47.5,
        80.0,
        547.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          188
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272371",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 160,
        "word_count": 26,
        "sentence_count": 0,
        "chinese_char_count": 63,
        "readability_score": 0.0,
        "information_density": 0.125,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44574761904761906,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "ae1caa76",
      "content": "担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n关联担保情况说明\n（5）关联方资金拆借\n单位： 元\n关联方 拆借金额 起始日 到期日 说明\n拆入\n拆出\n（6）关联方资产转让、债务重组情况\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n（7）关键管理人员报酬\n单位： 元\n项目 本期发生额 上期发生额\n关键管理人员报酬 8,152,800.00 7,761,100.00\n（8）其他关联交易\n6、关联方应收应付款项\n（1）应收项目\n单位： 元\n期末余额 期初余额\n项目名称 关联方\n账面余额 坏账准备 账面余额 坏账准备\n台州艾斐科技有限\n应收账款 63,451.70 3,172.59\n公司\n江西华邦药业有限\n应收账款 9,682.64 2,904.79\n公司\n小 计 9,682.64 2,904.79 63,451.70 3,172.59\n（2）应付项目\n单位： 元\n项目名称 关联方 期末账面余额 期初账面余额\n189\n委托方/出包方名 | 受托方/承包方名 | 委托/出包资产类 |  | 委托/出包终止日 | 托管费/出包费定 | 本期确认的托管\n--------------------------------------------------\n| 委托/出包起始日 | \n称 | 称 | 型 | 价依据 | 费/出包费\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "49c5acf6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 583,
      "page_number": 188,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "34x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          188
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272563",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 583,
        "word_count": 95,
        "sentence_count": 10,
        "chinese_char_count": 298,
        "readability_score": 0.0,
        "information_density": 0.03430531732418525,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5315604166666668,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "b2646ac1",
      "content": "关联方 | 拆借金额 | 起始日 | 到期日 | 说明\n--------------------------------------------------\n拆入 | \n拆出 |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3b8da62d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 89,
      "page_number": 189,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          189
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272765",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 89,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 19,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37298888888888887,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "5e122bc9",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n关键管理人员报酬 | 8,152,800.00 | 7,761,100.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "3a99f548"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 189,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          189
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272832",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 11,
        "sentence_count": 2,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37437777777777775,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "59b319ba",
      "content": "应付账款 浙江荣兴活性炭有限公司 171,167.79 816,333.28\n应付账款 浙江高盛钢结构有限公司 169,367.59 154,247.59\n应付账款 江西华邦药业有限公司 51,086.20\n台州市东港包装用品有限公\n应付账款 4,393.37\n司\n小 计 344,928.75 1,021,667.07\n7、关联方承诺\n8、其他\n十三、股份支付\n1、股份支付总体情况\n√ 适用 □ 不适用\n单位： 元\n公司本期授予的各项权益工具总额 0.00\n公司本期行权的各项权益工具总额 18,146,500.00\n公司本期失效的各项权益工具总额 105,000.00\n公司期末发行在外的股票期权行权价格的范围和合同剩余期限 0\n公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 0\n其他说明\n根据公司2015 年第一次临时股东大会审议通过的《浙江海翔药业股份有限公司限制性股票激励计划\n（草案）》及其摘要(以下简称激励计划)，公司首次授予激励对象限制性股票3,471.5万股，预留部分限制\n性股票380万股。根据公司2015年度股东大会决议审议通过的2015年度利润分配方案，上述限制性股票数\n量调整为7,703万股。截至2018年12月31日累计回购已获授但尚未解锁的限制性股票429.2万股，累计解锁\n限制性股票5,459.15万股。\n|  | 期末余额 |  | 期初余额 |\n--------------------------------------------------\n项目名称 | 关联方 | \n|  | 账面余额 | 坏账准备 | 账面余额 | 坏账准备\n| \n| 台州艾斐科技有限 | \n应收账款 | 63,451.70 | 3,172.59\n| 公司 | \n| \n| 江西华邦药业有限 | \n应收账款 |  | 9,682.64 | 2,904.79  |\n| 公司 | \n| \n小 计 |  | 9,682.64 | 2,904.79 | 63,451.70 | 3,172.59",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "aa863696"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 862,
      "page_number": 189,
      "bbox": [
        77.5,
        80.0,
        517.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "33x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 33,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收账款"
        ],
        "time_periods": [
          "2015",
          "2018-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          189
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272913",
        "report_type": "financial_report",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": "financial",
        "char_count": 862,
        "word_count": 105,
        "sentence_count": 25,
        "chinese_char_count": 415,
        "readability_score": 0.0,
        "information_density": 0.046403712296983764,
        "coherence_score": 0.7040159758352742,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5480807429466545,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收账款"
      ]
    },
    {
      "chunk_id": "968c3f81",
      "content": "根据公司2019年3月13日第五届董事会第二十一次会议决议，公司2018年度绩效考核已满足行权条件，\n对首次及预留授予激励对象持有的限制性股票1,814.65万股予以解锁。2、以权益结算的股份支付情况\n√ 适用 □ 不适用\n单位： 元\n授予日权益工具公允价值的确定方法 根据布莱克-斯科尔模型来计算期权的理论价值\n可行权权益工具数量的确定依据 无\n本期估计与上期估计有重大差异的原因 无\n应付账款 | 浙江荣兴活性炭有限公司 | 171,167.79 | 816,333.28\n--------------------------------------------------\n应付账款 | 浙江高盛钢结构有限公司 | 169,367.59 | 154,247.59\n应付账款 | 江西华邦药业有限公司 |  | 51,086.20\n| 台州市东港包装用品有限公  |\n应付账款 |  | 4,393.37 |\n| 司  |\n| \n小 计 |  | 344,928.75 | 1,021,667.07",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8ea6c307"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 451,
      "page_number": 190,
      "bbox": [
        81.5,
        80.0,
        513.5,
        440.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "14x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "应付账款",
          "应付"
        ],
        "time_periods": [
          "2018",
          "2019-3"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          190
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273205",
        "report_type": "financial_report",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 451,
        "word_count": 54,
        "sentence_count": 10,
        "chinese_char_count": 215,
        "readability_score": 0.0,
        "information_density": 0.0665188470066519,
        "coherence_score": 0.7571428571428571,
        "standards_profile_summary": {}
      },
      "quality_score": 0.49444932400932395,
      "relevance_score": 1.0,
      "keywords": [
        "权益"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付账款",
        "应付"
      ]
    },
    {
      "chunk_id": "511d502f",
      "content": "公司本期授予的各项权益工具总额 | 0.00\n\n--------------------------------------------------\n公司本期行权的各项权益工具总额 | 18,146,500.00\n公司本期失效的各项权益工具总额 | 105,000.00\n公司期末发行在外的股票期权行权价格的范围和合同剩余期限 | 0\n公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 | 0",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "657a4223"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 201,
      "page_number": 190,
      "bbox": [
        97.5,
        80.0,
        497.5,
        220.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "5x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "其他权益工具"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          190
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273358",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 201,
        "word_count": 16,
        "sentence_count": 3,
        "chinese_char_count": 101,
        "readability_score": 0.0,
        "information_density": 0.09950248756218907,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4740833333333333,
      "relevance_score": 1.0,
      "keywords": [
        "权益"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他权益工具"
      ]
    },
    {
      "chunk_id": "d5bf4564",
      "content": "以权益结算的股份支付计入资本公积的累计金额 174,493,817.84\n本期以权益结算的股份支付确认的费用总额 7,113,749.53\n其他说明\n3、以现金结算的股份支付情况\n□ 适用 √ 不适用\n4、股份支付的修改、终止情况\n5、其他\n十四、承诺及或有事项\n1、重要承诺事项\n资产负债表日存在的重要承诺\n(一) 重要承诺事项\n1. 已签订的尚未履行或尚未完全履行的对外投资合同及有关财务支出\n根据公司2016年9月28日第四届董事会第三十次会议决议，公司拟使用自有资金投资医健战略投资基\n金上海佳添冠投资合伙企业(有限合伙)。上海佳添冠投资合伙企业(有限合伙)目标规模20亿元，公司拟以自\n有资金不超过2亿元人民币认购该基金，截至本财务报表批准报出日，公司尚未实际出资。2. 根据公司2019年2月14日第五届董事会第二十次会议决议，台州前进公司拟与内蒙古生力资源（集\n团）有限责任公司共同投资设立内蒙古科菲化工有限公司(以下简称科菲化工公司)，科菲化工公司一期计\n划投资总额为50,000.00万元，其中台州前进公司计划投资24,500.00万元，占科菲化工公司49.00%的股权。\n授予日权益工具公允价值的确定方法 | 根据布莱克-斯科尔模型来计算期权的理论价值\n\n--------------------------------------------------\n可行权权益工具数量的确定依据 | 无\n本期估计与上期估计有重大差异的原因 | 无",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "422a6b04"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 629,
      "page_number": 190,
      "bbox": [
        47.5,
        80.0,
        547.5,
        520.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "19x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 19,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2016-9",
          "2019-2"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          190
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273435",
        "report_type": "financial_report",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "有限责任公司共同投资设立内蒙古科菲化工有限公司",
        "industry": null,
        "char_count": 629,
        "word_count": 35,
        "sentence_count": 10,
        "chinese_char_count": 436,
        "readability_score": 0.0,
        "information_density": 0.14308426073131955,
        "coherence_score": 0.6898514557338087,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5927667016990718,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "财务",
        "报表",
        "20亿元",
        "2亿元",
        "000.00万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0cacb069",
      "content": "根据公司2020年1月22日第六届董事会第二次会议，公司决定终止对科菲化工公司的投资。(二) 前期承诺履行情况\n1. 根据2015年10月30日公司2015年第三次临时股东大会审议通过的《关于公司非公开发行 A 股股票\n方案（修订稿）的议案》，公司非公开发行人民币普通股(A股)股票99,890,023股，募集资金净额为\n1,014,403,606.71元，上述募集资金全部用于投资建设以下项目：\n项目名称 项目实施主体 总投资额 募集资金计划投\n(万元) 入(万元)\n原料药及中间体CMO中心扩建项目 川南药业公司 46,034.58 40,000.00\n年产30亿片（粒）固体制剂技改项目 本公司 35,852.00 35,000.00\n医药综合研发中心 川南药业公司 15,073.00 15,000.00\n医药中试车间技改项目 本公司 9,256.00 9,000.00\n环保设施改造项目 本公司及子公司 15,502.00 14,000.00\n合 计 121,717.58 113,000.00\n截至2019年12月31日，本公司已使用募集资金直接投入上述项目44,720.30万元，根据公司2019年3月\n11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资项目并将结余募集资金用于永\n久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目的市场环境已发生较大变化，公司\n终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。2. 根据公司2018年第一次临时股东大会及第三次临时股东大会，公司拟以集中竞价交易方式回购公司\n以权益结算的股份支付计入资本公积的累计金额 | 174,493,817.84\n\n--------------------------------------------------\n本期以权益结算的股份支付确认的费用总额 | 7,113,749.53",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "1cf427ed"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 835,
      "page_number": 191,
      "bbox": [
        47.5,
        80.0,
        547.5,
        500.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "18x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [
          "资本公积"
        ],
        "time_periods": [
          "2015-10",
          "2019-12",
          "2019-3",
          "2020-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273624",
        "report_type": "financial_report",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "公司决定终止对科菲化工公司",
        "industry": "financial",
        "char_count": 835,
        "word_count": 54,
        "sentence_count": 21,
        "chinese_char_count": 460,
        "readability_score": 0.0,
        "information_density": 0.05988023952095809,
        "coherence_score": 0.6809090909090909,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5251478810879191,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资",
        "606.71元",
        "720.30万元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资本公积"
      ]
    },
    {
      "chunk_id": "da3970e9",
      "content": "股份，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，详见本财务报表附注库存股之\n说明。\n2、或有事项\n（1）资产负债表日存在的重要或有事项\n截至2019年12月31日，本公司不存在需要披露的重大或有事项。\n（2）公司没有需要披露的重要或有事项，也应予以说明\n公司不存在需要披露的重要或有事项。\n3、其他\n十五、资产负债表日后事项\n1、重要的非调整事项\n单位： 元\n对财务状况和经营成果的影\n项目 内容 无法估计影响数的原因\n响数\n2、利润分配情况\n单位： 元\n3、销售退回\n4、其他资产负债表日后事项说明\n拟分配的利润或股利 根据公司2020年1月22日第六届董事会第二次会议审议\n通过的2019年度利润分配预案，拟以2019年度总股本扣\n除存放于股票回购专用证券账户后的股份数量为基数，\n每10股派发现金股利3元(含税)。上述利润分配预案尚\n待公司股东大会审议批准。\n192\n项目名称 | 项目实施主体 | 总投资额\n(万元) | 募集资金计划投\n入(万元)\n--------------------------------------------------\n原料药及中间体CMO中心扩建项目 | 川南药业公司 | 46,034.58 | 40,000.00\n年产30亿片（粒）固体制剂技改项目 | 本公司 | 35,852.00 | 35,000.00\n医药综合研发中心 | 川南药业公司 | 15,073.00 | 15,000.00\n医药中试车间技改项目 | 本公司 | 9,256.00 | 9,000.00\n环保设施改造项目 | 本公司及子公司 | 15,502.00 | 14,000.00\n合 计 |  | 121,717.58 | 113,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "47b1e5ab"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 746,
      "page_number": 191,
      "bbox": [
        85.5,
        80.0,
        509.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "32x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019",
          "2019-12",
          "2020-1"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273879",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 746,
        "word_count": 85,
        "sentence_count": 17,
        "chinese_char_count": 405,
        "readability_score": 0.0,
        "information_density": 0.10723860589812333,
        "coherence_score": 0.6254494559217789,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6389044992283214,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表",
        "3元"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "805ad996",
      "content": "|  | 受影响的各个比较期间报表 |\n--------------------------------------------------\n会计差错更正的内容 | 处理程序 |  | 累积影响数\n|  | 项目名称 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "722958c9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 112,
      "page_number": 193,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          193
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274106",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.08928571428571427,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4575956989247311,
      "relevance_score": 1.0,
      "keywords": [
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "dea8fa86",
      "content": "期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n合并范围内关联往来组合 1,358,605.41\n账龄组合 129,361,454.03 7,187,815.25 5.56%\n合计 130,720,059.44 7,187,815.25 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n√ 适用 □ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 129,484,273.40\n1至2年 508,161.68\n2至3年 492,705.04\n3年以上 234,919.32\n3至4年 234,919.32\n合计 130,720,059.44\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n8,184,787.74 -996,972.49 7,187,815.25\n备\n合计 8,184,787.74 -996,972.49 7,187,815.25\n| 期末余额 | 期初余额 | \n--------------------------------------------------\n| 账面余额 |  | 坏账准备 | 账面余额 |  | 坏账准备  |\n类别 | \n| 计提比\n例 | 账面价值 | 账面价值\n| 金额 | 比例 | 金额 | 金额 | 比例 | 金额 | 计提比例 |\n| \n| \n其中： | \n按组合计提坏账准 | 130,720, |  | 7,187,81 | 5.50% | 123,532,2 | 157,389,6 |  | 8,184,787 |  | 149,204,89\n|  | 100.00% | 100.00% |  | 5.20% |\n备的应收账款 | 059.44 |  | 5.25 |  | 44.19 | 87.72 |  | .74 |  | 9.98\n| \n其中： | \n| 130,720, |  | 7,187,81 | 5.50% | 123,532,2\n44.19 | 157,389,6 |  | 8,184,787 |  | 149,204,89\n合计 |  | 100.00% | 100.00% |  | 5.20% |\n| 059.44 |  | 5.25 | 87.72 |  | .74 |  | 9.98\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "15559565"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1152,
      "page_number": 194,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "54x8",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 54,
        "column_count": 8,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274166",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 1152,
        "word_count": 210,
        "sentence_count": 38,
        "chinese_char_count": 341,
        "readability_score": 0.0,
        "information_density": 0.017361111111111112,
        "coherence_score": 0.4836111111111111,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5994191264662234,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收账款"
      ]
    },
    {
      "chunk_id": "ae492eba",
      "content": "| 期末余额 | \n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例 | 计提理由\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "10b0639c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 96,
      "page_number": 195,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274504",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3764129032258064,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "09edd9d1",
      "content": "| 期末余额  |\n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例\n| \n合并范围内关联往来组合 | 1,358,605.41  |\n账龄组合 | 129,361,454.03 | 7,187,815.25 | 5.56%\n合计 | 130,720,059.44 | 7,187,815.25 | --",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ec53bb61"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 205,
      "page_number": 195,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "6x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274562",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 205,
        "word_count": 31,
        "sentence_count": 6,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4267634218289085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "268b6779",
      "content": "| 期末余额  |\n--------------------------------------------------\n名称 | \n| 账面余额 | 坏账准备 | 计提比例\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "329870d4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 89,
      "page_number": 195,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274643",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 89,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37160000000000004,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "53ef65f6",
      "content": "账龄 | 账面余额\n\n--------------------------------------------------\n1年以内（含1年） | 129,484,273.40\n1至2年 | 508,161.68\n2至3年 | 492,705.04\n3年以上 | 234,919.32\n3至4年 | 234,919.32\n合计 | 130,720,059.44",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "c6499077"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 180,
      "page_number": 195,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274697",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 180,
        "word_count": 22,
        "sentence_count": 6,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45423575418994405,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6e6b4dc8",
      "content": "其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数\n单位名称 应收账款期末余额 坏账准备期末余额\n的比例\nACS DOBFAR S.P.A 30,318,565.17 23.19% 1,515,928.26\nFIS-FABBRICA ITALIANA\n23,576,101.39 18.04% 1,178,805.07\nSINTETICI S.P.A\nPFIZER ASIA\n19,767,647.40 15.12% 988,382.37\nMANUFACTURING PTE LTD\nBIDACHEM S.P.A 11,875,658.58 9.08% 593,782.93\nCENTRAL DE PRODUCTOS\n6,666,631.13 5.10% 333,331.56\nQUIMICOS S.A.DE C.V.\n合计 92,204,603.67 70.53%\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n2、其他应收款\n单位： 元\n项目 期末余额 期初余额\n应收股利 722,088,153.34\n|  | 本期变动金额 | \n--------------------------------------------------\n类别 | 期初余额 | 期末余额\n|  | 计提 | 收回或转回 | 核销 |\n| \n按组合计提坏账准 | \n| 8,184,787.74 | -996,972.49 | 7,187,815.25\n备 | \n| \n合计 | 8,184,787.74 | -996,972.49 | 7,187,815.25",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "bd617db9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 869,
      "page_number": 195,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "43x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 43,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274846",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 869,
        "word_count": 116,
        "sentence_count": 34,
        "chinese_char_count": 278,
        "readability_score": 0.0,
        "information_density": 0.03452243958573072,
        "coherence_score": 0.31999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4977640117994101,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "e59d59cf",
      "content": "| 款项是否由关联交\n--------------------------------------------------\n单位名称 | 应收账款性质 | 核销金额 | 核销原因 | 履行的核销程序 |\n| 易产生\n| \n\n> 注：其他应收款 467,513,480.14 320,967,765.38\n合计 467,513,480.14 1,043,055,918.72\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n台州前进公司 722,088,153.34\n合计 722,088,153.34\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n197",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e01609eb"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 472,
      "page_number": 196,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "30x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收账款性质",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          196
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275132",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 472,
        "word_count": 70,
        "sentence_count": 6,
        "chinese_char_count": 220,
        "readability_score": 0.0,
        "information_density": 0.08474576271186442,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4582947368421053,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收账款性质",
        "应收账款"
      ]
    },
    {
      "chunk_id": "f5ea1275",
      "content": "|  | 占应收账款期末余额合计数 |\n--------------------------------------------------\n单位名称 | 应收账款期末余额 |  | 坏账准备期末余额\n|  | 的比例 |\n| \nACS DOBFAR S.P.A | 30,318,565.17 | 23.19% | 1,515,928.26\nFIS-FABBRICA ITALIANA | \n| 23,576,101.39 | 18.04% | 1,178,805.07\nSINTETICI S.P.A | \n| \nPFIZER ASIA | \n| 19,767,647.40 | 15.12% | 988,382.37\nMANUFACTURING PTE LTD | \n| \nBIDACHEM S.P.A | 11,875,658.58 | 9.08% | 593,782.93\nCENTRAL DE PRODUCTOS | \n| 6,666,631.13 | 5.10% | 333,331.56\nQUIMICOS S.A.DE C.V. | \n| \n合计 | 92,204,603.67 | 70.53% |",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "bac723a0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 508,
      "page_number": 196,
      "bbox": [
        73.5,
        80.0,
        521.5,
        500.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "15x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "应收账款期末余额",
          "应收账款期末余额合计",
          "应收",
          "应收账款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          196
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275320",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 508,
        "word_count": 81,
        "sentence_count": 27,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.07874015748031496,
        "coherence_score": 0.3244285714285714,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43456896551724133,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收账款期末余额",
        "应收账款期末余额合计",
        "应收",
        "应收账款"
      ]
    },
    {
      "chunk_id": "48290539",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应收股利 |  | 722,088,153.34",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7f19576b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 92,
      "page_number": 196,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收股利"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          196
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275484",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 92,
        "word_count": 10,
        "sentence_count": 1,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.21739130434782608,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3662260869565217,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收股利"
      ]
    },
    {
      "chunk_id": "9a37b051",
      "content": "其他应收款 | 467,513,480.14 | 320,967,765.38\n--------------------------------------------------\n合计 | 467,513,480.14 | 1,043,055,918.72",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b3ae4b2a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 129,
      "page_number": 197,
      "bbox": [
        97.5,
        80.0,
        497.5,
        160.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "2x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "其他应收款",
          "应收款"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275530",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 129,
        "word_count": 11,
        "sentence_count": 4,
        "chinese_char_count": 7,
        "readability_score": 0.0,
        "information_density": 0.23255813953488375,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.35893953488372093,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "其他应收款",
        "应收款"
      ]
    },
    {
      "chunk_id": "518126ec",
      "content": "| 是否发生减值及其判断\n--------------------------------------------------\n借款单位 | 期末余额 | 逾期时间 | 逾期原因 |\n| 依据\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5d4c8584"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 98,
      "page_number": 197,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275588",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 98,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3833076923076923,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "d24d85ca",
      "content": "项目(或被投资单位) | 期末余额 | 期初余额\n--------------------------------------------------\n台州前进公司 |  | 722,088,153.34\n合计 |  | 722,088,153.34",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "612d45bf"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 125,
      "page_number": 197,
      "bbox": [
        97.5,
        80.0,
        497.5,
        180.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275637",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 125,
        "word_count": 14,
        "sentence_count": 2,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.08,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3788,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "479ea8d1",
      "content": "（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n往来款 459,656,754.37 320,145,265.41\n押金保证金 5,000.00 5,000.00\n应收暂付款 6,339,111.65 5,841,009.97\n应收出口退税 6,584,960.26\n其 他 63,177.77 76,177.77\n合计 472,649,004.05 326,067,453.15\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 5,099,687.77 5,099,687.77\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 35,836.14 35,836.14\n2019年12月31日余额 5,135,523.91 5,135,523.91\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 456,448,642.60\n1至2年 4,956,117.14\n2至3年 2,265,499.80\n3年以上 8,978,744.51\n3至4年 3,978,744.51\n5年以上 5,000,000.00\n合计 472,649,004.05\n| 是否发生减值及其判断\n--------------------------------------------------\n项目(或被投资单位) | 期末余额 | 账龄 | 未收回的原因 |\n| 依据\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f215b76f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 737,
      "page_number": 197,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "36x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275714",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 737,
        "word_count": 92,
        "sentence_count": 24,
        "chinese_char_count": 249,
        "readability_score": 0.0,
        "information_density": 0.013568521031207597,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45391620539289845,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "bb8d97f2",
      "content": "款项性质 | 期末账面余额 | 期初账面余额\n--------------------------------------------------\n往来款 | 459,656,754.37 | 320,145,265.41\n押金保证金 | 5,000.00 | 5,000.00\n应收暂付款 | 6,339,111.65 | 5,841,009.97\n应收出口退税 | 6,584,960.26 |\n其 他 | 63,177.77 | 76,177.77\n合计 | 472,649,004.05 | 326,067,453.15",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "98d39c7a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 264,
      "page_number": 198,
      "bbox": [
        97.5,
        80.0,
        497.5,
        260.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "7x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "应收暂付款",
          "应收",
          "应收出口退税"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275974",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 264,
        "word_count": 36,
        "sentence_count": 11,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.11363636363636362,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4000754716981132,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收暂付款",
        "应收",
        "应收出口退税"
      ]
    },
    {
      "chunk_id": "3a26f655",
      "content": "| 第一阶段 | 第二阶段 | 第三阶段 |\n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n| 用损失 | (未发生信用减值) | (已发生信用减值) |\n2019年1月1日余额 | 5,099,687.77 | 5,099,687.77\n2019年1月1日余额在 | \n| —— | —— | —— | ——\n本期 | \n| \n本期计提 | 35,836.14 | 35,836.14\n2019年12月31日余额 | 5,135,523.91 | 5,135,523.91",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "8c59e07a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 315,
      "page_number": 198,
      "bbox": [
        97.5,
        80.0,
        497.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276079",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 315,
        "word_count": 52,
        "sentence_count": 6,
        "chinese_char_count": 86,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5084459016393442,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "697b2baa",
      "content": "3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n川南药业公司 往来款 261,610,250.381年以内 55.35%\n台州振港公司 往来款 176,225,865.641年以内 37.28%\nGeneVida GmbH 往来款 4,592,945.061年以内 0.97%\nGeneVida GmbH 往来款 4,934,973.061-2年 1.04%\nGeneVida GmbH 往来款 2,227,737.932-3年 0.47%\nGeneVida GmbH 往来款 3,913,444.513年以上 0.84%\nPFIZER ASIA\nMANUFACTURING 应收暂付款 5,000,000.003年以上 1.06% 5,000,000.00\nPTE LTD\n台州前进公司 往来款 4,170,214.351年以内 0.88%\n合计 -- 462,675,430.93 -- 97.89% 5,000,000.00\n账龄 | 账面余额\n\n--------------------------------------------------\n1年以内（含1年） | 456,448,642.60\n1至2年 | 4,956,117.14\n2至3年 | 2,265,499.80\n3年以上 | 8,978,744.51\n3至4年 | 3,978,744.51\n5年以上 | 5,000,000.00\n合计 | 472,649,004.05",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "ebeef41e"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 899,
      "page_number": 198,
      "bbox": [
        77.5,
        80.0,
        517.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "42x2",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 42,
        "column_count": 2,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276193",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 899,
        "word_count": 115,
        "sentence_count": 27,
        "chinese_char_count": 331,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.531636943419806,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "dde24cbd",
      "content": "| 期初余额 | 本期变动金额 | \n--------------------------------------------------\n类别 | 期末余额\n|  | 计提 | 收回或转回 | 核销 |\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "b379f939"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 104,
      "page_number": 199,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          199
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276491",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 104,
        "word_count": 18,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.379778417266187,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ed1b703b",
      "content": "| 款项是否由关联交\n--------------------------------------------------\n单位名称 | 其他应收款性质 | 核销金额 | 核销原因 | 履行的核销程序 |\n| 易产生\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "dd9a769b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 110,
      "page_number": 199,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x5",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 5,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应收款性质",
          "其他应收款",
          "其他应收款性质"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          199
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276563",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 110,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.36363636363636365,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3919549668874172,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应收款性质",
        "其他应收款",
        "其他应收款性质"
      ]
    },
    {
      "chunk_id": "74d35e57",
      "content": "6）涉及政府补助的应收款项\n单位： 元\n预计收取的时间、金额\n单位名称 政府补助项目名称 期末余额 期末账龄\n及依据\n7）因金融资产转移而终止确认的其他应收款\n8）转移其他应收款且继续涉入形成的资产、负债金额\n其他说明：\n3、长期股权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n对子公司投资 3,215,993,761.24 3,215,993,761.24 3,213,363,387.02 3,213,363,387.02\n对联营、合营企\n54,774,633.09 23,347,592.79 31,427,040.30 60,541,058.62 23,347,592.79 37,193,465.83\n业投资\n合计 3,270,768,394.33 23,347,592.79 3,247,420,801.54 3,273,904,445.64 23,347,592.79 3,250,556,852.85\n（1）对子公司投资\n单位： 元\n期初余额(账 本期增减变动 期末余额(账面 减值准备期末\n被投资单位\n面价值) 追加投资 减少投资 计提减值准备 其他 价值) 余额\n928,629,850.7\n川南药业公司 928,629,850.78\n8\n海翔销售公司 37,599,318.92 37,599,318.92\n上海海翔公司 5,000,000.00 5,000,000.00\nGeneVida\n8,974,808.00 8,974,808.00\nGmbH\n2,227,917,460. 2,230,547,834.\n台州前进公司 2,630,374.22\n28 50\n港翔科技公司 5,241,949.04 5,241,949.04\n3,213,363,387. 3,215,993,761.\n合计 2,630,374.22\n02 24\n| 占其他应收款期末 |\n--------------------------------------------------\n单位名称 | 款项的性质 | 期末余额 | 账龄 |  | 坏账准备期末余额\n| 余额合计数的比例 |\n| \n川南药业公司 | 往来款 | 261,610,250.38 | 1年以内 | 55.35% |\n台州振港公司 | 往来款 | 176,225,865.64 | 1年以内 | 37.28% |\nGeneVida GmbH | 往来款 | 4,592,945.06 | 1年以内 | 0.97% |\nGeneVida GmbH | 往来款 | 4,934,973.06 | 1-2年 | 1.04% |\nGeneVida GmbH | 往来款 | 2,227,737.93 | 2-3年 | 0.47% |\nGeneVida GmbH | 往来款 | 3,913,444.51 | 3年以上 | 0.84% |\nPFIZER ASIA | \nMANUFACTURING | 应收暂付款 | 5,000,000.00 | 3年以上 | 1.06% | 5,000,000.00\nPTE LTD | \n台州前进公司 | 往来款 | 4,170,214.35 | 1年以内 | 0.88% |\n合计 | -- | 462,675,430.93 | -- | 97.89% | 5,000,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "493be468"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1423,
      "page_number": 199,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "52x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 52,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "应收暂付款",
          "应收",
          "应收款期末",
          "其他应收款",
          "其他应收款期末"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          199
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276624",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔科技公司",
        "industry": "financial",
        "char_count": 1423,
        "word_count": 208,
        "sentence_count": 52,
        "chinese_char_count": 346,
        "readability_score": 0.0,
        "information_density": 0.06324666198172874,
        "coherence_score": 0.3233333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5384664242040902,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收暂付款",
        "应收",
        "应收款期末",
        "其他应收款",
        "其他应收款期末"
      ]
    },
    {
      "chunk_id": "55012e2b",
      "content": "| 预计收取的时间、金额\n--------------------------------------------------\n单位名称 | 政府补助项目名称 | 期末余额 | 期末账龄 |\n| 及依据\n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "62af8cf4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 103,
      "page_number": 200,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "3x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          200
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276994",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 103,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4625555555555555,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0172c017",
      "content": "| 期末余额 | 期初余额  |\n--------------------------------------------------\n项目 | \n| 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n| \n对子公司投资 | 3,215,993,761.24 |  | 3,215,993,761.24 | 3,213,363,387.02 |  | 3,213,363,387.02\n对联营、合营企 | 54,774,633.09 | \n|  | 23,347,592.79 | 31,427,040.30 | 60,541,058.62 | 23,347,592.79 | 37,193,465.83\n业投资 | \n| \n合计 | 3,270,768,394.33 | 23,347,592.79 | 3,247,420,801.54 | 3,273,904,445.64 | 23,347,592.79 | 3,250,556,852.85",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "f5de2a97"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 438,
      "page_number": 200,
      "bbox": [
        47.5,
        80.0,
        547.5,
        320.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "8x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          200
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277060",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 438,
        "word_count": 63,
        "sentence_count": 16,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.022831050228310504,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5145992366412214,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "4b7d7b99",
      "content": "（2）对联营、合营企业投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n权益法下 宣告发放 减值准备\n投资单位 (账面价 其他综合 其他权益 计提减值 (账面价\n追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n23,345,37 -4,811,81 18,533,55 23,347,59\n制药厂有\n3.14 4.84 8.30 2.79\n限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n37,193,46 -5,766,42 31,427,04 23,347,59\n小计\n5.83 5.53 0.30 2.79\n37,193,46 -5,766,42 31,427,04 23,347,59\n合计\n5.83 5.53 0.30 2.79\n（3）其他说明\n4、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 797,912,055.33 574,154,902.09 805,112,431.82 606,077,442.30\n其他业务 14,347,583.53 12,941,502.94 19,986,172.05 13,769,464.63\n合计 812,259,638.86 587,096,405.03 825,098,603.87 619,846,906.93\n是否已执行新收入准则\n□ 是 √ 否\n其他说明：\n5、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n成本法核算的长期股权投资收益 1,000,000,000.00\n被投资单位 | 期初余额(账 | 本期增减变动 | 期末余额(账面 | 减值准备期末\n--------------------------------------------------\n| 面价值) | 追加投资 | 减少投资 | 计提减值准备 | 其他 | 价值) | 余额\n川南药业公司 | 928,629,850.7 | \n| 928,629,850.78 |\n| 8 | \n| \n海翔销售公司 | 37,599,318.92 | 37,599,318.92 |\n上海海翔公司 | 5,000,000.00 | 5,000,000.00 |\nGeneVida\nGmbH | \n| 8,974,808.00 | 8,974,808.00 |\n| \n台州前进公司 | 2,227,917,460. | 2,230,547,834. |\n|  | 2,630,374.22 | \n| 28 | 50 |\n| \n港翔科技公司 | 5,241,949.04 | 5,241,949.04 |\n合计 | 3,213,363,387.\n02 | 3,215,993,761.\n24 |\n|  | 2,630,374.22 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "7cac0725"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1245,
      "page_number": 200,
      "bbox": [
        47.5,
        80.0,
        547.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "61x7",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 61,
        "column_count": 7,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          200
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277210",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔科技公司",
        "industry": null,
        "char_count": 1245,
        "word_count": 199,
        "sentence_count": 44,
        "chinese_char_count": 312,
        "readability_score": 0.0,
        "information_density": 0.040160642570281124,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.545433321488911,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "收入",
        "成本",
        "利润",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "a4713556",
      "content": "|  | 本期增减变动 | \n--------------------------------------------------\n| 期初余额 | 期末余额 |\n| 权益法下 | 宣告发放 | 减值准备\n投资单位 | (账面价 | 其他综合 | 其他权益 |  | 计提减值 |  | (账面价 |\n|  | 追加投资 | 减少投资 | 确认的投 | 现金股利 |  | 其他 |  | 期末余额\n| 值) | 收益调整 | 变动 |  | 准备 |  | 值) |\n| 资损益 | 或利润 | \n| \n一、合营企业 | \n二、联营企业 | \n苏州第四 | \n| 23,345,37 | -4,811,81 | 18,533,55 | 23,347,59\n制药厂有 | \n| 3.14 | 4.84 | 8.30 | 2.79\n限公司 | \n| \n浙江高盛 | \n| 13,848,09 | -954,610. | 12,893,48 |\n钢结构有 | \n| 2.69 | 69 | 2.00 |\n限公司 | \n| \n| 37,193,46 | -5,766,42 | 31,427,04 | 23,347,59\n小计 | \n| 5.83 | 5.53 | 0.30 | 2.79\n| \n| 37,193,46\n5.83 | -5,766,42 | 31,427,04\n0.30 | 23,347,59\n2.79\n合计 | \n| 5.53 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "a20b0125"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 625,
      "page_number": 201,
      "bbox": [
        49.5,
        80.0,
        545.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "28x6",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 28,
        "column_count": 6,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277607",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 625,
        "word_count": 148,
        "sentence_count": 15,
        "chinese_char_count": 122,
        "readability_score": 0.0,
        "information_density": 0.08,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5797943567670971,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "利润"
      ]
    },
    {
      "chunk_id": "274b1b07",
      "content": "权益法核算的长期股权投资收益 -5,766,425.53 -4,216,789.49\n银行理财产品投资收益 1,161,540.45 1,928,422.22\n处置金融工具取得的投资收益 -30,625.74 -1,559,950.55\n合计 -4,635,510.82 996,151,682.18\n6、其他\n十八、补充资料\n1、当期非经常性损益明细表\n√ 适用 □ 不适用\n单位： 元\n项目 金额 说明\n非流动资产处置损益 -4,150,774.97\n越权审批或无正式批准文件的税收返还、\n1,828,299.60\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70\n除上述各项之外的其他营业外收入和支出 -1,973,019.24\n减：所得税影响额 3,519,880.50\n合计 19,572,324.86 --\n对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公\n开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应\n说明原因。□ 适用 √ 不适用\n2、净资产收益率及每股收益\n每股收益\n报告期利润 加权平均净资产收益率\n基本每股收益（元/股） 稀释每股收益（元/股）\n归属于公司普通股股东的净利润 14.07% 0.48 0.48\n扣除非经常性损益后归属于公司\n13.71% 0.47 0.47\n普通股股东的净利润\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n成本法核算的长期股权投资收益 |  | 1,000,000,000.00",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "e8029528"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 795,
      "page_number": 201,
      "bbox": [
        77.5,
        80.0,
        517.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "34x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "成本",
          "长期股权投资",
          "投资收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277879",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 795,
        "word_count": 73,
        "sentence_count": 23,
        "chinese_char_count": 398,
        "readability_score": 0.0,
        "information_density": 0.12578616352201258,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5340454514354886,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "成本",
        "长期股权投资",
        "投资收益"
      ]
    },
    {
      "chunk_id": "34855826",
      "content": "权益法核算的长期股权投资收益 | -5,766,425.53 | -4,216,789.49\n--------------------------------------------------\n银行理财产品投资收益 | 1,161,540.45 | 1,928,422.22\n处置金融工具取得的投资收益 | -30,625.74 | -1,559,950.55\n合计 | -4,635,510.82 | 996,151,682.18",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "d8d4c3b6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 217,
      "page_number": 202,
      "bbox": [
        97.5,
        80.0,
        497.5,
        200.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "4x3",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 3,
        "contains_financial_data": true,
        "accounting_items": [
          "长期",
          "长期股权投资",
          "投资收益"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.278149",
        "report_type": "financial_report",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": "financial",
        "char_count": 217,
        "word_count": 21,
        "sentence_count": 8,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.23041474654377883,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42869185867895543,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "长期",
        "长期股权投资",
        "投资收益"
      ]
    },
    {
      "chunk_id": "22c96c26",
      "content": "3、境内外会计准则下会计数据差异\n（1）同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（2）同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（3）境内外会计准则下会计数据差异原因说明，对已经境外审计机构审计的数据进行差异调节的，应注\n明该境外机构的名称\n4、其他\n203 第十三节 备查文件目录\n一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表。\n二、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。\n三、报告期内在中国证监会指定报刊上公开披露过的所有公司文件正本及公告原稿；\n四、载有公司法定代表人签名的2019年年度报告文本原件。\n五、其他备查文件。\n文件存放地：公司投资发展部\n浙江海翔药业股份有限公司\n法定代表人：杨思卫\n二零二零年一月二十二日\n204\n|  | 每股收益 |\n--------------------------------------------------\n报告期利润 | 加权平均净资产收益率  |\n|  | 基本每股收益（元/股） | 稀释每股收益（元/股）\n| \n归属于公司普通股股东的净利润 | 14.07% | 0.48 | 0.48\n扣除非经常性损益后归属于公司 | \n| 13.71% | 0.47 | 0.47\n普通股股东的净利润 | \n|",
      "chunk_type": "table_group",
      "parent_id": null,
      "child_ids": [
        "5312fd0f"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 614,
      "page_number": 202,
      "bbox": [
        97.5,
        80.0,
        497.5,
        680.0
      ],
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "25x4",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 25,
        "column_count": 4,
        "contains_financial_data": true,
        "accounting_items": [
          "每股收益",
          "资产",
          "基本每股收益",
          "利润",
          "稀释每股收益",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": true
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.278240",
        "report_type": "financial_report",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": "financial",
        "char_count": 614,
        "word_count": 60,
        "sentence_count": 10,
        "chinese_char_count": 403,
        "readability_score": 0.0,
        "information_density": 0.17915309446254074,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7031881533101045,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "利润",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "每股收益",
        "资产",
        "基本每股收益",
        "利润",
        "稀释每股收益",
        "净利润"
      ]
    },
    {
      "chunk_id": "efea3d1f",
      "content": "浙江海翔药业股份有限公司\n2019 年年度报告\n2020 年 01 月\n1 第一节重要提示、目录和释义\n公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真\n实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连\n带的法律责任。\n公司负责人杨思卫、主管会计工作负责人李进及会计机构负责人(会计主管\n人员)朱勇声明：保证年度报告中财务报告的真实、准确、完整。\n所有董事均已出席了审议本报告的董事会会议。\n本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的\n实质性承诺，敬请投资者注意投资风险。\n公司已在本报告中详细描述可能存在的相关风险，敬请投资者查阅本报告\n第四节“经营情况讨论与分析”中第九项“公司未来发展展望”。\n公司经本次董事会审议通过的利润分配预案为：以 1,555,709,365 为基数，\n向全体股东每 10 股派发现金红利 3 元（含税），送红股 0 股（含税），不以公积\n金转增股本。\n2",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "d82d5830"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 422,
      "page_number": 1,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          1
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.278647",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 422,
        "word_count": 31,
        "sentence_count": 6,
        "chinese_char_count": 326,
        "readability_score": 0.0,
        "information_density": 0.33175355450236965,
        "coherence_score": 0.732,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8622047393364929,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "投资",
        "经营",
        "股本",
        "股份",
        "股东",
        "分配",
        "红利",
        "派发"
      ]
    },
    {
      "chunk_id": "f91d7b7e",
      "content": "目录\n第一节重要提示、目录和释义 ......................................................................................................... 2\n第二节公司简介和主要财务指标 ..................................................................................................... 6\n第三节公司业务概要 ....................................................................................................................... 10\n第四节经营情况讨论与分析 ........................................................................................................... 14\n第五节重要事项 ............................................................................................................................... 28\n第六节股份变动及股东情况 ........................................................................................................... 48\n第七节优先股相关情况 ................................................................................................................... 55\n第八节可转换公司债券相关情况 ................................................................................................... 56\n第九节董事、监事、高级管理人员和员工情况 ........................................................................... 57\n第十节公司治理 ............................................................................................................................... 66\n第十一节公司债券相关情况 ........................................................................................................... 73\n第十二节 财务报告 ......................................................................................................................... 74\n第十三节 备查文件目录 ............................................................................................................... 204\n3。\n\n释义\n释义项 指 释义内容\n中国证监会、证监会 指 中国证券监督管理委员会\n深交所、交易所 指 深圳证券交易所\n本公司、公司、海翔药业 指 浙江海翔药业股份有限公司\n川南公司、川南药业 指 浙江海翔川南药业有限公司，公司全资子公司\n销售公司 指 浙江海翔药业销售有限公司，公司全资子公司\n上海海翔 指 上海海翔医药科技发展有限公司，公司全资子公司\n台州前进、前进公司 指 台州市前进化工有限公司，公司全资子公司\n盐城瓯华、瓯华化工 指 盐城市瓯华化学工业有限公司，公司合并报表范围内子公司\n振港染料 指 台州市振港染料化工有限公司，公司合并报表范围内子公司\n盛嘉环保 指 浙江盛嘉环保科技有限公司，公司合并报表范围内子公司\n苏州四药 指 苏州第四制药厂有限公司，公司参股公司\n高盛钢结构 指 浙江高盛钢结构有限公司，公司参股公司\n北华环保 指 江苏北华环保科技有限公司，盐城瓯华参股公司\n东港投资 指 浙江东港投资有限公司，公司控股股东\n报告期 指 2019年1-12月的会计区间\n《公司章程》 指 浙江海翔药业股份有限公司章程\nActive Pharmaceutical Ingredients(API)，即药物活性成分，具有药理活\n原料药、API 指\n性可用于药品生产的化学物质\nGMP 指 Good Manufacturing Practice，药品生产质量管理规范\n药品监督管理部门对药品研制、生产、经营、使用单位合乎相应质量\n药品认证 指\n管理规范的情况进行检查、评价并决定是否发给相应认证证书的过程\n药品监督管理部门依照法定程序，对拟上市销售药品的安全性、有效\n性、质量可控性等进行系统评价，并作出是否同意进行药物临床研究、\n药品注册 指\n生产药品或者进口药品的审批过程，包括对申请变更药品批准证明文\n件及其附件中载明内容的审批\nFDA 指 U.S.Food and Drug Administration，美国食品和药品监督管理局\nBI 指 德国勃林格殷格翰公司\nThe European Directorate for the Quality of Medicines & HealthCare，欧\nEDQM 指\n洲药品质量管理局\nUSP 指 U.S. Pharmacopeia，美国药典\n4。\n\n辉瑞、辉瑞公司 指 Pfizer Inc.是目前全球顶尖的以研发为基础的生物制药公司\nEco-passport，由TESTEX瑞士纺织检定有限公司于1993年创立的针\nECO认证 指\n对纺织品染料、助剂化学品等产品开展的生态环保认证。天祥认证，天祥集团是世界上规模最大的消费品测试、检验和认证公\nIntertek认证 指\n司之一\nEHS 指 Environment-Health-Safety，环境、健康、安全生产体系\n一种染料类型，染色时与纤维反应，二者之间形成共价键，成为整体，\n使耐洗和耐摩擦牢度高。用于棉等纤维素纤维、蛋白质纤维、锦纶、\n活性染料 指\n粘胶等合成纤维的染色，色泽鲜艳，色谱齐全，匀染性好，湿处理牢\n度优良\n一种水溶性较低的非离子型染料，在染色过程中呈分散状态进行染\n分散染料 指 色，主要用于涤纶及其混纺织物的印染，也可用于醋酸纤维、锦纶、\n丙纶、氯纶、腈纶等合成纤维的印染\n分子式为C22H16N2Na2O11S3，一种常温型蒽醌系列活性染料，拥有\nKN-R，活性艳蓝KN-R 指 鲜艳色光、优良匀染性、高亲和力、高日晒牢度等优点，主要用于对\n棉、麻、毛、丝的染色，是国家产业政策鼓励发展的一类染料\n氨基油 指 间-(β-羟乙基砜)苯胺，用于合成乙烯基砜染料，染料的关键中间体\n溴氨酸 指 一种红色针状结晶，重要的染料中间体，用于蒽醌型染料\n深蓝色粉末，易溶于水。\n\n该染料用于棉和黏胶纤维的染色，及其织物\nP-3R 指\n的印花，各项染色坚牢度优良，是重要的蓝色染料。一种高温型活性染料，色泽鲜艳，光牢度优异，因具有极好的耐盐碱\nKE-GN 指\n性能，广泛应用于连续染色、蜡染等\n一种中温型活性染料，色泽鲜艳，具有极好的耐盐碱性能，广泛应用\nDK-ER 指\n于浸染和连续染色的冷轧堆工艺\n5。\n\n第二节公司简介和主要财务指标\n一、公司信息\n股票简称 海翔药业 股票代码 002099\n股票上市证券交易所 深圳证券交易所\n公司的中文名称 浙江海翔药业股份有限公司\n公司的中文简称 海翔药业\n公司的外文名称（如有） ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD.\n公司的外文名称缩写（如有） HISOAR\n公司的法定代表人 杨思卫\n注册地址 浙江省台州市椒江区外沙支路100号\n注册地址的邮政编码 318000\n办公地址 浙江省台州市椒江区外沙支路100号\n办公地址的邮政编码 318000\n公司网址 http://www.hisoar.com\n电子信箱 stock@hisoar.com\n二、联系人和联系方式\n董事会秘书 证券事务代表\n姓名 许华青 蒋如东\n联系地址 浙江省台州市椒江区外沙支路100号 浙江省台州市椒江区外沙支路100号\n电话 0576-89088166 0576-89088166\n传真 0576-89088128 0576-89088128\n电子信箱 stock@hisoar.com stock@hisoar.com\n三、信息披露及备置地点\n公司选定的信息披露媒体的名称 《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n登载年度报告的中国证监会指定网站的网址 http://www.cninfo.com.cn\n公司年度报告备置地点 公司投资发展部\n6。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "e1f073d8",
        "ec9e853c",
        "f400dee5",
        "cf22afe7",
        "78885b27"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3971,
      "page_number": 3,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          3,
          4,
          5,
          6
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.278875",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 3971,
        "word_count": 251,
        "sentence_count": 1444,
        "chinese_char_count": 1628,
        "readability_score": 0.0,
        "information_density": 0.03525560312263913,
        "coherence_score": 0.6572626817136318,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7132963988919667,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "合并",
        "经营",
        "财务指标",
        "股份",
        "股东",
        "报告",
        "财务报告",
        "年度报告",
        "披露"
      ]
    },
    {
      "chunk_id": "42b4520a",
      "content": "四、注册变更情况\n组织机构代码 913300001482332737\n公司上市以来主营业务的变化情况（如\n无变更\n有）\n2010年9月，原控股股东罗邦鹏先生向其子罗煜竑先生转让其所持有的3,480万\n股（占总股本的21.68%）股份，使其成为公司控股股东。2014年4月，原控股股\n历次控股股东的变更情况（如有）\n东罗煜竑先生向王云富先生转让其所持有的5,940万股（占总股本的18.31%）股\n份，使其成为公司控股股东。五、其他有关资料\n公司聘请的会计师事务所\n会计师事务所名称 天健会计师事务所（特殊普通合伙）\n会计师事务所办公地址 浙江省杭州市江干区钱江路1366 号华润大厦B座\n签字会计师姓名 沈维华 汪兢\n公司聘请的报告期内履行持续督导职责的保荐机构\n□ 适用 √ 不适用\n公司聘请的报告期内履行持续督导职责的财务顾问\n□ 适用 √ 不适用\n六、主要会计数据和财务指标\n公司是否需追溯调整或重述以前年度会计数据\n□ 是 √ 否\n2019年 2018年 本年比上年增减 2017年\n营业收入（元） 2,941,412,770.30 2,718,608,796.51 8.20% 2,308,922,170.29\n归属于上市公司股东的净利润\n770,782,185.09 605,003,820.78 27.40% 342,217,155.60\n（元）\n归属于上市公司股东的扣除非经\n751,209,860.23 604,944,470.09 24.18% 301,310,316.13\n常性损益的净利润（元）\n经营活动产生的现金流量净额\n612,399,095.31 791,449,237.66 -22.62% 118,141,514.53\n（元）\n基本每股收益（元/股） 0.48 0.38 26.32% 0.22\n稀释每股收益（元/股） 0.48 0.38 26.32% 0.21\n加权平均净资产收益率 14.07% 11.35% 2.72% 6.90%\n2019年末 2018年末 本年末比上年末增减 2017年末\n总资产（元） 6,747,198,664.47 7,035,373,344.57 -4.10% 7,466,927,438.54\n7。\n\n归属于上市公司股东的净资产\n5,724,462,095.55 5,390,549,932.23 6.19% 5,142,008,176.75\n（元）\n七、境内外会计准则下会计数据差异\n1、同时按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。2、同时按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。八、分季度主要财务指标\n单位：元\n第一季度 第二季度 第三季度 第四季度\n营业收入 831,903,896.72 900,629,910.88 643,422,185.88 565,456,776.82\n归属于上市公司股东的净利润 202,484,692.73 293,308,368.91 194,299,384.33 80,689,739.12\n归属于上市公司股东的扣除非经\n193,305,262.65 289,682,381.16 190,626,850.03 77,595,366.39\n常性损益的净利润\n经营活动产生的现金流量净额 121,163,063.50 182,750,885.24 145,547,827.28 162,937,319.29\n上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异\n□ 是 √ 否\n九、非经常性损益项目及金额\n√ 适用 □ 不适用\n单位：元\n项目 2019年金额 2018年金额 2017年金额 说明\n非流动资产处置损益（包括已计提资产减\n-4,150,774.97 -102,273.45 23,519,733.42\n值准备的冲销部分）\n越权审批或无正式批准文件的税收返还、\n1,828,299.60 1,237,210.17 760,878.00\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27 10,554,527.86 8,815,813.87\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70 3,024,312.63 11,532,098.63\n8。\n\n除同公司正常经营业务相关的有效套期保\n值业务外，持有交易性金融资产、衍生金\n融资产、交易性金融负债、衍生金融负债\n产生的公允价值变动损益，以及处置交易 -449,486.55 -5,010,265.70\n性金融资产、衍生金融资产、交易性金融\n负债、衍生金融负债和其他债权投资取得\n的投资收益\n除上述各项之外的其他营业外收入和支出 -1,973,019.24 -12,795,318.78 2,111,133.99\n减：所得税影响额 3,519,880.50 1,409,621.19 822,552.74\n合计 19,572,324.86 59,350.69 40,906,839.47 --\n对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公\n开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应\n说明原因\n□ 适用 √ 不适用\n公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义、列举的非经常性损益\n项目界定为经常性损益的项目的情形。9。\n\n第三节公司业务概要\n一、报告期内公司从事的主要业务\n（一）主营业务介绍\n报告期内，公司主营业务分为医药和染料两大板块。1、医药板块主要从事特色中间体、原料药及相关制剂的生产与销售，同时提供国际制药\nCDMO/CMO专业服务。产品涵盖抗感染、心血管类、精神疾病领域、降糖类和免疫类等多个\n领域，具体如下：\n应用领域 产品名 适用症 类别\n抗感染 美罗培南系列（4-AA、MAP、用于重症感染以及以G-菌为主的混合性感染、原料药、中间体\n美罗培南粗品、美罗培南侧多重耐药菌感染、产酶菌感染。\n\n链）\n替比培南酯 全球首个口服碳青霉烯类新广谱抗生素，主要用原料药\n于治疗儿童肺炎、中耳炎、鼻窦炎等\n亚胺培南的关键中间体用于敏感菌所致的各种感染，特别适用于多种细中间体\nKETO 菌联合感染和需氧菌及厌氧菌的混合感染。西司他汀酸中间体 西司他汀酸与亚安培南共同使用 中间体\n用于由链球菌属、葡萄球菌属及厌氧菌等敏感菌\n盐酸克林霉素胶囊、盐酸克 制剂、原料药\n株所致的下述感染：中耳炎、鼻窦炎、化脓性扁\n林霉素\n桃体炎、肺炎；皮肤软组织感染\n用于敏感细菌引起的各种感染、败血症、骨髓炎\n克林霉素磷酸酯 原料药\n等\n盐酸克林霉素棕榈酸酯 用于革兰阳性菌引起的各种感染性疾病以及厌\n原料药\n氧菌引起的各种感染性疾病\n盐酸阿莫罗芬\n用于真菌引起的指（趾）甲感染 原料药\n联苯双酯\n用于治疗病毒性肝炎和药物性肝损伤引起转氨原料药\n酶升高\n伏格列波糖\n降糖类 改善糖尿病餐后高血糖 原料药\n瑞格列奈\n用于饮食控制、降低体重与运动不能有效控制高原料药\n血糖的2型糖尿病\n阿卡波糖片 用于胰岛素依赖型或非胰岛素依赖型的糖尿病 制剂\n心血管类 达比加群酯的关键中间体新一代口服抗凝药物直接凝血酶抑制剂(DTIs)，中间体\nOA、MD 用于预防非瓣膜性房颤患者的卒中和全身性栓\n10。\n\n塞\n琥珀酸美托洛尔 用于高血压、心绞痛的治疗 原料药\n兽药 氟苯尼考 用于鸡大肠杆菌病及鸭浆膜炎及鱼的杀鲑产生原料药\n单胞菌、鳗弧菌等，用于敏感细菌所致牛、猪、\n鸡肠道感染及支原体引起的慢性呼吸道病。用于缓解马的内脏绞痛、肌肉与骨骼紊乱引起的\n氟尼辛葡甲胺 原料药\n疼痛及抗炎；牛的各种疾病感染引起的急性炎症\n的控制；另外也可用于母猪乳房炎、子宫炎及无\n乳综合征的辅助治疗\n甲砜霉素\n用于流感杆菌、大肠杆菌、沙门菌属所致的呼吸原料药\n系统、肝胆系统、泌尿系统和消化系统的感染。富马酸喹硫平\n精神类 用于治疗精神分裂症 原料药\n上述部分产品通过了中国、美国、欧盟、日本、加拿大、印度、巴西等国家的官方认证。\n\n2、染料板块主要从事环保型活性染料、染料中间体以及颜料中间体的生产和销售，产品\n以蒽醌类活性染料为主，具体如下：\n主要类别 主要产品及用途\n染料 主要生产蓝色系列产品，包括活性艳蓝KN-R（HG）、KN-R（SR）、\nKN-R（SP），P-3R, KE-GN、KN-BB、ME-BP，活性翠蓝KN-G以及\n酸性蒽醌蓝等，主要用于棉、麻、丝等天然纤维织物的染色，具有较\n高的日晒牢度和优良的匀染性，适用于连续染色、冷轧堆等印染工艺。染颜料中间体 染料中间体 主要生产氨基油、溴氨酸、间位酯等染料中间体，用于合成乙烯基砜\n型染料、蒽醌型染料。颜料中间体 主要生产DCB等颜料中间体，主要用于颜料黄12，13，14，17，35，\n55，颜料橙13，颜料红38等中高档双芳胺类偶氮颜料\n（二）行业发展格局\n1、医药行业\n近年来，国内仿制药一致性评价、“集采”、药品上市许可持有人制度等政策相继落地，\n医改已经基本完成顶层设计，进入方向性稳定期，“提质降费”是当下乃至以后很长一段时间\n的主旋律。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "de163587",
        "28de7237",
        "55b392e7",
        "3f727636",
        "afd1fa03"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3967,
      "page_number": 7,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7,
          8,
          9,
          10,
          11
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.280808",
        "report_type": "其他",
        "fiscal_year": 2010,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3967,
        "word_count": 298,
        "sentence_count": 96,
        "chinese_char_count": 2387,
        "readability_score": 0.0,
        "information_density": 0.04789513486261658,
        "coherence_score": 0.7992741855345726,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8406856566675069,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "利润",
        "现金",
        "投资",
        "营业收入",
        "净利润",
        "所得税",
        "净资产"
      ]
    },
    {
      "chunk_id": "3d922d70",
      "content": "对国内药企而言，无论是仿制药“集采”，还是创新药医保谈判，其最终结果都是\n企业以较低价格来换取竞争机会。“集采”使得仿制药竞争聚焦于成本端，而原料药是生产成\n本的核心，拥有质优价廉原料药的“中间体+原料药+制剂”一体化企业竞争优势较为明显，将\n获得更大的生存空间。在当前背景下，医药企业通过加强自身研发能力或与CRO公司合作开\n展研发业务，实现产品创新和自身转型升级；有实力的企业还可以选择与自身产品线互补和\n可以拓宽临床领域的企业进行并购重组。\n\n我国医药工业经过多年的高速发展，国内部分仿制企业已经积累雄厚的技术和资金，相\n关生产车间通过欧美等发达国家cGMP认证，已具备开拓海外市场的能力。与此同时辉瑞、诺\n华等国际医药巨头纷纷剥离仿制药业务，专注创新药领域，仿制药市场格局无疑已经迎来巨\n变，无论是承接更多CDMO/CMO项目、整合国际仿制药资产，亦或是自有制剂产品扬帆出海，\n国内仿制药企业将迎来更大的机遇。11。\n\n2、染料行业\n染料生产涉及相对复杂的工艺，尤其是染料的合成、分离和后处理工艺复杂，工序长，\n对技术水平要求高。现代染料制造企业需要采用先进环保生产工艺，随着环保意识逐渐增强，\n国际市场加大对染料致癌芳香胺和环境激素等有害化学品的限制，越来越多的染料和助剂被\n禁止使用，凡涉及到禁用、过敏、重金属含量过高的染料都被限制，新的生产工艺和方法对\n企业的产品创新能力提出更高的要求，提高了行业进入壁垒。染料企业要迎合市场发展的需\n求，满足纺织印染供应新工艺、新纤维以及节能减排的要求，弥合染料新品种创制研发能力\n与国外先进水平的差距；加快生产方式的集成化与自动化、装备的现代化的升级改造。\n\n中国是全球最大染料生产国，产能和需求都稳居世界第一位，产量约占全球的70%。从\n全球范围来看，基础染料产品在国际上主要是中国染料企业和印度染料企业之间的竞争，发\n达国家企业已逐步退出基础染料合成业务，形成了主要依靠进口中国、印度两国的染料半成\n品来加工生产高附加值染料产品，或直接采购两国OEM厂商的染料产品并贴牌销售的经营模\n式。随着国内安全环保形势的持续趋严，部分染料小产能逐步退出市场，染料行业供给收缩，\n未来市场集中度将持续提升。\n\n3、公司行业地位\n公司是特色原料药企业，在原料药及制剂的海外注册、国际合作等领域处于国内同行业\n领先地位。公司盐酸克林霉素原料药早在2004年就通过美国的FDA认证，克林霉素系列产量\n稳居全球龙头地位。公司是国内较早掌握培南类关键中间体4-AA核心技术，并成为国内仅有\n的几家能够供应培南类系列原料药的企业之一。\n二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。\n\n与全球知名制药公司长期合作是公司的发展\n理念，公司是国内最早开展国际CDMO/CMO业务的企业之一，是德国勃林格殷格翰公司的在\n中国重要的战略合作伙伴，双方合作已超十周年，辉瑞、巴斯夫、赛诺菲、诺华、杨森、住\n友等国际医药企业亦是公司重要合作伙伴。公司子公司台州前进作为活性艳蓝染料领域的龙头，主持编制了“反应染料色光和强度的\n测定”等国家标准及活性艳蓝KN-R、氨基油等行业标准，起草发布了活性艳蓝KN-R“浙江制\n造”标准，并通过了浙江制造审核。台州前进是蓝标体系合作伙伴，其生产的KN-R、P-3R、\nKE-GN、DK-ER等产品亦通过了全球有机纺织化学品标准认证（GOTS 5.0）、ECO认证和\nIntertek认证，KN-R产品成功入选国家第三批制造业单项冠军，染料产品出口欧美亚等三十多\n个国家和地区。\n\n二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。\n\n2、主要境外资产情况\n□ 适用 √ 不适用\n三、核心竞争力分析\n（一）“中间体+原料药+制剂”一体化生产平台\n公司是国内最早开展特色中间体及原料药出口业务的企业之一，一直秉承质量即是企业\n生命的理念，不断完善质量体系建设和EHS体系建设。公司原料药生产场地多次通过美国\nFDA、欧盟EDQM、日本PMDA、澳大利亚TGA、中国等官方的cGMP检查，2019年10月川南\n药业连续第4次通过美国FDA的现场检查。公司在巩固特色原药板块的基础上向下游制剂延\n伸，建有通过欧盟EDQM和中国官方认证的固体制剂生产线，制剂产品已在英国、法国、德\n国等地实现销售，是国内少有具备制剂出口欧盟资质的企业。\n\n高品质的“中间体+原料药+制剂”\n一体化生产平台让公司具备参与全球医药产业链分工和竞争的能力。（二）全产业链经营模式\n染料原材料在染料生产成本中占比超过七成，而染料中间体占据了原材料绝大部分。公\n司染料板块多年来一直贯彻全产业链的经营理念，向上下游延伸产业链，完善产业链，已经\n形成从基础化学原料、中间体、滤饼、商品化染料的完善产业链。\n\n全产业链经营可以抵御中\n间体市场波动风险，增强抗风险的能力，提高盈利水平和市场份额。今后公司染料板块将以\n关键中间体为核心，拓展系列化、集群化的产品线。（三）精细化管理和安全环保优势\n公司在生产车间设计中融入“管道化、密闭化、自动化、信息化、连续化、可视化”理念，\n实现生产流程全程自动化控制，车间作业人员减少一半以上。\n\n生产现场积极推行精细化管理，\n以先进合成装备、丰富的合成经验,快速实现产业化，提升公司竞争能力。公司坚持走清洁化、\n绿色化的可持续发展道路，循环利用生产过程中产生废酸、有机溶剂、废盐等，一方面减少\n高COD废水排放，另一方面变废为宝节约资源，降低生产成本，实现源头减排、过程控制、\n末端治理、综合利用。近年来，公司坚持环保先行的理念，不断加大环保设施投入，对原有\n污水处理系统进行升级改造，增添多套废气处理设施RTO，各厂区新建固体废物焚烧炉，提\n升三废处理能力，切实履行公司的社会责任。\n\n（四）技术研发优势\n公司企业技术中心是“国家级企业技术中心”，拥有国家级博士后工作站、浙江省级院士\n专家工作站，建有海翔药业和台州前进两个省级企业研究院，已承担完成国家级项目13项，\n省级项目35项，拥有国内发明专利44项、PCT专利2项、国家标准7项、行业标准8项、浙江省\n级科技奖项11项。公司坚持环境友好理念，注重研究生产过程的节能降耗，减少排放和污染，\n在手性化学、低温反应、高效催化氢化反应、膜分离、酶催化、化学连续管道化反应、“绿色”\n氧化技术、“绿色”氯化技术、不对称氢化及其装备技术、不对称环丙烷化技术、副产物综合\n利用技术、三废回收利用技术等绿色合成技术具有优势。13。\n\n第四节经营情况讨论与分析\n一、概述\n2019年国内医疗体制改革进入深水区，随着新版《药品管理法》、药品上市许可持有人\n制度（MAH）、新版医保目录、一致性评价、集采扩围、医保谈判等政策细则持续推进，医\n药行业传统格局正在被打破，国内制药企业竞争加剧，行业集中度提升；部分国际医药巨头\n剥离仿制药业务，专注创新药领域，加大研发投入和创新，使得CRO/CDMO市场快速扩容，\n迎来行业发展黄金期；面对复杂多变的外部环境，公司坚持以研发创新、技术升级为驱动，\n以“关键中间体-原料药-制剂一体化发展”为策略，开发特色原料药工艺，以质优价廉的仿制药\n满足国内日益增长的基础医疗健康需求；同时深化国际合作，在国际制药巨头转移生产的机\n遇中建立更紧密更长久的CDMO/CMO合作关系。报告期内，医药板块培南系列、克林系列持\n续增长，CDMO/CMO合作产品增加，实现销售收入16.23亿元，同比增长10.52%，实现净利润2.95\n亿元，同比增长47.67%；染料板块受中美贸易不确定性影响，下游纺织印染行业需求低迷，\n在下半年染料景气度回落的市场环境下，染料板块仍然实现销售收入13.18亿元，同比增长\n5.46%，实现净利润4.76亿元，同比增长17.43%。2019年度上市公司主营业务继续增长创新高，\n实现营业收入29.41亿元，同比增长8.20%，实现归属母公司净利润7.71亿元，同比增长27.40%。\n\n（一）医药板块：夯实基础，扩大业务规模\n夯实药品质量基础。面对国内外日益提高的药品监管要求，公司质量体系贯彻落实“勤查\n严管、追溯有序、有效完善、持之以恒”工作方针，深入推进GMP常态化管理。报告期内，外\n沙厂区和川南药业通过6次官方检查，33次客户检查，川南药业连续第4次通过美国FDA的现\n场检查，外沙厂区顺利通过韩国MFDS现场检查。\n\n完成替比培南酯日本注册，盐酸阿莫罗芬\n印度、韩国注册，联苯双酯韩国注册，柳氮磺胺吡啶首次取得欧盟CEP证书，助力公司国际\n市场拓展。持续深化国际合作，扩大业务规模。报告期内，公司新拓展日本、印度合作客户，培南\n系列收入增长。\n\n同时完成培南产能扩产，为未来持续增长奠定基础；克林霉素系列拓展新的\n国际客户，国际高端市场收入快速增长。加深国际合作拓展，把握市场扩容机遇，与辉瑞、\nBI等公司多个合作项目技术对接有序推进，新增替比培南酯原料药等5个CDMO/CMO合作项\n目，新项目涉及抗感染、心血管类、降糖类等领域；制剂完成欧盟少量订单的生产供货，盐\n酸克林霉素胶囊的一致性评价申报材料已获CDE审评中心受理,另有3个自报或与国内企业联\n合申报品种，计划2020年提交一致性评价申报材料。（二）染料板块：新项目建成，产品序列扩展\n报告期内，公司通过加强库存管理、合理安排各厂区的生产任务，发挥全产业链优势，\n保证产品稳定供应。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "ec335cb2",
        "92f86a3f",
        "5c7d43af",
        "8add6151"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 4005,
      "page_number": 11,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.6999999999999998,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11,
          12,
          13,
          14
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.283091",
        "report_type": "其他",
        "fiscal_year": 2004,
        "fiscal_quarter": null,
        "company_code": "友等国际医药企业",
        "industry": null,
        "char_count": 4005,
        "word_count": 134,
        "sentence_count": 62,
        "chinese_char_count": 3227,
        "readability_score": 0.0,
        "information_density": 0.04494382022471911,
        "coherence_score": 0.6774759682155413,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9222971285892634,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "成本",
        "利润",
        "经营",
        "16.23亿元",
        "13.18亿元",
        "4.76亿元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "成本",
        "利润",
        "固定资产",
        "无形资产",
        "营业收入",
        "净利润",
        "母公司",
        "营业"
      ]
    },
    {
      "chunk_id": "ac0a59dc",
      "content": "根据市场变化情况调整销售策略，积极开发新客户、加强新产品推广，\nP-3R量价齐升，市场占有率进一步提升。1.55万吨活性染料项目及配套项目已按进度完成建\n设。该项目从源头设计控制为起点，以装备选型先进为支撑，融入生产控制自动化、工艺流\n程密封化、物料输送管道化、生产过程连续化等理念，新增多个活性染料及酸性染料品种，\n丰富产品序列；新增配套中间体产能，进一步巩固核心中间体优势，为后续以关键中间体为\n核心拓展活性、分散、酸性蒽醌系列化产品线的战略规划提供支持。\n\n（三）研发创新，稳步推进技术进步\n公司依托现有国家级企业技术中心、国家级博士后工作站、省级院士工作站、海翔药业\n和台州前进两个省级企业研究院等科研平台，联合国内高等院校合作，积极探索技术创新，\n14。\n\n统筹推进研发工作。报告期内，公司新启动原料药及中间体研发项目11项，制剂研发项目5\n项，提交申请发明专利3项；对全球仿制药、专利药的生命周期和市场需求进行跟踪分析，开\n展70余个产品调研，为今后公司研发项目选择提供信息支持。除新产品研发外，公司还对现\n有产品的技术工艺方面进行了60多项小试、中试开发，积极探索技术创新，不断优化生产工\n艺，力求实现绿色、安全、低耗的工艺路线，部分产品降低了原料和能耗成本，产品毛利率\n提升。\n\n新建微通道反应实验室，探索微通道反应在高温、高压以及危险化学反应中的应用，\n降低风险提高反应效率，全年开展了10个项目研究实验，部分项目已经完成技术开发，进入\n工业化阶段。（四）深化安全综合治理，筑牢环保风险底线\n公司深刻吸取江苏响水“3ꞏ21”重大安全事故的教训，把安全生产管理重心落到基层一线。加大安全环保投入，重点抓好工艺改造、装备提升、生产管理等关键环节；组织演练应急救\n援预案82起，开展警示教育培训、各类安全环保知识竞赛和消防技能比赛，不断提升各级安\n全生产管理水平和全员安全生产意识。\n\n加强三废处理设施日常管理和维护，确保设施稳定、\n正常运行；深化实施源头治理、综合治理、精准治理，落实车间工艺废水的分质分类和预处\n理工作，从源头上落实减量化措施；持续改造升级各厂区“三废”处理设施，提升末端处理能\n力；川南新建的危险废物焚烧系统投入运行，该项目于2019年12月取得危险废物经营许可证，\n具备了运营危险固废处理专业服务的资质。热平衡实验室开展工艺反应风险评估66项，为“新、\n改、扩”项目的安全条件审查提供数据和技术支撑。二、主营业务分析\n1、概述\n参见“经营情况讨论与分析”中的“一、概述”相关内容。\n\n2、收入与成本\n（1）营业收入构成\n单位：元\n2019年 2018年\n同比增减\n金额 占营业收入比重 金额 占营业收入比重\n营业收入合计 2,941,412,770.30 100% 2,718,608,796.51 100% 8.20%\n分行业\n医药 1,608,858,743.47 54.70% 1,441,591,423.51 53.03% 11.60%\n染料 1,316,830,162.67 44.77% 1,249,940,574.56 45.98% 5.35%\n其他 15,723,864.16 0.53% 27,076,798.44 1.00% -41.93%\n分产品\n原料药 1,020,477,644.34 34.69% 1,033,340,734.78 38.01% -1.24%\n医药中间体 583,792,425.63 19.85% 405,506,789.40 14.92% 43.97%\n制剂 4,588,673.50 0.16% 2,743,899.33 0.10% 67.23%\n15。\n\n染料 973,070,914.24 33.08% 844,776,715.53 31.07% 15.19%\n染料中间体 343,759,248.43 11.69% 405,163,859.03 14.90% -15.16%\n其他 15,723,864.16 0.53% 27,076,798.44 1.00% -41.93%\n分地区\n国内 1,512,860,024.18 51.43% 1,390,967,219.07 51.16% 8.76%\n国外 1,428,552,746.12 48.57% 1,327,641,577.44 48.84% 7.60%\n（2）占公司营业收入或营业利润10%以上的行业、产品或地区情况\n√ 适用 □ 不适用\n单位：元\n营业收入比上年 营业成本比上年 毛利率比上年同\n营业收入 营业成本 毛利率\n同期增减 同期增减 期增减\n分行业\n医药 1,608,858,743.47 983,149,430.95 38.89% 11.60% 1.30% 6.23%\n染料 1,316,830,162.67 465,697,259.49 64.63% 5.40% -10.70% 6.34%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分产品\n原料药 1,020,477,644.34 652,198,278.33 36.09% -1.20% -6.10% 3.30%\n医药中间体 583,792,425.63 328,224,382.60 43.78% 44.00% 20.30% 11.06%\n制剂 4,588,673.50 2,726,770.03 40.58% 67.20% -20.50% 65.65%\n染料 973,070,914.24 312,738,811.13 67.86% 15.20% -1.80% 5.56%\n染料中间体 343,759,248.43 152,958,448.36 55.50% -15.20% -24.60% 5.56%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分地区\n国内 1,512,860,024.18 745,641,007.79 50.71% 8.80% -8.00% 8.96%\n国外 1,428,552,746.12 717,518,353.25 49.77% 7.60% 2.20% 2.63%\n公司主营业务数据统计口径在报告期发生调整的情况下，公司最近1年按报告期末口径调整后的主营业务数据\n□ 适用 √ 不适用\n（3）公司实物销售收入是否大于劳务收入\n√ 是 □ 否\n行业分类 项目 单位 2019年 2018年 同比增减\n医药行业 销售量 千克 1,495,834.8 1,352,154.98 10.63%\n16。\n\n生产量 千克 1,578,601.92 1,380,545.9 14.35%\n库存量 千克 415,819.13 333,052.01 24.85%\n销售量 吨 12,857.65 13,393.7 -4.00%\n染料行业 生产量 吨 12,911.47 13,832.98 -6.66%\n库存量 吨 1,868.83 1,815.01 2.97%\n相关数据同比发生变动30%以上的原因说明\n□ 适用 √ 不适用\n（4）公司已签订的重大销售合同截至本报告期的履行情况\n□ 适用 √ 不适用\n（5）营业成本构成\n行业和产品分类\n单位：元\n2019年 2018年\n行业分类 项目 同比增减\n金额 占营业成本比重 金额 占营业成本比重\n医药行业 原料成本 788,091,701.93 80.16% 778,035,997.89 80.14% 0.02%\n医药行业 人工成本 53,109,659.74 5.40% 53,601,426.45 5.52% -0.12%\n医药行业 能源成本 47,606,219.00 4.84% 45,369,217.29 4.67% 0.17%\n医药行业 制造费用 94,341,850.29 9.60% 93,792,389.85 9.66% -0.07%\n染料行业 原料成本 337,976,777.23 72.57% 383,594,259.37 73.59% -1.01%\n染料行业 人工成本 33,802,565.03 7.26% 28,163,412.97 5.40% 1.86%\n染料行业 能源成本 34,241,371.69 7.35% 37,944,159.74 7.28% 0.07%\n染料行业 制造费用 59,676,545.54 12.81% 71,581,678.92 13.73% -0.92%\n其他业务 14,312,670.59 100.00% 19,862,133.71 100.00% 0.00%\n单位：元\n2019年 2018年\n产品分类 项目 同比增减\n金额 占营业成本比重 金额 占营业成本比重\n原料药 652,198,278.33 44.57% 694,525,290.09 45.94%\n医药中间体 328,224,382.60 22.43% 272,841,947.14 18.05%\n制剂 2,726,770.03 0.19% 3,431,794.24 0.23%\n染料 312,738,811.13 21.37% 318,486,635.33 21.06%\n染料中间体 152,958,448.36 10.45% 202,796,875.67 13.41%\n其他 14,312,670.59 0.98% 19,862,133.71 1.31%\n说明\n17。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "a7327a15",
        "bebcada5",
        "03f6dc50",
        "0dae2aba",
        "cf5e60c7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3925,
      "page_number": 14,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          14,
          15,
          16,
          17
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.285140",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3925,
        "word_count": 386,
        "sentence_count": 228,
        "chinese_char_count": 1422,
        "readability_score": 0.0,
        "information_density": 0.035668789808917196,
        "coherence_score": 0.3226001508548441,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7449171974522293,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "费用",
        "利润",
        "营业收入",
        "营业成本",
        "营业利润",
        "毛利率",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "707f6596",
      "content": "（6）报告期内合并范围是否发生变动\n√ 是 □ 否\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n（7）公司报告期内业务、产品或服务发生重大变化或调整有关情况\n□ 适用 √ 不适用\n（8）主要销售客户和主要供应商情况\n公司主要销售客户情况\n前五名客户合计销售金额（元） 649,326,403.37\n前五名客户合计销售金额占年度销售总额比例 22.08%\n前五名客户销售额中关联方销售额占年度销售总额比\n0.00%\n例\n公司前5大客户资料\n序号 客户名称 销售额（元） 占年度销售总额比例\n1 客户1 212,211,696.91 7.21%\n2 客户2 149,494,409.10 5.08%\n3 客户3 105,676,622.82 3.59%\n4 客户4 93,657,620.14 3.18%\n5 客户5 88,286,054.40 3.00%\n合计 -- 649,326,403.37 22.08%\n主要客户其他情况说明\n□ 适用 √ 不适用\n公司主要供应商情况\n前五名供应商合计采购金额（元） 328,471,523.80\n前五名供应商合计采购金额占年度采购总额比例 20.82%\n前五名供应商采购额中关联方采购额占年度采购总额\n0.00%\n比例\n公司前5名供应商资料\n序号 供应商名称 采购额（元） 占年度采购总额比例\n1 供应商1 144,631,621.96 9.17%\n2 供应商2 56,660,417.02 3.59%\n3 供应商3 52,856,752.15 3.35%\n18。\n\n4 供应商4 38,420,130.22 2.44%\n5 供应商5 35,902,602.45 2.28%\n合计 -- 328,471,523.80 20.82%\n主要供应商其他情况说明\n□ 适用 √ 不适用\n3、费用\n单位：元\n2019年 2018年 同比增减 重大变动说明\n销售费用 59,623,024.88 43,781,054.42 36.18%主要系佣金增加所致\n管理费用 386,185,538.84 349,284,396.57 10.56%\n财务费用 -37,865,156.06 -51,507,397.78 -26.49%\n研发费用 122,548,224.53 111,304,662.07 10.10%\n4、研发投入\n√ 适用 □ 不适用\n公司注重技术研发，坚持技术创新。报告期内，公司在新设备、新产品、新工艺、新材\n料、新应用技术等方面，开展了有针对性的研究创新。在提升公司产品质量与性能方面，取\n得了突出的成果，提高了公司产品综合竞争力。\n\n公司研发投入情况\n2019年 2018年 变动比例\n研发人员数量（人） 443 405 9.38%\n研发人员数量占比 13.45% 12.75% 0.70%\n研发投入金额（元） 122,548,224.53 111,304,662.07 10.10%\n研发投入占营业收入比例 4.17% 4.09% 0.08%\n研发投入资本化的金额（元） 0.00 0.00 0.00%\n资本化研发投入占研发投入\n0.00% 0.00% 0.00%\n的比例\n研发投入总额占营业收入的比重较上年发生显著变化的原因\n□ 适用 √ 不适用\n研发投入资本化率大幅变动的原因及其合理性说明\n□ 适用 √ 不适用\n5、现金流\n单位：元\n19。\n\n项目 2019年 2018年 同比增减\n经营活动现金流入小计 2,374,777,732.18 2,809,734,855.49 -15.48%\n经营活动现金流出小计 1,762,378,636.87 2,018,285,617.83 -12.68%\n经营活动产生的现金流量净\n612,399,095.31 791,449,237.66 -22.62%\n额\n投资活动现金流入小计 1,177,235,296.80 963,819,628.62 22.14%\n投资活动现金流出小计 440,639,977.78 2,061,240,331.20 -78.62%\n投资活动产生的现金流量净\n736,595,319.02 -1,097,420,702.58 -167.10%\n额\n筹资活动现金流入小计 285,000,000.00 1,388,743,300.00 -79.48%\n筹资活动现金流出小计 1,187,336,603.58 2,295,021,451.90 -48.26%\n筹资活动产生的现金流量净\n-902,336,603.58 -906,278,151.90 -0.43%\n额\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61 -138.81%\n相关数据同比发生重大变动的主要影响因素说明\n√ 适用 □ 不适用\n经营活动产生的现金流量净额减少主要系收回银行承兑汇票、信用证保证金等减少所致。投资活动产生的现金流量净额增加主要系去年同期购买银行理财产品及结构性存款较多所致。报告期内公司经营活动产生的现金净流量与本年度净利润存在重大差异的原因说明\n□ 适用 √ 不适用\n三、非主营业务分析\n□ 适用 √ 不适用\n四、资产及负债状况分析\n1、资产构成重大变动情况\n单位：元\n2019年末 2019年初\n比重增减 重大变动说明\n金额 占总资产比例 金额 占总资产比例\n货币资金 1,556,575,372.45 23.07% 1,956,089,124.33 27.80% -4.73%\n应收账款 459,781,564.19 6.81% 479,537,782.06 6.82% -0.01%\n存货 842,985,260.60 12.49% 905,418,218.49 12.87% -0.38%\n投资性房地产 11,206,951.46 0.17% 12,338,615.29 0.18% -0.01%\n长期股权投资 47,879,382.43 0.71% 66,088,139.79 0.94% -0.23%\n固定资产 1,724,407,333.34 25.56% 1,215,120,643.61 17.27% 8.29%\n20。\n\n在建工程 560,674,634.43 8.31% 674,333,677.99 9.58% -1.27%\n短期借款 200,267,029.59 2.97% 598,700,000.00 8.51% -5.54%\n2、以公允价值计量的资产和负债\n□ 适用 √ 不适用\n3、截至报告期末的资产权利受限情况\n项 目 期末账面价值 受限原因\n货币资金 30,797,464.00 开立银行承兑汇票\n固定资产 22,554,937.46 银行融资抵押\n无形资产 10,291,182.19 银行融资抵押\n合 计 63,643,583.65\n五、投资状况分析\n1、总体情况\n√ 适用 □ 不适用\n报告期投资额（元） 上年同期投资额（元） 变动幅度\n593,621,971.72 606,637,800.32 -2.15%\n2、报告期内获取的重大的股权投资情况\n□ 适用 √ 不适用\n3、报告期内正在进行的重大的非股权投资情况\n□ 适用 √ 不适用\n4、以公允价值计量的金融资产\n□ 适用 √ 不适用\n5、募集资金使用情况\n√ 适用 □ 不适用\n（1）募集资金总体使用情况\n√ 适用 □ 不适用\n单位：万元\n21。\n\n报告期内 累计变更 累计变更 尚未使用\n本期已使 已累计使 尚未使用 闲置两年\n募集资金 变更用途 用途的募 用途的募 募集资金\n募集年份 募集方式 用募集资 用募集资 募集资金 以上募集\n总额 的募集资 集资金总 集资金总 用途及去\n金总额 金总额 总额 资金金额\n金总额 额 额比例 向\n非公开发\n2016年 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 存放银行 0\n行股票\n合计 -- 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 -- 0\n募集资金总体使用情况说明\n1、经中国证券监督管理委员会证监许可〔2016〕765号文核准，并经深圳证券交易所同意，本公司由主承销商国泰君安证\n券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币普通股（A股）股票99,890,023股，发行价为每股人\n民币10.28元，共计募集资金1,026,869,436.44元，坐扣承销费和保荐费等10,000,000.00元（含税）后的募集资金为\n1,016,869,436.44元，已由主承销商国泰君安证券股份有限公司于2016年9月1日汇入本公司募集资金监管账户。扣除承\n销费及保荐费、律师费、会计师费用、登记费等发行费用12,465,829.73元后，本公司本次募集资金净额1,014,403,606.71\n元。上述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验证，并由其出具《验资报告》（天健验〔2016〕358号）。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "ad9090f3",
        "34ce908d",
        "941ae6d5",
        "b646df69"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3796,
      "page_number": 18,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18,
          19,
          20,
          21,
          22
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.287388",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "券股份有限公司",
        "industry": null,
        "char_count": 3796,
        "word_count": 423,
        "sentence_count": 167,
        "chinese_char_count": 1567,
        "readability_score": 0.0,
        "information_density": 0.05268703898840885,
        "coherence_score": 0.672884672838318,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7101159114857745,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务",
        "10.28元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收",
        "存货",
        "固定资产"
      ]
    },
    {
      "chunk_id": "c1b9f878",
      "content": "2、本公司以前年度已使用募集资金337,797,729.53元，以前年度收到的银行存款利息扣除银行手续费等的净额为\n16,576,229.98元，以前年度收到的理财产品收益金额为20,933,628.61元；2019年度实际使用募集资金480,021,367.74元（含\n永久性补充流动资金370,616,060.66 元），2019年度收到的银行存款利息扣除银行手续费等的净额为4,244,642.08元，2019\n年度收到的理财产品收益金额为8,695,157.17元；累计已使用募集资金817,819,097.27元，累计收到的银行存款利息扣除\n银行手续费等的净额为20,820,872.06元，累计收到的理财产品收益金额为29,628,785.78元。截至2019年12月31日，募\n集资金余额为人民币247,034,167.28元。（2）募集资金承诺项目情况\n√ 适用 □ 不适用\n单位：万元\n是否已变 截至期末项目达到 项目可行\n募集资金调整后投 截至期末 本报告期\n承诺投资项目和超募 更项目 本报告期 投资进度预定可使 是否达到性是否发\n承诺投资 资总额 累计投入 实现的效\n资金投向 (含部分 投入金额 (3)＝ 用状态日 预计效益生重大变\n总额 (1) 金额(2) 益\n变更) (2)/(1) 期 化\n承诺投资项目\n原料药及中间体CMO 2019年7\n否 40,000 28,440.36 4,548.29 28,796.95 101.25% 0.00[注] 否 否\n中心扩建项目 月[注]\n年产30亿片（粒）固\n是 35,000 不适用 是\n体制剂技改项目\n医药综合研发中心 否 15,000 15,000 2,521.91 2,611.91 17.41% 不适用 否\n医药中试车间技改项\n否 9,000 9,000 1,436.42 4,730.88 52.57% 不适用 否\n目\n环保设施改造项目 否 14,000 14,000 2,433.91 8,580.56 61.29% 不适用 否\n承诺投资项目小计 -- 113,000 66,440.3610,940.53 44,720.3 -- -- -- --\n超募资金投向\n22。\n\n无\n归还银行贷款（如有） -- -- -- -- --\n补充流动资金（如有） -- -- -- -- --\n超募资金投向小计 -- -- -- -- --\n合计 -- 113,000 66,440.3610,940.53 44,720.3 -- -- 0 -- --\n“医药综合研发中心项目”原实施地点为公司椒江区外沙厂区，考虑各子公司所在园区的长远发展规\n划，对子公司职能定位进行调整，公司将项目的实施主体由公司变更为全资子公司川南药业，实施\n地点变更为浙江省临海市，因此导致投资进度有所延缓。未达到计划进度或预 “医药中试车间技改项目” 主要是通过实施原料药和关键中间体产品的中试生产，为产品的中试开发\n计收益的情况和原因 提供工艺验证和数据收集，为开发大规模生产的产品提供必要的研发支持。该项目计划建设用地位\n（分具体项目） 于公司外沙厂区，需要拆除原有车间，在原址上新建厂房。\n\n由于原车间为药证体系注册车间，需要\n办理相关药证转移变更程序，故导致医药中试车间技改项目进度低于规划进度。“环保设施改造项目”为配合厂区产能整体规划、协同活性染料产业升级及配套项目建设规划需要，\n投入与实施计划有所延缓。根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资\n项目可行性发生重大 项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目\n变化的情况说明 的市场环境已发生较大变化，公司终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普\n通账户，用于永久补充公司流动资金。\n\n超募资金的金额、用途不适用\n及使用进展情况\n适用\n以前年度发生\n募集资金投资项目实\n施地点变更情况\n根据公司2018年8月28日第五届董事会第十八次会议审议通过的《关于变更部分募集资金投资项\n目实施主体和地点的议案》，公司将募集资金投资项目“医药综合研发中心”实施主体由公司变更为全\n资子公司浙江海翔川南药业有限公司，实施地点变更为浙江省临海市。不适用\n募集资金投资项目实\n施方式调整情况\n募集资金投资项目先 不适用\n期投入及置换情况\n用闲置募集资金暂时 不适用\n补充流动资金情况\n项目实施出现募集资 不适用\n金结余的金额及原因\n尚未使用的募集资金\n存放银行\n用途及去向\n23。\n\n募集资金使用及披露\n中存在的问题或其他 不存在重大问题\n情况\n[注]：该项目已于2019年7月部分投产，但生产的相关产品尚未实现销售，故本期未产生效益。（3）募集资金变更项目情况\n√ 适用 □ 不适用\n单位：万元\n变更后项目 变更后的项\n截至期末实截至期末投项目达到预\n变更后的项对应的原承拟投入募集本报告期实 本报告期实是否达到预目可行性是\n际累计投入 资进度 定可使用状\n目 诺项目 资金总额 际投入金额 现的效益 计效益 否发生重大\n金额(2) (3)=(2)/(1) 态日期\n(1) 变化\n年产30亿\n永久补充流片（粒）固\n37,061.61 37,061.61 37,061.61 100.00% 0 不适用 否\n动资金 体制剂技改\n项目\n合计 -- 37,061.61 37,061.61 37,061.61 -- -- 0 -- --\n根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分\n变更原因、决策程序及信息披露情况募集资金投资项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿\n说明(分具体项目) 片（粒）固体制剂技改项目的市场环境已发生较大变化，公司终止实施该项目并将结\n余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。未达到计划进度或预计收益的情况\n不适用\n和原因(分具体项目)\n变更后的项目可行性发生重大变化\n不适用\n的情况说明\n六、重大资产和股权出售\n1、出售重大资产情况\n□ 适用 √ 不适用\n公司报告期未出售重大资产。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "e7e09ec0",
        "4489d301",
        "14f81631"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2579,
      "page_number": 22,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22,
          23,
          24
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.289448",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2579,
        "word_count": 247,
        "sentence_count": 54,
        "chinese_char_count": 1598,
        "readability_score": 0.0,
        "information_density": 0.0426521907716169,
        "coherence_score": 0.7055287569573283,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8478480031019775,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "729.53元",
        "229.98元",
        "628.61元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "股权",
        "股东",
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "17399413",
      "content": "2、出售重大股权情况\n□ 适用 √ 不适用\n七、主要控股参股公司分析\n√ 适用 □ 不适用\n主要子公司及对公司净利润影响达10%以上的参股公司情况\n24。\n\n单位：元\n公司名称 公司类型 主要业务 注册资本 总资产 净资产 营业收入 营业利润 净利润\n浙江海翔药\n货物及技术 30,000,000.0 69,541,379.7 69,007,694.1 -1,190,555.1 -1,177,557.0\n业销售有限 子公司 6,399,758.49\n进出口 0 5 3 0 5\n公司\n浙江海翔川\n医药制造及 1,905,943,80 1,307,615,66 1,278,861,76 204,310,101. 183,572,535.\n南药业有限 子公司 740000000\n货物进出口 5.66 6.90 2.53 35 16\n公司\n上海海翔医\n医药化工技 16,566,791.9\n药科技发展 子公司 5,000,000.00 7,712,899.66 5,961,858.15 1,609,827.17 1,416,778.77\n术开发 9\n有限公司\n工原料、化\n台州港翔科 工机械及配\n子公司 5,000,000.00 5,444,685.96 5,116,968.43 0.00 -143,703.23 -145,514.30\n技有限公司 件、五金批\n发、零售\n主要产品染\n料、染料中\n台州市前进\n间体、溴盐 304,000,000. 1,540,527,12 1,254,548,70 1,202,406,88 485,937,936. 418,599,011.\n化工有限公 子公司\n制造、销售 00 2.83 0.45 0.92 39 39\n司\n货物及技术\n进出口\n医药中间体\n台州市振港 及化工产品\n110,000,000. 933,575,895. 617,871,041. 783,594,897. 128,045,956. 89,296,052.8\n染料化工有 子公司 制造，销售\n00 73 59 92 93 4\n限公司 货物及技术\n进出口\n盐城市瓯华\nDCB、1-氨基19,778,647.3 203,873,894. 186,550,175. 65,214,784.2 -48,941,877. -48,959,944.\n化学工业有 子公司\n蒽醌生产 7 28 49 5 12 21\n限公司\n盐城市瓯华 化工产品研\n化工研究院 子公司 发及其技术 1,080,000.00 1,071,232.47 1,071,232.47 -724.90 -724.90\n有限公司 转让\n报告期内取得和处置子公司的情况\n√ 适用 □ 不适用\n公司名称 报告期内取得和处置子公司方式 对整体生产经营和业绩的影响\n浙江盛嘉环保有限公司 设立 无\n主要控股参股公司情况说明\n八、公司控制的结构化主体情况\n□ 适用 √ 不适用\n25。\n\n九、公司未来发展的展望\n（一）2020年工作计划\n1、强化总部层面在采购、销售、财务、重大投资和人力资源、行政管理方面的核心作用，\n不断增强总部的战略研究和规划调控能力，强化主营业务层面的关键性作用，有效发挥和放\n大集团运营优势、降低运营成本、提高运营效率。2、各厂区根据自身战略定位，集中优势资源加快推进南洋涂新厂区产能及环保处理设施、\n外沙厂区新剂型制剂扩建等重大项目建设和推进，做好南洋涂区块二期项目规划，丰富项目\n储备。3、积极构建开放、协同、高效的共性技术研发平台，不断优化科技基础设施建设，逐步\n健全需求为导向、企业研究院为主体的产学研一体化的创新机制，加大对创新的支持力度，\n形成有效的创新激励机制。\n\n要在做好老产品技改的同时，布局新产品，不断向产业链上下游\n延伸，进一步拓展产业链优势，促进研发和销售的良性循环。4、持续改善质量体系和EHS体系建设，提高质量保证专业水平，牢固确立绿色发展理念，\n加大质量管理、EHS常规化教育和培训力度，不断强化员工“质量为先”的意识，加强风险防\n范和管控，保障生产经营合规有序运行。5、加强人才队伍建设，适应行业发展新阶段，深化人力资源制度变革，建立完善的人员\n激励机制和晋升机制，强化绩效管理，营造良好的、有序竞争的企业内部环境，做好科技人\n员的培养和储备。\n\n（二）公司面临的风险和应对措施\n1、业绩波动风险\n公司染料行业的发展周期与下游纺织印染行业的发展周期息息相关，纺织印染行业的市\n场景气度会对公司染料板块的业绩产生直接的影响。当下，国内外经济形势仍有多方面不稳\n定因素的存在，如果全球经济持续向下衰退，势必将导致纺织品产市场需求量下降，公司也\n将受到国内外下游产业对染料需求下降的影响，最终对公司未来的业绩产生不利影响。2、行业政策风险\n近年来，随着医药体制改革相关政策的逐步落地，国家对医药行业的管理力度不断加大。\n\n医保控费、一致性评价、两票制、“集采”常态化等一系列医药政策的实施，将彻底改变医药\n行业的现有格局，并对整个医药行业未来的发展产生深远的影响。3、原材料价格波动的风险\n随着公司经营规模的不断扩大，所需的原材料数量持续增长。当前国家安全、环政策持续\n趋严、供给侧改革去产能，原材料价格可能会大幅波动，这将直接导致公司成本增加，也有\n可能面临原材料供应不足的情形，对公司生产经营造成不利的影响。\n\n4、环保政策风险\n公司在生产经营过程中会产生一定的污染物。虽然公司已严格按照环保法律、法规和标\n准的要求进行处理和排放，但是随着整个社会环保意识的增强，新《环境保护法》等越来越\n严格的环保法律法规的颁布实施，企业执行的环保标准也将更高更严格，这不但将增加本公\n司在环保设施、排放治理等方面的支出，同时还可能因为未能及时满足环保新标准而受到相\n关部门处罚。5、安全生产风险\n公司现有产品生产过程中的原料包含易燃、易爆化学品、腐蚀性或有毒物质，部分生产工\n序为高温、高压环境。\n\n尽管公司配备有较完备的安全设施，制定了较为完善的事故预警、处\n理机制，整个生产过程处于受控状态，发生安全事故的可能性很小，但仍然不排除因生产操\n作不当或设备故障等其他因素，导致意外事故发生的可能，从而影响公司生产经营的正常进\n26。\n\n行。6、人才缺乏及流失的风险\n随着公司规模的不断扩大，新项目的不断拓展，以及新产品的持续研发，都需要增加相应\n的管理人才和专业技能人才。人才储备的不足，以及现有岗位人才的流失都有可能导致人才\n资源不能满足生产经营的需求。\n\n十、接待调研、沟通、采访等活动\n1、报告期内接待调研、沟通、采访等活动登记表\n√ 适用 □ 不适用\n接待时间 接待方式 接待对象类型 调研的基本情况索引\n具体内容详见互动易平台2019年3月\n2019年03月11日 实地调研 机构\n12日的投资者活动关系表\n具体内容详见互动易平台2019年4月\n2019年04月09日 实地调研 机构\n10日的投资者活动关系表\n具体内容详见互动易平台2019年4月\n2019年04月25日 实地调研 机构\n26日的投资者活动关系表\n具体内容详见互动易平台2019年5月\n2019年05月14日 实地调研 机构\n17日的投资者活动关系表\n具体内容详见互动易平台2019年5月\n2019年05月15日 实地调研 机构\n17日的投资者活动关系表\n具体内容详见互动易平台2019年6月\n2019年06月04日 实地调研 机构\n6日的投资者活动关系表\n具体内容详见互动易平台2019年6月\n2019年06月05日 实地调研 机构\n6日的投资者活动关系表\n具体内容详见互动易平台2019年9月\n2019年09月16日 实地调研 机构\n16日的投资者活动关系表\n27。\n\n第五节重要事项\n一、公司普通股利润分配及资本公积金转增股本情况\n报告期内普通股利润分配政策，特别是现金分红政策的制定、执行或调整情况\n√ 适用 □ 不适用\n公司第五届董事会第五次会议及2017年第一次临时股东大会审议通过了《公司未来三年（2017年-2019年）股东回报规划》。具体内容详见公司2016年12月19日于巨潮资讯网（http://www.cninfo.com.cn）刊登的《浙江海翔药业股份有限公司未来三年\n股东分红回报规划(2017-2019年) 》。现金分红政策的专项说明\n是否符合公司章程的规定或股东大会决议的要求： 是\n分红标准和比例是否明确和清晰： 是\n相关的决策程序和机制是否完备： 是\n独立董事是否履职尽责并发挥了应有的作用： 是\n中小股东是否有充分表达意见和诉求的机会，其合法权益是\n是\n否得到了充分保护：\n现金分红政策进行调整或变更的，条件及程序是否合规、透\n是\n明：\n公司近3年（包括本报告期）的普通股股利分配方案（预案）、资本公积金转增股本方案（预案）情况\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购\n专用证券账户的63,005,888股）为基数，向全体股东每10股派发现金红利3元（含税），预计\n派发现金股利466,712,809.50元(含税)。\n\n本年度不送红股，不以资本公积转增股本。2018年度公司以2019年4月9日总股本1,555,814,365股（扣除存放于股票回购专用证券账\n户的63,005,888股）为基数，向全体股东每10股派发现金红利3.00元（含税），合计派发现金\n股利466,744,309.50元（含税），不送红股，不以资本公积转增股本。2017年度公司以2018年4月3日总股本1,621,610,253股为基数，向全体股东每10股派发现\n金红利1.00元（含税），合计派发现金股利162,161,025.30元（含税），不送红股，不以资本\n公积转增股本。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "2b095fd2",
        "75acfc42",
        "5256f2d1",
        "c64435d4",
        "7843d7ac"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 4021,
      "page_number": 24,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24,
          25,
          26,
          27,
          28
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.290837",
        "report_type": "其他",
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 4021,
        "word_count": 299,
        "sentence_count": 82,
        "chinese_char_count": 2534,
        "readability_score": 0.0,
        "information_density": 0.04973887092762994,
        "coherence_score": 0.6839237112495815,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8520765978612286,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营",
        "财务",
        "3元",
        "809.50元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金",
        "投资",
        "营业收入",
        "净利润",
        "营业利润"
      ]
    },
    {
      "chunk_id": "2ce099ec",
      "content": "公司近三年（包括本报告期）普通股现金分红情况表\n单位：元\n现金分红总额\n现金分红金额 以其他方式现\n分红年度合并 （含其他方\n占合并报表中 以其他方式 金分红金额占\n报表中归属于 现金分红总额 式）占合并报\n现金分红金额 归属于上市公 （如回购股 合并报表中归\n分红年度 上市公司普通 （含其他方 表中归属于上\n（含税） 司普通股股东 份）现金分红 属于上市公司\n股股东的净利 式） 市公司普通股\n的净利润的比 的金额 普通股股东的\n润 股东的净利润\n率 净利润的比例\n的比率\n2019年 466,712,809.50 770,782,185.09 60.55% 19,996,827.22 2.59% 486,709,636.72 63.14%\n28。\n\n2018年 466,744,309.50 605,003,820.78 77.15% 281,514,686.68 46.53% 748,258,996.18 123.68%\n2017年 162,161,025.30 342,217,155.60 47.39% 0.00 0.00% 162,161,025.30 47.39%\n公司报告期内盈利且母公司可供普通股股东分配利润为正但未提出普通股现金红利分配预案\n□ 适用 √ 不适用\n二、本报告期利润分配及资本公积金转增股本情况\n√ 适用 □ 不适用\n每10股送红股数（股） 0\n每10股派息数（元）（含税） 3\n每10股转增数（股） 0\n分配预案的股本基数（股） 1,555,709,365\n现金分红金额（元）（含税） 466,712,809.50\n以其他方式（如回购股份）现金分红金额（元） 19,996,827.22\n现金分红总额（含其他方式）（元） 486,709,636.72\n可分配利润（元） 1,525,328,398.95\n现金分红总额（含其他方式）占利润分配总额的\n100%\n比例\n本次现金分红情况\n公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20％\n利润分配或资本公积金转增预案的详细情况说明\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购专用证券账户的63,005,888股）\n为基数，向全体股东每10股派发现金红利3元（含税），预计派发现金股利466,712,809.50元(含税)。本年度不送红股，\n不以资本公积转增股本。三、承诺事项履行情况\n1、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末\n尚未履行完毕的承诺事项\n√ 适用 □ 不适用\n承 履\n承诺类 承诺 诺 行\n承诺事由 承诺方 承诺内容\n型 时间 期 情\n限 况\n股改承诺\n收购报告书或权\n益变动报告书中\n所作承诺\n29。\n\n（一）本承诺人及本承诺人直接或间接控制的除海翔药业、台州前进\n及其子公司以外的企业目前不存在自营、与他人共同经营、为他人经\n营或以其他任何方式直接或间接从事与海翔药业、台州前进及其子公\n司相同、相似或构成实质竞争业务的情形；（二）在直接或间接持有海\n翔药业股份期间，本承诺人将不会采取参股、控股、自营、联营、合\n营、合作或者其他任何方式直接或间接从事与海翔药业、台州前进及\n其子公司现在和将来业务范围相同、相似或构成实质竞争的业务，也\n不会协助、促使或代表任何第三方以任何方式直接或间接从事与海翔\n药业、台州前进及其子公司现在和将来业务范围相同、相似或构成实\n质竞争的业务；（三）在直接或间接持有海翔药业股份期间，对于本承\n诺人直接或间接控制的其他企业，本承诺人将通过派出机构和人员（包\n括但不限于董事、总经理等）以及本承诺人在该等企业中的控制地位，\n王云富、\n关于同 保证该等企业比照前款规定履行与本承诺人相同的不竞争义务；（四）2014 严\n浙江东\n资产重组时所作 业竞争 如因国家政策调整等不可抗力原因导致本承诺人或本承诺人直接或间 年05 长 格\n港投资\n承诺 方面承 接控制的其他企业将来从事的业务与海翔药业、台州前进及其子公司 月05 期 履\n有限公\n诺 现在或将来从事的业务之间构成同业竞争时，则本承诺人将在海翔药 日 行\n司\n业、台州前进及其子公司提出异议后及时转让或终止该等业务或促使\n本承诺人直接或间接控制的其他企业及时转让或终止该等业务；如海\n翔药业、台州前进及其子公司进一步要求，海翔药业、台州前进及其\n子公司享有该等业务在同等条件下的优先受让权；（五）如从第三方获\n得任何与海翔药业经营的业务存在竞争或潜在竞争的商业机会，本承\n诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并\n尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上\n述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其\n子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述\n承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东\n因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归\n海翔药业所有。30。\n\n（一）本承诺人将采取措施尽量避免或减少本承诺人及本承诺人直接\n或间接控制的除海翔药业、台州前进及其子公司以外的其他企业与台\n州前进、海翔药业及其子公司之间发生关联交易；（二）对于无法避免\n的关联交易，将按照\"等价有偿、平等互利\"的原则，依法签订关联交易\n合同，参照市场同行的标准，公允确定关联交易的价格，并严格按照\n海翔药业的公司章程及有关法律法规履行批准关联交易的法定程序和\n信息披露义务；（三）本承诺人及本承诺人直接或间接控制的除海翔药\n王云富、 业、台州前进及其子公司以外的其他企业不通过关联交易损害海翔药\n关于关 2014 严\n浙江东 业、台州前进及其子公司及相关公司股东的合法权益；（四）本承诺人\n联交易、 年05 长 格\n港投资 及本承诺人直接或间接控制的除海翔药业、台州前进及其子公司以外\n资金方 月05 期 履\n有限公 的其他企业不通过向海翔药业、台州前进及其子公司借款或由海翔药\n面承诺 日 行\n司 业、台州前进及其子公司提供担保、代偿债务、代垫款项等各种名目\n侵占海翔药业、台州前进及其子公司的资金；（五）不利用股东地位及\n影响谋求与海翔药业、台州前进及其子公司在业务合作等方面给予本\n承诺人及本承诺人直接或间接控制的除海翔药业、台州前进及其子公\n司以外的其他企业优于市场第三方的权利；不利用股东地位及影响谋\n求与海翔药业、台州前进及其子公司达成交易的优先权利；（六）本承\n诺人愿意承担由于违反上述承诺给海翔药业、台州前进及其子公司造\n成的直接、间接的经济损失、索赔责任及额外的费用支出。首次公开发行或\n再融资时所作承\n诺\n股权激励承诺\n其他对公司中小\n股东所作承诺\n承诺是否按时履\n是\n行\n如承诺超期未履\n行完毕的，应当详\n细说明未完成履\n不适用\n行的具体原因及\n下一步的工作计\n划\n2、公司资产或项目存在盈利预测，且报告期仍处在盈利预测期间，公司就资产或项目达到原盈利预测及\n其原因做出说明\n□ 适用 √ 不适用\n四、控股股东及其关联方对上市公司的非经营性占用资金情况\n□ 适用 √ 不适用\n公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。31。\n\n五、董事会、监事会、独立董事（如有）对会计师事务所本报告期“非标准审计报告”的说明\n□ 适用 √ 不适用\n六、与上年度财务报告相比，会计政策、会计估计和核算方法发生变化的情况说明\n√ 适用 □ 不适用\n企业会计准则变化引起的会计政策变更\n1. 本公司根据财政部《关于修订印发2019年度一般企业财务报表格式的通知》(财会〔2019〕6号)和企\n业会计准则的要求编制2019年度财务报表，此项会计政策变更采用追溯调整法。2018年度财务报表受重要\n影响的报表项目和金额如下：\n原列报报表项目及金额 新列报报表项目及金额\n应收票据及应收账款 586,937,258.10应收票据 107,399,476.04\n应收账款 479,537,782.06\n应付票据及应付账款 791,915,463.78应付票据 490,006,533.85\n应付账款 301,908,929.93\n2. 本公司自2019年1月1日起执行财政部修订后的《企业会计准则第22号——金融工具确认和计量》《企\n业会计准则第23号——金融资产转移》《企业会计准则第24号——套期保值》以及《企业会计准则第37号\n——金融工具列报》（以下简称新金融工具准则）。根据相关新旧准则衔接规定，对可比期间信息不予调\n整，首次执行日执行新准则与原准则的差异追溯调整本报告期期初留存收益或其他综合收益。\n\n新金融工具准则改变了金融资产的分类和计量方式，确定了三个主要的计量类别：摊余成本；以公允\n价值计量且其变动计入其他综合收益；以公允价值计量且其变动计入当期损益。公司考虑自身业务模式，\n以及金融资产的合同现金流特征进行上述分类。权益类投资需按公允价值计量且其变动计入当期损益，但\n在初始确认时可选择按公允价值计量且其变动计入其他综合收益(处置时的利得或损失不能回转到损益，但\n股利收入计入当期损益)，且该选择不可撤销。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "6c0e25b6",
        "9ea183a9",
        "f00085dd",
        "eb0ca278"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3796,
      "page_number": 28,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28,
          29,
          30,
          31,
          32
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.293003",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3796,
        "word_count": 272,
        "sentence_count": 49,
        "chinese_char_count": 2778,
        "readability_score": 0.0,
        "information_density": 0.05268703898840885,
        "coherence_score": 0.7231430108763591,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8927291886195996,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收",
        "应付"
      ]
    },
    {
      "chunk_id": "e2e8d3d2",
      "content": "新金融工具准则要求金融资产减值计量由“已发生损失模型”改为“预期信用损失模型”，适用于以摊余\n成本计量的金融资产、以公允价值计量且其变动计入其他综合收益的金融资产、租赁应收款。(1) 执行新金融工具准则对公司2019年1月1日财务报表的主要影响如下：\n项 目 资产负债表\n2018年12月31日 新金融工具准则 2019年1月1日\n调整影响\n可供出售金融资产 1,800,000.00 -1,800,000.00\n其他权益工具投资 1,800,000.00 1,800,000.00\n应收票据 107,399,476.04 -107,399,476.04\n应收款项融资 107,399,476.04 107,399,476.04\n其他流动资产 227,882,993.23 -150,000,000.00 77,882,993.23\n交易性金融资产 150,000,000.00 150,000,000.00\n(2) 2019年1月1日，公司金融资产和金融负债按照新金融工具准则（以下简称新CAS22）和按原金融工\n具准则（以下简称原CAS22）的规定进行分类和计量结果对比如下表：\n项 目 原金融工具准则 新金融工具准则\n计量类别 账面价值 计量类别 账面价值\n货币资金 贷款和应收款项 1,956,089,124.33以摊余成本计量的金融资 1,956,089,124.33\n32。\n\n产\n应收票据 贷款和应收款项 107,399,476.04以公允价值计量且其变动 107,399,476.04\n计入其他综合收益的金融\n资产\n应收账款 贷款和应收款项 479,537,782.06以摊余成本计量的金融资 479,537,782.06\n产\n其他应收款 贷款和应收款项 10,817,853.96以摊余成本计量的金融资 10,817,853.96\n产\n其他流动资产-银可供出售金融资产 150,000,000.00以公允价值计量且其变动 150,000,000.00\n行理财产品 计入当期损益\n可供出售金融资可供出售金融资产 1,800,000.00以公允价值计量且其变动 1,800,000.00\n产 计入其他综合收益\n应付票据 其他金融负债 490,006,533.85以摊余成本计量的金融负 490,006,533.85\n债\n应付账款 其他金融负债 301,908,929.93以摊余成本计量的金融负 301,908,929.93\n债\n其他应付款 其他金融负债 24,723,304.20以摊余成本计量的金融负 24,723,304.20\n债\n(3) 2019年1月1日，公司原金融资产和金融负债账面价值调整为按照新金融工具准则的规定进行分类\n和计量的新金融资产和金融负债账面价值的调节表如下：\n项 目 按原金融工具准则列示的 重分类 重新计量 按新金融工具准则列示\n账面价值（2018年12月31 的账面价值（2019年1月1\n日） 日）\nA. 金融资产\na. 摊余成本\n货币资金\n按原CAS22 列示的余额 1,956,089,124.33 1,956,089,124.33\n和按新CAS22 列示的余\n额\n应收票据\n按原CAS22 列示的余额 107,399,476.04\n减：转出至公允价值计量 -107,399,476.04\n且其变动计入其他综合\n收益(新CAS22)\n按新CAS22 列示的余额\n应收账款\n按原CAS22 列示的余额 479,537,782.06 479,537,782.06\n和按新CAS22 列示的余\n额\n33。\n\n其他应收款\n按原CAS22 列示的余额 10,817,853.96 10,817,853.96\n和按新CAS22 列示的余\n额\n以摊余成本计量的总金 2,553,844,236.39 -107,399,476.04 2,446,444,760.35\n融资产\nb. 以公允价值计量且其变动计入当期损益\n其他流动资产-银行理财\n产品\n按原CAS22 列示的余额 150,000,000.00\n减：转出至公允价值计量 -150,000,000.00\n且其变动计入当期损益\n(新CAS22)\n按新CAS22 列示的余额\n交易性金融资产-银行理\n财产品\n按原CAS22 列示的余额\n加：自可供出售金融资产 150,000,000.00\n(原CAS22)转入\n按新CAS22 列示的余额 150,000,000.00\n以公允价值计量且其变 150,000,000.00 150,000,000.00\n动计入当期损益\nc. 以公允价值计量且其变动计入其他综合收益\n应收款项融资\n按原CAS22 列示的余额\n加：自应收票据(原 107,399,476.04\nCAS22)转入\n按新CAS22 列示的余额 107,399,476.04\n可供出售金融资产\n按原CAS22 列示的余额 1,800,000.00\n减：转出至公允价值计量 -1,800,000.00\n且其变动计入其他综合\n收益(新CAS22)\n按新CAS22 列示的余额\n其他权益工具投资\n按原CAS22 列示的余额\n加：自可供出售金融资产 1,800,000.00\n(原CAS22)转入\n34。\n\n按新CAS22 列示的余额 1,800,000.00\n以公允价值计量且其变 1,800,000.00 107,399,476.04 109,199,476.04\n动计入其他综合收益的\n总金融资产\nB. 金融负债\na. 摊余成本\n应付票据\n按原CAS22 列示的余额 490,006,533.85 490,006,533.85\n和按新CAS22 列示的余\n额\n应付账款\n按原CAS22 列示的余额 301,908,929.93 301,908,929.93\n和按新CAS22 列示的余\n额\n其他应付款\n按原CAS22 列示的余额 24,723,304.20 24,723,304.20\n和按新CAS22 列示的余\n额\n以摊余成本计量的总金 816,638,767.98 816,638,767.98\n融负债\n(4) 2019年1月1日，公司原金融资产减值准备期末金额调整为按照新金融工具准则的规定进行分类和\n计量的新损失准备的调节表如下：\n项 目 按原金融工具准则计提损失准 重分类 重新计量 按新金融工具准则计提\n备/按或有事项准则确认的预 损失准备（2019年1月1\n计负债（2018年12月31日） 日）\n贷款和应收款项(原CAS22)/以摊余成本计量的金融资产(新CAS22)\n应收账款 39,520,283.30 39,520,283.30\n其他应收款 17,101,274.23 17,101,274.23\n3. 本公司自2019年6月10日起执行经修订的《企业会计准则第7号——非货币性资产交换》，自2019\n年6月17日起执行经修订的《企业会计准则第12号——债务重组》。该项会计政策变更采用未来适用法处\n理。七、报告期内发生重大会计差错更正需追溯重述的情况说明\n□ 适用 √ 不适用\n公司报告期无重大会计差错更正需追溯重述的情况。\n\n八、与上年度财务报告相比，合并报表范围发生变化的情况说明\n√ 适用 □ 不适用\n35。\n\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n九、聘任、解聘会计师事务所情况\n现聘任的会计师事务所\n境内会计师事务所名称 天健会计师事务所（特殊普通合伙）\n境内会计师事务所报酬（万元） 170\n境内会计师事务所审计服务的连续年限 17年\n境内会计师事务所注册会计师姓名 沈维华 汪兢\n境内会计师事务所注册会计师审计服务的连续年限 沈维华1年 汪兢4年\n当期是否改聘会计师事务所\n□ 是 √ 否\n聘请内部控制审计会计师事务所、财务顾问或保荐人情况\n□ 适用 √ 不适用\n十、年度报告披露后面临暂停上市和终止上市情况\n□ 适用 √ 不适用\n十一、破产重整相关事项\n□ 适用 √ 不适用\n公司报告期未发生破产重整相关事项。十二、重大诉讼、仲裁事项\n√ 适用 □ 不适用\n披 披\n是否形 诉讼(仲\n涉案金额 诉讼(仲裁)进 露 露\n诉讼(仲裁)基本情况 成预计 诉讼(仲裁)审理结果及影响 裁)判决\n（万元） 展 日 索\n负债 执行情况\n期 引\n上海合契投资管理有限公司诉公 上海合契投资案件受理费由上海合契投资管理\n司、东港投资缔约过失责任纠纷一 2,500 否 管理有限公司有限公司负担，此前因诉讼被冻结/ / /\n案 已撤诉 的公司存款已经全部解除冻结。黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 204.01 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n36。\n\n黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 747.56 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n十三、处罚及整改情况\n□ 适用 √ 不适用\n公司报告期不存在处罚及整改情况。十四、公司及其控股股东、实际控制人的诚信状况\n□ 适用 √ 不适用\n十五、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况\n√ 适用 □ 不适用\n1、限制性股票激励计划简介\n（1）公司于2015年1月20日召开第四届董事会第十二次会议审议通过了《浙江海翔药业股\n份有限公司限制性股票激励计划（草案）》及其摘要等相关议案。随后公司向中国证监会上\n报了申请备案材料。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "46e58dec",
        "15249a0d",
        "fa137b47",
        "5473e1d3",
        "44d3a217"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3917,
      "page_number": 32,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32,
          33,
          34,
          35,
          36,
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.294909",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3917,
        "word_count": 392,
        "sentence_count": 92,
        "chinese_char_count": 2088,
        "readability_score": 0.0,
        "information_density": 0.04595353586928772,
        "coherence_score": 0.6931494922063539,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7238447791677304,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "应收",
        "应付",
        "资产负债表",
        "合并",
        "股权"
      ]
    },
    {
      "chunk_id": "cbe44cd6",
      "content": "（2）2015年2月17日，公司获悉报送的限制性股票激励计划（草案）及相关材料经中国证\n监会备案无异议。（3）2015年3月12日，公司2015年第一次临时股东大会审议通过了《浙江海翔药业股份有\n限公司限制性股票激励计划（草案）》及其摘要等相关，公司限制性股票激励计划已获批准。2、限制性股票激励计划授予情况\n2015年3月12日，公司第四届董事会第十四次会议审议通过了《关于向激励对象授予限制\n性股票的议案》。\n\n董事会同意以2015年3月12日为限制性股票的首次授权日，向335名激励对\n象授予3,473.5万股限制性股票，授予价格为4.5元/股，其他380万股限制性股票作为预留。2015年3月27日，公司发布了《关于限制性股票授予完成的公告》，由于2名激励对象因个人\n原因放弃认购其对应的全部限制性股票，合计2万股。公司实际向333名激励对象授予3471.5\n万股限制性股票，2015年3月31日完成上述限制性股票授予。\n\n3、限制性股股票激励计划预留部分第一次授予情况\n2015年9月26日，公司第四届董事会第十九次会议审议通过了《关于向激励对象授予预留\n部分限制性股票的议案》。董事会同意以2015年9月25日作为公司预留部分限制性股票的授予\n日，向公司董事、副董事长郭敏龙先生授予200万股预留部分限制性股票，授予价格为8.625\n元/股。2015年10月28日完成上述预留部分的授予登记。\n5、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于回购注销已离职激\n37。\n\n4、限制性股股票激励计划预留部分第二次授予情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于向激励对象授予预\n留部分限制性股票的议案》。董事会同意以2016年3月4日作为公司预留部分限制性股票的授\n予日，向公司总经理助理李芝龙先生授予360万股预留部分限制性股票，授予价格为5.075元/\n股。2016年4月22日完成上述预留部分的授予登记。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "dc3b6cc3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 858,
      "page_number": 37,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.296976",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 858,
        "word_count": 22,
        "sentence_count": 18,
        "chinese_char_count": 632,
        "readability_score": 0.0,
        "information_density": 0.05827505827505828,
        "coherence_score": 0.7970867860144275,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8946386946386946,
      "relevance_score": 1.0,
      "keywords": [
        "4.5元",
        "5.075元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "25403a8b",
      "content": "5、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于回购注销已离职激\n37。\n\n励对象所持已获授但尚未解锁的限制性股票的议案》。由于原激励对象林宇峰、丁春明已经\n离职，根据相关规定及股东大会授权，公司董事会对林宇峰、丁春明已离职激励对象所持已\n获授但尚未解锁的限制性股票共计24万股进行回购注销。2016年5月完成上述股票回购注销。\n\n6、限制性股股票激励计划第一期解锁情况\n2016年3月13日，公司第四届董事会第二十七次会议审议通过了《关于限制性股票激励计\n划首次授予的限制性股票第一个解锁期解锁条件成就的议案》。公司及首次授予限制性股票\n的激励对象均满足激励计划的规定相关解锁条件，第一个解锁期可解锁激励对象为331人，可\n申请解锁的限制性股票数量为1,729.75万股，占股权激励首次授予限制性股票总数的25%。2016年4月1日上述股票上市流通。\n\n7、限制股票第二期解锁情况：公司第五届董事会第七次会议审议通了《关于限制性股票\n激励计划首次授予部分第二个解锁期及预留授予部分第一个解锁期解锁条件成就的议案》，\n本次符合首次授予限制性股票第二期解锁条件的激励对象共计325人，解锁的限制性股票数量\n共计1716.25万股。预留授予的限制性股票第一期解锁数量为228万股，其中郭敏龙解锁120万\n股，李芝龙解锁108万股。上述股票已于2017年4月27日上市流通。\n\n8、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第七次会议审议通过了《关于回购注销部分限制性股\n票的议案》。由于原激励对象苗玉武等15人已经离职，潘官富不幸离世，根据相关规定及股\n东大会授权，公司董事会对上述激励对象所持已获授但尚未解锁的限制性股票共计115.7万股\n进行回购注销。2017年7月完成上述股票回购注销。\n\n9、限制股票第三期解锁情况：公司第五届董事会第十五次会议审议通过了《关于限制性\n股票激励计划首次授予部分第三个解锁期及预留授予部分第二个解锁期解锁条件成就的议\n案》。公司及激励对象均满足激励计划规定的首次授予限制性股票第三个解禁期及预留授予\n部分限制性股票第二个解禁期的解锁条件。本解锁期可解锁激励对象为313人，其中首次授予\n部分可申请解锁的限制性股票数量为1,665.15万股；预留授予部分可申请解锁的限制性股票数\n量为120万股。\n\n10、限制性股股票激励计划部分限制性股票回购注销情况\n2018年4月3日，公司第五届董事会第十五次会议审议通过了《关于回购注销部分限制性\n股票的议案》。由于原激励对象邓飞、冯红、周宏、李芝龙均已经离职，公司拟对其持有的\n已获授但尚未解锁的限制性股票进行回购注销，共回购注销279万限制性股票。2018年7月完\n成上述股票回购注销。\n\n11、限制股票第四期解锁情况：公司第五届董事会第二十一次会议审议通过了《关于限\n制性股票激励计划首次授予部分第四个解锁期及预留授予部分第三个解锁期解锁条件成就的\n议案》。公司及激励对象均满足激励计划规定的首次授予限制性股票第四个解禁期及预留授\n予部分限制性股票第三个解禁期的解锁条件。本解锁期可解锁激励对象为308人，其中首次授\n予部分可申请解锁的限制性股票数量为1,654.65万股；预留授予部分可申请解锁的限制性股票\n数量为160万股。\n\n12、限制性股股票激励计划部分限制性股票回购注销情况\n2019年3月13日，公司第五届董事会第二十一次会议审议通过了《关于回购注销部分限制\n性股票的议案》。由于原激励对象赵敏蔚、李建平、何明炬、许会凌、陈顺强均已经离职，\n公司拟对其持有的已获授但尚未解锁的限制性股票进行回购注销，共回购注销10.5万限制性\n股票。2019年6月完成上述股票回购注销。\n\n至此《浙江海翔药业股份有限公司限制性股票激励计划（草案）》已经全部实施完成。38。\n\n十六、重大关联交易\n1、与日常经营相关的关联交易\n√ 适用 □ 不适用\n关 是\n关 关 联 否\n可获\n联 联 交 占同类 获批的 超 关联\n关联 关联交易 得的\n关联关 交 交 易 关联交易 交易金 交易额 过 交易 披露\n交易 金额（万 同类 披露索引\n系 易 易 定 价格 额的比 度（万 获 结算 日期\n方 元） 交易\n类 内 价 例 元） 批 方式\n市价\n型 容 原 额\n则 度\n浙江 原 市 《2019年度日常关联交易预\n采 不同规格， 银行\n荣兴 控股股 料 场 2019 计的公告》公告编号\n购 单价从 存款 未偏\n活性 东持有 材 公 年02 2019-012，内容详见巨潮资讯\n活 5500元/吨 278.51 28.94% 2,800否 或承 离市\n炭有 其50%料 允 月18 网及《证券时报》、《上海证\n性 至15500元 兑汇 场价\n限公 股权 采 价 日 券报》、《中国证券报》、《证\n炭 /吨不等 票\n司 购 格 券日报》\n采\n原 购 市 《2019年度日常关联交易预\n江西 银行\n料 原 场 2019 计的公告》公告编号\n华邦 控股股 400元/千克 存款 未偏\n材 料 公 年02 2019-012，内容详见巨潮资讯\n药业 东控制 至420元/ 2,730.75 1.06% 5,000否 或承 离市\n料 药 允 月18 网及《证券时报》、《上海证\n有限 企业 千克 兑汇 场价\n采 中 价 日 券报》、《中国证券报》、《证\n公司 票\n购 间 格 券日报》\n体\n销 销\n售 售 市\n江西 银行\n原 原 场\n华邦 控股股 存款 未偏\n料 料 公 市场公允 不适\n药业 东控制 5 0.01% 不适用否 或承 离市 不适用\n药 药 允 价格 用\n有限 企业 兑汇 场价\n中 中 价\n公司 票\n间 间 格\n体 体\n台州\n市\n市东 采 采 银行\n场\n港包 控股股 购 购 存款 未偏\n公 市场公允 不适\n装用 东控制 原 原 0.44 0.00% 不适用否 或承 离市 不适用\n允 价格 用\n品有 企业 材 材 兑汇 场价\n价\n限公 料 料 票\n格\n司\n39。\n\n合计 -- -- 3,014.7 -- 7,800 -- -- -- -- --\n大额销货退回的详细情\n不适用\n况\n按类别对本期将发生的\n2019年度，公司与上述关联方日常关联交易的实际发生总金额未超过预计总金额。实际发生情况\n日常关联交易进行总金\n与预计存在较大差异的原因为：公司与关联方的年度日常关联交易预计是基于公司业务开展进行的\n额预计的，在报告期内\n初步判断，较难实现准确预计，因此与实际发生情况存在一定的差异。的实际履行情况（如有）\n交易价格与市场参考价\n格差异较大的原因（如 不适用\n适用）\n2、资产或股权收购、出售发生的关联交易\n□ 适用 √ 不适用\n公司报告期未发生资产或股权收购、出售的关联交易。\n\n3、共同对外投资的关联交易\n□ 适用 √ 不适用\n公司报告期未发生共同对外投资的关联交易。4、关联债权债务往来\n□ 适用 √ 不适用\n公司报告期不存在关联债权债务往来。5、其他重大关联交易\n√ 适用 □ 不适用\n台州艾斐科技有限公司系公司控股股东东港投资持股49%的企业，因其不具备单独设立变压器的资质，借用台州市振港\n染料化工有限公司变压器用电。\n\n台州艾斐科技有限公司和台州市振港染料化工有限公司电费由台州市振港染料化工有限公司\n统一向供电公司支付，台州市振港染料化工有限公司完成电费支付后再向台州艾斐科技有限公司收取相关电费。2019年度上\n述关联交易总金额为45.66万元。十七、重大合同及其履行情况\n1、托管、承包、租赁事项情况\n（1）托管情况\n□ 适用 √ 不适用\n公司报告期不存在托管情况。\n\n（2）承包情况\n□ 适用 √ 不适用\n公司报告期不存在承包情况。（3）租赁情况\n□ 适用 √ 不适用\n公司报告期不存在租赁情况。2、重大担保\n√ 适用 □ 不适用\n（1）担保情况\n单位：万元\n公司及其子公司对外担保情况（不包括对子公司的担保）\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n报告期内审批的对外担保额度合 报告期内对外担保实际发\n0 0\n计（A1） 生额合计（A2）\n报告期末已审批的对外担保额度 报告期末实际对外担保余\n0 0\n合计（A3） 额合计（A4）\n公司对子公司的担保情况\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n浙江海翔川南药业有 2018年04 2019年02月27 连带责任保 2019-02-27~\n20,000 5,000 是 否\n限公司 月04日 日 证 2019-05-17\n浙江海翔川南药业有 2018年04 2019年12月24 连带责任保 2019-12-24~\n20,000 42.4 否 否\n限公司 月04日 日 证 2020-12-24\n报告期内审批对子公司担保额度 报告期内对子公司担保实\n0 5,042.4\n合计（B1） 际发生额合计（B2）\n报告期末已审批的对子公司担保 报告期末对子公司实际担\n20,000 42.4\n额度合计（B3） 保余额合计（B4）\n子公司对子公司的担保情况\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n41。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "4b640e9c",
        "f7b89fc3",
        "c878486b",
        "a38d4530",
        "fb0deaf9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3927,
      "page_number": 37,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.6999999999999998,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37,
          38,
          39,
          40,
          41
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.297447",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 3927,
        "word_count": 473,
        "sentence_count": 58,
        "chinese_char_count": 2772,
        "readability_score": 0.0,
        "information_density": 0.040743570155334856,
        "coherence_score": 0.8052344166531964,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8823529411764706,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "经营",
        "5500元",
        "15500元",
        "400元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "经营",
        "股权",
        "股份",
        "股东",
        "回购",
        "报告",
        "披露",
        "债务"
      ]
    },
    {
      "chunk_id": "7d7b8238",
      "content": "台州市振港染料化工 2017年04 2019年01月15 连带责任保 2019-01-15~\n6,000 240 否 否\n有限公司 月21日 日 证 2020-01-15\n台州市振港染料化工 2017年04 2019年01月23 连带责任保 2019-01-23~\n6,000 172 否 否\n有限公司 月21日 日 证 2020-01-23\n台州市振港染料化工 2017年04 2019年03月22 连带责任保 2019-03-22~\n6,000 523.52 否 否\n有限公司 月21日 日 证 2020-03-22\n报告期内审批对子公司担保额度 报告期内对子公司担保实\n0 935.52\n合计（C1） 际发生额合计（C2）\n报告期末已审批的对子公司担保 报告期末对子公司实际担\n0 935.52\n额度合计（C3） 保余额合计（C4）\n公司担保总额（即前三大项的合计）\n报告期内审批担保额度合计 报告期内担保实际发生额\n0 5,977.92\n（A1+B1+C1） 合计（A2+B2+C2）\n报告期末已审批的担保额度合计 报告期末实际担保余额合\n20,000 977.92\n（A3+B3+C3） 计（A4+B4+C4）\n实际担保总额（即A4+B4+C4）占公司净资产的比例 0.17%\n其中：\n为股东、实际控制人及其关联方提供担保的余额（D） 0\n直接或间接为资产负债率超过70%的被担保对象提供的债务\n0\n担保余额（E）\n担保总额超过净资产50%部分的金额（F） 0\n上述三项担保金额合计（D+E+F） 0\n对未到期担保，报告期内已发生担保责任或可能承担连带清偿\n不适用\n责任的情况说明（如有）\n违反规定程序对外提供担保的说明（如有） 不适用\n采用复合方式担保的具体情况说明\n不适用\n（2）违规对外担保情况\n□ 适用 √ 不适用\n公司报告期无违规对外担保情况。3、委托他人进行现金资产管理情况\n（1）委托理财情况\n√ 适用 □ 不适用\n报告期内委托理财概况\n42。\n\n单位：万元\n具体类型 委托理财的资金来源 委托理财发生额 未到期余额 逾期未收回的金额\n银行理财产品 暂时闲置自有资金 10,000 0 0\n银行理财产品 暂时闲置募集资金 21,000 0 0\n合计 31,000 0 0\n单项金额重大或安全性较低、流动性较差、不保本的高风险委托理财具体情况\n□ 适用 √ 不适用\n委托理财出现预期无法收回本金或存在其他可能导致减值的情形\n□ 适用 √ 不适用\n（2）委托贷款情况\n□ 适用 √ 不适用\n公司报告期不存在委托贷款。4、其他重大合同\n□ 适用 √ 不适用\n公司报告期不存在其他重大合同。十八、社会责任情况\n1、履行社会责任情况\n(1)股东与债权人权益保护\n股东对公司的认可是公司保持稳定发展的基础，保障股东合法权益、维护中小投资者的\n基本利益是公司的根本义务和职责。\n\n公司自上市以来一直严格按照《公司法》、《证券法》、\n《上市公司治理准则》等法律法规，不断健全、完善公司法人治理结构和内部控制制度，持\n续深入开展治理活动，将股东的利益放在公司治理的重中之重，以做到充分保障投资者的各\n项权益。同时依据《信息披露管理制度》、《投资者关系管理制度》等法律法规及时、准确、\n完整、真实地进行信息披露。通过业绩说明会、电话、邮件及投资者互动平台等加强与投资\n者的交流，以便于公司广大股东与债权人能及时的了解公司的经营、财务及重大事项进展情\n况。\n\n公司多年来以稳健、诚信的经营原则，不断努力降低自身经营风险，财务风险、及债权\n人权益风险的目标为之奋斗，实现了股东利益与债权人利益的双赢，同时也增强了投资者对\n公司的认同度。公司2019年共召开3次股东大会，真实、准确和完整的完成各项信息披露，确\n保投资者及时全面了解公司的经营情况，保证了投资者的知情权。因股票市场出现波动，公\n司认为股价不能正确反映公司价值，决定用自有资金进行股份回购。\n\n截止2019年2月25日公司\n回购方案实施完成，公司通过集中竞价方式累计回购股份数量63,005,888股，占公司总股本的\n3.8921%，支付总金额301,511,513.90元（含交易费用）。维护了广大投资者利益，增强投资\n者对公司的投资信心。（2）员工权益保护\n公司多年以来一直将员工视为公司发展前进道路上最为宝贵的财富和动力源泉。\n\n格按照《劳动法》、《劳动合同法》、《社会保险法》等相关法律法规，从员工入职签订《劳\n动合同》，建立员工健康档案，缴纳各项法定社会保险与福利、组织员工入职体检、每年定\n期体检、离职体检等方方面面的工作，确保员工个人权益和身心健康得到全面的保障。公司\n遵循按劳分配、同工同酬的原则，根据员工的劳动成果、工作责任等要素制定薪酬管理制度\n和激励机制。公司注重员工职业规划，为员工规划多方向的职业发展通道，为员工搭建了一\n个公平公正、唯才适用的职业发展平台。\n\n同时公司通过各种渠道倾听员工心声，了解员工的\n确实需求，并采纳合理意见，积极帮助员工排解工作和生活中的实际困难，对员工购买住房、\n子女就学等遇到的困难，公司尽力帮助协调妥善解决；为大学毕业生提供临时住宿，为外来\n务工人员提供住房补贴，改善居住环境。公司还关注员工的业余生活，组织开展如员工子女\n夏利营、趣味运动会、球赛、长跑及公司年会等文娱休闲活动，使员工在休闲放松的同时，\n进一步增进了员工之间的交流沟通，不仅增强了员工的归属感，更提升了海翔这个大家庭的\n凝聚力。（3）供应商、客户权益保护\n公司始终遵循“诚信经营，客户至上”的经营理念，切实的履行了对供应商、客户的社会\n责任。\n\n公司建有完善的采购与供应商评价体系，严格把关监控原材料采购的每一环节，以确\n保原材料的质量和品质的绝对控制。同时也将遇到的问题及时的反馈给供应商，从而形成一\n种良性积极地交流与沟通。注重实地调研和与客户的交流互动，通过一线收集调查信息，为\n营销政策的制定和改进后续服务提供可靠依据。\n\n公司一方面加强对新客户的开发，同时对老\n客户进行走访，建立了良好的客户关系。严格的质量管理体系，才是客户增强信任度、忠实\n度的根本要素。公司积极构建和发展与供应商、客户的战略合作伙伴关系，注重与各相关方\n的沟通与协调，从而共同构筑信任与合作的平台。\n\n（4）环境保护和可持续发展\n公司一直坚持环境保护与企业发展齐头并进的原则，积极响应国家的最新环保政策，坚\n决执行国家和地方的环保法律法规，提倡绿色发展的经营理念。多年来通过主动加大环保投\n入，不断的对技术进行升级与改造、淘汰高能耗设备等方法，提高产能转化效率，达到节能\n减排的目的，公司各项排污指标均已达到甚至超越行业标准。公司未来将坚定不移的走安全\n健康的可持续发展的道路，从而最终实现企业与环境和谐发展的目标。\n\n（5）促进地方教育事业发展\n为积极履行社会责任、促进地方教育事业的发展，公司向台州职业技术学院涌泉奖助基\n金会捐赠人民币132万元，用于促进台州职业技术学院的发展，奖励优秀学生和教师，资助贫\n困学生顺利完成学业，为社会培养更多更好的优秀人才。2、履行精准扶贫社会责任情况\n公司报告年度暂未开展精准扶贫工作，也暂无后续精准扶贫计划。3、环境保护相关的情况\n上市公司及其子公司是否属于环境保护部门公布的重点排污单位\n是\n主要污染物\n公司或子公 排放口分布 执行的污染 核定的排放超标排放情\n及特征污染 排放方式 排放口数量 排放浓度 排放总量\n司名称 情况 物排放标准 总量 况\n物的名称\n44。\n\nCOD:66.45\nCOD≤500m 污水综合排COD：18.9\n浙江海翔药 吨/年(纳管\nCOD、氨 g/L；氨氮 放标准 吨(纳管量);\n业股份有限 间歇 1 厂界内 量)；氨氮：无\n氮、PH ≤35mg/L； （GB8978- 氨氮：1.32\n公司 4.65吨/年\nPH 6-9 1996） 吨(纳管量)\n(纳管量)\n化学合成类\n制药工业大\n浙江海翔药\nVOCs≤150 气污染物排未超过核定VOCs≤12.4\n业股份有限VOCs 连续 1 厂界内 无\n（mg/m3） 放标准 排放总量 2（吨/年）\n公司\nDB33/2015-\n2016\nCOD纳管\n195.45吨/\nCOD≤500/ 污水综合排COD纳管 年(排环境\n浙江海翔川\nCOD、氨 L；氨氮 放标准 190.84吨；量39.09\n南药业有限 间歇 1 厂界内 无\n氮、PH ≤35mg/L； （GB8978- 氨氮纳管 吨)；氨氮纳\n公司\nPH6-9 1996） 13.35吨 管13.68吨/\n年(排环境\n量5.91吨)\nVOCs≤150\n（mg/m3）； VOCs 22.13\n二氧化硫 污水综合排 吨/年；二氧\n浙江海翔川VOCs、二\n≤200 放标准 未超过核定化硫15.2吨\n南药业有限氧化硫、氮间歇 2 厂界内 无\n（mg/m3）；（GB8978- 排放总量 /年；氮氧化\n公司 氧化物\n氮氧化物 1996） 物36.78吨/\n≤400 年\n（mg/m3）\n浙江海翔川\n委托有资质 按照环评核\n南药业有限固废 / / / 3762.85吨 5129吨/年 无\n单位处置 实标准\n公司\n台州市前进\n污水综合排 COD：\n化工有限公 COD<500m COD：8.321\nCOD、氨 放标准 27.164吨/\n司、台州市 间歇 1 厂界内 g/L；氨氮 吨：氨氮： 无\n氮、PH （GB8978- 年；氨氮：\n振港染料化 <35mg/L 1.248吨\n1996） 3.551吨/年\n工有限公司\n45。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "9ebb7487",
        "60cb18b0",
        "99bd2a06",
        "baa98e38"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3932,
      "page_number": 42,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42,
          43,
          44,
          45
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.299628",
        "report_type": "其他",
        "fiscal_year": 2017,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3932,
        "word_count": 348,
        "sentence_count": 60,
        "chinese_char_count": 2623,
        "readability_score": 0.0,
        "information_density": 0.04577822990844354,
        "coherence_score": 0.6912282262428036,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8668362156663276,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "经营",
        "财务",
        "513.90元",
        "132万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "现金",
        "投资",
        "净资产",
        "资产负债率",
        "经营",
        "股本"
      ]
    },
    {
      "chunk_id": "4ff665f6",
      "content": "VOCs≤120\nVOCs：\n（mg/m3）；\n32.337吨/\n二氧化硫 大气污染综\n台州市前进VOCs、二 年；二氧化见其他应公\n<550 合排放标准未超过核定\n化工有限公氧化硫、氮连续 2 厂界内 硫：2.286 开的环境信\n（mg/m3）；（GB16297 排放总量\n司 氧化物 吨/年；氮氧息\n氮氧化物 -1996）\n化物17.562\n<240\n吨/年\n（mg/m3）\n台州市前进\n化工有限公\n委托有资质 按照环评核\n司、台州市危险固废 / / / 661.46吨 2384吨/年 无\n单位处置 实标准\n振港染料化\n工有限公司\nVOCs≤80\nVOCs：\n（mg/m3）；\n大气污染物 9.553吨/\n二氧化硫\n盐城市瓯华VOCs、二 综合排放标 年；二氧化\n≤550 未超过核定\n化学工业有氧化硫、氮间歇 8 厂界内 准 硫 10.875 无\n（mg/m3）； 排放总量\n限公司 氧化物 （GB16297 吨/年；氮氧\n氮氧化物\n-1996） 化物11.986\n≤240\n吨/年\n（mg/m3）\n盐城市瓯华 自行焚烧、\n按照环评核 6017.333吨\n化学工业有固废 委托资质单/ / / 2410.811吨 无\n实标准 /年\n限公司 位处置\n注：台州市振港染料化工有限公司与台州市前进化工有限公司排放浓度和执行的污染物排放标准相同，排放总量和核定的排\n放总量合并在台州市前进化工有限公司统计。防治污染设施的建设和运行情况\n公司在保证现有环保设施正常工作的同时加大了对新设备的投入，分别在母子公司新建了多\n处废水、废气及固废处理设施，有效的减少了污染物的排放。先进的数据实时监控系统，实\n现了对厂界内的污染物排放24小时不间断监测，并整理数据上传监控平台，保证废水废气达\n到排放标准。\n\n建设项目环境影响评价及其他环境保护行政许可情况\n项目严格执行环境许可制度，公司严格遵守环境保护许可法规。突发环境事件应急预案\n公司制定有完善的应急预案，包括厂级的环境事故应急预案和车间级的应急预案。所有应急\n预案都要进行培训，是员工熟悉应急预案，掌握应急技能。\n\n公司每年针对应急预案开展多次\n应急演练，提高员工在紧急情况下的应变能力。环境自行监测方案\n公司配置了环境污染防治检测设备，配备了专职日常检测分析与实验队伍，具备了较多项目\n的自行检测能力，为公司环境污染防治设施的正常稳定运行提供了保障。同时，定期委托其\n他机构进行特种污染因子的监测。\n\n其他应当公开的环境信息\n46。\n\n2019年8月，瓯华化工收到盐城市生态环境局出具的《行政处罚决定书》：2019年5月，盐城\n市生态环境局在现场检查中发现瓯华化工存在危废管理不规范情况，鉴于瓯华化工已主动整\n改到位，符合《盐城市生态环境局行政案件办理程序规定》第七条“主动消除或者减轻环境违\n法行为危害后果的”等从轻处罚的适用条款，对瓯华化工从轻处罚，处罚款人民币四万元。2019年10月，台州前进收到台州市生态环境局出具的《行政处罚决定书》： 2019年5月台州\n前进存在排放不符合大气污染物排放标准废气的情形，后果轻微，处罚款人民币十万元。其他环保相关信息\n无\n十九、其他重大事项的说明\n□ 适用 √ 不适用\n公司报告期不存在需要说明的其他重大事项。\n\n二十、公司子公司重大事项\n√ 适用 □ 不适用\n1、2019年4月，振港染料设立浙江盛嘉环保科技有限公司，注册资本1000万元，主要从事环\n保技术开发与咨询,污水处理。目前振港染料尚未实际出资。2、2019年7月，公司全资子公司台州港翔化工有限公司完成工商变更，股东由公司变更为川\n南药业。\n\n3、2019年12月，川南药业完成经营范围变更，增加“医药废物、废药物、药品等危险废物的\n收集、贮存、焚烧处置”。4、公司第五届董事会第二十三次会议通过了《关于对外投资参与设立合伙企业的议案》，同\n意公司出资2,000万元参与设立杭州寓鑫创业投资合伙企业（有限合伙）（以下简称：“寓鑫\n投资”）。截止目前寓鑫投资已募集18,710万元,后续可能新增其他有限合伙人，具体内容详见\n《关于对外投资参与设立合伙企业的进展公告》（公告编号：2020-002）。\n\n第六节股份变动及股东情况\n一、股份变动情况\n1、股份变动情况\n单位：股\n本次变动前 本次变动增减（＋，－） 本次变动后\n数量 比例 发行新股 送股 公积金转股 其他 小计 数量 比例\n一、有限售条件股份 27,076,100 1.68% -12,801,500 -12,801,500 14,274,600 0.88%\n3、其他内资持股 27,076,100 1.68% -12,801,500 -12,801,500 14,274,600 0.88%\n境内自然人持股 27,076,100 1.68% -12,801,500 -12,801,500 14,274,600 0.88%\n二、无限售条件股份 1,591,744,153 98.33% 12,696,500 12,696,500 1,604,440,653 99.12%\n1、人民币普通股 1,591,744,153 98.33% 12,696,500 12,696,500 1,604,440,653 99.12%\n三、股份总数 1,618,820,253 100.00% -105,000 -105,000 1,618,715,253 100.00%\n股份变动的原因\n√ 适用 □ 不适用\n（1）限制性股票激励计划第四个解锁期解锁\n公司于2019年3月13日召开第五届董事会第二十一次会议，审议通过了《关于限制性股票\n激励计划首次授予部分第四个解锁期及预留部分第三个解锁期解锁条件成就的议案》。本次\n符合解锁条件的激励对象共308人，其中符合首次授予限制性股票第四期解锁条件的激励对象\n共计307人，解锁的限制性股票数量为1,654.65万股。本次符合预留部分限制性股票第三期解\n锁条件的激励对象1人，解锁的限制性股票数量为160万股。\n\n（2）限制性股票回购注销\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。股份变动的批准情况\n□ 适用 √ 不适用\n股份变动的过户情况\n√ 适用 □ 不适用\n详情请见股份变动原因\n股份回购的实施进展情况\n√ 适用 □ 不适用\n公司本次回购公司股份相关议案已分别经公司2018年2月12日召开的第五届董事会第十\n四次会议、2018年2月26日召开的2018年第一次临时股东大会审议通过，并于2018年3月20日\n披露了《回购报告书》。\n\n内容详见公司于《中国证券报》、《上海证券报》、《证券时报》、\n《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《回购报告书》（公告编\n48。\n\n号:2018-019）。公司2018年10月16日召开的第五届董事会第十九次会议和2018年11月1日召开的2018年\n第三次临时股东大会审议通过了《关于调整回购股份事项的议案》，同意对回购方案进行调\n整：将原回购方案中“以自有资金进行股份回购，总金额不超过人民币30,000万元，回购股份\n用途包括但不限于用作注销以减少公司注册资本。”调整为“以自有资金进行股份回购，总金\n额不低于人民币30,000万元，不超过人民币50,000万元（含50,000万元），回购股份用途包括\n但不限于用作员工持股计划、股权激励计划或注销以减少公司注册资本。\n\n”具体内容详见公司\n于《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网\n（http://www.cninfo.com.cn）刊登的《回购报告书（调整后）》（公告编号:2018-093）。2019年2月26日，公司披露《关于回购公司股份实施完成的公告》：截止2019年2月25日，公\n司回购股份实施期限届满，回购股份已实施完成。公司通过集中竞价方式累计回购股份数量\n为63,005,888股，占公司当前总股本（1,618,820,253股）的3.8921%，最高成交价为5.57元/股，\n最低成交价为4.32元/股，支付的总金额301,511,513.90元（含交易费用）。\n\n公司本次回购的股\n份存放于公司回购专用证券账户，由于本次回购用途用于实施股权激励计划或员工持股计划，\n公司总股本不会发生变化。如果后续涉及股份注销，公司将按规定及时履行信息披露义务。公司本次回购股份用途将根据公司实际情况由股东大会授权董事会依据有关法律法规决定，\n公司将适时作出安排并及时披露。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "c7b582a4",
        "7f0f7009",
        "6b70a847",
        "515871a3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3589,
      "page_number": 46,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46,
          47,
          48,
          49
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.301633",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "台州市振港染料化工有限公司与台州市前进化工有限公司",
        "industry": null,
        "char_count": 3589,
        "word_count": 238,
        "sentence_count": 68,
        "chinese_char_count": 2267,
        "readability_score": 0.0,
        "information_density": 0.041794371691278906,
        "coherence_score": 0.7021964925468751,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8526609083310115,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "1000万元",
        "000万元",
        "710万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "投资",
        "合并",
        "经营",
        "股本",
        "股权",
        "股份",
        "股东",
        "总股本",
        "回购"
      ]
    },
    {
      "chunk_id": "792efe24",
      "content": "具体内容详见公司于《中国证券报》、《上海证券报》、\n《证券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于回购公\n司股份实施完成的公告》（公告编号:2019-019）。采用集中竞价方式减持回购股份的实施进展情况\n□ 适用 √ 不适用\n股份变动对最近一年和最近一期基本每股收益和稀释每股收益、归属于公司普通股股东的每股净资产等财务指标的影响\n□ 适用 √ 不适用\n公司认为必要或证券监管机构要求披露的其他内容\n□ 适用 √ 不适用\n2、限售股份变动情况\n√ 适用 □ 不适用\n单位：股\n本期增加限售股 本期解除限售股\n股东名称 期初限售股数 期末限售股数 限售原因 解除限售日期\n数 数\n299名限制性股 限制性股票激励\n12,696,500 0 12,696,500 0 2019年4月4日\n票激励对象 计划第四期解锁\n回购离职激励对\n回购5人限制性\n105,000 0 105,000 0象持有的尚未解 2019年6月24日\n股票\n禁的限制性股票\n合计 12,801,500 0 12,801,500 0 -- --\n49。\n\n二、证券发行与上市情况\n1、报告期内证券发行（不含优先股）情况\n□ 适用 √ 不适用\n2、公司股份总数及股东结构的变动、公司资产和负债结构的变动情况说明\n√ 适用 □ 不适用\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。3、现存的内部职工股情况\n□ 适用 √ 不适用\n三、股东和实际控制人情况\n1、公司股东数量及持股情况\n单位：股\n年度报告披露\n报告期末表决\n年度报告披露 日前上一月末\n权恢复的优先\n报告期末普通 日前上一月末 表决权恢复的\n71,441 71,441股股东总数 0 0\n股股东总数 普通股股东总 优先股股东总\n（如有）（参见\n数 数（如有）（参\n注8）\n见注8）\n持股5%以上的股东或前10名股东持股情况\n报告期内 持有有限 持有无限 质押或冻结情况\n报告期末\n股东名称 股东性质 持股比例 增减变动 售条件的 售条件的\n持股数量 股份状态 数量\n情况 股份数量 股份数量\n浙江东港投资有 553,982,5-2201741 553,982,5\n境内非国有法人 34.22% 0 质押 241,382,587\n限公司 873 87\n118,800,0 118,800,0\n王云富 境内自然人 7.34% 0 0\n00 00\n新昌勤进投资有 49,650,00-1435000 49,650,00\n境内非国有法人 3.07% 0\n限公司 00 0\n香港中央结算有 21,438,17 21,438,17\n境外法人 1.32% 18018169 0\n限公司 8 8\n14,350,00 14,350,00\n王丽英 境内自然人 0.89% 14350000 0\n0 0\n50。\n\n中央汇金资产管 10,540,40 10,540,40\n国有法人 0.65% 0 0\n理有限责任公司 0 0\n全国社保基金一 10,000,00 10,000,00\n其他 0.62% 10000000 0\n一七组合 0 0\n中国工商银行股\n份有限公司－国\n其他 0.53% 8,595,0008595000 0 8,595,000\n泰鑫睿混合型证\n券投资基金\n招商银行股份有\n限公司－汇添富\n医疗服务灵活配 其他 0.38% 6,100,0496100049 0 6,100,049\n置混合型证券投\n资基金\n-1618820\n叶小青 境内自然人 0.36% 5,796,235 0 5,796,235\n0\n战略投资者或一般法人因配售新股\n成为前10名股东的情况（如有）（参无\n见注3）\n1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n上述股东关联关系或一致行动的说 的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司\n明 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制\n人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n\n前10名无限售条件股东持股情况\n股份种类\n股东名称 报告期末持有无限售条件股份数量\n股份种类 数量\n浙江东港投资有限公司 553,982,587人民币普通股 553,982,587\n王云富 118,800,000人民币普通股 118,800,000\n新昌勤进投资有限公司 49,650,000人民币普通股 49,650,000\n香港中央结算有限公司 21,438,178人民币普通股 21,438,178\n王丽英 14,350,000人民币普通股 14,350,000\n中央汇金资产管理有限责任公司 10,540,400人民币普通股 10,540,400\n全国社保基金一一七组合 10,000,000人民币普通股 10,000,000\n中国工商银行股份有限公司－国泰\n8,595,000人民币普通股 8,595,000\n鑫睿混合型证券投资基金\n招商银行股份有限公司－汇添富医\n疗服务灵活配置混合型证券投资基 6,100,049人民币普通股 6,100,049\n金\n叶小青 5,796,235人民币普通股 5,796,235\n51。\n\n前10名无限售流通股股东之间，以 1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n及前10名无限售流通股股东和前10的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司\n名股东之间关联关系或一致行动的 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制\n说明 人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n\n1、新昌勤进投资有限公司通过普通账户持股1465万股，通过信用账户持股3500万\n前10名普通股股东参与融资融券业\n股。2、王丽英通过信用账户持股1435万股。3、其他股东不存在通过信用账户持股\n务情况说明（如有）（参见注4）\n的情况。\n3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。\n\n公司前10名普通股股东、前10名无限售条件普通股股东在报告期内是否进行约定购回交易\n□ 是 √ 否\n公司前10名普通股股东、前10名无限售条件普通股股东在报告期内未进行约定购回交易。2、公司控股股东情况\n控股股东性质：自然人控股\n控股股东类型：法人\n法定\n代表\n控股股东名 成立日\n人/单 组织机构代码 主要经营业务\n称 期\n位负\n责人\n国家法律、法规和政策允许的投资业务；股权投资、资产管理（未经金融\n1998 等监管部门批准，不得从事向公众融资存款、融资担保、代客理财等金融\n浙江东港投 王云 年07 服务）；机械设备、电子产品、工艺品、服装、家用电器、日用品、针纺织\n913310027046766827\n资有限公司 富 月09 品、金属材料、建材销售；黄金饰品加工、销售；房地产开发；市场摊位\n日 租赁；塑料原料销售；企业管理咨询服务；货物及技术进出口（国家法律、\n法规禁止或限制经营的项目除外）。控股股东报\n告期内控股\n和参股的其\n无\n他境内外上\n市公司的股\n权情况\n控股股东报告期内变更\n□ 适用 √ 不适用\n公司报告期控股股东未发生变更。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "5f5eb4bb",
        "df6954e4",
        "fc757829",
        "a5e0e4ca"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3134,
      "page_number": 49,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49,
          50,
          51,
          52
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.303619",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江东港投资有限公司",
        "industry": null,
        "char_count": 3134,
        "word_count": 324,
        "sentence_count": 37,
        "chinese_char_count": 1814,
        "readability_score": 0.0,
        "information_density": 0.05105296745373324,
        "coherence_score": 0.6772710005523264,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8315252074026802,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "净资产",
        "营业",
        "经营",
        "财务指标",
        "股权",
        "股份",
        "股东"
      ]
    },
    {
      "chunk_id": "5bf2139d",
      "content": "3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。\n\n是否取得其他国家或地区居\n实际控制人姓名 与实际控制人关系 国籍\n留权\n王云富 本人 中国 否\n一致行动（含协议、亲属、同\n王扬超 中国 否\n一控制）\n王云富先生自2003年3月起一直在东港集团任职，曾担任东港集团副董事长、总裁、党委\n副书记、工会主席等职务，2012年9月至今担任东港工贸集团有限公司执行董事、东港投\n资执行董事。王云富先生持有东港工贸集团有限公司73.20%的股权。王扬超先生系公司实际控制人王云富先生之子，2008年参加工作，曾担任东港工贸集团有\n主要职业及职务\n限公司销售经理、总裁助理，台州市振港染料化工有限公司常务副总、台州市前进化工有限\n公司总经理等职务。\n\n现担任台州市椒江区第十届政协委员会常委、台州市椒江区工商业联合\n会副会长、上海海翔医药科技发展有限公司执行董事等。王扬超先生未直接持有公司股票，\n持有东港工贸集团有限公司26.80%的股权，故王扬超先生间接持有公司股份。过去10年曾控股的境内外上\n无\n市公司情况\n实际控制人报告期内变更\n□ 适用 √ 不适用\n公司报告期实际控制人未发生变更。\n\n公司与实际控制人之间的产权及控制关系的方框图\n实际控制人通过信托或其他资产管理方式控制公司\n□ 适用 √ 不适用\n4、其他持股在10%以上的法人股东\n□ 适用 √ 不适用\n53。\n\n5、控股股东、实际控制人、重组方及其他承诺主体股份限制减持情况\n□ 适用 √ 不适用\n54 第七节优先股相关情况\n□ 适用 √ 不适用\n报告期公司不存在优先股。\n55\n第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。\n56 第九节董事、监事、高级管理人员和员工情况\n一、董事、监事和高级管理人员持股变动\n本期增持 本期减持\n任期起始 任期终止 期初持股 其他增减 期末持股\n姓名 职务 任职状态 性别 年龄 股份数量 股份数量\n日期 日期 数（股） 变动（股）数（股）\n（股） （股）\n2015年 2022年\n孙杨 董事长 现任 男 5308月25 11月12 4,400,000 0 0 0 4,400,000\n日 日\n2019年 2022年\n王扬超 副董事长 现任 男 3311月13 11月12 0 0 0 0 0\n日 日\n2014年 2022年\n董事、总\n杨思卫 现任 男 4612月08 11月12 4,857,800 0 0 0 4,857,800\n经理\n日 日\n2017年 2022年\n洪鸣 董事 现任 男 3705月31 11月12 315,000 0 78,750 0 236,250\n日 日\n2016年 2022年\n朱建伟 董事 现任 男 6410月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n姚冰 董事 现任 男 3811月13 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n苏为科 独立董事 现任 男 5910月17 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n毛美英 独立董事 现任 女 5710月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n张克坚 独立董事 现任 男 6411月13 11月12 0 0 0 0 0\n日 日\n监事会主 2019年 2022年\n陈敏杰 席、职工 现任 男 5211月13 11月12 0 0 0 0 0\n监事 日 日\n57。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "1d679fc2",
        "d1dad645"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1461,
      "page_number": 52,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52,
          53,
          54
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.305407",
        "report_type": "其他",
        "fiscal_year": 2003,
        "fiscal_quarter": null,
        "company_code": "月至今担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 1461,
        "word_count": 243,
        "sentence_count": 13,
        "chinese_char_count": 825,
        "readability_score": 0.0,
        "information_density": 0.04791238877481178,
        "coherence_score": 0.7909771588061062,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8258726899383984,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "股权",
        "股份",
        "股东",
        "报告",
        "债券"
      ]
    },
    {
      "chunk_id": "d3c145e7",
      "content": "第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。\n56 第九节董事、监事、高级管理人员和员工情况\n一、董事、监事和高级管理人员持股变动\n本期增持 本期减持\n任期起始 任期终止 期初持股 其他增减 期末持股\n姓名 职务 任职状态 性别 年龄 股份数量 股份数量\n日期 日期 数（股） 变动（股）数（股）\n（股） （股）\n2015年 2022年\n孙杨 董事长 现任 男 5308月25 11月12 4,400,000 0 0 0 4,400,000\n日 日\n2019年 2022年\n王扬超 副董事长 现任 男 3311月13 11月12 0 0 0 0 0\n日 日\n2014年 2022年\n董事、总\n杨思卫 现任 男 4612月08 11月12 4,857,800 0 0 0 4,857,800\n经理\n日 日\n2017年 2022年\n洪鸣 董事 现任 男 3705月31 11月12 315,000 0 78,750 0 236,250\n日 日\n2016年 2022年\n朱建伟 董事 现任 男 6410月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n姚冰 董事 现任 男 3811月13 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n苏为科 独立董事 现任 男 5910月17 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n毛美英 独立董事 现任 女 5710月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n张克坚 独立董事 现任 男 6411月13 11月12 0 0 0 0 0\n日 日\n监事会主 2019年 2022年\n陈敏杰 席、职工 现任 男 5211月13 11月12 0 0 0 0 0\n监事 日 日\n57。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "0834e224"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 770,
      "page_number": 56,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          56
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.306252",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 770,
        "word_count": 183,
        "sentence_count": 2,
        "chinese_char_count": 285,
        "readability_score": 0.0,
        "information_density": 0.03896103896103896,
        "coherence_score": 0.21,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6818181818181818,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "报告",
        "债券"
      ]
    },
    {
      "chunk_id": "310d2fef",
      "content": "2014年 2022年\n汪启华 监事 现任 男 5605月15 11月12 0 0 0 0 0\n日 日\n2012年 2022年\n龚伟中 监事 现任 男 5510月11 11月12 0 0 0 0 0\n日 日\n2017年 2022年\n常务副总\n李洪明 现任 男 5105月13 11月12 600,000 0 20,000 580,000\n经理\n日 日\n2011年 2022年\n沈利华 副总经理 现任 男 5402月23 11月12 1,200,000 0 0 0 1,200,000\n日 日\n副总经 2012年 2022年\n许华青 理、董事 现任 女 3909月19 11月12 1,260,000 0 315,000 0 945,000\n会秘书 日 日\n副总经 2016年 2022年\n李进 理、财务 现任 男 3610月17 11月12 0 0 0 0 0\n总监 日 日\n2013年 2022年\n毛文华 副总经理 现任 男 5307月19 11月12 1,800,000 0 450,000 0 1,350,000\n日 日\n2014年 2022年\n许国睿 副总经理 现任 男 4311月21 11月12 600,000 150,000 0 450,000\n日 日\n2015年 2019年\n原副董事\n郭敏龙 离任 男 5608月25 11月12 4,000,000 1,000,000 0 3,000,000\n长\n日 日\n2015年 2019年\n原独立董\n田利明 离任 男 6605月06 11月12 0 0 0 0 0\n事\n日 日\n原监事会 2004年 2019年\n郭世华 主席、职 离任 男 6004月01 11月12 0 0 0 0 0\n工监事 日 日\n19,032,80 17,019,05\n合计 -- -- -- -- -- -- 0 2,013,750 0\n0 0\n二、公司董事、监事、高级管理人员变动情况\n√ 适用 □ 不适用\n58。\n\n姓名 担任的职务 类型 日期 原因\n原董事、副董事 2019年11月12\n郭敏龙 任期满离任 换届离任\n长 日\n2019年11月12\n田利明 独立董事 任期满离任 换届离任\n日\n原监事会主席、 2019年11月12\n郭世华 任期满离任 换届离任\n职工监事 日\n原董事，现任副 2019年11月12\n沈利华 任免 董事职务换届离任，仍继续担任公司副总经理\n总经理 日\n三、任职情况\n公司现任董事、监事、高级管理人员专业背景、主要工作经历以及目前在公司的主要职责\n（一）董事\n1、孙杨先生，中国国籍，无境外永久居留权，生于1967年4月，大专文化，中共党员，工\n程师。历任东港集团东港精细化工厂车间主任、生产厂长、厂长、集团公司总裁助理、副总\n裁。2013年11月进入本公司工作，2014年8月被选举为公司董事，现任公司董事长，兼任公司\n全资子公司浙江海翔川南药业有限公司执行董事。\n\n2、王扬超先生，中国国籍，无境外居留权，生于1987年2月，长江商学院EMBA在读。2008\n年参加工作，曾担任东港工贸集团有限公司销售经理、总裁助理，台州市振港染料化工有限\n公司常务副总、台州市前进化工有限公司总经理等职务。现担任公司副董事长、台州市椒江\n区第十届政协委员会常委、台州市椒江区工商业联合会副会长、上海海翔医药科技发展有限\n公司执行董事等。\n\n3、杨思卫先生，中国国籍，无境外永久居留权，生于1974年8月，大学文化，中共党员，\n高级经济师，曾就职于南京恒信达化工有限公司任总经理，2002年进入盐城市瓯华化学工业\n有限公司工作至今，现任盐城瓯华董事长。曾获江苏省科技企业家、盐城市“杰出青年创新人\n才”、盐城市“优秀企业家”、滨海“十大杰出青年”等称号，曾担任盐城市第六、七届市人大代\n表。2014年12月8日起任公司董事，2015年1月20日起任公司总经理。\n\n4、洪鸣先生，中国国籍，无境外永久居留权，生于1983年12月，硕士研究生，中共党员，\n工程师。2006年进入浙江海翔药业股份有限公司工作，历任医药国际注册员，项目经理，业\n务发展高级经理，销售公司副总经理，现任医药板块营销中心总经理。2017年5月31日起任公\n司董事。\n\n5、朱建伟先生，美国国籍，生于1956年6月，讲席教授，上海医药工业研究院微生物药学\n硕士，上海医药工业研究院微生物遗传博士，美国Hood学院工商管理硕士。1991年9月至1997\n年9月在哈佛大学、Joslin糖尿病研究所担任高级研究员，1997年9月至2014年6月任美国\nFrederick国家癌症实验室技术运行总监，2012年9月至今任上海交通大学药学院院长，现担任\n浙江医药股份有限公司独立董事，也是国家千人计划引进的海外高层次人才。2016年10月17\n日起担任公司董事。\n\n6、姚冰先生，中国国籍，无境外永久居留权，生于1982年11月，中共党员，澳洲注册会\n计师。北京大学光华管理学院工商管理硕士在读，毕业于中国外交学院外交学专业硕士，浙\n江大学城市学院通信工程专业学士。2007年至2016年历任中国外交部北美与大洋洲司、驻加\n拿大、卡塔尔、新西兰等国外交官及领事官。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "c17483b7",
        "ad9ef880"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2140,
      "page_number": 58,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          58,
          59
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.306705",
        "report_type": "其他",
        "fiscal_year": 2014,
        "fiscal_quarter": null,
        "company_code": "曾担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 2140,
        "word_count": 254,
        "sentence_count": 19,
        "chinese_char_count": 1171,
        "readability_score": 0.0,
        "information_density": 0.009345794392523366,
        "coherence_score": 0.2488235294117647,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8188785046728972,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份"
      ]
    },
    {
      "chunk_id": "821959ae",
      "content": "2016年至2019年在普华永道任高级经理，负责\n中国企业海外投资并购咨询等业务。2019年11月13日起担任公司董事、副总经理。59。\n\n7、苏为科先生，中国国籍，无境外永久居留权，生于1961年2月，理学博士。历任浙江工\n学院有机化学教研室助教，浙江工业大学有机化工教研室讲师，副教授，现任浙江工业大学\n教授，兼任浙江省制药工程重点实验室主任，浙江省新药创制科技服务平台负责人，浙江省\n制药重中之重学科负责人，长三角绿色制药协同创新中心执行主任，国家化学原料药合成工\n程技术研究中心常务副主任。现担任兄弟科技股份有限公司、浙江花园生物高科股份有限公\n司的独立董事。\n\n2016年10月17日起担任公司独立董事。8、毛美英女士，中国国籍，无境外永久居留权，生于1963年10月，本科学历，高级会计\n师。历任临海长途客运公司计财科副科长，浙江台州高速公路建设开发股份有限公司主办会\n计，计财部副经理，台州市台金高速公路建设指挥部财务处处长。\n\n现在从事台州市沿海高速\n公路建设管理中心财务工作，现任浙江万盛股份有限公司、浙江伟星实业发展股份有限公司、\n永高股份有限公司、浙江永强集团股份有限公司独立董事。2016年10月17日起担任公司独立\n董事。9、张克坚先生，中国国籍，无境外永久居留权，生于1956年4月，教授、博士、博士生导\n师、享受国务院特殊津贴专家。\n\n一直从事药学相关的教学、研发管理工作,现任广东华南新药\n创制中心首席科学家。历任中国医学科学院药物研究所研究员、卫生部临床检验中心室主任、\n药品审评中心副主任、医疗器械技术审评中心副主任、中山大学药学院教授、广东华南新药\n创制中心副主任。现任亿帆医药股份有限公司独立董事、湖南方盛制药股份有限公司独立董\n事、华润医药集团有限公司（香港）独立非执行董事。\n\n（二）监事\n1、陈敏杰先生，中国国籍，无境外永久居留权，生于1968年6月，大专文化，中共党员，\n经济师、助理政工师。1987年进入天台七四三厂工作，1995年9月进入东港工贸集团有限公司\n工作，现在本公司从事行政事务及党群工作。2、汪启华先生，中国国籍，无境外永久居留权，生于1964年10月，硕士。\n\n2008年至2011\n年在新东港药业股份有限公司工作，任营销总监；2011年至2013年在以色列Teva公司任驻中\n国客户经理；2014年1月至今在浙江海翔药业股份有限公司工作，现任本公司监事，兼任公司\n全资子公司上海海翔医药科技发展有限公司监事，全资子公司浙江海翔药业销售有限公司执\n行董事，全资子公司台州港翔化工有限公司监事。3、龚伟中先生，中国国籍，无境外永久居留权，生于1965年9月，理学博士，研究员。曾\n任台州海翔医药化工科技有限公司总经理，现任浙江海翔药业股份有限公司政府项目部总监、\n浙江海翔药业股份有限公司党委书记，2012年10月11日起任公司监事。\n\n（三）高级管理人员\n1、李洪明先生，中国国籍，无境外永久居留权，生于1969年2月，天津大学化学工程专\n业本科学士学位，2005年毕业于美国匹兹堡大学，博士学位，曾担任上海瑞浦实业有限公司\n董事、总经理、海翔研究院院长、公司研发副总，现担任公司常务副总经理。2、沈利华先生，中国国籍，无境外永久居留权，生于1966年12月，大专文化。1985年起\n在公司工作至今，曾担任车间主任、QC主任、QA主任、台州泉丰医药化工有限公司副总经\n理、公司总经理助理、浙江普健制药有限公司总经理以及公司监事、董事等职务，2011年2\n月23日起担任公司副总经理。\n\n3、许华青女士，中国国籍，无境外永久居留权，生于1981年5月，大学文化。2005年1月\n起在公司工作至今，曾任公司证券事务代表，投资发展部经理。2007年2月取得深圳证券交易\n所董事会秘书资格证书。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "d49635f5",
        "0df9ccfd"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1576,
      "page_number": 59,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          59,
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.308292",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "现担任兄弟科技股份有限公司",
        "industry": null,
        "char_count": 1576,
        "word_count": 42,
        "sentence_count": 27,
        "chinese_char_count": 1223,
        "readability_score": 0.0,
        "information_density": 0.031725888324873094,
        "coherence_score": 0.2850771428571428,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9104060913705585,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股份",
        "证券"
      ]
    },
    {
      "chunk_id": "68b3b5d1",
      "content": "2012年9月19日起任公司副总经理、董事会秘书。4、李进先生，中国国籍，无永久境外居留权，生于1984年2月，中共党员，大学本科学历，\n会计师，注册会计师。2006年毕业于浙江财经学院。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "ddf7f7a6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 94,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.309238",
        "report_type": "其他",
        "fiscal_year": 2012,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 94,
        "word_count": 2,
        "sentence_count": 3,
        "chinese_char_count": 64,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6287404255319149,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "42eff880",
      "content": "2006-2016年就职于天健会计师事务所（特\n殊普通合伙），历任审计员、项目经理、部门经理等职，2016年10月17日起担任公司副总经\n60。\n\n理、财务总监。5、毛文华先生,中国国籍,无境外永久居留权,生于1967年8月,大学文化,工程师,质量工程师,\n执业药师,1988年毕业于浙江工学院（现浙江工业大学）化学工程专业。1988年分配至浙江温\n岭制药厂,先后服务于浙江永宁制药厂、浙江海正药业股份有限公司、浙江医药股份有限公司，\n2012年10月进入本公司工作至今，2013年7月19日起担任公司副总经理。\n\n6、许国睿先生，中国国籍，无境外永久居留权，生于1977年6月，中共党员，大学文化。2000年2月进入公司工作至今，曾获台州市椒江区青年岗位能手荣誉称号。历任浙江海翔药业\n销售有限公司部门经理，副总经理，常务副总经理，2014年11月20日起担任公司副总经理。\n\n在股东单位任职情况\n√ 适用 □ 不适用\n在股东单位 在股东单位是否\n任职人员姓名 股东单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n王扬超 东港工贸集团有限公司 监事 否\n在股东单位任\n无\n职情况的说明\n在其他单位任职情况\n√ 适用 □ 不适用\n在其他单位 在其他单位是否\n任职人员姓名 其他单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n朱建伟 上海交通大学药学院 院长 是\n朱建伟 浙江医药股份有限公司 独立董事 是\n苏为科 浙江工业大学 教授 是\n苏为科 浙江花园生物高科股份有限公司 独立董事 是\n苏为科 兄弟科技股份有限公司 独立董事 是\n执行董事兼\n苏为科 浙江天诺医药科技有限公司 是\n总经理\n毛美英 台州市沿海高速公路建设管理中心 职员 是\n毛美英 浙江万盛股份有限公司 独立董事 是\n毛美英 浙江伟星实业发展股份有限公司 独立董事 是\n毛美英 永高股份有限公司 独立董事 是\n毛美英 浙江永强集团股份有限公司 独立董事 是\n张克坚 亿帆医药股份有限公司 独立董事 是\n张克坚 湖南方盛制药股份有限公司 独立董事 是\n独立非执行\n张克坚 华润医药集团有限公司 是\n董事\n张克坚 广东华南新药创制中心 首席科学家 是\n孙杨 浙江海翔川南药业有限公司 执行董事 否\n61。\n\n杨思卫 盐城市瓯华化学工业有限公司 董事长 否\n王扬超 上海海翔医药科技发展有限公司 执行董事 否\n台州市椒江民营企业联合投资股份有限\n王扬超 董事 否\n公司\n李洪明 上海海翔医药科技发展有限公司 总经理 否\n汪启华 上海海翔医药科技发展有限公司 监事 否\n汪启华 浙江海翔药业销售有限公司执行董事 执行董事 否\n汪启华 台州港翔化工有限公司 监事 否\n公司现任及报告期内离任董事、监事和高级管理人员近三年证券监管机构处罚的情况\n□ 适用 √ 不适用\n四、董事、监事、高级管理人员报酬情况\n董事、监事、高级管理人员报酬的决策程序、确定依据、实际支付情况\n决策程序:公司按照《董事、监事、高级管理人员薪酬管理制度》，建立了高级管理人员的\n薪酬与公司业绩挂钩的绩效考核与激励约束机制，公司高级管理人员实行基本年薪和年终绩\n效考核相结合的薪酬制度。确定依据:年末根据公司年度经营目标完成情况以及高级管理人员的工作业绩，由董事会\n薪酬与考核委员会对高级管理人员进行年度绩效考核，并监督薪酬制度执行情况。公司则根\n据绩效考核结果兑现其绩效年薪，并进行奖惩。\n\n实际支付情况：报告期内，公司董事、监事、高管的薪酬根据薪酬计划按月发放。公司报告期内董事、监事和高级管理人员报酬情况\n单位：万元\n从公司获得的税 是否在公司关联\n姓名 职务 性别 年龄 任职状态\n前报酬总额 方获取报酬\n孙杨 董事、董事长 男 53现任 80.08 否\n王扬超 董事、副董事长 男 33现任 60.08 否\n杨思卫 董事、总经理 男 46现任 70.08 否\n洪鸣 董事 男 37现任 35.08 否\n朱建伟 董事 男 64现任 8 否\n姚冰 董事 男 38现任 13.98 否\n苏为科 独立董事 男 59现任 8 否\n毛美英 独立董事 女 57现任 8 否\n张克坚 独立董事 男 64现任 2 否\n监事会主席、职\n陈敏杰 男 52现任 10.94 否\n工监事\n汪启华 监事 男 56现任 45.08 否\n龚伟中 监事 男 55现任 26.54 否\n62。\n\n李洪明 常务副总经理 男 51现任 60.14 否\n沈利华 副总经理 男 54现任 60.08 否\n副总经理、董事\n许华青 女 39现任 60.08 否\n会秘书\n副总经理、财务\n李进 男 36现任 60.08 否\n总监\n毛文华 副总经理 男 53现任 60.08 否\n许国睿 副总经理 男 43现任 60.08 否\n原董事、副董事\n郭敏龙 男 56离任 68.08 否\n长\n田利明 原独立董事 男 66离任 6 否\n原监事会主席、\n郭世华 男 60离任 12.8 否\n职工监事\n合计 -- -- -- -- 815.28 --\n公司董事、高级管理人员报告期内被授予的股权激励情况\n√ 适用 □ 不适用\n单位：股\n报告期内 报告期新 限制性股\n报告期内 报告期内 报告期末 期初持有 本期已解 期末持有\n已行权股 授予限制 票的授予\n姓名 职务 可行权股 已行权股 市价（元/ 限制性股 锁股份数 限制性股\n数行权价 性股票数 价格（元/\n数 数 股） 票数量 量 票数量\n格（元/股） 量 股）\n孙杨 董事长 1,100,000 1,100,000 2.25 0\n董事，总经\n杨思卫 1,100,000 1,100,000 2.25 0\n理\n原副董事\n郭敏龙 1,600,000 1,600,000 4.3125 0\n长\n毛文华 副总经理 600,000 600,000 2.25 0\n副总经理，\n许华青 董事会秘 300,000 300,000 2.25 0\n书\n沈利华 副总经理 300,000 300,000 2.25 0\n洪鸣 董事 150,000 150,000 2.25 0\n李洪明 副总经理 150,000 150,000 2.25 0\n许国睿 副总经理 150,000 150,000 2.25 0\n合计 -- 0 0 -- -- 5,450,000 5,450,000 0 -- 0\n63。\n\n五、公司员工情况\n1、员工数量、专业构成及教育程度\n母公司在职员工的数量（人） 482\n主要子公司在职员工的数量（人） 2,812\n在职员工的数量合计（人） 3,294\n当期领取薪酬员工总人数（人） 3,294\n母公司及主要子公司需承担费用的离退休职工人数（人） 0\n专业构成\n专业构成类别 专业构成人数（人）\n生产人员 1,769\n销售人员 77\n技术人员 659\n财务人员 53\n行政人员 736\n合计 3,294\n教育程度\n教育程度类别 数量（人）\n硕士及以上 50\n本科 484\n大专 541\n其他学历 2,219\n合计 3,294\n2、薪酬政策\n公司按照《中华人民共和国劳动合同法》和国家及地方其他有关劳动法律、法规的规定，与\n员工签订劳动合同。公司严格执行国家用工制度、劳动保护制度、社会保障制度和医疗保障\n制度，按照国家规定为员工缴纳养老保险、医疗保险、工伤保险、失业保险、生育保险及公\n积金。公司向员工提供稳定而有竞争力的薪酬，实施了公平公正的绩效考核机制。\n\n3、培训计划\n公司一直非常重视员工培训，每年制定并下发年度培训计划，公司培训主要培训内容有GMP\n培训、安全生产培训、专业知识培训、管理能力培训等，采取内培为主，内外结合形式。通\n过培训，提高了公司员工整体的职业素质、专业技能，同时也满足了员工对自身职业能力提\n升的需求。64。\n\n4、劳务外包情况\n□ 适用 √ 不适用\n65 第十节公司治理\n一、公司治理的基本状况\n报告期内，公司严格按照《公司法》、《证券法》、《上市公司治理准则》、《深圳证\n券交易所股票上市规则》等有关法律法规的要求，不断地完善公司治理结构，建立健全内部\n控制制度，并进一步规范公司运作，努力提高公司治理水平。目前，公司整体运作比较规范、\n独立性强、信息披露规范，公司治理实际状况基本符合中国证监会发布的有关上市公司治理\n的规范性文件。公司本报告期内经过股东大会或董事会审议通过正在执行的制度及最新披露时间表如\n下：\n序号 制度名称 披露时间\n1 股东大会议事规则 2007年4月\n2 监事会议事规则 2007年4月\n3 董事会战略委员会议事规则 2007年6月\n4 董事会提名委员会议事规则 2007年6月\n5 董事会审计委员会议事规则 2007年6月\n6 董事会薪酬与考核委员会议事规则 2007年6月\n7 信息披露管理制度（2007年6月修订） 2007年6月\n8 股东大会累计投票制实施细则 2007年6月\n9 独立董事年报工作制度 2008年4月\n10 审计委员会年报工作规程 2008年4月\n11 内部信息保密制度 2008年8月\n12 防范控股股东及关联方资金占用管理办法 2008年8月\n13 董事、监事及高级管理人员薪酬管理制度 2009年4月\n14 突发事件处理制度 2009年10月\n15 首期股票期权激励实施考核办法 2009年12月\n16 年报信息披露重大差错责任追究制度 2010年3月\n17 建设工程招投标管理办法 2011年8月\n18 投资者关系管理制度（2011年9月修订） 2011年9月\n19 重大事项内部报告制度 2011年9月\n20 大股东、实际控制人行为规范及信息问询制度 2011年9月\n21 公司章程（2011年3月修订） 2011年3月\n66。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "27a391c7",
        "08405ae7",
        "9d1030bb",
        "4ef331bb",
        "918e48e8"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3993,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60,
          61,
          62,
          63,
          64,
          65
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.309372",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "浙江海正药业股份有限公司",
        "industry": null,
        "char_count": 3993,
        "word_count": 539,
        "sentence_count": 49,
        "chinese_char_count": 2609,
        "readability_score": 0.0,
        "information_density": 0.032556974705735035,
        "coherence_score": 0.5698198358410447,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8613573754069621,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "投资",
        "母公司",
        "经营",
        "股权",
        "股份",
        "股东",
        "分配",
        "审计",
        "报告"
      ]
    },
    {
      "chunk_id": "d4fdfa90",
      "content": "22 外部信息使用人管理制度 2012年4月\n23 内幕信息知情人登记管理制度 2012年4月\n24 董事会议事规则(2013年3月修订) 2013年3月\n25 控股子公司管理制度(2013年3月修订) 2013年3月\n26 对外提供财务资助管理制度 2013年3月\n27 募集资金管理制度（2014年4月修订） 2014年4月\n28 公司章程（2015年9月修订） 2015年9月\n29 授权管理制度 2015年12月\n30 风险投资管理制度 2016年1月\n31 公司章程（2016年3月修订） 2016年3月\n32 债务融资工具信息披露事务管理制度 2016年3月\n33 公司章程（2016年10月修订） 2016年10月\n34 衍生品投资管理制度 2017年1月\n35 公司章程（2017年4月修订） 2017年4月\n36 董事、监事和高级管理人员所持公司股份及其变动管理制度（2017 2017年8月\n年8月修订）\n37 公司章程（2018年4月修订） 2018年4月\n38 内部控制缺陷认定标准 2018年4月\n39 公司章程（2019年2月修订） 2019年2月\n40 内部审计制度（2019年2月修订） 2019年2月\n41 公司章程（2019年3月修订） 2019年3月\n公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件是否存在重大差异\n□ 是 √ 否\n公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件不存在重大差异。二、公司相对于控股股东在业务、人员、资产、机构、财务等方面的独立情况\n（一）业务方面：公司拥有独立完整的业务体系和自主经营能力，控股股东按照承诺未\n从事与公司业务相同或相近的业务活动。（二）人员方面：公司拥有独立的人事和劳资管理体系，公司总经理、副总经理、财务\n负责人和董事会秘书等高级管理人员均在本公司领取报酬。\n\n（三）资产方面：公司拥有独立的生产系统、辅助生产系统和配套设施，产、供、销系\n统完整独立。工业产权、商标、非专利技术、房屋所有权、土地所有权等无形资产和有形资\n产均由本公司拥有，产权界定清晰。（四）机构方面：公司设有健全的组织机构体系，股东大会、董事会、监事会及董事会\n下属专业委员会等内部机构独立运作，不受其他单位或个人的干涉。\n\n（五）财务方面：公司设有完整、独立的财务机构，配备了充足的专职财务会计人员，\n建立了独立的会计核算体系和财务管理制度，并独立开设银行账户、独立纳税、独立做出财\n务决策。公司与控股股东在业务、人员、资产、机构、财务等方面完全分开，具有独立完整\n的业务及自主经营能力。三、同业竞争情况\n□ 适用 √ 不适用\n四、报告期内召开的年度股东大会和临时股东大会的有关情况\n1、本报告期股东大会情况\n会议 投资者参\n会议届次 召开日期 披露日期 披露索引\n类型 与比例\n年度 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2018年年度 2019年032019年03\n股东 45.19% 及巨潮资讯网披露的《2018年年度股东大会决议公告》（公告编号：\n股东大会 月11日 月12日\n大会 2019-020）\n2019年第一 临时 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2019年032019年04\n次临时股东大 股东 45.07% 及巨潮资讯网披露的《2019年第一次临时股东大会决议公告》（公\n月29日 月01日\n会 大会 告编号：2019-027）\n2019年第二 临时 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2019年112019年11\n次临时股东大 股东 44.40% 及巨潮资讯网披露的《2019年第二次临时股东大会决议公告》（公\n月13日 月14日\n会 大会 告编号：2019-059）\n2、表决权恢复的优先股股东请求召开临时股东大会\n□ 适用 √ 不适用\n五、报告期内独立董事履行职责的情况\n1、独立董事出席董事会及股东大会的情况\n独立董事出席董事会及股东大会的情况\n是否连续两次\n本报告期应参 现场出席董事 以通讯方式参 委托出席董事 缺席董事会次 出席股东大会\n独立董事姓名 未亲自参加董\n加董事会次数 会次数 加董事会次数 会次数 数 次数\n事会会议\n田利明 5 0 3 2 0否 0\n毛美英 6 3 3 0 0否 3\n苏为科 6 2 3 1 0否 0\n张克坚 1 1 0 0 0否 0\n连续两次未亲自出席董事会的说明\n68。\n\n不适用\n2、独立董事对公司有关事项提出异议的情况\n独立董事对公司有关事项是否提出异议\n□ 是 √ 否\n报告期内独立董事对公司有关事项未提出异议。3、独立董事履行职责的其他说明\n独立董事对公司有关建议是否被采纳\n√ 是 □ 否\n独立董事对公司有关建议被采纳或未被采纳的说明\n公司独立董事勤勉尽责，严格按照中国证监会的相关规定及《公司章程》、《董事会议\n事规则》和《独立董事制度》开展工作，关注公司运作,独立履行职责,对公司内部控制建设、\n管理体系建设、人才梯队建设和重大决策等方面提出了很多宝贵的专业性建议，对公司财务\n及生产经营活动进行了有效监督，提高了公司决策的科学性，为完善公司监督机制，维护公\n司和全体股东的合法权益发挥了应有的作用。六、董事会下设专门委员会在报告期内履行职责情况\n（一）董事会下设审计委员会的履职情况\n董事会审计委员会在报告期内主要负责公司内部会计控制, 财务报表和公司其他财务事\n项实施监督工作。\n\n依据《中华人民共和国公司法》、《上市公司治理准则》、《董事会审计\n委员会工作细则》等法律规定，对公司内部控制情况进行了定期核查，监督与协助公司与外\n部审计机构的沟通，确保公司内部控制体系依法合规，有效的控制了相关风险的产生。公司\n审计委员会在2019年共召开了五次会议，对定期财务报告、生产经营控制、募集资金使用情\n况、控股股东及关联方资金占用等事项进行审议，并对会计师事务所的年度审计工作进行了\n总结评价，提出续聘会计师事务所的建议。（二）董事会下设的薪酬与考核委员会的履职情况\n公司董事会薪酬与考核委员会在报告期内依照《公司章程》、《董事会薪酬与考核委员\n会议事规则》的相关法律法规勤勉尽职的对公司限制性股票的激励对象作出年度考核审议并\n给出相关意见，同意解锁符合解锁条件激励对象限制性股票。\n\n核查了董事及公司高级管理人\n员的薪酬情况，并对第六届董事会独立董事薪酬进行了审核。（三）董事会下设的提名委员会的履职情况\n报告期内，董事会提名委员会根据《公司法》、《上市公司治理准则》以及《浙江海翔\n药业股份有限公司章程》、《浙江海翔药业股份有限公司董事会提名委员会议事规则》等有\n关法律法规和规章制度的规定，积极履行了职责。报告期内，提名委员会对上一年度董事、\n高管的任职情况进行总结，并对新一届董事、高管进行了提名审核。\n\n（四）董事会下设战略委员会的履职情况\n报告期内，董事会战略委员会勤勉尽职的履行了相关义务，依照《公司章程》、《董事\n会战略委员会议事规则》等相关法律法规对公司经营战略的情况进行了回顾与总结。2019年\n董事会战略委员会共召开二次会议，在对当前市场状况、公司实际情况的合理分析后给出了\n公司今后战略发展的方向以及合理的实施建议。并对公司对外投资参与设立合伙企业事项给\n69。\n\n出了建设性的建议和意见。七、监事会工作情况\n监事会在报告期内的监督活动中发现公司是否存在风险\n□ 是 √ 否\n监事会对报告期内的监督事项无异议。八、高级管理人员的考评及激励情况\n公司按照《董事、监事、高级管理人员薪酬管理制度》，建立了高级管理人员的薪酬与\n公司业绩挂钩的绩效考核与激励约束机制，公司高级管理人员实行基本年薪和年终绩效考核\n相结合的薪酬制度。\n\n规范董事、监事、高级管理人员薪酬决策机制。年末根据公司年度经营\n目标完成情况以及高级管理人员的工作业绩，由董事会薪酬与考核委员会对高级管理人员进\n行年度绩效考核，并监督薪酬制度执行情况。公司则根据绩效考核结果兑现其绩效年薪，并\n进行奖惩。\n\n公司董事会薪酬与考核委员会根据实际情况对公司董事、监事及高级管理人员进\n行考核后，一致认为：公司2019年度董事、高管薪酬方案严格执行董事及高级管理人员薪酬\n和考核管理制度，与公司经营业绩挂钩，董事、高管薪酬方案合理，薪酬发放的程序符合有\n关法律、法规及《公司章程》的规定。九、内部控制评价报告\n1、报告期内发现的内部控制重大缺陷的具体情况\n□ 是 √ 否\n2、内控自我评价报告\n内部控制评价报告全文披露日期 2020年01月23日\n详见本公司于2020年1月23日在巨潮资讯网披露的《2019年度内部控制自我评\n内部控制评价报告全文披露索引\n价报告》\n纳入评价范围单位资产总额占公司合并\n100.00%\n财务报表资产总额的比例\n纳入评价范围单位营业收入占公司合并\n100.00%\n财务报表营业收入的比例\n缺陷认定标准\n类别 财务报告 非财务报告\n70。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "cc41c7f3",
        "5af0429b",
        "b70fad9d",
        "512b46a6"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3710,
      "page_number": 67,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67,
          68,
          69,
          70
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.311542",
        "report_type": "其他",
        "fiscal_year": 2012,
        "fiscal_quarter": null,
        "company_code": "药业股份有限公司",
        "industry": null,
        "char_count": 3710,
        "word_count": 268,
        "sentence_count": 34,
        "chinese_char_count": 2757,
        "readability_score": 0.0,
        "information_density": 0.04851752021563342,
        "coherence_score": 0.7630206145282674,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8972506738544475,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "投资",
        "无形资产",
        "营业收入",
        "合并",
        "营业",
        "经营",
        "经营业绩"
      ]
    },
    {
      "chunk_id": "84cc49d3",
      "content": "重大缺陷：1、公司董事、监事或高级\n管理人员缺乏应有的胜任能力，或高级\n管理人员流失严重； 2、公司组织架构、\n业务流程存在重大缺陷，权责分配严重\n不合理，缺乏科学决策、良性运行机制\n和执行力； 3、公司对外担保业务未根\n据相关法律法规经过适当审批； 4、公\n司资产管理制度存在重大缺陷，大量长\n期资产使用效能低下，维护不当，存货\n严重积压或短缺； 5、公司核心技术管\n理存在缺陷，核心技术人员流失严重，\n核心技术已经出现严重过时的迹象；\n6、公司信息系统存在重大漏洞，导致\n内部相关数据收集、处理或传递错误或\n严重延误，或重要商业机密被泄露； 7、\n公司的安全生产管理、环保管理存在重\n重大缺陷：1、公司董事、监事或高级管理大缺陷，安全、环保事故频发，引起政\n人员舞弊；2、公司更正已公告的财务报告；府或监管机构调查或处罚； 8、公司的\n3、注册会计师发现未被公司内部控制识别质量管理存在重大缺陷，出现重大质量\n的当期财务报告重大错报；4、公司对重大问题引起政府或监管机构调查或引发\n经济业务的会计处理违反会计法律法规或 诉讼； 9、已向管理层汇报但经过合理\n《企业会计准则》； 5、公司随意变更会计期限后，管理层仍然没有对非财务报告\n政策或会计估计，导致相关财务信息严重 内部控制重大缺陷进行整改。重要缺\n失真； 6、公司缺乏对外提供财务报告的 陷：1、公司关键岗位人员缺乏应有的\n流程、审批权限等正式制度，或制度完全 胜任能力，或关键岗位人员流失严重；\n未得到执行；7、因财务报告相关的信息披2、公司组织架构、业务流程存在重要\n露差错导致监管机构处罚；8、公司凭证、缺陷，重要机构设计不合理，职能交叉\n账簿、报表等会计资料管理混乱，未按照 或缺失，运行效率低下；3、公司对外\n相关法律法规整理、归档或保存；9、已向担保业务虽经过适当审批，但存在重要\n管理层汇报但经过合理期限后，管理层仍 潜在经济损失风险；4、公司资产管理\n然没有对财务报告内部控制重大缺陷进行 制度存在重要缺陷，部分长期资产使用\n整改。重大缺陷：1、公司关键岗位人员舞效能低下，维护不当，大量存货积压或\n弊；2、注册会计师发现未被公司内部控制短缺；5、公司重要技术管理存在缺陷，\n识别的当期财务报告重要错报；3、对重要重要技术人员流失严重，关键技术出现\n定性标准\n经济业务的会计处理违反会计法律法规或 过时的迹象；6、公司信息系统的关键\n《企业会计准则》；4、公司频繁变更会计 环节存在漏洞，导致部分环节内部相关\n政策或会计估计，导致相关财务信息不具 数据收集、处理或传递错误或不及时，\n有可比性；5、公司虽有对外提供财务报告或商业机密存在被泄露的风险；7、公\n的正式制度，但制度未得到完全执行，对 司的安全生产管理、环保管理存在重要\n外信息披露未经适当审批或授权；6、公司缺陷，出现重要的安全、环保事故，引\n凭证、账簿、报表等会计资料管理部分环 起政府或监管机构关注；8、公司的质\n节存在漏洞，相关资料存在丢失、毁损或 量管理存在重要缺陷，出现重要质量问\n被未授权人员接触的风险； 7、已向管理 题引起大宗产品退货；9、已向管理层\n层汇报但经过合理期限后，管理层仍然没 汇报但经过合理期限后，管理层仍然没\n有对财务报告内部控制重要缺陷进行整 有对非财务报告内部控制。\n\n一般缺陷：\n改。一般缺陷：1、公司一般岗位人员舞 1、公司一般岗位人员缺乏应有的胜任\n71\n弊；2、注册会计师发现未被公司内部控制能力，或普通岗位人员流失严重；2、\n识别的当期财务报告一般错报；3、已向管公司组织架构、业务流程存在一般缺\n理层汇报但经过合理期限后，管理层仍然 陷，部分机构设计不合理，职能重叠，。\n\n重大缺陷 1、利润总额潜在错报：错报≥\n利润总额的10%或4000万元 2、资产总额\n潜在错报：错报≥资产总额的1% 3、经营\n收入潜在错报：错报≥营业收入的3 % 4、\n所有者权益潜在错报：错报≥所有者权益的\n2%； 重要缺陷 1、利润总额潜在错报：\n错报≥利润总额的5%<利润总额的10%或 重大缺陷非财务报告内部控制缺陷导\n利润总额2000万元≤错报<利润总额4000 致的直接财产损失金额≥利润总额的\n万元 2、资产总额潜在错报：资产总额的10%；重要缺陷利润总额的10%＞非财\n定量标准 0.5%≤错报<资产总额的1% 3、经营收 务报告内部控制缺陷导致的直接财产\n入潜在错报：营业收入的1.5%≤错报<经营损失金额≥利润总额的5%。一般缺陷非\n收入的3% 4、所有者权益潜在错报：所 财务报告内部控制缺陷导致的直接财\n有者权益1%≤错报<所有者权益的2%； 一产损失金额＜利润总额的5%。般缺陷 1、利润总额潜在错报：错报<利润\n总额的5%或错报<利润总额的2000万元\n2、资产总额潜在错报：错报<资产总额的\n0.5% 3、经营收入潜在错报：错报<营\n业收入的1.5% 4、所有者权益潜在错\n报：错报<所有者权益的1%\n财务报告重大缺陷数量（个） 0\n非财务报告重大缺陷数量（个） 0\n财务报告重要缺陷数量（个） 0\n非财务报告重要缺陷数量（个） 0\n十、内部控制审计报告或鉴证报告\n内部控制鉴证报告\n内部控制鉴证报告中的审议意见段\n我们认为，海翔药业公司按照深圳证券交易所《中小企业板上市公司规范运作指引(2015年修订)》规定于2019年12月31\n日在所有重大方面保持了有效的财务报告内部控制。\n\n内控鉴证报告披露情况 披露\n内部控制鉴证报告全文披露日期 2020年01月23日\n内部控制鉴证报告全文披露索引 巨潮资讯网\n内控鉴证报告意见类型 标准无保留意见\n非财务报告是否存在重大缺陷 否\n会计师事务所是否出具非标准意见的内部控制审计报告\n□ 是 √ 否\n会计师事务所出具的内部控制审计报告与董事会的自我评价报告意见是否一致\n√ 是 □ 否\n72。\n\n第十一节公司债券相关情况\n公司是否存在公开发行并在证券交易所上市，且在年度报告批准报出日未到期或到期未能全额兑付的公司债券\n否\n73 第十二节 财务报告\n一、审计报告\n审计意见类型 标准的无保留意见\n审计报告签署日期 2020年01月22日\n审计机构名称 天健会计师事务所（特殊普通合伙）\n审计报告文号 天健审〔2020〕58号\n注册会计师姓名 沈维华 汪兢\n审计报告正文\n审 计 报 告\n天健审〔2020〕58号\n浙江海翔药业股份有限公司全体股东：\n一、审计意见\n我们审计了浙江海翔药业股份有限公司（以下简称海翔药业公司）财务报表，包括 2019\n年12月31日的合并及母公司资产负债表，2019年度的合并及母公司利润表、合并及母公司\n现金流量表、合并及母公司所有者权益变动表，以及相关财务报表附注。我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了\n海翔药业公司 2019 年 12 月 31 日的合并及母公司财务状况，以及 2019 年度的合并及母公司\n经营成果和现金流量。二、形成审计意见的基础\n我们按照中国注册会计师审计准则的规定执行了审计工作。\n\n审计报告的“注册会计师对\n财务报表审计的责任”部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职\n业道德守则，我们独立于海翔药业公司，并履行了职业道德方面的其他责任。我们相信，我\n们获取的审计证据是充分、适当的，为发表审计意见提供了基础。\n\n三、关键审计事项\n关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这些事\n项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不\n对这些事项单独发表意见。(一) 收入确认\n1. 事项描述\n相关信息披露详见财务报表附注三(二十三)及附注五(二)1。\n\n海翔药业公司的营业收入主要来自于原料药及医药中间体和染料及染颜料中间体。2019\n74。\n\n年度，海翔药业公司财务报表所示营业收入项目金额为人民币 2,941,412,770.30 元(合并财\n务报表口径，下同)，其中主营业务收入为人民币2,925,688,906.14元，占营业收入的99.47%。如财务报表附注重要会计政策及会计估计所示，海翔药业公司产品销售区域分为国内和国外，\n且需要根据不同的手续进行收入确认。由于营业收入是海翔药业公司关键业绩指标之一，可能存在海翔药业公司管理层（以下\n简称管理层）通过不恰当的收入确认以达到特定目标或预期的固有风险。\n\n因此，我们将收入\n确认确定为关键审计事项。2. 审计应对\n针对收入确认，我们实施的审计程序主要包括：\n(1) 了解与收入确认相关的关键内部控制，评价其设计和执行是否有效，并测试相关内\n部控制的运行有效性；\n(2) 检查主要的销售合同，识别与商品所有权上的主要风险和报酬转移相关的条款，评\n价收入确认政策是否符合企业会计准则的规定；\n(3) 对收入和成本执行分析程序，判断销售收入和毛利变动的合理性；\n(4) 对于内销收入，以抽样方式检查与收入确认相关的支持性文件，包括销售合同、销\n售发票、出库单及签收单据等；对于出口收入，向海关直接获取报关出口数据并与账面记录\n核对，并以抽样方式检查销售合同、出口报关单、货运提单、销售发票等支持性文件；\n(5) 结合应收账款函证，以抽样方式向主要客户函证本期销售额；\n(6) 针对资产负债表日前后确认的销售收入执行截止性测试；\n(7) 检查与营业收入相关的信息是否已在财务报表中作出恰当列报。(二) 商誉减值\n1. 事项描述\n相关信息披露详见财务报表附注三(十八)及附注五(一)17。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "1a1c674f",
        "5e688650",
        "6fdb2b94",
        "0b27533c",
        "70116ff4"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3919,
      "page_number": 71,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71,
          72,
          73,
          74,
          75
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.313387",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 3919,
        "word_count": 238,
        "sentence_count": 36,
        "chinese_char_count": 3088,
        "readability_score": 0.0,
        "information_density": 0.05103342689461597,
        "coherence_score": 0.6867171517272226,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9151824445011483,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金",
        "应收",
        "存货",
        "商誉"
      ]
    },
    {
      "chunk_id": "5844ad06",
      "content": "截至 2019 年 12 月 31 日，海翔药业公司合并财务报表中商誉的账面价值为\n757,736,770.14元。管理层于每年年度终了对企业合并所形成的商誉进行减值测试，相关资\n产组或资产组组合的可收回金额按照预计未来现金流量现值计算确定。减值测试中采用的关\n键假设包括：详细预测期收入增长率、永续预测期增长率、毛利率、折现率等。\n\n由于商誉金额重大，且商誉减值测试涉及重大管理层判断，我们将商誉减值确定为关键\n审计事项。2. 审计中的应对\n针对商誉减值，我们实施的审计程序主要包括：\n(1) 了解与商誉确认相关的关键内部控制，评价其设计和执行是否有效，并测试相关内\n部控制的运行有效性；\n(2) 复核管理层以前年度对未来现金流量现值的预测和实际经营结果，评价管理层过往\n预测的准确性；\n(3) 了解并评价管理层聘用的外部估值专家的胜任能力、专业素质和客观性；\n(4) 评价管理层在减值测试中使用方法的合理性和一致性；\n(5) 了解海翔药业公司商誉所属资产组的认定和进行商誉减值测试时采用的关键假设和\n方法，并与公司管理层和外部估值专家讨论，评价相关的假设和方法的合理性，复核相关假\n设是否与总体经济环境、行业状况、经营情况、历史经验、运营计划、管理层使用的与财务\n报表相关的其他假设等相符；\n75。\n\n(6) 通过比照相关资产组的历史表现以及经营发展计划，复核现金流量预测水平和所采\n用折现率的合理性，测试管理层对预计未来现金流量现值的计算是否准确；\n(7) 测试管理层在减值测试中使用数据的准确性、完整性和相关性，并复核减值测试中\n有关信息的内在一致性；\n(8) 检查与商誉减值相关的信息是否已在财务报表中作出恰当列报。四、其他信息\n管理层对其他信息负责。其他信息包括年度报告中涵盖的信息，但不包括财务报表和我\n们的审计报告。\n\n我们对财务报表发表的审计意见不涵盖其他信息，我们也不对其他信息发表任何形式的\n鉴证结论。结合我们对财务报表的审计，我们的责任是阅读其他信息，在此过程中，考虑其他信息\n是否与财务报表或我们在审计过程中了解到的情况存在重大不一致或者似乎存在重大错报。基于我们已执行的工作，如果我们确定其他信息存在重大错报，我们应当报告该事实。\n\n在这方面，我们无任何事项需要报告。五、管理层和治理层对财务报表的责任\n管理层负责按照企业会计准则的规定编制财务报表，使其实现公允反映，并设计、执行\n和维护必要的内部控制，以使财务报表不存在由于舞弊或错误导致的重大错报。在编制财务报表时，管理层负责评估海翔药业公司的持续经营能力，披露与持续经营相\n关的事项（如适用），并运用持续经营假设，除非计划进行清算、终止运营或别无其他现实的\n选择。\n\n海翔药业公司治理层（以下简称治理层）负责监督海翔药业公司的财务报告过程。六、注册会计师对财务报表审计的责任\n我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大错报获取合理保\n证，并出具包含审计意见的审计报告。合理保证是高水平的保证，但并不能保证按照审计准\n则执行的审计在某一重大错报存在时总能发现。\n\n错报可能由于舞弊或错误导致，如果合理预\n期错报单独或汇总起来可能影响财务报表使用者依据财务报表作出的经济决策，则通常认为\n错报是重大的。在按照审计准则执行审计工作的过程中，我们运用职业判断，并保持职业怀疑。同时，\n我们也执行以下工作：\n(一) 识别和评估由于舞弊或错误导致的财务报表重大错报风险，设计和实施审计程序以\n应对这些风险，并获取充分、适当的审计证据，作为发表审计意见的基础。\n\n由于舞弊可能涉\n及串通、伪造、故意遗漏、虚假陈述或凌驾于内部控制之上，未能发现由于舞弊导致的重大\n错报的风险高于未能发现由于错误导致的重大错报的风险。(二) 了解与审计相关的内部控制，以设计恰当的审计程序，但目的并非对内部控制的有\n效性发表意见。(三) 评价管理层选用会计政策的恰当性和作出会计估计及相关披露的合理性。\n\n(四) 对管理层使用持续经营假设的恰当性得出结论。同时，根据获取的审计证据，就可\n能导致对海翔药业公司持续经营能力产生重大疑虑的事项或情况是否存在重大不确定性得出\n结论。如果我们得出结论认为存在重大不确定性，审计准则要求我们在审计报告中提请报表\n使用者注意财务报表中的相关披露；如果披露不充分，我们应当发表非无保留意见。\n\n结论基于截至审计报告日可获得的信息。然而，未来的事项或情况可能导致海翔药业公司不\n能持续经营。(五) 评价财务报表的总体列报、结构和内容，并评价财务报表是否公允反映相关交易和\n事项。\n\n(六) 就海翔药业公司中实体或业务活动的财务信息获取充分、适当的审计证据，以对财\n务报表发表审计意见。我们负责指导、监督和执行集团审计，并对审计意见承担全部责任。我们与治理层就计划的审计范围、时间安排和重大审计发现等事项进行沟通，包括沟通\n我们在审计中识别出的值得关注的内部控制缺陷。\n\n我们还就已遵守与独立性相关的职业道德要求向治理层提供声明，并与治理层沟通可能\n被合理认为影响我们独立性的所有关系和其他事项，以及相关的防范措施（如适用）。从与治理层沟通过的事项中，我们确定哪些事项对本期财务报表审计最为重要，因而构\n成关键审计事项。我们在审计报告中描述这些事项，除非法律法规禁止公开披露这些事项，\n或在极少数情形下，如果合理预期在审计报告中沟通某事项造成的负面后果超过在公众利益\n方面产生的益处，我们确定不应在审计报告中沟通该事项。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "682ee735",
        "2155473f",
        "11c2f84a"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2260,
      "page_number": 75,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          75,
          76,
          77
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.315441",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2260,
        "word_count": 83,
        "sentence_count": 37,
        "chinese_char_count": 1971,
        "readability_score": 0.0,
        "information_density": 0.07522123893805309,
        "coherence_score": 0.6795257451936008,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9488495575221239,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "现金流",
        "经营",
        "财务",
        "报表",
        "770.14元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "现金",
        "商誉",
        "合并",
        "毛利率",
        "经营",
        "审计",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "c06540ba",
      "content": "天健会计师事务所（特殊普通合伙） 中国注册会计师：沈维华\n（项目合伙人）\n中国·杭州 中国注册会计师：汪兢\n二〇二〇年一月二十二日\n二、财务报表\n财务附注中报表的单位为：元\n1、合并资产负债表\n编制单位：浙江海翔药业股份有限公司\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,556,575,372.45 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n77。\n\n应收票据 107,399,476.04\n应收账款 459,781,564.19 479,537,782.06\n应收款项融资 74,531,666.41\n预付款项 33,851,486.79 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 18,297,536.18 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 842,985,260.60 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动资产\n其他流动资产 76,406,931.14 227,882,993.23\n流动资产合计 3,062,429,817.76 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 47,879,382.43 66,088,139.79\n其他权益工具投资 20,000,000.00\n其他非流动金融资产\n投资性房地产 11,206,951.46 12,338,615.29\n固定资产 1,724,407,333.34 1,215,120,643.61\n在建工程 560,674,634.43 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 533,455,319.46 539,514,850.87\n78。\n\n开发支出\n商誉 757,736,770.14 757,736,770.14\n长期待摊费用 1,618,771.89 1,842,423.21\n递延所得税资产 27,339,683.56 32,487,223.69\n其他非流动资产 450,000.00 515,993.37\n非流动资产合计 3,684,768,846.71 3,301,778,337.96\n资产总计 6,747,198,664.47 7,035,373,344.57\n流动负债：\n短期借款 200,267,029.59 598,700,000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其变动计入当\n期损益的金融负债\n衍生金融负债\n应付票据 238,306,005.00 490,006,533.85\n应付账款 363,440,583.96 301,908,929.93\n预收款项 12,919,749.09 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n代理承销证券款\n应付职工薪酬 52,367,142.28 45,234,354.42\n应交税费 44,781,205.55 54,890,661.34\n其他应付款 28,200,073.22 24,723,304.20\n其中：应付利息 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 940,281,788.69 1,579,026,351.68\n79。\n\n非流动负债：\n保险合同准备金\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 1,333,333.00 12,971,002.47\n递延收益 50,594,091.52 44,650,629.91\n递延所得税负债 30,527,355.71 8,175,428.28\n其他非流动负债\n非流动负债合计 82,454,780.23 65,797,060.66\n负债合计 1,022,736,568.92 1,644,823,412.34\n所有者权益：\n股本 1,618,715,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,670,350,322.00 2,663,367,822.47\n减：库存股 301,511,513.90 325,880,561.68\n其他综合收益 -1,490,188.81 -51,779.23\n专项储备\n盈余公积 213,069,824.31 201,812,279.17\n一般风险准备\n未分配利润 1,525,328,398.95 1,232,481,918.50\n归属于母公司所有者权益合计 5,724,462,095.55 5,390,549,932.23\n少数股东权益\n所有者权益合计 5,724,462,095.55 5,390,549,932.23\n负债和所有者权益总计 6,747,198,664.47 7,035,373,344.57\n法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n80。\n\n2、母公司资产负债表\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,200,455,459.03 983,565,710.16\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n应收票据 20,885,763.88\n应收账款 123,532,244.19 149,204,899.98\n应收款项融资 6,422,715.29\n预付款项 2,178,567.27 5,554,458.78\n其他应收款 467,513,480.14 1,043,055,918.72\n其中：应收利息\n应收股利 7,222,088,153.34\n存货 96,708,887.42 84,396,333.98\n合同资产\n持有待售资产\n一年内到期的非流动资产\n其他流动资产 2,586,704.73 105,920,135.97\n流动资产合计 1,899,398,058.07 2,392,583,221.47\n非流动资产：\n债权投资\n可供出售金融资产 23,017,502.51\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,247,420,801.54 3,250,556,852.85\n其他权益工具投资 43,017,502.51\n其他非流动金融资产\n投资性房地产 15,051,583.93 16,409,402.65\n固定资产 190,528,741.25 182,948,202.54\n在建工程 5,125,110.57 20,490,208.35\n81。\n\n生产性生物资产\n油气资产\n使用权资产\n无形资产 15,682,148.91 17,059,632.32\n开发支出\n商誉\n长期待摊费用\n递延所得税资产 6,054,576.79 9,371,365.80\n其他非流动资产 450,000.00\n非流动资产合计 3,523,330,465.50 3,519,853,167.02\n资产总计 5,422,728,523.57 5,912,436,388.49\n流动负债：\n短期借款 200,267,029.59 287,000,000.00\n交易性金融负债\n以公允价值计量且其变动计入当\n期损益的金融负债\n衍生金融负债\n应付票据 178,855,770.00 202,286,262.85\n应付账款 21,476,176.18 25,423,635.65\n预收款项 4,099,111.19 7,777,982.57\n合同负债\n应付职工薪酬 7,965,755.58 6,439,699.82\n应交税费 12,495,191.97 948,517.30\n其他应付款 98,040,880.51 104,178,588.96\n其中：应付利息 805,795.63\n应付股利 2,051,370.43 2,051,370.43\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 523,199,915.02 678,420,562.15\n非流动负债：\n长期借款\n应付债券\n其中：优先股\n82。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "4da43839",
        "01ec69a9",
        "7884ee5b",
        "ff9c20fa",
        "fc61782c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3555,
      "page_number": 77,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77,
          78,
          79,
          80,
          81,
          82
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.316816",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 3555,
        "word_count": 344,
        "sentence_count": 150,
        "chinese_char_count": 1141,
        "readability_score": 0.0,
        "information_density": 0.05063291139240507,
        "coherence_score": 0.28562499999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5802812939521801,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "利润",
        "投资",
        "应收",
        "应付",
        "预收",
        "预付"
      ]
    },
    {
      "chunk_id": "f4491003",
      "content": "永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 1,333,333.00 12,971,002.47\n递延收益 1,269,332.86 1,262,720.34\n递延所得税负债\n其他非流动负债\n非流动负债合计 2,602,665.86 14,233,722.81\n负债合计 525,802,580.88 692,654,284.96\n所有者权益：\n股本 1,618,715,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,669,212,269.41 2,662,229,769.88\n减：库存股 301,511,513.90 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 213,069,824.31 201,812,279.17\n未分配利润 697,440,109.87 1,062,800,363.16\n所有者权益合计 4,896,925,942.69 5,219,782,103.53\n负债和所有者权益总计 5,422,728,523.57 5,912,436,388.49\n3、合并利润表\n单位：元\n项目 2019年度 2018年度\n一、营业总收入 2,941,412,770.30 2,718,608,796.51\n其中：营业收入 2,941,412,770.30 2,718,608,796.51\n利息收入\n已赚保费\n手续费及佣金收入\n二、营业总成本 2,020,492,002.44 1,996,990,314.89\n其中：营业成本 1,463,159,361.04 1,511,944,676.18\n83。\n\n利息支出\n手续费及佣金支出\n退保金\n赔付支出净额\n提取保险责任合同准备金\n净额\n保单红利支出\n分保费用\n税金及附加 26,841,009.21 32,182,923.43\n销售费用 59,623,024.88 43,781,054.42\n管理费用 386,185,538.84 349,284,396.57\n研发费用 122,548,224.53 111,304,662.07\n财务费用 -37,865,156.06 -51,507,397.78\n其中：利息费用 15,506,676.74 42,594,267.08\n利息收入 41,773,975.28 44,371,159.00\n加：其他收益 27,136,924.87 11,791,738.03\n投资收益（损失以“－”号填\n-15,240,062.55 -9,359,378.55\n列）\n其中：对联营企业和合营企业\n-16,759,549.80 -6,923,938.93\n的投资收益\n以摊余成本计量的金融\n资产终止确认收益\n汇兑收益（损失以“-”号填列）\n净敞口套期收益（损失以“－”\n号填列）\n公允价值变动收益（损失以\n5,010,265.70\n“－”号填列）\n信用减值损失（损失以“-”号填\n-2,502,149.00\n列）\n资产减值损失（损失以“-”号填\n-11,738,706.70 -18,867,903.52\n列）\n资产处置收益（损失以“-”号填\n244,580.94 659,231.88\n列）\n三、营业利润（亏损以“－”号填列） 918,821,355.42 710,852,435.16\n加：营业外收入 1,125,654.53 1,713,286.09\n减：营业外支出 7,494,029.68 15,270,110.20\n84。\n\n四、利润总额（亏损总额以“－”号填列） 912,452,980.27 697,295,611.05\n减：所得税费用 141,670,795.18 92,291,790.27\n五、净利润（净亏损以“－”号填列） 770,782,185.09 605,003,820.78\n（一）按经营持续性分类\n1.持续经营净利润（净亏损以“－”\n770,782,185.09 605,003,820.78\n号填列）\n2.终止经营净利润（净亏损以“－”\n号填列）\n（二）按所有权归属分类\n1.归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n2.少数股东损益\n六、其他综合收益的税后净额 -1,438,409.58 16,560.46\n归属母公司所有者的其他综合收益\n-1,438,409.58 16,560.46\n的税后净额\n（一）不能重分类进损益的其他综\n-1,800,000.00\n合收益\n1.重新计量设定受益计划变\n动额\n2.权益法下不能转损益的其\n他综合收益\n3.其他权益工具投资公允价\n-1,800,000.00\n值变动\n4.企业自身信用风险公允价\n值变动\n5.其他\n（二）将重分类进损益的其他综合\n361,590.42 16,560.46\n收益\n1.权益法下可转损益的其他\n综合收益\n2.其他债权投资公允价值变\n动\n3.可供出售金融资产公允价\n值变动损益\n4.金融资产重分类计入其他\n综合收益的金额\n5.持有至到期投资重分类为\n可供出售金融资产损益\n85。\n\n6.其他债权投资信用减值准\n备\n7.现金流量套期储备\n8.外币财务报表折算差额 361,590.42 16,560.46\n9.其他\n归属于少数股东的其他综合收益的\n税后净额\n七、综合收益总额 769,343,775.51 605,020,381.24\n归属于母公司所有者的综合收益\n769,343,775.51 605,020,381.24\n总额\n归属于少数股东的综合收益总额\n八、每股收益：\n（一）基本每股收益 0.48 0.38\n（二）稀释每股收益 0.48 0.38\n本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0.00元，上期被合并方实现的净利润为：0.00元。法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n4、母公司利润表\n单位：元\n项目 2019年度 2018年度\n一、营业收入 812,259,638.86 825,098,603.87\n减：营业成本 587,096,405.03 619,846,906.93\n税金及附加 5,519,793.76 6,987,907.49\n销售费用 16,512,217.50 13,811,113.34\n管理费用 54,148,420.30 76,492,418.62\n研发费用 34,026,076.54 27,532,948.31\n财务费用 -13,410,251.73 -18,322,346.97\n其中：利息费用 9,198,148.55 23,746,817.96\n利息收入 15,402,930.57 21,054,583.18\n加：其他收益 8,727,855.85 2,788,654.20\n投资收益（损失以“－”号填\n-4,635,510.82 996,151,682.18\n列）\n其中：对联营企业和合营企\n-5,766,425.53 -4,216,789.49\n业的投资收益\n86。\n\n以摊余成本计量的金融\n资产终止确认收益（损失以“-”号填\n列）\n净敞口套期收益（损失以\n“－”号填列）\n公允价值变动收益（损失以\n1,406,950.55\n“－”号填列）\n信用减值损失（损失以“-”号\n961,136.35\n填列）\n资产减值损失（损失以“-”号\n-4,457,462.80 -4,264,339.86\n填列）\n资产处置收益（损失以“-”号\n187,029.94 278,081.30\n填列）\n二、营业利润（亏损以“－”号填列） 129,150,025.98 1,095,110,684.52\n加：营业外收入 56,093.96 1,807,586.73\n减：营业外支出 2,735,128.50 12,741,122.39\n三、利润总额（亏损总额以“－”号填\n126,470,991.44 1,084,177,148.86\n列）\n减：所得税费用 13,895,540.09 -1,968,185.09\n四、净利润（净亏损以“－”号填列） 112,575,451.35 1,086,145,333.95\n（一）持续经营净利润（净亏损\n112,575,451.35 1,086,145,333.95\n以“－”号填列）\n（二）终止经营净利润（净亏损\n以“－”号填列）\n五、其他综合收益的税后净额\n（一）不能重分类进损益的其他\n综合收益\n1.重新计量设定受益计划\n变动额\n2.权益法下不能转损益的\n其他综合收益\n3.其他权益工具投资公允\n价值变动\n4.企业自身信用风险公允\n价值变动\n5.其他\n（二）将重分类进损益的其他综\n合收益\n87。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "2afd5211",
        "96a47f9e",
        "1523b74b",
        "ad5b30aa",
        "beff2997"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3581,
      "page_number": 83,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83,
          84,
          85,
          86,
          87
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.318733",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3581,
        "word_count": 321,
        "sentence_count": 165,
        "chinese_char_count": 1231,
        "readability_score": 0.0,
        "information_density": 0.05585032113934655,
        "coherence_score": 0.4012723214285714,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7375034906450713,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应付"
      ]
    },
    {
      "chunk_id": "78c777f4",
      "content": "1.权益法下可转损益的其\n他综合收益\n2.其他债权投资公允价值\n变动\n3.可供出售金融资产公允\n价值变动损益\n4.金融资产重分类计入其\n他综合收益的金额\n5.持有至到期投资重分类\n为可供出售金融资产损益\n6.其他债权投资信用减值\n准备\n7.现金流量套期储备\n8.外币财务报表折算差额\n9.其他\n六、综合收益总额 112,575,451.35 1,086,145,333.95\n七、每股收益：\n（一）基本每股收益\n（二）稀释每股收益\n5、合并现金流量表\n单位：元\n项目 2019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 2,018,927,512.97 1,988,078,802.41\n客户存款和同业存放款项净增加\n额\n向中央银行借款净增加额\n向其他金融机构拆入资金净增加\n额\n收到原保险合同保费取得的现金\n收到再保业务现金净额\n保户储金及投资款净增加额\n收取利息、手续费及佣金的现金\n拆入资金净增加额\n回购业务资金净增加额\n88\n\n代理买卖证券收到的现金净额\n收到的税费返还 105,999,603.44 49,705,278.88\n收到其他与经营活动有关的现金 249,850,615.77 771,950,774.20\n经营活动现金流入小计 2,374,777,732.18 2,809,734,855.49\n购买商品、接受劳务支付的现金 897,240,432.80 913,013,009.11\n客户贷款及垫款净增加额\n存放中央银行和同业款项净增加\n额\n支付原保险合同赔付款项的现金\n拆出资金净增加额\n支付利息、手续费及佣金的现金\n支付保单红利的现金\n支付给职工以及为职工支付的现\n311,715,734.86 280,419,788.03\n金\n支付的各项税费 269,810,257.63 208,588,464.73\n支付其他与经营活动有关的现金 283,612,211.58 616,264,355.96\n经营活动现金流出小计 1,762,378,636.87 2,018,285,617.83\n经营活动产生的现金流量净额 612,399,095.31 791,449,237.66\n二、投资活动产生的现金流量：\n收回投资收到的现金\n取得投资收益收到的现金\n处置固定资产、无形资产和其他\n5,019,341.20 4,418,098.64\n长期资产收回的现金净额\n处置子公司及其他营业单位收到\n的现金净额\n收到其他与投资活动有关的现金 1,172,215,955.60 959,401,529.98\n投资活动现金流入小计 1,177,235,296.80 963,819,628.62\n购建固定资产、无形资产和其他\n160,639,977.78 255,780,578.95\n长期资产支付的现金\n投资支付的现金 20,000,000.00\n质押贷款净增加额\n取得子公司及其他营业单位支付\n的现金净额\n支付其他与投资活动有关的现金 260,000,000.00 1,805,459,752.25\n投资活动现金流出小计 440,639,977.78 2,061,240,331.20\n投资活动产生的现金流量净额 736,595,319.02 -1,097,420,702.58\n89。\n\n三、筹资活动产生的现金流量：\n吸收投资收到的现金\n其中：子公司吸收少数股东投资\n收到的现金\n取得借款收到的现金 285,000,000.00 755,700,000.00\n收到其他与筹资活动有关的现金 633,043,300.00\n筹资活动现金流入小计 285,000,000.00 1,388,743,300.00\n偿还债务支付的现金 683,700,000.00 1,500,000,000.00\n分配股利、利润或偿付利息支付\n483,358,140.11 204,568,679.00\n的现金\n其中：子公司支付给少数股东的\n股利、利润\n支付其他与筹资活动有关的现金 20,278,463.47 590,452,772.90\n筹资活动现金流出小计 1,187,336,603.58 2,295,021,451.90\n筹资活动产生的现金流量净额 -902,336,603.58 -906,278,151.90\n四、汇率变动对现金及现金等价物的\n9,911,822.10 35,680,596.21\n影响\n五、现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n加：期初现金及现金等价物余额 1,069,208,275.60 2,245,777,296.21\n六、期末现金及现金等价物余额 1,525,777,908.45 1,069,208,275.60\n6、母公司现金流量表\n单位：元\n项目 2019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 794,479,241.27 765,335,887.08\n收到的税费返还 63,235,140.24 46,673,265.97\n收到其他与经营活动有关的现金 2,428,120,879.18 2,178,495,326.41\n经营活动现金流入小计 3,285,835,260.69 2,990,504,479.46\n购买商品、接受劳务支付的现金 576,564,206.12 485,651,890.91\n支付给职工以及为职工支付的现\n43,273,656.13 44,578,456.58\n金\n支付的各项税费 4,696,293.04 11,167,793.85\n支付其他与经营活动有关的现金 2,653,901,946.32 1,818,361,700.45\n经营活动现金流出小计 3,278,436,101.61 2,359,759,841.79\n90。\n\n经营活动产生的现金流量净额 7,399,159.08 630,744,637.67\n二、投资活动产生的现金流量：\n收回投资收到的现金\n取得投资收益收到的现金 722,088,153.34 160,759,162.54\n处置固定资产、无形资产和其他\n1,169,750.39 337,155.52\n长期资产收回的现金净额\n处置子公司及其他营业单位收到\n的现金净额\n收到其他与投资活动有关的现金 475,265,164.50 811,296,572.90\n投资活动现金流入小计 1,198,523,068.23 972,392,890.96\n购建固定资产、无形资产和其他\n984,040.99 10,199,423.26\n长期资产支付的现金\n投资支付的现金 20,000,000.00 156,121,497.07\n取得子公司及其他营业单位支付\n的现金净额\n支付其他与投资活动有关的现金 20,000,000.00 1,255,559,950.55\n投资活动现金流出小计 40,984,040.99 1,421,880,870.88\n投资活动产生的现金流量净额 1,157,539,027.24 -449,487,979.92\n三、筹资活动产生的现金流量：\n吸收投资收到的现金\n取得借款收到的现金 235,000,000.00 389,000,000.00\n收到其他与筹资活动有关的现金\n筹资活动现金流入小计 235,000,000.00 389,000,000.00\n偿还债务支付的现金 322,000,000.00 772,000,000.00\n分配股利、利润或偿付利息支付\n476,237,693.27 185,312,985.94\n的现金\n支付其他与筹资活动有关的现金 20,278,463.47 295,075,572.90\n筹资活动现金流出小计 818,516,156.74 1,252,388,558.84\n筹资活动产生的现金流量净额 -583,516,156.74 -863,388,558.84\n四、汇率变动对现金及现金等价物的\n4,468,592.83 11,626,754.25\n影响\n五、现金及现金等价物净增加额 585,890,622.41 -670,505,146.84\n加：期初现金及现金等价物余额 593,590,172.62 1,264,095,319.46\n六、期末现金及现金等价物余额 1,179,480,795.03 593,590,172.62\n91。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "09f53672",
        "e84cfe63",
        "9853802c",
        "dfeeb7b7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3460,
      "page_number": 88,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88,
          89,
          90,
          91
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.320643",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3460,
        "word_count": 267,
        "sentence_count": 132,
        "chinese_char_count": 1375,
        "readability_score": 0.0,
        "information_density": 0.05491329479768786,
        "coherence_score": 0.28333333333333327,
        "standards_profile_summary": {}
      },
      "quality_score": 0.545664739884393,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "利润",
        "现金",
        "投资",
        "固定资产",
        "无形资产",
        "现金流量表",
        "合并",
        "母公司"
      ]
    },
    {
      "chunk_id": "c5797387",
      "content": "7、合并所有者权益变动表\n本期金额\n单位：元\n2019年度\n归属于母公司所有者权益\n所有\n少数\n项目 其他权益工具 其他 一般 未分 者权\n资本 减：库 专项 盈余 股东\n股本 优先 永续 综合 风险 配利 其他 小计 益合\n股 债\n其他 公积 存股\n收益\n储备 公积\n准备 润\n权益\n计\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,\n一、上年期末余 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 549,93\n额 253.0 9.23\n2.47 68 17 8.50 2.23 2.23\n0\n加：会计政\n策变更\n前期\n差错更正\n同一\n控制下企业合\n并\n其他\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,\n二、本年期初余 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 549,93\n额 253.0 9.23\n2.47 68 17 8.50 2.23 2.23\n0\n三、本期增减变 -105, -24,36 11,257 292,84 333,91 333,91\n6,982, -1,438,\n动金额（减少以 000.0 9,047. ,545.1 6,480. 2,163. 2,163.\n499.53 409.58\n“－”号填列） 0 78 4 45 32 32\n770,78 769,34 769,34\n（一）综合收益 -1,438,\n2,185. 3,775. 3,775.\n总额 409.58\n09 51 51\n-105, -24,36 31,246 31,246\n（二）所有者投 6,982,\n000.0 9,047. ,547.3 ,547.3\n入和减少资本 499.53\n0 78 1 1\n-105, 19,996 -20,23 -20,23\n1．所有者投入 -131,2\n000.0 ,827.2 3,077. 3,077.\n的普通股 50.00\n0 2 22 22\n2．其他权益工\n具持有者投入\n资本\n92。\n\n3．股份支付计 -44,36 51,479 51,479\n7,113,\n入所有者权益 5,875. ,624.5 ,624.5\n749.53\n的金额 00 3 3\n4．其他\n11,257 -477,9 -466,6 -466,6\n（三）利润分配 ,545.1 35,704 78,159 78,159\n4 .64 .50 .50\n11,257 -11,25\n1．提取盈余公\n,545.1 7,545.\n积\n4 14\n2．提取一般风\n险准备\n-466,6 -466,6 -466,6\n3．对所有者（或\n78,159 78,159 78,159\n股东）的分配\n.50 .50 .50\n4．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储备\n18,997 18,997 18,997\n1．本期提取 ,055.9 ,055.9 ,055.9\n7 7 7\n93\n\n-18,99 -18,99 -18,99\n2．本期使用 7,055. 7,055. 7,055.\n97 97 97\n（六）其他\n1,618\n2,670, 301,51 213,06 1,525, 5,724, 5,724,\n四、本期期末余 ,715, -1,490,\n350,32 1,513. 9,824. 328,39 462,09 462,09\n额 253.0 188.81\n2.00 90 31 8.95 5.55 5.55\n0\n上期金额\n单位：元\n2018年年度\n归属于母公司所有者权益\n所有者\n项目 其他权益工具 其他 一般 未分 少数股\n资本 减：库 专项 盈余 权益合\n股本 优先 永续 综合 风险 配利 其他 小计 东权益\n其他 公积 存股 储备 公积 计\n股 债 收益 准备 润\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n一、上年期末 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.75 75\n0\n加：会计\n政策变更\n前期\n差错更正\n同一\n控制下企业合\n并\n其他\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n二、本年期初 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.75 75\n0\n三、本期增减\n-2,79 33,533 225,47 108,61 334,64 248,54\n变动金额（减 16,560 248,541\n0,000 ,011.2 7,311. 4,533. 4,962. 1,755.\n少以“－”号填 .46 ,755.48\n.00 2 68 40 08 48\n列）\n605,00 605,02\n（一）综合收 16,560 605,020\n3,820. 0,381.\n益总额 .46 ,381.24\n78 24\n94。\n\n（二）所有者 -2,79 33,533 225,47 -194,7 -194,73\n投入和减少资 0,000 ,011.2 7,311. 34,300 4,300.4\n本 .00 2 68 .46 6\n-2,79 -10,60 281,51 -294,9 -294,91\n1．所有者投入\n0,000 6,500. 4,686. 11,186 1,186.6\n的普通股\n.00 00 68 .68 8\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计 44,139 -56,03 100,17\n100,176\n入所有者权益 ,511.2 7,375. 6,886.\n,886.22\n的金额 2 00 22\n4．其他\n108,61 -270,3 -161,7 -161,74\n（三）利润分\n4,533. 58,858 44,325 4,325.3\n配\n40 .70 .30 0\n108,61 -108,6\n1．提取盈余公\n4,533. 14,533\n积\n40 .40\n2．提取一般风\n险准备\n3．对所有者 -161,7 -161,7 -161,74\n（或股东）的 44,325 44,325 4,325.3\n分配 .30 .30 0\n4．其他\n（四）所有者\n权益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n95。\n\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储\n备\n19,301 19,301\n19,301,\n1．本期提取 ,110.5 ,110.5\n110.51\n1 1\n-19,30 -19,30\n-19,301\n2．本期使用 1,110. 1,110.\n,110.51\n51 51\n（六）其他\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,5\n四、本期期末 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 49,932.\n余额 253.0 9.23\n2.47 68 17 8.50 2.23 23\n0\n8、母公司所有者权益变动表\n本期金额\n单位：元\n2019年度\n项目 其他权益工具 资本公 减：库存 其他综 专项储 盈余公 未分配 所有者权\n股本 其他\n优先股 永续债 其他 积 股 合收益 备 积 利润 益合计\n1,618,8 1,062,8\n一、上年期末余 2,662,22 325,880, 201,812, 5,219,782,\n20,253. 00,363.\n额 9,769.88 561.68 279.17 103.53\n00 16\n加：会计政\n策变更\n前期\n差错更正\n其他\n1,618,8 1,062,8\n二、本年期初余 2,662,22 325,880, 201,812, 5,219,782,\n20,253. 00,363.\n额 9,769.88 561.68 279.17 103.53\n00 16\n三、本期增减变 -365,36\n-105,00 6,982,49 -24,369, 11,257,5 -322,856,1\n动金额（减少以 0,253.2\n0.00 9.53 047.78 45.14 60.84\n“－”号填列） 9\n96。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "ecdd6fb4",
        "90bde835",
        "df325777",
        "eec826c5",
        "2ccbf163"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3679,
      "page_number": 92,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92,
          93,
          94,
          95,
          96
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.322530",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3679,
        "word_count": 658,
        "sentence_count": 152,
        "chinese_char_count": 769,
        "readability_score": 0.0,
        "information_density": 0.02989942919271541,
        "coherence_score": 0.6432344147226708,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6078553954879043,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "合并",
        "母公司",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "3d56abdc",
      "content": "112,57\n（一）综合收益 112,575,45\n5,451.3\n总额 1.35\n5\n（二）所有者投 -105,00 6,982,49 -24,369, 31,246,54\n入和减少资本 0.00 9.53 047.78 7.31\n1．所有者投入 -105,00 -131,250 19,996,8 -20,233,07\n的普通股 0.00 .00 27.22 7.22\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计\n7,113,74 -44,365, 51,479,62\n入所有者权益\n9.53 875.00 4.53\n的金额\n4．其他\n-477,93\n11,257,5 -466,678,1\n（三）利润分配 5,704.6\n45.14 59.50\n4\n1．提取盈余公 11,257,5 -11,257\n积 45.14 ,545.14\n-466,67\n2．对所有者（或 -466,678,1\n8,159.5\n股东）的分配 59.50\n0\n3．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n97。\n\n6．其他\n（五）专项储备\n6,960,83 6,960,833.\n1．本期提取\n3.11 11\n-6,960,8 -6,960,833\n2．本期使用\n33.11 .11\n（六）其他\n1,618,7 697,44\n四、本期期末余 2,669,21 301,511, 213,069, 4,896,925,\n15,253. 0,109.8\n额 2,269.41 513.90 824.31 942.69\n00 7\n上期金额\n单位：元\n2018年年度\n其他权益工具\n项目 资本公 减：库存 其他综 盈余公 未分配利 所有者权\n股本 优先 永续 专项储备 其他\n其他 积 股 合收益 积 润 益合计\n股 债\n1,621, 2,628,6\n一、上年期末余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n加：会计政\n策变更\n前期\n差错更正\n其他\n1,621, 2,628,6\n二、本年期初余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n三、本期增减变\n-2,790, 33,533,225,477, 108,614 815,786,4 729,666,70\n动金额（减少以\n000.00 011.22 311.68 ,533.40 75.25 8.19\n“－”号填列）\n（一）综合收益 1,086,145 1,086,145,3\n总额 ,333.95 33.95\n（二）所有者投 -2,790, 33,533,225,477, -194,734,30\n入和减少资本 000.00 011.22 311.68 0.46\n1．所有者投入 -2,790, -10,606,281,514, -294,911,18\n的普通股 000.00 500.00 686.68 6.68\n98。\n\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计\n44,139, -56,037, 100,176,88\n入所有者权益\n511.22 375.00 6.22\n的金额\n4．其他\n108,614 -270,358, -161,744,32\n（三）利润分配\n,533.40 858.70 5.30\n1．提取盈余公 108,614 -108,614,\n积 ,533.40 533.40\n2．对所有者（或 -161,744, -161,744,32\n股东）的分配 325.30 5.30\n3．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储备\n4,736,183 4,736,183.5\n1．本期提取\n.53 3\n-4,736,18 -4,736,183.\n2．本期使用\n3.53 53\n（六）其他\n99\n\n1,618, 2,662,2\n四、本期期末余 325,880, 201,812 1,062,800 5,219,782,1\n820,25 29,769.\n额 561.68 ,279.17 ,363.16 03.53\n3.00 88\n三、公司基本情况\n浙江海翔药业股份有限公司（以下简称公司或本公司）系经浙江省人民政府企业上市工作领导小组浙\n上市〔2004〕16号文批准，由罗邦鹏、上海复星化工医药投资有限公司、张志敏、张智岳、罗煜竑、郑志\n国、李维金、中化宁波(集团)有限公司、重庆医药工业研究院有限责任公司和浙江美阳国际石化医药工程\n设计有限公司共同发起，在原浙江海翔医药化工有限公司基础上整体变更设立的股份有限公司，于2004年\n5月13日在浙江省工商行政管理局登记注册，总部位于浙江省台州市。公司现持有统一社会信用代码为\n913300001482332737的营业执照，注册资本1,618,715,253.00元，股份总数1,618,715,253股(每股面值1元)。其中，有限售条件的流通股份A股14,274,600股；无限售条件的流通股份A股1,604,440,653股。\n\n公司股票已\n于2006年12月26日在深圳证券交易所挂牌交易。本公司属于医药化工行业。主要经营活动为药品的生产(范围详见《中华人民共和国药品生产许可证》)，\n化工原料及产品的生产，经营进出口业务。\n\n(依法须经批准的项目，经相关部门批准后方可开展经营活动。)\n产品主要有：原料药及医药中间体、染料及染颜料中间体。本财务报表业经公司2020年1月22日第六届董事会第二次会议批准对外报出。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "de3fdedf",
        "065b6141",
        "7ed2588b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2527,
      "page_number": 97,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97,
          98,
          99,
          100
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.324560",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 2527,
        "word_count": 300,
        "sentence_count": 90,
        "chinese_char_count": 861,
        "readability_score": 0.0,
        "information_density": 0.07123070834982193,
        "coherence_score": 0.6698417955644259,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7362880886426593,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表",
        "253.00元",
        "1元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "投资",
        "营业",
        "经营",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "a31d7651",
      "content": "2. 外币财务报表折算\n资产负债表中的资产和负债项目，采用资产负债表日的即期汇率折算；所有者权益项目除“未分配利\n润”项目外，其他项目采用交易发生日的即期汇率折算；利润表中的收入和费用项目，采用交易发生日即\n期汇率的近似汇率折算。按照上述折算产生的外币财务报表折算差额，计入其他综合收益。10、金融工具\n1. 金融资产和金融负债的分类\n金融资产在初始确认时划分为以下三类：(1) 以摊余成本计量的金融资产；(2) 以公允价值计量且其变\n102。\n\n动计入其他综合收益的金融资产；(3) 以公允价值计量且其变动计入当期损益的金融资产。金融负债在初始确认时划分为以下四类：(1) 以公允价值计量且其变动计入当期损益的金融负债；(2)\n金融资产转移不符合终止确认条件或继续涉入被转移金融资产所形成的金融负债；(3) 不属于上述(1)或(2)\n的财务担保合同，以及不属于上述(1)并以低于市场利率贷款的贷款承诺；(4) 以摊余成本计量的金融负债。2. 金融资产和金融负债的确认依据、计量方法和终止确认条件\n(1) 金融资产和金融负债的确认依据和初始计量方法\n公司成为金融工具合同的一方时，确认一项金融资产或金融负债。\n\n初始确认金融资产或金融负债时，\n按照公允价值计量；对于以公允价值计量且其变动计入当期损益的金融资产和金融负债，相关交易费用直\n接计入当期损益；对于其他类别的金融资产或金融负债，相关交易费用计入初始确认金额。但是，公司初\n始确认的应收账款未包含重大融资成分或公司不考虑未超过一年的合同中的融资成分的，按照交易价格进\n行初始计量。(2) 金融资产的后续计量方法\n1) 以摊余成本计量的金融资产\n采用实际利率法，按照摊余成本进行后续计量。\n\n以摊余成本计量且不属于任何套期关系的一部分的金\n融资产所产生的利得或损失，在终止确认、重分类、按照实际利率法摊销或确认减值时，计入当期损益。2) 以公允价值计量且其变动计入其他综合收益的债务工具投资\n采用公允价值进行后续计量。采用实际利率法计算的利息、减值损失或利得及汇兑损益计入当期损益，\n其他利得或损失计入其他综合收益。\n\n终止确认时，将之前计入其他综合收益的累计利得或损失从其他综合\n收益中转出，计入当期损益。3) 以公允价值计量且其变动计入其他综合收益的权益工具投资\n采用公允价值进行后续计量。获得的股利（属于投资成本收回部分的除外）计入当期损益，其他利得\n或损失计入其他综合收益。\n\n终止确认时，将之前计入其他综合收益的累计利得或损失从其他综合收益中转\n出，计入留存收益。4) 以公允价值计量且其变动计入当期损益的金融资产\n采用公允价值进行后续计量，产生的利得或损失（包括利息和股利收入)计入当期损益，除非该金融资\n产属于套期关系的一部分。(3) 金融负债的后续计量方法\n1) 以公允价值计量且其变动计入当期损益的金融负债\n此类金融负债包括交易性金融负债（含属于金融负债的衍生工具)和指定为以公允价值计量且其变动计\n入当期损益的金融负债。\n\n对于此类金融负债以公允价值进行后续计量。因公司自身信用风险变动引起的指\n定为以公允价值计量且其变动计入当期损益的金融负债的公允价值变动金额计入其他综合收益，除非该处\n理会造成或扩大损益中的会计错配。此类金融负债产生的其他利得或损失（包括利息费用、除因公司自身\n信用风险变动引起的公允价值变动)计入当期损益，除非该金融负债属于套期关系的一部分。\n\n终止确认时，\n将之前计入其他综合收益的累计利得或损失从其他综合收益中转出，计入留存收益。2) 金融资产转移不符合终止确认条件或继续涉入被转移金融资产所形成的金融负债\n按照《企业会计准则第23号——金融资产转移》相关规定进行计量。3) 不属于上述1)或2)的财务担保合同，以及不属于上述1)并以低于市场利率贷款的贷款承诺\n在初始确认后按照下列两项金额之中的较高者进行后续计量：① 按照金融工具的减值规定确定的损\n失准备金额；② 初始确认金额扣除按照相关规定所确定的累计摊销额后的余额。\n\n4) 以摊余成本计量的金融负债\n采用实际利率法以摊余成本计量。以摊余成本计量且不属于任何套期关系的一部分的金融负债所产生\n的利得或损失，在终止确认、按照实际利率法摊销时计入当期损益。(4) 金融资产和金融负债的终止确认\n1) 当满足下列条件之一时，终止确认金融资产：\n103。\n\n① 收取金融资产现金流量的合同权利已终止；\n② 金融资产已转移，且该转移满足《企业会计准则第23号——金融资产转移》关于金融资产终止确\n认的规定。2) 当金融负债（或其一部分）的现时义务已经解除时，相应终止确认该金融负债（或该部分金融负债）。3. 金融资产转移的确认依据和计量方法\n公司转移了金融资产所有权上几乎所有的风险和报酬的，终止确认该金融资产，并将转移中产生或保\n留的权利和义务单独确认为资产或负债；保留了金融资产所有权上几乎所有的风险和报酬的，继续确认所\n转移的金融资产。\n\n公司既没有转移也没有保留金融资产所有权上几乎所有的风险和报酬的，分别下列情况\n处理：(1) 未保留对该金融资产控制的，终止确认该金融资产，并将转移中产生或保留的权利和义务单独\n确认为资产或负债；(2) 保留了对该金融资产控制的，按照继续涉入所转移金融资产的程度确认有关金融\n资产，并相应确认有关负债。金融资产整体转移满足终止确认条件的，将下列两项金额的差额计入当期损益：(1) 所转移金融资产\n在终止确认日的账面价值；(2) 因转移金融资产而收到的对价，与原直接计入其他综合收益的公允价值变\n动累计额中对应终止确认部分的金额（涉及转移的金融资产为以公允价值计量且其变动计入其他综合收益\n的债务工具投资）之和。转移了金融资产的一部分，且该被转移部分整体满足终止确认条件的，将转移前\n金融资产整体的账面价值，在终止确认部分和继续确认部分之间，按照转移日各自的相对公允价值进行分\n摊，并将下列两项金额的差额计入当期损益：(1) 终止确认部分的账面价值；(2) 终止确认部分的对价，与\n原直接计入其他综合收益的公允价值变动累计额中对应终止确认部分的金额（涉及转移的金融资产为以公\n允价值计量且其变动计入其他综合收益的债务工具投资）之和。\n\n4. 金融资产和金融负债的公允价值确定方法\n公司采用在当前情况下适用并且有足够可利用数据和其他信息支持的估值技术确定相关金融资产和\n金融负债的公允价值。公司将估值技术使用的输入值分以下层级，并依次使用：\n(1) 第一层次输入值是在计量日能够取得的相同资产或负债在活跃市场上未经调整的报价；\n(2) 第二层次输入值是除第一层次输入值外相关资产或负债直接或间接可观察的输入值，包括：活跃\n市场中类似资产或负债的报价；非活跃市场中相同或类似资产或负债的报价；除报价以外的其他可观察输\n入值，如在正常报价间隔期间可观察的利率和收益率曲线等；市场验证的输入值等；\n(3) 第三层次输入值是相关资产或负债的不可观察输入值，包括不能直接观察或无法由可观察市场数\n据验证的利率、股票波动率、企业合并中承担的弃置义务的未来现金流量、使用自身数据作出的财务预测\n等。5. 金融工具减值\n(1) 金融工具减值计量和会计处理\n公司以预期信用损失为基础，对以摊余成本计量的金融资产、以公允价值计量且其变动计入其他综合\n收益的债务工具投资、租赁应收款、分类为以公允价值计量且其变动计入当期损益的金融负债以外的贷款\n承诺、不属于以公允价值计量且其变动计入当期损益的金融负债或不属于金融资产转移不符合终止确认条\n件或继续涉入被转移金融资产所形成的金融负债的财务担保合同进行减值处理并确认损失准备。\n\n预期信用损失，是指以发生违约的风险为权重的金融工具信用损失的加权平均值。信用损失，是指公\n司按照原实际利率折现的、根据合同应收的所有合同现金流量与预期收取的所有现金流量之间的差额，即\n全部现金短缺的现值。其中，对于公司购买或源生的已发生信用减值的金融资产，按照该金融资产经信用\n调整的实际利率折现。\n\n对于购买或源生的已发生信用减值的金融资产，公司在资产负债表日仅将自初始确认后整个存续期内\n预期信用损失的累计变动确认为损失准备。对于不含重大融资成分或者公司不考虑不超过一年的合同中的融资成分的应收账款，公司运用简化计\n量方法，按照相当于整个存续期内的预期信用损失金额计量损失准备。除上述计量方法以外的金融资产，公司在每个资产负债表日评估其信用风险自初始确认后是否已经显\n104。\n\n著增加。如果信用风险自初始确认后已显著增加，公司按照整个存续期内预期信用损失的金额计量损失准\n备；如果信用风险自初始确认后未显著增加，公司按照该金融工具未来12个月内预期信用损失的金额计量\n损失准备。公司利用可获得的合理且有依据的信息，包括前瞻性信息，通过比较金融工具在资产负债表日发生违\n约的风险与在初始确认日发生违约的风险，以确定金融工具的信用风险自初始确认后是否已显著增加。\n\n于资产负债表日，若公司判断金融工具只具有较低的信用风险，则假定该金融工具的信用风险自初始\n确认后并未显著增加。公司以单项金融工具或金融工具组合为基础评估预期信用风险和计量预期信用损失。当以金融工具组\n合为基础时，公司以共同风险特征为依据，将金融工具划分为不同组合。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "6627f889",
        "f7053ecb",
        "10e80b96",
        "1135caa9"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3815,
      "page_number": 102,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.6999999999999998,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          102,
          103,
          104,
          105
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.326131",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3815,
        "word_count": 135,
        "sentence_count": 54,
        "chinese_char_count": 3346,
        "readability_score": 0.0,
        "information_density": 0.05242463958060288,
        "coherence_score": 0.7151527293411837,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9508256880733945,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "融资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收"
      ]
    },
    {
      "chunk_id": "7ee07549",
      "content": "公司在每个资产负债表日重新计量预期信用损失，由此形成的损失准备的增加或转回金额，作为减值\n损失或利得计入当期损益。对于以摊余成本计量的金融资产，损失准备抵减该金融资产在资产负债表中列\n示的账面价值；对于以公允价值计量且其变动计入其他综合收益的债权投资，公司在其他综合收益中确认\n其损失准备，不抵减该金融资产的账面价值。(2) 按组合评估预期信用风险和计量预期信用损失的金融工具\n项 目 确定组合的依据 计量预期信用损失的方法\n其他应收款——应收出口退税组合 款项性质 参考历史信用损失经验，结合当前\n其他应收款——应收押金保证金组 状况以及对未来经济状况的预测，\n合 通过违约风险敞口和未来12个月\n内或整个存续期预期信用损失率，\n其他应收款——合并范围内关联往\n来组合\n计算预期信用损失\n其他应收款——应收拆借款组合\n其他应收款——应收暂付款等组合\n(3) 按组合计量预期信用损失的应收款项\n1) 具体组合及计量预期信用损失的方法\n项 目 确定组合的依据 计量预期信用损失的方法\n应收银行承兑汇票 票据类型 参考历史信用损失经验，结合当前状\n况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，计算预期信用损失\n应收账款——信用风险特征组账龄组合 参考历史信用损失经验，结合当前状\n合 况以及对未来经济状况的预测，编制\n应收账款账龄与整个存续期预期信用\n损失率对照表，计算预期信用损失\n应收账款——合并范围内关联合并范围内关联方 参考历史信用损失经验，结合当前状\n往来组合 况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，该组合预期信用损失率为0%\n2) 应收账款——信用风险特征组合的账龄与整个存续期预期信用损失率对照表\n账 龄 应收账款\n预期信用损失率(%)\n1年以内（含，下同） 5\n1-2年 30\n105。\n\n2-3年 80\n3年以上 100\n6. 金融资产和金融负债的抵销\n金融资产和金融负债在资产负债表内分别列示，不相互抵销。但同时满足下列条件的，公司以相互抵\n销后的净额在资产负债表内列示：(1) 公司具有抵销已确认金额的法定权利，且该种法定权利是当前可执\n行的；(2) 公司计划以净额结算，或同时变现该金融资产和清偿该金融负债。不满足终止确认条件的金融资产转移，公司不对已转移的金融资产和相关负债进行抵销。\n\n11、应收票据\n12、应收账款\n13、应收款项融资\n14、其他应收款\n其他应收款的预期信用损失的确定方法及会计处理方法\n15、存货\n(十一) 存货\n1. 存货的分类\n存货包括在日常活动中持有以备出售的产成品或商品、处在生产过程中的在产品、在生产过程或提供\n劳务过程中耗用的材料和物料等。2. 发出存货的计价方法\n发出存货采用月末一次加权平均法。3. 存货可变现净值的确定依据\n资产负债表日，存货采用成本与可变现净值孰低计量，按照单个存货成本高于可变现净值的差额计提\n存货跌价准备。\n(2) 包装物\n按照一次转销法进行摊销。106。\n\n直接用于出售的存货，在正常生产经营过程中以该存货的估计售价减去估计的销售费用和\n相关税费后的金额确定其可变现净值；需要经过加工的存货，在正常生产经营过程中以所生产的产成品的\n估计售价减去至完工时估计将要发生的成本、估计的销售费用和相关税费后的金额确定其可变现净值；资\n产负债表日，同一项存货中一部分有合同价格约定、其他部分不存在合同价格的，分别确定其可变现净值，\n并与其对应的成本进行比较，分别确定存货跌价准备的计提或转回的金额。4. 存货的盘存制度\n存货的盘存制度为永续盘存制。5. 低值易耗品和包装物的摊销方法\n(1) 低值易耗品\n按照一次转销法进行摊销。\n\n(2) 包装物\n按照一次转销法进行摊销。106。\n\n16、合同资产\n17、合同成本\n18、持有待售资产\n19、债权投资\n20、其他债权投资\n21、长期应收款\n22、长期股权投资\n1. 共同控制、重要影响的判断\n按照相关约定对某项安排存在共有的控制，并且该安排的相关活动必须经过分享控制权的参与方一致\n同意后才能决策，认定为共同控制。对被投资单位的财务和经营政策有参与决策的权力，但并不能够控制\n或者与其他方一起共同控制这些政策的制定，认定为重大影响。2. 投资成本的确定\n(1) 同一控制下的企业合并形成的，合并方以支付现金、转让非现金资产、承担债务或发行权益性证\n券作为合并对价的，在合并日按照取得被合并方所有者权益在最终控制方合并财务报表中的账面价值的份\n额作为其初始投资成本。\n\n长期股权投资初始投资成本与支付的合并对价的账面价值或发行股份的面值总额\n之间的差额调整资本公积；资本公积不足冲减的，调整留存收益。公司通过多次交易分步实现同一控制下企业合并形成的长期股权投资，判断是否属于“一揽子交易”。属于“一揽子交易”的，把各项交易作为一项取得控制权的交易进行会计处理。\n\n不属于“一揽子交易”的，在\n合并日，根据合并后应享有被合并方净资产在最终控制方合并财务报表中的账面价值的份额确定初始投资\n成本。合并日长期股权投资的初始投资成本，与达到合并前的长期股权投资账面价值加上合并日进一步取\n得股份新支付对价的账面价值之和的差额，调整资本公积；资本公积不足冲减的，调整留存收益。(2) 非同一控制下的企业合并形成的，在购买日按照支付的合并对价的公允价值作为其初始投资成本。\n\n公司通过多次交易分步实现非同一控制下企业合并形成的长期股权投资，区分个别财务报表和合并财\n务报表进行相关会计处理：\n1) 在个别财务报表中，按照原持有的股权投资的账面价值加上新增投资成本之和，作为改按成本法核\n算的初始投资成本。2) 在合并财务报表中，判断是否属于“一揽子交易”。属于“一揽子交易”的，把各项交易作为一项取得\n控制权的交易进行会计处理。\n\n不属于“一揽子交易”的，对于购买日之前持有的被购买方的股权，按照该股\n权在购买日的公允价值进行重新计量，公允价值与其账面价值的差额计入当期投资收益；购买日之前持有\n的被购买方的股权涉及权益法核算下的其他综合收益等的，与其相关的其他综合收益等转为购买日所属当\n期收益。但由于被投资方重新计量设定受益计划净负债或净资产变动而产生的其他综合收益除外。(3) 除企业合并形成以外的：以支付现金取得的，按照实际支付的购买价款作为其初始投资成本；以\n发行权益性证券取得的，按照发行权益性证券的公允价值作为其初始投资成本；以债务重组方式取得的，\n按《企业会计准则第12号——债务重组》确定其初始投资成本；以非货币性资产交换取得的，按《企业会\n计准则第7号——非货币性资产交换》确定其初始投资成本。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "0159d276",
        "09e3c75b",
        "76844fe1"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2748,
      "page_number": 105,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105,
          106,
          107
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.328075",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2748,
        "word_count": 143,
        "sentence_count": 39,
        "chinese_char_count": 2322,
        "readability_score": 0.0,
        "information_density": 0.06914119359534207,
        "coherence_score": 0.6784992230110902,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9379912663755459,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "费用",
        "现金",
        "投资",
        "应收",
        "存货",
        "销售费用"
      ]
    },
    {
      "chunk_id": "c94d9fa5",
      "content": "3. 后续计量及损益确认方法\n对被投资单位实施控制的长期股权投资采用成本法核算；对联营企业和合营企业的长期股权投资，采\n用权益法核算。107。\n\n4. 通过多次交易分步处置对子公司投资至丧失控制权的处理方法\n(1) 个别财务报表\n对处置的股权，其账面价值与实际取得价款之间的差额，计入当期损益。对于剩余股权，对被投资单\n位仍具有重大影响或者与其他方一起实施共同控制的，转为权益法核算；不能再对被投资单位实施控制、\n共同控制或重大影响的，按照《企业会计准则第22号——金融工具确认和计量》的相关规定进行核算。(2) 合并财务报表\n1) 通过多次交易分步处置对子公司投资至丧失控制权，且不属于“一揽子交易”的\n在丧失控制权之前，处置价款与处置长期股权投资相对应享有子公司自购买日或合并日开始持续计算\n的净资产份额之间的差额，调整资本公积（资本溢价），资本溢价不足冲减的，冲减留存收益。\n\n丧失对原子公司控制权时，对于剩余股权，按照其在丧失控制权日的公允价值进行重新计量。处置股\n权取得的对价与剩余股权公允价值之和，减去按原持股比例计算应享有原有子公司自购买日或合并日开始\n持续计算的净资产的份额之间的差额，计入丧失控制权当期的投资收益，同时冲减商誉。与原有子公司股\n权投资相关的其他综合收益等，应当在丧失控制权时转为当期投资收益。\n\n2) 通过多次交易分步处置对子公司投资至丧失控制权，且属于“一揽子交易”的\n将各项交易作为一项处置子公司并丧失控制权的交易进行会计处理。但是，在丧失控制权之前每一次\n处置价款与处置投资对应的享有该子公司净资产份额的差额，在合并财务报表中确认为其他综合收益，在\n丧失控制权时一并转入丧失控制权当期的损益。23、投资性房地产\n投资性房地产计量模式\n成本法计量\n折旧或摊销方法\n1. 投资性房地产包括已出租的土地使用权、持有并准备增值后转让的土地使用权和已出租的建筑物。\n\n2. 投资性房地产按照成本进行初始计量，采用成本模式进行后续计量，并采用与固定资产和无形资产\n相同的方法计提折旧或进行摊销。24、固定资产\n（1）确认条件\n固定资产是指为生产商品、提供劳务、出租或经营管理而持有的，使用年限超过一个会计年度的有形资产。固定资产在同时\n满足经济利益很可能流入、成本能够可靠计量时予以确认。\n\n（2）折旧方法\n类别 折旧方法 折旧年限 残值率 年折旧率\n房屋及建筑物 年限平均法 5-20 0、3、5或10 4.50-20.00\n通用设备 年限平均法 3-5 0、3、5或10 18.00-33.33\n专用设备 年限平均法 3-10 3、5或10 9.00-32.33\n运输工具 年限平均法 4-5 3、5或10 18.00-24.25\n108。\n\n（3）融资租入固定资产的认定依据、计价和折旧方法\n符合下列一项或数项标准的，认定为融资租赁：(1) 在租赁期届满时，租赁资产的所有权转移给承租人；(2) 承租人有购买\n租赁资产的选择权，所订立的购买价款预计将远低于行使选择权时租赁资产的公允价值，因而在租赁开始日就可以合理确定\n承租人将会行使这种选择权；(3) 即使资产的所有权不转移，但租赁期占租赁资产使用寿命的大部分 [ 通常占租赁资产使用\n寿命的75%以上（含75%）]；(4) 承租人在租赁开始日的最低租赁付款额现值，几乎相当于租赁开始日租赁资产公允价值\n[ 90%以上（含90%）]；出租人在租赁开始日的最低租赁收款额现值，几乎相当于租赁开始日租赁资产公允价值 [ 90%以上\n（含90%）]；(5) 租赁资产性质特殊，如果不作较大改造，只有承租人才能使用。融资租入的固定资产，按租赁开始日租\n赁资产的公允价值与最低租赁付款额的现值中较低者入账，按自有固定资产的折旧政策计提折旧。25、在建工程\n1. 在建工程同时满足经济利益很可能流入、成本能够可靠计量则予以确认。\n\n在建工程按建造该项资产\n达到预定可使用状态前所发生的实际成本计量。2. 在建工程达到预定可使用状态时，按工程实际成本转入固定资产。已达到预定可使用状态但尚未办\n理竣工决算的，先按估计价值转入固定资产，待办理竣工决算后再按实际成本调整原暂估价值，但不再调\n整原已计提的折旧。\n\n26、借款费用\n1. 借款费用资本化的确认原则\n公司发生的借款费用，可直接归属于符合资本化条件的资产的购建或者生产的，予以资本化，计入相\n关资产成本；其他借款费用，在发生时确认为费用，计入当期损益。2. 借款费用资本化期间\n(1) 当借款费用同时满足下列条件时，开始资本化：1) 资产支出已经发生；2) 借款费用已经发生；3) 为\n使资产达到预定可使用或可销售状态所必要的购建或者生产活动已经开始。(2) 若符合资本化条件的资产在购建或者生产过程中发生非正常中断，并且中断时间连续超过3个月，\n暂停借款费用的资本化；中断期间发生的借款费用确认为当期费用，直至资产的购建或者生产活动重新开\n始。\n\n(3) 当所购建或者生产符合资本化条件的资产达到预定可使用或可销售状态时，借款费用停止资本化。3. 借款费用资本化率以及资本化金额\n为购建或者生产符合资本化条件的资产而借入专门借款的，以专门借款当期实际发生的利息费用（包\n括按照实际利率法确定的折价或溢价的摊销），减去将尚未动用的借款资金存入银行取得的利息收入或进\n行暂时性投资取得的投资收益后的金额，确定应予资本化的利息金额；为购建或者生产符合资本化条件的\n资产占用了一般借款的，根据累计资产支出超过专门借款的资产支出加权平均数乘以占用一般借款的资本\n化率，计算确定一般借款应予资本化的利息金额。109。\n\n27、生物资产\n28、油气资产\n29、使用权资产\n30、无形资产\n（1）计价方法、使用寿命、减值测试\n1. 无形资产包括土地使用权、专利权及非专利技术等，按成本进行初始计量。2. 使用寿命有限的无形资产，在使用寿命内按照与该项无形资产有关的经济利益的预期实现方式系统\n合理地摊销，无法可靠确定预期实现方式的，采用直线法摊销。具体年限如下：\n项 目 摊销年限(年)\n土地使用权 50-70\n专利权 5-14.83\n非专利技术 5-10\n排污权 10\n软件 10\n特许使用权 5、6\n特许经营权 6\n（2）内部研究开发支出会计政策\n内部研究开发项目研究阶段的支出，于发生时计入当期损益。\n\n内部研究开发项目开发阶段的支出，同\n时满足下列条件的，确认为无形资产：(1) 完成该无形资产以使其能够使用或出售在技术上具有可行性；\n(2) 具有完成该无形资产并使用或出售的意图；(3) 无形资产产生经济利益的方式，包括能够证明运用该无\n形资产生产的产品存在市场或无形资产自身存在市场，无形资产将在内部使用的，能证明其有用性；(4) 有\n足够的技术、财务资源和其他资源支持，以完成该无形资产的开发，并有能力使用或出售该无形资产；(5)\n归属于该无形资产开发阶段的支出能够可靠地计量。31、长期资产减值\n对长期股权投资、采用成本模式计量的投资性房地产、固定资产、在建工程、使用寿命有限的无形资\n产等长期资产,在资产负债表日有迹象表明发生减值的，估计其可收回金额。对因企业合并所形成的商誉和\n使用寿命不确定的无形资产，无论是否存在减值迹象，每年都进行减值测试。\n\n商誉结合与其相关的资产组\n或者资产组组合进行减值测试。若上述长期资产的可收回金额低于其账面价值的，按其差额确认资产减值准备并计入当期损益。32、长期待摊费用\n长期待摊费用核算已经支出，摊销期限在1年以上（不含1年）的各项费用。\n\n长期待摊费用按实际发生\n110。\n\n额入账，在受益期或规定的期限内分期平均摊销。如果长期待摊的费用项目不能使以后会计期间受益则将\n尚未摊销的该项目的摊余价值全部转入当期损益。33、合同负债\n34、职工薪酬\n（1）短期薪酬的会计处理方法\n在职工为公司提供服务的会计期间，将实际发生的短期薪酬确认为负债，并计入当期损益或相关资产\n成本。\n\n（2）离职后福利的会计处理方法\n离职后福利分为设定提存计划和设定受益计划。(1) 在职工为公司提供服务的会计期间，根据设定提存计划计算的应缴存金额确认为负债，并计入当\n期损益或相关资产成本。(2) 对设定受益计划的会计处理通常包括下列步骤：\n1) 根据预期累计福利单位法，采用无偏且相互一致的精算假设对有关人口统计变量和财务变量等作出\n估计，计量设定受益计划所产生的义务，并确定相关义务的所属期间。\n\n同时，对设定受益计划所产生的义\n务予以折现，以确定设定受益计划义务的现值和当期服务成本；\n2) 设定受益计划存在资产的，将设定受益计划义务现值减去设定受益计划资产公允价值所形成的赤字\n或盈余确认为一项设定受益计划净负债或净资产。设定受益计划存在盈余的，以设定受益计划的盈余和资\n产上限两项的孰低者计量设定受益计划净资产；\n3) 期末，将设定受益计划产生的职工薪酬成本确认为服务成本、设定受益计划净负债或净资产的利息\n净额以及重新计量设定受益计划净负债或净资产所产生的变动等三部分，其中服务成本和设定受益计划净\n负债或净资产的利息净额计入当期损益或相关资产成本，重新计量设定受益计划净负债或净资产所产生的\n变动计入其他综合收益，并且在后续会计期间不允许转回至损益，但可以在权益范围内转移这些在其他综\n合收益确认的金额。（3）辞退福利的会计处理方法\n向职工提供的辞退福利，在下列两者孰早日确认辞退福利产生的职工薪酬负债，并计入当期损益：(1)\n公司不能单方面撤回因解除劳动关系计划或裁减建议所提供的辞退福利时；(2) 公司确认与涉及支付辞退\n福利的重组相关的成本或费用时。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "ef8479af",
        "d35a101e",
        "833ff901",
        "87716b12"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3960,
      "page_number": 107,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.6999999999999998,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          107,
          108,
          109,
          110,
          111
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.329383",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3960,
        "word_count": 187,
        "sentence_count": 66,
        "chinese_char_count": 3258,
        "readability_score": 0.0,
        "information_density": 0.05050505050505051,
        "coherence_score": 0.7200427461987586,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9290909090909092,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "投资",
        "固定资产",
        "无形资产",
        "商誉"
      ]
    },
    {
      "chunk_id": "e563af48",
      "content": "（4）其他长期职工福利的会计处理方法\n向职工提供的其他长期福利，符合设定提存计划条件的，按照设定提存计划的有关规定进行会计处理；\n除此之外的其他长期福利，按照设定受益计划的有关规定进行会计处理，为简化相关会计处理，将其产生\n的职工薪酬成本确认为服务成本、其他长期职工福利净负债或净资产的利息净额以及重新计量其他长期职\n工福利净负债或净资产所产生的变动等组成项目的总净额计入当期损益或相关资产成本。111。\n\n35、租赁负债\n36、预计负债\n1. 因对外提供担保、诉讼事项、产品质量保证、亏损合同等或有事项形成的义务成为公司承担的现时\n义务，履行该义务很可能导致经济利益流出公司，且该义务的金额能够可靠的计量时，公司将该项义务确\n认为预计负债。2. 公司按照履行相关现时义务所需支出的最佳估计数对预计负债进行初始计量，并在资产负债表日对\n预计负债的账面价值进行复核。37、股份支付\n1. 股份支付的种类\n包括以权益结算的股份支付和以现金结算的股份支付。\n\n2. 实施、修改、终止股份支付计划的相关会计处理\n(1) 以权益结算的股份支付\n授予后立即可行权的换取职工服务的以权益结算的股份支付，在授予日按照权益工具的公允价值计入\n相关成本或费用，相应调整资本公积。完成等待期内的服务或达到规定业绩条件才可行权的换取职工服务\n的以权益结算的股份支付，在等待期内的每个资产负债表日，以对可行权权益工具数量的最佳估计为基础，\n按权益工具授予日的公允价值，将当期取得的服务计入相关成本或费用，相应调整资本公积。换取其他方服务的权益结算的股份支付，如果其他方服务的公允价值能够可靠计量的，按照其他方服\n务在取得日的公允价值计量；如果其他方服务的公允价值不能可靠计量，但权益工具的公允价值能够可靠\n计量的，按照权益工具在服务取得日的公允价值计量，计入相关成本或费用，相应增加所有者权益。\n\n(2) 以现金结算的股份支付\n授予后立即可行权的换取职工服务的以现金结算的股份支付，在授予日按公司承担负债的公允价值计\n入相关成本或费用，相应增加负债。完成等待期内的服务或达到规定业绩条件才可行权的换取职工服务的\n以现金结算的股份支付，在等待期内的每个资产负债表日，以对可行权情况的最佳估计为基础，按公司承\n担负债的公允价值，将当期取得的服务计入相关成本或费用和相应的负债。(3) 修改、终止股份支付计划\n如果修改增加了所授予的权益工具的公允价值，公司按照权益工具公允价值的增加相应地确认取得服\n务的增加；如果修改增加了所授予的权益工具的数量，公司将增加的权益工具的公允价值相应地确认为取\n得服务的增加；如果公司按照有利于职工的方式修改可行权条件，公司在处理可行权条件时，考虑修改后\n的可行权条件。\n\n如果修改减少了授予的权益工具的公允价值，公司继续以权益工具在授予日的公允价值为基础，确认\n取得服务的金额，而不考虑权益工具公允价值的减少；如果修改减少了授予的权益工具的数量，公司将减\n少部分作为已授予的权益工具的取消来进行处理；如果以不利于职工的方式修改了可行权条件，在处理可\n行权条件时，不考虑修改后的可行权条件。如果公司在等待期内取消了所授予的权益工具或结算了所授予的权益工具（因未满足可行权条件而被\n取消的除外），则将取消或结算作为加速可行权处理，立即确认原本在剩余等待期内确认的金额。112。\n\n38、优先股、永续债等其他金融工具\n39、收入\n是否已执行新收入准则\n□ 是 √ 否\n1. 收入确认原则\n(1) 销售商品\n销售商品收入在同时满足下列条件时予以确认：1) 将商品所有权上的主要风险和报酬转移给购货方；\n2) 公司不再保留通常与所有权相联系的继续管理权，也不再对已售出的商品实施有效控制；3) 收入的金\n额能够可靠地计量；4) 相关的经济利益很可能流入；5) 相关的已发生或将发生的成本能够可靠地计量。(2) 提供劳务\n提供劳务交易的结果在资产负债表日能够可靠估计的（同时满足收入的金额能够可靠地计量、相关经\n济利益很可能流入、交易的完工进度能够可靠地确定、交易中已发生和将发生的成本能够可靠地计量），\n采用完工百分比法确认提供劳务的收入，并按已经发生的成本占估计总成本的比例确定提供劳务交易的完\n工进度。提供劳务交易的结果在资产负债表日不能够可靠估计的，若已经发生的劳务成本预计能够得到补\n偿，按已经发生的劳务成本金额确认提供劳务收入，并按相同金额结转劳务成本；若已经发生的劳务成本\n预计不能够得到补偿，将已经发生的劳务成本计入当期损益，不确认劳务收入。\n\n(3) 让渡资产使用权\n让渡资产使用权在同时满足相关的经济利益很可能流入、收入金额能够可靠计量时，确认让渡资产使\n用权的收入。利息收入按照他人使用本公司货币资金的时间和实际利率计算确定；使用费收入按有关合同\n或协议约定的收费时间和方法计算确定。2. 收入确认的具体方法\n公司主要销售原料药及医药中间体、染料及染颜料中间体等产品。\n\n内销产品收入确认需满足以下条件：\n公司已根据合同约定将产品交付给购货方，且产品销售收入金额已确定，已经收回货款或取得了收款凭证\n且相关的经济利益很可能流入，产品相关的成本能够可靠地计量。外销产品收入确认需满足以下条件：公\n司已根据合同约定将产品报关、离港，取得提单，且产品销售收入金额已确定，已经收回货款或取得了收\n款凭证且相关的经济利益很可能流入，产品相关的成本能够可靠地计量。40、政府补助\n1. 政府补助在同时满足下列条件时予以确认：(1) 公司能够满足政府补助所附的条件；(2) 公司能够收\n到政府补助。\n\n政府补助为货币性资产的，按照收到或应收的金额计量。政府补助为非货币性资产的，按照\n公允价值计量；公允价值不能可靠取得的，按照名义金额计量。2. 与资产相关的政府补助判断依据及会计处理方法\n政府文件规定用于购建或以其他方式形成长期资产的政府补助划分为与资产相关的政府补助。\n\n政府文\n件不明确的，以取得该补助必须具备的基本条件为基础进行判断，以购建或其他方式形成长期资产为基本\n条件的作为与资产相关的政府补助。与资产相关的政府补助，冲减相关资产的账面价值或确认为递延收益。与资产相关的政府补助确认为递延收益的，在相关资产使用寿命内按照合理、系统的方法分期计入损益。\n\n按照名义金额计量的政府补助，直接计入当期损益。相关资产在使用寿命结束前被出售、转让、报废或发\n生毁损的，将尚未分配的相关递延收益余额转入资产处置当期的损益。3. 与收益相关的政府补助判断依据及会计处理方法\n除与资产相关的政府补助之外的政府补助划分为与收益相关的政府补助。\n\n对于同时包含与资产相关部\n113。\n\n分和与收益相关部分的政府补助，难以区分与资产相关或与收益相关的，整体归类为与收益相关的政府补\n助。与收益相关的政府补助，用于补偿以后期间的相关成本费用或损失的，确认为递延收益，在确认相关\n成本费用或损失的期间，计入当期损益或冲减相关成本；用于补偿已发生的相关成本费用或损失的，直接\n计入当期损益或冲减相关成本。4. 与公司日常经营活动相关的政府补助，按照经济业务实质，计入其他收益或冲减相关成本费用。\n\n与\n公司日常活动无关的政府补助，计入营业外收支。41、递延所得税资产/递延所得税负债\n1. 根据资产、负债的账面价值与其计税基础之间的差额（未作为资产和负债确认的项目按照税法规定\n可以确定其计税基础的，该计税基础与其账面数之间的差额），按照预期收回该资产或清偿该负债期间的\n适用税率计算确认递延所得税资产或递延所得税负债。2. 确认递延所得税资产以很可能取得用来抵扣可抵扣暂时性差异的应纳税所得额为限。\n\n资产负债表\n日，有确凿证据表明未来期间很可能获得足够的应纳税所得额用来抵扣可抵扣暂时性差异的，确认以前会\n计期间未确认的递延所得税资产。3. 资产负债表日，对递延所得税资产的账面价值进行复核，如果未来期间很可能无法获得足够的应纳\n税所得额用以抵扣递延所得税资产的利益，则减记递延所得税资产的账面价值。在很可能获得足够的应纳\n税所得额时，转回减记的金额。\n\n4. 公司当期所得税和递延所得税作为所得税费用或收益计入当期损益，但不包括下列情况产生的所得\n税：(1) 企业合并；(2) 直接在所有者权益中确认的交易或者事项。42、租赁\n（1）经营租赁的会计处理方法\n公司为承租人时，在租赁期内各个期间按照直线法将租金计入相关资产成本或确认为当期损益，发生\n的初始直接费用，直接计入当期损益。或有租金在实际发生时计入当期损益。\n\n公司为出租人时，在租赁期内各个期间按照直线法将租金确认为当期损益，发生的初始直接费用，除\n金额较大的予以资本化并分期计入损益外，均直接计入当期损益。或有租金在实际发生时计入当期损益。（2）融资租赁的会计处理方法\n公司为承租人时，在租赁期开始日，公司以租赁开始日租赁资产公允价值与最低租赁付款额现值中两\n者较低者作为租入资产的入账价值，将最低租赁付款额作为长期应付款的入账价值，其差额为未确认融资\n费用，发生的初始直接费用，计入租赁资产价值。\n\n在租赁期各个期间，采用实际利率法计算确认当期的融\n资费用。公司为出租人时，在租赁期开始日，公司以租赁开始日最低租赁收款额与初始直接费用之和作为应收\n融资租赁款的入账价值，同时记录未担保余值；将最低租赁收款额、初始直接费用及未担保余值之和与其\n现值之和的差额确认为未实现融资收益。在租赁期各个期间，采用实际利率法计算确认当期的融资收入。\n\n43、其他重要的会计政策和会计估计\n与回购公司股份相关的会计处理方法\n因减少注册资本或奖励职工等原因收购本公司股份的，按实际支付的金额作为库存股处理，同时进行\n备查登记。如果将回购的股份注销，则将按注销股票面值和注销股数计算的股票面值总额与实际回购所支\n114。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "3b04fbe4",
        "2780c1a5",
        "7b453183",
        "e67a8af3"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 4027,
      "page_number": 111,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.6999999999999997,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          111,
          112,
          113,
          114
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.331319",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 4027,
        "word_count": 138,
        "sentence_count": 67,
        "chinese_char_count": 3548,
        "readability_score": 0.0,
        "information_density": 0.042215048423143775,
        "coherence_score": 0.7176508932902599,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9524211571889745,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "现金",
        "应收",
        "应付",
        "所得税"
      ]
    },
    {
      "chunk_id": "77cd7a88",
      "content": "付的金额之间的差额冲减资本公积，资本公积不足冲减的，冲减留存收益；如果将回购的股份奖励给本公\n司职工属于以权益结算的股份支付，于职工行权购买本公司股份收到价款时，转销交付职工的库存股成本\n和等待期内资本公积（其他资本公积）累计金额，同时，按照其差额调整资本公积（股本溢价）。44、重要会计政策和会计估计变更\n（1）重要会计政策变更\n√ 适用 □ 不适用\n会计政策变更的内容和原因 审批程序 备注\n本次会计政策变更已经公司第五届董事\n执行《关于修订印发2019年度一般企业\n会第二十三次会议及第五届监事第十九\n财务报表格式的通知》\n次会议审议通过\n财政部于2017年颁布了修订后的《企业\n会计准则第22号--金融工具确认和计\n量》、《企业会计准则第23号--金融资产\n本次会计政策变更已经公司第五届董事 公司根据新准则，已于2019年1月1日\n转移》、《企业会计准则第37号--金融工\n会第二十次会议及第五届监事第十六次 起将前期划分为可供出售金融资产的股\n具列报》三项会计准则，并要求单独在\n会议审议通过 权投资重分类至其他权益工具投资\n境内上市的企业自2019年1月1日起施\n行，根据新旧准则衔接规定，公司无需\n重述前期可比数。企业会计准则变化引起的会计政策变更\n1. 本公司根据财政部《关于修订印发2019年度一般企业财务报表格式的通知》(财会〔2019〕6号) 、\n《关于修订印发合并财务报表格式（2019版）的通知》(财会〔2019〕16号)和企业会计准则的要求编制2019\n年度财务报表，此项会计政策变更采用追溯调整法。\n\n2018年度财务报表受重要影响的报表项目和金额如下：\n原列报报表项目及金额 新列报报表项目及金额\n应收票据及应收账款 586,937,258.10应收票据 107,399,476.04\n应收账款 479,537,782.06\n应付票据及应付账款 791,915,463.78应付票据 490,006,533.85\n应付账款 301,908,929.93\n2. 本公司自2019年1月1日起执行财政部修订后的《企业会计准则第22号——金融工具确认和计量》《企\n业会计准则第23号——金融资产转移》《企业会计准则第24号——套期保值》以及《企业会计准则第37号\n——金融工具列报》（以下简称新金融工具准则）。根据相关新旧准则衔接规定，对可比期间信息不予调\n整，首次执行日执行新准则与原准则的差异追溯调整本报告期期初留存收益或其他综合收益。（2）重要会计估计变更\n□ 适用 √ 不适用\n（3）2019年起执行新金融工具准则、新收入准则或新租赁准则调整执行当年年初财务报表相关项目情况\n√ 适用 □ 不适用\n115。\n\n合并资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 1,956,089,124.33 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产 150,000,000.00 150,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 107,399,476.04 -107,399,476.04\n应收账款 479,537,782.06 479,537,782.06\n应收款项融资 107,399,476.04 107,399,476.04\n预付款项 46,449,558.50 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 10,817,853.96 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 905,418,218.49 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 227,882,993.23 77,882,993.23 -150,000,000.00\n流动资产合计 3,733,595,006.61 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00 0.00 -1,800,000.00\n其他债权投资\n116。\n\n持有至到期投资\n长期应收款\n长期股权投资 66,088,139.79 66,088,139.79\n其他权益工具投资 1,800,000.00 1,800,000.00\n其他非流动金融资产\n投资性房地产 12,338,615.29 12,338,615.29\n固定资产 1,215,120,643.61 1,215,120,643.61\n在建工程 674,333,677.99 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 539,514,850.87 539,514,850.87\n开发支出\n商誉 757,736,770.14 757,736,770.14\n长期待摊费用 1,842,423.21 1,842,423.21\n递延所得税资产 32,487,223.69 32,487,223.69\n其他非流动资产 515,993.37 515,993.37\n非流动资产合计 3,301,778,337.96 3,301,778,337.96\n资产总计 7,035,373,344.57 7,035,373,344.57\n流动负债：\n短期借款 598,700,000.00 598,700,000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 490,006,533.85 490,006,533.85\n应付账款 301,908,929.93 301,908,929.93\n预收款项 19,196,692.94 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n117。\n\n代理承销证券款\n应付职工薪酬 45,234,354.42 45,234,354.42\n应交税费 54,890,661.34 54,890,661.34\n其他应付款 24,723,304.20 24,723,304.20\n其中：应付利息 1,088,752.57 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动\n44,365,875.00 44,365,875.00\n负债\n其他流动负债\n流动负债合计 1,579,026,351.68 1,579,026,351.68\n非流动负债：\n保险合同准备金\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 12,971,002.47 12,971,002.47\n递延收益 44,650,629.91 44,650,629.91\n递延所得税负债 8,175,428.28 8,175,428.28\n其他非流动负债\n非流动负债合计 65,797,060.66 65,797,060.66\n负债合计 1,644,823,412.34 1,644,823,412.34\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,663,367,822.47 2,663,367,822.47\n118。\n\n减：库存股 325,880,561.68 325,880,561.68\n其他综合收益 -51,779.23 -51,779.23\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n一般风险准备\n未分配利润 1,232,481,918.50 1,232,481,918.50\n归属于母公司所有者权益\n5,390,549,932.23 5,390,549,932.23\n合计\n少数股东权益\n所有者权益合计 5,390,549,932.23 5,390,549,932.23\n负债和所有者权益总计 7,035,373,344.57 7,035,373,344.57\n调整情况说明\n母公司资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 983,565,710.16 983,565,710.16\n交易性金融资产 100,000,000.00 100,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 20,885,763.88 20,885,763.88\n应收账款 149,204,899.98 149,204,899.98 -149,204,899.98\n应收款项融资 149,204,899.98 149,204,899.98\n预付款项 5,554,458.78 5,554,458.78\n其他应收款 1,043,055,918.72 1,043,055,918.72\n其中：应收利息\n应收股利 7,222,088,153.34 722,088,153.34\n存货 84,396,333.98 84,396,333.98\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 105,920,135.97 5,920,135.97 -100,000,000.00\n119。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "0ac95618",
        "7316d530",
        "062b56ba",
        "03dab5e4",
        "11620f53"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3887,
      "page_number": 115,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115,
          116,
          117,
          118,
          119
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.333352",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3887,
        "word_count": 332,
        "sentence_count": 138,
        "chinese_char_count": 1578,
        "readability_score": 0.0,
        "information_density": 0.05145356315924878,
        "coherence_score": 0.796164781455104,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6669153588886031,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "应收",
        "应付"
      ]
    },
    {
      "chunk_id": "ca1b33e5",
      "content": "流动资产合计 2,392,583,221.47 2,392,583,221.47\n非流动资产：\n债权投资\n可供出售金融资产 23,017,502.51 -23,017,502.51\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,250,556,852.85 3,250,556,852.85\n其他权益工具投资 23,017,502.51 23,017,502.51\n其他非流动金融资产\n投资性房地产 16,409,402.65 16,409,402.65\n固定资产 182,948,202.54 182,948,202.54\n在建工程 20,490,208.35 20,490,208.35\n生产性生物资产\n油气资产\n使用权资产\n无形资产 17,059,632.32 17,059,632.32\n开发支出\n商誉\n长期待摊费用\n递延所得税资产 9,371,365.80 9,371,365.80\n其他非流动资产\n非流动资产合计 3,519,853,167.02 3,519,853,167.02\n资产总计 5,912,436,388.49 5,912,436,388.49\n流动负债：\n短期借款 287,000,000.00 287,000,000.00\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 202,286,262.85 202,286,262.85\n应付账款 25,423,635.65 25,423,635.65\n预收款项 7,777,982.57 7,777,982.57\n合同负债\n120。\n\n应付职工薪酬 6,439,699.82 6,439,699.82\n应交税费 948,517.30 948,517.30\n其他应付款 104,178,588.96 104,178,588.96\n其中：应付利息 805,795.63 805,795.63\n应付股利 2,051,370.43 2,051,370.43\n持有待售负债\n一年内到期的非流动\n44,365,875.00 44,365,875.00\n负债\n其他流动负债\n流动负债合计 678,420,562.15 678,420,562.15\n非流动负债：\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 12,971,002.47 12,971,002.47\n递延收益 1,262,720.34 1,262,720.34\n递延所得税负债\n其他非流动负债\n非流动负债合计 14,233,722.81 14,233,722.81\n负债合计 692,654,284.96 692,654,284.96\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,662,229,769.88 2,662,229,769.88\n减：库存股 325,880,561.68 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n121。\n\n未分配利润 1,062,800,363.16 1,062,800,363.16\n所有者权益合计 5,219,782,103.53 5,219,782,103.53\n负债和所有者权益总计 5,912,436,388.49 5,912,436,388.49\n调整情况说明\n（4）2019年起执行新金融工具准则或新租赁准则追溯调整前期比较数据说明\n□ 适用 √ 不适用\n45、其他\n六、税项\n1、主要税种及税率\n税种 计税依据 税率\n增值税 销售货物或提供应税劳务 19%、16%、13%、6%\n城市维护建设税 应缴流转税税额 7%、5%\n企业所得税 应纳税所得额 15%、16.5%、17%、20%、25%\n从价计征的，按房产原值一次减除30%\n房产税 后余值的1.2%计缴；从租计征的，按租 1.2%、12%\n金收入的12%计缴\n教育费附加 应缴流转税税额 3%\n地方教育附加 应缴流转税税额 2%\n存在不同企业所得税税率纳税主体的，披露情况说明\n纳税主体名称 所得税税率\n川南药业公司、台州前进公司、盐城瓯华\n公司、GeneVida GmbH 15%\n香港港翔公司 16.5%\nGANGXIANG（SINGAPORE） 17%\n上海海翔公司、东旭医化公司 20%\n除上述以外的其他纳税主体 25%\n2、税收优惠\n(二) 税收优惠\n1. 根据科学技术部火炬高科技产业开发中心国科火字〔2017〕201号文批复，川南药业公司通过高新\n技术企业复审备案，自2017年起减按15%的税率计缴企业所得税，认定有效期3年。2. 根据科学技术部火炬高科技产业开发中心国科火字〔2016〕149号文批复，台州前进公司通过高新\n122。\n\n技术企业复审备案，自2016年起减按15%的税率计缴企业所得税，认定有效期3年。认定资格有效期届满后，\n公司重新申请了高新技术企业资格认定，截至本财务报表批准报出日尚处于审核阶段，2019年度暂按15%\n的税率计缴。3. 根据江苏省科学技术厅、江苏省财政厅、江苏省国家税务局、江苏省地方税务局联合颁发的《高新\n技术企业证书》，盐城瓯华公司被认定为高新技术企业，自2017年起减按15%的税率计缴企业所得税，认\n定有效期3年。\n\n4. 根据国家税务总局下发的《关于实施小型微利企业普惠性所得税减免政策有关问题的公告》（国家\n税务总局公告2019年第2号），上海海翔公司、东旭医化公司享受小型微利企业的税收优惠政策，减按20%\n的税率计缴企业所得税；对港翔科技公司所得减按25%计入应纳税所得额，按20%的税率缴纳企业所得税。3、其他\n七、合并财务报表项目注释\n1、货币资金\n单位： 元\n项目 期末余额 期初余额\n库存现金 131,545.99 195,522.60\n银行存款 1,525,298,726.49 1,852,939,694.25\n其他货币资金 31,145,099.97 102,953,907.48\n合计 1,556,575,372.45 1,956,089,124.33\n其中：存放在境外的款项总额 649,218.69 2,180,766.37\n因抵押、质押或冻结等对使用\n30,797,464.00 136,880,848.73\n有限制的款项总额\n其他说明\n[注]:期末银行定期存款116,083,968.00元。2、交易性金融资产\n单位： 元\n项目 期末余额 期初余额\n其中：\n指定以公允价值计量且其变动计入当期\n150,000,000.00\n损益的金融资产\n其中：\n银行理财产品 150,000,000.00\n合计 150,000,000.00\n其他说明：\n123。\n\n3、衍生金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n4、应收票据\n（1）应收票据分类列示\n单位： 元\n项目 期末余额 期初余额\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n其中：\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收票据坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备收回或转回金额重要的：\n124\n\n□ 适用 √ 不适用\n（3）期末公司已质押的应收票据\n单位： 元\n项目 期末已质押金额\n（4）期末公司已背书或贴现且在资产负债表日尚未到期的应收票据\n单位： 元\n项目 期末终止确认金额 期末未终止确认金额\n（5）期末公司因出票人未履约而将其转应收账款的票据\n单位： 元\n项目 期末转应收账款金额\n其他说明\n（6）本期实际核销的应收票据情况\n单位： 元\n项目 核销金额\n其中重要的应收票据核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收票据性质 核销金额 核销原因 履行的核销程序\n易产生\n应收票据核销说明：\n5、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按信用风险特征组\n合计提坏账准备\n125",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "ca6c9bb9",
        "d3848548",
        "b4cf61ce",
        "a48868b1",
        "3ef4e788"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3622,
      "page_number": 120,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120,
          121,
          122,
          123,
          124,
          125
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.335435",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "公司重新申请了高新技术企业",
        "industry": null,
        "char_count": 3622,
        "word_count": 384,
        "sentence_count": 100,
        "chinese_char_count": 1765,
        "readability_score": 0.0,
        "information_density": 0.05521811154058531,
        "coherence_score": 0.4875489283843403,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7949199337382662,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "投资",
        "融资",
        "财务",
        "报表",
        "968.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收",
        "应付"
      ]
    },
    {
      "chunk_id": "6dae1ae0",
      "content": "按组合计提坏账准 500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n100.00% 8.19% 100.00% 7.61%\n备的应收账款 838.93 74.74 64.19 65.36 3.30 2.06\n其中：\n500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n合计 100.00% 8.19% 100.00% 7.61%\n838.93 74.74 64.19 65.36 3.30 2.06\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n账龄组合 500,776,838.93 40,995,274.74 8.19%\n合计 500,776,838.93 40,995,274.74 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 481,295,912.96\n1至2年 2,351,572.07\n2至3年 4,521,732.29\n3年以上 12,607,621.61\n3至4年 8,370,022.99\n5年以上 4,237,598.62\n合计 500,776,838.93\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n126。\n\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n39,520,283.30 1,474,991.44 40,995,274.74\n备\n合计 39,520,283.30 1,474,991.44 40,995,274.74\n其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数的\n单位名称 应收账款期末余额 坏账准备期末余额\n比例\n重庆天地药业有限责任\n85,994,787.83 17.17% 4,299,739.39\n公司\nACS DOBFAR S.P.A 30,318,565.17 6.05% 1,515,928.26\nFIS-FABBRICA\nITALIANA SINTETICI 23,576,101.39 4.71% 1,178,805.07\nS.P.A\nPFIZER ASIA\nMANUFACTURING 19,767,647.40 3.95% 988,382.37\nPTE LTD\n绍兴舜德进出口有限公\n18,868,983.58 3.77% 943,449.18\n司\n合计 178,526,085.37 35.65%\n127。\n\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n6、应收款项融资\n单位： 元\n项目 期末余额 期初余额\n应收票据 74,531,666.41 107,399,476.04\n合计 74,531,666.41 107,399,476.04\n应收款项融资本期增减变动及公允价值变动情况\n□ 适用 √ 不适用\n如是按照预期信用损失一般模型计提应收款项融资减值准备，请参照其他应收款的披露方式披露减值准备的相关信息：\n□ 适用 √ 不适用\n其他说明：\n7、预付款项\n（1）预付款项按账龄列示\n单位： 元\n期末余额 期初余额\n账龄\n金额 比例 金额 比例\n1年以内 29,093,214.59 85.94% 37,487,264.60 80.71%\n1至2年 2,278,425.47 6.73% 6,488,949.11 13.97%\n2至3年 683,976.07 2.02% 1,208,687.98 2.60%\n3年以上 1,795,870.66 5.31% 1,264,656.81 2.72%\n合计 33,851,486.79 -- 46,449,558.50 --\n账龄超过1年且金额重要的预付款项未及时结算原因的说明：\n（2）按预付对象归集的期末余额前五名的预付款情况\n期末余额前5名的预付款项合计数为9,950,421.65元，占预付款项期末余额合计数的比例为29.39%。其他说明：\n8、其他应收款\n单位： 元\n128。\n\n项目 期末余额 期初余额\n其他应收款 18,297,536.18 10,817,853.96\n合计 18,297,536.18 10,817,853.96\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n单位： 元\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n129\n\n（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n应收暂付款 19,403,087.81 21,023,388.15\n押金保证金 8,079,470.25 4,971,398.75\n应收出口退税 6,994,977.96\n拆借款 1,250,962.00 1,797,563.33\n其 他 697,469.95 126,777.96\n合计 36,425,967.97 27,919,128.19\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 17,101,274.23 17,101,274.23\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 1,027,157.56 1,027,157.56\n2019年12月31日余额 18,128,431.79 18,128,431.79\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 12,618,376.33\n1至2年 8,167,903.05\n2至3年 1,213,988.18\n3年以上 14,425,700.41\n3至4年 2,214,569.77\n4至5年 510,000.00\n5年以上 11,701,130.64\n合计 36,425,967.97\n130。\n\n3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n台州市椒江朝晖建\n押金保证金 2,950,000.001年以内 8.10% 147,500.00\n设投资有限公司\n台州市椒江朝晖建\n押金保证金 3,850,000.001-2年 10.57% 1,155,000.00\n设投资有限公司\n应收出口退税 应收出口退税 6,584,960.261年以内 18.08%\nPFIZER ASIA\nMANUFACTURIN 应收暂付款 5,000,000.003年以上 13.73% 5,000,000.00\nG PTE LTD\n浙江福仁瑞生物科\n应收暂付款 3,222,047.103年以上 8.85% 3,222,047.10\n技有限公司\n台州市中荣化工有\n应收暂付款 2,160,572.193年以上 5.93% 2,160,572.19\n限公司\n合计 -- 23,767,579.55 -- 65.26% 11,685,119.29\n131。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "f7c29b48",
        "83a3b5d7",
        "4ae189a4",
        "5bc215c5",
        "2285addc"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3745,
      "page_number": 126,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126,
          127,
          128,
          129,
          130,
          131
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.337427",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "设投资有限公司",
        "industry": null,
        "char_count": 3745,
        "word_count": 471,
        "sentence_count": 138,
        "chinese_char_count": 1534,
        "readability_score": 0.0,
        "information_density": 0.04005340453938584,
        "coherence_score": 0.5819514908767245,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7638451268357811,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资",
        "421.65元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "应收",
        "预付",
        "披露",
        "减值",
        "公允价值",
        "融资",
        "借款"
      ]
    },
    {
      "chunk_id": "5c911725",
      "content": "6）涉及政府补助的应收款项\n单位： 元\n预计收取的时间、金额\n单位名称 政府补助项目名称 期末余额 期末账龄\n及依据\n7）因金融资产转移而终止确认的其他应收款\n8）转移其他应收款且继续涉入形成的资产、负债金额\n其他说明：\n9、存货\n是否已执行新收入准则\n□ 是 √ 否\n（1）存货分类\n单位： 元\n期末余额 期初余额\n项目\n账面余额 跌价准备 账面价值 账面余额 跌价准备 账面价值\n原材料 209,787,752.67 2,975,404.23 206,812,348.44 243,008,744.60 2,867,227.10 240,141,517.50\n在产品 164,776,116.17 4,244,871.82 160,531,244.35 214,182,041.63 3,023,716.71 211,158,324.92\n库存商品 493,928,178.91 22,117,971.87 471,810,207.04 477,155,579.50 23,329,566.31 453,826,013.19\n委托加工物资 3,831,460.77 3,831,460.77 292,362.88 292,362.88\n合计 872,323,508.52 29,338,247.92 842,985,260.60 934,638,728.61 29,220,510.12 905,418,218.49\n（2）存货跌价准备\n单位： 元\n本期增加金额 本期减少金额\n项目 期初余额 期末余额\n计提 其他 转回或转销 其他\n原材料 2,867,227.10 2,011,138.75 1,902,961.62 2,975,404.23\n在产品 3,023,716.71 2,237,971.32 1,016,816.21 4,244,871.82\n库存商品 23,329,566.31 5,540,847.35 6,752,441.79 22,117,971.87\n合计 29,220,510.12 9,789,957.42 9,672,219.62 29,338,247.92\n132。\n\n（3）存货期末余额含有借款费用资本化金额的说明\n（4）期末建造合同形成的已完工未结算资产情况\n单位： 元\n项目 金额\n其他说明：\n10、合同资产\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n合同资产的账面价值在本期内发生的重大变动金额和原因：\n单位： 元\n项目 变动金额 变动原因\n如是按照预期信用损失一般模型计提合同资产坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n本期合同资产计提减值准备情况\n单位： 元\n项目 本期计提 本期转回 本期转销/核销 原因\n其他说明：\n11、持有待售资产\n单位： 元\n项目 期末账面余额 减值准备 期末账面价值 公允价值 预计处置费用 预计处置时间\n其他说明：\n12、一年内到期的非流动资产\n单位： 元\n项目 期末余额 期初余额\n重要的债权投资/其他债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n其他说明：\n133\n\n13、其他流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n待抵扣增值税进项税额 67,707,757.62 76,026,728.13\n员工购房借款 118,571.44\n预缴企业所得税 8,699,173.52 1,737,693.66\n银行理财产品\n合计 76,406,931.14 77,882,993.23\n其他说明：\n14、债权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n重要的债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n15、其他债权投资\n单位： 元\n134。\n\n累计在其他\n本期公允价 累计公允价 综合收益中\n项目 期初余额 应计利息 期末余额 成本 备注\n值变动 值变动 确认的损失\n准备\n重要的其他债权投资\n单位： 元\n期末余额 期初余额\n其他债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n16、长期应收款\n（1）长期应收款情况\n单位： 元\n期末余额 期初余额\n项目 折现率区间\n账面余额 坏账准备 账面价值 账面余额 坏账准备 账面价值\n坏账准备减值情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n135。\n\n（2）因金融资产转移而终止确认的长期应收款\n（3）转移长期应收款且继续涉入形成的资产、负债金额\n其他说明\n17、长期股权投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n被投资单 权益法下 宣告发放 减值准备\n(账面价 其他综合 其他权益 计提减值 (账面价\n位 追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n22,946,28 -4,811,81 18,134,47\n制药厂有\n7.25 4.84 2.41\n限公司\n江苏北华\n17,617,12 -4,471,33 13,145,79\n环保科技\n7.70 1.54 6.16\n有限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n滨海临海\n11,676,63 -6,521,79 1,449,207 3,705,631 7,730,979\n资产管理\n2.15 2.73 .56 .86 .27\n有限公司\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n小计\n9.79 49.80 .56 2.43 .27\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n合计\n9.79 49.80 .56 2.43 .27\n其他说明\n18、其他权益工具投资\n单位： 元\n项目 期末余额 期初余额\n杭州寓鑫创业投资合伙企业（有限合伙） 20,000,000.00\n滨海宏博环境技术服务股份有限公司 1,800,000.00\n合计 20,000,000.00 1,800,000.00\n136。\n\n分项披露本期非交易性权益工具投资\n单位： 元\n指定为以公允价\n其他综合收益转 其他综合收益转\n值计量且其变动\n项目名称 确认的股利收入 累计利得 累计损失 入留存收益的金 入留存收益的原\n计入其他综合收\n额 因\n益的原因\n其他说明：\n(2) 指定为以公允价值计量且其变动计入其他综合收益的权益工具投资的原因\n公司持有对杭州寓鑫创业投资合伙企业（有限合伙）、滨海宏博环境技术服务股份有限公司的股权投\n资属于非交易性权益工具投资，因此公司将其指定为以公允价值计量且其变动计入其他综合收益的权益工\n具投资。19、其他非流动金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n20、投资性房地产\n（1）采用成本计量模式的投资性房地产\n√ 适用 □ 不适用\n单位： 元\n项目 房屋、建筑物 土地使用权 在建工程 合计\n一、账面原值\n1.期初余额 26,022,834.98 26,022,834.98\n2.本期增加金额\n（1）外购\n（2）存货\\固定资产\n\\在建工程转入\n（3）企业合并增加\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 26,022,834.98 26,022,834.98\n137。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "58c89ba6",
        "54fb5f99",
        "728a9c7f",
        "c1765ba8",
        "3ec0ca56"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3641,
      "page_number": 132,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132,
          133,
          134,
          135,
          136,
          137
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.339496",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 3641,
        "word_count": 511,
        "sentence_count": 93,
        "chinese_char_count": 1822,
        "readability_score": 0.0,
        "information_density": 0.04943696786597089,
        "coherence_score": 0.7945012531328322,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8001647898928865,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收"
      ]
    },
    {
      "chunk_id": "2562245d",
      "content": "二、累计折旧和累计摊\n销\n1.期初余额 13,684,219.69 13,684,219.69\n2.本期增加金额 1,131,663.83 1,131,663.83\n（1）计提或摊销 1,131,663.83 1,131,663.83\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 14,815,883.52 14,815,883.52\n三、减值准备\n1.期初余额\n2.本期增加金额\n（1）计提\n3、本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额\n四、账面价值\n1.期末账面价值 11,206,951.46 11,206,951.46\n2.期初账面价值 12,338,615.29 12,338,615.29\n（2）采用公允价值计量模式的投资性房地产\n□ 适用 √ 不适用\n（3）未办妥产权证书的投资性房地产情况\n单位： 元\n项目 账面价值 未办妥产权证书原因\n其他说明\n138\n\n21、固定资产\n单位： 元\n项目 期末余额 期初余额\n固定资产 1,724,407,333.34 1,215,120,643.61\n合计 1,724,407,333.34 1,215,120,643.61\n（1）固定资产情况\n单位： 元\n项目 房屋及建筑物 通用设备 专用设备 运输工具 合计\n一、账面原值：\n1.期初余额 942,004,302.57 151,282,471.21 1,160,756,948.05 56,927,137.86 2,310,970,859.69\n2.本期增加金额 127,058,302.67 26,510,821.36 531,882,141.44 4,549,773.50 690,001,038.97\n（1）购置 363,159.41 320,013.97 4,549,773.50 5,232,946.88\n（2）在建工程\n127,058,302.67 26,147,661.95 531,562,127.47 684,768,092.09\n转入\n（3）企业合并\n增加\n3.本期减少金额 13,603,089.42 4,778,065.53 40,235,121.09 1,713,041.92 60,329,317.96\n（1）处置或报\n13,603,089.42 4,778,065.53 40,235,121.09 1,713,041.92 60,329,317.96\n废\n4.期末余额 1,055,459,515.82 173,015,227.04 1,652,403,968.40 59,763,869.44 2,940,642,580.70\n二、累计折旧\n1.期初余额 353,145,143.22 114,199,096.34 571,568,602.36 44,658,442.31 1,083,571,284.23\n2.本期增加金额 52,644,012.36 14,146,453.54 99,289,757.27 5,610,282.17 171,690,505.34\n（1）计提 52,644,012.36 14,146,453.54 99,289,757.27 5,610,282.17 171,690,505.34\n3.本期减少金额 9,335,681.39 4,537,067.86 35,777,262.22 1,569,383.59 51,219,395.06\n（1）处置或报\n9,335,681.39 4,537,067.86 35,777,262.22 1,569,383.59 51,219,395.06\n废\n4.期末余额 396,453,474.19 123,808,482.02 635,081,097.41 48,699,340.89 1,204,042,394.51\n三、减值准备\n1.期初余额 717,598.43 44,323.56 11,517,009.86 12,278,931.85\n139。\n\n2.本期增加金额 103,473.25 396,068.47 499,541.72\n（1）计提 103,473.25 396,068.47 499,541.72\n3.本期减少金额 585,620.72 585,620.72\n（1）处置或报\n585,620.72 585,620.72\n废\n4.期末余额 131,977.71 147,796.81 11,913,078.33 12,192,852.85\n四、账面价值\n1.期末账面价值 658,874,063.92 49,058,948.21 1,005,409,792.66 11,064,528.55 1,724,407,333.34\n2.期初账面价值 588,141,560.92 37,039,051.31 577,671,335.83 12,268,695.55 1,215,120,643.61\n（2）暂时闲置的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值 备注\n房屋及建筑物 96,021,538.73 24,413,427.38 71,608,111.35\n通用设备 6,855,762.41 5,595,164.87 143,649.07 1,116,948.47\n专用设备 145,417,971.06 110,109,458.33 732,234.31 34,576,278.42\n（3）通过融资租赁租入的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值\n（4）通过经营租赁租出的固定资产\n单位： 元\n项目 期末账面价值\n（5）未办妥产权证书的固定资产情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n公司及子公司房屋建筑物 136,044,964.45公司正在办理产权证书\n其他说明\n140。\n\n（6）固定资产清理\n单位： 元\n项目 期末余额 期初余额\n其他说明\n22、在建工程\n单位： 元\n项目 期末余额 期初余额\n在建工程 535,836,082.97 653,154,180.21\n工程物资 24,838,551.46 21,179,497.78\n合计 560,674,634.43 674,333,677.99\n（1）在建工程情况\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n公司及子公司房\n2,107,384.23 2,107,384.23 6,025,551.57 6,025,551.57\n屋建设工程\n原料药及中间体\nCMO中心扩建 198,852,943.52 198,852,943.52 165,628,666.75 165,628,666.75\n项目\n川南药业公司设\n9,204,900.26 9,204,900.26 7,184,188.76 7,184,188.76\n备安装工程\n环保设施改造项\n41,262,820.03 41,262,820.03 80,121,501.45 80,121,501.45\n目\n台州前进公司\n15500吨活性染\n36,676,707.08 36,676,707.08 147,592,362.30 147,592,362.30\n料产业升级及配\n套项目\n台州振港公司年\n产2500吨关健中\n6,050,304.05 6,050,304.05 42,843,192.74 42,843,192.74\n间体产业一体化\n项目\n台州振港公司年\n产700吨M-562\n285,309.30 285,309.30 93,276,176.18 93,276,176.18\n关键中间体产业\n一体化项目\n141。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "3687009b",
        "b1d833e0",
        "a98cc793",
        "6b4b7bc0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3166,
      "page_number": 138,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          138,
          139,
          140,
          141
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.341573",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3166,
        "word_count": 319,
        "sentence_count": 179,
        "chinese_char_count": 696,
        "readability_score": 0.0,
        "information_density": 0.04421983575489577,
        "coherence_score": 0.24145306090557486,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6722046746683512,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "固定资产",
        "合并",
        "经营",
        "折旧",
        "摊销",
        "减值",
        "公允价值",
        "账面价值"
      ]
    },
    {
      "chunk_id": "9eb06dd3",
      "content": "台州振港公司年\n产18500吨染料 68,227,065.54 68,227,065.54 5,450,450.43 5,450,450.43\n产业升级项目\n盐城瓯华公司设\n26,608,200.30 26,608,200.30 22,261,730.30 22,261,730.30\n备安装工程\n医药中试车间技\n17,149,684.37 17,149,684.37\n改项目\n医药综合研发中\n15,253,236.88 15,253,236.88 775,995.69 775,995.69\n心\n台州振港公司\n250吨美罗培南 44,267,447.48 44,267,447.48\n侧链项目\n零星工程 87,039,764.30 87,039,764.30 64,844,679.67 64,844,679.67\n合计 535,836,082.97 535,836,082.97 653,154,180.21 653,154,180.21\n（2）重要在建工程项目本期变动情况\n单位： 元\n本期转 工程累 其中：本\n本期其 利息资 本期利\n项目名 期初余 本期增 入固定 期末余 计投入 工程进 期利息 资金来\n预算数 他减少 本化累 息资本\n称 额 加金额 资产金 额 占预算 度 资本化 源\n金额 计金额 化率\n额 比例 金额\n公司及\n子公司 1,816,86 4,597,40 4,306,88 2,107,38 金融机\n房屋建 9.49 0.47 5.73 4.23 构贷款\n设工程\n原料药\n及中间\n46,034.5 165,628, 94,079,7 60,855,5 198,852, 募股资\n体CMO 70.92%70.00\n8 666.75 99.70 22.93 943.52 金\n中心扩\n建项目\n川南药\n业公司 7,184,18 31,205,6 29,184,9 9,204,90 金融机\n设备安 8.76 20.68 09.18 0.26 构贷款\n装工程\n环保设\n15,502.0 80,121,5 35,646,6 74,505,3 41,262,8 募股资\n施改造 75.01%75.00\n0 01.45 30.19 11.61 20.03 金\n项目\n142。\n\n台州前\n进公司\n15500吨\n活性染 40,160.0 147,592, 154,147, 265,062, 36,676,7 金融机\n75.13%75.00\n料产业 0 362.30 165.63 820.85 07.08 构贷款\n升级及\n配套项\n目\n台州振\n港公司\n产2500\n吨关健 42,843,1 12,166,1 48,959,0 6,050,30 金融机\n7,850.00 102.09%95.00\n中间体 92.74 71.56 60.25 4.05 构贷款\n产业一\n体化项\n目\n台州振\n港公司\n年产700\n吨\n10,000.0 93,276,1 10,517,0 103,507, 285,309. 金融机\nM-562 106.83%99.00\n0 76.18 68.25 935.13 30 构贷款\n关键中\n间体产\n业一体\n化项目\n台州振\n港公司\n年产\n80,000.0 5,450,45 82,575,2 19,798,6 68,227,0 金融机\n18500吨 13.86%15.00\n0 0.43 81.47 66.36 65.54 构贷款\n染料产\n业升级\n项目\n盐城瓯\n华公司 26,470,4 5,218,03 5,080,24 26,608,2 金融机\n设备安 12.38 4.21 6.29 00.30 构贷款\n装工程\n医药中\n试车间 17,149,6 6,878,35 24,028,0 募股资\n9,256.00 43.31%45.00\n技改项 84.37 9.38 43.75 金\n目\n143。\n\n医药综\n15,073.0 775,995. 35,025,9 20,548,7 15,253,2 募股资\n合研发 23.75%25\n0 69 51.78 10.59 36.88 金\n中心\n台州振\n港公司\n250吨美 16,000.0 44,267,4 44,267,4 金融机\n27.67%30\n罗培南 0 47.48 47.48 构贷款\n侧链项\n目\n零星工 64,844,6 51,125,0 28,929,9 87,039,7 金融机\n程 79.67 64.05 79.42 64.30 构贷款\n239,875. 653,154, 567,449, 684,768, 535,836,\n合计 -- -- --\n58 180.21 994.85 092.09 082.97\n（3）本期计提在建工程减值准备情况\n单位： 元\n项目 本期计提金额 计提原因\n其他说明\n（4）工程物资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n专用材料 9,806,701.25 9,806,701.25 7,121,142.67 7,121,142.67\n专用设备 15,031,850.21 15,031,850.21 14,058,355.11 14,058,355.11\n合计 24,838,551.46 24,838,551.46 21,179,497.78 21,179,497.78\n其他说明：\n23、生产性生物资产\n（1）采用成本计量模式的生产性生物资产\n□ 适用 √ 不适用\n（2）采用公允价值计量模式的生产性生物资产\n□ 适用 √ 不适用\n144。\n\n24、油气资产\n□ 适用 √ 不适用\n25、使用权资产\n单位： 元\n项目 合计\n其他说明：\n26、无形资产\n（1）无形资产情况\n单位： 元\n项目 土地使用权 专利权 非专利技术 排污权 特许使用权 特许经营权 软件 合计\n一、账面原值\n1.期初 505,413,741. 162,305,608. 11,915,094.3 688,369,268.\n3,072,760.00 3,143,452.96 1,168,163.69 1,350,447.87\n余额 33 72 7 94\n2.本期 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n增加金额 6 0\n（1） 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n购置 6 0\n（2）\n内部研发\n（3）\n企业合并增\n加\n3.本期减 11,116,461.1\n9,433,962.30 1,682,498.83\n少金额 3\n（1） 11,116,461.1\n9,433,962.30 1,682,498.83\n处置 3\n4.期末 527,186,739. 163,203,423. 701,568,832.\n2,481,132.07 4,011,789.99 1,460,954.13 1,168,163.69 2,056,629.92\n余额 19 12 11\n二、累计摊销\n1.期初 55,429,191.3 77,337,200.9 143,036,807.\n4,014,069.57 1,700,580.26 2,061,454.24 1,168,163.69 1,326,147.82\n余额 9 3 90\n145。\n\n2.本期 11,263,080.3 17,674,391.8 30,277,923.1\n563,042.72 517,839.30 205,844.64 53,724.30\n增加金额 6 1 3\n（1） 11,263,080.3 17,674,391.8 30,277,923.1\n563,042.72 517,839.30 205,844.64 53,724.30\n计提 6 1 3\n3.本期\n3,616,352.13 1,584,866.25 5,201,218.38\n减少金额\n（1）\n3,616,352.13 1,584,866.25 5,201,218.38\n处置\n4.期末 66,692,271.7 95,011,592.7 168,113,512.\n960,760.16 2,218,419.56 682,432.63 1,168,163.69 1,379,872.12\n余额 5 4 65\n三、减值准备\n1.期初\n5,817,610.17 5,817,610.17\n余额\n2.本期\n增加金额\n（1）\n计提\n3.本期\n5,817,610.17 5,817,610.17\n减少金额\n（1）处\n置\n4.期末\n余额\n四、账面价值\n1.期末 460,494,467. 68,191,830.3 533,455,319.\n1,520,371.91 1,793,370.43 778,521.50 676,757.80\n账面价值 44 8 46\n2.期初 449,984,549. 84,968,407.7 539,514,850.\n2,083,414.63 1,372,179.74 1,081,998.72 24,300.05\n账面价值 94 9 87\n本期末通过公司内部研发形成的无形资产占无形资产余额的比例。（2）未办妥产权证书的土地使用权情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n146。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "3121b911",
        "9c52f261",
        "8595d6f2",
        "17019779",
        "acc8db4c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3882,
      "page_number": 142,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142,
          143,
          144,
          145,
          146
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.343456",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3882,
        "word_count": 552,
        "sentence_count": 221,
        "chinese_char_count": 800,
        "readability_score": 0.0,
        "information_density": 0.033487892838742914,
        "coherence_score": 0.27657614292401306,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5563111798042246,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "无形资产",
        "合并",
        "经营",
        "摊销",
        "减值",
        "公允价值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "36447bd5",
      "content": "台州市枫南东路以北、东港大道以东 4,679,700.00公司正在办理产权证书\n其他说明：\n27、开发支出\n单位： 元\n本期增加金额 本期减少金额\n项目 期初余额 内部开发支 确认为无形 转入当期损 期末余额\n其他\n出 资产 益\n合计\n其他说明\n28、商誉\n（1）商誉账面原值\n单位： 元\n被投资单位名称 本期增加 本期减少\n或形成商誉的事 期初余额 期末余额\n企业合并形成的 处置\n项\n台州前进公司 757,736,770.14 757,736,770.14\n合计 757,736,770.14 757,736,770.14\n（2）商誉减值准备\n单位： 元\n被投资单位名称 本期增加 本期减少\n或形成商誉的事 期初余额 期末余额\n计提 处置\n项\n合计\n商誉所在资产组或资产组组合的相关信息\n资产组或资产组组合的构成 台州前进公司资产组\n资产组或资产组组合的账面价值 1,726,678,155.03\n分摊至本资产组或资产组组合的商誉账面价值及分摊 全部分摊至台州前进公司资产组\n方法\n包含商誉的资产组或资产组组合的账面价值 2,484,414,925.17\n资产组或资产组组合是否与购买日、以前年度商誉减 是\n值测试时所确定的资产组或资产组组合一致\n147。\n\n说明商誉减值测试过程、关键参数（如预计未来现金流量现值时的预测期增长率、稳定期增长率、利润率、折现率、预测期\n等）及商誉减值损失的确认方法：\n商誉的可收回金额按照预计未来现金流量的现值计算，其预计现金流量根据公司批准的5年期现金流\n量预测为基础，现金流量预测使用的折现率14.16%(2018年：13.00%)，公司根据历史实际经营数据、行业\n发展趋势、预期收入增长率、毛利率等指标编制预测未来5年现金流量，预测期以后的现金流量维持不变。减值测试中采用的其他关键数据包括：产品预计售价、销量、生产成本及其他相关费用。公司根据历史经验及对市场发展的预测确定上述关键数据。\n\n公司采用的折现率是反映当前市场货币时间价\n值和相关资产组特定风险的税前利率。上述对可收回金额的预计表明商誉并未出现减值损失。商誉减值测试的影响\n其他说明\n29、长期待摊费用\n单位： 元\n项目 期初余额 本期增加金额 本期摊销金额 其他减少金额 期末余额\n经营租入固定资产\n1,842,423.21 223,651.32 1,618,771.89\n改良支出\n合计 1,842,423.21 223,651.32 1,618,771.89\n其他说明\n30、递延所得税资产/递延所得税负债\n（1）未经抵销的递延所得税资产\n单位： 元\n期末余额 期初余额\n项目\n可抵扣暂时性差异 递延所得税资产 可抵扣暂时性差异 递延所得税资产\n资产减值准备 70,299,465.99 14,376,262.42 68,698,671.21 14,236,323.65\n内部交易未实现利润 39,421,112.05 6,246,640.41 62,503,070.92 9,773,506.85\n与资产相关的政府补助\n43,621,205.16 6,716,780.73 36,278,025.15 5,567,975.82\n分摊\n预计负债 11,637,669.47 2,909,417.37\n合计 153,341,783.20 27,339,683.56 179,117,436.75 32,487,223.69\n（2）未经抵销的递延所得税负债\n单位： 元\n项目 期末余额 期初余额\n148。\n\n应纳税暂时性差异 递延所得税负债 应纳税暂时性差异 递延所得税负债\n单位价值500万元以下\n固定资产一次性税前抵 179,410,105.32 30,527,355.71 44,259,216.46 8,175,428.28\n扣\n合计 179,410,105.32 30,527,355.71 44,259,216.46 8,175,428.28\n（3）以抵销后净额列示的递延所得税资产或负债\n单位： 元\n递延所得税资产和负债 抵销后递延所得税资产 递延所得税资产和负债 抵销后递延所得税资产\n项目\n期末互抵金额 或负债期末余额 期初互抵金额 或负债期初余额\n递延所得税资产 27,339,683.56 32,487,223.69\n递延所得税负债 30,527,355.71 8,175,428.28\n（4）未确认递延所得税资产明细\n单位： 元\n项目 期末余额 期初余额\n可抵扣暂时性差异 34,056.67 42,122.21\n可抵扣亏损 54,023,245.91 120,721,788.89\n合计 54,057,302.58 120,763,911.10\n（5）未确认递延所得税资产的可抵扣亏损将于以下年度到期\n单位： 元\n年份 期末金额 期初金额 备注\n2021年 106,844,539.90\n2022年 13,876,526.38 13,876,526.38\n2023年 722.61 722.61\n2024年 40,145,996.92\n合计 54,023,245.91 120,721,788.89 --\n其他说明：\n31、其他非流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n149。\n\n预付软件款 450,000.00 515,993.37\n合计 450,000.00 515,993.37\n其他说明：\n32、短期借款\n（1）短期借款分类\n单位： 元\n项目 期末余额 期初余额\n质押借款 76,700,000.00\n抵押借款 50,066,500.00 143,000,000.00\n保证借款 20,000,000.00\n信用借款 150,200,529.59 359,000,000.00\n合计 200,267,029.59 598,700,000.00\n短期借款分类的说明：\n（2）已逾期未偿还的短期借款情况\n本期末已逾期未偿还的短期借款总额为元，其中重要的已逾期未偿还的短期借款情况如下：\n单位： 元\n借款单位 期末余额 借款利率 逾期时间 逾期利率\n其他说明：\n33、交易性金融负债\n单位： 元\n项目 期末余额 期初余额\n其中：\n其中：\n其他说明：\n34、衍生金融负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n150\n\n35、应付票据\n单位： 元\n种类 期末余额 期初余额\n银行承兑汇票 238,306,005.00 490,006,533.85\n合计 238,306,005.00 490,006,533.85\n本期末已到期未支付的应付票据总额为元。36、应付账款\n（1）应付账款列示\n单位： 元\n项目 期末余额 期初余额\n货 款 139,912,212.13 157,970,026.94\n工程设备款 212,622,391.34 137,429,777.27\n其 他 10,905,980.49 6,509,125.72\n合计 363,440,583.96 301,908,929.93\n（2）账龄超过1年的重要应付账款\n单位： 元\n项目 期末余额 未偿还或结转的原因\n其他说明：\n37、预收款项\n是否已执行新收入准则\n□ 是 √ 否\n（1）预收款项列示\n单位： 元\n项目 期末余额 期初余额\n货 款 12,919,749.09 19,196,692.94\n合计 12,919,749.09 19,196,692.94\n（2）账龄超过1年的重要预收款项\n单位： 元\n151。\n\n项目 期末余额 未偿还或结转的原因\n（3）期末建造合同形成的已结算未完工项目情况\n单位： 元\n项目 金额\n其他说明：\n38、合同负债\n单位： 元\n项目 期末余额 期初余额\n报告期内账面价值发生重大变动的金额和原因\n单位： 元\n项目 变动金额 变动原因\n39、应付职工薪酬\n（1）应付职工薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n一、短期薪酬 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n二、离职后福利-设定提\n3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n存计划\n三、辞退福利 26,656.73 26,656.73\n合计 45,234,354.42 326,240,321.13 319,107,533.27 52,367,142.28\n（2）短期薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、工资、奖金、津贴和\n38,780,553.62 273,368,159.46 267,353,757.95 44,794,955.13\n补贴\n2、职工福利费 15,919,594.19 15,919,594.19\n3、社会保险费 2,440,565.13 8,976,976.99 8,845,418.72 2,572,123.40\n其中：医疗保险费 1,731,912.00 7,358,904.85 7,221,509.07 1,869,307.78\n工伤保险费 518,490.75 1,058,240.23 1,071,709.37 505,021.61\n生育保险费 190,162.38 559,831.91 552,200.28 197,794.01\n152。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "170e3cf8",
        "bab01330",
        "acb7a0db",
        "74aa6e04",
        "821fab08"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3866,
      "page_number": 147,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147,
          148,
          149,
          150,
          151,
          152
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.346085",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3866,
        "word_count": 423,
        "sentence_count": 134,
        "chinese_char_count": 1683,
        "readability_score": 0.0,
        "information_density": 0.04914640455250906,
        "coherence_score": 0.427299829568974,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7741334712881531,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "经营",
        "500万元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应付",
        "预收"
      ]
    },
    {
      "chunk_id": "ace38c86",
      "content": "4、住房公积金 286,968.00 9,072,162.00 9,110,730.00 248,400.00\n5、工会经费和职工教育\n132,082.69 2,529,511.30 1,766,967.57 894,626.42\n经费\n合计 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n（3）设定提存计划列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、基本养老保险 3,311,287.25 15,768,975.90 15,505,552.02 3,574,711.13\n2、失业保险费 282,897.73 578,284.56 578,856.09 282,326.20\n合计 3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n其他说明：\n40、应交税费\n单位： 元\n项目 期末余额 期初余额\n增值税 9,523,602.71 9,931,701.18\n企业所得税 28,390,504.27 37,886,210.59\n个人所得税 764,210.55 778,807.41\n城市维护建设税 501,005.62 756,017.40\n房产税 3,435,584.90 2,902,210.71\n土地使用税 1,583,236.07 1,592,945.01\n教育费附加 214,716.69 435,378.81\n地方教育附加 143,144.46 290,252.54\n印花税 123,171.95 107,074.83\n残疾人就业保障金 73,107.05 60,062.86\n环境保护税 28,921.28 150,000.00\n合计 44,781,205.55 54,890,661.34\n其他说明：\n41、其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付利息 1,088,752.57\n153。\n\n应付股利 2,051,370.43 2,051,370.43\n其他应付款 26,148,702.79 21,583,181.20\n合计 28,200,073.22 24,723,304.20\n（1）应付利息\n单位： 元\n项目 期末余额 期初余额\n短期借款应付利息 1,088,752.57\n合计 1,088,752.57\n重要的已逾期未支付的利息情况：\n单位： 元\n借款单位 逾期金额 逾期原因\n其他说明：\n（2）应付股利\n单位： 元\n项目 期末余额 期初余额\n发起人股东 2,051,370.43 2,051,370.43\n合计 2,051,370.43 2,051,370.43\n其他说明，包括重要的超过1年未支付的应付股利，应披露未支付原因：\n（3）其他应付款\n1）按款项性质列示其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付暂收款 14,988,518.12 11,511,834.54\n出口货物运保费及佣金 8,226,443.88 3,988,336.40\n押金保证金 920,310.00 2,476,025.00\n暂借款 350,000.00 1,345,413.90\n其 他 1,663,430.79 2,261,571.36\n合计 26,148,702.79 21,583,181.20\n2）账龄超过1年的重要其他应付款\n单位： 元\n154。\n\n项目 期末余额 未偿还或结转的原因\n其他说明\n42、持有待售负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n43、一年内到期的非流动负债\n单位： 元\n项目 期末余额 期初余额\n一年内到期的长期应付款 44,365,875.00\n合计 44,365,875.00\n其他说明：\n44、其他流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n短期应付债券的增减变动：\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n其他说明：\n45、长期借款\n（1）长期借款分类\n单位： 元\n项目 期末余额 期初余额\n长期借款分类的说明：\n其他说明，包括利率区间：\n155\n\n46、应付债券\n（1）应付债券\n单位： 元\n项目 期末余额 期初余额\n（2）应付债券的增减变动（不包括划分为金融负债的优先股、永续债等其他金融工具）\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n合计 -- -- --\n（3）可转换公司债券的转股条件、转股时间说明\n（4）划分为金融负债的其他金融工具说明\n期末发行在外的优先股、永续债等其他金融工具基本情况\n期末发行在外的优先股、永续债等金融工具变动情况表\n单位： 元\n发行在外的 期初 本期增加 本期减少 期末\n金融工具 数量 账面价值 数量 账面价值 数量 账面价值 数量 账面价值\n其他金融工具划分为金融负债的依据说明\n其他说明\n47、租赁负债\n单位：\n项目 期末余额 期初余额\n其他说明\n48、长期应付款\n单位： 元\n项目 期末余额 期初余额\n（1）按款项性质列示长期应付款\n单位： 元\n156\n\n项目 期末余额 期初余额\n其他说明：\n（2）专项应付款\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n其他说明：\n49、长期应付职工薪酬\n（1）长期应付职工薪酬表\n单位： 元\n项目 期末余额 期初余额\n（2）设定受益计划变动情况\n设定受益计划义务现值：\n单位： 元\n项目 本期发生额 上期发生额\n计划资产：\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划净负债（净资产）\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划的内容及与之相关风险、对公司未来现金流量、时间和不确定性的影响说明：\n设定受益计划重大精算假设及敏感性分析结果说明：\n其他说明：\n50、预计负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额 形成原因\n未支付合同义务及诉讼费 11,637,669.47\n未支付担保损失 1,333,333.00 1,333,333.00[注]\n157\n\n合计 1,333,333.00 12,971,002.47 --\n其他说明，包括重要预计负债的相关重要假设、估计说明：\n[注]：根据2000年12月16日浙江省台州市中级人民法院〔2000〕台经初字第204号《民事判决书》，公\n司为台州市染料化工(集团)公司向台州市椒江区财政局的4,000,000.00元借款提供保证，因该公司未按合同\n约定如期归还，本公司需承担三分之一的到期还款连带责任，并赔偿台州市椒江区财政局相应的损失，截\n至2019年12月31日该项判决尚未执行。对上述诉讼事项，公司已按应承担的连带责任计提预计负债\n1,333,333.00元。51、递延收益\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n政府补助 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n未实现售后租回损\n1,307,404.76 402,278.40 905,126.36\n益\n合计 44,650,629.91 12,900,000.00 6,956,538.39 50,594,091.52 --\n涉及政府补助的项目：\n单位： 元\n本期计入营\n本期新增补 本期计入其 本期冲减成 与资产相关/\n负债项目 期初余额 业外收入金 其他变动 期末余额\n助金额 他收益金额 本费用金额 与收益相关\n额\n年产400吨\n碳青霉烯类\n1,423,820.2\n抗生素关键 5,695,281.12 4,271,460.84 与资产相关\n8\n中间体\n4-AA项目\n年产1吨瑞\n格列奈、10\n吨卡洛芬、\n10吨阿托伐\n醌、50吨\nT1620、300\n235,862.40 117,931.20 117,931.20 与资产相关\n吨聚卡波菲\n钙、300吨\n4,4'-二氟二\n苯甲酮、100\n吨奈韦拉平\n产业化项目\n158。\n\n催化净化处\n理塔建设项 140,000.00 30,000.00 110,000.00 与资产相关\n目\n年产50吨培\n南类产品及\n132,000.00 48,000.00 84,000.00 与资产相关\n扩建厂房技\n改项目\n企业技术中\n心创新能力 133,333.33 40,000.00 93,333.33 与资产相关\n建设项目\n年产8亿元\n(粒)口服固 7,065,200.00 997,440.00 6,067,760.00 与资产相关\n体制剂项目\n临海市创新\n驱动加快推\n进工业经济 1,042,718.40 208,543.68 834,174.72 与资产相关\n转型升级政\n策\n省级工业与\n信息化专项\n资金回收溶 632,766.12 92,599.92 540,166.20 与资产相关\n剂循环化技\n改项目\n省工业化和\n信息化深度\n融合示范试 457,675.28 66,169.92 391,505.36 与资产相关\n点区财政补\n助\n浙江省化学\n原料药基地\n椒江区块循 263,333.33 40,000.00 223,333.33 与资产相关\n环化改造项\n目补助资金\n159。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "1114d1d8",
        "2dd41f41",
        "73bd12e0",
        "0ef8b4e6",
        "86a17610"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3883,
      "page_number": 153,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153,
          154,
          155,
          156,
          157,
          158,
          159
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.348215",
        "report_type": "资产负债表",
        "fiscal_year": 2000,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3883,
        "word_count": 492,
        "sentence_count": 129,
        "chinese_char_count": 1712,
        "readability_score": 0.0,
        "information_density": 0.043780582024208085,
        "coherence_score": 0.37589018656380235,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7763584857069277,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "现金流",
        "000.00元",
        "333.00元",
        "8亿元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "费用",
        "现金",
        "应付",
        "所得税",
        "净资产",
        "股东",
        "披露"
      ]
    },
    {
      "chunk_id": "9bbf7ee2",
      "content": "年产2吨盐\n酸阿莫罗\n芬、20吨阿\n特来马来酸\n盐、5吨多尼\n培南、20吨 2,090,683.87 281,889.96 1,808,793.91 与资产相关\n美罗培南、5\n吨比阿培\n南、60吨\nPHE产业化\n项目(续建)\n年产15000\n吨环保型活\n性艳蓝\n850,000.00 100,000.00 750,000.00 与资产相关\nKN-R商品\n染料技改项\n目\n大品种药物\n的生产技术\n改造-美罗\n860,416.67 2,000,000.00 291,265.91 2,569,150.76 与资产相关\n培南原料药\n绿色合成技\n术改造\n临海医化园\n区循环化改 490,000.00 105,000.00 385,000.00 与资产相关\n造项目\n南洋涂-固\n废减量化处 2,286,832.98 246,999.96 2,039,833.02 与资产相关\n置项目\n年产400吨\nMAP、100\n吨OA、200\n1,490,999.9\n吨DA、100 10,000,000.0\n11,962,166.31 20,471,166.40 与资产相关\n吨甲砜霉 0\n1\n素、10吨联\n苯双酯产业\n化新项目\n年产580吨\n柳氮磺胺吡\n2,115,735.00 248,910.00 1,866,825.00 与资产相关\n啶产业化项\n目\n160。\n\n清洁生产循\n环利用及三\n4,800,000.00 600,000.00 4,200,000.00 与资产相关\n废综合治理\n提升项目\n年产15500\n吨活性染料\n1,296,000.00 1,296,000.00 与资产相关\n产业升级及\n配套项目\n孵化器车间\n793,220.34 81,355.92 711,864.42 与资产相关\n技改项目\n浙江省化学\n原料药基地\n椒江区块循\n400,000.00 10,000.00 390,000.00 与资产相关\n环化改造项\n目补助资金\n项目补助\n年产700吨\nM-562关键\n500,000.00 33,333.33 466,666.67 与资产相关\n中间体产业\n一体化项目\n6,554,259.9\n12,900,000.0\n小 计 43,343,225.15 49,688,965.16\n0\n9\n其他说明：\n52、其他非流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n53、股本\n单位：元\n本次变动增减（+、-）\n期初余额 期末余额\n发行新股 送股 公积金转股 其他 小计\n1,618,820,253. 1,618,715,253.\n股份总数 -105,000.00 -105,000.00\n00 00\n其他说明：\n161。\n\n根据公司2019年第一次临时股东大会决议，公司按照每股人民币2.25元向赵敏蔚等5人回购其所持有的\n已获授但尚未解锁的限制性股票105,000股，并扣回原已现金分红的可撤销现金股利66,150.00元，实际于\n2019年5月20日归还激励对象出资170,100.00元，其中，减少实收资本105,000元，减少资本公积131,250.00\n元。上述减资业经天健会计师事务所(特殊普通合伙)审验，并由其出具《验资报告》(天健验〔2019〕158\n号)。上述事项公司已于2019年7月1日办妥工商变更登记手续。\n\n54、其他权益工具\n（1）期末发行在外的优先股、永续债等其他金融工具基本情况\n（2）期末发行在外的优先股、永续债等金融工具变动情况表\n单位： 元\n发行在外的 期初 本期增加 本期减少 期末\n金融工具 数量 账面价值 数量 账面价值 数量 账面价值 数量 账面价值\n其他权益工具本期增减变动情况、变动原因说明，以及相关会计处理的依据：\n其他说明：\n55、资本公积\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n资本溢价（股本溢价） 2,612,188,669.80 43,566,610.03 131,250.00 2,655,624,029.83\n其他资本公积 51,179,152.67 7,113,749.53 43,566,610.03 14,726,292.17\n合计 2,663,367,822.47 50,680,359.56 43,697,860.03 2,670,350,322.00\n其他说明，包括本期增减变动情况、变动原因说明：\n1) 公司本期因回购限制性股票减少资本公积(股本溢价) 131,250.00元。2) 公司本期因限制性股票行权，从资本公积(其他资本公积)转入资本公积(股本溢价) 43,566,610.03元。3) 公司本期确认股权激励费用7,113,749.53元，计入资本公积(其他资本公积)，详见本财务报表附注股\n份支付之说明。\n\n56、库存股\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n限制性人民币普通股 44,365,875.00 44,365,875.00\n股份回购 281,514,686.68 19,996,827.22 301,511,513.90\n合计 325,880,561.68 19,996,827.22 44,365,875.00 301,511,513.90\n其他说明，包括本期增减变动情况、变动原因说明：\n162。\n\n1）本期库存股减少44,365,875.00元，其中：①回购并注销赵敏蔚等5人已获授但尚未解锁的限制性股\n票105,000股，按回购价计算减少236,250.00元；②本期解锁减少库存股16,546,500股，每股授予价格2.25元，\n减少37,229,625.00元；③预留授予的限制性股票第一期解锁1,600,000股，每股授予价格4.3125元，减少\n6,900,000.00元。2）本期库存股增加19,996,827.22元，系本期回购股份增加的库存股，公司以集中竞价交易方式回购公\n司股份，回购价格不超过6.9元/股，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，回\n购股份拟用作员工持股计划、股权激励计划或注销以减少公司注册资本。本期公司回购股份4,528,000股，\n回购总成本19,996,827.22元，公司回购股份计划已实施完毕。\n\n57、其他综合收益\n单位： 元\n本期发生额\n减：前期\n减：前期计入\n本期所得 计入其他 税后归属 期末余\n项目 期初余额 其他综合收 减：所得 税后归属\n税前发生 综合收益 于少数股 额\n益当期转入 税费用 于母公司\n额 当期转入 东\n损益\n留存收益\n一、不能重分类进损益的其他综 -1,800,000 -1,800,000 -1,800,0\n合收益 .00 .00 00.00\n其他权益工具投资公允 -1,800,000 -1,800,000 -1,800,0\n价值变动 .00 .00 00.00\n二、将重分类进损益的其他综合 361,590.4 361,590.4 309,811.\n-51,779.23\n收益 2 2 19\n361,590.4 361,590.4 309,811.\n外币财务报表折算差额 -51,779.23\n2 2 19\n-1,438,409 -1,438,409 -1,490,1\n其他综合收益合计 -51,779.23\n.58 .58 88.81\n其他说明，包括对现金流量套期损益的有效部分转为被套期项目初始确认金额调整：\n58、专项储备\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n安全生产费 18,997,055.97 18,997,055.97\n合计 18,997,055.97 18,997,055.97\n其他说明，包括本期增减变动情况、变动原因说明：\n根据财政部、国家安监总局联合发布的《企业安全生产费用提取和使用管理办法》(财企〔2012〕16\n号)和财政部《关于印发企业会计准则解释第3号的通知》(财会〔2009〕8号)要求，公司、川南药业公司、\n台州前进公司、台州振港公司和盐城瓯华公司作为危险品生产企业本期提取并实际使用安全生产费用\n163。\n\n18,997,055.97元。59、盈余公积\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n法定盈余公积 201,812,279.17 11,257,545.14 213,069,824.31\n合计 201,812,279.17 11,257,545.14 213,069,824.31\n盈余公积说明，包括本期增减变动情况、变动原因说明：\n60、未分配利润\n单位： 元\n项目 本期 上期\n调整前上期末未分配利润 1,232,481,918.50 897,836,956.42\n调整后期初未分配利润 1,232,481,918.50 897,836,956.42\n加：本期归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n减：提取法定盈余公积 11,257,545.14 108,614,533.40\n应付普通股股利 466,678,159.50 161,744,325.30\n期末未分配利润 1,525,328,398.95 1,232,481,918.50\n调整期初未分配利润明细：\n1)、由于《企业会计准则》及其相关新规定进行追溯调整，影响期初未分配利润0.00元。2)、由于会计政策变更，影响期初未分配利润0.00元。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "9fe0c412",
        "7954891b",
        "5ee7b1b7",
        "a21254dd",
        "7d85c86c"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3875,
      "page_number": 160,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160,
          161,
          162,
          163,
          164
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.350406",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3875,
        "word_count": 374,
        "sentence_count": 141,
        "chinese_char_count": 1656,
        "readability_score": 0.0,
        "information_density": 0.05161290322580645,
        "coherence_score": 0.6913977503226996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7709419354838709,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应付"
      ]
    },
    {
      "chunk_id": "e0e625b5",
      "content": "3)、由于重大会计差错更正，影响期初未分配利润0.00元。4)、由于同一控制导致的合并范围变更，影响期初未分配利润0.00元。5)、其他调整合计影响期初未分配利润0.00元。\n\n61、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 2,925,688,906.14 1,449,500,049.29 2,691,787,601.50 1,492,180,658.53\n其他业务 15,723,864.16 13,659,311.75 26,821,195.01 19,764,017.65\n合计 2,941,412,770.30 1,463,159,361.04 2,718,608,796.51 1,511,944,676.18\n是否已执行新收入准则\n□ 是 √ 否\n其他说明\n164。\n\n62、税金及附加\n单位： 元\n项目 本期发生额 上期发生额\n城市维护建设税 8,979,337.87 11,136,827.27\n教育费附加 4,206,609.84 5,294,134.87\n房产税 5,843,558.13 6,064,374.46\n土地使用税 2,733,446.70 4,311,794.23\n车船使用税 92,034.56 91,578.70\n印花税 2,055,976.68 1,234,528.45\n环境保护税 125,638.87 520,262.21\n地方教育附加 2,804,406.56 3,529,423.24\n合计 26,841,009.21 32,182,923.43\n其他说明：\n63、销售费用\n单位： 元\n项目 本期发生额 上期发生额\n佣 金 23,106,866.17 4,449,906.56\n运输费 15,855,838.29 18,776,797.69\n职工薪酬 11,454,758.67 9,017,672.93\n宣传展览费 2,730,663.11 3,083,947.22\n保险费 2,384,650.11 1,684,252.56\n业务招待费 1,327,567.15 3,743,333.54\n差旅费 930,856.80 1,475,970.50\n邮寄费 306,320.89 564,905.56\n其 他 1,525,503.69 984,267.86\n合计 59,623,024.88 43,781,054.42\n其他说明：\n64、管理费用\n单位： 元\n项目 本期发生额 上期发生额\n职工薪酬 135,254,390.92 119,986,220.11\n折旧费 71,414,444.32 59,647,789.49\n165。\n\n修理费 54,078,791.78 25,798,829.44\n办公费 33,101,653.33 21,185,949.02\n无形资产摊销 29,011,624.85 28,842,167.28\n排污及废物处理费 15,278,838.29 7,077,717.42\n中介及咨询服务费 12,874,898.20 27,576,302.13\n业务招待费 10,763,238.07 6,012,227.78\n以股份支付换取的职工服务 6,036,351.55 37,421,812.71\n保险费 3,790,087.45 2,996,910.69\n差旅费 2,464,786.84 3,670,795.30\n实验检验费 1,934,413.09 1,767,427.11\n劳动保护费 1,919,068.07 2,136,408.20\n其 他 8,262,952.08 5,163,839.89\n合计 386,185,538.84 349,284,396.57\n其他说明：\n65、研发费用\n单位： 元\n项目 本期发生额 上期发生额\n直接材料 24,329,506.93 26,831,622.01\n职工薪酬 53,798,685.12 47,193,153.47\n直接费用 27,647,391.51 19,395,798.61\n委托外部研究开发费 15,764,779.23 11,166,389.47\n以股份支付换取的职工服务 1,007,861.74 6,717,698.51\n合计 122,548,224.53 111,304,662.07\n其他说明：\n66、财务费用\n单位： 元\n项目 本期发生额 上期发生额\n利息支出 15,506,676.74 42,594,267.08\n利息收入 -41,773,975.28 -44,371,159.00\n汇兑净损益 -12,759,207.59 -50,821,750.14\n金融机构手续费 1,161,350.07 1,091,244.28\n合计 -37,865,156.06 -51,507,397.78\n166。\n\n其他说明：\n67、其他收益\n单位： 元\n产生其他收益的来源 本期发生额 上期发生额\n与资产相关的政府补助 6,554,259.99 5,071,751.21\n与收益相关的政府补助 20,582,664.88 6,719,986.82\n合 计 27,136,924.87 11,791,738.03\n68、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n权益法核算的长期股权投资收益 -16,759,549.80 -6,923,938.93\n银行理财产品收益 2,079,074.70 3,024,312.63\n处置金融工具取得的投资收益 -559,587.45 -5,459,752.25\n合计 -15,240,062.55 -9,359,378.55\n其他说明：\n69、净敞口套期收益\n单位： 元\n项目 本期发生额 上期发生额\n其他说明：\n70、公允价值变动收益\n单位： 元\n产生公允价值变动收益的来源 本期发生额 上期发生额\n交易性金融负债 5,010,265.70\n合计 5,010,265.70\n其他说明：\n71、信用减值损失\n单位： 元\n项目 本期发生额 上期发生额\n坏账损失 -2,502,149.00\n167。\n\n合计 -2,502,149.00\n其他说明：\n72、资产减值损失\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 本期发生额 上期发生额\n一、坏账损失 -3,669,712.21\n二、存货跌价损失 -9,789,957.42 -3,098,809.43\n五、长期股权投资减值损失 -1,449,207.56 -6,281,771.71\n七、固定资产减值损失 -499,541.72\n十二、无形资产减值损失 -5,817,610.17\n合计 -11,738,706.70 -18,867,903.52\n其他说明：\n73、资产处置收益\n单位： 元\n资产处置收益的来源 本期发生额 上期发生额\n固定资产处置收益 244,580.94 659,231.88\n合 计 244,580.94 659,231.88\n74、营业外收入\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换利得 56,093.96 126,221.82 56,093.96\n无法支付款项 370,069.55\n违约及赔款收入 896,839.67 972,312.09 896,839.67\n其 他 172,720.90 244,682.63 172,720.90\n合计 1,125,654.53 1,713,286.09 1,125,654.53\n计入当期损益的政府补助：\n单位： 元\n补贴是否影 是否特殊补 本期发生金 上期发生金 与资产相关/\n补助项目 发放主体 发放原因 性质类型\n响当年盈亏 贴 额 额 与收益相关\n168。\n\n其他说明：\n75、营业外支出\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换损失 4,451,449.87 887,727.15 4,451,449.87\n对外捐赠 1,464,708.00 998,689.50 1,464,708.00\n罚款支出 81,087.21 781,984.81 81,087.21\n滞纳金 425,031.19 3,252.32 425,031.19\n合同义务损失 885,370.12 12,597,010.47 885,370.12\n其 他 186,383.29 1,445.95 186,383.29\n合计 7,494,029.68 15,270,110.20 7,494,029.68\n其他说明：\n76、所得税费用\n（1）所得税费用表\n单位： 元\n项目 本期发生额 上期发生额\n当期所得税费用 114,171,327.62 88,766,346.55\n递延所得税费用 27,499,467.56 3,525,443.72\n合计 141,670,795.18 92,291,790.27\n（2）会计利润与所得税费用调整过程\n单位： 元\n项目 本期发生额\n利润总额 912,452,980.27\n按法定/适用税率计算的所得税费用 228,113,245.07\n子公司适用不同税率的影响 -66,145,071.59\n调整以前期间所得税的影响 -5,756,005.36\n不可抵扣的成本、费用和损失的影响 9,475,292.73\n使用前期未确认递延所得税资产的可抵扣亏损的影响 -15,816,251.10\n本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏\n6,148,624.85\n损的影响\n169。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "7885e1c2",
        "3e762c3a",
        "f3c4d202",
        "e8f49612",
        "80aaf019"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3941,
      "page_number": 164,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164,
          165,
          166,
          167,
          168,
          169
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.352533",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3941,
        "word_count": 434,
        "sentence_count": 192,
        "chinese_char_count": 1145,
        "readability_score": 0.0,
        "information_density": 0.050748540979446845,
        "coherence_score": 0.6498144058888438,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5912966252220249,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "财务",
        "0.00元",
        "0.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "存货",
        "固定资产"
      ]
    },
    {
      "chunk_id": "c0ed08b9",
      "content": "购置节能环保设备抵减应纳税额的影响 -1,818,754.37\n研发费用加计扣除 -15,620,860.07\n权益法核算投资收益 3,090,575.02\n所得税费用 141,670,795.18\n其他说明\n77、其他综合收益\n详见附注合并资产负债表项目注释之其他综合收益说明。78、现金流量表项目\n（1）收到的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n收回银行承兑汇票、信用证保证金等 146,000,576.25 268,324,454.49\n收到银行存款利息收入 31,637,094.38 37,993,941.65\n收到政府补助 31,594,591.50 17,182,776.65\n支取为开立承兑汇票质押的定期存款 33,903,500.00 442,038,662.00\n收到房租收入 923,003.40 2,147,867.09\n其 他 5,791,850.24 4,263,072.32\n合计 249,850,615.77 771,950,774.20\n收到的其他与经营活动有关的现金说明：\n（2）支付的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n管理费用中付现支出 121,586,061.34 90,307,710.88\n支付银行承兑汇票、信用证保证金等 74,233,191.52 261,266,253.31\n销售费用中付现支出 43,113,653.73 30,879,918.69\n研发费用中付现支出 31,990,487.21 24,535,117.38\n财务费用中付现支出 1,161,350.07 1,091,244.28\n存入为开立承兑汇票质押的定期存款 189,843,512.00\n支付履约保证金 3,850,000.00\n其 他 11,527,467.71 14,490,599.42\n合计 283,612,211.58 616,264,355.96\n170。\n\n支付的其他与经营活动有关的现金说明：\n（3）收到的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n银行理财产品及结构性存款到期收回 1,160,000,000.00 550,000,000.00\n收到银行理财产品及结构性存款利息 12,215,955.60 9,401,529.98\n收回股权竞拍保证金 400,000,000.00\n合计 1,172,215,955.60 959,401,529.98\n收到的其他与投资活动有关的现金说明：\n（4）支付的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n购买银行理财产品及结构性存款 260,000,000.00 1,400,000,000.00\n支付股权竞拍保证金 400,000,000.00\n支付人民币外汇货币掉期交易损失 5,459,752.25\n合计 260,000,000.00 1,805,459,752.25\n支付的其他与投资活动有关的现金说明：\n（5）收到的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支取因银行借款质押的定期存款 632,143,300.00\n收回银行借款保证金 900,000.00\n合计 633,043,300.00\n收到的其他与筹资活动有关的现金说明：\n（6）支付的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支付公司股份回购款 19,996,827.22 281,514,686.68\n支付限制性股票回购款及利息 281,636.25 13,560,886.22\n存入因银行借款质押的定期存款 294,477,200.00\n171。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "5eb5a3da",
        "6b2ab967"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1538,
      "page_number": 170,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170,
          171
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.354742",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1538,
        "word_count": 137,
        "sentence_count": 58,
        "chinese_char_count": 624,
        "readability_score": 0.0,
        "information_density": 0.11703511053315993,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7158647594278282,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "费用",
        "现金",
        "投资",
        "销售费用",
        "管理费用",
        "研发费用"
      ]
    },
    {
      "chunk_id": "14dd88bb",
      "content": "初始确认日发生违约的风险，以确定金融工具预计存续期内发生违约风险的变化情况。当触发以下一个或多个定量、定性标准时，公司认为金融工具的信用风险已发生显著增加：\n1) 定量标准主要为资产负债表日剩余存续期违约概率较初始确认时上升超过一定比例；\n2) 定性标准主要为债务人经营或财务情况出现重大不利变化、现存的或预期的技术、市场、经济或法\n律环境变化并将对债务人对公司的还款能力产生重大不利影响等；\n3) 上限标准为债务人合同付款(包括本金和利息)逾期超过90天。(2) 违约和已发生信用减值资产的定义\n当金融工具符合以下一项或多项条件时，公司将该金融资产界定为已发生违约，其标准与已发生信用\n减值的定义一致：\n1) 定量标准\n债务人在合同付款日后逾期超过90天仍未付款；\n2) 定性标准\n① 债务人发生重大财务困难；\n② 债务人违反合同中对债务人的约束条款；\n③ 债务人很可能破产或进行其他财务重组；\n④ 债权人出于与债务人财务困难有关的经济或合同考虑，给予债务人在任何其他情况下都不会做出\n的让步。\n\n2. 预期信用损失的计量\n预期信用损失计量的关键参数包括违约概率、违约损失率和违约风险敞口。公司考虑历史统计数据(如\n交易对手评级、担保方式及抵质押物类别、还款方式等)的定量分析及前瞻性信息，建立违约概率、违约损\n失率及违约风险敞口模型。3. 金融工具损失准备期初余额与期末余额调节表详见本财务报表附注之说明。\n\n4. 信用风险敞口及信用风险集中度\n本公司的信用风险主要来自货币资金和应收款项。为控制上述相关风险，本公司分别采取了以下措施。(1) 货币资金\n本公司将银行存款和其他货币资金存放于信用评级较高的金融机构，故其信用风险较低。\n\n(2) 应收款项\n本公司持续对采用信用方式交易的客户进行信用评估。根据信用评估结果，本公司选择与经认可的且\n信用良好的客户进行交易，并对其应收款项余额进行监控，以确保本公司不会面临重大坏账风险。由于本公司仅与经认可的且信用良好的第三方进行交易，所以无需担保物。\n\n信用风险集中按照客户进\n行管理。截至2019年12月31日，本公司存在一定的信用集中风险，本公司应收账款的35.65%(2018年12月\n31日：34.79%)源于余额前五名客户。本公司对应收账款余额未持有任何担保物或其他信用增级。\n\n本公司所承受的最大信用风险敞口为资产负债表中每项金融资产的账面价值。(二) 流动性风险\n流动性风险，是指本公司在履行以交付现金或其他金融资产的方式结算的义务时发生资金短缺的风\n险。流动性风险可能源于无法尽快以公允价值售出金融资产；或者源于对方无法偿还其合同债务；或者源\n于提前到期的债务；或者源于无法产生预期的现金流量。\n\n为控制该项风险，本公司综合运用票据结算、银行借款等多种融资手段，并采取长、短期融资方式适\n当结合，优化融资结构的方法，保持融资持续性与灵活性之间的平衡。本公司已从多家商业银行取得银行\n授信额度以满足营运资金需求和资本开支。金融负债按剩余到期日分类\n项 目 期末数\n账面价值 未折现合同金额 1年以内 1-3年 3年以上\n银行借款 200,267,029.59 205,600,371.26 205,600,371.26\n184。\n\n应付票据 238,306,005.00 238,306,005.00 238,306,005.00\n应付账款 363,440,583.96 363,440,583.96 324,802,966.15 27,710,697.69 10,926,920.12\n其他应付款 28,200,073.22 28,200,073.22 15,005,415.27 6,245,135.70 6,949,522.25\n小 计 830,213,691.77 835,547,033.44 783,714,757.68 33,955,833.39 17,876,442.37\n(续上表)\n项 目 期初数\n账面价值 未折现合同金额 1年以内 1-3年 3年以上\n银行借款 598,700,000.00 611,954,988.49 611,954,988.49\n应付票据 490,006,533.85 490,006,533.85 490,006,533.85\n应付账款 301,908,929.93 301,908,929.93 279,305,463.32 13,367,311.11 9,236,155.50\n其他应付款 24,723,304.20 24,723,304.20 15,643,774.56 638,021.29 8,441,508.35\n一年内到期的非流 44,365,875.00 44,365,875.00 44,365,875.00\n动负债\n小 计 1,459,704,642.98 1,472,959,631.47 1,441,276,635.22 14,005,332.40 17,677,663.85\n(三) 市场风险\n市场风险，是指金融工具的公允价值或未来现金流量因市场价格变动而发生波动的风险。市场风险主\n要包括利率风险和外汇风险。1. 利率风险\n利率风险，是指金融工具的公允价值或未来现金流量因市场利率变动而发生波动的风险。\n\n固定利率的\n带息金融工具使本公司面临公允价值利率风险，浮动利率的带息金融工具使本公司面临现金流量利率风\n险。本公司根据市场环境来决定固定利率与浮动利率金融工具的比例，并通过定期审阅与监控维持适当的\n金融工具组合。本公司面临的现金流量利率风险主要与本公司以浮动利率计息的银行借款有关。\n\n截至2019年12月31日，本公司以浮动利率计息的银行借款人民币17,000.00万元(2018年12月31日：人民\n币20,100.00万元)，在其他变量不变的假设下，假定利率变动50个基准点，不会对本公司的利润总额和股东\n权益产生重大的影响。2. 外汇风险\n外汇风险，是指金融工具的公允价值或未来现金流量因外汇汇率变动而发生波动的风险。本公司面临\n的汇率变动的风险主要与本公司外币货币性资产和负债有关。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "117b2385",
        "a084a6f3",
        "86a624c7"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2518,
      "page_number": 184,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          184,
          185
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.355643",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2518,
        "word_count": 144,
        "sentence_count": 84,
        "chinese_char_count": 1549,
        "readability_score": 0.0,
        "information_density": 0.07942811755361398,
        "coherence_score": 0.6865198525321146,
        "standards_profile_summary": {}
      },
      "quality_score": 0.846068308181096,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金流",
        "融资",
        "经营",
        "财务",
        "报表",
        "000.00万元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金",
        "应收",
        "应付",
        "利润总额",
        "资产负债表",
        "经营"
      ]
    },
    {
      "chunk_id": "b55c64e1",
      "content": "股份，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，详见本财务报表附注库存股之\n说明。\n2、或有事项\n（1）资产负债表日存在的重要或有事项\n截至2019年12月31日，本公司不存在需要披露的重大或有事项。\n（2）公司没有需要披露的重要或有事项，也应予以说明\n公司不存在需要披露的重要或有事项。\n3、其他\n十五、资产负债表日后事项\n1、重要的非调整事项\n单位： 元\n对财务状况和经营成果的影\n项目 内容 无法估计影响数的原因\n响数\n2、利润分配情况\n单位： 元\n3、销售退回\n4、其他资产负债表日后事项说明\n拟分配的利润或股利 根据公司2020年1月22日第六届董事会第二次会议审议\n通过的2019年度利润分配预案，拟以2019年度总股本扣\n除存放于股票回购专用证券账户后的股份数量为基数，\n每10股派发现金股利3元(含税)。上述利润分配预案尚\n待公司股东大会审议批准。\n192\n\n十六、其他重要事项\n1、前期会计差错更正\n（1）追溯重述法\n单位： 元\n受影响的各个比较期间报表\n会计差错更正的内容 处理程序 累积影响数\n项目名称\n（2）未来适用法\n会计差错更正的内容 批准程序 采用未来适用法的原因\n2、债务重组\n3、资产置换\n（1）非货币性资产交换\n（2）其他资产置换\n4、年金计划\n5、终止经营\n单位： 元\n归属于母公司所\n项目 收入 费用 利润总额 所得税费用 净利润 有者的终止经营\n利润\n其他说明\n6、分部信息\n（1）报告分部的确定依据与会计政策\n公司以内部组织结构、管理要求、内部报告制度等为依据确定报告分部，并以行业分部为基础确定报\n告分部。分别对医药业务、染料业务的经营业绩进行考核。与各分部共同使用的资产、负债按照规模比例\n在不同的分部之间分配。\n（2）报告分部的财务信息\n单位： 元\n193\n\n项目 医药行业 染料行业 分部间抵销 合计\n主营业务收入 1,604,117,711.02 1,546,764,954.54 225,193,759.42 2,925,688,906.14\n主营业务成本 6,064,447,216.11 657,131,007.06 211,204,035.55 6,747,198,664.47\n资产总额 1,003,573,077.78 2,269,859,610.07 1,587,108,161.71 1,449,500,049.29\n负债总额 798,878,476.78 525,463,301.92 301,605,209.78 1,022,736,568.72\n（3）公司无报告分部的，或者不能披露各报告分部的资产总额和负债总额的，应说明原因\n（4）其他说明\n7、其他对投资者决策有影响的重要交易和事项\n根据江苏省盐城市委市政府于2019年6月14日发布的《盐城市化工产业安全环保整治提升实施方案》(盐\n办〔2019〕71号)(以下简称《方案》)，要求对盐城市化工园区内所有化工生产企业进行安全环保整治提升。盐城瓯华公司配合有关部门已按照《方案》要求进行停产并做好安全环保排查评估，同时根据评估结果制\n定并实施了“一企一策”整治方案。截至本财务报表批准报出日，盐城瓯华公司为达到恢复生产的标准仍在\n对环保及安全设施进行改造，相关闲置固定资产账面价值为6,057.05万元，已计提减值准备49.95万元。\n\n8、其他\n十七、母公司财务报表主要项目注释\n1、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按组合计提坏账准 130,720, 7,187,81 123,532,2157,389,6 8,184,787 149,204,89\n100.00% 5.50% 100.00% 5.20%\n备的应收账款 059.44 5.25 44.19 87.72 .74 9.98\n其中：\n130,720, 7,187,81 123,532,2157,389,6 8,184,787 149,204,89\n合计 100.00% 5.50% 100.00% 5.20%\n059.44 5.25 44.19 87.72 .74 9.98\n按单项计提坏账准备：\n单位： 元\n194。\n\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n合并范围内关联往来组合 1,358,605.41\n账龄组合 129,361,454.03 7,187,815.25 5.56%\n合计 130,720,059.44 7,187,815.25 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n√ 适用 □ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 129,484,273.40\n1至2年 508,161.68\n2至3年 492,705.04\n3年以上 234,919.32\n3至4年 234,919.32\n合计 130,720,059.44\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n8,184,787.74 -996,972.49 7,187,815.25\n备\n合计 8,184,787.74 -996,972.49 7,187,815.25\n195。\n\n其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数\n单位名称 应收账款期末余额 坏账准备期末余额\n的比例\nACS DOBFAR S.P.A 30,318,565.17 23.19% 1,515,928.26\nFIS-FABBRICA ITALIANA\n23,576,101.39 18.04% 1,178,805.07\nSINTETICI S.P.A\nPFIZER ASIA\n19,767,647.40 15.12% 988,382.37\nMANUFACTURING PTE LTD\nBIDACHEM S.P.A 11,875,658.58 9.08% 593,782.93\nCENTRAL DE PRODUCTOS\n6,666,631.13 5.10% 333,331.56\nQUIMICOS S.A.DE C.V.\n合计 92,204,603.67 70.53%\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n2、其他应收款\n单位： 元\n项目 期末余额 期初余额\n应收股利 722,088,153.34\n196。\n\n其他应收款 467,513,480.14 320,967,765.38\n合计 467,513,480.14 1,043,055,918.72\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n台州前进公司 722,088,153.34\n合计 722,088,153.34\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n197",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "38d76c48",
        "bbc405e9",
        "2e24a2f4",
        "666cb309",
        "4ec36aa0"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3400,
      "page_number": 192,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192,
          193,
          194,
          195,
          196,
          197
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.357077",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 3400,
        "word_count": 379,
        "sentence_count": 104,
        "chinese_char_count": 1683,
        "readability_score": 0.0,
        "information_density": 0.058823529411764705,
        "coherence_score": 0.6959205895583604,
        "standards_profile_summary": {}
      },
      "quality_score": 0.798,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收",
        "固定资产"
      ]
    },
    {
      "chunk_id": "55ff37e1",
      "content": "（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n往来款 459,656,754.37 320,145,265.41\n押金保证金 5,000.00 5,000.00\n应收暂付款 6,339,111.65 5,841,009.97\n应收出口退税 6,584,960.26\n其 他 63,177.77 76,177.77\n合计 472,649,004.05 326,067,453.15\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 5,099,687.77 5,099,687.77\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 35,836.14 35,836.14\n2019年12月31日余额 5,135,523.91 5,135,523.91\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 456,448,642.60\n1至2年 4,956,117.14\n2至3年 2,265,499.80\n3年以上 8,978,744.51\n3至4年 3,978,744.51\n5年以上 5,000,000.00\n合计 472,649,004.05\n198。\n\n3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n川南药业公司 往来款 261,610,250.381年以内 55.35%\n台州振港公司 往来款 176,225,865.641年以内 37.28%\nGeneVida GmbH 往来款 4,592,945.061年以内 0.97%\nGeneVida GmbH 往来款 4,934,973.061-2年 1.04%\nGeneVida GmbH 往来款 2,227,737.932-3年 0.47%\nGeneVida GmbH 往来款 3,913,444.513年以上 0.84%\nPFIZER ASIA\nMANUFACTURING 应收暂付款 5,000,000.003年以上 1.06% 5,000,000.00\nPTE LTD\n台州前进公司 往来款 4,170,214.351年以内 0.88%\n合计 -- 462,675,430.93 -- 97.89% 5,000,000.00\n199。\n\n6）涉及政府补助的应收款项\n单位： 元\n预计收取的时间、金额\n单位名称 政府补助项目名称 期末余额 期末账龄\n及依据\n7）因金融资产转移而终止确认的其他应收款\n8）转移其他应收款且继续涉入形成的资产、负债金额\n其他说明：\n3、长期股权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n对子公司投资 3,215,993,761.24 3,215,993,761.24 3,213,363,387.02 3,213,363,387.02\n对联营、合营企\n54,774,633.09 23,347,592.79 31,427,040.30 60,541,058.62 23,347,592.79 37,193,465.83\n业投资\n合计 3,270,768,394.33 23,347,592.79 3,247,420,801.54 3,273,904,445.64 23,347,592.79 3,250,556,852.85\n（1）对子公司投资\n单位： 元\n期初余额(账 本期增减变动 期末余额(账面 减值准备期末\n被投资单位\n面价值) 追加投资 减少投资 计提减值准备 其他 价值) 余额\n928,629,850.7\n川南药业公司 928,629,850.78\n8\n海翔销售公司 37,599,318.92 37,599,318.92\n上海海翔公司 5,000,000.00 5,000,000.00\nGeneVida\n8,974,808.00 8,974,808.00\nGmbH\n2,227,917,460. 2,230,547,834.\n台州前进公司 2,630,374.22\n28 50\n港翔科技公司 5,241,949.04 5,241,949.04\n3,213,363,387. 3,215,993,761.\n合计 2,630,374.22\n02 24\n200。\n\n（2）对联营、合营企业投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n权益法下 宣告发放 减值准备\n投资单位 (账面价 其他综合 其他权益 计提减值 (账面价\n追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n23,345,37 -4,811,81 18,533,55 23,347,59\n制药厂有\n3.14 4.84 8.30 2.79\n限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n37,193,46 -5,766,42 31,427,04 23,347,59\n小计\n5.83 5.53 0.30 2.79\n37,193,46 -5,766,42 31,427,04 23,347,59\n合计\n5.83 5.53 0.30 2.79\n（3）其他说明\n4、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 797,912,055.33 574,154,902.09 805,112,431.82 606,077,442.30\n其他业务 14,347,583.53 12,941,502.94 19,986,172.05 13,769,464.63\n合计 812,259,638.86 587,096,405.03 825,098,603.87 619,846,906.93\n是否已执行新收入准则\n□ 是 √ 否\n其他说明：\n5、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n成本法核算的长期股权投资收益 1,000,000,000.00\n201。\n\n权益法核算的长期股权投资收益 -5,766,425.53 -4,216,789.49\n银行理财产品投资收益 1,161,540.45 1,928,422.22\n处置金融工具取得的投资收益 -30,625.74 -1,559,950.55\n合计 -4,635,510.82 996,151,682.18\n6、其他\n十八、补充资料\n1、当期非经常性损益明细表\n√ 适用 □ 不适用\n单位： 元\n项目 金额 说明\n非流动资产处置损益 -4,150,774.97\n越权审批或无正式批准文件的税收返还、\n1,828,299.60\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70\n除上述各项之外的其他营业外收入和支出 -1,973,019.24\n减：所得税影响额 3,519,880.50\n合计 19,572,324.86 --\n对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公\n开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应\n说明原因。□ 适用 √ 不适用\n2、净资产收益率及每股收益\n每股收益\n报告期利润 加权平均净资产收益率\n基本每股收益（元/股） 稀释每股收益（元/股）\n归属于公司普通股股东的净利润 14.07% 0.48 0.48\n扣除非经常性损益后归属于公司\n13.71% 0.47 0.47\n普通股股东的净利润\n202。\n\n3、境内外会计准则下会计数据差异\n（1）同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（2）同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（3）境内外会计准则下会计数据差异原因说明，对已经境外审计机构审计的数据进行差异调节的，应注\n明该境外机构的名称\n4、其他\n203 第十三节 备查文件目录\n一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表。\n二、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。\n三、报告期内在中国证监会指定报刊上公开披露过的所有公司文件正本及公告原稿；\n四、载有公司法定代表人签名的2019年年度报告文本原件。\n五、其他备查文件。\n文件存放地：公司投资发展部\n浙江海翔药业股份有限公司\n法定代表人：杨思卫\n二零二零年一月二十二日\n204",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "e10e5096",
        "fe1b90b6",
        "b3931df4",
        "0237badf",
        "38ea36ec",
        "94641a99"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3986,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198,
          199,
          200,
          201,
          202,
          203
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.358902",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "港翔科技公司",
        "industry": null,
        "char_count": 3986,
        "word_count": 459,
        "sentence_count": 135,
        "chinese_char_count": 1696,
        "readability_score": 0.0,
        "information_density": 0.050175614651279475,
        "coherence_score": 0.5742318703698237,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7336176618163572,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "现金",
        "投资",
        "应收",
        "营业收入"
      ]
    },
    {
      "chunk_id": "20b9cdc5",
      "content": "公司本期将以下15家子公司纳入合并财务报表范围，情况详见本财务报表附注合并范围变更和其他主\n体中的权益之说明。序号 子公司名称 公司简称\n1 浙江海翔川南药业有限公司 川南药业公司\n2 浙江海翔药业销售有限公司 海翔销售公司\n3 上海海翔医药科技发展有限公司 上海海翔公司\n4 台州港翔科技有限公司 港翔科技公司\n5 港翔国际控股(香港)有限公司 香港港翔公司\n6 GeneVida GmbH GeneVida GmbH\n7 GANGXIANG INTERNATIONAL HOLDINGSGANGXIANG(SINGAPORE)\n（SINGAPORE）PTE.LTD\n8 台州港翔化工有限公司 港翔化工公司\n9 台州市前进化工有限公司 台州前进公司\n10 台州市振港染料化工有限公司 台州振港公司\n11 盐城市瓯华化学工业有限公司 盐城瓯华公司\n12 台州市东旭医化设备有限公司 台州东旭公司\n13 盐城市瓯华化工研究院有限公司 瓯华研究院\n14 盐城市瓯华环保科技有限公司 瓯华环保公司\n15 浙江盛嘉环保有限公司 盛嘉环保公司\n100。\n\n四、财务报表的编制基础\n1、编制基础\n本公司财务报表以持续经营为编制基础。2、持续经营\n本公司不存在导致对报告期末起12个月内的持续经营能力产生重大疑虑的事项或情况。五、重要会计政策及会计估计\n具体会计政策和会计估计提示：\n本公司根据实际生产经营特点针对应收款项坏账准备计提、固定资产折旧、无形资产摊销、收入确认\n等交易或事项制定了具体会计政策和会计估计。\n\n1、遵循企业会计准则的声明\n本公司所编制的财务报表符合企业会计准则的要求，真实、完整地反映了公司的财务状况、经营成果\n和现金流量等有关信息。2、会计期间\n会计年度自公历1月1日起至12月31日止。3、营业周期\n公司经营业务的营业周期较短，以12个月作为资产和负债的流动性划分标准。\n\n4、记账本位币\n采用人民币为记账本位币。5、同一控制下和非同一控制下企业合并的会计处理方法\n1. 同一控制下企业合并的会计处理方法\n公司在企业合并中取得的资产和负债，按照合并日被合并方在最终控制方合并财务报表中的账面价值\n计量。公司按照被合并方所有者权益在最终控制方合并财务报表中的账面价值份额与支付的合并对价账面\n价值或发行股份面值总额的差额，调整资本公积；资本公积不足冲减的，调整留存收益。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "bee13319"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 992,
      "page_number": 100,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          100,
          101
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.361420",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 992,
        "word_count": 73,
        "sentence_count": 13,
        "chinese_char_count": 745,
        "readability_score": 0.0,
        "information_density": 0.1814516129032258,
        "coherence_score": 0.724183260260626,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9004032258064516,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "现金流",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "现金",
        "应收",
        "固定资产",
        "无形资产",
        "合并",
        "营业"
      ]
    },
    {
      "chunk_id": "b0fc80f9",
      "content": "2. 非同一控制下企业合并的会计处理方法\n公司在购买日对合并成本大于合并中取得的被购买方可辨认净资产公允价值份额的差额，确认为商\n101。\n\n誉；如果合并成本小于合并中取得的被购买方可辨认净资产公允价值份额，首先对取得的被购买方各项可\n辨认资产、负债及或有负债的公允价值以及合并成本的计量进行复核，经复核后合并成本仍小于合并中取\n得的被购买方可辨认净资产公允价值份额的，其差额计入当期损益。6、合并财务报表的编制方法\n母公司将其控制的所有子公司纳入合并财务报表的合并范围。合并财务报表以母公司及其子公司的财\n务报表为基础，根据其他有关资料，由母公司按照《企业会计准则第33号——合并财务报表》编制。\n\n7、合营安排分类及共同经营会计处理方法\n1. 合营安排分为共同经营和合营企业。2. 当公司为共同经营的合营方时，确认与共同经营中利益份额相关的下列项目：\n(1) 确认单独所持有的资产，以及按持有份额确认共同持有的资产；\n(2) 确认单独所承担的负债，以及按持有份额确认共同承担的负债；\n(3) 确认出售公司享有的共同经营产出份额所产生的收入；\n(4) 按公司持有份额确认共同经营因出售资产所产生的收入；\n(5) 确认单独所发生的费用，以及按公司持有份额确认共同经营发生的费用。8、现金及现金等价物的确定标准\n列示于现金流量表中的现金是指库存现金以及可以随时用于支付的存款。\n\n现金等价物是指企业持有的\n期限短、流动性强、易于转换为已知金额现金、价值变动风险很小的投资。9、外币业务和外币报表折算\n1. 外币业务折算\n外币交易在初始确认时，采用交易发生日即期汇率的近似汇率折算为人民币金额。资产负债表日，外\n币货币性项目采用资产负债表日即期汇率折算，因汇率不同而产生的汇兑差额，除与购建符合资本化条件\n资产有关的外币专门借款本金及利息的汇兑差额外，计入当期损益；以历史成本计量的外币非货币性项目\n仍采用交易发生日即期汇率的近似汇率折算，不改变其人民币金额；以公允价值计量的外币非货币性项目，\n采用公允价值确定日的即期汇率折算，差额计入当期损益或其他综合收益。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "92d5ab85"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 879,
      "page_number": 101,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          101,
          102
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.361884",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 879,
        "word_count": 33,
        "sentence_count": 14,
        "chinese_char_count": 764,
        "readability_score": 0.0,
        "information_density": 0.21615472127417523,
        "coherence_score": 0.7289347016619744,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9476678043230944,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "现金流",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "现金",
        "投资",
        "净资产",
        "资产负债表",
        "现金流量表"
      ]
    },
    {
      "chunk_id": "2e75d2d7",
      "content": "对于外币资产和负债，如果出现短期的失衡\n情况，本公司会在必要时按市场汇率买卖外币，以确保将净风险敞口维持在可接受的水平。本公司期末外币货币性资产和负债情况详见本财务报表附注合并财务报表项目注释其他之外币货币\n性项目说明。十一、公允价值的披露\n1、以公允价值计量的资产和负债的期末公允价值\n单位： 元\n期末公允价值\n项目 第一层次公允价值计\n第二层次公允价值计量 第三层次公允价值计量 合计\n量\n一、持续的公允价值计量 -- -- -- --\n（2）权益工具投资 20,000,000.00 20,000,000.00\n185。\n\n（八）应收款项融资 74,531,666.41 74,531,666.41\n持续以公允价值计量的\n94,531,666.41 94,531,666.41\n负债总额\n二、非持续的公允价值计\n-- -- -- --\n量\n2、持续和非持续第一层次公允价值计量项目市价的确定依据\n3、持续和非持续第二层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n4、持续和非持续第三层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n5、持续的第三层次公允价值计量项目，期初与期末账面价值间的调节信息及不可观察参数敏感性分析\n1. 对于持有的应收票据，采用票面金额确定其公允价值；\n2.因被投资企业杭州寓鑫创业投资合伙企业（有限合伙）的经营环境和经营情况、财务状况未发生重\n大变化，所以公司按投资成本作为公允价值的合理估计进行计量；\n3.因被投资企业滨海宏博环境技术服务股份有限公司的经营环境和经营情况、财务状况恶化，所以公\n司以零元作为公允价值的合理估计进行计量。6、持续的公允价值计量项目，本期内发生各层级之间转换的，转换的原因及确定转换时点的政策\n7、本期内发生的估值技术变更及变更原因\n8、不以公允价值计量的金融资产和金融负债的公允价值情况\n9、其他\n十二、关联方及关联交易\n1、本企业的母公司情况\n母公司对本企业的 母公司对本企业的\n母公司名称 注册地 业务性质 注册资本\n持股比例 表决权比例\n浙江东港投资有限\n台州 投资 11,800万元 34.22% 34.22%\n公司\n本企业的母公司情况的说明\n浙江东港投资有限公司(以下简称东港投资公司)系由东港工贸集团有限公司100%持股的公司，于1998\n年7月9日在台州市工商行政管理局椒江分局登记注册，现持有统一社会信用代码为913310027046766827的\n营业执照，注册资本11,800万元。本企业最终控制方是王云富，间接通过东港投资公司持有本公司股份55,398.2587万股，直接持有本公司股份11,880万股，\n186。\n\n合计持股比例41.56%。其他说明：\n2、本企业的子公司情况\n本企业子公司的情况详见附注在其他主体中的权益之说明。3、本企业合营和联营企业情况\n本企业重要的合营或联营企业详见附注在其他主体中的权益之说明。\n\n本期与本公司发生关联方交易，或前期与本公司发生关联方交易形成余额的其他合营或联营企业情况如下：\n合营或联营企业名称 与本企业关系\n苏州第四制药厂有限公司 联营企业\n浙江高盛钢结构有限公司 联营企业\n其他说明\n4、其他关联方情况\n其他关联方名称 其他关联方与本企业关系\n浙江荣兴活性炭有限公司 控股股东之联营企业\n江西华邦药业有限公司 控股股东之联营企业\n台州艾斐科技有限公司 控股股东之联营企业\n台州市东港包装用品有限公司 控股股东之子公司\n其他说明\n5、关联交易情况\n（1）购销商品、提供和接受劳务的关联交易\n采购商品/接受劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 获批的交易额度 是否超过交易额度 上期发生额\n浙江高盛钢结构有\n工程建造 1,275,826.79\n限公司\n浙江荣兴活性炭有\n原材料 2,423,957.10 28,000,000.00否 3,914,565.88\n限公司\n江西华邦药业有限 原料药及医药中\n23,998,498.62 50,000,000.00否 809,858.52\n公司 间体\n台州市东港包装用\n原材料 4,393.37\n品有限公司\n187。\n\n出售商品/提供劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n苏州第四制药厂有限公司 原料药及医药中间体 261,061.95 504,310.34\n台州艾斐科技有限公司 电费 404,095.99 678,615.69\n江西华邦药业有限公司 设备销售 255,603.43\n江西华邦药业有限公司 原料药及医药中间体 44,247.79\n购销商品、提供和接受劳务的关联交易说明\n（2）关联受托管理/承包及委托管理/出包情况\n本公司受托管理/承包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名受托/承包资产类 托管收益/承包收 本期确认的托管\n受托/承包起始日受托/承包终止日\n称 称 型 益定价依据 收益/承包收益\n关联托管/承包情况说明\n本公司委托管理/出包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名委托/出包资产类 托管费/出包费定 本期确认的托管\n委托/出包起始日委托/出包终止日\n称 称 型 价依据 费/出包费\n关联管理/出包情况说明\n（3）关联租赁情况\n本公司作为出租方：\n单位： 元\n承租方名称 租赁资产种类 本期确认的租赁收入 上期确认的租赁收入\n本公司作为承租方：\n单位： 元\n出租方名称 租赁资产种类 本期确认的租赁费 上期确认的租赁费\n关联租赁情况说明\n（4）关联担保情况\n本公司作为担保方\n单位： 元\n被担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n本公司作为被担保方\n单位： 元\n188。\n\n担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n关联担保情况说明\n（5）关联方资金拆借\n单位： 元\n关联方 拆借金额 起始日 到期日 说明\n拆入\n拆出\n（6）关联方资产转让、债务重组情况\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n（7）关键管理人员报酬\n单位： 元\n项目 本期发生额 上期发生额\n关键管理人员报酬 8,152,800.00 7,761,100.00\n（8）其他关联交易\n6、关联方应收应付款项\n（1）应收项目\n单位： 元\n期末余额 期初余额\n项目名称 关联方\n账面余额 坏账准备 账面余额 坏账准备\n台州艾斐科技有限\n应收账款 63,451.70 3,172.59\n公司\n江西华邦药业有限\n应收账款 9,682.64 2,904.79\n公司\n小 计 9,682.64 2,904.79 63,451.70 3,172.59\n（2）应付项目\n单位： 元\n项目名称 关联方 期末账面余额 期初账面余额\n189\n\n应付账款 浙江荣兴活性炭有限公司 171,167.79 816,333.28\n应付账款 浙江高盛钢结构有限公司 169,367.59 154,247.59\n应付账款 江西华邦药业有限公司 51,086.20\n台州市东港包装用品有限公\n应付账款 4,393.37\n司\n小 计 344,928.75 1,021,667.07\n7、关联方承诺\n8、其他\n十三、股份支付\n1、股份支付总体情况\n√ 适用 □ 不适用\n单位： 元\n公司本期授予的各项权益工具总额 0.00\n公司本期行权的各项权益工具总额 18,146,500.00\n公司本期失效的各项权益工具总额 105,000.00\n公司期末发行在外的股票期权行权价格的范围和合同剩余期限 0\n公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 0\n其他说明\n根据公司2015 年第一次临时股东大会审议通过的《浙江海翔药业股份有限公司限制性股票激励计划\n（草案）》及其摘要(以下简称激励计划)，公司首次授予激励对象限制性股票3,471.5万股，预留部分限制\n性股票380万股。根据公司2015年度股东大会决议审议通过的2015年度利润分配方案，上述限制性股票数\n量调整为7,703万股。截至2018年12月31日累计回购已获授但尚未解锁的限制性股票429.2万股，累计解锁\n限制性股票5,459.15万股。\n\n根据公司2019年3月13日第五届董事会第二十一次会议决议，公司2018年度绩效考核已满足行权条件，\n对首次及预留授予激励对象持有的限制性股票1,814.65万股予以解锁。2、以权益结算的股份支付情况\n√ 适用 □ 不适用\n单位： 元\n授予日权益工具公允价值的确定方法 根据布莱克-斯科尔模型来计算期权的理论价值\n可行权权益工具数量的确定依据 无\n本期估计与上期估计有重大差异的原因 无\n190。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "982e5d57",
        "476451fe",
        "3e97a146",
        "13f6be1a",
        "80350609"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3568,
      "page_number": 185,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7000000000000001,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185,
          186,
          187,
          188,
          189,
          190
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.362302",
        "report_type": "财务报表附注",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "因被投资企业",
        "industry": null,
        "char_count": 3568,
        "word_count": 335,
        "sentence_count": 68,
        "chinese_char_count": 2433,
        "readability_score": 0.0,
        "information_density": 0.05605381165919282,
        "coherence_score": 0.8050088421599928,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8727578475336324,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "应收",
        "应付",
        "合并"
      ]
    },
    {
      "chunk_id": "da2eda41",
      "content": "以权益结算的股份支付计入资本公积的累计金额 174,493,817.84\n本期以权益结算的股份支付确认的费用总额 7,113,749.53\n其他说明\n3、以现金结算的股份支付情况\n□ 适用 √ 不适用\n4、股份支付的修改、终止情况\n5、其他\n十四、承诺及或有事项\n1、重要承诺事项\n资产负债表日存在的重要承诺\n(一) 重要承诺事项\n1. 已签订的尚未履行或尚未完全履行的对外投资合同及有关财务支出\n根据公司2016年9月28日第四届董事会第三十次会议决议，公司拟使用自有资金投资医健战略投资基\n金上海佳添冠投资合伙企业(有限合伙)。上海佳添冠投资合伙企业(有限合伙)目标规模20亿元，公司拟以自\n有资金不超过2亿元人民币认购该基金，截至本财务报表批准报出日，公司尚未实际出资。2. 根据公司2019年2月14日第五届董事会第二十次会议决议，台州前进公司拟与内蒙古生力资源（集\n团）有限责任公司共同投资设立内蒙古科菲化工有限公司(以下简称科菲化工公司)，科菲化工公司一期计\n划投资总额为50,000.00万元，其中台州前进公司计划投资24,500.00万元，占科菲化工公司49.00%的股权。\n\n根据公司2020年1月22日第六届董事会第二次会议，公司决定终止对科菲化工公司的投资。(二) 前期承诺履行情况\n1. 根据2015年10月30日公司2015年第三次临时股东大会审议通过的《关于公司非公开发行 A 股股票\n方案（修订稿）的议案》，公司非公开发行人民币普通股(A股)股票99,890,023股，募集资金净额为\n1,014,403,606.71元，上述募集资金全部用于投资建设以下项目：\n项目名称 项目实施主体 总投资额 募集资金计划投\n(万元) 入(万元)\n原料药及中间体CMO中心扩建项目 川南药业公司 46,034.58 40,000.00\n年产30亿片（粒）固体制剂技改项目 本公司 35,852.00 35,000.00\n医药综合研发中心 川南药业公司 15,073.00 15,000.00\n医药中试车间技改项目 本公司 9,256.00 9,000.00\n环保设施改造项目 本公司及子公司 15,502.00 14,000.00\n合 计 121,717.58 113,000.00\n截至2019年12月31日，本公司已使用募集资金直接投入上述项目44,720.30万元，根据公司2019年3月\n11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资项目并将结余募集资金用于永\n久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目的市场环境已发生较大变化，公司\n终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。2. 根据公司2018年第一次临时股东大会及第三次临时股东大会，公司拟以集中竞价交易方式回购公司\n191。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "3aad9ac6",
        "a9205a23"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1211,
      "page_number": 191,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.364296",
        "report_type": "财务报表附注",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "有限责任公司共同投资设立内蒙古科菲化工有限公司",
        "industry": null,
        "char_count": 1211,
        "word_count": 73,
        "sentence_count": 30,
        "chinese_char_count": 787,
        "readability_score": 0.0,
        "information_density": 0.1568951279933939,
        "coherence_score": 0.6942227682227682,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8599504541701073,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "财务",
        "报表",
        "20亿元",
        "2亿元",
        "000.00万元"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "现金",
        "投资",
        "资产负债表",
        "资本公积",
        "股权",
        "股份"
      ]
    },
    {
      "chunk_id": "61b29498",
      "content": "支付银行借款保证金 900,000.00\n合计 20,278,463.47 590,452,772.90\n支付的其他与筹资活动有关的现金说明：\n79、现金流量表补充资料\n（1）现金流量表补充资料\n单位： 元\n补充资料 本期金额 上期金额\n1．将净利润调节为经营活动现金流量： -- --\n净利润 770,782,185.09 605,003,820.78\n加：资产减值准备 14,240,855.70 18,867,903.52\n固定资产折旧、油气资产折耗、生产性生\n172,822,169.17 161,268,842.88\n物资产折旧\n无形资产摊销 30,277,923.13 31,103,003.79\n长期待摊费用摊销 223,651.32 162,421.24\n处置固定资产、无形资产和其他长期资产\n-244,580.94 -659,231.88\n的损失（收益以“－”号填列）\n固定资产报废损失（收益以“－”号填列） 4,395,355.91 761,505.33\n公允价值变动损失（收益以“－”号填列） -5,010,265.70\n财务费用（收益以“－”号填列） -7,552,032.06 -14,604,700.41\n投资损失（收益以“－”号填列） 15,240,062.55 9,359,378.55\n递延所得税资产减少（增加以“－”号填列） 5,147,540.13 -4,649,984.56\n递延所得税负债增加（减少以“－”号填列） 22,351,927.43 8,175,428.28\n存货的减少（增加以“－”号填列） 52,643,000.47 -99,308,067.53\n经营性应收项目的减少（增加以“－”号填\n-276,602,622.13 -71,443,627.33\n列）\n经营性应付项目的增加（减少以“－”号填\n-191,326,340.46 152,422,810.70\n列）\n经营活动产生的现金流量净额 612,399,095.31 791,449,237.66\n2．不涉及现金收支的重大投资和筹资活\n-- --\n动：\n3．现金及现金等价物净变动情况： -- --\n现金的期末余额 1,525,777,908.45 1,069,208,275.60\n减：现金的期初余额 1,069,208,275.60 2,245,777,296.21\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n172。\n\n（2）本期支付的取得子公司的现金净额\n单位： 元\n金额\n其中： --\n其中： --\n其中： --\n其他说明：\n（3）本期收到的处置子公司的现金净额\n单位： 元\n金额\n其中： --\n其中： --\n其中： --\n其他说明：\n（4）现金和现金等价物的构成\n单位： 元\n项目 期末余额 期初余额\n一、现金 1,525,777,908.45 1,069,208,275.60\n其中：库存现金 131,545.99 195,522.60\n可随时用于支付的银行存款 1,525,298,726.49 1,068,623,694.25\n可随时用于支付的其他货币资金 347,635.97 389,058.75\n三、期末现金及现金等价物余额 1,525,777,908.45 1,069,208,275.60\n其他说明：\n(1) 不涉及现金收支的商业汇票背书转让金额\n项 目 本期数 上期数\n背书转让的商业汇票金额 1,203,398,004.56 1,019,486,370.21\n其中：支付货款 763,162,260.55 663,084,419.99\n支付固定资产等长期资产购置款 440,235,744.01 356,401,950.22\n(2) 不属于现金及现金等价物的货币资金情况的说明\n项 目 期末数 期初数\n质押的定期存款 34,316,000.00\n结构性存款 750,000,000.00\n银行承兑汇票保证金 30,797,464.00 102,564,848.73\n173。\n\n小 计 30,797,464.00 886,880,848.73\n80、所有者权益变动表项目注释\n说明对上年期末余额进行调整的“其他”项目名称及调整金额等事项：\n81、所有权或使用权受到限制的资产\n单位： 元\n项目 期末账面价值 受限原因\n货币资金 30,797,464.00开立银行承兑汇票\n固定资产 22,554,937.46银行融资抵押\n无形资产 10,291,182.19银行融资抵押\n合计 63,643,583.65 --\n其他说明：\n82、外币货币性项目\n（1）外币货币性项目\n单位： 元\n项目 期末外币余额 折算汇率 期末折算人民币余额\n货币资金 -- -- 214,734,480.07\n其中：美元 30,636,838.136.9762 213,728,710.16\n欧元 40,660.307.8155 317,780.57\n港币\n英镑 75,189.279.1501 687,989.34\n应收账款 -- -- 146,207,835.41\n其中：美元 20,665,705.866.9762 144,168,097.22\n欧元 260,986.277.8155 2,039,738.19\n港币\n其他应收款 2,859.22\n其中：欧元 365.847.8155 2,859.22\n应付账款 5,296,661.70\n其中：美元 663,385.606.9762 4,627,910.62\n欧元 85,567.287.8155 668,751.08\n其他应付款 8,199,889.22\n174。\n\n其中：美元 789,910.036.9762 5,510,570.35\n欧元 342,262.847.8155 2,674,955.23\n英镑 1,569.789.1501 14,363.64\n长期借款 -- --\n其中：美元\n欧元\n港币\n其他说明：\n（2）境外经营实体说明，包括对于重要的境外经营实体，应披露其境外主要经营地、记账本位币及选择\n依据，记账本位币发生变化的还应披露原因。√ 适用 □ 不适用\n子公司 子公司类型 境外主要经营地 记账 选择依据\n本位币\nGeneVida GmbH 全资子公司 德国 欧元 根据公司经营所处经济环境选择\nGANGXIANG（SINGAPORE） 全资子公司 新加坡 人民币 根据公司经营所处经济环境选择\n香港港翔公司 全资子公司 香港 人民币 根据公司经营所处经济环境选择\n83、套期\n按照套期类别披露套期项目及相关套期工具、被套期风险的定性和定量信息：\n84、政府补助\n（1）政府补助基本情况\n单位： 元\n种类 金额 列报项目 计入当期损益的金额\n（2）政府补助退回情况\n□ 适用 √ 不适用\n其他说明：\n(1) 明细情况\n1) 与资产相关的政府补助\n项 目 期初递延收益 本期新增补助 本期摊销 期末递延收益 本期摊销 说明\n列报项目\n175。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "aee2dd2d",
        "5cda9b24",
        "e0c05d21",
        "b06beb2d"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2893,
      "page_number": 172,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172,
          173,
          174,
          175
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.365014",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2893,
        "word_count": 301,
        "sentence_count": 109,
        "chinese_char_count": 1098,
        "readability_score": 0.0,
        "information_density": 0.06567576909782233,
        "coherence_score": 0.40433566433566426,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7518147251987556,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收",
        "应付",
        "存货"
      ]
    },
    {
      "chunk_id": "33e91743",
      "content": "年产400吨碳青霉烯类抗生 5,695,281.12 1,423,820.28 4,271,460.84 其他收益\n素关键中间体4-AA项目\n年产1吨瑞格列奈、10吨卡洛 235,862.40 117,931.20 117,931.20 其他收益\n芬、10吨阿托伐醌、50吨\nT1620、300吨聚卡波菲钙、\n300吨4,4'-二氟二苯甲酮、100\n吨奈韦拉平产业化项目\n催化净化处理塔建设项目 140,000.00 30,000.00 110,000.00 其他收益\n年产50吨培南类产品及扩建 132,000.00 48,000.00 84,000.00 其他收益\n厂房技改项目\n企业技术中心创新能力建设 133,333.33 40,000.00 93,333.33 其他收益\n项目\n年产8亿元(粒)口服固体制剂 7,065,200.00 997,440.00 6,067,760.00 其他收益\n项目\n临海市创新驱动加快推进工 1,042,718.40 208,543.68 834,174.72 其他收益\n业经济转型升级政策\n省级工业与信息化专项资金 632,766.12 92,599.92 540,166.20 其他收益\n回收溶剂循环化技改项目\n省工业化和信息化深度融合 457,675.28 66,169.92 391,505.36 其他收益\n示范试点区财政补助\n浙江省化学原料药基地椒江 263,333.33 40,000.00 223,333.33 其他收益\n区块循环化改造项目补助资\n金\n年产2吨盐酸阿莫罗芬、20吨 2,090,683.87 281,889.96 1,808,793.91 其他收益\n阿特来马来酸盐、5吨多尼培\n南、20吨美罗培南、5吨比阿\n培南、60吨PHE产业化项目\n(续建)\n年产15000吨环保型活性艳 850,000.00 100,000.00 750,000.00 其他收益\n蓝KN-R商品染料技改项目\n大品种药物的生产技术改造- 860,416.67 2,000,000.00 291,265.91 2,569,150.76 其他收益\n美罗培南原料药绿色合成技\n术改造\n临海医化园区循环化改造项 490,000.00 105,000.00 385,000.00 其他收益\n目\n南洋涂—固废减量化处置项 2,286,832.98 246,999.96 2,039,833.02 其他收益\n目\n年产400吨MAP、100吨OA、 11,962,166.31 10,000,000.00 1,490,999.91 20,471,166.40 其他收益\n200吨DA、100吨甲砜霉素、\n10吨联苯双酯产业化新项目\n年产580吨柳氮磺胺吡啶产 2,115,735.00 248,910.00 1,866,825.00 其他收益\n业化项目\n176。\n\n清洁生产循环利用及三废综 4,800,000.00 600,000.00 4,200,000.00 其他收益\n合治理提升项目\n年产15500吨活性染料产业 1,296,000.00 1,296,000.00 其他收益\n升级及配套项目\n孵化器车间技改项目 793,220.34 81,355.92 711,864.42 其他收益\n浙江省化学原料药基地椒江 400,000.00 10,000.00 390,000.00 其他收益\n区块循环化改造项目补助资\n金项目补助\n年产700吨M-562关键中间体 500,000.00 33,333.33 466,666.67 其他收益\n产业一体化项目\n小 计 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n2) 与收益相关，且用于补偿公司已发生的相关成本费用或损失的政府补助\n项 目 金额 列报项目 说明\n税费返还 1,828,299.60 其他收益 临政办发〔2018〕166号\n财政专项基金 4,150,682.78 其他收益 台财企发〔2019〕34号、临财企〔2018〕\n55号、台财企发〔2018〕27号、椒区\n委发〔2019〕18号等\n政府奖励 14,486,841.50 其他收益 椒商务〔2018〕59号、椒商务〔2019〕\n51号、台政办函[2019]14号、椒江委\n发〔2019〕18号等\n科技补助 116,841.00 其他收益 台科〔2019〕87号等\n小 计 20,582,664.88\n(2) 本期计入当期损益的政府补助金额为27,136,924.87元。85、其他\n八、合并范围的变更\n1、非同一控制下企业合并\n（1）本期发生的非同一控制下企业合并\n单位： 元\n购买日至期 购买日至期\n被购买方名 股权取得时 股权取得成 股权取得比 股权取得方 购买日的确\n购买日 末被购买方 末被购买方\n称 点 本 例 式 定依据\n的收入 的净利润\n其他说明：\n（2）合并成本及商誉\n单位： 元\n177。\n\n合并成本\n合并成本公允价值的确定方法、或有对价及其变动的说明：\n大额商誉形成的主要原因：\n其他说明：\n（3）被购买方于购买日可辨认资产、负债\n单位： 元\n购买日公允价值 购买日账面价值\n可辨认资产、负债公允价值的确定方法：\n企业合并中承担的被购买方的或有负债：\n其他说明：\n（4）购买日之前持有的股权按照公允价值重新计量产生的利得或损失\n是否存在通过多次交易分步实现企业合并且在报告期内取得控制权的交易\n□ 是 √ 否\n（5）购买日或合并当期期末无法合理确定合并对价或被购买方可辨认资产、负债公允价值的相关说明\n（6）其他说明\n2、同一控制下企业合并\n（1）本期发生的同一控制下企业合并\n单位： 元\n合并当期期 合并当期期\n企业合并中 构成同一控 比较期间被 比较期间被\n被合并方名 合并日的确 初至合并日 初至合并日\n取得的权益 制下企业合 合并日 合并方的收 合并方的净\n称 定依据 被合并方的 被合并方的\n比例 并的依据 入 利润\n收入 净利润\n其他说明：\n（2）合并成本\n单位： 元\n合并成本\n或有对价及其变动的说明：\n其他说明：\n178\n\n（3）合并日被合并方资产、负债的账面价值\n单位： 元\n合并日 上期期末\n企业合并中承担的被合并方的或有负债：\n其他说明：\n3、反向购买\n交易基本信息、交易构成反向购买的依据、上市公司保留的资产、负债是否构成业务及其依据、合并成本的确定、按照权益\n性交易处理时调整权益的金额及其计算：\n4、处置子公司\n是否存在单次处置对子公司投资即丧失控制权的情形\n□ 是 √ 否\n是否存在通过多次交易分步处置对子公司投资且在本期丧失控制权的情形\n□ 是 √ 否\n5、其他原因的合并范围变动\n说明其他原因导致的合并范围变动（如，新设子公司、清算子公司等）及其相关情况：\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n6、其他\n九、在其他主体中的权益\n1、在子公司中的权益\n（1）企业集团的构成\n持股比例\n子公司名称 主要经营地 注册地 业务性质 取得方式\n直接 间接\n川南药业公司 台州市 台州市 医药制造 100.00% 设立\n海翔销售公司 台州市 台州市 医药销售 100.00% 设立\n上海海翔公司 上海市 上海市 技术研发 100.00% 设立\n179。\n\n台州东旭公司 台州市 台州市 设备制造 100.00% 设立\nGeneVida GmbH 德国多特蒙德 德国多特蒙德 医药销售 100.00% 设立\nGANGXIANG\n新加坡 新加坡 贸易 100.00% 设立\n（SINGAPORE）\n港翔化工公司 台州市 台州市 化工销售 100.00% 设立\n瓯华环保公司 盐城市 盐城市 技术研发 100.00% 设立\n盛嘉环保公司 台州市 台州市 技术研发 100.00% 设立\n非同一控制下企\n香港港翔公司 香港 香港 贸易 100.00%\n业合并\n非同一控制下企\n港翔科技公司 台州市 台州市 化工销售 100.00%\n业合并\n非同一控制下企\n台州前进公司 台州市 台州市 化工制造 100.00%\n业合并\n非同一控制下企\n台州振港公司 台州市 台州市 化工制造 9.27% 90.73%\n业合并\n非同一控制下企\n盐城瓯华公司 盐城市 盐城市 化工制造 100.00%\n业合并\n非同一控制下企\n瓯华研究院 盐城市 盐城市 技术研发 100.00%\n业合并\n在子公司的持股比例不同于表决权比例的说明：\n持有半数或以下表决权但仍控制被投资单位、以及持有半数以上表决权但不控制被投资单位的依据：\n对于纳入合并范围的重要的结构化主体，控制的依据：\n确定公司是代理人还是委托人的依据：\n其他说明：\n（2）重要的非全资子公司\n单位： 元\n本期归属于少数股东的 本期向少数股东宣告分\n子公司名称 少数股东持股比例 期末少数股东权益余额\n损益 派的股利\n子公司少数股东的持股比例不同于表决权比例的说明：\n其他说明：\n（3）重要非全资子公司的主要财务信息\n单位： 元\n期末余额 期初余额\n子公司\n流动资 非流动 资产合 流动负 非流动 负债合 流动资 非流动 资产合 流动负 非流动 负债合\n名称\n产 资产 计 债 负债 计 产 资产 计 债 负债 计\n180。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "b8ef424f",
        "22233eaf",
        "6601f973",
        "65c8625b"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 3842,
      "page_number": 176,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176,
          177,
          178,
          179,
          180
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.366677",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔化工公司",
        "industry": null,
        "char_count": 3842,
        "word_count": 460,
        "sentence_count": 98,
        "chinese_char_count": 2061,
        "readability_score": 0.0,
        "information_density": 0.052056220718375845,
        "coherence_score": 0.8013632831302526,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7683498178032274,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营",
        "财务",
        "8亿元"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "商誉",
        "净利润"
      ]
    },
    {
      "chunk_id": "5b871825",
      "content": "单位： 元\n本期发生额 上期发生额\n子公司名称 综合收益总 经营活动现 综合收益总 经营活动现\n营业收入 净利润 营业收入 净利润\n额 金流量 额 金流量\n其他说明：\n（4）使用企业集团资产和清偿企业集团债务的重大限制\n（5）向纳入合并财务报表范围的结构化主体提供的财务支持或其他支持\n其他说明：\n2、在子公司的所有者权益份额发生变化且仍控制子公司的交易\n（1）在子公司所有者权益份额发生变化的情况说明\n（2）交易对于少数股东权益及归属于母公司所有者权益的影响\n单位： 元\n其他说明\n3、在合营安排或联营企业中的权益\n（1）重要的合营企业或联营企业\n持股比例 对合营企业或联\n合营企业或联营\n主要经营地 注册地 业务性质 营企业投资的会\n企业名称 直接 间接\n计处理方法\n苏州第四制药厂\n常熟 常熟 医药制造 32.66% 权益法核算\n有限公司\n在合营企业或联营企业的持股比例不同于表决权比例的说明：\n持有20%以下表决权但具有重大影响，或者持有20%或以上表决权但不具有重大影响的依据：\n（2）重要合营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n其他说明\n181。\n\n（3）重要联营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n苏州第四制药厂有限公司 苏州第四制药厂有限公司\n流动资产 29,519,105.76 25,072,727.50\n非流动资产 84,757,893.18 93,352,602.90\n资产合计 114,276,998.94 118,425,330.40\n流动负债 36,442,141.82 25,462,418.24\n非流动负债 21,400,000.00 22,000,000.00\n负债合计 57,842,141.82 47,462,418.24\n归属于母公司股东权益 56,434,857.12 71,167,909.30\n按持股比例计算的净资产份额 18,431,624.34 23,243,439.18\n--其他 -297,151.93 -297,151.93\n对联营企业权益投资的账面价值 18,134,472.41 22,946,287.25\n营业收入 57,010,459.03 39,434,028.51\n净利润 -14,733,052.18 -10,672,428.70\n综合收益总额 -14,733,052.18 -10,672,428.70\n其他说明\n（4）不重要的合营企业和联营企业的汇总财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n合营企业： -- --\n投资账面价值合计 29,744,910.02 43,141,852.54\n下列各项按持股比例计算的合计数 -- --\n--净利润 -11,947,734.96 -3,438,323.72\n--综合收益总额 -11,947,734.96 -3,438,323.72\n联营企业： -- --\n下列各项按持股比例计算的合计数 -- --\n其他说明\n182。\n\n（5）合营企业或联营企业向本公司转移资金的能力存在重大限制的说明\n（6）合营企业或联营企业发生的超额亏损\n单位： 元\n累积未确认前期累计认的损 本期未确认的损失（或本期分\n合营企业或联营企业名称 本期末累积未确认的损失\n失 享的净利润）\n其他说明\n（7）与合营企业投资相关的未确认承诺\n（8）与合营企业或联营企业投资相关的或有负债\n4、重要的共同经营\n持股比例/享有的份额\n共同经营名称 主要经营地 注册地 业务性质\n直接 间接\n在共同经营中的持股比例或享有的份额不同于表决权比例的说明：\n共同经营为单独主体的，分类为共同经营的依据：\n其他说明\n5、在未纳入合并财务报表范围的结构化主体中的权益\n未纳入合并财务报表范围的结构化主体的相关说明：\n6、其他\n十、与金融工具相关的风险\n本公司从事风险管理的目标是在风险和收益之间取得平衡，将风险对本公司经营业绩的负面影响降至\n最低水平，使股东和其他权益投资者的利益最大化。基于该风险管理目标，本公司风险管理的基本策略是\n确认和分析本公司面临的各种风险，建立适当的风险承受底线和进行风险管理，并及时可靠地对各种风险\n进行监督，将风险控制在限定的范围内。本公司在日常活动中面临各种与金融工具相关的风险，主要包括信用风险、流动性风险及市场风险。\n\n管理层已审议并批准管理这些风险的政策，概括如下。(一) 信用风险\n信用风险，是指金融工具的一方不能履行义务，造成另一方发生财务损失的风险。1. 信用风险管理实务\n(1) 信用风险的评价方法\n公司在每个资产负债表日评估相关金融工具的信用风险自初始确认后是否已显著增加。\n\n在确定信用风\n险自初始确认后是否显著增加时，公司考虑在无须付出不必要的额外成本或努力即可获得合理且有依据的\n信息，包括基于历史数据的定性和定量分析、外部信用风险评级以及前瞻性信息。公司以单项金融工具或\n者具有相似信用风险特征的金融工具组合为基础，通过比较金融工具在资产负债表日发生违约的风险与在\n183。",
      "chunk_type": "text_group",
      "parent_id": null,
      "child_ids": [
        "7ed84545",
        "d553b711"
      ],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2105,
      "page_number": 181,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181,
          182,
          183
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.368885",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2105,
        "word_count": 175,
        "sentence_count": 44,
        "chinese_char_count": 1359,
        "readability_score": 0.0,
        "information_density": 0.09501187648456057,
        "coherence_score": 0.7093686495349711,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8582422802850356,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "营业收入",
        "净利润",
        "净资产"
      ]
    }
  ],
  "children": [
    {
      "chunk_id": "27342050",
      "content": " | 2019年 | 2018年 | 本年比上年增减 | 2017年\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "7e0484a5",
      "child_ids": [],
      "sibling_ids": [
        "7b39e477",
        "6462a9db",
        "9b736d33",
        "a3a23618",
        "eadd823a"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 385,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181649",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 85,
        "word_count": 9,
        "sentence_count": 0,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7439313984168865,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "7b39e477",
      "content": "营业收入（元） | 2,941,412,770.30 | 2,718,608,796.51 | 8.20% | 2,308,922,170.29",
      "chunk_type": "table_group",
      "parent_id": "7e0484a5",
      "child_ids": [],
      "sibling_ids": [
        "27342050",
        "6462a9db",
        "9b736d33",
        "a3a23618",
        "eadd823a"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 672,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业收入",
          "营业"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181670",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 72,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 5,
        "readability_score": 0.0,
        "information_density": 0.4166666666666667,
        "coherence_score": 0.2982,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7439313984168865,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业收入",
        "营业"
      ]
    },
    {
      "chunk_id": "6462a9db",
      "content": "归属于上市公司股东的净利润 |  |  |  | \n | 770,782,185.09 | 605,003,820.78 | 27.40% | 342,217,155.60\n（元） |  |  |  | \n |  |  |  | \n归属于上市公司股东的扣除非经 |  |  |  | \n | 751,209,860.23 | 604,944,470.09 | 24.18% | 301,310,316.13\n常性损益的净利润（元） |  |  |  | \n |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "7e0484a5",
      "child_ids": [],
      "sibling_ids": [
        "27342050",
        "7b39e477",
        "9b736d33",
        "a3a23618",
        "eadd823a"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1140,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "净利润",
          "股东"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181702",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 240,
        "word_count": 44,
        "sentence_count": 8,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.125,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7439313984168865,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "净利润",
        "股东"
      ]
    },
    {
      "chunk_id": "9b736d33",
      "content": "经营活动产生的现金流量净额 |  |  |  | \n | 612,399,095.31 | 791,449,237.66 | -22.62% | 118,141,514.53\n（元） |  |  |  | \n |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "7e0484a5",
      "child_ids": [],
      "sibling_ids": [
        "27342050",
        "7b39e477",
        "6462a9db",
        "a3a23618",
        "eadd823a"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1316,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "经营活动产生的现金流量"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181785",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 116,
        "word_count": 22,
        "sentence_count": 4,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.25862068965517243,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7439313984168865,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "经营活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "a3a23618",
      "content": "基本每股收益（元/股） | 0.48 | 0.38 | 26.32% | 0.22\n稀释每股收益（元/股） | 0.48 | 0.38 | 26.32% | 0.21",
      "chunk_type": "table_group",
      "parent_id": "7e0484a5",
      "child_ids": [],
      "sibling_ids": [
        "27342050",
        "7b39e477",
        "6462a9db",
        "9b736d33",
        "eadd823a"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1583,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "每股",
          "每股收益"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181804",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 83,
        "word_count": 18,
        "sentence_count": 8,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.24096385542168677,
        "coherence_score": 0.32766666666666666,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7439313984168865,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "每股",
        "每股收益"
      ]
    },
    {
      "chunk_id": "eadd823a",
      "content": "加权平均净资产收益率 | 14.07% | 11.35% | 2.72% | 6.90%\n | 2019年末 | 2018年末 | 本年末比上年末增减 | 2017年末\n总资产（元） | 6,747,198,664.47 | 7,035,373,344.57 | -4.10% | 7,466,927,438.54",
      "chunk_type": "table_group",
      "parent_id": "7e0484a5",
      "child_ids": [],
      "sibling_ids": [
        "27342050",
        "7b39e477",
        "6462a9db",
        "9b736d33",
        "a3a23618"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1957,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "净资产"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181828",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 157,
        "word_count": 26,
        "sentence_count": 8,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.12738853503184713,
        "coherence_score": 0.3523333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7439313984168865,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "净资产"
      ]
    },
    {
      "chunk_id": "2896b2fb",
      "content": " | 第一季度 | 第二季度 | 第三季度 | 第四季度\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "91815ffb",
      "child_ids": [],
      "sibling_ids": [
        "29bf3e0a",
        "1b17b8c5",
        "48a0e5eb"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 379,
      "page_number": 8,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181968",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 79,
        "word_count": 9,
        "sentence_count": 0,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.573545945945946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "29bf3e0a",
      "content": "营业收入 | 831,903,896.72 | 900,629,910.88 | 643,422,185.88 | 565,456,776.82",
      "chunk_type": "table_group",
      "parent_id": "91815ffb",
      "child_ids": [],
      "sibling_ids": [
        "2896b2fb",
        "1b17b8c5",
        "48a0e5eb"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 672,
      "page_number": 8,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业收入",
          "营业"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.181987",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 72,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 4,
        "readability_score": 0.0,
        "information_density": 0.4166666666666667,
        "coherence_score": 0.2982,
        "standards_profile_summary": {}
      },
      "quality_score": 0.573545945945946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业收入",
        "营业"
      ]
    },
    {
      "chunk_id": "1b17b8c5",
      "content": "归属于上市公司股东的净利润 | 202,484,692.73 | 293,308,368.91 | 194,299,384.33 | 80,689,739.12\n归属于上市公司股东的扣除非经 |  |  |  | \n | 193,305,262.65 | 289,682,381.16 | 190,626,850.03 | 77,595,366.39\n常性损益的净利润 |  |  |  | \n |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "91815ffb",
      "child_ids": [],
      "sibling_ids": [
        "2896b2fb",
        "29bf3e0a",
        "48a0e5eb"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1109,
      "page_number": 8,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "净利润",
          "股东"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182018",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 209,
        "word_count": 31,
        "sentence_count": 8,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.14354066985645936,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.573545945945946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "净利润",
        "股东"
      ]
    },
    {
      "chunk_id": "48a0e5eb",
      "content": "经营活动产生的现金流量净额 | 121,163,063.50 | 182,750,885.24 | 145,547,827.28 | 162,937,319.29",
      "chunk_type": "table_group",
      "parent_id": "91815ffb",
      "child_ids": [],
      "sibling_ids": [
        "2896b2fb",
        "29bf3e0a",
        "1b17b8c5"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1281,
      "page_number": 8,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "经营活动产生的现金流量"
        ],
        "time_periods": [
          "一",
          "三",
          "二"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182055",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 81,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.37037037037037035,
        "coherence_score": 0.3036,
        "standards_profile_summary": {}
      },
      "quality_score": 0.573545945945946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "经营活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "45a8a636",
      "content": "除同公司正常经营业务相关的有效套期保 |  |  |  | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "ed68d6a9",
      "child_ids": [],
      "sibling_ids": [
        "c916a52a",
        "f2d60fb1",
        "3ef4156f",
        "7f771917",
        "f69a06b2",
        "ab8914d9",
        "b1986928",
        "36df5def"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 381,
      "page_number": 9,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "营业",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          9
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182186",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 81,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.24691358024691357,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7690329670329671,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "3ef4156f",
      "content": "产生的公允价值变动损益，以及处置交易 |  | -449,486.55 | -5,010,265.70 | ",
      "chunk_type": "table_group",
      "parent_id": "ed68d6a9",
      "child_ids": [],
      "sibling_ids": [
        "45a8a636",
        "c916a52a",
        "f2d60fb1",
        "7f771917",
        "f69a06b2",
        "ab8914d9",
        "b1986928",
        "36df5def"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1254,
      "page_number": 9,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "公允价值",
          "价值",
          "公允价值变动损益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          9
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182227",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 54,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 17,
        "readability_score": 0.0,
        "information_density": 0.5555555555555556,
        "coherence_score": 0.30900000000000005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7690329670329671,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "公允价值",
        "价值",
        "公允价值变动损益"
      ]
    },
    {
      "chunk_id": "b1986928",
      "content": "除上述各项之外的其他营业外收入和支出 | -1,973,019.24 | -12,795,318.78 | 2,111,133.99 | ",
      "chunk_type": "table_group",
      "parent_id": "ed68d6a9",
      "child_ids": [],
      "sibling_ids": [
        "45a8a636",
        "c916a52a",
        "f2d60fb1",
        "3ef4156f",
        "7f771917",
        "f69a06b2",
        "ab8914d9",
        "36df5def"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2469,
      "page_number": 9,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          9
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182275",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 69,
        "word_count": 8,
        "sentence_count": 3,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.2898550724637682,
        "coherence_score": 0.30674999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7690329670329671,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业"
      ]
    },
    {
      "chunk_id": "36df5def",
      "content": "减：所得税影响额 | 3,519,880.50 | 1,409,621.19 | 822,552.74 | \n合计 | 19,572,324.86 | 59,350.69 | 40,906,839.47 | --",
      "chunk_type": "table_group",
      "parent_id": "ed68d6a9",
      "child_ids": [],
      "sibling_ids": [
        "45a8a636",
        "c916a52a",
        "f2d60fb1",
        "3ef4156f",
        "7f771917",
        "f69a06b2",
        "ab8914d9",
        "b1986928"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2806,
      "page_number": 9,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          9
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182294",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 106,
        "word_count": 17,
        "sentence_count": 6,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.09433962264150943,
        "coherence_score": 0.3454285714285714,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7690329670329671,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税"
      ]
    },
    {
      "chunk_id": "9e4cb574",
      "content": " | 2019年 |  | 2018年 |  | \n--------------------------------------------------\n |  |  |  |  | 同比增减",
      "chunk_type": "table_group",
      "parent_id": "accb05d8",
      "child_ids": [],
      "sibling_ids": [
        "0608ba8a"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 396,
      "page_number": 15,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          15
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182551",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4410036401456058,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0608ba8a",
      "content": " | 金额 | 占营业收入比重 | 金额 | 占营业收入比重 | \n |  |  |  |  | \n营业收入合计 | 2,941,412,770.30 | 100% | 2,718,608,796.51 | 100% | 8.20%\n分行业 |  |  |  |  | \n医药 | 1,608,858,743.47 | 54.70% | 1,441,591,423.51 | 53.03% | 11.60%\n染料 | 1,316,830,162.67 | 44.77% | 1,249,940,574.56 | 45.98% | 5.35%\n其他 | 15,723,864.16 | 0.53% | 27,076,798.44 | 1.00% | -41.93%\n分产品 |  |  |  |  | \n原料药 | 1,020,477,644.34 | 34.69% | 1,033,340,734.78 | 38.01% | -1.24%\n医药中间体 | 583,792,425.63 | 19.85% | 405,506,789.40 | 14.92% | 43.97%\n制剂 | 4,588,673.50 | 0.16% | 2,743,899.33 | 0.10% | 67.23%",
      "chunk_type": "table_group",
      "parent_id": "accb05d8",
      "child_ids": [],
      "sibling_ids": [
        "9e4cb574"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 1144,
      "page_number": 15,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业收入",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          15
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182603",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 544,
        "word_count": 103,
        "sentence_count": 33,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.0551470588235294,
        "coherence_score": 0.31799999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4410036401456058,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业收入",
        "营业"
      ]
    },
    {
      "chunk_id": "475c8be5",
      "content": " |  |  |  | 营业收入比上年 | 营业成本比上年 | 毛利率比上年同\n--------------------------------------------------\n | 营业收入 | 营业成本 | 毛利率 |  |  | \n |  |  |  | 同期增减 | 同期增减 | 期增减\n |  |  |  |  |  | \n分行业 |  |  |  |  |  | \n医药 | 1,608,858,743.47 | 983,149,430.95 | 38.89% | 11.60% | 1.30% | 6.23%\n染料 | 1,316,830,162.67 | 465,697,259.49 | 64.63% | 5.40% | -10.70% | 6.34%\n其他 | 15,723,864.16 | 14,312,670.59 | 8.97% | -41.90% | -27.90% | -17.67%\n分产品 |  |  |  |  |  | \n原料药 | 1,020,477,644.34 | 652,198,278.33 | 36.09% | -1.20% | -6.10% | 3.30%\n医药中间体 | 583,792,425.63 | 328,224,382.60 | 43.78% | 44.00% | 20.30% | 11.06%\n制剂 | 4,588,673.50 | 2,726,770.03 | 40.58% | 67.20% | -20.50% | 65.65%\n染料 | 973,070,914.24 | 312,738,811.13 | 67.86% | 15.20% | -1.80% | 5.56%\n染料中间体 | 343,759,248.43 | 152,958,448.36 | 55.50% | -15.20% | -24.60% | 5.56%\n其他 | 15,723,864.16 | 14,312,670.59 | 8.97% | -41.90% | -27.90% | -17.67%\n分地区 |  |  |  |  |  | \n国内 | 1,512,860,024.18 | 745,641,007.79 | 50.71% | 8.80% | -8.00% | 8.96%\n国外 | 1,428,552,746.12 | 717,518,353.25 | 49.77% | 7.60% | 2.20% | 2.63%",
      "chunk_type": "table_group",
      "parent_id": "9ce1abc4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1343,
      "page_number": 16,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 19,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "成本",
          "营业收入",
          "营业成本",
          "毛利率"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          16
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.182911",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1043,
        "word_count": 198,
        "sentence_count": 66,
        "chinese_char_count": 81,
        "readability_score": 0.0,
        "information_density": 0.05752636625119847,
        "coherence_score": 0.3167014925373134,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5066315116650687,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "营业收入",
        "营业成本",
        "毛利率",
        "营业"
      ]
    },
    {
      "chunk_id": "8c52a050",
      "content": " | 2019年 | 2018年 | 变动比例\n--------------------------------------------------\n研发人员数量（人） | 443 | 405 | 9.38%\n研发人员数量占比 | 13.45% | 12.75% | 0.70%\n研发投入金额（元） | 122,548,224.53 | 111,304,662.07 | 10.10%",
      "chunk_type": "table_group",
      "parent_id": "2aa37234",
      "child_ids": [],
      "sibling_ids": [
        "488c5f96"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 492,
      "page_number": 19,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183322",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 192,
        "word_count": 28,
        "sentence_count": 7,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.052083333333333336,
        "coherence_score": 0.54,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5586499001996008,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "488c5f96",
      "content": "研发投入占营业收入比例 | 4.17% | 4.09% | 0.08%\n研发投入资本化的金额（元） | 0.00 | 0.00 | 0.00%\n资本化研发投入占研发投入 |  |  | \n | 0.00% | 0.00% | 0.00%\n的比例 |  |  | \n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "2aa37234",
      "child_ids": [],
      "sibling_ids": [
        "8c52a050"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 741,
      "page_number": 19,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业收入",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183355",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 141,
        "word_count": 31,
        "sentence_count": 9,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.2127659574468085,
        "coherence_score": 0.34229999999999994,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5586499001996008,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业收入",
        "营业"
      ]
    },
    {
      "chunk_id": "5d5682df",
      "content": "项目 | 2019年 | 2018年 | 同比增减\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "865437d0",
        "65258f3e",
        "e787af75",
        "2e6ffc4c",
        "96eb2483",
        "766f0e4d",
        "e4783ee0"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 376,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183549",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 8,
        "sentence_count": 0,
        "chinese_char_count": 8,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "865437d0",
      "content": "经营活动现金流入小计 | 2,374,777,732.18 | 2,809,734,855.49 | -15.48%\n经营活动现金流出小计 | 1,762,378,636.87 | 2,018,285,617.83 | -12.68%",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "65258f3e",
        "e787af75",
        "2e6ffc4c",
        "96eb2483",
        "766f0e4d",
        "e4783ee0"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 717,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "经营活动现金流"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183570",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 117,
        "word_count": 14,
        "sentence_count": 6,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.25641025641025644,
        "coherence_score": 0.3501428571428572,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "经营活动现金流"
      ]
    },
    {
      "chunk_id": "65258f3e",
      "content": "经营活动产生的现金流量净 |  |  | \n | 612,399,095.31 | 791,449,237.66 | -22.62%\n额 |  |  | \n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "865437d0",
        "e787af75",
        "2e6ffc4c",
        "96eb2483",
        "766f0e4d",
        "e4783ee0"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 987,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "经营活动产生的现金流量"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183589",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 87,
        "word_count": 17,
        "sentence_count": 3,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.3448275862068966,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "经营活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "e787af75",
      "content": "投资活动现金流入小计 | 1,177,235,296.80 | 963,819,628.62 | 22.14%\n投资活动现金流出小计 | 440,639,977.78 | 2,061,240,331.20 | -78.62%",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "865437d0",
        "65258f3e",
        "2e6ffc4c",
        "96eb2483",
        "766f0e4d",
        "e4783ee0"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1312,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "投资活动"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183609",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 14,
        "sentence_count": 6,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.26785714285714285,
        "coherence_score": 0.348,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "投资活动"
      ]
    },
    {
      "chunk_id": "2e6ffc4c",
      "content": "投资活动产生的现金流量净 | 736,595,319.02 | -1,097,420,702.58 | \n |  |  | -167.10%\n额 |  |  | \n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "865437d0",
        "65258f3e",
        "e787af75",
        "96eb2483",
        "766f0e4d",
        "e4783ee0"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1591,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "投资活动",
          "投资活动产生的现金流量"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183627",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 91,
        "word_count": 17,
        "sentence_count": 3,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.4395604395604395,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "投资活动",
        "投资活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "96eb2483",
      "content": "筹资活动现金流入小计 | 285,000,000.00 | 1,388,743,300.00 | -79.48%\n筹资活动现金流出小计 | 1,187,336,603.58 | 2,295,021,451.90 | -48.26%",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "865437d0",
        "65258f3e",
        "e787af75",
        "2e6ffc4c",
        "766f0e4d",
        "e4783ee0"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1915,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "筹资活动"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183647",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 115,
        "word_count": 14,
        "sentence_count": 6,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.1739130434782609,
        "coherence_score": 0.3492857142857143,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "筹资活动"
      ]
    },
    {
      "chunk_id": "766f0e4d",
      "content": "筹资活动产生的现金流量净 | -902,336,603.58 | -906,278,151.90 | \n |  |  | -0.43%\n额 |  |  | \n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "865437d0",
        "65258f3e",
        "e787af75",
        "2e6ffc4c",
        "96eb2483",
        "e4783ee0"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2188,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "筹资活动",
          "筹资活动产生的现金流量"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183665",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 88,
        "word_count": 17,
        "sentence_count": 3,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.34090909090909094,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "筹资活动",
        "筹资活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "e4783ee0",
      "content": "现金及现金等价物净增加额 | 456,569,632.85 | -1,176,569,020.61 | -138.81%",
      "chunk_type": "table_group",
      "parent_id": "e04e42bf",
      "child_ids": [],
      "sibling_ids": [
        "5d5682df",
        "865437d0",
        "65258f3e",
        "e787af75",
        "2e6ffc4c",
        "96eb2483",
        "766f0e4d"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2460,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "现金及现金等价物"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.183680",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 60,
        "word_count": 7,
        "sentence_count": 3,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.33333333333333337,
        "coherence_score": 0.30000000000000004,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4640770252324037,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "现金及现金等价物"
      ]
    },
    {
      "chunk_id": "332682b7",
      "content": "公司名称 | 公司类型 | 主要业务 | 注册资本 | 总资产 | 净资产 | 营业收入 | 营业利润 | 净利润\n--------------------------------------------------\n浙江海翔药 |  |  |  |  |  |  |  | \n |  | 货物及技术 | 30,000,000.0 | 69,541,379.7 | 69,007,694.1 |  | -1,190,555.1 | -1,177,557.0\n业销售有限 | 子公司 |  |  |  |  | 6,399,758.49 |  | \n |  | 进出口 | 0 | 5 | 3 |  | 0 | 5\n公司 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n浙江海翔川 |  |  |  |  |  |  |  | \n |  | 医药制造及 |  | 1,905,943,80 | 1,307,615,66 | 1,278,861,76 | 204,310,101. | 183,572,535.\n南药业有限 | 子公司 |  | 740000000 |  |  |  |  | \n |  | 货物进出口 |  | 5.66 | 6.90 | 2.53 | 35 | 16\n公司 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n上海海翔医 |  |  |  |  |  |  |  | \n |  | 医药化工技 |  |  |  | 16,566,791.9 |  | \n药科技发展 | 子公司 |  | 5,000,000.00 | 7,712,899.66 | 5,961,858.15 |  | 1,609,827.17 | 1,416,778.77\n |  | 术开发 |  |  |  | 9 |  | \n有限公司 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | 工原料、化 |  |  |  |  |  | \n台州港翔科 |  | 工机械及配 |  |  |  |  |  | \n | 子公司 |  | 5,000,000.00 | 5,444,685.96 | 5,116,968.43 | 0.00 | -143,703.23 | -145,514.30\n技有限公司 |  | 件、五金批 |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | 发、零售 |  |  |  |  |  | \n |  | 主要产品染 |  |  |  |  |  | \n |  | 料、染料中 |  |  |  |  |  | \n台州市前进 |  |  |  |  |  |  |  | \n |  | 间体、溴盐 | 304,000,000. | 1,540,527,12 | 1,254,548,70 | 1,202,406,88 | 485,937,936. | 418,599,011.\n化工有限公 | 子公司 |  |  |  |  |  |  | \n |  | 制造、销售 | 00 | 2.83 | 0.45 | 0.92 | 39 | 39\n司 |  |  |  |  |  |  |  | \n |  | 货物及技术 |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | 进出口 |  |  |  |  |  | \n |  | 医药中间体 |  |  |  |  |  | \n台州市振港 |  | 及化工产品 |  |  |  |  |  | \n |  |  | 110,000,000. | 933,575,895. | 617,871,041. | 783,594,897. | 128,045,956. | 89,296,052.8\n染料化工有 | 子公司 | 制造，销售 |  |  |  |  |  | \n |  |  | 00 | 73 | 59 | 92 | 93 | 4\n限公司 |  | 货物及技术 |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | 进出口 |  |  |  |  |  | \n盐城市瓯华 |  |  |  |  |  |  |  | \n |  | DCB、1-氨基 | 19,778,647.3 | 203,873,894. | 186,550,175. | 65,214,784.2 | -48,941,877. | -48,959,944.\n化学工业有 | 子公司 |  |  |  |  |  |  | \n |  | 蒽醌生产 | 7 | 28 | 49 | 5 | 12 | 21\n限公司 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n盐城市瓯华 |  | 化工产品研 |  |  |  |  |  | \n化工研究院 | 子公司 | 发及其技术 | 1,080,000.00 | 1,071,232.47 | 1,071,232.47 |  | -724.90 | -724.90\n有限公司 |  | 转让 |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "2287f5cd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 2528,
      "page_number": 25,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 53,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入",
          "利润",
          "营业收入",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          25
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184148",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 2228,
        "word_count": 559,
        "sentence_count": 46,
        "chinese_char_count": 263,
        "readability_score": 0.0,
        "information_density": 0.03590664272890485,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7354129263913824,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "利润",
        "营业收入",
        "净利润",
        "营业利润",
        "净资产",
        "营业"
      ]
    },
    {
      "chunk_id": "c25307aa",
      "content": " |  |  | 产\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "f1774b12",
      "child_ids": [],
      "sibling_ids": [
        "faa8af50",
        "5a247d55",
        "0afef70c",
        "42cad80f",
        "e5f31e7e",
        "34209814",
        "b7b9da4a",
        "e7723898",
        "cfb442fa"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 361,
      "page_number": 33,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184336",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 61,
        "word_count": 5,
        "sentence_count": 0,
        "chinese_char_count": 1,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6809742738589212,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "42cad80f",
      "content": "应收账款 | 贷款和应收款项 | 479,537,782.06 | 以摊余成本计量的金融资\n产\n其他应收款 | 贷款和应收款项 | 10,817,853.96 | 以摊余成本计量的金融资\n产",
      "chunk_type": "table_group",
      "parent_id": "f1774b12",
      "child_ids": [],
      "sibling_ids": [
        "c25307aa",
        "faa8af50",
        "5a247d55",
        "0afef70c",
        "e5f31e7e",
        "34209814",
        "b7b9da4a",
        "e7723898",
        "cfb442fa"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1595,
      "page_number": 33,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "应收",
          "融资",
          "应收款项"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184390",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 95,
        "word_count": 16,
        "sentence_count": 2,
        "chinese_char_count": 47,
        "readability_score": 0.0,
        "information_density": 0.42105263157894735,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6809742738589212,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "应收",
        "融资",
        "应收款项"
      ]
    },
    {
      "chunk_id": "34209814",
      "content": "行理财产品 | 可供出售金融资产 | 150,000,000.00 | 以公允价值计量且其变动\n计入当期损益\n可供出售金融资\n产 | 可供出售金融资产 | 1,800,000.00 | 以公允价值计量且其变动",
      "chunk_type": "table_group",
      "parent_id": "f1774b12",
      "child_ids": [],
      "sibling_ids": [
        "c25307aa",
        "faa8af50",
        "5a247d55",
        "0afef70c",
        "42cad80f",
        "e5f31e7e",
        "b7b9da4a",
        "e7723898",
        "cfb442fa"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2204,
      "page_number": 33,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184422",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 104,
        "word_count": 16,
        "sentence_count": 2,
        "chinese_char_count": 57,
        "readability_score": 0.0,
        "information_density": 0.3846153846153846,
        "coherence_score": 0.5691666666666666,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6809742738589212,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "e7723898",
      "content": "应付票据 | 其他金融负债 | 490,006,533.85 | 以摊余成本计量的金融负\n债\n应付账款 | 其他金融负债 | 301,908,929.93 | 以摊余成本计量的金融负\n债",
      "chunk_type": "table_group",
      "parent_id": "f1774b12",
      "child_ids": [],
      "sibling_ids": [
        "c25307aa",
        "faa8af50",
        "5a247d55",
        "0afef70c",
        "42cad80f",
        "e5f31e7e",
        "34209814",
        "b7b9da4a",
        "cfb442fa"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2793,
      "page_number": 33,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "成本",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184454",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 93,
        "word_count": 16,
        "sentence_count": 2,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.3225806451612903,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6809742738589212,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "成本",
        "应付"
      ]
    },
    {
      "chunk_id": "ae85be09",
      "content": "内部控制评价报告全文披露日期 | 2020年01月23日 | \n--------------------------------------------------\n | 详见本公司于2020年1月23日在巨潮资讯网披露的《2019年度内部控制自我评 | \n内部控制评价报告全文披露索引 |  | \n | 价报告》 | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "e15d3ec9",
      "child_ids": [],
      "sibling_ids": [
        "07817199",
        "83f9d57c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 467,
      "page_number": 70,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告",
          "披露"
        ],
        "time_periods": [
          "2019",
          "2020-01",
          "2020-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          70
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184628",
        "report_type": null,
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 167,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 61,
        "readability_score": 0.0,
        "information_density": 0.11976047904191618,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7536740740740742,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "07817199",
      "content": "纳入评价范围单位资产总额占公司合并 |  | \n | 100.00% | \n财务报表资产总额的比例 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "e15d3ec9",
      "child_ids": [],
      "sibling_ids": [
        "ae85be09",
        "83f9d57c"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 662,
      "page_number": 70,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "合并"
        ],
        "time_periods": [
          "2019",
          "2020-01",
          "2020-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          70
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184671",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 62,
        "word_count": 11,
        "sentence_count": 1,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.32258064516129037,
        "coherence_score": 0.42999999999999994,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7536740740740742,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "合并"
      ]
    },
    {
      "chunk_id": "83f9d57c",
      "content": "纳入评价范围单位营业收入占公司合并 |  | \n | 100.00% | \n财务报表营业收入的比例 |  | \n |  | \n缺陷认定标准 |  | \n类别 | 财务报告 | 非财务报告",
      "chunk_type": "table_group",
      "parent_id": "e15d3ec9",
      "child_ids": [],
      "sibling_ids": [
        "ae85be09",
        "07817199"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 993,
      "page_number": 70,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业收入",
          "合并",
          "营业",
          "报告"
        ],
        "time_periods": [
          "2019",
          "2020-01",
          "2020-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          70
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184691",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 93,
        "word_count": 19,
        "sentence_count": 1,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.6451612903225806,
        "coherence_score": 0.3845454545454545,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7536740740740742,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业收入",
        "合并",
        "营业",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "e421143b",
      "content": " | 重大缺陷 1、利润总额潜在错报：错报≥ | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "e4f55902",
        "d9ee5f38"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 376,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "利润总额"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184834",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 5,
        "sentence_count": 0,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.26315789473684215,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "2843c03f",
      "content": " | 利润总额的10%或4000万元 2、资产总额 | \n | 潜在错报：错报≥资产总额的1% 3、经营 | ",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "e421143b",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "e4f55902",
        "d9ee5f38"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 655,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "利润",
          "利润总额",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184850",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 55,
        "word_count": 8,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.7272727272727273,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "利润",
        "利润总额",
        "经营"
      ]
    },
    {
      "chunk_id": "dec0894b",
      "content": " | 2%； 重要缺陷 1、利润总额潜在错报： | \n | 错报≥利润总额的5%<利润总额的10%或 | 重大缺陷非财务报告内部控制缺陷导\n | 利润总额2000万元≤错报<利润总额4000 | 致的直接财产损失金额≥利润总额的",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "e421143b",
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "e4f55902",
        "d9ee5f38"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1614,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "利润总额",
          "报告",
          "财务报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184893",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 114,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 68,
        "readability_score": 0.0,
        "information_density": 0.3508771929824562,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "利润总额",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "9fc26a80",
      "content": " | 万元 2、资产总额潜在错报：资产总额的 | 10%；重要缺陷利润总额的10%＞非财\n定量标准 | 0.5%≤错报<资产总额的1% 3、经营收 | 务报告内部控制缺陷导致的直接财产",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "e421143b",
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "e4f55902",
        "d9ee5f38"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1892,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "利润",
          "利润总额",
          "经营",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184914",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 92,
        "word_count": 11,
        "sentence_count": 1,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.5434782608695652,
        "coherence_score": 0.7761538461538462,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "利润",
        "利润总额",
        "经营",
        "报告"
      ]
    },
    {
      "chunk_id": "d0c20324",
      "content": " | 般缺陷 1、利润总额潜在错报：错报<利润 | \n | 总额的5%或错报<利润总额的2000万元 | ",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "e421143b",
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "06fcf9b3",
        "e4f55902",
        "d9ee5f38"
      ],
      "position": 9,
      "start_char": 2700,
      "end_char": 3053,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "利润总额"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184969",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 53,
        "word_count": 7,
        "sentence_count": 0,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.3773584905660377,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "e4f55902",
      "content": " | 0.5% 3、经营收入潜在错报：错报<营 | \n | 业收入的1.5% 4、所有者权益潜在错 | ",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "e421143b",
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "d9ee5f38"
      ],
      "position": 11,
      "start_char": 3300,
      "end_char": 3652,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "收入",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.184994",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 52,
        "word_count": 8,
        "sentence_count": 2,
        "chinese_char_count": 23,
        "readability_score": 0.0,
        "information_density": 0.5769230769230769,
        "coherence_score": 0.26199999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "收入",
        "经营"
      ]
    },
    {
      "chunk_id": "d9ee5f38",
      "content": " | 报：错报<所有者权益的1% | \n财务报告重大缺陷数量（个） | 0 | \n非财务报告重大缺陷数量（个） | 0 | \n财务报告重要缺陷数量（个） | 0 | \n非财务报告重要缺陷数量（个） | 0 | ",
      "chunk_type": "table_group",
      "parent_id": "8a13ff51",
      "child_ids": [],
      "sibling_ids": [
        "e421143b",
        "2843c03f",
        "7d0d3f6e",
        "1f14560b",
        "dec0894b",
        "9fc26a80",
        "1d9e61f8",
        "34891d11",
        "11b607ec",
        "d0c20324",
        "06fcf9b3",
        "e4f55902"
      ],
      "position": 12,
      "start_char": 3600,
      "end_char": 4005,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "报告",
          "财务报告",
          "所有者权益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.185014",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 105,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 55,
        "readability_score": 0.0,
        "information_density": 0.38095238095238093,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8549148099606816,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "报告",
        "财务报告",
        "所有者权益"
      ]
    },
    {
      "chunk_id": "422979b4",
      "content": "开发支出 |  | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "08411be3",
      "child_ids": [],
      "sibling_ids": [
        "9a967750",
        "b021e7e4",
        "d356db58",
        "0919af1d",
        "169be968",
        "4c91af4a",
        "3356d636",
        "1d4b50ae",
        "be63768c",
        "ffaa3b3e",
        "2d287494",
        "a8cf2b7e",
        "fbee28a0",
        "77a903d4",
        "38b0374e",
        "1d727939",
        "d12a39d9",
        "9600fe13",
        "f24174d7",
        "2c473c1f",
        "d091fc89",
        "3822210b",
        "50e7b266"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 361,
      "page_number": 79,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "开发支出"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          79
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.185394",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 61,
        "word_count": 4,
        "sentence_count": 0,
        "chinese_char_count": 4,
        "readability_score": 0.0,
        "information_density": 0.1639344262295082,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6993971631205673,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "开发支出"
      ]
    },
    {
      "chunk_id": "0919af1d",
      "content": "其他非流动资产 | 450,000.00 | 515,993.37\n非流动资产合计 | 3,684,768,846.71 | 3,301,778,337.96\n资产总计 | 6,747,198,664.47 | 7,035,373,344.57",
      "chunk_type": "table_group",
      "parent_id": "08411be3",
      "child_ids": [],
      "sibling_ids": [
        "422979b4",
        "9a967750",
        "b021e7e4",
        "d356db58",
        "169be968",
        "4c91af4a",
        "3356d636",
        "1d4b50ae",
        "be63768c",
        "ffaa3b3e",
        "2d287494",
        "a8cf2b7e",
        "fbee28a0",
        "77a903d4",
        "38b0374e",
        "1d727939",
        "d12a39d9",
        "9600fe13",
        "f24174d7",
        "2c473c1f",
        "d091fc89",
        "3822210b",
        "50e7b266"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1622,
      "page_number": 79,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          79
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.185454",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 122,
        "word_count": 15,
        "sentence_count": 6,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0819672131147541,
        "coherence_score": 0.3522857142857143,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6993971631205673,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "4c91af4a",
      "content": "短期借款 | 200,267,029.59 | 598,700,000.00\n向中央银行借款 |  | ",
      "chunk_type": "table_group",
      "parent_id": "08411be3",
      "child_ids": [],
      "sibling_ids": [
        "422979b4",
        "9a967750",
        "b021e7e4",
        "d356db58",
        "0919af1d",
        "169be968",
        "3356d636",
        "1d4b50ae",
        "be63768c",
        "ffaa3b3e",
        "2d287494",
        "a8cf2b7e",
        "fbee28a0",
        "77a903d4",
        "38b0374e",
        "1d727939",
        "d12a39d9",
        "9600fe13",
        "f24174d7",
        "2c473c1f",
        "d091fc89",
        "3822210b",
        "50e7b266"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2152,
      "page_number": 79,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "借款",
          "短期借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          79
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.185480",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 52,
        "word_count": 8,
        "sentence_count": 2,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.3846153846153846,
        "coherence_score": 0.352,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6993971631205673,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "借款",
        "短期借款"
      ]
    },
    {
      "chunk_id": "1d4b50ae",
      "content": "交易性金融负债 |  | \n以公允价值计量且其变动计入当 |  | \n |  | \n期损益的金融负债 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "08411be3",
      "child_ids": [],
      "sibling_ids": [
        "422979b4",
        "9a967750",
        "b021e7e4",
        "d356db58",
        "0919af1d",
        "169be968",
        "4c91af4a",
        "3356d636",
        "be63768c",
        "ffaa3b3e",
        "2d287494",
        "a8cf2b7e",
        "fbee28a0",
        "77a903d4",
        "38b0374e",
        "1d727939",
        "d12a39d9",
        "9600fe13",
        "f24174d7",
        "2c473c1f",
        "d091fc89",
        "3822210b",
        "50e7b266"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2763,
      "page_number": 79,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          79
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.185509",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 63,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.47619047619047616,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6993971631205673,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "50e7b266",
      "content": "持有待售负债 |  | \n一年内到期的非流动负债 |  | 44,365,875.00\n其他流动负债 |  | \n流动负债合计 | 940,281,788.69 | 1,579,026,351.68",
      "chunk_type": "table_group",
      "parent_id": "08411be3",
      "child_ids": [],
      "sibling_ids": [
        "422979b4",
        "9a967750",
        "b021e7e4",
        "d356db58",
        "0919af1d",
        "169be968",
        "4c91af4a",
        "3356d636",
        "1d4b50ae",
        "be63768c",
        "ffaa3b3e",
        "2d287494",
        "a8cf2b7e",
        "fbee28a0",
        "77a903d4",
        "38b0374e",
        "1d727939",
        "d12a39d9",
        "9600fe13",
        "f24174d7",
        "2c473c1f",
        "d091fc89",
        "3822210b"
      ],
      "position": 23,
      "start_char": 6900,
      "end_char": 7299,
      "page_number": 79,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          79
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.185684",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 99,
        "word_count": 15,
        "sentence_count": 3,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.10101010101010102,
        "coherence_score": 0.46499999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6993971631205673,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债"
      ]
    },
    {
      "chunk_id": "7ac61d68",
      "content": "生产性生物资产 |  | \n--------------------------------------------------\n油气资产 |  | ",
      "chunk_type": "table_group",
      "parent_id": "7c85b643",
      "child_ids": [],
      "sibling_ids": [
        "9de73d53",
        "907221bb",
        "a8fcf491",
        "767b11d3",
        "a55c326b",
        "82a55dac",
        "f7177951",
        "13ad63e8",
        "c7639c8e",
        "7a673bc3",
        "533a69ef",
        "93473c62",
        "965996cf",
        "2a87f808",
        "a5608201",
        "7252d4d0",
        "67004a9a",
        "e88ea4ef",
        "8ec2e77d",
        "bb59ac4b",
        "4d5e3ca8",
        "8fa3423d",
        "bcac073e"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 375,
      "page_number": 82,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          82
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.186064",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 75,
        "word_count": 7,
        "sentence_count": 0,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.13333333333333333,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6979381443298969,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "f7177951",
      "content": "其他非流动资产 | 450,000.00 | \n非流动资产合计 | 3,523,330,465.50 | 3,519,853,167.02\n资产总计 | 5,422,728,523.57 | 5,912,436,388.49",
      "chunk_type": "table_group",
      "parent_id": "7c85b643",
      "child_ids": [],
      "sibling_ids": [
        "7ac61d68",
        "9de73d53",
        "907221bb",
        "a8fcf491",
        "767b11d3",
        "a55c326b",
        "82a55dac",
        "13ad63e8",
        "c7639c8e",
        "7a673bc3",
        "533a69ef",
        "93473c62",
        "965996cf",
        "2a87f808",
        "a5608201",
        "7252d4d0",
        "67004a9a",
        "e88ea4ef",
        "8ec2e77d",
        "bb59ac4b",
        "4d5e3ca8",
        "8fa3423d",
        "bcac073e"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2512,
      "page_number": 82,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          82
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.186657",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 14,
        "sentence_count": 5,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.08928571428571427,
        "coherence_score": 0.266,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6979381443298969,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "7a673bc3",
      "content": "交易性金融负债 |  | \n以公允价值计量且其变动计入当 |  | \n |  | \n期损益的金融负债 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "7c85b643",
      "child_ids": [],
      "sibling_ids": [
        "7ac61d68",
        "9de73d53",
        "907221bb",
        "a8fcf491",
        "767b11d3",
        "a55c326b",
        "82a55dac",
        "f7177951",
        "13ad63e8",
        "c7639c8e",
        "533a69ef",
        "93473c62",
        "965996cf",
        "2a87f808",
        "a5608201",
        "7252d4d0",
        "67004a9a",
        "e88ea4ef",
        "8ec2e77d",
        "bb59ac4b",
        "4d5e3ca8",
        "8fa3423d",
        "bcac073e"
      ],
      "position": 10,
      "start_char": 3000,
      "end_char": 3363,
      "page_number": 82,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          82
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.186701",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 63,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.47619047619047616,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6979381443298969,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "4d5e3ca8",
      "content": "持有待售负债 |  | \n一年内到期的非流动负债 |  | 44,365,875.00\n其他流动负债 |  | \n流动负债合计 | 523,199,915.02 | 678,420,562.15\n非流动负债： |  | ",
      "chunk_type": "table_group",
      "parent_id": "7c85b643",
      "child_ids": [],
      "sibling_ids": [
        "7ac61d68",
        "9de73d53",
        "907221bb",
        "a8fcf491",
        "767b11d3",
        "a55c326b",
        "82a55dac",
        "f7177951",
        "13ad63e8",
        "c7639c8e",
        "7a673bc3",
        "533a69ef",
        "93473c62",
        "965996cf",
        "2a87f808",
        "a5608201",
        "7252d4d0",
        "67004a9a",
        "e88ea4ef",
        "8ec2e77d",
        "bb59ac4b",
        "8fa3423d",
        "bcac073e"
      ],
      "position": 21,
      "start_char": 6300,
      "end_char": 6710,
      "page_number": 82,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          82
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.186844",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 110,
        "word_count": 18,
        "sentence_count": 3,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.09090909090909091,
        "coherence_score": 0.46499999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6979381443298969,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债"
      ]
    },
    {
      "chunk_id": "db858b50",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "d3af29f9",
      "child_ids": [],
      "sibling_ids": [
        "fc6b5a20",
        "94a06612",
        "2c574e95",
        "db111d14",
        "04864a44"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 371,
      "page_number": 83,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.186974",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.597393607305936,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "491fafbc",
      "content": "利息支出 |  | \n--------------------------------------------------\n手续费及佣金支出 |  | \n退保金 |  | \n赔付支出净额 |  | \n提取保险责任合同准备金 |  | \n |  | \n净额 |  | \n |  | \n保单红利支出 |  | \n分保费用 |  | \n税金及附加 | 26,841,009.21 | 32,182,923.43",
      "chunk_type": "table_group",
      "parent_id": "e09f3121",
      "child_ids": [],
      "sibling_ids": [
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "e9246c2f",
        "c3518769",
        "e7f7d9ff",
        "205d22fd",
        "f2a16e4f",
        "0eef19f9",
        "37ca6157",
        "24bfa4f7"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 502,
      "page_number": 84,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 12,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "红利"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187414",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 202,
        "word_count": 34,
        "sentence_count": 2,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.09900990099009901,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7595687331536388,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "红利"
      ]
    },
    {
      "chunk_id": "e9246c2f",
      "content": "财务费用 | -37,865,156.06 | -51,507,397.78\n其中：利息费用 | 15,506,676.74 | 42,594,267.08",
      "chunk_type": "table_group",
      "parent_id": "e09f3121",
      "child_ids": [],
      "sibling_ids": [
        "491fafbc",
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "c3518769",
        "e7f7d9ff",
        "205d22fd",
        "f2a16e4f",
        "0eef19f9",
        "37ca6157",
        "24bfa4f7"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1578,
      "page_number": 84,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "财务费用"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187471",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 78,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.2564102564102564,
        "coherence_score": 0.3468,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7595687331536388,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "财务费用"
      ]
    },
    {
      "chunk_id": "c3518769",
      "content": "利息收入 | 41,773,975.28 | 44,371,159.00\n加：其他收益 | 27,136,924.87 | 11,791,738.03",
      "chunk_type": "table_group",
      "parent_id": "e09f3121",
      "child_ids": [],
      "sibling_ids": [
        "491fafbc",
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "e9246c2f",
        "e7f7d9ff",
        "205d22fd",
        "f2a16e4f",
        "0eef19f9",
        "37ca6157",
        "24bfa4f7"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1875,
      "page_number": 84,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187487",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 75,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.13333333333333333,
        "coherence_score": 0.345,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7595687331536388,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "e7f7d9ff",
      "content": "投资收益（损失以“－”号填 |  | \n | -15,240,062.55 | -9,359,378.55\n列） |  | \n |  | \n其中：对联营企业和合营企业 |  | \n | -16,759,549.80 | -6,923,938.93\n的投资收益 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "e09f3121",
      "child_ids": [],
      "sibling_ids": [
        "491fafbc",
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "e9246c2f",
        "c3518769",
        "205d22fd",
        "f2a16e4f",
        "0eef19f9",
        "37ca6157",
        "24bfa4f7"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2242,
      "page_number": 84,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "投资收益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187510",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 142,
        "word_count": 24,
        "sentence_count": 4,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.14084507042253522,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7595687331536388,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "投资收益"
      ]
    },
    {
      "chunk_id": "f2a16e4f",
      "content": "资产终止确认收益 |  | \n |  | \n汇兑收益（损失以“-”号填列） |  | \n净敞口套期收益（损失以“－” |  | \n |  | \n号填列） |  | \n |  | \n公允价值变动收益（损失以 |  | \n |  | 5,010,265.70\n“－”号填列） |  | \n |  | \n信用减值损失（损失以“-”号填 |  | \n | -2,502,149.00 | \n列） |  | \n |  | \n资产减值损失（损失以“-”号填 |  | \n | -11,738,706.70 | -18,867,903.52\n列） |  | \n |  | \n资产处置收益（损失以“-”号填 |  | \n | 244,580.94 | 659,231.88\n列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "e09f3121",
      "child_ids": [],
      "sibling_ids": [
        "491fafbc",
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "e9246c2f",
        "c3518769",
        "e7f7d9ff",
        "205d22fd",
        "0eef19f9",
        "37ca6157",
        "24bfa4f7"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 3044,
      "page_number": 84,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "减值",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187563",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 344,
        "word_count": 64,
        "sentence_count": 6,
        "chinese_char_count": 81,
        "readability_score": 0.0,
        "information_density": 0.11627906976744187,
        "coherence_score": 0.59,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7595687331536388,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "减值",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "0eef19f9",
      "content": "三、营业利润（亏损以“－”号填列） | 918,821,355.42 | 710,852,435.16",
      "chunk_type": "table_group",
      "parent_id": "e09f3121",
      "child_ids": [],
      "sibling_ids": [
        "491fafbc",
        "6ea8fc22",
        "5b0d3c2c",
        "ef30b159",
        "e9246c2f",
        "c3518769",
        "e7f7d9ff",
        "205d22fd",
        "f2a16e4f",
        "37ca6157",
        "24bfa4f7"
      ],
      "position": 9,
      "start_char": 2700,
      "end_char": 3051,
      "page_number": 84,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "营业利润",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          84
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187596",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 51,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.588235294117647,
        "coherence_score": 0.30600000000000005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7595687331536388,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "营业利润",
        "营业"
      ]
    },
    {
      "chunk_id": "48eafba5",
      "content": "6.其他债权投资信用减值准 |  | \n--------------------------------------------------\n |  | \n备 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "55f8b4ec",
      "child_ids": [],
      "sibling_ids": [
        "40640f87",
        "7a2c9711",
        "3f25670a",
        "c72adac8"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 392,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187724",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 92,
        "word_count": 11,
        "sentence_count": 1,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.21739130434782608,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7408526054590571,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "减值"
      ]
    },
    {
      "chunk_id": "40640f87",
      "content": "7.现金流量套期储备 |  | \n8.外币财务报表折算差额 | 361,590.42 | 16,560.46\n9.其他 |  | ",
      "chunk_type": "table_group",
      "parent_id": "55f8b4ec",
      "child_ids": [],
      "sibling_ids": [
        "48eafba5",
        "7a2c9711",
        "3f25670a",
        "c72adac8"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 665,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187740",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 65,
        "word_count": 11,
        "sentence_count": 5,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.15384615384615383,
        "coherence_score": 0.2425,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7408526054590571,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金"
      ]
    },
    {
      "chunk_id": "3f25670a",
      "content": "七、综合收益总额 | 769,343,775.51 | 605,020,381.24\n归属于母公司所有者的综合收益 | 769,343,775.51 | \n |  | 605,020,381.24\n总额 |  | \n |  | \n归属于少数股东的综合收益总额 |  | ",
      "chunk_type": "table_group",
      "parent_id": "55f8b4ec",
      "child_ids": [],
      "sibling_ids": [
        "48eafba5",
        "40640f87",
        "7a2c9711",
        "c72adac8"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1335,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "母公司",
          "股东",
          "综合收益总额"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187776",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 135,
        "word_count": 20,
        "sentence_count": 4,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.22222222222222218,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7408526054590571,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "母公司",
        "股东",
        "综合收益总额"
      ]
    },
    {
      "chunk_id": "c72adac8",
      "content": "八、每股收益： |  | \n（一）基本每股收益 | 0.48 | 0.38\n（二）稀释每股收益 | 0.48 | 0.38",
      "chunk_type": "table_group",
      "parent_id": "55f8b4ec",
      "child_ids": [],
      "sibling_ids": [
        "48eafba5",
        "40640f87",
        "7a2c9711",
        "3f25670a"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1561,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "每股",
          "每股收益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187793",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 61,
        "word_count": 13,
        "sentence_count": 4,
        "chinese_char_count": 19,
        "readability_score": 0.0,
        "information_density": 0.3278688524590164,
        "coherence_score": 0.3366,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7408526054590571,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "每股",
        "每股收益"
      ]
    },
    {
      "chunk_id": "e01edfba",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "ed0abeaa",
      "child_ids": [],
      "sibling_ids": [
        "591d46ad",
        "adb7ea04",
        "42f94a42",
        "7aee31d9",
        "8da49c66",
        "7b94c12b",
        "a101424a",
        "3ce461b0"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 371,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187952",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7407216494845361,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "adb7ea04",
      "content": "减：营业成本 | 587,096,405.03 | 619,846,906.93\n税金及附加 | 5,519,793.76 | 6,987,907.49",
      "chunk_type": "table_group",
      "parent_id": "ed0abeaa",
      "child_ids": [],
      "sibling_ids": [
        "e01edfba",
        "591d46ad",
        "42f94a42",
        "7aee31d9",
        "8da49c66",
        "7b94c12b",
        "a101424a",
        "3ce461b0"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 976,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "营业成本",
          "营业"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.187981",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.39473684210526316,
        "coherence_score": 0.3456,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7407216494845361,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "营业成本",
        "营业"
      ]
    },
    {
      "chunk_id": "7b94c12b",
      "content": "财务费用 | -13,410,251.73 | -18,322,346.97\n其中：利息费用 | 9,198,148.55 | 23,746,817.96",
      "chunk_type": "table_group",
      "parent_id": "ed0abeaa",
      "child_ids": [],
      "sibling_ids": [
        "e01edfba",
        "591d46ad",
        "adb7ea04",
        "42f94a42",
        "7aee31d9",
        "8da49c66",
        "a101424a",
        "3ce461b0"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2177,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "财务费用"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188049",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 77,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.2597402597402597,
        "coherence_score": 0.34620000000000006,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7407216494845361,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "财务费用"
      ]
    },
    {
      "chunk_id": "a101424a",
      "content": "利息收入 | 15,402,930.57 | 21,054,583.18\n加：其他收益 | 8,727,855.85 | 2,788,654.20",
      "chunk_type": "table_group",
      "parent_id": "ed0abeaa",
      "child_ids": [],
      "sibling_ids": [
        "e01edfba",
        "591d46ad",
        "adb7ea04",
        "42f94a42",
        "7aee31d9",
        "8da49c66",
        "7b94c12b",
        "3ce461b0"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2473,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188065",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 73,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.136986301369863,
        "coherence_score": 0.3438,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7407216494845361,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "3ce461b0",
      "content": "投资收益（损失以“－”号填\n列） |  | \n | -4,635,510.82 | 996,151,682.18\n |  | \n其中：对联营企业和合营企\n业的投资收益 |  | \n | -5,766,425.53 | -4,216,789.49\n |  | ",
      "chunk_type": "table_group",
      "parent_id": "ed0abeaa",
      "child_ids": [],
      "sibling_ids": [
        "e01edfba",
        "591d46ad",
        "adb7ea04",
        "42f94a42",
        "7aee31d9",
        "8da49c66",
        "7b94c12b",
        "a101424a"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2829,
      "page_number": 86,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "投资收益"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          86
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188086",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 129,
        "word_count": 20,
        "sentence_count": 4,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.15503875968992248,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7407216494845361,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "投资收益"
      ]
    },
    {
      "chunk_id": "c5dce1fe",
      "content": "以摊余成本计量的金融 |  | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "9cf7f8f3",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "2411be7e",
        "69274b47",
        "d9948b3e"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 367,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188388",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 67,
        "word_count": 4,
        "sentence_count": 0,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.14925373134328357,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本"
      ]
    },
    {
      "chunk_id": "9cf7f8f3",
      "content": "资产终止确认收益（损失以“-”号填 |  | \n列） |  | \n净敞口套期收益（损失以 |  | \n |  | \n“－”号填列） |  | \n |  | \n公允价值变动收益（损失以 |  | \n |  | 1,406,950.55\n“－”号填列） |  | \n |  | \n信用减值损失（损失以“-”号 |  | \n | 961,136.35 | \n填列） |  | \n |  | \n资产减值损失（损失以“-”号 |  | \n | -4,457,462.80 | -4,264,339.86\n填列） |  | \n |  | \n资产处置收益（损失以“-”号 |  | \n | 187,029.94 | 278,081.30\n填列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "c5dce1fe",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "2411be7e",
        "69274b47",
        "d9948b3e"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 928,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "减值",
          "公允价值",
          "价值"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188429",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 328,
        "word_count": 62,
        "sentence_count": 6,
        "chinese_char_count": 77,
        "readability_score": 0.0,
        "information_density": 0.12195121951219512,
        "coherence_score": 0.5445454545454546,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "减值",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "2e133bc2",
      "content": "二、营业利润（亏损以“－”号填列） | 129,150,025.98 | 1,095,110,684.52",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "c5dce1fe",
        "9cf7f8f3",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "2411be7e",
        "69274b47",
        "d9948b3e"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 953,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "营业利润",
          "营业"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188452",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 53,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.5660377358490566,
        "coherence_score": 0.308,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "营业利润",
        "营业"
      ]
    },
    {
      "chunk_id": "5f536937",
      "content": "三、利润总额（亏损总额以“－”号填 |  | \n | 126,470,991.44 | 1,084,177,148.86\n列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "c5dce1fe",
        "9cf7f8f3",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "9598c76c",
        "2411be7e",
        "69274b47",
        "d9948b3e"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1876,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "利润总额"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188491",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 12,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.26315789473684215,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "2411be7e",
      "content": "四、净利润（净亏损以“－”号填列） | 112,575,451.35 | 1,086,145,333.95\n（一）持续经营净利润（净亏损 |  | \n | 112,575,451.35 | 1,086,145,333.95\n以“－”号填列） |  | \n |  | \n（二）终止经营净利润（净亏损 |  | \n |  | \n以“－”号填列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "c5dce1fe",
        "9cf7f8f3",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "69274b47",
        "d9948b3e"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2583,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "净利润",
          "经营"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188529",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 183,
        "word_count": 27,
        "sentence_count": 4,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.1639344262295082,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "净利润",
        "经营"
      ]
    },
    {
      "chunk_id": "69274b47",
      "content": "五、其他综合收益的税后净额 |  | \n（一）不能重分类进损益的其他 |  | \n |  | \n综合收益 |  | \n |  | \n1.重新计量设定受益计划 |  | \n |  | \n变动额 |  | \n |  | \n2.权益法下不能转损益的 |  | \n |  | \n其他综合收益 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "c5dce1fe",
        "9cf7f8f3",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "2411be7e",
        "d9948b3e"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2854,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 13,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "其他综合收益"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188558",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 154,
        "word_count": 33,
        "sentence_count": 2,
        "chinese_char_count": 57,
        "readability_score": 0.0,
        "information_density": 0.12987012987012986,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "其他综合收益"
      ]
    },
    {
      "chunk_id": "d9948b3e",
      "content": "3.其他权益工具投资公允 |  | \n |  | \n价值变动 |  | \n |  | \n4.企业自身信用风险公允 |  | \n |  | \n价值变动 |  | \n |  | \n5.其他 |  | \n（二）将重分类进损益的其他综 |  | \n |  | \n合收益 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "66ea691f",
      "child_ids": [],
      "sibling_ids": [
        "c5dce1fe",
        "9cf7f8f3",
        "2e133bc2",
        "ec309528",
        "666bbb39",
        "5f536937",
        "9598c76c",
        "2411be7e",
        "69274b47"
      ],
      "position": 9,
      "start_char": 2700,
      "end_char": 3143,
      "page_number": 87,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 13,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "投资",
          "价值",
          "其他权益工具"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          87
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188585",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 143,
        "word_count": 33,
        "sentence_count": 3,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.27972027972027974,
        "coherence_score": 0.49,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7725978647686833,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "投资",
        "价值",
        "其他权益工具"
      ]
    },
    {
      "chunk_id": "642cd972",
      "content": "1.权益法下可转损益的其 |  | \n--------------------------------------------------\n |  | \n他综合收益 |  | \n |  | \n2.其他债权投资公允价值 |  | \n |  | \n变动 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "eb6da782",
      "child_ids": [],
      "sibling_ids": [
        "dce24ef3",
        "2821f176",
        "2284b8b8",
        "6174ec2f"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 437,
      "page_number": 88,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "投资",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188696",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 137,
        "word_count": 21,
        "sentence_count": 2,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.291970802919708,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7757090909090909,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "投资",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "dce24ef3",
      "content": "3.可供出售金融资产公允 |  | \n |  | \n价值变动损益 |  | \n |  | \n4.金融资产重分类计入其 |  | \n |  | \n他综合收益的金额 |  | \n |  | \n5.持有至到期投资重分类 |  | \n |  | \n为可供出售金融资产损益 |  | \n |  | \n6.其他债权投资信用减值 |  | \n |  | \n准备 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "eb6da782",
      "child_ids": [],
      "sibling_ids": [
        "642cd972",
        "2821f176",
        "2284b8b8",
        "6174ec2f"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 786,
      "page_number": 88,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 16,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "减值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188726",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 186,
        "word_count": 40,
        "sentence_count": 4,
        "chinese_char_count": 67,
        "readability_score": 0.0,
        "information_density": 0.26881720430107525,
        "coherence_score": 0.34444444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7757090909090909,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "减值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "36d9ef06",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "281add89",
      "child_ids": [],
      "sibling_ids": [
        "23216a95",
        "c0d70b4e",
        "146173a4",
        "acaa180d"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 371,
      "page_number": 88,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188903",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6264226555246053,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "23216a95",
      "content": "一、经营活动产生的现金流量： |  | \n销售商品、提供劳务收到的现金 | 2,018,927,512.97 | 1,988,078,802.41\n客户存款和同业存放款项净增加 |  | \n |  | \n额 |  | \n |  | \n向中央银行借款净增加额 |  | ",
      "chunk_type": "table_group",
      "parent_id": "281add89",
      "child_ids": [],
      "sibling_ids": [
        "36d9ef06",
        "c0d70b4e",
        "146173a4",
        "acaa180d"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 734,
      "page_number": 88,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "借款"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188925",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 134,
        "word_count": 21,
        "sentence_count": 2,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.22388059701492535,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6264226555246053,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "借款"
      ]
    },
    {
      "chunk_id": "146173a4",
      "content": "收到原保险合同保费取得的现金 |  | \n收到再保业务现金净额 |  | \n保户储金及投资款净增加额 |  | \n收取利息、手续费及佣金的现金 |  | ",
      "chunk_type": "table_group",
      "parent_id": "281add89",
      "child_ids": [],
      "sibling_ids": [
        "36d9ef06",
        "23216a95",
        "c0d70b4e",
        "acaa180d"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1277,
      "page_number": 88,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.188964",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 77,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.2597402597402597,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6264226555246053,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资"
      ]
    },
    {
      "chunk_id": "9540b71e",
      "content": "代理买卖证券收到的现金净额 |  | \n--------------------------------------------------\n收到的税费返还 | 105,999,603.44 | 49,705,278.88\n收到其他与经营活动有关的现金 | 249,850,615.77 | 771,950,774.20\n经营活动现金流入小计 | 2,374,777,732.18 | 2,809,734,855.49\n购买商品、接受劳务支付的现金 | 897,240,432.80 | 913,013,009.11\n客户贷款及垫款净增加额 |  | \n存放中央银行和同业款项净增加 |  | \n |  | \n额 |  | \n |  | \n支付原保险合同赔付款项的现金 |  | \n拆出资金净增加额 |  | \n支付利息、手续费及佣金的现金 |  | \n支付保单红利的现金 |  | \n支付给职工以及为职工支付的现 |  | \n | 311,715,734.86 | 280,419,788.03\n金 |  | \n |  | \n支付的各项税费 | 269,810,257.63 | 208,588,464.73\n支付其他与经营活动有关的现金 | 283,612,211.58 | 616,264,355.96\n经营活动现金流出小计 | 1,762,378,636.87 | 2,018,285,617.83",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "ce402e4b",
        "6cab59eb",
        "0ab8d664",
        "7bf63e9b",
        "a48459e9",
        "895bc68f"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 903,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "红利",
          "税费",
          "证券"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189509",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 603,
        "word_count": 76,
        "sentence_count": 16,
        "chinese_char_count": 173,
        "readability_score": 0.0,
        "information_density": 0.08291873963515754,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "红利",
        "税费",
        "证券"
      ]
    },
    {
      "chunk_id": "4f34561d",
      "content": "处置固定资产、无形资产和其他 |  | \n | 5,019,341.20 | 4,418,098.64",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "ce402e4b",
        "6cab59eb",
        "0ab8d664",
        "7bf63e9b",
        "a48459e9",
        "895bc68f"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1851,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189587",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 51,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.588235294117647,
        "coherence_score": 0.351,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "ce402e4b",
      "content": "长期资产收回的现金净额 |  | \n |  | \n处置子公司及其他营业单位收到 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "6cab59eb",
        "0ab8d664",
        "7bf63e9b",
        "a48459e9",
        "895bc68f"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2152,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "现金",
          "营业",
          "长期"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189601",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 52,
        "word_count": 10,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.7692307692307692,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "现金",
        "营业",
        "长期"
      ]
    },
    {
      "chunk_id": "6cab59eb",
      "content": "的现金净额 |  | \n |  | \n收到其他与投资活动有关的现金 | 1,172,215,955.60 | 959,401,529.98\n投资活动现金流入小计 | 1,177,235,296.80 | 963,819,628.62",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "ce402e4b",
        "0ab8d664",
        "7bf63e9b",
        "a48459e9",
        "895bc68f"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2516,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "投资活动"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189622",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 116,
        "word_count": 15,
        "sentence_count": 4,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.25862068965517243,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "投资活动"
      ]
    },
    {
      "chunk_id": "0ab8d664",
      "content": "购建固定资产、无形资产和其他 |  | \n | 160,639,977.78 | 255,780,578.95",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "ce402e4b",
        "6cab59eb",
        "7bf63e9b",
        "a48459e9",
        "895bc68f"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2755,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189638",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 55,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.5454545454545454,
        "coherence_score": 0.355,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "a48459e9",
      "content": "投资支付的现金 | 20,000,000.00 | \n质押贷款净增加额 |  | \n取得子公司及其他营业单位支付 |  | \n |  | \n的现金净额 |  | \n |  | \n支付其他与投资活动有关的现金 | 260,000,000.00 | 1,805,459,752.25\n投资活动现金流出小计 | 440,639,977.78 | 2,061,240,331.20",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "ce402e4b",
        "6cab59eb",
        "0ab8d664",
        "7bf63e9b",
        "895bc68f"
      ],
      "position": 10,
      "start_char": 3000,
      "end_char": 3486,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "营业",
          "投资活动"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189675",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 186,
        "word_count": 27,
        "sentence_count": 5,
        "chinese_char_count": 58,
        "readability_score": 0.0,
        "information_density": 0.2150537634408602,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "营业",
        "投资活动"
      ]
    },
    {
      "chunk_id": "895bc68f",
      "content": "投资活动产生的现金流量净额 | 736,595,319.02 | -1,097,420,702.58",
      "chunk_type": "table_group",
      "parent_id": "0049f295",
      "child_ids": [],
      "sibling_ids": [
        "9540b71e",
        "6e246567",
        "651f4967",
        "368aa0ff",
        "bee885a0",
        "4f34561d",
        "ce402e4b",
        "6cab59eb",
        "0ab8d664",
        "7bf63e9b",
        "a48459e9"
      ],
      "position": 11,
      "start_char": 3300,
      "end_char": 3650,
      "page_number": 89,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "投资活动",
          "投资活动产生的现金流量"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          89
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189692",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 50,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.8,
        "coherence_score": 0.305,
        "standards_profile_summary": {}
      },
      "quality_score": 0.724417670682731,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "投资活动",
        "投资活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "3e602bb9",
      "content": "三、筹资活动产生的现金流量： |  | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "842634b6",
      "child_ids": [],
      "sibling_ids": [
        "2ee55a88",
        "f084e5ef",
        "8b547886",
        "f6e6b5f8",
        "c9ee37e0",
        "aed89698",
        "98be7b42"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 371,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "筹资活动",
          "筹资活动产生的现金流量"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189863",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 4,
        "sentence_count": 0,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.4225352112676057,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.777431421446384,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "筹资活动",
        "筹资活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "2ee55a88",
      "content": "吸收投资收到的现金 |  | \n其中：子公司吸收少数股东投资 |  | \n |  | \n收到的现金 |  | \n |  | \n取得借款收到的现金 | 285,000,000.00 | 755,700,000.00\n收到其他与筹资活动有关的现金 |  | 633,043,300.00\n筹资活动现金流入小计 | 285,000,000.00 | 1,388,743,300.00\n偿还债务支付的现金 | 683,700,000.00 | 1,500,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "842634b6",
      "child_ids": [],
      "sibling_ids": [
        "3e602bb9",
        "f084e5ef",
        "8b547886",
        "f6e6b5f8",
        "c9ee37e0",
        "aed89698",
        "98be7b42"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 834,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "筹资活动",
          "股东",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189893",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 234,
        "word_count": 32,
        "sentence_count": 7,
        "chinese_char_count": 69,
        "readability_score": 0.0,
        "information_density": 0.25641025641025644,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.777431421446384,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "筹资活动",
        "股东",
        "借款",
        "债务"
      ]
    },
    {
      "chunk_id": "f084e5ef",
      "content": "分配股利、利润或偿付利息支付 |  | \n | 483,358,140.11 | 204,568,679.00",
      "chunk_type": "table_group",
      "parent_id": "842634b6",
      "child_ids": [],
      "sibling_ids": [
        "3e602bb9",
        "2ee55a88",
        "8b547886",
        "f6e6b5f8",
        "c9ee37e0",
        "aed89698",
        "98be7b42"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 955,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "分配",
          "配股"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189913",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 55,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.5454545454545454,
        "coherence_score": 0.355,
        "standards_profile_summary": {}
      },
      "quality_score": 0.777431421446384,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "分配",
        "配股"
      ]
    },
    {
      "chunk_id": "c9ee37e0",
      "content": "支付其他与筹资活动有关的现金 | 20,278,463.47 | 590,452,772.90\n筹资活动现金流出小计 | 1,187,336,603.58 | 2,295,021,451.90",
      "chunk_type": "table_group",
      "parent_id": "842634b6",
      "child_ids": [],
      "sibling_ids": [
        "3e602bb9",
        "2ee55a88",
        "f084e5ef",
        "8b547886",
        "f6e6b5f8",
        "aed89698",
        "98be7b42"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1896,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "筹资活动"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.189955",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.20833333333333334,
        "coherence_score": 0.35760000000000003,
        "standards_profile_summary": {}
      },
      "quality_score": 0.777431421446384,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "筹资活动"
      ]
    },
    {
      "chunk_id": "98be7b42",
      "content": "四、汇率变动对现金及现金等价物的 |  | \n | 9,911,822.10 | 35,680,596.21\n影响 |  | \n |  | \n五、现金及现金等价物净增加额 | 456,569,632.85 | -1,176,569,020.61\n加：期初现金及现金等价物余额 | 1,069,208,275.60 | 2,245,777,296.21\n六、期末现金及现金等价物余额 | 1,525,777,908.45 | 1,069,208,275.60",
      "chunk_type": "table_group",
      "parent_id": "842634b6",
      "child_ids": [],
      "sibling_ids": [
        "3e602bb9",
        "2ee55a88",
        "f084e5ef",
        "8b547886",
        "f6e6b5f8",
        "c9ee37e0",
        "aed89698"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2628,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "现金及现金等价物"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.190016",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 228,
        "word_count": 27,
        "sentence_count": 8,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.08771929824561404,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.777431421446384,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "现金及现金等价物"
      ]
    },
    {
      "chunk_id": "cc670f44",
      "content": "项目 | 2019年度 | 2018年度\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "6e3f4d62",
      "child_ids": [],
      "sibling_ids": [
        "4cf5cc5f",
        "34506370",
        "969d05a9",
        "82c8adbf",
        "746e7ab2"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 371,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.190363",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6336408364083641,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "34506370",
      "content": "销售商品、提供劳务收到的现金 | 794,479,241.27 | 765,335,887.08\n收到的税费返还 | 63,235,140.24 | 46,673,265.97\n收到其他与经营活动有关的现金 | 2,428,120,879.18 | 2,178,495,326.41",
      "chunk_type": "table_group",
      "parent_id": "6e3f4d62",
      "child_ids": [],
      "sibling_ids": [
        "cc670f44",
        "4cf5cc5f",
        "969d05a9",
        "82c8adbf",
        "746e7ab2"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1041,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "税费"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.190396",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 141,
        "word_count": 15,
        "sentence_count": 6,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.2127659574468085,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6336408364083641,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "税费"
      ]
    },
    {
      "chunk_id": "82c8adbf",
      "content": "购买商品、接受劳务支付的现金 | 576,564,206.12 | 485,651,890.91\n支付给职工以及为职工支付的现 |  | \n | 43,273,656.13 | 44,578,456.58\n金 |  | \n |  | \n支付的各项税费 | 4,696,293.04 | 11,167,793.85\n支付其他与经营活动有关的现金 | 2,653,901,946.32 | 1,818,361,700.45",
      "chunk_type": "table_group",
      "parent_id": "6e3f4d62",
      "child_ids": [],
      "sibling_ids": [
        "cc670f44",
        "4cf5cc5f",
        "34506370",
        "969d05a9",
        "746e7ab2"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1709,
      "page_number": 90,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "税费"
        ],
        "time_periods": [
          "2018",
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          90
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.190438",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 209,
        "word_count": 27,
        "sentence_count": 8,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.14354066985645936,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6336408364083641,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "税费"
      ]
    },
    {
      "chunk_id": "65a10cfc",
      "content": "经营活动产生的现金流量净额 | 7,399,159.08 | 630,744,637.67\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 396,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "经营",
          "经营活动产生的现金流量"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.190926",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 6,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.3125,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "经营",
        "经营活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "0abfe6e3",
      "content": "长期资产收回的现金净额 |  | \n |  | \n处置子公司及其他营业单位收到 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1852,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "现金",
          "营业",
          "长期"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.190990",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 52,
        "word_count": 10,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.7692307692307692,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "现金",
        "营业",
        "长期"
      ]
    },
    {
      "chunk_id": "fc89e327",
      "content": "的现金净额 |  | \n |  | \n收到其他与投资活动有关的现金 | 475,265,164.50 | 811,296,572.90\n投资活动现金流入小计 | 1,198,523,068.23 | 972,392,890.96",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 6,
      "start_char": 1800,
      "end_char": 2214,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "投资活动"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191010",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 114,
        "word_count": 15,
        "sentence_count": 4,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.26315789473684215,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "投资活动"
      ]
    },
    {
      "chunk_id": "c944a6c7",
      "content": "购建固定资产、无形资产和其他 |  | \n | 984,040.99 | 10,199,423.26",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 7,
      "start_char": 2100,
      "end_char": 2450,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191025",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 50,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.6,
        "coherence_score": 0.35,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "cb799283",
      "content": "投资支付的现金 | 20,000,000.00 | 156,121,497.07\n取得子公司及其他营业单位支付 |  | \n |  | \n的现金净额 |  | \n |  | \n支付其他与投资活动有关的现金 | 20,000,000.00 | 1,255,559,950.55\n投资活动现金流出小计 | 40,984,040.99 | 1,421,880,870.88",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 9,
      "start_char": 2700,
      "end_char": 3183,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "营业",
          "投资活动"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191063",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 183,
        "word_count": 25,
        "sentence_count": 6,
        "chinese_char_count": 50,
        "readability_score": 0.0,
        "information_density": 0.21857923497267756,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "营业",
        "投资活动"
      ]
    },
    {
      "chunk_id": "1bcce393",
      "content": "投资活动产生的现金流量净额 | 1,157,539,027.24 | -449,487,979.92",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 10,
      "start_char": 3000,
      "end_char": 3350,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "投资活动",
          "投资活动产生的现金流量"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191080",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 50,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.8,
        "coherence_score": 0.305,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "投资活动",
        "投资活动产生的现金流量"
      ]
    },
    {
      "chunk_id": "46269d27",
      "content": "吸收投资收到的现金 |  | \n取得借款收到的现金 | 235,000,000.00 | 389,000,000.00\n收到其他与筹资活动有关的现金 |  | \n筹资活动现金流入小计 | 235,000,000.00 | 389,000,000.00\n偿还债务支付的现金 | 322,000,000.00 | 772,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 12,
      "start_char": 3600,
      "end_char": 4069,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资",
          "筹资活动",
          "借款",
          "债务"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191115",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 169,
        "word_count": 21,
        "sentence_count": 6,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.2958579881656805,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资",
        "筹资活动",
        "借款",
        "债务"
      ]
    },
    {
      "chunk_id": "220f9a4f",
      "content": "分配股利、利润或偿付利息支付 |  | \n | 476,237,693.27 | 185,312,985.94",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "816cd9c9",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 13,
      "start_char": 3900,
      "end_char": 4255,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "分配",
          "配股"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191134",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 55,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.5454545454545454,
        "coherence_score": 0.355,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "分配",
        "配股"
      ]
    },
    {
      "chunk_id": "816cd9c9",
      "content": "的现金 |  | \n |  | \n支付其他与筹资活动有关的现金 | 20,278,463.47 | 295,075,572.90\n筹资活动现金流出小计 | 818,516,156.74 | 1,252,388,558.84",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "a0333ba3",
        "c6c68cd0"
      ],
      "position": 14,
      "start_char": 4200,
      "end_char": 4611,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "筹资活动"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191154",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 111,
        "word_count": 15,
        "sentence_count": 4,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.18018018018018017,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "筹资活动"
      ]
    },
    {
      "chunk_id": "c6c68cd0",
      "content": "四、汇率变动对现金及现金等价物的 |  | \n | 4,468,592.83 | 11,626,754.25\n影响 |  | \n |  | \n五、现金及现金等价物净增加额 | 585,890,622.41 | -670,505,146.84\n加：期初现金及现金等价物余额 | 593,590,172.62 | 1,264,095,319.46\n六、期末现金及现金等价物余额 | 1,179,480,795.03 | 593,590,172.62",
      "chunk_type": "table_group",
      "parent_id": "062a4bb5",
      "child_ids": [],
      "sibling_ids": [
        "65a10cfc",
        "7a0c47e3",
        "299a13eb",
        "41d7fa30",
        "c3868d6f",
        "0abfe6e3",
        "fc89e327",
        "c944a6c7",
        "36900d48",
        "cb799283",
        "1bcce393",
        "b91c7a22",
        "46269d27",
        "220f9a4f",
        "816cd9c9",
        "a0333ba3"
      ],
      "position": 16,
      "start_char": 4800,
      "end_char": 5322,
      "page_number": 91,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "现金及现金等价物"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          91
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191197",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 222,
        "word_count": 27,
        "sentence_count": 8,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.09009009009009009,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7827354260089686,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "现金及现金等价物"
      ]
    },
    {
      "chunk_id": "4ededcee",
      "content": "税种 | 计税依据 | 税率\n--------------------------------------------------\n增值税 | 销售货物或提供应税劳务 | 19%、16%、13%、6%\n城市维护建设税 | 应缴流转税税额 | 7%、5%",
      "chunk_type": "table_group",
      "parent_id": "93f482b7",
      "child_ids": [],
      "sibling_ids": [
        "d4fb6b72",
        "f4fab038"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 426,
      "page_number": 122,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "税率",
          "增值税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191283",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 126,
        "word_count": 16,
        "sentence_count": 0,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.15873015873015872,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.59435337995338,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "税率",
        "增值税"
      ]
    },
    {
      "chunk_id": "d4fb6b72",
      "content": "企业所得税 | 应纳税所得额 | 15%、16.5%、17%、20%、25%\n | 从价计征的，按房产原值一次减除30% | \n房产税 | 后余值的1.2%计缴；从租计征的，按租 | 1.2%、12%",
      "chunk_type": "table_group",
      "parent_id": "93f482b7",
      "child_ids": [],
      "sibling_ids": [
        "4ededcee",
        "f4fab038"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 700,
      "page_number": 122,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税",
          "企业所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191304",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 100,
        "word_count": 13,
        "sentence_count": 3,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.2,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.59435337995338,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税",
        "企业所得税"
      ]
    },
    {
      "chunk_id": "f4fab038",
      "content": " | 金收入的12%计缴 | \n教育费附加 | 应缴流转税税额 | 3%\n地方教育附加 | 应缴流转税税额 | 2%",
      "chunk_type": "table_group",
      "parent_id": "93f482b7",
      "child_ids": [],
      "sibling_ids": [
        "4ededcee",
        "d4fb6b72"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 958,
      "page_number": 122,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191320",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 58,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.1724137931034483,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.59435337995338,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "67e3bdd0",
      "content": " |  |  |  |  | 指定为以公允价 | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "e5b3f018",
      "child_ids": [],
      "sibling_ids": [
        "01d7eaf6",
        "a1cc7685"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 376,
      "page_number": 137,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          137
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191388",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 8,
        "sentence_count": 0,
        "chinese_char_count": 7,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40750144927536236,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "01d7eaf6",
      "content": " |  |  |  | 其他综合收益转 |  | 其他综合收益转\n |  |  |  |  | 值计量且其变动 | ",
      "chunk_type": "table_group",
      "parent_id": "e5b3f018",
      "child_ids": [],
      "sibling_ids": [
        "67e3bdd0",
        "a1cc7685"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 658,
      "page_number": 137,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "其他综合收益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          137
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191408",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 58,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 21,
        "readability_score": 0.0,
        "information_density": 0.1724137931034483,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40750144927536236,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "其他综合收益"
      ]
    },
    {
      "chunk_id": "a1cc7685",
      "content": "项目名称 | 确认的股利收入 | 累计利得 | 累计损失 | 入留存收益的金 |  | 入留存收益的原\n |  |  |  |  | 计入其他综合收 | \n |  |  |  | 额 |  | 因\n |  |  |  |  | 益的原因 | \n |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e5b3f018",
      "child_ids": [],
      "sibling_ids": [
        "67e3bdd0",
        "01d7eaf6"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1040,
      "page_number": 137,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          137
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191430",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 140,
        "word_count": 40,
        "sentence_count": 0,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.07142857142857142,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40750144927536236,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "5fb301c2",
      "content": " | 期末余额 |  | 期初余额 | \n--------------------------------------------------\n项目 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "f3f7ee61",
      "child_ids": [],
      "sibling_ids": [
        "0760ebd6",
        "cef61d74",
        "6aa9fbfc",
        "52d2bac7",
        "834ad36c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 386,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191709",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 86,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5929411764705883,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "0760ebd6",
      "content": " | 可抵扣暂时性差异 | 递延所得税资产 | 可抵扣暂时性差异 | 递延所得税资产\n |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "f3f7ee61",
      "child_ids": [],
      "sibling_ids": [
        "5fb301c2",
        "cef61d74",
        "6aa9fbfc",
        "52d2bac7",
        "834ad36c"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 655,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191725",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 55,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.36363636363636365,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5929411764705883,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "所得税"
      ]
    },
    {
      "chunk_id": "cef61d74",
      "content": "资产减值准备 | 70,299,465.99 | 14,376,262.42 | 68,698,671.21 | 14,236,323.65",
      "chunk_type": "table_group",
      "parent_id": "f3f7ee61",
      "child_ids": [],
      "sibling_ids": [
        "5fb301c2",
        "0760ebd6",
        "6aa9fbfc",
        "52d2bac7",
        "834ad36c"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 970,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191742",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 70,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.2857142857142857,
        "coherence_score": 0.29700000000000004,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5929411764705883,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "减值"
      ]
    },
    {
      "chunk_id": "6aa9fbfc",
      "content": "内部交易未实现利润 | 39,421,112.05 | 6,246,640.41 | 62,503,070.92 | 9,773,506.85",
      "chunk_type": "table_group",
      "parent_id": "f3f7ee61",
      "child_ids": [],
      "sibling_ids": [
        "5fb301c2",
        "0760ebd6",
        "cef61d74",
        "52d2bac7",
        "834ad36c"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1271,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191756",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 71,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.14084507042253522,
        "coherence_score": 0.2976,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5929411764705883,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润"
      ]
    },
    {
      "chunk_id": "52d2bac7",
      "content": "与资产相关的政府补助 |  |  |  | \n | 43,621,205.16 | 6,716,780.73 | 36,278,025.15 | 5,567,975.82\n分摊 |  |  |  | \n |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "f3f7ee61",
      "child_ids": [],
      "sibling_ids": [
        "5fb301c2",
        "0760ebd6",
        "cef61d74",
        "6aa9fbfc",
        "834ad36c"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1613,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191776",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 113,
        "word_count": 22,
        "sentence_count": 4,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.08849557522123894,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5929411764705883,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "834ad36c",
      "content": "预计负债 |  |  | 11,637,669.47 | 2,909,417.37\n合计 | 153,341,783.20 | 27,339,683.56 | 179,117,436.75 | 32,487,223.69",
      "chunk_type": "table_group",
      "parent_id": "f3f7ee61",
      "child_ids": [],
      "sibling_ids": [
        "5fb301c2",
        "0760ebd6",
        "cef61d74",
        "6aa9fbfc",
        "52d2bac7"
      ],
      "position": 5,
      "start_char": 1500,
      "end_char": 1910,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191796",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 110,
        "word_count": 16,
        "sentence_count": 6,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.09090909090909091,
        "coherence_score": 0.3471428571428572,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5929411764705883,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债"
      ]
    },
    {
      "chunk_id": "150f7c93",
      "content": " | 应纳税暂时性差异 | 递延所得税负债 | 应纳税暂时性差异 | 递延所得税负债\n--------------------------------------------------\n单位价值500万元以下 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "f1babdf9",
      "child_ids": [],
      "sibling_ids": [
        "bf3005b7"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 417,
      "page_number": 149,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "所得税",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191879",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 117,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.25641025641025644,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44857728937728936,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "所得税",
        "价值"
      ]
    },
    {
      "chunk_id": "bf3005b7",
      "content": "固定资产一次性税前抵 | 179,410,105.32 | 30,527,355.71 | 44,259,216.46 | 8,175,428.28\n扣 |  |  |  | \n合计 | 179,410,105.32 | 30,527,355.71 | 44,259,216.46 | 8,175,428.28",
      "chunk_type": "table_group",
      "parent_id": "f1babdf9",
      "child_ids": [],
      "sibling_ids": [
        "150f7c93"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 755,
      "page_number": 149,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.191904",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 155,
        "word_count": 23,
        "sentence_count": 8,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.12903225806451613,
        "coherence_score": 0.3516666666666667,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44857728937728936,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产"
      ]
    },
    {
      "chunk_id": "fe98a5ac",
      "content": " | 递延所得税资产和负债 | 抵销后递延所得税资产 | 递延所得税资产和负债 | 抵销后递延所得税资产\n--------------------------------------------------\n项目 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "d8e68070",
      "child_ids": [],
      "sibling_ids": [
        "98d96670",
        "2b75fe3f",
        "9de02a5e"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 418,
      "page_number": 149,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "所得税",
          "递延所得税资产和负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.192072",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 118,
        "word_count": 14,
        "sentence_count": 0,
        "chinese_char_count": 42,
        "readability_score": 0.0,
        "information_density": 0.33898305084745767,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4819862068965517,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "所得税",
        "递延所得税资产和负债"
      ]
    },
    {
      "chunk_id": "cba2f31b",
      "content": "业外收入金\n额 |  | 本期冲减成\n本费用金额 |  |  | \n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "dcd3c20c",
      "child_ids": [],
      "sibling_ids": [
        "0bced6b7",
        "50e685fa",
        "7102ff5b",
        "7ba8d1b4"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 684,
      "page_number": 158,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "费用"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          158
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.192391",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 84,
        "word_count": 10,
        "sentence_count": 0,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.23809523809523808,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7434640522875817,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "费用"
      ]
    },
    {
      "chunk_id": "7102ff5b",
      "content": "负债项目 | 期初余额 |  |  |  |  | 其他变动 | 期末余额 | \n |  | 助金额 |  | 他收益金额 |  |  |  | 与收益相关\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n年产400吨 |  |  |  | 1,423,820.2\n8 |  |  | 4,271,460.84 | \n碳青霉烯类 |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "dcd3c20c",
      "child_ids": [],
      "sibling_ids": [
        "0bced6b7",
        "cba2f31b",
        "50e685fa",
        "7ba8d1b4"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1414,
      "page_number": 158,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          158
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.192432",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 214,
        "word_count": 60,
        "sentence_count": 2,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.04672897196261682,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7434640522875817,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债"
      ]
    },
    {
      "chunk_id": "7ba8d1b4",
      "content": "抗生素关键 | 5,695,281.12 |  |  |  |  |  |  | 与资产相关\n中间体 |  |  |  |  |  |  |  | \n4-AA项目 |  |  |  |  |  |  |  | \n年产1吨瑞 |  |  |  | 117,931.20 |  |  | 117,931.20 | \n格列奈、10 |  |  |  |  |  |  |  | \n吨卡洛芬、 |  |  |  |  |  |  |  | \n10吨阿托伐 |  |  |  |  |  |  |  | \n醌、50吨 |  |  |  |  |  |  |  | \nT1620、300 |  |  |  |  |  |  |  | \n | 235,862.40 |  |  |  |  |  |  | 与资产相关\n吨聚卡波菲 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n钙、300吨 |  |  |  |  |  |  |  | \n4,4'-二氟二 |  |  |  |  |  |  |  | \n苯甲酮、100 |  |  |  |  |  |  |  | \n吨奈韦拉平 |  |  |  |  |  |  |  | \n产业化项目 |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "dcd3c20c",
      "child_ids": [],
      "sibling_ids": [
        "0bced6b7",
        "cba2f31b",
        "50e685fa",
        "7102ff5b"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 2062,
      "page_number": 158,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          158
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.192491",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 562,
        "word_count": 157,
        "sentence_count": 4,
        "chinese_char_count": 60,
        "readability_score": 0.0,
        "information_density": 0.017793594306049824,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7434640522875817,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "d0e9e900",
      "content": " | 本期发生额 |  | 上期发生额 | \n--------------------------------------------------\n项目 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "37cd38cd",
      "child_ids": [],
      "sibling_ids": [
        "fc51fc41"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 388,
      "page_number": 164,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.192770",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 88,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44937435897435896,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "fc51fc41",
      "content": " | 收入 | 成本 | 收入 | 成本\n |  |  |  | \n主营业务 | 2,925,688,906.14 | 1,449,500,049.29 | 2,691,787,601.50 | 1,492,180,658.53\n其他业务 | 15,723,864.16 | 13,659,311.75 | 26,821,195.01 | 19,764,017.65\n合计 | 2,941,412,770.30 | 1,463,159,361.04 | 2,718,608,796.51 | 1,511,944,676.18",
      "chunk_type": "table_group",
      "parent_id": "37cd38cd",
      "child_ids": [],
      "sibling_ids": [
        "d0e9e900"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 862,
      "page_number": 164,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "成本",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.192801",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 262,
        "word_count": 39,
        "sentence_count": 12,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.11450381679389313,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44937435897435896,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "营业"
      ]
    },
    {
      "chunk_id": "3b9c020d",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n利息支出 | 15,506,676.74 | 42,594,267.08",
      "chunk_type": "table_group",
      "parent_id": "ef05b1b6",
      "child_ids": [],
      "sibling_ids": [
        "8321dc03"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 406,
      "page_number": 166,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193021",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 106,
        "word_count": 11,
        "sentence_count": 2,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.35989743589743595,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "8321dc03",
      "content": "利息收入 | -41,773,975.28 | -44,371,159.00\n汇兑净损益 | -12,759,207.59 | -50,821,750.14\n金融机构手续费 | 1,161,350.07 | 1,091,244.28\n合计 | -37,865,156.06 | -51,507,397.78",
      "chunk_type": "table_group",
      "parent_id": "ef05b1b6",
      "child_ids": [],
      "sibling_ids": [
        "3b9c020d"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 753,
      "page_number": 166,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193045",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 153,
        "word_count": 20,
        "sentence_count": 8,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.06535947712418301,
        "coherence_score": 0.351,
        "standards_profile_summary": {}
      },
      "quality_score": 0.35989743589743595,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "748dfed3",
      "content": " |  |  | 计入当期非经常性损益的金\n--------------------------------------------------\n项目 | 本期发生额 | 上期发生额 | \n |  |  | 额\n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "3ca1f2fe",
      "child_ids": [],
      "sibling_ids": [
        "83671f89",
        "165a680c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 415,
      "page_number": 168,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193148",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 115,
        "word_count": 18,
        "sentence_count": 0,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.461839755351682,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "83671f89",
      "content": "非货币性资产交换利得 | 56,093.96 | 126,221.82 | 56,093.96\n无法支付款项 |  | 370,069.55 | ",
      "chunk_type": "table_group",
      "parent_id": "3ca1f2fe",
      "child_ids": [],
      "sibling_ids": [
        "748dfed3",
        "165a680c"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 673,
      "page_number": 168,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193166",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 73,
        "word_count": 12,
        "sentence_count": 4,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.136986301369863,
        "coherence_score": 0.3438,
        "standards_profile_summary": {}
      },
      "quality_score": 0.461839755351682,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "165a680c",
      "content": "违约及赔款收入 | 896,839.67 | 972,312.09 | 896,839.67\n其 他 | 172,720.90 | 244,682.63 | 172,720.90\n合计 | 1,125,654.53 | 1,713,286.09 | 1,125,654.53",
      "chunk_type": "table_group",
      "parent_id": "3ca1f2fe",
      "child_ids": [],
      "sibling_ids": [
        "748dfed3",
        "83671f89"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1037,
      "page_number": 168,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193187",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 137,
        "word_count": 22,
        "sentence_count": 9,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.072992700729927,
        "coherence_score": 0.34109999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.461839755351682,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "7c0576a5",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n收回银行承兑汇票、信用证保证金等 | 146,000,576.25 | 268,324,454.49",
      "chunk_type": "table_group",
      "parent_id": "a22bec99",
      "child_ids": [],
      "sibling_ids": [
        "6ed7d700",
        "1ab6814d"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 420,
      "page_number": 170,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193323",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 120,
        "word_count": 11,
        "sentence_count": 2,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.567687895716946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "6ed7d700",
      "content": "收到银行存款利息收入 | 31,637,094.38 | 37,993,941.65\n收到政府补助 | 31,594,591.50 | 17,182,776.65\n支取为开立承兑汇票质押的定期存款 | 33,903,500.00 | 442,038,662.00",
      "chunk_type": "table_group",
      "parent_id": "a22bec99",
      "child_ids": [],
      "sibling_ids": [
        "7c0576a5",
        "1ab6814d"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 731,
      "page_number": 170,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "银行存款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193346",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 131,
        "word_count": 15,
        "sentence_count": 6,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.15267175572519082,
        "coherence_score": 0.3561428571428572,
        "standards_profile_summary": {}
      },
      "quality_score": 0.567687895716946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "银行存款"
      ]
    },
    {
      "chunk_id": "1ab6814d",
      "content": "收到房租收入 | 923,003.40 | 2,147,867.09\n其 他 | 5,791,850.24 | 4,263,072.32\n合计 | 249,850,615.77 | 771,950,774.20",
      "chunk_type": "table_group",
      "parent_id": "a22bec99",
      "child_ids": [],
      "sibling_ids": [
        "7c0576a5",
        "6ed7d700"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1005,
      "page_number": 170,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193367",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 105,
        "word_count": 16,
        "sentence_count": 6,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.09523809523809523,
        "coherence_score": 0.345,
        "standards_profile_summary": {}
      },
      "quality_score": 0.567687895716946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入"
      ]
    },
    {
      "chunk_id": "07beb4ec",
      "content": "补充资料 | 本期金额 | 上期金额\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 369,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193754",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 69,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "edef274f",
      "content": "固定资产折旧、油气资产折耗、生产性生 |  | \n | 172,822,169.17 | 161,268,842.88",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1559,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "折旧"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193809",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 59,
        "word_count": 7,
        "sentence_count": 2,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.5084745762711865,
        "coherence_score": 0.359,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "折旧"
      ]
    },
    {
      "chunk_id": "886e325d",
      "content": "处置固定资产、无形资产和其他长期资产 |  | \n | -244,580.94 | -659,231.88\n的损失（收益以“－”号填列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 8,
      "start_char": 2400,
      "end_char": 2781,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产",
          "长期"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193864",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 81,
        "word_count": 12,
        "sentence_count": 2,
        "chinese_char_count": 26,
        "readability_score": 0.0,
        "information_density": 0.49382716049382713,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产",
        "长期"
      ]
    },
    {
      "chunk_id": "fd4102be",
      "content": "固定资产报废损失（收益以“－”号填列） | 4,395,355.91 | 761,505.33\n公允价值变动损失（收益以“－”号填列） |  | -5,010,265.70",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 9,
      "start_char": 2700,
      "end_char": 3086,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193883",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 86,
        "word_count": 9,
        "sentence_count": 3,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.4651162790697675,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "725598ab",
      "content": "财务费用（收益以“－”号填列） | -7,552,032.06 | -14,604,700.41\n投资损失（收益以“－”号填列） | 15,240,062.55 | 9,359,378.55",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 10,
      "start_char": 3000,
      "end_char": 3395,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "投资",
          "财务费用"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193903",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 95,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.3157894736842105,
        "coherence_score": 0.357,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "投资",
        "财务费用"
      ]
    },
    {
      "chunk_id": "04eb9ef1",
      "content": "递延所得税资产减少（增加以“－”号填列） | 5,147,540.13 | -4,649,984.56",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 11,
      "start_char": 3300,
      "end_char": 3651,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "所得税",
          "递延所得税资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193919",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 51,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 15,
        "readability_score": 0.0,
        "information_density": 0.588235294117647,
        "coherence_score": 0.30600000000000005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "所得税",
        "递延所得税资产"
      ]
    },
    {
      "chunk_id": "bc34dbab",
      "content": "递延所得税负债增加（减少以“－”号填列） | 22,351,927.43 | 8,175,428.28",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 12,
      "start_char": 3600,
      "end_char": 3951,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "所得税",
          "递延所得税负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193932",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 51,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 15,
        "readability_score": 0.0,
        "information_density": 0.588235294117647,
        "coherence_score": 0.30600000000000005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "所得税",
        "递延所得税负债"
      ]
    },
    {
      "chunk_id": "903d9dd4",
      "content": "经营性应收项目的减少（增加以“－”号填 |  | \n | -276,602,622.13 | -71,443,627.33\n列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 14,
      "start_char": 4200,
      "end_char": 4577,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193962",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 77,
        "word_count": 12,
        "sentence_count": 2,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.2597402597402597,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "经营"
      ]
    },
    {
      "chunk_id": "c6fb98a5",
      "content": "经营性应付项目的增加（减少以“－”号填 |  | \n | -191,326,340.46 | 152,422,810.70\n列） |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 15,
      "start_char": 4500,
      "end_char": 4877,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应付",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.193979",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 77,
        "word_count": 12,
        "sentence_count": 2,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.2597402597402597,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "经营"
      ]
    },
    {
      "chunk_id": "807cf6a2",
      "content": "2．不涉及现金收支的重大投资和筹资活 |  | \n | -- | --\n动： |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "8f702b34",
        "193d1f8e",
        "69958b6c"
      ],
      "position": 17,
      "start_char": 5100,
      "end_char": 5451,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194015",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 51,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 17,
        "readability_score": 0.0,
        "information_density": 0.39215686274509803,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "投资"
      ]
    },
    {
      "chunk_id": "193d1f8e",
      "content": "现金的期末余额 | 1,525,777,908.45 | 1,069,208,275.60\n减：现金的期初余额 | 1,069,208,275.60 | 2,245,777,296.21",
      "chunk_type": "table_group",
      "parent_id": "ac8833fb",
      "child_ids": [],
      "sibling_ids": [
        "07beb4ec",
        "fb7611c7",
        "156c4db5",
        "9094210c",
        "edef274f",
        "e72af857",
        "0440f8e1",
        "4331f1c9",
        "886e325d",
        "fd4102be",
        "725598ab",
        "04eb9ef1",
        "bc34dbab",
        "e5976c1b",
        "903d9dd4",
        "c6fb98a5",
        "9a243d0d",
        "807cf6a2",
        "8f702b34",
        "69958b6c"
      ],
      "position": 19,
      "start_char": 5700,
      "end_char": 6093,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194045",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 93,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 15,
        "readability_score": 0.0,
        "information_density": 0.1075268817204301,
        "coherence_score": 0.3558,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7737244897959183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金"
      ]
    },
    {
      "chunk_id": "bfdba451",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "5b532a7c",
      "child_ids": [],
      "sibling_ids": [
        "cf5f0183",
        "7c06d640",
        "0469ff6c",
        "40ceb3a0"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 367,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194150",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 67,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 10,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4758076124567474,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "cf5f0183",
      "content": "一、现金 | 1,525,777,908.45 | 1,069,208,275.60\n其中：库存现金 | 131,545.99 | 195,522.60",
      "chunk_type": "table_group",
      "parent_id": "5b532a7c",
      "child_ids": [],
      "sibling_ids": [
        "bfdba451",
        "7c06d640",
        "0469ff6c",
        "40ceb3a0"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 676,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194167",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 10,
        "sentence_count": 4,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.13157894736842107,
        "coherence_score": 0.3456,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4758076124567474,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金"
      ]
    },
    {
      "chunk_id": "7c06d640",
      "content": "可随时用于支付的银行存款 | 1,525,298,726.49 | 1,068,623,694.25",
      "chunk_type": "table_group",
      "parent_id": "5b532a7c",
      "child_ids": [],
      "sibling_ids": [
        "bfdba451",
        "cf5f0183",
        "0469ff6c",
        "40ceb3a0"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 950,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "银行存款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194216",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 50,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.2,
        "coherence_score": 0.305,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4758076124567474,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "银行存款"
      ]
    },
    {
      "chunk_id": "40ceb3a0",
      "content": "三、期末现金及现金等价物余额 | 1,525,777,908.45 | 1,069,208,275.60",
      "chunk_type": "table_group",
      "parent_id": "5b532a7c",
      "child_ids": [],
      "sibling_ids": [
        "bfdba451",
        "cf5f0183",
        "7c06d640",
        "0469ff6c"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1552,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "cash_flow",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "现金及现金等价物"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194282",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 52,
        "word_count": 5,
        "sentence_count": 2,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.3846153846153846,
        "coherence_score": 0.307,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4758076124567474,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "现金及现金等价物"
      ]
    },
    {
      "chunk_id": "203916cb",
      "content": " |  |  |  |  |  |  | 购买日至期 | 购买日至期\n--------------------------------------------------\n被购买方名 | 股权取得时 | 股权取得成 | 股权取得比 | 股权取得方 |  | 购买日的确 |  | \n |  |  |  |  | 购买日 |  | 末被购买方 | 末被购买方\n称 | 点 | 本 | 例 | 式 |  | 定依据 |  | ",
      "chunk_type": "table_group",
      "parent_id": "1d6ad1e5",
      "child_ids": [],
      "sibling_ids": [
        "58408333"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 511,
      "page_number": 177,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194357",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 211,
        "word_count": 50,
        "sentence_count": 0,
        "chinese_char_count": 61,
        "readability_score": 0.0,
        "information_density": 0.047393364928909956,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.466652736318408,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权"
      ]
    },
    {
      "chunk_id": "58408333",
      "content": " |  |  |  |  |  |  | 的收入 | 的净利润\n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "1d6ad1e5",
      "child_ids": [],
      "sibling_ids": [
        "203916cb"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 656,
      "page_number": 177,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194377",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 56,
        "word_count": 18,
        "sentence_count": 0,
        "chinese_char_count": 7,
        "readability_score": 0.0,
        "information_density": 0.5357142857142857,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.466652736318408,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "4412cc96",
      "content": " |  |  |  |  | 合并当期期 | 合并当期期 |  | \n--------------------------------------------------\n | 企业合并中 | 构成同一控 |  |  |  |  | 比较期间被 | 比较期间被\n被合并方名 |  |  |  | 合并日的确 | 初至合并日 | 初至合并日 |  | \n | 取得的权益 | 制下企业合 | 合并日 |  |  |  | 合并方的收 | 合并方的净\n称 |  |  |  | 定依据 | 被合并方的 | 被合并方的 |  | ",
      "chunk_type": "table_group",
      "parent_id": "8bcaa04f",
      "child_ids": [],
      "sibling_ids": [
        "d08862ef"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 562,
      "page_number": 178,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "合并"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          178
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194560",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 262,
        "word_count": 60,
        "sentence_count": 0,
        "chinese_char_count": 87,
        "readability_score": 0.0,
        "information_density": 0.07633587786259541,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5767247863247863,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "合并"
      ]
    },
    {
      "chunk_id": "d08862ef",
      "content": " | 比例 | 并的依据 |  |  |  |  | 入 | 利润\n |  |  |  |  | 收入 | 净利润 |  | \n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "8bcaa04f",
      "child_ids": [],
      "sibling_ids": [
        "4412cc96"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 688,
      "page_number": 178,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "利润",
          "净利润"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          178
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194585",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 88,
        "word_count": 30,
        "sentence_count": 0,
        "chinese_char_count": 14,
        "readability_score": 0.0,
        "information_density": 0.34090909090909094,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5767247863247863,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "8403be42",
      "content": " | 期末余额 |  |  |  |  |  | 期初余额 |  |  |  |  | \n--------------------------------------------------\n子公司 |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "86e8cb96",
      "child_ids": [],
      "sibling_ids": [
        "634e9580"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 435,
      "page_number": 180,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194667",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 135,
        "word_count": 28,
        "sentence_count": 0,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4759968348170128,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "634e9580",
      "content": " | 流动资 | 非流动 | 资产合 | 流动负 | 非流动 | 负债合 | 流动资 | 非流动 | 资产合 | 流动负 | 非流动 | 负债合\n名称 |  |  |  |  |  |  |  |  |  |  |  | \n | 产 | 资产 | 计 | 债 | 负债 | 计 | 产 | 资产 | 计 | 债 | 负债 | 计\n |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "86e8cb96",
      "child_ids": [],
      "sibling_ids": [
        "8403be42"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 801,
      "page_number": 180,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194706",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 201,
        "word_count": 73,
        "sentence_count": 0,
        "chinese_char_count": 54,
        "readability_score": 0.0,
        "information_density": 0.09950248756218907,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4759968348170128,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债"
      ]
    },
    {
      "chunk_id": "e7fc2e51",
      "content": " | 本期发生额 |  |  |  | 上期发生额 |  |  | \n--------------------------------------------------\n子公司名称 |  |  | 综合收益总 | 经营活动现 |  |  | 综合收益总 | 经营活动现",
      "chunk_type": "table_group",
      "parent_id": "ed58cd38",
      "child_ids": [],
      "sibling_ids": [
        "f5e40715"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 435,
      "page_number": 181,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194775",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 135,
        "word_count": 24,
        "sentence_count": 0,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.07407407407407407,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44984022988505745,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营"
      ]
    },
    {
      "chunk_id": "f5e40715",
      "content": " | 营业收入 | 净利润 |  |  | 营业收入 | 净利润 |  | \n |  |  | 额 | 金流量 |  |  | 额 | 金流量\n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "ed58cd38",
      "child_ids": [],
      "sibling_ids": [
        "e7fc2e51"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 696,
      "page_number": 181,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "利润",
          "营业收入",
          "净利润",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194796",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 32,
        "sentence_count": 0,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.5208333333333334,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44984022988505745,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "利润",
        "营业收入",
        "净利润",
        "营业"
      ]
    },
    {
      "chunk_id": "062f6755",
      "content": " | 期末余额/本期发生额 | 期初余额/上期发生额\n--------------------------------------------------\n | 苏州第四制药厂有限公司 | 苏州第四制药厂有限公司",
      "chunk_type": "table_group",
      "parent_id": "1101ee7d",
      "child_ids": [],
      "sibling_ids": [
        "ab714458",
        "a6ff97aa",
        "c41a1d06",
        "e9596674",
        "427af33f",
        "b0eb8b3b"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 406,
      "page_number": 182,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194956",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 106,
        "word_count": 9,
        "sentence_count": 0,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6073743922204214,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ab714458",
      "content": "流动资产 | 29,519,105.76 | 25,072,727.50\n非流动资产 | 84,757,893.18 | 93,352,602.90\n资产合计 | 114,276,998.94 | 118,425,330.40",
      "chunk_type": "table_group",
      "parent_id": "1101ee7d",
      "child_ids": [],
      "sibling_ids": [
        "062f6755",
        "a6ff97aa",
        "c41a1d06",
        "e9596674",
        "427af33f",
        "b0eb8b3b"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 713,
      "page_number": 182,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.194978",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 113,
        "word_count": 15,
        "sentence_count": 6,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.08849557522123894,
        "coherence_score": 0.3484285714285714,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6073743922204214,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "a6ff97aa",
      "content": "流动负债 | 36,442,141.82 | 25,462,418.24\n非流动负债 | 21,400,000.00 | 22,000,000.00\n负债合计 | 57,842,141.82 | 47,462,418.24\n归属于母公司股东权益 | 56,434,857.12 | 71,167,909.30",
      "chunk_type": "table_group",
      "parent_id": "1101ee7d",
      "child_ids": [],
      "sibling_ids": [
        "062f6755",
        "ab714458",
        "c41a1d06",
        "e9596674",
        "427af33f",
        "b0eb8b3b"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 1054,
      "page_number": 182,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 4,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "股东权益",
          "母公司",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195003",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 154,
        "word_count": 20,
        "sentence_count": 8,
        "chinese_char_count": 23,
        "readability_score": 0.0,
        "information_density": 0.3246753246753247,
        "coherence_score": 0.3513333333333334,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6073743922204214,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "股东权益",
        "母公司",
        "股东"
      ]
    },
    {
      "chunk_id": "c41a1d06",
      "content": "按持股比例计算的净资产份额 | 18,431,624.34 | 23,243,439.18\n--其他 | -297,151.93 | -297,151.93\n对联营企业权益投资的账面价值 | 18,134,472.41 | 22,946,287.25",
      "chunk_type": "table_group",
      "parent_id": "1101ee7d",
      "child_ids": [],
      "sibling_ids": [
        "062f6755",
        "ab714458",
        "a6ff97aa",
        "e9596674",
        "427af33f",
        "b0eb8b3b"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1325,
      "page_number": 182,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "投资",
          "净资产",
          "账面价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195027",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 125,
        "word_count": 15,
        "sentence_count": 6,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.48,
        "coherence_score": 0.35357142857142854,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6073743922204214,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "投资",
        "净资产",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "fb9ab767",
      "content": " |  | 对财务状况和经营成果的影 | \n--------------------------------------------------\n项目 | 内容 |  | 无法估计影响数的原因\n |  | 响数 | \n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "9ae69cb2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 618,
      "page_number": 192,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "balance_sheet",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营",
          "财务状况"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          192
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195209",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 118,
        "word_count": 18,
        "sentence_count": 0,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.16949152542372883,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3350531073446328,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营",
        "财务状况"
      ]
    },
    {
      "chunk_id": "5c608dba",
      "content": " |  |  |  |  |  | 归属于母公司所\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "f17a2761",
      "child_ids": [],
      "sibling_ids": [
        "9ca8f631",
        "83bd0fb6"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 376,
      "page_number": 193,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "母公司"
        ],
        "time_periods": [
          "2019-6"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          193
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195390",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 8,
        "sentence_count": 0,
        "chinese_char_count": 7,
        "readability_score": 0.0,
        "information_density": 0.13157894736842107,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4120737588652482,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "母公司"
      ]
    },
    {
      "chunk_id": "a03350b4",
      "content": "项目 | 医药行业 | 染料行业 | 分部间抵销 | 合计\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "59a01941",
      "child_ids": [],
      "sibling_ids": [
        "ac4533d6",
        "6b9e1608",
        "e7187c14",
        "7344d42d"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 380,
      "page_number": 194,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195648",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 80,
        "word_count": 10,
        "sentence_count": 0,
        "chinese_char_count": 17,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.536430303030303,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "ac4533d6",
      "content": "主营业务收入 | 1,604,117,711.02 | 1,546,764,954.54 | 225,193,759.42 | 2,925,688,906.14",
      "chunk_type": "table_group",
      "parent_id": "59a01941",
      "child_ids": [],
      "sibling_ids": [
        "a03350b4",
        "6b9e1608",
        "e7187c14",
        "7344d42d"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 680,
      "page_number": 194,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195665",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 80,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.25,
        "coherence_score": 0.30300000000000005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.536430303030303,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业"
      ]
    },
    {
      "chunk_id": "6b9e1608",
      "content": "主营业务成本 | 6,064,447,216.11 | 657,131,007.06 | 211,204,035.55 | 6,747,198,664.47",
      "chunk_type": "table_group",
      "parent_id": "59a01941",
      "child_ids": [],
      "sibling_ids": [
        "a03350b4",
        "ac4533d6",
        "e7187c14",
        "7344d42d"
      ],
      "position": 2,
      "start_char": 600,
      "end_char": 978,
      "page_number": 194,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "营业",
          "主营业务成本"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195681",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 78,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.3846153846153846,
        "coherence_score": 0.3018,
        "standards_profile_summary": {}
      },
      "quality_score": 0.536430303030303,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "营业",
        "主营业务成本"
      ]
    },
    {
      "chunk_id": "e7187c14",
      "content": "资产总额 | 1,003,573,077.78 | 2,269,859,610.07 | 1,587,108,161.71 | 1,449,500,049.29",
      "chunk_type": "table_group",
      "parent_id": "59a01941",
      "child_ids": [],
      "sibling_ids": [
        "a03350b4",
        "ac4533d6",
        "6b9e1608",
        "7344d42d"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1280,
      "page_number": 194,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195697",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 80,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 4,
        "readability_score": 0.0,
        "information_density": 0.125,
        "coherence_score": 0.30300000000000005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.536430303030303,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "7344d42d",
      "content": "负债总额 | 798,878,476.78 | 525,463,301.92 | 301,605,209.78 | 1,022,736,568.72",
      "chunk_type": "table_group",
      "parent_id": "59a01941",
      "child_ids": [],
      "sibling_ids": [
        "a03350b4",
        "ac4533d6",
        "6b9e1608",
        "e7187c14"
      ],
      "position": 4,
      "start_char": 1200,
      "end_char": 1574,
      "page_number": 194,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 1,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195712",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 74,
        "word_count": 9,
        "sentence_count": 4,
        "chinese_char_count": 4,
        "readability_score": 0.0,
        "information_density": 0.13513513513513514,
        "coherence_score": 0.2994,
        "standards_profile_summary": {}
      },
      "quality_score": 0.536430303030303,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债"
      ]
    },
    {
      "chunk_id": "4d0b6259",
      "content": " | 本期发生额 |  | 上期发生额 | \n--------------------------------------------------\n项目 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "0ec4b075",
      "child_ids": [],
      "sibling_ids": [
        "71e222aa"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 388,
      "page_number": 201,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195814",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 88,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44419900497512443,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "71e222aa",
      "content": " | 收入 | 成本 | 收入 | 成本\n |  |  |  | \n主营业务 | 797,912,055.33 | 574,154,902.09 | 805,112,431.82 | 606,077,442.30\n其他业务 | 14,347,583.53 | 12,941,502.94 | 19,986,172.05 | 13,769,464.63\n合计 | 812,259,638.86 | 587,096,405.03 | 825,098,603.87 | 619,846,906.93",
      "chunk_type": "table_group",
      "parent_id": "0ec4b075",
      "child_ids": [],
      "sibling_ids": [
        "4d0b6259"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 846,
      "page_number": 201,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "成本",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195845",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 246,
        "word_count": 39,
        "sentence_count": 12,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.12195121951219512,
        "coherence_score": 0.3567692307692307,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44419900497512443,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "营业"
      ]
    },
    {
      "chunk_id": "5393cac1",
      "content": "项目 | 金额 | 说明\n--------------------------------------------------",
      "chunk_type": "table_group",
      "parent_id": "be6ff6d4",
      "child_ids": [],
      "sibling_ids": [
        "1a5b3dc8",
        "86e633ff",
        "76de9d35"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 363,
      "page_number": 202,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195951",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 63,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.673966761095373,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": []
    },
    {
      "chunk_id": "1a5b3dc8",
      "content": "非流动资产处置损益 | -4,150,774.97 | \n越权审批或无正式批准文件的税收返还、 |  | \n | 1,828,299.60 | \n减免 |  | \n |  | \n计入当期损益的政府补助（与企业业务密 |  | \n切相关，按照国家统一标准定额或定量享 | 25,308,625.27 | \n受的政府补助除外） |  | \n委托他人投资或管理资产的损益 | 2,079,074.70 | ",
      "chunk_type": "table_group",
      "parent_id": "be6ff6d4",
      "child_ids": [],
      "sibling_ids": [
        "5393cac1",
        "86e633ff",
        "76de9d35"
      ],
      "position": 1,
      "start_char": 300,
      "end_char": 800,
      "page_number": 202,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "税收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.195979",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 200,
        "word_count": 29,
        "sentence_count": 4,
        "chinese_char_count": 84,
        "readability_score": 0.0,
        "information_density": 0.15,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.673966761095373,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "税收"
      ]
    },
    {
      "chunk_id": "76de9d35",
      "content": "减：所得税影响额 | 3,519,880.50 | \n合计 | 19,572,324.86 | --",
      "chunk_type": "table_group",
      "parent_id": "be6ff6d4",
      "child_ids": [],
      "sibling_ids": [
        "5393cac1",
        "1a5b3dc8",
        "86e633ff"
      ],
      "position": 3,
      "start_char": 900,
      "end_char": 1250,
      "page_number": 202,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "income_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.196011",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 50,
        "word_count": 9,
        "sentence_count": 2,
        "chinese_char_count": 9,
        "readability_score": 0.0,
        "information_density": 0.2,
        "coherence_score": 0.26,
        "standards_profile_summary": {}
      },
      "quality_score": 0.673966761095373,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税"
      ]
    },
    {
      "chunk_id": "c7b90b54",
      "content": "释义项 | 指 | 释义内容\n--------------------------------------------------\n中国证监会、证监会 | 指 | 中国证券监督管理委员会\n深交所、交易所 | 指 | 深圳证券交易所\n本公司、公司、海翔药业 | 指 | 浙江海翔药业股份有限公司\n川南公司、川南药业 | 指 | 浙江海翔川南药业有限公司，公司全资子公司\n销售公司 | 指 | 浙江海翔药业销售有限公司，公司全资子公司\n上海海翔 | 指 | 上海海翔医药科技发展有限公司，公司全资子公司\n台州前进、前进公司 | 指 | 台州市前进化工有限公司，公司全资子公司\n盐城瓯华、瓯华化工 | 指 | 盐城市瓯华化学工业有限公司，公司合并报表范围内子公司\n振港染料 | 指 | 台州市振港染料化工有限公司，公司合并报表范围内子公司\n盛嘉环保 | 指 | 浙江盛嘉环保科技有限公司，公司合并报表范围内子公司\n苏州四药 | 指 | 苏州第四制药厂有限公司，公司参股公司\n高盛钢结构 | 指 | 浙江高盛钢结构有限公司，公司参股公司\n北华环保 | 指 | 江苏北华环保科技有限公司，盐城瓯华参股公司\n东港投资 | 指 | 浙江东港投资有限公司，公司控股股东\n报告期 | 指 | 2019年1-12月的会计区间\n《公司章程》 | 指 | 浙江海翔药业股份有限公司章程\n |  | Active Pharmaceutical Ingredients(API)，即药物活性成分，具有药理活\n原料药、API | 指 | \n |  | 性可用于药品生产的化学物质\n |  | \nGMP | 指 | Good Manufacturing Practice，药品生产质量管理规范\n |  | 药品监督管理部门对药品研制、生产、经营、使用单位合乎相应质量\n药品认证 | 指 | \n |  | 管理规范的情况进行检查、评价并决定是否发给相应认证证书的过程\n |  | \n |  | 药品监督管理部门依照法定程序，对拟上市销售药品的安全性、有效\n |  | 性、质量可控性等进行系统评价，并作出是否同意进行药物临床研究、\n药品注册 | 指 | \n |  | 生产药品或者进口药品的审批过程，包括对申请变更药品批准证明文\n |  | \n |  | 件及其附件中载明内容的审批\nFDA | 指 | U.S.Food and Drug Administration，美国食品和药品监督管理局\nBI | 指 | 德国勃林格殷格翰公司\n |  | The European Directorate for the Quality of Medicines & HealthCare，欧\nEDQM | 指 | \n |  | 洲药品质量管理局\n |  | \nUSP | 指 | U.S. Pharmacopeia，美国药典",
      "chunk_type": "table_group",
      "parent_id": "23b40e2e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1692,
      "page_number": 4,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "financial_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 40,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "合并",
          "经营",
          "股份",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          4
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.199205",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1192,
        "word_count": 177,
        "sentence_count": 4,
        "chinese_char_count": 626,
        "readability_score": 0.0,
        "information_density": 0.0587248322147651,
        "coherence_score": 0.4826632836798167,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8575503355704699,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "合并",
        "经营",
        "股份",
        "股东",
        "报告",
        "证券"
      ]
    },
    {
      "chunk_id": "ad8a07e1",
      "content": "辉瑞、辉瑞公司 | 指 | Pfizer Inc.是目前全球顶尖的以研发为基础的生物制药公司\n--------------------------------------------------\n |  | Eco-passport，由TESTEX瑞士纺织检定有限公司于1993年创立的针\nECO认证 | 指 | \n |  | 对纺织品染料、助剂化学品等产品开展的生态环保认证。\n |  | \n |  | 天祥认证，天祥集团是世界上规模最大的消费品测试、检验和认证公\nIntertek认证 | 指 | \n |  | 司之一\n |  | \nEHS | 指 | Environment-Health-Safety，环境、健康、安全生产体系\n |  | 一种染料类型，染色时与纤维反应，二者之间形成共价键，成为整体，\n |  | 使耐洗和耐摩擦牢度高。用于棉等纤维素纤维、蛋白质纤维、锦纶、\n活性染料 | 指 | \n |  | 粘胶等合成纤维的染色，色泽鲜艳，色谱齐全，匀染性好，湿处理牢\n |  | \n |  | 度优良\n |  | 一种水溶性较低的非离子型染料，在染色过程中呈分散状态进行染\n分散染料 | 指 | 色，主要用于涤纶及其混纺织物的印染，也可用于醋酸纤维、锦纶、\n |  | 丙纶、氯纶、腈纶等合成纤维的印染\n |  | 分子式为C22H16N2Na2O11S3，一种常温型蒽醌系列活性染料，拥有\nKN-R，活性艳蓝KN-R | 指 | 鲜艳色光、优良匀染性、高亲和力、高日晒牢度等优点，主要用于对\n |  | 棉、麻、毛、丝的染色，是国家产业政策鼓励发展的一类染料\n氨基油 | 指 | 间-(β-羟乙基砜)苯胺，用于合成乙烯基砜染料，染料的关键中间体\n溴氨酸 | 指 | 一种红色针状结晶，重要的染料中间体，用于蒽醌型染料\n |  | 深蓝色粉末，易溶于水。该染料用于棉和黏胶纤维的染色，及其织物\nP-3R | 指 | \n |  | 的印花，各项染色坚牢度优良，是重要的蓝色染料。\n |  | \n |  | 一种高温型活性染料，色泽鲜艳，光牢度优异，因具有极好的耐盐碱\nKE-GN | 指 | \n |  | 性能，广泛应用于连续染色、蜡染等\n |  | \n |  | 一种中温型活性染料，色泽鲜艳，具有极好的耐盐碱性能，广泛应用\nDK-ER | 指 | \n |  | 于浸染和连续染色的冷轧堆工艺\n |  | ",
      "chunk_type": "table_group",
      "parent_id": "eef800c4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1511,
      "page_number": 5,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          5
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.199676",
        "report_type": null,
        "fiscal_year": 1993,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1011,
        "word_count": 122,
        "sentence_count": 5,
        "chinese_char_count": 537,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.2794415173867229,
        "standards_profile_summary": {}
      },
      "quality_score": 0.659347181008902,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "f6d5642b",
      "content": "【表格内容】\n股票简称 | 海翔药业 | 股票代码 | 002099\n--------------------------------------------------\n股票上市证券交易所 | 深圳证券交易所 | | \n公司的中文名称 | 浙江海翔药业股份有限公司 | | \n公司的中文简称 | 海翔药业 | | \n公司的外文名称（如有） | ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD. | | \n公司的外文名称缩写（如有） | HISOAR | | \n公司的法定代表人 | 杨思卫 | | \n注册地址 | 浙江省台州市椒江区外沙支路100号 | | \n注册地址的邮政编码 | 318000 | | \n办公地址 | 浙江省台州市椒江区外沙支路100号 | | \n办公地址的邮政编码 | 318000 | | \n公司网址 | http://www.hisoar.com | | \n电子信箱 | stock@hisoar.com | |",
      "chunk_type": "table_group",
      "parent_id": "8d0a05c3",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 435,
      "page_number": 6,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          6
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.199861",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 435,
        "word_count": 72,
        "sentence_count": 5,
        "chinese_char_count": 155,
        "readability_score": 0.0,
        "information_density": 0.04597701149425288,
        "coherence_score": 0.8344444444444445,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5395605442176871,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "证券"
      ]
    },
    {
      "chunk_id": "a5d961f9",
      "content": "【表格内容】\n| 董事会秘书 | 证券事务代表\n--------------------------------------------------\n姓名 | 许华青 | 蒋如东\n联系地址 | 浙江省台州市椒江区外沙支路100号 | 浙江省台州市椒江区外沙支路100号\n电话 | 0576-89088166 | 0576-89088166\n传真 | 0576-89088128 | 0576-89088128\n电子信箱 | stock@hisoar.com | stock@hisoar.com",
      "chunk_type": "table_group",
      "parent_id": "6a80a320",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 247,
      "page_number": 6,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          6
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.199972",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 247,
        "word_count": 31,
        "sentence_count": 2,
        "chinese_char_count": 63,
        "readability_score": 0.0,
        "information_density": 0.04048582995951417,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4099219917012448,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "证券"
      ]
    },
    {
      "chunk_id": "adf35dfb",
      "content": "【说明】四、注册变更情况\n组织机构代码 913300001482332737\n公司上市以来主营业务的变化情况（如\n无变更\n有）\n2010年9月，原控股股东罗邦鹏先生向其子罗煜竑先生转让其所持有的3,480万\n股（占总股本的21.68%）股份，使其成为公司控股股东。2014年4月，原控股股\n历次控股股东的变更情况（如有）\n东罗煜竑先生向王云富先生转让其所持有的5,940万股（占总股本的18.31%）股\n份，使其成为公司控股股东。五、其他有关资料\n公司聘请的会计师事务所\n会计师事务所名称 天健会计师事务所（特殊普通合伙）\n会计师事务所办公地址 浙江省杭州市江干区钱江路1366 号华润大厦B座\n签字会计师姓名 沈维华 汪兢\n公司聘请的报告期内履行持续督导职责的保荐机构\n□ 适用 √ 不适用\n公司聘请的报告期内履行持续督导职责的财务顾问\n□ 适用 √ 不适用\n六、主要会计数据和财务指标\n公司是否需追溯调整或重述以前年度会计数据\n□ 是 √ 否\n2019年 2018年 本年比上年增减 2017年\n营业收入（元） 2,941,412,770.30 2,718,608,796.51 8.20% 2,308,922,170.29\n归属于上市公司股东的净利润\n770,782,185.09 605,003,820.78 27.40% 342,217,155.60\n（元）\n归属于上市公司股东的扣除非经\n751,209,860.23 604,944,470.09 24.18% 301,310,316.13\n常性损益的净利润（元）\n经营活动产生的现金流量净额\n612,399,095.31 791,449,237.66 -22.62% 118,141,514.53\n（元）\n基本每股收益（元/股） 0.48 0.38 26.32% 0.22\n稀释每股收益（元/股） 0.48 0.38 26.32% 0.21\n加权平均净资产收益率 14.07% 11.35% 2.72% 6.90%\n2019年末 2018年末 本年末比上年末增减 2017年末\n总资产（元） 6,747,198,664.47 7,035,373,344.57 -4.10% 7,466,927,438.54\n7。\n\n【表格内容】\n公司选定的信息披露媒体的名称 | 证券时报 中国证券报 上海证券报 证券日报 \n--------------------------------------------------\n登载年度报告的中国证监会指定网站的网址 | http://www.cninfo.com.cn\n公司年度报告备置地点 | 公司投资发展部",
      "chunk_type": "table_group",
      "parent_id": "120612aa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1105,
      "page_number": 6,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入",
          "利润",
          "现金",
          "投资",
          "营业收入",
          "净利润",
          "净资产",
          "营业",
          "经营"
        ],
        "time_periods": [
          "2010-9",
          "2014-4"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          6
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200303",
        "report_type": null,
        "fiscal_year": 2010,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1105,
        "word_count": 102,
        "sentence_count": 40,
        "chinese_char_count": 489,
        "readability_score": 0.0,
        "information_density": 0.09049773755656107,
        "coherence_score": 0.7933333333333332,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6069998102106663,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "利润",
        "现金",
        "投资",
        "营业收入",
        "净利润",
        "净资产",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "d6a3fe5e",
      "content": "【表格内容】\n组织机构代码 | 913300001482332737\n--------------------------------------------------\n公司上市以来主营业务的变化情况（如 | \n | 无变更\n有） | \n | \n | 2010年9月，原控股股东罗邦鹏先生向其子罗煜竑先生转让其所持有的3,480万\n | 股（占总股本的21.68%）股份，使其成为公司控股股东。2014年4月，原控股股\n历次控股股东的变更情况（如有） | \n | 东罗煜竑先生向王云富先生转让其所持有的5,940万股（占总股本的18.31%）股\n | \n | 份，使其成为公司控股股东。",
      "chunk_type": "table_group",
      "parent_id": "3de1bf48",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 294,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "营业",
          "股本",
          "股份",
          "股东",
          "总股本"
        ],
        "time_periods": [
          "2010-9",
          "2014-4"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200465",
        "report_type": null,
        "fiscal_year": 2010,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 294,
        "word_count": 23,
        "sentence_count": 4,
        "chinese_char_count": 133,
        "readability_score": 0.0,
        "information_density": 0.17006802721088438,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5581549361207897,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "营业",
        "股本",
        "股份",
        "股东",
        "总股本"
      ]
    },
    {
      "chunk_id": "64c35536",
      "content": "【表格内容】\n会计师事务所名称 | 天健会计师事务所（特殊普通合伙）\n--------------------------------------------------\n会计师事务所办公地址 | 浙江省杭州市江干区钱江路1366 号华润大厦B座\n签字会计师姓名 | 沈维华 汪兢",
      "chunk_type": "table_group",
      "parent_id": "e19d656c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 140,
      "page_number": 7,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200542",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 140,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 66,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5298581453634085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "eaf1984a",
      "content": "【表格内容】\n归属于上市公司股东的净资产 | | | | \n--------------------------------------------------\n | 5,724,462,095.55 | 5,390,549,932.23 | 6.19% | 5,142,008,176.75\n（元） | | | | \n | | | |",
      "chunk_type": "table_group",
      "parent_id": "b66c6c60",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 168,
      "page_number": 8,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "净资产",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200609",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 168,
        "word_count": 24,
        "sentence_count": 4,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.17857142857142858,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5131473684210526,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "净资产",
        "股东"
      ]
    },
    {
      "chunk_id": "69fb08ea",
      "content": "【表格内容】\n项目 | 2019年金额 | 2018年金额 | 2017年金额 | 说明\n--------------------------------------------------\n非流动资产处置损益（包括已计提资产减 | -4,150,774.97 | | | \n | | -102,273.45 | 23,519,733.42 | \n值准备的冲销部分） | | | | \n | | | | \n越权审批或无正式批准文件的税收返还 | 1,828,299.60 | | | \n | | 1,237,210.17 | 760,878.00 | \n减免 | | | | \n | | | | \n计入当期损益的政府补助（与企业业务密 | 25,308,625.27 | | | \n切相关，按照国家统一标准定额或定量享 | | 10,554,527.86 | 8,815,813.87 | \n受的政府补助除外） | | | | \n委托他人投资或管理资产的损益 | 2,079,074.70 | 3,024,312.63 | 11,532,098.63 |",
      "chunk_type": "table_group",
      "parent_id": "73ae1737",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 477,
      "page_number": 8,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "税收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          8
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.200750",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 477,
        "word_count": 79,
        "sentence_count": 12,
        "chinese_char_count": 117,
        "readability_score": 0.0,
        "information_density": 0.0628930817610063,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5667067204301075,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "税收"
      ]
    },
    {
      "chunk_id": "8a33bf30",
      "content": "【表格内容】\n应用领域 | 产品名 | 适用症 | 类别\n--------------------------------------------------\n抗感染 | 美罗培南系列（4-AA MAP \n美罗培南粗品 美罗培南侧\n链） | 用于重症感染以及以G-菌为主的混合性感染 \n多重耐药菌感染 产酶菌感染。 | 原料药 中间体\n | 替比培南酯 | 全球首个口服碳青霉烯类新广谱抗生素，主要用\n于治疗儿童肺炎 中耳炎 鼻窦炎等 | 原料药\n | 亚胺培南的关键中间体\nKETO | 用于敏感菌所致的各种感染，特别适用于多种细\n菌联合感染和需氧菌及厌氧菌的混合感染。 | 中间体\n | 西司他汀酸中间体 | 西司他汀酸与亚安培南共同使用 | 中间体\n | 盐酸克林霉素胶囊 盐酸克\n林霉素 | 用于由链球菌属 葡萄球菌属及厌氧菌等敏感菌\n株所致的下述感染：中耳炎 鼻窦炎 化脓性扁\n桃体炎 肺炎；皮肤软组织感染 | 制剂 原料药\n | 克林霉素磷酸酯 | 用于敏感细菌引起的各种感染 败血症 骨髓炎\n等 | 原料药\n | 盐酸克林霉素棕榈酸酯 | 用于革兰阳性菌引起的各种感染性疾病以及厌\n氧菌引起的各种感染性疾病 | 原料药\n | 盐酸阿莫罗芬 | 用于真菌引起的指（趾）甲感染 | 原料药\n | 联苯双酯 | 用于治疗病毒性肝炎和药物性肝损伤引起转氨\n酶升高 | 原料药\n降糖类 | 伏格列波糖 | 改善糖尿病餐后高血糖 | 原料药\n | 瑞格列奈 | 用于饮食控制 降低体重与运动不能有效控制高\n血糖的2型糖尿病 | 原料药\n | 阿卡波糖片 | 用于胰岛素依赖型或非胰岛素依赖型的糖尿病 | 制剂\n心血管类 | 达比加群酯的关键中间体\nOA MD | 新一代口服抗凝药物直接凝血酶抑制剂(DTIs)，\n用于预防非瓣膜性房颤患者的卒中和全身性栓 | 中间体",
      "chunk_type": "table_group",
      "parent_id": "d63f4959",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 784,
      "page_number": 10,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          10
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201005",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 784,
        "word_count": 121,
        "sentence_count": 2,
        "chinese_char_count": 523,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.2926415094339623,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6001930501930502,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "afd729e5",
      "content": "【表格内容】\n| | 塞 | \n--------------------------------------------------\n | 琥珀酸美托洛尔 | 用于高血压 心绞痛的治疗 | 原料药\n兽药 | 氟苯尼考 | 用于鸡大肠杆菌病及鸭浆膜炎及鱼的杀鲑产生\n单胞菌 鳗弧菌等，用于敏感细菌所致牛 猪 \n鸡肠道感染及支原体引起的慢性呼吸道病。 | 原料药\n | 氟尼辛葡甲胺 | 用于缓解马的内脏绞痛 肌肉与骨骼紊乱引起的\n疼痛及抗炎；牛的各种疾病感染引起的急性炎症\n的控制；另外也可用于母猪乳房炎 子宫炎及无\n乳综合征的辅助治疗 | 原料药\n | 甲砜霉素 | 用于流感杆菌 大肠杆菌 沙门菌属所致的呼吸\n系统 肝胆系统 泌尿系统和消化系统的感染。 | 原料药\n精神类 | 富马酸喹硫平 | 用于治疗精神分裂症 | 原料药",
      "chunk_type": "table_group",
      "parent_id": "c23f5de2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 364,
      "page_number": 11,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201164",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 364,
        "word_count": 53,
        "sentence_count": 2,
        "chinese_char_count": 232,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.6973273273273274,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5670646239554318,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "6df6da27",
      "content": "【表格内容】\n主要类别 | | 主要产品及用途\n--------------------------------------------------\n染料 | | 主要生产蓝色系列产品，包括活性艳蓝KN-R（HG） KN-R（SR） \nKN-R（SP），P-3R, KE-GN KN-BB ME-BP，活性翠蓝KN-G以及\n酸性蒽醌蓝等，主要用于棉 麻 丝等天然纤维织物的染色，具有较\n高的日晒牢度和优良的匀染性，适用于连续染色 冷轧堆等印染工艺。\n染颜料中间体 | 染料中间体 | 主要生产氨基油 溴氨酸 间位酯等染料中间体，用于合成乙烯基砜\n型染料 蒽醌型染料。\n | 颜料中间体 | 主要生产DCB等颜料中间体，主要用于颜料黄12，13，14，17，35，\n55，颜料橙13，颜料红38等中高档双芳胺类偶氮颜料",
      "chunk_type": "table_group",
      "parent_id": "8fb6ba79",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 358,
      "page_number": 11,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201308",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 358,
        "word_count": 34,
        "sentence_count": 2,
        "chinese_char_count": 179,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3983333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5449626062322946,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "473b1f0f",
      "content": "【标题】二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。\n\n【表格内容】\n| \n--------------------------------------------------\n主要资产 | 重大变化说明\n | \n股权资产 | 无重大变化\n固定资产 | 主要系川南 前进 振港在建工程转固所致。\n无形资产 | 无重大变化\n在建工程 | 无重大变化",
      "chunk_type": "table_group",
      "parent_id": "d69b547b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 250,
      "page_number": 12,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产",
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          12
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.201408",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 250,
        "word_count": 33,
        "sentence_count": 3,
        "chinese_char_count": 143,
        "readability_score": 0.0,
        "information_density": 0.16,
        "coherence_score": 0.4319047619047619,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6128553826030085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产",
        "股权"
      ]
    },
    {
      "chunk_id": "ec6e87ae",
      "content": "染料 | 973,070,914.24 | 33.08% | 844,776,715.53 | 31.07% | 15.19%\n--------------------------------------------------\n染料中间体 | 343,759,248.43 | 11.69% | 405,163,859.03 | 14.90% | -15.16%\n其他 | 15,723,864.16 | 0.53% | 27,076,798.44 | 1.00% | -41.93%\n分地区 |  |  |  |  | \n国内 | 1,512,860,024.18 | 51.43% | 1,390,967,219.07 | 51.16% | 8.76%\n国外 | 1,428,552,746.12 | 48.57% | 1,327,641,577.44 | 48.84% | 7.60%",
      "chunk_type": "table_group",
      "parent_id": "5aa8bf83",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 896,
      "page_number": 16,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          16
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.201982",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 396,
        "word_count": 62,
        "sentence_count": 25,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.025252525252525256,
        "coherence_score": 0.3156923076923077,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3205212121212121,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "af3574f9",
      "content": "【表格内容】\n| 生产量 | 千克 | 1,578,601.92 | 1,380,545.9 | 14.35%\n--------------------------------------------------\n | 库存量 | 千克 | 415,819.13 | 333,052.01 | 24.85%\n | 销售量 | 吨 | 12,857.65 | 13,393.7 | -4.00%\n染料行业 | 生产量 | 吨 | 12,911.47 | 13,832.98 | -6.66%\n | 库存量 | 吨 | 1,868.83 | 1,815.01 | 2.97%",
      "chunk_type": "table_group",
      "parent_id": "b7065e21",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 285,
      "page_number": 17,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          17
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.202522",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 285,
        "word_count": 53,
        "sentence_count": 15,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.03508771929824561,
        "coherence_score": 0.32343749999999993,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39477849462365594,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "8817494b",
      "content": "【表格内容】\n| | 2019年 | | 2018年 | | \n--------------------------------------------------\n行业分类 | 项目 | | | | | 同比增减\n | | 金额 | 占营业成本比重 | 金额 | 占营业成本比重 | \n | | | | | | \n医药行业 | 原料成本 | 788,091,701.93 | 80.16% | 778,035,997.89 | 80.14% | 0.02%\n医药行业 | 人工成本 | 53,109,659.74 | 5.40% | 53,601,426.45 | 5.52% | -0.12%\n医药行业 | 能源成本 | 47,606,219.00 | 4.84% | 45,369,217.29 | 4.67% | 0.17%\n医药行业 | 制造费用 | 94,341,850.29 | 9.60% | 93,792,389.85 | 9.66% | -0.07%\n染料行业 | 原料成本 | 337,976,777.23 | 72.57% | 383,594,259.37 | 73.59% | -1.01%\n染料行业 | 人工成本 | 33,802,565.03 | 7.26% | 28,163,412.97 | 5.40% | 1.86%\n染料行业 | 能源成本 | 34,241,371.69 | 7.35% | 37,944,159.74 | 7.28% | 0.07%\n染料行业 | 制造费用 | 59,676,545.54 | 12.81% | 71,581,678.92 | 13.73% | -0.92%\n其他业务 | | 14,312,670.59 | 100.00% | 19,862,133.71 | 100.00% | 0.00%",
      "chunk_type": "table_group",
      "parent_id": "f1c78b02",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 782,
      "page_number": 17,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "费用",
          "营业成本",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          17
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.202742",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 782,
        "word_count": 151,
        "sentence_count": 45,
        "chinese_char_count": 102,
        "readability_score": 0.0,
        "information_density": 0.05115089514066497,
        "coherence_score": 0.32099999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4769409282700422,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "费用",
        "营业成本",
        "营业"
      ]
    },
    {
      "chunk_id": "ce8601f7",
      "content": " |  | 2019年 |  | 2018年 |  | \n--------------------------------------------------\n产品分类 | 项目 |  |  |  |  | 同比增减\n |  | 金额 | 占营业成本比重 | 金额 | 占营业成本比重 | \n |  |  |  |  |  | \n原料药 |  | 652,198,278.33 | 44.57% | 694,525,290.09 | 45.94% | \n医药中间体 |  | 328,224,382.60 | 22.43% | 272,841,947.14 | 18.05% | \n制剂 |  | 2,726,770.03 | 0.19% | 3,431,794.24 | 0.23% | \n染料 |  | 312,738,811.13 | 21.37% | 318,486,635.33 | 21.06% | \n染料中间体 |  | 152,958,448.36 | 10.45% | 202,796,875.67 | 13.41% | \n其他 |  | 14,312,670.59 | 0.98% | 19,862,133.71 | 1.31% | ",
      "chunk_type": "table_group",
      "parent_id": "fdff3777",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1027,
      "page_number": 17,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "营业成本",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          17
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.203051",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 527,
        "word_count": 100,
        "sentence_count": 24,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.05692599620493359,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44456040480708414,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "营业成本",
        "营业"
      ]
    },
    {
      "chunk_id": "b38a66b8",
      "content": "【表格内容】\n公司名称 | 股权取得方式 | 股权取得时点 | 出资额\n--------------------------------------------------\n盛嘉环保公司 | 设立 | 2019/4/29 |",
      "chunk_type": "table_group",
      "parent_id": "fcb8e670",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 112,
      "page_number": 18,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203113",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.08928571428571427,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3844075471698113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权"
      ]
    },
    {
      "chunk_id": "26c74f3c",
      "content": "【表格内容】\n前五名客户合计销售金额（元） | 649,326,403.37\n--------------------------------------------------\n前五名客户合计销售金额占年度销售总额比例 | 22.08%\n前五名客户销售额中关联方销售额占年度销售总额比 | \n | 0.00%\n例 | \n |",
      "chunk_type": "table_group",
      "parent_id": "9d8c041f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 163,
      "page_number": 18,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203205",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 163,
        "word_count": 15,
        "sentence_count": 3,
        "chinese_char_count": 60,
        "readability_score": 0.0,
        "information_density": 0.06134969325153374,
        "coherence_score": 0.5423809523809524,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48490318471337573,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "8faec516",
      "content": "【表格内容】\n序号 | 客户名称 | 销售额（元） | 占年度销售总额比例\n--------------------------------------------------\n1 | 客户1 | 212,211,696.91 | 7.21%\n2 | 客户2 | 149,494,409.10 | 5.08%\n3 | 客户3 | 105,676,622.82 | 3.59%\n4 | 客户4 | 93,657,620.14 | 3.18%\n5 | 客户5 | 88,286,054.40 | 3.00%\n合计 | -- | 649,326,403.37 | 22.08%",
      "chunk_type": "table_group",
      "parent_id": "2e7d222d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 285,
      "page_number": 18,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203410",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 285,
        "word_count": 51,
        "sentence_count": 12,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.03508771929824561,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.472326618705036,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "56c6cb8e",
      "content": "【表格内容】\n前五名供应商合计采购金额（元） | 328,471,523.80\n--------------------------------------------------\n前五名供应商合计采购金额占年度采购总额比例 | 20.82%\n前五名供应商采购额中关联方采购额占年度采购总额 | \n | 0.00%\n比例 | \n |",
      "chunk_type": "table_group",
      "parent_id": "a9803204",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 166,
      "page_number": 18,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203507",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 166,
        "word_count": 15,
        "sentence_count": 3,
        "chinese_char_count": 63,
        "readability_score": 0.0,
        "information_density": 0.06024096385542169,
        "coherence_score": 0.5344444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4873125,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "60c07ce0",
      "content": "【说明】4 供应商4 38,420,130.22 2.44%\n5 供应商5 35,902,602.45 2.28%\n合计 -- 328,471,523.80 20.82%\n主要供应商其他情况说明\n□ 适用 √ 不适用\n3、费用\n单位：元\n2019年 2018年 同比增减 重大变动说明\n销售费用 59,623,024.88 43,781,054.42 36.18%主要系佣金增加所致\n管理费用 386,185,538.84 349,284,396.57 10.56%\n财务费用 -37,865,156.06 -51,507,397.78 -26.49%\n研发费用 122,548,224.53 111,304,662.07 10.10%\n4、研发投入\n√ 适用 □ 不适用\n公司注重技术研发，坚持技术创新。报告期内，公司在新设备、新产品、新工艺、新材\n料、新应用技术等方面，开展了有针对性的研究创新。在提升公司产品质量与性能方面，取\n得了突出的成果，提高了公司产品综合竞争力。\n\n【表格内容】\n序号 | 供应商名称 | 采购额（元） | 占年度采购总额比例\n--------------------------------------------------\n1 | 供应商1 | 144,631,621.96 | 9.17%\n2 | 供应商2 | 56,660,417.02 | 3.59%\n3 | 供应商3 | 52,856,752.15 | 3.35%",
      "chunk_type": "table_group",
      "parent_id": "6c4890fc",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 629,
      "page_number": 18,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "销售费用",
          "管理费用",
          "研发费用",
          "财务费用",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203695",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 629,
        "word_count": 77,
        "sentence_count": 27,
        "chinese_char_count": 197,
        "readability_score": 0.0,
        "information_density": 0.09538950715421304,
        "coherence_score": 0.4099999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5389862226274453,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "销售费用",
        "管理费用",
        "研发费用",
        "财务费用",
        "报告"
      ]
    },
    {
      "chunk_id": "4ff3b3da",
      "content": "【说明】公司研发投入情况\n2019年 2018年 变动比例\n研发人员数量（人） 443 405 9.38%\n研发人员数量占比 13.45% 12.75% 0.70%\n研发投入金额（元） 122,548,224.53 111,304,662.07 10.10%\n研发投入占营业收入比例 4.17% 4.09% 0.08%\n研发投入资本化的金额（元） 0.00 0.00 0.00%\n资本化研发投入占研发投入\n0.00% 0.00% 0.00%\n的比例\n研发投入总额占营业收入的比重较上年发生显著变化的原因\n□ 适用 √ 不适用\n研发投入资本化率大幅变动的原因及其合理性说明\n□ 适用 √ 不适用\n5、现金流\n单位：元\n19。\n\n【表格内容】\n4 | 供应商4 | 38,420,130.22 | 2.44%\n--------------------------------------------------\n5 | 供应商5 | 35,902,602.45 | 2.28%\n合计 | -- | 328,471,523.80 | 20.82%",
      "chunk_type": "table_group",
      "parent_id": "4cf6f8bd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 470,
      "page_number": 19,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "现金",
          "营业收入",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203864",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 470,
        "word_count": 65,
        "sentence_count": 23,
        "chinese_char_count": 151,
        "readability_score": 0.0,
        "information_density": 0.0851063829787234,
        "coherence_score": 0.4002086466165414,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4460019109663409,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "现金",
        "营业收入",
        "营业"
      ]
    },
    {
      "chunk_id": "3d540ab4",
      "content": "【表格内容】\n| 2019年 | 2018年 | 同比增减 | 重大变动说明\n--------------------------------------------------\n销售费用 | 59,623,024.88 | 43,781,054.42 | 36.18% | 主要系佣金增加所致\n管理费用 | 386,185,538.84 | 349,284,396.57 | 10.56% | \n财务费用 | -37,865,156.06 | -51,507,397.78 | -26.49% | \n研发费用 | 122,548,224.53 | 111,304,662.07 | 10.10% |",
      "chunk_type": "table_group",
      "parent_id": "56e887d3",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 300,
      "page_number": 19,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "销售费用",
          "管理费用",
          "研发费用",
          "财务费用"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          19
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.203981",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 300,
        "word_count": 43,
        "sentence_count": 12,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.16666666666666669,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4361468926553672,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "销售费用",
        "管理费用",
        "研发费用",
        "财务费用"
      ]
    },
    {
      "chunk_id": "ee851b7f",
      "content": "【说明】在建工程 560,674,634.43 8.31% 674,333,677.99 9.58% -1.27%\n短期借款 200,267,029.59 2.97% 598,700,000.00 8.51% -5.54%\n2、以公允价值计量的资产和负债\n□ 适用 √ 不适用\n3、截至报告期末的资产权利受限情况\n项 目 期末账面价值 受限原因\n货币资金 30,797,464.00 开立银行承兑汇票\n固定资产 22,554,937.46 银行融资抵押\n无形资产 10,291,182.19 银行融资抵押\n合 计 63,643,583.65\n五、投资状况分析\n1、总体情况\n√ 适用 □ 不适用\n报告期投资额（元） 上年同期投资额（元） 变动幅度\n593,621,971.72 606,637,800.32 -2.15%\n2、报告期内获取的重大的股权投资情况\n□ 适用 √ 不适用\n3、报告期内正在进行的重大的非股权投资情况\n□ 适用 √ 不适用\n4、以公允价值计量的金融资产\n□ 适用 √ 不适用\n5、募集资金使用情况\n√ 适用 □ 不适用\n（1）募集资金总体使用情况\n√ 适用 □ 不适用\n单位：万元\n21。\n\n【表格内容】\n| 2019年末 | | 2019年初 | | | \n--------------------------------------------------\n | | | | | 比重增减 | 重大变动说明\n | 金额 | 占总资产比例 | 金额 | 占总资产比例 | | \n | | | | | | \n货币资金 | 1,556,575,372.45 | 23.07% | 1,956,089,124.33 | 27.80% | -4.73% | \n应收账款 | 459,781,564.19 | 6.81% | 479,537,782.06 | 6.82% | -0.01% | \n存货 | 842,985,260.60 | 12.49% | 905,418,218.49 | 12.87% | -0.38% | \n投资性房地产 | 11,206,951.46 | 0.17% | 12,338,615.29 | 0.18% | -0.01% | \n长期股权投资 | 47,879,382.43 | 0.71% | 66,088,139.79 | 0.94% | -0.23% | \n固定资产 | 1,724,407,333.34 | 25.56% | 1,215,120,643.61 | 17.27% | 8.29% |",
      "chunk_type": "table_group",
      "parent_id": "548081b0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1077,
      "page_number": 20,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "投资",
          "应收",
          "存货",
          "固定资产",
          "无形资产",
          "股权",
          "报告",
          "公允价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          20
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204281",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1077,
        "word_count": 179,
        "sentence_count": 48,
        "chinese_char_count": 278,
        "readability_score": 0.0,
        "information_density": 0.09285051067780872,
        "coherence_score": 0.43999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5713641425756668,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "应收",
        "存货",
        "固定资产",
        "无形资产",
        "股权",
        "报告",
        "公允价值"
      ]
    },
    {
      "chunk_id": "6be31084",
      "content": "【表格内容】\n在建工程 | 560,674,634.43 | 8.31% | 674,333,677.99 | 9.58% | -1.27% | \n--------------------------------------------------\n短期借款 | 200,267,029.59 | 2.97% | 598,700,000.00 | 8.51% | -5.54% |",
      "chunk_type": "table_group",
      "parent_id": "885eeb58",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 190,
      "page_number": 21,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          21
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204387",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 190,
        "word_count": 26,
        "sentence_count": 10,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.05263157894736842,
        "coherence_score": 0.3518181818181818,
        "standards_profile_summary": {}
      },
      "quality_score": 0.36832173913043476,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "借款"
      ]
    },
    {
      "chunk_id": "6e3edbe8",
      "content": "【表格内容】\n项 目 | 期末账面价值 | 受限原因\n--------------------------------------------------\n货币资金 | 30,797,464.00 | 开立银行承兑汇票\n固定资产 | 22,554,937.46 | 银行融资抵押\n无形资产 | 10,291,182.19 | 银行融资抵押\n合 计 | 63,643,583.65 |",
      "chunk_type": "table_group",
      "parent_id": "948753c7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 191,
      "page_number": 21,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产",
          "账面价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          21
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204461",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 191,
        "word_count": 28,
        "sentence_count": 4,
        "chinese_char_count": 50,
        "readability_score": 0.0,
        "information_density": 0.31413612565445026,
        "coherence_score": 0.5233333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4326306306306306,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "4186d45a",
      "content": "【说明】报告期内 累计变更 累计变更 尚未使用\n本期已使 已累计使 尚未使用 闲置两年\n募集资金 变更用途 用途的募 用途的募 募集资金\n募集年份 募集方式 用募集资 用募集资 募集资金 以上募集\n总额 的募集资 集资金总 集资金总 用途及去\n金总额 金总额 总额 资金金额\n金总额 额 额比例 向\n非公开发\n2016年 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 存放银行 0\n行股票\n合计 -- 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 -- 0\n募集资金总体使用情况说明\n1、经中国证券监督管理委员会证监许可〔2016〕765号文核准，并经深圳证券交易所同意，本公司由主承销商国泰君安证\n券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币普通股（A股）股票99,890,023股，发行价为每股人\n民币10.28元，共计募集资金1,026,869,436.44元，坐扣承销费和保荐费等10,000,000.00元（含税）后的募集资金为\n1,016,869,436.44元，已由主承销商国泰君安证券股份有限公司于2016年9月1日汇入本公司募集资金监管账户。扣除承\n销费及保荐费、律师费、会计师费用、登记费等发行费用12,465,829.73元后，本公司本次募集资金净额1,014,403,606.71\n元。上述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验证，并由其出具《验资报告》（天健验〔2016〕358号）。\n\n【表格内容】\n报告期投资额（元） | 上年同期投资额（元） | 变动幅度\n--------------------------------------------------\n593,621,971.72 | 606,637,800.32 | -2.15%",
      "chunk_type": "table_group",
      "parent_id": "aa891f1c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 841,
      "page_number": 21,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "投资",
          "股份",
          "每股",
          "报告",
          "证券"
        ],
        "time_periods": [
          "2016-9"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          21
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.204693",
        "report_type": null,
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "券股份有限公司",
        "industry": null,
        "char_count": 841,
        "word_count": 74,
        "sentence_count": 26,
        "chinese_char_count": 398,
        "readability_score": 0.0,
        "information_density": 0.0713436385255648,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.538262154940777,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "投资",
        "股份",
        "每股",
        "报告",
        "证券"
      ]
    },
    {
      "chunk_id": "901a9a1f",
      "content": " |  |  | 本期已使\n用募集资\n金总额 |  | 报告期内 | 累计变更 | 累计变更 |  | 尚未使用\n募集资金\n用途及去\n向 | \n--------------------------------------------------\n |  |  |  | 已累计使 |  |  |  | 尚未使用 |  | 闲置两年\n |  | 募集资金 |  |  | 变更用途 | 用途的募 | 用途的募 |  |  | \n募集年份 | 募集方式 |  |  | 用募集资 |  |  |  | 募集资金 |  | 以上募集\n |  | 总额 |  |  | 的募集资 | 集资金总 | 集资金总 |  |  | \n |  |  |  | 金总额 |  |  |  | 总额 |  | 资金金额\n |  |  |  |  | 金总额 | 额 | 额比例 |  |  | \n |  |  |  |  |  |  |  |  |  | \n | 非公开发 |  |  |  |  |  |  |  |  | \n2016年 |  | 101,440.36 | 48,002.14 | 81,781.91 | 37,061.61 | 37,061.61 | 36.54% | 24,703.42 | 存放银行 | 0\n | 行股票 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n合计 | -- | 101,440.36 | 48,002.14 | 81,781.91 | 37,061.61 | 37,061.61 | 36.54% | 24,703.42 | -- | 0\n募集资金总体使用情况说明 |  |  |  |  |  |  |  |  |  | \n1、经中国证券监督管理委员会证监许可〔2016〕765号文核准，并经深圳证券交易所同意，本公司由主承销商国泰君安证 |  |  |  |  |  |  |  |  |  | \n券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币普通股（A股）股票99,890,023股，发行价为每股人 |  |  |  |  |  |  |  |  |  | \n民币10.28元，共计募集资金1,026,869,436.44元，坐扣承销费和保荐费等10,000,000.00元（含税）后的募集资金为 |  |  |  |  |  |  |  |  |  | \n1,016,869,436.44元，已由主承销商国泰君安证券股份有限公司于2016年9月1日汇入本公司募集资金监管账户。扣除承 |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "0b0dde60",
      "child_ids": [],
      "sibling_ids": [
        "27b5491e"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1631,
      "page_number": 22,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份",
          "每股",
          "报告",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.205253",
        "report_type": null,
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "券股份有限公司",
        "industry": null,
        "char_count": 1131,
        "word_count": 241,
        "sentence_count": 19,
        "chinese_char_count": 296,
        "readability_score": 0.0,
        "information_density": 0.03536693191865605,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6558818295070297,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "每股",
        "报告",
        "证券"
      ]
    },
    {
      "chunk_id": "27b5491e",
      "content": "销费及保荐费、律师费、会计师费用、登记费等发行费用12,465,829.73元后，本公司本次募集资金净额1,014,403,606.71 |  |  |  |  |  |  |  |  |  | \n元。上述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验证，并由其出具《验资报告》（天健验〔2016〕358号）。 |  |  |  |  |  |  |  |  |  | \n2、本公司以前年度已使用募集资金337,797,729.53元，以前年度收到的银行存款利息扣除银行手续费等的净额为 |  |  |  |  |  |  |  |  |  | \n16,576,229.98元，以前年度收到的理财产品收益金额为20,933,628.61元；2019年度实际使用募集资金480,021,367.74元（含 |  |  |  |  |  |  |  |  |  | \n永久性补充流动资金370,616,060.66 元），2019年度收到的银行存款利息扣除银行手续费等的净额为4,244,642.08元，2019 |  |  |  |  |  |  |  |  |  | \n年度收到的理财产品收益金额为8,695,157.17元；累计已使用募集资金817,819,097.27元，累计收到的银行存款利息扣除 |  |  |  |  |  |  |  |  |  | \n银行手续费等的净额为20,820,872.06元，累计收到的理财产品收益金额为29,628,785.78元。截至2019年12月31日，募 |  |  |  |  |  |  |  |  |  | \n集资金余额为人民币247,034,167.28元。 |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "0b0dde60",
      "child_ids": [],
      "sibling_ids": [
        "901a9a1f"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1741,
      "page_number": 22,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          22
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.205355",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 741,
        "word_count": 89,
        "sentence_count": 17,
        "chinese_char_count": 261,
        "readability_score": 0.0,
        "information_density": 0.026990553306342778,
        "coherence_score": 0.3172222222222222,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6558818295070297,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "报告"
      ]
    },
    {
      "chunk_id": "b9be9d4b",
      "content": "【表格内容】\n| 是否已变 | | | | | 截至期末 | 项目达到 | | | 项目可行\n--------------------------------------------------\n | | 募集资金 | 调整后投 | | 截至期末 | | | 本报告期 | | \n承诺投资项目和超募 | 更项目 | | | 本报告期 | | 投资进度 | 预定可使 | | 是否达到 | 性是否发\n | | 承诺投资 | 资总额 | | 累计投入 | | | 实现的效 | | \n资金投向 | (含部分 | | | 投入金额 | | (3) | 用状态日 | | 预计效益 | 生重大变\n | | 总额 | (1) | | 金额(2) | | | 益 | | \n | 变更) | | | | | (2)/(1) | 期 | | | 化\n | | | | | | | | | | \n承诺投资项目 | | | | | | | | | | \n原料药及中间体CMO | | | | | | | 2019年7 | | | \n | 否 | 40,000 | 28,440.36 | 4,548.29 | 28,796.95 | 101.25% | | 0.00[注] | 否 | 否\n中心扩建项目 | | | | | | | 月[注] | | | \n | | | | | | | | | | \n年产30亿片（粒）固 | | | | | | | | | | \n | 是 | 35,000 | | | | | | | 不适用 | 是\n体制剂技改项目 | | | | | | | | | | \n | | | | | | | | | | \n医药综合研发中心 | 否 | 15,000 | 15,000 | 2,521.91 | 2,611.91 | 17.41% | | | 不适用 | 否\n医药中试车间技改项 | | | | | | | | | | \n | 否 | 9,000 | 9,000 | 1,436.42 | 4,730.88 | 52.57% | | | 不适用 | 否\n目 | | | | | | | | | | \n | | | | | | | | | | \n环保设施改造项目 | 否 | 14,000 | 14,000 | 2,433.91 | 8,580.56 | 61.29% | | | 不适用 | 否\n承诺投资项目小计 | -- | 113,000 | 66,440.36 | 10,940.53 | 44,720.3 | -- | -- | | -- | --\n超募资金投向 | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "43d67af9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1111,
      "page_number": 22,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.205629",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1111,
        "word_count": 345,
        "sentence_count": 17,
        "chinese_char_count": 214,
        "readability_score": 0.0,
        "information_density": 0.018001800180018002,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.524960380348653,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "报告"
      ]
    },
    {
      "chunk_id": "2eb363c1",
      "content": "无 |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n归还银行贷款（如有） | -- |  |  |  |  |  | -- | -- | -- | --\n补充流动资金（如有） | -- |  |  |  |  |  | -- | -- | -- | --\n超募资金投向小计 | -- |  |  |  |  | -- | -- |  | -- | --\n合计 | -- | 113,000 | 66,440.36 | 10,940.53 | 44,720.3 | -- | -- | 0 | -- | --\n | “医药综合研发中心项目”原实施地点为公司椒江区外沙厂区，考虑各子公司所在园区的长远发展规 |  |  |  |  |  |  |  |  | \n | 划，对子公司职能定位进行调整，公司将项目的实施主体由公司变更为全资子公司川南药业，实施 |  |  |  |  |  |  |  |  | \n | 地点变更为浙江省临海市，因此导致投资进度有所延缓。 |  |  |  |  |  |  |  |  | \n未达到计划进度或预 | “医药中试车间技改项目” 主要是通过实施原料药和关键中间体产品的中试生产，为产品的中试开发 |  |  |  |  |  |  |  |  | \n计收益的情况和原因 | 提供工艺验证和数据收集，为开发大规模生产的产品提供必要的研发支持。该项目计划建设用地位 |  |  |  |  |  |  |  |  | \n（分具体项目） | 于公司外沙厂区，需要拆除原有车间，在原址上新建厂房。由于原车间为药证体系注册车间，需要 |  |  |  |  |  |  |  |  | \n | 办理相关药证转移变更程序，故导致医药中试车间技改项目进度低于规划进度。 |  |  |  |  |  |  |  |  | \n | “环保设施改造项目”为配合厂区产能整体规划、协同活性染料产业升级及配套项目建设规划需要， |  |  |  |  |  |  |  |  | \n | 投入与实施计划有所延缓。 |  |  |  |  |  |  |  |  | \n | 根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资 |  |  |  |  |  |  |  |  | \n项目可行性发生重大 | 项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目 |  |  |  |  |  |  |  |  | \n变化的情况说明 | 的市场环境已发生较大变化，公司终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普 |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "830ca2b4",
      "child_ids": [],
      "sibling_ids": [
        "13925b03"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1701,
      "page_number": 23,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          23
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.206102",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1201,
        "word_count": 223,
        "sentence_count": 9,
        "chinese_char_count": 482,
        "readability_score": 0.0,
        "information_density": 0.01665278934221482,
        "coherence_score": 0.6740816326530612,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6656480661352229,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东"
      ]
    },
    {
      "chunk_id": "13925b03",
      "content": " | 通账户，用于永久补充公司流动资金。 |  |  |  |  |  |  |  |  | \n超募资金的金额、用途 | 不适用 |  |  |  |  |  |  |  |  | \n及使用进展情况 |  |  |  |  |  |  |  |  |  | \n | 适用 |  |  |  |  |  |  |  |  | \n | 以前年度发生 |  |  |  |  |  |  |  |  | \n募集资金投资项目实 |  |  |  |  |  |  |  |  |  | \n | 根据公司2018年8月28日第五届董事会第十八次会议审议通过的《关于变更部分募集资金投资项\n目实施主体和地点的议案》，公司将募集资金投资项目“医药综合研发中心”实施主体由公司变更为全\n资子公司浙江海翔川南药业有限公司，实施地点变更为浙江省临海市。 |  |  |  |  |  |  |  |  | \n施地点变更情况 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n | 不适用 |  |  |  |  |  |  |  |  | \n募集资金投资项目实 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n施方式调整情况 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n募集资金投资项目先 | 不适用 |  |  |  |  |  |  |  |  | \n期投入及置换情况 |  |  |  |  |  |  |  |  |  | \n用闲置募集资金暂时 | 不适用 |  |  |  |  |  |  |  |  | \n补充流动资金情况 |  |  |  |  |  |  |  |  |  | \n项目实施出现募集资 | 不适用 |  |  |  |  |  |  |  |  | \n金结余的金额及原因 |  |  |  |  |  |  |  |  |  | \n尚未使用的募集资金 |  |  |  |  |  |  |  |  |  | \n | 存放银行 |  |  |  |  |  |  |  |  | \n用途及去向 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "830ca2b4",
      "child_ids": [],
      "sibling_ids": [
        "2eb363c1"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2056,
      "page_number": 23,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          23
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.206233",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1056,
        "word_count": 276,
        "sentence_count": 2,
        "chinese_char_count": 263,
        "readability_score": 0.0,
        "information_density": 0.00946969696969697,
        "coherence_score": 0.7021428571428572,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6656480661352229,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资"
      ]
    },
    {
      "chunk_id": "3ff19b8c",
      "content": "【标题】2、出售重大股权情况\n□ 适用 √ 不适用\n七、主要控股参股公司分析\n√ 适用 □ 不适用\n主要子公司及对公司净利润影响达10%以上的参股公司情况\n24。\n\n【表格内容】\n募集资金使用及披露 | \n--------------------------------------------------\n中存在的问题或其他 | 不存在重大问题\n情况 |",
      "chunk_type": "table_group",
      "parent_id": "5860c420",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 178,
      "page_number": 24,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "净利润",
          "股权",
          "披露"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.206335",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 178,
        "word_count": 21,
        "sentence_count": 1,
        "chinese_char_count": 86,
        "readability_score": 0.0,
        "information_density": 0.22471910112359553,
        "coherence_score": 0.21,
        "standards_profile_summary": {}
      },
      "quality_score": 0.46909765260956277,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "净利润",
        "股权",
        "披露"
      ]
    },
    {
      "chunk_id": "b2df5fb0",
      "content": " |  | 变更后项目 |  |  |  |  |  |  | 变更后的项\n--------------------------------------------------\n |  |  |  | 截至期末实 | 截至期末投 | 项目达到预 |  |  | \n变更后的项 | 对应的原承 | 拟投入募集 | 本报告期实 |  |  |  | 本报告期实 | 是否达到预 | 目可行性是\n |  |  |  | 际累计投入 | 资进度 | 定可使用状 |  |  | \n目 | 诺项目 | 资金总额 | 际投入金额 |  |  |  | 现的效益 | 计效益 | 否发生重大\n |  |  |  | 金额(2) | (3)=(2)/(1) | 态日期 |  |  | \n |  | (1) |  |  |  |  |  |  | 变化\n |  |  |  |  |  |  |  |  | \n | 年产30亿 |  |  |  |  |  |  |  | \n永久补充流 | 片（粒）固 |  |  |  |  |  |  |  | \n |  | 37,061.61 | 37,061.61 | 37,061.61 | 100.00% |  | 0 | 不适用 | 否\n动资金 | 体制剂技改 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n | 项目 |  |  |  |  |  |  |  | \n合计 | -- | 37,061.61 | 37,061.61 | 37,061.61 | -- | -- | 0 | -- | --\n |  |  | 根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分 |  |  |  |  |  | \n变更原因、决策程序及信息披露情况 |  |  | 募集资金投资项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿 |  |  |  |  |  | \n说明(分具体项目) |  |  | 片（粒）固体制剂技改项目的市场环境已发生较大变化，公司终止实施该项目并将结 |  |  |  |  |  | \n |  |  | 余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。 |  |  |  |  |  | \n未达到计划进度或预计收益的情况 |  |  |  |  |  |  |  |  | \n |  |  | 不适用 |  |  |  |  |  | \n和原因(分具体项目) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n变更后的项目可行性发生重大变化 |  |  |  |  |  |  |  |  | \n |  |  | 不适用 |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "047f2ae0",
      "child_ids": [],
      "sibling_ids": [
        "dda86cc4"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1708,
      "page_number": 24,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股东",
          "报告",
          "披露"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.206822",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1208,
        "word_count": 291,
        "sentence_count": 9,
        "chinese_char_count": 320,
        "readability_score": 0.0,
        "information_density": 0.033112582781456956,
        "coherence_score": 0.6881818181818182,
        "standards_profile_summary": {}
      },
      "quality_score": 0.643498817966903,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东",
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "dda86cc4",
      "content": "的情况说明 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "047f2ae0",
      "child_ids": [],
      "sibling_ids": [
        "b2df5fb0"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1060,
      "page_number": 24,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 2,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          24
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.206881",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 60,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 5,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.643498817966903,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "57f538e0",
      "content": "【表格内容】\n公司名称 | 报告期内取得和处置子公司方式 | 对整体生产经营和业绩的影响\n--------------------------------------------------\n浙江盛嘉环保有限公司 | 设立 | 无",
      "chunk_type": "table_group",
      "parent_id": "c37746c0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 115,
      "page_number": 25,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          25
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.206928",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 115,
        "word_count": 12,
        "sentence_count": 0,
        "chinese_char_count": 48,
        "readability_score": 0.0,
        "information_density": 0.1739130434782609,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4077111111111111,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营",
        "报告"
      ]
    },
    {
      "chunk_id": "ced0c1a8",
      "content": "接待时间 | 接待方式 | 接待对象类型 | 调研的基本情况索引\n--------------------------------------------------\n |  |  | 具体内容详见互动易平台2019年3月\n2019年03月11日 | 实地调研 | 机构 | \n |  |  | 12日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年4月\n2019年04月09日 | 实地调研 | 机构 | \n |  |  | 10日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年4月\n2019年04月25日 | 实地调研 | 机构 | \n |  |  | 26日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年5月\n2019年05月14日 | 实地调研 | 机构 | \n |  |  | 17日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年5月\n2019年05月15日 | 实地调研 | 机构 | \n |  |  | 17日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年6月\n2019年06月04日 | 实地调研 | 机构 | \n |  |  | 6日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年6月\n2019年06月05日 | 实地调研 | 机构 | \n |  |  | 6日的投资者活动关系表\n |  |  | \n |  |  | 具体内容详见互动易平台2019年9月\n2019年09月16日 | 实地调研 | 机构 | \n |  |  | 16日的投资者活动关系表\n |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "6c614835",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1277,
      "page_number": 27,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "投资者"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          27
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.207224",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 777,
        "word_count": 144,
        "sentence_count": 0,
        "chinese_char_count": 279,
        "readability_score": 0.0,
        "information_density": 0.025740025740025742,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4577220077220078,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "投资者"
      ]
    },
    {
      "chunk_id": "3764960c",
      "content": "【说明】公司近三年（包括本报告期）普通股现金分红情况表\n单位：元\n现金分红总额\n现金分红金额 以其他方式现\n分红年度合并 （含其他方\n占合并报表中 以其他方式 金分红金额占\n报表中归属于 现金分红总额 式）占合并报\n现金分红金额 归属于上市公 （如回购股 合并报表中归\n分红年度 上市公司普通 （含其他方 表中归属于上\n（含税） 司普通股股东 份）现金分红 属于上市公司\n股股东的净利 式） 市公司普通股\n的净利润的比 的金额 普通股股东的\n润 股东的净利润\n率 净利润的比例\n的比率\n2019年 466,712,809.50 770,782,185.09 60.55% 19,996,827.22 2.59% 486,709,636.72 63.14%\n28。\n\n【表格内容】\n现金分红政策的专项说明 | \n--------------------------------------------------\n是否符合公司章程的规定或股东大会决议的要求： | 是\n分红标准和比例是否明确和清晰： | 是\n相关的决策程序和机制是否完备： | 是\n独立董事是否履职尽责并发挥了应有的作用： | 是\n中小股东是否有充分表达意见和诉求的机会，其合法权益是 | \n | 是\n否得到了充分保护： | \n | \n现金分红政策进行调整或变更的，条件及程序是否合规 透 | \n | 是\n明： | \n |",
      "chunk_type": "table_group",
      "parent_id": "ba3a345e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 593,
      "page_number": 28,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "现金",
          "净利润",
          "合并",
          "股东",
          "分红",
          "回购",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.207418",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 593,
        "word_count": 76,
        "sentence_count": 8,
        "chinese_char_count": 342,
        "readability_score": 0.0,
        "information_density": 0.15177065767284992,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7084883296010017,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "现金",
        "净利润",
        "合并",
        "股东",
        "分红",
        "回购",
        "报告"
      ]
    },
    {
      "chunk_id": "a9c20f8d",
      "content": " |  |  |  |  |  |  | 现金分红总额\n--------------------------------------------------\n |  |  | 现金分红金额 |  | 以其他方式现 |  | \n |  | 分红年度合并 |  |  |  |  | （含其他方\n |  |  | 占合并报表中 | 以其他方式 | 金分红金额占 |  | \n |  | 报表中归属于 |  |  |  | 现金分红总额 | 式）占合并报\n | 现金分红金额 |  | 归属于上市公 | （如回购股 | 合并报表中归 |  | \n分红年度 |  | 上市公司普通 |  |  |  | （含其他方 | 表中归属于上\n | （含税） |  | 司普通股股东 | 份）现金分红 | 属于上市公司 |  | \n |  | 股股东的净利 |  |  |  | 式） | 市公司普通股\n |  |  | 的净利润的比 | 的金额 | 普通股股东的 |  | \n |  | 润 |  |  |  |  | 股东的净利润\n |  |  | 率 |  | 净利润的比例 |  | \n |  |  |  |  |  |  | 的比率\n |  |  |  |  |  |  | \n2019年 | 466,712,809.50 | 770,782,185.09 | 60.55% | 19,996,827.22 | 2.59% | 486,709,636.72 | 63.14%",
      "chunk_type": "table_group",
      "parent_id": "b68c66aa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1133,
      "page_number": 28,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "financial_statement",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 16,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "现金",
          "净利润",
          "合并",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          28
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.207754",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 633,
        "word_count": 148,
        "sentence_count": 7,
        "chinese_char_count": 169,
        "readability_score": 0.0,
        "information_density": 0.11058451816745656,
        "coherence_score": 0.745955766192733,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7800947867298578,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "净利润",
        "合并",
        "股东",
        "分红",
        "回购"
      ]
    },
    {
      "chunk_id": "f73c7fb6",
      "content": "【表格内容】\n2018年 | 466,744,309.50 | 605,003,820.78 | 77.15% | 281,514,686.68 | 46.53% | 748,258,996.18 | 123.68%\n--------------------------------------------------\n2017年 | 162,161,025.30 | 342,217,155.60 | 47.39% | 0.00 | 0.00% | 162,161,025.30 | 47.39%",
      "chunk_type": "table_group",
      "parent_id": "f3ebfbfb",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 249,
      "page_number": 29,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          29
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.207999",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 249,
        "word_count": 32,
        "sentence_count": 14,
        "chinese_char_count": 6,
        "readability_score": 0.0,
        "information_density": 0.04016064257028112,
        "coherence_score": 0.3498,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37463966942148763,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "db4ce2aa",
      "content": "【表格内容】\n每10股送红股数（股） | 0\n--------------------------------------------------\n每10股派息数（元）（含税） | 3\n每10股转增数（股） | 0\n分配预案的股本基数（股） | 1,555,709,365\n现金分红金额（元）（含税） | 466,712,809.50\n以其他方式（如回购股份）现金分红金额（元） | 19,996,827.22\n现金分红总额（含其他方式）（元） | 486,709,636.72\n可分配利润（元） | 1,525,328,398.95\n现金分红总额（含其他方式）占利润分配总额的 | \n | 100%\n比例 | \n | \n本次现金分红情况 | \n公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20 | \n利润分配或资本公积金转增预案的详细情况说明 | \n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购专用证券账户的63,005,888股） | \n为基数，向全体股东每10股派发现金红利3元（含税），预计派发现金股利466,712,809.50元(含税)。本年度不送红股， | \n不以资本公积转增股本。 |",
      "chunk_type": "table_group",
      "parent_id": "b99c9734",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 558,
      "page_number": 29,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "现金",
          "股本",
          "资本公积",
          "股份",
          "股东",
          "分配",
          "分红",
          "红利",
          "派发"
        ],
        "time_periods": [
          "2019",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          29
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.208165",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 558,
        "word_count": 45,
        "sentence_count": 7,
        "chinese_char_count": 258,
        "readability_score": 0.0,
        "information_density": 0.17921146953405018,
        "coherence_score": 0.8258355264806878,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6355635925256178,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配",
        "分红",
        "红利",
        "派发"
      ]
    },
    {
      "chunk_id": "e6815786",
      "content": "【说明】（一）本承诺人及本承诺人直接或间接控制的除海翔药业、台州前进\n及其子公司以外的企业目前不存在自营、与他人共同经营、为他人经\n营或以其他任何方式直接或间接从事与海翔药业、台州前进及其子公\n司相同、相似或构成实质竞争业务的情形；（二）在直接或间接持有海\n翔药业股份期间，本承诺人将不会采取参股、控股、自营、联营、合\n营、合作或者其他任何方式直接或间接从事与海翔药业、台州前进及\n其子公司现在和将来业务范围相同、相似或构成实质竞争的业务，也\n不会协助、促使或代表任何第三方以任何方式直接或间接从事与海翔\n药业、台州前进及其子公司现在和将来业务范围相同、相似或构成实\n质竞争的业务；（三）在直接或间接持有海翔药业股份期间，对于本承\n诺人直接或间接控制的其他企业，本承诺人将通过派出机构和人员（包\n括但不限于董事、总经理等）以及本承诺人在该等企业中的控制地位，\n王云富、\n关于同 保证该等企业比照前款规定履行与本承诺人相同的不竞争义务；（四）2014 严\n浙江东\n资产重组时所作 业竞争 如因国家政策调整等不可抗力原因导致本承诺人或本承诺人直接或间 年05 长 格\n港投资\n承诺 方面承 接控制的其他企业将来从事的业务与海翔药业、台州前进及其子公司 月05 期 履\n有限公\n诺 现在或将来从事的业务之间构成同业竞争时，则本承诺人将在海翔药 日 行\n司\n业、台州前进及其子公司提出异议后及时转让或终止该等业务或促使\n本承诺人直接或间接控制的其他企业及时转让或终止该等业务；如海\n翔药业、台州前进及其子公司进一步要求，海翔药业、台州前进及其\n子公司享有该等业务在同等条件下的优先受让权；（五）如从第三方获\n得任何与海翔药业经营的业务存在竞争或潜在竞争的商业机会，本承\n诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并\n尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上\n述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其\n子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述\n承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东\n因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归\n海翔药业所有。30。\n\n【表格内容】\n| | | | | 承 | 履\n--------------------------------------------------\n | | 承诺类 | | 承诺 | 诺 | 行\n承诺事由 | 承诺方 | | 承诺内容 | | | \n | | 型 | | 时间 | 期 | 情\n | | | | | | \n | | | | | 限 | 况\n股改承诺 | | | | | | \n收购报告书或权 | | | | | | \n益变动报告书中 | | | | | | \n所作承诺 | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "ec00a3a4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1184,
      "page_number": 29,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "经营",
          "股份",
          "股东",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          29
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.208462",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1184,
        "word_count": 129,
        "sentence_count": 2,
        "chinese_char_count": 863,
        "readability_score": 0.0,
        "information_density": 0.05067567567567568,
        "coherence_score": 0.6765573770491804,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5322409647701225,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "经营",
        "股份",
        "股东",
        "报告"
      ]
    },
    {
      "chunk_id": "def42295",
      "content": " |  |  | （一）本承诺人及本承诺人直接或间接控制的除海翔药业、台州前进 |  |  | \n--------------------------------------------------\n |  |  | 及其子公司以外的企业目前不存在自营、与他人共同经营、为他人经 |  |  | \n |  |  | 营或以其他任何方式直接或间接从事与海翔药业、台州前进及其子公 |  |  | \n |  |  | 司相同、相似或构成实质竞争业务的情形；（二）在直接或间接持有海 |  |  | \n |  |  | 翔药业股份期间，本承诺人将不会采取参股、控股、自营、联营、合 |  |  | \n |  |  | 营、合作或者其他任何方式直接或间接从事与海翔药业、台州前进及 |  |  | \n |  |  | 其子公司现在和将来业务范围相同、相似或构成实质竞争的业务，也 |  |  | \n |  |  | 不会协助、促使或代表任何第三方以任何方式直接或间接从事与海翔 |  |  | \n |  |  | 药业、台州前进及其子公司现在和将来业务范围相同、相似或构成实 |  |  | \n |  |  | 质竞争的业务；（三）在直接或间接持有海翔药业股份期间，对于本承 |  |  | \n |  |  | 诺人直接或间接控制的其他企业，本承诺人将通过派出机构和人员（包 |  |  | \n |  |  | 括但不限于董事、总经理等）以及本承诺人在该等企业中的控制地位， |  |  | \n | 王云富、 |  |  |  |  | \n |  | 关于同 | 保证该等企业比照前款规定履行与本承诺人相同的不竞争义务；（四） | 2014 |  | 严\n | 浙江东 |  |  |  |  | \n资产重组时所作 |  | 业竞争 | 如因国家政策调整等不可抗力原因导致本承诺人或本承诺人直接或间 | 年05 | 长 | 格\n | 港投资 |  |  |  |  | \n承诺 |  | 方面承 | 接控制的其他企业将来从事的业务与海翔药业、台州前进及其子公司 | 月05 | 期 | 履\n | 有限公 |  |  |  |  | \n |  | 诺 | 现在或将来从事的业务之间构成同业竞争时，则本承诺人将在海翔药 | 日 |  | 行\n | 司 |  |  |  |  | \n |  |  | 业、台州前进及其子公司提出异议后及时转让或终止该等业务或促使 |  |  | \n |  |  |  |  |  | \n |  |  | 本承诺人直接或间接控制的其他企业及时转让或终止该等业务；如海 |  |  | \n |  |  | 翔药业、台州前进及其子公司进一步要求，海翔药业、台州前进及其 |  |  | \n |  |  | 子公司享有该等业务在同等条件下的优先受让权；（五）如从第三方获 |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "cf537023",
      "child_ids": [],
      "sibling_ids": [
        "dd1acf3c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1700,
      "page_number": 30,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "经营",
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          30
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.208955",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1200,
        "word_count": 198,
        "sentence_count": 0,
        "chinese_char_count": 603,
        "readability_score": 0.0,
        "information_density": 0.03333333333333333,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7877282377919321,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "经营",
        "股份"
      ]
    },
    {
      "chunk_id": "dd1acf3c",
      "content": " |  |  | 得任何与海翔药业经营的业务存在竞争或潜在竞争的商业机会，本承 |  |  | \n |  |  | 诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并 |  |  | \n |  |  | 尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上 |  |  | \n |  |  | 述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其 |  |  | \n |  |  | 子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述 |  |  | \n |  |  | 承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东 |  |  | \n |  |  | 因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归 |  |  | \n |  |  | 海翔药业所有。 |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "cf537023",
      "child_ids": [],
      "sibling_ids": [
        "def42295"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1369,
      "page_number": 30,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          30
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.209039",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 369,
        "word_count": 56,
        "sentence_count": 1,
        "chinese_char_count": 205,
        "readability_score": 0.0,
        "information_density": 0.05420054200542006,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7877282377919321,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营",
        "股东"
      ]
    },
    {
      "chunk_id": "acfa7db5",
      "content": " |  |  | （一）本承诺人将采取措施尽量避免或减少本承诺人及本承诺人直接 |  |  | \n--------------------------------------------------\n |  |  | 或间接控制的除海翔药业、台州前进及其子公司以外的其他企业与台 |  |  | \n |  |  | 州前进、海翔药业及其子公司之间发生关联交易；（二）对于无法避免 |  |  | \n |  |  | 的关联交易，将按照\"等价有偿、平等互利\"的原则，依法签订关联交易 |  |  | \n |  |  | 合同，参照市场同行的标准，公允确定关联交易的价格，并严格按照 |  |  | \n |  |  | 海翔药业的公司章程及有关法律法规履行批准关联交易的法定程序和 |  |  | \n |  |  | 信息披露义务；（三）本承诺人及本承诺人直接或间接控制的除海翔药 |  |  | \n | 王云富、 |  | 业、台州前进及其子公司以外的其他企业不通过关联交易损害海翔药 |  |  | \n |  | 关于关 |  | 2014 |  | 严\n | 浙江东 |  | 业、台州前进及其子公司及相关公司股东的合法权益；（四）本承诺人 |  |  | \n |  | 联交易、 |  | 年05 | 长 | 格\n | 港投资 |  | 及本承诺人直接或间接控制的除海翔药业、台州前进及其子公司以外 |  |  | \n |  | 资金方 |  | 月05 | 期 | 履\n | 有限公 |  | 的其他企业不通过向海翔药业、台州前进及其子公司借款或由海翔药 |  |  | \n |  | 面承诺 |  | 日 |  | 行\n | 司 |  | 业、台州前进及其子公司提供担保、代偿债务、代垫款项等各种名目 |  |  | \n |  |  |  |  |  | \n |  |  | 侵占海翔药业、台州前进及其子公司的资金；（五）不利用股东地位及 |  |  | \n |  |  | 影响谋求与海翔药业、台州前进及其子公司在业务合作等方面给予本 |  |  | \n |  |  | 承诺人及本承诺人直接或间接控制的除海翔药业、台州前进及其子公 |  |  | \n |  |  | 司以外的其他企业优于市场第三方的权利；不利用股东地位及影响谋 |  |  | \n |  |  | 求与海翔药业、台州前进及其子公司达成交易的优先权利；（六）本承 |  |  | \n |  |  | 诺人愿意承担由于违反上述承诺给海翔药业、台州前进及其子公司造 |  |  | \n |  |  | 成的直接、间接的经济损失、索赔责任及额外的费用支出。 |  |  | \n首次公开发行或 |  |  |  |  |  | \n再融资时所作承 |  |  |  |  |  | \n诺 |  |  |  |  |  | \n股权激励承诺 |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "c4fe433b",
      "child_ids": [],
      "sibling_ids": [
        "b0ee4083"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1720,
      "page_number": 31,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 29,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "费用",
          "投资",
          "股权",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          31
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.209330",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1220,
        "word_count": 211,
        "sentence_count": 1,
        "chinese_char_count": 585,
        "readability_score": 0.0,
        "information_density": 0.07377049180327869,
        "coherence_score": 0.41393442622950816,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7555275325767128,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "费用",
        "投资",
        "股权",
        "股东",
        "披露",
        "融资",
        "借款",
        "债务"
      ]
    },
    {
      "chunk_id": "b0ee4083",
      "content": "其他对公司中小 |  |  |  |  |  | \n |  |  |  |  |  | \n股东所作承诺 |  |  |  |  |  | \n |  |  |  |  |  | \n承诺是否按时履 |  |  |  |  |  | \n | 是 |  |  |  |  | \n行 |  |  |  |  |  | \n |  |  |  |  |  | \n如承诺超期未履 |  |  |  |  |  | \n行完毕的，应当详 |  |  |  |  |  | \n细说明未完成履 |  |  |  |  |  | \n | 不适用 |  |  |  |  | \n行的具体原因及 |  |  |  |  |  | \n |  |  |  |  |  | \n下一步的工作计 |  |  |  |  |  | \n划 |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "c4fe433b",
      "child_ids": [],
      "sibling_ids": [
        "acfa7db5"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1365,
      "page_number": 31,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 16,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          31
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.209413",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 365,
        "word_count": 108,
        "sentence_count": 0,
        "chinese_char_count": 61,
        "readability_score": 0.0,
        "information_density": 0.0273972602739726,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7555275325767128,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股东"
      ]
    },
    {
      "chunk_id": "7b5b7c37",
      "content": "【表格内容】\n原列报报表项目及金额 | | \n--------------------------------------------------\n应收票据及应收账款 | 586,937,258.10 | 应收票据\n | | 应收账款\n应付票据及应付账款 | 791,915,463.78 | 应付票据\n | | 应付账款",
      "chunk_type": "table_group",
      "parent_id": "3709ff15",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 161,
      "page_number": 32,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209492",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 161,
        "word_count": 21,
        "sentence_count": 2,
        "chinese_char_count": 48,
        "readability_score": 0.0,
        "information_density": 0.12422360248447203,
        "coherence_score": 0.48333333333333334,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43177154989384287,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "应付"
      ]
    },
    {
      "chunk_id": "bc005c17",
      "content": "【表格内容】\n项 目 | | \n--------------------------------------------------\n | 2018年12月31日 | 新金融工具准则\n调整影响\n可供出售金融资产 | 1,800,000.00 | -1,800,000.00\n其他权益工具投资 | | 1,800,000.00\n应收票据 | 107,399,476.04 | -107,399,476.04\n应收款项融资 | | 107,399,476.04\n其他流动资产 | 227,882,993.23 | -150,000,000.00\n交易性金融资产 | | 150,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "45e2b9f4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 297,
      "page_number": 32,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "投资",
          "应收",
          "融资"
        ],
        "time_periods": [
          "2018-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209602",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 297,
        "word_count": 38,
        "sentence_count": 9,
        "chinese_char_count": 59,
        "readability_score": 0.0,
        "information_density": 0.16835016835016833,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47852789115646255,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "投资",
        "应收",
        "融资"
      ]
    },
    {
      "chunk_id": "72d82696",
      "content": "【表格内容】\n项 目 | 原金融工具准则 | | \n--------------------------------------------------\n | 计量类别 | 账面价值 | 计量类别\n货币资金 | 贷款和应收款项 | 1,956,089,124.33 | 以摊余成本计量的金融资",
      "chunk_type": "table_group",
      "parent_id": "63d75739",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 146,
      "page_number": 32,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "应收",
          "账面价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209668",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 146,
        "word_count": 21,
        "sentence_count": 1,
        "chinese_char_count": 47,
        "readability_score": 0.0,
        "information_density": 0.3424657534246575,
        "coherence_score": 0.24,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43240476190476196,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "应收",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "b023f503",
      "content": "【表格内容】\n货币资金 | | | \n--------------------------------------------------\n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 1,956,089,124.33 | | \n | | | \n应收票据 | | | \n按原CAS22 列示的余额 | 107,399,476.04 | | \n减：转出至公允价值计量\n且其变动计入其他综合\n收益(新CAS22) | | -107,399,476.04 | \n按新CAS22 列示的余额 | | | \n | | | \n应收账款 | | | \n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 479,537,782.06 | | \n | | |",
      "chunk_type": "table_group",
      "parent_id": "d7c1acbd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 336,
      "page_number": 33,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          33
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209784",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 336,
        "word_count": 59,
        "sentence_count": 4,
        "chinese_char_count": 83,
        "readability_score": 0.0,
        "information_density": 0.08928571428571429,
        "coherence_score": 0.45666666666666667,
        "standards_profile_summary": {}
      },
      "quality_score": 0.503651724137931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "3f946eab",
      "content": "【表格内容】\n其他应收款 | | | \n--------------------------------------------------\n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 10,817,853.96 | | \n以摊余成本计量的总金\n融资产 | 2,553,844,236.39 | -107,399,476.04 |",
      "chunk_type": "table_group",
      "parent_id": "e0b47cf2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 175,
      "page_number": 34,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "成本",
          "应收",
          "融资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          34
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209862",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 175,
        "word_count": 22,
        "sentence_count": 3,
        "chinese_char_count": 37,
        "readability_score": 0.0,
        "information_density": 0.22857142857142856,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4548457364341085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "应收",
        "融资"
      ]
    },
    {
      "chunk_id": "132ff8c7",
      "content": "【表格内容】\n其他流动资产-银行理财\n产品 | | | \n--------------------------------------------------\n按原CAS22 列示的余额 | 150,000,000.00 | | \n减：转出至公允价值计量\n且其变动计入当期损益\n(新CAS22) | | -150,000,000.00 | \n按新CAS22 列示的余额 | | | \n | | | \n交易性金融资产-银行理\n财产品 | | | \n按原CAS22 列示的余额 | | | \n加：自可供出售金融资产\n(原CAS22)转入 | | 150,000,000.00 | \n按新CAS22 列示的余额 | | | \n以公允价值计量且其变\n动计入当期损益 | 150,000,000.00 | |",
      "chunk_type": "table_group",
      "parent_id": "b48e3113",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 349,
      "page_number": 34,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          34
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.209975",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 349,
        "word_count": 55,
        "sentence_count": 4,
        "chinese_char_count": 108,
        "readability_score": 0.0,
        "information_density": 0.1146131805157593,
        "coherence_score": 0.35333333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5485873723305477,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "23ee8b82",
      "content": "【表格内容】\n应收款项融资 | | | \n--------------------------------------------------\n按原CAS22 列示的余额 | | | \n加：自应收票据(原\nCAS22)转入 | | 107,399,476.04 | \n按新CAS22 列示的余额 | | | \n | | | \n可供出售金融资产 | | | \n按原CAS22 列示的余额 | 1,800,000.00 | | \n减：转出至公允价值计量\n且其变动计入其他综合\n收益(新CAS22) | | -1,800,000.00 | \n按新CAS22 列示的余额 | | | \n | | | \n其他权益工具投资 | | | \n按原CAS22 列示的余额 | | | \n加：自可供出售金融资产\n(原CAS22)转入 | | 1,800,000.00 |",
      "chunk_type": "table_group",
      "parent_id": "8d03083b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 375,
      "page_number": 34,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "投资",
          "应收",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          34
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210106",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 375,
        "word_count": 65,
        "sentence_count": 4,
        "chinese_char_count": 106,
        "readability_score": 0.0,
        "information_density": 0.18666666666666668,
        "coherence_score": 0.43,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5839971014492754,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "投资",
        "应收",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "1e7afd2b",
      "content": "【标题】八、与上年度财务报告相比，合并报表范围发生变化的情况说明\n√ 适用 □ 不适用\n35。\n\n【表格内容】\n按新CAS22 列示的余额 | | | \n--------------------------------------------------\n以公允价值计量且其变\n动计入其他综合收益的\n总金融资产 | 1,800,000.00 | 107,399,476.04 |",
      "chunk_type": "table_group",
      "parent_id": "9236ce33",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 189,
      "page_number": 35,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": true,
        "table_type": "financial_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "合并",
          "报告",
          "财务报告",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          35
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210191",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 189,
        "word_count": 21,
        "sentence_count": 3,
        "chinese_char_count": 69,
        "readability_score": 0.0,
        "information_density": 0.37037037037037035,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5275232649338806,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "合并",
        "报告",
        "财务报告",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "1d974035",
      "content": "【表格内容】\n应付票据 | | | \n--------------------------------------------------\n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 490,006,533.85 | | \n | | | \n应付账款 | | | \n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 301,908,929.93 | | \n | | | \n其他应付款 | | | \n按原CAS22 列示的余额\n和按新CAS22 列示的余\n额 | 24,723,304.20 | | \n以摊余成本计量的总金\n融负债 | 816,638,767.98 | |",
      "chunk_type": "table_group",
      "parent_id": "167c568d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 301,
      "page_number": 35,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "成本",
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          35
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210298",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 301,
        "word_count": 53,
        "sentence_count": 4,
        "chinese_char_count": 75,
        "readability_score": 0.0,
        "information_density": 0.09966777408637875,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4879326860841424,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "成本",
        "应付"
      ]
    },
    {
      "chunk_id": "3fd02199",
      "content": "【说明】合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n九、聘任、解聘会计师事务所情况\n现聘任的会计师事务所\n境内会计师事务所名称 天健会计师事务所（特殊普通合伙）\n境内会计师事务所报酬（万元） 170\n境内会计师事务所审计服务的连续年限 17年\n境内会计师事务所注册会计师姓名 沈维华 汪兢\n境内会计师事务所注册会计师审计服务的连续年限 沈维华1年 汪兢4年\n当期是否改聘会计师事务所\n□ 是 √ 否\n聘请内部控制审计会计师事务所、财务顾问或保荐人情况\n□ 适用 √ 不适用\n十、年度报告披露后面临暂停上市和终止上市情况\n□ 适用 √ 不适用\n十一、破产重整相关事项\n□ 适用 √ 不适用\n公司报告期未发生破产重整相关事项。十二、重大诉讼、仲裁事项\n√ 适用 □ 不适用\n披 披\n是否形 诉讼(仲\n涉案金额 诉讼(仲裁)进 露 露\n诉讼(仲裁)基本情况 成预计 诉讼(仲裁)审理结果及影响 裁)判决\n（万元） 展 日 索\n负债 执行情况\n期 引\n上海合契投资管理有限公司诉公 上海合契投资案件受理费由上海合契投资管理\n司、东港投资缔约过失责任纠纷一 2,500 否 管理有限公司有限公司负担，此前因诉讼被冻结/ / /\n案 已撤诉 的公司存款已经全部解除冻结。黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 204.01 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n36。\n\n【表格内容】\n应收账款 | 39,520,283.30 | | \n--------------------------------------------------\n其他应收款 | 17,101,274.23 | |",
      "chunk_type": "table_group",
      "parent_id": "774224ca",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 759,
      "page_number": 35,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "投资",
          "应收",
          "合并",
          "股权",
          "审计",
          "报告",
          "年度报告",
          "披露"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          35
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210532",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 759,
        "word_count": 101,
        "sentence_count": 6,
        "chinese_char_count": 494,
        "readability_score": 0.0,
        "information_density": 0.11857707509881424,
        "coherence_score": 0.28418487394957986,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4885876817792986,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "投资",
        "应收",
        "合并",
        "股权",
        "审计",
        "报告",
        "年度报告",
        "披露"
      ]
    },
    {
      "chunk_id": "7ef72279",
      "content": "【表格内容】\n公司名称 | 股权取得方式 | 股权取得时点 | 出资额\n--------------------------------------------------\n盛嘉环保公司 | 设立 | 2019/4/29 |",
      "chunk_type": "table_group",
      "parent_id": "953275f2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 112,
      "page_number": 36,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          36
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210636",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.08928571428571427,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3844075471698113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权"
      ]
    },
    {
      "chunk_id": "8ded8675",
      "content": "【表格内容】\n境内会计师事务所名称 | 天健会计师事务所（特殊普通合伙）\n--------------------------------------------------\n境内会计师事务所报酬（万元） | 170\n境内会计师事务所审计服务的连续年限 | 17年\n境内会计师事务所注册会计师姓名 | 沈维华 汪兢\n境内会计师事务所注册会计师审计服务的连续年限 | 沈维华1年 汪兢4年",
      "chunk_type": "table_group",
      "parent_id": "8326dc32",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 193,
      "page_number": 36,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "审计"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          36
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210707",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 193,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 107,
        "readability_score": 0.0,
        "information_density": 0.05181347150259068,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5869311827956989,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "审计"
      ]
    },
    {
      "chunk_id": "0c17f621",
      "content": "【说明】黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 747.56 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n十三、处罚及整改情况\n□ 适用 √ 不适用\n公司报告期不存在处罚及整改情况。十四、公司及其控股股东、实际控制人的诚信状况\n□ 适用 √ 不适用\n十五、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况\n√ 适用 □ 不适用\n1、限制性股票激励计划简介\n（1）公司于2015年1月20日召开第四届董事会第十二次会议审议通过了《浙江海翔药业股\n份有限公司限制性股票激励计划（草案）》及其摘要等相关议案。随后公司向中国证监会上\n报了申请备案材料。\n\n【表格内容】\n| | | | | | 披 | 披\n--------------------------------------------------\n | | 是否形 | | | 诉讼(仲 | | \n | 涉案金额 | | 诉讼(仲裁)进 | | | 露 | 露\n诉讼(仲裁)基本情况 | | 成预计 | | 诉讼(仲裁)审理结果及影响 | 裁)判决 | | \n | （万元） | | 展 | | | 日 | 索\n | | 负债 | | | 执行情况 | | \n | | | | | | 期 | 引\n | | | | | | | \n上海合契投资管理有限公司诉公 | | | 上海合契投资 | 案件受理费由上海合契投资管理 | | | \n司 东港投资缔约过失责任纠纷一 | 2,500 | 否 | 管理有限公司 | 有限公司负担，此前因诉讼被冻结 | / | / | /\n案 | | | 已撤诉 | 的公司存款已经全部解除冻结。 | | | \n黄小留 张伟诉江苏天腾建设集团 | | | | | | | \n有限公司 江苏海阔生物医药有限 | 204.01 | 否 | 败诉，已结案 | 已支付全部款项 | 已执行 | / | /\n公司建设工程施工合同纠纷一案 | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "f7d0299a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 851,
      "page_number": 36,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "投资",
          "股权",
          "股东",
          "报告"
        ],
        "time_periods": [
          "2015-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          36
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.210923",
        "report_type": null,
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 851,
        "word_count": 175,
        "sentence_count": 6,
        "chinese_char_count": 441,
        "readability_score": 0.0,
        "information_density": 0.05875440658049354,
        "coherence_score": 0.5582290084357953,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6753263122709767,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "投资",
        "股权",
        "股东",
        "报告"
      ]
    },
    {
      "chunk_id": "707eee20",
      "content": "【标题】5、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于回购注销已离职激\n37。\n\n【说明】励对象所持已获授但尚未解锁的限制性股票的议案》。由于原激励对象林宇峰、丁春明已经\n离职，根据相关规定及股东大会授权，公司董事会对林宇峰、丁春明已离职激励对象所持已\n获授但尚未解锁的限制性股票共计24万股进行回购注销。2016年5月完成上述股票回购注销。\n\n【表格内容】\n黄小留 张伟诉江苏天腾建设集团 | | | | | | | \n--------------------------------------------------\n有限公司 江苏海阔生物医药有限 | 747.56 | 否 | 败诉，已结案 | 已支付全部款项 | 已执行 | / | /\n公司建设工程施工合同纠纷一案 | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "6b94f7dd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 388,
      "page_number": 37,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股东",
          "回购"
        ],
        "time_periods": [
          "2016-3",
          "2016-5"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.211066",
        "report_type": null,
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 388,
        "word_count": 41,
        "sentence_count": 5,
        "chinese_char_count": 231,
        "readability_score": 0.0,
        "information_density": 0.051546391752577324,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6137956655246796,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "2dc4bb41",
      "content": " |  |  |  | 关 |  |  |  |  | 是 |  |  |  | \n--------------------------------------------------\n |  | 关 | 关 | 联 |  |  |  |  | 否 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 可获 |  | \n |  | 联 | 联 | 交 |  |  | 占同类 | 获批的 | 超 | 关联 |  |  | \n关联 |  |  |  |  |  | 关联交易 |  |  |  |  | 得的 |  | \n | 关联关 | 交 | 交 | 易 | 关联交易 |  | 交易金 | 交易额 | 过 | 交易 |  | 披露 | \n交易 |  |  |  |  |  | 金额（万 |  |  |  |  | 同类 |  | 披露索引\n | 系 | 易 | 易 | 定 | 价格 |  | 额的比 | 度（万 | 获 | 结算 |  | 日期 | \n方 |  |  |  |  |  | 元） |  |  |  |  | 交易 |  | \n |  | 类 | 内 | 价 |  |  | 例 | 元） | 批 | 方式 |  |  | \n |  |  |  |  |  |  |  |  |  |  | 市价 |  | \n |  | 型 | 容 | 原 |  |  |  |  | 额 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | 则 |  |  |  |  | 度 |  |  |  | \n浙江 |  | 原 |  | 市 |  |  |  |  |  |  |  |  | 《2019年度日常关联交易预\n |  |  | 采 |  | 不同规格， |  |  |  |  | 银行 |  |  | \n荣兴 | 控股股 | 料 |  | 场 |  |  |  |  |  |  |  | 2019 | 计的公告》公告编号\n |  |  | 购 |  | 单价从 |  |  |  |  | 存款 | 未偏 |  | \n活性 | 东持有 | 材 |  | 公 |  |  |  |  |  |  |  | 年02 | 2019-012，内容详见巨潮资讯\n |  |  | 活 |  | 5500元/吨 | 278.51 | 28.94% | 2,800 | 否 | 或承 | 离市 |  | \n炭有 | 其50% | 料 |  | 允 |  |  |  |  |  |  |  | 月18 | 网及《证券时报》、《上海证\n |  |  | 性 |  | 至15500元 |  |  |  |  | 兑汇 | 场价 |  | ",
      "chunk_type": "table_group",
      "parent_id": "679f44cc",
      "child_ids": [],
      "sibling_ids": [
        "f29accbc",
        "c251d22b"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1677,
      "page_number": 39,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "披露",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          39
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.211688",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1177,
        "word_count": 386,
        "sentence_count": 2,
        "chinese_char_count": 185,
        "readability_score": 0.0,
        "information_density": 0.016992353440951572,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5408120924718435,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "披露",
        "证券"
      ]
    },
    {
      "chunk_id": "f29accbc",
      "content": "限公 | 股权 | 采 |  | 价 |  |  |  |  |  |  |  | 日 | 券报》、《中国证券报》、《证\n |  |  | 炭 |  | /吨不等 |  |  |  |  | 票 |  |  | \n司 |  | 购 |  | 格 |  |  |  |  |  |  |  |  | 券日报》\n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | 采 |  |  |  |  |  |  |  |  |  | \n |  | 原 | 购 | 市 |  |  |  |  |  |  |  |  | 《2019年度日常关联交易预\n江西 |  |  |  |  |  |  |  |  |  | 银行 |  |  | \n |  | 料 | 原 | 场 |  |  |  |  |  |  |  | 2019 | 计的公告》公告编号\n华邦 | 控股股 |  |  |  | 400元/千克 |  |  |  |  | 存款 | 未偏 |  | \n |  | 材 | 料 | 公 |  |  |  |  |  |  |  | 年02 | 2019-012，内容详见巨潮资讯\n药业 | 东控制 |  |  |  | 至420元/ | 2,730.75 | 1.06% | 5,000 | 否 | 或承 | 离市 |  | \n |  | 料 | 药 | 允 |  |  |  |  |  |  |  | 月18 | 网及《证券时报》、《上海证\n有限 | 企业 |  |  |  | 千克 |  |  |  |  | 兑汇 | 场价 |  | \n |  | 采 | 中 | 价 |  |  |  |  |  |  |  | 日 | 券报》、《中国证券报》、《证\n公司 |  |  |  |  |  |  |  |  |  | 票 |  |  | \n |  | 购 | 间 | 格 |  |  |  |  |  |  |  |  | 券日报》\n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | 体 |  |  |  |  |  |  |  |  |  | \n |  | 销 | 销 |  |  |  |  |  |  |  |  |  | \n |  | 售 | 售 | 市 |  |  |  |  |  |  |  |  | \n江西 |  |  |  |  |  |  |  |  |  | 银行 |  |  | \n |  | 原 | 原 | 场 |  |  |  |  |  |  |  |  | \n华邦 | 控股股 |  |  |  |  |  |  |  |  | 存款 | 未偏 |  | \n |  | 料 | 料 | 公 | 市场公允 |  |  |  |  |  |  | 不适 | ",
      "chunk_type": "table_group",
      "parent_id": "679f44cc",
      "child_ids": [],
      "sibling_ids": [
        "2dc4bb41",
        "c251d22b"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2192,
      "page_number": 39,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          39
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.211823",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1192,
        "word_count": 397,
        "sentence_count": 2,
        "chinese_char_count": 165,
        "readability_score": 0.0,
        "information_density": 0.016778523489932886,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5408120924718435,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权",
        "证券"
      ]
    },
    {
      "chunk_id": "c251d22b",
      "content": "药业 | 东控制 |  |  |  |  | 5 | 0.01% | 不适用 | 否 | 或承 | 离市 |  | 不适用\n |  | 药 | 药 | 允 | 价格 |  |  |  |  |  |  | 用 | \n有限 | 企业 |  |  |  |  |  |  |  |  | 兑汇 | 场价 |  | \n |  | 中 | 中 | 价 |  |  |  |  |  |  |  |  | \n公司 |  |  |  |  |  |  |  |  |  | 票 |  |  | \n |  | 间 | 间 | 格 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | 体 | 体 |  |  |  |  |  |  |  |  |  | \n台州 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | 市 |  |  |  |  |  |  |  |  | \n市东 |  | 采 | 采 |  |  |  |  |  |  | 银行 |  |  | \n |  |  |  | 场 |  |  |  |  |  |  |  |  | \n港包 | 控股股 | 购 | 购 |  |  |  |  |  |  | 存款 | 未偏 |  | \n |  |  |  | 公 | 市场公允 |  |  |  |  |  |  | 不适 | \n装用 | 东控制 | 原 | 原 |  |  | 0.44 | 0.00% | 不适用 | 否 | 或承 | 离市 |  | 不适用\n |  |  |  | 允 | 价格 |  |  |  |  |  |  | 用 | \n品有 | 企业 | 材 | 材 |  |  |  |  |  |  | 兑汇 | 场价 |  | \n |  |  |  | 价 |  |  |  |  |  |  |  |  | \n限公 |  | 料 | 料 |  |  |  |  |  |  | 票 |  |  | \n |  |  |  | 格 |  |  |  |  |  |  |  |  | \n司 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "679f44cc",
      "child_ids": [],
      "sibling_ids": [
        "2dc4bb41",
        "f29accbc"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 2503,
      "page_number": 39,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          39
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.211996",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1003,
        "word_count": 357,
        "sentence_count": 3,
        "chinese_char_count": 109,
        "readability_score": 0.0,
        "information_density": 0.009970089730807579,
        "coherence_score": 0.3271428571428572,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5408120924718435,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "f764b28b",
      "content": "【说明】台州艾斐科技有限公司和台州市振港染料化工有限公司电费由台州市振港染料化工有限公司\n统一向供电公司支付，台州市振港染料化工有限公司完成电费支付后再向台州艾斐科技有限公司收取相关电费。2019年度上\n述关联交易总金额为45.66万元。十七、重大合同及其履行情况\n1、托管、承包、租赁事项情况\n（1）托管情况\n□ 适用 √ 不适用\n公司报告期不存在托管情况。\n\n【表格内容】\n合计 | -- | -- | 3,014.7 | -- | 7,800 | -- | -- | -- | -- | --\n--------------------------------------------------\n大额销货退回的详细情 | | | | | | | | | | \n | 不适用 | | | | | | | | | \n况 | | | | | | | | | | \n | | | | | | | | | | \n按类别对本期将发生的 | | | | | | | | | | \n | 2019年度，公司与上述关联方日常关联交易的实际发生总金额未超过预计总金额。实际发生情况 | | | | | | | | | \n日常关联交易进行总金 | | | | | | | | | | \n | 与预计存在较大差异的原因为：公司与关联方的年度日常关联交易预计是基于公司业务开展进行的 | | | | | | | | | \n额预计的，在报告期内 | | | | | | | | | | \n | 初步判断，较难实现准确预计，因此与实际发生情况存在一定的差异。 | | | | | | | | | \n的实际履行情况（如有） | | | | | | | | | | \n | | | | | | | | | | \n交易价格与市场参考价 | | | | | | | | | | \n格差异较大的原因（如 | 不适用 | | | | | | | | | \n适用） | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "b922751c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 833,
      "page_number": 40,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          40
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.212210",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司和台州市振港染料化工有限公司电费由台州市振港染料化工有限公司",
        "industry": null,
        "char_count": 833,
        "word_count": 197,
        "sentence_count": 7,
        "chinese_char_count": 336,
        "readability_score": 0.0,
        "information_density": 0.012004801920768308,
        "coherence_score": 0.6751282051282051,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6041709090909092,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告"
      ]
    },
    {
      "chunk_id": "2c0675db",
      "content": "公司及其子公司对外担保情况（不包括对子公司的担保） |  |  |  |  |  |  |  | \n--------------------------------------------------\n | 担保额度 |  |  |  |  |  |  | \n |  |  |  | 实际担保金 |  |  | 是否履行 | 是否为关\n担保对象名称 | 相关公告 | 担保额度 | 实际发生日期 |  | 担保类型 | 担保期 |  | \n |  |  |  | 额 |  |  | 完毕 | 联方担保\n | 披露日期 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n报告期内审批的对外担保额度合 |  |  |  | 报告期内对外担保实际发 |  |  |  | \n |  | 0 |  |  |  | 0 |  | \n计（A1） |  |  |  | 生额合计（A2） |  |  |  | \n |  |  |  |  |  |  |  | \n报告期末已审批的对外担保额度 |  |  |  | 报告期末实际对外担保余 |  |  |  | \n |  | 0 |  |  |  | 0 |  | \n合计（A3） |  |  |  | 额合计（A4） |  |  |  | \n |  |  |  |  |  |  |  | \n公司对子公司的担保情况 |  |  |  |  |  |  |  | \n | 担保额度 |  |  |  |  |  |  | \n |  |  |  | 实际担保金 |  |  | 是否履行 | 是否为关\n担保对象名称 | 相关公告 | 担保额度 | 实际发生日期 |  | 担保类型 | 担保期 |  | \n |  |  |  | 额 |  |  | 完毕 | 联方担保\n | 披露日期 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n浙江海翔川南药业有 | 2018年04 |  | 2019年02月27 |  | 连带责任保 | 2019-02-27~ |  | \n |  | 20,000 |  | 5,000 |  |  | 是 | 否\n限公司 | 月04日 |  | 日 |  | 证 | 2019-05-17 |  | \n |  |  |  |  |  |  |  | \n浙江海翔川南药业有 | 2018年04 |  | 2019年12月24 |  | 连带责任保 | 2019-12-24~ |  | \n |  | 20,000 |  | 42.4 |  |  | 否 | 否\n限公司 | 月04日 |  | 日 |  | 证 | 2020-12-24 |  | \n |  |  |  |  |  |  |  | \n报告期内审批对子公司担保额度 |  |  |  | 报告期内对子公司担保实 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "9794f116",
      "child_ids": [],
      "sibling_ids": [
        "8a399f08"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1723,
      "page_number": 41,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告",
          "披露"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          41
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.212715",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1223,
        "word_count": 321,
        "sentence_count": 1,
        "chinese_char_count": 281,
        "readability_score": 0.0,
        "information_density": 0.016353229762878167,
        "coherence_score": 0.33999999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5681818181818181,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "8a399f08",
      "content": " |  | 0 |  |  |  | 5,042.4 |  | \n合计（B1） |  |  |  | 际发生额合计（B2） |  |  |  | \n |  |  |  |  |  |  |  | \n报告期末已审批的对子公司担保 |  |  |  | 报告期末对子公司实际担 |  |  |  | \n |  | 20,000 |  |  |  | 42.4 |  | \n额度合计（B3） |  |  |  | 保余额合计（B4） |  |  |  | \n |  |  |  |  |  |  |  | \n子公司对子公司的担保情况 |  |  |  |  |  |  |  | \n | 担保额度 |  |  |  |  |  |  | \n |  |  |  | 实际担保金 |  |  | 是否履行 | 是否为关\n担保对象名称 | 相关公告 | 担保额度 | 实际发生日期 |  | 担保类型 | 担保期 |  | \n |  |  |  | 额 |  |  | 完毕 | 联方担保\n | 披露日期 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "9794f116",
      "child_ids": [],
      "sibling_ids": [
        "2c0675db"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1492,
      "page_number": 41,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告",
          "披露"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          41
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.212814",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 492,
        "word_count": 137,
        "sentence_count": 2,
        "chinese_char_count": 109,
        "readability_score": 0.0,
        "information_density": 0.04065040650406504,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5681818181818181,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "f8e16881",
      "content": "台州市振港染料化工 | 2017年04 |  | 2019年01月15 |  | 连带责任保 | 2019-01-15~ |  | \n--------------------------------------------------\n |  | 6,000 |  | 240 |  |  | 否 | 否\n有限公司 | 月21日 |  | 日 |  | 证 | 2020-01-15 |  | \n |  |  |  |  |  |  |  | \n台州市振港染料化工 | 2017年04 |  | 2019年01月23 |  | 连带责任保 | 2019-01-23~ |  | \n |  | 6,000 |  | 172 |  |  | 否 | 否\n有限公司 | 月21日 |  | 日 |  | 证 | 2020-01-23 |  | \n |  |  |  |  |  |  |  | \n台州市振港染料化工 | 2017年04 |  | 2019年03月22 |  | 连带责任保 | 2019-03-22~ |  | \n |  | 6,000 |  | 523.52 |  |  | 否 | 否\n有限公司 | 月21日 |  | 日 |  | 证 | 2020-03-22 |  | \n |  |  |  |  |  |  |  | \n报告期内审批对子公司担保额度 |  |  |  | 报告期内对子公司担保实 |  |  |  | \n |  | 0 |  |  |  | 935.52 |  | \n合计（C1） |  |  |  | 际发生额合计（C2） |  |  |  | \n |  |  |  |  |  |  |  | \n报告期末已审批的对子公司担保 |  |  |  | 报告期末对子公司实际担 |  |  |  | \n |  | 0 |  |  |  | 935.52 |  | \n额度合计（C3） |  |  |  | 保余额合计（C4） |  |  |  | \n |  |  |  |  |  |  |  | \n公司担保总额（即前三大项的合计） |  |  |  |  |  |  |  | \n报告期内审批担保额度合计 |  |  |  | 报告期内担保实际发生额 |  |  |  | \n |  | 0 |  |  |  | 5,977.92 |  | \n（A1+B1+C1） |  |  |  | 合计（A2+B2+C2） |  |  |  | \n |  |  |  |  |  |  |  | \n报告期末已审批的担保额度合计 |  |  |  | 报告期末实际担保余额合 |  |  |  | \n |  | 20,000 |  |  |  | 977.92 |  | \n（A3+B3+C3） |  |  |  | 计（A4+B4+C4） |  |  |  | \n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "19342b54",
      "child_ids": [],
      "sibling_ids": [
        "e7a7cab9"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1719,
      "page_number": 42,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.213311",
        "report_type": null,
        "fiscal_year": 2017,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1219,
        "word_count": 300,
        "sentence_count": 5,
        "chinese_char_count": 213,
        "readability_score": 0.0,
        "information_density": 0.008203445447087777,
        "coherence_score": 0.3230769230769231,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7613597733711048,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告"
      ]
    },
    {
      "chunk_id": "e7a7cab9",
      "content": "实际担保总额（即A4+B4+C4）占公司净资产的比例 |  |  |  | 0.17% |  |  |  | \n其中： |  |  |  |  |  |  |  | \n为股东、实际控制人及其关联方提供担保的余额（D） |  |  |  | 0 |  |  |  | \n直接或间接为资产负债率超过70%的被担保对象提供的债务 |  |  |  |  |  |  |  | \n |  |  |  | 0 |  |  |  | \n担保余额（E） |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n担保总额超过净资产50%部分的金额（F） |  |  |  | 0 |  |  |  | \n上述三项担保金额合计（D+E+F） |  |  |  | 0 |  |  |  | \n对未到期担保，报告期内已发生担保责任或可能承担连带清偿 |  |  |  |  |  |  |  | \n |  |  |  | 不适用 |  |  |  | \n责任的情况说明（如有） |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n违反规定程序对外提供担保的说明（如有） |  |  |  | 不适用 |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "19342b54",
      "child_ids": [],
      "sibling_ids": [
        "f8e16881"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1545,
      "page_number": 42,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "净资产",
          "资产负债率",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          42
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.213406",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 545,
        "word_count": 129,
        "sentence_count": 1,
        "chinese_char_count": 148,
        "readability_score": 0.0,
        "information_density": 0.12844036697247704,
        "coherence_score": 0.61,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7613597733711048,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "净资产",
        "资产负债率",
        "股东",
        "报告",
        "债务"
      ]
    },
    {
      "chunk_id": "5f05445a",
      "content": "【说明】截止2019年2月25日公司\n回购方案实施完成，公司通过集中竞价方式累计回购股份数量63,005,888股，占公司总股本的\n3.8921%，支付总金额301,511,513.90元（含交易费用）。维护了广大投资者利益，增强投资\n者对公司的投资信心。（2）员工权益保护\n公司多年以来一直将员工视为公司发展前进道路上最为宝贵的财富和动力源泉。\n\n【表格内容】\n具体类型 | 委托理财的资金来源 | 委托理财发生额 | 未到期余额 | 逾期未收回的金额\n--------------------------------------------------\n银行理财产品 | 暂时闲置自有资金 | 10,000 | 0 | 0\n银行理财产品 | 暂时闲置募集资金 | 21,000 | 0 | 0\n合计 | | 31,000 | 0 | 0",
      "chunk_type": "table_group",
      "parent_id": "a16cbec0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 370,
      "page_number": 43,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "费用",
          "投资",
          "股本",
          "股份",
          "总股本",
          "回购",
          "投资者"
        ],
        "time_periods": [
          "2019-2"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          43
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.213534",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 370,
        "word_count": 42,
        "sentence_count": 5,
        "chinese_char_count": 184,
        "readability_score": 0.0,
        "information_density": 0.21621621621621617,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4854817357001972,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "费用",
        "投资",
        "股本",
        "股份",
        "总股本",
        "回购",
        "投资者"
      ]
    },
    {
      "chunk_id": "ff694486",
      "content": "【说明】（5）促进地方教育事业发展\n为积极履行社会责任、促进地方教育事业的发展，公司向台州职业技术学院涌泉奖助基\n金会捐赠人民币132万元，用于促进台州职业技术学院的发展，奖励优秀学生和教师，资助贫\n困学生顺利完成学业，为社会培养更多更好的优秀人才。2、履行精准扶贫社会责任情况\n公司报告年度暂未开展精准扶贫工作，也暂无后续精准扶贫计划。3、环境保护相关的情况\n上市公司及其子公司是否属于环境保护部门公布的重点排污单位\n是\n主要污染物\n公司或子公 排放口分布 执行的污染 核定的排放超标排放情\n及特征污染 排放方式 排放口数量 排放浓度 排放总量\n司名称 情况 物排放标准 总量 况\n物的名称\n44。\n\n【表格内容】\n| 主要污染物 | | | | | | | | \n--------------------------------------------------\n公司或子公 | | | | 排放口分布 | | 执行的污染 | | 核定的排放 | 超标排放情\n | 及特征污染 | 排放方式 | 排放口数量 | | 排放浓度 | | 排放总量 | | \n司名称 | | | | 情况 | | 物排放标准 | | 总量 | 况\n | 物的名称 | | | | | | | | \n | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "b2325fc5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 559,
      "page_number": 44,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          44
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.213706",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 559,
        "word_count": 97,
        "sentence_count": 3,
        "chinese_char_count": 326,
        "readability_score": 0.0,
        "information_density": 0.017889087656529516,
        "coherence_score": 0.8671428571428572,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4980210961484132,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告"
      ]
    },
    {
      "chunk_id": "ef03799f",
      "content": " |  |  |  |  |  |  |  | COD:66.45 | \n--------------------------------------------------\n |  |  |  |  | COD≤500m | 污水综合排 | COD：18.9 |  | \n浙江海翔药 |  |  |  |  |  |  |  | 吨/年(纳管 | \n | COD、氨 |  |  |  | g/L；氨氮 | 放标准 | 吨(纳管量); |  | \n业股份有限 |  | 间歇 | 1 | 厂界内 |  |  |  | 量)；氨氮： | 无\n | 氮、PH |  |  |  | ≤35mg/L； | （GB8978- | 氨氮：1.32 |  | \n公司 |  |  |  |  |  |  |  | 4.65吨/年 | \n |  |  |  |  | PH 6-9 | 1996） | 吨(纳管量) |  | \n |  |  |  |  |  |  |  | (纳管量) | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | 化学合成类 |  |  | \n |  |  |  |  |  | 制药工业大 |  |  | \n浙江海翔药 |  |  |  |  |  |  |  |  | \n |  |  |  |  | VOCs≤150 | 气污染物排 | 未超过核定 | VOCs≤12.4 | \n业股份有限 | VOCs | 连续 | 1 | 厂界内 |  |  |  |  | 无\n |  |  |  |  | （mg/m3） | 放标准 | 排放总量 | 2（吨/年） | \n公司 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | DB33/2015- |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | 2016 |  |  | \n |  |  |  |  |  |  |  | COD纳管 | \n |  |  |  |  |  |  |  | 195.45吨/ | \n |  |  |  |  | COD≤500/ | 污水综合排 | COD纳管 | 年(排环境 | \n浙江海翔川 |  |  |  |  |  |  |  |  | \n | COD、氨 |  |  |  | L；氨氮 | 放标准 | 190.84吨； | 量39.09 | \n南药业有限 |  | 间歇 | 1 | 厂界内 |  |  |  |  | 无\n | 氮、PH |  |  |  | ≤35mg/L； | （GB8978- | 氨氮纳管 | 吨)；氨氮纳 | \n公司 |  |  |  |  |  |  |  |  | \n |  |  |  |  | PH6-9 | 1996） | 13.35吨 | 管13.68吨/ | ",
      "chunk_type": "table_group",
      "parent_id": "e734f6ff",
      "child_ids": [],
      "sibling_ids": [
        "bcef109b"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1729,
      "page_number": 45,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          45
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.214277",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1229,
        "word_count": 336,
        "sentence_count": 10,
        "chinese_char_count": 151,
        "readability_score": 0.0,
        "information_density": 0.008136696501220505,
        "coherence_score": 0.31363636363636366,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5380698151950718,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份"
      ]
    },
    {
      "chunk_id": "bcef109b",
      "content": " |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | 年(排环境 | \n |  |  |  |  |  |  |  | 量5.91吨) | \n |  |  |  |  | VOCs≤150 |  |  |  | \n |  |  |  |  | （mg/m3）； |  |  | VOCs 22.13 | \n |  |  |  |  | 二氧化硫 | 污水综合排 |  | 吨/年；二氧 | \n浙江海翔川 | VOCs、二 |  |  |  |  |  |  |  | \n |  |  |  |  | ≤200 | 放标准 | 未超过核定 | 化硫15.2吨 | \n南药业有限 | 氧化硫、氮 | 间歇 | 2 | 厂界内 |  |  |  |  | 无\n |  |  |  |  | （mg/m3）； | （GB8978- | 排放总量 | /年；氮氧化 | \n公司 | 氧化物 |  |  |  |  |  |  |  | \n |  |  |  |  | 氮氧化物 | 1996） |  | 物36.78吨/ | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  | ≤400 |  |  | 年 | \n |  |  |  |  | （mg/m3） |  |  |  | \n浙江海翔川 |  |  |  |  |  |  |  |  | \n |  | 委托有资质 |  |  |  | 按照环评核 |  |  | \n南药业有限 | 固废 |  | / | / | / |  | 3762.85吨 | 5129吨/年 | 无\n |  | 单位处置 |  |  |  | 实标准 |  |  | \n公司 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n台州市前进 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | 污水综合排 |  | COD： | \n化工有限公 |  |  |  |  | COD<500m |  | COD：8.321 |  | \n | COD、氨 |  |  |  |  | 放标准 |  | 27.164吨/ | \n司、台州市 |  | 间歇 | 1 | 厂界内 | g/L；氨氮 |  | 吨：氨氮： |  | 无\n | 氮、PH |  |  |  |  | （GB8978- |  | 年；氨氮： | \n振港染料化 |  |  |  |  | <35mg/L |  | 1.248吨 |  | \n |  |  |  |  |  | 1996） |  | 3.551吨/年 | \n工有限公司 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e734f6ff",
      "child_ids": [],
      "sibling_ids": [
        "ef03799f"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2205,
      "page_number": 45,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 31,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          45
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.214547",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1205,
        "word_count": 351,
        "sentence_count": 9,
        "chinese_char_count": 158,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.2884615384615385,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5380698151950718,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "fd685657",
      "content": " |  |  |  |  | VOCs≤120 |  |  |  | \n--------------------------------------------------\n |  |  |  |  |  |  |  | VOCs： | \n |  |  |  |  | （mg/m3）； |  |  |  | \n |  |  |  |  |  |  |  | 32.337吨/ | \n |  |  |  |  | 二氧化硫 | 大气污染综 |  |  | \n台州市前进 | VOCs、二 |  |  |  |  |  |  | 年；二氧化 | 见其他应公\n |  |  |  |  | <550 | 合排放标准 | 未超过核定 |  | \n化工有限公 | 氧化硫、氮 | 连续 | 2 | 厂界内 |  |  |  | 硫：2.286 | 开的环境信\n |  |  |  |  | （mg/m3）； | （GB16297 | 排放总量 |  | \n司 | 氧化物 |  |  |  |  |  |  | 吨/年；氮氧 | 息\n |  |  |  |  | 氮氧化物 | -1996） |  |  | \n |  |  |  |  |  |  |  | 化物17.562 | \n |  |  |  |  | <240 |  |  |  | \n |  |  |  |  |  |  |  | 吨/年 | \n |  |  |  |  | （mg/m3） |  |  |  | \n |  |  |  |  |  |  |  |  | \n台州市前进 |  |  |  |  |  |  |  |  | \n化工有限公 |  |  |  |  |  |  |  |  | \n |  | 委托有资质 |  |  |  | 按照环评核 |  |  | \n司、台州市 | 危险固废 |  | / | / | / |  | 661.46吨 | 2384吨/年 | 无\n |  | 单位处置 |  |  |  | 实标准 |  |  | \n振港染料化 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n工有限公司 |  |  |  |  |  |  |  |  | \n |  |  |  |  | VOCs≤80 |  |  |  | \n |  |  |  |  |  |  |  | VOCs： | \n |  |  |  |  | （mg/m3）； |  |  |  | \n |  |  |  |  |  | 大气污染物 |  | 9.553吨/ | \n |  |  |  |  | 二氧化硫 |  |  |  | \n盐城市瓯华 | VOCs、二 |  |  |  |  | 综合排放标 |  | 年；二氧化 | \n |  |  |  |  | ≤550 |  | 未超过核定 |  | ",
      "chunk_type": "table_group",
      "parent_id": "c3867489",
      "child_ids": [],
      "sibling_ids": [
        "1e8432dd"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1712,
      "page_number": 46,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.215047",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1212,
        "word_count": 341,
        "sentence_count": 5,
        "chinese_char_count": 155,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5392255892255893,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "1e8432dd",
      "content": "化学工业有 | 氧化硫、氮 | 间歇 | 8 | 厂界内 |  | 准 |  | 硫 10.875 | 无\n |  |  |  |  | （mg/m3）； |  | 排放总量 |  | \n限公司 | 氧化物 |  |  |  |  | （GB16297 |  | 吨/年；氮氧 | \n |  |  |  |  | 氮氧化物 |  |  |  | \n |  |  |  |  |  | -1996） |  | 化物11.986 | \n |  |  |  |  | ≤240 |  |  |  | \n |  |  |  |  |  |  |  | 吨/年 | \n |  |  |  |  | （mg/m3） |  |  |  | \n |  |  |  |  |  |  |  |  | \n盐城市瓯华 |  | 自行焚烧、 |  |  |  |  |  |  | \n |  |  |  |  |  | 按照环评核 |  | 6017.333吨 | \n化学工业有 | 固废 | 委托资质单 | / | / | / |  | 2410.811吨 |  | 无\n |  |  |  |  |  | 实标准 |  | /年 | \n限公司 |  | 位处置 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "c3867489",
      "child_ids": [],
      "sibling_ids": [
        "fd685657"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1569,
      "page_number": 46,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          46
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.215206",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 569,
        "word_count": 172,
        "sentence_count": 4,
        "chinese_char_count": 78,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5392255892255893,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "2df7644f",
      "content": "【说明】内容详见公司于《中国证券报》、《上海证券报》、《证券时报》、\n《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《回购报告书》（公告编\n48。\n\n【表格内容】\n| 本次变动前 | | 本次变动增减（ ， ） | | | | | 本次变动后 | \n--------------------------------------------------\n | | | | | | | | | \n | 数量 | 比例 | 发行新股 | 送股 | 公积金转股 | 其他 | 小计 | 数量 | 比例\n | | | | | | | | | \n一 有限售条件股份 | 27,076,100 | 1.68% | | | | -12,801,500 | -12,801,500 | 14,274,600 | 0.88%\n3 其他内资持股 | 27,076,100 | 1.68% | | | | -12,801,500 | -12,801,500 | 14,274,600 | 0.88%\n境内自然人持股 | 27,076,100 | 1.68% | | | | -12,801,500 | -12,801,500 | 14,274,600 | 0.88%\n二 无限售条件股份 | 1,591,744,153 | 98.33% | | | | 12,696,500 | 12,696,500 | 1,604,440,653 | 99.12%\n1 人民币普通股 | 1,591,744,153 | 98.33% | | | | 12,696,500 | 12,696,500 | 1,604,440,653 | 99.12%\n三 股份总数 | 1,618,820,253 | 100.00% | | | | -105,000 | -105,000 | 1,618,715,253 | 100.00%",
      "chunk_type": "table_group",
      "parent_id": "43c42095",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 809,
      "page_number": 48,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份",
          "回购",
          "报告",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          48
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.215429",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 809,
        "word_count": 156,
        "sentence_count": 16,
        "chinese_char_count": 127,
        "readability_score": 0.0,
        "information_density": 0.049443757725587144,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5567466120344366,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "回购",
        "报告",
        "证券"
      ]
    },
    {
      "chunk_id": "6196e0a2",
      "content": "【说明】具体内容详见公司于《中国证券报》、《上海证券报》、\n《证券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于回购公\n司股份实施完成的公告》（公告编号:2019-019）。采用集中竞价方式减持回购股份的实施进展情况\n□ 适用 √ 不适用\n股份变动对最近一年和最近一期基本每股收益和稀释每股收益、归属于公司普通股股东的每股净资产等财务指标的影响\n□ 适用 √ 不适用\n公司认为必要或证券监管机构要求披露的其他内容\n□ 适用 √ 不适用\n2、限售股份变动情况\n√ 适用 □ 不适用\n单位：股\n本期增加限售股 本期解除限售股\n股东名称 期初限售股数 期末限售股数 限售原因 解除限售日期\n数 数\n299名限制性股 限制性股票激励\n12,696,500 0 12,696,500 0 2019年4月4日\n票激励对象 计划第四期解锁\n回购离职激励对\n回购5人限制性\n105,000 0 105,000 0象持有的尚未解 2019年6月24日\n股票\n禁的限制性股票\n合计 12,801,500 0 12,801,500 0 -- --\n49。\n\n【表格内容】\n| | 本期增加限售股 | 本期解除限售股 | | | \n--------------------------------------------------\n股东名称 | 期初限售股数 | | | 期末限售股数 | 限售原因 | 解除限售日期\n | | 数 | 数 | | | \n | | | | | | \n299名限制性股 | | | | | 限制性股票激励 | \n | 12,696,500 | 0 | 12,696,500 | 0 | | 2019年4月4日\n票激励对象 | | | | | 计划第四期解锁 | \n | | | | | | \n | | | | | 回购离职激励对 | \n回购5人限制性 | | | | | | \n | 105,000 | 0 | 105,000 | 0 | 象持有的尚未解 | 2019年6月24日\n股票 | | | | | | \n | | | | | 禁的限制性股票 | \n | | | | | | \n合计 | 12,801,500 | 0 | 12,801,500 | 0 | -- | --",
      "chunk_type": "table_group",
      "parent_id": "b6968622",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 968,
      "page_number": 49,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "净资产",
          "财务指标",
          "股份",
          "股东",
          "每股",
          "限售股",
          "回购",
          "披露",
          "证券"
        ],
        "time_periods": [
          "2019-4",
          "2019-6"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.215702",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 968,
        "word_count": 185,
        "sentence_count": 5,
        "chinese_char_count": 392,
        "readability_score": 0.0,
        "information_density": 0.10330578512396696,
        "coherence_score": 0.4992857142857143,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6069286492346283,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "净资产",
        "财务指标",
        "股份",
        "股东",
        "每股",
        "限售股",
        "回购",
        "披露",
        "证券"
      ]
    },
    {
      "chunk_id": "db21cf29",
      "content": " |  |  | 年度报告披露\n日前上一月末\n普通股股东总\n数 |  |  |  |  |  |  |  | 年度报告披露 |  | \n--------------------------------------------------\n |  |  |  |  |  |  | 报告期末表决 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 日前上一月末 |  | \n |  |  |  |  |  |  | 权恢复的优先 |  |  |  |  |  | \n报告期末普通 |  |  |  |  |  |  |  |  |  |  | 表决权恢复的 |  | \n | 71,441 |  |  |  | 71,441 |  | 股股东总数 |  | 0 |  |  |  | 0\n股股东总数 |  |  |  |  |  |  |  |  |  |  | 优先股股东总 |  | \n |  |  |  |  |  |  | （如有）（参见 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 数（如有）（参 |  | \n |  |  |  |  |  |  | 注8） |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 见注8） |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n持股5%以上的股东或前10名股东持股情况 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | 报告期内 |  | 持有有限 | 持有无限 | 质押或冻结情况 |  |  | \n |  |  |  |  | 报告期末 |  |  |  |  |  |  |  | \n股东名称 |  | 股东性质 |  | 持股比例 |  | 增减变动 |  | 售条件的 | 售条件的 |  |  |  | \n |  |  |  |  | 持股数量 |  |  |  |  | 股份状态 |  | 数量 | \n |  |  |  |  |  | 情况 |  | 股份数量 | 股份数量 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n浙江东港投资有\n限公司 |  | 境内非国有法人 |  | 34.22% | 553,982,5\n87 | -2201741\n3 |  | 0 | 553,982,5\n87 |  |  |  | \n |  |  |  |  |  |  |  |  |  | 质押 |  | 241,382,587 | \n |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "091a1209",
      "child_ids": [],
      "sibling_ids": [
        "65d546e8"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1698,
      "page_number": 50,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股份",
          "股东",
          "报告",
          "年度报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          50
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.216192",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1198,
        "word_count": 339,
        "sentence_count": 1,
        "chinese_char_count": 184,
        "readability_score": 0.0,
        "information_density": 0.05008347245409015,
        "coherence_score": 0.583889816360601,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6037651677373305,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股份",
        "股东",
        "报告",
        "年度报告",
        "披露"
      ]
    },
    {
      "chunk_id": "65d546e8",
      "content": "王云富 |  | 境内自然人 |  | 7.34% | 118,800,0\n00 | 0 |  | 0 | 118,800,0\n00 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n新昌勤进投资有\n限公司 |  | 境内非国有法人 |  | 3.07% | 49,650,00\n0 | -1435000\n0 |  | 0 | 49,650,00\n0 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n香港中央结算有\n限公司 |  | 境外法人 |  | 1.32% | 21,438,17\n8 | 18018169 |  | 0 | 21,438,17\n8 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n王丽英 |  | 境内自然人 |  | 0.89% | 14,350,00\n0 | 14350000 |  | 0 | 14,350,00\n0 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "091a1209",
      "child_ids": [],
      "sibling_ids": [
        "db21cf29"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1669,
      "page_number": 50,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          50
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.216286",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 669,
        "word_count": 195,
        "sentence_count": 4,
        "chinese_char_count": 47,
        "readability_score": 0.0,
        "information_density": 0.014947683109118084,
        "coherence_score": 0.32,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6037651677373305,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资"
      ]
    },
    {
      "chunk_id": "0a00d7d6",
      "content": "中央汇金资产管\n理有限责任公司 | 国有法人 | 0.65% | 10,540,40\n0 | 0 | 0 | 10,540,40\n0 |  | \n--------------------------------------------------\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n全国社保基金一\n一七组合 | 其他 | 0.62% | 10,000,00\n0 | 10000000 | 0 | 10,000,00\n0 |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n中国工商银行股\n份有限公司－国\n泰鑫睿混合型证\n券投资基金 | 其他 | 0.53% | 8,595,000 | 8595000 | 0 | 8,595,000 |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n招商银行股份有\n限公司－汇添富\n医疗服务灵活配\n置混合型证券投\n资基金 | 其他 | 0.38% | 6,100,049 | 6100049 | 0 | 6,100,049 |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n叶小青 | 境内自然人 | 0.36% | 5,796,235 | -1618820\n0 | 0 | 5,796,235 |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n战略投资者或一般法人因配售新股 |  |  |  |  |  |  |  | \n成为前10名股东的情况（如有）（参 |  | 无 |  |  |  |  |  | \n见注3） |  |  |  |  |  |  |  | \n |  | 1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00% |  |  |  |  |  | \n上述股东关联关系或一致行动的说 |  | 的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司 |  |  |  |  |  | \n明 |  | 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制 |  |  |  |  |  | \n |  | 人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。 |  |  |  |  |  | \n前10名无限售条件股东持股情况 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | 股份种类 | \n股东名称 |  | 报告期末持有无限售条件股份数量 |  |  |  |  |  | \n |  |  |  |  |  |  | 股份种类 | 数量",
      "chunk_type": "table_group",
      "parent_id": "7e819619",
      "child_ids": [],
      "sibling_ids": [
        "4a471fe8"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1733,
      "page_number": 51,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 41,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "股权",
          "股份",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          51
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.216772",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1233,
        "word_count": 274,
        "sentence_count": 10,
        "chinese_char_count": 299,
        "readability_score": 0.0,
        "information_density": 0.064882400648824,
        "coherence_score": 0.50670600162206,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7053936348408709,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "股权",
        "股份",
        "股东",
        "报告",
        "投资者",
        "证券"
      ]
    },
    {
      "chunk_id": "4a471fe8",
      "content": " |  |  |  |  |  |  |  | \n浙江东港投资有限公司 |  | 553,982,587 |  |  |  |  | 人民币普通股 | 553,982,587\n王云富 |  | 118,800,000 |  |  |  |  | 人民币普通股 | 118,800,000\n新昌勤进投资有限公司 |  | 49,650,000 |  |  |  |  | 人民币普通股 | 49,650,000\n香港中央结算有限公司 |  | 21,438,178 |  |  |  |  | 人民币普通股 | 21,438,178\n王丽英 |  | 14,350,000 |  |  |  |  | 人民币普通股 | 14,350,000\n中央汇金资产管理有限责任公司 |  | 10,540,400 |  |  |  |  | 人民币普通股 | 10,540,400\n全国社保基金一一七组合 |  | 10,000,000 |  |  |  |  | 人民币普通股 | 10,000,000\n中国工商银行股份有限公司－国泰\n鑫睿混合型证券投资基金 |  | 8,595,000 |  |  |  |  |  | \n |  |  |  |  |  |  | 人民币普通股 | 8,595,000\n |  |  |  |  |  |  |  | \n招商银行股份有限公司－汇添富医\n疗服务灵活配置混合型证券投资基\n金 |  | 6,100,049 |  |  |  |  |  | \n |  |  |  |  |  |  | 人民币普通股 | 6,100,049\n |  |  |  |  |  |  |  | \n叶小青 |  | 5,796,235 |  |  |  |  | 人民币普通股 | 5,796,235",
      "chunk_type": "table_group",
      "parent_id": "7e819619",
      "child_ids": [],
      "sibling_ids": [
        "0a00d7d6"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1756,
      "page_number": 51,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 18,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "股份",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          51
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.216878",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江东港投资有限公司",
        "industry": null,
        "char_count": 756,
        "word_count": 163,
        "sentence_count": 0,
        "chinese_char_count": 179,
        "readability_score": 0.0,
        "information_density": 0.05291005291005292,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7053936348408709,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "股份",
        "证券"
      ]
    },
    {
      "chunk_id": "ab4d61a4",
      "content": "【标题】3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。\n\n【表格内容】\n前10名无限售流通股股东之间，以 | 1 王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n--------------------------------------------------\n及前10名无限售流通股股东和前10 | 的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司\n名股东之间关联关系或一致行动的 | 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制\n说明 | 人。2 其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n | 1 新昌勤进投资有限公司通过普通账户持股1465万股，通过信用账户持股3500万\n前10名普通股股东参与融资融券业 | \n | 股。2 王丽英通过信用账户持股1435万股。3 其他股东不存在通过信用账户持股\n务情况说明（如有）（参见注4） | \n | 的情况。\n |",
      "chunk_type": "table_group",
      "parent_id": "42ab74e4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 478,
      "page_number": 52,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股权",
          "股份",
          "股东",
          "流通股",
          "融资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.217035",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "新昌勤进投资有限公司",
        "industry": null,
        "char_count": 478,
        "word_count": 34,
        "sentence_count": 9,
        "chinese_char_count": 283,
        "readability_score": 0.0,
        "information_density": 0.12552301255230125,
        "coherence_score": 0.7594642857142857,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6740412836438924,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股权",
        "股份",
        "股东",
        "流通股",
        "融资"
      ]
    },
    {
      "chunk_id": "3b329931",
      "content": "【说明】是否取得其他国家或地区居\n实际控制人姓名 与实际控制人关系 国籍\n留权\n王云富 本人 中国 否\n一致行动（含协议、亲属、同\n王扬超 中国 否\n一控制）\n王云富先生自2003年3月起一直在东港集团任职，曾担任东港集团副董事长、总裁、党委\n副书记、工会主席等职务，2012年9月至今担任东港工贸集团有限公司执行董事、东港投\n资执行董事。王云富先生持有东港工贸集团有限公司73.20%的股权。王扬超先生系公司实际控制人王云富先生之子，2008年参加工作，曾担任东港工贸集团有\n主要职业及职务\n限公司销售经理、总裁助理，台州市振港染料化工有限公司常务副总、台州市前进化工有限\n公司总经理等职务。\n\n【表格内容】\n| 法定 | | | \n--------------------------------------------------\n | 代表 | | | \n控股股东名 | | 成立日 | | \n | 人/单 | | 组织机构代码 | 主要经营业务\n称 | | 期 | | \n | 位负 | | | \n | | | | \n | 责人 | | | \n | | | | 国家法律 法规和政策允许的投资业务；股权投资 资产管理（未经金融\n | | 1998 | | 等监管部门批准，不得从事向公众融资存款 融资担保 代客理财等金融\n浙江东港投 | 王云 | 年07 | | 服务）；机械设备 电子产品 工艺品 服装 家用电器 日用品 针纺织\n | | | 913310027046766827 | \n资有限公司 | 富 | 月09 | | 品 金属材料 建材销售；黄金饰品加工 销售；房地产开发；市场摊位\n | | | | \n | | 日 | | 租赁；塑料原料销售；企业管理咨询服务；货物及技术进出口（国家法律 \n | | | | 法规禁止或限制经营的项目除外）。\n控股股东报 | | | | \n告期内控股 | | | | \n和参股的其 | | | | \n | 无 | | | \n他境内外上 | | | | \n | | | | \n市公司的股 | | | | \n权情况 | | | |",
      "chunk_type": "table_group",
      "parent_id": "199fb6e6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 892,
      "page_number": 52,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "营业",
          "经营",
          "股权",
          "股东",
          "内控",
          "融资"
        ],
        "time_periods": [
          "2003-3",
          "2012-9"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.217300",
        "report_type": null,
        "fiscal_year": 2003,
        "fiscal_quarter": null,
        "company_code": "月至今担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 892,
        "word_count": 164,
        "sentence_count": 5,
        "chinese_char_count": 469,
        "readability_score": 0.0,
        "information_density": 0.08968609865470853,
        "coherence_score": 0.27992145514675487,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6981643217012494,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "营业",
        "经营",
        "股权",
        "股东",
        "内控",
        "融资"
      ]
    },
    {
      "chunk_id": "e0e86f1c",
      "content": "【说明】公司与实际控制人之间的产权及控制关系的方框图\n实际控制人通过信托或其他资产管理方式控制公司\n□ 适用 √ 不适用\n4、其他持股在10%以上的法人股东\n□ 适用 √ 不适用\n53。\n\n【表格内容】\n| | | 是否取得其他国家或地区居\n--------------------------------------------------\n实际控制人姓名 | 与实际控制人关系 | 国籍 | \n | | | 留权\n | | | \n王云富 | 本人 | 中国 | 否\n | 一致行动（含协议 亲属 同 | | \n王扬超 | | 中国 | 否\n | 一控制） | | \n | | | \n | 王云富先生自2003年3月起一直在东港集团任职，曾担任东港集团副董事长 总裁 党委 | | \n | 副书记 工会主席等职务，2012年9月至今担任东港工贸集团有限公司执行董事 东港投 | | \n | 资执行董事。王云富先生持有东港工贸集团有限公司73.20%的股权。 | | \n | 王扬超先生系公司实际控制人王云富先生之子，2008年参加工作，曾担任东港工贸集团有 | | \n主要职业及职务 | | | \n | 限公司销售经理 总裁助理，台州市振港染料化工有限公司常务副总 台州市前进化工有限 | | \n | | | \n | 公司总经理等职务。现担任台州市椒江区第十届政协委员会常委 台州市椒江区工商业联合 | | \n | 会副会长 上海海翔医药科技发展有限公司执行董事等。王扬超先生未直接持有公司股票， | | \n | 持有东港工贸集团有限公司26.80%的股权，故王扬超先生间接持有公司股份。 | | \n过去10年曾控股的境内外上 | | | \n | 无 | | \n市公司情况 | | | \n | | |",
      "chunk_type": "table_group",
      "parent_id": "301e7560",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 751,
      "page_number": 53,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "股权",
          "股份",
          "股东"
        ],
        "time_periods": [
          "2003-3",
          "2012-9"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          53
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.217522",
        "report_type": null,
        "fiscal_year": 2003,
        "fiscal_quarter": null,
        "company_code": "月至今担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 751,
        "word_count": 119,
        "sentence_count": 8,
        "chinese_char_count": 421,
        "readability_score": 0.0,
        "information_density": 0.053262316910785625,
        "coherence_score": 0.5963337575029304,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6601532953851739,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "股权",
        "股份",
        "股东"
      ]
    },
    {
      "chunk_id": "c92f906a",
      "content": " |  |  |  |  |  |  |  | 本期增持 | 本期减持 |  | \n--------------------------------------------------\n |  |  |  |  | 任期起始 | 任期终止 | 期初持股 |  |  | 其他增减 | 期末持股\n姓名 | 职务 | 任职状态 | 性别 | 年龄 |  |  |  | 股份数量 | 股份数量 |  | \n |  |  |  |  | 日期 | 日期 | 数（股） |  |  | 变动（股） | 数（股）\n |  |  |  |  |  |  |  | （股） | （股） |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2015年 | 2022年 |  |  |  |  | \n孙杨 | 董事长 | 现任 | 男 | 53 | 08月25 | 11月12 | 4,400,000 | 0 | 0 | 0 | 4,400,000\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2019年 | 2022年 |  |  |  |  | \n王扬超 | 副董事长 | 现任 | 男 | 33 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2014年 | 2022年 |  |  |  |  | \n | 董事、总 |  |  |  |  |  |  |  |  |  | \n杨思卫 |  | 现任 | 男 | 46 | 12月08 | 11月12 | 4,857,800 | 0 | 0 | 0 | 4,857,800\n | 经理 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2017年 | 2022年 |  |  |  |  | \n洪鸣 | 董事 | 现任 | 男 | 37 | 05月31 | 11月12 | 315,000 | 0 | 78,750 | 0 | 236,250\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2016年 | 2022年 |  |  |  |  | \n朱建伟 | 董事 | 现任 | 男 | 64 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2019年 | 2022年 |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "610aa661",
      "child_ids": [],
      "sibling_ids": [
        "3bb68113"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1720,
      "page_number": 57,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          57
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.218224",
        "report_type": null,
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1220,
        "word_count": 380,
        "sentence_count": 0,
        "chinese_char_count": 137,
        "readability_score": 0.0,
        "information_density": 0.00819672131147541,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5345541401273886,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份"
      ]
    },
    {
      "chunk_id": "3bb68113",
      "content": "姚冰 | 董事 | 现任 | 男 | 38 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2016年 | 2022年 |  |  |  |  | \n苏为科 | 独立董事 | 现任 | 男 | 59 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2016年 | 2022年 |  |  |  |  | \n毛美英 | 独立董事 | 现任 | 女 | 57 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2019年 | 2022年 |  |  |  |  | \n张克坚 | 独立董事 | 现任 | 男 | 64 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n | 监事会主 |  |  |  | 2019年 | 2022年 |  |  |  |  | \n陈敏杰 | 席、职工 | 现任 | 男 | 52 | 11月13 | 11月12 | 0 | 0 | 0 | 0 | 0\n | 监事 |  |  |  | 日 | 日 |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "610aa661",
      "child_ids": [],
      "sibling_ids": [
        "c92f906a"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1663,
      "page_number": 57,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 14,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          57
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.218423",
        "report_type": null,
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 663,
        "word_count": 234,
        "sentence_count": 0,
        "chinese_char_count": 80,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5345541401273886,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "632ba9ca",
      "content": " |  |  |  |  | 2014年 | 2022年 |  |  |  |  | \n--------------------------------------------------\n汪启华 | 监事 | 现任 | 男 | 56 | 05月15 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2012年 | 2022年 |  |  |  |  | \n龚伟中 | 监事 | 现任 | 男 | 55 | 10月11 | 11月12 | 0 | 0 | 0 | 0 | 0\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2017年 | 2022年 |  |  |  |  | \n | 常务副总 |  |  |  |  |  |  |  |  |  | \n李洪明 |  | 现任 | 男 | 51 | 05月13 | 11月12 | 600,000 | 0 | 20,000 |  | 580,000\n | 经理 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2011年 | 2022年 |  |  |  |  | \n沈利华 | 副总经理 | 现任 | 男 | 54 | 02月23 | 11月12 | 1,200,000 | 0 | 0 | 0 | 1,200,000\n |  |  |  |  | 日 | 日 |  |  |  |  | \n | 副总经 |  |  |  | 2012年 | 2022年 |  |  |  |  | \n许华青 | 理、董事 | 现任 | 女 | 39 | 09月19 | 11月12 | 1,260,000 | 0 | 315,000 | 0 | 945,000\n | 会秘书 |  |  |  | 日 | 日 |  |  |  |  | \n | 副总经 |  |  |  | 2016年 | 2022年 |  |  |  |  | \n李进 | 理、财务 | 现任 | 男 | 36 | 10月17 | 11月12 | 0 | 0 | 0 | 0 | 0\n | 总监 |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2013年 | 2022年 |  |  |  |  | \n毛文华 | 副总经理 | 现任 | 男 | 53 | 07月19 | 11月12 | 1,800,000 | 0 | 450,000 | 0 | 1,350,000\n |  |  |  |  | 日 | 日 |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b4aa5502",
      "child_ids": [],
      "sibling_ids": [
        "ce6df800"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1721,
      "page_number": 58,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 25,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          58
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.219047",
        "report_type": null,
        "fiscal_year": 2014,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1221,
        "word_count": 381,
        "sentence_count": 0,
        "chinese_char_count": 118,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5926243052426018,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "ce6df800",
      "content": " |  |  |  |  | 2014年 | 2022年 |  |  |  |  | \n许国睿 | 副总经理 | 现任 | 男 | 43 | 11月21 | 11月12 | 600,000 |  | 150,000 | 0 | 450,000\n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  | 2015年 | 2019年 |  |  |  |  | \n | 原副董事 |  |  |  |  |  |  |  |  |  | \n郭敏龙 |  | 离任 | 男 | 56 | 08月25 | 11月12 | 4,000,000 |  | 1,000,000 | 0 | 3,000,000\n | 长 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2015年 | 2019年 |  |  |  |  | \n | 原独立董 |  |  |  |  |  |  |  |  |  | \n田利明 |  | 离任 | 男 | 66 | 05月06 | 11月12 | 0 | 0 | 0 | 0 | 0\n | 事 |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | 原监事会 |  |  |  | 2004年 | 2019年 |  |  |  |  | \n郭世华 | 主席、职 | 离任 | 男 | 60 | 04月01 | 11月12 | 0 | 0 | 0 | 0 | 0\n | 工监事 |  |  |  | 日 | 日 |  |  |  |  | \n |  |  |  |  |  |  | 19,032,80 |  |  |  | 17,019,05\n合计 | -- | -- | -- | -- | -- | -- |  | 0 | 2,013,750 | 0 | \n |  |  |  |  |  |  | 0 |  |  |  | 0\n |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b4aa5502",
      "child_ids": [],
      "sibling_ids": [
        "632ba9ca"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1997,
      "page_number": 58,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          58
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.219337",
        "report_type": null,
        "fiscal_year": 2014,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 997,
        "word_count": 322,
        "sentence_count": 0,
        "chinese_char_count": 74,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5926243052426018,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "656edd5d",
      "content": "【说明】7、苏为科先生，中国国籍，无境外永久居留权，生于1961年2月，理学博士。历任浙江工\n学院有机化学教研室助教，浙江工业大学有机化工教研室讲师，副教授，现任浙江工业大学\n教授，兼任浙江省制药工程重点实验室主任，浙江省新药创制科技服务平台负责人，浙江省\n制药重中之重学科负责人，长三角绿色制药协同创新中心执行主任，国家化学原料药合成工\n程技术研究中心常务副主任。现担任兄弟科技股份有限公司、浙江花园生物高科股份有限公\n司的独立董事。\n\n【表格内容】\n姓名 | 担任的职务 | 类型 | 日期 | 原因\n--------------------------------------------------\n | 原董事 副董事 | | 2019年11月12 | \n郭敏龙 | | 任期满离任 | | 换届离任\n | 长 | | 日 | \n | | | | \n | | | 2019年11月12 | \n田利明 | 独立董事 | 任期满离任 | | 换届离任\n | | | 日 | \n | | | | \n | 原监事会主席 | | 2019年11月12 | \n郭世华 | | 任期满离任 | | 换届离任\n | 职工监事 | | 日 | \n | | | | \n | 原董事，现任副 | | 2019年11月12 | \n沈利华 | | 任免 | | 董事职务换届离任，仍继续担任公司副总经理\n | 总经理 | | 日 | \n | | | |",
      "chunk_type": "table_group",
      "parent_id": "41b949b7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 618,
      "page_number": 59,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份"
        ],
        "time_periods": [
          "1961-2",
          "2019-11"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          59
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.219551",
        "report_type": null,
        "fiscal_year": 1961,
        "fiscal_quarter": null,
        "company_code": "现担任兄弟科技股份有限公司",
        "industry": null,
        "char_count": 618,
        "word_count": 109,
        "sentence_count": 3,
        "chinese_char_count": 307,
        "readability_score": 0.0,
        "information_density": 0.016181229773462785,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6009974495200925,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份"
      ]
    },
    {
      "chunk_id": "a837499d",
      "content": "【说明】在股东单位任职情况\n√ 适用 □ 不适用\n在股东单位 在股东单位是否\n任职人员姓名 股东单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n王扬超 东港工贸集团有限公司 监事 否\n在股东单位任\n无\n职情况的说明\n在其他单位任职情况\n√ 适用 □ 不适用\n在其他单位 在其他单位是否\n任职人员姓名 其他单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n朱建伟 上海交通大学药学院 院长 是\n朱建伟 浙江医药股份有限公司 独立董事 是\n苏为科 浙江工业大学 教授 是\n苏为科 浙江花园生物高科股份有限公司 独立董事 是\n苏为科 兄弟科技股份有限公司 独立董事 是\n执行董事兼\n苏为科 浙江天诺医药科技有限公司 是\n总经理\n毛美英 台州市沿海高速公路建设管理中心 职员 是\n毛美英 浙江万盛股份有限公司 独立董事 是\n毛美英 浙江伟星实业发展股份有限公司 独立董事 是\n毛美英 永高股份有限公司 独立董事 是\n毛美英 浙江永强集团股份有限公司 独立董事 是\n张克坚 亿帆医药股份有限公司 独立董事 是\n张克坚 湖南方盛制药股份有限公司 独立董事 是\n独立非执行\n张克坚 华润医药集团有限公司 是\n董事\n张克坚 广东华南新药创制中心 首席科学家 是\n孙杨 浙江海翔川南药业有限公司 执行董事 否\n61。\n\n【表格内容】\n| 股东单位名称 | 在股东单位\n担任的职务 | | 任期终止日期 | 在股东单位是否\n--------------------------------------------------\n任职人员姓名 | | | 任期起始日期 | | \n | | | | | 领取报酬津贴\n | | | | | \n王扬超 | 东港工贸集团有限公司 | 监事 | | | 否\n在股东单位任 | | | | | \n | 无 | | | | \n职情况的说明 | | | | | \n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "335e623e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 813,
      "page_number": 61,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          61
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.219789",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "东港工贸集团有限公司",
        "industry": null,
        "char_count": 813,
        "word_count": 162,
        "sentence_count": 1,
        "chinese_char_count": 536,
        "readability_score": 0.0,
        "information_density": 0.02460024600246002,
        "coherence_score": 0.4690140845070422,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5615759444737305,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "股东"
      ]
    },
    {
      "chunk_id": "5673cb33",
      "content": " |  | 在其他单位 |  |  | 在其他单位是否\n--------------------------------------------------\n任职人员姓名 | 其他单位名称 |  | 任期起始日期 | 任期终止日期 | \n |  | 担任的职务 |  |  | 领取报酬津贴\n |  |  |  |  | \n朱建伟 | 上海交通大学药学院 | 院长 |  |  | 是\n朱建伟 | 浙江医药股份有限公司 | 独立董事 |  |  | 是\n苏为科 | 浙江工业大学 | 教授 |  |  | 是\n苏为科 | 浙江花园生物高科股份有限公司 | 独立董事 |  |  | 是\n苏为科 | 兄弟科技股份有限公司 | 独立董事 |  |  | 是\n |  | 执行董事兼 |  |  | \n苏为科 | 浙江天诺医药科技有限公司 |  |  |  | 是\n |  | 总经理 |  |  | \n |  |  |  |  | \n毛美英 | 台州市沿海高速公路建设管理中心 | 职员 |  |  | 是\n毛美英 | 浙江万盛股份有限公司 | 独立董事 |  |  | 是\n毛美英 | 浙江伟星实业发展股份有限公司 | 独立董事 |  |  | 是\n毛美英 | 永高股份有限公司 | 独立董事 |  |  | 是\n毛美英 | 浙江永强集团股份有限公司 | 独立董事 |  |  | 是\n张克坚 | 亿帆医药股份有限公司 | 独立董事 |  |  | 是\n张克坚 | 湖南方盛制药股份有限公司 | 独立董事 |  |  | 是\n |  | 独立非执行 |  |  | \n张克坚 | 华润医药集团有限公司 |  |  |  | 是\n |  | 董事 |  |  | \n |  |  |  |  | \n张克坚 | 广东华南新药创制中心 | 首席科学家 |  |  | 是\n孙杨 | 浙江海翔川南药业有限公司 | 执行董事 |  |  | 否",
      "chunk_type": "table_group",
      "parent_id": "b3b29d6c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1316,
      "page_number": 61,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          61
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.220080",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江医药股份有限公司",
        "industry": null,
        "char_count": 816,
        "word_count": 205,
        "sentence_count": 0,
        "chinese_char_count": 350,
        "readability_score": 0.0,
        "information_density": 0.012254901960784314,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47867647058823526,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份"
      ]
    },
    {
      "chunk_id": "f7656261",
      "content": "【说明】实际支付情况：报告期内，公司董事、监事、高管的薪酬根据薪酬计划按月发放。公司报告期内董事、监事和高级管理人员报酬情况\n单位：万元\n从公司获得的税 是否在公司关联\n姓名 职务 性别 年龄 任职状态\n前报酬总额 方获取报酬\n孙杨 董事、董事长 男 53现任 80.08 否\n王扬超 董事、副董事长 男 33现任 60.08 否\n杨思卫 董事、总经理 男 46现任 70.08 否\n洪鸣 董事 男 37现任 35.08 否\n朱建伟 董事 男 64现任 8 否\n姚冰 董事 男 38现任 13.98 否\n苏为科 独立董事 男 59现任 8 否\n毛美英 独立董事 女 57现任 8 否\n张克坚 独立董事 男 64现任 2 否\n监事会主席、职\n陈敏杰 男 52现任 10.94 否\n工监事\n汪启华 监事 男 56现任 45.08 否\n龚伟中 监事 男 55现任 26.54 否\n62。\n\n【表格内容】\n杨思卫 | 盐城市瓯华化学工业有限公司 | 董事长 | | | 否\n--------------------------------------------------\n王扬超 | 上海海翔医药科技发展有限公司 | 执行董事 | | | 否\n | 台州市椒江民营企业联合投资股份有限 | | | | \n王扬超 | | 董事 | | | 否\n | 公司 | | | | \n | | | | | \n李洪明 | 上海海翔医药科技发展有限公司 | 总经理 | | | 否\n汪启华 | 上海海翔医药科技发展有限公司 | 监事 | | | 否\n汪启华 | 浙江海翔药业销售有限公司执行董事 | 执行董事 | | | 否\n汪启华 | 台州港翔化工有限公司 | 监事 | | | 否",
      "chunk_type": "table_group",
      "parent_id": "4feccbad",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 732,
      "page_number": 62,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股份",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          62
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.220300",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 732,
        "word_count": 166,
        "sentence_count": 10,
        "chinese_char_count": 374,
        "readability_score": 0.0,
        "information_density": 0.04098360655737705,
        "coherence_score": 0.52625,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5286880643760674,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股份",
        "报告"
      ]
    },
    {
      "chunk_id": "405a67ee",
      "content": " |  |  |  |  | 从公司获得的税 | 是否在公司关联\n--------------------------------------------------\n姓名 | 职务 | 性别 | 年龄 | 任职状态 |  | \n |  |  |  |  | 前报酬总额 | 方获取报酬\n |  |  |  |  |  | \n孙杨 | 董事、董事长 | 男 | 53 | 现任 | 80.08 | 否\n王扬超 | 董事、副董事长 | 男 | 33 | 现任 | 60.08 | 否\n杨思卫 | 董事、总经理 | 男 | 46 | 现任 | 70.08 | 否\n洪鸣 | 董事 | 男 | 37 | 现任 | 35.08 | 否\n朱建伟 | 董事 | 男 | 64 | 现任 | 8 | 否\n姚冰 | 董事 | 男 | 38 | 现任 | 13.98 | 否\n苏为科 | 独立董事 | 男 | 59 | 现任 | 8 | 否\n毛美英 | 独立董事 | 女 | 57 | 现任 | 8 | 否\n张克坚 | 独立董事 | 男 | 64 | 现任 | 2 | 否\n | 监事会主席、职 |  |  |  |  | \n陈敏杰 |  | 男 | 52 | 现任 | 10.94 | 否\n | 工监事 |  |  |  |  | \n |  |  |  |  |  | \n汪启华 | 监事 | 男 | 56 | 现任 | 45.08 | 否\n龚伟中 | 监事 | 男 | 55 | 现任 | 26.54 | 否",
      "chunk_type": "table_group",
      "parent_id": "baf5727d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1147,
      "page_number": 62,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 20,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          62
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.220761",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 647,
        "word_count": 209,
        "sentence_count": 8,
        "chinese_char_count": 164,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5486554621848739,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5760432766615147,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "0efc4530",
      "content": "【表格内容】\n李洪明 | 常务副总经理 | 男 | 51 | 现任 | 60.14 | 否\n--------------------------------------------------\n沈利华 | 副总经理 | 男 | 54 | 现任 | 60.08 | 否\n | 副总经理 董事 | | | | | \n许华青 | | 女 | 39 | 现任 | 60.08 | 否\n | 会秘书 | | | | | \n | | | | | | \n | 副总经理 财务 | | | | | \n李进 | | 男 | 36 | 现任 | 60.08 | 否\n | 总监 | | | | | \n | | | | | | \n毛文华 | 副总经理 | 男 | 53 | 现任 | 60.08 | 否\n许国睿 | 副总经理 | 男 | 43 | 现任 | 60.08 | 否\n | 原董事 副董事 | | | | | \n郭敏龙 | | 男 | 56 | 离任 | 68.08 | 否\n | 长 | | | | | \n | | | | | | \n田利明 | 原独立董事 | 男 | 66 | 离任 | 6 | 否\n | 原监事会主席 | | | | | \n郭世华 | | 男 | 60 | 离任 | 12.8 | 否\n | 职工监事 | | | | | \n | | | | | | \n合计 | -- | -- | -- | -- | 815.28 | --",
      "chunk_type": "table_group",
      "parent_id": "ec0353f7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 617,
      "page_number": 63,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          63
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.221027",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 617,
        "word_count": 211,
        "sentence_count": 9,
        "chinese_char_count": 125,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5119047619047619,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5605447276361819,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "58e6c0b0",
      "content": "【表格内容】\n| | | | 报告期内 | | | | 报告期新 | 限制性股 | \n--------------------------------------------------\n | | 报告期内 | 报告期内 | | 报告期末 | 期初持有 | 本期已解 | | | 期末持有\n | | | | 已行权股 | | | | 授予限制 | 票的授予 | \n姓名 | 职务 | 可行权股 | 已行权股 | | 市价（元/ | 限制性股 | 锁股份数 | | | 限制性股\n | | | | 数行权价 | | | | 性股票数 | 价格（元/ | \n | | 数 | 数 | | 股） | 票数量 | 量 | | | 票数量\n | | | | 格（元/股） | | | | 量 | 股） | \n | | | | | | | | | | \n孙杨 | 董事长 | | | | | 1,100,000 | 1,100,000 | | 2.25 | 0\n | 董事，总经 | | | | | | | | | \n杨思卫 | | | | | | 1,100,000 | 1,100,000 | | 2.25 | 0\n | 理 | | | | | | | | | \n | | | | | | | | | | \n | 原副董事 | | | | | | | | | \n郭敏龙 | | | | | | 1,600,000 | 1,600,000 | | 4.3125 | 0\n | 长 | | | | | | | | | \n | | | | | | | | | | \n毛文华 | 副总经理 | | | | | 600,000 | 600,000 | | 2.25 | 0\n | 副总经理， | | | | | | | | | \n许华青 | 董事会秘 | | | | | 300,000 | 300,000 | | 2.25 | 0\n | 书 | | | | | | | | | \n沈利华 | 副总经理 | | | | | 300,000 | 300,000 | | 2.25 | 0\n洪鸣 | 董事 | | | | | 150,000 | 150,000 | | 2.25 | 0\n李洪明 | 副总经理 | | | | | 150,000 | 150,000 | | 2.25 | 0\n许国睿 | 副总经理 | | | | | 150,000 | 150,000 | | 2.25 | 0\n合计 | -- | 0 | 0 | -- | -- | 5,450,000 | 5,450,000 | 0 | -- | 0",
      "chunk_type": "table_group",
      "parent_id": "13b0b0b4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1099,
      "page_number": 63,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          63
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.221293",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1099,
        "word_count": 363,
        "sentence_count": 9,
        "chinese_char_count": 172,
        "readability_score": 0.0,
        "information_density": 0.018198362147406732,
        "coherence_score": 0.41555555555555557,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5201600000000001,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "报告"
      ]
    },
    {
      "chunk_id": "c12c1774",
      "content": "【说明】4、劳务外包情况\n□ 适用 √ 不适用\n65 第十节公司治理\n一、公司治理的基本状况\n报告期内，公司严格按照《公司法》、《证券法》、《上市公司治理准则》、《深圳证\n券交易所股票上市规则》等有关法律法规的要求，不断地完善公司治理结构，建立健全内部\n控制制度，并进一步规范公司运作，努力提高公司治理水平。目前，公司整体运作比较规范、\n独立性强、信息披露规范，公司治理实际状况基本符合中国证监会发布的有关上市公司治理\n的规范性文件。公司本报告期内经过股东大会或董事会审议通过正在执行的制度及最新披露时间表如\n下：\n序号 制度名称 披露时间\n1 股东大会议事规则 2007年4月\n2 监事会议事规则 2007年4月\n3 董事会战略委员会议事规则 2007年6月\n4 董事会提名委员会议事规则 2007年6月\n5 董事会审计委员会议事规则 2007年6月\n6 董事会薪酬与考核委员会议事规则 2007年6月\n7 信息披露管理制度（2007年6月修订） 2007年6月\n8 股东大会累计投票制实施细则 2007年6月\n9 独立董事年报工作制度 2008年4月\n10 审计委员会年报工作规程 2008年4月\n11 内部信息保密制度 2008年8月\n12 防范控股股东及关联方资金占用管理办法 2008年8月\n13 董事、监事及高级管理人员薪酬管理制度 2009年4月\n14 突发事件处理制度 2009年10月\n15 首期股票期权激励实施考核办法 2009年12月\n16 年报信息披露重大差错责任追究制度 2010年3月\n17 建设工程招投标管理办法 2011年8月\n18 投资者关系管理制度（2011年9月修订） 2011年9月\n19 重大事项内部报告制度 2011年9月\n20 大股东、实际控制人行为规范及信息问询制度 2011年9月\n21 公司章程（2011年3月修订） 2011年3月\n66。\n\n【表格内容】\n母公司在职员工的数量（人） | 482\n--------------------------------------------------\n主要子公司在职员工的数量（人） | 2,812\n在职员工的数量合计（人） | 3,294\n当期领取薪酬员工总人数（人） | 3,294\n母公司及主要子公司需承担费用的离退休职工人数（人） | 0\n专业构成 | \n专业构成类别 | 专业构成人数（人）\n生产人员 | 1,769\n销售人员 | 77\n技术人员 | 659\n财务人员 | 53\n行政人员 | 736\n合计 | 3,294\n教育程度 | \n教育程度类别 | 数量（人）\n硕士及以上 | 50\n本科 | 484\n大专 | 541\n其他学历 | 2,219\n合计 | 3,294",
      "chunk_type": "table_group",
      "parent_id": "87f8cb8f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1142,
      "page_number": 64,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "投资",
          "母公司",
          "股东",
          "审计",
          "报告",
          "披露",
          "投资者",
          "证券"
        ],
        "time_periods": [
          "2007-4",
          "2007-6",
          "2008-4",
          "2008-8",
          "2009-10",
          "2009-12",
          "2009-4",
          "2010-3",
          "2011-3",
          "2011-8",
          "2011-9"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          64
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.221653",
        "report_type": null,
        "fiscal_year": 2007,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1142,
        "word_count": 141,
        "sentence_count": 3,
        "chinese_char_count": 658,
        "readability_score": 0.0,
        "information_density": 0.07880910683012259,
        "coherence_score": 0.49864627779373033,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6090778927450221,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "投资",
        "母公司",
        "股东",
        "审计",
        "报告",
        "披露",
        "投资者",
        "证券"
      ]
    },
    {
      "chunk_id": "d42e3989",
      "content": "序号 | 制度名称 | 披露时间\n--------------------------------------------------\n1 | 股东大会议事规则 | 2007年4月\n2 | 监事会议事规则 | 2007年4月\n3 | 董事会战略委员会议事规则 | 2007年6月\n4 | 董事会提名委员会议事规则 | 2007年6月\n5 | 董事会审计委员会议事规则 | 2007年6月\n6 | 董事会薪酬与考核委员会议事规则 | 2007年6月\n7 | 信息披露管理制度（2007年6月修订） | 2007年6月\n8 | 股东大会累计投票制实施细则 | 2007年6月\n9 | 独立董事年报工作制度 | 2008年4月\n10 | 审计委员会年报工作规程 | 2008年4月\n11 | 内部信息保密制度 | 2008年8月\n12 | 防范控股股东及关联方资金占用管理办法 | 2008年8月\n13 | 董事、监事及高级管理人员薪酬管理制度 | 2009年4月\n14 | 突发事件处理制度 | 2009年10月\n15 | 首期股票期权激励实施考核办法 | 2009年12月\n16 | 年报信息披露重大差错责任追究制度 | 2010年3月\n17 | 建设工程招投标管理办法 | 2011年8月\n18 | 投资者关系管理制度（2011年9月修订） | 2011年9月\n19 | 重大事项内部报告制度 | 2011年9月\n20 | 大股东、实际控制人行为规范及信息问询制度 | 2011年9月\n21 | 公司章程（2011年3月修订） | 2011年3月",
      "chunk_type": "table_group",
      "parent_id": "8dbb1dcc",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1173,
      "page_number": 66,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股东",
          "审计",
          "报告",
          "披露"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          66
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.222053",
        "report_type": null,
        "fiscal_year": 2007,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 673,
        "word_count": 111,
        "sentence_count": 0,
        "chinese_char_count": 306,
        "readability_score": 0.0,
        "information_density": 0.08915304606240712,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7697374938088162,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东",
        "审计",
        "报告",
        "披露",
        "投资者"
      ]
    },
    {
      "chunk_id": "bcee98c0",
      "content": "【说明】（三）资产方面：公司拥有独立的生产系统、辅助生产系统和配套设施，产、供、销系\n统完整独立。工业产权、商标、非专利技术、房屋所有权、土地所有权等无形资产和有形资\n产均由本公司拥有，产权界定清晰。（四）机构方面：公司设有健全的组织机构体系，股东大会、董事会、监事会及董事会\n下属专业委员会等内部机构独立运作，不受其他单位或个人的干涉。\n\n【表格内容】\n22 | 外部信息使用人管理制度 | 2012年4月\n--------------------------------------------------\n23 | 内幕信息知情人登记管理制度 | 2012年4月\n24 | 董事会议事规则(2013年3月修订) | 2013年3月\n25 | 控股子公司管理制度(2013年3月修订) | 2013年3月\n26 | 对外提供财务资助管理制度 | 2013年3月\n27 | 募集资金管理制度（2014年4月修订） | 2014年4月\n28 | 公司章程（2015年9月修订） | 2015年9月\n29 | 授权管理制度 | 2015年12月\n30 | 风险投资管理制度 | 2016年1月\n31 | 公司章程（2016年3月修订） | 2016年3月\n32 | 债务融资工具信息披露事务管理制度 | 2016年3月\n33 | 公司章程（2016年10月修订） | 2016年10月\n34 | 衍生品投资管理制度 | 2017年1月\n35 | 公司章程（2017年4月修订） | 2017年4月\n36 | 董事 监事和高级管理人员所持公司股份及其变动管理制度（2017\n年8月修订） | 2017年8月\n37 | 公司章程（2018年4月修订） | 2018年4月\n38 | 内部控制缺陷认定标准 | 2018年4月\n39 | 公司章程（2019年2月修订） | 2019年2月\n40 | 内部审计制度（2019年2月修订） | 2019年2月\n41 | 公司章程（2019年3月修订） | 2019年3月",
      "chunk_type": "table_group",
      "parent_id": "92b7b3eb",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 853,
      "page_number": 67,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "无形资产",
          "股份",
          "股东",
          "审计",
          "披露",
          "融资",
          "债务"
        ],
        "time_periods": [
          "2012-4",
          "2013-3",
          "2014-4",
          "2015-12",
          "2015-9",
          "2016-1",
          "2016-10",
          "2016-3",
          "2017-1",
          "2017-4"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.222309",
        "report_type": null,
        "fiscal_year": 2012,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 853,
        "word_count": 108,
        "sentence_count": 3,
        "chinese_char_count": 402,
        "readability_score": 0.0,
        "information_density": 0.10550996483001174,
        "coherence_score": 0.28904761904761905,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7193313131313132,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "无形资产",
        "股份",
        "股东",
        "审计",
        "披露",
        "融资",
        "债务"
      ]
    },
    {
      "chunk_id": "7d24f3af",
      "content": " | 会议 | 投资者参 |  |  | \n--------------------------------------------------\n会议届次 |  |  | 召开日期 | 披露日期 | 披露索引\n | 类型 | 与比例 |  |  | \n |  |  |  |  | \n | 年度 |  |  |  | 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2018年年度 |  |  | 2019年03 | 2019年03 | \n | 股东 | 45.19% |  |  | 及巨潮资讯网披露的《2018年年度股东大会决议公告》（公告编号：\n股东大会 |  |  | 月11日 | 月12日 | \n | 大会 |  |  |  | 2019-020）\n |  |  |  |  | \n2019年第一 | 临时 |  |  |  | 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n |  |  | 2019年03 | 2019年04 | \n次临时股东大 | 股东 | 45.07% |  |  | 及巨潮资讯网披露的《2019年第一次临时股东大会决议公告》（公\n |  |  | 月29日 | 月01日 | \n会 | 大会 |  |  |  | 告编号：2019-027）\n |  |  |  |  | \n2019年第二 | 临时 |  |  |  | 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n |  |  | 2019年11 | 2019年11 | \n次临时股东大 | 股东 | 44.40% |  |  | 及巨潮资讯网披露的《2019年第二次临时股东大会决议公告》（公\n |  |  | 月13日 | 月14日 | \n会 | 大会 |  |  |  | 告编号：2019-059）\n |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e82aa735",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1295,
      "page_number": 68,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "股东",
          "披露",
          "投资者",
          "证券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          68
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.222690",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 795,
        "word_count": 160,
        "sentence_count": 3,
        "chinese_char_count": 231,
        "readability_score": 0.0,
        "information_density": 0.06289308176100629,
        "coherence_score": 0.97,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6538364779874213,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东",
        "披露",
        "投资者",
        "证券"
      ]
    },
    {
      "chunk_id": "0fc20f73",
      "content": "【说明】不适用\n2、独立董事对公司有关事项提出异议的情况\n独立董事对公司有关事项是否提出异议\n□ 是 √ 否\n报告期内独立董事对公司有关事项未提出异议。3、独立董事履行职责的其他说明\n独立董事对公司有关建议是否被采纳\n√ 是 □ 否\n独立董事对公司有关建议被采纳或未被采纳的说明\n公司独立董事勤勉尽责，严格按照中国证监会的相关规定及《公司章程》、《董事会议\n事规则》和《独立董事制度》开展工作，关注公司运作,独立履行职责,对公司内部控制建设、\n管理体系建设、人才梯队建设和重大决策等方面提出了很多宝贵的专业性建议，对公司财务\n及生产经营活动进行了有效监督，提高了公司决策的科学性，为完善公司监督机制，维护公\n司和全体股东的合法权益发挥了应有的作用。六、董事会下设专门委员会在报告期内履行职责情况\n（一）董事会下设审计委员会的履职情况\n董事会审计委员会在报告期内主要负责公司内部会计控制, 财务报表和公司其他财务事\n项实施监督工作。\n\n【表格内容】\n独立董事出席董事会及股东大会的情况 | | | | | | | \n--------------------------------------------------\n | | | | | | 是否连续两次 | \n | 本报告期应参 | 现场出席董事 | 以通讯方式参 | 委托出席董事 | 缺席董事会次 | | 出席股东大会\n独立董事姓名 | | | | | | 未亲自参加董 | \n | 加董事会次数 | 会次数 | 加董事会次数 | 会次数 | 数 | | 次数\n | | | | | | 事会会议 | \n | | | | | | | \n田利明 | 5 | 0 | 3 | 2 | 0 | 否 | 0\n毛美英 | 6 | 3 | 3 | 0 | 0 | 否 | 3\n苏为科 | 6 | 2 | 3 | 1 | 0 | 否 | 0\n张克坚 | 1 | 1 | 0 | 0 | 0 | 否 | 0",
      "chunk_type": "table_group",
      "parent_id": "f79a9af7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 823,
      "page_number": 68,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "经营",
          "股东",
          "审计",
          "报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          68
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.222919",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 823,
        "word_count": 151,
        "sentence_count": 3,
        "chinese_char_count": 475,
        "readability_score": 0.0,
        "information_density": 0.06075334143377885,
        "coherence_score": 0.28935483870967743,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6148477387474488,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "经营",
        "股东",
        "审计",
        "报告"
      ]
    },
    {
      "chunk_id": "05bf3860",
      "content": " |  | 重大缺陷：1、公司董事、监事或高级\n--------------------------------------------------\n |  | 管理人员缺乏应有的胜任能力，或高级\n |  | 管理人员流失严重； 2、公司组织架构、\n |  | 业务流程存在重大缺陷，权责分配严重\n |  | 不合理，缺乏科学决策、良性运行机制\n |  | 和执行力； 3、公司对外担保业务未根\n |  | 据相关法律法规经过适当审批； 4、公\n |  | 司资产管理制度存在重大缺陷，大量长\n |  | 期资产使用效能低下，维护不当，存货\n |  | 严重积压或短缺； 5、公司核心技术管\n |  | 理存在缺陷，核心技术人员流失严重，\n |  | 核心技术已经出现严重过时的迹象；\n |  | 6、公司信息系统存在重大漏洞，导致\n |  | 内部相关数据收集、处理或传递错误或\n |  | 严重延误，或重要商业机密被泄露； 7、\n |  | 公司的安全生产管理、环保管理存在重\n | 重大缺陷：1、公司董事、监事或高级管理 | 大缺陷，安全、环保事故频发，引起政\n | 人员舞弊；2、公司更正已公告的财务报告； | 府或监管机构调查或处罚； 8、公司的\n | 3、注册会计师发现未被公司内部控制识别 | 质量管理存在重大缺陷，出现重大质量\n | 的当期财务报告重大错报；4、公司对重大 | 问题引起政府或监管机构调查或引发\n | 经济业务的会计处理违反会计法律法规或 | 诉讼； 9、已向管理层汇报但经过合理\n | 《企业会计准则》； 5、公司随意变更会计 | 期限后，管理层仍然没有对非财务报告\n | 政策或会计估计，导致相关财务信息严重 | 内部控制重大缺陷进行整改。重要缺\n | 失真； 6、公司缺乏对外提供财务报告的 | 陷：1、公司关键岗位人员缺乏应有的\n | 流程、审批权限等正式制度，或制度完全 | 胜任能力，或关键岗位人员流失严重；\n | 未得到执行；7、因财务报告相关的信息披 | 2、公司组织架构、业务流程存在重要\n | 露差错导致监管机构处罚；8、公司凭证、 | 缺陷，重要机构设计不合理，职能交叉\n | 账簿、报表等会计资料管理混乱，未按照 | 或缺失，运行效率低下；3、公司对外\n | 相关法律法规整理、归档或保存；9、已向 | 担保业务虽经过适当审批，但存在重要\n | 管理层汇报但经过合理期限后，管理层仍 | 潜在经济损失风险；4、公司资产管理\n | 然没有对财务报告内部控制重大缺陷进行 | 制度存在重要缺陷，部分长期资产使用\n | 整改。重大缺陷：1、公司关键岗位人员舞 | 效能低下，维护不当，大量存货积压或\n | 弊；2、注册会计师发现未被公司内部控制 | 短缺；5、公司重要技术管理存在缺陷，\n | 识别的当期财务报告重要错报；3、对重要 | 重要技术人员流失严重，关键技术出现\n定性标准 |  | ",
      "chunk_type": "table_group",
      "parent_id": "99fda42c",
      "child_ids": [],
      "sibling_ids": [
        "7052d525"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1722,
      "page_number": 71,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": true,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "存货",
          "分配",
          "报告",
          "财务报告"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.223419",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1222,
        "word_count": 133,
        "sentence_count": 2,
        "chinese_char_count": 796,
        "readability_score": 0.0,
        "information_density": 0.0409165302782324,
        "coherence_score": 0.7920315745741587,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9022508038585209,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "存货",
        "分配",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "7052d525",
      "content": " | 经济业务的会计处理违反会计法律法规或 | 过时的迹象；6、公司信息系统的关键\n |  | \n | 《企业会计准则》；4、公司频繁变更会计 | 环节存在漏洞，导致部分环节内部相关\n | 政策或会计估计，导致相关财务信息不具 | 数据收集、处理或传递错误或不及时，\n | 有可比性；5、公司虽有对外提供财务报告 | 或商业机密存在被泄露的风险；7、公\n | 的正式制度，但制度未得到完全执行，对 | 司的安全生产管理、环保管理存在重要\n | 外信息披露未经适当审批或授权；6、公司 | 缺陷，出现重要的安全、环保事故，引\n | 凭证、账簿、报表等会计资料管理部分环 | 起政府或监管机构关注；8、公司的质\n | 节存在漏洞，相关资料存在丢失、毁损或 | 量管理存在重要缺陷，出现重要质量问\n | 被未授权人员接触的风险； 7、已向管理 | 题引起大宗产品退货；9、已向管理层\n | 层汇报但经过合理期限后，管理层仍然没 | 汇报但经过合理期限后，管理层仍然没\n | 有对财务报告内部控制重要缺陷进行整 | 有对非财务报告内部控制。一般缺陷：\n | 改。 一般缺陷：1、公司一般岗位人员舞 | 1、公司一般岗位人员缺乏应有的胜任\n7\n | 弊；2、注册会计师发现未被公司内部控制 | 能力，或普通岗位人员流失严重；2、\n | 识别的当期财务报告一般错报；3、已向管 | 公司组织架构、业务流程存在一般缺\n | 理层汇报但经过合理期限后，管理层仍然 | 陷，部分机构设计不合理，职能重叠，",
      "chunk_type": "table_group",
      "parent_id": "99fda42c",
      "child_ids": [],
      "sibling_ids": [
        "05bf3860"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1643,
      "page_number": 71,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": true,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "报告",
          "财务报告",
          "披露"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          71
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.223531",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 643,
        "word_count": 65,
        "sentence_count": 2,
        "chinese_char_count": 462,
        "readability_score": 0.0,
        "information_density": 0.04665629860031104,
        "coherence_score": 0.6914285714285715,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9022508038585209,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告",
        "财务报告",
        "披露"
      ]
    },
    {
      "chunk_id": "512ca336",
      "content": "【说明】第十一节公司债券相关情况\n公司是否存在公开发行并在证券交易所上市，且在年度报告批准报出日未到期或到期未能全额兑付的公司债券\n否\n73 第十二节 财务报告\n一、审计报告\n审计意见类型 标准的无保留意见\n审计报告签署日期 2020年01月22日\n审计机构名称 天健会计师事务所（特殊普通合伙）\n审计报告文号 天健审〔2020〕58号\n注册会计师姓名 沈维华 汪兢\n审计报告正文\n审 计 报 告\n天健审〔2020〕58号\n浙江海翔药业股份有限公司全体股东：\n一、审计意见\n我们审计了浙江海翔药业股份有限公司（以下简称海翔药业公司）财务报表，包括 2019\n年12月31日的合并及母公司资产负债表，2019年度的合并及母公司利润表、合并及母公司\n现金流量表、合并及母公司所有者权益变动表，以及相关财务报表附注。我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了\n海翔药业公司 2019 年 12 月 31 日的合并及母公司财务状况，以及 2019 年度的合并及母公司\n经营成果和现金流量。二、形成审计意见的基础\n我们按照中国注册会计师审计准则的规定执行了审计工作。\n\n【表格内容】\n内部控制鉴证报告中的审议意见段 | \n--------------------------------------------------\n我们认为，海翔药业公司按照深圳证券交易所 中小企业板上市公司规范运作指引(2015年修订) 规定于2019年12月31 | \n日在所有重大方面保持了有效的财务报告内部控制。 | \n内控鉴证报告披露情况 | 披露\n内部控制鉴证报告全文披露日期 | 2020年01月23日\n内部控制鉴证报告全文披露索引 | 巨潮资讯网\n内控鉴证报告意见类型 | 标准无保留意见\n非财务报告是否存在重大缺陷 | 否",
      "chunk_type": "table_group",
      "parent_id": "b90b744c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 770,
      "page_number": 72,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "利润",
          "现金",
          "资产负债表",
          "利润表",
          "现金流量表",
          "合并",
          "母公司"
        ],
        "time_periods": [
          "2019",
          "2019-12",
          "2020-01"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          72
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.223756",
        "report_type": null,
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 770,
        "word_count": 66,
        "sentence_count": 4,
        "chinese_char_count": 545,
        "readability_score": 0.0,
        "information_density": 0.12987012987012986,
        "coherence_score": 0.31021621621621626,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6404977443609022,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金",
        "资产负债表",
        "利润表",
        "现金流量表",
        "合并",
        "母公司"
      ]
    },
    {
      "chunk_id": "42a335da",
      "content": "【说明】年度，海翔药业公司财务报表所示营业收入项目金额为人民币 2,941,412,770.30 元(合并财\n务报表口径，下同)，其中主营业务收入为人民币2,925,688,906.14元，占营业收入的99.47%。如财务报表附注重要会计政策及会计估计所示，海翔药业公司产品销售区域分为国内和国外，\n且需要根据不同的手续进行收入确认。由于营业收入是海翔药业公司关键业绩指标之一，可能存在海翔药业公司管理层（以下\n简称管理层）通过不恰当的收入确认以达到特定目标或预期的固有风险。\n\n【表格内容】\n审计意见类型 | 标准的无保留意见\n--------------------------------------------------\n审计报告签署日期 | 2020年01月22日\n审计机构名称 | 天健会计师事务所（特殊普通合伙）\n审计报告文号 | 天健审 2020 58号\n注册会计师姓名 | 沈维华 汪兢",
      "chunk_type": "table_group",
      "parent_id": "971f53cf",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 403,
      "page_number": 74,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "营业收入",
          "合并",
          "营业",
          "审计",
          "报告",
          "审计报告"
        ],
        "time_periods": [
          "2020-01"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          74
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.223903",
        "report_type": null,
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 403,
        "word_count": 26,
        "sentence_count": 6,
        "chinese_char_count": 250,
        "readability_score": 0.0,
        "information_density": 0.17369727047146402,
        "coherence_score": 0.7267374005305041,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6735111389385808,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "营业收入",
        "合并",
        "营业",
        "审计",
        "报告",
        "审计报告"
      ]
    },
    {
      "chunk_id": "4f5a50b1",
      "content": "【说明】天健会计师事务所（特殊普通合伙） 中国注册会计师：沈维华\n（项目合伙人）\n中国·杭州 中国注册会计师：汪兢\n二〇二〇年一月二十二日\n二、财务报表\n财务附注中报表的单位为：元\n1、合并资产负债表\n编制单位：浙江海翔药业股份有限公司\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,556,575,372.45 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n77。\n\n【表格内容】\n项目 | 2019年12月31日 | 2018年12月31日\n--------------------------------------------------\n流动资产： | | \n货币资金 | 1,556,575,372.45 | 1,956,089,124.33\n结算备付金 | | \n拆出资金 | | \n交易性金融资产 | | \n以公允价值计量且其变动计入当 | | \n | | \n期损益的金融资产 | | \n | | \n衍生金融资产 | |",
      "chunk_type": "table_group",
      "parent_id": "df939867",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 484,
      "page_number": 77,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "资产负债表",
          "合并",
          "股份",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [
          "2018-12",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.224070",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 484,
        "word_count": 62,
        "sentence_count": 5,
        "chinese_char_count": 220,
        "readability_score": 0.0,
        "information_density": 0.1652892561983471,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.620983212267958,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "资产负债表",
        "合并",
        "股份",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "99420158",
      "content": "应收票据 |  | 107,399,476.04\n--------------------------------------------------\n应收账款 | 459,781,564.19 | 479,537,782.06\n应收款项融资 | 74,531,666.41 | \n预付款项 | 33,851,486.79 | 46,449,558.50\n应收保费 |  | \n应收分保账款 |  | \n应收分保合同准备金 |  | \n其他应收款 | 18,297,536.18 | 10,817,853.96\n其中：应收利息 |  | \n应收股利 |  | \n买入返售金融资产 |  | \n存货 | 842,985,260.60 | 905,418,218.49\n合同资产 |  | \n持有待售资产 |  | \n一年内到期的非流动资产 |  | \n其他流动资产 | 76,406,931.14 | 227,882,993.23\n流动资产合计 | 3,062,429,817.76 | 3,733,595,006.61\n非流动资产： |  | \n发放贷款和垫款 |  | \n债权投资 |  | \n可供出售金融资产 |  | 1,800,000.00\n其他债权投资 |  | \n持有至到期投资 |  | \n长期应收款 |  | \n长期股权投资 | 47,879,382.43 | 66,088,139.79\n其他权益工具投资 | 20,000,000.00 | \n其他非流动金融资产 |  | \n投资性房地产 | 11,206,951.46 | 12,338,615.29\n固定资产 | 1,724,407,333.34 | 1,215,120,643.61\n在建工程 | 560,674,634.43 | 674,333,677.99\n生产性生物资产 |  | \n油气资产 |  | \n使用权资产 |  | \n无形资产 | 533,455,319.46 | 539,514,850.87",
      "chunk_type": "table_group",
      "parent_id": "4fe8d535",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1343,
      "page_number": 78,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "投资",
          "应收",
          "预付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          78
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.224477",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 843,
        "word_count": 129,
        "sentence_count": 26,
        "chinese_char_count": 194,
        "readability_score": 0.0,
        "information_density": 0.11862396204033214,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7023724792408066,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "投资",
        "应收",
        "预付",
        "存货",
        "固定资产",
        "无形资产",
        "股权",
        "融资"
      ]
    },
    {
      "chunk_id": "0e829aa5",
      "content": "非流动负债： |  | \n--------------------------------------------------\n保险合同准备金 |  | \n长期借款 |  | \n应付债券 |  | \n其中：优先股 |  | \n永续债 |  | \n租赁负债 |  | \n长期应付款 |  | \n长期应付职工薪酬 |  | \n预计负债 | 1,333,333.00 | 12,971,002.47\n递延收益 | 50,594,091.52 | 44,650,629.91\n递延所得税负债 | 30,527,355.71 | 8,175,428.28\n其他非流动负债 |  | \n非流动负债合计 | 82,454,780.23 | 65,797,060.66\n负债合计 | 1,022,736,568.92 | 1,644,823,412.34\n所有者权益： |  | \n股本 | 1,618,715,253.00 | 1,618,820,253.00\n其他权益工具 |  | \n其中：优先股 |  | \n永续债 |  | \n资本公积 | 2,670,350,322.00 | 2,663,367,822.47\n减：库存股 | 301,511,513.90 | 325,880,561.68\n其他综合收益 | -1,490,188.81 | -51,779.23\n专项储备 |  | \n盈余公积 | 213,069,824.31 | 201,812,279.17\n一般风险准备 |  | \n未分配利润 | 1,525,328,398.95 | 1,232,481,918.50\n归属于母公司所有者权益合计 | 5,724,462,095.55 | 5,390,549,932.23\n少数股东权益 |  | \n所有者权益合计 | 5,724,462,095.55 | 5,390,549,932.23\n负债和所有者权益总计 | 6,747,198,664.47 | 7,035,373,344.57",
      "chunk_type": "table_group",
      "parent_id": "c17679af",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1345,
      "page_number": 80,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "利润",
          "应付",
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          80
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.224901",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 845,
        "word_count": 122,
        "sentence_count": 28,
        "chinese_char_count": 168,
        "readability_score": 0.0,
        "information_density": 0.1183431952662722,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7596449704142012,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "利润",
        "应付",
        "所得税",
        "股东权益",
        "母公司",
        "股本",
        "资本公积",
        "未分配利润"
      ]
    },
    {
      "chunk_id": "c110ad36",
      "content": "项目 | 2019年12月31日 | 2018年12月31日\n--------------------------------------------------\n流动资产： |  | \n货币资金 | 1,200,455,459.03 | 983,565,710.16\n交易性金融资产 |  | \n以公允价值计量且其变动计入当 |  | \n |  | \n期损益的金融资产 |  | \n |  | \n衍生金融资产 |  | \n应收票据 |  | 20,885,763.88\n应收账款 | 123,532,244.19 | 149,204,899.98\n应收款项融资 | 6,422,715.29 | \n预付款项 | 2,178,567.27 | 5,554,458.78\n其他应收款 | 467,513,480.14 | 1,043,055,918.72\n其中：应收利息 |  | \n应收股利 |  | 7,222,088,153.34\n存货 | 96,708,887.42 | 84,396,333.98\n合同资产 |  | \n持有待售资产 |  | \n一年内到期的非流动资产 |  | \n其他流动资产 | 2,586,704.73 | 105,920,135.97\n流动资产合计 | 1,899,398,058.07 | 2,392,583,221.47\n非流动资产： |  | \n债权投资 |  | \n可供出售金融资产 |  | 23,017,502.51\n其他债权投资 |  | \n持有至到期投资 |  | \n长期应收款 |  | \n长期股权投资 | 3,247,420,801.54 | 3,250,556,852.85\n其他权益工具投资 | 43,017,502.51 | \n其他非流动金融资产 |  | \n投资性房地产 | 15,051,583.93 | 16,409,402.65\n固定资产 | 190,528,741.25 | 182,948,202.54\n在建工程 | 5,125,110.57 | 20,490,208.35",
      "chunk_type": "table_group",
      "parent_id": "4f31ed89",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1372,
      "page_number": 81,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 35,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "投资",
          "应收",
          "预付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          81
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.225330",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 872,
        "word_count": 130,
        "sentence_count": 27,
        "chinese_char_count": 191,
        "readability_score": 0.0,
        "information_density": 0.11467889908256881,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6990443425076454,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "投资",
        "应收",
        "预付",
        "存货",
        "固定资产",
        "股权",
        "公允价值",
        "融资"
      ]
    },
    {
      "chunk_id": "d9eae77e",
      "content": "永续债 |  | \n--------------------------------------------------\n租赁负债 |  | \n长期应付款 |  | \n长期应付职工薪酬 |  | \n预计负债 | 1,333,333.00 | 12,971,002.47\n递延收益 | 1,269,332.86 | 1,262,720.34\n递延所得税负债 |  | \n其他非流动负债 |  | \n非流动负债合计 | 2,602,665.86 | 14,233,722.81\n负债合计 | 525,802,580.88 | 692,654,284.96\n所有者权益： |  | \n股本 | 1,618,715,253.00 | 1,618,820,253.00\n其他权益工具 |  | \n其中：优先股 |  | \n永续债 |  | \n资本公积 | 2,669,212,269.41 | 2,662,229,769.88\n减：库存股 | 301,511,513.90 | 325,880,561.68\n其他综合收益 |  | \n专项储备 |  | \n盈余公积 | 213,069,824.31 | 201,812,279.17\n未分配利润 | 697,440,109.87 | 1,062,800,363.16\n所有者权益合计 | 4,896,925,942.69 | 5,219,782,103.53\n负债和所有者权益总计 | 5,422,728,523.57 | 5,912,436,388.49",
      "chunk_type": "table_group",
      "parent_id": "821f4587",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1148,
      "page_number": 83,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "利润",
          "应付",
          "所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          83
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.225711",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 648,
        "word_count": 92,
        "sentence_count": 22,
        "chinese_char_count": 118,
        "readability_score": 0.0,
        "information_density": 0.1388888888888889,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7546296296296297,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "利润",
        "应付",
        "所得税",
        "股本",
        "资本公积",
        "未分配利润",
        "分配"
      ]
    },
    {
      "chunk_id": "4c6d2722",
      "content": "四、利润总额（亏损总额以“－”号填列） | 912,452,980.27 | 697,295,611.05\n--------------------------------------------------\n减：所得税费用 | 141,670,795.18 | 92,291,790.27\n五、净利润（净亏损以“－”号填列） | 770,782,185.09 | 605,003,820.78\n（一）按经营持续性分类 |  | \n1.持续经营净利润（净亏损以“－” |  | \n | 770,782,185.09 | 605,003,820.78\n号填列） |  | \n |  | \n2.终止经营净利润（净亏损以“－” |  | \n |  | \n号填列） |  | \n |  | \n（二）按所有权归属分类 |  | \n1.归属于母公司所有者的净利润 | 770,782,185.09 | 605,003,820.78\n2.少数股东损益 |  | \n六、其他综合收益的税后净额 | -1,438,409.58 | 16,560.46\n归属母公司所有者的其他综合收益 |  | \n | -1,438,409.58 | 16,560.46\n的税后净额 |  | \n |  | \n（一）不能重分类进损益的其他综 |  | \n | -1,800,000.00 | \n合收益 |  | \n |  | \n1.重新计量设定受益计划变 |  | \n |  | \n动额 |  | \n |  | \n2.权益法下不能转损益的其 |  | \n |  | \n他综合收益 |  | \n |  | \n3.其他权益工具投资公允价 |  | \n | -1,800,000.00 | \n值变动 |  | \n |  | \n4.企业自身信用风险公允价 |  | \n |  | \n值变动 |  | \n |  | \n5.其他 |  | \n（二）将重分类进损益的其他综合 |  | \n | 361,590.42 | 16,560.46\n收益 |  | \n |  | \n1.权益法下可转损益的其他 |  | \n |  | \n综合收益 |  | \n |  | \n2.其他债权投资公允价值变 |  | \n |  | \n动 |  | \n |  | \n3.可供出售金融资产公允价 |  | \n |  | \n值变动损益 |  | \n |  | \n4.金融资产重分类计入其他 |  | \n |  | \n综合收益的金额 |  | \n |  | \n5.持有至到期投资重分类为 |  | \n |  | \n可供出售金融资产损益 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "643035c4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1592,
      "page_number": 85,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 66,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "费用",
          "利润",
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          85
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.226171",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1092,
        "word_count": 186,
        "sentence_count": 32,
        "chinese_char_count": 299,
        "readability_score": 0.0,
        "information_density": 0.09157509157509157,
        "coherence_score": 0.3213333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7821428571428571,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "费用",
        "利润",
        "投资",
        "净利润",
        "利润总额",
        "所得税",
        "母公司",
        "经营"
      ]
    },
    {
      "chunk_id": "d9a4d167",
      "content": " | 2019年度 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n | 归属于母公司所有者权益 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 所有\n |  |  |  |  |  |  |  |  |  |  |  |  |  | 少数 | \n项目 |  | 其他权益工具 |  |  |  |  | 其他 |  |  | 一般 | 未分 |  |  |  | 者权\n |  |  |  |  | 资本 | 减：库 |  | 专项 | 盈余 |  |  |  |  | 股东 | \n | 股本 | 优先 | 永续 |  |  |  | 综合 |  |  | 风险 | 配利 | 其他 | 小计 |  | 益合\n |  |  |  | 其他 | 公积 | 存股 |  | 储备 | 公积 |  |  |  |  | 权益 | \n |  | 股 | 债 |  |  |  | 收益 |  |  | 准备 | 润 |  |  |  | 计\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 1,618 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2,663, | 325,88 |  |  | 201,81 |  | 1,232, |  | 5,390, |  | 5,390,\n一、上年期末余 | ,820, |  |  |  |  |  | -51,77 |  |  |  |  |  |  |  | \n |  |  |  |  | 367,82 | 0,561. |  |  | 2,279. |  | 481,91 |  | 549,93 |  | 549,93\n额 | 253.0 |  |  |  |  |  | 9.23 |  |  |  |  |  |  |  | \n |  |  |  |  | 2.47 | 68 |  |  | 17 |  | 8.50 |  | 2.23 |  | 2.23\n | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n加：会计政 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "07ab5c41",
      "child_ids": [],
      "sibling_ids": [
        "317f4c1f",
        "0c2beaf7",
        "2ab2c3ac"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1687,
      "page_number": 92,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 21,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "母公司",
          "股本",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.226746",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1187,
        "word_count": 364,
        "sentence_count": 8,
        "chinese_char_count": 92,
        "readability_score": 0.0,
        "information_density": 0.03369839932603201,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7138903672166046,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "母公司",
        "股本",
        "股东"
      ]
    },
    {
      "chunk_id": "317f4c1f",
      "content": "策变更 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n前期 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n差错更正 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n同一 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n控制下企业合 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n并 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 1,618 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2,663, | 325,88 |  |  | 201,81 |  | 1,232, |  | 5,390, |  | 5,390,\n二、本年期初余 | ,820, |  |  |  |  |  | -51,77 |  |  |  |  |  |  |  | \n |  |  |  |  | 367,82 | 0,561. |  |  | 2,279. |  | 481,91 |  | 549,93 |  | 549,93\n额 | 253.0 |  |  |  |  |  | 9.23 |  |  |  |  |  |  |  | \n |  |  |  |  | 2.47 | 68 |  |  | 17 |  | 8.50 |  | 2.23 |  | 2.23\n | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n三、本期增减变 | -105, |  |  |  |  | -24,36 |  |  | 11,257 |  | 292,84 |  | 333,91 |  | 333,91\n |  |  |  |  | 6,982, |  | -1,438, |  |  |  |  |  |  |  | \n动金额（减少以 | 000.0 |  |  |  |  | 9,047. |  |  | ,545.1 |  | 6,480. |  | 2,163. |  | 2,163.",
      "chunk_type": "table_group",
      "parent_id": "07ab5c41",
      "child_ids": [],
      "sibling_ids": [
        "d9a4d167",
        "0c2beaf7",
        "2ab2c3ac"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2208,
      "page_number": 92,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 21,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.227066",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1208,
        "word_count": 364,
        "sentence_count": 14,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.7311258278145696,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7138903672166046,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "0c2beaf7",
      "content": " |  |  |  |  | 499.53 |  | 409.58 |  |  |  |  |  |  |  | \n“－”号填列） | 0 |  |  |  |  | 78 |  |  | 4 |  | 45 |  | 32 |  | 32\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 770,78 |  | 769,34 |  | 769,34\n（一）综合收益 |  |  |  |  |  |  | -1,438, |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 2,185. |  | 3,775. |  | 3,775.\n总额 |  |  |  |  |  |  | 409.58 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 09 |  | 51 |  | 51\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | -105, |  |  |  |  | -24,36 |  |  |  |  |  |  | 31,246 |  | 31,246\n（二）所有者投 |  |  |  |  | 6,982, |  |  |  |  |  |  |  |  |  | \n | 000.0 |  |  |  |  | 9,047. |  |  |  |  |  |  | ,547.3 |  | ,547.3\n入和减少资本 |  |  |  |  | 499.53 |  |  |  |  |  |  |  |  |  | \n | 0 |  |  |  |  | 78 |  |  |  |  |  |  | 1 |  | 1\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | -105, |  |  |  |  | 19,996 |  |  |  |  |  |  | -20,23 |  | -20,23\n1．所有者投入 |  |  |  |  | -131,2 |  |  |  |  |  |  |  |  |  | \n | 000.0 |  |  |  |  | ,827.2 |  |  |  |  |  |  | 3,077. |  | 3,077.\n的普通股 |  |  |  |  | 50.00 |  |  |  |  |  |  |  |  |  | \n | 0 |  |  |  |  | 2 |  |  |  |  |  |  | 22 |  | 22\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "07ab5c41",
      "child_ids": [],
      "sibling_ids": [
        "d9a4d167",
        "317f4c1f",
        "2ab2c3ac"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 2708,
      "page_number": 92,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 21,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.227403",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1208,
        "word_count": 369,
        "sentence_count": 16,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7138903672166046,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "2ab2c3ac",
      "content": "2．其他权益工 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n具持有者投入 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n资本 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "07ab5c41",
      "child_ids": [],
      "sibling_ids": [
        "d9a4d167",
        "317f4c1f",
        "0c2beaf7"
      ],
      "position": 3,
      "start_char": 1500,
      "end_char": 2152,
      "page_number": 92,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 3,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          92
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.227465",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 152,
        "word_count": 48,
        "sentence_count": 0,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.06578947368421054,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7138903672166046,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益"
      ]
    },
    {
      "chunk_id": "2185a88a",
      "content": "3．股份支付计 |  |  |  |  |  | -44,36 |  |  |  |  |  |  | 51,479 |  | 51,479\n--------------------------------------------------\n |  |  |  |  | 7,113, |  |  |  |  |  |  |  |  |  | \n入所有者权益 |  |  |  |  |  | 5,875. |  |  |  |  |  |  | ,624.5 |  | ,624.5\n |  |  |  |  | 749.53 |  |  |  |  |  |  |  |  |  | \n的金额 |  |  |  |  |  | 00 |  |  |  |  |  |  | 3 |  | 3\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n4．其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 11,257 |  | -477,9 |  | -466,6 |  | -466,6\n（三）利润分配 |  |  |  |  |  |  |  |  | ,545.1 |  | 35,704 |  | 78,159 |  | 78,159\n |  |  |  |  |  |  |  |  | 4 |  | .64 |  | .50 |  | .50\n |  |  |  |  |  |  |  |  | 11,257 |  | -11,25 |  |  |  | \n1．提取盈余公 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | ,545.1 |  | 7,545. |  |  |  | \n积 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 4 |  | 14 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2．提取一般风 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n险准备 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | -466,6 |  | -466,6 |  | -466,6",
      "chunk_type": "table_group",
      "parent_id": "ec3ee607",
      "child_ids": [],
      "sibling_ids": [
        "fff15a46",
        "0080fa2a"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1716,
      "page_number": 93,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "股份",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          93
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.228022",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1216,
        "word_count": 357,
        "sentence_count": 10,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.03289473684210527,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7132696390658174,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "股份",
        "分配"
      ]
    },
    {
      "chunk_id": "fff15a46",
      "content": "3．对所有者（或 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 78,159 |  | 78,159 |  | 78,159\n股东）的分配 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | .50 |  | .50 |  | .50\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n4．其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n（四）所有者权 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n益内部结转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n1．资本公积转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2．盈余公积转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n3．盈余公积弥 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n补亏损 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n4．设定受益计 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n划变动额结转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n留存收益 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "ec3ee607",
      "child_ids": [],
      "sibling_ids": [
        "2185a88a",
        "0080fa2a"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2171,
      "page_number": 93,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资本公积",
          "股东",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          93
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.228146",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1171,
        "word_count": 367,
        "sentence_count": 3,
        "chinese_char_count": 67,
        "readability_score": 0.0,
        "information_density": 0.02561912894961571,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7132696390658174,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资本公积",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "0080fa2a",
      "content": "5．其他综合收 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n益结转留存收 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n益 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n6．其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n（五）专项储备 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | 18,997 |  |  |  |  | 18,997 |  | 18,997\n1．本期提取 |  |  |  |  |  |  |  | ,055.9 |  |  |  |  | ,055.9 |  | ,055.9\n |  |  |  |  |  |  |  | 7 |  |  |  |  | 7 |  | 7",
      "chunk_type": "table_group",
      "parent_id": "ec3ee607",
      "child_ids": [],
      "sibling_ids": [
        "2185a88a",
        "fff15a46"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 1937,
      "page_number": 93,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          93
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.228280",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 437,
        "word_count": 135,
        "sentence_count": 3,
        "chinese_char_count": 23,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7132696390658174,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "cea3cc32",
      "content": "【表格内容】\n| | | | | | | | -18,99 | | | | | -18,99 | | -18,99\n--------------------------------------------------\n2 本期使用 | | | | | | | | 7,055 | . | | | | 7,055. | | 7,055.\n | | | | | | | | 97 | | | | | 97 | | 97\n（六）其他 | | | | | | | | | | | | | | | \n | 1,618 | | | | 2,670, | | -1,490\n.\n188.81 | , | 213,0 | 6 | 1,525 | , | 5,724, | | 5,724,\n462,09\n5.55\n | | | | | | 301,51 | | | | | | | | | \n四 本期期末余 | ,715, | | | | | | | | | | | | | | \n | | | | | 350,32 | 1,513 | | | 9,824 | . | 328,3 | 9 | 462,09 | | \n额 | 253.0 | | | | | | | | | | | | | | \n | | | | | 2.00 | 90 | | | 31 | | 8.9 | 5 | 5.55 | | \n | 0 | | | | | | | | | | | | | | \n | | | | | | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "434db5fd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 658,
      "page_number": 94,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          94
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.228614",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 658,
        "word_count": 229,
        "sentence_count": 11,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5026649746192894,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "fee5306c",
      "content": " | 2018年年度 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n | 归属于母公司所有者权益 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 所有者\n项目 |  | 其他权益工具 |  |  |  |  | 其他 |  |  | 一般 | 未分 |  |  | 少数股 | \n |  |  |  |  | 资本 | 减：库 |  | 专项 | 盈余 |  |  |  |  |  | 权益合\n | 股本 | 优先 | 永续 |  |  |  | 综合 |  |  | 风险 | 配利 | 其他 | 小计 | 东权益 | \n |  |  |  | 其他 | 公积 | 存股 |  | 储备 | 公积 |  |  |  |  |  | 计\n |  | 股 | 债 |  |  |  | 收益 |  |  | 准备 | 润 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 1,621 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2,629, | 100,40 |  |  | 93,197 |  | 897,83 |  | 5,142, |  | 5,142,0\n一、上年期末 | ,610, |  |  |  |  |  | -68,33 |  |  |  |  |  |  |  | \n |  |  |  |  | 834,81 | 3,250. |  |  | ,745.7 |  | 6,956. |  | 008,17 |  | 08,176.\n余额 | 253.0 |  |  |  |  |  | 9.69 |  |  |  |  |  |  |  | \n |  |  |  |  | 1.25 | 00 |  |  | 7 |  | 42 |  | 6.75 |  | 75\n | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n加：会计 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n政策变更 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "98f5d356",
      "child_ids": [],
      "sibling_ids": [
        "d4077427",
        "5a7cf280"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1688,
      "page_number": 94,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 21,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "母公司",
          "股本"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          94
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.229160",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1188,
        "word_count": 363,
        "sentence_count": 8,
        "chinese_char_count": 96,
        "readability_score": 0.0,
        "information_density": 0.02525252525252525,
        "coherence_score": 0.5683501683501684,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6478231292517007,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "母公司",
        "股本"
      ]
    },
    {
      "chunk_id": "d4077427",
      "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n前期 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n差错更正 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n同一 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n控制下企业合 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n并 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 1,621 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 2,629, | 100,40 |  |  | 93,197 |  | 897,83 |  | 5,142, |  | 5,142,0\n二、本年期初 | ,610, |  |  |  |  |  | -68,33 |  |  |  |  |  |  |  | \n |  |  |  |  | 834,81 | 3,250. |  |  | ,745.7 |  | 6,956. |  | 008,17 |  | 08,176.\n余额 | 253.0 |  |  |  |  |  | 9.69 |  |  |  |  |  |  |  | \n |  |  |  |  | 1.25 | 00 |  |  | 7 |  | 42 |  | 6.75 |  | 75\n | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n三、本期增减 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | -2,79 |  |  |  | 33,533 | 225,47 |  |  | 108,61 |  | 334,64 |  | 248,54 |  | \n变动金额（减 |  |  |  |  |  |  | 16,560 |  |  |  |  |  |  |  | 248,541\n | 0,000 |  |  |  | ,011.2 | 7,311. |  |  | 4,533. |  | 4,962. |  | 1,755. |  | ",
      "chunk_type": "table_group",
      "parent_id": "98f5d356",
      "child_ids": [],
      "sibling_ids": [
        "fee5306c",
        "5a7cf280"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2200,
      "page_number": 94,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 21,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          94
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.229489",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1200,
        "word_count": 363,
        "sentence_count": 13,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.5666666666666667,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6478231292517007,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "5a7cf280",
      "content": "少以“－”号填 |  |  |  |  |  |  | .46 |  |  |  |  |  |  |  | ,755.48\n | .00 |  |  |  | 2 | 68 |  |  | 40 |  | 08 |  | 48 |  | \n列） |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | 605,00 |  | 605,02 |  | \n（一）综合收 |  |  |  |  |  |  | 16,560 |  |  |  |  |  |  |  | 605,020\n |  |  |  |  |  |  |  |  |  |  | 3,820. |  | 0,381. |  | \n益总额 |  |  |  |  |  |  | .46 |  |  |  |  |  |  |  | ,381.24\n |  |  |  |  |  |  |  |  |  |  | 78 |  | 24 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "98f5d356",
      "child_ids": [],
      "sibling_ids": [
        "fee5306c",
        "d4077427"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 2050,
      "page_number": 94,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 10,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          94
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.229671",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 550,
        "word_count": 172,
        "sentence_count": 7,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6478231292517007,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "d083741b",
      "content": "（二）所有者 | -2,79 |  |  |  | 33,533 | 225,47 |  |  |  |  |  |  | -194,7 |  | -194,73\n--------------------------------------------------\n投入和减少资 | 0,000 |  |  |  | ,011.2 | 7,311. |  |  |  |  |  |  | 34,300 |  | 4,300.4\n本 | .00 |  |  |  | 2 | 68 |  |  |  |  |  |  | .46 |  | 6\n | -2,79 |  |  |  | -10,60 | 281,51 |  |  |  |  |  |  | -294,9 |  | -294,91\n1．所有者投入 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 0,000 |  |  |  | 6,500. | 4,686. |  |  |  |  |  |  | 11,186 |  | 1,186.6\n的普通股 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | .00 |  |  |  | 00 | 68 |  |  |  |  |  |  | .68 |  | 8\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2．其他权益工 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n具持有者投入 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n资本 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n3．股份支付计 |  |  |  |  | 44,139 | -56,03 |  |  |  |  |  |  | 100,17 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,176\n入所有者权益 |  |  |  |  | ,511.2 | 7,375. |  |  |  |  |  |  | 6,886. |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ,886.22\n的金额 |  |  |  |  | 2 | 00 |  |  |  |  |  |  | 22 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n4．其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "910ad1a2",
      "child_ids": [],
      "sibling_ids": [
        "e528d8e6",
        "86e612fb"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1679,
      "page_number": 95,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 20,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          95
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.230230",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1179,
        "word_count": 339,
        "sentence_count": 14,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.016963528413910096,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7129558541266794,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "股份"
      ]
    },
    {
      "chunk_id": "e528d8e6",
      "content": " |  |  |  |  |  |  |  |  | 108,61 |  | -270,3 |  | -161,7 |  | -161,74\n（三）利润分 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 4,533. |  | 58,858 |  | 44,325 |  | 4,325.3\n配 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 40 |  | .70 |  | .30 |  | 0\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 108,61 |  | -108,6 |  |  |  | \n1．提取盈余公 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 4,533. |  | 14,533 |  |  |  | \n积 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 40 |  | .40 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2．提取一般风 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n险准备 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n3．对所有者 |  |  |  |  |  |  |  |  |  |  | -161,7 |  | -161,7 |  | -161,74\n（或股东）的 |  |  |  |  |  |  |  |  |  |  | 44,325 |  | 44,325 |  | 4,325.3\n分配 |  |  |  |  |  |  |  |  |  |  | .30 |  | .30 |  | 0\n4．其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n（四）所有者 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "910ad1a2",
      "child_ids": [],
      "sibling_ids": [
        "d083741b",
        "86e612fb"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2193,
      "page_number": 95,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 22,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "股东",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          95
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.230520",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1193,
        "word_count": 368,
        "sentence_count": 9,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.025146689019279127,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7129558541266794,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "86e612fb",
      "content": "权益内部结转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n1．资本公积转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n2．盈余公积转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n3．盈余公积弥 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n补亏损 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n4．设定受益计 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n划变动额结转 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n留存收益 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "910ad1a2",
      "child_ids": [],
      "sibling_ids": [
        "d083741b",
        "e528d8e6"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 2252,
      "page_number": 95,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "资本公积"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          95
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.230645",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 752,
        "word_count": 237,
        "sentence_count": 0,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.026595744680851064,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7129558541266794,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "资本公积"
      ]
    },
    {
      "chunk_id": "f34ce0f1",
      "content": "5．其他综合收 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n益结转留存收 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n益 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n6．其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n（五）专项储\n备 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | 19,301 |  |  |  |  | 19,301 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,301,\n1．本期提取 |  |  |  |  |  |  |  | ,110.5 |  |  |  |  | ,110.5 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 110.51\n |  |  |  |  |  |  |  | 1 |  |  |  |  | 1 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | -19,30 |  |  |  |  | -19,30 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -19,301\n2．本期使用 |  |  |  |  |  |  |  | 1,110. |  |  |  |  | 1,110. |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ,110.51\n |  |  |  |  |  |  |  | 51 |  |  |  |  | 51 |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n（六）其他 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 1,618 |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "86748755",
      "child_ids": [],
      "sibling_ids": [
        "1ed9d086"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1645,
      "page_number": 96,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          96
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.231091",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1145,
        "word_count": 342,
        "sentence_count": 6,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5069899244332494,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "1ed9d086",
      "content": " |  |  |  |  | 2,663, | 325,88 |  |  | 201,81 |  | 1,232, |  | 5,390, |  | 5,390,5\n四、本期期末 | ,820, |  |  |  |  |  | -51,77 |  |  |  |  |  |  |  | \n |  |  |  |  | 367,82 | 0,561. |  |  | 2,279. |  | 481,91 |  | 549,93 |  | 49,932.\n余额 | 253.0 |  |  |  |  |  | 9.23 |  |  |  |  |  |  |  | \n |  |  |  |  | 2.47 | 68 |  |  | 17 |  | 8.50 |  | 2.23 |  | 23\n | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "86748755",
      "child_ids": [],
      "sibling_ids": [
        "f34ce0f1"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1442,
      "page_number": 96,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 7,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          96
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.231256",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 442,
        "word_count": 130,
        "sentence_count": 8,
        "chinese_char_count": 7,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5069899244332494,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "4c60e0d4",
      "content": " | 2019年度 |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n项目 | 股本 | 其他权益工具 |  |  | 资本公 | 减：库存 | 其他综 | 专项储 | 盈余公 | 未分配 |  | 所有者权\n |  |  |  |  |  |  |  |  |  |  | 其他 | \n |  | 优先股 | 永续债 | 其他 | 积 | 股 | 合收益 | 备 | 积 | 利润 |  | 益合计\n |  |  |  |  |  |  |  |  |  |  |  | \n | 1,618,8\n20,253.\n00 |  |  |  | 2,662,22\n9,769.88 |  |  |  | 201,812,\n279.17 | 1,062,8 |  | \n一、上年期末余 |  |  |  |  |  | 325,880, |  |  |  |  |  | 5,219,782,\n |  |  |  |  |  |  |  |  |  | 00,363. |  | \n额 |  |  |  |  |  | 561.68 |  |  |  |  |  | 103.53\n |  |  |  |  |  |  |  |  |  | 16 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n加：会计政 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n策变更 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n前期 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n差错更正 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n其他 |  |  |  |  |  |  |  |  |  |  |  | \n | 1,618,8\n20,253.\n00 |  |  |  | 2,662,22\n9,769.88 |  |  |  | 201,812,\n279.17 | 1,062,8 |  | \n二、本年期初余 |  |  |  |  |  | 325,880, |  |  |  |  |  | 5,219,782,\n |  |  |  |  |  |  |  |  |  | 00,363. |  | \n额 |  |  |  |  |  | 561.68 |  |  |  |  |  | 103.53",
      "chunk_type": "table_group",
      "parent_id": "c81c55e4",
      "child_ids": [],
      "sibling_ids": [
        "cc606c36"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1721,
      "page_number": 96,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 33,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "股本",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          96
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.231671",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1221,
        "word_count": 347,
        "sentence_count": 12,
        "chinese_char_count": 85,
        "readability_score": 0.0,
        "information_density": 0.03276003276003276,
        "coherence_score": 0.7276003276003276,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7184842883548983,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "股本",
        "分配"
      ]
    },
    {
      "chunk_id": "cc606c36",
      "content": " |  |  |  |  |  |  |  |  |  | 16 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n三、本期增减变 | -105,00\n0.00 |  |  |  | 6,982,49\n9.53 |  |  |  | 11,257,5\n45.14 | -365,36 |  | \n |  |  |  |  |  | -24,369, |  |  |  |  |  | -322,856,1\n动金额（减少以 |  |  |  |  |  |  |  |  |  | 0,253.2 |  | \n |  |  |  |  |  | 047.78 |  |  |  |  |  | 60.84\n“－”号填列） |  |  |  |  |  |  |  |  |  | 9 |  | \n |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "c81c55e4",
      "child_ids": [],
      "sibling_ids": [
        "4c60e0d4"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1401,
      "page_number": 96,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          96
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.231813",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 401,
        "word_count": 113,
        "sentence_count": 6,
        "chinese_char_count": 15,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7184842883548983,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "fc0e4285",
      "content": " |  |  |  |  |  |  |  |  |  | 112,57 |  | \n--------------------------------------------------\n（一）综合收益 |  |  |  |  |  |  |  |  |  |  |  | 112,575,45\n |  |  |  |  |  |  |  |  |  | 5,451.3 |  | \n总额 |  |  |  |  |  |  |  |  |  |  |  | 1.35\n |  |  |  |  |  |  |  |  |  | 5 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n（二）所有者投 | -105,00 |  |  |  | 6,982,49 | -24,369, |  |  |  |  |  | 31,246,54\n |  |  |  |  |  |  |  |  |  |  |  | \n入和减少资本 | 0.00 |  |  |  | 9.53 | 047.78 |  |  |  |  |  | 7.31\n |  |  |  |  |  |  |  |  |  |  |  | \n1．所有者投入 | -105,00 |  |  |  | -131,250 | 19,996,8 |  |  |  |  |  | -20,233,07\n |  |  |  |  |  |  |  |  |  |  |  | \n的普通股 | 0.00 |  |  |  | .00 | 27.22 |  |  |  |  |  | 7.22\n |  |  |  |  |  |  |  |  |  |  |  | \n2．其他权益工 |  |  |  |  |  |  |  |  |  |  |  | \n具持有者投入 |  |  |  |  |  |  |  |  |  |  |  | \n资本 |  |  |  |  |  |  |  |  |  |  |  | \n3．股份支付计 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 7,113,74 | -44,365, |  |  |  |  |  | 51,479,62\n入所有者权益 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 9.53 | 875.00 |  |  |  |  |  | 4.53\n的金额 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n4．其他 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | -477,93 |  | ",
      "chunk_type": "table_group",
      "parent_id": "c2bff2eb",
      "child_ids": [],
      "sibling_ids": [
        "7bcc853a",
        "b8f3f381"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1716,
      "page_number": 97,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.232332",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1216,
        "word_count": 342,
        "sentence_count": 13,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.016447368421052634,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.71588683351469,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "股份"
      ]
    },
    {
      "chunk_id": "7bcc853a",
      "content": " |  |  |  |  |  |  |  |  | 11,257,5 |  |  | -466,678,1\n（三）利润分配 |  |  |  |  |  |  |  |  |  | 5,704.6 |  | \n |  |  |  |  |  |  |  |  | 45.14 |  |  | 59.50\n |  |  |  |  |  |  |  |  |  | 4 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n1．提取盈余公 |  |  |  |  |  |  |  |  | 11,257,5 | -11,257 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n积 |  |  |  |  |  |  |  |  | 45.14 | ,545.14 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | -466,67 |  | \n2．对所有者（或 |  |  |  |  |  |  |  |  |  |  |  | -466,678,1\n |  |  |  |  |  |  |  |  |  | 8,159.5 |  | \n股东）的分配 |  |  |  |  |  |  |  |  |  |  |  | 59.50\n |  |  |  |  |  |  |  |  |  | 0 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n3．其他 |  |  |  |  |  |  |  |  |  |  |  | \n（四）所有者权 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n益内部结转 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n1．资本公积转 |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  | \n2．盈余公积转 |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  | \n3．盈余公积弥 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "c2bff2eb",
      "child_ids": [],
      "sibling_ids": [
        "fc0e4285",
        "b8f3f381"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2210,
      "page_number": 97,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 28,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "资本公积",
          "股东",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.232457",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1210,
        "word_count": 366,
        "sentence_count": 7,
        "chinese_char_count": 60,
        "readability_score": 0.0,
        "information_density": 0.03305785123966942,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.71588683351469,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "资本公积",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "b8f3f381",
      "content": "补亏损 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n4．设定受益计 |  |  |  |  |  |  |  |  |  |  |  | \n划变动额结转 |  |  |  |  |  |  |  |  |  |  |  | \n留存收益 |  |  |  |  |  |  |  |  |  |  |  | \n5．其他综合收 |  |  |  |  |  |  |  |  |  |  |  | \n益结转留存收 |  |  |  |  |  |  |  |  |  |  |  | \n益 |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "c2bff2eb",
      "child_ids": [],
      "sibling_ids": [
        "fc0e4285",
        "7bcc853a"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 1829,
      "page_number": 97,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 8,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          97
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.232542",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 329,
        "word_count": 103,
        "sentence_count": 0,
        "chinese_char_count": 30,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.71588683351469,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "0de0f855",
      "content": "【表格内容】\n6 其他 | | | | | | | | | | | | \n--------------------------------------------------\n（五）专项储备 | | | | | | | | | | | | \n | | | | | | | | 6,960,83 | | | | 6,960,833.\n\n1 本期提取 | | | | | | | | | | | | \n | | | | | | | | 3.11 | | | | \n | | | | | | | | | | | | \n | | | | | | | | -6,960,8 | | | | -6,960,833\n.11\n2 本期使用 | | | | | | | | | | | | \n | | | | | | | | 33.11 | | | | \n | | | | | | | | | | | | \n（六）其他 | | | | | | | | | | | | \n | 1,618,\n15,253\n0 | 7 | | | | | | | | 697,44 | | 4,896,925,\n942.69\n四 本期期末余 | | | | | 2,669,21 | 301,511, | | | 213,069, | | | \n | | . | | | | | | | | 0,109.8 | | \n额 | | | | | 2,269.41 | 513.90 | | | 824.31 | | | \n | | 0 | | | | | | | | 7 | | \n | | | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "dafb8c7e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 694,
      "page_number": 98,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          98
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.232833",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 694,
        "word_count": 241,
        "sentence_count": 10,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.504360465116279,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "8d49a5f0",
      "content": " | 2018年年度 |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n |  | 其他权益工具 |  |  |  |  |  |  |  |  |  | \n项目 |  |  |  |  | 资本公 | 减：库存 | 其他综 |  | 盈余公 | 未分配利 |  | 所有者权\n | 股本 | 优先 | 永续 |  |  |  |  | 专项储备 |  |  | 其他 | \n |  |  |  | 其他 | 积 | 股 | 合收益 |  | 积 | 润 |  | 益合计\n |  | 股 | 债 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n | 1,621, |  |  |  | 2,628,6 |  |  |  |  |  |  | \n一、上年期末余 |  |  |  |  |  | 100,403, |  |  | 93,197, | 247,013,8 |  | 4,490,115,3\n | 610,25 |  |  |  | 96,758. |  |  |  |  |  |  | \n额 |  |  |  |  |  | 250.00 |  |  | 745.77 | 87.91 |  | 95.34\n | 3.00 |  |  |  | 66 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n加：会计政 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n策变更 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n前期 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n差错更正 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n其他 |  |  |  |  |  |  |  |  |  |  |  | \n | 1,621, |  |  |  | 2,628,6 |  |  |  |  |  |  | \n二、本年期初余 |  |  |  |  |  | 100,403, |  |  | 93,197, | 247,013,8 |  | 4,490,115,3\n | 610,25 |  |  |  | 96,758. |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "1eef0e46",
      "child_ids": [],
      "sibling_ids": [
        "00b24f32"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1718,
      "page_number": 98,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "股本",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          98
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.233280",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1218,
        "word_count": 354,
        "sentence_count": 7,
        "chinese_char_count": 85,
        "readability_score": 0.0,
        "information_density": 0.024630541871921183,
        "coherence_score": 0.7284072249589492,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6499855449551895,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "股本",
        "分配"
      ]
    },
    {
      "chunk_id": "00b24f32",
      "content": "额 |  |  |  |  |  | 250.00 |  |  | 745.77 | 87.91 |  | 95.34\n | 3.00 |  |  |  | 66 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n三、本期增减变 | -2,790,\n000.00 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 33,533, | 225,477, |  |  | 108,614 | 815,786,4 |  | 729,666,70\n动金额（减少以 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 011.22 | 311.68 |  |  | ,533.40 | 75.25 |  | 8.19\n“－”号填列） |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n（一）综合收益 |  |  |  |  |  |  |  |  |  | 1,086,145 |  | 1,086,145,3\n |  |  |  |  |  |  |  |  |  |  |  | \n总额 |  |  |  |  |  |  |  |  |  | ,333.95 |  | 33.95\n |  |  |  |  |  |  |  |  |  |  |  | \n（二）所有者投 | -2,790,\n000.00 |  |  |  | 33,533, | 225,477, |  |  |  |  |  | -194,734,30\n |  |  |  |  |  |  |  |  |  |  |  | \n入和减少资本 |  |  |  |  | 011.22 | 311.68 |  |  |  |  |  | 0.46\n |  |  |  |  |  |  |  |  |  |  |  | \n1．所有者投入 | -2,790,\n000.00 |  |  |  | -10,606, | 281,514, |  |  |  |  |  | -294,911,18\n |  |  |  |  |  |  |  |  |  |  |  | \n的普通股 |  |  |  |  | 500.00 | 686.68 |  |  |  |  |  | 6.68\n |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "1eef0e46",
      "child_ids": [],
      "sibling_ids": [
        "8d49a5f0"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2087,
      "page_number": 98,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          98
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.233620",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1087,
        "word_count": 300,
        "sentence_count": 21,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6499855449551895,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "f47a5d13",
      "content": "2．其他权益工 |  |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n具持有者投入 |  |  |  |  |  |  |  |  |  |  |  | \n资本 |  |  |  |  |  |  |  |  |  |  |  | \n3．股份支付计 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 44,139, | -56,037, |  |  |  |  |  | 100,176,88\n入所有者权益 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | 511.22 | 375.00 |  |  |  |  |  | 6.22\n的金额 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n4．其他 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | 108,614 | -270,358, |  | -161,744,32\n（三）利润分配 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | ,533.40 | 858.70 |  | 5.30\n |  |  |  |  |  |  |  |  |  |  |  | \n1．提取盈余公 |  |  |  |  |  |  |  |  | 108,614 | -108,614, |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n积 |  |  |  |  |  |  |  |  | ,533.40 | 533.40 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n2．对所有者（或 |  |  |  |  |  |  |  |  |  | -161,744, |  | -161,744,32\n |  |  |  |  |  |  |  |  |  |  |  | \n股东）的分配 |  |  |  |  |  |  |  |  |  | 325.30 |  | 5.30\n |  |  |  |  |  |  |  |  |  |  |  | \n3．其他 |  |  |  |  |  |  |  |  |  |  |  | \n（四）所有者权 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "65f83155",
      "child_ids": [],
      "sibling_ids": [
        "d4fff770"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1694,
      "page_number": 99,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "股份",
          "股东",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          99
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.234040",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1194,
        "word_count": 335,
        "sentence_count": 10,
        "chinese_char_count": 57,
        "readability_score": 0.0,
        "information_density": 0.04187604690117253,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7169764560099132,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "d4fff770",
      "content": "益内部结转 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n1．资本公积转 |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  | \n2．盈余公积转 |  |  |  |  |  |  |  |  |  |  |  | \n增资本（或股 |  |  |  |  |  |  |  |  |  |  |  | \n本） |  |  |  |  |  |  |  |  |  |  |  | \n3．盈余公积弥 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n补亏损 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n4．设定受益计 |  |  |  |  |  |  |  |  |  |  |  | \n划变动额结转 |  |  |  |  |  |  |  |  |  |  |  | \n留存收益 |  |  |  |  |  |  |  |  |  |  |  | \n5．其他综合收 |  |  |  |  |  |  |  |  |  |  |  | \n益结转留存收 |  |  |  |  |  |  |  |  |  |  |  | \n益 |  |  |  |  |  |  |  |  |  |  |  | \n6．其他 |  |  |  |  |  |  |  |  |  |  |  | \n（五）专项储备 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | 4,736,183 |  |  |  | 4,736,183.5\n1．本期提取 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | .53 |  |  |  | 3\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | -4,736,18 |  |  |  | -4,736,183.\n2．本期使用 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | 3.53 |  |  |  | 53\n |  |  |  |  |  |  |  |  |  |  |  | \n（六）其他 |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "65f83155",
      "child_ids": [],
      "sibling_ids": [
        "f47a5d13"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2226,
      "page_number": 99,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 29,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资本公积"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          99
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.234167",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1226,
        "word_count": 376,
        "sentence_count": 4,
        "chinese_char_count": 80,
        "readability_score": 0.0,
        "information_density": 0.008156606851549755,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7169764560099132,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资本公积"
      ]
    },
    {
      "chunk_id": "c063642c",
      "content": "【说明】公司本期将以下15家子公司纳入合并财务报表范围，情况详见本财务报表附注合并范围变更和其他主\n体中的权益之说明。序号 子公司名称 公司简称\n1 浙江海翔川南药业有限公司 川南药业公司\n2 浙江海翔药业销售有限公司 海翔销售公司\n3 上海海翔医药科技发展有限公司 上海海翔公司\n4 台州港翔科技有限公司 港翔科技公司\n5 港翔国际控股(香港)有限公司 香港港翔公司\n6 GeneVida GmbH GeneVida GmbH\n7 GANGXIANG INTERNATIONAL HOLDINGSGANGXIANG(SINGAPORE)\n（SINGAPORE）PTE.LTD\n8 台州港翔化工有限公司 港翔化工公司\n9 台州市前进化工有限公司 台州前进公司\n10 台州市振港染料化工有限公司 台州振港公司\n11 盐城市瓯华化学工业有限公司 盐城瓯华公司\n12 台州市东旭医化设备有限公司 台州东旭公司\n13 盐城市瓯华化工研究院有限公司 瓯华研究院\n14 盐城市瓯华环保科技有限公司 瓯华环保公司\n15 浙江盛嘉环保有限公司 盛嘉环保公司\n100。\n\n【表格内容】\n| 1,618, | | | | 2,662,2 | | | | | | | \n--------------------------------------------------\n四 本期期末余 | | | | | | 325,880, | | | 201,812 | 1,062,800 | | 5,219,782,1\n | 820,25 | | | | 29,769. | | | | | | | \n额 | | | | | | 561.68 | | | ,279.17 | ,363.16 | | 03.53\n | 3.00 | | | | 88 | | | | | | | \n | | | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "bd43d7b2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 800,
      "page_number": 100,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "合并"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          100
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234393",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 800,
        "word_count": 145,
        "sentence_count": 9,
        "chinese_char_count": 308,
        "readability_score": 0.0,
        "information_density": 0.025,
        "coherence_score": 0.6073913043478261,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5974821984795563,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "合并"
      ]
    },
    {
      "chunk_id": "62975253",
      "content": "【表格内容】\n序号 | 子公司名称\n--------------------------------------------------\n1 | 浙江海翔川南药业有限公司\n2 | 浙江海翔药业销售有限公司\n3 | 上海海翔医药科技发展有限公司\n4 | 台州港翔科技有限公司\n5 | 港翔国际控股(香港)有限公司\n6 | GeneVida GmbH\n7 | GANGXIANG INTERNATIONAL HOLDINGS\n（SINGAPORE）PTE.LTD\n8 | 台州港翔化工有限公司\n9 | 台州市前进化工有限公司\n10 | 台州市振港染料化工有限公司\n11 | 盐城市瓯华化学工业有限公司\n12 | 台州市东旭医化设备有限公司\n13 | 盐城市瓯华化工研究院有限公司\n14 | 盐城市瓯华环保科技有限公司\n15 | 浙江盛嘉环保有限公司",
      "chunk_type": "table_group",
      "parent_id": "22971add",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 372,
      "page_number": 100,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          100
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234559",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 372,
        "word_count": 54,
        "sentence_count": 1,
        "chinese_char_count": 168,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3342857142857143,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5403972602739726,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "19e461f3",
      "content": "【说明】公司在每个资产负债表日重新计量预期信用损失，由此形成的损失准备的增加或转回金额，作为减值\n损失或利得计入当期损益。对于以摊余成本计量的金融资产，损失准备抵减该金融资产在资产负债表中列\n示的账面价值；对于以公允价值计量且其变动计入其他综合收益的债权投资，公司在其他综合收益中确认\n其损失准备，不抵减该金融资产的账面价值。(2) 按组合评估预期信用风险和计量预期信用损失的金融工具\n项 目 确定组合的依据 计量预期信用损失的方法\n其他应收款——应收出口退税组合 款项性质 参考历史信用损失经验，结合当前\n其他应收款——应收押金保证金组 状况以及对未来经济状况的预测，\n合 通过违约风险敞口和未来12个月\n内或整个存续期预期信用损失率，\n其他应收款——合并范围内关联往\n来组合\n计算预期信用损失\n其他应收款——应收拆借款组合\n其他应收款——应收暂付款等组合\n(3) 按组合计量预期信用损失的应收款项\n1) 具体组合及计量预期信用损失的方法\n项 目 确定组合的依据 计量预期信用损失的方法\n应收银行承兑汇票 票据类型 参考历史信用损失经验，结合当前状\n况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，计算预期信用损失\n应收账款——信用风险特征组账龄组合 参考历史信用损失经验，结合当前状\n合 况以及对未来经济状况的预测，编制\n应收账款账龄与整个存续期预期信用\n损失率对照表，计算预期信用损失\n应收账款——合并范围内关联合并范围内关联方 参考历史信用损失经验，结合当前状\n往来组合 况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，该组合预期信用损失率为0%\n2) 应收账款——信用风险特征组合的账龄与整个存续期预期信用损失率对照表\n账 龄 应收账款\n预期信用损失率(%)\n1年以内（含，下同） 5\n1-2年 30\n105。\n\n【表格内容】\n确定组合的依据 | 计量预期信用损失的方法\n--------------------------------------------------\n款项性质 | 参考历史信用损失经验，结合当前\n状况以及对未来经济状况的预测，\n通过违约风险敞口和未来12个月\n内或整个存续期预期信用损失率，\n计算预期信用损失",
      "chunk_type": "table_group",
      "parent_id": "34128b8a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 949,
      "page_number": 105,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "成本",
          "投资",
          "应收",
          "资产负债表",
          "合并",
          "减值",
          "公允价值",
          "账面价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234798",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 949,
        "word_count": 71,
        "sentence_count": 3,
        "chinese_char_count": 750,
        "readability_score": 0.0,
        "information_density": 0.1053740779768177,
        "coherence_score": 0.4156962025316456,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6497152524167562,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "成本",
        "投资",
        "应收",
        "资产负债表",
        "合并",
        "减值",
        "公允价值",
        "账面价值"
      ]
    },
    {
      "chunk_id": "611d289d",
      "content": "【表格内容】\n项 目 | 确定组合的依据\n--------------------------------------------------\n应收银行承兑汇票 | 票据类型\n应收账款 信用风险特征组\n合 | 账龄组合\n应收账款 合并范围内关联\n往来组合 | 合并范围内关联方",
      "chunk_type": "table_group",
      "parent_id": "d20de2c8",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 138,
      "page_number": 105,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "合并"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234912",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 138,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 64,
        "readability_score": 0.0,
        "information_density": 0.1449275362318841,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5276025062656642,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "合并"
      ]
    },
    {
      "chunk_id": "2caef8b7",
      "content": "【表格内容】\n账 龄\n--------------------------------------------------\n1年以内（含，下同）\n1-2年",
      "chunk_type": "table_group",
      "parent_id": "5e01f864",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 77,
      "page_number": 105,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.234962",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 77,
        "word_count": 6,
        "sentence_count": 0,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43328571428571433,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "0b263586",
      "content": "【标题】(2) 包装物\n按照一次转销法进行摊销。106。\n\n【说明】16、合同资产\n17、合同成本\n18、持有待售资产\n19、债权投资\n20、其他债权投资\n21、长期应收款\n22、长期股权投资\n1. 共同控制、重要影响的判断\n按照相关约定对某项安排存在共有的控制，并且该安排的相关活动必须经过分享控制权的参与方一致\n同意后才能决策，认定为共同控制。对被投资单位的财务和经营政策有参与决策的权力，但并不能够控制\n或者与其他方一起共同控制这些政策的制定，认定为重大影响。2. 投资成本的确定\n(1) 同一控制下的企业合并形成的，合并方以支付现金、转让非现金资产、承担债务或发行权益性证\n券作为合并对价的，在合并日按照取得被合并方所有者权益在最终控制方合并财务报表中的账面价值的份\n额作为其初始投资成本。\n\n【表格内容】\n2-3年\n--------------------------------------------------\n3年以上",
      "chunk_type": "table_group",
      "parent_id": "3cac7f61",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 418,
      "page_number": 106,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": true,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "成本",
          "现金",
          "投资",
          "应收",
          "合并",
          "经营",
          "股权",
          "摊销"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          106
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235085",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 418,
        "word_count": 24,
        "sentence_count": 7,
        "chinese_char_count": 285,
        "readability_score": 0.0,
        "information_density": 0.23923444976076555,
        "coherence_score": 0.7075,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48862176991150447,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "成本",
        "现金",
        "投资",
        "应收",
        "合并",
        "经营",
        "股权",
        "摊销"
      ]
    },
    {
      "chunk_id": "cba70c57",
      "content": "【说明】（3）融资租入固定资产的认定依据、计价和折旧方法\n符合下列一项或数项标准的，认定为融资租赁：(1) 在租赁期届满时，租赁资产的所有权转移给承租人；(2) 承租人有购买\n租赁资产的选择权，所订立的购买价款预计将远低于行使选择权时租赁资产的公允价值，因而在租赁开始日就可以合理确定\n承租人将会行使这种选择权；(3) 即使资产的所有权不转移，但租赁期占租赁资产使用寿命的大部分 [ 通常占租赁资产使用\n寿命的75%以上（含75%）]；(4) 承租人在租赁开始日的最低租赁付款额现值，几乎相当于租赁开始日租赁资产公允价值\n[ 90%以上（含90%）]；出租人在租赁开始日的最低租赁收款额现值，几乎相当于租赁开始日租赁资产公允价值 [ 90%以上\n（含90%）]；(5) 租赁资产性质特殊，如果不作较大改造，只有承租人才能使用。融资租入的固定资产，按租赁开始日租\n赁资产的公允价值与最低租赁付款额的现值中较低者入账，按自有固定资产的折旧政策计提折旧。25、在建工程\n1. 在建工程同时满足经济利益很可能流入、成本能够可靠计量则予以确认。\n\n【表格内容】\n类别 | 折旧方法 | 折旧年限 | 残值率 | 年折旧率\n--------------------------------------------------\n房屋及建筑物 | 年限平均法 | 5-20 | 0 3 5或10 | 4.50-20.00\n通用设备 | 年限平均法 | 3-5 | 0 3 5或10 | 18.00-33.33\n专用设备 | 年限平均法 | 3-10 | 3 5或10 | 9.00-32.33\n运输工具 | 年限平均法 | 4-5 | 3 5或10 | 18.00-24.25",
      "chunk_type": "table_group",
      "parent_id": "7b74e087",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 730,
      "page_number": 108,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "成本",
          "固定资产",
          "折旧",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          108
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235292",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 730,
        "word_count": 73,
        "sentence_count": 12,
        "chinese_char_count": 434,
        "readability_score": 0.0,
        "information_density": 0.09589041095890412,
        "coherence_score": 0.8691333519709254,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6040720610950325,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "固定资产",
        "折旧",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "4763f525",
      "content": "【表格内容】\n项 目\n--------------------------------------------------\n土地使用权\n专利权\n非专利技术\n排污权\n软件\n特许使用权\n特许经营权",
      "chunk_type": "table_group",
      "parent_id": "46562e7e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 96,
      "page_number": 110,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          110
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235378",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 96,
        "word_count": 11,
        "sentence_count": 0,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.10416666666666667,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.393361797752809,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营"
      ]
    },
    {
      "chunk_id": "a42cfe49",
      "content": "【表格内容】\n会计政策变更的内容和原因 | 审批程序 | 备注\n--------------------------------------------------\n | 本次会计政策变更已经公司第五届董事 | \n执行 关于修订印发2019年度一般企业 | | \n | 会第二十三次会议及第五届监事第十九 | \n财务报表格式的通知 | | \n | 次会议审议通过 | \n | | \n财政部于2017年颁布了修订后的 企业 | | \n会计准则第22号--金融工具确认和计 | | \n量 企业会计准则第23号--金融资产 | | \n | 本次会计政策变更已经公司第五届董事 | 公司根据新准则，已于2019年1月1日\n转移 企业会计准则第37号--金融工 | | \n | 会第二十次会议及第五届监事第十六次 | 起将前期划分为可供出售金融资产的股\n具列报 三项会计准则，并要求单独在 | | \n | 会议审议通过 | 权投资重分类至其他权益工具投资\n境内上市的企业自2019年1月1日起施 | | \n | | \n行，根据新旧准则衔接规定，公司无需 | | \n重述前期可比数。 | |",
      "chunk_type": "table_group",
      "parent_id": "1269de41",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 489,
      "page_number": 115,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "financial_statement",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "投资",
          "融资"
        ],
        "time_periods": [
          "2019",
          "2019-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235518",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 489,
        "word_count": 67,
        "sentence_count": 1,
        "chinese_char_count": 274,
        "readability_score": 0.0,
        "information_density": 0.081799591002045,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6809999999999999,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "投资",
        "融资"
      ]
    },
    {
      "chunk_id": "f54c2ca2",
      "content": "【说明】合并资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 1,956,089,124.33 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产 150,000,000.00 150,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 107,399,476.04 -107,399,476.04\n应收账款 479,537,782.06 479,537,782.06\n应收款项融资 107,399,476.04 107,399,476.04\n预付款项 46,449,558.50 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 10,817,853.96 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 905,418,218.49 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 227,882,993.23 77,882,993.23 -150,000,000.00\n流动资产合计 3,733,595,006.61 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00 0.00 -1,800,000.00\n其他债权投资\n116。\n\n【表格内容】\n原列报报表项目及金额 | | \n--------------------------------------------------\n应收票据及应收账款 | 586,937,258.10 | 应收票据\n | | 应收账款\n应付票据及应付账款 | 791,915,463.78 | 应付票据\n | | 应付账款",
      "chunk_type": "table_group",
      "parent_id": "45f07711",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 779,
      "page_number": 115,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "投资",
          "应收",
          "应付",
          "预付",
          "存货",
          "资产负债表",
          "合并",
          "公允价值"
        ],
        "time_periods": [
          "2018-12",
          "2019-01"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.235776",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 779,
        "word_count": 84,
        "sentence_count": 27,
        "chinese_char_count": 248,
        "readability_score": 0.0,
        "information_density": 0.12836970474967907,
        "coherence_score": 0.42222222222222217,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5372432480070505,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "应收",
        "应付",
        "预付",
        "存货",
        "资产负债表",
        "合并",
        "公允价值"
      ]
    },
    {
      "chunk_id": "4d7f3d73",
      "content": "项目 | 2018年12月31日 | 2019年01月01日 | 调整数\n--------------------------------------------------\n流动资产： |  |  | \n货币资金 | 1,956,089,124.33 | 1,956,089,124.33 | \n结算备付金 |  |  | \n拆出资金 |  |  | \n交易性金融资产 |  | 150,000,000.00 | 150,000,000.00\n以公允价值计量且其 |  |  | \n变动计入当期损益的金融 |  |  | \n资产 |  |  | \n衍生金融资产 |  |  | \n应收票据 | 107,399,476.04 |  | -107,399,476.04\n应收账款 | 479,537,782.06 | 479,537,782.06 | \n应收款项融资 |  | 107,399,476.04 | 107,399,476.04\n预付款项 | 46,449,558.50 | 46,449,558.50 | \n应收保费 |  |  | \n应收分保账款 |  |  | \n应收分保合同准备金 |  |  | \n其他应收款 | 10,817,853.96 | 10,817,853.96 | \n其中：应收利息 |  |  | \n应收股利 |  |  | \n买入返售金融资产 |  |  | \n存货 | 905,418,218.49 | 905,418,218.49 | \n合同资产 |  |  | \n持有待售资产 |  |  | \n一年内到期的非流动 |  |  | \n |  |  | \n资产 |  |  | \n |  |  | \n其他流动资产 | 227,882,993.23 | 77,882,993.23 | -150,000,000.00\n流动资产合计 | 3,733,595,006.61 | 3,733,595,006.61 | \n非流动资产： |  |  | \n发放贷款和垫款 |  |  | \n债权投资 |  |  | \n可供出售金融资产 | 1,800,000.00 | 0.00 | -1,800,000.00\n其他债权投资 |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "cc714fbb",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1435,
      "page_number": 116,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "应收",
          "预付",
          "存货"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          116
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.236212",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 935,
        "word_count": 166,
        "sentence_count": 24,
        "chinese_char_count": 188,
        "readability_score": 0.0,
        "information_density": 0.0855614973262032,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6269875222816399,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "应收",
        "预付",
        "存货",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "e2e56250",
      "content": "持有至到期投资 |  |  | \n--------------------------------------------------\n长期应收款 |  |  | \n长期股权投资 | 66,088,139.79 | 66,088,139.79 | \n其他权益工具投资 |  | 1,800,000.00 | 1,800,000.00\n其他非流动金融资产 |  |  | \n投资性房地产 | 12,338,615.29 | 12,338,615.29 | \n固定资产 | 1,215,120,643.61 | 1,215,120,643.61 | \n在建工程 | 674,333,677.99 | 674,333,677.99 | \n生产性生物资产 |  |  | \n油气资产 |  |  | \n使用权资产 |  |  | \n无形资产 | 539,514,850.87 | 539,514,850.87 | \n开发支出 |  |  | \n商誉 | 757,736,770.14 | 757,736,770.14 | \n长期待摊费用 | 1,842,423.21 | 1,842,423.21 | \n递延所得税资产 | 32,487,223.69 | 32,487,223.69 | \n其他非流动资产 | 515,993.37 | 515,993.37 | \n非流动资产合计 | 3,301,778,337.96 | 3,301,778,337.96 | \n资产总计 | 7,035,373,344.57 | 7,035,373,344.57 | \n流动负债： |  |  | \n短期借款 | 598,700,000.00 | 598,700,000.00 | \n向中央银行借款 |  |  | \n拆入资金 |  |  | \n交易性金融负债 |  |  | \n以公允价值计量且其 |  |  | \n变动计入当期损益的金融 |  |  | \n负债 |  |  | \n衍生金融负债 |  |  | \n应付票据 | 490,006,533.85 | 490,006,533.85 | \n应付账款 | 301,908,929.93 | 301,908,929.93 | \n预收款项 | 19,196,692.94 | 19,196,692.94 | \n合同负债 |  |  | \n卖出回购金融资产款 |  |  | \n吸收存款及同业存放 |  |  | \n代理买卖证券款 |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "dfcc4d26",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1538,
      "page_number": 117,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "费用",
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          117
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.236668",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1038,
        "word_count": 173,
        "sentence_count": 32,
        "chinese_char_count": 201,
        "readability_score": 0.0,
        "information_density": 0.09633911368015413,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7580924855491329,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "投资",
        "应收",
        "应付",
        "预收",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "a339f62a",
      "content": "代理承销证券款 |  |  | \n--------------------------------------------------\n应付职工薪酬 | 45,234,354.42 | 45,234,354.42 | \n应交税费 | 54,890,661.34 | 54,890,661.34 | \n其他应付款 | 24,723,304.20 | 24,723,304.20 | \n其中：应付利息 | 1,088,752.57 | 1,088,752.57 | \n应付股利 | 2,051,370.43 | 2,051,370.43 | \n应付手续费及佣金 |  |  | \n应付分保账款 |  |  | \n持有待售负债 |  |  | \n一年内到期的非流动 |  |  | \n | 44,365,875.00 | 44,365,875.00 | \n负债 |  |  | \n |  |  | \n其他流动负债 |  |  | \n流动负债合计 | 1,579,026,351.68 | 1,579,026,351.68 | \n非流动负债： |  |  | \n保险合同准备金 |  |  | \n长期借款 |  |  | \n应付债券 |  |  | \n其中：优先股 |  |  | \n永续债 |  |  | \n租赁负债 |  |  | \n长期应付款 |  |  | \n长期应付职工薪酬 |  |  | \n预计负债 | 12,971,002.47 | 12,971,002.47 | \n递延收益 | 44,650,629.91 | 44,650,629.91 | \n递延所得税负债 | 8,175,428.28 | 8,175,428.28 | \n其他非流动负债 |  |  | \n非流动负债合计 | 65,797,060.66 | 65,797,060.66 | \n负债合计 | 1,644,823,412.34 | 1,644,823,412.34 | \n所有者权益： |  |  | \n股本 | 1,618,820,253.00 | 1,618,820,253.00 | \n其他权益工具 |  |  | \n其中：优先股 |  |  | \n永续债 |  |  | \n资本公积 | 2,663,367,822.47 | 2,663,367,822.47 | ",
      "chunk_type": "table_group",
      "parent_id": "e9e275e1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1475,
      "page_number": 118,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "应付",
          "所得税",
          "股本"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          118
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.237200",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 975,
        "word_count": 171,
        "sentence_count": 28,
        "chinese_char_count": 178,
        "readability_score": 0.0,
        "information_density": 0.10256410256410256,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6881025641025642,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "应付",
        "所得税",
        "股本",
        "资本公积",
        "税费",
        "借款",
        "证券",
        "债券"
      ]
    },
    {
      "chunk_id": "733ffe1d",
      "content": "【表格内容】\n减：库存股 | 325,880,561.68 | 325,880,561.68 | \n--------------------------------------------------\n其他综合收益 | -51,779.23 | -51,779.23 | \n专项储备 | | | \n盈余公积 | 201,812,279.17 | 201,812,279.17 | \n一般风险准备 | | | \n未分配利润 | 1,232,481,918.50 | 1,232,481,918.50 | \n归属于母公司所有者权益 | | | \n | 5,390,549,932.23 | 5,390,549,932.23 | \n合计 | | | \n | | | \n少数股东权益 | | | \n所有者权益合计 | 5,390,549,932.23 | 5,390,549,932.23 | \n负债和所有者权益总计 | 7,035,373,344.57 | 7,035,373,344.57 |",
      "chunk_type": "table_group",
      "parent_id": "62549ae5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 444,
      "page_number": 119,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "利润",
          "股东权益",
          "母公司",
          "未分配利润",
          "股东",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          119
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.237401",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 444,
        "word_count": 66,
        "sentence_count": 14,
        "chinese_char_count": 69,
        "readability_score": 0.0,
        "information_density": 0.18018018018018017,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6116666666666667,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "利润",
        "股东权益",
        "母公司",
        "未分配利润",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "14e57db4",
      "content": "项目 | 2018年12月31日 | 2019年01月01日 | 调整数\n--------------------------------------------------\n流动资产： |  |  | \n货币资金 | 983,565,710.16 | 983,565,710.16 | \n交易性金融资产 |  | 100,000,000.00 | 100,000,000.00\n以公允价值计量且其 |  |  | \n变动计入当期损益的金融 |  |  | \n资产 |  |  | \n衍生金融资产 |  |  | \n应收票据 | 20,885,763.88 | 20,885,763.88 | \n应收账款 | 149,204,899.98 | 149,204,899.98 | -149,204,899.98\n应收款项融资 |  | 149,204,899.98 | 149,204,899.98\n预付款项 | 5,554,458.78 | 5,554,458.78 | \n其他应收款 | 1,043,055,918.72 | 1,043,055,918.72 | \n其中：应收利息 |  |  | \n应收股利 | 7,222,088,153.34 | 722,088,153.34 | \n存货 | 84,396,333.98 | 84,396,333.98 | \n合同资产 |  |  | \n持有待售资产 |  |  | \n一年内到期的非流动 |  |  | \n |  |  | \n资产 |  |  | \n |  |  | \n其他流动资产 | 105,920,135.97 | 5,920,135.97 | -100,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "856c451f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1220,
      "page_number": 119,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 24,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "应收",
          "预付",
          "存货",
          "公允价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          119
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.237774",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 720,
        "word_count": 116,
        "sentence_count": 22,
        "chinese_char_count": 116,
        "readability_score": 0.0,
        "information_density": 0.09722222222222222,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.615,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "应收",
        "预付",
        "存货",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "f18aab49",
      "content": "流动资产合计 | 2,392,583,221.47 | 2,392,583,221.47 | \n--------------------------------------------------\n非流动资产： |  |  | \n债权投资 |  |  | \n可供出售金融资产 | 23,017,502.51 |  | -23,017,502.51\n其他债权投资 |  |  | \n持有至到期投资 |  |  | \n长期应收款 |  |  | \n长期股权投资 | 3,250,556,852.85 | 3,250,556,852.85 | \n其他权益工具投资 |  | 23,017,502.51 | 23,017,502.51\n其他非流动金融资产 |  |  | \n投资性房地产 | 16,409,402.65 | 16,409,402.65 | \n固定资产 | 182,948,202.54 | 182,948,202.54 | \n在建工程 | 20,490,208.35 | 20,490,208.35 | \n生产性生物资产 |  |  | \n油气资产 |  |  | \n使用权资产 |  |  | \n无形资产 | 17,059,632.32 | 17,059,632.32 | \n开发支出 |  |  | \n商誉 |  |  | \n长期待摊费用 |  |  | \n递延所得税资产 | 9,371,365.80 | 9,371,365.80 | \n其他非流动资产 |  |  | \n非流动资产合计 | 3,519,853,167.02 | 3,519,853,167.02 | \n资产总计 | 5,912,436,388.49 | 5,912,436,388.49 | \n流动负债： |  |  | \n短期借款 | 287,000,000.00 | 287,000,000.00 | \n交易性金融负债 |  |  | \n以公允价值计量且其 |  |  | \n变动计入当期损益的金融 |  |  | \n负债 |  |  | \n衍生金融负债 |  |  | \n应付票据 | 202,286,262.85 | 202,286,262.85 | \n应付账款 | 25,423,635.65 | 25,423,635.65 | \n预收款项 | 7,777,982.57 | 7,777,982.57 | \n合同负债 |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b91ec86e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1513,
      "page_number": 120,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "费用",
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          120
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.238206",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1013,
        "word_count": 171,
        "sentence_count": 30,
        "chinese_char_count": 194,
        "readability_score": 0.0,
        "information_density": 0.09871668311944717,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7574531095755183,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "投资",
        "应收",
        "应付",
        "预收",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "b1221aa3",
      "content": "应付职工薪酬 | 6,439,699.82 | 6,439,699.82 | \n--------------------------------------------------\n应交税费 | 948,517.30 | 948,517.30 | \n其他应付款 | 104,178,588.96 | 104,178,588.96 | \n其中：应付利息 | 805,795.63 | 805,795.63 | \n应付股利 | 2,051,370.43 | 2,051,370.43 | \n持有待售负债 |  |  | \n一年内到期的非流动 |  |  | \n | 44,365,875.00 | 44,365,875.00 | \n负债 |  |  | \n |  |  | \n其他流动负债 |  |  | \n流动负债合计 | 678,420,562.15 | 678,420,562.15 | \n非流动负债： |  |  | \n长期借款 |  |  | \n应付债券 |  |  | \n其中：优先股 |  |  | \n永续债 |  |  | \n租赁负债 |  |  | \n长期应付款 |  |  | \n长期应付职工薪酬 |  |  | \n预计负债 | 12,971,002.47 | 12,971,002.47 | \n递延收益 | 1,262,720.34 | 1,262,720.34 | \n递延所得税负债 |  |  | \n其他非流动负债 |  |  | \n非流动负债合计 | 14,233,722.81 | 14,233,722.81 | \n负债合计 | 692,654,284.96 | 692,654,284.96 | \n所有者权益： |  |  | \n股本 | 1,618,820,253.00 | 1,618,820,253.00 | \n其他权益工具 |  |  | \n其中：优先股 |  |  | \n永续债 |  |  | \n资本公积 | 2,662,229,769.88 | 2,662,229,769.88 | \n减：库存股 | 325,880,561.68 | 325,880,561.68 | \n其他综合收益 |  |  | \n专项储备 |  |  | \n盈余公积 | 201,812,279.17 | 201,812,279.17 | ",
      "chunk_type": "table_group",
      "parent_id": "2b9e08d0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1478,
      "page_number": 121,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 37,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "应付",
          "所得税",
          "股本"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          121
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.238625",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 978,
        "word_count": 173,
        "sentence_count": 30,
        "chinese_char_count": 168,
        "readability_score": 0.0,
        "information_density": 0.09202453987730061,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6848670756646216,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "应付",
        "所得税",
        "股本",
        "资本公积",
        "税费",
        "借款",
        "债券"
      ]
    },
    {
      "chunk_id": "5ddbe025",
      "content": "【表格内容】\n未分配利润 | 1,062,800,363.16 | 1,062,800,363.16 | \n--------------------------------------------------\n所有者权益合计 | 5,219,782,103.53 | 5,219,782,103.53 | \n负债和所有者权益总计 | 5,912,436,388.49 | 5,912,436,388.49 |",
      "chunk_type": "table_group",
      "parent_id": "9820a769",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 204,
      "page_number": 122,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "利润",
          "未分配利润",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.238730",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 204,
        "word_count": 20,
        "sentence_count": 6,
        "chinese_char_count": 26,
        "readability_score": 0.0,
        "information_density": 0.2450980392156863,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4812666666666667,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "利润",
        "未分配利润",
        "分配"
      ]
    },
    {
      "chunk_id": "16938d13",
      "content": "【说明】技术企业复审备案，自2016年起减按15%的税率计缴企业所得税，认定有效期3年。认定资格有效期届满后，\n公司重新申请了高新技术企业资格认定，截至本财务报表批准报出日尚处于审核阶段，2019年度暂按15%\n的税率计缴。3. 根据江苏省科学技术厅、江苏省财政厅、江苏省国家税务局、江苏省地方税务局联合颁发的《高新\n技术企业证书》，盐城瓯华公司被认定为高新技术企业，自2017年起减按15%的税率计缴企业所得税，认\n定有效期3年。\n\n【表格内容】\n纳税主体名称 | 所得税税率\n--------------------------------------------------\n川南药业公司 台州前进公司 盐城瓯华 | \n公司 GeneVida GmbH | 15%\n香港港翔公司 | 16.5%\nGANGXIANG（SINGAPORE） | 17%\n上海海翔公司 东旭医化公司 | 20%\n除上述以外的其他纳税主体 | 25%",
      "chunk_type": "table_group",
      "parent_id": "57e6dfab",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 416,
      "page_number": 122,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税",
          "税率",
          "企业所得税"
        ],
        "time_periods": [
          "2019"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          122
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.238850",
        "report_type": null,
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "公司重新申请了高新技术企业",
        "industry": null,
        "char_count": 416,
        "word_count": 33,
        "sentence_count": 5,
        "chinese_char_count": 231,
        "readability_score": 0.0,
        "information_density": 0.07211538461538461,
        "coherence_score": 0.429803958718766,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5821156435057828,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税",
        "税率",
        "企业所得税"
      ]
    },
    {
      "chunk_id": "6f39363b",
      "content": "项目 | 期末余额 | 期初余额\n--------------------------------------------------\n库存现金 | 131,545.99 | 195,522.60\n银行存款 | 1,525,298,726.49 | 1,852,939,694.25\n其他货币资金 | 31,145,099.97 | 102,953,907.48\n合计 | 1,556,575,372.45 | 1,956,089,124.33\n其中：存放在境外的款项总额 | 649,218.69 | 2,180,766.37\n因抵押、质押或冻结等对使用 |  | \n | 30,797,464.00 | 136,880,848.73\n有限制的款项总额 |  | \n |  | ",
      "chunk_type": "table_group",
      "parent_id": "d86aeed2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 840,
      "page_number": 123,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          123
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.239179",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 340,
        "word_count": 43,
        "sentence_count": 12,
        "chinese_char_count": 58,
        "readability_score": 0.0,
        "information_density": 0.029411764705882353,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4871764705882353,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金"
      ]
    },
    {
      "chunk_id": "2e317a4e",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n其中： | | \n指定以公允价值计量且其变动计入当期 | | \n | | 150,000,000.00\n损益的金融资产 | | \n | | \n其中： | | \n银行理财产品 | | 150,000,000.00\n合计 | | 150,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "e605b08c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 202,
      "page_number": 123,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          123
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239266",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 202,
        "word_count": 32,
        "sentence_count": 3,
        "chinese_char_count": 50,
        "readability_score": 0.0,
        "information_density": 0.19801980198019803,
        "coherence_score": 0.34615384615384615,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5079234811165846,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "5cee8e4b",
      "content": "【表格内容】\n| 期末余额 | | | | | 期初余额 | | | | \n--------------------------------------------------\n | 账面余额 | | 坏账准备 | | | 账面余额 | | 坏账准备 | | \n类别 | | | | | | | | | | \n | | | | 计提比 | 账面价值 | | | | | 账面价值\n | 金额 | 比例 | 金额 | | | 金额 | 比例 | 金额 | 计提比例 | \n | | | | 例 | | | | | | \n | | | | | | | | | | \n其中： | | | | | | | | | | \n其中： | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "9eda933c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 329,
      "page_number": 124,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239359",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 329,
        "word_count": 112,
        "sentence_count": 0,
        "chinese_char_count": 62,
        "readability_score": 0.0,
        "information_density": 0.060790273556231,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5001650385604113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "a07c7192",
      "content": "【表格内容】\n| 期末余额 | | | \n--------------------------------------------------\n名称 | | | | \n | 账面余额 | 坏账准备 | 计提比例 | 计提理由\n | | | |\n\n【注释】□ 适用 √ 不适用\n（3）期末公司已质押的应收票据\n单位： 元\n项目 期末已质押金额\n（4）期末公司已背书或贴现且在资产负债表日尚未到期的应收票据\n单位： 元\n项目 期末终止确认金额 期末未终止确认金额\n（5）期末公司因出票人未履约而将其转应收账款的票据\n单位： 元\n项目 期末转应收账款金额\n其他说明\n（6）本期实际核销的应收票据情况\n单位： 元\n项目 核销金额\n其中重要的应收票据核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收票据性质 核销金额 核销原因 履行的核销程序\n易产生\n应收票据核销说明：\n5、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按信用风险特征组\n合计提坏账准备\n125",
      "chunk_type": "table_group",
      "parent_id": "92c0c488",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 506,
      "page_number": 124,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "应收",
          "资产负债表",
          "披露",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239518",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 506,
        "word_count": 87,
        "sentence_count": 0,
        "chinese_char_count": 314,
        "readability_score": 0.0,
        "information_density": 0.1383399209486166,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4857289991728701,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "应收",
        "资产负债表",
        "披露",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "6f871627",
      "content": "【表格内容】\n| 期末余额 | | \n--------------------------------------------------\n名称 | | | \n | 账面余额 | 坏账准备 | 计提比例\n | | |",
      "chunk_type": "table_group",
      "parent_id": "76a51acb",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 124,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239591",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37160000000000004,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "471e6c9b",
      "content": "【表格内容】\n| | 本期变动金额 | | | \n--------------------------------------------------\n类别 | 期初余额 | | | | 期末余额\n | | 计提 | 收回或转回 | 核销 | \n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "f840dc22",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 133,
      "page_number": 124,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          124
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239650",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 133,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.379778417266187,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "4b593500",
      "content": "【表格内容】\n| | | | | 款项是否由关联交\n--------------------------------------------------\n单位名称 | 应收票据性质 | 核销金额 | 核销原因 | 履行的核销程序 | \n | | | | | 易产生\n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "ee5ba752",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 143,
      "page_number": 125,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          125
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.239715",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 143,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.06993006993006994,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.391,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "04a6eb64",
      "content": "【说明】按组合计提坏账准 500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n100.00% 8.19% 100.00% 7.61%\n备的应收账款 838.93 74.74 64.19 65.36 3.30 2.06\n其中：\n500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n合计 100.00% 8.19% 100.00% 7.61%\n838.93 74.74 64.19 65.36 3.30 2.06\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n账龄组合 500,776,838.93 40,995,274.74 8.19%\n合计 500,776,838.93 40,995,274.74 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 481,295,912.96\n1至2年 2,351,572.07\n2至3年 4,521,732.29\n3年以上 12,607,621.61\n3至4年 8,370,022.99\n5年以上 4,237,598.62\n合计 500,776,838.93\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n126。\n\n【表格内容】\n| 期末余额 | | | | | 期初余额 | | | | \n--------------------------------------------------\n | 账面余额 | | 坏账准备 | | | 账面余额 | | 坏账准备 | | \n类别 | | | | | | | | | | \n | | | | 计提比 | 账面价值 | | | | | 账面价值\n | 金额 | 比例 | 金额 | | | 金额 | 比例 | 金额 | 计提比例 | \n | | | | 例 | | | | | | \n | | | | | | | | | | \n其中： | | | | | | | | | | \n按信用风险特征组 | | | | | | | | | | \n | | | | | | | | | | \n合计提坏账准备 | | | | | | | | | | \n | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "d5d0b5ef",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1155,
      "page_number": 125,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "披露",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          125
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240021",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1155,
        "word_count": 239,
        "sentence_count": 33,
        "chinese_char_count": 327,
        "readability_score": 0.0,
        "information_density": 0.03463203463203463,
        "coherence_score": 0.4974458874458874,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5864292005369922,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "披露",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "3decfc2e",
      "content": "【表格内容】\n按组合计提坏账准 | 500,776, | | 40,995,2 | 8.19% | 459,781,5 | 519,058,0 | | 39,520,28 | | 479,537,78\n--------------------------------------------------\n | | 100.00% | | | | | 100.00% | | 7.61% | \n备的应收账款 | 838.93 | | 74.74 | | 64.19 | 65.36 | | 3.30 | | 2.06\n | | | | | | | | | | \n其中： | | | | | | | | | | \n | 500,776, | | 40,995,2 | 8.19% | 459,781,5\n64.19 | 519,058,0 | | 39,520,28 | | 479,537,78\n合计 | | 100.00% | | | | | 100.00% | | 7.61% | \n | 838.93 | | 74.74 | | | 65.36 | | 3.30 | | 2.06\n | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "4e458774",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 513,
      "page_number": 126,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240199",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 513,
        "word_count": 128,
        "sentence_count": 20,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.019493177387914232,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5048128342245989,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "c7be2afe",
      "content": "【表格内容】\n| 期末余额 | | | \n--------------------------------------------------\n名称 | | | | \n | 账面余额 | 坏账准备 | 计提比例 | 计提理由\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "7fd72e76",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 121,
      "page_number": 126,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240266",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 121,
        "word_count": 24,
        "sentence_count": 0,
        "chinese_char_count": 26,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3764129032258064,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "f65cd186",
      "content": "【表格内容】\n| 期末余额 | | \n--------------------------------------------------\n名称 | | | \n | 账面余额 | 坏账准备 | 计提比例\n | | | \n账龄组合 | 500,776,838.93 | 40,995,274.74 | 8.19%\n合计 | 500,776,838.93 | 40,995,274.74 | --",
      "chunk_type": "table_group",
      "parent_id": "c70de7f9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 196,
      "page_number": 126,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240526",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 196,
        "word_count": 33,
        "sentence_count": 5,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.05102040816326531,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3824615384615385,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "77491d95",
      "content": "【表格内容】\n| 期末余额 | | \n--------------------------------------------------\n名称 | | | \n | 账面余额 | 坏账准备 | 计提比例\n | | |",
      "chunk_type": "table_group",
      "parent_id": "92604267",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 126,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240605",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37160000000000004,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "f3fa2d23",
      "content": "【说明】单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n39,520,283.30 1,474,991.44 40,995,274.74\n备\n合计 39,520,283.30 1,474,991.44 40,995,274.74\n其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数的\n单位名称 应收账款期末余额 坏账准备期末余额\n比例\n重庆天地药业有限责任\n85,994,787.83 17.17% 4,299,739.39\n公司\nACS DOBFAR S.P.A 30,318,565.17 6.05% 1,515,928.26\nFIS-FABBRICA\nITALIANA SINTETICI 23,576,101.39 4.71% 1,178,805.07\nS.P.A\nPFIZER ASIA\nMANUFACTURING 19,767,647.40 3.95% 988,382.37\nPTE LTD\n绍兴舜德进出口有限公\n18,868,983.58 3.77% 943,449.18\n司\n合计 178,526,085.37 35.65%\n127。\n\n【表格内容】\n账龄 | 账面余额\n--------------------------------------------------\n1年以内（含1年） | 481,295,912.96\n1至2年 | 2,351,572.07\n2至3年 | 4,521,732.29\n3年以上 | 12,607,621.61\n3至4年 | 8,370,022.99\n5年以上 | 4,237,598.62\n合计 | 500,776,838.93",
      "chunk_type": "table_group",
      "parent_id": "6df6959c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 882,
      "page_number": 126,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.240902",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 882,
        "word_count": 109,
        "sentence_count": 35,
        "chinese_char_count": 272,
        "readability_score": 0.0,
        "information_density": 0.011337868480725623,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5274025687815834,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "3294b9a8",
      "content": "【表格内容】\n| | 本期变动金额 | | | \n--------------------------------------------------\n类别 | 期初余额 | | | | 期末余额\n | | 计提 | 收回或转回 | 核销 | \n | | | | | \n按组合计提坏账准 | | | | | \n | 39,520,283.30 | 1,474,991.44 | | | 40,995,274.74\n备 | | | | | \n | | | | | \n合计 | 39,520,283.30 | 1,474,991.44 | | | 40,995,274.74",
      "chunk_type": "table_group",
      "parent_id": "40e41f6f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 285,
      "page_number": 127,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          127
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241123",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 285,
        "word_count": 63,
        "sentence_count": 6,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4038470588235294,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "f3ed3dbc",
      "content": "【表格内容】\n| | | | | 款项是否由关联交\n--------------------------------------------------\n单位名称 | 应收账款性质 | 核销金额 | 核销原因 | 履行的核销程序 | \n | | | | | 易产生\n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "d2292020",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 143,
      "page_number": 127,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          127
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241188",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 143,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.06993006993006994,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.391,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "10c035aa",
      "content": "【说明】（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n6、应收款项融资\n单位： 元\n项目 期末余额 期初余额\n应收票据 74,531,666.41 107,399,476.04\n合计 74,531,666.41 107,399,476.04\n应收款项融资本期增减变动及公允价值变动情况\n□ 适用 √ 不适用\n如是按照预期信用损失一般模型计提应收款项融资减值准备，请参照其他应收款的披露方式披露减值准备的相关信息：\n□ 适用 √ 不适用\n其他说明：\n7、预付款项\n（1）预付款项按账龄列示\n单位： 元\n期末余额 期初余额\n账龄\n金额 比例 金额 比例\n1年以内 29,093,214.59 85.94% 37,487,264.60 80.71%\n1至2年 2,278,425.47 6.73% 6,488,949.11 13.97%\n2至3年 683,976.07 2.02% 1,208,687.98 2.60%\n3年以上 1,795,870.66 5.31% 1,264,656.81 2.72%\n合计 33,851,486.79 -- 46,449,558.50 --\n账龄超过1年且金额重要的预付款项未及时结算原因的说明：\n（2）按预付对象归集的期末余额前五名的预付款情况\n期末余额前5名的预付款项合计数为9,950,421.65元，占预付款项期末余额合计数的比例为29.39%。其他说明：\n8、其他应收款\n单位： 元\n128。\n\n【表格内容】\n| | 占应收账款期末余额合计数的 | \n--------------------------------------------------\n单位名称 | 应收账款期末余额 | | 坏账准备期末余额\n | | 比例 | \n | | | \n重庆天地药业有限责任 | | | \n | 85,994,787.83 | 17.17% | 4,299,739.39\n公司 | | | \n | | | \nACS DOBFAR S.P.A | 30,318,565.17 | 6.05% | 1,515,928.26\nFIS-FABBRICA | | | \nITALIANA SINTETICI | 23,576,101.39 | 4.71% | 1,178,805.07\nS.P.A | | | \nPFIZER ASIA | | | \nMANUFACTURING | 19,767,647.40 | 3.95% | 988,382.37\nPTE LTD | | | \n绍兴舜德进出口有限公 | | | \n | 18,868,983.58 | 3.77% | 943,449.18\n司 | | | \n | | | \n合计 | 178,526,085.37 | 35.65% |",
      "chunk_type": "table_group",
      "parent_id": "06e6f574",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1187,
      "page_number": 127,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "应收",
          "预付",
          "披露",
          "减值",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          127
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241527",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1187,
        "word_count": 170,
        "sentence_count": 47,
        "chinese_char_count": 353,
        "readability_score": 0.0,
        "information_density": 0.07582139848357203,
        "coherence_score": 0.47849199663016007,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5403344131251108,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "应收",
        "预付",
        "披露",
        "减值",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "667e8c6b",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应收票据 | 74,531,666.41 | 107,399,476.04\n合计 | 74,531,666.41 | 107,399,476.04\n\n【注释】项目 期末余额 期初余额\n其他应收款 18,297,536.18 10,817,853.96\n合计 18,297,536.18 10,817,853.96\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n单位： 元\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n129",
      "chunk_type": "table_group",
      "parent_id": "62c3fafa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 483,
      "page_number": 128,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "应收",
          "减值",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          128
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.241752",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 483,
        "word_count": 71,
        "sentence_count": 8,
        "chinese_char_count": 210,
        "readability_score": 0.0,
        "information_density": 0.08281573498964803,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4386454125730818,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收",
        "减值",
        "借款"
      ]
    },
    {
      "chunk_id": "dbb80de0",
      "content": "【表格内容】\n| 期末余额 | | 期初余额 | \n--------------------------------------------------\n账龄 | | | | \n | 金额 | 比例 | 金额 | 比例\n | | | | \n1年以内 | 29,093,214.59 | 85.94% | 37,487,264.60 | 80.71%\n1至2年 | 2,278,425.47 | 6.73% | 6,488,949.11 | 13.97%\n2至3年 | 683,976.07 | 2.02% | 1,208,687.98 | 2.60%\n3年以上 | 1,795,870.66 | 5.31% | 1,264,656.81 | 2.72%\n合计 | 33,851,486.79 | -- | 46,449,558.50 | --",
      "chunk_type": "table_group",
      "parent_id": "80a2bcba",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 371,
      "page_number": 128,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          128
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242047",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 371,
        "word_count": 70,
        "sentence_count": 18,
        "chinese_char_count": 34,
        "readability_score": 0.0,
        "information_density": 0.026954177897574122,
        "coherence_score": 0.3285789473684211,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4114967741935484,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "8ac56729",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n其他应收款 | 18,297,536.18 | 10,817,853.96\n合计 | 18,297,536.18 | 10,817,853.96",
      "chunk_type": "table_group",
      "parent_id": "11b7be59",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 147,
      "page_number": 129,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          129
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242124",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 147,
        "word_count": 17,
        "sentence_count": 4,
        "chinese_char_count": 21,
        "readability_score": 0.0,
        "information_density": 0.06802721088435373,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3712142857142858,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "170d3530",
      "content": "【表格内容】\n| | | | 是否发生减值及其判断\n--------------------------------------------------\n借款单位 | 期末余额 | 逾期时间 | 逾期原因 | \n | | | | 依据\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "6ed50665",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 126,
      "page_number": 129,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          129
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242177",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 126,
        "word_count": 24,
        "sentence_count": 0,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.15873015873015872,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3833076923076923,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值",
        "借款"
      ]
    },
    {
      "chunk_id": "796d8dad",
      "content": "【说明】（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n应收暂付款 19,403,087.81 21,023,388.15\n押金保证金 8,079,470.25 4,971,398.75\n应收出口退税 6,994,977.96\n拆借款 1,250,962.00 1,797,563.33\n其 他 697,469.95 126,777.96\n合计 36,425,967.97 27,919,128.19\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 17,101,274.23 17,101,274.23\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 1,027,157.56 1,027,157.56\n2019年12月31日余额 18,128,431.79 18,128,431.79\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 12,618,376.33\n1至2年 8,167,903.05\n2至3年 1,213,988.18\n3年以上 14,425,700.41\n3至4年 2,214,569.77\n4至5年 510,000.00\n5年以上 11,701,130.64\n合计 36,425,967.97\n130。\n\n【表格内容】\n| | | | 是否发生减值及其判断\n--------------------------------------------------\n项目(或被投资单位) | 期末余额 | 账龄 | 未收回的原因 | \n | | | | 依据\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "3f2dddf6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 807,
      "page_number": 129,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "应收",
          "披露",
          "减值",
          "借款"
        ],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          129
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242465",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 807,
        "word_count": 105,
        "sentence_count": 26,
        "chinese_char_count": 257,
        "readability_score": 0.0,
        "information_density": 0.06195786864931846,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45310017825311943,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收",
        "披露",
        "减值",
        "借款"
      ]
    },
    {
      "chunk_id": "4fa471fc",
      "content": "【表格内容】\n款项性质 | 期末账面余额 | 期初账面余额\n--------------------------------------------------\n应收暂付款 | 19,403,087.81 | 21,023,388.15\n押金保证金 | 8,079,470.25 | 4,971,398.75\n应收出口退税 | 6,994,977.96 | \n拆借款 | 1,250,962.00 | 1,797,563.33\n其 他 | 697,469.95 | 126,777.96\n合计 | 36,425,967.97 | 27,919,128.19",
      "chunk_type": "table_group",
      "parent_id": "3c144538",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 278,
      "page_number": 130,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          130
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242597",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 278,
        "word_count": 37,
        "sentence_count": 11,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.07194244604316548,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4007867158671587,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "借款"
      ]
    },
    {
      "chunk_id": "fccaf255",
      "content": "【表格内容】\n| 第一阶段 | 第二阶段 | 第三阶段 | \n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n | 用损失 | (未发生信用减值) | (已发生信用减值) | \n2019年1月1日余额 | 17,101,274.23 | | | 17,101,274.23\n2019年1月1日余额在 | | | | \n | | | | \n本期 | | | | \n | | | | \n本期计提 | 1,027,157.56 | | | 1,027,157.56\n2019年12月31日余额 | 18,128,431.79 | | | 18,128,431.79",
      "chunk_type": "table_group",
      "parent_id": "818facd7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 356,
      "page_number": 130,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值"
        ],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          130
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.242715",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 356,
        "word_count": 64,
        "sentence_count": 6,
        "chinese_char_count": 90,
        "readability_score": 0.0,
        "information_density": 0.02808988764044944,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5095085106382979,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值"
      ]
    },
    {
      "chunk_id": "8178e0c1",
      "content": "【说明】3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n台州市椒江朝晖建\n押金保证金 2,950,000.001年以内 8.10% 147,500.00\n设投资有限公司\n台州市椒江朝晖建\n押金保证金 3,850,000.001-2年 10.57% 1,155,000.00\n设投资有限公司\n应收出口退税 应收出口退税 6,584,960.261年以内 18.08%\nPFIZER ASIA\nMANUFACTURIN 应收暂付款 5,000,000.003年以上 13.73% 5,000,000.00\nG PTE LTD\n浙江福仁瑞生物科\n应收暂付款 3,222,047.103年以上 8.85% 3,222,047.10\n技有限公司\n台州市中荣化工有\n应收暂付款 2,160,572.193年以上 5.93% 2,160,572.19\n限公司\n合计 -- 23,767,579.55 -- 65.26% 11,685,119.29\n131。\n\n【表格内容】\n账龄 | 账面余额\n--------------------------------------------------\n1年以内（含1年） | 12,618,376.33\n1至2年 | 8,167,903.05\n2至3年 | 1,213,988.18\n3年以上 | 14,425,700.41\n3至4年 | 2,214,569.77\n4至5年 | 510,000.00\n5年以上 | 11,701,130.64\n合计 | 36,425,967.97",
      "chunk_type": "table_group",
      "parent_id": "6f306362",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 930,
      "page_number": 130,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          130
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243009",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "设投资有限公司",
        "industry": null,
        "char_count": 930,
        "word_count": 117,
        "sentence_count": 29,
        "chinese_char_count": 382,
        "readability_score": 0.0,
        "information_density": 0.02150537634408602,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5388379888268156,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收"
      ]
    },
    {
      "chunk_id": "ed522f98",
      "content": "【表格内容】\n| | 本期变动金额 | | | \n--------------------------------------------------\n类别 | 期初余额 | | | | 期末余额\n | | 计提 | 收回或转回 | 核销 | \n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "4941a7e6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 133,
      "page_number": 131,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          131
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243112",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 133,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.379778417266187,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "c56297c7",
      "content": "【表格内容】\n| | | | | 款项是否由关联交\n--------------------------------------------------\n单位名称 | 其他应收款性质 | 核销金额 | 核销原因 | 履行的核销程序 | \n | | | | | 易产生\n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "bf066a71",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 144,
      "page_number": 131,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          131
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243196",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 144,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.06944444444444445,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3919549668874172,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "55798439",
      "content": " |  |  |  | 占其他应收款期末 | \n--------------------------------------------------\n单位名称 | 款项的性质 | 期末余额 | 账龄 |  | 坏账准备期末余额\n |  |  |  | 余额合计数的比例 | \n |  |  |  |  | \n台州市椒江朝晖建 |  |  |  |  | \n | 押金保证金 | 2,950,000.00 | 1年以内 | 8.10% | 147,500.00\n设投资有限公司 |  |  |  |  | \n |  |  |  |  | \n台州市椒江朝晖建 |  |  |  |  | \n | 押金保证金 | 3,850,000.00 | 1-2年 | 10.57% | 1,155,000.00\n设投资有限公司 |  |  |  |  | \n |  |  |  |  | \n应收出口退税 | 应收出口退税 | 6,584,960.26 | 1年以内 | 18.08% | \nPFIZER ASIA |  |  |  |  | \nMANUFACTURIN | 应收暂付款 | 5,000,000.00 | 3年以上 | 13.73% | 5,000,000.00\nG PTE LTD |  |  |  |  | \n浙江福仁瑞生物科 |  |  |  |  | \n | 应收暂付款 | 3,222,047.10 | 3年以上 | 8.85% | 3,222,047.10\n技有限公司 |  |  |  |  | \n |  |  |  |  | \n台州市中荣化工有 |  |  |  |  | \n | 应收暂付款 | 2,160,572.19 | 3年以上 | 5.93% | 2,160,572.19\n限公司 |  |  |  |  | \n |  |  |  |  | \n合计 | -- | 23,767,579.55 | -- | 65.26% | 11,685,119.29",
      "chunk_type": "table_group",
      "parent_id": "4fd37fe5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1337,
      "page_number": 131,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 26,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          131
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.243633",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "设投资有限公司",
        "industry": null,
        "char_count": 837,
        "word_count": 183,
        "sentence_count": 20,
        "chinese_char_count": 148,
        "readability_score": 0.0,
        "information_density": 0.023894862604540025,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40304659498207884,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收"
      ]
    },
    {
      "chunk_id": "dfe87941",
      "content": "【表格内容】\n| | | | 预计收取的时间 金额\n--------------------------------------------------\n单位名称 | 政府补助项目名称 | 期末余额 | 期末账龄 | \n | | | | 及依据\n | | | |\n\n【注释】（3）存货期末余额含有借款费用资本化金额的说明\n（4）期末建造合同形成的已完工未结算资产情况\n单位： 元\n项目 金额\n其他说明：\n10、合同资产\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n合同资产的账面价值在本期内发生的重大变动金额和原因：\n单位： 元\n项目 变动金额 变动原因\n如是按照预期信用损失一般模型计提合同资产坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n本期合同资产计提减值准备情况\n单位： 元\n项目 本期计提 本期转回 本期转销/核销 原因\n其他说明：\n11、持有待售资产\n单位： 元\n项目 期末账面余额 减值准备 期末账面价值 公允价值 预计处置费用 预计处置时间\n其他说明：\n12、一年内到期的非流动资产\n单位： 元\n项目 期末余额 期初余额\n重要的债权投资/其他债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n其他说明：\n133",
      "chunk_type": "table_group",
      "parent_id": "bcbe60b0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 594,
      "page_number": 132,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "费用",
          "投资",
          "应收",
          "存货",
          "披露",
          "减值",
          "公允价值",
          "账面价值",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.243843",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 594,
        "word_count": 97,
        "sentence_count": 0,
        "chinese_char_count": 388,
        "readability_score": 0.0,
        "information_density": 0.16835016835016833,
        "coherence_score": 0.7067003367003368,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5653979949179949,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "费用",
        "投资",
        "应收",
        "存货",
        "披露",
        "减值",
        "公允价值",
        "账面价值",
        "借款"
      ]
    },
    {
      "chunk_id": "8d6452d8",
      "content": "【表格内容】\n| 期末余额 | | | 期初余额 | | \n--------------------------------------------------\n项目 | | | | | | \n | 账面余额 | 跌价准备 | 账面价值 | 账面余额 | 跌价准备 | 账面价值\n | | | | | | \n原材料 | 209,787,752.67 | 2,975,404.23 | 206,812,348.44 | 243,008,744.60 | 2,867,227.10 | 240,141,517.50\n在产品 | 164,776,116.17 | 4,244,871.82 | 160,531,244.35 | 214,182,041.63 | 3,023,716.71 | 211,158,324.92\n库存商品 | 493,928,178.91 | 22,117,971.87 | 471,810,207.04 | 477,155,579.50 | 23,329,566.31 | 453,826,013.19\n委托加工物资 | 3,831,460.77 | | 3,831,460.77 | 292,362.88 | | 292,362.88\n合计 | 872,323,508.52 | 29,338,247.92 | 842,985,260.60 | 934,638,728.61 | 29,220,510.12 | 905,418,218.49",
      "chunk_type": "table_group",
      "parent_id": "f2c97ddb",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 632,
      "page_number": 132,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244049",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 632,
        "word_count": 98,
        "sentence_count": 28,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.03164556962025316,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4371684867394696,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "5a55afa7",
      "content": "【表格内容】\n| | 本期增加金额 | | 本期减少金额 | | \n--------------------------------------------------\n项目 | 期初余额 | | | | | 期末余额\n | | 计提 | 其他 | 转回或转销 | 其他 | \n | | | | | | \n原材料 | 2,867,227.10 | 2,011,138.75 | | 1,902,961.62 | | 2,975,404.23\n在产品 | 3,023,716.71 | 2,237,971.32 | | 1,016,816.21 | | 4,244,871.82\n库存商品 | 23,329,566.31 | 5,540,847.35 | | 6,752,441.79 | | 22,117,971.87\n合计 | 29,220,510.12 | 9,789,957.42 | | 9,672,219.62 | | 29,338,247.92",
      "chunk_type": "table_group",
      "parent_id": "9efc9393",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 428,
      "page_number": 132,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244425",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 428,
        "word_count": 79,
        "sentence_count": 16,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42883702031602705,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "fdaab395",
      "content": "【表格内容】\n| 期末余额 | | | 期初余额 | | \n--------------------------------------------------\n项目 | | | | | | \n | 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n | | | | | |\n\n【注释】13、其他流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n待抵扣增值税进项税额 67,707,757.62 76,026,728.13\n员工购房借款 118,571.44\n预缴企业所得税 8,699,173.52 1,737,693.66\n银行理财产品\n合计 76,406,931.14 77,882,993.23\n其他说明：\n14、债权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n重要的债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n15、其他债权投资\n单位： 元\n134。",
      "chunk_type": "table_group",
      "parent_id": "ad9182dd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 644,
      "page_number": 133,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入",
          "投资",
          "所得税",
          "增值税",
          "企业所得税",
          "减值",
          "账面价值",
          "借款",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          133
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244624",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 644,
        "word_count": 115,
        "sentence_count": 8,
        "chinese_char_count": 317,
        "readability_score": 0.0,
        "information_density": 0.15527950310559005,
        "coherence_score": 0.67,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4953651960784313,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "投资",
        "所得税",
        "增值税",
        "企业所得税",
        "减值",
        "账面价值",
        "借款",
        "价值"
      ]
    },
    {
      "chunk_id": "8a9232d4",
      "content": "【表格内容】\n| 期末余额 | | | | 期初余额 | | | \n--------------------------------------------------\n债权项目 | | | | | | | | \n | 面值 | 票面利率 | 实际利率 | 到期日 | 面值 | 票面利率 | 实际利率 | 到期日\n | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "961a27dc",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 174,
      "page_number": 133,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          133
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244720",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 174,
        "word_count": 45,
        "sentence_count": 0,
        "chinese_char_count": 42,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39291914893617014,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "50169758",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n待抵扣增值税进项税额 | 67,707,757.62 | 76,026,728.13\n员工购房借款 | | 118,571.44\n预缴企业所得税 | 8,699,173.52 | 1,737,693.66\n银行理财产品 | | \n合计 | 76,406,931.14 | 77,882,993.23",
      "chunk_type": "table_group",
      "parent_id": "916258d4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 224,
      "page_number": 134,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税",
          "增值税",
          "企业所得税",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244804",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 224,
        "word_count": 29,
        "sentence_count": 7,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.17857142857142855,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3968821917808219,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税",
        "增值税",
        "企业所得税",
        "借款"
      ]
    },
    {
      "chunk_id": "abafbf69",
      "content": "【表格内容】\n| 期末余额 | | | 期初余额 | | \n--------------------------------------------------\n项目 | | | | | | \n | 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "52bc0594",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 152,
      "page_number": 134,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244860",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 152,
        "word_count": 35,
        "sentence_count": 0,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.19736842105263158,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38887499999999997,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "c9331500",
      "content": "【表格内容】\n| 期末余额 | | | | 期初余额 | | | \n--------------------------------------------------\n债权项目 | | | | | | | | \n | 面值 | 票面利率 | 实际利率 | 到期日 | 面值 | 票面利率 | 实际利率 | 到期日\n | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "9ba4ae64",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 174,
      "page_number": 134,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.244944",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 174,
        "word_count": 45,
        "sentence_count": 0,
        "chinese_char_count": 42,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39291914893617014,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "cc74da56",
      "content": "【说明】累计在其他\n本期公允价 累计公允价 综合收益中\n项目 期初余额 应计利息 期末余额 成本 备注\n值变动 值变动 确认的损失\n准备\n重要的其他债权投资\n单位： 元\n期末余额 期初余额\n其他债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n16、长期应收款\n（1）长期应收款情况\n单位： 元\n期末余额 期初余额\n项目 折现率区间\n账面余额 坏账准备 账面价值 账面余额 坏账准备 账面价值\n坏账准备减值情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n135。\n\n【表格内容】\n| 第一阶段 | 第二阶段 | 第三阶段 | \n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n | 用损失 | (未发生信用减值) | (已发生信用减值) | \n2019年1月1日余额在 | | | | \n | | | | \n本期 | | | | \n | | | |",
      "chunk_type": "table_group",
      "parent_id": "6a87a989",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 755,
      "page_number": 134,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "投资",
          "应收",
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [
          "2019-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          134
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245172",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 755,
        "word_count": 137,
        "sentence_count": 1,
        "chinese_char_count": 457,
        "readability_score": 0.0,
        "information_density": 0.07947019867549669,
        "coherence_score": 0.8666666666666667,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5943122916908324,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "投资",
        "应收",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "2044b463",
      "content": "【表格内容】\n| | | | | | | 累计在其他 | \n--------------------------------------------------\n | | | 本期公允价 | | | 累计公允价 | 综合收益中 | \n项目 | 期初余额 | 应计利息 | | 期末余额 | 成本 | | | 备注\n | | | 值变动 | | | 值变动 | 确认的损失 | \n | | | | | | | | \n | | | | | | | 准备 |",
      "chunk_type": "table_group",
      "parent_id": "a7809248",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 226,
      "page_number": 135,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245279",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 226,
        "word_count": 64,
        "sentence_count": 0,
        "chinese_char_count": 55,
        "readability_score": 0.0,
        "information_density": 0.04424778761061947,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4390114209827357,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本"
      ]
    },
    {
      "chunk_id": "cf87435a",
      "content": "【表格内容】\n| 期末余额 | | | | 期初余额 | | | \n--------------------------------------------------\n其他债权项目 | | | | | | | | \n | 面值 | 票面利率 | 实际利率 | 到期日 | 面值 | 票面利率 | 实际利率 | 到期日\n | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "774ce348",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 176,
      "page_number": 135,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245350",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 176,
        "word_count": 45,
        "sentence_count": 0,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.394578947368421,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "ddbe9e32",
      "content": "【表格内容】\n| 第一阶段 | 第二阶段 | 第三阶段 | \n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n | 用损失 | (未发生信用减值) | (已发生信用减值) | \n2019年1月1日余额在 | | | | \n | | | | \n本期 | | | | \n | | | |",
      "chunk_type": "table_group",
      "parent_id": "30113caf",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 218,
      "page_number": 135,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值"
        ],
        "time_periods": [
          "2019-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245424",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 218,
        "word_count": 43,
        "sentence_count": 0,
        "chinese_char_count": 76,
        "readability_score": 0.0,
        "information_density": 0.04587155963302752,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4929519313304721,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值"
      ]
    },
    {
      "chunk_id": "54060f52",
      "content": "【表格内容】\n| 期末余额 | | | 期初余额 | | | \n--------------------------------------------------\n项目 | | | | | | | 折现率区间\n | 账面余额 | 坏账准备 | 账面价值 | 账面余额 | 坏账准备 | 账面价值 | \n | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "56967ec5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 166,
      "page_number": 135,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245490",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 166,
        "word_count": 40,
        "sentence_count": 0,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.12048192771084339,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3934508474576271,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "695140ea",
      "content": "【说明】（2）因金融资产转移而终止确认的长期应收款\n（3）转移长期应收款且继续涉入形成的资产、负债金额\n其他说明\n17、长期股权投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n被投资单 权益法下 宣告发放 减值准备\n(账面价 其他综合 其他权益 计提减值 (账面价\n位 追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n22,946,28 -4,811,81 18,134,47\n制药厂有\n7.25 4.84 2.41\n限公司\n江苏北华\n17,617,12 -4,471,33 13,145,79\n环保科技\n7.70 1.54 6.16\n有限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n滨海临海\n11,676,63 -6,521,79 1,449,207 3,705,631 7,730,979\n资产管理\n2.15 2.73 .56 .86 .27\n有限公司\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n小计\n9.79 49.80 .56 2.43 .27\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n合计\n9.79 49.80 .56 2.43 .27\n其他说明\n18、其他权益工具投资\n单位： 元\n项目 期末余额 期初余额\n杭州寓鑫创业投资合伙企业（有限合伙） 20,000,000.00\n滨海宏博环境技术服务股份有限公司 1,800,000.00\n合计 20,000,000.00 1,800,000.00\n136。\n\n【表格内容】\n| 第一阶段 | 第二阶段 | 第三阶段 | \n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n | 用损失 | (未发生信用减值) | (已发生信用减值) | \n2019年1月1日余额在 | | | | \n | | | | \n本期 | | | | \n | | | |",
      "chunk_type": "table_group",
      "parent_id": "ca5cf851",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 974,
      "page_number": 135,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "利润",
          "现金",
          "投资",
          "应收",
          "股权",
          "股份",
          "减值"
        ],
        "time_periods": [
          "2019-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          135
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.245790",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 974,
        "word_count": 154,
        "sentence_count": 29,
        "chinese_char_count": 336,
        "readability_score": 0.0,
        "information_density": 0.1026694045174538,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5994247995475264,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金",
        "投资",
        "应收",
        "股权",
        "股份",
        "减值"
      ]
    },
    {
      "chunk_id": "e6a9a1a9",
      "content": " |  | 本期增减变动 |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n | 期初余额 |  |  |  |  |  |  |  |  | 期末余额 | \n被投资单 |  |  |  | 权益法下 |  |  | 宣告发放 |  |  |  | 减值准备\n | (账面价 |  |  |  | 其他综合 | 其他权益 |  | 计提减值 |  | (账面价 | \n位 |  | 追加投资 | 减少投资 | 确认的投 |  |  | 现金股利 |  | 其他 |  | 期末余额\n | 值) |  |  |  | 收益调整 | 变动 |  | 准备 |  | 值) | \n |  |  |  | 资损益 |  |  | 或利润 |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n一、合营企业 |  |  |  |  |  |  |  |  |  |  | \n二、联营企业 |  |  |  |  |  |  |  |  |  |  | \n苏州第四 |  |  |  |  |  |  |  |  |  |  | \n | 22,946,28 |  |  | -4,811,81 |  |  |  |  |  | 18,134,47 | \n制药厂有 |  |  |  |  |  |  |  |  |  |  | \n | 7.25 |  |  | 4.84 |  |  |  |  |  | 2.41 | \n限公司 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n江苏北华 |  |  |  |  |  |  |  |  |  |  | \n | 17,617,12 |  |  | -4,471,33 |  |  |  |  |  | 13,145,79 | \n环保科技 |  |  |  |  |  |  |  |  |  |  | \n | 7.70 |  |  | 1.54 |  |  |  |  |  | 6.16 | \n有限公司 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n浙江高盛 |  |  |  |  |  |  |  |  |  |  | \n | 13,848,09 |  |  | -954,610. |  |  |  |  |  | 12,893,48 | \n钢结构有 |  |  |  |  |  |  |  |  |  |  | \n | 2.69 |  |  | 69 |  |  |  |  |  | 2.00 | \n限公司 |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "0bbccb4b",
      "child_ids": [],
      "sibling_ids": [
        "0efedd64"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1720,
      "page_number": 136,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 28,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "现金",
          "投资",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          136
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.246124",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1220,
        "word_count": 353,
        "sentence_count": 9,
        "chinese_char_count": 131,
        "readability_score": 0.0,
        "information_density": 0.04098360655737705,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7227789256198347,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "现金",
        "投资",
        "减值"
      ]
    },
    {
      "chunk_id": "0efedd64",
      "content": " |  |  |  |  |  |  |  |  |  |  | \n滨海临海 |  |  |  |  |  |  |  |  |  |  | \n | 11,676,63 |  |  | -6,521,79 |  |  |  | 1,449,207 |  | 3,705,631 | 7,730,979\n资产管理 |  |  |  |  |  |  |  |  |  |  | \n | 2.15 |  |  | 2.73 |  |  |  | .56 |  | .86 | .27\n有限公司 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | 66,088,13 |  |  | -16,759,5 |  |  |  | 1,449,207 |  | 47,879,38 | 7,730,979\n小计 |  |  |  |  |  |  |  |  |  |  | \n | 9.79 |  |  | 49.80 |  |  |  | .56 |  | 2.43 | .27\n |  |  |  |  |  |  |  |  |  |  | \n | 66,088,13 |  |  | -16,759,5 |  |  |  | 1,449,207 |  | 47,879,38 | 7,730,979\n合计 |  |  |  |  |  |  |  |  |  |  | \n | 9.79 |  |  | 49.80 |  |  |  | .56 |  | 2.43 | .27\n |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "0bbccb4b",
      "child_ids": [],
      "sibling_ids": [
        "e6a9a1a9"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1715,
      "page_number": 136,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 15,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          136
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.246228",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 715,
        "word_count": 200,
        "sentence_count": 15,
        "chinese_char_count": 16,
        "readability_score": 0.0,
        "information_density": 0.013986013986013984,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7227789256198347,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "2174e9de",
      "content": "【说明】分项披露本期非交易性权益工具投资\n单位： 元\n指定为以公允价\n其他综合收益转 其他综合收益转\n值计量且其变动\n项目名称 确认的股利收入 累计利得 累计损失 入留存收益的金 入留存收益的原\n计入其他综合收\n额 因\n益的原因\n其他说明：\n(2) 指定为以公允价值计量且其变动计入其他综合收益的权益工具投资的原因\n公司持有对杭州寓鑫创业投资合伙企业（有限合伙）、滨海宏博环境技术服务股份有限公司的股权投\n资属于非交易性权益工具投资，因此公司将其指定为以公允价值计量且其变动计入其他综合收益的权益工\n具投资。19、其他非流动金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n20、投资性房地产\n（1）采用成本计量模式的投资性房地产\n√ 适用 □ 不适用\n单位： 元\n项目 房屋、建筑物 土地使用权 在建工程 合计\n一、账面原值\n1.期初余额 26,022,834.98 26,022,834.98\n2.本期增加金额\n（1）外购\n（2）存货\\固定资产\n\\在建工程转入\n（3）企业合并增加\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 26,022,834.98 26,022,834.98\n137。\n\n【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n杭州寓鑫创业投资合伙企业（有限合伙） | 20,000,000.00 | \n滨海宏博环境技术服务股份有限公司 | | 1,800,000.00\n合计 | 20,000,000.00 | 1,800,000.00",
      "chunk_type": "table_group",
      "parent_id": "da27651d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 692,
      "page_number": 136,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "收入",
          "成本",
          "投资",
          "存货",
          "固定资产",
          "合并",
          "股权",
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          136
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.246455",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 692,
        "word_count": 78,
        "sentence_count": 14,
        "chinese_char_count": 392,
        "readability_score": 0.0,
        "information_density": 0.14450867052023122,
        "coherence_score": 0.661004918680214,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5985989590110605,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "投资",
        "存货",
        "固定资产",
        "合并",
        "股权",
        "股份"
      ]
    },
    {
      "chunk_id": "1fc8fd8f",
      "content": "【说明】二、累计折旧和累计摊\n销\n1.期初余额 13,684,219.69 13,684,219.69\n2.本期增加金额 1,131,663.83 1,131,663.83\n（1）计提或摊销 1,131,663.83 1,131,663.83\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 14,815,883.52 14,815,883.52\n三、减值准备\n1.期初余额\n2.本期增加金额\n（1）计提\n3、本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额\n四、账面价值\n1.期末账面价值 11,206,951.46 11,206,951.46\n2.期初账面价值 12,338,615.29 12,338,615.29\n（2）采用公允价值计量模式的投资性房地产\n□ 适用 √ 不适用\n（3）未办妥产权证书的投资性房地产情况\n单位： 元\n项目 账面价值 未办妥产权证书原因\n其他说明\n138\n\n【表格内容】\n项目 | 房屋 建筑物 | 土地使用权 | 在建工程 | 合计\n--------------------------------------------------\n一 账面原值 | | | | \n1.期初余额 | 26,022,834.98 | | | 26,022,834.98\n2.本期增加金额 | | | | \n（1）外购 | | | | \n（2）存货\\固定资产 | | | | \n | | | | \n\\在建工程转入 | | | | \n | | | | \n（3）企业合并增加 | | | | \n | | | | \n3.本期减少金额 | | | | \n（1）处置 | | | | \n（2）其他转出 | | | | \n | | | | \n4.期末余额 | 26,022,834.98 | | | 26,022,834.98",
      "chunk_type": "table_group",
      "parent_id": "93b03853",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 776,
      "page_number": 137,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "存货",
          "固定资产",
          "合并",
          "折旧",
          "摊销",
          "减值",
          "公允价值",
          "账面价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          137
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.246727",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 776,
        "word_count": 133,
        "sentence_count": 29,
        "chinese_char_count": 226,
        "readability_score": 0.0,
        "information_density": 0.1288659793814433,
        "coherence_score": 0.2811111111111111,
        "standards_profile_summary": {}
      },
      "quality_score": 0.63633588127769,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "存货",
        "固定资产",
        "合并",
        "折旧",
        "摊销",
        "减值",
        "公允价值",
        "账面价值"
      ]
    },
    {
      "chunk_id": "42f45e7d",
      "content": "二、累计折旧和累计摊 |  |  |  | \n--------------------------------------------------\n |  |  |  | \n销 |  |  |  | \n |  |  |  | \n1.期初余额 | 13,684,219.69 |  |  | 13,684,219.69\n2.本期增加金额 | 1,131,663.83 |  |  | 1,131,663.83\n（1）计提或摊销 | 1,131,663.83 |  |  | 1,131,663.83\n |  |  |  | \n3.本期减少金额 |  |  |  | \n（1）处置 |  |  |  | \n（2）其他转出 |  |  |  | \n |  |  |  | \n4.期末余额 | 14,815,883.52 |  |  | 14,815,883.52\n三、减值准备 |  |  |  | \n1.期初余额 |  |  |  | \n2.本期增加金额 |  |  |  | \n（1）计提 |  |  |  | \n |  |  |  | \n3、本期减少金额 |  |  |  | \n（1）处置 |  |  |  | \n（2）其他转出 |  |  |  | \n |  |  |  | \n4.期末余额 |  |  |  | \n四、账面价值 |  |  |  | \n1.期末账面价值 | 11,206,951.46 |  |  | 11,206,951.46\n2.期初账面价值 | 12,338,615.29 |  |  | 12,338,615.29",
      "chunk_type": "table_group",
      "parent_id": "4ec83b43",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1172,
      "page_number": 138,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "折旧",
          "摊销",
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          138
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.247214",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 672,
        "word_count": 137,
        "sentence_count": 21,
        "chinese_char_count": 91,
        "readability_score": 0.0,
        "information_density": 0.0744047619047619,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.540625,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "折旧",
        "摊销",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "4ded2c59",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n固定资产 | 1,724,407,333.34 | 1,215,120,643.61\n合计 | 1,724,407,333.34 | 1,215,120,643.61",
      "chunk_type": "table_group",
      "parent_id": "564244f7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 158,
      "page_number": 139,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          139
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.247297",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 158,
        "word_count": 17,
        "sentence_count": 4,
        "chinese_char_count": 20,
        "readability_score": 0.0,
        "information_density": 0.12658227848101264,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40442737306843274,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产"
      ]
    },
    {
      "chunk_id": "e0e8bfe4",
      "content": "项目 | 房屋及建筑物 | 通用设备 | 专用设备 | 运输工具 | 合计\n--------------------------------------------------\n一、账面原值： |  |  |  |  | \n1.期初余额 | 942,004,302.57 | 151,282,471.21 | 1,160,756,948.05 | 56,927,137.86 | 2,310,970,859.69\n2.本期增加金额 | 127,058,302.67 | 26,510,821.36 | 531,882,141.44 | 4,549,773.50 | 690,001,038.97\n（1）购置 |  | 363,159.41 | 320,013.97 | 4,549,773.50 | 5,232,946.88\n（2）在建工程 |  |  |  |  | \n | 127,058,302.67 | 26,147,661.95 | 531,562,127.47 |  | 684,768,092.09\n转入 |  |  |  |  | \n |  |  |  |  | \n（3）企业合并 |  |  |  |  | \n |  |  |  |  | \n增加 |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n3.本期减少金额 | 13,603,089.42 | 4,778,065.53 | 40,235,121.09 | 1,713,041.92 | 60,329,317.96\n（1）处置或报 |  |  |  |  | \n | 13,603,089.42 | 4,778,065.53 | 40,235,121.09 | 1,713,041.92 | 60,329,317.96\n废 |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n4.期末余额 | 1,055,459,515.82 | 173,015,227.04 | 1,652,403,968.40 | 59,763,869.44 | 2,940,642,580.70\n二、累计折旧 |  |  |  |  | \n1.期初余额 | 353,145,143.22 | 114,199,096.34 | 571,568,602.36 | 44,658,442.31 | 1,083,571,284.23\n2.本期增加金额 | 52,644,012.36 | 14,146,453.54 | 99,289,757.27 | 5,610,282.17 | 171,690,505.34\n（1）计提 | 52,644,012.36 | 14,146,453.54 | 99,289,757.27 | 5,610,282.17 | 171,690,505.34\n |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "e47e440f",
      "child_ids": [],
      "sibling_ids": [
        "129a0eb4"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1720,
      "page_number": 139,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "合并",
          "折旧"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          139
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.248232",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1220,
        "word_count": 201,
        "sentence_count": 54,
        "chinese_char_count": 83,
        "readability_score": 0.0,
        "information_density": 0.01639344262295082,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5862637362637362,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "合并",
        "折旧"
      ]
    },
    {
      "chunk_id": "129a0eb4",
      "content": "3.本期减少金额 | 9,335,681.39 | 4,537,067.86 | 35,777,262.22 | 1,569,383.59 | 51,219,395.06\n（1）处置或报 |  |  |  |  | \n | 9,335,681.39 | 4,537,067.86 | 35,777,262.22 | 1,569,383.59 | 51,219,395.06\n废 |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n4.期末余额 | 396,453,474.19 | 123,808,482.02 | 635,081,097.41 | 48,699,340.89 | 1,204,042,394.51\n三、减值准备 |  |  |  |  | \n1.期初余额 | 717,598.43 | 44,323.56 | 11,517,009.86 |  | 12,278,931.85",
      "chunk_type": "table_group",
      "parent_id": "e47e440f",
      "child_ids": [],
      "sibling_ids": [
        "e0e8bfe4"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1417,
      "page_number": 139,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          139
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.248309",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 417,
        "word_count": 70,
        "sentence_count": 22,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.023980815347721823,
        "coherence_score": 0.23439130434782607,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5862637362637362,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值"
      ]
    },
    {
      "chunk_id": "ccd4c167",
      "content": "【表格内容】\n2.本期增加金额 | | 103,473.25 | 396,068.47 | | 499,541.72\n--------------------------------------------------\n（1）计提 | | 103,473.25 | 396,068.47 | | 499,541.72\n | | | | | \n3.本期减少金额 | 585,620.72 | | | | 585,620.72\n（1）处置或报 | | | | | \n | 585,620.72 | | | | 585,620.72\n废 | | | | | \n | | | | | \n | | | | | \n4.期末余额 | 131,977.71 | 147,796.81 | 11,913,078.33 | | 12,192,852.85\n四 账面价值 | | | | | \n1.期末账面价值 | 658,874,063.92 | 49,058,948.21 | 1,005,409,792.66 | 11,064,528.55 | 1,724,407,333.34\n2.期初账面价值 | 588,141,560.92 | 37,039,051.31 | 577,671,335.83 | 12,268,695.55 | 1,215,120,643.61",
      "chunk_type": "table_group",
      "parent_id": "aea48e63",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 575,
      "page_number": 140,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          140
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248493",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 575,
        "word_count": 101,
        "sentence_count": 29,
        "chinese_char_count": 44,
        "readability_score": 0.0,
        "information_density": 0.034782608695652174,
        "coherence_score": 0.23750000000000002,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5099502487562189,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "f5a142a1",
      "content": "【表格内容】\n项目 | 账面原值 | 累计折旧 | 减值准备 | 账面价值 | 备注\n--------------------------------------------------\n房屋及建筑物 | 96,021,538.73 | 24,413,427.38 | | 71,608,111.35 | \n通用设备 | 6,855,762.41 | 5,595,164.87 | 143,649.07 | 1,116,948.47 | \n专用设备 | 145,417,971.06 | 110,109,458.33 | 732,234.31 | 34,576,278.42 |",
      "chunk_type": "table_group",
      "parent_id": "5afa9890",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 289,
      "page_number": 140,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "折旧",
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          140
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248604",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 289,
        "word_count": 42,
        "sentence_count": 11,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.13840830449826988,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39975774647887324,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "折旧",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "2c5feb35",
      "content": "【说明】（6）固定资产清理\n单位： 元\n项目 期末余额 期初余额\n其他说明\n22、在建工程\n单位： 元\n项目 期末余额 期初余额\n在建工程 535,836,082.97 653,154,180.21\n工程物资 24,838,551.46 21,179,497.78\n合计 560,674,634.43 674,333,677.99\n（1）在建工程情况\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n公司及子公司房\n2,107,384.23 2,107,384.23 6,025,551.57 6,025,551.57\n屋建设工程\n原料药及中间体\nCMO中心扩建 198,852,943.52 198,852,943.52 165,628,666.75 165,628,666.75\n项目\n川南药业公司设\n9,204,900.26 9,204,900.26 7,184,188.76 7,184,188.76\n备安装工程\n环保设施改造项\n41,262,820.03 41,262,820.03 80,121,501.45 80,121,501.45\n目\n台州前进公司\n15500吨活性染\n36,676,707.08 36,676,707.08 147,592,362.30 147,592,362.30\n料产业升级及配\n套项目\n台州振港公司年\n产2500吨关健中\n6,050,304.05 6,050,304.05 42,843,192.74 42,843,192.74\n间体产业一体化\n项目\n台州振港公司年\n产700吨M-562\n285,309.30 285,309.30 93,276,176.18 93,276,176.18\n关键中间体产业\n一体化项目\n141。\n\n【表格内容】\n项目 | 账面价值 | 未办妥产权证书的原因\n--------------------------------------------------\n公司及子公司房屋建筑物 | 136,044,964.45 | 公司正在办理产权证书",
      "chunk_type": "table_group",
      "parent_id": "68338bb8",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 883,
      "page_number": 140,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          140
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.248892",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 883,
        "word_count": 96,
        "sentence_count": 36,
        "chinese_char_count": 243,
        "readability_score": 0.0,
        "information_density": 0.056625141562853906,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47146198210265855,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "39cb9e76",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n在建工程 | 535,836,082.97 | 653,154,180.21\n工程物资 | 24,838,551.46 | 21,179,497.78\n合计 | 560,674,634.43 | 674,333,677.99",
      "chunk_type": "table_group",
      "parent_id": "7642bc9c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 187,
      "page_number": 141,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          141
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.249091",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 187,
        "word_count": 22,
        "sentence_count": 6,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37766666666666665,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "dd39912f",
      "content": " | 期末余额 |  |  | 期初余额 |  | \n--------------------------------------------------\n项目 |  |  |  |  |  | \n | 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n |  |  |  |  |  | \n公司及子公司房 |  |  |  |  |  | \n | 2,107,384.23 |  | 2,107,384.23 | 6,025,551.57 |  | 6,025,551.57\n屋建设工程 |  |  |  |  |  | \n |  |  |  |  |  | \n原料药及中间体 |  |  |  |  |  | \nCMO中心扩建 | 198,852,943.52 |  | 198,852,943.52 | 165,628,666.75 |  | 165,628,666.75\n项目 |  |  |  |  |  | \n川南药业公司设 |  |  |  |  |  | \n | 9,204,900.26 |  | 9,204,900.26 | 7,184,188.76 |  | 7,184,188.76\n备安装工程 |  |  |  |  |  | \n |  |  |  |  |  | \n环保设施改造项 |  |  |  |  |  | \n | 41,262,820.03 |  | 41,262,820.03 | 80,121,501.45 |  | 80,121,501.45\n目 |  |  |  |  |  | \n |  |  |  |  |  | \n台州前进公司 |  |  |  |  |  | \n15500吨活性染 |  |  |  |  |  | \n | 36,676,707.08 |  | 36,676,707.08 | 147,592,362.30 |  | 147,592,362.30\n料产业升级及配 |  |  |  |  |  | \n |  |  |  |  |  | \n套项目 |  |  |  |  |  | \n台州振港公司年 |  |  |  |  |  | \n产2500吨关健中 |  |  |  |  |  | \n | 6,050,304.05 |  | 6,050,304.05 | 42,843,192.74 |  | 42,843,192.74\n间体产业一体化 |  |  |  |  |  | \n |  |  |  |  |  | \n项目 |  |  |  |  |  | \n台州振港公司年 |  |  |  |  |  | \n产700吨M-562 |  |  |  |  |  | \n | 285,309.30 |  | 285,309.30 | 93,276,176.18 |  | 93,276,176.18\n关键中间体产业 |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "09512d7a",
      "child_ids": [],
      "sibling_ids": [
        "e7e585cf"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1725,
      "page_number": 141,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 36,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          141
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.249587",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1225,
        "word_count": 268,
        "sentence_count": 28,
        "chinese_char_count": 136,
        "readability_score": 0.0,
        "information_density": 0.024489795918367346,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38335962145110414,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "60340a56",
      "content": "【表格内容】\n台州振港公司年 | | | | | | \n--------------------------------------------------\n产18500吨染料 | 68,227,065.54 | | 68,227,065.54 | 5,450,450.43 | | 5,450,450.43\n产业升级项目 | | | | | | \n盐城瓯华公司设\n备安装工程 | | | | | | \n | 26,608,200.30 | | 26,608,200.30 | 22,261,730.30 | | 22,261,730.30\n | | | | | | \n医药中试车间技\n改项目 | | | | | | \n | | | | 17,149,684.37 | | 17,149,684.37\n | | | | | | \n医药综合研发中\n心 | | | | | | \n | 15,253,236.88 | | 15,253,236.88 | 775,995.69 | | 775,995.69\n | | | | | | \n台州振港公司 | | | | | | \n250吨美罗培南 | 44,267,447.48 | | 44,267,447.48 | | | \n侧链项目 | | | | | | \n零星工程 | 87,039,764.30 | | 87,039,764.30 | 64,844,679.67 | | 64,844,679.67\n合计 | 535,836,082.97 | | 535,836,082.97 | 653,154,180.21 | | 653,154,180.21",
      "chunk_type": "table_group",
      "parent_id": "c2e28c5c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 700,
      "page_number": 142,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.250144",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 700,
        "word_count": 142,
        "sentence_count": 24,
        "chinese_char_count": 72,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4384210526315789,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "e3c77ac7",
      "content": " |  | 期初余\n额 |  | 本期转 |  |  | 工程累 |  |  | 其中：本\n期利息\n资本化\n金额 |  | \n--------------------------------------------------\n |  |  |  |  | 本期其 |  |  |  | 利息资 |  | 本期利 | \n项目名 |  |  | 本期增 | 入固定 |  | 期末余 | 计投入 | 工程进 |  |  |  | 资金来\n | 预算数 |  |  |  | 他减少 |  |  |  | 本化累 |  | 息资本 | \n称 |  |  | 加金额 | 资产金 |  | 额 | 占预算 | 度 |  |  |  | 源\n |  |  |  |  | 金额 |  |  |  | 计金额 |  | 化率 | \n |  |  |  | 额 |  |  | 比例 |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n公司及 |  | 1,816,86\n9.49 |  |  |  |  |  |  |  |  |  | \n子公司 |  |  | 4,597,40 | 4,306,88 |  | 2,107,38 |  |  |  |  |  | 金融机\n |  |  |  |  |  |  |  |  |  |  |  | \n房屋建 |  |  | 0.47 | 5.73 |  | 4.23 |  |  |  |  |  | 构贷款\n |  |  |  |  |  |  |  |  |  |  |  | \n设工程 |  |  |  |  |  |  |  |  |  |  |  | \n原料药 |  |  |  |  |  |  |  |  |  |  |  | \n及中间 |  |  |  |  |  |  |  |  |  |  |  | \n | 46,034.5 | 165,628, | 94,079,7 | 60,855,5 |  | 198,852, |  |  |  |  |  | 募股资\n体CMO |  |  |  |  |  |  | 70.92% | 70.00 |  |  |  | \n | 8 | 666.75 | 99.70 | 22.93 |  | 943.52 |  |  |  |  |  | 金\n中心扩 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n建项目 |  |  |  |  |  |  |  |  |  |  |  | \n川南药 |  | 7,184,18\n8.76 |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b3bfd3b2",
      "child_ids": [],
      "sibling_ids": [
        "0a52b103"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1669,
      "page_number": 142,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 30,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.250591",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1169,
        "word_count": 347,
        "sentence_count": 12,
        "chinese_char_count": 124,
        "readability_score": 0.0,
        "information_density": 0.00855431993156544,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5931115002918856,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "0a52b103",
      "content": "业公司 |  |  | 31,205,6 | 29,184,9 |  | 9,204,90 |  |  |  |  |  | 金融机\n |  |  |  |  |  |  |  |  |  |  |  | \n设备安 |  |  | 20.68 | 09.18 |  | 0.26 |  |  |  |  |  | 构贷款\n |  |  |  |  |  |  |  |  |  |  |  | \n装工程 |  |  |  |  |  |  |  |  |  |  |  | \n环保设 |  |  |  |  |  |  |  |  |  |  |  | \n | 15,502.0 | 80,121,5 | 35,646,6 | 74,505,3 |  | 41,262,8 |  |  |  |  |  | 募股资\n施改造 |  |  |  |  |  |  | 75.01% | 75.00 |  |  |  | \n | 0 | 01.45 | 30.19 | 11.61 |  | 20.03 |  |  |  |  |  | 金\n项目 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b3bfd3b2",
      "child_ids": [],
      "sibling_ids": [
        "e3c77ac7"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1543,
      "page_number": 142,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          142
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.250772",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 543,
        "word_count": 160,
        "sentence_count": 10,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.01841620626151013,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5931115002918856,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "1ad06896",
      "content": "台州前 |  |  |  |  |  |  |  |  |  |  |  | \n--------------------------------------------------\n进公司 |  |  |  |  |  |  |  |  |  |  |  | \n15500吨 |  |  |  |  |  |  |  |  |  |  |  | \n活性染 | 40,160.0 | 147,592, | 154,147, | 265,062, |  | 36,676,7 |  |  |  |  |  | 金融机\n |  |  |  |  |  |  | 75.13% | 75.00 |  |  |  | \n料产业 | 0 | 362.30 | 165.63 | 820.85 |  | 07.08 |  |  |  |  |  | 构贷款\n |  |  |  |  |  |  |  |  |  |  |  | \n升级及 |  |  |  |  |  |  |  |  |  |  |  | \n配套项 |  |  |  |  |  |  |  |  |  |  |  | \n目 |  |  |  |  |  |  |  |  |  |  |  | \n台州振 |  |  |  |  |  |  |  |  |  |  |  | \n港公司 |  |  |  |  |  |  |  |  |  |  |  | \n产2500 |  |  |  |  |  |  |  |  |  |  |  | \n吨关健 |  | 42,843,1 | 12,166,1 | 48,959,0 |  | 6,050,30 |  |  |  |  |  | 金融机\n | 7,850.00 |  |  |  |  |  | 102.09% | 95.00 |  |  |  | \n中间体 |  | 92.74 | 71.56 | 60.25 |  | 4.05 |  |  |  |  |  | 构贷款\n |  |  |  |  |  |  |  |  |  |  |  | \n产业一 |  |  |  |  |  |  |  |  |  |  |  | \n体化项 |  |  |  |  |  |  |  |  |  |  |  | \n目 |  |  |  |  |  |  |  |  |  |  |  | \n台州振 |  |  |  |  |  |  |  |  |  |  |  | \n港公司 |  |  |  |  |  |  |  |  |  |  |  | \n年产700 |  |  |  |  |  |  |  |  |  |  |  | \n吨 |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "98785df3",
      "child_ids": [],
      "sibling_ids": [
        "1cae9046",
        "ef0642dd"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1657,
      "page_number": 143,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 25,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          143
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.251480",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1157,
        "word_count": 336,
        "sentence_count": 14,
        "chinese_char_count": 61,
        "readability_score": 0.0,
        "information_density": 0.008643042350907518,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3654674874951904,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "1cae9046",
      "content": " | 10,000.0 | 93,276,1 | 10,517,0 | 103,507, |  | 285,309. |  |  |  |  |  | 金融机\nM-562 |  |  |  |  |  |  | 106.83% | 99.00 |  |  |  | \n | 0 | 76.18 | 68.25 | 935.13 |  | 30 |  |  |  |  |  | 构贷款\n关键中 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n间体产 |  |  |  |  |  |  |  |  |  |  |  | \n业一体 |  |  |  |  |  |  |  |  |  |  |  | \n化项目 |  |  |  |  |  |  |  |  |  |  |  | \n台州振 |  |  |  |  |  |  |  |  |  |  |  | \n港公司 |  |  |  |  |  |  |  |  |  |  |  | \n年产 |  |  |  |  |  |  |  |  |  |  |  | \n | 80,000.0 | 5,450,45 | 82,575,2 | 19,798,6 |  | 68,227,0 |  |  |  |  |  | 金融机\n18500吨 |  |  |  |  |  |  | 13.86% | 15.00 |  |  |  | \n | 0 | 0.43 | 81.47 | 66.36 |  | 65.54 |  |  |  |  |  | 构贷款\n染料产 |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n业升级 |  |  |  |  |  |  |  |  |  |  |  | \n项目 |  |  |  |  |  |  |  |  |  |  |  | \n盐城瓯 |  |  |  |  |  |  |  |  |  |  |  | \n华公司 |  | 26,470,4 | 5,218,03 | 5,080,24 |  | 26,608,2 |  |  |  |  |  | 金融机\n |  |  |  |  |  |  |  |  |  |  |  | \n设备安 |  | 12.38 | 4.21 | 6.29 |  | 00.30 |  |  |  |  |  | 构贷款\n |  |  |  |  |  |  |  |  |  |  |  | \n装工程 |  |  |  |  |  |  |  |  |  |  |  | \n医药中 |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "98785df3",
      "child_ids": [],
      "sibling_ids": [
        "1ad06896",
        "ef0642dd"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 2188,
      "page_number": 143,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 25,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          143
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.251794",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1188,
        "word_count": 355,
        "sentence_count": 18,
        "chinese_char_count": 62,
        "readability_score": 0.0,
        "information_density": 0.008417508417508417,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3654674874951904,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "ef0642dd",
      "content": "试车间 |  | 17,149,6 | 6,878,35 | 24,028,0 |  |  |  |  |  |  |  | 募股资\n | 9,256.00 |  |  |  |  |  | 43.31% | 45.00 |  |  |  | \n技改项 |  | 84.37 | 9.38 | 43.75 |  |  |  |  |  |  |  | 金\n |  |  |  |  |  |  |  |  |  |  |  | \n目 |  |  |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "98785df3",
      "child_ids": [],
      "sibling_ids": [
        "1ad06896",
        "1cae9046"
      ],
      "position": 2,
      "start_char": 1000,
      "end_char": 1752,
      "page_number": 143,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          143
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.251906",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 252,
        "word_count": 74,
        "sentence_count": 6,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.03968253968253968,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3654674874951904,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "59bc02e6",
      "content": "【表格内容】\n医药综 | | | | | | | | | | | | \n--------------------------------------------------\n | 15,073.0 | 775,995. | 35,025,9 | 20,548,7 | | 15,253,2 | | | | | | 募股资\n合研发 | | | | | | | 23.75% | 25 | | | | \n | 0 | 69 | 51.78 | 10.59 | | 36.88 | | | | | | 金\n中心 | | | | | | | | | | | | \n | | | | | | | | | | | | \n台州振 | | | 44,267,4\n47.48 | | | | | | | | | \n港公司 | | | | | | | | | | | | \n250吨美 | 16,000.0 | | | | | 44,267,4 | | | | | | 金融机\n | | | | | | | 27.67% | 30 | | | | \n罗培南 | 0 | | | | | 47.48 | | | | | | 构贷款\n | | | | | | | | | | | | \n侧链项 | | | | | | | | | | | | \n目 | | | | | | | | | | | | \n零星工 | | 64,844,6 | 51,125,0 | 28,929,9 | | 87,039,7 | | | | | | 金融机\n | | | | | | | | | | | | \n程 | | 79.67 | 64.05 | 79.42 | | 64.30 | | | | | | 构贷款\n | | | | | | | | | | | | \n | 239,875. | 653,154, | 567,449, | 684,768, | | 535,836, | | | | | | \n合计 | | | | | | | -- | -- | | | | --\n | 58 | 180.21 | 994.85 | 092.09 | | 082.97 | | | | | | \n | | | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "15c04e0d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 949,
      "page_number": 144,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          144
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.252313",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 949,
        "word_count": 325,
        "sentence_count": 19,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.01053740779768177,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.430890052356021,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "cbe94e99",
      "content": "【说明】24、油气资产\n□ 适用 √ 不适用\n25、使用权资产\n单位： 元\n项目 合计\n其他说明：\n26、无形资产\n（1）无形资产情况\n单位： 元\n项目 土地使用权 专利权 非专利技术 排污权 特许使用权 特许经营权 软件 合计\n一、账面原值\n1.期初 505,413,741. 162,305,608. 11,915,094.3 688,369,268.\n3,072,760.00 3,143,452.96 1,168,163.69 1,350,447.87\n余额 33 72 7 94\n2.本期 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n增加金额 6 0\n（1） 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n购置 6 0\n（2）\n内部研发\n（3）\n企业合并增\n加\n3.本期减 11,116,461.1\n9,433,962.30 1,682,498.83\n少金额 3\n（1） 11,116,461.1\n9,433,962.30 1,682,498.83\n处置 3\n4.期末 527,186,739. 163,203,423. 701,568,832.\n2,481,132.07 4,011,789.99 1,460,954.13 1,168,163.69 2,056,629.92\n余额 19 12 11\n二、累计摊销\n1.期初 55,429,191.3 77,337,200.9 143,036,807.\n4,014,069.57 1,700,580.26 2,061,454.24 1,168,163.69 1,326,147.82\n余额 9 3 90\n145。\n\n【表格内容】\n项目 | 期末余额 | | | 期初余额 | | \n--------------------------------------------------\n | 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n专用材料 | 9,806,701.25 | | 9,806,701.25 | 7,121,142.67 | | 7,121,142.67\n专用设备 | 15,031,850.21 | | 15,031,850.21 | 14,058,355.11 | | 14,058,355.11\n合计 | 24,838,551.46 | | 24,838,551.46 | 21,179,497.78 | | 21,179,497.78",
      "chunk_type": "table_group",
      "parent_id": "034e7683",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1100,
      "page_number": 144,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "无形资产",
          "合并",
          "经营",
          "摊销",
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          144
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.252691",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1100,
        "word_count": 158,
        "sentence_count": 58,
        "chinese_char_count": 168,
        "readability_score": 0.0,
        "information_density": 0.07272727272727272,
        "coherence_score": 0.2359322033898305,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4947734951067677,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "无形资产",
        "合并",
        "经营",
        "摊销",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "e0ec1ad9",
      "content": "项目 | 土地使用权 | 专利权 | 非专利技术 | 排污权 | 特许使用权 | 特许经营权 | 软件 | 合计\n--------------------------------------------------\n一、账面原值 |  |  |  |  |  |  |  | \n1.期初 | 505,413,741. | 162,305,608. | 11,915,094.3 |  |  |  |  | 688,369,268.\n |  |  |  | 3,072,760.00 | 3,143,452.96 | 1,168,163.69 | 1,350,447.87 | \n余额 | 33 | 72 | 7 |  |  |  |  | 94\n |  |  |  |  |  |  |  | \n2.本期 | 21,772,997.8 |  |  |  |  |  |  | 24,316,024.3\n |  | 897,814.40 |  | 939,029.99 |  |  | 706,182.05 | \n增加金额 | 6 |  |  |  |  |  |  | 0\n |  |  |  |  |  |  |  | \n（1） | 21,772,997.8 |  |  |  |  |  |  | 24,316,024.3\n |  | 897,814.40 |  | 939,029.99 |  |  | 706,182.05 | \n购置 | 6 |  |  |  |  |  |  | 0\n |  |  |  |  |  |  |  | \n（2） |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n内部研发 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n（3） |  |  |  |  |  |  |  | \n企业合并增 |  |  |  |  |  |  |  | \n加 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n3.本期减 |  |  |  |  |  |  |  | 11,116,461.1\n |  |  | 9,433,962.30 |  | 1,682,498.83 |  |  | \n少金额 |  |  |  |  |  |  |  | 3\n |  |  |  |  |  |  |  | \n（1） |  |  |  |  |  |  |  | 11,116,461.1\n |  |  | 9,433,962.30 |  | 1,682,498.83 |  |  | \n处置 |  |  |  |  |  |  |  | 3\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "87c1e09d",
      "child_ids": [],
      "sibling_ids": [
        "b2be2f03"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1700,
      "page_number": 145,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "合并",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          145
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.253251",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1200,
        "word_count": 308,
        "sentence_count": 27,
        "chinese_char_count": 67,
        "readability_score": 0.0,
        "information_density": 0.016666666666666666,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.581256332320162,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "合并",
        "经营"
      ]
    },
    {
      "chunk_id": "b2be2f03",
      "content": "4.期末 | 527,186,739. | 163,203,423. |  |  |  |  |  | 701,568,832.\n |  |  | 2,481,132.07 | 4,011,789.99 | 1,460,954.13 | 1,168,163.69 | 2,056,629.92 | \n余额 | 19 | 12 |  |  |  |  |  | 11\n |  |  |  |  |  |  |  | \n二、累计摊销 |  |  |  |  |  |  |  | \n1.期初 | 55,429,191.3 | 77,337,200.9 |  |  |  |  |  | 143,036,807.\n |  |  | 4,014,069.57 | 1,700,580.26 | 2,061,454.24 | 1,168,163.69 | 1,326,147.82 | \n余额 | 9 | 3 |  |  |  |  |  | 90\n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "87c1e09d",
      "child_ids": [],
      "sibling_ids": [
        "e0ec1ad9"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1444,
      "page_number": 145,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 9,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "摊销"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          145
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.253340",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 444,
        "word_count": 99,
        "sentence_count": 18,
        "chinese_char_count": 13,
        "readability_score": 0.0,
        "information_density": 0.02252252252252252,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.581256332320162,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "摊销"
      ]
    },
    {
      "chunk_id": "1d942764",
      "content": "2.本期 | 11,263,080.3 | 17,674,391.8 |  |  |  |  |  | 30,277,923.1\n--------------------------------------------------\n |  |  | 563,042.72 | 517,839.30 | 205,844.64 |  | 53,724.30 | \n增加金额 | 6 | 1 |  |  |  |  |  | 3\n |  |  |  |  |  |  |  | \n（1） | 11,263,080.3 | 17,674,391.8 |  |  |  |  |  | 30,277,923.1\n |  |  | 563,042.72 | 517,839.30 | 205,844.64 |  | 53,724.30 | \n计提 | 6 | 1 |  |  |  |  |  | 3\n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n3.本期 |  |  |  |  |  |  |  | \n |  |  | 3,616,352.13 |  | 1,584,866.25 |  |  | 5,201,218.38\n减少金额 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n（1） |  |  |  |  |  |  |  | \n |  |  | 3,616,352.13 |  | 1,584,866.25 |  |  | 5,201,218.38\n处置 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n4.期末 | 66,692,271.7 | 95,011,592.7 |  |  |  |  |  | 168,113,512.\n |  |  | 960,760.16 | 2,218,419.56 | 682,432.63 | 1,168,163.69 | 1,379,872.12 | \n余额 | 5 | 4 |  |  |  |  |  | 65\n |  |  |  |  |  |  |  | \n三、减值准备 |  |  |  |  |  |  |  | \n1.期初 |  |  |  |  |  |  |  | \n |  |  | 5,817,610.17 |  |  |  |  | 5,817,610.17\n余额 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n2.本期 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n增加金额 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "91d0cb27",
      "child_ids": [],
      "sibling_ids": [
        "adbb5ccf"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1725,
      "page_number": 146,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 32,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          146
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.253831",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1225,
        "word_count": 303,
        "sentence_count": 35,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.008163265306122448,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5092480149462868,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值"
      ]
    },
    {
      "chunk_id": "adbb5ccf",
      "content": "（1） |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n计提 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n3.本期 |  |  |  |  |  |  |  | \n |  |  | 5,817,610.17 |  |  |  |  | 5,817,610.17\n减少金额 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n（1）处 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n置 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n4.期末 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n余额 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n四、账面价值 |  |  |  |  |  |  |  | \n1.期末 | 460,494,467. | 68,191,830.3 |  |  |  |  |  | 533,455,319.\n |  |  | 1,520,371.91 | 1,793,370.43 | 778,521.50 |  | 676,757.80 | \n账面价值 | 44 | 8 |  |  |  |  |  | 46\n |  |  |  |  |  |  |  | \n2.期初 | 449,984,549. | 84,968,407.7 |  |  |  |  |  | 539,514,850.\n |  |  | 2,083,414.63 | 1,372,179.74 | 1,081,998.72 |  | 24,300.05 | \n账面价值 | 94 | 9 |  |  |  |  |  | 87\n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "91d0cb27",
      "child_ids": [],
      "sibling_ids": [
        "1d942764"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1915,
      "page_number": 146,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 27,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          146
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.253948",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 915,
        "word_count": 251,
        "sentence_count": 20,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.02185792349726776,
        "coherence_score": 0.4099999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5092480149462868,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "93baef37",
      "content": "【表格内容】\n| | 本期增加金额 | | | 本期减少金额 | | | \n--------------------------------------------------\n项目 | 期初余额 | 内部开发支 | | | 确认为无形 | 转入当期损 | | 期末余额\n | | | 其他 | | | | | \n | | 出 | | | 资产 | 益 | | \n | | | | | | | | \n | | | | | | | | \n合计 | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "5ae6fa07",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 236,
      "page_number": 147,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254042",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 236,
        "word_count": 71,
        "sentence_count": 0,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.04237288135593221,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4373333333333334,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "0ae5ddf1",
      "content": "【表格内容】\n被投资单位名称 | | 本期增加 | | 本期减少 | | \n--------------------------------------------------\n或形成商誉的事 | 期初余额 | | | | | 期末余额\n | | 企业合并形成的 | | 处置 | | \n项 | | | | | | \n | | | | | | \n台州前进公司 | 757,736,770.14 | | | | | 757,736,770.14\n合计 | 757,736,770.14 | | | | | 757,736,770.14",
      "chunk_type": "table_group",
      "parent_id": "be16f134",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 266,
      "page_number": 147,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "商誉",
          "合并"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254141",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 266,
        "word_count": 59,
        "sentence_count": 4,
        "chinese_char_count": 52,
        "readability_score": 0.0,
        "information_density": 0.11278195488721805,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4408204413472706,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "商誉",
        "合并"
      ]
    },
    {
      "chunk_id": "a7a854b1",
      "content": "【表格内容】\n被投资单位名称 | | 本期增加 | | 本期减少 | | \n--------------------------------------------------\n或形成商誉的事 | 期初余额 | | | | | 期末余额\n | | 计提 | | 处置 | | \n项 | | | | | | \n | | | | | | \n | | | | | | \n合计 | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "71305218",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 196,
      "page_number": 147,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "商誉"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254211",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 196,
        "word_count": 54,
        "sentence_count": 0,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.10204081632653061,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39422727272727276,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "商誉"
      ]
    },
    {
      "chunk_id": "056217dc",
      "content": "【说明】说明商誉减值测试过程、关键参数（如预计未来现金流量现值时的预测期增长率、稳定期增长率、利润率、折现率、预测期\n等）及商誉减值损失的确认方法：\n商誉的可收回金额按照预计未来现金流量的现值计算，其预计现金流量根据公司批准的5年期现金流\n量预测为基础，现金流量预测使用的折现率14.16%(2018年：13.00%)，公司根据历史实际经营数据、行业\n发展趋势、预期收入增长率、毛利率等指标编制预测未来5年现金流量，预测期以后的现金流量维持不变。减值测试中采用的其他关键数据包括：产品预计售价、销量、生产成本及其他相关费用。公司根据历史经验及对市场发展的预测确定上述关键数据。\n\n【表格内容】\n资产组或资产组组合的构成\n--------------------------------------------------\n资产组或资产组组合的账面价值\n分摊至本资产组或资产组组合的商誉账面价值及分摊\n方法\n包含商誉的资产组或资产组组合的账面价值\n资产组或资产组组合是否与购买日 以前年度商誉减\n值测试时所确定的资产组或资产组组合一致",
      "chunk_type": "table_group",
      "parent_id": "9b2a270d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 466,
      "page_number": 147,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入",
          "成本",
          "费用",
          "利润",
          "现金",
          "商誉",
          "毛利率",
          "经营",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254343",
        "report_type": null,
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 466,
        "word_count": 15,
        "sentence_count": 5,
        "chinese_char_count": 355,
        "readability_score": 0.0,
        "information_density": 0.21459227467811157,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6853589784574399,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "商誉",
        "毛利率",
        "经营",
        "减值"
      ]
    },
    {
      "chunk_id": "a42f3396",
      "content": "【说明】公司采用的折现率是反映当前市场货币时间价\n值和相关资产组特定风险的税前利率。上述对可收回金额的预计表明商誉并未出现减值损失。商誉减值测试的影响\n其他说明\n29、长期待摊费用\n单位： 元\n项目 期初余额 本期增加金额 本期摊销金额 其他减少金额 期末余额\n经营租入固定资产\n1,842,423.21 223,651.32 1,618,771.89\n改良支出\n合计 1,842,423.21 223,651.32 1,618,771.89\n其他说明\n30、递延所得税资产/递延所得税负债\n（1）未经抵销的递延所得税资产\n单位： 元\n期末余额 期初余额\n项目\n可抵扣暂时性差异 递延所得税资产 可抵扣暂时性差异 递延所得税资产\n资产减值准备 70,299,465.99 14,376,262.42 68,698,671.21 14,236,323.65\n内部交易未实现利润 39,421,112.05 6,246,640.41 62,503,070.92 9,773,506.85\n与资产相关的政府补助\n43,621,205.16 6,716,780.73 36,278,025.15 5,567,975.82\n分摊\n预计负债 11,637,669.47 2,909,417.37\n合计 153,341,783.20 27,339,683.56 179,117,436.75 32,487,223.69\n（2）未经抵销的递延所得税负债\n单位： 元\n项目 期末余额 期初余额\n148。\n\n【表格内容】\n项目 | 期初余额 | 本期增加金额 | 本期摊销金额 | 其他减少金额 | 期末余额\n--------------------------------------------------\n经营租入固定资产 | | | | | \n | 1,842,423.21 | | 223,651.32 | | 1,618,771.89\n改良支出 | | | | | \n | | | | | \n合计 | 1,842,423.21 | | 223,651.32 | | 1,618,771.89",
      "chunk_type": "table_group",
      "parent_id": "7efd13f7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 891,
      "page_number": 148,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "费用",
          "利润",
          "固定资产",
          "商誉",
          "所得税",
          "经营",
          "摊销",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          148
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254612",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 891,
        "word_count": 111,
        "sentence_count": 33,
        "chinese_char_count": 302,
        "readability_score": 0.0,
        "information_density": 0.1122334455667789,
        "coherence_score": 0.4028571428571428,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5430298556687565,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "费用",
        "利润",
        "固定资产",
        "商誉",
        "所得税",
        "经营",
        "摊销",
        "减值"
      ]
    },
    {
      "chunk_id": "168321ea",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n可抵扣暂时性差异 | 34,056.67 | 42,122.21\n可抵扣亏损 | 54,023,245.91 | 120,721,788.89\n合计 | 54,057,302.58 | 120,763,911.10",
      "chunk_type": "table_group",
      "parent_id": "07731e98",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 182,
      "page_number": 149,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.254788",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 182,
        "word_count": 22,
        "sentence_count": 6,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38142857142857145,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "1e6a7e94",
      "content": "【表格内容】\n年份 | 期末金额 | 期初金额 | 备注\n--------------------------------------------------\n2021年 | | 106,844,539.90 | \n2022年 | 13,876,526.38 | 13,876,526.38 | \n2023年 | 722.61 | 722.61 | \n2024年 | 40,145,996.92 | | \n合计 | 54,023,245.91 | 120,721,788.89 | --",
      "chunk_type": "table_group",
      "parent_id": "e2f8b0da",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 243,
      "page_number": 149,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          149
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255017",
        "report_type": null,
        "fiscal_year": 2021,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 243,
        "word_count": 38,
        "sentence_count": 8,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38394453781512605,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "cb92d055",
      "content": "【表格内容】\n预付软件款 | 450,000.00 | 515,993.37\n--------------------------------------------------\n合计 | 450,000.00 | 515,993.37\n\n【注释】35、应付票据\n单位： 元\n种类 期末余额 期初余额\n银行承兑汇票 238,306,005.00 490,006,533.85\n合计 238,306,005.00 490,006,533.85\n本期末已到期未支付的应付票据总额为元。36、应付账款\n（1）应付账款列示\n单位： 元\n项目 期末余额 期初余额\n货 款 139,912,212.13 157,970,026.94\n工程设备款 212,622,391.34 137,429,777.27\n其 他 10,905,980.49 6,509,125.72\n合计 363,440,583.96 301,908,929.93\n（2）账龄超过1年的重要应付账款\n单位： 元\n项目 期末余额 未偿还或结转的原因\n其他说明：\n37、预收款项\n是否已执行新收入准则\n□ 是 √ 否\n（1）预收款项列示\n单位： 元\n项目 期末余额 期初余额\n货 款 12,919,749.09 19,196,692.94\n合计 12,919,749.09 19,196,692.94\n（2）账龄超过1年的重要预收款项\n单位： 元\n151。",
      "chunk_type": "table_group",
      "parent_id": "7799ef07",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 604,
      "page_number": 150,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "应付",
          "预收",
          "预付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          150
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255224",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 604,
        "word_count": 75,
        "sentence_count": 22,
        "chinese_char_count": 178,
        "readability_score": 0.0,
        "information_density": 0.06622516556291391,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43689755469755465,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "应付",
        "预收",
        "预付"
      ]
    },
    {
      "chunk_id": "4fb988a9",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n质押借款 | | 76,700,000.00\n抵押借款 | 50,066,500.00 | 143,000,000.00\n保证借款 | | 20,000,000.00\n信用借款 | 150,200,529.59 | 359,000,000.00\n合计 | 200,267,029.59 | 598,700,000.00",
      "chunk_type": "table_group",
      "parent_id": "40da044a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 234,
      "page_number": 150,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          150
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255328",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 234,
        "word_count": 30,
        "sentence_count": 8,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.042735042735042736,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38914061135371175,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "借款"
      ]
    },
    {
      "chunk_id": "1f625329",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n其中： | | \n其中： | |",
      "chunk_type": "table_group",
      "parent_id": "5f4b1f72",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 91,
      "page_number": 150,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          150
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255379",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 91,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4415379310344828,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "a7dda85d",
      "content": "【表格内容】\n种类 | 期末余额 | 期初余额\n--------------------------------------------------\n银行承兑汇票 | 238,306,005.00 | 490,006,533.85\n合计 | 238,306,005.00 | 490,006,533.85",
      "chunk_type": "table_group",
      "parent_id": "2c5a3e91",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 152,
      "page_number": 151,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          151
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255529",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 152,
        "word_count": 17,
        "sentence_count": 4,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37262068965517237,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "18281271",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n货 款 | 139,912,212.13 | 157,970,026.94\n工程设备款 | 212,622,391.34 | 137,429,777.27\n其 他 | 10,905,980.49 | 6,509,125.72\n合计 | 363,440,583.96 | 301,908,929.93",
      "chunk_type": "table_group",
      "parent_id": "f4b11d2c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 224,
      "page_number": 151,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          151
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.255742",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 224,
        "word_count": 29,
        "sentence_count": 8,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3829161290322581,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "ab736b15",
      "content": "【说明】项目 期末余额 未偿还或结转的原因\n（3）期末建造合同形成的已结算未完工项目情况\n单位： 元\n项目 金额\n其他说明：\n38、合同负债\n单位： 元\n项目 期末余额 期初余额\n报告期内账面价值发生重大变动的金额和原因\n单位： 元\n项目 变动金额 变动原因\n39、应付职工薪酬\n（1）应付职工薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n一、短期薪酬 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n二、离职后福利-设定提\n3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n存计划\n三、辞退福利 26,656.73 26,656.73\n合计 45,234,354.42 326,240,321.13 319,107,533.27 52,367,142.28\n（2）短期薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、工资、奖金、津贴和\n38,780,553.62 273,368,159.46 267,353,757.95 44,794,955.13\n补贴\n2、职工福利费 15,919,594.19 15,919,594.19\n3、社会保险费 2,440,565.13 8,976,976.99 8,845,418.72 2,572,123.40\n其中：医疗保险费 1,731,912.00 7,358,904.85 7,221,509.07 1,869,307.78\n工伤保险费 518,490.75 1,058,240.23 1,071,709.37 505,021.61\n生育保险费 190,162.38 559,831.91 552,200.28 197,794.01\n152。\n\n【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n货 款 | 12,919,749.09 | 19,196,692.94\n合计 | 12,919,749.09 | 19,196,692.94",
      "chunk_type": "table_group",
      "parent_id": "9a2bd5e2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 928,
      "page_number": 151,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "应付",
          "报告",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          151
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.256027",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 928,
        "word_count": 105,
        "sentence_count": 41,
        "chinese_char_count": 237,
        "readability_score": 0.0,
        "information_density": 0.05387931034482759,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44382862725940403,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "应付",
        "报告",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "d99c8e22",
      "content": "【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n一 短期薪酬 | 41,640,169.44 | 309,866,403.94 | 302,996,468.43 | 48,510,104.95\n二 离职后福利-设定提 | | | | \n | 3,594,184.98 | 16,347,260.46 | 16,084,408.11 | 3,857,037.33\n存计划 | | | | \n | | | | \n三 辞退福利 | | 26,656.73 | 26,656.73 | \n合计 | 45,234,354.42 | 326,240,321.13 | 319,107,533.27 | 52,367,142.28",
      "chunk_type": "table_group",
      "parent_id": "9c43f18f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 373,
      "page_number": 152,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          152
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.256359",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 373,
        "word_count": 61,
        "sentence_count": 14,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4919553191489362,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "44b387ce",
      "content": "项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n1、工资、奖金、津贴和 |  |  |  | \n | 38,780,553.62 | 273,368,159.46 | 267,353,757.95 | 44,794,955.13\n补贴 |  |  |  | \n |  |  |  | \n2、职工福利费 |  | 15,919,594.19 | 15,919,594.19 | \n3、社会保险费 | 2,440,565.13 | 8,976,976.99 | 8,845,418.72 | 2,572,123.40\n其中：医疗保险费 | 1,731,912.00 | 7,358,904.85 | 7,221,509.07 | 1,869,307.78\n工伤保险费 | 518,490.75 | 1,058,240.23 | 1,071,709.37 | 505,021.61\n生育保险费 | 190,162.38 | 559,831.91 | 552,200.28 | 197,794.01",
      "chunk_type": "table_group",
      "parent_id": "a25a699c",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1003,
      "page_number": 152,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 11,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          152
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.256973",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 503,
        "word_count": 75,
        "sentence_count": 22,
        "chinese_char_count": 54,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.53220675944334,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "d0ed0b6c",
      "content": "【表格内容】\n4 住房公积金 | 286,968.00 | 9,072,162.00 | 9,110,730.00 | 248,400.00\n--------------------------------------------------\n5 工会经费和职工教育 | | | | \n | 132,082.69 | 2,529,511.30 | 1,766,967.57 | 894,626.42\n经费 | | | | \n | | | | \n合计 | 41,640,169.44 | 309,866,403.94 | 302,996,468.43 | 48,510,104.95",
      "chunk_type": "table_group",
      "parent_id": "e87f6766",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 290,
      "page_number": 153,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257227",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 290,
        "word_count": 44,
        "sentence_count": 12,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.46764657534246573,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "fc78e6fe",
      "content": "【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n1 基本养老保险 | 3,311,287.25 | 15,768,975.90 | 15,505,552.02 | 3,574,711.13\n2 失业保险费 | 282,897.73 | 578,284.56 | 578,856.09 | 282,326.20\n合计 | 3,594,184.98 | 16,347,260.46 | 16,084,408.11 | 3,857,037.33",
      "chunk_type": "table_group",
      "parent_id": "f042c2ec",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 284,
      "page_number": 153,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257462",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 284,
        "word_count": 40,
        "sentence_count": 12,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4721870036101083,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "860b5a23",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n增值税 | 9,523,602.71 | 9,931,701.18\n企业所得税 | 28,390,504.27 | 37,886,210.59\n个人所得税 | 764,210.55 | 778,807.41\n城市维护建设税 | 501,005.62 | 756,017.40\n房产税 | 3,435,584.90 | 2,902,210.71\n土地使用税 | 1,583,236.07 | 1,592,945.01\n教育费附加 | 214,716.69 | 435,378.81\n地方教育附加 | 143,144.46 | 290,252.54\n印花税 | 123,171.95 | 107,074.83\n残疾人就业保障金 | 73,107.05 | 60,062.86\n环境保护税 | 28,921.28 | 150,000.00\n合计 | 44,781,205.55 | 54,890,661.34",
      "chunk_type": "table_group",
      "parent_id": "6e37a4e6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 476,
      "page_number": 153,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "所得税",
          "增值税",
          "企业所得税"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257613",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 476,
        "word_count": 67,
        "sentence_count": 24,
        "chinese_char_count": 71,
        "readability_score": 0.0,
        "information_density": 0.06302521008403361,
        "coherence_score": 0.32711999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4402285714285714,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "所得税",
        "增值税",
        "企业所得税"
      ]
    },
    {
      "chunk_id": "a3e95421",
      "content": "【说明】应付股利 2,051,370.43 2,051,370.43\n其他应付款 26,148,702.79 21,583,181.20\n合计 28,200,073.22 24,723,304.20\n（1）应付利息\n单位： 元\n项目 期末余额 期初余额\n短期借款应付利息 1,088,752.57\n合计 1,088,752.57\n重要的已逾期未支付的利息情况：\n单位： 元\n借款单位 逾期金额 逾期原因\n其他说明：\n（2）应付股利\n单位： 元\n项目 期末余额 期初余额\n发起人股东 2,051,370.43 2,051,370.43\n合计 2,051,370.43 2,051,370.43\n其他说明，包括重要的超过1年未支付的应付股利，应披露未支付原因：\n（3）其他应付款\n1）按款项性质列示其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付暂收款 14,988,518.12 11,511,834.54\n出口货物运保费及佣金 8,226,443.88 3,988,336.40\n押金保证金 920,310.00 2,476,025.00\n暂借款 350,000.00 1,345,413.90\n其 他 1,663,430.79 2,261,571.36\n合计 26,148,702.79 21,583,181.20\n2）账龄超过1年的重要其他应付款\n单位： 元\n154。\n\n【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应付利息 | | 1,088,752.57",
      "chunk_type": "table_group",
      "parent_id": "09935bed",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 687,
      "page_number": 153,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应付",
          "股东",
          "披露",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257831",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 687,
        "word_count": 80,
        "sentence_count": 26,
        "chinese_char_count": 216,
        "readability_score": 0.0,
        "information_density": 0.05822416302765647,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4458489326765189,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "股东",
        "披露",
        "借款"
      ]
    },
    {
      "chunk_id": "f598936f",
      "content": "【表格内容】\n应付股利 | 2,051,370.43 | 2,051,370.43\n--------------------------------------------------\n其他应付款 | 26,148,702.79 | 21,583,181.20\n合计 | 28,200,073.22 | 24,723,304.20",
      "chunk_type": "table_group",
      "parent_id": "f70d23f8",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 165,
      "page_number": 154,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.257918",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 165,
        "word_count": 17,
        "sentence_count": 6,
        "chinese_char_count": 15,
        "readability_score": 0.0,
        "information_density": 0.06060606060606061,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3670430379746836,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付"
      ]
    },
    {
      "chunk_id": "c29d556d",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n短期借款应付利息 | | 1,088,752.57\n合计 | | 1,088,752.57\n\n【注释】项目 期末余额 未偿还或结转的原因\n其他说明\n42、持有待售负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n43、一年内到期的非流动负债\n单位： 元\n项目 期末余额 期初余额\n一年内到期的长期应付款 44,365,875.00\n合计 44,365,875.00\n其他说明：\n44、其他流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n短期应付债券的增减变动：\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n其他说明：\n45、长期借款\n（1）长期借款分类\n单位： 元\n项目 期末余额 期初余额\n长期借款分类的说明：\n其他说明，包括利率区间：\n155",
      "chunk_type": "table_group",
      "parent_id": "a24bfdfc",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 463,
      "page_number": 154,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "收入",
          "应付",
          "借款",
          "债券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258062",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 463,
        "word_count": 75,
        "sentence_count": 4,
        "chinese_char_count": 246,
        "readability_score": 0.0,
        "information_density": 0.1079913606911447,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4743566148781565,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "收入",
        "应付",
        "借款",
        "债券"
      ]
    },
    {
      "chunk_id": "d296142a",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n发起人股东 | 2,051,370.43 | 2,051,370.43\n合计 | 2,051,370.43 | 2,051,370.43",
      "chunk_type": "table_group",
      "parent_id": "befa82f6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 143,
      "page_number": 154,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258134",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 143,
        "word_count": 17,
        "sentence_count": 4,
        "chinese_char_count": 21,
        "readability_score": 0.0,
        "information_density": 0.06993006993006994,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4042833333333334,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股东"
      ]
    },
    {
      "chunk_id": "c95ddaab",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应付暂收款 | 14,988,518.12 | 11,511,834.54\n出口货物运保费及佣金 | 8,226,443.88 | 3,988,336.40\n押金保证金 | 920,310.00 | 2,476,025.00\n暂借款 | 350,000.00 | 1,345,413.90\n其 他 | 1,663,430.79 | 2,261,571.36\n合计 | 26,148,702.79 | 21,583,181.20",
      "chunk_type": "table_group",
      "parent_id": "45381ec9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 288,
      "page_number": 154,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应付",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          154
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258232",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 288,
        "word_count": 38,
        "sentence_count": 12,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.06944444444444445,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4009508896797153,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "借款"
      ]
    },
    {
      "chunk_id": "0b856f40",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n一年内到期的长期应付款 | | 44,365,875.00\n合计 | | 44,365,875.00",
      "chunk_type": "table_group",
      "parent_id": "f555640d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 125,
      "page_number": 155,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应付"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          155
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258291",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 125,
        "word_count": 15,
        "sentence_count": 2,
        "chinese_char_count": 27,
        "readability_score": 0.0,
        "information_density": 0.08,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37775000000000003,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付"
      ]
    },
    {
      "chunk_id": "7ae98d0c",
      "content": "【说明】46、应付债券\n（1）应付债券\n单位： 元\n项目 期末余额 期初余额\n（2）应付债券的增减变动（不包括划分为金融负债的优先股、永续债等其他金融工具）\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n合计 -- -- --\n（3）可转换公司债券的转股条件、转股时间说明\n（4）划分为金融负债的其他金融工具说明\n期末发行在外的优先股、永续债等其他金融工具基本情况\n期末发行在外的优先股、永续债等金融工具变动情况表\n单位： 元\n发行在外的 期初 本期增加 本期减少 期末\n金融工具 数量 账面价值 数量 账面价值 数量 账面价值 数量 账面价值\n其他金融工具划分为金融负债的依据说明\n其他说明\n47、租赁负债\n单位：\n项目 期末余额 期初余额\n其他说明\n48、长期应付款\n单位： 元\n项目 期末余额 期初余额\n（1）按款项性质列示长期应付款\n单位： 元\n156\n\n【表格内容】\n| | | | | | | 按面值计 | 溢折价摊 | | | \n--------------------------------------------------\n债券名称 | 面值 | 发行日期 | 债券期限 | 发行金额 | 期初余额 | 本期发行 | | | 本期偿还 | | 期末余额\n | | | | | | | 提利息 | 销 | | | \n | | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "13742204",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 632,
      "page_number": 155,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "应付",
          "账面价值",
          "价值",
          "债券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          155
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258455",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 632,
        "word_count": 124,
        "sentence_count": 0,
        "chinese_char_count": 361,
        "readability_score": 0.0,
        "information_density": 0.07911392405063292,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4993595995215062,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "应付",
        "账面价值",
        "价值",
        "债券"
      ]
    },
    {
      "chunk_id": "5667550f",
      "content": "【表格内容】\n| | | | | | | 按面值计 | 溢折价摊 | | | \n--------------------------------------------------\n债券名称 | 面值 | 发行日期 | 债券期限 | 发行金额 | 期初余额 | 本期发行 | | | 本期偿还 | | 期末余额\n | | | | | | | 提利息 | 销 | | | \n | | | | | | | | | | | \n | | | | | | | | | | | \n合计 | -- | -- | -- | | | | | | | |\n\n【注释】项目 期末余额 期初余额\n其他说明：\n（2）专项应付款\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n其他说明：\n49、长期应付职工薪酬\n（1）长期应付职工薪酬表\n单位： 元\n项目 期末余额 期初余额\n（2）设定受益计划变动情况\n设定受益计划义务现值：\n单位： 元\n项目 本期发生额 上期发生额\n计划资产：\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划净负债（净资产）\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划的内容及与之相关风险、对公司未来现金流量、时间和不确定性的影响说明：\n设定受益计划重大精算假设及敏感性分析结果说明：\n其他说明：\n50、预计负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额 形成原因\n未支付合同义务及诉讼费 11,637,669.47\n未支付担保损失 1,333,333.00 1,333,333.00[注]\n157",
      "chunk_type": "table_group",
      "parent_id": "ee79cb68",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 683,
      "page_number": 156,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "收入",
          "现金",
          "应付",
          "净资产",
          "债券"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          156
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258667",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 683,
        "word_count": 146,
        "sentence_count": 3,
        "chinese_char_count": 328,
        "readability_score": 0.0,
        "information_density": 0.10248901903367495,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5302035358190197,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "现金",
        "应付",
        "净资产",
        "债券"
      ]
    },
    {
      "chunk_id": "8efe9dd1",
      "content": "【表格内容】\n发行在外的 | 期初 | | 本期增加 | | 本期减少 | | 期末 | \n--------------------------------------------------\n金融工具 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值",
      "chunk_type": "table_group",
      "parent_id": "e4c44824",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 149,
      "page_number": 156,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          156
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.258751",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 149,
        "word_count": 32,
        "sentence_count": 0,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.1342281879194631,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.400551724137931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "41c2d9b2",
      "content": "【说明】合计 1,333,333.00 12,971,002.47 --\n其他说明，包括重要预计负债的相关重要假设、估计说明：\n[注]：根据2000年12月16日浙江省台州市中级人民法院〔2000〕台经初字第204号《民事判决书》，公\n司为台州市染料化工(集团)公司向台州市椒江区财政局的4,000,000.00元借款提供保证，因该公司未按合同\n约定如期归还，本公司需承担三分之一的到期还款连带责任，并赔偿台州市椒江区财政局相应的损失，截\n至2019年12月31日该项判决尚未执行。对上述诉讼事项，公司已按应承担的连带责任计提预计负债\n1,333,333.00元。51、递延收益\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n政府补助 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n未实现售后租回损\n1,307,404.76 402,278.40 905,126.36\n益\n合计 44,650,629.91 12,900,000.00 6,956,538.39 50,594,091.52 --\n涉及政府补助的项目：\n单位： 元\n本期计入营\n本期新增补 本期计入其 本期冲减成 与资产相关/\n负债项目 期初余额 业外收入金 其他变动 期末余额\n助金额 他收益金额 本费用金额 与收益相关\n额\n年产400吨\n碳青霉烯类\n1,423,820.2\n抗生素关键 5,695,281.12 4,271,460.84 与资产相关\n8\n中间体\n4-AA项目\n年产1吨瑞\n格列奈、10\n吨卡洛芬、\n10吨阿托伐\n醌、50吨\nT1620、300\n235,862.40 117,931.20 117,931.20 与资产相关\n吨聚卡波菲\n钙、300吨\n4,4'-二氟二\n苯甲酮、100\n吨奈韦拉平\n产业化项目\n158。\n\n【表格内容】\n项目 | 期末余额 | 期初余额 | 形成原因\n--------------------------------------------------\n未支付合同义务及诉讼费 | | 11,637,669.47 | \n未支付担保损失 | 1,333,333.00 | 1,333,333.00 | [注]",
      "chunk_type": "table_group",
      "parent_id": "95e48eb4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 952,
      "page_number": 157,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "收入",
          "费用",
          "借款"
        ],
        "time_periods": [
          "2000-12",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          157
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.259052",
        "report_type": null,
        "fiscal_year": 2000,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 952,
        "word_count": 100,
        "sentence_count": 27,
        "chinese_char_count": 403,
        "readability_score": 0.0,
        "information_density": 0.052521008403361345,
        "coherence_score": 0.5325840336134453,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5012662820845216,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "费用",
        "借款"
      ]
    },
    {
      "chunk_id": "24cfd0ab",
      "content": "【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额 | 形成原因\n--------------------------------------------------\n政府补助 | 43,343,225.15 | 12,900,000.00 | 6,554,259.99 | 49,688,965.16 | \n未实现售后租回损 | | | | | \n | 1,307,404.76 | | 402,278.40 | 905,126.36 | \n益 | | | | | \n | | | | | \n合计 | 44,650,629.91 | 12,900,000.00 | 6,956,538.39 | 50,594,091.52 | --",
      "chunk_type": "table_group",
      "parent_id": "b4947f33",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 329,
      "page_number": 158,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          158
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.259359",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 329,
        "word_count": 59,
        "sentence_count": 11,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4085671641791045,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "0c2b20e3",
      "content": "【表格内容】\n催化净化处 | | | | 30,000.00 | | | 110,000.00 | \n--------------------------------------------------\n理塔建设项 | 140,000.00 | | | | | | | 与资产相关\n目 | | | | | | | | \n年产50吨培 | | | | 48,000.00 | | | 84,000.00 | \n南类产品及 | | | | | | | | \n | 132,000.00 | | | | | | | 与资产相关\n扩建厂房技 | | | | | | | | \n | | | | | | | | \n改项目 | | | | | | | | \n企业技术中 | | | | 40,000.00 | | | 93,333.33 | \n心创新能力 | 133,333.33 | | | | | | | 与资产相关\n建设项目 | | | | | | | | \n年产8亿元 | | | | 997,440.00 | | | 6,067,760.00 | \n(粒)口服固 | 7,065,200.00 | | | | | | | 与资产相关\n体制剂项目 | | | | | | | | \n临海市创新 | | | | 208,543.68 | | | 834,174.72 | \n驱动加快推 | | | | | | | | \n进工业经济 | 1,042,718.40 | | | | | | | 与资产相关\n转型升级政 | | | | | | | | \n策 | | | | | | | | \n省级工业与 | | | | 92,599.92 | | | 540,166.20 | \n信息化专项 | | | | | | | | \n资金回收溶 | 632,766.12 | | | | | | | 与资产相关\n剂循环化技 | | | | | | | | \n改项目 | | | | | | | | \n省工业化和 | | | | 66,169.92 | | | 391,505.36 | \n信息化深度 | | | | | | | | \n融合示范试 | 457,675.28 | | | | | | | 与资产相关\n点区财政补 | | | | | | | | \n助 | | | | | | | | \n浙江省化学 | | | | 40,000.00 | | | 223,333.33 | \n原料药基地 | | | | | | | | \n椒江区块循 | 263,333.33 | | | | | | | 与资产相关\n环化改造项 | | | | | | | | \n目补助资金 | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "e7572896",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1138,
      "page_number": 159,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          159
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.259646",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1138,
        "word_count": 347,
        "sentence_count": 24,
        "chinese_char_count": 189,
        "readability_score": 0.0,
        "information_density": 0.008787346221441124,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47884331116038437,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "e0bfd64a",
      "content": "年产2吨盐 |  |  |  | 281,889.96 |  |  | 1,808,793.91 | \n--------------------------------------------------\n酸阿莫罗 |  |  |  |  |  |  |  | \n芬、20吨阿 |  |  |  |  |  |  |  | \n特来马来酸 |  |  |  |  |  |  |  | \n盐、5吨多尼 |  |  |  |  |  |  |  | \n培南、20吨 | 2,090,683.87 |  |  |  |  |  |  | 与资产相关\n美罗培南、5 |  |  |  |  |  |  |  | \n吨比阿培 |  |  |  |  |  |  |  | \n南、60吨 |  |  |  |  |  |  |  | \nPHE产业化 |  |  |  |  |  |  |  | \n项目(续建) |  |  |  |  |  |  |  | \n年产15000 |  |  |  | 100,000.00 |  |  | 750,000.00 | \n吨环保型活 |  |  |  |  |  |  |  | \n性艳蓝 |  |  |  |  |  |  |  | \n | 850,000.00 |  |  |  |  |  |  | 与资产相关\nKN-R商品 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n染料技改项 |  |  |  |  |  |  |  | \n目 |  |  |  |  |  |  |  | \n大品种药物 |  |  |  | 291,265.91 |  |  | 2,569,150.76 | \n的生产技术 |  |  |  |  |  |  |  | \n改造-美罗 |  |  |  |  |  |  |  | \n | 860,416.67 | 2,000,000.00 |  |  |  |  |  | 与资产相关\n培南原料药 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n绿色合成技 |  |  |  |  |  |  |  | \n术改造 |  |  |  |  |  |  |  | \n临海医化园 |  |  |  | 105,000.00 |  |  | 385,000.00 | \n区循环化改 | 490,000.00 |  |  |  |  |  |  | 与资产相关\n造项目 |  |  |  |  |  |  |  | \n南洋涂-固 |  |  |  | 246,999.96 |  |  | 2,039,833.02 | \n废减量化处 | 2,286,832.98 |  |  |  |  |  |  | 与资产相关\n置项目 |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b29f2ee7",
      "child_ids": [],
      "sibling_ids": [
        "c4aadda2"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1712,
      "page_number": 160,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.260107",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1212,
        "word_count": 315,
        "sentence_count": 16,
        "chinese_char_count": 135,
        "readability_score": 0.0,
        "information_density": 0.00825082508250825,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.597157914549219,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "c4aadda2",
      "content": "年产400吨 |  |  |  | 1,490,999.9\n1 |  |  | 20,471,166.40 | \nMAP、100 |  |  |  |  |  |  |  | \n吨OA、200 |  |  |  |  |  |  |  | \n吨DA、100 |  | 10,000,000.0 |  |  |  |  |  | \n | 11,962,166.31 |  |  |  |  |  |  | 与资产相关\n吨甲砜霉 |  | 0 |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n素、10吨联 |  |  |  |  |  |  |  | \n苯双酯产业 |  |  |  |  |  |  |  | \n化新项目 |  |  |  |  |  |  |  | \n年产580吨 |  |  |  | 248,910.00 |  |  | 1,866,825.00 | \n柳氮磺胺吡 |  |  |  |  |  |  |  | \n | 2,115,735.00 |  |  |  |  |  |  | 与资产相关\n啶产业化项 |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n目 |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b29f2ee7",
      "child_ids": [],
      "sibling_ids": [
        "e0bfd64a"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1558,
      "page_number": 160,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 17,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          160
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.260192",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 558,
        "word_count": 151,
        "sentence_count": 7,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.017921146953405017,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.597157914549219,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "a61e6174",
      "content": "【表格内容】\n清洁生产循 | | | | 600,000.00 | | | 4,200,000.00 | \n--------------------------------------------------\n环利用及三 | | | | | | | | \n | 4,800,000.00 | | | | | | | 与资产相关\n废综合治理 | | | | | | | | \n | | | | | | | | \n提升项目 | | | | | | | | \n年产15500 | | | | | | | 1,296,000.00 | \n吨活性染料 | | | | | | | | \n | 1,296,000.00 | | | | | | | 与资产相关\n产业升级及 | | | | | | | | \n | | | | | | | | \n配套项目 | | | | | | | | \n孵化器车间 | | | | 81,355.92 | | | 711,864.42 | \n | 793,220.34 | | | | | | | 与资产相关\n技改项目 | | | | | | | | \n | | | | | | | | \n浙江省化学 | | | | 10,000.00 | | | 390,000.00 | \n原料药基地 | | | | | | | | \n椒江区块循 | | | | | | | | \n | | 400,000.00 | | | | | | 与资产相关\n环化改造项 | | | | | | | | \n | | | | | | | | \n目补助资金 | | | | | | | | \n项目补助 | | | | | | | | \n年产700吨 | | | | 33,333.33 | | | 466,666.67 | \nM-562关键 | | | | | | | | \n | | 500,000.00 | | | | | | 与资产相关\n中间体产业 | | | | | | | | \n | | | | | | | | \n一体化项目 | | | | | | | | \n | | | | 6,554,259.9\n9 | | | 49,688,965.16 | \n | | 12,900,000.0 | | | | | | \n小 计 | 43,343,225.15 | | | | | | | \n | | 0 | | | | | | \n | | | | | | | | \n | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "67470ee5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1049,
      "page_number": 161,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          161
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260448",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1049,
        "word_count": 337,
        "sentence_count": 18,
        "chinese_char_count": 119,
        "readability_score": 0.0,
        "information_density": 0.009532888465204958,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47185214211076276,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "4995afe1",
      "content": "【说明】根据公司2019年第一次临时股东大会决议，公司按照每股人民币2.25元向赵敏蔚等5人回购其所持有的\n已获授但尚未解锁的限制性股票105,000股，并扣回原已现金分红的可撤销现金股利66,150.00元，实际于\n2019年5月20日归还激励对象出资170,100.00元，其中，减少实收资本105,000元，减少资本公积131,250.00\n元。上述减资业经天健会计师事务所(特殊普通合伙)审验，并由其出具《验资报告》(天健验〔2019〕158\n号)。上述事项公司已于2019年7月1日办妥工商变更登记手续。\n\n【表格内容】\n| | 本次变动增减（+ -） | | | | | \n--------------------------------------------------\n | 期初余额 | | | | | | 期末余额\n | | 发行新股 | 送股 | 公积金转股 | 其他 | 小计 | \n | | | | | | | \n | 1,618,820,253. | | | | | | 1,618,715,253.\n\n股份总数 | | | | | -105,000.00 | -105,000.00 | \n | 00 | | | | | | \n | | | | | | |\n\n【注释】56、库存股\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n限制性人民币普通股 44,365,875.00 44,365,875.00\n股份回购 281,514,686.68 19,996,827.22 301,511,513.90\n合计 325,880,561.68 19,996,827.22 44,365,875.00 301,511,513.90\n其他说明，包括本期增减变动情况、变动原因说明：\n162。",
      "chunk_type": "table_group",
      "parent_id": "3e727022",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 762,
      "page_number": 161,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "现金",
          "资本公积",
          "股份",
          "股东",
          "分红",
          "每股",
          "回购",
          "报告"
        ],
        "time_periods": [
          "2019-5",
          "2019-7"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          161
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260690",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 762,
        "word_count": 100,
        "sentence_count": 21,
        "chinese_char_count": 259,
        "readability_score": 0.0,
        "information_density": 0.10498687664041995,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5898376096557675,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "现金",
        "资本公积",
        "股份",
        "股东",
        "分红",
        "每股",
        "回购",
        "报告"
      ]
    },
    {
      "chunk_id": "dfb9874f",
      "content": "【表格内容】\n发行在外的 | 期初 | | 本期增加 | | 本期减少 | | 期末 | \n--------------------------------------------------\n金融工具 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值 | 数量 | 账面价值",
      "chunk_type": "table_group",
      "parent_id": "e4c64bb1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 149,
      "page_number": 162,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          162
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260771",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 149,
        "word_count": 32,
        "sentence_count": 0,
        "chinese_char_count": 49,
        "readability_score": 0.0,
        "information_density": 0.1342281879194631,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.400551724137931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "43ff81ff",
      "content": "【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n资本溢价（股本溢价） | 2,612,188,669.80 | 43,566,610.03 | 131,250.00 | 2,655,624,029.83\n其他资本公积 | 51,179,152.67 | 7,113,749.53 | 43,566,610.03 | 14,726,292.17\n合计 | 2,663,367,822.47 | 50,680,359.56 | 43,697,860.03 | 2,670,350,322.00",
      "chunk_type": "table_group",
      "parent_id": "aa94d04e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 309,
      "page_number": 162,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股本",
          "资本公积"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          162
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.260901",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 309,
        "word_count": 38,
        "sentence_count": 12,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.06472491909385114,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.477287417218543,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股本",
        "资本公积"
      ]
    },
    {
      "chunk_id": "98b6ece3",
      "content": "【说明】1）本期库存股减少44,365,875.00元，其中：①回购并注销赵敏蔚等5人已获授但尚未解锁的限制性股\n票105,000股，按回购价计算减少236,250.00元；②本期解锁减少库存股16,546,500股，每股授予价格2.25元，\n减少37,229,625.00元；③预留授予的限制性股票第一期解锁1,600,000股，每股授予价格4.3125元，减少\n6,900,000.00元。2）本期库存股增加19,996,827.22元，系本期回购股份增加的库存股，公司以集中竞价交易方式回购公\n司股份，回购价格不超过6.9元/股，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，回\n购股份拟用作员工持股计划、股权激励计划或注销以减少公司注册资本。本期公司回购股份4,528,000股，\n回购总成本19,996,827.22元，公司回购股份计划已实施完毕。\n\n【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n限制性人民币普通股 | 44,365,875.00 | | 44,365,875.00 | \n股份回购 | 281,514,686.68 | 19,996,827.22 | | 301,511,513.90\n合计 | 325,880,561.68 | 19,996,827.22 | 44,365,875.00 | 301,511,513.90",
      "chunk_type": "table_group",
      "parent_id": "ab7f3107",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 652,
      "page_number": 162,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "成本",
          "股权",
          "股份",
          "每股",
          "回购"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          162
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.261167",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 652,
        "word_count": 46,
        "sentence_count": 21,
        "chinese_char_count": 260,
        "readability_score": 0.0,
        "information_density": 0.07668711656441718,
        "coherence_score": 0.623165578557134,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4817970947942135,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "股权",
        "股份",
        "每股",
        "回购"
      ]
    },
    {
      "chunk_id": "eade4ff5",
      "content": " |  | 本期发生额 |  |  |  |  |  | \n--------------------------------------------------\n |  |  |  | 减：前期 |  |  |  | \n |  |  | 减：前期计入 |  |  |  |  | \n |  | 本期所得 |  | 计入其他 |  |  | 税后归属 | 期末余\n项目 | 期初余额 |  | 其他综合收 |  | 减：所得 | 税后归属 |  | \n |  | 税前发生 |  | 综合收益 |  |  | 于少数股 | 额\n |  |  | 益当期转入 |  | 税费用 | 于母公司 |  | \n |  | 额 |  | 当期转入 |  |  | 东 | \n |  |  | 损益 |  |  |  |  | \n |  |  |  | 留存收益 |  |  |  | \n |  |  |  |  |  |  |  | \n一、不能重分类进损益的其他综 |  | -1,800,000 |  |  |  | -1,800,000\n.00 |  | -1,800,0\n |  |  |  |  |  |  |  | \n合收益 |  | .00 |  |  |  |  |  | 00.00\n |  |  |  |  |  |  |  | \n其他权益工具投资公允 |  | -1,800,000 |  |  |  | -1,800,000\n.00 |  | -1,800,0\n |  |  |  |  |  |  |  | \n价值变动 |  | .00 |  |  |  |  |  | 00.00\n |  |  |  |  |  |  |  | \n二、将重分类进损益的其他综合 |  | 361,590.4 |  |  |  | 361,590.4\n2 |  | 309,811.\n | -51,779.23 |  |  |  |  |  |  | \n收益 |  | 2 |  |  |  |  |  | 19\n |  |  |  |  |  |  |  | \n |  | 361,590.4 |  |  |  | 361,590.4\n2 |  | 309,811.\n外币财务报表折算差额 | -51,779.23 |  |  |  |  |  |  | \n |  | 2 |  |  |  |  |  | 19\n |  |  |  |  |  |  |  | \n |  | -1,438,409 |  |  |  | -1,438,409\n.58 |  | -1,490,1\n88.81\n其他综合收益合计 | -51,779.23 |  |  |  |  |  |  | \n |  | .58 |  |  |  |  |  | \n |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "a0fed92a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1689,
      "page_number": 163,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 38,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "费用",
          "投资",
          "母公司",
          "税费"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          163
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.261629",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1189,
        "word_count": 314,
        "sentence_count": 18,
        "chinese_char_count": 146,
        "readability_score": 0.0,
        "information_density": 0.050462573591253154,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7368376787216149,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "费用",
        "投资",
        "母公司",
        "税费",
        "价值"
      ]
    },
    {
      "chunk_id": "6d1b49b9",
      "content": "【说明】18,997,055.97元。59、盈余公积\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n法定盈余公积 201,812,279.17 11,257,545.14 213,069,824.31\n合计 201,812,279.17 11,257,545.14 213,069,824.31\n盈余公积说明，包括本期增减变动情况、变动原因说明：\n60、未分配利润\n单位： 元\n项目 本期 上期\n调整前上期末未分配利润 1,232,481,918.50 897,836,956.42\n调整后期初未分配利润 1,232,481,918.50 897,836,956.42\n加：本期归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n减：提取法定盈余公积 11,257,545.14 108,614,533.40\n应付普通股股利 466,678,159.50 161,744,325.30\n期末未分配利润 1,525,328,398.95 1,232,481,918.50\n调整期初未分配利润明细：\n1)、由于《企业会计准则》及其相关新规定进行追溯调整，影响期初未分配利润0.00元。2)、由于会计政策变更，影响期初未分配利润0.00元。\n\n【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n安全生产费 | | 18,997,055.97 | 18,997,055.97 | \n合计 | | 18,997,055.97 | 18,997,055.97 |",
      "chunk_type": "table_group",
      "parent_id": "0d680efd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 713,
      "page_number": 163,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "应付",
          "净利润",
          "母公司",
          "未分配利润",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          163
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.261888",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 713,
        "word_count": 68,
        "sentence_count": 28,
        "chinese_char_count": 221,
        "readability_score": 0.0,
        "information_density": 0.08415147265077139,
        "coherence_score": 0.7963636363636364,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4748099692889204,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "应付",
        "净利润",
        "母公司",
        "未分配利润",
        "分配"
      ]
    },
    {
      "chunk_id": "db7dce5c",
      "content": "【说明】61、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 2,925,688,906.14 1,449,500,049.29 2,691,787,601.50 1,492,180,658.53\n其他业务 15,723,864.16 13,659,311.75 26,821,195.01 19,764,017.65\n合计 2,941,412,770.30 1,463,159,361.04 2,718,608,796.51 1,511,944,676.18\n是否已执行新收入准则\n□ 是 √ 否\n其他说明\n164。\n\n【表格内容】\n项目 | 期初余额 | 本期增加 | 本期减少 | 期末余额\n--------------------------------------------------\n法定盈余公积 | 201,812,279.17 | 11,257,545.14 | | 213,069,824.31\n合计 | 201,812,279.17 | 11,257,545.14 | | 213,069,824.31",
      "chunk_type": "table_group",
      "parent_id": "ab8b3ddf",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 487,
      "page_number": 164,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "收入",
          "成本",
          "营业收入",
          "营业成本",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262071",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 487,
        "word_count": 59,
        "sentence_count": 19,
        "chinese_char_count": 90,
        "readability_score": 0.0,
        "information_density": 0.1026694045174538,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4506567392609574,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "营业收入",
        "营业成本",
        "营业"
      ]
    },
    {
      "chunk_id": "5abcdc1d",
      "content": "【表格内容】\n项目 | 本期 | 上期\n--------------------------------------------------\n调整前上期末未分配利润 | 1,232,481,918.50 | 897,836,956.42\n调整后期初未分配利润 | 1,232,481,918.50 | 897,836,956.42\n加：本期归属于母公司所有者的净利润 | 770,782,185.09 | 605,003,820.78\n减：提取法定盈余公积 | 11,257,545.14 | 108,614,533.40\n应付普通股股利 | 466,678,159.50 | 161,744,325.30\n期末未分配利润 | 1,525,328,398.95 | 1,232,481,918.50",
      "chunk_type": "table_group",
      "parent_id": "bfa62e7a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 349,
      "page_number": 164,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "应付",
          "净利润",
          "母公司",
          "未分配利润",
          "分配"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262213",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 349,
        "word_count": 37,
        "sentence_count": 12,
        "chinese_char_count": 70,
        "readability_score": 0.0,
        "information_density": 0.17191977077363896,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.530680701754386,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "应付",
        "净利润",
        "母公司",
        "未分配利润",
        "分配"
      ]
    },
    {
      "chunk_id": "4a32deda",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n城市维护建设税 | 8,979,337.87 | 11,136,827.27\n教育费附加 | 4,206,609.84 | 5,294,134.87\n房产税 | 5,843,558.13 | 6,064,374.46\n土地使用税 | 2,733,446.70 | 4,311,794.23\n车船使用税 | 92,034.56 | 91,578.70\n印花税 | 2,055,976.68 | 1,234,528.45\n环境保护税 | 125,638.87 | 520,262.21\n地方教育附加 | 2,804,406.56 | 3,529,423.24\n合计 | 26,841,009.21 | 32,182,923.43",
      "chunk_type": "table_group",
      "parent_id": "eda47e53",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 389,
      "page_number": 165,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          165
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262559",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 389,
        "word_count": 52,
        "sentence_count": 18,
        "chinese_char_count": 57,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42221151832460735,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "510b2bd4",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n佣 金 | 23,106,866.17 | 4,449,906.56\n运输费 | 15,855,838.29 | 18,776,797.69\n职工薪酬 | 11,454,758.67 | 9,017,672.93\n宣传展览费 | 2,730,663.11 | 3,083,947.22\n保险费 | 2,384,650.11 | 1,684,252.56\n业务招待费 | 1,327,567.15 | 3,743,333.54\n差旅费 | 930,856.80 | 1,475,970.50\n邮寄费 | 306,320.89 | 564,905.56\n其 他 | 1,525,503.69 | 984,267.86\n合计 | 59,623,024.88 | 43,781,054.42",
      "chunk_type": "table_group",
      "parent_id": "e082340d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 418,
      "page_number": 165,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          165
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.262949",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 418,
        "word_count": 59,
        "sentence_count": 20,
        "chinese_char_count": 48,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3297142857142857,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42325839416058386,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "9da15536",
      "content": "【说明】修理费 54,078,791.78 25,798,829.44\n办公费 33,101,653.33 21,185,949.02\n无形资产摊销 29,011,624.85 28,842,167.28\n排污及废物处理费 15,278,838.29 7,077,717.42\n中介及咨询服务费 12,874,898.20 27,576,302.13\n业务招待费 10,763,238.07 6,012,227.78\n以股份支付换取的职工服务 6,036,351.55 37,421,812.71\n保险费 3,790,087.45 2,996,910.69\n差旅费 2,464,786.84 3,670,795.30\n实验检验费 1,934,413.09 1,767,427.11\n劳动保护费 1,919,068.07 2,136,408.20\n其 他 8,262,952.08 5,163,839.89\n合计 386,185,538.84 349,284,396.57\n其他说明：\n65、研发费用\n单位： 元\n项目 本期发生额 上期发生额\n直接材料 24,329,506.93 26,831,622.01\n职工薪酬 53,798,685.12 47,193,153.47\n直接费用 27,647,391.51 19,395,798.61\n委托外部研究开发费 15,764,779.23 11,166,389.47\n以股份支付换取的职工服务 1,007,861.74 6,717,698.51\n合计 122,548,224.53 111,304,662.07\n其他说明：\n66、财务费用\n单位： 元\n项目 本期发生额 上期发生额\n利息支出 15,506,676.74 42,594,267.08\n利息收入 -41,773,975.28 -44,371,159.00\n汇兑净损益 -12,759,207.59 -50,821,750.14\n金融机构手续费 1,161,350.07 1,091,244.28\n合计 -37,865,156.06 -51,507,397.78\n166。\n\n【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n职工薪酬 | 135,254,390.92 | 119,986,220.11\n折旧费 | 71,414,444.32 | 59,647,789.49",
      "chunk_type": "table_group",
      "parent_id": "55f40b49",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1043,
      "page_number": 165,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入",
          "费用",
          "无形资产",
          "研发费用",
          "财务费用",
          "股份",
          "折旧",
          "摊销"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          165
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263263",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1043,
        "word_count": 105,
        "sentence_count": 53,
        "chinese_char_count": 193,
        "readability_score": 0.0,
        "information_density": 0.0862895493767977,
        "coherence_score": 0.3279444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.470921336996337,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "费用",
        "无形资产",
        "研发费用",
        "财务费用",
        "股份",
        "折旧",
        "摊销"
      ]
    },
    {
      "chunk_id": "69e46533",
      "content": "【表格内容】\n修理费 | 54,078,791.78 | 25,798,829.44\n--------------------------------------------------\n办公费 | 33,101,653.33 | 21,185,949.02\n无形资产摊销 | 29,011,624.85 | 28,842,167.28\n排污及废物处理费 | 15,278,838.29 | 7,077,717.42\n中介及咨询服务费 | 12,874,898.20 | 27,576,302.13\n业务招待费 | 10,763,238.07 | 6,012,227.78\n以股份支付换取的职工服务 | 6,036,351.55 | 37,421,812.71\n保险费 | 3,790,087.45 | 2,996,910.69\n差旅费 | 2,464,786.84 | 3,670,795.30\n实验检验费 | 1,934,413.09 | 1,767,427.11\n劳动保护费 | 1,919,068.07 | 2,136,408.20\n其 他 | 8,262,952.08 | 5,163,839.89\n合计 | 386,185,538.84 | 349,284,396.57",
      "chunk_type": "table_group",
      "parent_id": "a1e7abbe",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 541,
      "page_number": 166,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "无形资产",
          "股份",
          "摊销"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263479",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 541,
        "word_count": 68,
        "sentence_count": 26,
        "chinese_char_count": 69,
        "readability_score": 0.0,
        "information_density": 0.07393715341959335,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4765917602996254,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "无形资产",
        "股份",
        "摊销"
      ]
    },
    {
      "chunk_id": "4b2c8f8f",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n直接材料 | 24,329,506.93 | 26,831,622.01\n职工薪酬 | 53,798,685.12 | 47,193,153.47\n直接费用 | 27,647,391.51 | 19,395,798.61\n委托外部研究开发费 | 15,764,779.23 | 11,166,389.47\n以股份支付换取的职工服务 | 1,007,861.74 | 6,717,698.51\n合计 | 122,548,224.53 | 111,304,662.07",
      "chunk_type": "table_group",
      "parent_id": "13e24905",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 309,
      "page_number": 166,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "股份"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          166
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263603",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 309,
        "word_count": 37,
        "sentence_count": 12,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.06472491909385114,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4087443708609271,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "股份"
      ]
    },
    {
      "chunk_id": "4f77682b",
      "content": "【表格内容】\n产生其他收益的来源 | 本期发生额 | 上期发生额\n--------------------------------------------------\n与资产相关的政府补助 | 6,554,259.99 | 5,071,751.21\n与收益相关的政府补助 | 20,582,664.88 | 6,719,986.82\n合 计 | 27,136,924.87 | 11,791,738.03",
      "chunk_type": "table_group",
      "parent_id": "78d5e183",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 202,
      "page_number": 167,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263681",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 202,
        "word_count": 23,
        "sentence_count": 6,
        "chinese_char_count": 45,
        "readability_score": 0.0,
        "information_density": 0.04950495049504951,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42887179487179494,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "8ebd7ded",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n权益法核算的长期股权投资收益 | -16,759,549.80 | -6,923,938.93\n银行理财产品收益 | 2,079,074.70 | 3,024,312.63\n处置金融工具取得的投资收益 | -559,587.45 | -5,459,752.25\n合计 | -15,240,062.55 | -9,359,378.55",
      "chunk_type": "table_group",
      "parent_id": "2c0ee58e",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 243,
      "page_number": 167,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "投资",
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263772",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 243,
        "word_count": 27,
        "sentence_count": 8,
        "chinese_char_count": 53,
        "readability_score": 0.0,
        "information_density": 0.12345679012345678,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43667740112994347,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "投资",
        "股权"
      ]
    },
    {
      "chunk_id": "6c562208",
      "content": "【表格内容】\n产生公允价值变动收益的来源 | 本期发生额 | 上期发生额\n--------------------------------------------------\n交易性金融负债 | | 5,010,265.70\n合计 | | 5,010,265.70",
      "chunk_type": "table_group",
      "parent_id": "19cda2ae",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 132,
      "page_number": 167,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.263844",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 132,
        "word_count": 15,
        "sentence_count": 2,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.22727272727272724,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4215286089238845,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "8b94aabc",
      "content": "【说明】合计 -2,502,149.00\n其他说明：\n72、资产减值损失\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 本期发生额 上期发生额\n一、坏账损失 -3,669,712.21\n二、存货跌价损失 -9,789,957.42 -3,098,809.43\n五、长期股权投资减值损失 -1,449,207.56 -6,281,771.71\n七、固定资产减值损失 -499,541.72\n十二、无形资产减值损失 -5,817,610.17\n合计 -11,738,706.70 -18,867,903.52\n其他说明：\n73、资产处置收益\n单位： 元\n资产处置收益的来源 本期发生额 上期发生额\n固定资产处置收益 244,580.94 659,231.88\n合 计 244,580.94 659,231.88\n74、营业外收入\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换利得 56,093.96 126,221.82 56,093.96\n无法支付款项 370,069.55\n违约及赔款收入 896,839.67 972,312.09 896,839.67\n其 他 172,720.90 244,682.63 172,720.90\n合计 1,125,654.53 1,713,286.09 1,125,654.53\n计入当期损益的政府补助：\n单位： 元\n补贴是否影 是否特殊补 本期发生金 上期发生金 与资产相关/\n补助项目 发放主体 发放原因 性质类型\n响当年盈亏 贴 额 额 与收益相关\n168。\n\n【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n坏账损失 | -2,502,149.00 |",
      "chunk_type": "table_group",
      "parent_id": "3478e7a5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 777,
      "page_number": 167,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入",
          "投资",
          "存货",
          "固定资产",
          "无形资产",
          "营业",
          "股权",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          167
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264118",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 777,
        "word_count": 99,
        "sentence_count": 29,
        "chinese_char_count": 275,
        "readability_score": 0.0,
        "information_density": 0.11583011583011585,
        "coherence_score": 0.4044444444444444,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4645213941416389,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "投资",
        "存货",
        "固定资产",
        "无形资产",
        "营业",
        "股权",
        "减值"
      ]
    },
    {
      "chunk_id": "be0d5055",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n一 坏账损失 | | -3,669,712.21\n二 存货跌价损失 | -9,789,957.42 | -3,098,809.43\n五 长期股权投资减值损失 | -1,449,207.56 | -6,281,771.71\n七 固定资产减值损失 | -499,541.72 | \n十二 无形资产减值损失 | | -5,817,610.17\n合计 | -11,738,706.70 | -18,867,903.52",
      "chunk_type": "table_group",
      "parent_id": "9e7090bd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 282,
      "page_number": 168,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "投资",
          "存货",
          "固定资产",
          "无形资产",
          "股权",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264243",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 282,
        "word_count": 39,
        "sentence_count": 9,
        "chinese_char_count": 60,
        "readability_score": 0.0,
        "information_density": 0.24822695035460995,
        "coherence_score": 0.43999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5190582430806258,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "存货",
        "固定资产",
        "无形资产",
        "股权",
        "减值"
      ]
    },
    {
      "chunk_id": "1b99bbcd",
      "content": "【表格内容】\n资产处置收益的来源 | 本期发生额 | 上期发生额\n--------------------------------------------------\n固定资产处置收益 | 244,580.94 | 659,231.88\n合 计 | 244,580.94 | 659,231.88",
      "chunk_type": "table_group",
      "parent_id": "d6525bee",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 148,
      "page_number": 168,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264308",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 148,
        "word_count": 18,
        "sentence_count": 4,
        "chinese_char_count": 33,
        "readability_score": 0.0,
        "information_density": 0.13513513513513514,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4173843971631206,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产"
      ]
    },
    {
      "chunk_id": "d5913a39",
      "content": "【说明】其他说明：\n75、营业外支出\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换损失 4,451,449.87 887,727.15 4,451,449.87\n对外捐赠 1,464,708.00 998,689.50 1,464,708.00\n罚款支出 81,087.21 781,984.81 81,087.21\n滞纳金 425,031.19 3,252.32 425,031.19\n合同义务损失 885,370.12 12,597,010.47 885,370.12\n其 他 186,383.29 1,445.95 186,383.29\n合计 7,494,029.68 15,270,110.20 7,494,029.68\n其他说明：\n76、所得税费用\n（1）所得税费用表\n单位： 元\n项目 本期发生额 上期发生额\n当期所得税费用 114,171,327.62 88,766,346.55\n递延所得税费用 27,499,467.56 3,525,443.72\n合计 141,670,795.18 92,291,790.27\n（2）会计利润与所得税费用调整过程\n单位： 元\n项目 本期发生额\n利润总额 912,452,980.27\n按法定/适用税率计算的所得税费用 228,113,245.07\n子公司适用不同税率的影响 -66,145,071.59\n调整以前期间所得税的影响 -5,756,005.36\n不可抵扣的成本、费用和损失的影响 9,475,292.73\n使用前期未确认递延所得税资产的可抵扣亏损的影响 -15,816,251.10\n本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏\n6,148,624.85\n损的影响\n169。\n\n【表格内容】\n| | | | 补贴是否影 | 是否特殊补 | 本期发生金 | 上期发生金 | 与资产相关/\n--------------------------------------------------\n补助项目 | 发放主体 | 发放原因 | 性质类型 | | | | | \n | | | | 响当年盈亏 | 贴 | 额 | 额 | 与收益相关\n | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "4ce09e01",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 940,
      "page_number": 168,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "成本",
          "费用",
          "利润",
          "利润总额",
          "所得税",
          "营业",
          "税费",
          "税率"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          168
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264585",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 940,
        "word_count": 124,
        "sentence_count": 35,
        "chinese_char_count": 309,
        "readability_score": 0.0,
        "information_density": 0.09574468085106383,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5448651362984218,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "费用",
        "利润",
        "利润总额",
        "所得税",
        "营业",
        "税费",
        "税率"
      ]
    },
    {
      "chunk_id": "ba0d923c",
      "content": "【表格内容】\n| | | 计入当期非经常性损益的金\n--------------------------------------------------\n项目 | 本期发生额 | 上期发生额 | \n | | | 额\n | | | \n非货币性资产交换损失 | 4,451,449.87 | 887,727.15 | 4,451,449.87\n对外捐赠 | 1,464,708.00 | 998,689.50 | 1,464,708.00\n罚款支出 | 81,087.21 | 781,984.81 | 81,087.21\n滞纳金 | 425,031.19 | 3,252.32 | 425,031.19\n合同义务损失 | 885,370.12 | 12,597,010.47 | 885,370.12\n其 他 | 186,383.29 | 1,445.95 | 186,383.29\n合计 | 7,494,029.68 | 15,270,110.20 | 7,494,029.68",
      "chunk_type": "table_group",
      "parent_id": "270a4035",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 439,
      "page_number": 169,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          169
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264766",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 439,
        "word_count": 69,
        "sentence_count": 21,
        "chinese_char_count": 60,
        "readability_score": 0.0,
        "information_density": 0.022779043280182234,
        "coherence_score": 0.32986363636363636,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4652677296886864,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "6dca7ea4",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n当期所得税费用 | 114,171,327.62 | 88,766,346.55\n递延所得税费用 | 27,499,467.56 | 3,525,443.72\n合计 | 141,670,795.18 | 92,291,790.27",
      "chunk_type": "table_group",
      "parent_id": "911c12fe",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 192,
      "page_number": 169,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "所得税",
          "税费"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          169
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.264851",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 192,
        "word_count": 22,
        "sentence_count": 6,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.15625,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.38470270270270274,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "所得税",
        "税费"
      ]
    },
    {
      "chunk_id": "128ee669",
      "content": "【说明】购置节能环保设备抵减应纳税额的影响 -1,818,754.37\n研发费用加计扣除 -15,620,860.07\n权益法核算投资收益 3,090,575.02\n所得税费用 141,670,795.18\n其他说明\n77、其他综合收益\n详见附注合并资产负债表项目注释之其他综合收益说明。78、现金流量表项目\n（1）收到的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n收回银行承兑汇票、信用证保证金等 146,000,576.25 268,324,454.49\n收到银行存款利息收入 31,637,094.38 37,993,941.65\n收到政府补助 31,594,591.50 17,182,776.65\n支取为开立承兑汇票质押的定期存款 33,903,500.00 442,038,662.00\n收到房租收入 923,003.40 2,147,867.09\n其 他 5,791,850.24 4,263,072.32\n合计 249,850,615.77 771,950,774.20\n收到的其他与经营活动有关的现金说明：\n（2）支付的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n管理费用中付现支出 121,586,061.34 90,307,710.88\n支付银行承兑汇票、信用证保证金等 74,233,191.52 261,266,253.31\n销售费用中付现支出 43,113,653.73 30,879,918.69\n研发费用中付现支出 31,990,487.21 24,535,117.38\n财务费用中付现支出 1,161,350.07 1,091,244.28\n存入为开立承兑汇票质押的定期存款 189,843,512.00\n支付履约保证金 3,850,000.00\n其 他 11,527,467.71 14,490,599.42\n合计 283,612,211.58 616,264,355.96\n170。\n\n【表格内容】\n项目 | 本期发生额\n--------------------------------------------------\n利润总额 | 912,452,980.27\n按法定/适用税率计算的所得税费用 | 228,113,245.07\n子公司适用不同税率的影响 | -66,145,071.59\n调整以前期间所得税的影响 | -5,756,005.36\n不可抵扣的成本 费用和损失的影响 | 9,475,292.73\n使用前期未确认递延所得税资产的可抵扣亏损的影响 | -15,816,251.10\n本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏 | \n | 6,148,624.85\n损的影响 | \n |",
      "chunk_type": "table_group",
      "parent_id": "5ca46c40",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1149,
      "page_number": 169,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "收入",
          "成本",
          "费用",
          "利润",
          "现金",
          "投资",
          "销售费用"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          169
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265203",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1149,
        "word_count": 104,
        "sentence_count": 43,
        "chinese_char_count": 416,
        "readability_score": 0.0,
        "information_density": 0.08703220191470844,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7259048402230546,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "销售费用"
      ]
    },
    {
      "chunk_id": "2b49fe8d",
      "content": "【表格内容】\n购置节能环保设备抵减应纳税额的影响 | -1,818,754.37\n--------------------------------------------------\n研发费用加计扣除 | -15,620,860.07\n权益法核算投资收益 | 3,090,575.02\n所得税费用 | 141,670,795.18",
      "chunk_type": "table_group",
      "parent_id": "dc66fe96",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 165,
      "page_number": 170,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "费用",
          "投资",
          "研发费用",
          "所得税",
          "税费"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265316",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 165,
        "word_count": 14,
        "sentence_count": 4,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.36363636363636365,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4269586497890295,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "费用",
        "投资",
        "研发费用",
        "所得税",
        "税费"
      ]
    },
    {
      "chunk_id": "ca144f34",
      "content": "【说明】支付的其他与经营活动有关的现金说明：\n（3）收到的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n银行理财产品及结构性存款到期收回 1,160,000,000.00 550,000,000.00\n收到银行理财产品及结构性存款利息 12,215,955.60 9,401,529.98\n收回股权竞拍保证金 400,000,000.00\n合计 1,172,215,955.60 959,401,529.98\n收到的其他与投资活动有关的现金说明：\n（4）支付的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n购买银行理财产品及结构性存款 260,000,000.00 1,400,000,000.00\n支付股权竞拍保证金 400,000,000.00\n支付人民币外汇货币掉期交易损失 5,459,752.25\n合计 260,000,000.00 1,805,459,752.25\n支付的其他与投资活动有关的现金说明：\n（5）收到的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支取因银行借款质押的定期存款 632,143,300.00\n收回银行借款保证金 900,000.00\n合计 633,043,300.00\n收到的其他与筹资活动有关的现金说明：\n（6）支付的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支付公司股份回购款 19,996,827.22 281,514,686.68\n支付限制性股票回购款及利息 281,636.25 13,560,886.22\n存入因银行借款质押的定期存款 294,477,200.00\n171。\n\n【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n管理费用中付现支出 | 121,586,061.34 | 90,307,710.88\n支付银行承兑汇票 信用证保证金等 | 74,233,191.52 | 261,266,253.31\n销售费用中付现支出 | 43,113,653.73 | 30,879,918.69\n研发费用中付现支出 | 31,990,487.21 | 24,535,117.38\n财务费用中付现支出 | 1,161,350.07 | 1,091,244.28\n存入为开立承兑汇票质押的定期存款 | | 189,843,512.00\n支付履约保证金 | | 3,850,000.00\n其 他 | 11,527,467.71 | 14,490,599.42\n合计 | 283,612,211.58 | 616,264,355.96",
      "chunk_type": "table_group",
      "parent_id": "b5a18281",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1139,
      "page_number": 170,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "费用",
          "现金",
          "投资",
          "销售费用",
          "管理费用",
          "研发费用",
          "财务费用",
          "经营",
          "投资活动",
          "筹资活动"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265653",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1139,
        "word_count": 116,
        "sentence_count": 38,
        "chinese_char_count": 428,
        "readability_score": 0.0,
        "information_density": 0.08779631255487269,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6235731697288407,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "现金",
        "投资",
        "销售费用",
        "管理费用",
        "研发费用",
        "财务费用",
        "经营",
        "投资活动",
        "筹资活动"
      ]
    },
    {
      "chunk_id": "41da8c21",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n银行理财产品及结构性存款到期收回 | 1,160,000,000.00 | 550,000,000.00\n收到银行理财产品及结构性存款利息 | 12,215,955.60 | 9,401,529.98\n收回股权竞拍保证金 | | 400,000,000.00\n合计 | 1,172,215,955.60 | 959,401,529.98",
      "chunk_type": "table_group",
      "parent_id": "e29eb8bf",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 245,
      "page_number": 171,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265794",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 245,
        "word_count": 26,
        "sentence_count": 7,
        "chinese_char_count": 59,
        "readability_score": 0.0,
        "information_density": 0.04081632653061224,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40731882845188283,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权"
      ]
    },
    {
      "chunk_id": "eec1f644",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n购买银行理财产品及结构性存款 | 260,000,000.00 | 1,400,000,000.00\n支付股权竞拍保证金 | | 400,000,000.00\n支付人民币外汇货币掉期交易损失 | | 5,459,752.25\n合计 | 260,000,000.00 | 1,805,459,752.25",
      "chunk_type": "table_group",
      "parent_id": "0e72e9ae",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 228,
      "page_number": 171,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265883",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 228,
        "word_count": 25,
        "sentence_count": 6,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.04385964912280702,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4045775784753363,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权"
      ]
    },
    {
      "chunk_id": "29b71a62",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n支取因银行借款质押的定期存款 | | 632,143,300.00\n收回银行借款保证金 | | 900,000.00\n合计 | | 633,043,300.00",
      "chunk_type": "table_group",
      "parent_id": "95b073b4",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 157,
      "page_number": 171,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.265948",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 157,
        "word_count": 19,
        "sentence_count": 3,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.06369426751592357,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39187450980392163,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "借款"
      ]
    },
    {
      "chunk_id": "d7bc52bd",
      "content": "项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n支付公司股份回购款 | 19,996,827.22 | 281,514,686.68\n支付限制性股票回购款及利息 | 281,636.25 | 13,560,886.22\n存入因银行借款质押的定期存款 |  | 294,477,200.00",
      "chunk_type": "table_group",
      "parent_id": "a8fed66b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 690,
      "page_number": 171,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股份",
          "回购",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          171
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.266242",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 190,
        "word_count": 20,
        "sentence_count": 5,
        "chinese_char_count": 48,
        "readability_score": 0.0,
        "information_density": 0.15789473684210525,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3017894736842105,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "回购",
        "借款"
      ]
    },
    {
      "chunk_id": "92f9d5e9",
      "content": "【表格内容】\n支付银行借款保证金 | | 900,000.00\n--------------------------------------------------\n合计 | 20,278,463.47 | 590,452,772.90",
      "chunk_type": "table_group",
      "parent_id": "f20bfb40",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 118,
      "page_number": 172,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266299",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 118,
        "word_count": 11,
        "sentence_count": 3,
        "chinese_char_count": 15,
        "readability_score": 0.0,
        "information_density": 0.08474576271186442,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.36213214285714285,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "借款"
      ]
    },
    {
      "chunk_id": "1e1054c7",
      "content": "【表格内容】\n| 金额\n--------------------------------------------------\n其中： | --\n其中： | --\n其中： | --",
      "chunk_type": "table_group",
      "parent_id": "977bf425",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 89,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266349",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 89,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43105783132530123,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "625fd629",
      "content": "【表格内容】\n| 金额\n--------------------------------------------------\n其中： | --\n其中： | --\n其中： | --",
      "chunk_type": "table_group",
      "parent_id": "8543c023",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 89,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266426",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 89,
        "word_count": 13,
        "sentence_count": 0,
        "chinese_char_count": 12,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43105783132530123,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "d5570ea4",
      "content": "【表格内容】\n项 目 | 本期数\n--------------------------------------------------\n背书转让的商业汇票金额 | 1,203,398,004.56\n其中：支付货款 | 763,162,260.55\n支付固定资产等长期资产购置款 | 440,235,744.01",
      "chunk_type": "table_group",
      "parent_id": "d4cca396",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 155,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266489",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 155,
        "word_count": 15,
        "sentence_count": 3,
        "chinese_char_count": 40,
        "readability_score": 0.0,
        "information_density": 0.12903225806451613,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4994198198198198,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产"
      ]
    },
    {
      "chunk_id": "5d5d5d29",
      "content": "【说明】小 计 30,797,464.00 886,880,848.73\n80、所有者权益变动表项目注释\n说明对上年期末余额进行调整的“其他”项目名称及调整金额等事项：\n81、所有权或使用权受到限制的资产\n单位： 元\n项目 期末账面价值 受限原因\n货币资金 30,797,464.00开立银行承兑汇票\n固定资产 22,554,937.46银行融资抵押\n无形资产 10,291,182.19银行融资抵押\n合计 63,643,583.65 --\n其他说明：\n82、外币货币性项目\n（1）外币货币性项目\n单位： 元\n项目 期末外币余额 折算汇率 期末折算人民币余额\n货币资金 -- -- 214,734,480.07\n其中：美元 30,636,838.136.9762 213,728,710.16\n欧元 40,660.307.8155 317,780.57\n港币\n英镑 75,189.279.1501 687,989.34\n应收账款 -- -- 146,207,835.41\n其中：美元 20,665,705.866.9762 144,168,097.22\n欧元 260,986.277.8155 2,039,738.19\n港币\n其他应收款 2,859.22\n其中：欧元 365.847.8155 2,859.22\n应付账款 5,296,661.70\n其中：美元 663,385.606.9762 4,627,910.62\n欧元 85,567.287.8155 668,751.08\n其他应付款 8,199,889.22\n174。\n\n【表格内容】\n项 目 | 期末数\n--------------------------------------------------\n质押的定期存款 | \n结构性存款 | \n银行承兑汇票保证金 | 30,797,464.00",
      "chunk_type": "table_group",
      "parent_id": "26cf3279",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 778,
      "page_number": 173,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "应收",
          "应付",
          "固定资产",
          "无形资产",
          "账面价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          173
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266727",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 778,
        "word_count": 84,
        "sentence_count": 37,
        "chinese_char_count": 229,
        "readability_score": 0.0,
        "information_density": 0.11568123393316194,
        "coherence_score": 0.39749999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47363422930651855,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "应收",
        "应付",
        "固定资产",
        "无形资产",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "801f5cd5",
      "content": "【表格内容】\n项目 | 期末账面价值 | 受限原因\n--------------------------------------------------\n货币资金 | 30,797,464.00 | 开立银行承兑汇票\n固定资产 | 22,554,937.46 | 银行融资抵押\n无形资产 | 10,291,182.19 | 银行融资抵押\n合计 | 63,643,583.65 | --",
      "chunk_type": "table_group",
      "parent_id": "1c414f7a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 192,
      "page_number": 174,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "固定资产",
          "无形资产",
          "账面价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          174
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.266825",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 192,
        "word_count": 27,
        "sentence_count": 4,
        "chinese_char_count": 50,
        "readability_score": 0.0,
        "information_density": 0.3125,
        "coherence_score": 0.49,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4326306306306306,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "无形资产",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "22082417",
      "content": "【说明】其中：美元 789,910.036.9762 5,510,570.35\n欧元 342,262.847.8155 2,674,955.23\n英镑 1,569.789.1501 14,363.64\n长期借款 -- --\n其中：美元\n欧元\n港币\n其他说明：\n（2）境外经营实体说明，包括对于重要的境外经营实体，应披露其境外主要经营地、记账本位币及选择\n依据，记账本位币发生变化的还应披露原因。√ 适用 □ 不适用\n子公司 子公司类型 境外主要经营地 记账 选择依据\n本位币\nGeneVida GmbH 全资子公司 德国 欧元 根据公司经营所处经济环境选择\nGANGXIANG（SINGAPORE） 全资子公司 新加坡 人民币 根据公司经营所处经济环境选择\n香港港翔公司 全资子公司 香港 人民币 根据公司经营所处经济环境选择\n83、套期\n按照套期类别披露套期项目及相关套期工具、被套期风险的定性和定量信息：\n84、政府补助\n（1）政府补助基本情况\n单位： 元\n种类 金额 列报项目 计入当期损益的金额\n（2）政府补助退回情况\n□ 适用 √ 不适用\n其他说明：\n(1) 明细情况\n1) 与资产相关的政府补助\n项 目 期初递延收益 本期新增补助 本期摊销 期末递延收益 本期摊销 说明\n列报项目\n175。\n\n【表格内容】\n项目 | 期末外币余额 | 折算汇率 | 期末折算人民币余额\n--------------------------------------------------\n货币资金 | -- | -- | 214,734,480.07\n其中：美元 | 30,636,838.13 | 6.9762 | 213,728,710.16\n欧元 | 40,660.30 | 7.8155 | 317,780.57\n港币 | | | \n英镑 | 75,189.27 | 9.1501 | 687,989.34\n应收账款 | -- | -- | 146,207,835.41\n其中：美元 | 20,665,705.86 | 6.9762 | 144,168,097.22\n欧元 | 260,986.27 | 7.8155 | 2,039,738.19\n港币 | | | \n其他应收款 | | | 2,859.22\n其中：欧元 | 365.84 | 7.8155 | 2,859.22\n应付账款 | | | 5,296,661.70\n其中：美元 | 663,385.60 | 6.9762 | 4,627,910.62\n欧元 | 85,567.28 | 7.8155 | 668,751.08\n其他应付款 | | | 8,199,889.22",
      "chunk_type": "table_group",
      "parent_id": "392168dd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1120,
      "page_number": 174,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "应收",
          "应付",
          "经营",
          "披露",
          "摊销",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          174
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.267140",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1120,
        "word_count": 175,
        "sentence_count": 40,
        "chinese_char_count": 397,
        "readability_score": 0.0,
        "information_density": 0.0625,
        "coherence_score": 0.2821212121212121,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6126392601468647,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "应收",
        "应付",
        "经营",
        "披露",
        "摊销",
        "借款"
      ]
    },
    {
      "chunk_id": "fff0881e",
      "content": "【表格内容】\n其中：美元 | 789,910.03 | 6.9762 | 5,510,570.35\n--------------------------------------------------\n欧元 | 342,262.84 | 7.8155 | 2,674,955.23\n英镑 | 1,569.78 | 9.1501 | 14,363.64\n长期借款 | -- | -- | \n其中：美元 | | | \n欧元 | | | \n港币 | | | \n | | |",
      "chunk_type": "table_group",
      "parent_id": "1ebfd7a0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 233,
      "page_number": 175,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          175
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.267265",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 233,
        "word_count": 44,
        "sentence_count": 9,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.04291845493562232,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4597659574468085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "借款"
      ]
    },
    {
      "chunk_id": "7d13e027",
      "content": "子公司 | 子公司类型 | 境外主要经营地 | 记账\n本位币\n--------------------------------------------------\nGeneVida GmbH | 全资子公司 | 德国 | 欧元\nGANGXIANG（SINGAPORE） | 全资子公司 | 新加坡 | 人民币\n香港港翔公司 | 全资子公司 | 香港 | 人民币",
      "chunk_type": "table_group",
      "parent_id": "05f162c2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 680,
      "page_number": 175,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 6,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          175
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.267590",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 180,
        "word_count": 31,
        "sentence_count": 0,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.05555555555555556,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4653333333333333,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营"
      ]
    },
    {
      "chunk_id": "e2770d93",
      "content": "年产400吨碳青霉烯类抗生\n素关键中间体4-AA项目 | 5,695,281.12 |  | 1,423,820.28 | 4,271,460.84 | 其他收益\n--------------------------------------------------\n年产1吨瑞格列奈、10吨卡洛\n芬、10吨阿托伐醌、50吨\nT1620、300吨聚卡波菲钙、\n300吨4,4'-二氟二苯甲酮、100\n吨奈韦拉平产业化项目 | 235,862.40 |  | 117,931.20 | 117,931.20 | 其他收益\n催化净化处理塔建设项目 | 140,000.00 |  | 30,000.00 | 110,000.00 | 其他收益\n年产50吨培南类产品及扩建\n厂房技改项目 | 132,000.00 |  | 48,000.00 | 84,000.00 | 其他收益\n企业技术中心创新能力建设\n项目 | 133,333.33 |  | 40,000.00 | 93,333.33 | 其他收益\n年产8亿元(粒)口服固体制剂\n项目 | 7,065,200.00 |  | 997,440.00 | 6,067,760.00 | 其他收益\n临海市创新驱动加快推进工\n业经济转型升级政策 | 1,042,718.40 |  | 208,543.68 | 834,174.72 | 其他收益\n省级工业与信息化专项资金\n回收溶剂循环化技改项目 | 632,766.12 |  | 92,599.92 | 540,166.20 | 其他收益\n省工业化和信息化深度融合\n示范试点区财政补助 | 457,675.28 |  | 66,169.92 | 391,505.36 | 其他收益\n浙江省化学原料药基地椒江\n区块循环化改造项目补助资\n金 | 263,333.33 |  | 40,000.00 | 223,333.33 | 其他收益\n年产2吨盐酸阿莫罗芬、20吨\n阿特来马来酸盐、5吨多尼培\n南、20吨美罗培南、5吨比阿\n培南、60吨PHE产业化项目\n(续建) | 2,090,683.87 |  | 281,889.96 | 1,808,793.91 | 其他收益\n年产15000吨环保型活性艳\n蓝KN-R商品染料技改项目 | 850,000.00 |  | 100,000.00 | 750,000.00 | 其他收益\n大品种药物的生产技术改造-\n美罗培南原料药绿色合成技\n术改造 | 860,416.67 | 2,000,000.00 | 291,265.91 | 2,569,150.76 | 其他收益\n临海医化园区循环化改造项\n目 | 490,000.00 |  | 105,000.00 | 385,000.00 | 其他收益\n南洋涂—固废减量化处置项\n目 | 2,286,832.98 |  | 246,999.96 | 2,039,833.02 | 其他收益",
      "chunk_type": "table_group",
      "parent_id": "09a1705a",
      "child_ids": [],
      "sibling_ids": [
        "b00332c9"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1735,
      "page_number": 176,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 38,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "金额数据"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.268304",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1235,
        "word_count": 174,
        "sentence_count": 46,
        "chinese_char_count": 373,
        "readability_score": 0.0,
        "information_density": 0.008097165991902834,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5875175315568022,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "b00332c9",
      "content": "年产400吨MAP、100吨OA、\n200吨DA、100吨甲砜霉素、\n10吨联苯双酯产业化新项目 | 11,962,166.31 | 10,000,000.00 | 1,490,999.91 | 20,471,166.40 | 其他收益\n年产580吨柳氮磺胺吡啶产\n业化项目 | 2,115,735.00 |  | 248,910.00 | 1,866,825.00 | 其他收益",
      "chunk_type": "table_group",
      "parent_id": "09a1705a",
      "child_ids": [],
      "sibling_ids": [
        "e2770d93"
      ],
      "position": 1,
      "start_char": 500,
      "end_char": 1190,
      "page_number": 176,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 5,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          176
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.268469",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 190,
        "word_count": 24,
        "sentence_count": 7,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5875175315568022,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "719472c5",
      "content": "【表格内容】\n清洁生产循环利用及三废综\n合治理提升项目 | 4,800,000.00 | | 600,000.00 | 4,200,000.00 | 其他收益\n--------------------------------------------------\n年产15500吨活性染料产业\n升级及配套项目 | 1,296,000.00 | | | 1,296,000.00 | 其他收益\n孵化器车间技改项目 | 793,220.34 | | 81,355.92 | 711,864.42 | 其他收益\n浙江省化学原料药基地椒江\n区块循环化改造项目补助资\n金项目补助 | | 400,000.00 | 10,000.00 | 390,000.00 | 其他收益\n年产700吨M-562关键中间体\n产业一体化项目 | | 500,000.00 | 33,333.33 | 466,666.67 | 其他收益\n小 计 | 43,343,225.15 | 12,900,000.00 | 6,554,259.99 | 49,688,965.16 |\n\n【注释】合并成本\n合并成本公允价值的确定方法、或有对价及其变动的说明：\n大额商誉形成的主要原因：\n其他说明：\n（3）被购买方于购买日可辨认资产、负债\n单位： 元\n购买日公允价值 购买日账面价值\n可辨认资产、负债公允价值的确定方法：\n企业合并中承担的被购买方的或有负债：\n其他说明：\n（4）购买日之前持有的股权按照公允价值重新计量产生的利得或损失\n是否存在通过多次交易分步实现企业合并且在报告期内取得控制权的交易\n□ 是 √ 否\n（5）购买日或合并当期期末无法合理确定合并对价或被购买方可辨认资产、负债公允价值的相关说明\n（6）其他说明\n2、同一控制下企业合并\n（1）本期发生的同一控制下企业合并\n单位： 元\n合并当期期 合并当期期\n企业合并中 构成同一控 比较期间被 比较期间被\n被合并方名 合并日的确 初至合并日 初至合并日\n取得的权益 制下企业合 合并日 合并方的收 合并方的净\n称 定依据 被合并方的 被合并方的\n比例 并的依据 入 利润\n收入 净利润\n其他说明：\n（2）合并成本\n单位： 元\n合并成本\n或有对价及其变动的说明：\n其他说明：\n178",
      "chunk_type": "table_group",
      "parent_id": "2cea3f80",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 950,
      "page_number": 177,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "收入",
          "成本",
          "利润",
          "商誉",
          "净利润",
          "合并",
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268778",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 950,
        "word_count": 124,
        "sentence_count": 18,
        "chinese_char_count": 492,
        "readability_score": 0.0,
        "information_density": 0.10526315789473684,
        "coherence_score": 0.6105263157894736,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5866779638339592,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "商誉",
        "净利润",
        "合并",
        "股权"
      ]
    },
    {
      "chunk_id": "8a86ed82",
      "content": "【表格内容】\n项 目 | 金额 | 列报项目\n--------------------------------------------------\n税费返还 | 1,828,299.60 | 其他收益\n财政专项基金 | 4,150,682.78 | 其他收益\n政府奖励 | 14,486,841.50 | 其他收益\n科技补助 | 116,841.00 | 其他收益\n小 计 | 20,582,664.88 |",
      "chunk_type": "table_group",
      "parent_id": "350dd579",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 204,
      "page_number": 177,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "税费"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          177
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268909",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 204,
        "word_count": 33,
        "sentence_count": 5,
        "chinese_char_count": 48,
        "readability_score": 0.0,
        "information_density": 0.049019607843137254,
        "coherence_score": 0.5525,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3979333333333333,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "税费"
      ]
    },
    {
      "chunk_id": "758b4b06",
      "content": "【表格内容】\n| | \n--------------------------------------------------\n | 购买日公允价值 | 购买日账面价值",
      "chunk_type": "table_group",
      "parent_id": "ef357d95",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 83,
      "page_number": 178,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "公允价值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          178
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268953",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 83,
        "word_count": 8,
        "sentence_count": 0,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.3614457831325301,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.36752307692307695,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "公允价值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "ec4d95b6",
      "content": "【表格内容】\n| | \n--------------------------------------------------\n | 合并日 | 上期期末",
      "chunk_type": "table_group",
      "parent_id": "9b623bc7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 76,
      "page_number": 179,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "合并"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          179
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.268991",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 76,
        "word_count": 8,
        "sentence_count": 0,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.13157894736842107,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3873220657276995,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "合并"
      ]
    },
    {
      "chunk_id": "c4abb088",
      "content": "【表格内容】\n公司名称 | 股权取得方式 | 股权取得时点 | 出资额\n--------------------------------------------------\n盛嘉环保公司 | 设立 | 2019/4/29 |",
      "chunk_type": "table_group",
      "parent_id": "bdd781a2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 112,
      "page_number": 179,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股权"
        ],
        "time_periods": [
          "2019-4-29"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          179
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269042",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 112,
        "word_count": 15,
        "sentence_count": 0,
        "chinese_char_count": 31,
        "readability_score": 0.0,
        "information_density": 0.08928571428571427,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3844075471698113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权"
      ]
    },
    {
      "chunk_id": "05deb6f7",
      "content": "【说明】台州东旭公司 台州市 台州市 设备制造 100.00% 设立\nGeneVida GmbH 德国多特蒙德 德国多特蒙德 医药销售 100.00% 设立\nGANGXIANG\n新加坡 新加坡 贸易 100.00% 设立\n（SINGAPORE）\n港翔化工公司 台州市 台州市 化工销售 100.00% 设立\n瓯华环保公司 盐城市 盐城市 技术研发 100.00% 设立\n盛嘉环保公司 台州市 台州市 技术研发 100.00% 设立\n非同一控制下企\n香港港翔公司 香港 香港 贸易 100.00%\n业合并\n非同一控制下企\n港翔科技公司 台州市 台州市 化工销售 100.00%\n业合并\n非同一控制下企\n台州前进公司 台州市 台州市 化工制造 100.00%\n业合并\n非同一控制下企\n台州振港公司 台州市 台州市 化工制造 9.27% 90.73%\n业合并\n非同一控制下企\n盐城瓯华公司 盐城市 盐城市 化工制造 100.00%\n业合并\n非同一控制下企\n瓯华研究院 盐城市 盐城市 技术研发 100.00%\n业合并\n在子公司的持股比例不同于表决权比例的说明：\n持有半数或以下表决权但仍控制被投资单位、以及持有半数以上表决权但不控制被投资单位的依据：\n对于纳入合并范围的重要的结构化主体，控制的依据：\n确定公司是代理人还是委托人的依据：\n其他说明：\n（2）重要的非全资子公司\n单位： 元\n本期归属于少数股东的 本期向少数股东宣告分\n子公司名称 少数股东持股比例 期末少数股东权益余额\n损益 派的股利\n子公司少数股东的持股比例不同于表决权比例的说明：\n其他说明：\n（3）重要非全资子公司的主要财务信息\n单位： 元\n期末余额 期初余额\n子公司\n流动资 非流动 资产合 流动负 非流动 负债合 流动资 非流动 资产合 流动负 非流动 负债合\n名称\n产 资产 计 债 负债 计 产 资产 计 债 负债 计\n180。\n\n【表格内容】\n| | | | 持股比例 | | \n--------------------------------------------------\n子公司名称 | 主要经营地 | 注册地 | 业务性质 | | | 取得方式\n | | | | 直接 | 间接 | \n | | | | | | \n川南药业公司 | 台州市 | 台州市 | 医药制造 | 100.00% | | 设立\n海翔销售公司 | 台州市 | 台州市 | 医药销售 | 100.00% | | 设立\n上海海翔公司 | 上海市 | 上海市 | 技术研发 | 100.00% | | 设立",
      "chunk_type": "table_group",
      "parent_id": "2dda88e1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1078,
      "page_number": 179,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "投资",
          "股东权益",
          "合并",
          "经营",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          179
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269350",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔化工公司",
        "industry": null,
        "char_count": 1078,
        "word_count": 200,
        "sentence_count": 17,
        "chinese_char_count": 615,
        "readability_score": 0.0,
        "information_density": 0.07421150278293136,
        "coherence_score": 0.5130792772444945,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5506578397212544,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "投资",
        "股东权益",
        "合并",
        "经营",
        "股东"
      ]
    },
    {
      "chunk_id": "781f7d04",
      "content": "台州东旭公司 | 台州市 | 台州市 | 设备制造 | 100.00% |  | 设立\n--------------------------------------------------\nGeneVida GmbH | 德国多特蒙德 | 德国多特蒙德 | 医药销售 | 100.00% |  | 设立\nGANGXIANG |  |  |  |  |  | \n | 新加坡 | 新加坡 | 贸易 | 100.00% |  | 设立\n（SINGAPORE） |  |  |  |  |  | \n |  |  |  |  |  | \n港翔化工公司 | 台州市 | 台州市 | 化工销售 | 100.00% |  | 设立\n瓯华环保公司 | 盐城市 | 盐城市 | 技术研发 |  | 100.00% | 设立\n盛嘉环保公司 | 台州市 | 台州市 | 技术研发 |  | 100.00% | 设立\n |  |  |  |  |  | 非同一控制下企\n香港港翔公司 | 香港 | 香港 | 贸易 | 100.00% |  | \n |  |  |  |  |  | 业合并\n |  |  |  |  |  | \n |  |  |  |  |  | 非同一控制下企\n港翔科技公司 | 台州市 | 台州市 | 化工销售 | 100.00% |  | \n |  |  |  |  |  | 业合并\n |  |  |  |  |  | \n |  |  |  |  |  | 非同一控制下企\n台州前进公司 | 台州市 | 台州市 | 化工制造 | 100.00% |  | \n |  |  |  |  |  | 业合并\n |  |  |  |  |  | \n |  |  |  |  |  | 非同一控制下企\n台州振港公司 | 台州市 | 台州市 | 化工制造 | 9.27% | 90.73% | \n |  |  |  |  |  | 业合并\n |  |  |  |  |  | \n |  |  |  |  |  | 非同一控制下企\n盐城瓯华公司 | 盐城市 | 盐城市 | 化工制造 |  | 100.00% | \n |  |  |  |  |  | 业合并\n |  |  |  |  |  | \n |  |  |  |  |  | 非同一控制下企\n瓯华研究院 | 盐城市 | 盐城市 | 技术研发 |  | 100.00% | \n |  |  |  |  |  | 业合并\n |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "b8ea5f10",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1549,
      "page_number": 180,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 34,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "合并"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.269710",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔化工公司",
        "industry": null,
        "char_count": 1049,
        "word_count": 280,
        "sentence_count": 13,
        "chinese_char_count": 251,
        "readability_score": 0.0,
        "information_density": 0.009532888465204958,
        "coherence_score": 0.5742266824085005,
        "standards_profile_summary": {}
      },
      "quality_score": 0.63844931680966,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "合并"
      ]
    },
    {
      "chunk_id": "1a5f2524",
      "content": "【表格内容】\n| | 本期归属于少数股东的 | 本期向少数股东宣告分 | \n--------------------------------------------------\n子公司名称 | 少数股东持股比例 | | | 期末少数股东权益余额\n | | 损益 | 派的股利 | \n | | | |",
      "chunk_type": "table_group",
      "parent_id": "4a538d8b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 149,
      "page_number": 180,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "股东权益",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          180
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269800",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 149,
        "word_count": 25,
        "sentence_count": 0,
        "chinese_char_count": 53,
        "readability_score": 0.0,
        "information_density": 0.20134228187919465,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4705421633554083,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "股东权益",
        "股东"
      ]
    },
    {
      "chunk_id": "57cc9dd7",
      "content": "【表格内容】\n| | | | 持股比例 | | 对合营企业或联\n--------------------------------------------------\n合营企业或联营 | | | | | | \n | 主要经营地 | 注册地 | 业务性质 | | | 营企业投资的会\n企业名称 | | | | 直接 | 间接 | \n | | | | | | 计处理方法\n | | | | | | \n苏州第四制药厂 | | | | | | \n | 常熟 | 常熟 | 医药制造 | 32.66% | | 权益法核算\n有限公司 | | | | | | \n | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "e31580aa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 285,
      "page_number": 181,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "投资",
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.269883",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 285,
        "word_count": 80,
        "sentence_count": 1,
        "chinese_char_count": 78,
        "readability_score": 0.0,
        "information_density": 0.10526315789473684,
        "coherence_score": 0.21,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45702083333333327,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "投资",
        "经营"
      ]
    },
    {
      "chunk_id": "dc030c73",
      "content": "【说明】（3）重要联营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n苏州第四制药厂有限公司 苏州第四制药厂有限公司\n流动资产 29,519,105.76 25,072,727.50\n非流动资产 84,757,893.18 93,352,602.90\n资产合计 114,276,998.94 118,425,330.40\n流动负债 36,442,141.82 25,462,418.24\n非流动负债 21,400,000.00 22,000,000.00\n负债合计 57,842,141.82 47,462,418.24\n归属于母公司股东权益 56,434,857.12 71,167,909.30\n按持股比例计算的净资产份额 18,431,624.34 23,243,439.18\n--其他 -297,151.93 -297,151.93\n对联营企业权益投资的账面价值 18,134,472.41 22,946,287.25\n营业收入 57,010,459.03 39,434,028.51\n净利润 -14,733,052.18 -10,672,428.70\n综合收益总额 -14,733,052.18 -10,672,428.70\n其他说明\n（4）不重要的合营企业和联营企业的汇总财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n合营企业： -- --\n投资账面价值合计 29,744,910.02 43,141,852.54\n下列各项按持股比例计算的合计数 -- --\n--净利润 -11,947,734.96 -3,438,323.72\n--综合收益总额 -11,947,734.96 -3,438,323.72\n联营企业： -- --\n下列各项按持股比例计算的合计数 -- --\n其他说明\n182。\n\n【表格内容】\n| 期末余额/本期发生额 | 期初余额/上期发生额\n--------------------------------------------------\n | |",
      "chunk_type": "table_group",
      "parent_id": "84e81b0a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 866,
      "page_number": 181,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "收入",
          "利润",
          "投资",
          "营业收入",
          "净利润",
          "净资产",
          "股东权益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270135",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 866,
        "word_count": 83,
        "sentence_count": 33,
        "chinese_char_count": 262,
        "readability_score": 0.0,
        "information_density": 0.11547344110854503,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47831471643933954,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "投资",
        "营业收入",
        "净利润",
        "净资产",
        "股东权益"
      ]
    },
    {
      "chunk_id": "33f4de73",
      "content": "【说明】（5）合营企业或联营企业向本公司转移资金的能力存在重大限制的说明\n（6）合营企业或联营企业发生的超额亏损\n单位： 元\n累积未确认前期累计认的损 本期未确认的损失（或本期分\n合营企业或联营企业名称 本期末累积未确认的损失\n失 享的净利润）\n其他说明\n（7）与合营企业投资相关的未确认承诺\n（8）与合营企业或联营企业投资相关的或有负债\n4、重要的共同经营\n持股比例/享有的份额\n共同经营名称 主要经营地 注册地 业务性质\n直接 间接\n在共同经营中的持股比例或享有的份额不同于表决权比例的说明：\n共同经营为单独主体的，分类为共同经营的依据：\n其他说明\n5、在未纳入合并财务报表范围的结构化主体中的权益\n未纳入合并财务报表范围的结构化主体的相关说明：\n6、其他\n十、与金融工具相关的风险\n本公司从事风险管理的目标是在风险和收益之间取得平衡，将风险对本公司经营业绩的负面影响降至\n最低水平，使股东和其他权益投资者的利益最大化。基于该风险管理目标，本公司风险管理的基本策略是\n确认和分析本公司面临的各种风险，建立适当的风险承受底线和进行风险管理，并及时可靠地对各种风险\n进行监督，将风险控制在限定的范围内。本公司在日常活动中面临各种与金融工具相关的风险，主要包括信用风险、流动性风险及市场风险。\n\n【表格内容】\n| 期末余额/本期发生额 | 期初余额/上期发生额\n--------------------------------------------------\n合营企业： | -- | --\n投资账面价值合计 | 29,744,910.02 | 43,141,852.54\n下列各项按持股比例计算的合计数 | -- | --\n--净利润 | -11,947,734.96 | -3,438,323.72\n--综合收益总额 | -11,947,734.96 | -3,438,323.72\n联营企业： | -- | --\n下列各项按持股比例计算的合计数 | -- | --",
      "chunk_type": "table_group",
      "parent_id": "74e314a6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 836,
      "page_number": 182,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "利润",
          "投资",
          "净利润",
          "合并",
          "营业",
          "经营",
          "经营业绩",
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          182
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270374",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 836,
        "word_count": 73,
        "sentence_count": 9,
        "chinese_char_count": 551,
        "readability_score": 0.0,
        "information_density": 0.11961722488038277,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6657675057589877,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "利润",
        "投资",
        "净利润",
        "合并",
        "营业",
        "经营",
        "经营业绩",
        "股东"
      ]
    },
    {
      "chunk_id": "baeabad9",
      "content": "【表格内容】\n| 累积未确认前期累计认的损 | 本期未确认的损失（或本期分 | \n--------------------------------------------------\n合营企业或联营企业名称 | | | 本期末累积未确认的损失\n | 失 | 享的净利润） | \n | | |",
      "chunk_type": "table_group",
      "parent_id": "402f0cfd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 145,
      "page_number": 183,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "利润",
          "净利润"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          183
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270483",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 145,
        "word_count": 20,
        "sentence_count": 0,
        "chinese_char_count": 56,
        "readability_score": 0.0,
        "information_density": 0.13793103448275862,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5163,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "净利润"
      ]
    },
    {
      "chunk_id": "a3b8e576",
      "content": "【表格内容】\n| | | | 持股比例/享有的份额 | \n--------------------------------------------------\n共同经营名称 | 主要经营地 | 注册地 | 业务性质 | | \n | | | | 直接 | 间接\n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "31fc7687",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 140,
      "page_number": 183,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "经营"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          183
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270536",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 140,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 35,
        "readability_score": 0.0,
        "information_density": 0.07142857142857142,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3860493150684931,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营"
      ]
    },
    {
      "chunk_id": "5b4ab087",
      "content": "【表格内容】\n项 目 | | | | \n--------------------------------------------------\n | 账面价值 | 未折现合同金额 | 1年以内 | 1-3年\n银行借款 | 200,267,029.59 | 205,600,371.26 | 205,600,371.26 |",
      "chunk_type": "table_group",
      "parent_id": "d54ccfbe",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 160,
      "page_number": 184,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "账面价值",
          "借款",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          184
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270600",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 160,
        "word_count": 24,
        "sentence_count": 3,
        "chinese_char_count": 25,
        "readability_score": 0.0,
        "information_density": 0.1875,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3764636942675159,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "账面价值",
        "借款",
        "价值"
      ]
    },
    {
      "chunk_id": "15fecc71",
      "content": "【说明】对于外币资产和负债，如果出现短期的失衡\n情况，本公司会在必要时按市场汇率买卖外币，以确保将净风险敞口维持在可接受的水平。本公司期末外币货币性资产和负债情况详见本财务报表附注合并财务报表项目注释其他之外币货币\n性项目说明。十一、公允价值的披露\n1、以公允价值计量的资产和负债的期末公允价值\n单位： 元\n期末公允价值\n项目 第一层次公允价值计\n第二层次公允价值计量 第三层次公允价值计量 合计\n量\n一、持续的公允价值计量 -- -- -- --\n（2）权益工具投资 20,000,000.00 20,000,000.00\n185。\n\n【表格内容】\n应付票据 | 238,306,005.00 | 238,306,005.00 | 238,306,005.00 | \n--------------------------------------------------\n应付账款 | 363,440,583.96 | 363,440,583.96 | 324,802,966.15 | 27,710,697.69\n其他应付款 | 28,200,073.22 | 28,200,073.22 | 15,005,415.27 | 6,245,135.70\n小 计 | 830,213,691.77 | 835,547,033.44 | 783,714,757.68 | 33,955,833.39",
      "chunk_type": "table_group",
      "parent_id": "64017ac5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 597,
      "page_number": 185,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "投资",
          "应付",
          "合并",
          "披露",
          "公允价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270787",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 597,
        "word_count": 60,
        "sentence_count": 20,
        "chinese_char_count": 212,
        "readability_score": 0.0,
        "information_density": 0.15075376884422112,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5058234902810846,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "投资",
        "应付",
        "合并",
        "披露",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "91bdcafd",
      "content": "【表格内容】\n项 目 | | | | \n--------------------------------------------------\n | 账面价值 | 未折现合同金额 | 1年以内 | 1-3年\n银行借款 | 598,700,000.00 | 611,954,988.49 | 611,954,988.49 | \n应付票据 | 490,006,533.85 | 490,006,533.85 | 490,006,533.85 | \n应付账款 | 301,908,929.93 | 301,908,929.93 | 279,305,463.32 | 13,367,311.11\n其他应付款 | 24,723,304.20 | 24,723,304.20 | 15,643,774.56 | 638,021.29\n一年内到期的非流\n动负债 | 44,365,875.00 | 44,365,875.00 | 44,365,875.00 | \n小 计 | 1,459,704,642.98 | 1,472,959,631.47 | 1,441,276,635.22 | 14,005,332.40",
      "chunk_type": "table_group",
      "parent_id": "429f3daa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 500,
      "page_number": 185,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "应付",
          "账面价值",
          "借款",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.270976",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 500,
        "word_count": 69,
        "sentence_count": 21,
        "chinese_char_count": 51,
        "readability_score": 0.0,
        "information_density": 0.1,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47174704301075265,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "应付",
        "账面价值",
        "借款",
        "价值"
      ]
    },
    {
      "chunk_id": "c1fef151",
      "content": "【说明】（八）应收款项融资 74,531,666.41 74,531,666.41\n持续以公允价值计量的\n94,531,666.41 94,531,666.41\n负债总额\n二、非持续的公允价值计\n-- -- -- --\n量\n2、持续和非持续第一层次公允价值计量项目市价的确定依据\n3、持续和非持续第二层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n4、持续和非持续第三层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n5、持续的第三层次公允价值计量项目，期初与期末账面价值间的调节信息及不可观察参数敏感性分析\n1. 对于持有的应收票据，采用票面金额确定其公允价值；\n2.因被投资企业杭州寓鑫创业投资合伙企业（有限合伙）的经营环境和经营情况、财务状况未发生重\n大变化，所以公司按投资成本作为公允价值的合理估计进行计量；\n3.因被投资企业滨海宏博环境技术服务股份有限公司的经营环境和经营情况、财务状况恶化，所以公\n司以零元作为公允价值的合理估计进行计量。6、持续的公允价值计量项目，本期内发生各层级之间转换的，转换的原因及确定转换时点的政策\n7、本期内发生的估值技术变更及变更原因\n8、不以公允价值计量的金融资产和金融负债的公允价值情况\n9、其他\n十二、关联方及关联交易\n1、本企业的母公司情况\n母公司对本企业的 母公司对本企业的\n母公司名称 注册地 业务性质 注册资本\n持股比例 表决权比例\n浙江东港投资有限\n台州 投资 11,800万元 34.22% 34.22%\n公司\n本企业的母公司情况的说明\n浙江东港投资有限公司(以下简称东港投资公司)系由东港工贸集团有限公司100%持股的公司，于1998\n年7月9日在台州市工商行政管理局椒江分局登记注册，现持有统一社会信用代码为913310027046766827的\n营业执照，注册资本11,800万元。本企业最终控制方是王云富，间接通过东港投资公司持有本公司股份55,398.2587万股，直接持有本公司股份11,880万股，\n186。\n\n【表格内容】\n| 期末公允价值 | | | \n--------------------------------------------------\n项目 | 第一层次公允价值计 | | | \n | | 第二层次公允价值计量 | 第三层次公允价值计量 | 合计\n | 量 | | | \n | | | | \n一 持续的公允价值计量 | -- | -- | -- | --\n（2）权益工具投资 | | | 20,000,000.00 | 20,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "98cf114b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1087,
      "page_number": 185,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "成本",
          "投资",
          "应收",
          "母公司",
          "营业",
          "经营",
          "财务状况"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271295",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "因被投资企业",
        "industry": null,
        "char_count": 1087,
        "word_count": 94,
        "sentence_count": 15,
        "chinese_char_count": 682,
        "readability_score": 0.0,
        "information_density": 0.09199632014719412,
        "coherence_score": 0.7056732348111658,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6448451374720684,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "应收",
        "母公司",
        "营业",
        "经营",
        "财务状况"
      ]
    },
    {
      "chunk_id": "d14fcaf9",
      "content": "【表格内容】\n（八）应收款项融资 | | | 74,531,666.41 | 74,531,666.41\n--------------------------------------------------\n持续以公允价值计量的 | | | | \n | | | 94,531,666.41 | 94,531,666.41\n负债总额 | | | | \n | | | | \n二 非持续的公允价值计 | | | | \n | -- | -- | -- | --\n量 | | | | \n | | | |\n\n【注释】合计持股比例41.56%。其他说明：\n2、本企业的子公司情况\n本企业子公司的情况详见附注在其他主体中的权益之说明。3、本企业合营和联营企业情况\n本企业重要的合营或联营企业详见附注在其他主体中的权益之说明。",
      "chunk_type": "table_group",
      "parent_id": "808d2ee0",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 354,
      "page_number": 186,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "负债",
          "权益",
          "应收",
          "公允价值",
          "融资",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          186
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271458",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 354,
        "word_count": 56,
        "sentence_count": 8,
        "chinese_char_count": 123,
        "readability_score": 0.0,
        "information_density": 0.1694915254237288,
        "coherence_score": 0.44625,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5953244202108324,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "应收",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "47afde7e",
      "content": "【表格内容】\n| | | | 母公司对本企业的 | 母公司对本企业的\n--------------------------------------------------\n母公司名称 | 注册地 | 业务性质 | 注册资本 | | \n | | | | 持股比例 | 表决权比例\n | | | | | \n浙江东港投资有限 | | | | | \n | 台州 | 投资 | 11,800万元 | 34.22% | 34.22%\n公司 | | | | | \n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "0d9d1efa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 235,
      "page_number": 186,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "母公司"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          186
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271561",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 235,
        "word_count": 57,
        "sentence_count": 2,
        "chinese_char_count": 61,
        "readability_score": 0.0,
        "information_density": 0.0851063829787234,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4093944664031621,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "母公司"
      ]
    },
    {
      "chunk_id": "0adffc87",
      "content": "【说明】本期与本公司发生关联方交易，或前期与本公司发生关联方交易形成余额的其他合营或联营企业情况如下：\n合营或联营企业名称 与本企业关系\n苏州第四制药厂有限公司 联营企业\n浙江高盛钢结构有限公司 联营企业\n其他说明\n4、其他关联方情况\n其他关联方名称 其他关联方与本企业关系\n浙江荣兴活性炭有限公司 控股股东之联营企业\n江西华邦药业有限公司 控股股东之联营企业\n台州艾斐科技有限公司 控股股东之联营企业\n台州市东港包装用品有限公司 控股股东之子公司\n其他说明\n5、关联交易情况\n（1）购销商品、提供和接受劳务的关联交易\n采购商品/接受劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 获批的交易额度 是否超过交易额度 上期发生额\n浙江高盛钢结构有\n工程建造 1,275,826.79\n限公司\n浙江荣兴活性炭有\n原材料 2,423,957.10 28,000,000.00否 3,914,565.88\n限公司\n江西华邦药业有限 原料药及医药中\n23,998,498.62 50,000,000.00否 809,858.52\n公司 间体\n台州市东港包装用\n原材料 4,393.37\n品有限公司\n187。\n\n【表格内容】\n合营或联营企业名称 | 与本企业关系\n--------------------------------------------------\n苏州第四制药厂有限公司 | 联营企业\n浙江高盛钢结构有限公司 | 联营企业",
      "chunk_type": "table_group",
      "parent_id": "9afae774",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 619,
      "page_number": 187,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          187
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271760",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 619,
        "word_count": 64,
        "sentence_count": 9,
        "chinese_char_count": 389,
        "readability_score": 0.0,
        "information_density": 0.01615508885298869,
        "coherence_score": 0.6834407601106214,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5083787280479963,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股东"
      ]
    },
    {
      "chunk_id": "4421c7df",
      "content": "【表格内容】\n其他关联方名称 | 其他关联方与本企业关系\n--------------------------------------------------\n浙江荣兴活性炭有限公司 | 控股股东之联营企业\n江西华邦药业有限公司 | 控股股东之联营企业\n台州艾斐科技有限公司 | 控股股东之联营企业\n台州市东港包装用品有限公司 | 控股股东之子公司",
      "chunk_type": "table_group",
      "parent_id": "8b179ad9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 174,
      "page_number": 187,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "股东"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          187
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.271844",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 174,
        "word_count": 17,
        "sentence_count": 0,
        "chinese_char_count": 101,
        "readability_score": 0.0,
        "information_density": 0.05747126436781609,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4788590818363273,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "股东"
      ]
    },
    {
      "chunk_id": "10633d78",
      "content": "【说明】出售商品/提供劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n苏州第四制药厂有限公司 原料药及医药中间体 261,061.95 504,310.34\n台州艾斐科技有限公司 电费 404,095.99 678,615.69\n江西华邦药业有限公司 设备销售 255,603.43\n江西华邦药业有限公司 原料药及医药中间体 44,247.79\n购销商品、提供和接受劳务的关联交易说明\n（2）关联受托管理/承包及委托管理/出包情况\n本公司受托管理/承包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名受托/承包资产类 托管收益/承包收 本期确认的托管\n受托/承包起始日受托/承包终止日\n称 称 型 益定价依据 收益/承包收益\n关联托管/承包情况说明\n本公司委托管理/出包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名委托/出包资产类 托管费/出包费定 本期确认的托管\n委托/出包起始日委托/出包终止日\n称 称 型 价依据 费/出包费\n关联管理/出包情况说明\n（3）关联租赁情况\n本公司作为出租方：\n单位： 元\n承租方名称 租赁资产种类 本期确认的租赁收入 上期确认的租赁收入\n本公司作为承租方：\n单位： 元\n出租方名称 租赁资产种类 本期确认的租赁费 上期确认的租赁费\n关联租赁情况说明\n（4）关联担保情况\n本公司作为担保方\n单位： 元\n被担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n本公司作为被担保方\n单位： 元\n188。\n\n【表格内容】\n关联方 | 关联交易内容 | 本期发生额 | 获批的交易额度 | 是否超过交易额度 | 上期发生额\n--------------------------------------------------\n浙江高盛钢结构有 | | | | | \n | 工程建造 | | | | 1,275,826.79\n限公司 | | | | | \n | | | | | \n浙江荣兴活性炭有 | | | | | \n | 原材料 | 2,423,957.10 | 28,000,000.00 | 否 | 3,914,565.88\n限公司 | | | | | \n | | | | | \n江西华邦药业有限 | 原料药及医药中 | | | | \n | | 23,998,498.62 | 50,000,000.00 | 否 | 809,858.52\n公司 | 间体 | | | | \n | | | | | \n台州市东港包装用 | | | | | \n | 原材料 | 4,393.37 | | | \n品有限公司 | | | | | \n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "6d55126a",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1111,
      "page_number": 187,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "收入"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          187
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272137",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 1111,
        "word_count": 194,
        "sentence_count": 15,
        "chinese_char_count": 560,
        "readability_score": 0.0,
        "information_density": 0.018001800180018002,
        "coherence_score": 0.42157894736842105,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5687928802588997,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入"
      ]
    },
    {
      "chunk_id": "3b58924c",
      "content": "【表格内容】\n关联方 | 关联交易内容 | 本期发生额 | 上期发生额\n--------------------------------------------------\n苏州第四制药厂有限公司 | 原料药及医药中间体 | 261,061.95 | 504,310.34\n台州艾斐科技有限公司 | 电费 | 404,095.99 | 678,615.69\n江西华邦药业有限公司 | 设备销售 | | 255,603.43\n江西华邦药业有限公司 | 原料药及医药中间体 | 44,247.79 |",
      "chunk_type": "table_group",
      "parent_id": "429f915d",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 248,
      "page_number": 188,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          188
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272351",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 248,
        "word_count": 35,
        "sentence_count": 6,
        "chinese_char_count": 88,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42545185185185186,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "53a4ccb9",
      "content": "【表格内容】\n委托方/出包方名 | 受托方/承包方名 | 受托/承包资产类 | | 受托/承包终止日 | 托管收益/承包收 | 本期确认的托管\n--------------------------------------------------\n | | | 受托/承包起始日 | | | \n称 | 称 | 型 | | | 益定价依据 | 收益/承包收益\n | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "59aa1ded",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 190,
      "page_number": 188,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          188
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272548",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 190,
        "word_count": 38,
        "sentence_count": 0,
        "chinese_char_count": 67,
        "readability_score": 0.0,
        "information_density": 0.05263157894736842,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.44574761904761906,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "49c5acf6",
      "content": "【说明】担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n关联担保情况说明\n（5）关联方资金拆借\n单位： 元\n关联方 拆借金额 起始日 到期日 说明\n拆入\n拆出\n（6）关联方资产转让、债务重组情况\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n（7）关键管理人员报酬\n单位： 元\n项目 本期发生额 上期发生额\n关键管理人员报酬 8,152,800.00 7,761,100.00\n（8）其他关联交易\n6、关联方应收应付款项\n（1）应收项目\n单位： 元\n期末余额 期初余额\n项目名称 关联方\n账面余额 坏账准备 账面余额 坏账准备\n台州艾斐科技有限\n应收账款 63,451.70 3,172.59\n公司\n江西华邦药业有限\n应收账款 9,682.64 2,904.79\n公司\n小 计 9,682.64 2,904.79 63,451.70 3,172.59\n（2）应付项目\n单位： 元\n项目名称 关联方 期末账面余额 期初账面余额\n189\n\n【表格内容】\n委托方/出包方名 | 受托方/承包方名 | 委托/出包资产类 | | 委托/出包终止日 | 托管费/出包费定 | 本期确认的托管\n--------------------------------------------------\n | | | 委托/出包起始日 | | | \n称 | 称 | 型 | | | 价依据 | 费/出包费\n | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "ae1caa76",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 618,
      "page_number": 188,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "应收",
          "应付",
          "债务"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          188
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272732",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 618,
        "word_count": 107,
        "sentence_count": 10,
        "chinese_char_count": 304,
        "readability_score": 0.0,
        "information_density": 0.06472491909385114,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5315604166666668,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "应收",
        "应付",
        "债务"
      ]
    },
    {
      "chunk_id": "3b8da62d",
      "content": "【表格内容】\n关联方 | 拆借金额 | 起始日 | 到期日 | 说明\n--------------------------------------------------\n拆入 | | | | \n拆出 | | | |",
      "chunk_type": "table_group",
      "parent_id": "b2646ac1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 189,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          189
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272822",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 21,
        "sentence_count": 0,
        "chinese_char_count": 23,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37298888888888887,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "3a99f548",
      "content": "【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n关键管理人员报酬 | 8,152,800.00 | 7,761,100.00",
      "chunk_type": "table_group",
      "parent_id": "5e122bc9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 115,
      "page_number": 189,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          189
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.272903",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 115,
        "word_count": 12,
        "sentence_count": 2,
        "chinese_char_count": 24,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37437777777777775,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "aa863696",
      "content": "【说明】应付账款 浙江荣兴活性炭有限公司 171,167.79 816,333.28\n应付账款 浙江高盛钢结构有限公司 169,367.59 154,247.59\n应付账款 江西华邦药业有限公司 51,086.20\n台州市东港包装用品有限公\n应付账款 4,393.37\n司\n小 计 344,928.75 1,021,667.07\n7、关联方承诺\n8、其他\n十三、股份支付\n1、股份支付总体情况\n√ 适用 □ 不适用\n单位： 元\n公司本期授予的各项权益工具总额 0.00\n公司本期行权的各项权益工具总额 18,146,500.00\n公司本期失效的各项权益工具总额 105,000.00\n公司期末发行在外的股票期权行权价格的范围和合同剩余期限 0\n公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 0\n其他说明\n根据公司2015 年第一次临时股东大会审议通过的《浙江海翔药业股份有限公司限制性股票激励计划\n（草案）》及其摘要(以下简称激励计划)，公司首次授予激励对象限制性股票3,471.5万股，预留部分限制\n性股票380万股。根据公司2015年度股东大会决议审议通过的2015年度利润分配方案，上述限制性股票数\n量调整为7,703万股。截至2018年12月31日累计回购已获授但尚未解锁的限制性股票429.2万股，累计解锁\n限制性股票5,459.15万股。\n\n【表格内容】\n| | 期末余额 | | 期初余额 | \n--------------------------------------------------\n项目名称 | 关联方 | | | | \n | | 账面余额 | 坏账准备 | 账面余额 | 坏账准备\n | | | | | \n | 台州艾斐科技有限 | | | | \n应收账款 | | | | 63,451.70 | 3,172.59\n | 公司 | | | | \n | | | | | \n | 江西华邦药业有限 | | | | \n应收账款 | | 9,682.64 | 2,904.79 | | \n | 公司 | | | | \n | | | | | \n小 计 | | 9,682.64 | 2,904.79 | 63,451.70 | 3,172.59",
      "chunk_type": "table_group",
      "parent_id": "59b319ba",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 940,
      "page_number": 189,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "应收",
          "应付",
          "股份",
          "股东",
          "分配",
          "回购"
        ],
        "time_periods": [
          "2015",
          "2018-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          189
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273163",
        "report_type": null,
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 940,
        "word_count": 137,
        "sentence_count": 25,
        "chinese_char_count": 421,
        "readability_score": 0.0,
        "information_density": 0.0851063829787234,
        "coherence_score": 0.684763371797164,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5480807429466545,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "应收",
        "应付",
        "股份",
        "股东",
        "分配",
        "回购"
      ]
    },
    {
      "chunk_id": "8ea6c307",
      "content": "【说明】根据公司2019年3月13日第五届董事会第二十一次会议决议，公司2018年度绩效考核已满足行权条件，\n对首次及预留授予激励对象持有的限制性股票1,814.65万股予以解锁。2、以权益结算的股份支付情况\n√ 适用 □ 不适用\n单位： 元\n授予日权益工具公允价值的确定方法 根据布莱克-斯科尔模型来计算期权的理论价值\n可行权权益工具数量的确定依据 无\n本期估计与上期估计有重大差异的原因 无\n190。\n\n【表格内容】\n应付账款 | 浙江荣兴活性炭有限公司 | 171,167.79 | 816,333.28\n--------------------------------------------------\n应付账款 | 浙江高盛钢结构有限公司 | 169,367.59 | 154,247.59\n应付账款 | 江西华邦药业有限公司 | | 51,086.20\n | 台州市东港包装用品有限公 | | \n应付账款 | | 4,393.37 | \n | 司 | | \n | | | \n小 计 | | 344,928.75 | 1,021,667.07",
      "chunk_type": "table_group",
      "parent_id": "968c3f81",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 477,
      "page_number": 190,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "应付",
          "股份",
          "公允价值",
          "价值"
        ],
        "time_periods": [
          "2018",
          "2019-3"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          190
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273333",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 477,
        "word_count": 60,
        "sentence_count": 11,
        "chinese_char_count": 221,
        "readability_score": 0.0,
        "information_density": 0.10482180293501049,
        "coherence_score": 0.7428571428571429,
        "standards_profile_summary": {}
      },
      "quality_score": 0.49444932400932395,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "应付",
        "股份",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "657a4223",
      "content": "【表格内容】\n公司本期授予的各项权益工具总额 | 0.00\n--------------------------------------------------\n公司本期行权的各项权益工具总额 | 18,146,500.00\n公司本期失效的各项权益工具总额 | 105,000.00\n公司期末发行在外的股票期权行权价格的范围和合同剩余期限 | 0\n公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 | 0",
      "chunk_type": "table_group",
      "parent_id": "511d502f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 207,
      "page_number": 190,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          190
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273420",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 207,
        "word_count": 17,
        "sentence_count": 3,
        "chinese_char_count": 105,
        "readability_score": 0.0,
        "information_density": 0.04830917874396136,
        "coherence_score": 0.6,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4740833333333333,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益"
      ]
    },
    {
      "chunk_id": "422a6b04",
      "content": "【说明】以权益结算的股份支付计入资本公积的累计金额 174,493,817.84\n本期以权益结算的股份支付确认的费用总额 7,113,749.53\n其他说明\n3、以现金结算的股份支付情况\n□ 适用 √ 不适用\n4、股份支付的修改、终止情况\n5、其他\n十四、承诺及或有事项\n1、重要承诺事项\n资产负债表日存在的重要承诺\n(一) 重要承诺事项\n1. 已签订的尚未履行或尚未完全履行的对外投资合同及有关财务支出\n根据公司2016年9月28日第四届董事会第三十次会议决议，公司拟使用自有资金投资医健战略投资基\n金上海佳添冠投资合伙企业(有限合伙)。上海佳添冠投资合伙企业(有限合伙)目标规模20亿元，公司拟以自\n有资金不超过2亿元人民币认购该基金，截至本财务报表批准报出日，公司尚未实际出资。2. 根据公司2019年2月14日第五届董事会第二十次会议决议，台州前进公司拟与内蒙古生力资源（集\n团）有限责任公司共同投资设立内蒙古科菲化工有限公司(以下简称科菲化工公司)，科菲化工公司一期计\n划投资总额为50,000.00万元，其中台州前进公司计划投资24,500.00万元，占科菲化工公司49.00%的股权。\n\n【表格内容】\n授予日权益工具公允价值的确定方法 | 根据布莱克-斯科尔模型来计算期权的理论价值\n--------------------------------------------------\n可行权权益工具数量的确定依据 | 无\n本期估计与上期估计有重大差异的原因 | 无",
      "chunk_type": "table_group",
      "parent_id": "d5bf4564",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 640,
      "page_number": 190,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "权益",
          "费用",
          "现金",
          "投资",
          "资产负债表",
          "资本公积",
          "股权",
          "股份"
        ],
        "time_periods": [
          "2016-9",
          "2019-2"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          190
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273589",
        "report_type": null,
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "有限责任公司共同投资设立内蒙古科菲化工有限公司",
        "industry": null,
        "char_count": 640,
        "word_count": 36,
        "sentence_count": 10,
        "chinese_char_count": 442,
        "readability_score": 0.0,
        "information_density": 0.15625,
        "coherence_score": 0.6843864318864319,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5927667016990718,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "现金",
        "投资",
        "资产负债表",
        "资本公积",
        "股权",
        "股份"
      ]
    },
    {
      "chunk_id": "1cf427ed",
      "content": "【说明】根据公司2020年1月22日第六届董事会第二次会议，公司决定终止对科菲化工公司的投资。(二) 前期承诺履行情况\n1. 根据2015年10月30日公司2015年第三次临时股东大会审议通过的《关于公司非公开发行 A 股股票\n方案（修订稿）的议案》，公司非公开发行人民币普通股(A股)股票99,890,023股，募集资金净额为\n1,014,403,606.71元，上述募集资金全部用于投资建设以下项目：\n项目名称 项目实施主体 总投资额 募集资金计划投\n(万元) 入(万元)\n原料药及中间体CMO中心扩建项目 川南药业公司 46,034.58 40,000.00\n年产30亿片（粒）固体制剂技改项目 本公司 35,852.00 35,000.00\n医药综合研发中心 川南药业公司 15,073.00 15,000.00\n医药中试车间技改项目 本公司 9,256.00 9,000.00\n环保设施改造项目 本公司及子公司 15,502.00 14,000.00\n合 计 121,717.58 113,000.00\n截至2019年12月31日，本公司已使用募集资金直接投入上述项目44,720.30万元，根据公司2019年3月\n11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资项目并将结余募集资金用于永\n久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目的市场环境已发生较大变化，公司\n终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。2. 根据公司2018年第一次临时股东大会及第三次临时股东大会，公司拟以集中竞价交易方式回购公司\n191。\n\n【表格内容】\n以权益结算的股份支付计入资本公积的累计金额 | 174,493,817.84\n--------------------------------------------------\n本期以权益结算的股份支付确认的费用总额 | 7,113,749.53",
      "chunk_type": "table_group",
      "parent_id": "0cacb069",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 851,
      "page_number": 191,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "费用",
          "投资",
          "资本公积",
          "股份",
          "股东",
          "回购"
        ],
        "time_periods": [
          "2015-10",
          "2019-12",
          "2019-3",
          "2020-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.273839",
        "report_type": null,
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": "公司决定终止对科菲化工公司",
        "industry": null,
        "char_count": 851,
        "word_count": 56,
        "sentence_count": 22,
        "chinese_char_count": 466,
        "readability_score": 0.0,
        "information_density": 0.08225616921269095,
        "coherence_score": 0.6795454545454545,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5251478810879191,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "费用",
        "投资",
        "资本公积",
        "股份",
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "47b1e5ab",
      "content": "【说明】股份，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，详见本财务报表附注库存股之\n说明。\n2、或有事项\n（1）资产负债表日存在的重要或有事项\n截至2019年12月31日，本公司不存在需要披露的重大或有事项。\n（2）公司没有需要披露的重要或有事项，也应予以说明\n公司不存在需要披露的重要或有事项。\n3、其他\n十五、资产负债表日后事项\n1、重要的非调整事项\n单位： 元\n对财务状况和经营成果的影\n项目 内容 无法估计影响数的原因\n响数\n2、利润分配情况\n单位： 元\n3、销售退回\n4、其他资产负债表日后事项说明\n拟分配的利润或股利 根据公司2020年1月22日第六届董事会第二次会议审议\n通过的2019年度利润分配预案，拟以2019年度总股本扣\n除存放于股票回购专用证券账户后的股份数量为基数，\n每10股派发现金股利3元(含税)。上述利润分配预案尚\n待公司股东大会审议批准。\n192\n\n【表格内容】\n项目名称 | 项目实施主体 | 总投资额\n(万元) | 募集资金计划投\n入(万元)\n--------------------------------------------------\n原料药及中间体CMO中心扩建项目 | 川南药业公司 | 46,034.58 | 40,000.00\n年产30亿片（粒）固体制剂技改项目 | 本公司 | 35,852.00 | 35,000.00\n医药综合研发中心 | 川南药业公司 | 15,073.00 | 15,000.00\n医药中试车间技改项目 | 本公司 | 9,256.00 | 9,000.00\n环保设施改造项目 | 本公司及子公司 | 15,502.00 | 14,000.00\n合 计 | | 121,717.58 | 113,000.00",
      "chunk_type": "table_group",
      "parent_id": "da3970e9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 757,
      "page_number": 191,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "利润",
          "现金",
          "投资",
          "资产负债表",
          "经营",
          "股本",
          "财务状况",
          "股份"
        ],
        "time_periods": [
          "2019",
          "2019-12",
          "2020-1"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274069",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 757,
        "word_count": 86,
        "sentence_count": 17,
        "chinese_char_count": 411,
        "readability_score": 0.0,
        "information_density": 0.13210039630118892,
        "coherence_score": 0.6215537337788484,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6389044992283214,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "利润",
        "现金",
        "投资",
        "资产负债表",
        "经营",
        "股本",
        "财务状况",
        "股份"
      ]
    },
    {
      "chunk_id": "722958c9",
      "content": "【表格内容】\n| | 受影响的各个比较期间报表 | \n--------------------------------------------------\n会计差错更正的内容 | 处理程序 | | 累积影响数\n | | 项目名称 | \n | | |",
      "chunk_type": "table_group",
      "parent_id": "805ad996",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 124,
      "page_number": 193,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          193
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274155",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 124,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 38,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.7300000000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4575956989247311,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "15559565",
      "content": " | 期末余额 |  |  |  |  | 期初余额 |  |  |  | \n--------------------------------------------------\n | 账面余额 |  | 坏账准备 |  |  | 账面余额 |  | 坏账准备 |  | \n类别 |  |  |  |  |  |  |  |  |  | \n |  |  |  | 计提比\n例 | 账面价值 |  |  |  |  | 账面价值\n | 金额 | 比例 | 金额 |  |  | 金额 | 比例 | 金额 | 计提比例 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n其中： |  |  |  |  |  |  |  |  |  | \n按组合计提坏账准 | 130,720, |  | 7,187,81 | 5.50% | 123,532,2 | 157,389,6 |  | 8,184,787 |  | 149,204,89\n |  | 100.00% |  |  |  |  | 100.00% |  | 5.20% | \n备的应收账款 | 059.44 |  | 5.25 |  | 44.19 | 87.72 |  | .74 |  | 9.98\n |  |  |  |  |  |  |  |  |  | \n其中： |  |  |  |  |  |  |  |  |  | \n | 130,720, |  | 7,187,81 | 5.50% | 123,532,2\n44.19 | 157,389,6 |  | 8,184,787 |  | 149,204,89\n合计 |  | 100.00% |  |  |  |  | 100.00% |  | 5.20% | \n | 059.44 |  | 5.25 |  |  | 87.72 |  | .74 |  | 9.98\n |  |  |  |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "dea8fa86",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1363,
      "page_number": 194,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 20,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          194
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.274471",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 863,
        "word_count": 226,
        "sentence_count": 20,
        "chinese_char_count": 74,
        "readability_score": 0.0,
        "information_density": 0.03476245654692932,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5257242178447277,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "10b0639c",
      "content": "【表格内容】\n| 期末余额 | | | \n--------------------------------------------------\n名称 | | | | \n | 账面余额 | 坏账准备 | 计提比例 | 计提理由\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "ae492eba",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 121,
      "page_number": 195,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274552",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 121,
        "word_count": 24,
        "sentence_count": 0,
        "chinese_char_count": 26,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3764129032258064,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "ec53bb61",
      "content": "【表格内容】\n| 期末余额 | | \n--------------------------------------------------\n名称 | | | \n | 账面余额 | 坏账准备 | 计提比例\n | | | \n合并范围内关联往来组合 | 1,358,605.41 | | \n账龄组合 | 129,361,454.03 | 7,187,815.25 | 5.56%\n合计 | 130,720,059.44 | 7,187,815.25 | --",
      "chunk_type": "table_group",
      "parent_id": "09edd9d1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 226,
      "page_number": 195,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "合并"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274630",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 226,
        "word_count": 38,
        "sentence_count": 6,
        "chinese_char_count": 39,
        "readability_score": 0.0,
        "information_density": 0.04424778761061947,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4267634218289085,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "合并"
      ]
    },
    {
      "chunk_id": "329870d4",
      "content": "【表格内容】\n| 期末余额 | | \n--------------------------------------------------\n名称 | | | \n | 账面余额 | 坏账准备 | 计提比例\n | | |",
      "chunk_type": "table_group",
      "parent_id": "268b6779",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 108,
      "page_number": 195,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274687",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 108,
        "word_count": 19,
        "sentence_count": 0,
        "chinese_char_count": 22,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.37160000000000004,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "c6499077",
      "content": "【表格内容】\n账龄 | 账面余额\n--------------------------------------------------\n1年以内（含1年） | 129,484,273.40\n1至2年 | 508,161.68\n2至3年 | 492,705.04\n3年以上 | 234,919.32\n3至4年 | 234,919.32\n合计 | 130,720,059.44",
      "chunk_type": "table_group",
      "parent_id": "53ef65f6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 186,
      "page_number": 195,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.274834",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 186,
        "word_count": 23,
        "sentence_count": 6,
        "chinese_char_count": 26,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45423575418994405,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "bd617db9",
      "content": "【说明】其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数\n单位名称 应收账款期末余额 坏账准备期末余额\n的比例\nACS DOBFAR S.P.A 30,318,565.17 23.19% 1,515,928.26\nFIS-FABBRICA ITALIANA\n23,576,101.39 18.04% 1,178,805.07\nSINTETICI S.P.A\nPFIZER ASIA\n19,767,647.40 15.12% 988,382.37\nMANUFACTURING PTE LTD\nBIDACHEM S.P.A 11,875,658.58 9.08% 593,782.93\nCENTRAL DE PRODUCTOS\n6,666,631.13 5.10% 333,331.56\nQUIMICOS S.A.DE C.V.\n合计 92,204,603.67 70.53%\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n2、其他应收款\n单位： 元\n项目 期末余额 期初余额\n应收股利 722,088,153.34\n196。\n\n【表格内容】\n| | 本期变动金额 | | | \n--------------------------------------------------\n类别 | 期初余额 | | | | 期末余额\n | | 计提 | 收回或转回 | 核销 | \n | | | | | \n按组合计提坏账准 | | | | | \n | 8,184,787.74 | -996,972.49 | | | 7,187,815.25\n备 | | | | | \n | | | | | \n合计 | 8,184,787.74 | -996,972.49 | | | 7,187,815.25",
      "chunk_type": "table_group",
      "parent_id": "6e6b4dc8",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 939,
      "page_number": 195,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "负债",
          "应收",
          "融资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          195
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275090",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 939,
        "word_count": 143,
        "sentence_count": 35,
        "chinese_char_count": 284,
        "readability_score": 0.0,
        "information_density": 0.04259850905218317,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4977640117994101,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "应收",
        "融资"
      ]
    },
    {
      "chunk_id": "e01609eb",
      "content": "【表格内容】\n| | | | | 款项是否由关联交\n--------------------------------------------------\n单位名称 | 应收账款性质 | 核销金额 | 核销原因 | 履行的核销程序 | \n | | | | | 易产生\n | | | | |\n\n【注释】其他应收款 467,513,480.14 320,967,765.38\n合计 467,513,480.14 1,043,055,918.72\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n台州前进公司 722,088,153.34\n合计 722,088,153.34\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n197",
      "chunk_type": "table_group",
      "parent_id": "e59d59cf",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 505,
      "page_number": 196,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "应收",
          "减值",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          196
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275293",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 505,
        "word_count": 82,
        "sentence_count": 6,
        "chinese_char_count": 225,
        "readability_score": 0.0,
        "information_density": 0.07920792079207921,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4582947368421053,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收",
        "减值",
        "借款"
      ]
    },
    {
      "chunk_id": "bac723a0",
      "content": "【表格内容】\n| | 占应收账款期末余额合计数 | \n--------------------------------------------------\n单位名称 | 应收账款期末余额 | | 坏账准备期末余额\n | | 的比例 | \n | | | \nACS DOBFAR S.P.A | 30,318,565.17 | 23.19% | 1,515,928.26\nFIS-FABBRICA ITALIANA | | | \n | 23,576,101.39 | 18.04% | 1,178,805.07\nSINTETICI S.P.A | | | \n | | | \nPFIZER ASIA | | | \n | 19,767,647.40 | 15.12% | 988,382.37\nMANUFACTURING PTE LTD | | | \n | | | \nBIDACHEM S.P.A | 11,875,658.58 | 9.08% | 593,782.93\nCENTRAL DE PRODUCTOS | | | \n | 6,666,631.13 | 5.10% | 333,331.56\nQUIMICOS S.A.DE C.V. | | | \n | | | \n合计 | 92,204,603.67 | 70.53% |",
      "chunk_type": "table_group",
      "parent_id": "f5ea1275",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 562,
      "page_number": 196,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          196
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275463",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 562,
        "word_count": 102,
        "sentence_count": 27,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.017793594306049824,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.43456896551724133,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "7f19576b",
      "content": "【表格内容】\n项目 | 期末余额 | 期初余额\n--------------------------------------------------\n应收股利 | | 722,088,153.34",
      "chunk_type": "table_group",
      "parent_id": "48290539",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 98,
      "page_number": 196,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          196
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275520",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 98,
        "word_count": 11,
        "sentence_count": 1,
        "chinese_char_count": 18,
        "readability_score": 0.0,
        "information_density": 0.10204081632653061,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3662260869565217,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "b3ae4b2a",
      "content": "【表格内容】\n其他应收款 | 467,513,480.14 | 320,967,765.38\n--------------------------------------------------\n合计 | 467,513,480.14 | 1,043,055,918.72",
      "chunk_type": "table_group",
      "parent_id": "9a37b051",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 136,
      "page_number": 197,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275578",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 136,
        "word_count": 12,
        "sentence_count": 4,
        "chinese_char_count": 11,
        "readability_score": 0.0,
        "information_density": 0.07352941176470587,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.35893953488372093,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "5d4c8584",
      "content": "【表格内容】\n| | | | 是否发生减值及其判断\n--------------------------------------------------\n借款单位 | 期末余额 | 逾期时间 | 逾期原因 | \n | | | | 依据\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "518126ec",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 126,
      "page_number": 197,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值",
          "借款"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275627",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 126,
        "word_count": 24,
        "sentence_count": 0,
        "chinese_char_count": 32,
        "readability_score": 0.0,
        "information_density": 0.15873015873015872,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3833076923076923,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值",
        "借款"
      ]
    },
    {
      "chunk_id": "612d45bf",
      "content": "【表格内容】\n项目(或被投资单位) | 期末余额 | 期初余额\n--------------------------------------------------\n台州前进公司 | | 722,088,153.34\n合计 | | 722,088,153.34",
      "chunk_type": "table_group",
      "parent_id": "d24d85ca",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 130,
      "page_number": 197,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275703",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 130,
        "word_count": 15,
        "sentence_count": 2,
        "chinese_char_count": 28,
        "readability_score": 0.0,
        "information_density": 0.07692307692307691,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3788,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资"
      ]
    },
    {
      "chunk_id": "f215b76f",
      "content": "【说明】（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n往来款 459,656,754.37 320,145,265.41\n押金保证金 5,000.00 5,000.00\n应收暂付款 6,339,111.65 5,841,009.97\n应收出口退税 6,584,960.26\n其 他 63,177.77 76,177.77\n合计 472,649,004.05 326,067,453.15\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 5,099,687.77 5,099,687.77\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 35,836.14 35,836.14\n2019年12月31日余额 5,135,523.91 5,135,523.91\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 456,448,642.60\n1至2年 4,956,117.14\n2至3年 2,265,499.80\n3年以上 8,978,744.51\n3至4年 3,978,744.51\n5年以上 5,000,000.00\n合计 472,649,004.05\n198。\n\n【表格内容】\n| | | | 是否发生减值及其判断\n--------------------------------------------------\n项目(或被投资单位) | 期末余额 | 账龄 | 未收回的原因 | \n | | | | 依据\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "479ea8d1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 775,
      "page_number": 197,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "应收",
          "披露",
          "减值"
        ],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          197
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.275938",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 775,
        "word_count": 103,
        "sentence_count": 25,
        "chinese_char_count": 255,
        "readability_score": 0.0,
        "information_density": 0.05161290322580645,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45391620539289845,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收",
        "披露",
        "减值"
      ]
    },
    {
      "chunk_id": "98d39c7a",
      "content": "【表格内容】\n款项性质 | 期末账面余额 | 期初账面余额\n--------------------------------------------------\n往来款 | 459,656,754.37 | 320,145,265.41\n押金保证金 | 5,000.00 | 5,000.00\n应收暂付款 | 6,339,111.65 | 5,841,009.97\n应收出口退税 | 6,584,960.26 | \n其 他 | 63,177.77 | 76,177.77\n合计 | 472,649,004.05 | 326,067,453.15",
      "chunk_type": "table_group",
      "parent_id": "bb8d97f2",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 272,
      "page_number": 198,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276063",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 272,
        "word_count": 37,
        "sentence_count": 11,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.036764705882352935,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4000754716981132,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "8c59e07a",
      "content": "【表格内容】\n| 第一阶段 | 第二阶段 | 第三阶段 | \n--------------------------------------------------\n坏账准备 | 未来12个月预期信 | 整个存续期预期信用损失 | 整个存续期预期信用损失 | 合计\n | 用损失 | (未发生信用减值) | (已发生信用减值) | \n2019年1月1日余额 | 5,099,687.77 | | | 5,099,687.77\n2019年1月1日余额在 | | | | \n | | | | \n本期 | | | | \n | | | | \n本期计提 | 35,836.14 | | | 35,836.14\n2019年12月31日余额 | 5,135,523.91 | | | 5,135,523.91",
      "chunk_type": "table_group",
      "parent_id": "3a26f655",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 346,
      "page_number": 198,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "减值"
        ],
        "time_periods": [
          "2019-1",
          "2019-12"
        ],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276173",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 346,
        "word_count": 64,
        "sentence_count": 6,
        "chinese_char_count": 90,
        "readability_score": 0.0,
        "information_density": 0.028901734104046246,
        "coherence_score": 0.79,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5084459016393442,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "减值"
      ]
    },
    {
      "chunk_id": "ebeef41e",
      "content": "【说明】3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n川南药业公司 往来款 261,610,250.381年以内 55.35%\n台州振港公司 往来款 176,225,865.641年以内 37.28%\nGeneVida GmbH 往来款 4,592,945.061年以内 0.97%\nGeneVida GmbH 往来款 4,934,973.061-2年 1.04%\nGeneVida GmbH 往来款 2,227,737.932-3年 0.47%\nGeneVida GmbH 往来款 3,913,444.513年以上 0.84%\nPFIZER ASIA\nMANUFACTURING 应收暂付款 5,000,000.003年以上 1.06% 5,000,000.00\nPTE LTD\n台州前进公司 往来款 4,170,214.351年以内 0.88%\n合计 -- 462,675,430.93 -- 97.89% 5,000,000.00\n199。\n\n【表格内容】\n账龄 | 账面余额\n--------------------------------------------------\n1年以内（含1年） | 456,448,642.60\n1至2年 | 4,956,117.14\n2至3年 | 2,265,499.80\n3年以上 | 8,978,744.51\n3至4年 | 3,978,744.51\n5年以上 | 5,000,000.00\n合计 | 472,649,004.05",
      "chunk_type": "table_group",
      "parent_id": "697b2baa",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 915,
      "page_number": 198,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276449",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 915,
        "word_count": 117,
        "sentence_count": 28,
        "chinese_char_count": 337,
        "readability_score": 0.0,
        "information_density": 0.01092896174863388,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.531636943419806,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "b379f939",
      "content": "【表格内容】\n| 期初余额 | 本期变动金额 | | | \n--------------------------------------------------\n类别 | | | | | 期末余额\n | | 计提 | 收回或转回 | 核销 | \n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "dde24cbd",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 133,
      "page_number": 199,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          199
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276552",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 133,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 29,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.379778417266187,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "dd9a769b",
      "content": "【表格内容】\n| | | | | 款项是否由关联交\n--------------------------------------------------\n单位名称 | 其他应收款性质 | 核销金额 | 核销原因 | 履行的核销程序 | \n | | | | | 易产生\n | | | | |",
      "chunk_type": "table_group",
      "parent_id": "ed1b703b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 144,
      "page_number": 199,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          199
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.276612",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 144,
        "word_count": 29,
        "sentence_count": 0,
        "chinese_char_count": 41,
        "readability_score": 0.0,
        "information_density": 0.06944444444444445,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3919549668874172,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "493be468",
      "content": " |  |  |  | 占其他应收款期末 | \n--------------------------------------------------\n单位名称 | 款项的性质 | 期末余额 | 账龄 |  | 坏账准备期末余额\n |  |  |  | 余额合计数的比例 | \n |  |  |  |  | \n川南药业公司 | 往来款 | 261,610,250.38 | 1年以内 | 55.35% | \n台州振港公司 | 往来款 | 176,225,865.64 | 1年以内 | 37.28% | \nGeneVida GmbH | 往来款 | 4,592,945.06 | 1年以内 | 0.97% | \nGeneVida GmbH | 往来款 | 4,934,973.06 | 1-2年 | 1.04% | \nGeneVida GmbH | 往来款 | 2,227,737.93 | 2-3年 | 0.47% | \nGeneVida GmbH | 往来款 | 3,913,444.51 | 3年以上 | 0.84% | \nPFIZER ASIA |  |  |  |  | \nMANUFACTURING | 应收暂付款 | 5,000,000.00 | 3年以上 | 1.06% | 5,000,000.00\nPTE LTD |  |  |  |  | \n台州前进公司 | 往来款 | 4,170,214.35 | 1年以内 | 0.88% | \n合计 | -- | 462,675,430.93 | -- | 97.89% | 5,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "74d35e57",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1180,
      "page_number": 199,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 16,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "应收"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          199
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.276962",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 680,
        "word_count": 138,
        "sentence_count": 20,
        "chinese_char_count": 105,
        "readability_score": 0.0,
        "information_density": 0.014705882352941176,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39632352941176474,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收"
      ]
    },
    {
      "chunk_id": "62af8cf4",
      "content": "【表格内容】\n| | | | 预计收取的时间 金额\n--------------------------------------------------\n单位名称 | 政府补助项目名称 | 期末余额 | 期末账龄 | \n | | | | 及依据\n | | | |",
      "chunk_type": "table_group",
      "parent_id": "55012e2b",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 131,
      "page_number": 200,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": false,
        "accounting_items": [],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          200
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277045",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 131,
        "word_count": 25,
        "sentence_count": 0,
        "chinese_char_count": 36,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.33,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4625555555555555,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "f5de2a97",
      "content": "【表格内容】\n| 期末余额 | | | 期初余额 | | \n--------------------------------------------------\n项目 | | | | | | \n | 账面余额 | 减值准备 | 账面价值 | 账面余额 | 减值准备 | 账面价值\n | | | | | | \n对子公司投资 | 3,215,993,761.24 | | 3,215,993,761.24 | 3,213,363,387.02 | | 3,213,363,387.02\n对联营 合营企 | 54,774,633.09 | | | | | \n | | 23,347,592.79 | 31,427,040.30 | 60,541,058.62 | 23,347,592.79 | 37,193,465.83\n业投资 | | | | | | \n | | | | | | \n合计 | 3,270,768,394.33 | 23,347,592.79 | 3,247,420,801.54 | 3,273,904,445.64 | 23,347,592.79 | 3,250,556,852.85",
      "chunk_type": "table_group",
      "parent_id": "0172c017",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 500,
      "page_number": 200,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "减值",
          "账面价值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          200
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277190",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 500,
        "word_count": 92,
        "sentence_count": 16,
        "chinese_char_count": 55,
        "readability_score": 0.0,
        "information_density": 0.08,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5145992366412214,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "7cac0725",
      "content": "被投资单位 | 期初余额(账 | 本期增减变动 |  |  |  | 期末余额(账面 | 减值准备期末\n--------------------------------------------------\n | 面价值) | 追加投资 | 减少投资 | 计提减值准备 | 其他 | 价值) | 余额\n川南药业公司 | 928,629,850.7 |  |  |  |  |  | \n |  |  |  |  |  | 928,629,850.78 | \n | 8 |  |  |  |  |  | \n |  |  |  |  |  |  | \n海翔销售公司 | 37,599,318.92 |  |  |  |  | 37,599,318.92 | \n上海海翔公司 | 5,000,000.00 |  |  |  |  | 5,000,000.00 | \nGeneVida\nGmbH |  |  |  |  |  |  | \n | 8,974,808.00 |  |  |  |  | 8,974,808.00 | \n |  |  |  |  |  |  | \n台州前进公司 | 2,227,917,460. |  |  |  |  | 2,230,547,834. | \n |  | 2,630,374.22 |  |  |  |  | \n | 28 |  |  |  |  | 50 | \n |  |  |  |  |  |  | \n港翔科技公司 | 5,241,949.04 |  |  |  |  | 5,241,949.04 | \n合计 | 3,213,363,387.\n02 |  |  |  |  | 3,215,993,761.\n24 | \n |  | 2,630,374.22 |  |  |  |  | \n |  |  |  |  |  |  | ",
      "chunk_type": "table_group",
      "parent_id": "4b7d7b99",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1284,
      "page_number": 200,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {},
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 23,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "投资",
          "减值",
          "价值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "",
        "page_numbers": [
          200
        ],
        "extraction_method": "table_split",
        "processing_timestamp": "2025-11-26T15:26:54.277566",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔科技公司",
        "industry": null,
        "char_count": 784,
        "word_count": 175,
        "sentence_count": 16,
        "chinese_char_count": 83,
        "readability_score": 0.0,
        "information_density": 0.03826530612244898,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3817602040816327,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "减值",
        "价值"
      ]
    },
    {
      "chunk_id": "a20b0125",
      "content": "【表格内容】\n| | 本期增减变动 | | | | | | | | | \n--------------------------------------------------\n | 期初余额 | | | | | | | | | 期末余额 | \n | | | | 权益法下 | | | 宣告发放 | | | | 减值准备\n投资单位 | (账面价 | | | | 其他综合 | 其他权益 | | 计提减值 | | (账面价 | \n | | 追加投资 | 减少投资 | 确认的投 | | | 现金股利 | | 其他 | | 期末余额\n | 值) | | | | 收益调整 | 变动 | | 准备 | | 值) | \n | | | | 资损益 | | | 或利润 | | | | \n | | | | | | | | | | | \n一 合营企业 | | | | | | | | | | | \n二 联营企业 | | | | | | | | | | | \n苏州第四 | | | | | | | | | | | \n | 23,345,37 | | | -4,811,81 | | | | | | 18,533,55 | 23,347,59\n制药厂有 | | | | | | | | | | | \n | 3.14 | | | 4.84 | | | | | | 8.30 | 2.79\n限公司 | | | | | | | | | | | \n | | | | | | | | | | | \n浙江高盛 | | | | | | | | | | | \n | 13,848,09 | | | -954,610. | | | | | | 12,893,48 | \n钢结构有 | | | | | | | | | | | \n | 2.69 | | | 69 | | | | | | 2.00 | \n限公司 | | | | | | | | | | | \n | | | | | | | | | | | \n | 37,193,46 | | | -5,766,42 | | | | | | 31,427,04 | 23,347,59\n小计 | | | | | | | | | | | \n | 5.83 | | | 5.53 | | | | | | 0.30 | 2.79\n | | | | | | | | | | | \n | 37,193,46\n5.83 | | | -5,766,42 | | | | | | 31,427,04\n0.30 | 23,347,59\n2.79\n合计 | | | | | | | | | | | \n | | | | 5.53 | | | | | | | \n | | | | | | | | | | |",
      "chunk_type": "table_group",
      "parent_id": "a4713556",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 1143,
      "page_number": 201,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "利润",
          "现金",
          "投资",
          "减值"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.277837",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1143,
        "word_count": 399,
        "sentence_count": 15,
        "chinese_char_count": 126,
        "readability_score": 0.0,
        "information_density": 0.043744531933508315,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5797943567670971,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "现金",
        "投资",
        "减值"
      ]
    },
    {
      "chunk_id": "e8029528",
      "content": "【说明】权益法核算的长期股权投资收益 -5,766,425.53 -4,216,789.49\n银行理财产品投资收益 1,161,540.45 1,928,422.22\n处置金融工具取得的投资收益 -30,625.74 -1,559,950.55\n合计 -4,635,510.82 996,151,682.18\n6、其他\n十八、补充资料\n1、当期非经常性损益明细表\n√ 适用 □ 不适用\n单位： 元\n项目 金额 说明\n非流动资产处置损益 -4,150,774.97\n越权审批或无正式批准文件的税收返还、\n1,828,299.60\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70\n除上述各项之外的其他营业外收入和支出 -1,973,019.24\n减：所得税影响额 3,519,880.50\n合计 19,572,324.86 --\n对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公\n开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应\n说明原因。□ 适用 √ 不适用\n2、净资产收益率及每股收益\n每股收益\n报告期利润 加权平均净资产收益率\n基本每股收益（元/股） 稀释每股收益（元/股）\n归属于公司普通股股东的净利润 14.07% 0.48 0.48\n扣除非经常性损益后归属于公司\n13.71% 0.47 0.47\n普通股股东的净利润\n202。\n\n【表格内容】\n项目 | 本期发生额 | 上期发生额\n--------------------------------------------------\n成本法核算的长期股权投资收益 | | 1,000,000,000.00",
      "chunk_type": "table_group",
      "parent_id": "274b1b07",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 811,
      "page_number": 201,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "权益",
          "收入",
          "成本",
          "利润",
          "投资",
          "净利润",
          "所得税",
          "净资产",
          "营业"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          201
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.278111",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 811,
        "word_count": 75,
        "sentence_count": 24,
        "chinese_char_count": 404,
        "readability_score": 0.0,
        "information_density": 0.12330456226880396,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5340454514354886,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "净利润",
        "所得税",
        "净资产",
        "营业"
      ]
    },
    {
      "chunk_id": "d8d4c3b6",
      "content": "【表格内容】\n权益法核算的长期股权投资收益 | -5,766,425.53 | -4,216,789.49\n--------------------------------------------------\n银行理财产品投资收益 | 1,161,540.45 | 1,928,422.22\n处置金融工具取得的投资收益 | -30,625.74 | -1,559,950.55\n合计 | -4,635,510.82 | 996,151,682.18",
      "chunk_type": "table_group",
      "parent_id": "34855826",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 224,
      "page_number": 202,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "权益",
          "投资",
          "股权"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.278227",
        "report_type": null,
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 224,
        "word_count": 22,
        "sentence_count": 8,
        "chinese_char_count": 43,
        "readability_score": 0.0,
        "information_density": 0.13392857142857142,
        "coherence_score": 0.39,
        "standards_profile_summary": {}
      },
      "quality_score": 0.42869185867895543,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "投资",
        "股权"
      ]
    },
    {
      "chunk_id": "5312fd0f",
      "content": "【说明】3、境内外会计准则下会计数据差异\n（1）同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（2）同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（3）境内外会计准则下会计数据差异原因说明，对已经境外审计机构审计的数据进行差异调节的，应注\n明该境外机构的名称\n4、其他\n203 第十三节 备查文件目录\n一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表。\n二、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。\n三、报告期内在中国证监会指定报刊上公开披露过的所有公司文件正本及公告原稿；\n四、载有公司法定代表人签名的2019年年度报告文本原件。\n五、其他备查文件。\n文件存放地：公司投资发展部\n浙江海翔药业股份有限公司\n法定代表人：杨思卫\n二零二零年一月二十二日\n204\n\n【表格内容】\n| | 每股收益 | \n--------------------------------------------------\n报告期利润 | 加权平均净资产收益率 | | \n | | 基本每股收益（元/股） | 稀释每股收益（元/股）\n | | | \n归属于公司普通股股东的净利润 | 14.07% | 0.48 | 0.48\n扣除非经常性损益后归属于公司 | | | \n | 13.71% | 0.47 | 0.47\n普通股股东的净利润 | | | \n | | |",
      "chunk_type": "table_group",
      "parent_id": "22c96c26",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 647,
      "page_number": 202,
      "bbox": null,
      "element_type": "table",
      "extraction_confidence": 0.8,
      "is_table": true,
      "table_structure_preserved": true,
      "table_metadata": {
        "table_dimensions": "0x0",
        "has_header": false,
        "table_type": "other",
        "numeric_summary": {
          "total_values": 0,
          "numeric_values": 0,
          "min_value": null,
          "max_value": null,
          "has_negative_values": false,
          "has_percentage": false,
          "currency_detected": false
        },
        "high_value": false,
        "extraction_confidence": 0.8,
        "row_count": 0,
        "column_count": 0,
        "contains_financial_data": true,
        "accounting_items": [
          "资产",
          "利润",
          "投资",
          "净利润",
          "净资产",
          "会计数据",
          "股份",
          "股东",
          "每股",
          "审计"
        ],
        "time_periods": [],
        "bbox_estimated": false
      },
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          202
        ],
        "extraction_method": "table_group",
        "processing_timestamp": "2025-11-26T15:26:54.278417",
        "report_type": null,
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 647,
        "word_count": 70,
        "sentence_count": 10,
        "chinese_char_count": 409,
        "readability_score": 0.0,
        "information_density": 0.1545595054095827,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7031881533101045,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "利润",
        "投资",
        "净利润",
        "净资产",
        "会计数据",
        "股份",
        "股东",
        "每股",
        "审计"
      ]
    },
    {
      "chunk_id": "d82d5830",
      "content": "浙江海翔药业股份有限公司\n2019 年年度报告\n2020 年 01 月\n1 第一节重要提示、目录和释义\n公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真\n实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连\n带的法律责任。\n公司负责人杨思卫、主管会计工作负责人李进及会计机构负责人(会计主管\n人员)朱勇声明：保证年度报告中财务报告的真实、准确、完整。\n所有董事均已出席了审议本报告的董事会会议。\n本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的\n实质性承诺，敬请投资者注意投资风险。\n公司已在本报告中详细描述可能存在的相关风险，敬请投资者查阅本报告\n第四节“经营情况讨论与分析”中第九项“公司未来发展展望”。\n公司经本次董事会审议通过的利润分配预案为：以 1,555,709,365 为基数，\n向全体股东每 10 股派发现金红利 3 元（含税），送红股 0 股（含税），不以公积\n金转增股本。\n2",
      "chunk_type": "child",
      "parent_id": "efea3d1f",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 422,
      "page_number": 1,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          1
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.278806",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 422,
        "word_count": 31,
        "sentence_count": 6,
        "chinese_char_count": 326,
        "readability_score": 0.0,
        "information_density": 0.33175355450236965,
        "coherence_score": 0.732,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8622047393364929,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "投资",
        "经营",
        "股本",
        "股份",
        "股东",
        "分配",
        "红利",
        "派发"
      ]
    },
    {
      "chunk_id": "e1f073d8",
      "content": "目录\n第一节重要提示、目录和释义 ......................................................................................................... 2\n第二节公司简介和主要财务指标 ..................................................................................................... 6\n第三节公司业务概要 ....................................................................................................................... 10\n第四节经营情况讨论与分析 ........................................................................................................... 14\n第五节重要事项 ............................................................................................................................... 28\n第六节股份变动及股东情况 ........................................................................................................... 48\n第七节优先股相关情况 ................................................................................................................... 55\n第八节可转换公司债券相关情况 ................................................................................................... 56\n第九节董事、监事、高级管理人员和员工情况 ........................................................................... 57\n第十节公司治理 ................................................................................",
      "chunk_type": "child",
      "parent_id": "f91d7b7e",
      "child_ids": [],
      "sibling_ids": [
        "ec9e853c",
        "f400dee5",
        "cf22afe7",
        "78885b27"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1200,
      "page_number": 3,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          3
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.279861",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1200,
        "word_count": 30,
        "sentence_count": 1035,
        "chinese_char_count": 117,
        "readability_score": 0.0,
        "information_density": 0.058333333333333334,
        "coherence_score": 0.6655555555555556,
        "standards_profile_summary": {}
      },
      "quality_score": 0.33899999999999997,
      "relevance_score": 1.0,
      "keywords": [
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营",
        "财务指标",
        "股份",
        "股东",
        "债券"
      ]
    },
    {
      "chunk_id": "ec9e853c",
      "content": "........ 56\n第九节董事、监事、高级管理人员和员工情况 ........................................................................... 57\n第十节公司治理 ............................................................................................................................... 66\n第十一节公司债券相关情况 ........................................................................................................... 73\n第十二节 财务报告 ......................................................................................................................... 74\n第十三节 备查文件目录 ............................................................................................................... 204\n3。",
      "chunk_type": "child",
      "parent_id": "f91d7b7e",
      "child_ids": [],
      "sibling_ids": [
        "e1f073d8",
        "f400dee5",
        "cf22afe7",
        "78885b27"
      ],
      "position": 1,
      "start_char": 1000,
      "end_char": 1640,
      "page_number": 3,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          3
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.280033",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 640,
        "word_count": 20,
        "sentence_count": 550,
        "chinese_char_count": 55,
        "readability_score": 0.0,
        "information_density": 0.0625,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.3578125,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告",
        "财务报告",
        "债券"
      ]
    },
    {
      "chunk_id": "f400dee5",
      "content": ".................................................................. 74\n第十三节 备查文件目录 ............................................................................................................... 204\n3。\n\n释义\n释义项 指 释义内容\n中国证监会、证监会 指 中国证券监督管理委员会\n深交所、交易所 指 深圳证券交易所\n本公司、公司、海翔药业 指 浙江海翔药业股份有限公司\n川南公司、川南药业 指 浙江海翔川南药业有限公司，公司全资子公司\n销售公司 指 浙江海翔药业销售有限公司，公司全资子公司\n上海海翔 指 上海海翔医药科技发展有限公司，公司全资子公司\n台州前进、前进公司 指 台州市前进化工有限公司，公司全资子公司\n盐城瓯华、瓯华化工 指 盐城市瓯华化学工业有限公司，公司合并报表范围内子公司\n振港染料 指 台州市振港染料化工有限公司，公司合并报表范围内子公司\n盛嘉环保 指 浙江盛嘉环保科技有限公司，公司合并报表范围内子公司\n苏州四药 指 苏州第四制药厂有限公司，公司参股公司\n高盛钢结构 指 浙江高盛钢结构有限公司，公司参股公司\n北华环保 指 江苏北华环保科技有限公司，盐城瓯华参股公司\n东港投资 指 浙江东港投资有限公司，公司控股股东\n报告期 指 2019年1-12月的会计区间\n《公司章程》 指 浙江海翔药业股份有限公司章程\nActive Pharmaceutical Ingredients(API)，即药物活性成分，具有药理活\n原料药、API 指\n性可用于药品生产的化学物质\nGMP 指 Good Manufacturing Practice，药品生产质量管理规范\n药品监督管理部门对药品研制、生产、经营、使用单位合乎相应质量\n药品认证 指\n管理规范的情况进行检查、评价并决定是否发给相应认证证书的过程\n药品监督管理部门依照法定程序，对拟上市销售药品的安全性、有效\n性、质量可控性等进行系统评价，并作出是否同意进行药物临床研究、\n药品注册 指\n生产药品或者进口药品的审批过程，包括对申请变更药品批准证明文\n件及其附件中载明内容的审批\nFDA 指 U.S.Food and Drug Administration，美国食品和药品监督管理局\nBI 指 德国勃林格殷格翰公司\nThe European Directorate for the Quality of Medicines & HealthCare，欧\nEDQM 指\n洲药品质量管理局\nUSP 指 U.S. Pharmacopeia，美国药典\n4。",
      "chunk_type": "child",
      "parent_id": "f91d7b7e",
      "child_ids": [],
      "sibling_ids": [
        "e1f073d8",
        "ec9e853c",
        "cf22afe7",
        "78885b27"
      ],
      "position": 2,
      "start_char": 1440,
      "end_char": 2597,
      "page_number": 3,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          3
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.280176",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1157,
        "word_count": 107,
        "sentence_count": 183,
        "chinese_char_count": 638,
        "readability_score": 0.0,
        "information_density": 0.08643042350907519,
        "coherence_score": 0.4860866534697633,
        "standards_profile_summary": {}
      },
      "quality_score": 0.805790838375108,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "合并",
        "经营",
        "股份",
        "股东",
        "报告",
        "证券"
      ]
    },
    {
      "chunk_id": "cf22afe7",
      "content": "文\n件及其附件中载明内容的审批\nFDA 指 U.S.Food and Drug Administration，美国食品和药品监督管理局\nBI 指 德国勃林格殷格翰公司\nThe European Directorate for the Quality of Medicines & HealthCare，欧\nEDQM 指\n洲药品质量管理局\nUSP 指 U.S. Pharmacopeia，美国药典\n4。\n\n辉瑞、辉瑞公司 指 Pfizer Inc.是目前全球顶尖的以研发为基础的生物制药公司\nEco-passport，由TESTEX瑞士纺织检定有限公司于1993年创立的针\nECO认证 指\n对纺织品染料、助剂化学品等产品开展的生态环保认证。天祥认证，天祥集团是世界上规模最大的消费品测试、检验和认证公\nIntertek认证 指\n司之一\nEHS 指 Environment-Health-Safety，环境、健康、安全生产体系\n一种染料类型，染色时与纤维反应，二者之间形成共价键，成为整体，\n使耐洗和耐摩擦牢度高。用于棉等纤维素纤维、蛋白质纤维、锦纶、\n活性染料 指\n粘胶等合成纤维的染色，色泽鲜艳，色谱齐全，匀染性好，湿处理牢\n度优良\n一种水溶性较低的非离子型染料，在染色过程中呈分散状态进行染\n分散染料 指 色，主要用于涤纶及其混纺织物的印染，也可用于醋酸纤维、锦纶、\n丙纶、氯纶、腈纶等合成纤维的印染\n分子式为C22H16N2Na2O11S3，一种常温型蒽醌系列活性染料，拥有\nKN-R，活性艳蓝KN-R 指 鲜艳色光、优良匀染性、高亲和力、高日晒牢度等优点，主要用于对\n棉、麻、毛、丝的染色，是国家产业政策鼓励发展的一类染料\n氨基油 指 间-(β-羟乙基砜)苯胺，用于合成乙烯基砜染料，染料的关键中间体\n溴氨酸 指 一种红色针状结晶，重要的染料中间体，用于蒽醌型染料\n深蓝色粉末，易溶于水。\n\n该染料用于棉和黏胶纤维的染色，及其织物\nP-3R 指\n的印花，各项染色坚牢度优良，是重要的蓝色染料。一种高温型活性染料，色泽鲜艳，光牢度优异，因具有极好的耐盐碱\nKE-GN 指\n性能，广泛应用于连续染色、蜡染等\n一种中温型活性染料，色泽鲜艳，具有极好的耐盐碱性能，广泛应用\nDK-ER 指\n于浸染和连续染色的冷轧堆工艺\n5。",
      "chunk_type": "child",
      "parent_id": "f91d7b7e",
      "child_ids": [],
      "sibling_ids": [
        "e1f073d8",
        "ec9e853c",
        "f400dee5",
        "78885b27"
      ],
      "position": 3,
      "start_char": 2397,
      "end_char": 3358,
      "page_number": 3,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          3
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.280466",
        "report_type": "其他",
        "fiscal_year": 1993,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 961,
        "word_count": 78,
        "sentence_count": 11,
        "chinese_char_count": 590,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.2759009483667018,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8455775234131113,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "78885b27",
      "content": "种红色针状结晶，重要的染料中间体，用于蒽醌型染料\n深蓝色粉末，易溶于水。\n\n该染料用于棉和黏胶纤维的染色，及其织物\nP-3R 指\n的印花，各项染色坚牢度优良，是重要的蓝色染料。一种高温型活性染料，色泽鲜艳，光牢度优异，因具有极好的耐盐碱\nKE-GN 指\n性能，广泛应用于连续染色、蜡染等\n一种中温型活性染料，色泽鲜艳，具有极好的耐盐碱性能，广泛应用\nDK-ER 指\n于浸染和连续染色的冷轧堆工艺\n5。\n\n第二节公司简介和主要财务指标\n一、公司信息\n股票简称 海翔药业 股票代码 002099\n股票上市证券交易所 深圳证券交易所\n公司的中文名称 浙江海翔药业股份有限公司\n公司的中文简称 海翔药业\n公司的外文名称（如有） ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD.\n公司的外文名称缩写（如有） HISOAR\n公司的法定代表人 杨思卫\n注册地址 浙江省台州市椒江区外沙支路100号\n注册地址的邮政编码 318000\n办公地址 浙江省台州市椒江区外沙支路100号\n办公地址的邮政编码 318000\n公司网址 http://www.hisoar.com\n电子信箱 stock@hisoar.com\n二、联系人和联系方式\n董事会秘书 证券事务代表\n姓名 许华青 蒋如东\n联系地址 浙江省台州市椒江区外沙支路100号 浙江省台州市椒江区外沙支路100号\n电话 0576-89088166 0576-89088166\n传真 0576-89088128 0576-89088128\n电子信箱 stock@hisoar.com stock@hisoar.com\n三、信息披露及备置地点\n公司选定的信息披露媒体的名称 《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n登载年度报告的中国证监会指定网站的网址 http://www.cninfo.com.cn\n公司年度报告备置地点 公司投资发展部\n6。",
      "chunk_type": "child",
      "parent_id": "f91d7b7e",
      "child_ids": [],
      "sibling_ids": [
        "e1f073d8",
        "ec9e853c",
        "f400dee5",
        "cf22afe7"
      ],
      "position": 4,
      "start_char": 3158,
      "end_char": 3971,
      "page_number": 3,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          3
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.280659",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 813,
        "word_count": 73,
        "sentence_count": 14,
        "chinese_char_count": 470,
        "readability_score": 0.0,
        "information_density": 0.1107011070110701,
        "coherence_score": 0.7314838709677419,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8312423124231243,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "财务指标",
        "股份",
        "报告",
        "年度报告",
        "披露",
        "证券"
      ]
    },
    {
      "chunk_id": "de163587",
      "content": "四、注册变更情况\n组织机构代码 913300001482332737\n公司上市以来主营业务的变化情况（如\n无变更\n有）\n2010年9月，原控股股东罗邦鹏先生向其子罗煜竑先生转让其所持有的3,480万\n股（占总股本的21.68%）股份，使其成为公司控股股东。2014年4月，原控股股\n历次控股股东的变更情况（如有）\n东罗煜竑先生向王云富先生转让其所持有的5,940万股（占总股本的18.31%）股\n份，使其成为公司控股股东。五、其他有关资料\n公司聘请的会计师事务所\n会计师事务所名称 天健会计师事务所（特殊普通合伙）\n会计师事务所办公地址 浙江省杭州市江干区钱江路1366 号华润大厦B座\n签字会计师姓名 沈维华 汪兢\n公司聘请的报告期内履行持续督导职责的保荐机构\n□ 适用 √ 不适用\n公司聘请的报告期内履行持续督导职责的财务顾问\n□ 适用 √ 不适用\n六、主要会计数据和财务指标\n公司是否需追溯调整或重述以前年度会计数据\n□ 是 √ 否\n2019年 2018年 本年比上年增减 2017年\n营业收入（元） 2,941,412,770.30 2,718,608,796.51 8.20% 2,308,922,170.29\n归属于上市公司股东的净利润\n770,782,185.09 605,003,820.78 27.40% 342,217,155.60\n（元）\n归属于上市公司股东的扣除非经\n751,209,860.23 604,944,470.09 24.18% 301,310,316.13\n常性损益的净利润（元）\n经营活动产生的现金流量净额\n612,399,095.31 791,449,237.66 -22.62% 118,141,514.53\n（元）\n基本每股收益（元/股） 0.48 0.38 26.32% 0.22\n稀释每股收益（元/股） 0.48 0.38 26.32% 0.21\n加权平均净资产收益率 14.07% 11.35% 2.72% 6.90%\n2019年末 2018年末 本年末比上年末增减 2017年末\n总资产（元） 6,747,198,664.47 7,035,373,344.57 -4.10% 7,466,927,438.54\n7。\n\n归属于上市公司股东的净资产\n5,724,462,095.55 5,390,549,932.23 6.19% 5,142,008,176.75\n（元）\n七、境内外会计准则下会计数据差异\n1、同时按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。",
      "chunk_type": "child",
      "parent_id": "42b4520a",
      "child_ids": [],
      "sibling_ids": [
        "28de7237",
        "55b392e7",
        "3f727636",
        "afd1fa03"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1125,
      "page_number": 7,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.281852",
        "report_type": "其他",
        "fiscal_year": 2010,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1125,
        "word_count": 101,
        "sentence_count": 42,
        "chinese_char_count": 531,
        "readability_score": 0.0,
        "information_density": 0.14222222222222222,
        "coherence_score": 0.7933333333333332,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7888,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润",
        "现金流",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "利润",
        "现金",
        "营业收入",
        "净利润",
        "净资产",
        "营业",
        "经营",
        "股本"
      ]
    },
    {
      "chunk_id": "28de7237",
      "content": "438.54\n7。\n\n归属于上市公司股东的净资产\n5,724,462,095.55 5,390,549,932.23 6.19% 5,142,008,176.75\n（元）\n七、境内外会计准则下会计数据差异\n1、同时按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。2、同时按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n公司报告期不存在按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。八、分季度主要财务指标\n单位：元\n第一季度 第二季度 第三季度 第四季度\n营业收入 831,903,896.72 900,629,910.88 643,422,185.88 565,456,776.82\n归属于上市公司股东的净利润 202,484,692.73 293,308,368.91 194,299,384.33 80,689,739.12\n归属于上市公司股东的扣除非经\n193,305,262.65 289,682,381.16 190,626,850.03 77,595,366.39\n常性损益的净利润\n经营活动产生的现金流量净额 121,163,063.50 182,750,885.24 145,547,827.28 162,937,319.29\n上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异\n□ 是 √ 否\n九、非经常性损益项目及金额\n√ 适用 □ 不适用\n单位：元\n项目 2019年金额 2018年金额 2017年金额 说明\n非流动资产处置损益（包括已计提资产减\n-4,150,774.97 -102,273.45 23,519,733.42\n值准备的冲销部分）\n越权审批或无正式批准文件的税收返还、\n1,828,299.60 1,237,210.17 760,878.00\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27 10,554,527.86 8,815,813.87\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70 3,024,312.63 11,532,098.63\n8。",
      "chunk_type": "child",
      "parent_id": "42b4520a",
      "child_ids": [],
      "sibling_ids": [
        "de163587",
        "55b392e7",
        "3f727636",
        "afd1fa03"
      ],
      "position": 1,
      "start_char": 925,
      "end_char": 1938,
      "page_number": 7,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.282113",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1013,
        "word_count": 83,
        "sentence_count": 37,
        "chinese_char_count": 459,
        "readability_score": 0.0,
        "information_density": 0.16781836130306022,
        "coherence_score": 0.97,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6737413622902271,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "利润",
        "现金",
        "投资",
        "营业收入",
        "净利润",
        "净资产",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "55b392e7",
      "content": "无正式批准文件的税收返还、\n1,828,299.60 1,237,210.17 760,878.00\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27 10,554,527.86 8,815,813.87\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70 3,024,312.63 11,532,098.63\n8。\n\n除同公司正常经营业务相关的有效套期保\n值业务外，持有交易性金融资产、衍生金\n融资产、交易性金融负债、衍生金融负债\n产生的公允价值变动损益，以及处置交易 -449,486.55 -5,010,265.70\n性金融资产、衍生金融资产、交易性金融\n负债、衍生金融负债和其他债权投资取得\n的投资收益\n除上述各项之外的其他营业外收入和支出 -1,973,019.24 -12,795,318.78 2,111,133.99\n减：所得税影响额 3,519,880.50 1,409,621.19 822,552.74\n合计 19,572,324.86 59,350.69 40,906,839.47 --\n对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公\n开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应\n说明原因\n□ 适用 √ 不适用\n公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义、列举的非经常性损益\n项目界定为经常性损益的项目的情形。9。\n\n第三节公司业务概要\n一、报告期内公司从事的主要业务\n（一）主营业务介绍\n报告期内，公司主营业务分为医药和染料两大板块。1、医药板块主要从事特色中间体、原料药及相关制剂的生产与销售，同时提供国际制药\nCDMO/CMO专业服务。产品涵盖抗感染、心血管类、精神疾病领域、降糖类和免疫类等多个\n领域，具体如下：\n应用领域 产品名 适用症 类别\n抗感染 美罗培南系列（4-AA、MAP、用于重症感染以及以G-菌为主的混合性感染、原料药、中间体\n美罗培南粗品、美罗培南侧多重耐药菌感染、产酶菌感染。\n\n链）\n替比培南酯 全球首个口服碳青霉烯类新广谱抗生素，主要用原料药\n于治疗儿童肺炎、中耳炎、鼻窦炎等\n亚胺培南的关键中间体用于敏感菌所致的各种感染，特别适用于多种细中间体\nKETO 菌联合感染和需氧菌及厌氧菌的混合感染。",
      "chunk_type": "child",
      "parent_id": "42b4520a",
      "child_ids": [],
      "sibling_ids": [
        "de163587",
        "28de7237",
        "3f727636",
        "afd1fa03"
      ],
      "position": 2,
      "start_char": 1738,
      "end_char": 2795,
      "page_number": 7,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.282338",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1057,
        "word_count": 67,
        "sentence_count": 27,
        "chinese_char_count": 657,
        "readability_score": 0.0,
        "information_density": 0.15137180700094607,
        "coherence_score": 0.67625,
        "standards_profile_summary": {}
      },
      "quality_score": 0.848628192999054,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "投资",
        "所得税",
        "营业",
        "经营",
        "报告",
        "披露",
        "税收"
      ]
    },
    {
      "chunk_id": "3f727636",
      "content": "域 产品名 适用症 类别\n抗感染 美罗培南系列（4-AA、MAP、用于重症感染以及以G-菌为主的混合性感染、原料药、中间体\n美罗培南粗品、美罗培南侧多重耐药菌感染、产酶菌感染。\n\n链）\n替比培南酯 全球首个口服碳青霉烯类新广谱抗生素，主要用原料药\n于治疗儿童肺炎、中耳炎、鼻窦炎等\n亚胺培南的关键中间体用于敏感菌所致的各种感染，特别适用于多种细中间体\nKETO 菌联合感染和需氧菌及厌氧菌的混合感染。西司他汀酸中间体 西司他汀酸与亚安培南共同使用 中间体\n用于由链球菌属、葡萄球菌属及厌氧菌等敏感菌\n盐酸克林霉素胶囊、盐酸克 制剂、原料药\n株所致的下述感染：中耳炎、鼻窦炎、化脓性扁\n林霉素\n桃体炎、肺炎；皮肤软组织感染\n用于敏感细菌引起的各种感染、败血症、骨髓炎\n克林霉素磷酸酯 原料药\n等\n盐酸克林霉素棕榈酸酯 用于革兰阳性菌引起的各种感染性疾病以及厌\n原料药\n氧菌引起的各种感染性疾病\n盐酸阿莫罗芬\n用于真菌引起的指（趾）甲感染 原料药\n联苯双酯\n用于治疗病毒性肝炎和药物性肝损伤引起转氨原料药\n酶升高\n伏格列波糖\n降糖类 改善糖尿病餐后高血糖 原料药\n瑞格列奈\n用于饮食控制、降低体重与运动不能有效控制高原料药\n血糖的2型糖尿病\n阿卡波糖片 用于胰岛素依赖型或非胰岛素依赖型的糖尿病 制剂\n心血管类 达比加群酯的关键中间体新一代口服抗凝药物直接凝血酶抑制剂(DTIs)，中间体\nOA、MD 用于预防非瓣膜性房颤患者的卒中和全身性栓\n10。\n\n塞\n琥珀酸美托洛尔 用于高血压、心绞痛的治疗 原料药\n兽药 氟苯尼考 用于鸡大肠杆菌病及鸭浆膜炎及鱼的杀鲑产生原料药\n单胞菌、鳗弧菌等，用于敏感细菌所致牛、猪、\n鸡肠道感染及支原体引起的慢性呼吸道病。用于缓解马的内脏绞痛、肌肉与骨骼紊乱引起的\n氟尼辛葡甲胺 原料药\n疼痛及抗炎；牛的各种疾病感染引起的急性炎症\n的控制；另外也可用于母猪乳房炎、子宫炎及无\n乳综合征的辅助治疗\n甲砜霉素\n用于流感杆菌、大肠杆菌、沙门菌属所致的呼吸原料药\n系统、肝胆系统、泌尿系统和消化系统的感染。富马酸喹硫平\n精神类 用于治疗精神分裂症 原料药\n上述部分产品通过了中国、美国、欧盟、日本、加拿大、印度、巴西等国家的官方认证。\n\n2、染料板块主要从事环保型活性染料、染料中间体以及颜料中间体的生产和销售，产品\n以蒽醌类活性染料为主，具体如下：\n主要类别 主要产品及用途\n染料 主要生产蓝色系列产品，包括活性艳蓝KN-R（HG）、KN-R（SR）、\nKN-R（SP），P-3R, KE-GN、KN-BB、ME-BP，活性翠蓝KN-G以及\n酸性蒽醌蓝等，主要用于棉、麻、丝等天然纤维织物的染色，具有较\n高的日晒牢度和优良的匀染性，适用于连续染色、冷轧堆等印染工艺。染颜料中间体 染料中间体 主要生产氨基油、溴氨酸、间位酯等染料中间体，用于合成乙烯基砜\n型染料、蒽醌型染料。",
      "chunk_type": "child",
      "parent_id": "42b4520a",
      "child_ids": [],
      "sibling_ids": [
        "de163587",
        "28de7237",
        "55b392e7",
        "afd1fa03"
      ],
      "position": 3,
      "start_char": 2595,
      "end_char": 3793,
      "page_number": 7,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.282777",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1198,
        "word_count": 85,
        "sentence_count": 8,
        "chinese_char_count": 960,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.6947726871933199,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9205342237061771,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "afd1fa03",
      "content": "\n染料 主要生产蓝色系列产品，包括活性艳蓝KN-R（HG）、KN-R（SR）、\nKN-R（SP），P-3R, KE-GN、KN-BB、ME-BP，活性翠蓝KN-G以及\n酸性蒽醌蓝等，主要用于棉、麻、丝等天然纤维织物的染色，具有较\n高的日晒牢度和优良的匀染性，适用于连续染色、冷轧堆等印染工艺。染颜料中间体 染料中间体 主要生产氨基油、溴氨酸、间位酯等染料中间体，用于合成乙烯基砜\n型染料、蒽醌型染料。颜料中间体 主要生产DCB等颜料中间体，主要用于颜料黄12，13，14，17，35，\n55，颜料橙13，颜料红38等中高档双芳胺类偶氮颜料\n（二）行业发展格局\n1、医药行业\n近年来，国内仿制药一致性评价、“集采”、药品上市许可持有人制度等政策相继落地，\n医改已经基本完成顶层设计，进入方向性稳定期，“提质降费”是当下乃至以后很长一段时间\n的主旋律。",
      "chunk_type": "child",
      "parent_id": "42b4520a",
      "child_ids": [],
      "sibling_ids": [
        "de163587",
        "28de7237",
        "55b392e7",
        "3f727636"
      ],
      "position": 4,
      "start_char": 3593,
      "end_char": 3967,
      "page_number": 7,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          7
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.283013",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 374,
        "word_count": 16,
        "sentence_count": 3,
        "chinese_char_count": 249,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3166569767441861,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7907101604278075,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "ec335cb2",
      "content": "对国内药企而言，无论是仿制药“集采”，还是创新药医保谈判，其最终结果都是\n企业以较低价格来换取竞争机会。“集采”使得仿制药竞争聚焦于成本端，而原料药是生产成\n本的核心，拥有质优价廉原料药的“中间体+原料药+制剂”一体化企业竞争优势较为明显，将\n获得更大的生存空间。在当前背景下，医药企业通过加强自身研发能力或与CRO公司合作开\n展研发业务，实现产品创新和自身转型升级；有实力的企业还可以选择与自身产品线互补和\n可以拓宽临床领域的企业进行并购重组。\n\n我国医药工业经过多年的高速发展，国内部分仿制企业已经积累雄厚的技术和资金，相\n关生产车间通过欧美等发达国家cGMP认证，已具备开拓海外市场的能力。与此同时辉瑞、诺\n华等国际医药巨头纷纷剥离仿制药业务，专注创新药领域，仿制药市场格局无疑已经迎来巨\n变，无论是承接更多CDMO/CMO项目、整合国际仿制药资产，亦或是自有制剂产品扬帆出海，\n国内仿制药企业将迎来更大的机遇。11。\n\n2、染料行业\n染料生产涉及相对复杂的工艺，尤其是染料的合成、分离和后处理工艺复杂，工序长，\n对技术水平要求高。现代染料制造企业需要采用先进环保生产工艺，随着环保意识逐渐增强，\n国际市场加大对染料致癌芳香胺和环境激素等有害化学品的限制，越来越多的染料和助剂被\n禁止使用，凡涉及到禁用、过敏、重金属含量过高的染料都被限制，新的生产工艺和方法对\n企业的产品创新能力提出更高的要求，提高了行业进入壁垒。染料企业要迎合市场发展的需\n求，满足纺织印染供应新工艺、新纤维以及节能减排的要求，弥合染料新品种创制研发能力\n与国外先进水平的差距；加快生产方式的集成化与自动化、装备的现代化的升级改造。\n\n中国是全球最大染料生产国，产能和需求都稳居世界第一位，产量约占全球的70%。从\n全球范围来看，基础染料产品在国际上主要是中国染料企业和印度染料企业之间的竞争，发\n达国家企业已逐步退出基础染料合成业务，形成了主要依靠进口中国、印度两国的染料半成\n品来加工生产高附加值染料产品，或直接采购两国OEM厂商的染料产品并贴牌销售的经营模\n式。随着国内安全环保形势的持续趋严，部分染料小产能逐步退出市场，染料行业供给收缩，\n未来市场集中度将持续提升。\n\n3、公司行业地位\n公司是特色原料药企业，在原料药及制剂的海外注册、国际合作等领域处于国内同行业\n领先地位。公司盐酸克林霉素原料药早在2004年就通过美国的FDA认证，克林霉素系列产量\n稳居全球龙头地位。公司是国内较早掌握培南类关键中间体4-AA核心技术，并成为国内仅有\n的几家能够供应培南类系列原料药的企业之一。\n二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。",
      "chunk_type": "child",
      "parent_id": "3d922d70",
      "child_ids": [],
      "sibling_ids": [
        "92f86a3f",
        "5c7d43af",
        "8add6151"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1183,
      "page_number": 11,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.284160",
        "report_type": "其他",
        "fiscal_year": 2004,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1183,
        "word_count": 42,
        "sentence_count": 17,
        "chinese_char_count": 1018,
        "readability_score": 0.0,
        "information_density": 0.0760777683854607,
        "coherence_score": 0.6783809523809523,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9442096365173289,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "固定资产",
        "无形资产",
        "经营",
        "股权"
      ]
    },
    {
      "chunk_id": "92f86a3f",
      "content": "酸克林霉素原料药早在2004年就通过美国的FDA认证，克林霉素系列产量\n稳居全球龙头地位。公司是国内较早掌握培南类关键中间体4-AA核心技术，并成为国内仅有\n的几家能够供应培南类系列原料药的企业之一。\n二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。\n\n与全球知名制药公司长期合作是公司的发展\n理念，公司是国内最早开展国际CDMO/CMO业务的企业之一，是德国勃林格殷格翰公司的在\n中国重要的战略合作伙伴，双方合作已超十周年，辉瑞、巴斯夫、赛诺菲、诺华、杨森、住\n友等国际医药企业亦是公司重要合作伙伴。公司子公司台州前进作为活性艳蓝染料领域的龙头，主持编制了“反应染料色光和强度的\n测定”等国家标准及活性艳蓝KN-R、氨基油等行业标准，起草发布了活性艳蓝KN-R“浙江制\n造”标准，并通过了浙江制造审核。台州前进是蓝标体系合作伙伴，其生产的KN-R、P-3R、\nKE-GN、DK-ER等产品亦通过了全球有机纺织化学品标准认证（GOTS 5.0）、ECO认证和\nIntertek认证，KN-R产品成功入选国家第三批制造业单项冠军，染料产品出口欧美亚等三十多\n个国家和地区。\n\n二、主要资产重大变化情况\n1、主要资产重大变化情况\n主要资产 重大变化说明\n股权资产 无重大变化\n固定资产 主要系川南、前进、振港在建工程转固所致。无形资产 无重大变化\n在建工程 无重大变化\n12。\n\n2、主要境外资产情况\n□ 适用 √ 不适用\n三、核心竞争力分析\n（一）“中间体+原料药+制剂”一体化生产平台\n公司是国内最早开展特色中间体及原料药出口业务的企业之一，一直秉承质量即是企业\n生命的理念，不断完善质量体系建设和EHS体系建设。公司原料药生产场地多次通过美国\nFDA、欧盟EDQM、日本PMDA、澳大利亚TGA、中国等官方的cGMP检查，2019年10月川南\n药业连续第4次通过美国FDA的现场检查。公司在巩固特色原药板块的基础上向下游制剂延\n伸，建有通过欧盟EDQM和中国官方认证的固体制剂生产线，制剂产品已在英国、法国、德\n国等地实现销售，是国内少有具备制剂出口欧盟资质的企业。\n\n高品质的“中间体+原料药+制剂”\n一体化生产平台让公司具备参与全球医药产业链分工和竞争的能力。（二）全产业链经营模式\n染料原材料在染料生产成本中占比超过七成，而染料中间体占据了原材料绝大部分。公\n司染料板块多年来一直贯彻全产业链的经营理念，向上下游延伸产业链，完善产业链，已经\n形成从基础化学原料、中间体、滤饼、商品化染料的完善产业链。\n\n全产业链经营可以抵御中\n间体市场波动风险，增强抗风险的能力，提高盈利水平和市场份额。",
      "chunk_type": "child",
      "parent_id": "3d922d70",
      "child_ids": [],
      "sibling_ids": [
        "ec335cb2",
        "5c7d43af",
        "8add6151"
      ],
      "position": 1,
      "start_char": 983,
      "end_char": 2156,
      "page_number": 11,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.284427",
        "report_type": "其他",
        "fiscal_year": 2004,
        "fiscal_quarter": null,
        "company_code": "友等国际医药企业",
        "industry": null,
        "char_count": 1173,
        "word_count": 57,
        "sentence_count": 17,
        "chinese_char_count": 914,
        "readability_score": 0.0,
        "information_density": 0.07672634271099744,
        "coherence_score": 0.28904516806722685,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9116794543904518,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "固定资产",
        "无形资产",
        "经营",
        "股权"
      ]
    },
    {
      "chunk_id": "5c7d43af",
      "content": "+制剂”\n一体化生产平台让公司具备参与全球医药产业链分工和竞争的能力。（二）全产业链经营模式\n染料原材料在染料生产成本中占比超过七成，而染料中间体占据了原材料绝大部分。公\n司染料板块多年来一直贯彻全产业链的经营理念，向上下游延伸产业链，完善产业链，已经\n形成从基础化学原料、中间体、滤饼、商品化染料的完善产业链。\n\n全产业链经营可以抵御中\n间体市场波动风险，增强抗风险的能力，提高盈利水平和市场份额。今后公司染料板块将以\n关键中间体为核心，拓展系列化、集群化的产品线。（三）精细化管理和安全环保优势\n公司在生产车间设计中融入“管道化、密闭化、自动化、信息化、连续化、可视化”理念，\n实现生产流程全程自动化控制，车间作业人员减少一半以上。\n\n生产现场积极推行精细化管理，\n以先进合成装备、丰富的合成经验,快速实现产业化，提升公司竞争能力。公司坚持走清洁化、\n绿色化的可持续发展道路，循环利用生产过程中产生废酸、有机溶剂、废盐等，一方面减少\n高COD废水排放，另一方面变废为宝节约资源，降低生产成本，实现源头减排、过程控制、\n末端治理、综合利用。近年来，公司坚持环保先行的理念，不断加大环保设施投入，对原有\n污水处理系统进行升级改造，增添多套废气处理设施RTO，各厂区新建固体废物焚烧炉，提\n升三废处理能力，切实履行公司的社会责任。\n\n（四）技术研发优势\n公司企业技术中心是“国家级企业技术中心”，拥有国家级博士后工作站、浙江省级院士\n专家工作站，建有海翔药业和台州前进两个省级企业研究院，已承担完成国家级项目13项，\n省级项目35项，拥有国内发明专利44项、PCT专利2项、国家标准7项、行业标准8项、浙江省\n级科技奖项11项。公司坚持环境友好理念，注重研究生产过程的节能降耗，减少排放和污染，\n在手性化学、低温反应、高效催化氢化反应、膜分离、酶催化、化学连续管道化反应、“绿色”\n氧化技术、“绿色”氯化技术、不对称氢化及其装备技术、不对称环丙烷化技术、副产物综合\n利用技术、三废回收利用技术等绿色合成技术具有优势。13。\n\n第四节经营情况讨论与分析\n一、概述\n2019年国内医疗体制改革进入深水区，随着新版《药品管理法》、药品上市许可持有人\n制度（MAH）、新版医保目录、一致性评价、集采扩围、医保谈判等政策细则持续推进，医\n药行业传统格局正在被打破，国内制药企业竞争加剧，行业集中度提升；部分国际医药巨头\n剥离仿制药业务，专注创新药领域，加大研发投入和创新，使得CRO/CDMO市场快速扩容，\n迎来行业发展黄金期；面对复杂多变的外部环境，公司坚持以研发创新、技术升级为驱动，\n以“关键中间体-原料药-制剂一体化发展”为策略，开发特色原料药工艺，以质优价廉的仿制药\n满足国内日益增长的基础医疗健康需求；同时深化国际合作，在国际制药巨头转移生产的机\n遇中建立更紧密更长久的CDMO/CMO合作关系。",
      "chunk_type": "child",
      "parent_id": "3d922d70",
      "child_ids": [],
      "sibling_ids": [
        "ec335cb2",
        "92f86a3f",
        "8add6151"
      ],
      "position": 2,
      "start_char": 1956,
      "end_char": 3154,
      "page_number": 11,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.284726",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1198,
        "word_count": 35,
        "sentence_count": 13,
        "chinese_char_count": 991,
        "readability_score": 0.0,
        "information_density": 0.0333889816360601,
        "coherence_score": 0.6863097726554751,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9308848080133556,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "经营"
      ]
    },
    {
      "chunk_id": "8add6151",
      "content": "际医药巨头\n剥离仿制药业务，专注创新药领域，加大研发投入和创新，使得CRO/CDMO市场快速扩容，\n迎来行业发展黄金期；面对复杂多变的外部环境，公司坚持以研发创新、技术升级为驱动，\n以“关键中间体-原料药-制剂一体化发展”为策略，开发特色原料药工艺，以质优价廉的仿制药\n满足国内日益增长的基础医疗健康需求；同时深化国际合作，在国际制药巨头转移生产的机\n遇中建立更紧密更长久的CDMO/CMO合作关系。报告期内，医药板块培南系列、克林系列持\n续增长，CDMO/CMO合作产品增加，实现销售收入16.23亿元，同比增长10.52%，实现净利润2.95\n亿元，同比增长47.67%；染料板块受中美贸易不确定性影响，下游纺织印染行业需求低迷，\n在下半年染料景气度回落的市场环境下，染料板块仍然实现销售收入13.18亿元，同比增长\n5.46%，实现净利润4.76亿元，同比增长17.43%。2019年度上市公司主营业务继续增长创新高，\n实现营业收入29.41亿元，同比增长8.20%，实现归属母公司净利润7.71亿元，同比增长27.40%。\n\n（一）医药板块：夯实基础，扩大业务规模\n夯实药品质量基础。面对国内外日益提高的药品监管要求，公司质量体系贯彻落实“勤查\n严管、追溯有序、有效完善、持之以恒”工作方针，深入推进GMP常态化管理。报告期内，外\n沙厂区和川南药业通过6次官方检查，33次客户检查，川南药业连续第4次通过美国FDA的现\n场检查，外沙厂区顺利通过韩国MFDS现场检查。\n\n完成替比培南酯日本注册，盐酸阿莫罗芬\n印度、韩国注册，联苯双酯韩国注册，柳氮磺胺吡啶首次取得欧盟CEP证书，助力公司国际\n市场拓展。持续深化国际合作，扩大业务规模。报告期内，公司新拓展日本、印度合作客户，培南\n系列收入增长。\n\n同时完成培南产能扩产，为未来持续增长奠定基础；克林霉素系列拓展新的\n国际客户，国际高端市场收入快速增长。加深国际合作拓展，把握市场扩容机遇，与辉瑞、\nBI等公司多个合作项目技术对接有序推进，新增替比培南酯原料药等5个CDMO/CMO合作项\n目，新项目涉及抗感染、心血管类、降糖类等领域；制剂完成欧盟少量订单的生产供货，盐\n酸克林霉素胶囊的一致性评价申报材料已获CDE审评中心受理,另有3个自报或与国内企业联\n合申报品种，计划2020年提交一致性评价申报材料。（二）染料板块：新项目建成，产品序列扩展\n报告期内，公司通过加强库存管理、合理安排各厂区的生产任务，发挥全产业链优势，\n保证产品稳定供应。",
      "chunk_type": "child",
      "parent_id": "3d922d70",
      "child_ids": [],
      "sibling_ids": [
        "ec335cb2",
        "92f86a3f",
        "5c7d43af"
      ],
      "position": 3,
      "start_char": 2954,
      "end_char": 4005,
      "page_number": 11,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          11
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.284980",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1051,
        "word_count": 28,
        "sentence_count": 24,
        "chinese_char_count": 804,
        "readability_score": 0.0,
        "information_density": 0.11417697431018078,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9059942911512846,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "利润",
        "16.23亿元",
        "13.18亿元",
        "4.76亿元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "利润",
        "营业收入",
        "净利润",
        "母公司",
        "营业",
        "报告"
      ]
    },
    {
      "chunk_id": "a7327a15",
      "content": "根据市场变化情况调整销售策略，积极开发新客户、加强新产品推广，\nP-3R量价齐升，市场占有率进一步提升。1.55万吨活性染料项目及配套项目已按进度完成建\n设。该项目从源头设计控制为起点，以装备选型先进为支撑，融入生产控制自动化、工艺流\n程密封化、物料输送管道化、生产过程连续化等理念，新增多个活性染料及酸性染料品种，\n丰富产品序列；新增配套中间体产能，进一步巩固核心中间体优势，为后续以关键中间体为\n核心拓展活性、分散、酸性蒽醌系列化产品线的战略规划提供支持。\n\n（三）研发创新，稳步推进技术进步\n公司依托现有国家级企业技术中心、国家级博士后工作站、省级院士工作站、海翔药业\n和台州前进两个省级企业研究院等科研平台，联合国内高等院校合作，积极探索技术创新，\n14。\n\n统筹推进研发工作。报告期内，公司新启动原料药及中间体研发项目11项，制剂研发项目5\n项，提交申请发明专利3项；对全球仿制药、专利药的生命周期和市场需求进行跟踪分析，开\n展70余个产品调研，为今后公司研发项目选择提供信息支持。除新产品研发外，公司还对现\n有产品的技术工艺方面进行了60多项小试、中试开发，积极探索技术创新，不断优化生产工\n艺，力求实现绿色、安全、低耗的工艺路线，部分产品降低了原料和能耗成本，产品毛利率\n提升。\n\n新建微通道反应实验室，探索微通道反应在高温、高压以及危险化学反应中的应用，\n降低风险提高反应效率，全年开展了10个项目研究实验，部分项目已经完成技术开发，进入\n工业化阶段。（四）深化安全综合治理，筑牢环保风险底线\n公司深刻吸取江苏响水“3ꞏ21”重大安全事故的教训，把安全生产管理重心落到基层一线。加大安全环保投入，重点抓好工艺改造、装备提升、生产管理等关键环节；组织演练应急救\n援预案82起，开展警示教育培训、各类安全环保知识竞赛和消防技能比赛，不断提升各级安\n全生产管理水平和全员安全生产意识。\n\n加强三废处理设施日常管理和维护，确保设施稳定、\n正常运行；深化实施源头治理、综合治理、精准治理，落实车间工艺废水的分质分类和预处\n理工作，从源头上落实减量化措施；持续改造升级各厂区“三废”处理设施，提升末端处理能\n力；川南新建的危险废物焚烧系统投入运行，该项目于2019年12月取得危险废物经营许可证，\n具备了运营危险固废处理专业服务的资质。热平衡实验室开展工艺反应风险评估66项，为“新、\n改、扩”项目的安全条件审查提供数据和技术支撑。二、主营业务分析\n1、概述\n参见“经营情况讨论与分析”中的“一、概述”相关内容。",
      "chunk_type": "child",
      "parent_id": "ac0a59dc",
      "child_ids": [],
      "sibling_ids": [
        "bebcada5",
        "03f6dc50",
        "0dae2aba",
        "cf5e60c7"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1058,
      "page_number": 14,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          14
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.286318",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1058,
        "word_count": 30,
        "sentence_count": 14,
        "chinese_char_count": 891,
        "readability_score": 0.0,
        "information_density": 0.0661625708884688,
        "coherence_score": 0.5290359168241966,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9368620037807185,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "毛利率",
        "营业",
        "经营",
        "报告"
      ]
    },
    {
      "chunk_id": "bebcada5",
      "content": "分类和预处\n理工作，从源头上落实减量化措施；持续改造升级各厂区“三废”处理设施，提升末端处理能\n力；川南新建的危险废物焚烧系统投入运行，该项目于2019年12月取得危险废物经营许可证，\n具备了运营危险固废处理专业服务的资质。热平衡实验室开展工艺反应风险评估66项，为“新、\n改、扩”项目的安全条件审查提供数据和技术支撑。二、主营业务分析\n1、概述\n参见“经营情况讨论与分析”中的“一、概述”相关内容。\n\n2、收入与成本\n（1）营业收入构成\n单位：元\n2019年 2018年\n同比增减\n金额 占营业收入比重 金额 占营业收入比重\n营业收入合计 2,941,412,770.30 100% 2,718,608,796.51 100% 8.20%\n分行业\n医药 1,608,858,743.47 54.70% 1,441,591,423.51 53.03% 11.60%\n染料 1,316,830,162.67 44.77% 1,249,940,574.56 45.98% 5.35%\n其他 15,723,864.16 0.53% 27,076,798.44 1.00% -41.93%\n分产品\n原料药 1,020,477,644.34 34.69% 1,033,340,734.78 38.01% -1.24%\n医药中间体 583,792,425.63 19.85% 405,506,789.40 14.92% 43.97%\n制剂 4,588,673.50 0.16% 2,743,899.33 0.10% 67.23%\n15。",
      "chunk_type": "child",
      "parent_id": "ac0a59dc",
      "child_ids": [],
      "sibling_ids": [
        "a7327a15",
        "03f6dc50",
        "0dae2aba",
        "cf5e60c7"
      ],
      "position": 1,
      "start_char": 858,
      "end_char": 1520,
      "page_number": 14,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          14
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.286539",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 662,
        "word_count": 62,
        "sentence_count": 37,
        "chinese_char_count": 228,
        "readability_score": 0.0,
        "information_density": 0.12084592145015105,
        "coherence_score": 0.23367567567567568,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7377643504531721,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "营业收入",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "03f6dc50",
      "content": " 27,076,798.44 1.00% -41.93%\n分产品\n原料药 1,020,477,644.34 34.69% 1,033,340,734.78 38.01% -1.24%\n医药中间体 583,792,425.63 19.85% 405,506,789.40 14.92% 43.97%\n制剂 4,588,673.50 0.16% 2,743,899.33 0.10% 67.23%\n15。\n\n染料 973,070,914.24 33.08% 844,776,715.53 31.07% 15.19%\n染料中间体 343,759,248.43 11.69% 405,163,859.03 14.90% -15.16%\n其他 15,723,864.16 0.53% 27,076,798.44 1.00% -41.93%\n分地区\n国内 1,512,860,024.18 51.43% 1,390,967,219.07 51.16% 8.76%\n国外 1,428,552,746.12 48.57% 1,327,641,577.44 48.84% 7.60%\n（2）占公司营业收入或营业利润10%以上的行业、产品或地区情况\n√ 适用 □ 不适用\n单位：元\n营业收入比上年 营业成本比上年 毛利率比上年同\n营业收入 营业成本 毛利率\n同期增减 同期增减 期增减\n分行业\n医药 1,608,858,743.47 983,149,430.95 38.89% 11.60% 1.30% 6.23%\n染料 1,316,830,162.67 465,697,259.49 64.63% 5.40% -10.70% 6.34%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分产品\n原料药 1,020,477,644.34 652,198,278.33 36.09% -1.20% -6.10% 3.30%\n医药中间体 583,792,425.63 328,224,382.60 43.78% 44.00% 20.30% 11.06%\n制剂 4,588,673.50 2,726,770.03 40.58% 67.20% -20.50% 65.65%\n染料 973,070,914.24 312,738,811.13 67.86% 15.20% -1.80% 5.56%\n染料中间体 343,759,248.43 152,958,448.36 55.50% -15.20% -24.60% 5.56%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分地区\n国内 1,512,860,024.18 745,641,007.79 50.71% 8.",
      "chunk_type": "child",
      "parent_id": "ac0a59dc",
      "child_ids": [],
      "sibling_ids": [
        "a7327a15",
        "bebcada5",
        "0dae2aba",
        "cf5e60c7"
      ],
      "position": 2,
      "start_char": 1320,
      "end_char": 2514,
      "page_number": 14,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          14
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.286738",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1194,
        "word_count": 140,
        "sentence_count": 102,
        "chinese_char_count": 140,
        "readability_score": 0.0,
        "information_density": 0.09212730318257957,
        "coherence_score": 0.3051176470588235,
        "standards_profile_summary": {}
      },
      "quality_score": 0.39715242881072027,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "利润",
        "营业收入",
        "营业成本",
        "营业利润",
        "毛利率",
        "营业"
      ]
    },
    {
      "chunk_id": "0dae2aba",
      "content": "7.86% 15.20% -1.80% 5.56%\n染料中间体 343,759,248.43 152,958,448.36 55.50% -15.20% -24.60% 5.56%\n其他 15,723,864.16 14,312,670.59 8.97% -41.90% -27.90% -17.67%\n分地区\n国内 1,512,860,024.18 745,641,007.79 50.71% 8.80% -8.00% 8.96%\n国外 1,428,552,746.12 717,518,353.25 49.77% 7.60% 2.20% 2.63%\n公司主营业务数据统计口径在报告期发生调整的情况下，公司最近1年按报告期末口径调整后的主营业务数据\n□ 适用 √ 不适用\n（3）公司实物销售收入是否大于劳务收入\n√ 是 □ 否\n行业分类 项目 单位 2019年 2018年 同比增减\n医药行业 销售量 千克 1,495,834.8 1,352,154.98 10.63%\n16。\n\n生产量 千克 1,578,601.92 1,380,545.9 14.35%\n库存量 千克 415,819.13 333,052.01 24.85%\n销售量 吨 12,857.65 13,393.7 -4.00%\n染料行业 生产量 吨 12,911.47 13,832.98 -6.66%\n库存量 吨 1,868.83 1,815.01 2.97%\n相关数据同比发生变动30%以上的原因说明\n□ 适用 √ 不适用\n（4）公司已签订的重大销售合同截至本报告期的履行情况\n□ 适用 √ 不适用\n（5）营业成本构成\n行业和产品分类\n单位：元\n2019年 2018年\n行业分类 项目 同比增减\n金额 占营业成本比重 金额 占营业成本比重\n医药行业 原料成本 788,091,701.93 80.16% 778,035,997.89 80.14% 0.02%\n医药行业 人工成本 53,109,659.74 5.40% 53,601,426.45 5.52% -0.12%\n医药行业 能源成本 47,606,219.00 4.84% 45,369,217.29 4.67% 0.17%\n医药行业 制造费用 94,341,850.29 9.60% 93,792,389.85 9.66% -0.07%\n染料行业 原料成本 337,976,777.23 72.57% 383,594,259.37 73.59% -1.01%\n染料行业 人工成本 33,802,565.03 7.26% 28,163,412.97 5.40% 1.86%\n染料行业 能源成本 34,241,371.69 7.35% 37,944,159.74 7.28% 0.07%\n染料行业 制造费用 59,676,545.54 12.",
      "chunk_type": "child",
      "parent_id": "ac0a59dc",
      "child_ids": [],
      "sibling_ids": [
        "a7327a15",
        "bebcada5",
        "03f6dc50",
        "cf5e60c7"
      ],
      "position": 3,
      "start_char": 2314,
      "end_char": 3501,
      "page_number": 14,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          14
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.287022",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1187,
        "word_count": 157,
        "sentence_count": 84,
        "chinese_char_count": 292,
        "readability_score": 0.0,
        "information_density": 0.06739679865206402,
        "coherence_score": 0.31239285714285714,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5121314237573715,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "费用",
        "营业成本",
        "营业",
        "报告"
      ]
    },
    {
      "chunk_id": "cf5e60c7",
      "content": "染料行业 原料成本 337,976,777.23 72.57% 383,594,259.37 73.59% -1.01%\n染料行业 人工成本 33,802,565.03 7.26% 28,163,412.97 5.40% 1.86%\n染料行业 能源成本 34,241,371.69 7.35% 37,944,159.74 7.28% 0.07%\n染料行业 制造费用 59,676,545.54 12.81% 71,581,678.92 13.73% -0.92%\n其他业务 14,312,670.59 100.00% 19,862,133.71 100.00% 0.00%\n单位：元\n2019年 2018年\n产品分类 项目 同比增减\n金额 占营业成本比重 金额 占营业成本比重\n原料药 652,198,278.33 44.57% 694,525,290.09 45.94%\n医药中间体 328,224,382.60 22.43% 272,841,947.14 18.05%\n制剂 2,726,770.03 0.19% 3,431,794.24 0.23%\n染料 312,738,811.13 21.37% 318,486,635.33 21.06%\n染料中间体 152,958,448.36 10.45% 202,796,875.67 13.41%\n其他 14,312,670.59 0.98% 19,862,133.71 1.31%\n说明\n17。",
      "chunk_type": "child",
      "parent_id": "ac0a59dc",
      "child_ids": [],
      "sibling_ids": [
        "a7327a15",
        "bebcada5",
        "03f6dc50",
        "0dae2aba"
      ],
      "position": 4,
      "start_char": 3301,
      "end_char": 3925,
      "page_number": 14,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          14
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.287270",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 624,
        "word_count": 76,
        "sentence_count": 50,
        "chinese_char_count": 90,
        "readability_score": 0.0,
        "information_density": 0.08012820512820512,
        "coherence_score": 0.30744,
        "standards_profile_summary": {}
      },
      "quality_score": 0.40576923076923077,
      "relevance_score": 1.0,
      "keywords": [
        "成本"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "费用",
        "营业成本",
        "营业"
      ]
    },
    {
      "chunk_id": "ad9090f3",
      "content": "（6）报告期内合并范围是否发生变动\n√ 是 □ 否\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n（7）公司报告期内业务、产品或服务发生重大变化或调整有关情况\n□ 适用 √ 不适用\n（8）主要销售客户和主要供应商情况\n公司主要销售客户情况\n前五名客户合计销售金额（元） 649,326,403.37\n前五名客户合计销售金额占年度销售总额比例 22.08%\n前五名客户销售额中关联方销售额占年度销售总额比\n0.00%\n例\n公司前5大客户资料\n序号 客户名称 销售额（元） 占年度销售总额比例\n1 客户1 212,211,696.91 7.21%\n2 客户2 149,494,409.10 5.08%\n3 客户3 105,676,622.82 3.59%\n4 客户4 93,657,620.14 3.18%\n5 客户5 88,286,054.40 3.00%\n合计 -- 649,326,403.37 22.08%\n主要客户其他情况说明\n□ 适用 √ 不适用\n公司主要供应商情况\n前五名供应商合计采购金额（元） 328,471,523.80\n前五名供应商合计采购金额占年度采购总额比例 20.82%\n前五名供应商采购额中关联方采购额占年度采购总额\n0.00%\n比例\n公司前5名供应商资料\n序号 供应商名称 采购额（元） 占年度采购总额比例\n1 供应商1 144,631,621.96 9.17%\n2 供应商2 56,660,417.02 3.59%\n3 供应商3 52,856,752.15 3.35%\n18。\n\n4 供应商4 38,420,130.22 2.44%\n5 供应商5 35,902,602.45 2.28%\n合计 -- 328,471,523.80 20.82%\n主要供应商其他情况说明\n□ 适用 √ 不适用\n3、费用\n单位：元\n2019年 2018年 同比增减 重大变动说明\n销售费用 59,623,024.88 43,781,054.42 36.18%主要系佣金增加所致\n管理费用 386,185,538.84 349,284,396.57 10.56%\n财务费用 -37,865,156.06 -51,507,397.78 -26.49%\n研发费用 122,548,224.53 111,304,662.07 10.10%\n4、研发投入\n√ 适用 □ 不适用\n公司注重技术研发，坚持技术创新。报告期内，公司在新设备、新产品、新工艺、新材\n料、新应用技术等方面，开展了有针对性的研究创新。在提升公司产品质量与性能方面，取\n得了突出的成果，提高了公司产品综合竞争力。",
      "chunk_type": "child",
      "parent_id": "707f6596",
      "child_ids": [],
      "sibling_ids": [
        "34ce908d",
        "941ae6d5",
        "b646df69"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1126,
      "page_number": 18,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.288516",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1126,
        "word_count": 136,
        "sentence_count": 46,
        "chinese_char_count": 486,
        "readability_score": 0.0,
        "information_density": 0.07992895204262877,
        "coherence_score": 0.5508926728586171,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7726465364120781,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "销售费用",
        "管理费用",
        "研发费用",
        "财务费用",
        "合并",
        "股权",
        "报告"
      ]
    },
    {
      "chunk_id": "34ce908d",
      "content": " -37,865,156.06 -51,507,397.78 -26.49%\n研发费用 122,548,224.53 111,304,662.07 10.10%\n4、研发投入\n√ 适用 □ 不适用\n公司注重技术研发，坚持技术创新。报告期内，公司在新设备、新产品、新工艺、新材\n料、新应用技术等方面，开展了有针对性的研究创新。在提升公司产品质量与性能方面，取\n得了突出的成果，提高了公司产品综合竞争力。\n\n公司研发投入情况\n2019年 2018年 变动比例\n研发人员数量（人） 443 405 9.38%\n研发人员数量占比 13.45% 12.75% 0.70%\n研发投入金额（元） 122,548,224.53 111,304,662.07 10.10%\n研发投入占营业收入比例 4.17% 4.09% 0.08%\n研发投入资本化的金额（元） 0.00 0.00 0.00%\n资本化研发投入占研发投入\n0.00% 0.00% 0.00%\n的比例\n研发投入总额占营业收入的比重较上年发生显著变化的原因\n□ 适用 √ 不适用\n研发投入资本化率大幅变动的原因及其合理性说明\n□ 适用 √ 不适用\n5、现金流\n单位：元\n19。\n\n项目 2019年 2018年 同比增减\n经营活动现金流入小计 2,374,777,732.18 2,809,734,855.49 -15.48%\n经营活动现金流出小计 1,762,378,636.87 2,018,285,617.83 -12.68%\n经营活动产生的现金流量净\n612,399,095.31 791,449,237.66 -22.62%\n额\n投资活动现金流入小计 1,177,235,296.80 963,819,628.62 22.14%\n投资活动现金流出小计 440,639,977.78 2,061,240,331.20 -78.62%\n投资活动产生的现金流量净\n736,595,319.02 -1,097,420,702.58 -167.10%\n额\n筹资活动现金流入小计 285,000,000.00 1,388,743,300.00 -79.48%\n筹资活动现金流出小计 1,187,336,603.58 2,295,021,451.90 -48.26%\n筹资活动产生的现金流量净\n-902,336,603.58 -906,278,151.90 -0.43%\n额\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61 -138.81%\n相关数据同比发生重大变动的主要影响因素说明\n√ 适用 □ 不适用\n经营活动产生的现金流量净额减少主要系收回银行承兑汇票、信用证保证金等减少所致。投资活动产生的现金流量净额增加主要系去年同期购买银行理财产品及结构性存款较多所致。",
      "chunk_type": "child",
      "parent_id": "707f6596",
      "child_ids": [],
      "sibling_ids": [
        "ad9090f3",
        "941ae6d5",
        "b646df69"
      ],
      "position": 1,
      "start_char": 926,
      "end_char": 2100,
      "page_number": 18,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.288769",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1174,
        "word_count": 110,
        "sentence_count": 58,
        "chinese_char_count": 459,
        "readability_score": 0.0,
        "information_density": 0.1192504258943782,
        "coherence_score": 0.4066198830409356,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6863713798977853,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "费用",
        "现金",
        "投资",
        "营业收入",
        "研发费用",
        "营业",
        "经营",
        "投资活动",
        "筹资活动"
      ]
    },
    {
      "chunk_id": "941ae6d5",
      "content": "603.58 -906,278,151.90 -0.43%\n额\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61 -138.81%\n相关数据同比发生重大变动的主要影响因素说明\n√ 适用 □ 不适用\n经营活动产生的现金流量净额减少主要系收回银行承兑汇票、信用证保证金等减少所致。投资活动产生的现金流量净额增加主要系去年同期购买银行理财产品及结构性存款较多所致。报告期内公司经营活动产生的现金净流量与本年度净利润存在重大差异的原因说明\n□ 适用 √ 不适用\n三、非主营业务分析\n□ 适用 √ 不适用\n四、资产及负债状况分析\n1、资产构成重大变动情况\n单位：元\n2019年末 2019年初\n比重增减 重大变动说明\n金额 占总资产比例 金额 占总资产比例\n货币资金 1,556,575,372.45 23.07% 1,956,089,124.33 27.80% -4.73%\n应收账款 459,781,564.19 6.81% 479,537,782.06 6.82% -0.01%\n存货 842,985,260.60 12.49% 905,418,218.49 12.87% -0.38%\n投资性房地产 11,206,951.46 0.17% 12,338,615.29 0.18% -0.01%\n长期股权投资 47,879,382.43 0.71% 66,088,139.79 0.94% -0.23%\n固定资产 1,724,407,333.34 25.56% 1,215,120,643.61 17.27% 8.29%\n20。\n\n在建工程 560,674,634.43 8.31% 674,333,677.99 9.58% -1.27%\n短期借款 200,267,029.59 2.97% 598,700,000.00 8.51% -5.54%\n2、以公允价值计量的资产和负债\n□ 适用 √ 不适用\n3、截至报告期末的资产权利受限情况\n项 目 期末账面价值 受限原因\n货币资金 30,797,464.00 开立银行承兑汇票\n固定资产 22,554,937.46 银行融资抵押\n无形资产 10,291,182.19 银行融资抵押\n合 计 63,643,583.65\n五、投资状况分析\n1、总体情况\n√ 适用 □ 不适用\n报告期投资额（元） 上年同期投资额（元） 变动幅度\n593,621,971.72 606,637,800.32 -2.15%\n2、报告期内获取的重大的股权投资情况\n□ 适用 √ 不适用\n3、报告期内正在进行的重大的非股权投资情况\n□ 适用 √ 不适用\n4、以公允价值计量的金融资产\n□ 适用 √ 不适用\n5、募集资金使用情况\n√ 适用 □ 不适用\n（1）募集资金总体使用情况\n√ 适用 □ 不适用\n单位：万元\n21。",
      "chunk_type": "child",
      "parent_id": "707f6596",
      "child_ids": [],
      "sibling_ids": [
        "ad9090f3",
        "34ce908d",
        "b646df69"
      ],
      "position": 2,
      "start_char": 1900,
      "end_char": 3087,
      "page_number": 18,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.289059",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1187,
        "word_count": 144,
        "sentence_count": 57,
        "chinese_char_count": 465,
        "readability_score": 0.0,
        "information_density": 0.14321819713563605,
        "coherence_score": 0.43466666666666665,
        "standards_profile_summary": {}
      },
      "quality_score": 0.608340353833193,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "利润",
        "现金",
        "投资",
        "应收",
        "存货",
        "固定资产",
        "无形资产",
        "净利润"
      ]
    },
    {
      "chunk_id": "b646df69",
      "content": "） 上年同期投资额（元） 变动幅度\n593,621,971.72 606,637,800.32 -2.15%\n2、报告期内获取的重大的股权投资情况\n□ 适用 √ 不适用\n3、报告期内正在进行的重大的非股权投资情况\n□ 适用 √ 不适用\n4、以公允价值计量的金融资产\n□ 适用 √ 不适用\n5、募集资金使用情况\n√ 适用 □ 不适用\n（1）募集资金总体使用情况\n√ 适用 □ 不适用\n单位：万元\n21。\n\n报告期内 累计变更 累计变更 尚未使用\n本期已使 已累计使 尚未使用 闲置两年\n募集资金 变更用途 用途的募 用途的募 募集资金\n募集年份 募集方式 用募集资 用募集资 募集资金 以上募集\n总额 的募集资 集资金总 集资金总 用途及去\n金总额 金总额 总额 资金金额\n金总额 额 额比例 向\n非公开发\n2016年 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 存放银行 0\n行股票\n合计 -- 101,440.36 48,002.14 81,781.91 37,061.61 37,061.61 36.54% 24,703.42 -- 0\n募集资金总体使用情况说明\n1、经中国证券监督管理委员会证监许可〔2016〕765号文核准，并经深圳证券交易所同意，本公司由主承销商国泰君安证\n券股份有限公司采用非公开发行方式，向特定对象非公开发行人民币普通股（A股）股票99,890,023股，发行价为每股人\n民币10.28元，共计募集资金1,026,869,436.44元，坐扣承销费和保荐费等10,000,000.00元（含税）后的募集资金为\n1,016,869,436.44元，已由主承销商国泰君安证券股份有限公司于2016年9月1日汇入本公司募集资金监管账户。扣除承\n销费及保荐费、律师费、会计师费用、登记费等发行费用12,465,829.73元后，本公司本次募集资金净额1,014,403,606.71\n元。上述募集资金到位情况业经天健会计师事务所(特殊普通合伙)验证，并由其出具《验资报告》（天健验〔2016〕358号）。",
      "chunk_type": "child",
      "parent_id": "707f6596",
      "child_ids": [],
      "sibling_ids": [
        "ad9090f3",
        "34ce908d",
        "941ae6d5"
      ],
      "position": 3,
      "start_char": 2887,
      "end_char": 3796,
      "page_number": 18,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          18
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.289308",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "券股份有限公司",
        "industry": null,
        "char_count": 909,
        "word_count": 95,
        "sentence_count": 27,
        "chinese_char_count": 479,
        "readability_score": 0.0,
        "information_density": 0.17601760176017603,
        "coherence_score": 0.6778947368421053,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8107810781078109,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "10.28元",
        "436.44元",
        "000.00元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "费用",
        "投资",
        "股权",
        "股份",
        "每股",
        "报告",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "e7e09ec0",
      "content": "2、本公司以前年度已使用募集资金337,797,729.53元，以前年度收到的银行存款利息扣除银行手续费等的净额为\n16,576,229.98元，以前年度收到的理财产品收益金额为20,933,628.61元；2019年度实际使用募集资金480,021,367.74元（含\n永久性补充流动资金370,616,060.66 元），2019年度收到的银行存款利息扣除银行手续费等的净额为4,244,642.08元，2019\n年度收到的理财产品收益金额为8,695,157.17元；累计已使用募集资金817,819,097.27元，累计收到的银行存款利息扣除\n银行手续费等的净额为20,820,872.06元，累计收到的理财产品收益金额为29,628,785.78元。截至2019年12月31日，募\n集资金余额为人民币247,034,167.28元。（2）募集资金承诺项目情况\n√ 适用 □ 不适用\n单位：万元\n是否已变 截至期末项目达到 项目可行\n募集资金调整后投 截至期末 本报告期\n承诺投资项目和超募 更项目 本报告期 投资进度预定可使 是否达到性是否发\n承诺投资 资总额 累计投入 实现的效\n资金投向 (含部分 投入金额 (3)＝ 用状态日 预计效益生重大变\n总额 (1) 金额(2) 益\n变更) (2)/(1) 期 化\n承诺投资项目\n原料药及中间体CMO 2019年7\n否 40,000 28,440.36 4,548.29 28,796.95 101.25% 0.00[注] 否 否\n中心扩建项目 月[注]\n年产30亿片（粒）固\n是 35,000 不适用 是\n体制剂技改项目\n医药综合研发中心 否 15,000 15,000 2,521.91 2,611.91 17.41% 不适用 否\n医药中试车间技改项\n否 9,000 9,000 1,436.42 4,730.88 52.57% 不适用 否\n目\n环保设施改造项目 否 14,000 14,000 2,433.91 8,580.56 61.29% 不适用 否\n承诺投资项目小计 -- 113,000 66,440.3610,940.53 44,720.3 -- -- -- --\n超募资金投向\n22。\n\n无\n归还银行贷款（如有） -- -- -- -- --\n补充流动资金（如有） -- -- -- -- --\n超募资金投向小计 -- -- -- -- --\n合计 -- 113,000 66,440.3610,940.53 44,720.3 -- -- 0 -- --\n“医药综合研发中心项目”原实施地点为公司椒江区外沙厂区，考虑各子公司所在园区的长远发展规\n划，对子公司职能定位进行调整，公司将项目的实施主体由公司变更为全资子公司川南药业，实施\n地点变更为浙江省临海市，因此导致投资进度有所延缓。",
      "chunk_type": "child",
      "parent_id": "c1b9f878",
      "child_ids": [],
      "sibling_ids": [
        "4489d301",
        "14f81631"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1179,
      "page_number": 22,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.290246",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1179,
        "word_count": 132,
        "sentence_count": 35,
        "chinese_char_count": 544,
        "readability_score": 0.0,
        "information_density": 0.05089058524173028,
        "coherence_score": 0.7283333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7845631891433418,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "729.53元",
        "229.98元",
        "628.61元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "报告"
      ]
    },
    {
      "chunk_id": "4489d301",
      "content": "-- --\n超募资金投向小计 -- -- -- -- --\n合计 -- 113,000 66,440.3610,940.53 44,720.3 -- -- 0 -- --\n“医药综合研发中心项目”原实施地点为公司椒江区外沙厂区，考虑各子公司所在园区的长远发展规\n划，对子公司职能定位进行调整，公司将项目的实施主体由公司变更为全资子公司川南药业，实施\n地点变更为浙江省临海市，因此导致投资进度有所延缓。未达到计划进度或预 “医药中试车间技改项目” 主要是通过实施原料药和关键中间体产品的中试生产，为产品的中试开发\n计收益的情况和原因 提供工艺验证和数据收集，为开发大规模生产的产品提供必要的研发支持。该项目计划建设用地位\n（分具体项目） 于公司外沙厂区，需要拆除原有车间，在原址上新建厂房。\n\n由于原车间为药证体系注册车间，需要\n办理相关药证转移变更程序，故导致医药中试车间技改项目进度低于规划进度。“环保设施改造项目”为配合厂区产能整体规划、协同活性染料产业升级及配套项目建设规划需要，\n投入与实施计划有所延缓。根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资\n项目可行性发生重大 项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目\n变化的情况说明 的市场环境已发生较大变化，公司终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普\n通账户，用于永久补充公司流动资金。\n\n超募资金的金额、用途不适用\n及使用进展情况\n适用\n以前年度发生\n募集资金投资项目实\n施地点变更情况\n根据公司2018年8月28日第五届董事会第十八次会议审议通过的《关于变更部分募集资金投资项\n目实施主体和地点的议案》，公司将募集资金投资项目“医药综合研发中心”实施主体由公司变更为全\n资子公司浙江海翔川南药业有限公司，实施地点变更为浙江省临海市。不适用\n募集资金投资项目实\n施方式调整情况\n募集资金投资项目先 不适用\n期投入及置换情况\n用闲置募集资金暂时 不适用\n补充流动资金情况\n项目实施出现募集资 不适用\n金结余的金额及原因\n尚未使用的募集资金\n存放银行\n用途及去向\n23。\n\n募集资金使用及披露\n中存在的问题或其他 不存在重大问题\n情况\n[注]：该项目已于2019年7月部分投产，但生产的相关产品尚未实现销售，故本期未产生效益。",
      "chunk_type": "child",
      "parent_id": "c1b9f878",
      "child_ids": [],
      "sibling_ids": [
        "e7e09ec0",
        "14f81631"
      ],
      "position": 1,
      "start_char": 979,
      "end_char": 1986,
      "page_number": 22,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.290495",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1007,
        "word_count": 68,
        "sentence_count": 13,
        "chinese_char_count": 789,
        "readability_score": 0.0,
        "information_density": 0.039721946375372394,
        "coherence_score": 0.711523397237683,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9134061569016882,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东",
        "披露"
      ]
    },
    {
      "chunk_id": "14f81631",
      "content": "江省临海市。不适用\n募集资金投资项目实\n施方式调整情况\n募集资金投资项目先 不适用\n期投入及置换情况\n用闲置募集资金暂时 不适用\n补充流动资金情况\n项目实施出现募集资 不适用\n金结余的金额及原因\n尚未使用的募集资金\n存放银行\n用途及去向\n23。\n\n募集资金使用及披露\n中存在的问题或其他 不存在重大问题\n情况\n[注]：该项目已于2019年7月部分投产，但生产的相关产品尚未实现销售，故本期未产生效益。（3）募集资金变更项目情况\n√ 适用 □ 不适用\n单位：万元\n变更后项目 变更后的项\n截至期末实截至期末投项目达到预\n变更后的项对应的原承拟投入募集本报告期实 本报告期实是否达到预目可行性是\n际累计投入 资进度 定可使用状\n目 诺项目 资金总额 际投入金额 现的效益 计效益 否发生重大\n金额(2) (3)=(2)/(1) 态日期\n(1) 变化\n年产30亿\n永久补充流片（粒）固\n37,061.61 37,061.61 37,061.61 100.00% 0 不适用 否\n动资金 体制剂技改\n项目\n合计 -- 37,061.61 37,061.61 37,061.61 -- -- 0 -- --\n根据公司2019年3月11日2018 年度股东大会会议审议通过的《关于终止实施部分\n变更原因、决策程序及信息披露情况募集资金投资项目并将结余募集资金用于永久性补充流动资金的议案》，因年产30 亿\n说明(分具体项目) 片（粒）固体制剂技改项目的市场环境已发生较大变化，公司终止实施该项目并将结\n余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。未达到计划进度或预计收益的情况\n不适用\n和原因(分具体项目)\n变更后的项目可行性发生重大变化\n不适用\n的情况说明\n六、重大资产和股权出售\n1、出售重大资产情况\n□ 适用 √ 不适用\n公司报告期未出售重大资产。",
      "chunk_type": "child",
      "parent_id": "c1b9f878",
      "child_ids": [],
      "sibling_ids": [
        "e7e09ec0",
        "4489d301"
      ],
      "position": 2,
      "start_char": 1786,
      "end_char": 2579,
      "page_number": 22,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          22
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.290711",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 793,
        "word_count": 89,
        "sentence_count": 13,
        "chinese_char_count": 543,
        "readability_score": 0.0,
        "information_density": 0.1008827238335435,
        "coherence_score": 0.7213358070500928,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8738965952080706,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "股权",
        "股东",
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "2b095fd2",
      "content": "2、出售重大股权情况\n□ 适用 √ 不适用\n七、主要控股参股公司分析\n√ 适用 □ 不适用\n主要子公司及对公司净利润影响达10%以上的参股公司情况\n24。\n\n单位：元\n公司名称 公司类型 主要业务 注册资本 总资产 净资产 营业收入 营业利润 净利润\n浙江海翔药\n货物及技术 30,000,000.0 69,541,379.7 69,007,694.1 -1,190,555.1 -1,177,557.0\n业销售有限 子公司 6,399,758.49\n进出口 0 5 3 0 5\n公司\n浙江海翔川\n医药制造及 1,905,943,80 1,307,615,66 1,278,861,76 204,310,101. 183,572,535.\n南药业有限 子公司 740000000\n货物进出口 5.66 6.90 2.53 35 16\n公司\n上海海翔医\n医药化工技 16,566,791.9\n药科技发展 子公司 5,000,000.00 7,712,899.66 5,961,858.15 1,609,827.17 1,416,778.77\n术开发 9\n有限公司\n工原料、化\n台州港翔科 工机械及配\n子公司 5,000,000.00 5,444,685.96 5,116,968.43 0.00 -143,703.23 -145,514.30\n技有限公司 件、五金批\n发、零售\n主要产品染\n料、染料中\n台州市前进\n间体、溴盐 304,000,000. 1,540,527,12 1,254,548,70 1,202,406,88 485,937,936. 418,599,011.\n化工有限公 子公司\n制造、销售 00 2.83 0.45 0.92 39 39\n司\n货物及技术\n进出口\n医药中间体\n台州市振港 及化工产品\n110,000,000. 933,575,895. 617,871,041. 783,594,897. 128,045,956. 89,296,052.8\n染料化工有 子公司 制造，销售\n00 73 59 92 93 4\n限公司 货物及技术\n进出口\n盐城市瓯华\nDCB、1-氨基19,778,647.3 203,873,894. 186,550,175. 65,214,784.2 -48,941,877. -48,959,944.\n化学工业有 子公司\n蒽醌生产 7 28 49 5 12 21\n限公司\n盐城市瓯华 化工产品研\n化工研究院 子公司 发及其技术 1,080,000.00 1,071,232.47 1,071,232.47 -724.90 -724.",
      "chunk_type": "child",
      "parent_id": "17399413",
      "child_ids": [],
      "sibling_ids": [
        "75acfc42",
        "5256f2d1",
        "c64435d4",
        "7843d7ac"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1092,
      "page_number": 24,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.291948",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1092,
        "word_count": 152,
        "sentence_count": 47,
        "chinese_char_count": 313,
        "readability_score": 0.0,
        "information_density": 0.1098901098901099,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.45586080586080585,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "利润"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "利润",
        "营业收入",
        "净利润",
        "营业利润",
        "净资产",
        "营业",
        "股权"
      ]
    },
    {
      "chunk_id": "75acfc42",
      "content": "CB、1-氨基19,778,647.3 203,873,894. 186,550,175. 65,214,784.2 -48,941,877. -48,959,944.\n化学工业有 子公司\n蒽醌生产 7 28 49 5 12 21\n限公司\n盐城市瓯华 化工产品研\n化工研究院 子公司 发及其技术 1,080,000.00 1,071,232.47 1,071,232.47 -724.90 -724.90\n有限公司 转让\n报告期内取得和处置子公司的情况\n√ 适用 □ 不适用\n公司名称 报告期内取得和处置子公司方式 对整体生产经营和业绩的影响\n浙江盛嘉环保有限公司 设立 无\n主要控股参股公司情况说明\n八、公司控制的结构化主体情况\n□ 适用 √ 不适用\n25。\n\n九、公司未来发展的展望\n（一）2020年工作计划\n1、强化总部层面在采购、销售、财务、重大投资和人力资源、行政管理方面的核心作用，\n不断增强总部的战略研究和规划调控能力，强化主营业务层面的关键性作用，有效发挥和放\n大集团运营优势、降低运营成本、提高运营效率。2、各厂区根据自身战略定位，集中优势资源加快推进南洋涂新厂区产能及环保处理设施、\n外沙厂区新剂型制剂扩建等重大项目建设和推进，做好南洋涂区块二期项目规划，丰富项目\n储备。3、积极构建开放、协同、高效的共性技术研发平台，不断优化科技基础设施建设，逐步\n健全需求为导向、企业研究院为主体的产学研一体化的创新机制，加大对创新的支持力度，\n形成有效的创新激励机制。\n\n要在做好老产品技改的同时，布局新产品，不断向产业链上下游\n延伸，进一步拓展产业链优势，促进研发和销售的良性循环。4、持续改善质量体系和EHS体系建设，提高质量保证专业水平，牢固确立绿色发展理念，\n加大质量管理、EHS常规化教育和培训力度，不断强化员工“质量为先”的意识，加强风险防\n范和管控，保障生产经营合规有序运行。5、加强人才队伍建设，适应行业发展新阶段，深化人力资源制度变革，建立完善的人员\n激励机制和晋升机制，强化绩效管理，营造良好的、有序竞争的企业内部环境，做好科技人\n员的培养和储备。\n\n（二）公司面临的风险和应对措施\n1、业绩波动风险\n公司染料行业的发展周期与下游纺织印染行业的发展周期息息相关，纺织印染行业的市\n场景气度会对公司染料板块的业绩产生直接的影响。当下，国内外经济形势仍有多方面不稳\n定因素的存在，如果全球经济持续向下衰退，势必将导致纺织品产市场需求量下降，公司也\n将受到国内外下游产业对染料需求下降的影响，最终对公司未来的业绩产生不利影响。2、行业政策风险\n近年来，随着医药体制改革相关政策的逐步落地，国家对医药行业的管理力度不断加大。\n\n医保控费、一致性评价、两票制、“集采”常态化等一系列医药政策的实施，将彻底改变医药\n行业的现有格局，并对整个医药行业未来的发展产生深远的影响。",
      "chunk_type": "child",
      "parent_id": "17399413",
      "child_ids": [],
      "sibling_ids": [
        "2b095fd2",
        "5256f2d1",
        "c64435d4",
        "7843d7ac"
      ],
      "position": 1,
      "start_char": 892,
      "end_char": 2088,
      "page_number": 24,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.292211",
        "report_type": "其他",
        "fiscal_year": 2020,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1196,
        "word_count": 70,
        "sentence_count": 22,
        "chinese_char_count": 884,
        "readability_score": 0.0,
        "information_density": 0.07525083612040133,
        "coherence_score": 0.6728571428571428,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8956521739130434,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "投资",
        "营业",
        "经营",
        "报告"
      ]
    },
    {
      "chunk_id": "5256f2d1",
      "content": "定因素的存在，如果全球经济持续向下衰退，势必将导致纺织品产市场需求量下降，公司也\n将受到国内外下游产业对染料需求下降的影响，最终对公司未来的业绩产生不利影响。2、行业政策风险\n近年来，随着医药体制改革相关政策的逐步落地，国家对医药行业的管理力度不断加大。\n\n医保控费、一致性评价、两票制、“集采”常态化等一系列医药政策的实施，将彻底改变医药\n行业的现有格局，并对整个医药行业未来的发展产生深远的影响。3、原材料价格波动的风险\n随着公司经营规模的不断扩大，所需的原材料数量持续增长。当前国家安全、环政策持续\n趋严、供给侧改革去产能，原材料价格可能会大幅波动，这将直接导致公司成本增加，也有\n可能面临原材料供应不足的情形，对公司生产经营造成不利的影响。\n\n4、环保政策风险\n公司在生产经营过程中会产生一定的污染物。虽然公司已严格按照环保法律、法规和标\n准的要求进行处理和排放，但是随着整个社会环保意识的增强，新《环境保护法》等越来越\n严格的环保法律法规的颁布实施，企业执行的环保标准也将更高更严格，这不但将增加本公\n司在环保设施、排放治理等方面的支出，同时还可能因为未能及时满足环保新标准而受到相\n关部门处罚。5、安全生产风险\n公司现有产品生产过程中的原料包含易燃、易爆化学品、腐蚀性或有毒物质，部分生产工\n序为高温、高压环境。\n\n尽管公司配备有较完备的安全设施，制定了较为完善的事故预警、处\n理机制，整个生产过程处于受控状态，发生安全事故的可能性很小，但仍然不排除因生产操\n作不当或设备故障等其他因素，导致意外事故发生的可能，从而影响公司生产经营的正常进\n26。\n\n行。6、人才缺乏及流失的风险\n随着公司规模的不断扩大，新项目的不断拓展，以及新产品的持续研发，都需要增加相应\n的管理人才和专业技能人才。人才储备的不足，以及现有岗位人才的流失都有可能导致人才\n资源不能满足生产经营的需求。",
      "chunk_type": "child",
      "parent_id": "17399413",
      "child_ids": [],
      "sibling_ids": [
        "2b095fd2",
        "75acfc42",
        "c64435d4",
        "7843d7ac"
      ],
      "position": 2,
      "start_char": 1888,
      "end_char": 2680,
      "page_number": 24,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.292471",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 792,
        "word_count": 24,
        "sentence_count": 12,
        "chinese_char_count": 697,
        "readability_score": 0.0,
        "information_density": 0.05050505050505051,
        "coherence_score": 0.7041379310344827,
        "standards_profile_summary": {}
      },
      "quality_score": 0.952020202020202,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "经营"
      ]
    },
    {
      "chunk_id": "c64435d4",
      "content": "、处\n理机制，整个生产过程处于受控状态，发生安全事故的可能性很小，但仍然不排除因生产操\n作不当或设备故障等其他因素，导致意外事故发生的可能，从而影响公司生产经营的正常进\n26。\n\n行。6、人才缺乏及流失的风险\n随着公司规模的不断扩大，新项目的不断拓展，以及新产品的持续研发，都需要增加相应\n的管理人才和专业技能人才。人才储备的不足，以及现有岗位人才的流失都有可能导致人才\n资源不能满足生产经营的需求。\n\n十、接待调研、沟通、采访等活动\n1、报告期内接待调研、沟通、采访等活动登记表\n√ 适用 □ 不适用\n接待时间 接待方式 接待对象类型 调研的基本情况索引\n具体内容详见互动易平台2019年3月\n2019年03月11日 实地调研 机构\n12日的投资者活动关系表\n具体内容详见互动易平台2019年4月\n2019年04月09日 实地调研 机构\n10日的投资者活动关系表\n具体内容详见互动易平台2019年4月\n2019年04月25日 实地调研 机构\n26日的投资者活动关系表\n具体内容详见互动易平台2019年5月\n2019年05月14日 实地调研 机构\n17日的投资者活动关系表\n具体内容详见互动易平台2019年5月\n2019年05月15日 实地调研 机构\n17日的投资者活动关系表\n具体内容详见互动易平台2019年6月\n2019年06月04日 实地调研 机构\n6日的投资者活动关系表\n具体内容详见互动易平台2019年6月\n2019年06月05日 实地调研 机构\n6日的投资者活动关系表\n具体内容详见互动易平台2019年9月\n2019年09月16日 实地调研 机构\n16日的投资者活动关系表\n27。\n\n第五节重要事项\n一、公司普通股利润分配及资本公积金转增股本情况\n报告期内普通股利润分配政策，特别是现金分红政策的制定、执行或调整情况\n√ 适用 □ 不适用\n公司第五届董事会第五次会议及2017年第一次临时股东大会审议通过了《公司未来三年（2017年-2019年）股东回报规划》。具体内容详见公司2016年12月19日于巨潮资讯网（http://www.cninfo.com.cn）刊登的《浙江海翔药业股份有限公司未来三年\n股东分红回报规划(2017-2019年) 》。",
      "chunk_type": "child",
      "parent_id": "17399413",
      "child_ids": [],
      "sibling_ids": [
        "2b095fd2",
        "75acfc42",
        "5256f2d1",
        "7843d7ac"
      ],
      "position": 3,
      "start_char": 2480,
      "end_char": 3412,
      "page_number": 24,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.292655",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 932,
        "word_count": 69,
        "sentence_count": 10,
        "chinese_char_count": 642,
        "readability_score": 0.0,
        "information_density": 0.13948497854077252,
        "coherence_score": 0.6853191489361703,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8755364806866952,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "投资",
        "经营",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配",
        "分红"
      ]
    },
    {
      "chunk_id": "7843d7ac",
      "content": "期内普通股利润分配政策，特别是现金分红政策的制定、执行或调整情况\n√ 适用 □ 不适用\n公司第五届董事会第五次会议及2017年第一次临时股东大会审议通过了《公司未来三年（2017年-2019年）股东回报规划》。具体内容详见公司2016年12月19日于巨潮资讯网（http://www.cninfo.com.cn）刊登的《浙江海翔药业股份有限公司未来三年\n股东分红回报规划(2017-2019年) 》。现金分红政策的专项说明\n是否符合公司章程的规定或股东大会决议的要求： 是\n分红标准和比例是否明确和清晰： 是\n相关的决策程序和机制是否完备： 是\n独立董事是否履职尽责并发挥了应有的作用： 是\n中小股东是否有充分表达意见和诉求的机会，其合法权益是\n是\n否得到了充分保护：\n现金分红政策进行调整或变更的，条件及程序是否合规、透\n是\n明：\n公司近3年（包括本报告期）的普通股股利分配方案（预案）、资本公积金转增股本方案（预案）情况\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购\n专用证券账户的63,005,888股）为基数，向全体股东每10股派发现金红利3元（含税），预计\n派发现金股利466,712,809.50元(含税)。\n\n本年度不送红股，不以资本公积转增股本。2018年度公司以2019年4月9日总股本1,555,814,365股（扣除存放于股票回购专用证券账\n户的63,005,888股）为基数，向全体股东每10股派发现金红利3.00元（含税），合计派发现金\n股利466,744,309.50元（含税），不送红股，不以资本公积转增股本。2017年度公司以2018年4月3日总股本1,621,610,253股为基数，向全体股东每10股派发现\n金红利1.00元（含税），合计派发现金股利162,161,025.30元（含税），不送红股，不以资本\n公积转增股本。",
      "chunk_type": "child",
      "parent_id": "17399413",
      "child_ids": [],
      "sibling_ids": [
        "2b095fd2",
        "75acfc42",
        "5256f2d1",
        "c64435d4"
      ],
      "position": 4,
      "start_char": 3212,
      "end_char": 4021,
      "page_number": 24,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          24
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.292862",
        "report_type": "其他",
        "fiscal_year": 2017,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 809,
        "word_count": 31,
        "sentence_count": 14,
        "chinese_char_count": 512,
        "readability_score": 0.0,
        "information_density": 0.1854140914709518,
        "coherence_score": 0.734078341013825,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8531520395550061,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润",
        "3元",
        "809.50元",
        "3.00元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "现金",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配",
        "分红",
        "红利"
      ]
    },
    {
      "chunk_id": "6c0e25b6",
      "content": "公司近三年（包括本报告期）普通股现金分红情况表\n单位：元\n现金分红总额\n现金分红金额 以其他方式现\n分红年度合并 （含其他方\n占合并报表中 以其他方式 金分红金额占\n报表中归属于 现金分红总额 式）占合并报\n现金分红金额 归属于上市公 （如回购股 合并报表中归\n分红年度 上市公司普通 （含其他方 表中归属于上\n（含税） 司普通股股东 份）现金分红 属于上市公司\n股股东的净利 式） 市公司普通股\n的净利润的比 的金额 普通股股东的\n润 股东的净利润\n率 净利润的比例\n的比率\n2019年 466,712,809.50 770,782,185.09 60.55% 19,996,827.22 2.59% 486,709,636.72 63.14%\n28。\n\n2018年 466,744,309.50 605,003,820.78 77.15% 281,514,686.68 46.53% 748,258,996.18 123.68%\n2017年 162,161,025.30 342,217,155.60 47.39% 0.00 0.00% 162,161,025.30 47.39%\n公司报告期内盈利且母公司可供普通股股东分配利润为正但未提出普通股现金红利分配预案\n□ 适用 √ 不适用\n二、本报告期利润分配及资本公积金转增股本情况\n√ 适用 □ 不适用\n每10股送红股数（股） 0\n每10股派息数（元）（含税） 3\n每10股转增数（股） 0\n分配预案的股本基数（股） 1,555,709,365\n现金分红金额（元）（含税） 466,712,809.50\n以其他方式（如回购股份）现金分红金额（元） 19,996,827.22\n现金分红总额（含其他方式）（元） 486,709,636.72\n可分配利润（元） 1,525,328,398.95\n现金分红总额（含其他方式）占利润分配总额的\n100%\n比例\n本次现金分红情况\n公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20％\n利润分配或资本公积金转增预案的详细情况说明\n2019年度公司拟以截至2019年12月31日的总股本1,555,709,365股（扣除存放于股票回购专用证券账户的63,005,888股）\n为基数，向全体股东每10股派发现金红利3元（含税），预计派发现金股利466,712,809.50元(含税)。本年度不送红股，\n不以资本公积转增股本。三、承诺事项履行情况\n1、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末\n尚未履行完毕的承诺事项\n√ 适用 □ 不适用\n承 履\n承诺类 承诺 诺 行\n承诺事由 承诺方 承诺内容\n型 时间 期 情\n限 况\n股改承诺\n收购报告书或权\n益变动报告书中\n所作承诺\n29。",
      "chunk_type": "child",
      "parent_id": "2ce099ec",
      "child_ids": [],
      "sibling_ids": [
        "9ea183a9",
        "f00085dd",
        "eb0ca278"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1186,
      "page_number": 28,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.294020",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1186,
        "word_count": 122,
        "sentence_count": 30,
        "chinese_char_count": 635,
        "readability_score": 0.0,
        "information_density": 0.11804384485666106,
        "coherence_score": 0.6934219743157348,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8141652613827994,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "报表",
        "3元",
        "809.50元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "净利润",
        "合并",
        "母公司",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "9ea183a9",
      "content": "预计派发现金股利466,712,809.50元(含税)。本年度不送红股，\n不以资本公积转增股本。三、承诺事项履行情况\n1、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末\n尚未履行完毕的承诺事项\n√ 适用 □ 不适用\n承 履\n承诺类 承诺 诺 行\n承诺事由 承诺方 承诺内容\n型 时间 期 情\n限 况\n股改承诺\n收购报告书或权\n益变动报告书中\n所作承诺\n29。\n\n（一）本承诺人及本承诺人直接或间接控制的除海翔药业、台州前进\n及其子公司以外的企业目前不存在自营、与他人共同经营、为他人经\n营或以其他任何方式直接或间接从事与海翔药业、台州前进及其子公\n司相同、相似或构成实质竞争业务的情形；（二）在直接或间接持有海\n翔药业股份期间，本承诺人将不会采取参股、控股、自营、联营、合\n营、合作或者其他任何方式直接或间接从事与海翔药业、台州前进及\n其子公司现在和将来业务范围相同、相似或构成实质竞争的业务，也\n不会协助、促使或代表任何第三方以任何方式直接或间接从事与海翔\n药业、台州前进及其子公司现在和将来业务范围相同、相似或构成实\n质竞争的业务；（三）在直接或间接持有海翔药业股份期间，对于本承\n诺人直接或间接控制的其他企业，本承诺人将通过派出机构和人员（包\n括但不限于董事、总经理等）以及本承诺人在该等企业中的控制地位，\n王云富、\n关于同 保证该等企业比照前款规定履行与本承诺人相同的不竞争义务；（四）2014 严\n浙江东\n资产重组时所作 业竞争 如因国家政策调整等不可抗力原因导致本承诺人或本承诺人直接或间 年05 长 格\n港投资\n承诺 方面承 接控制的其他企业将来从事的业务与海翔药业、台州前进及其子公司 月05 期 履\n有限公\n诺 现在或将来从事的业务之间构成同业竞争时，则本承诺人将在海翔药 日 行\n司\n业、台州前进及其子公司提出异议后及时转让或终止该等业务或促使\n本承诺人直接或间接控制的其他企业及时转让或终止该等业务；如海\n翔药业、台州前进及其子公司进一步要求，海翔药业、台州前进及其\n子公司享有该等业务在同等条件下的优先受让权；（五）如从第三方获\n得任何与海翔药业经营的业务存在竞争或潜在竞争的商业机会，本承\n诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并\n尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上\n述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其\n子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述\n承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东\n因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归\n海翔药业所有。30。",
      "chunk_type": "child",
      "parent_id": "2ce099ec",
      "child_ids": [],
      "sibling_ids": [
        "6c0e25b6",
        "f00085dd",
        "eb0ca278"
      ],
      "position": 1,
      "start_char": 986,
      "end_char": 2112,
      "page_number": 28,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.294295",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1126,
        "word_count": 76,
        "sentence_count": 6,
        "chinese_char_count": 951,
        "readability_score": 0.0,
        "information_density": 0.12433392539964476,
        "coherence_score": 0.6730303030303031,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9378330373001778,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "经营",
        "809.50元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "现金",
        "投资",
        "经营",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "派发",
        "转增"
      ]
    },
    {
      "chunk_id": "f00085dd",
      "content": "本承\n诺人及本承诺人直接或间接控制的其他企业将立即通知海翔药业，并\n尽力将该商业机会让与海翔药业及其子公司；（六）如本承诺人违反上\n述承诺，海翔药业、台州前进及其子公司、海翔药业、台州前进及其\n子公司的其他股东有权根据本承诺函依法申请强制本承诺人履行上述\n承诺，并赔偿海翔药业及其子公司、海翔药业及其子公司的其他股东\n因此遭受的全部损失；同时本承诺人因违反上述承诺所取得的利益归\n海翔药业所有。30。\n\n（一）本承诺人将采取措施尽量避免或减少本承诺人及本承诺人直接\n或间接控制的除海翔药业、台州前进及其子公司以外的其他企业与台\n州前进、海翔药业及其子公司之间发生关联交易；（二）对于无法避免\n的关联交易，将按照\"等价有偿、平等互利\"的原则，依法签订关联交易\n合同，参照市场同行的标准，公允确定关联交易的价格，并严格按照\n海翔药业的公司章程及有关法律法规履行批准关联交易的法定程序和\n信息披露义务；（三）本承诺人及本承诺人直接或间接控制的除海翔药\n王云富、 业、台州前进及其子公司以外的其他企业不通过关联交易损害海翔药\n关于关 2014 严\n浙江东 业、台州前进及其子公司及相关公司股东的合法权益；（四）本承诺人\n联交易、 年05 长 格\n港投资 及本承诺人直接或间接控制的除海翔药业、台州前进及其子公司以外\n资金方 月05 期 履\n有限公 的其他企业不通过向海翔药业、台州前进及其子公司借款或由海翔药\n面承诺 日 行\n司 业、台州前进及其子公司提供担保、代偿债务、代垫款项等各种名目\n侵占海翔药业、台州前进及其子公司的资金；（五）不利用股东地位及\n影响谋求与海翔药业、台州前进及其子公司在业务合作等方面给予本\n承诺人及本承诺人直接或间接控制的除海翔药业、台州前进及其子公\n司以外的其他企业优于市场第三方的权利；不利用股东地位及影响谋\n求与海翔药业、台州前进及其子公司达成交易的优先权利；（六）本承\n诺人愿意承担由于违反上述承诺给海翔药业、台州前进及其子公司造\n成的直接、间接的经济损失、索赔责任及额外的费用支出。首次公开发行或\n再融资时所作承\n诺\n股权激励承诺\n其他对公司中小\n股东所作承诺\n承诺是否按时履\n是\n行\n如承诺超期未履\n行完毕的，应当详\n细说明未完成履\n不适用\n行的具体原因及\n下一步的工作计\n划\n2、公司资产或项目存在盈利预测，且报告期仍处在盈利预测期间，公司就资产或项目达到原盈利预测及\n其原因做出说明\n□ 适用 √ 不适用\n四、控股股东及其关联方对上市公司的非经营性占用资金情况\n□ 适用 √ 不适用\n公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。31。",
      "chunk_type": "child",
      "parent_id": "2ce099ec",
      "child_ids": [],
      "sibling_ids": [
        "6c0e25b6",
        "9ea183a9",
        "eb0ca278"
      ],
      "position": 2,
      "start_char": 1912,
      "end_char": 3007,
      "page_number": 28,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.294536",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1095,
        "word_count": 73,
        "sentence_count": 5,
        "chinese_char_count": 940,
        "readability_score": 0.0,
        "information_density": 0.13698630136986303,
        "coherence_score": 0.6873913043478261,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9433789954337899,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "费用",
        "投资",
        "经营",
        "股权",
        "股东",
        "报告",
        "披露",
        "融资"
      ]
    },
    {
      "chunk_id": "eb0ca278",
      "content": "\n承诺是否按时履\n是\n行\n如承诺超期未履\n行完毕的，应当详\n细说明未完成履\n不适用\n行的具体原因及\n下一步的工作计\n划\n2、公司资产或项目存在盈利预测，且报告期仍处在盈利预测期间，公司就资产或项目达到原盈利预测及\n其原因做出说明\n□ 适用 √ 不适用\n四、控股股东及其关联方对上市公司的非经营性占用资金情况\n□ 适用 √ 不适用\n公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。31。\n\n五、董事会、监事会、独立董事（如有）对会计师事务所本报告期“非标准审计报告”的说明\n□ 适用 √ 不适用\n六、与上年度财务报告相比，会计政策、会计估计和核算方法发生变化的情况说明\n√ 适用 □ 不适用\n企业会计准则变化引起的会计政策变更\n1. 本公司根据财政部《关于修订印发2019年度一般企业财务报表格式的通知》(财会〔2019〕6号)和企\n业会计准则的要求编制2019年度财务报表，此项会计政策变更采用追溯调整法。2018年度财务报表受重要\n影响的报表项目和金额如下：\n原列报报表项目及金额 新列报报表项目及金额\n应收票据及应收账款 586,937,258.10应收票据 107,399,476.04\n应收账款 479,537,782.06\n应付票据及应付账款 791,915,463.78应付票据 490,006,533.85\n应付账款 301,908,929.93\n2. 本公司自2019年1月1日起执行财政部修订后的《企业会计准则第22号——金融工具确认和计量》《企\n业会计准则第23号——金融资产转移》《企业会计准则第24号——套期保值》以及《企业会计准则第37号\n——金融工具列报》（以下简称新金融工具准则）。根据相关新旧准则衔接规定，对可比期间信息不予调\n整，首次执行日执行新准则与原准则的差异追溯调整本报告期期初留存收益或其他综合收益。\n\n新金融工具准则改变了金融资产的分类和计量方式，确定了三个主要的计量类别：摊余成本；以公允\n价值计量且其变动计入其他综合收益；以公允价值计量且其变动计入当期损益。公司考虑自身业务模式，\n以及金融资产的合同现金流特征进行上述分类。权益类投资需按公允价值计量且其变动计入当期损益，但\n在初始确认时可选择按公允价值计量且其变动计入其他综合收益(处置时的利得或损失不能回转到损益，但\n股利收入计入当期损益)，且该选择不可撤销。",
      "chunk_type": "child",
      "parent_id": "2ce099ec",
      "child_ids": [],
      "sibling_ids": [
        "6c0e25b6",
        "9ea183a9",
        "f00085dd"
      ],
      "position": 3,
      "start_char": 2807,
      "end_char": 3796,
      "page_number": 28,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          28
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.294761",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 989,
        "word_count": 59,
        "sentence_count": 16,
        "chinese_char_count": 737,
        "readability_score": 0.0,
        "information_density": 0.20222446916076847,
        "coherence_score": 0.7904557511454062,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8980788675429727,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "现金",
        "投资",
        "应收",
        "应付",
        "经营",
        "股东"
      ]
    },
    {
      "chunk_id": "46e58dec",
      "content": "新金融工具准则要求金融资产减值计量由“已发生损失模型”改为“预期信用损失模型”，适用于以摊余\n成本计量的金融资产、以公允价值计量且其变动计入其他综合收益的金融资产、租赁应收款。(1) 执行新金融工具准则对公司2019年1月1日财务报表的主要影响如下：\n项 目 资产负债表\n2018年12月31日 新金融工具准则 2019年1月1日\n调整影响\n可供出售金融资产 1,800,000.00 -1,800,000.00\n其他权益工具投资 1,800,000.00 1,800,000.00\n应收票据 107,399,476.04 -107,399,476.04\n应收款项融资 107,399,476.04 107,399,476.04\n其他流动资产 227,882,993.23 -150,000,000.00 77,882,993.23\n交易性金融资产 150,000,000.00 150,000,000.00\n(2) 2019年1月1日，公司金融资产和金融负债按照新金融工具准则（以下简称新CAS22）和按原金融工\n具准则（以下简称原CAS22）的规定进行分类和计量结果对比如下表：\n项 目 原金融工具准则 新金融工具准则\n计量类别 账面价值 计量类别 账面价值\n货币资金 贷款和应收款项 1,956,089,124.33以摊余成本计量的金融资 1,956,089,124.33\n32。\n\n产\n应收票据 贷款和应收款项 107,399,476.04以公允价值计量且其变动 107,399,476.04\n计入其他综合收益的金融\n资产\n应收账款 贷款和应收款项 479,537,782.06以摊余成本计量的金融资 479,537,782.06\n产\n其他应收款 贷款和应收款项 10,817,853.96以摊余成本计量的金融资 10,817,853.96\n产\n其他流动资产-银可供出售金融资产 150,000,000.00以公允价值计量且其变动 150,000,000.00\n行理财产品 计入当期损益\n可供出售金融资可供出售金融资产 1,800,000.00以公允价值计量且其变动 1,800,000.00\n产 计入其他综合收益\n应付票据 其他金融负债 490,006,533.85以摊余成本计量的金融负 490,006,533.85\n债\n应付账款 其他金融负债 301,908,929.93以摊余成本计量的金融负 301,908,929.93\n债\n其他应付款 其他金融负债 24,723,304.20以摊余成本计量的金融负 24,723,304.",
      "chunk_type": "child",
      "parent_id": "e2e8d3d2",
      "child_ids": [],
      "sibling_ids": [
        "15249a0d",
        "fa137b47",
        "5473e1d3",
        "44d3a217"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1071,
      "page_number": 32,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.295997",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1071,
        "word_count": 86,
        "sentence_count": 33,
        "chinese_char_count": 502,
        "readability_score": 0.0,
        "information_density": 0.1680672268907563,
        "coherence_score": 0.6743010752688172,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6275443510737628,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "应收",
        "应付",
        "资产负债表",
        "减值",
        "公允价值"
      ]
    },
    {
      "chunk_id": "15249a0d",
      "content": "00.00以公允价值计量且其变动 1,800,000.00\n产 计入其他综合收益\n应付票据 其他金融负债 490,006,533.85以摊余成本计量的金融负 490,006,533.85\n债\n应付账款 其他金融负债 301,908,929.93以摊余成本计量的金融负 301,908,929.93\n债\n其他应付款 其他金融负债 24,723,304.20以摊余成本计量的金融负 24,723,304.20\n债\n(3) 2019年1月1日，公司原金融资产和金融负债账面价值调整为按照新金融工具准则的规定进行分类\n和计量的新金融资产和金融负债账面价值的调节表如下：\n项 目 按原金融工具准则列示的 重分类 重新计量 按新金融工具准则列示\n账面价值（2018年12月31 的账面价值（2019年1月1\n日） 日）\nA. 金融资产\na. 摊余成本\n货币资金\n按原CAS22 列示的余额 1,956,089,124.33 1,956,089,124.33\n和按新CAS22 列示的余\n额\n应收票据\n按原CAS22 列示的余额 107,399,476.04\n减：转出至公允价值计量 -107,399,476.04\n且其变动计入其他综合\n收益(新CAS22)\n按新CAS22 列示的余额\n应收账款\n按原CAS22 列示的余额 479,537,782.06 479,537,782.06\n和按新CAS22 列示的余\n额\n33。",
      "chunk_type": "child",
      "parent_id": "e2e8d3d2",
      "child_ids": [],
      "sibling_ids": [
        "46e58dec",
        "fa137b47",
        "5473e1d3",
        "44d3a217"
      ],
      "position": 1,
      "start_char": 871,
      "end_char": 1476,
      "page_number": 32,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.296208",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 605,
        "word_count": 63,
        "sentence_count": 17,
        "chinese_char_count": 281,
        "readability_score": 0.0,
        "information_density": 0.21487603305785125,
        "coherence_score": 0.6405785123966943,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6841322314049587,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "成本",
        "融资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "成本",
        "应收",
        "应付",
        "公允价值",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "fa137b47",
      "content": " 1,956,089,124.33\n和按新CAS22 列示的余\n额\n应收票据\n按原CAS22 列示的余额 107,399,476.04\n减：转出至公允价值计量 -107,399,476.04\n且其变动计入其他综合\n收益(新CAS22)\n按新CAS22 列示的余额\n应收账款\n按原CAS22 列示的余额 479,537,782.06 479,537,782.06\n和按新CAS22 列示的余\n额\n33。\n\n其他应收款\n按原CAS22 列示的余额 10,817,853.96 10,817,853.96\n和按新CAS22 列示的余\n额\n以摊余成本计量的总金 2,553,844,236.39 -107,399,476.04 2,446,444,760.35\n融资产\nb. 以公允价值计量且其变动计入当期损益\n其他流动资产-银行理财\n产品\n按原CAS22 列示的余额 150,000,000.00\n减：转出至公允价值计量 -150,000,000.00\n且其变动计入当期损益\n(新CAS22)\n按新CAS22 列示的余额\n交易性金融资产-银行理\n财产品\n按原CAS22 列示的余额\n加：自可供出售金融资产 150,000,000.00\n(原CAS22)转入\n按新CAS22 列示的余额 150,000,000.00\n以公允价值计量且其变 150,000,000.00 150,000,000.00\n动计入当期损益\nc. 以公允价值计量且其变动计入其他综合收益\n应收款项融资\n按原CAS22 列示的余额\n加：自应收票据(原 107,399,476.04\nCAS22)转入\n按新CAS22 列示的余额 107,399,476.04\n可供出售金融资产\n按原CAS22 列示的余额 1,800,000.00\n减：转出至公允价值计量 -1,800,000.00\n且其变动计入其他综合\n收益(新CAS22)\n按新CAS22 列示的余额\n其他权益工具投资\n按原CAS22 列示的余额\n加：自可供出售金融资产 1,800,000.00\n(原CAS22)转入\n34。",
      "chunk_type": "child",
      "parent_id": "e2e8d3d2",
      "child_ids": [],
      "sibling_ids": [
        "46e58dec",
        "15249a0d",
        "5473e1d3",
        "44d3a217"
      ],
      "position": 2,
      "start_char": 1276,
      "end_char": 2147,
      "page_number": 32,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.296367",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 871,
        "word_count": 91,
        "sentence_count": 25,
        "chinese_char_count": 343,
        "readability_score": 0.0,
        "information_density": 0.14925373134328357,
        "coherence_score": 0.32604395604395603,
        "standards_profile_summary": {}
      },
      "quality_score": 0.595292766934558,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "成本",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "成本",
        "投资",
        "应收",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "5473e1d3",
      "content": "4\nCAS22)转入\n按新CAS22 列示的余额 107,399,476.04\n可供出售金融资产\n按原CAS22 列示的余额 1,800,000.00\n减：转出至公允价值计量 -1,800,000.00\n且其变动计入其他综合\n收益(新CAS22)\n按新CAS22 列示的余额\n其他权益工具投资\n按原CAS22 列示的余额\n加：自可供出售金融资产 1,800,000.00\n(原CAS22)转入\n34。\n\n按新CAS22 列示的余额 1,800,000.00\n以公允价值计量且其变 1,800,000.00 107,399,476.04 109,199,476.04\n动计入其他综合收益的\n总金融资产\nB. 金融负债\na. 摊余成本\n应付票据\n按原CAS22 列示的余额 490,006,533.85 490,006,533.85\n和按新CAS22 列示的余\n额\n应付账款\n按原CAS22 列示的余额 301,908,929.93 301,908,929.93\n和按新CAS22 列示的余\n额\n其他应付款\n按原CAS22 列示的余额 24,723,304.20 24,723,304.20\n和按新CAS22 列示的余\n额\n以摊余成本计量的总金 816,638,767.98 816,638,767.98\n融负债\n(4) 2019年1月1日，公司原金融资产减值准备期末金额调整为按照新金融工具准则的规定进行分类和\n计量的新损失准备的调节表如下：\n项 目 按原金融工具准则计提损失准 重分类 重新计量 按新金融工具准则计提\n备/按或有事项准则确认的预 损失准备（2019年1月1\n计负债（2018年12月31日） 日）\n贷款和应收款项(原CAS22)/以摊余成本计量的金融资产(新CAS22)\n应收账款 39,520,283.30 39,520,283.30\n其他应收款 17,101,274.23 17,101,274.23\n3. 本公司自2019年6月10日起执行经修订的《企业会计准则第7号——非货币性资产交换》，自2019\n年6月17日起执行经修订的《企业会计准则第12号——债务重组》。该项会计政策变更采用未来适用法处\n理。七、报告期内发生重大会计差错更正需追溯重述的情况说明\n□ 适用 √ 不适用\n公司报告期无重大会计差错更正需追溯重述的情况。\n\n八、与上年度财务报告相比，合并报表范围发生变化的情况说明\n√ 适用 □ 不适用\n35。",
      "chunk_type": "child",
      "parent_id": "e2e8d3d2",
      "child_ids": [],
      "sibling_ids": [
        "46e58dec",
        "15249a0d",
        "fa137b47",
        "44d3a217"
      ],
      "position": 3,
      "start_char": 1947,
      "end_char": 2967,
      "page_number": 32,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.296570",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1020,
        "word_count": 98,
        "sentence_count": 28,
        "chinese_char_count": 485,
        "readability_score": 0.0,
        "information_density": 0.17647058823529413,
        "coherence_score": 0.7003030303030302,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7107843137254902,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "应收",
        "应付",
        "合并",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "44d3a217",
      "content": "19年6月10日起执行经修订的《企业会计准则第7号——非货币性资产交换》，自2019\n年6月17日起执行经修订的《企业会计准则第12号——债务重组》。该项会计政策变更采用未来适用法处\n理。七、报告期内发生重大会计差错更正需追溯重述的情况说明\n□ 适用 √ 不适用\n公司报告期无重大会计差错更正需追溯重述的情况。\n\n八、与上年度财务报告相比，合并报表范围发生变化的情况说明\n√ 适用 □ 不适用\n35。\n\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n九、聘任、解聘会计师事务所情况\n现聘任的会计师事务所\n境内会计师事务所名称 天健会计师事务所（特殊普通合伙）\n境内会计师事务所报酬（万元） 170\n境内会计师事务所审计服务的连续年限 17年\n境内会计师事务所注册会计师姓名 沈维华 汪兢\n境内会计师事务所注册会计师审计服务的连续年限 沈维华1年 汪兢4年\n当期是否改聘会计师事务所\n□ 是 √ 否\n聘请内部控制审计会计师事务所、财务顾问或保荐人情况\n□ 适用 √ 不适用\n十、年度报告披露后面临暂停上市和终止上市情况\n□ 适用 √ 不适用\n十一、破产重整相关事项\n□ 适用 √ 不适用\n公司报告期未发生破产重整相关事项。十二、重大诉讼、仲裁事项\n√ 适用 □ 不适用\n披 披\n是否形 诉讼(仲\n涉案金额 诉讼(仲裁)进 露 露\n诉讼(仲裁)基本情况 成预计 诉讼(仲裁)审理结果及影响 裁)判决\n（万元） 展 日 索\n负债 执行情况\n期 引\n上海合契投资管理有限公司诉公 上海合契投资案件受理费由上海合契投资管理\n司、东港投资缔约过失责任纠纷一 2,500 否 管理有限公司有限公司负担，此前因诉讼被冻结/ / /\n案 已撤诉 的公司存款已经全部解除冻结。黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 204.01 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n36。\n\n黄小留、张伟诉江苏天腾建设集团\n有限公司、江苏海阔生物医药有限 747.56 否 败诉，已结案已支付全部款项 已执行 / /\n公司建设工程施工合同纠纷一案\n十三、处罚及整改情况\n□ 适用 √ 不适用\n公司报告期不存在处罚及整改情况。十四、公司及其控股股东、实际控制人的诚信状况\n□ 适用 √ 不适用\n十五、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况\n√ 适用 □ 不适用\n1、限制性股票激励计划简介\n（1）公司于2015年1月20日召开第四届董事会第十二次会议审议通过了《浙江海翔药业股\n份有限公司限制性股票激励计划（草案）》及其摘要等相关议案。随后公司向中国证监会上\n报了申请备案材料。",
      "chunk_type": "child",
      "parent_id": "e2e8d3d2",
      "child_ids": [],
      "sibling_ids": [
        "46e58dec",
        "15249a0d",
        "fa137b47",
        "5473e1d3"
      ],
      "position": 4,
      "start_char": 2767,
      "end_char": 3917,
      "page_number": 32,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          32
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.296808",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1150,
        "word_count": 131,
        "sentence_count": 12,
        "chinese_char_count": 862,
        "readability_score": 0.0,
        "information_density": 0.13043478260869565,
        "coherence_score": 0.696858170078509,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8998260869565218,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "合并",
        "股权",
        "股东",
        "审计",
        "报告",
        "财务报告",
        "年度报告"
      ]
    },
    {
      "chunk_id": "dc3b6cc3",
      "content": "（2）2015年2月17日，公司获悉报送的限制性股票激励计划（草案）及相关材料经中国证\n监会备案无异议。（3）2015年3月12日，公司2015年第一次临时股东大会审议通过了《浙江海翔药业股份有\n限公司限制性股票激励计划（草案）》及其摘要等相关，公司限制性股票激励计划已获批准。2、限制性股票激励计划授予情况\n2015年3月12日，公司第四届董事会第十四次会议审议通过了《关于向激励对象授予限制\n性股票的议案》。\n\n董事会同意以2015年3月12日为限制性股票的首次授权日，向335名激励对\n象授予3,473.5万股限制性股票，授予价格为4.5元/股，其他380万股限制性股票作为预留。2015年3月27日，公司发布了《关于限制性股票授予完成的公告》，由于2名激励对象因个人\n原因放弃认购其对应的全部限制性股票，合计2万股。公司实际向333名激励对象授予3471.5\n万股限制性股票，2015年3月31日完成上述限制性股票授予。\n\n3、限制性股股票激励计划预留部分第一次授予情况\n2015年9月26日，公司第四届董事会第十九次会议审议通过了《关于向激励对象授予预留\n部分限制性股票的议案》。董事会同意以2015年9月25日作为公司预留部分限制性股票的授予\n日，向公司董事、副董事长郭敏龙先生授予200万股预留部分限制性股票，授予价格为8.625\n元/股。2015年10月28日完成上述预留部分的授予登记。\n5、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于回购注销已离职激\n37。\n\n4、限制性股股票激励计划预留部分第二次授予情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于向激励对象授予预\n留部分限制性股票的议案》。董事会同意以2016年3月4日作为公司预留部分限制性股票的授\n予日，向公司总经理助理李芝龙先生授予360万股预留部分限制性股票，授予价格为5.075元/\n股。2016年4月22日完成上述预留部分的授予登记。",
      "chunk_type": "child",
      "parent_id": "cbe44cd6",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 858,
      "page_number": 37,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.297300",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 858,
        "word_count": 22,
        "sentence_count": 18,
        "chinese_char_count": 632,
        "readability_score": 0.0,
        "information_density": 0.05827505827505828,
        "coherence_score": 0.7970867860144275,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8946386946386946,
      "relevance_score": 1.0,
      "keywords": [
        "4.5元",
        "5.075元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "4b640e9c",
      "content": "5、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第二十六次会议审议通过了《关于回购注销已离职激\n37。\n\n励对象所持已获授但尚未解锁的限制性股票的议案》。由于原激励对象林宇峰、丁春明已经\n离职，根据相关规定及股东大会授权，公司董事会对林宇峰、丁春明已离职激励对象所持已\n获授但尚未解锁的限制性股票共计24万股进行回购注销。2016年5月完成上述股票回购注销。\n\n6、限制性股股票激励计划第一期解锁情况\n2016年3月13日，公司第四届董事会第二十七次会议审议通过了《关于限制性股票激励计\n划首次授予的限制性股票第一个解锁期解锁条件成就的议案》。公司及首次授予限制性股票\n的激励对象均满足激励计划的规定相关解锁条件，第一个解锁期可解锁激励对象为331人，可\n申请解锁的限制性股票数量为1,729.75万股，占股权激励首次授予限制性股票总数的25%。2016年4月1日上述股票上市流通。\n\n7、限制股票第二期解锁情况：公司第五届董事会第七次会议审议通了《关于限制性股票\n激励计划首次授予部分第二个解锁期及预留授予部分第一个解锁期解锁条件成就的议案》，\n本次符合首次授予限制性股票第二期解锁条件的激励对象共计325人，解锁的限制性股票数量\n共计1716.25万股。预留授予的限制性股票第一期解锁数量为228万股，其中郭敏龙解锁120万\n股，李芝龙解锁108万股。上述股票已于2017年4月27日上市流通。\n\n8、限制性股股票激励计划部分限制性股票回购注销情况\n2016年3月4日，公司第四届董事会第七次会议审议通过了《关于回购注销部分限制性股\n票的议案》。由于原激励对象苗玉武等15人已经离职，潘官富不幸离世，根据相关规定及股\n东大会授权，公司董事会对上述激励对象所持已获授但尚未解锁的限制性股票共计115.7万股\n进行回购注销。2017年7月完成上述股票回购注销。\n\n9、限制股票第三期解锁情况：公司第五届董事会第十五次会议审议通过了《关于限制性\n股票激励计划首次授予部分第三个解锁期及预留授予部分第二个解锁期解锁条件成就的议\n案》。公司及激励对象均满足激励计划规定的首次授予限制性股票第三个解禁期及预留授予\n部分限制性股票第二个解禁期的解锁条件。本解锁期可解锁激励对象为313人，其中首次授予\n部分可申请解锁的限制性股票数量为1,665.15万股；预留授予部分可申请解锁的限制性股票数\n量为120万股。\n\n10、限制性股股票激励计划部分限制性股票回购注销情况\n2018年4月3日，公司第五届董事会第十五次会议审议通过了《关于回购注销部分限制性\n股票的议案》。由于原激励对象邓飞、冯红、周宏、李芝龙均已经离职，公司拟对其持有的\n已获授但尚未解锁的限制性股票进行回购注销，共回购注销279万限制性股票。2018年7月完\n成上述股票回购注销。",
      "chunk_type": "child",
      "parent_id": "25403a8b",
      "child_ids": [],
      "sibling_ids": [
        "f7b89fc3",
        "c878486b",
        "a38d4530",
        "fb0deaf9"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1187,
      "page_number": 37,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.298571",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1187,
        "word_count": 32,
        "sentence_count": 23,
        "chinese_char_count": 965,
        "readability_score": 0.0,
        "information_density": 0.02527379949452401,
        "coherence_score": 0.686043956043956,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9251895534962089,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权",
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "f7b89fc3",
      "content": ".15万股；预留授予部分可申请解锁的限制性股票数\n量为120万股。\n\n10、限制性股股票激励计划部分限制性股票回购注销情况\n2018年4月3日，公司第五届董事会第十五次会议审议通过了《关于回购注销部分限制性\n股票的议案》。由于原激励对象邓飞、冯红、周宏、李芝龙均已经离职，公司拟对其持有的\n已获授但尚未解锁的限制性股票进行回购注销，共回购注销279万限制性股票。2018年7月完\n成上述股票回购注销。\n\n11、限制股票第四期解锁情况：公司第五届董事会第二十一次会议审议通过了《关于限\n制性股票激励计划首次授予部分第四个解锁期及预留授予部分第三个解锁期解锁条件成就的\n议案》。公司及激励对象均满足激励计划规定的首次授予限制性股票第四个解禁期及预留授\n予部分限制性股票第三个解禁期的解锁条件。本解锁期可解锁激励对象为308人，其中首次授\n予部分可申请解锁的限制性股票数量为1,654.65万股；预留授予部分可申请解锁的限制性股票\n数量为160万股。\n\n12、限制性股股票激励计划部分限制性股票回购注销情况\n2019年3月13日，公司第五届董事会第二十一次会议审议通过了《关于回购注销部分限制\n性股票的议案》。由于原激励对象赵敏蔚、李建平、何明炬、许会凌、陈顺强均已经离职，\n公司拟对其持有的已获授但尚未解锁的限制性股票进行回购注销，共回购注销10.5万限制性\n股票。2019年6月完成上述股票回购注销。\n\n至此《浙江海翔药业股份有限公司限制性股票激励计划（草案）》已经全部实施完成。38。",
      "chunk_type": "child",
      "parent_id": "25403a8b",
      "child_ids": [],
      "sibling_ids": [
        "4b640e9c",
        "c878486b",
        "a38d4530",
        "fb0deaf9"
      ],
      "position": 1,
      "start_char": 987,
      "end_char": 1629,
      "page_number": 37,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.298814",
        "report_type": "其他",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 642,
        "word_count": 19,
        "sentence_count": 15,
        "chinese_char_count": 520,
        "readability_score": 0.0,
        "information_density": 0.031152647975077878,
        "coherence_score": 0.71625,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9239875389408101,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "回购"
      ]
    },
    {
      "chunk_id": "c878486b",
      "content": "股票回购注销情况\n2019年3月13日，公司第五届董事会第二十一次会议审议通过了《关于回购注销部分限制\n性股票的议案》。由于原激励对象赵敏蔚、李建平、何明炬、许会凌、陈顺强均已经离职，\n公司拟对其持有的已获授但尚未解锁的限制性股票进行回购注销，共回购注销10.5万限制性\n股票。2019年6月完成上述股票回购注销。\n\n至此《浙江海翔药业股份有限公司限制性股票激励计划（草案）》已经全部实施完成。38。\n\n十六、重大关联交易\n1、与日常经营相关的关联交易\n√ 适用 □ 不适用\n关 是\n关 关 联 否\n可获\n联 联 交 占同类 获批的 超 关联\n关联 关联交易 得的\n关联关 交 交 易 关联交易 交易金 交易额 过 交易 披露\n交易 金额（万 同类 披露索引\n系 易 易 定 价格 额的比 度（万 获 结算 日期\n方 元） 交易\n类 内 价 例 元） 批 方式\n市价\n型 容 原 额\n则 度\n浙江 原 市 《2019年度日常关联交易预\n采 不同规格， 银行\n荣兴 控股股 料 场 2019 计的公告》公告编号\n购 单价从 存款 未偏\n活性 东持有 材 公 年02 2019-012，内容详见巨潮资讯\n活 5500元/吨 278.51 28.94% 2,800否 或承 离市\n炭有 其50%料 允 月18 网及《证券时报》、《上海证\n性 至15500元 兑汇 场价\n限公 股权 采 价 日 券报》、《中国证券报》、《证\n炭 /吨不等 票\n司 购 格 券日报》\n采\n原 购 市 《2019年度日常关联交易预\n江西 银行\n料 原 场 2019 计的公告》公告编号\n华邦 控股股 400元/千克 存款 未偏\n材 料 公 年02 2019-012，内容详见巨潮资讯\n药业 东控制 至420元/ 2,730.75 1.06% 5,000否 或承 离市\n料 药 允 月18 网及《证券时报》、《上海证\n有限 企业 千克 兑汇 场价\n采 中 价 日 券报》、《中国证券报》、《证\n公司 票\n购 间 格 券日报》\n体\n销 销\n售 售 市\n江西 银行\n原 原 场\n华邦 控股股 存款 未偏\n料 料 公 市场公允 不适\n药业 东控制 5 0.01% 不适用否 或承 离市 不适用\n药 药 允 价格 用\n有限 企业 兑汇 场价\n中 中 价\n公司 票\n间 间 格\n体 体\n台州\n市\n市东 采 采 银行\n场\n港包 控股股 购 购 存款 未偏\n公 市场公允 不适\n装用 东控制 原 原 0.44 0.00% 不适用否 或承 离市 不适用\n允 价格 用\n品有 企业 材 材 兑汇 场价\n价\n限公 料 料 票\n格\n司\n39。",
      "chunk_type": "child",
      "parent_id": "25403a8b",
      "child_ids": [],
      "sibling_ids": [
        "4b640e9c",
        "f7b89fc3",
        "a38d4530",
        "fb0deaf9"
      ],
      "position": 2,
      "start_char": 1429,
      "end_char": 2524,
      "page_number": 37,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.299004",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1095,
        "word_count": 263,
        "sentence_count": 14,
        "chinese_char_count": 642,
        "readability_score": 0.0,
        "information_density": 0.09132420091324202,
        "coherence_score": 0.8916619457507173,
        "standards_profile_summary": {}
      },
      "quality_score": 0.781095890410959,
      "relevance_score": 1.0,
      "keywords": [
        "经营",
        "5500元",
        "15500元",
        "400元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营",
        "股权",
        "股份",
        "回购",
        "披露",
        "证券"
      ]
    },
    {
      "chunk_id": "a38d4530",
      "content": " 不适\n药业 东控制 5 0.01% 不适用否 或承 离市 不适用\n药 药 允 价格 用\n有限 企业 兑汇 场价\n中 中 价\n公司 票\n间 间 格\n体 体\n台州\n市\n市东 采 采 银行\n场\n港包 控股股 购 购 存款 未偏\n公 市场公允 不适\n装用 东控制 原 原 0.44 0.00% 不适用否 或承 离市 不适用\n允 价格 用\n品有 企业 材 材 兑汇 场价\n价\n限公 料 料 票\n格\n司\n39。\n\n合计 -- -- 3,014.7 -- 7,800 -- -- -- -- --\n大额销货退回的详细情\n不适用\n况\n按类别对本期将发生的\n2019年度，公司与上述关联方日常关联交易的实际发生总金额未超过预计总金额。实际发生情况\n日常关联交易进行总金\n与预计存在较大差异的原因为：公司与关联方的年度日常关联交易预计是基于公司业务开展进行的\n额预计的，在报告期内\n初步判断，较难实现准确预计，因此与实际发生情况存在一定的差异。的实际履行情况（如有）\n交易价格与市场参考价\n格差异较大的原因（如 不适用\n适用）\n2、资产或股权收购、出售发生的关联交易\n□ 适用 √ 不适用\n公司报告期未发生资产或股权收购、出售的关联交易。\n\n3、共同对外投资的关联交易\n□ 适用 √ 不适用\n公司报告期未发生共同对外投资的关联交易。4、关联债权债务往来\n□ 适用 √ 不适用\n公司报告期不存在关联债权债务往来。5、其他重大关联交易\n√ 适用 □ 不适用\n台州艾斐科技有限公司系公司控股股东东港投资持股49%的企业，因其不具备单独设立变压器的资质，借用台州市振港\n染料化工有限公司变压器用电。\n\n台州艾斐科技有限公司和台州市振港染料化工有限公司电费由台州市振港染料化工有限公司\n统一向供电公司支付，台州市振港染料化工有限公司完成电费支付后再向台州艾斐科技有限公司收取相关电费。2019年度上\n述关联交易总金额为45.66万元。十七、重大合同及其履行情况\n1、托管、承包、租赁事项情况\n（1）托管情况\n□ 适用 √ 不适用\n公司报告期不存在托管情况。\n\n（2）承包情况\n□ 适用 √ 不适用\n公司报告期不存在承包情况。（3）租赁情况\n□ 适用 √ 不适用\n公司报告期不存在租赁情况。",
      "chunk_type": "child",
      "parent_id": "25403a8b",
      "child_ids": [],
      "sibling_ids": [
        "4b640e9c",
        "f7b89fc3",
        "c878486b",
        "fb0deaf9"
      ],
      "position": 3,
      "start_char": 2324,
      "end_char": 3254,
      "page_number": 37,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.299242",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 930,
        "word_count": 139,
        "sentence_count": 17,
        "chinese_char_count": 664,
        "readability_score": 0.0,
        "information_density": 0.0967741935483871,
        "coherence_score": 0.8538449530009633,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8855913978494623,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "45.66万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "股权",
        "股东",
        "报告",
        "债务"
      ]
    },
    {
      "chunk_id": "fb0deaf9",
      "content": "一向供电公司支付，台州市振港染料化工有限公司完成电费支付后再向台州艾斐科技有限公司收取相关电费。2019年度上\n述关联交易总金额为45.66万元。十七、重大合同及其履行情况\n1、托管、承包、租赁事项情况\n（1）托管情况\n□ 适用 √ 不适用\n公司报告期不存在托管情况。\n\n（2）承包情况\n□ 适用 √ 不适用\n公司报告期不存在承包情况。（3）租赁情况\n□ 适用 √ 不适用\n公司报告期不存在租赁情况。2、重大担保\n√ 适用 □ 不适用\n（1）担保情况\n单位：万元\n公司及其子公司对外担保情况（不包括对子公司的担保）\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n报告期内审批的对外担保额度合 报告期内对外担保实际发\n0 0\n计（A1） 生额合计（A2）\n报告期末已审批的对外担保额度 报告期末实际对外担保余\n0 0\n合计（A3） 额合计（A4）\n公司对子公司的担保情况\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n浙江海翔川南药业有 2018年04 2019年02月27 连带责任保 2019-02-27~\n20,000 5,000 是 否\n限公司 月04日 日 证 2019-05-17\n浙江海翔川南药业有 2018年04 2019年12月24 连带责任保 2019-12-24~\n20,000 42.4 否 否\n限公司 月04日 日 证 2020-12-24\n报告期内审批对子公司担保额度 报告期内对子公司担保实\n0 5,042.4\n合计（B1） 际发生额合计（B2）\n报告期末已审批的对子公司担保 报告期末对子公司实际担\n20,000 42.4\n额度合计（B3） 保余额合计（B4）\n子公司对子公司的担保情况\n担保额度\n实际担保金 是否履行 是否为关\n担保对象名称 相关公告 担保额度 实际发生日期 担保类型 担保期\n额 完毕 联方担保\n披露日期\n41。",
      "chunk_type": "child",
      "parent_id": "25403a8b",
      "child_ids": [],
      "sibling_ids": [
        "4b640e9c",
        "f7b89fc3",
        "c878486b",
        "a38d4530"
      ],
      "position": 4,
      "start_char": 3054,
      "end_char": 3927,
      "page_number": 37,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          37
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.299474",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "台州市振港染料化工有限公司完成电费支付后再向台州艾斐科技有限公司",
        "industry": null,
        "char_count": 873,
        "word_count": 124,
        "sentence_count": 10,
        "chinese_char_count": 552,
        "readability_score": 0.0,
        "information_density": 0.03436426116838488,
        "coherence_score": 0.4462579185520362,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8529209621993128,
      "relevance_score": 1.0,
      "keywords": [
        "45.66万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "报告",
        "披露"
      ]
    },
    {
      "chunk_id": "9ebb7487",
      "content": "台州市振港染料化工 2017年04 2019年01月15 连带责任保 2019-01-15~\n6,000 240 否 否\n有限公司 月21日 日 证 2020-01-15\n台州市振港染料化工 2017年04 2019年01月23 连带责任保 2019-01-23~\n6,000 172 否 否\n有限公司 月21日 日 证 2020-01-23\n台州市振港染料化工 2017年04 2019年03月22 连带责任保 2019-03-22~\n6,000 523.52 否 否\n有限公司 月21日 日 证 2020-03-22\n报告期内审批对子公司担保额度 报告期内对子公司担保实\n0 935.52\n合计（C1） 际发生额合计（C2）\n报告期末已审批的对子公司担保 报告期末对子公司实际担\n0 935.52\n额度合计（C3） 保余额合计（C4）\n公司担保总额（即前三大项的合计）\n报告期内审批担保额度合计 报告期内担保实际发生额\n0 5,977.92\n（A1+B1+C1） 合计（A2+B2+C2）\n报告期末已审批的担保额度合计 报告期末实际担保余额合\n20,000 977.92\n（A3+B3+C3） 计（A4+B4+C4）\n实际担保总额（即A4+B4+C4）占公司净资产的比例 0.17%\n其中：\n为股东、实际控制人及其关联方提供担保的余额（D） 0\n直接或间接为资产负债率超过70%的被担保对象提供的债务\n0\n担保余额（E）\n担保总额超过净资产50%部分的金额（F） 0\n上述三项担保金额合计（D+E+F） 0\n对未到期担保，报告期内已发生担保责任或可能承担连带清偿\n不适用\n责任的情况说明（如有）\n违反规定程序对外提供担保的说明（如有） 不适用\n采用复合方式担保的具体情况说明\n不适用\n（2）违规对外担保情况\n□ 适用 √ 不适用\n公司报告期无违规对外担保情况。3、委托他人进行现金资产管理情况\n（1）委托理财情况\n√ 适用 □ 不适用\n报告期内委托理财概况\n42。\n\n单位：万元\n具体类型 委托理财的资金来源 委托理财发生额 未到期余额 逾期未收回的金额\n银行理财产品 暂时闲置自有资金 10,000 0 0\n银行理财产品 暂时闲置募集资金 21,000 0 0\n合计 31,000 0 0\n单项金额重大或安全性较低、流动性较差、不保本的高风险委托理财具体情况\n□ 适用 √ 不适用\n委托理财出现预期无法收回本金或存在其他可能导致减值的情形\n□ 适用 √ 不适用\n（2）委托贷款情况\n□ 适用 √ 不适用\n公司报告期不存在委托贷款。4、其他重大合同\n□ 适用 √ 不适用\n公司报告期不存在其他重大合同。十八、社会责任情况\n1、履行社会责任情况\n(1)股东与债权人权益保护\n股东对公司的认可是公司保持稳定发展的基础，保障股东合法权益、维护中小投资者的\n基本利益是公司的根本义务和职责。",
      "chunk_type": "child",
      "parent_id": "7d7b8238",
      "child_ids": [],
      "sibling_ids": [
        "60cb18b0",
        "99bd2a06",
        "baa98e38"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1193,
      "page_number": 42,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.300707",
        "report_type": "其他",
        "fiscal_year": 2017,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1193,
        "word_count": 144,
        "sentence_count": 11,
        "chinese_char_count": 703,
        "readability_score": 0.0,
        "information_density": 0.1173512154233026,
        "coherence_score": 0.7946664969522113,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8357082984073763,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "现金",
        "投资",
        "净资产",
        "资产负债率",
        "股东",
        "报告",
        "减值"
      ]
    },
    {
      "chunk_id": "60cb18b0",
      "content": "\n委托理财出现预期无法收回本金或存在其他可能导致减值的情形\n□ 适用 √ 不适用\n（2）委托贷款情况\n□ 适用 √ 不适用\n公司报告期不存在委托贷款。4、其他重大合同\n□ 适用 √ 不适用\n公司报告期不存在其他重大合同。十八、社会责任情况\n1、履行社会责任情况\n(1)股东与债权人权益保护\n股东对公司的认可是公司保持稳定发展的基础，保障股东合法权益、维护中小投资者的\n基本利益是公司的根本义务和职责。\n\n公司自上市以来一直严格按照《公司法》、《证券法》、\n《上市公司治理准则》等法律法规，不断健全、完善公司法人治理结构和内部控制制度，持\n续深入开展治理活动，将股东的利益放在公司治理的重中之重，以做到充分保障投资者的各\n项权益。同时依据《信息披露管理制度》、《投资者关系管理制度》等法律法规及时、准确、\n完整、真实地进行信息披露。通过业绩说明会、电话、邮件及投资者互动平台等加强与投资\n者的交流，以便于公司广大股东与债权人能及时的了解公司的经营、财务及重大事项进展情\n况。\n\n公司多年来以稳健、诚信的经营原则，不断努力降低自身经营风险，财务风险、及债权\n人权益风险的目标为之奋斗，实现了股东利益与债权人利益的双赢，同时也增强了投资者对\n公司的认同度。公司2019年共召开3次股东大会，真实、准确和完整的完成各项信息披露，确\n保投资者及时全面了解公司的经营情况，保证了投资者的知情权。因股票市场出现波动，公\n司认为股价不能正确反映公司价值，决定用自有资金进行股份回购。\n\n截止2019年2月25日公司\n回购方案实施完成，公司通过集中竞价方式累计回购股份数量63,005,888股，占公司总股本的\n3.8921%，支付总金额301,511,513.90元（含交易费用）。维护了广大投资者利益，增强投资\n者对公司的投资信心。（2）员工权益保护\n公司多年以来一直将员工视为公司发展前进道路上最为宝贵的财富和动力源泉。\n\n格按照《劳动法》、《劳动合同法》、《社会保险法》等相关法律法规，从员工入职签订《劳\n动合同》，建立员工健康档案，缴纳各项法定社会保险与福利、组织员工入职体检、每年定\n期体检、离职体检等方方面面的工作，确保员工个人权益和身心健康得到全面的保障。公司\n遵循按劳分配、同工同酬的原则，根据员工的劳动成果、工作责任等要素制定薪酬管理制度\n和激励机制。公司注重员工职业规划，为员工规划多方向的职业发展通道，为员工搭建了一\n个公平公正、唯才适用的职业发展平台。\n\n同时公司通过各种渠道倾听员工心声，了解员工的\n确实需求，并采纳合理意见，积极帮助员工排解工作和生活中的实际困难，对员工购买住房、\n子女就学等遇到的困难，公司尽力帮助协调妥善解决；为大学毕业生提供临时住宿，为外来\n务工人员提供住房补贴，改善居住环境。",
      "chunk_type": "child",
      "parent_id": "7d7b8238",
      "child_ids": [],
      "sibling_ids": [
        "9ebb7487",
        "99bd2a06",
        "baa98e38"
      ],
      "position": 1,
      "start_char": 993,
      "end_char": 2149,
      "page_number": 42,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.300964",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1156,
        "word_count": 47,
        "sentence_count": 18,
        "chinese_char_count": 948,
        "readability_score": 0.0,
        "information_density": 0.12975778546712802,
        "coherence_score": 0.6909625668449197,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9280276816608997,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资",
        "经营",
        "财务",
        "513.90元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "费用",
        "投资",
        "经营",
        "股本",
        "股份",
        "股东",
        "分配",
        "总股本",
        "回购"
      ]
    },
    {
      "chunk_id": "99bd2a06",
      "content": "作责任等要素制定薪酬管理制度\n和激励机制。公司注重员工职业规划，为员工规划多方向的职业发展通道，为员工搭建了一\n个公平公正、唯才适用的职业发展平台。\n\n同时公司通过各种渠道倾听员工心声，了解员工的\n确实需求，并采纳合理意见，积极帮助员工排解工作和生活中的实际困难，对员工购买住房、\n子女就学等遇到的困难，公司尽力帮助协调妥善解决；为大学毕业生提供临时住宿，为外来\n务工人员提供住房补贴，改善居住环境。公司还关注员工的业余生活，组织开展如员工子女\n夏利营、趣味运动会、球赛、长跑及公司年会等文娱休闲活动，使员工在休闲放松的同时，\n进一步增进了员工之间的交流沟通，不仅增强了员工的归属感，更提升了海翔这个大家庭的\n凝聚力。（3）供应商、客户权益保护\n公司始终遵循“诚信经营，客户至上”的经营理念，切实的履行了对供应商、客户的社会\n责任。\n\n公司建有完善的采购与供应商评价体系，严格把关监控原材料采购的每一环节，以确\n保原材料的质量和品质的绝对控制。同时也将遇到的问题及时的反馈给供应商，从而形成一\n种良性积极地交流与沟通。注重实地调研和与客户的交流互动，通过一线收集调查信息，为\n营销政策的制定和改进后续服务提供可靠依据。\n\n公司一方面加强对新客户的开发，同时对老\n客户进行走访，建立了良好的客户关系。严格的质量管理体系，才是客户增强信任度、忠实\n度的根本要素。公司积极构建和发展与供应商、客户的战略合作伙伴关系，注重与各相关方\n的沟通与协调，从而共同构筑信任与合作的平台。\n\n（4）环境保护和可持续发展\n公司一直坚持环境保护与企业发展齐头并进的原则，积极响应国家的最新环保政策，坚\n决执行国家和地方的环保法律法规，提倡绿色发展的经营理念。多年来通过主动加大环保投\n入，不断的对技术进行升级与改造、淘汰高能耗设备等方法，提高产能转化效率，达到节能\n减排的目的，公司各项排污指标均已达到甚至超越行业标准。公司未来将坚定不移的走安全\n健康的可持续发展的道路，从而最终实现企业与环境和谐发展的目标。\n\n（5）促进地方教育事业发展\n为积极履行社会责任、促进地方教育事业的发展，公司向台州职业技术学院涌泉奖助基\n金会捐赠人民币132万元，用于促进台州职业技术学院的发展，奖励优秀学生和教师，资助贫\n困学生顺利完成学业，为社会培养更多更好的优秀人才。2、履行精准扶贫社会责任情况\n公司报告年度暂未开展精准扶贫工作，也暂无后续精准扶贫计划。3、环境保护相关的情况\n上市公司及其子公司是否属于环境保护部门公布的重点排污单位\n是\n主要污染物\n公司或子公 排放口分布 执行的污染 核定的排放超标排放情\n及特征污染 排放方式 排放口数量 排放浓度 排放总量\n司名称 情况 物排放标准 总量 况\n物的名称\n44。",
      "chunk_type": "child",
      "parent_id": "7d7b8238",
      "child_ids": [],
      "sibling_ids": [
        "9ebb7487",
        "60cb18b0",
        "baa98e38"
      ],
      "position": 2,
      "start_char": 1949,
      "end_char": 3091,
      "page_number": 42,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.301222",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1142,
        "word_count": 50,
        "sentence_count": 17,
        "chinese_char_count": 999,
        "readability_score": 0.0,
        "information_density": 0.05253940455341506,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9499124343257443,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "经营",
        "132万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "经营",
        "报告"
      ]
    },
    {
      "chunk_id": "baa98e38",
      "content": "困学生顺利完成学业，为社会培养更多更好的优秀人才。2、履行精准扶贫社会责任情况\n公司报告年度暂未开展精准扶贫工作，也暂无后续精准扶贫计划。3、环境保护相关的情况\n上市公司及其子公司是否属于环境保护部门公布的重点排污单位\n是\n主要污染物\n公司或子公 排放口分布 执行的污染 核定的排放超标排放情\n及特征污染 排放方式 排放口数量 排放浓度 排放总量\n司名称 情况 物排放标准 总量 况\n物的名称\n44。\n\nCOD:66.45\nCOD≤500m 污水综合排COD：18.9\n浙江海翔药 吨/年(纳管\nCOD、氨 g/L；氨氮 放标准 吨(纳管量);\n业股份有限 间歇 1 厂界内 量)；氨氮：无\n氮、PH ≤35mg/L； （GB8978- 氨氮：1.32\n公司 4.65吨/年\nPH 6-9 1996） 吨(纳管量)\n(纳管量)\n化学合成类\n制药工业大\n浙江海翔药\nVOCs≤150 气污染物排未超过核定VOCs≤12.4\n业股份有限VOCs 连续 1 厂界内 无\n（mg/m3） 放标准 排放总量 2（吨/年）\n公司\nDB33/2015-\n2016\nCOD纳管\n195.45吨/\nCOD≤500/ 污水综合排COD纳管 年(排环境\n浙江海翔川\nCOD、氨 L；氨氮 放标准 190.84吨；量39.09\n南药业有限 间歇 1 厂界内 无\n氮、PH ≤35mg/L； （GB8978- 氨氮纳管 吨)；氨氮纳\n公司\nPH6-9 1996） 13.35吨 管13.68吨/\n年(排环境\n量5.91吨)\nVOCs≤150\n（mg/m3）； VOCs 22.13\n二氧化硫 污水综合排 吨/年；二氧\n浙江海翔川VOCs、二\n≤200 放标准 未超过核定化硫15.2吨\n南药业有限氧化硫、氮间歇 2 厂界内 无\n（mg/m3）；（GB8978- 排放总量 /年；氮氧化\n公司 氧化物\n氮氧化物 1996） 物36.78吨/\n≤400 年\n（mg/m3）\n浙江海翔川\n委托有资质 按照环评核\n南药业有限固废 / / / 3762.85吨 5129吨/年 无\n单位处置 实标准\n公司\n台州市前进\n污水综合排 COD：\n化工有限公 COD<500m COD：8.321\nCOD、氨 放标准 27.164吨/\n司、台州市 间歇 1 厂界内 g/L；氨氮 吨：氨氮： 无\n氮、PH （GB8978- 年；氨氮：\n振港染料化 <35mg/L 1.248吨\n1996） 3.551吨/年\n工有限公司\n45。",
      "chunk_type": "child",
      "parent_id": "7d7b8238",
      "child_ids": [],
      "sibling_ids": [
        "9ebb7487",
        "60cb18b0",
        "99bd2a06"
      ],
      "position": 3,
      "start_char": 2891,
      "end_char": 3932,
      "page_number": 42,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          42
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.301472",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1041,
        "word_count": 155,
        "sentence_count": 23,
        "chinese_char_count": 478,
        "readability_score": 0.0,
        "information_density": 0.01921229586935639,
        "coherence_score": 0.6958741258741259,
        "standards_profile_summary": {}
      },
      "quality_score": 0.783669548511047,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "报告"
      ]
    },
    {
      "chunk_id": "c7b582a4",
      "content": "VOCs≤120\nVOCs：\n（mg/m3）；\n32.337吨/\n二氧化硫 大气污染综\n台州市前进VOCs、二 年；二氧化见其他应公\n<550 合排放标准未超过核定\n化工有限公氧化硫、氮连续 2 厂界内 硫：2.286 开的环境信\n（mg/m3）；（GB16297 排放总量\n司 氧化物 吨/年；氮氧息\n氮氧化物 -1996）\n化物17.562\n<240\n吨/年\n（mg/m3）\n台州市前进\n化工有限公\n委托有资质 按照环评核\n司、台州市危险固废 / / / 661.46吨 2384吨/年 无\n单位处置 实标准\n振港染料化\n工有限公司\nVOCs≤80\nVOCs：\n（mg/m3）；\n大气污染物 9.553吨/\n二氧化硫\n盐城市瓯华VOCs、二 综合排放标 年；二氧化\n≤550 未超过核定\n化学工业有氧化硫、氮间歇 8 厂界内 准 硫 10.875 无\n（mg/m3）； 排放总量\n限公司 氧化物 （GB16297 吨/年；氮氧\n氮氧化物\n-1996） 化物11.986\n≤240\n吨/年\n（mg/m3）\n盐城市瓯华 自行焚烧、\n按照环评核 6017.333吨\n化学工业有固废 委托资质单/ / / 2410.811吨 无\n实标准 /年\n限公司 位处置\n注：台州市振港染料化工有限公司与台州市前进化工有限公司排放浓度和执行的污染物排放标准相同，排放总量和核定的排\n放总量合并在台州市前进化工有限公司统计。防治污染设施的建设和运行情况\n公司在保证现有环保设施正常工作的同时加大了对新设备的投入，分别在母子公司新建了多\n处废水、废气及固废处理设施，有效的减少了污染物的排放。先进的数据实时监控系统，实\n现了对厂界内的污染物排放24小时不间断监测，并整理数据上传监控平台，保证废水废气达\n到排放标准。\n\n建设项目环境影响评价及其他环境保护行政许可情况\n项目严格执行环境许可制度，公司严格遵守环境保护许可法规。突发环境事件应急预案\n公司制定有完善的应急预案，包括厂级的环境事故应急预案和车间级的应急预案。所有应急\n预案都要进行培训，是员工熟悉应急预案，掌握应急技能。\n\n公司每年针对应急预案开展多次\n应急演练，提高员工在紧急情况下的应变能力。环境自行监测方案\n公司配置了环境污染防治检测设备，配备了专职日常检测分析与实验队伍，具备了较多项目\n的自行检测能力，为公司环境污染防治设施的正常稳定运行提供了保障。同时，定期委托其\n他机构进行特种污染因子的监测。\n\n其他应当公开的环境信息\n46。",
      "chunk_type": "child",
      "parent_id": "4ff665f6",
      "child_ids": [],
      "sibling_ids": [
        "7f0f7009",
        "6b70a847",
        "515871a3"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1041,
      "page_number": 46,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.302745",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州市振港染料化工有限公司与台州市前进化工有限公司",
        "industry": null,
        "char_count": 1041,
        "word_count": 102,
        "sentence_count": 19,
        "chinese_char_count": 696,
        "readability_score": 0.0,
        "information_density": 0.009606147934678195,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8674351585014408,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "合并"
      ]
    },
    {
      "chunk_id": "7f0f7009",
      "content": "间级的应急预案。所有应急\n预案都要进行培训，是员工熟悉应急预案，掌握应急技能。\n\n公司每年针对应急预案开展多次\n应急演练，提高员工在紧急情况下的应变能力。环境自行监测方案\n公司配置了环境污染防治检测设备，配备了专职日常检测分析与实验队伍，具备了较多项目\n的自行检测能力，为公司环境污染防治设施的正常稳定运行提供了保障。同时，定期委托其\n他机构进行特种污染因子的监测。\n\n其他应当公开的环境信息\n46。\n\n2019年8月，瓯华化工收到盐城市生态环境局出具的《行政处罚决定书》：2019年5月，盐城\n市生态环境局在现场检查中发现瓯华化工存在危废管理不规范情况，鉴于瓯华化工已主动整\n改到位，符合《盐城市生态环境局行政案件办理程序规定》第七条“主动消除或者减轻环境违\n法行为危害后果的”等从轻处罚的适用条款，对瓯华化工从轻处罚，处罚款人民币四万元。2019年10月，台州前进收到台州市生态环境局出具的《行政处罚决定书》： 2019年5月台州\n前进存在排放不符合大气污染物排放标准废气的情形，后果轻微，处罚款人民币十万元。其他环保相关信息\n无\n十九、其他重大事项的说明\n□ 适用 √ 不适用\n公司报告期不存在需要说明的其他重大事项。\n\n二十、公司子公司重大事项\n√ 适用 □ 不适用\n1、2019年4月，振港染料设立浙江盛嘉环保科技有限公司，注册资本1000万元，主要从事环\n保技术开发与咨询,污水处理。目前振港染料尚未实际出资。2、2019年7月，公司全资子公司台州港翔化工有限公司完成工商变更，股东由公司变更为川\n南药业。\n\n3、2019年12月，川南药业完成经营范围变更，增加“医药废物、废药物、药品等危险废物的\n收集、贮存、焚烧处置”。4、公司第五届董事会第二十三次会议通过了《关于对外投资参与设立合伙企业的议案》，同\n意公司出资2,000万元参与设立杭州寓鑫创业投资合伙企业（有限合伙）（以下简称：“寓鑫\n投资”）。截止目前寓鑫投资已募集18,710万元,后续可能新增其他有限合伙人，具体内容详见\n《关于对外投资参与设立合伙企业的进展公告》（公告编号：2020-002）。",
      "chunk_type": "child",
      "parent_id": "4ff665f6",
      "child_ids": [],
      "sibling_ids": [
        "c7b582a4",
        "6b70a847",
        "515871a3"
      ],
      "position": 1,
      "start_char": 841,
      "end_char": 1728,
      "page_number": 46,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.302978",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "振港染料设立浙江盛嘉环保科技有限公司",
        "industry": null,
        "char_count": 887,
        "word_count": 35,
        "sentence_count": 15,
        "chinese_char_count": 700,
        "readability_score": 0.0,
        "information_density": 0.10146561443066518,
        "coherence_score": 0.7271405190554127,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9156708004509584,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "1000万元",
        "000万元",
        "710万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "经营",
        "股东",
        "报告"
      ]
    },
    {
      "chunk_id": "6b70a847",
      "content": "“医药废物、废药物、药品等危险废物的\n收集、贮存、焚烧处置”。4、公司第五届董事会第二十三次会议通过了《关于对外投资参与设立合伙企业的议案》，同\n意公司出资2,000万元参与设立杭州寓鑫创业投资合伙企业（有限合伙）（以下简称：“寓鑫\n投资”）。截止目前寓鑫投资已募集18,710万元,后续可能新增其他有限合伙人，具体内容详见\n《关于对外投资参与设立合伙企业的进展公告》（公告编号：2020-002）。\n\n第六节股份变动及股东情况\n一、股份变动情况\n1、股份变动情况\n单位：股\n本次变动前 本次变动增减（＋，－） 本次变动后\n数量 比例 发行新股 送股 公积金转股 其他 小计 数量 比例\n一、有限售条件股份 27,076,100 1.68% -12,801,500 -12,801,500 14,274,600 0.88%\n3、其他内资持股 27,076,100 1.68% -12,801,500 -12,801,500 14,274,600 0.88%\n境内自然人持股 27,076,100 1.68% -12,801,500 -12,801,500 14,274,600 0.88%\n二、无限售条件股份 1,591,744,153 98.33% 12,696,500 12,696,500 1,604,440,653 99.12%\n1、人民币普通股 1,591,744,153 98.33% 12,696,500 12,696,500 1,604,440,653 99.12%\n三、股份总数 1,618,820,253 100.00% -105,000 -105,000 1,618,715,253 100.00%\n股份变动的原因\n√ 适用 □ 不适用\n（1）限制性股票激励计划第四个解锁期解锁\n公司于2019年3月13日召开第五届董事会第二十一次会议，审议通过了《关于限制性股票\n激励计划首次授予部分第四个解锁期及预留部分第三个解锁期解锁条件成就的议案》。本次\n符合解锁条件的激励对象共308人，其中符合首次授予限制性股票第四期解锁条件的激励对象\n共计307人，解锁的限制性股票数量为1,654.65万股。本次符合预留部分限制性股票第三期解\n锁条件的激励对象1人，解锁的限制性股票数量为160万股。\n\n（2）限制性股票回购注销\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。",
      "chunk_type": "child",
      "parent_id": "4ff665f6",
      "child_ids": [],
      "sibling_ids": [
        "c7b582a4",
        "7f0f7009",
        "515871a3"
      ],
      "position": 2,
      "start_char": 1528,
      "end_char": 2600,
      "page_number": 46,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.303187",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1072,
        "word_count": 78,
        "sentence_count": 22,
        "chinese_char_count": 542,
        "readability_score": 0.0,
        "information_density": 0.06529850746268656,
        "coherence_score": 0.7972294372294373,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8022388059701493,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "000万元",
        "710万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股份",
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "515871a3",
      "content": "的激励对象\n共计307人，解锁的限制性股票数量为1,654.65万股。本次符合预留部分限制性股票第三期解\n锁条件的激励对象1人，解锁的限制性股票数量为160万股。\n\n（2）限制性股票回购注销\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。股份变动的批准情况\n□ 适用 √ 不适用\n股份变动的过户情况\n√ 适用 □ 不适用\n详情请见股份变动原因\n股份回购的实施进展情况\n√ 适用 □ 不适用\n公司本次回购公司股份相关议案已分别经公司2018年2月12日召开的第五届董事会第十\n四次会议、2018年2月26日召开的2018年第一次临时股东大会审议通过，并于2018年3月20日\n披露了《回购报告书》。\n\n内容详见公司于《中国证券报》、《上海证券报》、《证券时报》、\n《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《回购报告书》（公告编\n48。\n\n号:2018-019）。公司2018年10月16日召开的第五届董事会第十九次会议和2018年11月1日召开的2018年\n第三次临时股东大会审议通过了《关于调整回购股份事项的议案》，同意对回购方案进行调\n整：将原回购方案中“以自有资金进行股份回购，总金额不超过人民币30,000万元，回购股份\n用途包括但不限于用作注销以减少公司注册资本。”调整为“以自有资金进行股份回购，总金\n额不低于人民币30,000万元，不超过人民币50,000万元（含50,000万元），回购股份用途包括\n但不限于用作员工持股计划、股权激励计划或注销以减少公司注册资本。\n\n”具体内容详见公司\n于《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网\n（http://www.cninfo.com.cn）刊登的《回购报告书（调整后）》（公告编号:2018-093）。2019年2月26日，公司披露《关于回购公司股份实施完成的公告》：截止2019年2月25日，公\n司回购股份实施期限届满，回购股份已实施完成。公司通过集中竞价方式累计回购股份数量\n为63,005,888股，占公司当前总股本（1,618,820,253股）的3.8921%，最高成交价为5.57元/股，\n最低成交价为4.32元/股，支付的总金额301,511,513.90元（含交易费用）。\n\n公司本次回购的股\n份存放于公司回购专用证券账户，由于本次回购用途用于实施股权激励计划或员工持股计划，\n公司总股本不会发生变化。如果后续涉及股份注销，公司将按规定及时履行信息披露义务。公司本次回购股份用途将根据公司实际情况由股东大会授权董事会依据有关法律法规决定，\n公司将适时作出安排并及时披露。",
      "chunk_type": "child",
      "parent_id": "4ff665f6",
      "child_ids": [],
      "sibling_ids": [
        "c7b582a4",
        "7f0f7009",
        "6b70a847"
      ],
      "position": 3,
      "start_char": 2400,
      "end_char": 3589,
      "page_number": 46,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          46
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.303433",
        "report_type": "其他",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1189,
        "word_count": 44,
        "sentence_count": 27,
        "chinese_char_count": 806,
        "readability_score": 0.0,
        "information_density": 0.10933557611438183,
        "coherence_score": 0.7921878668318769,
        "standards_profile_summary": {}
      },
      "quality_score": 0.871152228763667,
      "relevance_score": 1.0,
      "keywords": [
        "000万元",
        "000万元",
        "000万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "股本",
        "股权",
        "股份",
        "股东",
        "总股本",
        "回购",
        "报告",
        "披露",
        "证券"
      ]
    },
    {
      "chunk_id": "5f5eb4bb",
      "content": "具体内容详见公司于《中国证券报》、《上海证券报》、\n《证券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于回购公\n司股份实施完成的公告》（公告编号:2019-019）。采用集中竞价方式减持回购股份的实施进展情况\n□ 适用 √ 不适用\n股份变动对最近一年和最近一期基本每股收益和稀释每股收益、归属于公司普通股股东的每股净资产等财务指标的影响\n□ 适用 √ 不适用\n公司认为必要或证券监管机构要求披露的其他内容\n□ 适用 √ 不适用\n2、限售股份变动情况\n√ 适用 □ 不适用\n单位：股\n本期增加限售股 本期解除限售股\n股东名称 期初限售股数 期末限售股数 限售原因 解除限售日期\n数 数\n299名限制性股 限制性股票激励\n12,696,500 0 12,696,500 0 2019年4月4日\n票激励对象 计划第四期解锁\n回购离职激励对\n回购5人限制性\n105,000 0 105,000 0象持有的尚未解 2019年6月24日\n股票\n禁的限制性股票\n合计 12,801,500 0 12,801,500 0 -- --\n49。\n\n二、证券发行与上市情况\n1、报告期内证券发行（不含优先股）情况\n□ 适用 √ 不适用\n2、公司股份总数及股东结构的变动、公司资产和负债结构的变动情况说明\n√ 适用 □ 不适用\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。",
      "chunk_type": "child",
      "parent_id": "792efe24",
      "child_ids": [],
      "sibling_ids": [
        "df6954e4",
        "fc757829",
        "a5e0e4ca"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 681,
      "page_number": 49,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.304524",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 681,
        "word_count": 72,
        "sentence_count": 8,
        "chinese_char_count": 432,
        "readability_score": 0.0,
        "information_density": 0.19089574155653452,
        "coherence_score": 0.6138123385193033,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8180616740088107,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "净资产",
        "财务指标",
        "股份",
        "股东",
        "每股",
        "限售股",
        "回购",
        "报告"
      ]
    },
    {
      "chunk_id": "df6954e4",
      "content": "--\n49。\n\n二、证券发行与上市情况\n1、报告期内证券发行（不含优先股）情况\n□ 适用 √ 不适用\n2、公司股份总数及股东结构的变动、公司资产和负债结构的变动情况说明\n√ 适用 □ 不适用\n公司第五届董事会第二十一次会议和2018年年度股东大会审议通过的《关于回购注销部\n分限制性股票的议案》。本次回购注销的限制性股票为离职的激励对象赵敏蔚、李建平、何\n明炬、许会凌、陈顺强5人，合计10.5万股。3、现存的内部职工股情况\n□ 适用 √ 不适用\n三、股东和实际控制人情况\n1、公司股东数量及持股情况\n单位：股\n年度报告披露\n报告期末表决\n年度报告披露 日前上一月末\n权恢复的优先\n报告期末普通 日前上一月末 表决权恢复的\n71,441 71,441股股东总数 0 0\n股股东总数 普通股股东总 优先股股东总\n（如有）（参见\n数 数（如有）（参\n注8）\n见注8）\n持股5%以上的股东或前10名股东持股情况\n报告期内 持有有限 持有无限 质押或冻结情况\n报告期末\n股东名称 股东性质 持股比例 增减变动 售条件的 售条件的\n持股数量 股份状态 数量\n情况 股份数量 股份数量\n浙江东港投资有 553,982,5-2201741 553,982,5\n境内非国有法人 34.22% 0 质押 241,382,587\n限公司 873 87\n118,800,0 118,800,0\n王云富 境内自然人 7.34% 0 0\n00 00\n新昌勤进投资有 49,650,00-1435000 49,650,00\n境内非国有法人 3.07% 0\n限公司 00 0\n香港中央结算有 21,438,17 21,438,17\n境外法人 1.32% 18018169 0\n限公司 8 8\n14,350,00 14,350,00\n王丽英 境内自然人 0.89% 14350000 0\n0 0\n50。\n\n中央汇金资产管 10,540,40 10,540,40\n国有法人 0.65% 0 0\n理有限责任公司 0 0\n全国社保基金一 10,000,00 10,000,00\n其他 0.62% 10000000 0\n一七组合 0 0\n中国工商银行股\n份有限公司－国\n其他 0.53% 8,595,0008595000 0 8,595,000\n泰鑫睿混合型证\n券投资基金\n招商银行股份有\n限公司－汇添富\n医疗服务灵活配 其他 0.38% 6,100,0496100049 0 6,100,049\n置混合型证券投\n资基金\n-1618820\n叶小青 境内自然人 0.36% 5,796,235 0 5,796,235\n0\n战略投资者或一般法人因配售新股\n成为前10名股东的情况（如有）（参无\n见注3）\n1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n上述股东关联关系或一致行动的说 的股权。",
      "chunk_type": "child",
      "parent_id": "792efe24",
      "child_ids": [],
      "sibling_ids": [
        "5f5eb4bb",
        "fc757829",
        "a5e0e4ca"
      ],
      "position": 1,
      "start_char": 481,
      "end_char": 1676,
      "page_number": 49,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.304709",
        "report_type": "其他",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1195,
        "word_count": 163,
        "sentence_count": 18,
        "chinese_char_count": 594,
        "readability_score": 0.0,
        "information_density": 0.10878661087866111,
        "coherence_score": 0.7137728937728938,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7749790794979079,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "股权",
        "股份",
        "股东",
        "回购",
        "报告",
        "年度报告",
        "披露"
      ]
    },
    {
      "chunk_id": "fc757829",
      "content": ".38% 6,100,0496100049 0 6,100,049\n置混合型证券投\n资基金\n-1618820\n叶小青 境内自然人 0.36% 5,796,235 0 5,796,235\n0\n战略投资者或一般法人因配售新股\n成为前10名股东的情况（如有）（参无\n见注3）\n1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n上述股东关联关系或一致行动的说 的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司\n明 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制\n人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n\n前10名无限售条件股东持股情况\n股份种类\n股东名称 报告期末持有无限售条件股份数量\n股份种类 数量\n浙江东港投资有限公司 553,982,587人民币普通股 553,982,587\n王云富 118,800,000人民币普通股 118,800,000\n新昌勤进投资有限公司 49,650,000人民币普通股 49,650,000\n香港中央结算有限公司 21,438,178人民币普通股 21,438,178\n王丽英 14,350,000人民币普通股 14,350,000\n中央汇金资产管理有限责任公司 10,540,400人民币普通股 10,540,400\n全国社保基金一一七组合 10,000,000人民币普通股 10,000,000\n中国工商银行股份有限公司－国泰\n8,595,000人民币普通股 8,595,000\n鑫睿混合型证券投资基金\n招商银行股份有限公司－汇添富医\n疗服务灵活配置混合型证券投资基 6,100,049人民币普通股 6,100,049\n金\n叶小青 5,796,235人民币普通股 5,796,235\n51。\n\n前10名无限售流通股股东之间，以 1、王云富先生持有东港工贸集团73.20%的股权，东港工贸集团持有东港投资100.00%\n及前10名无限售流通股股东和前10的股权。王云富先生直接持有上市公司11,880万股股份，通过东港投资间接上市公司\n名股东之间关联关系或一致行动的 553,982,587股股份，合计持有上市公司672,782,587股股份，为上市公司的实际控制\n说明 人。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n\n1、新昌勤进投资有限公司通过普通账户持股1465万股，通过信用账户持股3500万\n前10名普通股股东参与融资融券业\n股。2、王丽英通过信用账户持股1435万股。3、其他股东不存在通过信用账户持股\n务情况说明（如有）（参见注4）\n的情况。\n3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。",
      "chunk_type": "child",
      "parent_id": "792efe24",
      "child_ids": [],
      "sibling_ids": [
        "5f5eb4bb",
        "df6954e4",
        "a5e0e4ca"
      ],
      "position": 2,
      "start_char": 1476,
      "end_char": 2656,
      "page_number": 49,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.305026",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江东港投资有限公司",
        "industry": null,
        "char_count": 1180,
        "word_count": 79,
        "sentence_count": 17,
        "chinese_char_count": 675,
        "readability_score": 0.0,
        "information_density": 0.11016949152542373,
        "coherence_score": 0.692436466996526,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8288135593220338,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "股权",
        "股份",
        "股东",
        "流通股",
        "报告",
        "投资者",
        "融资",
        "证券"
      ]
    },
    {
      "chunk_id": "a5e0e4ca",
      "content": "。2、其他股东之间未知是否存在关联关系，也未知是否属于一致行动人。\n\n1、新昌勤进投资有限公司通过普通账户持股1465万股，通过信用账户持股3500万\n前10名普通股股东参与融资融券业\n股。2、王丽英通过信用账户持股1435万股。3、其他股东不存在通过信用账户持股\n务情况说明（如有）（参见注4）\n的情况。\n3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。\n\n公司前10名普通股股东、前10名无限售条件普通股股东在报告期内是否进行约定购回交易\n□ 是 √ 否\n公司前10名普通股股东、前10名无限售条件普通股股东在报告期内未进行约定购回交易。2、公司控股股东情况\n控股股东性质：自然人控股\n控股股东类型：法人\n法定\n代表\n控股股东名 成立日\n人/单 组织机构代码 主要经营业务\n称 期\n位负\n责人\n国家法律、法规和政策允许的投资业务；股权投资、资产管理（未经金融\n1998 等监管部门批准，不得从事向公众融资存款、融资担保、代客理财等金融\n浙江东港投 王云 年07 服务）；机械设备、电子产品、工艺品、服装、家用电器、日用品、针纺织\n913310027046766827\n资有限公司 富 月09 品、金属材料、建材销售；黄金饰品加工、销售；房地产开发；市场摊位\n日 租赁；塑料原料销售；企业管理咨询服务；货物及技术进出口（国家法律、\n法规禁止或限制经营的项目除外）。控股股东报\n告期内控股\n和参股的其\n无\n他境内外上\n市公司的股\n权情况\n控股股东报告期内变更\n□ 适用 √ 不适用\n公司报告期控股股东未发生变更。",
      "chunk_type": "child",
      "parent_id": "792efe24",
      "child_ids": [],
      "sibling_ids": [
        "5f5eb4bb",
        "df6954e4",
        "fc757829"
      ],
      "position": 3,
      "start_char": 2456,
      "end_char": 3134,
      "page_number": 49,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          49
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.305279",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "新昌勤进投资有限公司",
        "industry": null,
        "char_count": 678,
        "word_count": 56,
        "sentence_count": 9,
        "chinese_char_count": 505,
        "readability_score": 0.0,
        "information_density": 0.19174041297935102,
        "coherence_score": 0.7189450991664272,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8979351032448377,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "营业",
        "经营",
        "股权",
        "股东",
        "报告",
        "内控",
        "融资"
      ]
    },
    {
      "chunk_id": "1d679fc2",
      "content": "3、公司实际控制人及其一致行动人\n实际控制人性质：境内自然人\n实际控制人类型：自然人\n52。\n\n是否取得其他国家或地区居\n实际控制人姓名 与实际控制人关系 国籍\n留权\n王云富 本人 中国 否\n一致行动（含协议、亲属、同\n王扬超 中国 否\n一控制）\n王云富先生自2003年3月起一直在东港集团任职，曾担任东港集团副董事长、总裁、党委\n副书记、工会主席等职务，2012年9月至今担任东港工贸集团有限公司执行董事、东港投\n资执行董事。王云富先生持有东港工贸集团有限公司73.20%的股权。王扬超先生系公司实际控制人王云富先生之子，2008年参加工作，曾担任东港工贸集团有\n主要职业及职务\n限公司销售经理、总裁助理，台州市振港染料化工有限公司常务副总、台州市前进化工有限\n公司总经理等职务。\n\n现担任台州市椒江区第十届政协委员会常委、台州市椒江区工商业联合\n会副会长、上海海翔医药科技发展有限公司执行董事等。王扬超先生未直接持有公司股票，\n持有东港工贸集团有限公司26.80%的股权，故王扬超先生间接持有公司股份。过去10年曾控股的境内外上\n无\n市公司情况\n实际控制人报告期内变更\n□ 适用 √ 不适用\n公司报告期实际控制人未发生变更。\n\n公司与实际控制人之间的产权及控制关系的方框图\n实际控制人通过信托或其他资产管理方式控制公司\n□ 适用 √ 不适用\n4、其他持股在10%以上的法人股东\n□ 适用 √ 不适用\n53。\n\n5、控股股东、实际控制人、重组方及其他承诺主体股份限制减持情况\n□ 适用 √ 不适用\n54 第七节优先股相关情况\n□ 适用 √ 不适用\n报告期公司不存在优先股。\n55\n第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。",
      "chunk_type": "child",
      "parent_id": "5bf2139d",
      "child_ids": [],
      "sibling_ids": [
        "d1dad645"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 733,
      "page_number": 52,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.305903",
        "report_type": "其他",
        "fiscal_year": 2003,
        "fiscal_quarter": null,
        "company_code": "月至今担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 733,
        "word_count": 66,
        "sentence_count": 12,
        "chinese_char_count": 574,
        "readability_score": 0.0,
        "information_density": 0.09549795361527967,
        "coherence_score": 0.8237932641521157,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9132332878581173,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "股权",
        "股份",
        "股东",
        "报告",
        "债券"
      ]
    },
    {
      "chunk_id": "d1dad645",
      "content": "系的方框图\n实际控制人通过信托或其他资产管理方式控制公司\n□ 适用 √ 不适用\n4、其他持股在10%以上的法人股东\n□ 适用 √ 不适用\n53。\n\n5、控股股东、实际控制人、重组方及其他承诺主体股份限制减持情况\n□ 适用 √ 不适用\n54 第七节优先股相关情况\n□ 适用 √ 不适用\n报告期公司不存在优先股。\n55\n第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。\n56 第九节董事、监事、高级管理人员和员工情况\n一、董事、监事和高级管理人员持股变动\n本期增持 本期减持\n任期起始 任期终止 期初持股 其他增减 期末持股\n姓名 职务 任职状态 性别 年龄 股份数量 股份数量\n日期 日期 数（股） 变动（股）数（股）\n（股） （股）\n2015年 2022年\n孙杨 董事长 现任 男 5308月25 11月12 4,400,000 0 0 0 4,400,000\n日 日\n2019年 2022年\n王扬超 副董事长 现任 男 3311月13 11月12 0 0 0 0 0\n日 日\n2014年 2022年\n董事、总\n杨思卫 现任 男 4612月08 11月12 4,857,800 0 0 0 4,857,800\n经理\n日 日\n2017年 2022年\n洪鸣 董事 现任 男 3705月31 11月12 315,000 0 78,750 0 236,250\n日 日\n2016年 2022年\n朱建伟 董事 现任 男 6410月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n姚冰 董事 现任 男 3811月13 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n苏为科 独立董事 现任 男 5910月17 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n毛美英 独立董事 现任 女 5710月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n张克坚 独立董事 现任 男 6411月13 11月12 0 0 0 0 0\n日 日\n监事会主 2019年 2022年\n陈敏杰 席、职工 现任 男 5211月13 11月12 0 0 0 0 0\n监事 日 日\n57。",
      "chunk_type": "child",
      "parent_id": "5bf2139d",
      "child_ids": [],
      "sibling_ids": [
        "1d679fc2"
      ],
      "position": 1,
      "start_char": 533,
      "end_char": 1461,
      "page_number": 52,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          52
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.306090",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 928,
        "word_count": 208,
        "sentence_count": 4,
        "chinese_char_count": 392,
        "readability_score": 0.0,
        "information_density": 0.06465517241379311,
        "coherence_score": 0.43871853546910755,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6952586206896552,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "股份",
        "股东",
        "报告",
        "债券"
      ]
    },
    {
      "chunk_id": "0834e224",
      "content": "第八节可转换公司债券相关情况\n□ 适用 √ 不适用\n报告期公司不存在可转换公司债券。\n56 第九节董事、监事、高级管理人员和员工情况\n一、董事、监事和高级管理人员持股变动\n本期增持 本期减持\n任期起始 任期终止 期初持股 其他增减 期末持股\n姓名 职务 任职状态 性别 年龄 股份数量 股份数量\n日期 日期 数（股） 变动（股）数（股）\n（股） （股）\n2015年 2022年\n孙杨 董事长 现任 男 5308月25 11月12 4,400,000 0 0 0 4,400,000\n日 日\n2019年 2022年\n王扬超 副董事长 现任 男 3311月13 11月12 0 0 0 0 0\n日 日\n2014年 2022年\n董事、总\n杨思卫 现任 男 4612月08 11月12 4,857,800 0 0 0 4,857,800\n经理\n日 日\n2017年 2022年\n洪鸣 董事 现任 男 3705月31 11月12 315,000 0 78,750 0 236,250\n日 日\n2016年 2022年\n朱建伟 董事 现任 男 6410月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n姚冰 董事 现任 男 3811月13 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n苏为科 独立董事 现任 男 5910月17 11月12 0 0 0 0 0\n日 日\n2016年 2022年\n毛美英 独立董事 现任 女 5710月17 11月12 0 0 0 0 0\n日 日\n2019年 2022年\n张克坚 独立董事 现任 男 6411月13 11月12 0 0 0 0 0\n日 日\n监事会主 2019年 2022年\n陈敏杰 席、职工 现任 男 5211月13 11月12 0 0 0 0 0\n监事 日 日\n57。",
      "chunk_type": "child",
      "parent_id": "d3c145e7",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 770,
      "page_number": 56,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          56
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.306552",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 770,
        "word_count": 183,
        "sentence_count": 2,
        "chinese_char_count": 285,
        "readability_score": 0.0,
        "information_density": 0.03896103896103896,
        "coherence_score": 0.21,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6818181818181818,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "报告",
        "债券"
      ]
    },
    {
      "chunk_id": "c17483b7",
      "content": "2014年 2022年\n汪启华 监事 现任 男 5605月15 11月12 0 0 0 0 0\n日 日\n2012年 2022年\n龚伟中 监事 现任 男 5510月11 11月12 0 0 0 0 0\n日 日\n2017年 2022年\n常务副总\n李洪明 现任 男 5105月13 11月12 600,000 0 20,000 580,000\n经理\n日 日\n2011年 2022年\n沈利华 副总经理 现任 男 5402月23 11月12 1,200,000 0 0 0 1,200,000\n日 日\n副总经 2012年 2022年\n许华青 理、董事 现任 女 3909月19 11月12 1,260,000 0 315,000 0 945,000\n会秘书 日 日\n副总经 2016年 2022年\n李进 理、财务 现任 男 3610月17 11月12 0 0 0 0 0\n总监 日 日\n2013年 2022年\n毛文华 副总经理 现任 男 5307月19 11月12 1,800,000 0 450,000 0 1,350,000\n日 日\n2014年 2022年\n许国睿 副总经理 现任 男 4311月21 11月12 600,000 150,000 0 450,000\n日 日\n2015年 2019年\n原副董事\n郭敏龙 离任 男 5608月25 11月12 4,000,000 1,000,000 0 3,000,000\n长\n日 日\n2015年 2019年\n原独立董\n田利明 离任 男 6605月06 11月12 0 0 0 0 0\n事\n日 日\n原监事会 2004年 2019年\n郭世华 主席、职 离任 男 6004月01 11月12 0 0 0 0 0\n工监事 日 日\n19,032,80 17,019,05\n合计 -- -- -- -- -- -- 0 2,013,750 0\n0 0\n二、公司董事、监事、高级管理人员变动情况\n√ 适用 □ 不适用\n58。\n\n姓名 担任的职务 类型 日期 原因\n原董事、副董事 2019年11月12\n郭敏龙 任期满离任 换届离任\n长 日\n2019年11月12\n田利明 独立董事 任期满离任 换届离任\n日\n原监事会主席、 2019年11月12\n郭世华 任期满离任 换届离任\n职工监事 日\n原董事，现任副 2019年11月12\n沈利华 任免 董事职务换届离任，仍继续担任公司副总经理\n总经理 日\n三、任职情况\n公司现任董事、监事、高级管理人员专业背景、主要工作经历以及目前在公司的主要职责\n（一）董事\n1、孙杨先生，中国国籍，无境外永久居留权，生于1967年4月，大专文化，中共党员，工\n程师。历任东港集团东港精细化工厂车间主任、生产厂长、厂长、集团公司总裁助理、副总\n裁。",
      "chunk_type": "child",
      "parent_id": "310d2fef",
      "child_ids": [],
      "sibling_ids": [
        "ad9ef880"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1149,
      "page_number": 58,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          58
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.307801",
        "report_type": "其他",
        "fiscal_year": 2014,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1149,
        "word_count": 229,
        "sentence_count": 3,
        "chinese_char_count": 438,
        "readability_score": 0.0,
        "information_density": 0.008703220191470844,
        "coherence_score": 0.3997058823529412,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6221932114882507,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "ad9ef880",
      "content": "\n职工监事 日\n原董事，现任副 2019年11月12\n沈利华 任免 董事职务换届离任，仍继续担任公司副总经理\n总经理 日\n三、任职情况\n公司现任董事、监事、高级管理人员专业背景、主要工作经历以及目前在公司的主要职责\n（一）董事\n1、孙杨先生，中国国籍，无境外永久居留权，生于1967年4月，大专文化，中共党员，工\n程师。历任东港集团东港精细化工厂车间主任、生产厂长、厂长、集团公司总裁助理、副总\n裁。2013年11月进入本公司工作，2014年8月被选举为公司董事，现任公司董事长，兼任公司\n全资子公司浙江海翔川南药业有限公司执行董事。\n\n2、王扬超先生，中国国籍，无境外居留权，生于1987年2月，长江商学院EMBA在读。2008\n年参加工作，曾担任东港工贸集团有限公司销售经理、总裁助理，台州市振港染料化工有限\n公司常务副总、台州市前进化工有限公司总经理等职务。现担任公司副董事长、台州市椒江\n区第十届政协委员会常委、台州市椒江区工商业联合会副会长、上海海翔医药科技发展有限\n公司执行董事等。\n\n3、杨思卫先生，中国国籍，无境外永久居留权，生于1974年8月，大学文化，中共党员，\n高级经济师，曾就职于南京恒信达化工有限公司任总经理，2002年进入盐城市瓯华化学工业\n有限公司工作至今，现任盐城瓯华董事长。曾获江苏省科技企业家、盐城市“杰出青年创新人\n才”、盐城市“优秀企业家”、滨海“十大杰出青年”等称号，曾担任盐城市第六、七届市人大代\n表。2014年12月8日起任公司董事，2015年1月20日起任公司总经理。\n\n4、洪鸣先生，中国国籍，无境外永久居留权，生于1983年12月，硕士研究生，中共党员，\n工程师。2006年进入浙江海翔药业股份有限公司工作，历任医药国际注册员，项目经理，业\n务发展高级经理，销售公司副总经理，现任医药板块营销中心总经理。2017年5月31日起任公\n司董事。\n\n5、朱建伟先生，美国国籍，生于1956年6月，讲席教授，上海医药工业研究院微生物药学\n硕士，上海医药工业研究院微生物遗传博士，美国Hood学院工商管理硕士。1991年9月至1997\n年9月在哈佛大学、Joslin糖尿病研究所担任高级研究员，1997年9月至2014年6月任美国\nFrederick国家癌症实验室技术运行总监，2012年9月至今任上海交通大学药学院院长，现担任\n浙江医药股份有限公司独立董事，也是国家千人计划引进的海外高层次人才。2016年10月17\n日起担任公司董事。\n\n6、姚冰先生，中国国籍，无境外永久居留权，生于1982年11月，中共党员，澳洲注册会\n计师。北京大学光华管理学院工商管理硕士在读，毕业于中国外交学院外交学专业硕士，浙\n江大学城市学院通信工程专业学士。2007年至2016年历任中国外交部北美与大洋洲司、驻加\n拿大、卡塔尔、新西兰等国外交官及领事官。",
      "chunk_type": "child",
      "parent_id": "310d2fef",
      "child_ids": [],
      "sibling_ids": [
        "c17483b7"
      ],
      "position": 1,
      "start_char": 949,
      "end_char": 2140,
      "page_number": 58,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          58
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.308086",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "曾担任东港工贸集团有限公司",
        "industry": null,
        "char_count": 1191,
        "word_count": 40,
        "sentence_count": 18,
        "chinese_char_count": 883,
        "readability_score": 0.0,
        "information_density": 0.008396305625524769,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.896557514693535,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份"
      ]
    },
    {
      "chunk_id": "d49635f5",
      "content": "2016年至2019年在普华永道任高级经理，负责\n中国企业海外投资并购咨询等业务。2019年11月13日起担任公司董事、副总经理。59。\n\n7、苏为科先生，中国国籍，无境外永久居留权，生于1961年2月，理学博士。历任浙江工\n学院有机化学教研室助教，浙江工业大学有机化工教研室讲师，副教授，现任浙江工业大学\n教授，兼任浙江省制药工程重点实验室主任，浙江省新药创制科技服务平台负责人，浙江省\n制药重中之重学科负责人，长三角绿色制药协同创新中心执行主任，国家化学原料药合成工\n程技术研究中心常务副主任。现担任兄弟科技股份有限公司、浙江花园生物高科股份有限公\n司的独立董事。\n\n2016年10月17日起担任公司独立董事。8、毛美英女士，中国国籍，无境外永久居留权，生于1963年10月，本科学历，高级会计\n师。历任临海长途客运公司计财科副科长，浙江台州高速公路建设开发股份有限公司主办会\n计，计财部副经理，台州市台金高速公路建设指挥部财务处处长。\n\n现在从事台州市沿海高速\n公路建设管理中心财务工作，现任浙江万盛股份有限公司、浙江伟星实业发展股份有限公司、\n永高股份有限公司、浙江永强集团股份有限公司独立董事。2016年10月17日起担任公司独立\n董事。9、张克坚先生，中国国籍，无境外永久居留权，生于1956年4月，教授、博士、博士生导\n师、享受国务院特殊津贴专家。\n\n一直从事药学相关的教学、研发管理工作,现任广东华南新药\n创制中心首席科学家。历任中国医学科学院药物研究所研究员、卫生部临床检验中心室主任、\n药品审评中心副主任、医疗器械技术审评中心副主任、中山大学药学院教授、广东华南新药\n创制中心副主任。现任亿帆医药股份有限公司独立董事、湖南方盛制药股份有限公司独立董\n事、华润医药集团有限公司（香港）独立非执行董事。\n\n（二）监事\n1、陈敏杰先生，中国国籍，无境外永久居留权，生于1968年6月，大专文化，中共党员，\n经济师、助理政工师。1987年进入天台七四三厂工作，1995年9月进入东港工贸集团有限公司\n工作，现在本公司从事行政事务及党群工作。2、汪启华先生，中国国籍，无境外永久居留权，生于1964年10月，硕士。\n\n2008年至2011\n年在新东港药业股份有限公司工作，任营销总监；2011年至2013年在以色列Teva公司任驻中\n国客户经理；2014年1月至今在浙江海翔药业股份有限公司工作，现任本公司监事，兼任公司\n全资子公司上海海翔医药科技发展有限公司监事，全资子公司浙江海翔药业销售有限公司执\n行董事，全资子公司台州港翔化工有限公司监事。3、龚伟中先生，中国国籍，无境外永久居留权，生于1965年9月，理学博士，研究员。曾\n任台州海翔医药化工科技有限公司总经理，现任浙江海翔药业股份有限公司政府项目部总监、\n浙江海翔药业股份有限公司党委书记，2012年10月11日起任公司监事。",
      "chunk_type": "child",
      "parent_id": "821959ae",
      "child_ids": [],
      "sibling_ids": [
        "0df9ccfd"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1199,
      "page_number": 59,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          59
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.308870",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "现担任兄弟科技股份有限公司",
        "industry": null,
        "char_count": 1199,
        "word_count": 32,
        "sentence_count": 21,
        "chinese_char_count": 946,
        "readability_score": 0.0,
        "information_density": 0.03336113427856547,
        "coherence_score": 0.2808157894736842,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9155963302752295,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股份"
      ]
    },
    {
      "chunk_id": "0df9ccfd",
      "content": "司工作，现任本公司监事，兼任公司\n全资子公司上海海翔医药科技发展有限公司监事，全资子公司浙江海翔药业销售有限公司执\n行董事，全资子公司台州港翔化工有限公司监事。3、龚伟中先生，中国国籍，无境外永久居留权，生于1965年9月，理学博士，研究员。曾\n任台州海翔医药化工科技有限公司总经理，现任浙江海翔药业股份有限公司政府项目部总监、\n浙江海翔药业股份有限公司党委书记，2012年10月11日起任公司监事。\n\n（三）高级管理人员\n1、李洪明先生，中国国籍，无境外永久居留权，生于1969年2月，天津大学化学工程专\n业本科学士学位，2005年毕业于美国匹兹堡大学，博士学位，曾担任上海瑞浦实业有限公司\n董事、总经理、海翔研究院院长、公司研发副总，现担任公司常务副总经理。2、沈利华先生，中国国籍，无境外永久居留权，生于1966年12月，大专文化。1985年起\n在公司工作至今，曾担任车间主任、QC主任、QA主任、台州泉丰医药化工有限公司副总经\n理、公司总经理助理、浙江普健制药有限公司总经理以及公司监事、董事等职务，2011年2\n月23日起担任公司副总经理。\n\n3、许华青女士，中国国籍，无境外永久居留权，生于1981年5月，大学文化。2005年1月\n起在公司工作至今，曾任公司证券事务代表，投资发展部经理。2007年2月取得深圳证券交易\n所董事会秘书资格证书。",
      "chunk_type": "child",
      "parent_id": "821959ae",
      "child_ids": [],
      "sibling_ids": [
        "d49635f5"
      ],
      "position": 1,
      "start_char": 999,
      "end_char": 1576,
      "page_number": 59,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          59
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.309128",
        "report_type": "其他",
        "fiscal_year": 1965,
        "fiscal_quarter": null,
        "company_code": "全资子公司上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 577,
        "word_count": 15,
        "sentence_count": 9,
        "chinese_char_count": 443,
        "readability_score": 0.0,
        "information_density": 0.06932409012131716,
        "coherence_score": 0.3214285714285714,
        "standards_profile_summary": {}
      },
      "quality_score": 0.907105719237435,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股份",
        "证券"
      ]
    },
    {
      "chunk_id": "ddf7f7a6",
      "content": "2012年9月19日起任公司副总经理、董事会秘书。4、李进先生，中国国籍，无永久境外居留权，生于1984年2月，中共党员，大学本科学历，\n会计师，注册会计师。2006年毕业于浙江财经学院。",
      "chunk_type": "child",
      "parent_id": "68b3b5d1",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 94,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.309336",
        "report_type": "其他",
        "fiscal_year": 2012,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 94,
        "word_count": 2,
        "sentence_count": 3,
        "chinese_char_count": 64,
        "readability_score": 0.0,
        "information_density": 0.0,
        "coherence_score": 0.3,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6287404255319149,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": false,
      "financial_indicators": []
    },
    {
      "chunk_id": "27a391c7",
      "content": "2006-2016年就职于天健会计师事务所（特\n殊普通合伙），历任审计员、项目经理、部门经理等职，2016年10月17日起担任公司副总经\n60。\n\n理、财务总监。5、毛文华先生,中国国籍,无境外永久居留权,生于1967年8月,大学文化,工程师,质量工程师,\n执业药师,1988年毕业于浙江工学院（现浙江工业大学）化学工程专业。1988年分配至浙江温\n岭制药厂,先后服务于浙江永宁制药厂、浙江海正药业股份有限公司、浙江医药股份有限公司，\n2012年10月进入本公司工作至今，2013年7月19日起担任公司副总经理。\n\n6、许国睿先生，中国国籍，无境外永久居留权，生于1977年6月，中共党员，大学文化。2000年2月进入公司工作至今，曾获台州市椒江区青年岗位能手荣誉称号。历任浙江海翔药业\n销售有限公司部门经理，副总经理，常务副总经理，2014年11月20日起担任公司副总经理。\n\n在股东单位任职情况\n√ 适用 □ 不适用\n在股东单位 在股东单位是否\n任职人员姓名 股东单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n王扬超 东港工贸集团有限公司 监事 否\n在股东单位任\n无\n职情况的说明\n在其他单位任职情况\n√ 适用 □ 不适用\n在其他单位 在其他单位是否\n任职人员姓名 其他单位名称 任期起始日期 任期终止日期\n担任的职务 领取报酬津贴\n朱建伟 上海交通大学药学院 院长 是\n朱建伟 浙江医药股份有限公司 独立董事 是\n苏为科 浙江工业大学 教授 是\n苏为科 浙江花园生物高科股份有限公司 独立董事 是\n苏为科 兄弟科技股份有限公司 独立董事 是\n执行董事兼\n苏为科 浙江天诺医药科技有限公司 是\n总经理\n毛美英 台州市沿海高速公路建设管理中心 职员 是\n毛美英 浙江万盛股份有限公司 独立董事 是\n毛美英 浙江伟星实业发展股份有限公司 独立董事 是\n毛美英 永高股份有限公司 独立董事 是\n毛美英 浙江永强集团股份有限公司 独立董事 是\n张克坚 亿帆医药股份有限公司 独立董事 是\n张克坚 湖南方盛制药股份有限公司 独立董事 是\n独立非执行\n张克坚 华润医药集团有限公司 是\n董事\n张克坚 广东华南新药创制中心 首席科学家 是\n孙杨 浙江海翔川南药业有限公司 执行董事 否\n61。",
      "chunk_type": "child",
      "parent_id": "42eff880",
      "child_ids": [],
      "sibling_ids": [
        "08405ae7",
        "9d1030bb",
        "4ef331bb",
        "918e48e8"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 950,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.310483",
        "report_type": "其他",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "浙江海正药业股份有限公司",
        "industry": null,
        "char_count": 950,
        "word_count": 109,
        "sentence_count": 8,
        "chinese_char_count": 727,
        "readability_score": 0.0,
        "information_density": 0.05263157894736842,
        "coherence_score": 0.27,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9061052631578947,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股份",
        "股东",
        "分配",
        "审计"
      ]
    },
    {
      "chunk_id": "08405ae7",
      "content": "司 独立董事 是\n毛美英 浙江伟星实业发展股份有限公司 独立董事 是\n毛美英 永高股份有限公司 独立董事 是\n毛美英 浙江永强集团股份有限公司 独立董事 是\n张克坚 亿帆医药股份有限公司 独立董事 是\n张克坚 湖南方盛制药股份有限公司 独立董事 是\n独立非执行\n张克坚 华润医药集团有限公司 是\n董事\n张克坚 广东华南新药创制中心 首席科学家 是\n孙杨 浙江海翔川南药业有限公司 执行董事 否\n61。\n\n杨思卫 盐城市瓯华化学工业有限公司 董事长 否\n王扬超 上海海翔医药科技发展有限公司 执行董事 否\n台州市椒江民营企业联合投资股份有限\n王扬超 董事 否\n公司\n李洪明 上海海翔医药科技发展有限公司 总经理 否\n汪启华 上海海翔医药科技发展有限公司 监事 否\n汪启华 浙江海翔药业销售有限公司执行董事 执行董事 否\n汪启华 台州港翔化工有限公司 监事 否\n公司现任及报告期内离任董事、监事和高级管理人员近三年证券监管机构处罚的情况\n□ 适用 √ 不适用\n四、董事、监事、高级管理人员报酬情况\n董事、监事、高级管理人员报酬的决策程序、确定依据、实际支付情况\n决策程序:公司按照《董事、监事、高级管理人员薪酬管理制度》，建立了高级管理人员的\n薪酬与公司业绩挂钩的绩效考核与激励约束机制，公司高级管理人员实行基本年薪和年终绩\n效考核相结合的薪酬制度。确定依据:年末根据公司年度经营目标完成情况以及高级管理人员的工作业绩，由董事会\n薪酬与考核委员会对高级管理人员进行年度绩效考核，并监督薪酬制度执行情况。公司则根\n据绩效考核结果兑现其绩效年薪，并进行奖惩。\n\n实际支付情况：报告期内，公司董事、监事、高管的薪酬根据薪酬计划按月发放。公司报告期内董事、监事和高级管理人员报酬情况\n单位：万元\n从公司获得的税 是否在公司关联\n姓名 职务 性别 年龄 任职状态\n前报酬总额 方获取报酬\n孙杨 董事、董事长 男 53现任 80.08 否\n王扬超 董事、副董事长 男 33现任 60.08 否\n杨思卫 董事、总经理 男 46现任 70.08 否\n洪鸣 董事 男 37现任 35.08 否\n朱建伟 董事 男 64现任 8 否\n姚冰 董事 男 38现任 13.98 否\n苏为科 独立董事 男 59现任 8 否\n毛美英 独立董事 女 57现任 8 否\n张克坚 独立董事 男 64现任 2 否\n监事会主席、职\n陈敏杰 男 52现任 10.94 否\n工监事\n汪启华 监事 男 56现任 45.08 否\n龚伟中 监事 男 55现任 26.54 否\n62。",
      "chunk_type": "child",
      "parent_id": "42eff880",
      "child_ids": [],
      "sibling_ids": [
        "27a391c7",
        "9d1030bb",
        "4ef331bb",
        "918e48e8"
      ],
      "position": 1,
      "start_char": 750,
      "end_char": 1813,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.310699",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "浙江伟星实业发展股份有限公司",
        "industry": null,
        "char_count": 1063,
        "word_count": 163,
        "sentence_count": 14,
        "chinese_char_count": 790,
        "readability_score": 0.0,
        "information_density": 0.0658513640639699,
        "coherence_score": 0.48518081511983946,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7948259642521166,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "经营",
        "股份",
        "报告",
        "证券"
      ]
    },
    {
      "chunk_id": "9d1030bb",
      "content": "否\n洪鸣 董事 男 37现任 35.08 否\n朱建伟 董事 男 64现任 8 否\n姚冰 董事 男 38现任 13.98 否\n苏为科 独立董事 男 59现任 8 否\n毛美英 独立董事 女 57现任 8 否\n张克坚 独立董事 男 64现任 2 否\n监事会主席、职\n陈敏杰 男 52现任 10.94 否\n工监事\n汪启华 监事 男 56现任 45.08 否\n龚伟中 监事 男 55现任 26.54 否\n62。\n\n李洪明 常务副总经理 男 51现任 60.14 否\n沈利华 副总经理 男 54现任 60.08 否\n副总经理、董事\n许华青 女 39现任 60.08 否\n会秘书\n副总经理、财务\n李进 男 36现任 60.08 否\n总监\n毛文华 副总经理 男 53现任 60.08 否\n许国睿 副总经理 男 43现任 60.08 否\n原董事、副董事\n郭敏龙 男 56离任 68.08 否\n长\n田利明 原独立董事 男 66离任 6 否\n原监事会主席、\n郭世华 男 60离任 12.8 否\n职工监事\n合计 -- -- -- -- 815.28 --\n公司董事、高级管理人员报告期内被授予的股权激励情况\n√ 适用 □ 不适用\n单位：股\n报告期内 报告期新 限制性股\n报告期内 报告期内 报告期末 期初持有 本期已解 期末持有\n已行权股 授予限制 票的授予\n姓名 职务 可行权股 已行权股 市价（元/ 限制性股 锁股份数 限制性股\n数行权价 性股票数 价格（元/\n数 数 股） 票数量 量 票数量\n格（元/股） 量 股）\n孙杨 董事长 1,100,000 1,100,000 2.25 0\n董事，总经\n杨思卫 1,100,000 1,100,000 2.25 0\n理\n原副董事\n郭敏龙 1,600,000 1,600,000 4.3125 0\n长\n毛文华 副总经理 600,000 600,000 2.25 0\n副总经理，\n许华青 董事会秘 300,000 300,000 2.25 0\n书\n沈利华 副总经理 300,000 300,000 2.25 0\n洪鸣 董事 150,000 150,000 2.25 0\n李洪明 副总经理 150,000 150,000 2.25 0\n许国睿 副总经理 150,000 150,000 2.25 0\n合计 -- 0 0 -- -- 5,450,000 5,450,000 0 -- 0\n63。",
      "chunk_type": "child",
      "parent_id": "42eff880",
      "child_ids": [],
      "sibling_ids": [
        "27a391c7",
        "08405ae7",
        "4ef331bb",
        "918e48e8"
      ],
      "position": 2,
      "start_char": 1613,
      "end_char": 2619,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.310944",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1006,
        "word_count": 230,
        "sentence_count": 25,
        "chinese_char_count": 414,
        "readability_score": 0.0,
        "information_density": 0.03976143141153081,
        "coherence_score": 0.4549783549783549,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6286282306163022,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "股权",
        "股份",
        "报告"
      ]
    },
    {
      "chunk_id": "4ef331bb",
      "content": "事会秘 300,000 300,000 2.25 0\n书\n沈利华 副总经理 300,000 300,000 2.25 0\n洪鸣 董事 150,000 150,000 2.25 0\n李洪明 副总经理 150,000 150,000 2.25 0\n许国睿 副总经理 150,000 150,000 2.25 0\n合计 -- 0 0 -- -- 5,450,000 5,450,000 0 -- 0\n63。\n\n五、公司员工情况\n1、员工数量、专业构成及教育程度\n母公司在职员工的数量（人） 482\n主要子公司在职员工的数量（人） 2,812\n在职员工的数量合计（人） 3,294\n当期领取薪酬员工总人数（人） 3,294\n母公司及主要子公司需承担费用的离退休职工人数（人） 0\n专业构成\n专业构成类别 专业构成人数（人）\n生产人员 1,769\n销售人员 77\n技术人员 659\n财务人员 53\n行政人员 736\n合计 3,294\n教育程度\n教育程度类别 数量（人）\n硕士及以上 50\n本科 484\n大专 541\n其他学历 2,219\n合计 3,294\n2、薪酬政策\n公司按照《中华人民共和国劳动合同法》和国家及地方其他有关劳动法律、法规的规定，与\n员工签订劳动合同。公司严格执行国家用工制度、劳动保护制度、社会保障制度和医疗保障\n制度，按照国家规定为员工缴纳养老保险、医疗保险、工伤保险、失业保险、生育保险及公\n积金。公司向员工提供稳定而有竞争力的薪酬，实施了公平公正的绩效考核机制。\n\n3、培训计划\n公司一直非常重视员工培训，每年制定并下发年度培训计划，公司培训主要培训内容有GMP\n培训、安全生产培训、专业知识培训、管理能力培训等，采取内培为主，内外结合形式。通\n过培训，提高了公司员工整体的职业素质、专业技能，同时也满足了员工对自身职业能力提\n升的需求。64。\n\n4、劳务外包情况\n□ 适用 √ 不适用\n65 第十节公司治理\n一、公司治理的基本状况\n报告期内，公司严格按照《公司法》、《证券法》、《上市公司治理准则》、《深圳证\n券交易所股票上市规则》等有关法律法规的要求，不断地完善公司治理结构，建立健全内部\n控制制度，并进一步规范公司运作，努力提高公司治理水平。目前，公司整体运作比较规范、\n独立性强、信息披露规范，公司治理实际状况基本符合中国证监会发布的有关上市公司治理\n的规范性文件。",
      "chunk_type": "child",
      "parent_id": "42eff880",
      "child_ids": [],
      "sibling_ids": [
        "27a391c7",
        "08405ae7",
        "9d1030bb",
        "918e48e8"
      ],
      "position": 3,
      "start_char": 2419,
      "end_char": 3414,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.311199",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 995,
        "word_count": 105,
        "sentence_count": 14,
        "chinese_char_count": 619,
        "readability_score": 0.0,
        "information_density": 0.06030150753768845,
        "coherence_score": 0.5787828029034059,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8488442211055276,
      "relevance_score": 1.0,
      "keywords": [
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "母公司",
        "报告",
        "披露",
        "证券"
      ]
    },
    {
      "chunk_id": "918e48e8",
      "content": " √ 不适用\n65 第十节公司治理\n一、公司治理的基本状况\n报告期内，公司严格按照《公司法》、《证券法》、《上市公司治理准则》、《深圳证\n券交易所股票上市规则》等有关法律法规的要求，不断地完善公司治理结构，建立健全内部\n控制制度，并进一步规范公司运作，努力提高公司治理水平。目前，公司整体运作比较规范、\n独立性强、信息披露规范，公司治理实际状况基本符合中国证监会发布的有关上市公司治理\n的规范性文件。公司本报告期内经过股东大会或董事会审议通过正在执行的制度及最新披露时间表如\n下：\n序号 制度名称 披露时间\n1 股东大会议事规则 2007年4月\n2 监事会议事规则 2007年4月\n3 董事会战略委员会议事规则 2007年6月\n4 董事会提名委员会议事规则 2007年6月\n5 董事会审计委员会议事规则 2007年6月\n6 董事会薪酬与考核委员会议事规则 2007年6月\n7 信息披露管理制度（2007年6月修订） 2007年6月\n8 股东大会累计投票制实施细则 2007年6月\n9 独立董事年报工作制度 2008年4月\n10 审计委员会年报工作规程 2008年4月\n11 内部信息保密制度 2008年8月\n12 防范控股股东及关联方资金占用管理办法 2008年8月\n13 董事、监事及高级管理人员薪酬管理制度 2009年4月\n14 突发事件处理制度 2009年10月\n15 首期股票期权激励实施考核办法 2009年12月\n16 年报信息披露重大差错责任追究制度 2010年3月\n17 建设工程招投标管理办法 2011年8月\n18 投资者关系管理制度（2011年9月修订） 2011年9月\n19 重大事项内部报告制度 2011年9月\n20 大股东、实际控制人行为规范及信息问询制度 2011年9月\n21 公司章程（2011年3月修订） 2011年3月\n66。",
      "chunk_type": "child",
      "parent_id": "42eff880",
      "child_ids": [],
      "sibling_ids": [
        "27a391c7",
        "08405ae7",
        "9d1030bb",
        "4ef331bb"
      ],
      "position": 4,
      "start_char": 3214,
      "end_char": 3993,
      "page_number": 60,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          60
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.311403",
        "report_type": "其他",
        "fiscal_year": 2007,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 779,
        "word_count": 78,
        "sentence_count": 3,
        "chinese_char_count": 508,
        "readability_score": 0.0,
        "information_density": 0.10269576379974325,
        "coherence_score": 0.5882540394477231,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8608472400513478,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东",
        "审计",
        "报告",
        "披露",
        "投资者",
        "证券"
      ]
    },
    {
      "chunk_id": "cc41c7f3",
      "content": "22 外部信息使用人管理制度 2012年4月\n23 内幕信息知情人登记管理制度 2012年4月\n24 董事会议事规则(2013年3月修订) 2013年3月\n25 控股子公司管理制度(2013年3月修订) 2013年3月\n26 对外提供财务资助管理制度 2013年3月\n27 募集资金管理制度（2014年4月修订） 2014年4月\n28 公司章程（2015年9月修订） 2015年9月\n29 授权管理制度 2015年12月\n30 风险投资管理制度 2016年1月\n31 公司章程（2016年3月修订） 2016年3月\n32 债务融资工具信息披露事务管理制度 2016年3月\n33 公司章程（2016年10月修订） 2016年10月\n34 衍生品投资管理制度 2017年1月\n35 公司章程（2017年4月修订） 2017年4月\n36 董事、监事和高级管理人员所持公司股份及其变动管理制度（2017 2017年8月\n年8月修订）\n37 公司章程（2018年4月修订） 2018年4月\n38 内部控制缺陷认定标准 2018年4月\n39 公司章程（2019年2月修订） 2019年2月\n40 内部审计制度（2019年2月修订） 2019年2月\n41 公司章程（2019年3月修订） 2019年3月\n公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件是否存在重大差异\n□ 是 √ 否\n公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件不存在重大差异。二、公司相对于控股股东在业务、人员、资产、机构、财务等方面的独立情况\n（一）业务方面：公司拥有独立完整的业务体系和自主经营能力，控股股东按照承诺未\n从事与公司业务相同或相近的业务活动。（二）人员方面：公司拥有独立的人事和劳资管理体系，公司总经理、副总经理、财务\n负责人和董事会秘书等高级管理人员均在本公司领取报酬。\n\n（三）资产方面：公司拥有独立的生产系统、辅助生产系统和配套设施，产、供、销系\n统完整独立。工业产权、商标、非专利技术、房屋所有权、土地所有权等无形资产和有形资\n产均由本公司拥有，产权界定清晰。（四）机构方面：公司设有健全的组织机构体系，股东大会、董事会、监事会及董事会\n下属专业委员会等内部机构独立运作，不受其他单位或个人的干涉。\n\n（五）财务方面：公司设有完整、独立的财务机构，配备了充足的专职财务会计人员，\n建立了独立的会计核算体系和财务管理制度，并独立开设银行账户、独立纳税、独立做出财\n务决策。公司与控股股东在业务、人员、资产、机构、财务等方面完全分开，具有独立完整\n的业务及自主经营能力。",
      "chunk_type": "child",
      "parent_id": "d4fdfa90",
      "child_ids": [],
      "sibling_ids": [
        "5af0429b",
        "b70fad9d",
        "512b46a6"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1092,
      "page_number": 67,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.312525",
        "report_type": "其他",
        "fiscal_year": 2012,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1092,
        "word_count": 78,
        "sentence_count": 8,
        "chinese_char_count": 727,
        "readability_score": 0.0,
        "information_density": 0.13736263736263737,
        "coherence_score": 0.30819136745607334,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8663003663003663,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "融资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "无形资产",
        "经营",
        "股份",
        "股东",
        "审计",
        "披露",
        "融资",
        "债务"
      ]
    },
    {
      "chunk_id": "5af0429b",
      "content": "机构方面：公司设有健全的组织机构体系，股东大会、董事会、监事会及董事会\n下属专业委员会等内部机构独立运作，不受其他单位或个人的干涉。\n\n（五）财务方面：公司设有完整、独立的财务机构，配备了充足的专职财务会计人员，\n建立了独立的会计核算体系和财务管理制度，并独立开设银行账户、独立纳税、独立做出财\n务决策。公司与控股股东在业务、人员、资产、机构、财务等方面完全分开，具有独立完整\n的业务及自主经营能力。三、同业竞争情况\n□ 适用 √ 不适用\n四、报告期内召开的年度股东大会和临时股东大会的有关情况\n1、本报告期股东大会情况\n会议 投资者参\n会议届次 召开日期 披露日期 披露索引\n类型 与比例\n年度 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2018年年度 2019年032019年03\n股东 45.19% 及巨潮资讯网披露的《2018年年度股东大会决议公告》（公告编号：\n股东大会 月11日 月12日\n大会 2019-020）\n2019年第一 临时 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2019年032019年04\n次临时股东大 股东 45.07% 及巨潮资讯网披露的《2019年第一次临时股东大会决议公告》（公\n月29日 月01日\n会 大会 告编号：2019-027）\n2019年第二 临时 详见在《证券时报》、《中国证券报》、《上海证券报》、《证券日报》\n2019年112019年11\n次临时股东大 股东 44.40% 及巨潮资讯网披露的《2019年第二次临时股东大会决议公告》（公\n月13日 月14日\n会 大会 告编号：2019-059）\n2、表决权恢复的优先股股东请求召开临时股东大会\n□ 适用 √ 不适用\n五、报告期内独立董事履行职责的情况\n1、独立董事出席董事会及股东大会的情况\n独立董事出席董事会及股东大会的情况\n是否连续两次\n本报告期应参 现场出席董事 以通讯方式参 委托出席董事 缺席董事会次 出席股东大会\n独立董事姓名 未亲自参加董\n加董事会次数 会次数 加董事会次数 会次数 数 次数\n事会会议\n田利明 5 0 3 2 0否 0\n毛美英 6 3 3 0 0否 3\n苏为科 6 2 3 1 0否 0\n张克坚 1 1 0 0 0否 0\n连续两次未亲自出席董事会的说明\n68。\n\n不适用\n2、独立董事对公司有关事项提出异议的情况\n独立董事对公司有关事项是否提出异议\n□ 是 √ 否\n报告期内独立董事对公司有关事项未提出异议。",
      "chunk_type": "child",
      "parent_id": "d4fdfa90",
      "child_ids": [],
      "sibling_ids": [
        "cc41c7f3",
        "b70fad9d",
        "512b46a6"
      ],
      "position": 1,
      "start_char": 892,
      "end_char": 1939,
      "page_number": 67,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.312764",
        "report_type": "其他",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1047,
        "word_count": 120,
        "sentence_count": 8,
        "chinese_char_count": 697,
        "readability_score": 0.0,
        "information_density": 0.1146131805157593,
        "coherence_score": 0.8415507518796993,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8662846227316141,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "经营",
        "股东",
        "报告",
        "披露",
        "投资者",
        "证券"
      ]
    },
    {
      "chunk_id": "b70fad9d",
      "content": "未亲自参加董\n加董事会次数 会次数 加董事会次数 会次数 数 次数\n事会会议\n田利明 5 0 3 2 0否 0\n毛美英 6 3 3 0 0否 3\n苏为科 6 2 3 1 0否 0\n张克坚 1 1 0 0 0否 0\n连续两次未亲自出席董事会的说明\n68。\n\n不适用\n2、独立董事对公司有关事项提出异议的情况\n独立董事对公司有关事项是否提出异议\n□ 是 √ 否\n报告期内独立董事对公司有关事项未提出异议。3、独立董事履行职责的其他说明\n独立董事对公司有关建议是否被采纳\n√ 是 □ 否\n独立董事对公司有关建议被采纳或未被采纳的说明\n公司独立董事勤勉尽责，严格按照中国证监会的相关规定及《公司章程》、《董事会议\n事规则》和《独立董事制度》开展工作，关注公司运作,独立履行职责,对公司内部控制建设、\n管理体系建设、人才梯队建设和重大决策等方面提出了很多宝贵的专业性建议，对公司财务\n及生产经营活动进行了有效监督，提高了公司决策的科学性，为完善公司监督机制，维护公\n司和全体股东的合法权益发挥了应有的作用。六、董事会下设专门委员会在报告期内履行职责情况\n（一）董事会下设审计委员会的履职情况\n董事会审计委员会在报告期内主要负责公司内部会计控制, 财务报表和公司其他财务事\n项实施监督工作。\n\n依据《中华人民共和国公司法》、《上市公司治理准则》、《董事会审计\n委员会工作细则》等法律规定，对公司内部控制情况进行了定期核查，监督与协助公司与外\n部审计机构的沟通，确保公司内部控制体系依法合规，有效的控制了相关风险的产生。公司\n审计委员会在2019年共召开了五次会议，对定期财务报告、生产经营控制、募集资金使用情\n况、控股股东及关联方资金占用等事项进行审议，并对会计师事务所的年度审计工作进行了\n总结评价，提出续聘会计师事务所的建议。（二）董事会下设的薪酬与考核委员会的履职情况\n公司董事会薪酬与考核委员会在报告期内依照《公司章程》、《董事会薪酬与考核委员\n会议事规则》的相关法律法规勤勉尽职的对公司限制性股票的激励对象作出年度考核审议并\n给出相关意见，同意解锁符合解锁条件激励对象限制性股票。\n\n核查了董事及公司高级管理人\n员的薪酬情况，并对第六届董事会独立董事薪酬进行了审核。（三）董事会下设的提名委员会的履职情况\n报告期内，董事会提名委员会根据《公司法》、《上市公司治理准则》以及《浙江海翔\n药业股份有限公司章程》、《浙江海翔药业股份有限公司董事会提名委员会议事规则》等有\n关法律法规和规章制度的规定，积极履行了职责。报告期内，提名委员会对上一年度董事、\n高管的任职情况进行总结，并对新一届董事、高管进行了提名审核。\n\n（四）董事会下设战略委员会的履职情况\n报告期内，董事会战略委员会勤勉尽职的履行了相关义务，依照《公司章程》、《董事\n会战略委员会议事规则》等相关法律法规对公司经营战略的情况进行了回顾与总结。",
      "chunk_type": "child",
      "parent_id": "d4fdfa90",
      "child_ids": [],
      "sibling_ids": [
        "cc41c7f3",
        "5af0429b",
        "512b46a6"
      ],
      "position": 2,
      "start_char": 1739,
      "end_char": 2939,
      "page_number": 67,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.313003",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "药业股份有限公司",
        "industry": null,
        "char_count": 1200,
        "word_count": 79,
        "sentence_count": 11,
        "chinese_char_count": 994,
        "readability_score": 0.0,
        "information_density": 0.09166666666666666,
        "coherence_score": 0.6841616654163541,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9313333333333333,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "经营",
        "股份",
        "股东",
        "审计",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "512b46a6",
      "content": "程》、《浙江海翔药业股份有限公司董事会提名委员会议事规则》等有\n关法律法规和规章制度的规定，积极履行了职责。报告期内，提名委员会对上一年度董事、\n高管的任职情况进行总结，并对新一届董事、高管进行了提名审核。\n\n（四）董事会下设战略委员会的履职情况\n报告期内，董事会战略委员会勤勉尽职的履行了相关义务，依照《公司章程》、《董事\n会战略委员会议事规则》等相关法律法规对公司经营战略的情况进行了回顾与总结。2019年\n董事会战略委员会共召开二次会议，在对当前市场状况、公司实际情况的合理分析后给出了\n公司今后战略发展的方向以及合理的实施建议。并对公司对外投资参与设立合伙企业事项给\n69。\n\n出了建设性的建议和意见。七、监事会工作情况\n监事会在报告期内的监督活动中发现公司是否存在风险\n□ 是 √ 否\n监事会对报告期内的监督事项无异议。八、高级管理人员的考评及激励情况\n公司按照《董事、监事、高级管理人员薪酬管理制度》，建立了高级管理人员的薪酬与\n公司业绩挂钩的绩效考核与激励约束机制，公司高级管理人员实行基本年薪和年终绩效考核\n相结合的薪酬制度。\n\n规范董事、监事、高级管理人员薪酬决策机制。年末根据公司年度经营\n目标完成情况以及高级管理人员的工作业绩，由董事会薪酬与考核委员会对高级管理人员进\n行年度绩效考核，并监督薪酬制度执行情况。公司则根据绩效考核结果兑现其绩效年薪，并\n进行奖惩。\n\n公司董事会薪酬与考核委员会根据实际情况对公司董事、监事及高级管理人员进\n行考核后，一致认为：公司2019年度董事、高管薪酬方案严格执行董事及高级管理人员薪酬\n和考核管理制度，与公司经营业绩挂钩，董事、高管薪酬方案合理，薪酬发放的程序符合有\n关法律、法规及《公司章程》的规定。九、内部控制评价报告\n1、报告期内发现的内部控制重大缺陷的具体情况\n□ 是 √ 否\n2、内控自我评价报告\n内部控制评价报告全文披露日期 2020年01月23日\n详见本公司于2020年1月23日在巨潮资讯网披露的《2019年度内部控制自我评\n内部控制评价报告全文披露索引\n价报告》\n纳入评价范围单位资产总额占公司合并\n100.00%\n财务报表资产总额的比例\n纳入评价范围单位营业收入占公司合并\n100.00%\n财务报表营业收入的比例\n缺陷认定标准\n类别 财务报告 非财务报告\n70。",
      "chunk_type": "child",
      "parent_id": "d4fdfa90",
      "child_ids": [],
      "sibling_ids": [
        "cc41c7f3",
        "5af0429b",
        "b70fad9d"
      ],
      "position": 3,
      "start_char": 2739,
      "end_char": 3710,
      "page_number": 67,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          67
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.313236",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 971,
        "word_count": 49,
        "sentence_count": 15,
        "chinese_char_count": 806,
        "readability_score": 0.0,
        "information_density": 0.16477857878475796,
        "coherence_score": 0.7559781290138433,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9320288362512874,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "投资",
        "营业收入",
        "合并",
        "营业",
        "经营",
        "经营业绩",
        "股份",
        "报告"
      ]
    },
    {
      "chunk_id": "1a1c674f",
      "content": "重大缺陷：1、公司董事、监事或高级\n管理人员缺乏应有的胜任能力，或高级\n管理人员流失严重； 2、公司组织架构、\n业务流程存在重大缺陷，权责分配严重\n不合理，缺乏科学决策、良性运行机制\n和执行力； 3、公司对外担保业务未根\n据相关法律法规经过适当审批； 4、公\n司资产管理制度存在重大缺陷，大量长\n期资产使用效能低下，维护不当，存货\n严重积压或短缺； 5、公司核心技术管\n理存在缺陷，核心技术人员流失严重，\n核心技术已经出现严重过时的迹象；\n6、公司信息系统存在重大漏洞，导致\n内部相关数据收集、处理或传递错误或\n严重延误，或重要商业机密被泄露； 7、\n公司的安全生产管理、环保管理存在重\n重大缺陷：1、公司董事、监事或高级管理大缺陷，安全、环保事故频发，引起政\n人员舞弊；2、公司更正已公告的财务报告；府或监管机构调查或处罚； 8、公司的\n3、注册会计师发现未被公司内部控制识别质量管理存在重大缺陷，出现重大质量\n的当期财务报告重大错报；4、公司对重大问题引起政府或监管机构调查或引发\n经济业务的会计处理违反会计法律法规或 诉讼； 9、已向管理层汇报但经过合理\n《企业会计准则》； 5、公司随意变更会计期限后，管理层仍然没有对非财务报告\n政策或会计估计，导致相关财务信息严重 内部控制重大缺陷进行整改。重要缺\n失真； 6、公司缺乏对外提供财务报告的 陷：1、公司关键岗位人员缺乏应有的\n流程、审批权限等正式制度，或制度完全 胜任能力，或关键岗位人员流失严重；\n未得到执行；7、因财务报告相关的信息披2、公司组织架构、业务流程存在重要\n露差错导致监管机构处罚；8、公司凭证、缺陷，重要机构设计不合理，职能交叉\n账簿、报表等会计资料管理混乱，未按照 或缺失，运行效率低下；3、公司对外\n相关法律法规整理、归档或保存；9、已向担保业务虽经过适当审批，但存在重要\n管理层汇报但经过合理期限后，管理层仍 潜在经济损失风险；4、公司资产管理\n然没有对财务报告内部控制重大缺陷进行 制度存在重要缺陷，部分长期资产使用\n整改。",
      "chunk_type": "child",
      "parent_id": "84cc49d3",
      "child_ids": [],
      "sibling_ids": [
        "5e688650",
        "6fdb2b94",
        "0b27533c",
        "70116ff4"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 855,
      "page_number": 71,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.314431",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 855,
        "word_count": 48,
        "sentence_count": 2,
        "chinese_char_count": 702,
        "readability_score": 0.0,
        "information_density": 0.0935672514619883,
        "coherence_score": 0.7433734939759036,
        "standards_profile_summary": {}
      },
      "quality_score": 0.928421052631579,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "存货",
        "分配",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "5e688650",
      "content": "架构、业务流程存在重要\n露差错导致监管机构处罚；8、公司凭证、缺陷，重要机构设计不合理，职能交叉\n账簿、报表等会计资料管理混乱，未按照 或缺失，运行效率低下；3、公司对外\n相关法律法规整理、归档或保存；9、已向担保业务虽经过适当审批，但存在重要\n管理层汇报但经过合理期限后，管理层仍 潜在经济损失风险；4、公司资产管理\n然没有对财务报告内部控制重大缺陷进行 制度存在重要缺陷，部分长期资产使用\n整改。重大缺陷：1、公司关键岗位人员舞效能低下，维护不当，大量存货积压或\n弊；2、注册会计师发现未被公司内部控制短缺；5、公司重要技术管理存在缺陷，\n识别的当期财务报告重要错报；3、对重要重要技术人员流失严重，关键技术出现\n定性标准\n经济业务的会计处理违反会计法律法规或 过时的迹象；6、公司信息系统的关键\n《企业会计准则》；4、公司频繁变更会计 环节存在漏洞，导致部分环节内部相关\n政策或会计估计，导致相关财务信息不具 数据收集、处理或传递错误或不及时，\n有可比性；5、公司虽有对外提供财务报告或商业机密存在被泄露的风险；7、公\n的正式制度，但制度未得到完全执行，对 司的安全生产管理、环保管理存在重要\n外信息披露未经适当审批或授权；6、公司缺陷，出现重要的安全、环保事故，引\n凭证、账簿、报表等会计资料管理部分环 起政府或监管机构关注；8、公司的质\n节存在漏洞，相关资料存在丢失、毁损或 量管理存在重要缺陷，出现重要质量问\n被未授权人员接触的风险； 7、已向管理 题引起大宗产品退货；9、已向管理层\n层汇报但经过合理期限后，管理层仍然没 汇报但经过合理期限后，管理层仍然没\n有对财务报告内部控制重要缺陷进行整 有对非财务报告内部控制。\n\n一般缺陷：\n改。一般缺陷：1、公司一般岗位人员舞 1、公司一般岗位人员缺乏应有的胜任\n71\n弊；2、注册会计师发现未被公司内部控制能力，或普通岗位人员流失严重；2、\n识别的当期财务报告一般错报；3、已向管公司组织架构、业务流程存在一般缺\n理层汇报但经过合理期限后，管理层仍然 陷，部分机构设计不合理，职能重叠，。\n\n重大缺陷 1、利润总额潜在错报：错报≥\n利润总额的10%或4000万元 2、资产总额\n潜在错报：错报≥资产总额的1% 3、经营\n收入潜在错报：错报≥营业收入的3 % 4、\n所有者权益潜在错报：错报≥所有者权益的\n2%； 重要缺陷 1、利润总额潜在错报：\n错报≥利润总额的5%<利润总额的10%或 重大缺陷非财务报告内部控制缺陷导\n利润总额2000万元≤错报<利润总额4000 致的直接财产损失金额≥利润总额的\n万元 2、资产总额潜在错报：资产总额的10%；重要缺陷利润总额的10%＞非财\n定量标准 0.5%≤错报<资产总额的1% 3、经营收 务报告内部控制缺陷导致的直接财产\n入潜在错报：营业收入的1.5%≤错报<经营损失金额≥利润总额的5%。",
      "chunk_type": "child",
      "parent_id": "84cc49d3",
      "child_ids": [],
      "sibling_ids": [
        "1a1c674f",
        "6fdb2b94",
        "0b27533c",
        "70116ff4"
      ],
      "position": 1,
      "start_char": 655,
      "end_char": 1853,
      "page_number": 71,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.314647",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1198,
        "word_count": 66,
        "sentence_count": 7,
        "chinese_char_count": 939,
        "readability_score": 0.0,
        "information_density": 0.15859766277128545,
        "coherence_score": 0.7261702376770871,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9135225375626044,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "利润",
        "经营",
        "财务",
        "报表",
        "4000万元",
        "2000万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "利润",
        "存货",
        "营业收入",
        "利润总额",
        "营业",
        "经营",
        "报告"
      ]
    },
    {
      "chunk_id": "6fdb2b94",
      "content": "在错报：\n错报≥利润总额的5%<利润总额的10%或 重大缺陷非财务报告内部控制缺陷导\n利润总额2000万元≤错报<利润总额4000 致的直接财产损失金额≥利润总额的\n万元 2、资产总额潜在错报：资产总额的10%；重要缺陷利润总额的10%＞非财\n定量标准 0.5%≤错报<资产总额的1% 3、经营收 务报告内部控制缺陷导致的直接财产\n入潜在错报：营业收入的1.5%≤错报<经营损失金额≥利润总额的5%。一般缺陷非\n收入的3% 4、所有者权益潜在错报：所 财务报告内部控制缺陷导致的直接财\n有者权益1%≤错报<所有者权益的2%； 一产损失金额＜利润总额的5%。般缺陷 1、利润总额潜在错报：错报<利润\n总额的5%或错报<利润总额的2000万元\n2、资产总额潜在错报：错报<资产总额的\n0.5% 3、经营收入潜在错报：错报<营\n业收入的1.5% 4、所有者权益潜在错\n报：错报<所有者权益的1%\n财务报告重大缺陷数量（个） 0\n非财务报告重大缺陷数量（个） 0\n财务报告重要缺陷数量（个） 0\n非财务报告重要缺陷数量（个） 0\n十、内部控制审计报告或鉴证报告\n内部控制鉴证报告\n内部控制鉴证报告中的审议意见段\n我们认为，海翔药业公司按照深圳证券交易所《中小企业板上市公司规范运作指引(2015年修订)》规定于2019年12月31\n日在所有重大方面保持了有效的财务报告内部控制。\n\n内控鉴证报告披露情况 披露\n内部控制鉴证报告全文披露日期 2020年01月23日\n内部控制鉴证报告全文披露索引 巨潮资讯网\n内控鉴证报告意见类型 标准无保留意见\n非财务报告是否存在重大缺陷 否\n会计师事务所是否出具非标准意见的内部控制审计报告\n□ 是 √ 否\n会计师事务所出具的内部控制审计报告与董事会的自我评价报告意见是否一致\n√ 是 □ 否\n72。\n\n第十一节公司债券相关情况\n公司是否存在公开发行并在证券交易所上市，且在年度报告批准报出日未到期或到期未能全额兑付的公司债券\n否\n73 第十二节 财务报告\n一、审计报告\n审计意见类型 标准的无保留意见\n审计报告签署日期 2020年01月22日\n审计机构名称 天健会计师事务所（特殊普通合伙）\n审计报告文号 天健审〔2020〕58号\n注册会计师姓名 沈维华 汪兢\n审计报告正文\n审 计 报 告\n天健审〔2020〕58号\n浙江海翔药业股份有限公司全体股东：\n一、审计意见\n我们审计了浙江海翔药业股份有限公司（以下简称海翔药业公司）财务报表，包括 2019\n年12月31日的合并及母公司资产负债表，2019年度的合并及母公司利润表、合并及母公司\n现金流量表、合并及母公司所有者权益变动表，以及相关财务报表附注。",
      "chunk_type": "child",
      "parent_id": "84cc49d3",
      "child_ids": [],
      "sibling_ids": [
        "1a1c674f",
        "5e688650",
        "0b27533c",
        "70116ff4"
      ],
      "position": 2,
      "start_char": 1653,
      "end_char": 2769,
      "page_number": 71,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.314905",
        "report_type": "其他",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1116,
        "word_count": 89,
        "sentence_count": 9,
        "chinese_char_count": 828,
        "readability_score": 0.0,
        "information_density": 0.17921146953405018,
        "coherence_score": 0.8155510092335945,
        "standards_profile_summary": {}
      },
      "quality_score": 0.896774193548387,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "现金流",
        "经营",
        "财务",
        "报表",
        "2000万元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "现金",
        "营业收入",
        "利润总额",
        "资产负债表",
        "利润表"
      ]
    },
    {
      "chunk_id": "0b27533c",
      "content": " 天健审〔2020〕58号\n注册会计师姓名 沈维华 汪兢\n审计报告正文\n审 计 报 告\n天健审〔2020〕58号\n浙江海翔药业股份有限公司全体股东：\n一、审计意见\n我们审计了浙江海翔药业股份有限公司（以下简称海翔药业公司）财务报表，包括 2019\n年12月31日的合并及母公司资产负债表，2019年度的合并及母公司利润表、合并及母公司\n现金流量表、合并及母公司所有者权益变动表，以及相关财务报表附注。我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了\n海翔药业公司 2019 年 12 月 31 日的合并及母公司财务状况，以及 2019 年度的合并及母公司\n经营成果和现金流量。二、形成审计意见的基础\n我们按照中国注册会计师审计准则的规定执行了审计工作。\n\n审计报告的“注册会计师对\n财务报表审计的责任”部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职\n业道德守则，我们独立于海翔药业公司，并履行了职业道德方面的其他责任。我们相信，我\n们获取的审计证据是充分、适当的，为发表审计意见提供了基础。\n\n三、关键审计事项\n关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这些事\n项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不\n对这些事项单独发表意见。(一) 收入确认\n1. 事项描述\n相关信息披露详见财务报表附注三(二十三)及附注五(二)1。\n\n海翔药业公司的营业收入主要来自于原料药及医药中间体和染料及染颜料中间体。2019\n74。\n\n年度，海翔药业公司财务报表所示营业收入项目金额为人民币 2,941,412,770.30 元(合并财\n务报表口径，下同)，其中主营业务收入为人民币2,925,688,906.14元，占营业收入的99.47%。如财务报表附注重要会计政策及会计估计所示，海翔药业公司产品销售区域分为国内和国外，\n且需要根据不同的手续进行收入确认。由于营业收入是海翔药业公司关键业绩指标之一，可能存在海翔药业公司管理层（以下\n简称管理层）通过不恰当的收入确认以达到特定目标或预期的固有风险。\n\n因此，我们将收入\n确认确定为关键审计事项。",
      "chunk_type": "child",
      "parent_id": "84cc49d3",
      "child_ids": [],
      "sibling_ids": [
        "1a1c674f",
        "5e688650",
        "6fdb2b94",
        "70116ff4"
      ],
      "position": 3,
      "start_char": 2569,
      "end_char": 3479,
      "page_number": 71,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.315151",
        "report_type": "其他",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 910,
        "word_count": 49,
        "sentence_count": 19,
        "chinese_char_count": 713,
        "readability_score": 0.0,
        "information_density": 0.2197802197802198,
        "coherence_score": 0.6936380533137687,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9134065934065934,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "现金流",
        "经营",
        "财务",
        "报表",
        "906.14元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "现金",
        "营业收入",
        "资产负债表",
        "利润表",
        "现金流量表"
      ]
    },
    {
      "chunk_id": "70116ff4",
      "content": "下同)，其中主营业务收入为人民币2,925,688,906.14元，占营业收入的99.47%。如财务报表附注重要会计政策及会计估计所示，海翔药业公司产品销售区域分为国内和国外，\n且需要根据不同的手续进行收入确认。由于营业收入是海翔药业公司关键业绩指标之一，可能存在海翔药业公司管理层（以下\n简称管理层）通过不恰当的收入确认以达到特定目标或预期的固有风险。\n\n因此，我们将收入\n确认确定为关键审计事项。2. 审计应对\n针对收入确认，我们实施的审计程序主要包括：\n(1) 了解与收入确认相关的关键内部控制，评价其设计和执行是否有效，并测试相关内\n部控制的运行有效性；\n(2) 检查主要的销售合同，识别与商品所有权上的主要风险和报酬转移相关的条款，评\n价收入确认政策是否符合企业会计准则的规定；\n(3) 对收入和成本执行分析程序，判断销售收入和毛利变动的合理性；\n(4) 对于内销收入，以抽样方式检查与收入确认相关的支持性文件，包括销售合同、销\n售发票、出库单及签收单据等；对于出口收入，向海关直接获取报关出口数据并与账面记录\n核对，并以抽样方式检查销售合同、出口报关单、货运提单、销售发票等支持性文件；\n(5) 结合应收账款函证，以抽样方式向主要客户函证本期销售额；\n(6) 针对资产负债表日前后确认的销售收入执行截止性测试；\n(7) 检查与营业收入相关的信息是否已在财务报表中作出恰当列报。(二) 商誉减值\n1. 事项描述\n相关信息披露详见财务报表附注三(十八)及附注五(一)17。",
      "chunk_type": "child",
      "parent_id": "84cc49d3",
      "child_ids": [],
      "sibling_ids": [
        "1a1c674f",
        "5e688650",
        "6fdb2b94",
        "0b27533c"
      ],
      "position": 4,
      "start_char": 3279,
      "end_char": 3919,
      "page_number": 71,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          71
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.315336",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 640,
        "word_count": 29,
        "sentence_count": 10,
        "chinese_char_count": 517,
        "readability_score": 0.0,
        "information_density": 0.265625,
        "coherence_score": 0.7059113300492611,
        "standards_profile_summary": {}
      },
      "quality_score": 0.923125,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "财务",
        "报表",
        "906.14元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "应收",
        "商誉",
        "营业收入",
        "资产负债表",
        "营业",
        "审计"
      ]
    },
    {
      "chunk_id": "682ee735",
      "content": "截至 2019 年 12 月 31 日，海翔药业公司合并财务报表中商誉的账面价值为\n757,736,770.14元。管理层于每年年度终了对企业合并所形成的商誉进行减值测试，相关资\n产组或资产组组合的可收回金额按照预计未来现金流量现值计算确定。减值测试中采用的关\n键假设包括：详细预测期收入增长率、永续预测期增长率、毛利率、折现率等。\n\n由于商誉金额重大，且商誉减值测试涉及重大管理层判断，我们将商誉减值确定为关键\n审计事项。2. 审计中的应对\n针对商誉减值，我们实施的审计程序主要包括：\n(1) 了解与商誉确认相关的关键内部控制，评价其设计和执行是否有效，并测试相关内\n部控制的运行有效性；\n(2) 复核管理层以前年度对未来现金流量现值的预测和实际经营结果，评价管理层过往\n预测的准确性；\n(3) 了解并评价管理层聘用的外部估值专家的胜任能力、专业素质和客观性；\n(4) 评价管理层在减值测试中使用方法的合理性和一致性；\n(5) 了解海翔药业公司商誉所属资产组的认定和进行商誉减值测试时采用的关键假设和\n方法，并与公司管理层和外部估值专家讨论，评价相关的假设和方法的合理性，复核相关假\n设是否与总体经济环境、行业状况、经营情况、历史经验、运营计划、管理层使用的与财务\n报表相关的其他假设等相符；\n75。\n\n(6) 通过比照相关资产组的历史表现以及经营发展计划，复核现金流量预测水平和所采\n用折现率的合理性，测试管理层对预计未来现金流量现值的计算是否准确；\n(7) 测试管理层在减值测试中使用数据的准确性、完整性和相关性，并复核减值测试中\n有关信息的内在一致性；\n(8) 检查与商誉减值相关的信息是否已在财务报表中作出恰当列报。四、其他信息\n管理层对其他信息负责。其他信息包括年度报告中涵盖的信息，但不包括财务报表和我\n们的审计报告。\n\n我们对财务报表发表的审计意见不涵盖其他信息，我们也不对其他信息发表任何形式的\n鉴证结论。结合我们对财务报表的审计，我们的责任是阅读其他信息，在此过程中，考虑其他信息\n是否与财务报表或我们在审计过程中了解到的情况存在重大不一致或者似乎存在重大错报。基于我们已执行的工作，如果我们确定其他信息存在重大错报，我们应当报告该事实。\n\n在这方面，我们无任何事项需要报告。五、管理层和治理层对财务报表的责任\n管理层负责按照企业会计准则的规定编制财务报表，使其实现公允反映，并设计、执行\n和维护必要的内部控制，以使财务报表不存在由于舞弊或错误导致的重大错报。在编制财务报表时，管理层负责评估海翔药业公司的持续经营能力，披露与持续经营相\n关的事项（如适用），并运用持续经营假设，除非计划进行清算、终止运营或别无其他现实的\n选择。\n\n海翔药业公司治理层（以下简称治理层）负责监督海翔药业公司的财务报告过程。",
      "chunk_type": "child",
      "parent_id": "5844ad06",
      "child_ids": [],
      "sibling_ids": [
        "2155473f",
        "11c2f84a"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1162,
      "page_number": 75,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          75
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.316196",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1162,
        "word_count": 49,
        "sentence_count": 17,
        "chinese_char_count": 988,
        "readability_score": 0.0,
        "information_density": 0.14629948364888126,
        "coherence_score": 0.6845612752903529,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9401032702237522,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "现金流",
        "经营",
        "财务",
        "报表",
        "770.14元"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "现金",
        "商誉",
        "合并",
        "毛利率",
        "经营",
        "审计",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "2155473f",
      "content": "的责任\n管理层负责按照企业会计准则的规定编制财务报表，使其实现公允反映，并设计、执行\n和维护必要的内部控制，以使财务报表不存在由于舞弊或错误导致的重大错报。在编制财务报表时，管理层负责评估海翔药业公司的持续经营能力，披露与持续经营相\n关的事项（如适用），并运用持续经营假设，除非计划进行清算、终止运营或别无其他现实的\n选择。\n\n海翔药业公司治理层（以下简称治理层）负责监督海翔药业公司的财务报告过程。六、注册会计师对财务报表审计的责任\n我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大错报获取合理保\n证，并出具包含审计意见的审计报告。合理保证是高水平的保证，但并不能保证按照审计准\n则执行的审计在某一重大错报存在时总能发现。\n\n错报可能由于舞弊或错误导致，如果合理预\n期错报单独或汇总起来可能影响财务报表使用者依据财务报表作出的经济决策，则通常认为\n错报是重大的。在按照审计准则执行审计工作的过程中，我们运用职业判断，并保持职业怀疑。同时，\n我们也执行以下工作：\n(一) 识别和评估由于舞弊或错误导致的财务报表重大错报风险，设计和实施审计程序以\n应对这些风险，并获取充分、适当的审计证据，作为发表审计意见的基础。\n\n由于舞弊可能涉\n及串通、伪造、故意遗漏、虚假陈述或凌驾于内部控制之上，未能发现由于舞弊导致的重大\n错报的风险高于未能发现由于错误导致的重大错报的风险。(二) 了解与审计相关的内部控制，以设计恰当的审计程序，但目的并非对内部控制的有\n效性发表意见。(三) 评价管理层选用会计政策的恰当性和作出会计估计及相关披露的合理性。\n\n(四) 对管理层使用持续经营假设的恰当性得出结论。同时，根据获取的审计证据，就可\n能导致对海翔药业公司持续经营能力产生重大疑虑的事项或情况是否存在重大不确定性得出\n结论。如果我们得出结论认为存在重大不确定性，审计准则要求我们在审计报告中提请报表\n使用者注意财务报表中的相关披露；如果披露不充分，我们应当发表非无保留意见。\n\n结论基于截至审计报告日可获得的信息。然而，未来的事项或情况可能导致海翔药业公司不\n能持续经营。(五) 评价财务报表的总体列报、结构和内容，并评价财务报表是否公允反映相关交易和\n事项。\n\n(六) 就海翔药业公司中实体或业务活动的财务信息获取充分、适当的审计证据，以对财\n务报表发表审计意见。我们负责指导、监督和执行集团审计，并对审计意见承担全部责任。我们与治理层就计划的审计范围、时间安排和重大审计发现等事项进行沟通，包括沟通\n我们在审计中识别出的值得关注的内部控制缺陷。\n\n我们还就已遵守与独立性相关的职业道德要求向治理层提供声明，并与治理层沟通可能\n被合理认为影响我们独立性的所有关系和其他事项，以及相关的防范措施（如适用）。从与治理层沟通过的事项中，我们确定哪些事项对本期财务报表审计最为重要，因而构\n成关键审计事项。",
      "chunk_type": "child",
      "parent_id": "5844ad06",
      "child_ids": [],
      "sibling_ids": [
        "682ee735",
        "11c2f84a"
      ],
      "position": 1,
      "start_char": 962,
      "end_char": 2160,
      "page_number": 75,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          75
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.316444",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1198,
        "word_count": 38,
        "sentence_count": 22,
        "chinese_char_count": 1068,
        "readability_score": 0.0,
        "information_density": 0.07512520868113523,
        "coherence_score": 0.6754331633279002,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9565943238731218,
      "relevance_score": 1.0,
      "keywords": [
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "经营",
        "审计",
        "报告",
        "财务报告",
        "审计报告",
        "披露"
      ]
    },
    {
      "chunk_id": "11c2f84a",
      "content": "并对审计意见承担全部责任。我们与治理层就计划的审计范围、时间安排和重大审计发现等事项进行沟通，包括沟通\n我们在审计中识别出的值得关注的内部控制缺陷。\n\n我们还就已遵守与独立性相关的职业道德要求向治理层提供声明，并与治理层沟通可能\n被合理认为影响我们独立性的所有关系和其他事项，以及相关的防范措施（如适用）。从与治理层沟通过的事项中，我们确定哪些事项对本期财务报表审计最为重要，因而构\n成关键审计事项。我们在审计报告中描述这些事项，除非法律法规禁止公开披露这些事项，\n或在极少数情形下，如果合理预期在审计报告中沟通某事项造成的负面后果超过在公众利益\n方面产生的益处，我们确定不应在审计报告中沟通该事项。",
      "chunk_type": "child",
      "parent_id": "5844ad06",
      "child_ids": [],
      "sibling_ids": [
        "682ee735",
        "2155473f"
      ],
      "position": 2,
      "start_char": 1960,
      "end_char": 2260,
      "page_number": 75,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          75
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.316636",
        "report_type": "其他",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 300,
        "word_count": 7,
        "sentence_count": 5,
        "chinese_char_count": 276,
        "readability_score": 0.0,
        "information_density": 0.2,
        "coherence_score": 0.7093750000000001,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8480000000000001,
      "relevance_score": 1.0,
      "keywords": [
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "其他"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "审计",
        "报告",
        "审计报告",
        "披露"
      ]
    },
    {
      "chunk_id": "4da43839",
      "content": "天健会计师事务所（特殊普通合伙） 中国注册会计师：沈维华\n（项目合伙人）\n中国·杭州 中国注册会计师：汪兢\n二〇二〇年一月二十二日\n二、财务报表\n财务附注中报表的单位为：元\n1、合并资产负债表\n编制单位：浙江海翔药业股份有限公司\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,556,575,372.45 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n77。\n\n应收票据 107,399,476.04\n应收账款 459,781,564.19 479,537,782.06\n应收款项融资 74,531,666.41\n预付款项 33,851,486.79 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 18,297,536.18 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 842,985,260.60 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动资产\n其他流动资产 76,406,931.14 227,882,993.23\n流动资产合计 3,062,429,817.76 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 47,879,382.43 66,088,139.79\n其他权益工具投资 20,000,000.00\n其他非流动金融资产\n投资性房地产 11,206,951.46 12,338,615.29\n固定资产 1,724,407,333.34 1,215,120,643.61\n在建工程 560,674,634.43 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 533,455,319.46 539,514,850.87\n78。",
      "chunk_type": "child",
      "parent_id": "c06540ba",
      "child_ids": [],
      "sibling_ids": [
        "01ec69a9",
        "7884ee5b",
        "ff9c20fa",
        "fc61782c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 865,
      "page_number": 77,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.317792",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 865,
        "word_count": 86,
        "sentence_count": 30,
        "chinese_char_count": 348,
        "readability_score": 0.0,
        "information_density": 0.19653179190751444,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7036994219653179,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "投资",
        "应收",
        "预付",
        "存货",
        "固定资产",
        "无形资产",
        "资产负债表"
      ]
    },
    {
      "chunk_id": "01ec69a9",
      "content": "\n其他权益工具投资 20,000,000.00\n其他非流动金融资产\n投资性房地产 11,206,951.46 12,338,615.29\n固定资产 1,724,407,333.34 1,215,120,643.61\n在建工程 560,674,634.43 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 533,455,319.46 539,514,850.87\n78。\n\n开发支出\n商誉 757,736,770.14 757,736,770.14\n长期待摊费用 1,618,771.89 1,842,423.21\n递延所得税资产 27,339,683.56 32,487,223.69\n其他非流动资产 450,000.00 515,993.37\n非流动资产合计 3,684,768,846.71 3,301,778,337.96\n资产总计 6,747,198,664.47 7,035,373,344.57\n流动负债：\n短期借款 200,267,029.59 598,700,000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其变动计入当\n期损益的金融负债\n衍生金融负债\n应付票据 238,306,005.00 490,006,533.85\n应付账款 363,440,583.96 301,908,929.93\n预收款项 12,919,749.09 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n代理承销证券款\n应付职工薪酬 52,367,142.28 45,234,354.42\n应交税费 44,781,205.55 54,890,661.34\n其他应付款 28,200,073.22 24,723,304.20\n其中：应付利息 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 940,281,788.69 1,579,026,351.68\n79。",
      "chunk_type": "child",
      "parent_id": "c06540ba",
      "child_ids": [],
      "sibling_ids": [
        "4da43839",
        "7884ee5b",
        "ff9c20fa",
        "fc61782c"
      ],
      "position": 1,
      "start_char": 665,
      "end_char": 1574,
      "page_number": 77,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.317993",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 909,
        "word_count": 86,
        "sentence_count": 43,
        "chinese_char_count": 258,
        "readability_score": 0.0,
        "information_density": 0.16501650165016502,
        "coherence_score": 0.3033333333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.47953795379537956,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "投资",
        "应付",
        "预收",
        "固定资产",
        "无形资产",
        "商誉"
      ]
    },
    {
      "chunk_id": "7884ee5b",
      "content": "5 54,890,661.34\n其他应付款 28,200,073.22 24,723,304.20\n其中：应付利息 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 940,281,788.69 1,579,026,351.68\n79。\n\n非流动负债：\n保险合同准备金\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 1,333,333.00 12,971,002.47\n递延收益 50,594,091.52 44,650,629.91\n递延所得税负债 30,527,355.71 8,175,428.28\n其他非流动负债\n非流动负债合计 82,454,780.23 65,797,060.66\n负债合计 1,022,736,568.92 1,644,823,412.34\n所有者权益：\n股本 1,618,715,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,670,350,322.00 2,663,367,822.47\n减：库存股 301,511,513.90 325,880,561.68\n其他综合收益 -1,490,188.81 -51,779.23\n专项储备\n盈余公积 213,069,824.31 201,812,279.17\n一般风险准备\n未分配利润 1,525,328,398.95 1,232,481,918.50\n归属于母公司所有者权益合计 5,724,462,095.55 5,390,549,932.23\n少数股东权益\n所有者权益合计 5,724,462,095.55 5,390,549,932.23\n负债和所有者权益总计 6,747,198,664.47 7,035,373,344.57\n法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n80。",
      "chunk_type": "child",
      "parent_id": "c06540ba",
      "child_ids": [],
      "sibling_ids": [
        "4da43839",
        "01ec69a9",
        "ff9c20fa",
        "fc61782c"
      ],
      "position": 2,
      "start_char": 1374,
      "end_char": 2250,
      "page_number": 77,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.318205",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 876,
        "word_count": 83,
        "sentence_count": 39,
        "chinese_char_count": 254,
        "readability_score": 0.0,
        "information_density": 0.14840182648401828,
        "coherence_score": 0.31999999999999995,
        "standards_profile_summary": {}
      },
      "quality_score": 0.604337899543379,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "利润",
        "应付",
        "所得税",
        "股东权益",
        "母公司",
        "股本",
        "资本公积",
        "未分配利润"
      ]
    },
    {
      "chunk_id": "ff9c20fa",
      "content": ".95 1,232,481,918.50\n归属于母公司所有者权益合计 5,724,462,095.55 5,390,549,932.23\n少数股东权益\n所有者权益合计 5,724,462,095.55 5,390,549,932.23\n负债和所有者权益总计 6,747,198,664.47 7,035,373,344.57\n法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n80。\n\n2、母公司资产负债表\n单位：元\n项目 2019年12月31日 2018年12月31日\n流动资产：\n货币资金 1,200,455,459.03 983,565,710.16\n交易性金融资产\n以公允价值计量且其变动计入当\n期损益的金融资产\n衍生金融资产\n应收票据 20,885,763.88\n应收账款 123,532,244.19 149,204,899.98\n应收款项融资 6,422,715.29\n预付款项 2,178,567.27 5,554,458.78\n其他应收款 467,513,480.14 1,043,055,918.72\n其中：应收利息\n应收股利 7,222,088,153.34\n存货 96,708,887.42 84,396,333.98\n合同资产\n持有待售资产\n一年内到期的非流动资产\n其他流动资产 2,586,704.73 105,920,135.97\n流动资产合计 1,899,398,058.07 2,392,583,221.47\n非流动资产：\n债权投资\n可供出售金融资产 23,017,502.51\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,247,420,801.54 3,250,556,852.85\n其他权益工具投资 43,017,502.51\n其他非流动金融资产\n投资性房地产 15,051,583.93 16,409,402.65\n固定资产 190,528,741.25 182,948,202.54\n在建工程 5,125,110.57 20,490,208.35\n81。",
      "chunk_type": "child",
      "parent_id": "c06540ba",
      "child_ids": [],
      "sibling_ids": [
        "4da43839",
        "01ec69a9",
        "7884ee5b",
        "fc61782c"
      ],
      "position": 3,
      "start_char": 2050,
      "end_char": 2916,
      "page_number": 77,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.318404",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 866,
        "word_count": 80,
        "sentence_count": 37,
        "chinese_char_count": 266,
        "readability_score": 0.0,
        "information_density": 0.17321016166281755,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5787528868360277,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "投资",
        "应收",
        "预付",
        "存货",
        "固定资产",
        "资产负债表",
        "股东权益"
      ]
    },
    {
      "chunk_id": "fc61782c",
      "content": "其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,247,420,801.54 3,250,556,852.85\n其他权益工具投资 43,017,502.51\n其他非流动金融资产\n投资性房地产 15,051,583.93 16,409,402.65\n固定资产 190,528,741.25 182,948,202.54\n在建工程 5,125,110.57 20,490,208.35\n81。\n\n生产性生物资产\n油气资产\n使用权资产\n无形资产 15,682,148.91 17,059,632.32\n开发支出\n商誉\n长期待摊费用\n递延所得税资产 6,054,576.79 9,371,365.80\n其他非流动资产 450,000.00\n非流动资产合计 3,523,330,465.50 3,519,853,167.02\n资产总计 5,422,728,523.57 5,912,436,388.49\n流动负债：\n短期借款 200,267,029.59 287,000,000.00\n交易性金融负债\n以公允价值计量且其变动计入当\n期损益的金融负债\n衍生金融负债\n应付票据 178,855,770.00 202,286,262.85\n应付账款 21,476,176.18 25,423,635.65\n预收款项 4,099,111.19 7,777,982.57\n合同负债\n应付职工薪酬 7,965,755.58 6,439,699.82\n应交税费 12,495,191.97 948,517.30\n其他应付款 98,040,880.51 104,178,588.96\n其中：应付利息 805,795.63\n应付股利 2,051,370.43 2,051,370.43\n持有待售负债\n一年内到期的非流动负债 44,365,875.00\n其他流动负债\n流动负债合计 523,199,915.02 678,420,562.15\n非流动负债：\n长期借款\n应付债券\n其中：优先股\n82。",
      "chunk_type": "child",
      "parent_id": "c06540ba",
      "child_ids": [],
      "sibling_ids": [
        "4da43839",
        "01ec69a9",
        "7884ee5b",
        "ff9c20fa"
      ],
      "position": 4,
      "start_char": 2716,
      "end_char": 3555,
      "page_number": 77,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          77
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.318597",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 839,
        "word_count": 83,
        "sentence_count": 40,
        "chinese_char_count": 243,
        "readability_score": 0.0,
        "information_density": 0.17878426698450536,
        "coherence_score": 0.30749999999999994,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5231227651966627,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "投资",
        "应收",
        "应付",
        "预收",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "2afd5211",
      "content": "永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 1,333,333.00 12,971,002.47\n递延收益 1,269,332.86 1,262,720.34\n递延所得税负债\n其他非流动负债\n非流动负债合计 2,602,665.86 14,233,722.81\n负债合计 525,802,580.88 692,654,284.96\n所有者权益：\n股本 1,618,715,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,669,212,269.41 2,662,229,769.88\n减：库存股 301,511,513.90 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 213,069,824.31 201,812,279.17\n未分配利润 697,440,109.87 1,062,800,363.16\n所有者权益合计 4,896,925,942.69 5,219,782,103.53\n负债和所有者权益总计 5,422,728,523.57 5,912,436,388.49\n3、合并利润表\n单位：元\n项目 2019年度 2018年度\n一、营业总收入 2,941,412,770.30 2,718,608,796.51\n其中：营业收入 2,941,412,770.30 2,718,608,796.51\n利息收入\n已赚保费\n手续费及佣金收入\n二、营业总成本 2,020,492,002.44 1,996,990,314.89\n其中：营业成本 1,463,159,361.04 1,511,944,676.18\n83。",
      "chunk_type": "child",
      "parent_id": "f4491003",
      "child_ids": [],
      "sibling_ids": [
        "96a47f9e",
        "1523b74b",
        "ad5b30aa",
        "beff2997"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 702,
      "page_number": 83,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.319681",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 702,
        "word_count": 66,
        "sentence_count": 31,
        "chinese_char_count": 172,
        "readability_score": 0.0,
        "information_density": 0.21367521367521367,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5475783475783476,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "收入",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "应付",
        "营业收入",
        "营业成本",
        "所得税",
        "利润表"
      ]
    },
    {
      "chunk_id": "96a47f9e",
      "content": "年度 2018年度\n一、营业总收入 2,941,412,770.30 2,718,608,796.51\n其中：营业收入 2,941,412,770.30 2,718,608,796.51\n利息收入\n已赚保费\n手续费及佣金收入\n二、营业总成本 2,020,492,002.44 1,996,990,314.89\n其中：营业成本 1,463,159,361.04 1,511,944,676.18\n83。\n\n利息支出\n手续费及佣金支出\n退保金\n赔付支出净额\n提取保险责任合同准备金\n净额\n保单红利支出\n分保费用\n税金及附加 26,841,009.21 32,182,923.43\n销售费用 59,623,024.88 43,781,054.42\n管理费用 386,185,538.84 349,284,396.57\n研发费用 122,548,224.53 111,304,662.07\n财务费用 -37,865,156.06 -51,507,397.78\n其中：利息费用 15,506,676.74 42,594,267.08\n利息收入 41,773,975.28 44,371,159.00\n加：其他收益 27,136,924.87 11,791,738.03\n投资收益（损失以“－”号填\n-15,240,062.55 -9,359,378.55\n列）\n其中：对联营企业和合营企业\n-16,759,549.80 -6,923,938.93\n的投资收益\n以摊余成本计量的金融\n资产终止确认收益\n汇兑收益（损失以“-”号填列）\n净敞口套期收益（损失以“－”\n号填列）\n公允价值变动收益（损失以\n5,010,265.70\n“－”号填列）\n信用减值损失（损失以“-”号填\n-2,502,149.00\n列）\n资产减值损失（损失以“-”号填\n-11,738,706.70 -18,867,903.52\n列）\n资产处置收益（损失以“-”号填\n244,580.94 659,231.88\n列）\n三、营业利润（亏损以“－”号填列） 918,821,355.42 710,852,435.16\n加：营业外收入 1,125,654.53 1,713,286.09\n减：营业外支出 7,494,029.68 15,270,110.20\n84。",
      "chunk_type": "child",
      "parent_id": "f4491003",
      "child_ids": [],
      "sibling_ids": [
        "2afd5211",
        "1523b74b",
        "ad5b30aa",
        "beff2997"
      ],
      "position": 1,
      "start_char": 502,
      "end_char": 1460,
      "page_number": 83,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.319864",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 958,
        "word_count": 87,
        "sentence_count": 42,
        "chinese_char_count": 265,
        "readability_score": 0.0,
        "information_density": 0.16701461377870563,
        "coherence_score": 0.5475,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7106471816283925,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "成本",
        "利润",
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "营业收入",
        "营业成本",
        "销售费用",
        "管理费用"
      ]
    },
    {
      "chunk_id": "1523b74b",
      "content": "“-”号填\n-11,738,706.70 -18,867,903.52\n列）\n资产处置收益（损失以“-”号填\n244,580.94 659,231.88\n列）\n三、营业利润（亏损以“－”号填列） 918,821,355.42 710,852,435.16\n加：营业外收入 1,125,654.53 1,713,286.09\n减：营业外支出 7,494,029.68 15,270,110.20\n84。\n\n四、利润总额（亏损总额以“－”号填列） 912,452,980.27 697,295,611.05\n减：所得税费用 141,670,795.18 92,291,790.27\n五、净利润（净亏损以“－”号填列） 770,782,185.09 605,003,820.78\n（一）按经营持续性分类\n1.持续经营净利润（净亏损以“－”\n770,782,185.09 605,003,820.78\n号填列）\n2.终止经营净利润（净亏损以“－”\n号填列）\n（二）按所有权归属分类\n1.归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n2.少数股东损益\n六、其他综合收益的税后净额 -1,438,409.58 16,560.46\n归属母公司所有者的其他综合收益\n-1,438,409.58 16,560.46\n的税后净额\n（一）不能重分类进损益的其他综\n-1,800,000.00\n合收益\n1.重新计量设定受益计划变\n动额\n2.权益法下不能转损益的其\n他综合收益\n3.其他权益工具投资公允价\n-1,800,000.00\n值变动\n4.企业自身信用风险公允价\n值变动\n5.其他\n（二）将重分类进损益的其他综合\n361,590.42 16,560.46\n收益\n1.权益法下可转损益的其他\n综合收益\n2.其他债权投资公允价值变\n动\n3.可供出售金融资产公允价\n值变动损益\n4.金融资产重分类计入其他\n综合收益的金额\n5.持有至到期投资重分类为\n可供出售金融资产损益\n85。\n\n6.其他债权投资信用减值准\n备\n7.现金流量套期储备\n8.外币财务报表折算差额 361,590.42 16,560.46\n9.其他\n归属于少数股东的其他综合收益的\n税后净额\n七、综合收益总额 769,343,775.51 605,020,381.24\n归属于母公司所有者的综合收益\n769,343,775.51 605,020,381.24\n总额\n归属于少数股东的综合收益总额\n八、每股收益：\n（一）基本每股收益 0.48 0.38\n（二）稀释每股收益 0.48 0.38\n本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0.00元，上期被合并方实现的净利润为：0.00元。",
      "chunk_type": "child",
      "parent_id": "f4491003",
      "child_ids": [],
      "sibling_ids": [
        "2afd5211",
        "96a47f9e",
        "ad5b30aa",
        "beff2997"
      ],
      "position": 2,
      "start_char": 1260,
      "end_char": 2403,
      "page_number": 83,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.320088",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1143,
        "word_count": 99,
        "sentence_count": 61,
        "chinese_char_count": 488,
        "readability_score": 0.0,
        "information_density": 0.17497812773403326,
        "coherence_score": 0.28002263856362214,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7707786526684164,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "利润",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "费用",
        "利润",
        "现金",
        "投资",
        "净利润",
        "营业利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "ad5b30aa",
      "content": "额 769,343,775.51 605,020,381.24\n归属于母公司所有者的综合收益\n769,343,775.51 605,020,381.24\n总额\n归属于少数股东的综合收益总额\n八、每股收益：\n（一）基本每股收益 0.48 0.38\n（二）稀释每股收益 0.48 0.38\n本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0.00元，上期被合并方实现的净利润为：0.00元。法定代表人：杨思卫 主管会计工作负责人：李进 会计机构负责人：朱勇\n4、母公司利润表\n单位：元\n项目 2019年度 2018年度\n一、营业收入 812,259,638.86 825,098,603.87\n减：营业成本 587,096,405.03 619,846,906.93\n税金及附加 5,519,793.76 6,987,907.49\n销售费用 16,512,217.50 13,811,113.34\n管理费用 54,148,420.30 76,492,418.62\n研发费用 34,026,076.54 27,532,948.31\n财务费用 -13,410,251.73 -18,322,346.97\n其中：利息费用 9,198,148.55 23,746,817.96\n利息收入 15,402,930.57 21,054,583.18\n加：其他收益 8,727,855.85 2,788,654.20\n投资收益（损失以“－”号填\n-4,635,510.82 996,151,682.18\n列）\n其中：对联营企业和合营企\n-5,766,425.53 -4,216,789.49\n业的投资收益\n86。",
      "chunk_type": "child",
      "parent_id": "f4491003",
      "child_ids": [],
      "sibling_ids": [
        "2afd5211",
        "96a47f9e",
        "1523b74b",
        "beff2997"
      ],
      "position": 3,
      "start_char": 2203,
      "end_char": 2906,
      "page_number": 83,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.320319",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 703,
        "word_count": 62,
        "sentence_count": 36,
        "chinese_char_count": 210,
        "readability_score": 0.0,
        "information_density": 0.24182076813655762,
        "coherence_score": 0.2760833333333333,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7194879089615931,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润",
        "投资",
        "财务",
        "0.00元",
        "0.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "营业收入",
        "营业成本",
        "销售费用",
        "管理费用",
        "研发费用"
      ]
    },
    {
      "chunk_id": "beff2997",
      "content": "7\n其中：利息费用 9,198,148.55 23,746,817.96\n利息收入 15,402,930.57 21,054,583.18\n加：其他收益 8,727,855.85 2,788,654.20\n投资收益（损失以“－”号填\n-4,635,510.82 996,151,682.18\n列）\n其中：对联营企业和合营企\n-5,766,425.53 -4,216,789.49\n业的投资收益\n86。\n\n以摊余成本计量的金融\n资产终止确认收益（损失以“-”号填\n列）\n净敞口套期收益（损失以\n“－”号填列）\n公允价值变动收益（损失以\n1,406,950.55\n“－”号填列）\n信用减值损失（损失以“-”号\n961,136.35\n填列）\n资产减值损失（损失以“-”号\n-4,457,462.80 -4,264,339.86\n填列）\n资产处置收益（损失以“-”号\n187,029.94 278,081.30\n填列）\n二、营业利润（亏损以“－”号填列） 129,150,025.98 1,095,110,684.52\n加：营业外收入 56,093.96 1,807,586.73\n减：营业外支出 2,735,128.50 12,741,122.39\n三、利润总额（亏损总额以“－”号填\n126,470,991.44 1,084,177,148.86\n列）\n减：所得税费用 13,895,540.09 -1,968,185.09\n四、净利润（净亏损以“－”号填列） 112,575,451.35 1,086,145,333.95\n（一）持续经营净利润（净亏损\n112,575,451.35 1,086,145,333.95\n以“－”号填列）\n（二）终止经营净利润（净亏损\n以“－”号填列）\n五、其他综合收益的税后净额\n（一）不能重分类进损益的其他\n综合收益\n1.重新计量设定受益计划\n变动额\n2.权益法下不能转损益的\n其他综合收益\n3.其他权益工具投资公允\n价值变动\n4.企业自身信用风险公允\n价值变动\n5.其他\n（二）将重分类进损益的其他综\n合收益\n87。",
      "chunk_type": "child",
      "parent_id": "f4491003",
      "child_ids": [],
      "sibling_ids": [
        "2afd5211",
        "96a47f9e",
        "1523b74b",
        "ad5b30aa"
      ],
      "position": 4,
      "start_char": 2706,
      "end_char": 3581,
      "page_number": 83,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          83
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.320502",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 875,
        "word_count": 78,
        "sentence_count": 37,
        "chinese_char_count": 314,
        "readability_score": 0.0,
        "information_density": 0.19428571428571428,
        "coherence_score": 0.4207142857142857,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7435428571428571,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "净利润",
        "营业利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "09f53672",
      "content": "1.权益法下可转损益的其\n他综合收益\n2.其他债权投资公允价值\n变动\n3.可供出售金融资产公允\n价值变动损益\n4.金融资产重分类计入其\n他综合收益的金额\n5.持有至到期投资重分类\n为可供出售金融资产损益\n6.其他债权投资信用减值\n准备\n7.现金流量套期储备\n8.外币财务报表折算差额\n9.其他\n六、综合收益总额 112,575,451.35 1,086,145,333.95\n七、每股收益：\n（一）基本每股收益\n（二）稀释每股收益\n5、合并现金流量表\n单位：元\n项目 2019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 2,018,927,512.97 1,988,078,802.41\n客户存款和同业存放款项净增加\n额\n向中央银行借款净增加额\n向其他金融机构拆入资金净增加\n额\n收到原保险合同保费取得的现金\n收到再保业务现金净额\n保户储金及投资款净增加额\n收取利息、手续费及佣金的现金\n拆入资金净增加额\n回购业务资金净增加额\n88\n\n代理买卖证券收到的现金净额\n收到的税费返还 105,999,603.44 49,705,278.88\n收到其他与经营活动有关的现金 249,850,615.77 771,950,774.20\n经营活动现金流入小计 2,374,777,732.18 2,809,734,855.49\n购买商品、接受劳务支付的现金 897,240,432.80 913,013,009.11\n客户贷款及垫款净增加额\n存放中央银行和同业款项净增加\n额\n支付原保险合同赔付款项的现金\n拆出资金净增加额\n支付利息、手续费及佣金的现金\n支付保单红利的现金\n支付给职工以及为职工支付的现\n311,715,734.86 280,419,788.03\n金\n支付的各项税费 269,810,257.63 208,588,464.73\n支付其他与经营活动有关的现金 283,612,211.58 616,264,355.96\n经营活动现金流出小计 1,762,378,636.87 2,018,285,617.83\n经营活动产生的现金流量净额 612,399,095.31 791,449,237.66\n二、投资活动产生的现金流量：\n收回投资收到的现金\n取得投资收益收到的现金\n处置固定资产、无形资产和其他\n5,019,341.20 4,418,098.64\n长期资产收回的现金净额\n处置子公司及其他营业单位收到\n的现金净额\n收到其他与投资活动有关的现金 1,172,215,955.60 959,401,529.98\n投资活动现金流入小计 1,177,235,296.80 963,819,628.62\n购建固定资产、无形资产和其他\n160,639,977.78 255,780,578.95\n长期资产支付的现金\n投资支付的现金 20,000,000.",
      "chunk_type": "child",
      "parent_id": "78c777f4",
      "child_ids": [],
      "sibling_ids": [
        "e84cfe63",
        "9853802c",
        "dfeeb7b7"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1194,
      "page_number": 88,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.321652",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1194,
        "word_count": 99,
        "sentence_count": 40,
        "chinese_char_count": 603,
        "readability_score": 0.0,
        "information_density": 0.15075376884422112,
        "coherence_score": 0.2866666666666666,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6025125628140704,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "现金流",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "现金",
        "投资",
        "固定资产",
        "无形资产",
        "现金流量表",
        "合并",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "e84cfe63",
      "content": "64\n长期资产收回的现金净额\n处置子公司及其他营业单位收到\n的现金净额\n收到其他与投资活动有关的现金 1,172,215,955.60 959,401,529.98\n投资活动现金流入小计 1,177,235,296.80 963,819,628.62\n购建固定资产、无形资产和其他\n160,639,977.78 255,780,578.95\n长期资产支付的现金\n投资支付的现金 20,000,000.00\n质押贷款净增加额\n取得子公司及其他营业单位支付\n的现金净额\n支付其他与投资活动有关的现金 260,000,000.00 1,805,459,752.25\n投资活动现金流出小计 440,639,977.78 2,061,240,331.20\n投资活动产生的现金流量净额 736,595,319.02 -1,097,420,702.58\n89。\n\n三、筹资活动产生的现金流量：\n吸收投资收到的现金\n其中：子公司吸收少数股东投资\n收到的现金\n取得借款收到的现金 285,000,000.00 755,700,000.00\n收到其他与筹资活动有关的现金 633,043,300.00\n筹资活动现金流入小计 285,000,000.00 1,388,743,300.00\n偿还债务支付的现金 683,700,000.00 1,500,000,000.00\n分配股利、利润或偿付利息支付\n483,358,140.11 204,568,679.00\n的现金\n其中：子公司支付给少数股东的\n股利、利润\n支付其他与筹资活动有关的现金 20,278,463.47 590,452,772.90\n筹资活动现金流出小计 1,187,336,603.58 2,295,021,451.90\n筹资活动产生的现金流量净额 -902,336,603.58 -906,278,151.90\n四、汇率变动对现金及现金等价物的\n9,911,822.10 35,680,596.21\n影响\n五、现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n加：期初现金及现金等价物余额 1,069,208,275.60 2,245,777,296.21\n六、期末现金及现金等价物余额 1,525,777,908.45 1,069,208,275.60\n6、母公司现金流量表\n单位：元\n项目 2019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 794,479,241.27 765,335,887.08\n收到的税费返还 63,235,140.24 46,673,265.97\n收到其他与经营活动有关的现金 2,428,120,879.18 2,178,495,326.41\n经营活动现金流入小计 3,285,835,260.69 2,990,504,479.",
      "chunk_type": "child",
      "parent_id": "78c777f4",
      "child_ids": [],
      "sibling_ids": [
        "09f53672",
        "9853802c",
        "dfeeb7b7"
      ],
      "position": 1,
      "start_char": 994,
      "end_char": 2188,
      "page_number": 88,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.321927",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1194,
        "word_count": 90,
        "sentence_count": 45,
        "chinese_char_count": 427,
        "readability_score": 0.0,
        "information_density": 0.1256281407035176,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5309882747068677,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "利润",
        "现金",
        "投资",
        "固定资产",
        "无形资产",
        "现金流量表",
        "母公司",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "9853802c",
      "content": "019年度 2018年度\n一、经营活动产生的现金流量：\n销售商品、提供劳务收到的现金 794,479,241.27 765,335,887.08\n收到的税费返还 63,235,140.24 46,673,265.97\n收到其他与经营活动有关的现金 2,428,120,879.18 2,178,495,326.41\n经营活动现金流入小计 3,285,835,260.69 2,990,504,479.46\n购买商品、接受劳务支付的现金 576,564,206.12 485,651,890.91\n支付给职工以及为职工支付的现\n43,273,656.13 44,578,456.58\n金\n支付的各项税费 4,696,293.04 11,167,793.85\n支付其他与经营活动有关的现金 2,653,901,946.32 1,818,361,700.45\n经营活动现金流出小计 3,278,436,101.61 2,359,759,841.79\n90。\n\n经营活动产生的现金流量净额 7,399,159.08 630,744,637.67\n二、投资活动产生的现金流量：\n收回投资收到的现金\n取得投资收益收到的现金 722,088,153.34 160,759,162.54\n处置固定资产、无形资产和其他\n1,169,750.39 337,155.52\n长期资产收回的现金净额\n处置子公司及其他营业单位收到\n的现金净额\n收到其他与投资活动有关的现金 475,265,164.50 811,296,572.90\n投资活动现金流入小计 1,198,523,068.23 972,392,890.96\n购建固定资产、无形资产和其他\n984,040.99 10,199,423.26\n长期资产支付的现金\n投资支付的现金 20,000,000.00 156,121,497.07\n取得子公司及其他营业单位支付\n的现金净额\n支付其他与投资活动有关的现金 20,000,000.00 1,255,559,950.55\n投资活动现金流出小计 40,984,040.99 1,421,880,870.88\n投资活动产生的现金流量净额 1,157,539,027.24 -449,487,979.92\n三、筹资活动产生的现金流量：\n吸收投资收到的现金\n取得借款收到的现金 235,000,000.00 389,000,000.00\n收到其他与筹资活动有关的现金\n筹资活动现金流入小计 235,000,000.00 389,000,000.00\n偿还债务支付的现金 322,000,000.00 772,000,000.00\n分配股利、利润或偿付利息支付\n476,237,693.27 185,312,985.94\n的现金\n支付其他与筹资活动有关的现金 20,278,463.47 295,075,572.",
      "chunk_type": "child",
      "parent_id": "78c777f4",
      "child_ids": [],
      "sibling_ids": [
        "09f53672",
        "e84cfe63",
        "dfeeb7b7"
      ],
      "position": 2,
      "start_char": 1988,
      "end_char": 3178,
      "page_number": 88,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.322211",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1190,
        "word_count": 89,
        "sentence_count": 49,
        "chinese_char_count": 409,
        "readability_score": 0.0,
        "information_density": 0.12605042016806722,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4878991596638655,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "利润",
        "现金",
        "投资",
        "固定资产",
        "无形资产",
        "营业",
        "经营",
        "投资活动",
        "筹资活动"
      ]
    },
    {
      "chunk_id": "dfeeb7b7",
      "content": "89,000,000.00\n收到其他与筹资活动有关的现金\n筹资活动现金流入小计 235,000,000.00 389,000,000.00\n偿还债务支付的现金 322,000,000.00 772,000,000.00\n分配股利、利润或偿付利息支付\n476,237,693.27 185,312,985.94\n的现金\n支付其他与筹资活动有关的现金 20,278,463.47 295,075,572.90\n筹资活动现金流出小计 818,516,156.74 1,252,388,558.84\n筹资活动产生的现金流量净额 -583,516,156.74 -863,388,558.84\n四、汇率变动对现金及现金等价物的\n4,468,592.83 11,626,754.25\n影响\n五、现金及现金等价物净增加额 585,890,622.41 -670,505,146.84\n加：期初现金及现金等价物余额 593,590,172.62 1,264,095,319.46\n六、期末现金及现金等价物余额 1,179,480,795.03 593,590,172.62\n91。",
      "chunk_type": "child",
      "parent_id": "78c777f4",
      "child_ids": [],
      "sibling_ids": [
        "09f53672",
        "e84cfe63",
        "9853802c"
      ],
      "position": 3,
      "start_char": 2978,
      "end_char": 3460,
      "page_number": 88,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          88
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.322448",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 482,
        "word_count": 35,
        "sentence_count": 22,
        "chinese_char_count": 142,
        "readability_score": 0.0,
        "information_density": 0.16597510373443983,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4692829875518672,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "现金流"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "利润",
        "现金",
        "筹资活动",
        "分配",
        "配股",
        "债务"
      ]
    },
    {
      "chunk_id": "ecdd6fb4",
      "content": "7、合并所有者权益变动表\n本期金额\n单位：元\n2019年度\n归属于母公司所有者权益\n所有\n少数\n项目 其他权益工具 其他 一般 未分 者权\n资本 减：库 专项 盈余 股东\n股本 优先 永续 综合 风险 配利 其他 小计 益合\n股 债\n其他 公积 存股\n收益\n储备 公积\n准备 润\n权益\n计\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,\n一、上年期末余 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 549,93\n额 253.0 9.23\n2.47 68 17 8.50 2.23 2.23\n0\n加：会计政\n策变更\n前期\n差错更正\n同一\n控制下企业合\n并\n其他\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,\n二、本年期初余 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 549,93\n额 253.0 9.23\n2.47 68 17 8.50 2.23 2.23\n0\n三、本期增减变 -105, -24,36 11,257 292,84 333,91 333,91\n6,982, -1,438,\n动金额（减少以 000.0 9,047. ,545.1 6,480. 2,163. 2,163.\n499.53 409.58\n“－”号填列） 0 78 4 45 32 32\n770,78 769,34 769,34\n（一）综合收益 -1,438,\n2,185. 3,775. 3,775.\n总额 409.58\n09 51 51\n-105, -24,36 31,246 31,246\n（二）所有者投 6,982,\n000.0 9,047. ,547.3 ,547.3\n入和减少资本 499.53\n0 78 1 1\n-105, 19,996 -20,23 -20,23\n1．所有者投入 -131,2\n000.0 ,827.2 3,077. 3,077.\n的普通股 50.00\n0 2 22 22\n2．其他权益工\n具持有者投入\n资本\n92。",
      "chunk_type": "child",
      "parent_id": "c5797387",
      "child_ids": [],
      "sibling_ids": [
        "90bde835",
        "df325777",
        "eec826c5",
        "2ccbf163"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 913,
      "page_number": 92,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.323609",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 913,
        "word_count": 173,
        "sentence_count": 39,
        "chinese_char_count": 191,
        "readability_score": 0.0,
        "information_density": 0.06571741511500548,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5479737130339539,
      "relevance_score": 1.0,
      "keywords": [
        "权益"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "合并",
        "母公司",
        "股本",
        "股东"
      ]
    },
    {
      "chunk_id": "90bde835",
      "content": "5, -24,36 31,246 31,246\n（二）所有者投 6,982,\n000.0 9,047. ,547.3 ,547.3\n入和减少资本 499.53\n0 78 1 1\n-105, 19,996 -20,23 -20,23\n1．所有者投入 -131,2\n000.0 ,827.2 3,077. 3,077.\n的普通股 50.00\n0 2 22 22\n2．其他权益工\n具持有者投入\n资本\n92。\n\n3．股份支付计 -44,36 51,479 51,479\n7,113,\n入所有者权益 5,875. ,624.5 ,624.5\n749.53\n的金额 00 3 3\n4．其他\n11,257 -477,9 -466,6 -466,6\n（三）利润分配 ,545.1 35,704 78,159 78,159\n4 .64 .50 .50\n11,257 -11,25\n1．提取盈余公\n,545.1 7,545.\n积\n4 14\n2．提取一般风\n险准备\n-466,6 -466,6 -466,6\n3．对所有者（或\n78,159 78,159 78,159\n股东）的分配\n.50 .50 .50\n4．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储备\n18,997 18,997 18,997\n1．本期提取 ,055.9 ,055.9 ,055.9\n7 7 7\n93\n\n-18,99 -18,99 -18,99\n2．本期使用 7,055. 7,055. 7,055.\n97 97 97\n（六）其他\n1,618\n2,670, 301,51 213,06 1,525, 5,724, 5,724,\n四、本期期末余 ,715, -1,490,\n350,32 1,513. 9,824. 328,39 462,09 462,09\n额 253.0 188.81\n2.00 90 31 8.95 5.55 5.55\n0\n上期金额\n单位：元\n2018年年度\n归属于母公司所有者权益\n所有者\n项目 其他权益工具 其他 一般 未分 少数股\n资本 减：库 专项 盈余 权益合\n股本 优先 永续 综合 风险 配利 其他 小计 东权益\n其他 公积 存股 储备 公积 计\n股 债 收益 准备 润\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n一、上年期末 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.",
      "chunk_type": "child",
      "parent_id": "c5797387",
      "child_ids": [],
      "sibling_ids": [
        "ecdd6fb4",
        "df325777",
        "eec826c5",
        "2ccbf163"
      ],
      "position": 1,
      "start_char": 713,
      "end_char": 1872,
      "page_number": 92,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.323844",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1159,
        "word_count": 212,
        "sentence_count": 46,
        "chinese_char_count": 268,
        "readability_score": 0.0,
        "information_density": 0.08628127696289906,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6383951682484901,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "母公司",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "df325777",
      "content": "合\n股本 优先 永续 综合 风险 配利 其他 小计 东权益\n其他 公积 存股 储备 公积 计\n股 债 收益 准备 润\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n一、上年期末 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.75 75\n0\n加：会计\n政策变更\n前期\n差错更正\n同一\n控制下企业合\n并\n其他\n1,621\n2,629, 100,40 93,197 897,83 5,142, 5,142,0\n二、本年期初 ,610, -68,33\n834,81 3,250. ,745.7 6,956. 008,17 08,176.\n余额 253.0 9.69\n1.25 00 7 42 6.75 75\n0\n三、本期增减\n-2,79 33,533 225,47 108,61 334,64 248,54\n变动金额（减 16,560 248,541\n0,000 ,011.2 7,311. 4,533. 4,962. 1,755.\n少以“－”号填 .46 ,755.48\n.00 2 68 40 08 48\n列）\n605,00 605,02\n（一）综合收 16,560 605,020\n3,820. 0,381.\n益总额 .46 ,381.24\n78 24\n94。",
      "chunk_type": "child",
      "parent_id": "c5797387",
      "child_ids": [],
      "sibling_ids": [
        "ecdd6fb4",
        "90bde835",
        "eec826c5",
        "2ccbf163"
      ],
      "position": 2,
      "start_char": 1672,
      "end_char": 2289,
      "page_number": 92,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.324062",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 617,
        "word_count": 120,
        "sentence_count": 29,
        "chinese_char_count": 98,
        "readability_score": 0.0,
        "information_density": 0.04862236628849271,
        "coherence_score": 0.76,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5094003241491085,
      "relevance_score": 1.0,
      "keywords": [
        "权益"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "股本"
      ]
    },
    {
      "chunk_id": "eec826c5",
      "content": "108,61 334,64 248,54\n变动金额（减 16,560 248,541\n0,000 ,011.2 7,311. 4,533. 4,962. 1,755.\n少以“－”号填 .46 ,755.48\n.00 2 68 40 08 48\n列）\n605,00 605,02\n（一）综合收 16,560 605,020\n3,820. 0,381.\n益总额 .46 ,381.24\n78 24\n94。\n\n（二）所有者 -2,79 33,533 225,47 -194,7 -194,73\n投入和减少资 0,000 ,011.2 7,311. 34,300 4,300.4\n本 .00 2 68 .46 6\n-2,79 -10,60 281,51 -294,9 -294,91\n1．所有者投入\n0,000 6,500. 4,686. 11,186 1,186.6\n的普通股\n.00 00 68 .68 8\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计 44,139 -56,03 100,17\n100,176\n入所有者权益 ,511.2 7,375. 6,886.\n,886.22\n的金额 2 00 22\n4．其他\n108,61 -270,3 -161,7 -161,74\n（三）利润分\n4,533. 58,858 44,325 4,325.3\n配\n40 .70 .30 0\n108,61 -108,6\n1．提取盈余公\n4,533. 14,533\n积\n40 .40\n2．提取一般风\n险准备\n3．对所有者 -161,7 -161,7 -161,74\n（或股东）的 44,325 44,325 4,325.3\n分配 .30 .30 0\n4．其他\n（四）所有者\n权益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n95。",
      "chunk_type": "child",
      "parent_id": "c5797387",
      "child_ids": [],
      "sibling_ids": [
        "ecdd6fb4",
        "90bde835",
        "df325777",
        "2ccbf163"
      ],
      "position": 3,
      "start_char": 2089,
      "end_char": 2897,
      "page_number": 92,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.324216",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 808,
        "word_count": 139,
        "sentence_count": 37,
        "chinese_char_count": 152,
        "readability_score": 0.0,
        "information_density": 0.09900990099009901,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6752475247524752,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "2ccbf163",
      "content": "盈余公\n4,533. 14,533\n积\n40 .40\n2．提取一般风\n险准备\n3．对所有者 -161,7 -161,7 -161,74\n（或股东）的 44,325 44,325 4,325.3\n分配 .30 .30 0\n4．其他\n（四）所有者\n权益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n95。\n\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储\n备\n19,301 19,301\n19,301,\n1．本期提取 ,110.5 ,110.5\n110.51\n1 1\n-19,30 -19,30\n-19,301\n2．本期使用 1,110. 1,110.\n,110.51\n51 51\n（六）其他\n1,618\n2,663, 325,88 201,81 1,232, 5,390, 5,390,5\n四、本期期末 ,820, -51,77\n367,82 0,561. 2,279. 481,91 549,93 49,932.\n余额 253.0 9.23\n2.47 68 17 8.50 2.23 23\n0\n8、母公司所有者权益变动表\n本期金额\n单位：元\n2019年度\n项目 其他权益工具 资本公 减：库存 其他综 专项储 盈余公 未分配 所有者权\n股本 其他\n优先股 永续债 其他 积 股 合收益 备 积 利润 益合计\n1,618,8 1,062,8\n一、上年期末余 2,662,22 325,880, 201,812, 5,219,782,\n20,253. 00,363.\n额 9,769.88 561.68 279.17 103.53\n00 16\n加：会计政\n策变更\n前期\n差错更正\n其他\n1,618,8 1,062,8\n二、本年期初余 2,662,22 325,880, 201,812, 5,219,782,\n20,253. 00,363.\n额 9,769.88 561.68 279.17 103.53\n00 16\n三、本期增减变 -365,36\n-105,00 6,982,49 -24,369, 11,257,5 -322,856,1\n动金额（减少以 0,253.2\n0.00 9.53 047.78 45.14 60.84\n“－”号填列） 9\n96。",
      "chunk_type": "child",
      "parent_id": "c5797387",
      "child_ids": [],
      "sibling_ids": [
        "ecdd6fb4",
        "90bde835",
        "df325777",
        "eec826c5"
      ],
      "position": 4,
      "start_char": 2697,
      "end_char": 3679,
      "page_number": 92,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          92
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.324411",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 982,
        "word_count": 165,
        "sentence_count": 39,
        "chinese_char_count": 234,
        "readability_score": 0.0,
        "information_density": 0.09164969450101833,
        "coherence_score": 0.693529411764706,
        "standards_profile_summary": {}
      },
      "quality_score": 0.685539714867617,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "母公司",
        "股本",
        "资本公积",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "de3fdedf",
      "content": "112,57\n（一）综合收益 112,575,45\n5,451.3\n总额 1.35\n5\n（二）所有者投 -105,00 6,982,49 -24,369, 31,246,54\n入和减少资本 0.00 9.53 047.78 7.31\n1．所有者投入 -105,00 -131,250 19,996,8 -20,233,07\n的普通股 0.00 .00 27.22 7.22\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计\n7,113,74 -44,365, 51,479,62\n入所有者权益\n9.53 875.00 4.53\n的金额\n4．其他\n-477,93\n11,257,5 -466,678,1\n（三）利润分配 5,704.6\n45.14 59.50\n4\n1．提取盈余公 11,257,5 -11,257\n积 45.14 ,545.14\n-466,67\n2．对所有者（或 -466,678,1\n8,159.5\n股东）的分配 59.50\n0\n3．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n97。\n\n6．其他\n（五）专项储备\n6,960,83 6,960,833.\n1．本期提取\n3.11 11\n-6,960,8 -6,960,833\n2．本期使用\n33.11 .11\n（六）其他\n1,618,7 697,44\n四、本期期末余 2,669,21 301,511, 213,069, 4,896,925,\n15,253. 0,109.8\n额 2,269.41 513.90 824.31 942.69\n00 7\n上期金额\n单位：元\n2018年年度\n其他权益工具\n项目 资本公 减：库存 其他综 盈余公 未分配利 所有者权\n股本 优先 永续 专项储备 其他\n其他 积 股 合收益 积 润 益合计\n股 债\n1,621, 2,628,6\n一、上年期末余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n加：会计政\n策变更\n前期\n差错更正\n其他\n1,621, 2,628,6\n二、本年期初余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n三、本期增减变\n-2,790, 33,533,225,477, 108,614 815,786,4 729,666,70\n动金额（减少以\n000.00 011.22 311.68 ,533.40 75.25 8.",
      "chunk_type": "child",
      "parent_id": "3d56abdc",
      "child_ids": [],
      "sibling_ids": [
        "065b6141",
        "7ed2588b"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1186,
      "page_number": 97,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.325384",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1186,
        "word_count": 183,
        "sentence_count": 49,
        "chinese_char_count": 276,
        "readability_score": 0.0,
        "information_density": 0.07588532883642496,
        "coherence_score": 0.6547681281618887,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6839797639123103,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "股本",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "065b6141",
      "content": "期初余 100,403, 93,197, 247,013,8 4,490,115,3\n610,25 96,758.\n额 250.00 745.77 87.91 95.34\n3.00 66\n三、本期增减变\n-2,790, 33,533,225,477, 108,614 815,786,4 729,666,70\n动金额（减少以\n000.00 011.22 311.68 ,533.40 75.25 8.19\n“－”号填列）\n（一）综合收益 1,086,145 1,086,145,3\n总额 ,333.95 33.95\n（二）所有者投 -2,790, 33,533,225,477, -194,734,30\n入和减少资本 000.00 011.22 311.68 0.46\n1．所有者投入 -2,790, -10,606,281,514, -294,911,18\n的普通股 000.00 500.00 686.68 6.68\n98。\n\n2．其他权益工\n具持有者投入\n资本\n3．股份支付计\n44,139, -56,037, 100,176,88\n入所有者权益\n511.22 375.00 6.22\n的金额\n4．其他\n108,614 -270,358, -161,744,32\n（三）利润分配\n,533.40 858.70 5.30\n1．提取盈余公 108,614 -108,614,\n积 ,533.40 533.40\n2．对所有者（或 -161,744, -161,744,32\n股东）的分配 325.30 5.30\n3．其他\n（四）所有者权\n益内部结转\n1．资本公积转\n增资本（或股\n本）\n2．盈余公积转\n增资本（或股\n本）\n3．盈余公积弥\n补亏损\n4．设定受益计\n划变动额结转\n留存收益\n5．其他综合收\n益结转留存收\n益\n6．其他\n（五）专项储备\n4,736,183 4,736,183.5\n1．本期提取\n.53 3\n-4,736,18 -4,736,183.\n2．本期使用\n3.53 53\n（六）其他\n99\n\n1,618, 2,662,2\n四、本期期末余 325,880, 201,812 1,062,800 5,219,782,1\n820,25 29,769.\n额 561.68 ,279.17 ,363.16 03.53\n3.",
      "chunk_type": "child",
      "parent_id": "3d56abdc",
      "child_ids": [],
      "sibling_ids": [
        "de3fdedf",
        "7ed2588b"
      ],
      "position": 1,
      "start_char": 986,
      "end_char": 1951,
      "page_number": 97,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.325704",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 965,
        "word_count": 131,
        "sentence_count": 43,
        "chinese_char_count": 190,
        "readability_score": 0.0,
        "information_density": 0.08290155440414507,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6787564766839378,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "资本公积",
        "股份",
        "股东",
        "分配"
      ]
    },
    {
      "chunk_id": "7ed2588b",
      "content": "（五）专项储备\n4,736,183 4,736,183.5\n1．本期提取\n.53 3\n-4,736,18 -4,736,183.\n2．本期使用\n3.53 53\n（六）其他\n99\n\n1,618, 2,662,2\n四、本期期末余 325,880, 201,812 1,062,800 5,219,782,1\n820,25 29,769.\n额 561.68 ,279.17 ,363.16 03.53\n3.00 88\n三、公司基本情况\n浙江海翔药业股份有限公司（以下简称公司或本公司）系经浙江省人民政府企业上市工作领导小组浙\n上市〔2004〕16号文批准，由罗邦鹏、上海复星化工医药投资有限公司、张志敏、张智岳、罗煜竑、郑志\n国、李维金、中化宁波(集团)有限公司、重庆医药工业研究院有限责任公司和浙江美阳国际石化医药工程\n设计有限公司共同发起，在原浙江海翔医药化工有限公司基础上整体变更设立的股份有限公司，于2004年\n5月13日在浙江省工商行政管理局登记注册，总部位于浙江省台州市。公司现持有统一社会信用代码为\n913300001482332737的营业执照，注册资本1,618,715,253.00元，股份总数1,618,715,253股(每股面值1元)。其中，有限售条件的流通股份A股14,274,600股；无限售条件的流通股份A股1,604,440,653股。\n\n公司股票已\n于2006年12月26日在深圳证券交易所挂牌交易。本公司属于医药化工行业。主要经营活动为药品的生产(范围详见《中华人民共和国药品生产许可证》)，\n化工原料及产品的生产，经营进出口业务。\n\n(依法须经批准的项目，经相关部门批准后方可开展经营活动。)\n产品主要有：原料药及医药中间体、染料及染颜料中间体。本财务报表业经公司2020年1月22日第六届董事会第二次会议批准对外报出。",
      "chunk_type": "child",
      "parent_id": "3d56abdc",
      "child_ids": [],
      "sibling_ids": [
        "de3fdedf",
        "065b6141"
      ],
      "position": 2,
      "start_char": 1751,
      "end_char": 2527,
      "page_number": 97,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          97
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.325968",
        "report_type": "资产负债表",
        "fiscal_year": 2004,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 776,
        "word_count": 41,
        "sentence_count": 20,
        "chinese_char_count": 434,
        "readability_score": 0.0,
        "information_density": 0.1675257731958763,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8237113402061855,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "财务",
        "报表",
        "253.00元",
        "1元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "营业",
        "经营",
        "股份",
        "每股",
        "流通股",
        "证券"
      ]
    },
    {
      "chunk_id": "6627f889",
      "content": "2. 外币财务报表折算\n资产负债表中的资产和负债项目，采用资产负债表日的即期汇率折算；所有者权益项目除“未分配利\n润”项目外，其他项目采用交易发生日的即期汇率折算；利润表中的收入和费用项目，采用交易发生日即\n期汇率的近似汇率折算。按照上述折算产生的外币财务报表折算差额，计入其他综合收益。10、金融工具\n1. 金融资产和金融负债的分类\n金融资产在初始确认时划分为以下三类：(1) 以摊余成本计量的金融资产；(2) 以公允价值计量且其变\n102。\n\n动计入其他综合收益的金融资产；(3) 以公允价值计量且其变动计入当期损益的金融资产。金融负债在初始确认时划分为以下四类：(1) 以公允价值计量且其变动计入当期损益的金融负债；(2)\n金融资产转移不符合终止确认条件或继续涉入被转移金融资产所形成的金融负债；(3) 不属于上述(1)或(2)\n的财务担保合同，以及不属于上述(1)并以低于市场利率贷款的贷款承诺；(4) 以摊余成本计量的金融负债。2. 金融资产和金融负债的确认依据、计量方法和终止确认条件\n(1) 金融资产和金融负债的确认依据和初始计量方法\n公司成为金融工具合同的一方时，确认一项金融资产或金融负债。\n\n初始确认金融资产或金融负债时，\n按照公允价值计量；对于以公允价值计量且其变动计入当期损益的金融资产和金融负债，相关交易费用直\n接计入当期损益；对于其他类别的金融资产或金融负债，相关交易费用计入初始确认金额。但是，公司初\n始确认的应收账款未包含重大融资成分或公司不考虑未超过一年的合同中的融资成分的，按照交易价格进\n行初始计量。(2) 金融资产的后续计量方法\n1) 以摊余成本计量的金融资产\n采用实际利率法，按照摊余成本进行后续计量。\n\n以摊余成本计量且不属于任何套期关系的一部分的金\n融资产所产生的利得或损失，在终止确认、重分类、按照实际利率法摊销或确认减值时，计入当期损益。2) 以公允价值计量且其变动计入其他综合收益的债务工具投资\n采用公允价值进行后续计量。采用实际利率法计算的利息、减值损失或利得及汇兑损益计入当期损益，\n其他利得或损失计入其他综合收益。\n\n终止确认时，将之前计入其他综合收益的累计利得或损失从其他综合\n收益中转出，计入当期损益。3) 以公允价值计量且其变动计入其他综合收益的权益工具投资\n采用公允价值进行后续计量。获得的股利（属于投资成本收回部分的除外）计入当期损益，其他利得\n或损失计入其他综合收益。\n\n终止确认时，将之前计入其他综合收益的累计利得或损失从其他综合收益中转\n出，计入留存收益。4) 以公允价值计量且其变动计入当期损益的金融资产\n采用公允价值进行后续计量，产生的利得或损失（包括利息和股利收入)计入当期损益，除非该金融资\n产属于套期关系的一部分。",
      "chunk_type": "child",
      "parent_id": "a31d7651",
      "child_ids": [],
      "sibling_ids": [
        "f7053ecb",
        "10e80b96",
        "1135caa9"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1149,
      "page_number": 102,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          102
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.327211",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1149,
        "word_count": 46,
        "sentence_count": 20,
        "chinese_char_count": 983,
        "readability_score": 0.0,
        "information_density": 0.17406440382941687,
        "coherence_score": 0.5433920063549796,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9422106179286336,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "应收",
        "资产负债表"
      ]
    },
    {
      "chunk_id": "f7053ecb",
      "content": "他综合收益的权益工具投资\n采用公允价值进行后续计量。获得的股利（属于投资成本收回部分的除外）计入当期损益，其他利得\n或损失计入其他综合收益。\n\n终止确认时，将之前计入其他综合收益的累计利得或损失从其他综合收益中转\n出，计入留存收益。4) 以公允价值计量且其变动计入当期损益的金融资产\n采用公允价值进行后续计量，产生的利得或损失（包括利息和股利收入)计入当期损益，除非该金融资\n产属于套期关系的一部分。(3) 金融负债的后续计量方法\n1) 以公允价值计量且其变动计入当期损益的金融负债\n此类金融负债包括交易性金融负债（含属于金融负债的衍生工具)和指定为以公允价值计量且其变动计\n入当期损益的金融负债。\n\n对于此类金融负债以公允价值进行后续计量。因公司自身信用风险变动引起的指\n定为以公允价值计量且其变动计入当期损益的金融负债的公允价值变动金额计入其他综合收益，除非该处\n理会造成或扩大损益中的会计错配。此类金融负债产生的其他利得或损失（包括利息费用、除因公司自身\n信用风险变动引起的公允价值变动)计入当期损益，除非该金融负债属于套期关系的一部分。\n\n终止确认时，\n将之前计入其他综合收益的累计利得或损失从其他综合收益中转出，计入留存收益。2) 金融资产转移不符合终止确认条件或继续涉入被转移金融资产所形成的金融负债\n按照《企业会计准则第23号——金融资产转移》相关规定进行计量。3) 不属于上述1)或2)的财务担保合同，以及不属于上述1)并以低于市场利率贷款的贷款承诺\n在初始确认后按照下列两项金额之中的较高者进行后续计量：① 按照金融工具的减值规定确定的损\n失准备金额；② 初始确认金额扣除按照相关规定所确定的累计摊销额后的余额。\n\n4) 以摊余成本计量的金融负债\n采用实际利率法以摊余成本计量。以摊余成本计量且不属于任何套期关系的一部分的金融负债所产生\n的利得或损失，在终止确认、按照实际利率法摊销时计入当期损益。(4) 金融资产和金融负债的终止确认\n1) 当满足下列条件之一时，终止确认金融资产：\n103。\n\n① 收取金融资产现金流量的合同权利已终止；\n② 金融资产已转移，且该转移满足《企业会计准则第23号——金融资产转移》关于金融资产终止确\n认的规定。2) 当金融负债（或其一部分）的现时义务已经解除时，相应终止确认该金融负债（或该部分金融负债）。3. 金融资产转移的确认依据和计量方法\n公司转移了金融资产所有权上几乎所有的风险和报酬的，终止确认该金融资产，并将转移中产生或保\n留的权利和义务单独确认为资产或负债；保留了金融资产所有权上几乎所有的风险和报酬的，继续确认所\n转移的金融资产。",
      "chunk_type": "child",
      "parent_id": "a31d7651",
      "child_ids": [],
      "sibling_ids": [
        "6627f889",
        "10e80b96",
        "1135caa9"
      ],
      "position": 1,
      "start_char": 949,
      "end_char": 2047,
      "page_number": 102,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          102
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.327448",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1098,
        "word_count": 44,
        "sentence_count": 18,
        "chinese_char_count": 950,
        "readability_score": 0.0,
        "information_density": 0.17304189435336975,
        "coherence_score": 0.5300246570588667,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9460837887067395,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "现金流",
        "投资",
        "融资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "现金",
        "投资",
        "摊销",
        "减值"
      ]
    },
    {
      "chunk_id": "10e80b96",
      "content": "会计准则第23号——金融资产转移》关于金融资产终止确\n认的规定。2) 当金融负债（或其一部分）的现时义务已经解除时，相应终止确认该金融负债（或该部分金融负债）。3. 金融资产转移的确认依据和计量方法\n公司转移了金融资产所有权上几乎所有的风险和报酬的，终止确认该金融资产，并将转移中产生或保\n留的权利和义务单独确认为资产或负债；保留了金融资产所有权上几乎所有的风险和报酬的，继续确认所\n转移的金融资产。\n\n公司既没有转移也没有保留金融资产所有权上几乎所有的风险和报酬的，分别下列情况\n处理：(1) 未保留对该金融资产控制的，终止确认该金融资产，并将转移中产生或保留的权利和义务单独\n确认为资产或负债；(2) 保留了对该金融资产控制的，按照继续涉入所转移金融资产的程度确认有关金融\n资产，并相应确认有关负债。金融资产整体转移满足终止确认条件的，将下列两项金额的差额计入当期损益：(1) 所转移金融资产\n在终止确认日的账面价值；(2) 因转移金融资产而收到的对价，与原直接计入其他综合收益的公允价值变\n动累计额中对应终止确认部分的金额（涉及转移的金融资产为以公允价值计量且其变动计入其他综合收益\n的债务工具投资）之和。转移了金融资产的一部分，且该被转移部分整体满足终止确认条件的，将转移前\n金融资产整体的账面价值，在终止确认部分和继续确认部分之间，按照转移日各自的相对公允价值进行分\n摊，并将下列两项金额的差额计入当期损益：(1) 终止确认部分的账面价值；(2) 终止确认部分的对价，与\n原直接计入其他综合收益的公允价值变动累计额中对应终止确认部分的金额（涉及转移的金融资产为以公\n允价值计量且其变动计入其他综合收益的债务工具投资）之和。\n\n4. 金融资产和金融负债的公允价值确定方法\n公司采用在当前情况下适用并且有足够可利用数据和其他信息支持的估值技术确定相关金融资产和\n金融负债的公允价值。公司将估值技术使用的输入值分以下层级，并依次使用：\n(1) 第一层次输入值是在计量日能够取得的相同资产或负债在活跃市场上未经调整的报价；\n(2) 第二层次输入值是除第一层次输入值外相关资产或负债直接或间接可观察的输入值，包括：活跃\n市场中类似资产或负债的报价；非活跃市场中相同或类似资产或负债的报价；除报价以外的其他可观察输\n入值，如在正常报价间隔期间可观察的利率和收益率曲线等；市场验证的输入值等；\n(3) 第三层次输入值是相关资产或负债的不可观察输入值，包括不能直接观察或无法由可观察市场数\n据验证的利率、股票波动率、企业合并中承担的弃置义务的未来现金流量、使用自身数据作出的财务预测\n等。",
      "chunk_type": "child",
      "parent_id": "a31d7651",
      "child_ids": [],
      "sibling_ids": [
        "6627f889",
        "f7053ecb",
        "1135caa9"
      ],
      "position": 2,
      "start_char": 1847,
      "end_char": 2938,
      "page_number": 102,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          102
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.327698",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1091,
        "word_count": 38,
        "sentence_count": 10,
        "chinese_char_count": 960,
        "readability_score": 0.0,
        "information_density": 0.1466544454628781,
        "coherence_score": 0.719011815357042,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9519706691109076,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "现金流",
        "投资",
        "融资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "现金",
        "投资",
        "合并",
        "公允价值",
        "账面价值",
        "估值",
        "融资",
        "债务"
      ]
    },
    {
      "chunk_id": "1135caa9",
      "content": "直接或间接可观察的输入值，包括：活跃\n市场中类似资产或负债的报价；非活跃市场中相同或类似资产或负债的报价；除报价以外的其他可观察输\n入值，如在正常报价间隔期间可观察的利率和收益率曲线等；市场验证的输入值等；\n(3) 第三层次输入值是相关资产或负债的不可观察输入值，包括不能直接观察或无法由可观察市场数\n据验证的利率、股票波动率、企业合并中承担的弃置义务的未来现金流量、使用自身数据作出的财务预测\n等。5. 金融工具减值\n(1) 金融工具减值计量和会计处理\n公司以预期信用损失为基础，对以摊余成本计量的金融资产、以公允价值计量且其变动计入其他综合\n收益的债务工具投资、租赁应收款、分类为以公允价值计量且其变动计入当期损益的金融负债以外的贷款\n承诺、不属于以公允价值计量且其变动计入当期损益的金融负债或不属于金融资产转移不符合终止确认条\n件或继续涉入被转移金融资产所形成的金融负债的财务担保合同进行减值处理并确认损失准备。\n\n预期信用损失，是指以发生违约的风险为权重的金融工具信用损失的加权平均值。信用损失，是指公\n司按照原实际利率折现的、根据合同应收的所有合同现金流量与预期收取的所有现金流量之间的差额，即\n全部现金短缺的现值。其中，对于公司购买或源生的已发生信用减值的金融资产，按照该金融资产经信用\n调整的实际利率折现。\n\n对于购买或源生的已发生信用减值的金融资产，公司在资产负债表日仅将自初始确认后整个存续期内\n预期信用损失的累计变动确认为损失准备。对于不含重大融资成分或者公司不考虑不超过一年的合同中的融资成分的应收账款，公司运用简化计\n量方法，按照相当于整个存续期内的预期信用损失金额计量损失准备。除上述计量方法以外的金融资产，公司在每个资产负债表日评估其信用风险自初始确认后是否已经显\n104。\n\n著增加。如果信用风险自初始确认后已显著增加，公司按照整个存续期内预期信用损失的金额计量损失准\n备；如果信用风险自初始确认后未显著增加，公司按照该金融工具未来12个月内预期信用损失的金额计量\n损失准备。公司利用可获得的合理且有依据的信息，包括前瞻性信息，通过比较金融工具在资产负债表日发生违\n约的风险与在初始确认日发生违约的风险，以确定金融工具的信用风险自初始确认后是否已显著增加。\n\n于资产负债表日，若公司判断金融工具只具有较低的信用风险，则假定该金融工具的信用风险自初始\n确认后并未显著增加。公司以单项金融工具或金融工具组合为基础评估预期信用风险和计量预期信用损失。当以金融工具组\n合为基础时，公司以共同风险特征为依据，将金融工具划分为不同组合。",
      "chunk_type": "child",
      "parent_id": "a31d7651",
      "child_ids": [],
      "sibling_ids": [
        "6627f889",
        "f7053ecb",
        "10e80b96"
      ],
      "position": 3,
      "start_char": 2738,
      "end_char": 3815,
      "page_number": 102,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          102
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.327925",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1077,
        "word_count": 29,
        "sentence_count": 15,
        "chinese_char_count": 982,
        "readability_score": 0.0,
        "information_density": 0.15784586815227483,
        "coherence_score": 0.7189732925027043,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9647168059424327,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "成本",
        "现金流",
        "投资",
        "融资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "成本",
        "现金",
        "投资",
        "应收",
        "资产负债表",
        "合并",
        "减值",
        "公允价值"
      ]
    },
    {
      "chunk_id": "0159d276",
      "content": "公司在每个资产负债表日重新计量预期信用损失，由此形成的损失准备的增加或转回金额，作为减值\n损失或利得计入当期损益。对于以摊余成本计量的金融资产，损失准备抵减该金融资产在资产负债表中列\n示的账面价值；对于以公允价值计量且其变动计入其他综合收益的债权投资，公司在其他综合收益中确认\n其损失准备，不抵减该金融资产的账面价值。(2) 按组合评估预期信用风险和计量预期信用损失的金融工具\n项 目 确定组合的依据 计量预期信用损失的方法\n其他应收款——应收出口退税组合 款项性质 参考历史信用损失经验，结合当前\n其他应收款——应收押金保证金组 状况以及对未来经济状况的预测，\n合 通过违约风险敞口和未来12个月\n内或整个存续期预期信用损失率，\n其他应收款——合并范围内关联往\n来组合\n计算预期信用损失\n其他应收款——应收拆借款组合\n其他应收款——应收暂付款等组合\n(3) 按组合计量预期信用损失的应收款项\n1) 具体组合及计量预期信用损失的方法\n项 目 确定组合的依据 计量预期信用损失的方法\n应收银行承兑汇票 票据类型 参考历史信用损失经验，结合当前状\n况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，计算预期信用损失\n应收账款——信用风险特征组账龄组合 参考历史信用损失经验，结合当前状\n合 况以及对未来经济状况的预测，编制\n应收账款账龄与整个存续期预期信用\n损失率对照表，计算预期信用损失\n应收账款——合并范围内关联合并范围内关联方 参考历史信用损失经验，结合当前状\n往来组合 况以及对未来经济状况的预测，通过\n违约风险敞口和整个存续期预期信用\n损失率，该组合预期信用损失率为0%\n2) 应收账款——信用风险特征组合的账龄与整个存续期预期信用损失率对照表\n账 龄 应收账款\n预期信用损失率(%)\n1年以内（含，下同） 5\n1-2年 30\n105。\n\n2-3年 80\n3年以上 100\n6. 金融资产和金融负债的抵销\n金融资产和金融负债在资产负债表内分别列示，不相互抵销。但同时满足下列条件的，公司以相互抵\n销后的净额在资产负债表内列示：(1) 公司具有抵销已确认金额的法定权利，且该种法定权利是当前可执\n行的；(2) 公司计划以净额结算，或同时变现该金融资产和清偿该金融负债。不满足终止确认条件的金融资产转移，公司不对已转移的金融资产和相关负债进行抵销。\n\n11、应收票据\n12、应收账款\n13、应收款项融资\n14、其他应收款\n其他应收款的预期信用损失的确定方法及会计处理方法\n15、存货\n(十一) 存货\n1. 存货的分类\n存货包括在日常活动中持有以备出售的产成品或商品、处在生产过程中的在产品、在生产过程或提供\n劳务过程中耗用的材料和物料等。2. 发出存货的计价方法\n发出存货采用月末一次加权平均法。",
      "chunk_type": "child",
      "parent_id": "7ee07549",
      "child_ids": [],
      "sibling_ids": [
        "09e3c75b",
        "76844fe1"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1162,
      "page_number": 105,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.328798",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1162,
        "word_count": 84,
        "sentence_count": 11,
        "chinese_char_count": 958,
        "readability_score": 0.0,
        "information_density": 0.12908777969018934,
        "coherence_score": 0.6586785236182826,
        "standards_profile_summary": {}
      },
      "quality_score": 0.929776247848537,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "成本",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "成本",
        "投资",
        "应收",
        "存货",
        "资产负债表",
        "合并",
        "减值",
        "公允价值"
      ]
    },
    {
      "chunk_id": "09e3c75b",
      "content": "产转移，公司不对已转移的金融资产和相关负债进行抵销。\n\n11、应收票据\n12、应收账款\n13、应收款项融资\n14、其他应收款\n其他应收款的预期信用损失的确定方法及会计处理方法\n15、存货\n(十一) 存货\n1. 存货的分类\n存货包括在日常活动中持有以备出售的产成品或商品、处在生产过程中的在产品、在生产过程或提供\n劳务过程中耗用的材料和物料等。2. 发出存货的计价方法\n发出存货采用月末一次加权平均法。3. 存货可变现净值的确定依据\n资产负债表日，存货采用成本与可变现净值孰低计量，按照单个存货成本高于可变现净值的差额计提\n存货跌价准备。\n(2) 包装物\n按照一次转销法进行摊销。106。\n\n直接用于出售的存货，在正常生产经营过程中以该存货的估计售价减去估计的销售费用和\n相关税费后的金额确定其可变现净值；需要经过加工的存货，在正常生产经营过程中以所生产的产成品的\n估计售价减去至完工时估计将要发生的成本、估计的销售费用和相关税费后的金额确定其可变现净值；资\n产负债表日，同一项存货中一部分有合同价格约定、其他部分不存在合同价格的，分别确定其可变现净值，\n并与其对应的成本进行比较，分别确定存货跌价准备的计提或转回的金额。4. 存货的盘存制度\n存货的盘存制度为永续盘存制。5. 低值易耗品和包装物的摊销方法\n(1) 低值易耗品\n按照一次转销法进行摊销。\n\n(2) 包装物\n按照一次转销法进行摊销。106。\n\n16、合同资产\n17、合同成本\n18、持有待售资产\n19、债权投资\n20、其他债权投资\n21、长期应收款\n22、长期股权投资\n1. 共同控制、重要影响的判断\n按照相关约定对某项安排存在共有的控制，并且该安排的相关活动必须经过分享控制权的参与方一致\n同意后才能决策，认定为共同控制。对被投资单位的财务和经营政策有参与决策的权力，但并不能够控制\n或者与其他方一起共同控制这些政策的制定，认定为重大影响。2. 投资成本的确定\n(1) 同一控制下的企业合并形成的，合并方以支付现金、转让非现金资产、承担债务或发行权益性证\n券作为合并对价的，在合并日按照取得被合并方所有者权益在最终控制方合并财务报表中的账面价值的份\n额作为其初始投资成本。\n\n长期股权投资初始投资成本与支付的合并对价的账面价值或发行股份的面值总额\n之间的差额调整资本公积；资本公积不足冲减的，调整留存收益。公司通过多次交易分步实现同一控制下企业合并形成的长期股权投资，判断是否属于“一揽子交易”。属于“一揽子交易”的，把各项交易作为一项取得控制权的交易进行会计处理。\n\n不属于“一揽子交易”的，在\n合并日，根据合并后应享有被合并方净资产在最终控制方合并财务报表中的账面价值的份额确定初始投资\n成本。",
      "chunk_type": "child",
      "parent_id": "7ee07549",
      "child_ids": [],
      "sibling_ids": [
        "0159d276",
        "76844fe1"
      ],
      "position": 1,
      "start_char": 962,
      "end_char": 2093,
      "page_number": 105,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.329034",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1131,
        "word_count": 57,
        "sentence_count": 25,
        "chinese_char_count": 945,
        "readability_score": 0.0,
        "information_density": 0.16799292661361626,
        "coherence_score": 0.5314607810033074,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9342175066312999,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "费用",
        "现金",
        "投资",
        "应收",
        "存货",
        "销售费用"
      ]
    },
    {
      "chunk_id": "76844fe1",
      "content": "本与支付的合并对价的账面价值或发行股份的面值总额\n之间的差额调整资本公积；资本公积不足冲减的，调整留存收益。公司通过多次交易分步实现同一控制下企业合并形成的长期股权投资，判断是否属于“一揽子交易”。属于“一揽子交易”的，把各项交易作为一项取得控制权的交易进行会计处理。\n\n不属于“一揽子交易”的，在\n合并日，根据合并后应享有被合并方净资产在最终控制方合并财务报表中的账面价值的份额确定初始投资\n成本。合并日长期股权投资的初始投资成本，与达到合并前的长期股权投资账面价值加上合并日进一步取\n得股份新支付对价的账面价值之和的差额，调整资本公积；资本公积不足冲减的，调整留存收益。(2) 非同一控制下的企业合并形成的，在购买日按照支付的合并对价的公允价值作为其初始投资成本。\n\n公司通过多次交易分步实现非同一控制下企业合并形成的长期股权投资，区分个别财务报表和合并财\n务报表进行相关会计处理：\n1) 在个别财务报表中，按照原持有的股权投资的账面价值加上新增投资成本之和，作为改按成本法核\n算的初始投资成本。2) 在合并财务报表中，判断是否属于“一揽子交易”。属于“一揽子交易”的，把各项交易作为一项取得\n控制权的交易进行会计处理。\n\n不属于“一揽子交易”的，对于购买日之前持有的被购买方的股权，按照该股\n权在购买日的公允价值进行重新计量，公允价值与其账面价值的差额计入当期投资收益；购买日之前持有\n的被购买方的股权涉及权益法核算下的其他综合收益等的，与其相关的其他综合收益等转为购买日所属当\n期收益。但由于被投资方重新计量设定受益计划净负债或净资产变动而产生的其他综合收益除外。(3) 除企业合并形成以外的：以支付现金取得的，按照实际支付的购买价款作为其初始投资成本；以\n发行权益性证券取得的，按照发行权益性证券的公允价值作为其初始投资成本；以债务重组方式取得的，\n按《企业会计准则第12号——债务重组》确定其初始投资成本；以非货币性资产交换取得的，按《企业会\n计准则第7号——非货币性资产交换》确定其初始投资成本。",
      "chunk_type": "child",
      "parent_id": "7ee07549",
      "child_ids": [],
      "sibling_ids": [
        "0159d276",
        "09e3c75b"
      ],
      "position": 2,
      "start_char": 1893,
      "end_char": 2748,
      "page_number": 105,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          105
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.329256",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 855,
        "word_count": 22,
        "sentence_count": 12,
        "chinese_char_count": 756,
        "readability_score": 0.0,
        "information_density": 0.19883040935672514,
        "coherence_score": 0.6244461745840861,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9536842105263159,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "现金",
        "投资",
        "净资产",
        "合并",
        "资本公积",
        "股权"
      ]
    },
    {
      "chunk_id": "ef8479af",
      "content": "3. 后续计量及损益确认方法\n对被投资单位实施控制的长期股权投资采用成本法核算；对联营企业和合营企业的长期股权投资，采\n用权益法核算。107。\n\n4. 通过多次交易分步处置对子公司投资至丧失控制权的处理方法\n(1) 个别财务报表\n对处置的股权，其账面价值与实际取得价款之间的差额，计入当期损益。对于剩余股权，对被投资单\n位仍具有重大影响或者与其他方一起实施共同控制的，转为权益法核算；不能再对被投资单位实施控制、\n共同控制或重大影响的，按照《企业会计准则第22号——金融工具确认和计量》的相关规定进行核算。(2) 合并财务报表\n1) 通过多次交易分步处置对子公司投资至丧失控制权，且不属于“一揽子交易”的\n在丧失控制权之前，处置价款与处置长期股权投资相对应享有子公司自购买日或合并日开始持续计算\n的净资产份额之间的差额，调整资本公积（资本溢价），资本溢价不足冲减的，冲减留存收益。\n\n丧失对原子公司控制权时，对于剩余股权，按照其在丧失控制权日的公允价值进行重新计量。处置股\n权取得的对价与剩余股权公允价值之和，减去按原持股比例计算应享有原有子公司自购买日或合并日开始\n持续计算的净资产的份额之间的差额，计入丧失控制权当期的投资收益，同时冲减商誉。与原有子公司股\n权投资相关的其他综合收益等，应当在丧失控制权时转为当期投资收益。\n\n2) 通过多次交易分步处置对子公司投资至丧失控制权，且属于“一揽子交易”的\n将各项交易作为一项处置子公司并丧失控制权的交易进行会计处理。但是，在丧失控制权之前每一次\n处置价款与处置投资对应的享有该子公司净资产份额的差额，在合并财务报表中确认为其他综合收益，在\n丧失控制权时一并转入丧失控制权当期的损益。23、投资性房地产\n投资性房地产计量模式\n成本法计量\n折旧或摊销方法\n1. 投资性房地产包括已出租的土地使用权、持有并准备增值后转让的土地使用权和已出租的建筑物。\n\n2. 投资性房地产按照成本进行初始计量，采用成本模式进行后续计量，并采用与固定资产和无形资产\n相同的方法计提折旧或进行摊销。24、固定资产\n（1）确认条件\n固定资产是指为生产商品、提供劳务、出租或经营管理而持有的，使用年限超过一个会计年度的有形资产。固定资产在同时\n满足经济利益很可能流入、成本能够可靠计量时予以确认。\n\n（2）折旧方法\n类别 折旧方法 折旧年限 残值率 年折旧率\n房屋及建筑物 年限平均法 5-20 0、3、5或10 4.50-20.00\n通用设备 年限平均法 3-5 0、3、5或10 18.00-33.33\n专用设备 年限平均法 3-10 3、5或10 9.00-32.33\n运输工具 年限平均法 4-5 3、5或10 18.00-24.25\n108。",
      "chunk_type": "child",
      "parent_id": "c94d9fa5",
      "child_ids": [],
      "sibling_ids": [
        "d35a101e",
        "833ff901",
        "87716b12"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1136,
      "page_number": 107,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          107
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.330368",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1136,
        "word_count": 63,
        "sentence_count": 27,
        "chinese_char_count": 895,
        "readability_score": 0.0,
        "information_density": 0.14964788732394368,
        "coherence_score": 0.7969002436743047,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9151408450704226,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "成本",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "成本",
        "投资",
        "固定资产",
        "无形资产",
        "商誉",
        "净资产",
        "合并",
        "经营"
      ]
    },
    {
      "chunk_id": "d35a101e",
      "content": "利益很可能流入、成本能够可靠计量时予以确认。\n\n（2）折旧方法\n类别 折旧方法 折旧年限 残值率 年折旧率\n房屋及建筑物 年限平均法 5-20 0、3、5或10 4.50-20.00\n通用设备 年限平均法 3-5 0、3、5或10 18.00-33.33\n专用设备 年限平均法 3-10 3、5或10 9.00-32.33\n运输工具 年限平均法 4-5 3、5或10 18.00-24.25\n108。\n\n（3）融资租入固定资产的认定依据、计价和折旧方法\n符合下列一项或数项标准的，认定为融资租赁：(1) 在租赁期届满时，租赁资产的所有权转移给承租人；(2) 承租人有购买\n租赁资产的选择权，所订立的购买价款预计将远低于行使选择权时租赁资产的公允价值，因而在租赁开始日就可以合理确定\n承租人将会行使这种选择权；(3) 即使资产的所有权不转移，但租赁期占租赁资产使用寿命的大部分 [ 通常占租赁资产使用\n寿命的75%以上（含75%）]；(4) 承租人在租赁开始日的最低租赁付款额现值，几乎相当于租赁开始日租赁资产公允价值\n[ 90%以上（含90%）]；出租人在租赁开始日的最低租赁收款额现值，几乎相当于租赁开始日租赁资产公允价值 [ 90%以上\n（含90%）]；(5) 租赁资产性质特殊，如果不作较大改造，只有承租人才能使用。融资租入的固定资产，按租赁开始日租\n赁资产的公允价值与最低租赁付款额的现值中较低者入账，按自有固定资产的折旧政策计提折旧。25、在建工程\n1. 在建工程同时满足经济利益很可能流入、成本能够可靠计量则予以确认。\n\n在建工程按建造该项资产\n达到预定可使用状态前所发生的实际成本计量。2. 在建工程达到预定可使用状态时，按工程实际成本转入固定资产。已达到预定可使用状态但尚未办\n理竣工决算的，先按估计价值转入固定资产，待办理竣工决算后再按实际成本调整原暂估价值，但不再调\n整原已计提的折旧。\n\n26、借款费用\n1. 借款费用资本化的确认原则\n公司发生的借款费用，可直接归属于符合资本化条件的资产的购建或者生产的，予以资本化，计入相\n关资产成本；其他借款费用，在发生时确认为费用，计入当期损益。2. 借款费用资本化期间\n(1) 当借款费用同时满足下列条件时，开始资本化：1) 资产支出已经发生；2) 借款费用已经发生；3) 为\n使资产达到预定可使用或可销售状态所必要的购建或者生产活动已经开始。(2) 若符合资本化条件的资产在购建或者生产过程中发生非正常中断，并且中断时间连续超过3个月，\n暂停借款费用的资本化；中断期间发生的借款费用确认为当期费用，直至资产的购建或者生产活动重新开\n始。\n\n(3) 当所购建或者生产符合资本化条件的资产达到预定可使用或可销售状态时，借款费用停止资本化。",
      "chunk_type": "child",
      "parent_id": "c94d9fa5",
      "child_ids": [],
      "sibling_ids": [
        "ef8479af",
        "833ff901",
        "87716b12"
      ],
      "position": 1,
      "start_char": 936,
      "end_char": 2086,
      "page_number": 107,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          107
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.330623",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1150,
        "word_count": 70,
        "sentence_count": 24,
        "chinese_char_count": 861,
        "readability_score": 0.0,
        "information_density": 0.10434782608695652,
        "coherence_score": 0.8143748473748473,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8994782608695653,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "费用",
        "固定资产",
        "折旧",
        "公允价值",
        "融资",
        "借款",
        "价值"
      ]
    },
    {
      "chunk_id": "833ff901",
      "content": "经发生；2) 借款费用已经发生；3) 为\n使资产达到预定可使用或可销售状态所必要的购建或者生产活动已经开始。(2) 若符合资本化条件的资产在购建或者生产过程中发生非正常中断，并且中断时间连续超过3个月，\n暂停借款费用的资本化；中断期间发生的借款费用确认为当期费用，直至资产的购建或者生产活动重新开\n始。\n\n(3) 当所购建或者生产符合资本化条件的资产达到预定可使用或可销售状态时，借款费用停止资本化。3. 借款费用资本化率以及资本化金额\n为购建或者生产符合资本化条件的资产而借入专门借款的，以专门借款当期实际发生的利息费用（包\n括按照实际利率法确定的折价或溢价的摊销），减去将尚未动用的借款资金存入银行取得的利息收入或进\n行暂时性投资取得的投资收益后的金额，确定应予资本化的利息金额；为购建或者生产符合资本化条件的\n资产占用了一般借款的，根据累计资产支出超过专门借款的资产支出加权平均数乘以占用一般借款的资本\n化率，计算确定一般借款应予资本化的利息金额。109。\n\n27、生物资产\n28、油气资产\n29、使用权资产\n30、无形资产\n（1）计价方法、使用寿命、减值测试\n1. 无形资产包括土地使用权、专利权及非专利技术等，按成本进行初始计量。2. 使用寿命有限的无形资产，在使用寿命内按照与该项无形资产有关的经济利益的预期实现方式系统\n合理地摊销，无法可靠确定预期实现方式的，采用直线法摊销。具体年限如下：\n项 目 摊销年限(年)\n土地使用权 50-70\n专利权 5-14.83\n非专利技术 5-10\n排污权 10\n软件 10\n特许使用权 5、6\n特许经营权 6\n（2）内部研究开发支出会计政策\n内部研究开发项目研究阶段的支出，于发生时计入当期损益。\n\n内部研究开发项目开发阶段的支出，同\n时满足下列条件的，确认为无形资产：(1) 完成该无形资产以使其能够使用或出售在技术上具有可行性；\n(2) 具有完成该无形资产并使用或出售的意图；(3) 无形资产产生经济利益的方式，包括能够证明运用该无\n形资产生产的产品存在市场或无形资产自身存在市场，无形资产将在内部使用的，能证明其有用性；(4) 有\n足够的技术、财务资源和其他资源支持，以完成该无形资产的开发，并有能力使用或出售该无形资产；(5)\n归属于该无形资产开发阶段的支出能够可靠地计量。31、长期资产减值\n对长期股权投资、采用成本模式计量的投资性房地产、固定资产、在建工程、使用寿命有限的无形资\n产等长期资产,在资产负债表日有迹象表明发生减值的，估计其可收回金额。对因企业合并所形成的商誉和\n使用寿命不确定的无形资产，无论是否存在减值迹象，每年都进行减值测试。\n\n商誉结合与其相关的资产组\n或者资产组组合进行减值测试。若上述长期资产的可收回金额低于其账面价值的，按其差额确认资产减值准备并计入当期损益。",
      "chunk_type": "child",
      "parent_id": "c94d9fa5",
      "child_ids": [],
      "sibling_ids": [
        "ef8479af",
        "d35a101e",
        "87716b12"
      ],
      "position": 2,
      "start_char": 1886,
      "end_char": 3061,
      "page_number": 107,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          107
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.330894",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1175,
        "word_count": 58,
        "sentence_count": 17,
        "chinese_char_count": 973,
        "readability_score": 0.0,
        "information_density": 0.1446808510638298,
        "coherence_score": 0.6956552220689192,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9312340425531915,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "投资",
        "固定资产",
        "无形资产",
        "商誉",
        "资产负债表"
      ]
    },
    {
      "chunk_id": "87716b12",
      "content": "值\n对长期股权投资、采用成本模式计量的投资性房地产、固定资产、在建工程、使用寿命有限的无形资\n产等长期资产,在资产负债表日有迹象表明发生减值的，估计其可收回金额。对因企业合并所形成的商誉和\n使用寿命不确定的无形资产，无论是否存在减值迹象，每年都进行减值测试。\n\n商誉结合与其相关的资产组\n或者资产组组合进行减值测试。若上述长期资产的可收回金额低于其账面价值的，按其差额确认资产减值准备并计入当期损益。32、长期待摊费用\n长期待摊费用核算已经支出，摊销期限在1年以上（不含1年）的各项费用。\n\n长期待摊费用按实际发生\n110。\n\n额入账，在受益期或规定的期限内分期平均摊销。如果长期待摊的费用项目不能使以后会计期间受益则将\n尚未摊销的该项目的摊余价值全部转入当期损益。33、合同负债\n34、职工薪酬\n（1）短期薪酬的会计处理方法\n在职工为公司提供服务的会计期间，将实际发生的短期薪酬确认为负债，并计入当期损益或相关资产\n成本。\n\n（2）离职后福利的会计处理方法\n离职后福利分为设定提存计划和设定受益计划。(1) 在职工为公司提供服务的会计期间，根据设定提存计划计算的应缴存金额确认为负债，并计入当\n期损益或相关资产成本。(2) 对设定受益计划的会计处理通常包括下列步骤：\n1) 根据预期累计福利单位法，采用无偏且相互一致的精算假设对有关人口统计变量和财务变量等作出\n估计，计量设定受益计划所产生的义务，并确定相关义务的所属期间。\n\n同时，对设定受益计划所产生的义\n务予以折现，以确定设定受益计划义务的现值和当期服务成本；\n2) 设定受益计划存在资产的，将设定受益计划义务现值减去设定受益计划资产公允价值所形成的赤字\n或盈余确认为一项设定受益计划净负债或净资产。设定受益计划存在盈余的，以设定受益计划的盈余和资\n产上限两项的孰低者计量设定受益计划净资产；\n3) 期末，将设定受益计划产生的职工薪酬成本确认为服务成本、设定受益计划净负债或净资产的利息\n净额以及重新计量设定受益计划净负债或净资产所产生的变动等三部分，其中服务成本和设定受益计划净\n负债或净资产的利息净额计入当期损益或相关资产成本，重新计量设定受益计划净负债或净资产所产生的\n变动计入其他综合收益，并且在后续会计期间不允许转回至损益，但可以在权益范围内转移这些在其他综\n合收益确认的金额。（3）辞退福利的会计处理方法\n向职工提供的辞退福利，在下列两者孰早日确认辞退福利产生的职工薪酬负债，并计入当期损益：(1)\n公司不能单方面撤回因解除劳动关系计划或裁减建议所提供的辞退福利时；(2) 公司确认与涉及支付辞退\n福利的重组相关的成本或费用时。",
      "chunk_type": "child",
      "parent_id": "c94d9fa5",
      "child_ids": [],
      "sibling_ids": [
        "ef8479af",
        "d35a101e",
        "833ff901"
      ],
      "position": 3,
      "start_char": 2861,
      "end_char": 3960,
      "page_number": 107,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          107
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.331148",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1099,
        "word_count": 39,
        "sentence_count": 15,
        "chinese_char_count": 963,
        "readability_score": 0.0,
        "information_density": 0.14558689717925385,
        "coherence_score": 0.7263458569222851,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9505004549590537,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "费用",
        "投资",
        "固定资产",
        "无形资产",
        "商誉",
        "净资产"
      ]
    },
    {
      "chunk_id": "3b04fbe4",
      "content": "（4）其他长期职工福利的会计处理方法\n向职工提供的其他长期福利，符合设定提存计划条件的，按照设定提存计划的有关规定进行会计处理；\n除此之外的其他长期福利，按照设定受益计划的有关规定进行会计处理，为简化相关会计处理，将其产生\n的职工薪酬成本确认为服务成本、其他长期职工福利净负债或净资产的利息净额以及重新计量其他长期职\n工福利净负债或净资产所产生的变动等组成项目的总净额计入当期损益或相关资产成本。111。\n\n35、租赁负债\n36、预计负债\n1. 因对外提供担保、诉讼事项、产品质量保证、亏损合同等或有事项形成的义务成为公司承担的现时\n义务，履行该义务很可能导致经济利益流出公司，且该义务的金额能够可靠的计量时，公司将该项义务确\n认为预计负债。2. 公司按照履行相关现时义务所需支出的最佳估计数对预计负债进行初始计量，并在资产负债表日对\n预计负债的账面价值进行复核。37、股份支付\n1. 股份支付的种类\n包括以权益结算的股份支付和以现金结算的股份支付。\n\n2. 实施、修改、终止股份支付计划的相关会计处理\n(1) 以权益结算的股份支付\n授予后立即可行权的换取职工服务的以权益结算的股份支付，在授予日按照权益工具的公允价值计入\n相关成本或费用，相应调整资本公积。完成等待期内的服务或达到规定业绩条件才可行权的换取职工服务\n的以权益结算的股份支付，在等待期内的每个资产负债表日，以对可行权权益工具数量的最佳估计为基础，\n按权益工具授予日的公允价值，将当期取得的服务计入相关成本或费用，相应调整资本公积。换取其他方服务的权益结算的股份支付，如果其他方服务的公允价值能够可靠计量的，按照其他方服\n务在取得日的公允价值计量；如果其他方服务的公允价值不能可靠计量，但权益工具的公允价值能够可靠\n计量的，按照权益工具在服务取得日的公允价值计量，计入相关成本或费用，相应增加所有者权益。\n\n(2) 以现金结算的股份支付\n授予后立即可行权的换取职工服务的以现金结算的股份支付，在授予日按公司承担负债的公允价值计\n入相关成本或费用，相应增加负债。完成等待期内的服务或达到规定业绩条件才可行权的换取职工服务的\n以现金结算的股份支付，在等待期内的每个资产负债表日，以对可行权情况的最佳估计为基础，按公司承\n担负债的公允价值，将当期取得的服务计入相关成本或费用和相应的负债。(3) 修改、终止股份支付计划\n如果修改增加了所授予的权益工具的公允价值，公司按照权益工具公允价值的增加相应地确认取得服\n务的增加；如果修改增加了所授予的权益工具的数量，公司将增加的权益工具的公允价值相应地确认为取\n得服务的增加；如果公司按照有利于职工的方式修改可行权条件，公司在处理可行权条件时，考虑修改后\n的可行权条件。",
      "chunk_type": "child",
      "parent_id": "e563af48",
      "child_ids": [],
      "sibling_ids": [
        "2780c1a5",
        "7b453183",
        "e67a8af3"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1135,
      "page_number": 111,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          111
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.332434",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1135,
        "word_count": 37,
        "sentence_count": 15,
        "chinese_char_count": 1010,
        "readability_score": 0.0,
        "information_density": 0.12334801762114538,
        "coherence_score": 0.7512316463161945,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9559471365638768,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "费用",
        "现金",
        "净资产",
        "资产负债表",
        "资本公积",
        "股份"
      ]
    },
    {
      "chunk_id": "2780c1a5",
      "content": "按公司承\n担负债的公允价值，将当期取得的服务计入相关成本或费用和相应的负债。(3) 修改、终止股份支付计划\n如果修改增加了所授予的权益工具的公允价值，公司按照权益工具公允价值的增加相应地确认取得服\n务的增加；如果修改增加了所授予的权益工具的数量，公司将增加的权益工具的公允价值相应地确认为取\n得服务的增加；如果公司按照有利于职工的方式修改可行权条件，公司在处理可行权条件时，考虑修改后\n的可行权条件。\n\n如果修改减少了授予的权益工具的公允价值，公司继续以权益工具在授予日的公允价值为基础，确认\n取得服务的金额，而不考虑权益工具公允价值的减少；如果修改减少了授予的权益工具的数量，公司将减\n少部分作为已授予的权益工具的取消来进行处理；如果以不利于职工的方式修改了可行权条件，在处理可\n行权条件时，不考虑修改后的可行权条件。如果公司在等待期内取消了所授予的权益工具或结算了所授予的权益工具（因未满足可行权条件而被\n取消的除外），则将取消或结算作为加速可行权处理，立即确认原本在剩余等待期内确认的金额。112。\n\n38、优先股、永续债等其他金融工具\n39、收入\n是否已执行新收入准则\n□ 是 √ 否\n1. 收入确认原则\n(1) 销售商品\n销售商品收入在同时满足下列条件时予以确认：1) 将商品所有权上的主要风险和报酬转移给购货方；\n2) 公司不再保留通常与所有权相联系的继续管理权，也不再对已售出的商品实施有效控制；3) 收入的金\n额能够可靠地计量；4) 相关的经济利益很可能流入；5) 相关的已发生或将发生的成本能够可靠地计量。(2) 提供劳务\n提供劳务交易的结果在资产负债表日能够可靠估计的（同时满足收入的金额能够可靠地计量、相关经\n济利益很可能流入、交易的完工进度能够可靠地确定、交易中已发生和将发生的成本能够可靠地计量），\n采用完工百分比法确认提供劳务的收入，并按已经发生的成本占估计总成本的比例确定提供劳务交易的完\n工进度。提供劳务交易的结果在资产负债表日不能够可靠估计的，若已经发生的劳务成本预计能够得到补\n偿，按已经发生的劳务成本金额确认提供劳务收入，并按相同金额结转劳务成本；若已经发生的劳务成本\n预计不能够得到补偿，将已经发生的劳务成本计入当期损益，不确认劳务收入。\n\n(3) 让渡资产使用权\n让渡资产使用权在同时满足相关的经济利益很可能流入、收入金额能够可靠计量时，确认让渡资产使\n用权的收入。利息收入按照他人使用本公司货币资金的时间和实际利率计算确定；使用费收入按有关合同\n或协议约定的收费时间和方法计算确定。2. 收入确认的具体方法\n公司主要销售原料药及医药中间体、染料及染颜料中间体等产品。\n\n内销产品收入确认需满足以下条件：\n公司已根据合同约定将产品交付给购货方，且产品销售收入金额已确定，已经收回货款或取得了收款凭证\n且相关的经济利益很可能流入，产品相关的成本能够可靠地计量。",
      "chunk_type": "child",
      "parent_id": "e563af48",
      "child_ids": [],
      "sibling_ids": [
        "3b04fbe4",
        "7b453183",
        "e67a8af3"
      ],
      "position": 1,
      "start_char": 935,
      "end_char": 2135,
      "page_number": 111,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          111
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.332697",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1200,
        "word_count": 48,
        "sentence_count": 14,
        "chinese_char_count": 1052,
        "readability_score": 0.0,
        "information_density": 0.125,
        "coherence_score": 0.7104074811146595,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9506666666666668,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "资产负债表",
        "股份",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "7b453183",
      "content": "的收入。利息收入按照他人使用本公司货币资金的时间和实际利率计算确定；使用费收入按有关合同\n或协议约定的收费时间和方法计算确定。2. 收入确认的具体方法\n公司主要销售原料药及医药中间体、染料及染颜料中间体等产品。\n\n内销产品收入确认需满足以下条件：\n公司已根据合同约定将产品交付给购货方，且产品销售收入金额已确定，已经收回货款或取得了收款凭证\n且相关的经济利益很可能流入，产品相关的成本能够可靠地计量。外销产品收入确认需满足以下条件：公\n司已根据合同约定将产品报关、离港，取得提单，且产品销售收入金额已确定，已经收回货款或取得了收\n款凭证且相关的经济利益很可能流入，产品相关的成本能够可靠地计量。40、政府补助\n1. 政府补助在同时满足下列条件时予以确认：(1) 公司能够满足政府补助所附的条件；(2) 公司能够收\n到政府补助。\n\n政府补助为货币性资产的，按照收到或应收的金额计量。政府补助为非货币性资产的，按照\n公允价值计量；公允价值不能可靠取得的，按照名义金额计量。2. 与资产相关的政府补助判断依据及会计处理方法\n政府文件规定用于购建或以其他方式形成长期资产的政府补助划分为与资产相关的政府补助。\n\n政府文\n件不明确的，以取得该补助必须具备的基本条件为基础进行判断，以购建或其他方式形成长期资产为基本\n条件的作为与资产相关的政府补助。与资产相关的政府补助，冲减相关资产的账面价值或确认为递延收益。与资产相关的政府补助确认为递延收益的，在相关资产使用寿命内按照合理、系统的方法分期计入损益。\n\n按照名义金额计量的政府补助，直接计入当期损益。相关资产在使用寿命结束前被出售、转让、报废或发\n生毁损的，将尚未分配的相关递延收益余额转入资产处置当期的损益。3. 与收益相关的政府补助判断依据及会计处理方法\n除与资产相关的政府补助之外的政府补助划分为与收益相关的政府补助。\n\n对于同时包含与资产相关部\n113。\n\n分和与收益相关部分的政府补助，难以区分与资产相关或与收益相关的，整体归类为与收益相关的政府补\n助。与收益相关的政府补助，用于补偿以后期间的相关成本费用或损失的，确认为递延收益，在确认相关\n成本费用或损失的期间，计入当期损益或冲减相关成本；用于补偿已发生的相关成本费用或损失的，直接\n计入当期损益或冲减相关成本。4. 与公司日常经营活动相关的政府补助，按照经济业务实质，计入其他收益或冲减相关成本费用。\n\n与\n公司日常活动无关的政府补助，计入营业外收支。41、递延所得税资产/递延所得税负债\n1. 根据资产、负债的账面价值与其计税基础之间的差额（未作为资产和负债确认的项目按照税法规定\n可以确定其计税基础的，该计税基础与其账面数之间的差额），按照预期收回该资产或清偿该负债期间的\n适用税率计算确认递延所得税资产或递延所得税负债。",
      "chunk_type": "child",
      "parent_id": "e563af48",
      "child_ids": [],
      "sibling_ids": [
        "3b04fbe4",
        "2780c1a5",
        "e67a8af3"
      ],
      "position": 2,
      "start_char": 1935,
      "end_char": 3102,
      "page_number": 111,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          111
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.332950",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1167,
        "word_count": 38,
        "sentence_count": 27,
        "chinese_char_count": 1031,
        "readability_score": 0.0,
        "information_density": 0.12853470437017994,
        "coherence_score": 0.7731379721386511,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9533847472150814,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "应收",
        "所得税",
        "营业",
        "经营",
        "分配"
      ]
    },
    {
      "chunk_id": "e67a8af3",
      "content": "经营活动相关的政府补助，按照经济业务实质，计入其他收益或冲减相关成本费用。\n\n与\n公司日常活动无关的政府补助，计入营业外收支。41、递延所得税资产/递延所得税负债\n1. 根据资产、负债的账面价值与其计税基础之间的差额（未作为资产和负债确认的项目按照税法规定\n可以确定其计税基础的，该计税基础与其账面数之间的差额），按照预期收回该资产或清偿该负债期间的\n适用税率计算确认递延所得税资产或递延所得税负债。2. 确认递延所得税资产以很可能取得用来抵扣可抵扣暂时性差异的应纳税所得额为限。\n\n资产负债表\n日，有确凿证据表明未来期间很可能获得足够的应纳税所得额用来抵扣可抵扣暂时性差异的，确认以前会\n计期间未确认的递延所得税资产。3. 资产负债表日，对递延所得税资产的账面价值进行复核，如果未来期间很可能无法获得足够的应纳\n税所得额用以抵扣递延所得税资产的利益，则减记递延所得税资产的账面价值。在很可能获得足够的应纳\n税所得额时，转回减记的金额。\n\n4. 公司当期所得税和递延所得税作为所得税费用或收益计入当期损益，但不包括下列情况产生的所得\n税：(1) 企业合并；(2) 直接在所有者权益中确认的交易或者事项。42、租赁\n（1）经营租赁的会计处理方法\n公司为承租人时，在租赁期内各个期间按照直线法将租金计入相关资产成本或确认为当期损益，发生\n的初始直接费用，直接计入当期损益。或有租金在实际发生时计入当期损益。\n\n公司为出租人时，在租赁期内各个期间按照直线法将租金确认为当期损益，发生的初始直接费用，除\n金额较大的予以资本化并分期计入损益外，均直接计入当期损益。或有租金在实际发生时计入当期损益。（2）融资租赁的会计处理方法\n公司为承租人时，在租赁期开始日，公司以租赁开始日租赁资产公允价值与最低租赁付款额现值中两\n者较低者作为租入资产的入账价值，将最低租赁付款额作为长期应付款的入账价值，其差额为未确认融资\n费用，发生的初始直接费用，计入租赁资产价值。\n\n在租赁期各个期间，采用实际利率法计算确认当期的融\n资费用。公司为出租人时，在租赁期开始日，公司以租赁开始日最低租赁收款额与初始直接费用之和作为应收\n融资租赁款的入账价值，同时记录未担保余值；将最低租赁收款额、初始直接费用及未担保余值之和与其\n现值之和的差额确认为未实现融资收益。在租赁期各个期间，采用实际利率法计算确认当期的融资收入。\n\n43、其他重要的会计政策和会计估计\n与回购公司股份相关的会计处理方法\n因减少注册资本或奖励职工等原因收购本公司股份的，按实际支付的金额作为库存股处理，同时进行\n备查登记。如果将回购的股份注销，则将按注销股票面值和注销股数计算的股票面值总额与实际回购所支\n114。",
      "chunk_type": "child",
      "parent_id": "e563af48",
      "child_ids": [],
      "sibling_ids": [
        "3b04fbe4",
        "2780c1a5",
        "7b453183"
      ],
      "position": 3,
      "start_char": 2902,
      "end_char": 4027,
      "page_number": 111,
      "bbox": null,
      "element_type": "list",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          111
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.333188",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1125,
        "word_count": 36,
        "sentence_count": 22,
        "chinese_char_count": 993,
        "readability_score": 0.0,
        "information_density": 0.1511111111111111,
        "coherence_score": 0.6972529469265711,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9530666666666667,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "费用",
        "应收",
        "应付",
        "所得税",
        "资产负债表"
      ]
    },
    {
      "chunk_id": "0ac95618",
      "content": "付的金额之间的差额冲减资本公积，资本公积不足冲减的，冲减留存收益；如果将回购的股份奖励给本公\n司职工属于以权益结算的股份支付，于职工行权购买本公司股份收到价款时，转销交付职工的库存股成本\n和等待期内资本公积（其他资本公积）累计金额，同时，按照其差额调整资本公积（股本溢价）。44、重要会计政策和会计估计变更\n（1）重要会计政策变更\n√ 适用 □ 不适用\n会计政策变更的内容和原因 审批程序 备注\n本次会计政策变更已经公司第五届董事\n执行《关于修订印发2019年度一般企业\n会第二十三次会议及第五届监事第十九\n财务报表格式的通知》\n次会议审议通过\n财政部于2017年颁布了修订后的《企业\n会计准则第22号--金融工具确认和计\n量》、《企业会计准则第23号--金融资产\n本次会计政策变更已经公司第五届董事 公司根据新准则，已于2019年1月1日\n转移》、《企业会计准则第37号--金融工\n会第二十次会议及第五届监事第十六次 起将前期划分为可供出售金融资产的股\n具列报》三项会计准则，并要求单独在\n会议审议通过 权投资重分类至其他权益工具投资\n境内上市的企业自2019年1月1日起施\n行，根据新旧准则衔接规定，公司无需\n重述前期可比数。企业会计准则变化引起的会计政策变更\n1. 本公司根据财政部《关于修订印发2019年度一般企业财务报表格式的通知》(财会〔2019〕6号) 、\n《关于修订印发合并财务报表格式（2019版）的通知》(财会〔2019〕16号)和企业会计准则的要求编制2019\n年度财务报表，此项会计政策变更采用追溯调整法。\n\n2018年度财务报表受重要影响的报表项目和金额如下：\n原列报报表项目及金额 新列报报表项目及金额\n应收票据及应收账款 586,937,258.10应收票据 107,399,476.04\n应收账款 479,537,782.06\n应付票据及应付账款 791,915,463.78应付票据 490,006,533.85\n应付账款 301,908,929.93\n2. 本公司自2019年1月1日起执行财政部修订后的《企业会计准则第22号——金融工具确认和计量》《企\n业会计准则第23号——金融资产转移》《企业会计准则第24号——套期保值》以及《企业会计准则第37号\n——金融工具列报》（以下简称新金融工具准则）。根据相关新旧准则衔接规定，对可比期间信息不予调\n整，首次执行日执行新准则与原准则的差异追溯调整本报告期期初留存收益或其他综合收益。（2）重要会计估计变更\n□ 适用 √ 不适用\n（3）2019年起执行新金融工具准则、新收入准则或新租赁准则调整执行当年年初财务报表相关项目情况\n√ 适用 □ 不适用\n115。",
      "chunk_type": "child",
      "parent_id": "77cd7a88",
      "child_ids": [],
      "sibling_ids": [
        "7316d530",
        "062b56ba",
        "03dab5e4",
        "11620f53"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1121,
      "page_number": 115,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.334424",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1121,
        "word_count": 63,
        "sentence_count": 14,
        "chinese_char_count": 803,
        "readability_score": 0.0,
        "information_density": 0.16057091882247992,
        "coherence_score": 0.7918726434855468,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8865298840321141,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "投资",
        "应收",
        "应付",
        "合并",
        "股本",
        "资本公积"
      ]
    },
    {
      "chunk_id": "7316d530",
      "content": "第24号——套期保值》以及《企业会计准则第37号\n——金融工具列报》（以下简称新金融工具准则）。根据相关新旧准则衔接规定，对可比期间信息不予调\n整，首次执行日执行新准则与原准则的差异追溯调整本报告期期初留存收益或其他综合收益。（2）重要会计估计变更\n□ 适用 √ 不适用\n（3）2019年起执行新金融工具准则、新收入准则或新租赁准则调整执行当年年初财务报表相关项目情况\n√ 适用 □ 不适用\n115。\n\n合并资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 1,956,089,124.33 1,956,089,124.33\n结算备付金\n拆出资金\n交易性金融资产 150,000,000.00 150,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 107,399,476.04 -107,399,476.04\n应收账款 479,537,782.06 479,537,782.06\n应收款项融资 107,399,476.04 107,399,476.04\n预付款项 46,449,558.50 46,449,558.50\n应收保费\n应收分保账款\n应收分保合同准备金\n其他应收款 10,817,853.96 10,817,853.96\n其中：应收利息\n应收股利\n买入返售金融资产\n存货 905,418,218.49 905,418,218.49\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 227,882,993.23 77,882,993.23 -150,000,000.00\n流动资产合计 3,733,595,006.61 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00 0.00 -1,800,000.00\n其他债权投资\n116。",
      "chunk_type": "child",
      "parent_id": "77cd7a88",
      "child_ids": [],
      "sibling_ids": [
        "0ac95618",
        "062b56ba",
        "03dab5e4",
        "11620f53"
      ],
      "position": 1,
      "start_char": 921,
      "end_char": 1735,
      "page_number": 115,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.334648",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 814,
        "word_count": 76,
        "sentence_count": 28,
        "chinese_char_count": 350,
        "readability_score": 0.0,
        "information_density": 0.20884520884520885,
        "coherence_score": 0.5557002457002457,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7668304668304669,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "投资",
        "融资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "投资",
        "应收",
        "预付",
        "存货",
        "资产负债表",
        "合并",
        "报告"
      ]
    },
    {
      "chunk_id": "062b56ba",
      "content": "18,218.49\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 227,882,993.23 77,882,993.23 -150,000,000.00\n流动资产合计 3,733,595,006.61 3,733,595,006.61\n非流动资产：\n发放贷款和垫款\n债权投资\n可供出售金融资产 1,800,000.00 0.00 -1,800,000.00\n其他债权投资\n116。\n\n持有至到期投资\n长期应收款\n长期股权投资 66,088,139.79 66,088,139.79\n其他权益工具投资 1,800,000.00 1,800,000.00\n其他非流动金融资产\n投资性房地产 12,338,615.29 12,338,615.29\n固定资产 1,215,120,643.61 1,215,120,643.61\n在建工程 674,333,677.99 674,333,677.99\n生产性生物资产\n油气资产\n使用权资产\n无形资产 539,514,850.87 539,514,850.87\n开发支出\n商誉 757,736,770.14 757,736,770.14\n长期待摊费用 1,842,423.21 1,842,423.21\n递延所得税资产 32,487,223.69 32,487,223.69\n其他非流动资产 515,993.37 515,993.37\n非流动资产合计 3,301,778,337.96 3,301,778,337.96\n资产总计 7,035,373,344.57 7,035,373,344.57\n流动负债：\n短期借款 598,700,000.00 598,700,000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 490,006,533.85 490,006,533.85\n应付账款 301,908,929.93 301,908,929.93\n预收款项 19,196,692.94 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n117。",
      "chunk_type": "child",
      "parent_id": "77cd7a88",
      "child_ids": [],
      "sibling_ids": [
        "0ac95618",
        "7316d530",
        "03dab5e4",
        "11620f53"
      ],
      "position": 2,
      "start_char": 1535,
      "end_char": 2446,
      "page_number": 115,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.334857",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 911,
        "word_count": 89,
        "sentence_count": 43,
        "chinese_char_count": 264,
        "readability_score": 0.0,
        "information_density": 0.16465422612513722,
        "coherence_score": 0.45999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4817782656421514,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "投资",
        "应收",
        "应付",
        "预收",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "03dab5e4",
      "content": "000.00\n向中央银行借款\n拆入资金\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 490,006,533.85 490,006,533.85\n应付账款 301,908,929.93 301,908,929.93\n预收款项 19,196,692.94 19,196,692.94\n合同负债\n卖出回购金融资产款\n吸收存款及同业存放\n代理买卖证券款\n117。\n\n代理承销证券款\n应付职工薪酬 45,234,354.42 45,234,354.42\n应交税费 54,890,661.34 54,890,661.34\n其他应付款 24,723,304.20 24,723,304.20\n其中：应付利息 1,088,752.57 1,088,752.57\n应付股利 2,051,370.43 2,051,370.43\n应付手续费及佣金\n应付分保账款\n持有待售负债\n一年内到期的非流动\n44,365,875.00 44,365,875.00\n负债\n其他流动负债\n流动负债合计 1,579,026,351.68 1,579,026,351.68\n非流动负债：\n保险合同准备金\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 12,971,002.47 12,971,002.47\n递延收益 44,650,629.91 44,650,629.91\n递延所得税负债 8,175,428.28 8,175,428.28\n其他非流动负债\n非流动负债合计 65,797,060.66 65,797,060.66\n负债合计 1,644,823,412.34 1,644,823,412.34\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,663,367,822.47 2,663,367,822.47\n118。",
      "chunk_type": "child",
      "parent_id": "77cd7a88",
      "child_ids": [],
      "sibling_ids": [
        "0ac95618",
        "7316d530",
        "062b56ba",
        "11620f53"
      ],
      "position": 3,
      "start_char": 2246,
      "end_char": 3079,
      "page_number": 115,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.335061",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 833,
        "word_count": 85,
        "sentence_count": 37,
        "chinese_char_count": 265,
        "readability_score": 0.0,
        "information_density": 0.16806722689075632,
        "coherence_score": 0.41999999999999993,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5533013205282112,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "应付",
        "预收",
        "所得税",
        "股本",
        "资本公积",
        "回购",
        "税费"
      ]
    },
    {
      "chunk_id": "11620f53",
      "content": ",175,428.28\n其他非流动负债\n非流动负债合计 65,797,060.66 65,797,060.66\n负债合计 1,644,823,412.34 1,644,823,412.34\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,663,367,822.47 2,663,367,822.47\n118。\n\n减：库存股 325,880,561.68 325,880,561.68\n其他综合收益 -51,779.23 -51,779.23\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n一般风险准备\n未分配利润 1,232,481,918.50 1,232,481,918.50\n归属于母公司所有者权益\n5,390,549,932.23 5,390,549,932.23\n合计\n少数股东权益\n所有者权益合计 5,390,549,932.23 5,390,549,932.23\n负债和所有者权益总计 7,035,373,344.57 7,035,373,344.57\n调整情况说明\n母公司资产负债表\n单位：元\n项目 2018年12月31日 2019年01月01日 调整数\n流动资产：\n货币资金 983,565,710.16 983,565,710.16\n交易性金融资产 100,000,000.00 100,000,000.00\n以公允价值计量且其\n变动计入当期损益的金融\n资产\n衍生金融资产\n应收票据 20,885,763.88 20,885,763.88\n应收账款 149,204,899.98 149,204,899.98 -149,204,899.98\n应收款项融资 149,204,899.98 149,204,899.98\n预付款项 5,554,458.78 5,554,458.78\n其他应收款 1,043,055,918.72 1,043,055,918.72\n其中：应收利息\n应收股利 7,222,088,153.34 722,088,153.34\n存货 84,396,333.98 84,396,333.98\n合同资产\n持有待售资产\n一年内到期的非流动\n资产\n其他流动资产 105,920,135.97 5,920,135.97 -100,000,000.00\n119。",
      "chunk_type": "child",
      "parent_id": "77cd7a88",
      "child_ids": [],
      "sibling_ids": [
        "0ac95618",
        "7316d530",
        "062b56ba",
        "03dab5e4"
      ],
      "position": 4,
      "start_char": 2879,
      "end_char": 3887,
      "page_number": 115,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          115
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.335267",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1008,
        "word_count": 94,
        "sentence_count": 47,
        "chinese_char_count": 241,
        "readability_score": 0.0,
        "information_density": 0.1488095238095238,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5146825396825396,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "利润",
        "应收",
        "预付",
        "存货",
        "资产负债表",
        "股东权益",
        "母公司"
      ]
    },
    {
      "chunk_id": "ca6c9bb9",
      "content": "流动资产合计 2,392,583,221.47 2,392,583,221.47\n非流动资产：\n债权投资\n可供出售金融资产 23,017,502.51 -23,017,502.51\n其他债权投资\n持有至到期投资\n长期应收款\n长期股权投资 3,250,556,852.85 3,250,556,852.85\n其他权益工具投资 23,017,502.51 23,017,502.51\n其他非流动金融资产\n投资性房地产 16,409,402.65 16,409,402.65\n固定资产 182,948,202.54 182,948,202.54\n在建工程 20,490,208.35 20,490,208.35\n生产性生物资产\n油气资产\n使用权资产\n无形资产 17,059,632.32 17,059,632.32\n开发支出\n商誉\n长期待摊费用\n递延所得税资产 9,371,365.80 9,371,365.80\n其他非流动资产\n非流动资产合计 3,519,853,167.02 3,519,853,167.02\n资产总计 5,912,436,388.49 5,912,436,388.49\n流动负债：\n短期借款 287,000,000.00 287,000,000.00\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 202,286,262.85 202,286,262.85\n应付账款 25,423,635.65 25,423,635.65\n预收款项 7,777,982.57 7,777,982.57\n合同负债\n120。",
      "chunk_type": "child",
      "parent_id": "ca1b33e5",
      "child_ids": [],
      "sibling_ids": [
        "d3848548",
        "b4cf61ce",
        "a48868b1",
        "3ef4e788"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 682,
      "page_number": 120,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.336469",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 682,
        "word_count": 66,
        "sentence_count": 31,
        "chinese_char_count": 194,
        "readability_score": 0.0,
        "information_density": 0.219941348973607,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4797653958944282,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "投资",
        "应收",
        "应付",
        "预收",
        "固定资产",
        "无形资产"
      ]
    },
    {
      "chunk_id": "d3848548",
      "content": "436,388.49\n流动负债：\n短期借款 287,000,000.00 287,000,000.00\n交易性金融负债\n以公允价值计量且其\n变动计入当期损益的金融\n负债\n衍生金融负债\n应付票据 202,286,262.85 202,286,262.85\n应付账款 25,423,635.65 25,423,635.65\n预收款项 7,777,982.57 7,777,982.57\n合同负债\n120。\n\n应付职工薪酬 6,439,699.82 6,439,699.82\n应交税费 948,517.30 948,517.30\n其他应付款 104,178,588.96 104,178,588.96\n其中：应付利息 805,795.63 805,795.63\n应付股利 2,051,370.43 2,051,370.43\n持有待售负债\n一年内到期的非流动\n44,365,875.00 44,365,875.00\n负债\n其他流动负债\n流动负债合计 678,420,562.15 678,420,562.15\n非流动负债：\n长期借款\n应付债券\n其中：优先股\n永续债\n租赁负债\n长期应付款\n长期应付职工薪酬\n预计负债 12,971,002.47 12,971,002.47\n递延收益 1,262,720.34 1,262,720.34\n递延所得税负债\n其他非流动负债\n非流动负债合计 14,233,722.81 14,233,722.81\n负债合计 692,654,284.96 692,654,284.96\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,662,229,769.88 2,662,229,769.88\n减：库存股 325,880,561.68 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n121。",
      "chunk_type": "child",
      "parent_id": "ca1b33e5",
      "child_ids": [],
      "sibling_ids": [
        "ca6c9bb9",
        "b4cf61ce",
        "a48868b1",
        "3ef4e788"
      ],
      "position": 1,
      "start_char": 482,
      "end_char": 1320,
      "page_number": 120,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.336637",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 838,
        "word_count": 86,
        "sentence_count": 41,
        "chinese_char_count": 227,
        "readability_score": 0.0,
        "information_density": 0.1431980906921241,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5694510739856802,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "应付",
        "预收",
        "所得税",
        "股本",
        "资本公积",
        "税费",
        "公允价值",
        "借款"
      ]
    },
    {
      "chunk_id": "b4cf61ce",
      "content": ",654,284.96\n所有者权益：\n股本 1,618,820,253.00 1,618,820,253.00\n其他权益工具\n其中：优先股\n永续债\n资本公积 2,662,229,769.88 2,662,229,769.88\n减：库存股 325,880,561.68 325,880,561.68\n其他综合收益\n专项储备\n盈余公积 201,812,279.17 201,812,279.17\n121。\n\n未分配利润 1,062,800,363.16 1,062,800,363.16\n所有者权益合计 5,219,782,103.53 5,219,782,103.53\n负债和所有者权益总计 5,912,436,388.49 5,912,436,388.49\n调整情况说明\n（4）2019年起执行新金融工具准则或新租赁准则追溯调整前期比较数据说明\n□ 适用 √ 不适用\n45、其他\n六、税项\n1、主要税种及税率\n税种 计税依据 税率\n增值税 销售货物或提供应税劳务 19%、16%、13%、6%\n城市维护建设税 应缴流转税税额 7%、5%\n企业所得税 应纳税所得额 15%、16.5%、17%、20%、25%\n从价计征的，按房产原值一次减除30%\n房产税 后余值的1.2%计缴；从租计征的，按租 1.2%、12%\n金收入的12%计缴\n教育费附加 应缴流转税税额 3%\n地方教育附加 应缴流转税税额 2%\n存在不同企业所得税税率纳税主体的，披露情况说明\n纳税主体名称 所得税税率\n川南药业公司、台州前进公司、盐城瓯华\n公司、GeneVida GmbH 15%\n香港港翔公司 16.5%\nGANGXIANG（SINGAPORE） 17%\n上海海翔公司、东旭医化公司 20%\n除上述以外的其他纳税主体 25%\n2、税收优惠\n(二) 税收优惠\n1. 根据科学技术部火炬高科技产业开发中心国科火字〔2017〕201号文批复，川南药业公司通过高新\n技术企业复审备案，自2017年起减按15%的税率计缴企业所得税，认定有效期3年。2. 根据科学技术部火炬高科技产业开发中心国科火字〔2016〕149号文批复，台州前进公司通过高新\n122。\n\n技术企业复审备案，自2016年起减按15%的税率计缴企业所得税，认定有效期3年。认定资格有效期届满后，\n公司重新申请了高新技术企业资格认定，截至本财务报表批准报出日尚处于审核阶段，2019年度暂按15%\n的税率计缴。3. 根据江苏省科学技术厅、江苏省财政厅、江苏省国家税务局、江苏省地方税务局联合颁发的《高新\n技术企业证书》，盐城瓯华公司被认定为高新技术企业，自2017年起减按15%的税率计缴企业所得税，认\n定有效期3年。",
      "chunk_type": "child",
      "parent_id": "ca1b33e5",
      "child_ids": [],
      "sibling_ids": [
        "ca6c9bb9",
        "d3848548",
        "a48868b1",
        "3ef4e788"
      ],
      "position": 2,
      "start_char": 1120,
      "end_char": 2245,
      "page_number": 120,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.336856",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "公司重新申请了高新技术企业",
        "industry": null,
        "char_count": 1125,
        "word_count": 90,
        "sentence_count": 28,
        "chinese_char_count": 582,
        "readability_score": 0.0,
        "information_density": 0.14222222222222222,
        "coherence_score": 0.40665420683323494,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8069333333333333,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "收入",
        "利润",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "收入",
        "利润",
        "所得税",
        "股本",
        "资本公积",
        "未分配利润",
        "分配",
        "披露"
      ]
    },
    {
      "chunk_id": "a48868b1",
      "content": "16年起减按15%的税率计缴企业所得税，认定有效期3年。认定资格有效期届满后，\n公司重新申请了高新技术企业资格认定，截至本财务报表批准报出日尚处于审核阶段，2019年度暂按15%\n的税率计缴。3. 根据江苏省科学技术厅、江苏省财政厅、江苏省国家税务局、江苏省地方税务局联合颁发的《高新\n技术企业证书》，盐城瓯华公司被认定为高新技术企业，自2017年起减按15%的税率计缴企业所得税，认\n定有效期3年。\n\n4. 根据国家税务总局下发的《关于实施小型微利企业普惠性所得税减免政策有关问题的公告》（国家\n税务总局公告2019年第2号），上海海翔公司、东旭医化公司享受小型微利企业的税收优惠政策，减按20%\n的税率计缴企业所得税；对港翔科技公司所得减按25%计入应纳税所得额，按20%的税率缴纳企业所得税。3、其他\n七、合并财务报表项目注释\n1、货币资金\n单位： 元\n项目 期末余额 期初余额\n库存现金 131,545.99 195,522.60\n银行存款 1,525,298,726.49 1,852,939,694.25\n其他货币资金 31,145,099.97 102,953,907.48\n合计 1,556,575,372.45 1,956,089,124.33\n其中：存放在境外的款项总额 649,218.69 2,180,766.37\n因抵押、质押或冻结等对使用\n30,797,464.00 136,880,848.73\n有限制的款项总额\n其他说明\n[注]:期末银行定期存款116,083,968.00元。2、交易性金融资产\n单位： 元\n项目 期末余额 期初余额\n其中：\n指定以公允价值计量且其变动计入当期\n150,000,000.00\n损益的金融资产\n其中：\n银行理财产品 150,000,000.00\n合计 150,000,000.00\n其他说明：\n123。",
      "chunk_type": "child",
      "parent_id": "ca1b33e5",
      "child_ids": [],
      "sibling_ids": [
        "ca6c9bb9",
        "d3848548",
        "b4cf61ce",
        "3ef4e788"
      ],
      "position": 3,
      "start_char": 2045,
      "end_char": 2828,
      "page_number": 120,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.337078",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "公司重新申请了高新技术企业",
        "industry": null,
        "char_count": 783,
        "word_count": 54,
        "sentence_count": 24,
        "chinese_char_count": 427,
        "readability_score": 0.0,
        "information_density": 0.19157088122605365,
        "coherence_score": 0.3135486694677871,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8181353767560664,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资",
        "财务",
        "报表",
        "968.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "现金",
        "所得税",
        "合并",
        "税收",
        "税率",
        "企业所得税",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "3ef4e788",
      "content": "\n30,797,464.00 136,880,848.73\n有限制的款项总额\n其他说明\n[注]:期末银行定期存款116,083,968.00元。2、交易性金融资产\n单位： 元\n项目 期末余额 期初余额\n其中：\n指定以公允价值计量且其变动计入当期\n150,000,000.00\n损益的金融资产\n其中：\n银行理财产品 150,000,000.00\n合计 150,000,000.00\n其他说明：\n123。\n\n3、衍生金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n4、应收票据\n（1）应收票据分类列示\n单位： 元\n项目 期末余额 期初余额\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n其中：\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收票据坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备收回或转回金额重要的：\n124\n\n□ 适用 √ 不适用\n（3）期末公司已质押的应收票据\n单位： 元\n项目 期末已质押金额\n（4）期末公司已背书或贴现且在资产负债表日尚未到期的应收票据\n单位： 元\n项目 期末终止确认金额 期末未终止确认金额\n（5）期末公司因出票人未履约而将其转应收账款的票据\n单位： 元\n项目 期末转应收账款金额\n其他说明\n（6）本期实际核销的应收票据情况\n单位： 元\n项目 核销金额\n其中重要的应收票据核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收票据性质 核销金额 核销原因 履行的核销程序\n易产生\n应收票据核销说明：\n5、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按信用风险特征组\n合计提坏账准备\n125",
      "chunk_type": "child",
      "parent_id": "ca1b33e5",
      "child_ids": [],
      "sibling_ids": [
        "ca6c9bb9",
        "d3848548",
        "b4cf61ce",
        "a48868b1"
      ],
      "position": 4,
      "start_char": 2628,
      "end_char": 3622,
      "page_number": 120,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          120
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.337269",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 994,
        "word_count": 156,
        "sentence_count": 8,
        "chinese_char_count": 676,
        "readability_score": 0.0,
        "information_density": 0.130784708249497,
        "coherence_score": 0.5481016533986528,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8720321931589536,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资",
        "968.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "应收",
        "资产负债表",
        "披露",
        "公允价值",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "f7c29b48",
      "content": "按组合计提坏账准 500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n100.00% 8.19% 100.00% 7.61%\n备的应收账款 838.93 74.74 64.19 65.36 3.30 2.06\n其中：\n500,776, 40,995,2 459,781,5519,058,0 39,520,28 479,537,78\n合计 100.00% 8.19% 100.00% 7.61%\n838.93 74.74 64.19 65.36 3.30 2.06\n按单项计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n账龄组合 500,776,838.93 40,995,274.74 8.19%\n合计 500,776,838.93 40,995,274.74 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 481,295,912.96\n1至2年 2,351,572.07\n2至3年 4,521,732.29\n3年以上 12,607,621.61\n3至4年 8,370,022.99\n5年以上 4,237,598.62\n合计 500,776,838.93\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n126。",
      "chunk_type": "child",
      "parent_id": "6dae1ae0",
      "child_ids": [],
      "sibling_ids": [
        "83a3b5d7",
        "4ae189a4",
        "5bc215c5",
        "2285addc"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 742,
      "page_number": 126,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.338467",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 742,
        "word_count": 96,
        "sentence_count": 33,
        "chinese_char_count": 250,
        "readability_score": 0.0,
        "information_density": 0.026954177897574122,
        "coherence_score": 0.5795417789757412,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7347708894878706,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "披露"
      ]
    },
    {
      "chunk_id": "83a3b5d7",
      "content": "适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 481,295,912.96\n1至2年 2,351,572.07\n2至3年 4,521,732.29\n3年以上 12,607,621.61\n3至4年 8,370,022.99\n5年以上 4,237,598.62\n合计 500,776,838.93\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n126。\n\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n39,520,283.30 1,474,991.44 40,995,274.74\n备\n合计 39,520,283.30 1,474,991.44 40,995,274.74\n其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数的\n单位名称 应收账款期末余额 坏账准备期末余额\n比例\n重庆天地药业有限责任\n85,994,787.83 17.17% 4,299,739.39\n公司\nACS DOBFAR S.P.A 30,318,565.17 6.05% 1,515,928.26\nFIS-FABBRICA\nITALIANA SINTETICI 23,576,101.39 4.71% 1,178,805.07\nS.P.A\nPFIZER ASIA\nMANUFACTURING 19,767,647.40 3.95% 988,382.37\nPTE LTD\n绍兴舜德进出口有限公\n18,868,983.58 3.77% 943,449.18\n司\n合计 178,526,085.37 35.65%\n127。",
      "chunk_type": "child",
      "parent_id": "6dae1ae0",
      "child_ids": [],
      "sibling_ids": [
        "f7c29b48",
        "4ae189a4",
        "5bc215c5",
        "2285addc"
      ],
      "position": 1,
      "start_char": 542,
      "end_char": 1405,
      "page_number": 126,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.338648",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 863,
        "word_count": 108,
        "sentence_count": 36,
        "chinese_char_count": 305,
        "readability_score": 0.0,
        "information_density": 0.02317497103128621,
        "coherence_score": 0.295,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7413673232908459,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "披露"
      ]
    },
    {
      "chunk_id": "4ae189a4",
      "content": "ICA\nITALIANA SINTETICI 23,576,101.39 4.71% 1,178,805.07\nS.P.A\nPFIZER ASIA\nMANUFACTURING 19,767,647.40 3.95% 988,382.37\nPTE LTD\n绍兴舜德进出口有限公\n18,868,983.58 3.77% 943,449.18\n司\n合计 178,526,085.37 35.65%\n127。\n\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n6、应收款项融资\n单位： 元\n项目 期末余额 期初余额\n应收票据 74,531,666.41 107,399,476.04\n合计 74,531,666.41 107,399,476.04\n应收款项融资本期增减变动及公允价值变动情况\n□ 适用 √ 不适用\n如是按照预期信用损失一般模型计提应收款项融资减值准备，请参照其他应收款的披露方式披露减值准备的相关信息：\n□ 适用 √ 不适用\n其他说明：\n7、预付款项\n（1）预付款项按账龄列示\n单位： 元\n期末余额 期初余额\n账龄\n金额 比例 金额 比例\n1年以内 29,093,214.59 85.94% 37,487,264.60 80.71%\n1至2年 2,278,425.47 6.73% 6,488,949.11 13.97%\n2至3年 683,976.07 2.02% 1,208,687.98 2.60%\n3年以上 1,795,870.66 5.31% 1,264,656.81 2.72%\n合计 33,851,486.79 -- 46,449,558.50 --\n账龄超过1年且金额重要的预付款项未及时结算原因的说明：\n（2）按预付对象归集的期末余额前五名的预付款情况\n期末余额前5名的预付款项合计数为9,950,421.65元，占预付款项期末余额合计数的比例为29.39%。其他说明：\n8、其他应收款\n单位： 元\n128。",
      "chunk_type": "child",
      "parent_id": "6dae1ae0",
      "child_ids": [],
      "sibling_ids": [
        "f7c29b48",
        "83a3b5d7",
        "5bc215c5",
        "2285addc"
      ],
      "position": 2,
      "start_char": 1205,
      "end_char": 2049,
      "page_number": 126,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.338847",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 844,
        "word_count": 93,
        "sentence_count": 40,
        "chinese_char_count": 300,
        "readability_score": 0.0,
        "information_density": 0.15402843601895735,
        "coherence_score": 0.5469668246445497,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7421800947867299,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资",
        "421.65元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "应收",
        "预付",
        "披露",
        "减值",
        "公允价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "5bc215c5",
      "content": ",870.66 5.31% 1,264,656.81 2.72%\n合计 33,851,486.79 -- 46,449,558.50 --\n账龄超过1年且金额重要的预付款项未及时结算原因的说明：\n（2）按预付对象归集的期末余额前五名的预付款情况\n期末余额前5名的预付款项合计数为9,950,421.65元，占预付款项期末余额合计数的比例为29.39%。其他说明：\n8、其他应收款\n单位： 元\n128。\n\n项目 期末余额 期初余额\n其他应收款 18,297,536.18 10,817,853.96\n合计 18,297,536.18 10,817,853.96\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n单位： 元\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n129\n\n（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n应收暂付款 19,403,087.81 21,023,388.15\n押金保证金 8,079,470.25 4,971,398.75\n应收出口退税 6,994,977.96\n拆借款 1,250,962.00 1,797,563.33\n其 他 697,469.95 126,777.96\n合计 36,425,967.97 27,919,128.19\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 17,101,274.23 17,101,274.23\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 1,027,157.56 1,027,157.56\n2019年12月31日余额 18,128,431.79 18,128,431.79\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 12,618,376.33\n1至2年 8,167,903.05\n2至3年 1,213,988.18\n3年以上 14,425,700.41\n3至4年 2,214,569.77\n4至5年 510,000.00\n5年以上 11,701,130.64\n合计 36,425,967.",
      "chunk_type": "child",
      "parent_id": "6dae1ae0",
      "child_ids": [],
      "sibling_ids": [
        "f7c29b48",
        "83a3b5d7",
        "4ae189a4",
        "2285addc"
      ],
      "position": 3,
      "start_char": 1849,
      "end_char": 3044,
      "page_number": 126,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.339087",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1195,
        "word_count": 150,
        "sentence_count": 39,
        "chinese_char_count": 499,
        "readability_score": 0.0,
        "information_density": 0.06694560669456068,
        "coherence_score": 0.6847280334728033,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7670292887029289,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "421.65元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收",
        "预付",
        "披露",
        "减值",
        "借款"
      ]
    },
    {
      "chunk_id": "2285addc",
      "content": "\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 12,618,376.33\n1至2年 8,167,903.05\n2至3年 1,213,988.18\n3年以上 14,425,700.41\n3至4年 2,214,569.77\n4至5年 510,000.00\n5年以上 11,701,130.64\n合计 36,425,967.97\n130。\n\n3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n台州市椒江朝晖建\n押金保证金 2,950,000.001年以内 8.10% 147,500.00\n设投资有限公司\n台州市椒江朝晖建\n押金保证金 3,850,000.001-2年 10.57% 1,155,000.00\n设投资有限公司\n应收出口退税 应收出口退税 6,584,960.261年以内 18.08%\nPFIZER ASIA\nMANUFACTURIN 应收暂付款 5,000,000.003年以上 13.73% 5,000,000.00\nG PTE LTD\n浙江福仁瑞生物科\n应收暂付款 3,222,047.103年以上 8.85% 3,222,047.10\n技有限公司\n台州市中荣化工有\n应收暂付款 2,160,572.193年以上 5.93% 2,160,572.19\n限公司\n合计 -- 23,767,579.55 -- 65.26% 11,685,119.29\n131。",
      "chunk_type": "child",
      "parent_id": "6dae1ae0",
      "child_ids": [],
      "sibling_ids": [
        "f7c29b48",
        "83a3b5d7",
        "4ae189a4",
        "5bc215c5"
      ],
      "position": 4,
      "start_char": 2844,
      "end_char": 3745,
      "page_number": 126,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          126
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.339352",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "设投资有限公司",
        "industry": null,
        "char_count": 901,
        "word_count": 115,
        "sentence_count": 30,
        "chinese_char_count": 410,
        "readability_score": 0.0,
        "information_density": 0.04439511653718091,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.76503884572697,
      "relevance_score": 1.0,
      "keywords": [
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "应收",
        "披露"
      ]
    },
    {
      "chunk_id": "58c89ba6",
      "content": "6）涉及政府补助的应收款项\n单位： 元\n预计收取的时间、金额\n单位名称 政府补助项目名称 期末余额 期末账龄\n及依据\n7）因金融资产转移而终止确认的其他应收款\n8）转移其他应收款且继续涉入形成的资产、负债金额\n其他说明：\n9、存货\n是否已执行新收入准则\n□ 是 √ 否\n（1）存货分类\n单位： 元\n期末余额 期初余额\n项目\n账面余额 跌价准备 账面价值 账面余额 跌价准备 账面价值\n原材料 209,787,752.67 2,975,404.23 206,812,348.44 243,008,744.60 2,867,227.10 240,141,517.50\n在产品 164,776,116.17 4,244,871.82 160,531,244.35 214,182,041.63 3,023,716.71 211,158,324.92\n库存商品 493,928,178.91 22,117,971.87 471,810,207.04 477,155,579.50 23,329,566.31 453,826,013.19\n委托加工物资 3,831,460.77 3,831,460.77 292,362.88 292,362.88\n合计 872,323,508.52 29,338,247.92 842,985,260.60 934,638,728.61 29,220,510.12 905,418,218.49\n（2）存货跌价准备\n单位： 元\n本期增加金额 本期减少金额\n项目 期初余额 期末余额\n计提 其他 转回或转销 其他\n原材料 2,867,227.10 2,011,138.75 1,902,961.62 2,975,404.23\n在产品 3,023,716.71 2,237,971.32 1,016,816.21 4,244,871.82\n库存商品 23,329,566.31 5,540,847.35 6,752,441.79 22,117,971.87\n合计 29,220,510.12 9,789,957.42 9,672,219.62 29,338,247.92\n132。",
      "chunk_type": "child",
      "parent_id": "5c911725",
      "child_ids": [],
      "sibling_ids": [
        "54fb5f99",
        "728a9c7f",
        "c1765ba8",
        "3ec0ca56"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 901,
      "page_number": 132,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.340597",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 901,
        "word_count": 96,
        "sentence_count": 45,
        "chinese_char_count": 216,
        "readability_score": 0.0,
        "information_density": 0.13318534961154274,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5956714761376248,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "应收",
        "存货",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "54fb5f99",
      "content": "902,961.62 2,975,404.23\n在产品 3,023,716.71 2,237,971.32 1,016,816.21 4,244,871.82\n库存商品 23,329,566.31 5,540,847.35 6,752,441.79 22,117,971.87\n合计 29,220,510.12 9,789,957.42 9,672,219.62 29,338,247.92\n132。\n\n（3）存货期末余额含有借款费用资本化金额的说明\n（4）期末建造合同形成的已完工未结算资产情况\n单位： 元\n项目 金额\n其他说明：\n10、合同资产\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n合同资产的账面价值在本期内发生的重大变动金额和原因：\n单位： 元\n项目 变动金额 变动原因\n如是按照预期信用损失一般模型计提合同资产坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n□ 适用 √ 不适用\n本期合同资产计提减值准备情况\n单位： 元\n项目 本期计提 本期转回 本期转销/核销 原因\n其他说明：\n11、持有待售资产\n单位： 元\n项目 期末账面余额 减值准备 期末账面价值 公允价值 预计处置费用 预计处置时间\n其他说明：\n12、一年内到期的非流动资产\n单位： 元\n项目 期末余额 期初余额\n重要的债权投资/其他债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n其他说明：\n133\n\n13、其他流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n待抵扣增值税进项税额 67,707,757.62 76,026,728.13\n员工购房借款 118,571.44\n预缴企业所得税 8,699,173.52 1,737,693.66\n银行理财产品\n合计 76,406,931.14 77,882,993.23\n其他说明：\n14、债权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n重要的债权投资\n单位： 元\n期末余额 期初余额\n债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n15、其他债权投资\n单位： 元\n134。",
      "chunk_type": "child",
      "parent_id": "5c911725",
      "child_ids": [],
      "sibling_ids": [
        "58c89ba6",
        "728a9c7f",
        "c1765ba8",
        "3ec0ca56"
      ],
      "position": 1,
      "start_char": 701,
      "end_char": 1848,
      "page_number": 132,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.340834",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1147,
        "word_count": 170,
        "sentence_count": 23,
        "chinese_char_count": 636,
        "readability_score": 0.0,
        "information_density": 0.1133391455972101,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.821795989537925,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "费用",
        "投资",
        "应收",
        "存货",
        "所得税",
        "披露",
        "增值税",
        "企业所得税"
      ]
    },
    {
      "chunk_id": "728a9c7f",
      "content": "面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n15、其他债权投资\n单位： 元\n134。\n\n累计在其他\n本期公允价 累计公允价 综合收益中\n项目 期初余额 应计利息 期末余额 成本 备注\n值变动 值变动 确认的损失\n准备\n重要的其他债权投资\n单位： 元\n期末余额 期初余额\n其他债权项目\n面值 票面利率 实际利率 到期日 面值 票面利率 实际利率 到期日\n减值准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n其他说明：\n16、长期应收款\n（1）长期应收款情况\n单位： 元\n期末余额 期初余额\n项目 折现率区间\n账面余额 坏账准备 账面价值 账面余额 坏账准备 账面价值\n坏账准备减值情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n135。",
      "chunk_type": "child",
      "parent_id": "5c911725",
      "child_ids": [],
      "sibling_ids": [
        "58c89ba6",
        "54fb5f99",
        "c1765ba8",
        "3ec0ca56"
      ],
      "position": 2,
      "start_char": 1648,
      "end_char": 2381,
      "page_number": 132,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.341065",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 733,
        "word_count": 128,
        "sentence_count": 2,
        "chinese_char_count": 514,
        "readability_score": 0.0,
        "information_density": 0.10914051841746249,
        "coherence_score": 0.82,
        "standards_profile_summary": {}
      },
      "quality_score": 0.826057298772169,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "投资",
        "应收",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "c1765ba8",
      "content": "项目 折现率区间\n账面余额 坏账准备 账面价值 账面余额 坏账准备 账面价值\n坏账准备减值情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额在\n—— —— —— ——\n本期\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n135。\n\n（2）因金融资产转移而终止确认的长期应收款\n（3）转移长期应收款且继续涉入形成的资产、负债金额\n其他说明\n17、长期股权投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n被投资单 权益法下 宣告发放 减值准备\n(账面价 其他综合 其他权益 计提减值 (账面价\n位 追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n22,946,28 -4,811,81 18,134,47\n制药厂有\n7.25 4.84 2.41\n限公司\n江苏北华\n17,617,12 -4,471,33 13,145,79\n环保科技\n7.70 1.54 6.16\n有限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n滨海临海\n11,676,63 -6,521,79 1,449,207 3,705,631 7,730,979\n资产管理\n2.15 2.73 .56 .86 .27\n有限公司\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n小计\n9.79 49.80 .56 2.43 .27\n66,088,13 -16,759,5 1,449,207 47,879,38 7,730,979\n合计\n9.79 49.80 .56 2.43 .27\n其他说明\n18、其他权益工具投资\n单位： 元\n项目 期末余额 期初余额\n杭州寓鑫创业投资合伙企业（有限合伙） 20,000,000.00\n滨海宏博环境技术服务股份有限公司 1,800,000.00\n合计 20,000,000.00 1,800,000.00\n136。",
      "chunk_type": "child",
      "parent_id": "5c911725",
      "child_ids": [],
      "sibling_ids": [
        "58c89ba6",
        "54fb5f99",
        "728a9c7f",
        "3ec0ca56"
      ],
      "position": 3,
      "start_char": 2181,
      "end_char": 3133,
      "page_number": 132,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.341246",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 952,
        "word_count": 145,
        "sentence_count": 30,
        "chinese_char_count": 398,
        "readability_score": 0.0,
        "information_density": 0.16806722689075632,
        "coherence_score": 0.672020202020202,
        "standards_profile_summary": {}
      },
      "quality_score": 0.640546218487395,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金",
        "投资",
        "应收",
        "股权",
        "股份",
        "减值"
      ]
    },
    {
      "chunk_id": "3ec0ca56",
      "content": "-16,759,5 1,449,207 47,879,38 7,730,979\n合计\n9.79 49.80 .56 2.43 .27\n其他说明\n18、其他权益工具投资\n单位： 元\n项目 期末余额 期初余额\n杭州寓鑫创业投资合伙企业（有限合伙） 20,000,000.00\n滨海宏博环境技术服务股份有限公司 1,800,000.00\n合计 20,000,000.00 1,800,000.00\n136。\n\n分项披露本期非交易性权益工具投资\n单位： 元\n指定为以公允价\n其他综合收益转 其他综合收益转\n值计量且其变动\n项目名称 确认的股利收入 累计利得 累计损失 入留存收益的金 入留存收益的原\n计入其他综合收\n额 因\n益的原因\n其他说明：\n(2) 指定为以公允价值计量且其变动计入其他综合收益的权益工具投资的原因\n公司持有对杭州寓鑫创业投资合伙企业（有限合伙）、滨海宏博环境技术服务股份有限公司的股权投\n资属于非交易性权益工具投资，因此公司将其指定为以公允价值计量且其变动计入其他综合收益的权益工\n具投资。19、其他非流动金融资产\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n20、投资性房地产\n（1）采用成本计量模式的投资性房地产\n√ 适用 □ 不适用\n单位： 元\n项目 房屋、建筑物 土地使用权 在建工程 合计\n一、账面原值\n1.期初余额 26,022,834.98 26,022,834.98\n2.本期增加金额\n（1）外购\n（2）存货\\固定资产\n\\在建工程转入\n（3）企业合并增加\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 26,022,834.98 26,022,834.98\n137。",
      "chunk_type": "child",
      "parent_id": "5c911725",
      "child_ids": [],
      "sibling_ids": [
        "58c89ba6",
        "54fb5f99",
        "728a9c7f",
        "c1765ba8"
      ],
      "position": 4,
      "start_char": 2933,
      "end_char": 3641,
      "page_number": 132,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          132
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.341458",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "滨海宏博环境技术服务股份有限公司",
        "industry": null,
        "char_count": 708,
        "word_count": 83,
        "sentence_count": 20,
        "chinese_char_count": 403,
        "readability_score": 0.0,
        "information_density": 0.22598870056497175,
        "coherence_score": 0.619976872104774,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8276836158192091,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "投资",
        "存货",
        "固定资产",
        "合并",
        "股权",
        "股份"
      ]
    },
    {
      "chunk_id": "3687009b",
      "content": "二、累计折旧和累计摊\n销\n1.期初余额 13,684,219.69 13,684,219.69\n2.本期增加金额 1,131,663.83 1,131,663.83\n（1）计提或摊销 1,131,663.83 1,131,663.83\n3.本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额 14,815,883.52 14,815,883.52\n三、减值准备\n1.期初余额\n2.本期增加金额\n（1）计提\n3、本期减少金额\n（1）处置\n（2）其他转出\n4.期末余额\n四、账面价值\n1.期末账面价值 11,206,951.46 11,206,951.46\n2.期初账面价值 12,338,615.29 12,338,615.29\n（2）采用公允价值计量模式的投资性房地产\n□ 适用 √ 不适用\n（3）未办妥产权证书的投资性房地产情况\n单位： 元\n项目 账面价值 未办妥产权证书原因\n其他说明\n138\n\n21、固定资产\n单位： 元\n项目 期末余额 期初余额\n固定资产 1,724,407,333.34 1,215,120,643.61\n合计 1,724,407,333.34 1,215,120,643.61\n（1）固定资产情况\n单位： 元\n项目 房屋及建筑物 通用设备 专用设备 运输工具 合计\n一、账面原值：\n1.期初余额 942,004,302.57 151,282,471.21 1,160,756,948.05 56,927,137.86 2,310,970,859.69\n2.本期增加金额 127,058,302.67 26,510,821.36 531,882,141.44 4,549,773.50 690,001,038.97\n（1）购置 363,159.41 320,013.97 4,549,773.50 5,232,946.88\n（2）在建工程\n127,058,302.67 26,147,661.95 531,562,127.47 684,768,092.09\n转入\n（3）企业合并\n增加\n3.本期减少金额 13,603,089.42 4,778,065.53 40,235,121.09 1,713,041.92 60,329,317.96\n（1）处置或报\n13,603,089.42 4,778,065.53 40,235,121.09 1,713,041.92 60,329,317.96\n废\n4.期末余额 1,055,459,515.82 173,015,227.04 1,652,403,968.40 59,763,869.44 2,940,642,580.70\n二、累计折旧\n1.期初余额 353,145,143.22 114,199,096.34 571,568,602.36 44,658,442.31 1,083,571,284.23\n2.",
      "chunk_type": "child",
      "parent_id": "2562245d",
      "child_ids": [],
      "sibling_ids": [
        "b1d833e0",
        "a98cc793",
        "6b4b7bc0"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1192,
      "page_number": 138,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          138
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.342570",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1192,
        "word_count": 119,
        "sentence_count": 69,
        "chinese_char_count": 258,
        "readability_score": 0.0,
        "information_density": 0.10067114093959732,
        "coherence_score": 0.23182608695652174,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6865771812080537,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "投资",
        "固定资产",
        "合并",
        "折旧",
        "摊销",
        "减值",
        "公允价值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "b1d833e0",
      "content": "1.92 60,329,317.96\n废\n4.期末余额 1,055,459,515.82 173,015,227.04 1,652,403,968.40 59,763,869.44 2,940,642,580.70\n二、累计折旧\n1.期初余额 353,145,143.22 114,199,096.34 571,568,602.36 44,658,442.31 1,083,571,284.23\n2.本期增加金额 52,644,012.36 14,146,453.54 99,289,757.27 5,610,282.17 171,690,505.34\n（1）计提 52,644,012.36 14,146,453.54 99,289,757.27 5,610,282.17 171,690,505.34\n3.本期减少金额 9,335,681.39 4,537,067.86 35,777,262.22 1,569,383.59 51,219,395.06\n（1）处置或报\n9,335,681.39 4,537,067.86 35,777,262.22 1,569,383.59 51,219,395.06\n废\n4.期末余额 396,453,474.19 123,808,482.02 635,081,097.41 48,699,340.89 1,204,042,394.51\n三、减值准备\n1.期初余额 717,598.43 44,323.56 11,517,009.86 12,278,931.85\n139。",
      "chunk_type": "child",
      "parent_id": "2562245d",
      "child_ids": [],
      "sibling_ids": [
        "3687009b",
        "a98cc793",
        "6b4b7bc0"
      ],
      "position": 1,
      "start_char": 992,
      "end_char": 1648,
      "page_number": 138,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          138
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.342817",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 656,
        "word_count": 54,
        "sentence_count": 48,
        "chinese_char_count": 46,
        "readability_score": 0.0,
        "information_density": 0.03048780487804878,
        "coherence_score": 0.22099999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4423780487804878,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "折旧",
        "减值"
      ]
    },
    {
      "chunk_id": "a98cc793",
      "content": "067.86 35,777,262.22 1,569,383.59 51,219,395.06\n废\n4.期末余额 396,453,474.19 123,808,482.02 635,081,097.41 48,699,340.89 1,204,042,394.51\n三、减值准备\n1.期初余额 717,598.43 44,323.56 11,517,009.86 12,278,931.85\n139。\n\n2.本期增加金额 103,473.25 396,068.47 499,541.72\n（1）计提 103,473.25 396,068.47 499,541.72\n3.本期减少金额 585,620.72 585,620.72\n（1）处置或报\n585,620.72 585,620.72\n废\n4.期末余额 131,977.71 147,796.81 11,913,078.33 12,192,852.85\n四、账面价值\n1.期末账面价值 658,874,063.92 49,058,948.21 1,005,409,792.66 11,064,528.55 1,724,407,333.34\n2.期初账面价值 588,141,560.92 37,039,051.31 577,671,335.83 12,268,695.55 1,215,120,643.61\n（2）暂时闲置的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值 备注\n房屋及建筑物 96,021,538.73 24,413,427.38 71,608,111.35\n通用设备 6,855,762.41 5,595,164.87 143,649.07 1,116,948.47\n专用设备 145,417,971.06 110,109,458.33 732,234.31 34,576,278.42\n（3）通过融资租赁租入的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值\n（4）通过经营租赁租出的固定资产\n单位： 元\n项目 期末账面价值\n（5）未办妥产权证书的固定资产情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n公司及子公司房屋建筑物 136,044,964.45公司正在办理产权证书\n其他说明\n140。",
      "chunk_type": "child",
      "parent_id": "2562245d",
      "child_ids": [],
      "sibling_ids": [
        "3687009b",
        "b1d833e0",
        "6b4b7bc0"
      ],
      "position": 2,
      "start_char": 1448,
      "end_char": 2409,
      "page_number": 138,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          138
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.343025",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 961,
        "word_count": 97,
        "sentence_count": 58,
        "chinese_char_count": 220,
        "readability_score": 0.0,
        "information_density": 0.11446409989594172,
        "coherence_score": 0.2297068965517241,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6725286160249739,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "经营",
        "折旧",
        "减值",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "6b4b7bc0",
      "content": "8.33 732,234.31 34,576,278.42\n（3）通过融资租赁租入的固定资产情况\n单位： 元\n项目 账面原值 累计折旧 减值准备 账面价值\n（4）通过经营租赁租出的固定资产\n单位： 元\n项目 期末账面价值\n（5）未办妥产权证书的固定资产情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n公司及子公司房屋建筑物 136,044,964.45公司正在办理产权证书\n其他说明\n140。\n\n（6）固定资产清理\n单位： 元\n项目 期末余额 期初余额\n其他说明\n22、在建工程\n单位： 元\n项目 期末余额 期初余额\n在建工程 535,836,082.97 653,154,180.21\n工程物资 24,838,551.46 21,179,497.78\n合计 560,674,634.43 674,333,677.99\n（1）在建工程情况\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n公司及子公司房\n2,107,384.23 2,107,384.23 6,025,551.57 6,025,551.57\n屋建设工程\n原料药及中间体\nCMO中心扩建 198,852,943.52 198,852,943.52 165,628,666.75 165,628,666.75\n项目\n川南药业公司设\n9,204,900.26 9,204,900.26 7,184,188.76 7,184,188.76\n备安装工程\n环保设施改造项\n41,262,820.03 41,262,820.03 80,121,501.45 80,121,501.45\n目\n台州前进公司\n15500吨活性染\n36,676,707.08 36,676,707.08 147,592,362.30 147,592,362.30\n料产业升级及配\n套项目\n台州振港公司年\n产2500吨关健中\n6,050,304.05 6,050,304.05 42,843,192.74 42,843,192.74\n间体产业一体化\n项目\n台州振港公司年\n产700吨M-562\n285,309.30 285,309.30 93,276,176.18 93,276,176.18\n关键中间体产业\n一体化项目\n141。",
      "chunk_type": "child",
      "parent_id": "2562245d",
      "child_ids": [],
      "sibling_ids": [
        "3687009b",
        "b1d833e0",
        "a98cc793"
      ],
      "position": 3,
      "start_char": 2209,
      "end_char": 3166,
      "page_number": 138,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          138
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.343275",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 957,
        "word_count": 110,
        "sentence_count": 40,
        "chinese_char_count": 318,
        "readability_score": 0.0,
        "information_density": 0.11494252873563218,
        "coherence_score": 0.3245454545454545,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7150470219435736,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "固定资产",
        "经营",
        "折旧",
        "减值",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "3121b911",
      "content": "台州振港公司年\n产18500吨染料 68,227,065.54 68,227,065.54 5,450,450.43 5,450,450.43\n产业升级项目\n盐城瓯华公司设\n26,608,200.30 26,608,200.30 22,261,730.30 22,261,730.30\n备安装工程\n医药中试车间技\n17,149,684.37 17,149,684.37\n改项目\n医药综合研发中\n15,253,236.88 15,253,236.88 775,995.69 775,995.69\n心\n台州振港公司\n250吨美罗培南 44,267,447.48 44,267,447.48\n侧链项目\n零星工程 87,039,764.30 87,039,764.30 64,844,679.67 64,844,679.67\n合计 535,836,082.97 535,836,082.97 653,154,180.21 653,154,180.21\n（2）重要在建工程项目本期变动情况\n单位： 元\n本期转 工程累 其中：本\n本期其 利息资 本期利\n项目名 期初余 本期增 入固定 期末余 计投入 工程进 期利息 资金来\n预算数 他减少 本化累 息资本\n称 额 加金额 资产金 额 占预算 度 资本化 源\n金额 计金额 化率\n额 比例 金额\n公司及\n子公司 1,816,86 4,597,40 4,306,88 2,107,38 金融机\n房屋建 9.49 0.47 5.73 4.23 构贷款\n设工程\n原料药\n及中间\n46,034.5 165,628, 94,079,7 60,855,5 198,852, 募股资\n体CMO 70.92%70.00\n8 666.75 99.70 22.93 943.52 金\n中心扩\n建项目\n川南药\n业公司 7,184,18 31,205,6 29,184,9 9,204,90 金融机\n设备安 8.76 20.68 09.18 0.26 构贷款\n装工程\n环保设\n15,502.0 80,121,5 35,646,6 74,505,3 41,262,8 募股资\n施改造 75.01%75.00\n0 01.45 30.19 11.61 20.03 金\n项目\n142。",
      "chunk_type": "child",
      "parent_id": "9eb06dd3",
      "child_ids": [],
      "sibling_ids": [
        "9c52f261",
        "8595d6f2",
        "17019779",
        "acc8db4c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 945,
      "page_number": 142,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.344679",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 945,
        "word_count": 138,
        "sentence_count": 47,
        "chinese_char_count": 236,
        "readability_score": 0.0,
        "information_density": 0.021164021164021166,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4792592592592592,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "9c52f261",
      "content": ".52 金\n中心扩\n建项目\n川南药\n业公司 7,184,18 31,205,6 29,184,9 9,204,90 金融机\n设备安 8.76 20.68 09.18 0.26 构贷款\n装工程\n环保设\n15,502.0 80,121,5 35,646,6 74,505,3 41,262,8 募股资\n施改造 75.01%75.00\n0 01.45 30.19 11.61 20.03 金\n项目\n142。\n\n台州前\n进公司\n15500吨\n活性染 40,160.0 147,592, 154,147, 265,062, 36,676,7 金融机\n75.13%75.00\n料产业 0 362.30 165.63 820.85 07.08 构贷款\n升级及\n配套项\n目\n台州振\n港公司\n产2500\n吨关健 42,843,1 12,166,1 48,959,0 6,050,30 金融机\n7,850.00 102.09%95.00\n中间体 92.74 71.56 60.25 4.05 构贷款\n产业一\n体化项\n目\n台州振\n港公司\n年产700\n吨\n10,000.0 93,276,1 10,517,0 103,507, 285,309. 金融机\nM-562 106.83%99.00\n0 76.18 68.25 935.13 30 构贷款\n关键中\n间体产\n业一体\n化项目\n台州振\n港公司\n年产\n80,000.0 5,450,45 82,575,2 19,798,6 68,227,0 金融机\n18500吨 13.86%15.00\n0 0.43 81.47 66.36 65.54 构贷款\n染料产\n业升级\n项目\n盐城瓯\n华公司 26,470,4 5,218,03 5,080,24 26,608,2 金融机\n设备安 12.38 4.21 6.29 00.30 构贷款\n装工程\n医药中\n试车间 17,149,6 6,878,35 24,028,0 募股资\n9,256.00 43.31%45.00\n技改项 84.37 9.38 43.75 金\n目\n143。",
      "chunk_type": "child",
      "parent_id": "9eb06dd3",
      "child_ids": [],
      "sibling_ids": [
        "3121b911",
        "8595d6f2",
        "17019779",
        "acc8db4c"
      ],
      "position": 1,
      "start_char": 745,
      "end_char": 1613,
      "page_number": 142,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.345265",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 868,
        "word_count": 147,
        "sentence_count": 52,
        "chinese_char_count": 171,
        "readability_score": 0.0,
        "information_density": 0.01152073732718894,
        "coherence_score": 0.24216993464052286,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4133640552995392,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "8595d6f2",
      "content": "7 66.36 65.54 构贷款\n染料产\n业升级\n项目\n盐城瓯\n华公司 26,470,4 5,218,03 5,080,24 26,608,2 金融机\n设备安 12.38 4.21 6.29 00.30 构贷款\n装工程\n医药中\n试车间 17,149,6 6,878,35 24,028,0 募股资\n9,256.00 43.31%45.00\n技改项 84.37 9.38 43.75 金\n目\n143。\n\n医药综\n15,073.0 775,995. 35,025,9 20,548,7 15,253,2 募股资\n合研发 23.75%25\n0 69 51.78 10.59 36.88 金\n中心\n台州振\n港公司\n250吨美 16,000.0 44,267,4 44,267,4 金融机\n27.67%30\n罗培南 0 47.48 47.48 构贷款\n侧链项\n目\n零星工 64,844,6 51,125,0 28,929,9 87,039,7 金融机\n程 79.67 64.05 79.42 64.30 构贷款\n239,875. 653,154, 567,449, 684,768, 535,836,\n合计 -- -- --\n58 180.21 994.85 092.09 082.97\n（3）本期计提在建工程减值准备情况\n单位： 元\n项目 本期计提金额 计提原因\n其他说明\n（4）工程物资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n专用材料 9,806,701.25 9,806,701.25 7,121,142.67 7,121,142.67\n专用设备 15,031,850.21 15,031,850.21 14,058,355.11 14,058,355.11\n合计 24,838,551.46 24,838,551.46 21,179,497.78 21,179,497.78\n其他说明：\n23、生产性生物资产\n（1）采用成本计量模式的生产性生物资产\n□ 适用 √ 不适用\n（2）采用公允价值计量模式的生产性生物资产\n□ 适用 √ 不适用\n144。",
      "chunk_type": "child",
      "parent_id": "9eb06dd3",
      "child_ids": [],
      "sibling_ids": [
        "3121b911",
        "9c52f261",
        "17019779",
        "acc8db4c"
      ],
      "position": 2,
      "start_char": 1413,
      "end_char": 2316,
      "page_number": 142,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.345476",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 903,
        "word_count": 140,
        "sentence_count": 45,
        "chinese_char_count": 227,
        "readability_score": 0.0,
        "information_density": 0.08859357696567,
        "coherence_score": 0.32714285714285707,
        "standards_profile_summary": {}
      },
      "quality_score": 0.616500553709856,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "减值",
        "公允价值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "17019779",
      "content": "15,031,850.21 15,031,850.21 14,058,355.11 14,058,355.11\n合计 24,838,551.46 24,838,551.46 21,179,497.78 21,179,497.78\n其他说明：\n23、生产性生物资产\n（1）采用成本计量模式的生产性生物资产\n□ 适用 √ 不适用\n（2）采用公允价值计量模式的生产性生物资产\n□ 适用 √ 不适用\n144。\n\n24、油气资产\n□ 适用 √ 不适用\n25、使用权资产\n单位： 元\n项目 合计\n其他说明：\n26、无形资产\n（1）无形资产情况\n单位： 元\n项目 土地使用权 专利权 非专利技术 排污权 特许使用权 特许经营权 软件 合计\n一、账面原值\n1.期初 505,413,741. 162,305,608. 11,915,094.3 688,369,268.\n3,072,760.00 3,143,452.96 1,168,163.69 1,350,447.87\n余额 33 72 7 94\n2.本期 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n增加金额 6 0\n（1） 21,772,997.8 24,316,024.3\n897,814.40 939,029.99 706,182.05\n购置 6 0\n（2）\n内部研发\n（3）\n企业合并增\n加\n3.本期减 11,116,461.1\n9,433,962.30 1,682,498.83\n少金额 3\n（1） 11,116,461.1\n9,433,962.30 1,682,498.83\n处置 3\n4.期末 527,186,739. 163,203,423. 701,568,832.\n2,481,132.07 4,011,789.99 1,460,954.13 1,168,163.69 2,056,629.92\n余额 19 12 11\n二、累计摊销\n1.期初 55,429,191.3 77,337,200.9 143,036,807.\n4,014,069.57 1,700,580.26 2,061,454.24 1,168,163.69 1,326,147.82\n余额 9 3 90\n145。",
      "chunk_type": "child",
      "parent_id": "9eb06dd3",
      "child_ids": [],
      "sibling_ids": [
        "3121b911",
        "9c52f261",
        "8595d6f2",
        "acc8db4c"
      ],
      "position": 3,
      "start_char": 2116,
      "end_char": 3073,
      "page_number": 142,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.345683",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 957,
        "word_count": 124,
        "sentence_count": 55,
        "chinese_char_count": 175,
        "readability_score": 0.0,
        "information_density": 0.11494252873563218,
        "coherence_score": 0.2528896551724138,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6731452455590387,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "无形资产",
        "合并",
        "经营",
        "摊销",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "acc8db4c",
      "content": "32.07 4,011,789.99 1,460,954.13 1,168,163.69 2,056,629.92\n余额 19 12 11\n二、累计摊销\n1.期初 55,429,191.3 77,337,200.9 143,036,807.\n4,014,069.57 1,700,580.26 2,061,454.24 1,168,163.69 1,326,147.82\n余额 9 3 90\n145。\n\n2.本期 11,263,080.3 17,674,391.8 30,277,923.1\n563,042.72 517,839.30 205,844.64 53,724.30\n增加金额 6 1 3\n（1） 11,263,080.3 17,674,391.8 30,277,923.1\n563,042.72 517,839.30 205,844.64 53,724.30\n计提 6 1 3\n3.本期\n3,616,352.13 1,584,866.25 5,201,218.38\n减少金额\n（1）\n3,616,352.13 1,584,866.25 5,201,218.38\n处置\n4.期末 66,692,271.7 95,011,592.7 168,113,512.\n960,760.16 2,218,419.56 682,432.63 1,168,163.69 1,379,872.12\n余额 5 4 65\n三、减值准备\n1.期初\n5,817,610.17 5,817,610.17\n余额\n2.本期\n增加金额\n（1）\n计提\n3.本期\n5,817,610.17 5,817,610.17\n减少金额\n（1）处\n置\n4.期末\n余额\n四、账面价值\n1.期末 460,494,467. 68,191,830.3 533,455,319.\n1,520,371.91 1,793,370.43 778,521.50 676,757.80\n账面价值 44 8 46\n2.期初 449,984,549. 84,968,407.7 539,514,850.\n2,083,414.63 1,372,179.74 1,081,998.72 24,300.05\n账面价值 94 9 87\n本期末通过公司内部研发形成的无形资产占无形资产余额的比例。（2）未办妥产权证书的土地使用权情况\n单位： 元\n项目 账面价值 未办妥产权证书的原因\n146。",
      "chunk_type": "child",
      "parent_id": "9eb06dd3",
      "child_ids": [],
      "sibling_ids": [
        "3121b911",
        "9c52f261",
        "8595d6f2",
        "17019779"
      ],
      "position": 4,
      "start_char": 2873,
      "end_char": 3882,
      "page_number": 142,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          142
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.345907",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1009,
        "word_count": 120,
        "sentence_count": 72,
        "chinese_char_count": 139,
        "readability_score": 0.0,
        "information_density": 0.06937561942517344,
        "coherence_score": 0.3520416666666667,
        "standards_profile_summary": {}
      },
      "quality_score": 0.563230921704658,
      "relevance_score": 1.0,
      "keywords": [
        "资产"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "无形资产",
        "摊销",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "170e3cf8",
      "content": "台州市枫南东路以北、东港大道以东 4,679,700.00公司正在办理产权证书\n其他说明：\n27、开发支出\n单位： 元\n本期增加金额 本期减少金额\n项目 期初余额 内部开发支 确认为无形 转入当期损 期末余额\n其他\n出 资产 益\n合计\n其他说明\n28、商誉\n（1）商誉账面原值\n单位： 元\n被投资单位名称 本期增加 本期减少\n或形成商誉的事 期初余额 期末余额\n企业合并形成的 处置\n项\n台州前进公司 757,736,770.14 757,736,770.14\n合计 757,736,770.14 757,736,770.14\n（2）商誉减值准备\n单位： 元\n被投资单位名称 本期增加 本期减少\n或形成商誉的事 期初余额 期末余额\n计提 处置\n项\n合计\n商誉所在资产组或资产组组合的相关信息\n资产组或资产组组合的构成 台州前进公司资产组\n资产组或资产组组合的账面价值 1,726,678,155.03\n分摊至本资产组或资产组组合的商誉账面价值及分摊 全部分摊至台州前进公司资产组\n方法\n包含商誉的资产组或资产组组合的账面价值 2,484,414,925.17\n资产组或资产组组合是否与购买日、以前年度商誉减 是\n值测试时所确定的资产组或资产组组合一致\n147。\n\n说明商誉减值测试过程、关键参数（如预计未来现金流量现值时的预测期增长率、稳定期增长率、利润率、折现率、预测期\n等）及商誉减值损失的确认方法：\n商誉的可收回金额按照预计未来现金流量的现值计算，其预计现金流量根据公司批准的5年期现金流\n量预测为基础，现金流量预测使用的折现率14.16%(2018年：13.00%)，公司根据历史实际经营数据、行业\n发展趋势、预期收入增长率、毛利率等指标编制预测未来5年现金流量，预测期以后的现金流量维持不变。减值测试中采用的其他关键数据包括：产品预计售价、销量、生产成本及其他相关费用。公司根据历史经验及对市场发展的预测确定上述关键数据。\n\n公司采用的折现率是反映当前市场货币时间价\n值和相关资产组特定风险的税前利率。上述对可收回金额的预计表明商誉并未出现减值损失。",
      "chunk_type": "child",
      "parent_id": "36447bd5",
      "child_ids": [],
      "sibling_ids": [
        "bab01330",
        "acb7a0db",
        "74aa6e04",
        "821fab08"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 880,
      "page_number": 147,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.347120",
        "report_type": "资产负债表",
        "fiscal_year": 2018,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 880,
        "word_count": 73,
        "sentence_count": 15,
        "chinese_char_count": 640,
        "readability_score": 0.0,
        "information_density": 0.19318181818181818,
        "coherence_score": 0.588210942375702,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8909090909090909,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "成本",
        "利润",
        "现金流",
        "投资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "投资",
        "商誉",
        "合并",
        "毛利率"
      ]
    },
    {
      "chunk_id": "bab01330",
      "content": "13.00%)，公司根据历史实际经营数据、行业\n发展趋势、预期收入增长率、毛利率等指标编制预测未来5年现金流量，预测期以后的现金流量维持不变。减值测试中采用的其他关键数据包括：产品预计售价、销量、生产成本及其他相关费用。公司根据历史经验及对市场发展的预测确定上述关键数据。\n\n公司采用的折现率是反映当前市场货币时间价\n值和相关资产组特定风险的税前利率。上述对可收回金额的预计表明商誉并未出现减值损失。商誉减值测试的影响\n其他说明\n29、长期待摊费用\n单位： 元\n项目 期初余额 本期增加金额 本期摊销金额 其他减少金额 期末余额\n经营租入固定资产\n1,842,423.21 223,651.32 1,618,771.89\n改良支出\n合计 1,842,423.21 223,651.32 1,618,771.89\n其他说明\n30、递延所得税资产/递延所得税负债\n（1）未经抵销的递延所得税资产\n单位： 元\n期末余额 期初余额\n项目\n可抵扣暂时性差异 递延所得税资产 可抵扣暂时性差异 递延所得税资产\n资产减值准备 70,299,465.99 14,376,262.42 68,698,671.21 14,236,323.65\n内部交易未实现利润 39,421,112.05 6,246,640.41 62,503,070.92 9,773,506.85\n与资产相关的政府补助\n43,621,205.16 6,716,780.73 36,278,025.15 5,567,975.82\n分摊\n预计负债 11,637,669.47 2,909,417.37\n合计 153,341,783.20 27,339,683.56 179,117,436.75 32,487,223.69\n（2）未经抵销的递延所得税负债\n单位： 元\n项目 期末余额 期初余额\n148。",
      "chunk_type": "child",
      "parent_id": "36447bd5",
      "child_ids": [],
      "sibling_ids": [
        "170e3cf8",
        "acb7a0db",
        "74aa6e04",
        "821fab08"
      ],
      "position": 1,
      "start_char": 680,
      "end_char": 1456,
      "page_number": 147,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.347321",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 776,
        "word_count": 66,
        "sentence_count": 31,
        "chinese_char_count": 370,
        "readability_score": 0.0,
        "information_density": 0.21907216494845363,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7907216494845362,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "利润",
        "现金流",
        "经营"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "利润",
        "现金",
        "固定资产",
        "商誉",
        "所得税"
      ]
    },
    {
      "chunk_id": "acb7a0db",
      "content": "与资产相关的政府补助\n43,621,205.16 6,716,780.73 36,278,025.15 5,567,975.82\n分摊\n预计负债 11,637,669.47 2,909,417.37\n合计 153,341,783.20 27,339,683.56 179,117,436.75 32,487,223.69\n（2）未经抵销的递延所得税负债\n单位： 元\n项目 期末余额 期初余额\n148。\n\n应纳税暂时性差异 递延所得税负债 应纳税暂时性差异 递延所得税负债\n单位价值500万元以下\n固定资产一次性税前抵 179,410,105.32 30,527,355.71 44,259,216.46 8,175,428.28\n扣\n合计 179,410,105.32 30,527,355.71 44,259,216.46 8,175,428.28\n（3）以抵销后净额列示的递延所得税资产或负债\n单位： 元\n递延所得税资产和负债 抵销后递延所得税资产 递延所得税资产和负债 抵销后递延所得税资产\n项目\n期末互抵金额 或负债期末余额 期初互抵金额 或负债期初余额\n递延所得税资产 27,339,683.56 32,487,223.69\n递延所得税负债 30,527,355.71 8,175,428.28\n（4）未确认递延所得税资产明细\n单位： 元\n项目 期末余额 期初余额\n可抵扣暂时性差异 34,056.67 42,122.21\n可抵扣亏损 54,023,245.91 120,721,788.89\n合计 54,057,302.58 120,763,911.10\n（5）未确认递延所得税资产的可抵扣亏损将于以下年度到期\n单位： 元\n年份 期末金额 期初金额 备注\n2021年 106,844,539.90\n2022年 13,876,526.38 13,876,526.38\n2023年 722.61 722.61\n2024年 40,145,996.92\n合计 54,023,245.91 120,721,788.89 --\n其他说明：\n31、其他非流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n149。",
      "chunk_type": "child",
      "parent_id": "36447bd5",
      "child_ids": [],
      "sibling_ids": [
        "170e3cf8",
        "bab01330",
        "74aa6e04",
        "821fab08"
      ],
      "position": 2,
      "start_char": 1256,
      "end_char": 2179,
      "page_number": 147,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.347538",
        "report_type": "资产负债表",
        "fiscal_year": 2021,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 923,
        "word_count": 104,
        "sentence_count": 38,
        "chinese_char_count": 319,
        "readability_score": 0.0,
        "information_density": 0.10834236186348863,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6982665222101841,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "500万元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "固定资产",
        "所得税",
        "价值"
      ]
    },
    {
      "chunk_id": "74aa6e04",
      "content": "金额 期初金额 备注\n2021年 106,844,539.90\n2022年 13,876,526.38 13,876,526.38\n2023年 722.61 722.61\n2024年 40,145,996.92\n合计 54,023,245.91 120,721,788.89 --\n其他说明：\n31、其他非流动资产\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n149。\n\n预付软件款 450,000.00 515,993.37\n合计 450,000.00 515,993.37\n其他说明：\n32、短期借款\n（1）短期借款分类\n单位： 元\n项目 期末余额 期初余额\n质押借款 76,700,000.00\n抵押借款 50,066,500.00 143,000,000.00\n保证借款 20,000,000.00\n信用借款 150,200,529.59 359,000,000.00\n合计 200,267,029.59 598,700,000.00\n短期借款分类的说明：\n（2）已逾期未偿还的短期借款情况\n本期末已逾期未偿还的短期借款总额为元，其中重要的已逾期未偿还的短期借款情况如下：\n单位： 元\n借款单位 期末余额 借款利率 逾期时间 逾期利率\n其他说明：\n33、交易性金融负债\n单位： 元\n项目 期末余额 期初余额\n其中：\n其中：\n其他说明：\n34、衍生金融负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n150\n\n35、应付票据\n单位： 元\n种类 期末余额 期初余额\n银行承兑汇票 238,306,005.00 490,006,533.85\n合计 238,306,005.00 490,006,533.85\n本期末已到期未支付的应付票据总额为元。36、应付账款\n（1）应付账款列示\n单位： 元\n项目 期末余额 期初余额\n货 款 139,912,212.13 157,970,026.94\n工程设备款 212,622,391.34 137,429,777.27\n其 他 10,905,980.49 6,509,125.72\n合计 363,440,583.96 301,908,929.93\n（2）账龄超过1年的重要应付账款\n单位： 元\n项目 期末余额 未偿还或结转的原因\n其他说明：\n37、预收款项\n是否已执行新收入准则\n□ 是 √ 否\n（1）预收款项列示\n单位： 元\n项目 期末余额 期初余额\n货 款 12,919,749.09 19,196,692.94\n合计 12,919,749.09 19,196,692.94\n（2）账龄超过1年的重要预收款项\n单位： 元\n151。",
      "chunk_type": "child",
      "parent_id": "36447bd5",
      "child_ids": [],
      "sibling_ids": [
        "170e3cf8",
        "bab01330",
        "acb7a0db",
        "821fab08"
      ],
      "position": 3,
      "start_char": 1979,
      "end_char": 3087,
      "page_number": 147,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.347782",
        "report_type": "资产负债表",
        "fiscal_year": 2021,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1108,
        "word_count": 148,
        "sentence_count": 39,
        "chinese_char_count": 405,
        "readability_score": 0.0,
        "information_density": 0.09025270758122743,
        "coherence_score": 0.4905054151624548,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7462093862815884,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "应付",
        "预收",
        "预付",
        "借款"
      ]
    },
    {
      "chunk_id": "821fab08",
      "content": "929.93\n（2）账龄超过1年的重要应付账款\n单位： 元\n项目 期末余额 未偿还或结转的原因\n其他说明：\n37、预收款项\n是否已执行新收入准则\n□ 是 √ 否\n（1）预收款项列示\n单位： 元\n项目 期末余额 期初余额\n货 款 12,919,749.09 19,196,692.94\n合计 12,919,749.09 19,196,692.94\n（2）账龄超过1年的重要预收款项\n单位： 元\n151。\n\n项目 期末余额 未偿还或结转的原因\n（3）期末建造合同形成的已结算未完工项目情况\n单位： 元\n项目 金额\n其他说明：\n38、合同负债\n单位： 元\n项目 期末余额 期初余额\n报告期内账面价值发生重大变动的金额和原因\n单位： 元\n项目 变动金额 变动原因\n39、应付职工薪酬\n（1）应付职工薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n一、短期薪酬 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n二、离职后福利-设定提\n3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n存计划\n三、辞退福利 26,656.73 26,656.73\n合计 45,234,354.42 326,240,321.13 319,107,533.27 52,367,142.28\n（2）短期薪酬列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、工资、奖金、津贴和\n38,780,553.62 273,368,159.46 267,353,757.95 44,794,955.13\n补贴\n2、职工福利费 15,919,594.19 15,919,594.19\n3、社会保险费 2,440,565.13 8,976,976.99 8,845,418.72 2,572,123.40\n其中：医疗保险费 1,731,912.00 7,358,904.85 7,221,509.07 1,869,307.78\n工伤保险费 518,490.75 1,058,240.23 1,071,709.37 505,021.61\n生育保险费 190,162.38 559,831.91 552,200.28 197,794.01\n152。",
      "chunk_type": "child",
      "parent_id": "36447bd5",
      "child_ids": [],
      "sibling_ids": [
        "170e3cf8",
        "bab01330",
        "acb7a0db",
        "74aa6e04"
      ],
      "position": 4,
      "start_char": 2887,
      "end_char": 3866,
      "page_number": 147,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          147
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.348032",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 979,
        "word_count": 118,
        "sentence_count": 43,
        "chinese_char_count": 305,
        "readability_score": 0.0,
        "information_density": 0.09193054136874362,
        "coherence_score": 0.30999999999999994,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7246169560776302,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "收入"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "收入",
        "应付",
        "预收",
        "报告",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "1114d1d8",
      "content": "4、住房公积金 286,968.00 9,072,162.00 9,110,730.00 248,400.00\n5、工会经费和职工教育\n132,082.69 2,529,511.30 1,766,967.57 894,626.42\n经费\n合计 41,640,169.44 309,866,403.94 302,996,468.43 48,510,104.95\n（3）设定提存计划列示\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n1、基本养老保险 3,311,287.25 15,768,975.90 15,505,552.02 3,574,711.13\n2、失业保险费 282,897.73 578,284.56 578,856.09 282,326.20\n合计 3,594,184.98 16,347,260.46 16,084,408.11 3,857,037.33\n其他说明：\n40、应交税费\n单位： 元\n项目 期末余额 期初余额\n增值税 9,523,602.71 9,931,701.18\n企业所得税 28,390,504.27 37,886,210.59\n个人所得税 764,210.55 778,807.41\n城市维护建设税 501,005.62 756,017.40\n房产税 3,435,584.90 2,902,210.71\n土地使用税 1,583,236.07 1,592,945.01\n教育费附加 214,716.69 435,378.81\n地方教育附加 143,144.46 290,252.54\n印花税 123,171.95 107,074.83\n残疾人就业保障金 73,107.05 60,062.86\n环境保护税 28,921.28 150,000.00\n合计 44,781,205.55 54,890,661.34\n其他说明：\n41、其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付利息 1,088,752.57\n153。",
      "chunk_type": "child",
      "parent_id": "ace38c86",
      "child_ids": [],
      "sibling_ids": [
        "2dd41f41",
        "73bd12e0",
        "0ef8b4e6",
        "86a17610"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 836,
      "page_number": 153,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.349383",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 836,
        "word_count": 92,
        "sentence_count": 50,
        "chinese_char_count": 164,
        "readability_score": 0.0,
        "information_density": 0.05980861244019139,
        "coherence_score": 0.32016,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5220095693779904,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "所得税",
        "税费",
        "增值税",
        "企业所得税"
      ]
    },
    {
      "chunk_id": "2dd41f41",
      "content": "1\n地方教育附加 143,144.46 290,252.54\n印花税 123,171.95 107,074.83\n残疾人就业保障金 73,107.05 60,062.86\n环境保护税 28,921.28 150,000.00\n合计 44,781,205.55 54,890,661.34\n其他说明：\n41、其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付利息 1,088,752.57\n153。\n\n应付股利 2,051,370.43 2,051,370.43\n其他应付款 26,148,702.79 21,583,181.20\n合计 28,200,073.22 24,723,304.20\n（1）应付利息\n单位： 元\n项目 期末余额 期初余额\n短期借款应付利息 1,088,752.57\n合计 1,088,752.57\n重要的已逾期未支付的利息情况：\n单位： 元\n借款单位 逾期金额 逾期原因\n其他说明：\n（2）应付股利\n单位： 元\n项目 期末余额 期初余额\n发起人股东 2,051,370.43 2,051,370.43\n合计 2,051,370.43 2,051,370.43\n其他说明，包括重要的超过1年未支付的应付股利，应披露未支付原因：\n（3）其他应付款\n1）按款项性质列示其他应付款\n单位： 元\n项目 期末余额 期初余额\n应付暂收款 14,988,518.12 11,511,834.54\n出口货物运保费及佣金 8,226,443.88 3,988,336.40\n押金保证金 920,310.00 2,476,025.00\n暂借款 350,000.00 1,345,413.90\n其 他 1,663,430.79 2,261,571.36\n合计 26,148,702.79 21,583,181.20\n2）账龄超过1年的重要其他应付款\n单位： 元\n154。",
      "chunk_type": "child",
      "parent_id": "ace38c86",
      "child_ids": [],
      "sibling_ids": [
        "1114d1d8",
        "73bd12e0",
        "0ef8b4e6",
        "86a17610"
      ],
      "position": 1,
      "start_char": 636,
      "end_char": 1423,
      "page_number": 153,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.349586",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 787,
        "word_count": 95,
        "sentence_count": 37,
        "chinese_char_count": 246,
        "readability_score": 0.0,
        "information_density": 0.050825921219822115,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7250317662007624,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应付",
        "股东",
        "披露",
        "借款"
      ]
    },
    {
      "chunk_id": "73bd12e0",
      "content": "12 11,511,834.54\n出口货物运保费及佣金 8,226,443.88 3,988,336.40\n押金保证金 920,310.00 2,476,025.00\n暂借款 350,000.00 1,345,413.90\n其 他 1,663,430.79 2,261,571.36\n合计 26,148,702.79 21,583,181.20\n2）账龄超过1年的重要其他应付款\n单位： 元\n154。\n\n项目 期末余额 未偿还或结转的原因\n其他说明\n42、持有待售负债\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n43、一年内到期的非流动负债\n单位： 元\n项目 期末余额 期初余额\n一年内到期的长期应付款 44,365,875.00\n合计 44,365,875.00\n其他说明：\n44、其他流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n短期应付债券的增减变动：\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n其他说明：\n45、长期借款\n（1）长期借款分类\n单位： 元\n项目 期末余额 期初余额\n长期借款分类的说明：\n其他说明，包括利率区间：\n155\n\n46、应付债券\n（1）应付债券\n单位： 元\n项目 期末余额 期初余额\n（2）应付债券的增减变动（不包括划分为金融负债的优先股、永续债等其他金融工具）\n单位： 元\n按面值计 溢折价摊\n债券名称 面值 发行日期 债券期限 发行金额 期初余额 本期发行 本期偿还 期末余额\n提利息 销\n合计 -- -- --\n（3）可转换公司债券的转股条件、转股时间说明\n（4）划分为金融负债的其他金融工具说明\n期末发行在外的优先股、永续债等其他金融工具基本情况\n期末发行在外的优先股、永续债等金融工具变动情况表\n单位： 元\n发行在外的 期初 本期增加 本期减少 期末\n金融工具 数量 账面价值 数量 账面价值 数量 账面价值 数量 账面价值\n其他金融工具划分为金融负债的依据说明\n其他说明\n47、租赁负债\n单位：\n项目 期末余额 期初余额\n其他说明\n48、长期应付款\n单位： 元\n项目 期末余额 期初余额\n（1）按款项性质列示长期应付款\n单位： 元\n156\n\n项目 期末余额 期初余额\n其他说明：\n（2）专项应付款\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n其他说明：\n49、长期应付职工薪酬\n（1）长期应付职工薪酬表\n单位： 元\n项目 期末余额 期初余额\n（2）设定受益计划变动情况\n设定受益计划义务现值：\n单位： 元\n项目 本期发生额 上期发生额\n计划资产：\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划净负债（净资产）\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划的内容及与之相关风险、",
      "chunk_type": "child",
      "parent_id": "ace38c86",
      "child_ids": [],
      "sibling_ids": [
        "1114d1d8",
        "2dd41f41",
        "0ef8b4e6",
        "86a17610"
      ],
      "position": 2,
      "start_char": 1223,
      "end_char": 2423,
      "page_number": 153,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.349808",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1200,
        "word_count": 188,
        "sentence_count": 14,
        "chinese_char_count": 742,
        "readability_score": 0.0,
        "information_density": 0.1,
        "coherence_score": 0.32840746054519365,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8473333333333333,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "应付",
        "净资产",
        "账面价值",
        "借款",
        "价值",
        "债券"
      ]
    },
    {
      "chunk_id": "0ef8b4e6",
      "content": "余额 本期增加 本期减少 期末余额 形成原因\n其他说明：\n49、长期应付职工薪酬\n（1）长期应付职工薪酬表\n单位： 元\n项目 期末余额 期初余额\n（2）设定受益计划变动情况\n设定受益计划义务现值：\n单位： 元\n项目 本期发生额 上期发生额\n计划资产：\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划净负债（净资产）\n单位： 元\n项目 本期发生额 上期发生额\n设定受益计划的内容及与之相关风险、对公司未来现金流量、时间和不确定性的影响说明：\n设定受益计划重大精算假设及敏感性分析结果说明：\n其他说明：\n50、预计负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额 形成原因\n未支付合同义务及诉讼费 11,637,669.47\n未支付担保损失 1,333,333.00 1,333,333.00[注]\n157\n\n合计 1,333,333.00 12,971,002.47 --\n其他说明，包括重要预计负债的相关重要假设、估计说明：\n[注]：根据2000年12月16日浙江省台州市中级人民法院〔2000〕台经初字第204号《民事判决书》，公\n司为台州市染料化工(集团)公司向台州市椒江区财政局的4,000,000.00元借款提供保证，因该公司未按合同\n约定如期归还，本公司需承担三分之一的到期还款连带责任，并赔偿台州市椒江区财政局相应的损失，截\n至2019年12月31日该项判决尚未执行。对上述诉讼事项，公司已按应承担的连带责任计提预计负债\n1,333,333.00元。51、递延收益\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额 形成原因\n政府补助 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n未实现售后租回损\n1,307,404.76 402,278.40 905,126.36\n益\n合计 44,650,629.91 12,900,000.00 6,956,538.39 50,594,091.52 --\n涉及政府补助的项目：\n单位： 元\n本期计入营\n本期新增补 本期计入其 本期冲减成 与资产相关/\n负债项目 期初余额 业外收入金 其他变动 期末余额\n助金额 他收益金额 本费用金额 与收益相关\n额\n年产400吨\n碳青霉烯类\n1,423,820.2\n抗生素关键 5,695,281.12 4,271,460.84 与资产相关\n8\n中间体\n4-AA项目\n年产1吨瑞\n格列奈、10\n吨卡洛芬、\n10吨阿托伐\n醌、50吨\nT1620、300\n235,862.40 117,931.20 117,931.20 与资产相关\n吨聚卡波菲\n钙、300吨\n4,4'-二氟二\n苯甲酮、100\n吨奈韦拉平\n产业化项目\n158。",
      "chunk_type": "child",
      "parent_id": "ace38c86",
      "child_ids": [],
      "sibling_ids": [
        "1114d1d8",
        "2dd41f41",
        "73bd12e0",
        "86a17610"
      ],
      "position": 3,
      "start_char": 2223,
      "end_char": 3384,
      "page_number": 153,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.350060",
        "report_type": "资产负债表",
        "fiscal_year": 2000,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1161,
        "word_count": 132,
        "sentence_count": 27,
        "chinese_char_count": 612,
        "readability_score": 0.0,
        "information_density": 0.12058570198105083,
        "coherence_score": 0.49726528854435825,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8108527131782945,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "现金流",
        "000.00元",
        "333.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "费用",
        "现金",
        "应付",
        "净资产",
        "借款"
      ]
    },
    {
      "chunk_id": "86a17610",
      "content": "00吨\n碳青霉烯类\n1,423,820.2\n抗生素关键 5,695,281.12 4,271,460.84 与资产相关\n8\n中间体\n4-AA项目\n年产1吨瑞\n格列奈、10\n吨卡洛芬、\n10吨阿托伐\n醌、50吨\nT1620、300\n235,862.40 117,931.20 117,931.20 与资产相关\n吨聚卡波菲\n钙、300吨\n4,4'-二氟二\n苯甲酮、100\n吨奈韦拉平\n产业化项目\n158。\n\n催化净化处\n理塔建设项 140,000.00 30,000.00 110,000.00 与资产相关\n目\n年产50吨培\n南类产品及\n132,000.00 48,000.00 84,000.00 与资产相关\n扩建厂房技\n改项目\n企业技术中\n心创新能力 133,333.33 40,000.00 93,333.33 与资产相关\n建设项目\n年产8亿元\n(粒)口服固 7,065,200.00 997,440.00 6,067,760.00 与资产相关\n体制剂项目\n临海市创新\n驱动加快推\n进工业经济 1,042,718.40 208,543.68 834,174.72 与资产相关\n转型升级政\n策\n省级工业与\n信息化专项\n资金回收溶 632,766.12 92,599.92 540,166.20 与资产相关\n剂循环化技\n改项目\n省工业化和\n信息化深度\n融合示范试 457,675.28 66,169.92 391,505.36 与资产相关\n点区财政补\n助\n浙江省化学\n原料药基地\n椒江区块循 263,333.33 40,000.00 223,333.33 与资产相关\n环化改造项\n目补助资金\n159。",
      "chunk_type": "child",
      "parent_id": "ace38c86",
      "child_ids": [],
      "sibling_ids": [
        "1114d1d8",
        "2dd41f41",
        "73bd12e0",
        "0ef8b4e6"
      ],
      "position": 4,
      "start_char": 3184,
      "end_char": 3883,
      "page_number": 153,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          153
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.350284",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 699,
        "word_count": 93,
        "sentence_count": 32,
        "chinese_char_count": 251,
        "readability_score": 0.0,
        "information_density": 0.04291845493562232,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48655221745350496,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "8亿元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产"
      ]
    },
    {
      "chunk_id": "9fe0c412",
      "content": "年产2吨盐\n酸阿莫罗\n芬、20吨阿\n特来马来酸\n盐、5吨多尼\n培南、20吨 2,090,683.87 281,889.96 1,808,793.91 与资产相关\n美罗培南、5\n吨比阿培\n南、60吨\nPHE产业化\n项目(续建)\n年产15000\n吨环保型活\n性艳蓝\n850,000.00 100,000.00 750,000.00 与资产相关\nKN-R商品\n染料技改项\n目\n大品种药物\n的生产技术\n改造-美罗\n860,416.67 2,000,000.00 291,265.91 2,569,150.76 与资产相关\n培南原料药\n绿色合成技\n术改造\n临海医化园\n区循环化改 490,000.00 105,000.00 385,000.00 与资产相关\n造项目\n南洋涂-固\n废减量化处 2,286,832.98 246,999.96 2,039,833.02 与资产相关\n置项目\n年产400吨\nMAP、100\n吨OA、200\n1,490,999.9\n吨DA、100 10,000,000.0\n11,962,166.31 20,471,166.40 与资产相关\n吨甲砜霉 0\n1\n素、10吨联\n苯双酯产业\n化新项目\n年产580吨\n柳氮磺胺吡\n2,115,735.00 248,910.00 1,866,825.00 与资产相关\n啶产业化项\n目\n160。\n\n清洁生产循\n环利用及三\n4,800,000.00 600,000.00 4,200,000.00 与资产相关\n废综合治理\n提升项目\n年产15500\n吨活性染料\n1,296,000.00 1,296,000.00 与资产相关\n产业升级及\n配套项目\n孵化器车间\n793,220.34 81,355.92 711,864.42 与资产相关\n技改项目\n浙江省化学\n原料药基地\n椒江区块循\n400,000.00 10,000.00 390,000.00 与资产相关\n环化改造项\n目补助资金\n项目补助\n年产700吨\nM-562关键\n500,000.00 33,333.33 466,666.67 与资产相关\n中间体产业\n一体化项目\n6,554,259.9\n12,900,000.0\n小 计 43,343,225.15 49,688,965.16\n0\n9\n其他说明：\n52、其他非流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n53、股本\n单位：元\n本次变动增减（+、-）\n期初余额 期末余额\n发行新股 送股 公积金转股 其他 小计\n1,618,820,253. 1,618,715,253.\n股份总数 -105,000.00 -105,000.00\n00 00\n其他说明：\n161。",
      "chunk_type": "child",
      "parent_id": "9bbf7ee2",
      "child_ids": [],
      "sibling_ids": [
        "7954891b",
        "5ee7b1b7",
        "a21254dd",
        "7d85c86c"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1134,
      "page_number": 160,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.351519",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1134,
        "word_count": 153,
        "sentence_count": 47,
        "chinese_char_count": 377,
        "readability_score": 0.0,
        "information_density": 0.07054673721340388,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5520282186948854,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "股本",
        "股份"
      ]
    },
    {
      "chunk_id": "7954891b",
      "content": "965.16\n0\n9\n其他说明：\n52、其他非流动负债\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 期末余额 期初余额\n其他说明：\n53、股本\n单位：元\n本次变动增减（+、-）\n期初余额 期末余额\n发行新股 送股 公积金转股 其他 小计\n1,618,820,253. 1,618,715,253.\n股份总数 -105,000.00 -105,000.00\n00 00\n其他说明：\n161。\n\n根据公司2019年第一次临时股东大会决议，公司按照每股人民币2.25元向赵敏蔚等5人回购其所持有的\n已获授但尚未解锁的限制性股票105,000股，并扣回原已现金分红的可撤销现金股利66,150.00元，实际于\n2019年5月20日归还激励对象出资170,100.00元，其中，减少实收资本105,000元，减少资本公积131,250.00\n元。上述减资业经天健会计师事务所(特殊普通合伙)审验，并由其出具《验资报告》(天健验〔2019〕158\n号)。上述事项公司已于2019年7月1日办妥工商变更登记手续。\n\n54、其他权益工具\n（1）期末发行在外的优先股、永续债等其他金融工具基本情况\n（2）期末发行在外的优先股、永续债等金融工具变动情况表\n单位： 元\n发行在外的 期初 本期增加 本期减少 期末\n金融工具 数量 账面价值 数量 账面价值 数量 账面价值 数量 账面价值\n其他权益工具本期增减变动情况、变动原因说明，以及相关会计处理的依据：\n其他说明：\n55、资本公积\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n资本溢价（股本溢价） 2,612,188,669.80 43,566,610.03 131,250.00 2,655,624,029.83\n其他资本公积 51,179,152.67 7,113,749.53 43,566,610.03 14,726,292.17\n合计 2,663,367,822.47 50,680,359.56 43,697,860.03 2,670,350,322.00\n其他说明，包括本期增减变动情况、变动原因说明：\n1) 公司本期因回购限制性股票减少资本公积(股本溢价) 131,250.00元。2) 公司本期因限制性股票行权，从资本公积(其他资本公积)转入资本公积(股本溢价) 43,566,610.03元。3) 公司本期确认股权激励费用7,113,749.53元，计入资本公积(其他资本公积)，详见本财务报表附注股\n份支付之说明。",
      "chunk_type": "child",
      "parent_id": "9bbf7ee2",
      "child_ids": [],
      "sibling_ids": [
        "9fe0c412",
        "5ee7b1b7",
        "a21254dd",
        "7d85c86c"
      ],
      "position": 1,
      "start_char": 934,
      "end_char": 1981,
      "page_number": 160,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.351780",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1047,
        "word_count": 92,
        "sentence_count": 31,
        "chinese_char_count": 536,
        "readability_score": 0.0,
        "information_density": 0.17191977077363896,
        "coherence_score": 0.7031764705882353,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8047755491881567,
      "relevance_score": 1.0,
      "keywords": [
        "负债",
        "权益",
        "收入",
        "财务",
        "报表",
        "2.25元",
        "150.00元",
        "100.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "负债",
        "权益",
        "收入",
        "费用",
        "现金",
        "股本",
        "资本公积",
        "股权",
        "股份",
        "股东"
      ]
    },
    {
      "chunk_id": "5ee7b1b7",
      "content": "2,670,350,322.00\n其他说明，包括本期增减变动情况、变动原因说明：\n1) 公司本期因回购限制性股票减少资本公积(股本溢价) 131,250.00元。2) 公司本期因限制性股票行权，从资本公积(其他资本公积)转入资本公积(股本溢价) 43,566,610.03元。3) 公司本期确认股权激励费用7,113,749.53元，计入资本公积(其他资本公积)，详见本财务报表附注股\n份支付之说明。\n\n56、库存股\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n限制性人民币普通股 44,365,875.00 44,365,875.00\n股份回购 281,514,686.68 19,996,827.22 301,511,513.90\n合计 325,880,561.68 19,996,827.22 44,365,875.00 301,511,513.90\n其他说明，包括本期增减变动情况、变动原因说明：\n162。\n\n1）本期库存股减少44,365,875.00元，其中：①回购并注销赵敏蔚等5人已获授但尚未解锁的限制性股\n票105,000股，按回购价计算减少236,250.00元；②本期解锁减少库存股16,546,500股，每股授予价格2.25元，\n减少37,229,625.00元；③预留授予的限制性股票第一期解锁1,600,000股，每股授予价格4.3125元，减少\n6,900,000.00元。2）本期库存股增加19,996,827.22元，系本期回购股份增加的库存股，公司以集中竞价交易方式回购公\n司股份，回购价格不超过6.9元/股，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，回\n购股份拟用作员工持股计划、股权激励计划或注销以减少公司注册资本。本期公司回购股份4,528,000股，\n回购总成本19,996,827.22元，公司回购股份计划已实施完毕。",
      "chunk_type": "child",
      "parent_id": "9bbf7ee2",
      "child_ids": [],
      "sibling_ids": [
        "9fe0c412",
        "7954891b",
        "a21254dd",
        "7d85c86c"
      ],
      "position": 2,
      "start_char": 1781,
      "end_char": 2582,
      "page_number": 160,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.352005",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 801,
        "word_count": 42,
        "sentence_count": 29,
        "chinese_char_count": 398,
        "readability_score": 0.0,
        "information_density": 0.17478152309612985,
        "coherence_score": 0.586511419549093,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7987515605493134,
      "relevance_score": 1.0,
      "keywords": [
        "成本",
        "财务",
        "报表",
        "250.00元",
        "610.03元",
        "749.53元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "成本",
        "费用",
        "股本",
        "资本公积",
        "股权",
        "股份",
        "每股",
        "回购"
      ]
    },
    {
      "chunk_id": "a21254dd",
      "content": "000.00元。2）本期库存股增加19,996,827.22元，系本期回购股份增加的库存股，公司以集中竞价交易方式回购公\n司股份，回购价格不超过6.9元/股，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，回\n购股份拟用作员工持股计划、股权激励计划或注销以减少公司注册资本。本期公司回购股份4,528,000股，\n回购总成本19,996,827.22元，公司回购股份计划已实施完毕。\n\n57、其他综合收益\n单位： 元\n本期发生额\n减：前期\n减：前期计入\n本期所得 计入其他 税后归属 期末余\n项目 期初余额 其他综合收 减：所得 税后归属\n税前发生 综合收益 于少数股 额\n益当期转入 税费用 于母公司\n额 当期转入 东\n损益\n留存收益\n一、不能重分类进损益的其他综 -1,800,000 -1,800,000 -1,800,0\n合收益 .00 .00 00.00\n其他权益工具投资公允 -1,800,000 -1,800,000 -1,800,0\n价值变动 .00 .00 00.00\n二、将重分类进损益的其他综合 361,590.4 361,590.4 309,811.\n-51,779.23\n收益 2 2 19\n361,590.4 361,590.4 309,811.\n外币财务报表折算差额 -51,779.23\n2 2 19\n-1,438,409 -1,438,409 -1,490,1\n其他综合收益合计 -51,779.23\n.58 .58 88.81\n其他说明，包括对现金流量套期损益的有效部分转为被套期项目初始确认金额调整：\n58、专项储备\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n安全生产费 18,997,055.97 18,997,055.97\n合计 18,997,055.97 18,997,055.97\n其他说明，包括本期增减变动情况、变动原因说明：\n根据财政部、国家安监总局联合发布的《企业安全生产费用提取和使用管理办法》(财企〔2012〕16\n号)和财政部《关于印发企业会计准则解释第3号的通知》(财会〔2009〕8号)要求，公司、川南药业公司、\n台州前进公司、台州振港公司和盐城瓯华公司作为危险品生产企业本期提取并实际使用安全生产费用\n163。\n\n18,997,055.97元。",
      "chunk_type": "child",
      "parent_id": "9bbf7ee2",
      "child_ids": [],
      "sibling_ids": [
        "9fe0c412",
        "7954891b",
        "5ee7b1b7",
        "7d85c86c"
      ],
      "position": 3,
      "start_char": 2382,
      "end_char": 3353,
      "page_number": 160,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.352199",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 971,
        "word_count": 97,
        "sentence_count": 32,
        "chinese_char_count": 488,
        "readability_score": 0.0,
        "information_density": 0.19567456230690009,
        "coherence_score": 0.27784313725490195,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8010298661174047,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "成本",
        "现金流",
        "投资",
        "财务",
        "报表",
        "000.00元",
        "827.22元",
        "6.9元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "成本",
        "费用",
        "现金",
        "投资",
        "母公司",
        "股权",
        "股份",
        "回购",
        "税费"
      ]
    },
    {
      "chunk_id": "7d85c86c",
      "content": "97,055.97\n其他说明，包括本期增减变动情况、变动原因说明：\n根据财政部、国家安监总局联合发布的《企业安全生产费用提取和使用管理办法》(财企〔2012〕16\n号)和财政部《关于印发企业会计准则解释第3号的通知》(财会〔2009〕8号)要求，公司、川南药业公司、\n台州前进公司、台州振港公司和盐城瓯华公司作为危险品生产企业本期提取并实际使用安全生产费用\n163。\n\n18,997,055.97元。59、盈余公积\n单位： 元\n项目 期初余额 本期增加 本期减少 期末余额\n法定盈余公积 201,812,279.17 11,257,545.14 213,069,824.31\n合计 201,812,279.17 11,257,545.14 213,069,824.31\n盈余公积说明，包括本期增减变动情况、变动原因说明：\n60、未分配利润\n单位： 元\n项目 本期 上期\n调整前上期末未分配利润 1,232,481,918.50 897,836,956.42\n调整后期初未分配利润 1,232,481,918.50 897,836,956.42\n加：本期归属于母公司所有者的净利润 770,782,185.09 605,003,820.78\n减：提取法定盈余公积 11,257,545.14 108,614,533.40\n应付普通股股利 466,678,159.50 161,744,325.30\n期末未分配利润 1,525,328,398.95 1,232,481,918.50\n调整期初未分配利润明细：\n1)、由于《企业会计准则》及其相关新规定进行追溯调整，影响期初未分配利润0.00元。2)、由于会计政策变更，影响期初未分配利润0.00元。",
      "chunk_type": "child",
      "parent_id": "9bbf7ee2",
      "child_ids": [],
      "sibling_ids": [
        "9fe0c412",
        "7954891b",
        "5ee7b1b7",
        "a21254dd"
      ],
      "position": 4,
      "start_char": 3153,
      "end_char": 3875,
      "page_number": 160,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          160
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.352400",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 722,
        "word_count": 49,
        "sentence_count": 26,
        "chinese_char_count": 323,
        "readability_score": 0.0,
        "information_density": 0.15235457063711913,
        "coherence_score": 0.8690909090909091,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7789473684210526,
      "relevance_score": 1.0,
      "keywords": [
        "利润",
        "055.97元",
        "0.00元",
        "0.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "利润",
        "应付",
        "净利润",
        "母公司",
        "未分配利润",
        "分配"
      ]
    },
    {
      "chunk_id": "7885e1c2",
      "content": "3)、由于重大会计差错更正，影响期初未分配利润0.00元。4)、由于同一控制导致的合并范围变更，影响期初未分配利润0.00元。5)、其他调整合计影响期初未分配利润0.00元。\n\n61、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 2,925,688,906.14 1,449,500,049.29 2,691,787,601.50 1,492,180,658.53\n其他业务 15,723,864.16 13,659,311.75 26,821,195.01 19,764,017.65\n合计 2,941,412,770.30 1,463,159,361.04 2,718,608,796.51 1,511,944,676.18\n是否已执行新收入准则\n□ 是 √ 否\n其他说明\n164。\n\n62、税金及附加\n单位： 元\n项目 本期发生额 上期发生额\n城市维护建设税 8,979,337.87 11,136,827.27\n教育费附加 4,206,609.84 5,294,134.87\n房产税 5,843,558.13 6,064,374.46\n土地使用税 2,733,446.70 4,311,794.23\n车船使用税 92,034.56 91,578.70\n印花税 2,055,976.68 1,234,528.45\n环境保护税 125,638.87 520,262.21\n地方教育附加 2,804,406.56 3,529,423.24\n合计 26,841,009.21 32,182,923.43\n其他说明：\n63、销售费用\n单位： 元\n项目 本期发生额 上期发生额\n佣 金 23,106,866.17 4,449,906.56\n运输费 15,855,838.29 18,776,797.69\n职工薪酬 11,454,758.67 9,017,672.93\n宣传展览费 2,730,663.11 3,083,947.22\n保险费 2,384,650.11 1,684,252.56\n业务招待费 1,327,567.15 3,743,333.54\n差旅费 930,856.80 1,475,970.50\n邮寄费 306,320.89 564,905.56\n其 他 1,525,503.69 984,267.86\n合计 59,623,024.88 43,781,054.42\n其他说明：\n64、管理费用\n单位： 元\n项目 本期发生额 上期发生额\n职工薪酬 135,254,390.92 119,986,220.11\n折旧费 71,414,444.32 59,647,789.49\n165。",
      "chunk_type": "child",
      "parent_id": "e0e625b5",
      "child_ids": [],
      "sibling_ids": [
        "3e762c3a",
        "f3c4d202",
        "e8f49612",
        "80aaf019"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1120,
      "page_number": 164,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.353677",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1120,
        "word_count": 119,
        "sentence_count": 62,
        "chinese_char_count": 265,
        "readability_score": 0.0,
        "information_density": 0.14285714285714285,
        "coherence_score": 0.7575268817204301,
        "standards_profile_summary": {}
      },
      "quality_score": 0.56875,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润",
        "0.00元",
        "0.00元",
        "0.00元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "费用",
        "利润",
        "营业收入",
        "营业成本",
        "销售费用",
        "管理费用",
        "合并",
        "营业"
      ]
    },
    {
      "chunk_id": "3e762c3a",
      "content": "5,970.50\n邮寄费 306,320.89 564,905.56\n其 他 1,525,503.69 984,267.86\n合计 59,623,024.88 43,781,054.42\n其他说明：\n64、管理费用\n单位： 元\n项目 本期发生额 上期发生额\n职工薪酬 135,254,390.92 119,986,220.11\n折旧费 71,414,444.32 59,647,789.49\n165。\n\n修理费 54,078,791.78 25,798,829.44\n办公费 33,101,653.33 21,185,949.02\n无形资产摊销 29,011,624.85 28,842,167.28\n排污及废物处理费 15,278,838.29 7,077,717.42\n中介及咨询服务费 12,874,898.20 27,576,302.13\n业务招待费 10,763,238.07 6,012,227.78\n以股份支付换取的职工服务 6,036,351.55 37,421,812.71\n保险费 3,790,087.45 2,996,910.69\n差旅费 2,464,786.84 3,670,795.30\n实验检验费 1,934,413.09 1,767,427.11\n劳动保护费 1,919,068.07 2,136,408.20\n其 他 8,262,952.08 5,163,839.89\n合计 386,185,538.84 349,284,396.57\n其他说明：\n65、研发费用\n单位： 元\n项目 本期发生额 上期发生额\n直接材料 24,329,506.93 26,831,622.01\n职工薪酬 53,798,685.12 47,193,153.47\n直接费用 27,647,391.51 19,395,798.61\n委托外部研究开发费 15,764,779.23 11,166,389.47\n以股份支付换取的职工服务 1,007,861.74 6,717,698.51\n合计 122,548,224.53 111,304,662.07\n其他说明：\n66、财务费用\n单位： 元\n项目 本期发生额 上期发生额\n利息支出 15,506,676.74 42,594,267.08\n利息收入 -41,773,975.28 -44,371,159.00\n汇兑净损益 -12,759,207.59 -50,821,750.14\n金融机构手续费 1,161,350.07 1,091,244.28\n合计 -37,865,156.06 -51,507,397.78\n166。",
      "chunk_type": "child",
      "parent_id": "e0e625b5",
      "child_ids": [],
      "sibling_ids": [
        "7885e1c2",
        "f3c4d202",
        "e8f49612",
        "80aaf019"
      ],
      "position": 1,
      "start_char": 920,
      "end_char": 2008,
      "page_number": 164,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.353938",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1088,
        "word_count": 113,
        "sentence_count": 61,
        "chinese_char_count": 205,
        "readability_score": 0.0,
        "information_density": 0.11948529411764705,
        "coherence_score": 0.3235081967213115,
        "standards_profile_summary": {}
      },
      "quality_score": 0.48566176470588235,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入",
        "费用",
        "无形资产",
        "管理费用",
        "研发费用",
        "财务费用",
        "股份",
        "折旧",
        "摊销"
      ]
    },
    {
      "chunk_id": "f3c4d202",
      "content": "务费用\n单位： 元\n项目 本期发生额 上期发生额\n利息支出 15,506,676.74 42,594,267.08\n利息收入 -41,773,975.28 -44,371,159.00\n汇兑净损益 -12,759,207.59 -50,821,750.14\n金融机构手续费 1,161,350.07 1,091,244.28\n合计 -37,865,156.06 -51,507,397.78\n166。\n\n其他说明：\n67、其他收益\n单位： 元\n产生其他收益的来源 本期发生额 上期发生额\n与资产相关的政府补助 6,554,259.99 5,071,751.21\n与收益相关的政府补助 20,582,664.88 6,719,986.82\n合 计 27,136,924.87 11,791,738.03\n68、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n权益法核算的长期股权投资收益 -16,759,549.80 -6,923,938.93\n银行理财产品收益 2,079,074.70 3,024,312.63\n处置金融工具取得的投资收益 -559,587.45 -5,459,752.25\n合计 -15,240,062.55 -9,359,378.55\n其他说明：\n69、净敞口套期收益\n单位： 元\n项目 本期发生额 上期发生额\n其他说明：\n70、公允价值变动收益\n单位： 元\n产生公允价值变动收益的来源 本期发生额 上期发生额\n交易性金融负债 5,010,265.70\n合计 5,010,265.70\n其他说明：\n71、信用减值损失\n单位： 元\n项目 本期发生额 上期发生额\n坏账损失 -2,502,149.00\n167。",
      "chunk_type": "child",
      "parent_id": "e0e625b5",
      "child_ids": [],
      "sibling_ids": [
        "7885e1c2",
        "3e762c3a",
        "e8f49612",
        "80aaf019"
      ],
      "position": 2,
      "start_char": 1808,
      "end_char": 2524,
      "page_number": 164,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.354171",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 716,
        "word_count": 85,
        "sentence_count": 29,
        "chinese_char_count": 250,
        "readability_score": 0.0,
        "information_density": 0.20949720670391062,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6910614525139664,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "费用",
        "投资",
        "股权",
        "减值",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "e8f49612",
      "content": " -9,359,378.55\n其他说明：\n69、净敞口套期收益\n单位： 元\n项目 本期发生额 上期发生额\n其他说明：\n70、公允价值变动收益\n单位： 元\n产生公允价值变动收益的来源 本期发生额 上期发生额\n交易性金融负债 5,010,265.70\n合计 5,010,265.70\n其他说明：\n71、信用减值损失\n单位： 元\n项目 本期发生额 上期发生额\n坏账损失 -2,502,149.00\n167。\n\n合计 -2,502,149.00\n其他说明：\n72、资产减值损失\n是否已执行新收入准则\n□ 是 √ 否\n单位： 元\n项目 本期发生额 上期发生额\n一、坏账损失 -3,669,712.21\n二、存货跌价损失 -9,789,957.42 -3,098,809.43\n五、长期股权投资减值损失 -1,449,207.56 -6,281,771.71\n七、固定资产减值损失 -499,541.72\n十二、无形资产减值损失 -5,817,610.17\n合计 -11,738,706.70 -18,867,903.52\n其他说明：\n73、资产处置收益\n单位： 元\n资产处置收益的来源 本期发生额 上期发生额\n固定资产处置收益 244,580.94 659,231.88\n合 计 244,580.94 659,231.88\n74、营业外收入\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换利得 56,093.96 126,221.82 56,093.96\n无法支付款项 370,069.55\n违约及赔款收入 896,839.67 972,312.09 896,839.67\n其 他 172,720.90 244,682.63 172,720.90\n合计 1,125,654.53 1,713,286.09 1,125,654.53\n计入当期损益的政府补助：\n单位： 元\n补贴是否影 是否特殊补 本期发生金 上期发生金 与资产相关/\n补助项目 发放主体 发放原因 性质类型\n响当年盈亏 贴 额 额 与收益相关\n168。",
      "chunk_type": "child",
      "parent_id": "e0e625b5",
      "child_ids": [],
      "sibling_ids": [
        "7885e1c2",
        "3e762c3a",
        "f3c4d202",
        "80aaf019"
      ],
      "position": 3,
      "start_char": 2324,
      "end_char": 3198,
      "page_number": 164,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.354357",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 874,
        "word_count": 117,
        "sentence_count": 33,
        "chinese_char_count": 355,
        "readability_score": 0.0,
        "information_density": 0.16018306636155605,
        "coherence_score": 0.32714285714285707,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7199084668192219,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "投资",
        "存货",
        "固定资产",
        "无形资产",
        "营业",
        "股权",
        "减值"
      ]
    },
    {
      "chunk_id": "80aaf019",
      "content": "839.67 972,312.09 896,839.67\n其 他 172,720.90 244,682.63 172,720.90\n合计 1,125,654.53 1,713,286.09 1,125,654.53\n计入当期损益的政府补助：\n单位： 元\n补贴是否影 是否特殊补 本期发生金 上期发生金 与资产相关/\n补助项目 发放主体 发放原因 性质类型\n响当年盈亏 贴 额 额 与收益相关\n168。\n\n其他说明：\n75、营业外支出\n单位： 元\n计入当期非经常性损益的金\n项目 本期发生额 上期发生额\n额\n非货币性资产交换损失 4,451,449.87 887,727.15 4,451,449.87\n对外捐赠 1,464,708.00 998,689.50 1,464,708.00\n罚款支出 81,087.21 781,984.81 81,087.21\n滞纳金 425,031.19 3,252.32 425,031.19\n合同义务损失 885,370.12 12,597,010.47 885,370.12\n其 他 186,383.29 1,445.95 186,383.29\n合计 7,494,029.68 15,270,110.20 7,494,029.68\n其他说明：\n76、所得税费用\n（1）所得税费用表\n单位： 元\n项目 本期发生额 上期发生额\n当期所得税费用 114,171,327.62 88,766,346.55\n递延所得税费用 27,499,467.56 3,525,443.72\n合计 141,670,795.18 92,291,790.27\n（2）会计利润与所得税费用调整过程\n单位： 元\n项目 本期发生额\n利润总额 912,452,980.27\n按法定/适用税率计算的所得税费用 228,113,245.07\n子公司适用不同税率的影响 -66,145,071.59\n调整以前期间所得税的影响 -5,756,005.36\n不可抵扣的成本、费用和损失的影响 9,475,292.73\n使用前期未确认递延所得税资产的可抵扣亏损的影响 -15,816,251.10\n本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏\n6,148,624.85\n损的影响\n169。",
      "chunk_type": "child",
      "parent_id": "e0e625b5",
      "child_ids": [],
      "sibling_ids": [
        "7885e1c2",
        "3e762c3a",
        "f3c4d202",
        "e8f49612"
      ],
      "position": 4,
      "start_char": 2998,
      "end_char": 3941,
      "page_number": 164,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          164
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.354575",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 943,
        "word_count": 106,
        "sentence_count": 45,
        "chinese_char_count": 321,
        "readability_score": 0.0,
        "information_density": 0.12725344644750797,
        "coherence_score": 0.2960869565217391,
        "standards_profile_summary": {}
      },
      "quality_score": 0.642948038176034,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "成本",
        "利润"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "成本",
        "费用",
        "利润",
        "利润总额",
        "所得税",
        "营业",
        "税费",
        "税率"
      ]
    },
    {
      "chunk_id": "5eb5a3da",
      "content": "购置节能环保设备抵减应纳税额的影响 -1,818,754.37\n研发费用加计扣除 -15,620,860.07\n权益法核算投资收益 3,090,575.02\n所得税费用 141,670,795.18\n其他说明\n77、其他综合收益\n详见附注合并资产负债表项目注释之其他综合收益说明。78、现金流量表项目\n（1）收到的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n收回银行承兑汇票、信用证保证金等 146,000,576.25 268,324,454.49\n收到银行存款利息收入 31,637,094.38 37,993,941.65\n收到政府补助 31,594,591.50 17,182,776.65\n支取为开立承兑汇票质押的定期存款 33,903,500.00 442,038,662.00\n收到房租收入 923,003.40 2,147,867.09\n其 他 5,791,850.24 4,263,072.32\n合计 249,850,615.77 771,950,774.20\n收到的其他与经营活动有关的现金说明：\n（2）支付的其他与经营活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n管理费用中付现支出 121,586,061.34 90,307,710.88\n支付银行承兑汇票、信用证保证金等 74,233,191.52 261,266,253.31\n销售费用中付现支出 43,113,653.73 30,879,918.69\n研发费用中付现支出 31,990,487.21 24,535,117.38\n财务费用中付现支出 1,161,350.07 1,091,244.28\n存入为开立承兑汇票质押的定期存款 189,843,512.00\n支付履约保证金 3,850,000.00\n其 他 11,527,467.71 14,490,599.42\n合计 283,612,211.58 616,264,355.96\n170。",
      "chunk_type": "child",
      "parent_id": "c0ed08b9",
      "child_ids": [],
      "sibling_ids": [
        "6b2ab967"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 830,
      "page_number": 170,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.355257",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 830,
        "word_count": 73,
        "sentence_count": 36,
        "chinese_char_count": 292,
        "readability_score": 0.0,
        "information_density": 0.21686746987951805,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6033734939759036,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "费用",
        "现金",
        "投资",
        "销售费用",
        "管理费用",
        "研发费用"
      ]
    },
    {
      "chunk_id": "6b2ab967",
      "content": ".69\n研发费用中付现支出 31,990,487.21 24,535,117.38\n财务费用中付现支出 1,161,350.07 1,091,244.28\n存入为开立承兑汇票质押的定期存款 189,843,512.00\n支付履约保证金 3,850,000.00\n其 他 11,527,467.71 14,490,599.42\n合计 283,612,211.58 616,264,355.96\n170。\n\n支付的其他与经营活动有关的现金说明：\n（3）收到的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n银行理财产品及结构性存款到期收回 1,160,000,000.00 550,000,000.00\n收到银行理财产品及结构性存款利息 12,215,955.60 9,401,529.98\n收回股权竞拍保证金 400,000,000.00\n合计 1,172,215,955.60 959,401,529.98\n收到的其他与投资活动有关的现金说明：\n（4）支付的其他与投资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n购买银行理财产品及结构性存款 260,000,000.00 1,400,000,000.00\n支付股权竞拍保证金 400,000,000.00\n支付人民币外汇货币掉期交易损失 5,459,752.25\n合计 260,000,000.00 1,805,459,752.25\n支付的其他与投资活动有关的现金说明：\n（5）收到的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支取因银行借款质押的定期存款 632,143,300.00\n收回银行借款保证金 900,000.00\n合计 633,043,300.00\n收到的其他与筹资活动有关的现金说明：\n（6）支付的其他与筹资活动有关的现金\n单位： 元\n项目 本期发生额 上期发生额\n支付公司股份回购款 19,996,827.22 281,514,686.68\n支付限制性股票回购款及利息 281,636.25 13,560,886.22\n存入因银行借款质押的定期存款 294,477,200.00\n171。",
      "chunk_type": "child",
      "parent_id": "c0ed08b9",
      "child_ids": [],
      "sibling_ids": [
        "5eb5a3da"
      ],
      "position": 1,
      "start_char": 630,
      "end_char": 1538,
      "page_number": 170,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          170
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.355472",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 908,
        "word_count": 83,
        "sentence_count": 34,
        "chinese_char_count": 377,
        "readability_score": 0.0,
        "information_density": 0.14317180616740088,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7634361233480176,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "费用",
        "现金",
        "投资",
        "研发费用",
        "财务费用",
        "经营",
        "投资活动",
        "筹资活动",
        "股权",
        "股份"
      ]
    },
    {
      "chunk_id": "117b2385",
      "content": "初始确认日发生违约的风险，以确定金融工具预计存续期内发生违约风险的变化情况。当触发以下一个或多个定量、定性标准时，公司认为金融工具的信用风险已发生显著增加：\n1) 定量标准主要为资产负债表日剩余存续期违约概率较初始确认时上升超过一定比例；\n2) 定性标准主要为债务人经营或财务情况出现重大不利变化、现存的或预期的技术、市场、经济或法\n律环境变化并将对债务人对公司的还款能力产生重大不利影响等；\n3) 上限标准为债务人合同付款(包括本金和利息)逾期超过90天。(2) 违约和已发生信用减值资产的定义\n当金融工具符合以下一项或多项条件时，公司将该金融资产界定为已发生违约，其标准与已发生信用\n减值的定义一致：\n1) 定量标准\n债务人在合同付款日后逾期超过90天仍未付款；\n2) 定性标准\n① 债务人发生重大财务困难；\n② 债务人违反合同中对债务人的约束条款；\n③ 债务人很可能破产或进行其他财务重组；\n④ 债权人出于与债务人财务困难有关的经济或合同考虑，给予债务人在任何其他情况下都不会做出\n的让步。\n\n2. 预期信用损失的计量\n预期信用损失计量的关键参数包括违约概率、违约损失率和违约风险敞口。公司考虑历史统计数据(如\n交易对手评级、担保方式及抵质押物类别、还款方式等)的定量分析及前瞻性信息，建立违约概率、违约损\n失率及违约风险敞口模型。3. 金融工具损失准备期初余额与期末余额调节表详见本财务报表附注之说明。\n\n4. 信用风险敞口及信用风险集中度\n本公司的信用风险主要来自货币资金和应收款项。为控制上述相关风险，本公司分别采取了以下措施。(1) 货币资金\n本公司将银行存款和其他货币资金存放于信用评级较高的金融机构，故其信用风险较低。\n\n(2) 应收款项\n本公司持续对采用信用方式交易的客户进行信用评估。根据信用评估结果，本公司选择与经认可的且\n信用良好的客户进行交易，并对其应收款项余额进行监控，以确保本公司不会面临重大坏账风险。由于本公司仅与经认可的且信用良好的第三方进行交易，所以无需担保物。\n\n信用风险集中按照客户进\n行管理。截至2019年12月31日，本公司存在一定的信用集中风险，本公司应收账款的35.65%(2018年12月\n31日：34.79%)源于余额前五名客户。本公司对应收账款余额未持有任何担保物或其他信用增级。\n\n本公司所承受的最大信用风险敞口为资产负债表中每项金融资产的账面价值。(二) 流动性风险\n流动性风险，是指本公司在履行以交付现金或其他金融资产的方式结算的义务时发生资金短缺的风\n险。流动性风险可能源于无法尽快以公允价值售出金融资产；或者源于对方无法偿还其合同债务；或者源\n于提前到期的债务；或者源于无法产生预期的现金流量。",
      "chunk_type": "child",
      "parent_id": "14dd88bb",
      "child_ids": [],
      "sibling_ids": [
        "a084a6f3",
        "86a624c7"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1130,
      "page_number": 184,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          184
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.356457",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1130,
        "word_count": 48,
        "sentence_count": 23,
        "chinese_char_count": 956,
        "readability_score": 0.0,
        "information_density": 0.15044247787610618,
        "coherence_score": 0.6857945402244398,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9384070796460178,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "现金流",
        "融资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "现金",
        "应收",
        "资产负债表",
        "经营",
        "减值",
        "公允价值",
        "账面价值",
        "融资"
      ]
    },
    {
      "chunk_id": "a084a6f3",
      "content": "%)源于余额前五名客户。本公司对应收账款余额未持有任何担保物或其他信用增级。\n\n本公司所承受的最大信用风险敞口为资产负债表中每项金融资产的账面价值。(二) 流动性风险\n流动性风险，是指本公司在履行以交付现金或其他金融资产的方式结算的义务时发生资金短缺的风\n险。流动性风险可能源于无法尽快以公允价值售出金融资产；或者源于对方无法偿还其合同债务；或者源\n于提前到期的债务；或者源于无法产生预期的现金流量。\n\n为控制该项风险，本公司综合运用票据结算、银行借款等多种融资手段，并采取长、短期融资方式适\n当结合，优化融资结构的方法，保持融资持续性与灵活性之间的平衡。本公司已从多家商业银行取得银行\n授信额度以满足营运资金需求和资本开支。金融负债按剩余到期日分类\n项 目 期末数\n账面价值 未折现合同金额 1年以内 1-3年 3年以上\n银行借款 200,267,029.59 205,600,371.26 205,600,371.26\n184。\n\n应付票据 238,306,005.00 238,306,005.00 238,306,005.00\n应付账款 363,440,583.96 363,440,583.96 324,802,966.15 27,710,697.69 10,926,920.12\n其他应付款 28,200,073.22 28,200,073.22 15,005,415.27 6,245,135.70 6,949,522.25\n小 计 830,213,691.77 835,547,033.44 783,714,757.68 33,955,833.39 17,876,442.37\n(续上表)\n项 目 期初数\n账面价值 未折现合同金额 1年以内 1-3年 3年以上\n银行借款 598,700,000.00 611,954,988.49 611,954,988.49\n应付票据 490,006,533.85 490,006,533.85 490,006,533.85\n应付账款 301,908,929.93 301,908,929.93 279,305,463.32 13,367,311.11 9,236,155.50\n其他应付款 24,723,304.20 24,723,304.20 15,643,774.56 638,021.29 8,441,508.35\n一年内到期的非流 44,365,875.00 44,365,875.00 44,365,875.00\n动负债\n小 计 1,459,704,642.98 1,472,959,631.47 1,441,276,635.22 14,005,332.40 17,677,663.85\n(三) 市场风险\n市场风险，是指金融工具的公允价值或未来现金流量因市场价格变动而发生波动的风险。市场风险主\n要包括利率风险和外汇风险。",
      "chunk_type": "child",
      "parent_id": "14dd88bb",
      "child_ids": [],
      "sibling_ids": [
        "117b2385",
        "86a624c7"
      ],
      "position": 1,
      "start_char": 930,
      "end_char": 2123,
      "page_number": 184,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          184
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.356718",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1193,
        "word_count": 90,
        "sentence_count": 55,
        "chinese_char_count": 451,
        "readability_score": 0.0,
        "information_density": 0.1173512154233026,
        "coherence_score": 0.30382352941176466,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6901089689857502,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "现金流",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "现金",
        "应收",
        "应付",
        "资产负债表",
        "公允价值",
        "账面价值",
        "融资",
        "借款"
      ]
    },
    {
      "chunk_id": "86a624c7",
      "content": "的非流 44,365,875.00 44,365,875.00 44,365,875.00\n动负债\n小 计 1,459,704,642.98 1,472,959,631.47 1,441,276,635.22 14,005,332.40 17,677,663.85\n(三) 市场风险\n市场风险，是指金融工具的公允价值或未来现金流量因市场价格变动而发生波动的风险。市场风险主\n要包括利率风险和外汇风险。1. 利率风险\n利率风险，是指金融工具的公允价值或未来现金流量因市场利率变动而发生波动的风险。\n\n固定利率的\n带息金融工具使本公司面临公允价值利率风险，浮动利率的带息金融工具使本公司面临现金流量利率风\n险。本公司根据市场环境来决定固定利率与浮动利率金融工具的比例，并通过定期审阅与监控维持适当的\n金融工具组合。本公司面临的现金流量利率风险主要与本公司以浮动利率计息的银行借款有关。\n\n截至2019年12月31日，本公司以浮动利率计息的银行借款人民币17,000.00万元(2018年12月31日：人民\n币20,100.00万元)，在其他变量不变的假设下，假定利率变动50个基准点，不会对本公司的利润总额和股东\n权益产生重大的影响。2. 外汇风险\n外汇风险，是指金融工具的公允价值或未来现金流量因外汇汇率变动而发生波动的风险。本公司面临\n的汇率变动的风险主要与本公司外币货币性资产和负债有关。",
      "chunk_type": "child",
      "parent_id": "14dd88bb",
      "child_ids": [],
      "sibling_ids": [
        "117b2385",
        "a084a6f3"
      ],
      "position": 2,
      "start_char": 1923,
      "end_char": 2518,
      "page_number": 184,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          184
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.356974",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 595,
        "word_count": 28,
        "sentence_count": 21,
        "chinese_char_count": 390,
        "readability_score": 0.0,
        "information_density": 0.2857142857142857,
        "coherence_score": 0.29957142857142854,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8621848739495799,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金流",
        "000.00万元",
        "100.00万元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "利润",
        "现金",
        "利润总额",
        "股东",
        "公允价值",
        "借款",
        "价值"
      ]
    },
    {
      "chunk_id": "38d76c48",
      "content": "股份，回购股份的资金总额不低于人民币 3 亿元，不超过人民币 5 亿元，详见本财务报表附注库存股之\n说明。\n2、或有事项\n（1）资产负债表日存在的重要或有事项\n截至2019年12月31日，本公司不存在需要披露的重大或有事项。\n（2）公司没有需要披露的重要或有事项，也应予以说明\n公司不存在需要披露的重要或有事项。\n3、其他\n十五、资产负债表日后事项\n1、重要的非调整事项\n单位： 元\n对财务状况和经营成果的影\n项目 内容 无法估计影响数的原因\n响数\n2、利润分配情况\n单位： 元\n3、销售退回\n4、其他资产负债表日后事项说明\n拟分配的利润或股利 根据公司2020年1月22日第六届董事会第二次会议审议\n通过的2019年度利润分配预案，拟以2019年度总股本扣\n除存放于股票回购专用证券账户后的股份数量为基数，\n每10股派发现金股利3元(含税)。上述利润分配预案尚\n待公司股东大会审议批准。\n192\n\n十六、其他重要事项\n1、前期会计差错更正\n（1）追溯重述法\n单位： 元\n受影响的各个比较期间报表\n会计差错更正的内容 处理程序 累积影响数\n项目名称\n（2）未来适用法\n会计差错更正的内容 批准程序 采用未来适用法的原因\n2、债务重组\n3、资产置换\n（1）非货币性资产交换\n（2）其他资产置换\n4、年金计划\n5、终止经营\n单位： 元\n归属于母公司所\n项目 收入 费用 利润总额 所得税费用 净利润 有者的终止经营\n利润\n其他说明\n6、分部信息\n（1）报告分部的确定依据与会计政策\n公司以内部组织结构、管理要求、内部报告制度等为依据确定报告分部，并以行业分部为基础确定报\n告分部。分别对医药业务、染料业务的经营业绩进行考核。与各分部共同使用的资产、负债按照规模比例\n在不同的分部之间分配。",
      "chunk_type": "child",
      "parent_id": "b55c64e1",
      "child_ids": [],
      "sibling_ids": [
        "bbc405e9",
        "2e24a2f4",
        "666cb309",
        "4ec36aa0"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 742,
      "page_number": 192,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.357959",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 742,
        "word_count": 70,
        "sentence_count": 8,
        "chinese_char_count": 568,
        "readability_score": 0.0,
        "information_density": 0.24258760107816713,
        "coherence_score": 0.7038235294117647,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9061994609164421,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "利润",
        "经营",
        "财务",
        "报表",
        "3元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "费用",
        "利润",
        "现金",
        "净利润",
        "利润总额",
        "所得税",
        "资产负债表"
      ]
    },
    {
      "chunk_id": "bbc405e9",
      "content": "产置换\n4、年金计划\n5、终止经营\n单位： 元\n归属于母公司所\n项目 收入 费用 利润总额 所得税费用 净利润 有者的终止经营\n利润\n其他说明\n6、分部信息\n（1）报告分部的确定依据与会计政策\n公司以内部组织结构、管理要求、内部报告制度等为依据确定报告分部，并以行业分部为基础确定报\n告分部。分别对医药业务、染料业务的经营业绩进行考核。与各分部共同使用的资产、负债按照规模比例\n在不同的分部之间分配。\n（2）报告分部的财务信息\n单位： 元\n193\n\n项目 医药行业 染料行业 分部间抵销 合计\n主营业务收入 1,604,117,711.02 1,546,764,954.54 225,193,759.42 2,925,688,906.14\n主营业务成本 6,064,447,216.11 657,131,007.06 211,204,035.55 6,747,198,664.47\n资产总额 1,003,573,077.78 2,269,859,610.07 1,587,108,161.71 1,449,500,049.29\n负债总额 798,878,476.78 525,463,301.92 301,605,209.78 1,022,736,568.72\n（3）公司无报告分部的，或者不能披露各报告分部的资产总额和负债总额的，应说明原因\n（4）其他说明\n7、其他对投资者决策有影响的重要交易和事项\n根据江苏省盐城市委市政府于2019年6月14日发布的《盐城市化工产业安全环保整治提升实施方案》(盐\n办〔2019〕71号)(以下简称《方案》)，要求对盐城市化工园区内所有化工生产企业进行安全环保整治提升。盐城瓯华公司配合有关部门已按照《方案》要求进行停产并做好安全环保排查评估，同时根据评估结果制\n定并实施了“一企一策”整治方案。截至本财务报表批准报出日，盐城瓯华公司为达到恢复生产的标准仍在\n对环保及安全设施进行改造，相关闲置固定资产账面价值为6,057.05万元，已计提减值准备49.95万元。",
      "chunk_type": "child",
      "parent_id": "b55c64e1",
      "child_ids": [],
      "sibling_ids": [
        "38d76c48",
        "2e24a2f4",
        "666cb309",
        "4ec36aa0"
      ],
      "position": 1,
      "start_char": 542,
      "end_char": 1393,
      "page_number": 192,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.358126",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 851,
        "word_count": 56,
        "sentence_count": 24,
        "chinese_char_count": 468,
        "readability_score": 0.0,
        "information_density": 0.23501762632197415,
        "coherence_score": 0.5568694781738259,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8199764982373678,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表",
        "057.05万元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "利润",
        "投资",
        "固定资产",
        "净利润",
        "利润总额"
      ]
    },
    {
      "chunk_id": "2e24a2f4",
      "content": "\n办〔2019〕71号)(以下简称《方案》)，要求对盐城市化工园区内所有化工生产企业进行安全环保整治提升。盐城瓯华公司配合有关部门已按照《方案》要求进行停产并做好安全环保排查评估，同时根据评估结果制\n定并实施了“一企一策”整治方案。截至本财务报表批准报出日，盐城瓯华公司为达到恢复生产的标准仍在\n对环保及安全设施进行改造，相关闲置固定资产账面价值为6,057.05万元，已计提减值准备49.95万元。\n\n8、其他\n十七、母公司财务报表主要项目注释\n1、应收账款\n（1）应收账款分类披露\n单位： 元\n期末余额 期初余额\n账面余额 坏账准备 账面余额 坏账准备\n类别\n计提比 账面价值 账面价值\n金额 比例 金额 金额 比例 金额 计提比例\n例\n其中：\n按组合计提坏账准 130,720, 7,187,81 123,532,2157,389,6 8,184,787 149,204,89\n100.00% 5.50% 100.00% 5.20%\n备的应收账款 059.44 5.25 44.19 87.72 .74 9.98\n其中：\n130,720, 7,187,81 123,532,2157,389,6 8,184,787 149,204,89\n合计 100.00% 5.50% 100.00% 5.20%\n059.44 5.25 44.19 87.72 .74 9.98\n按单项计提坏账准备：\n单位： 元\n194。\n\n期末余额\n名称\n账面余额 坏账准备 计提比例 计提理由\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n合并范围内关联往来组合 1,358,605.41\n账龄组合 129,361,454.03 7,187,815.25 5.56%\n合计 130,720,059.44 7,187,815.25 --\n确定该组合依据的说明：\n按组合计提坏账准备：\n单位： 元\n期末余额\n名称\n账面余额 坏账准备 计提比例\n确定该组合依据的说明：\n如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：\n√ 适用 □ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 129,484,273.40\n1至2年 508,161.68\n2至3年 492,705.04\n3年以上 234,919.32\n3至4年 234,919.32\n合计 130,720,059.44\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n8,184,787.74 -996,972.49 7,187,815.25\n备\n合计 8,184,787.74 -996,972.49 7,187,815.25\n195。",
      "chunk_type": "child",
      "parent_id": "b55c64e1",
      "child_ids": [],
      "sibling_ids": [
        "38d76c48",
        "bbc405e9",
        "666cb309",
        "4ec36aa0"
      ],
      "position": 2,
      "start_char": 1193,
      "end_char": 2386,
      "page_number": 192,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.358362",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1193,
        "word_count": 143,
        "sentence_count": 45,
        "chinese_char_count": 544,
        "readability_score": 0.0,
        "information_density": 0.1173512154233026,
        "coherence_score": 0.7054506604506605,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7823973176865047,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "财务",
        "报表",
        "057.05万元",
        "49.95万元"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "应收",
        "固定资产",
        "合并",
        "母公司",
        "披露",
        "减值",
        "账面价值",
        "价值"
      ]
    },
    {
      "chunk_id": "666cb309",
      "content": "\n3至4年 234,919.32\n合计 130,720,059.44\n（2）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n按组合计提坏账准\n8,184,787.74 -996,972.49 7,187,815.25\n备\n合计 8,184,787.74 -996,972.49 7,187,815.25\n195。\n\n其中本期坏账准备收回或转回金额重要的：\n单位： 元\n单位名称 收回或转回金额 收回方式\n（3）本期实际核销的应收账款情况\n单位： 元\n项目 核销金额\n其中重要的应收账款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 应收账款性质 核销金额 核销原因 履行的核销程序\n易产生\n应收账款核销说明：\n（4）按欠款方归集的期末余额前五名的应收账款情况\n单位： 元\n占应收账款期末余额合计数\n单位名称 应收账款期末余额 坏账准备期末余额\n的比例\nACS DOBFAR S.P.A 30,318,565.17 23.19% 1,515,928.26\nFIS-FABBRICA ITALIANA\n23,576,101.39 18.04% 1,178,805.07\nSINTETICI S.P.A\nPFIZER ASIA\n19,767,647.40 15.12% 988,382.37\nMANUFACTURING PTE LTD\nBIDACHEM S.P.A 11,875,658.58 9.08% 593,782.93\nCENTRAL DE PRODUCTOS\n6,666,631.13 5.10% 333,331.56\nQUIMICOS S.A.DE C.V.\n合计 92,204,603.67 70.53%\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n2、其他应收款\n单位： 元\n项目 期末余额 期初余额\n应收股利 722,088,153.34\n196。",
      "chunk_type": "child",
      "parent_id": "b55c64e1",
      "child_ids": [],
      "sibling_ids": [
        "38d76c48",
        "bbc405e9",
        "2e24a2f4",
        "4ec36aa0"
      ],
      "position": 3,
      "start_char": 2186,
      "end_char": 3042,
      "page_number": 192,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.358617",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 856,
        "word_count": 105,
        "sentence_count": 38,
        "chinese_char_count": 311,
        "readability_score": 0.0,
        "information_density": 0.08177570093457943,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7453271028037383,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "应收",
        "融资"
      ]
    },
    {
      "chunk_id": "4ec36aa0",
      "content": "\nCENTRAL DE PRODUCTOS\n6,666,631.13 5.10% 333,331.56\nQUIMICOS S.A.DE C.V.\n合计 92,204,603.67 70.53%\n（5）因金融资产转移而终止确认的应收账款\n（6）转移应收账款且继续涉入形成的资产、负债金额\n其他说明：\n2、其他应收款\n单位： 元\n项目 期末余额 期初余额\n应收股利 722,088,153.34\n196。\n\n其他应收款 467,513,480.14 320,967,765.38\n合计 467,513,480.14 1,043,055,918.72\n（1）应收利息\n1）应收利息分类\n单位： 元\n项目 期末余额 期初余额\n2）重要逾期利息\n是否发生减值及其判断\n借款单位 期末余额 逾期时间 逾期原因\n依据\n其他说明：\n3）坏账准备计提情况\n□ 适用 √ 不适用\n（2）应收股利\n1）应收股利分类\n单位： 元\n项目(或被投资单位) 期末余额 期初余额\n台州前进公司 722,088,153.34\n合计 722,088,153.34\n2）重要的账龄超过1年的应收股利\n单位： 元\n是否发生减值及其判断\n项目(或被投资单位) 期末余额 账龄 未收回的原因\n依据\n3）坏账准备计提情况\n□ 适用 √ 不适用\n其他说明：\n197",
      "chunk_type": "child",
      "parent_id": "b55c64e1",
      "child_ids": [],
      "sibling_ids": [
        "38d76c48",
        "bbc405e9",
        "2e24a2f4",
        "666cb309"
      ],
      "position": 4,
      "start_char": 2842,
      "end_char": 3400,
      "page_number": 192,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          192
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.358792",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 558,
        "word_count": 77,
        "sentence_count": 17,
        "chinese_char_count": 248,
        "readability_score": 0.0,
        "information_density": 0.1971326164874552,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7777777777777777,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "应收",
        "减值",
        "融资",
        "借款"
      ]
    },
    {
      "chunk_id": "e10e5096",
      "content": "（3）其他应收款\n1）其他应收款按款项性质分类情况\n单位： 元\n款项性质 期末账面余额 期初账面余额\n往来款 459,656,754.37 320,145,265.41\n押金保证金 5,000.00 5,000.00\n应收暂付款 6,339,111.65 5,841,009.97\n应收出口退税 6,584,960.26\n其 他 63,177.77 76,177.77\n合计 472,649,004.05 326,067,453.15\n2）坏账准备计提情况\n单位： 元\n第一阶段 第二阶段 第三阶段\n坏账准备 未来12个月预期信 整个存续期预期信用损失 整个存续期预期信用损失 合计\n用损失 (未发生信用减值) (已发生信用减值)\n2019年1月1日余额 5,099,687.77 5,099,687.77\n2019年1月1日余额在\n—— —— —— ——\n本期\n本期计提 35,836.14 35,836.14\n2019年12月31日余额 5,135,523.91 5,135,523.91\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 456,448,642.60\n1至2年 4,956,117.14\n2至3年 2,265,499.80\n3年以上 8,978,744.51\n3至4年 3,978,744.51\n5年以上 5,000,000.00\n合计 472,649,004.05\n198。",
      "chunk_type": "child",
      "parent_id": "55ff37e1",
      "child_ids": [],
      "sibling_ids": [
        "fe1b90b6",
        "b3931df4",
        "0237badf",
        "38ea36ec",
        "94641a99"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 637,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.360040",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 637,
        "word_count": 79,
        "sentence_count": 25,
        "chinese_char_count": 217,
        "readability_score": 0.0,
        "information_density": 0.04709576138147566,
        "coherence_score": 0.6699999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6717425431711146,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "披露",
        "减值"
      ]
    },
    {
      "chunk_id": "fe1b90b6",
      "content": "35,523.91\n损失准备本期变动金额重大的账面余额变动情况\n□ 适用 √ 不适用\n按账龄披露\n单位： 元\n账龄 账面余额\n1年以内（含1年） 456,448,642.60\n1至2年 4,956,117.14\n2至3年 2,265,499.80\n3年以上 8,978,744.51\n3至4年 3,978,744.51\n5年以上 5,000,000.00\n合计 472,649,004.05\n198。\n\n3）本期计提、收回或转回的坏账准备情况\n本期计提坏账准备情况：\n单位： 元\n本期变动金额\n类别 期初余额 期末余额\n计提 收回或转回 核销\n其中本期坏账准备转回或收回金额重要的：\n单位： 元\n单位名称 转回或收回金额 收回方式\n4）本期实际核销的其他应收款情况\n单位： 元\n项目 核销金额\n其中重要的其他应收款核销情况：\n单位： 元\n款项是否由关联交\n单位名称 其他应收款性质 核销金额 核销原因 履行的核销程序\n易产生\n其他应收款核销说明：\n5）按欠款方归集的期末余额前五名的其他应收款情况\n单位： 元\n占其他应收款期末\n单位名称 款项的性质 期末余额 账龄 坏账准备期末余额\n余额合计数的比例\n川南药业公司 往来款 261,610,250.381年以内 55.35%\n台州振港公司 往来款 176,225,865.641年以内 37.28%\nGeneVida GmbH 往来款 4,592,945.061年以内 0.97%\nGeneVida GmbH 往来款 4,934,973.061-2年 1.04%\nGeneVida GmbH 往来款 2,227,737.932-3年 0.47%\nGeneVida GmbH 往来款 3,913,444.513年以上 0.84%\nPFIZER ASIA\nMANUFACTURING 应收暂付款 5,000,000.003年以上 1.06% 5,000,000.00\nPTE LTD\n台州前进公司 往来款 4,170,214.351年以内 0.88%\n合计 -- 462,675,430.93 -- 97.89% 5,000,000.00\n199。",
      "chunk_type": "child",
      "parent_id": "55ff37e1",
      "child_ids": [],
      "sibling_ids": [
        "e10e5096",
        "b3931df4",
        "0237badf",
        "38ea36ec",
        "94641a99"
      ],
      "position": 1,
      "start_char": 437,
      "end_char": 1334,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.360236",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 897,
        "word_count": 117,
        "sentence_count": 30,
        "chinese_char_count": 365,
        "readability_score": 0.0,
        "information_density": 0.02229654403567447,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.747045707915273,
      "relevance_score": 1.0,
      "keywords": [],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "应收",
        "披露"
      ]
    },
    {
      "chunk_id": "b3931df4",
      "content": "\nGeneVida GmbH 往来款 3,913,444.513年以上 0.84%\nPFIZER ASIA\nMANUFACTURING 应收暂付款 5,000,000.003年以上 1.06% 5,000,000.00\nPTE LTD\n台州前进公司 往来款 4,170,214.351年以内 0.88%\n合计 -- 462,675,430.93 -- 97.89% 5,000,000.00\n199。\n\n6）涉及政府补助的应收款项\n单位： 元\n预计收取的时间、金额\n单位名称 政府补助项目名称 期末余额 期末账龄\n及依据\n7）因金融资产转移而终止确认的其他应收款\n8）转移其他应收款且继续涉入形成的资产、负债金额\n其他说明：\n3、长期股权投资\n单位： 元\n期末余额 期初余额\n项目\n账面余额 减值准备 账面价值 账面余额 减值准备 账面价值\n对子公司投资 3,215,993,761.24 3,215,993,761.24 3,213,363,387.02 3,213,363,387.02\n对联营、合营企\n54,774,633.09 23,347,592.79 31,427,040.30 60,541,058.62 23,347,592.79 37,193,465.83\n业投资\n合计 3,270,768,394.33 23,347,592.79 3,247,420,801.54 3,273,904,445.64 23,347,592.79 3,250,556,852.85\n（1）对子公司投资\n单位： 元\n期初余额(账 本期增减变动 期末余额(账面 减值准备期末\n被投资单位\n面价值) 追加投资 减少投资 计提减值准备 其他 价值) 余额\n928,629,850.7\n川南药业公司 928,629,850.78\n8\n海翔销售公司 37,599,318.92 37,599,318.92\n上海海翔公司 5,000,000.00 5,000,000.00\nGeneVida\n8,974,808.00 8,974,808.00\nGmbH\n2,227,917,460. 2,230,547,834.\n台州前进公司 2,630,374.22\n28 50\n港翔科技公司 5,241,949.04 5,241,949.04\n3,213,363,387. 3,215,993,761.\n合计 2,630,374.22\n02 24\n200。",
      "chunk_type": "child",
      "parent_id": "55ff37e1",
      "child_ids": [],
      "sibling_ids": [
        "e10e5096",
        "fe1b90b6",
        "0237badf",
        "38ea36ec",
        "94641a99"
      ],
      "position": 2,
      "start_char": 1134,
      "end_char": 2149,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.360484",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔科技公司",
        "industry": null,
        "char_count": 1015,
        "word_count": 114,
        "sentence_count": 44,
        "chinese_char_count": 269,
        "readability_score": 0.0,
        "information_density": 0.12807881773399016,
        "coherence_score": 0.4099999999999999,
        "standards_profile_summary": {}
      },
      "quality_score": 0.5685714285714286,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "投资",
        "融资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "投资",
        "应收",
        "股权",
        "减值",
        "账面价值",
        "融资",
        "价值"
      ]
    },
    {
      "chunk_id": "0237badf",
      "content": "0 5,000,000.00\nGeneVida\n8,974,808.00 8,974,808.00\nGmbH\n2,227,917,460. 2,230,547,834.\n台州前进公司 2,630,374.22\n28 50\n港翔科技公司 5,241,949.04 5,241,949.04\n3,213,363,387. 3,215,993,761.\n合计 2,630,374.22\n02 24\n200。\n\n（2）对联营、合营企业投资\n单位： 元\n本期增减变动\n期初余额 期末余额\n权益法下 宣告发放 减值准备\n投资单位 (账面价 其他综合 其他权益 计提减值 (账面价\n追加投资 减少投资 确认的投 现金股利 其他 期末余额\n值) 收益调整 变动 准备 值)\n资损益 或利润\n一、合营企业\n二、联营企业\n苏州第四\n23,345,37 -4,811,81 18,533,55 23,347,59\n制药厂有\n3.14 4.84 8.30 2.79\n限公司\n浙江高盛\n13,848,09 -954,610. 12,893,48\n钢结构有\n2.69 69 2.00\n限公司\n37,193,46 -5,766,42 31,427,04 23,347,59\n小计\n5.83 5.53 0.30 2.79\n37,193,46 -5,766,42 31,427,04 23,347,59\n合计\n5.83 5.53 0.30 2.79\n（3）其他说明\n4、营业收入和营业成本\n单位： 元\n本期发生额 上期发生额\n项目\n收入 成本 收入 成本\n主营业务 797,912,055.33 574,154,902.09 805,112,431.82 606,077,442.30\n其他业务 14,347,583.53 12,941,502.94 19,986,172.05 13,769,464.63\n合计 812,259,638.86 587,096,405.03 825,098,603.87 619,846,906.93\n是否已执行新收入准则\n□ 是 √ 否\n其他说明：\n5、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n成本法核算的长期股权投资收益 1,000,000,000.00\n201。",
      "chunk_type": "child",
      "parent_id": "55ff37e1",
      "child_ids": [],
      "sibling_ids": [
        "e10e5096",
        "fe1b90b6",
        "b3931df4",
        "38ea36ec",
        "94641a99"
      ],
      "position": 3,
      "start_char": 1949,
      "end_char": 2888,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.360729",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔科技公司",
        "industry": null,
        "char_count": 939,
        "word_count": 131,
        "sentence_count": 41,
        "chinese_char_count": 243,
        "readability_score": 0.0,
        "information_density": 0.1597444089456869,
        "coherence_score": 0.39999999999999997,
        "standards_profile_summary": {}
      },
      "quality_score": 0.563258785942492,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "收入",
        "成本",
        "利润",
        "投资"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "收入",
        "成本",
        "利润",
        "现金",
        "投资",
        "营业收入",
        "营业成本",
        "营业",
        "股权"
      ]
    },
    {
      "chunk_id": "38ea36ec",
      "content": "83.53 12,941,502.94 19,986,172.05 13,769,464.63\n合计 812,259,638.86 587,096,405.03 825,098,603.87 619,846,906.93\n是否已执行新收入准则\n□ 是 √ 否\n其他说明：\n5、投资收益\n单位： 元\n项目 本期发生额 上期发生额\n成本法核算的长期股权投资收益 1,000,000,000.00\n201。\n\n权益法核算的长期股权投资收益 -5,766,425.53 -4,216,789.49\n银行理财产品投资收益 1,161,540.45 1,928,422.22\n处置金融工具取得的投资收益 -30,625.74 -1,559,950.55\n合计 -4,635,510.82 996,151,682.18\n6、其他\n十八、补充资料\n1、当期非经常性损益明细表\n√ 适用 □ 不适用\n单位： 元\n项目 金额 说明\n非流动资产处置损益 -4,150,774.97\n越权审批或无正式批准文件的税收返还、\n1,828,299.60\n减免\n计入当期损益的政府补助（与企业业务密\n切相关，按照国家统一标准定额或定量享 25,308,625.27\n受的政府补助除外）\n委托他人投资或管理资产的损益 2,079,074.70\n除上述各项之外的其他营业外收入和支出 -1,973,019.24\n减：所得税影响额 3,519,880.50\n合计 19,572,324.86 --\n对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公\n开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应\n说明原因。□ 适用 √ 不适用\n2、净资产收益率及每股收益\n每股收益\n报告期利润 加权平均净资产收益率\n基本每股收益（元/股） 稀释每股收益（元/股）\n归属于公司普通股股东的净利润 14.07% 0.48 0.48\n扣除非经常性损益后归属于公司\n13.71% 0.47 0.47\n普通股股东的净利润\n202。\n\n3、境内外会计准则下会计数据差异\n（1）同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（2）同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（3）境内外会计准则下会计数据差异原因说明，对已经境外审计机构审计的数据进行差异调节的，应注\n明该境外机构的名称\n4、其他\n203 第十三节 备查文件目录\n一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表。\n二、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。",
      "chunk_type": "child",
      "parent_id": "55ff37e1",
      "child_ids": [],
      "sibling_ids": [
        "e10e5096",
        "fe1b90b6",
        "b3931df4",
        "0237badf",
        "94641a99"
      ],
      "position": 4,
      "start_char": 2688,
      "end_char": 3856,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.361026",
        "report_type": "资产负债表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1168,
        "word_count": 107,
        "sentence_count": 35,
        "chinese_char_count": 647,
        "readability_score": 0.0,
        "information_density": 0.1541095890410959,
        "coherence_score": 0.6524657534246576,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8215753424657535,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "净利润",
        "所得税",
        "净资产",
        "营业"
      ]
    },
    {
      "chunk_id": "94641a99",
      "content": "）同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况\n□ 适用 √ 不适用\n（3）境内外会计准则下会计数据差异原因说明，对已经境外审计机构审计的数据进行差异调节的，应注\n明该境外机构的名称\n4、其他\n203 第十三节 备查文件目录\n一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表。\n二、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。\n三、报告期内在中国证监会指定报刊上公开披露过的所有公司文件正本及公告原稿；\n四、载有公司法定代表人签名的2019年年度报告文本原件。\n五、其他备查文件。\n文件存放地：公司投资发展部\n浙江海翔药业股份有限公司\n法定代表人：杨思卫\n二零二零年一月二十二日\n204",
      "chunk_type": "child",
      "parent_id": "55ff37e1",
      "child_ids": [],
      "sibling_ids": [
        "e10e5096",
        "fe1b90b6",
        "b3931df4",
        "0237badf",
        "38ea36ec"
      ],
      "position": 5,
      "start_char": 3656,
      "end_char": 3986,
      "page_number": 198,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          198
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.361231",
        "report_type": "资产负债表",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 330,
        "word_count": 21,
        "sentence_count": 4,
        "chinese_char_count": 275,
        "readability_score": 0.0,
        "information_density": 0.4545454545454546,
        "coherence_score": 0.7,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8313333333333335,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "利润",
        "投资",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "资产负债表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "利润",
        "投资",
        "净利润",
        "净资产",
        "会计数据",
        "股份",
        "审计",
        "报告",
        "财务报告"
      ]
    },
    {
      "chunk_id": "bee13319",
      "content": "公司本期将以下15家子公司纳入合并财务报表范围，情况详见本财务报表附注合并范围变更和其他主\n体中的权益之说明。序号 子公司名称 公司简称\n1 浙江海翔川南药业有限公司 川南药业公司\n2 浙江海翔药业销售有限公司 海翔销售公司\n3 上海海翔医药科技发展有限公司 上海海翔公司\n4 台州港翔科技有限公司 港翔科技公司\n5 港翔国际控股(香港)有限公司 香港港翔公司\n6 GeneVida GmbH GeneVida GmbH\n7 GANGXIANG INTERNATIONAL HOLDINGSGANGXIANG(SINGAPORE)\n（SINGAPORE）PTE.LTD\n8 台州港翔化工有限公司 港翔化工公司\n9 台州市前进化工有限公司 台州前进公司\n10 台州市振港染料化工有限公司 台州振港公司\n11 盐城市瓯华化学工业有限公司 盐城瓯华公司\n12 台州市东旭医化设备有限公司 台州东旭公司\n13 盐城市瓯华化工研究院有限公司 瓯华研究院\n14 盐城市瓯华环保科技有限公司 瓯华环保公司\n15 浙江盛嘉环保有限公司 盛嘉环保公司\n100。\n\n四、财务报表的编制基础\n1、编制基础\n本公司财务报表以持续经营为编制基础。2、持续经营\n本公司不存在导致对报告期末起12个月内的持续经营能力产生重大疑虑的事项或情况。五、重要会计政策及会计估计\n具体会计政策和会计估计提示：\n本公司根据实际生产经营特点针对应收款项坏账准备计提、固定资产折旧、无形资产摊销、收入确认\n等交易或事项制定了具体会计政策和会计估计。\n\n1、遵循企业会计准则的声明\n本公司所编制的财务报表符合企业会计准则的要求，真实、完整地反映了公司的财务状况、经营成果\n和现金流量等有关信息。2、会计期间\n会计年度自公历1月1日起至12月31日止。3、营业周期\n公司经营业务的营业周期较短，以12个月作为资产和负债的流动性划分标准。\n\n4、记账本位币\n采用人民币为记账本位币。5、同一控制下和非同一控制下企业合并的会计处理方法\n1. 同一控制下企业合并的会计处理方法\n公司在企业合并中取得的资产和负债，按照合并日被合并方在最终控制方合并财务报表中的账面价值\n计量。公司按照被合并方所有者权益在最终控制方合并财务报表中的账面价值份额与支付的合并对价账面\n价值或发行股份面值总额的差额，调整资本公积；资本公积不足冲减的，调整留存收益。",
      "chunk_type": "child",
      "parent_id": "20b9cdc5",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 992,
      "page_number": 100,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          100
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.361748",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "上海海翔医药科技发展有限公司",
        "industry": null,
        "char_count": 992,
        "word_count": 73,
        "sentence_count": 13,
        "chinese_char_count": 745,
        "readability_score": 0.0,
        "information_density": 0.1814516129032258,
        "coherence_score": 0.724183260260626,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9004032258064516,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "现金流",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "现金",
        "应收",
        "固定资产",
        "无形资产",
        "合并",
        "营业"
      ]
    },
    {
      "chunk_id": "92d5ab85",
      "content": "2. 非同一控制下企业合并的会计处理方法\n公司在购买日对合并成本大于合并中取得的被购买方可辨认净资产公允价值份额的差额，确认为商\n101。\n\n誉；如果合并成本小于合并中取得的被购买方可辨认净资产公允价值份额，首先对取得的被购买方各项可\n辨认资产、负债及或有负债的公允价值以及合并成本的计量进行复核，经复核后合并成本仍小于合并中取\n得的被购买方可辨认净资产公允价值份额的，其差额计入当期损益。6、合并财务报表的编制方法\n母公司将其控制的所有子公司纳入合并财务报表的合并范围。合并财务报表以母公司及其子公司的财\n务报表为基础，根据其他有关资料，由母公司按照《企业会计准则第33号——合并财务报表》编制。\n\n7、合营安排分类及共同经营会计处理方法\n1. 合营安排分为共同经营和合营企业。2. 当公司为共同经营的合营方时，确认与共同经营中利益份额相关的下列项目：\n(1) 确认单独所持有的资产，以及按持有份额确认共同持有的资产；\n(2) 确认单独所承担的负债，以及按持有份额确认共同承担的负债；\n(3) 确认出售公司享有的共同经营产出份额所产生的收入；\n(4) 按公司持有份额确认共同经营因出售资产所产生的收入；\n(5) 确认单独所发生的费用，以及按公司持有份额确认共同经营发生的费用。8、现金及现金等价物的确定标准\n列示于现金流量表中的现金是指库存现金以及可以随时用于支付的存款。\n\n现金等价物是指企业持有的\n期限短、流动性强、易于转换为已知金额现金、价值变动风险很小的投资。9、外币业务和外币报表折算\n1. 外币业务折算\n外币交易在初始确认时，采用交易发生日即期汇率的近似汇率折算为人民币金额。资产负债表日，外\n币货币性项目采用资产负债表日即期汇率折算，因汇率不同而产生的汇兑差额，除与购建符合资本化条件\n资产有关的外币专门借款本金及利息的汇兑差额外，计入当期损益；以历史成本计量的外币非货币性项目\n仍采用交易发生日即期汇率的近似汇率折算，不改变其人民币金额；以公允价值计量的外币非货币性项目，\n采用公允价值确定日的即期汇率折算，差额计入当期损益或其他综合收益。",
      "chunk_type": "child",
      "parent_id": "b0fc80f9",
      "child_ids": [],
      "sibling_ids": [],
      "position": 0,
      "start_char": 0,
      "end_char": 879,
      "page_number": 101,
      "bbox": null,
      "element_type": "title",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          101
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.362170",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 879,
        "word_count": 33,
        "sentence_count": 14,
        "chinese_char_count": 764,
        "readability_score": 0.0,
        "information_density": 0.21615472127417523,
        "coherence_score": 0.7289347016619744,
        "standards_profile_summary": {}
      },
      "quality_score": 0.9476678043230944,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "收入",
        "成本",
        "现金流",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "收入",
        "成本",
        "费用",
        "现金",
        "投资",
        "净资产",
        "资产负债表",
        "现金流量表"
      ]
    },
    {
      "chunk_id": "982e5d57",
      "content": "对于外币资产和负债，如果出现短期的失衡\n情况，本公司会在必要时按市场汇率买卖外币，以确保将净风险敞口维持在可接受的水平。本公司期末外币货币性资产和负债情况详见本财务报表附注合并财务报表项目注释其他之外币货币\n性项目说明。十一、公允价值的披露\n1、以公允价值计量的资产和负债的期末公允价值\n单位： 元\n期末公允价值\n项目 第一层次公允价值计\n第二层次公允价值计量 第三层次公允价值计量 合计\n量\n一、持续的公允价值计量 -- -- -- --\n（2）权益工具投资 20,000,000.00 20,000,000.00\n185。\n\n（八）应收款项融资 74,531,666.41 74,531,666.41\n持续以公允价值计量的\n94,531,666.41 94,531,666.41\n负债总额\n二、非持续的公允价值计\n-- -- -- --\n量\n2、持续和非持续第一层次公允价值计量项目市价的确定依据\n3、持续和非持续第二层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n4、持续和非持续第三层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息\n5、持续的第三层次公允价值计量项目，期初与期末账面价值间的调节信息及不可观察参数敏感性分析\n1. 对于持有的应收票据，采用票面金额确定其公允价值；\n2.因被投资企业杭州寓鑫创业投资合伙企业（有限合伙）的经营环境和经营情况、财务状况未发生重\n大变化，所以公司按投资成本作为公允价值的合理估计进行计量；\n3.因被投资企业滨海宏博环境技术服务股份有限公司的经营环境和经营情况、财务状况恶化，所以公\n司以零元作为公允价值的合理估计进行计量。6、持续的公允价值计量项目，本期内发生各层级之间转换的，转换的原因及确定转换时点的政策\n7、本期内发生的估值技术变更及变更原因\n8、不以公允价值计量的金融资产和金融负债的公允价值情况\n9、其他\n十二、关联方及关联交易\n1、本企业的母公司情况\n母公司对本企业的 母公司对本企业的\n母公司名称 注册地 业务性质 注册资本\n持股比例 表决权比例\n浙江东港投资有限\n台州 投资 11,800万元 34.22% 34.22%\n公司\n本企业的母公司情况的说明\n浙江东港投资有限公司(以下简称东港投资公司)系由东港工贸集团有限公司100%持股的公司，于1998\n年7月9日在台州市工商行政管理局椒江分局登记注册，现持有统一社会信用代码为913310027046766827的\n营业执照，注册资本11,800万元。本企业最终控制方是王云富，间接通过东港投资公司持有本公司股份55,398.2587万股，直接持有本公司股份11,880万股，\n186。\n\n合计持股比例41.56%。其他说明：\n2、本企业的子公司情况\n本企业子公司的情况详见附注在其他主体中的权益之说明。",
      "chunk_type": "child",
      "parent_id": "2e75d2d7",
      "child_ids": [],
      "sibling_ids": [
        "476451fe",
        "3e97a146",
        "13f6be1a",
        "80350609"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1176,
      "page_number": 185,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.363306",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "因被投资企业",
        "industry": null,
        "char_count": 1176,
        "word_count": 73,
        "sentence_count": 21,
        "chinese_char_count": 855,
        "readability_score": 0.0,
        "information_density": 0.17006802721088438,
        "coherence_score": 0.6949712643678161,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8908163265306122,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "融资",
        "经营",
        "财务",
        "报表",
        "800万元"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "投资",
        "应收",
        "合并",
        "母公司",
        "营业",
        "经营"
      ]
    },
    {
      "chunk_id": "476451fe",
      "content": "7月9日在台州市工商行政管理局椒江分局登记注册，现持有统一社会信用代码为913310027046766827的\n营业执照，注册资本11,800万元。本企业最终控制方是王云富，间接通过东港投资公司持有本公司股份55,398.2587万股，直接持有本公司股份11,880万股，\n186。\n\n合计持股比例41.56%。其他说明：\n2、本企业的子公司情况\n本企业子公司的情况详见附注在其他主体中的权益之说明。3、本企业合营和联营企业情况\n本企业重要的合营或联营企业详见附注在其他主体中的权益之说明。\n\n本期与本公司发生关联方交易，或前期与本公司发生关联方交易形成余额的其他合营或联营企业情况如下：\n合营或联营企业名称 与本企业关系\n苏州第四制药厂有限公司 联营企业\n浙江高盛钢结构有限公司 联营企业\n其他说明\n4、其他关联方情况\n其他关联方名称 其他关联方与本企业关系\n浙江荣兴活性炭有限公司 控股股东之联营企业\n江西华邦药业有限公司 控股股东之联营企业\n台州艾斐科技有限公司 控股股东之联营企业\n台州市东港包装用品有限公司 控股股东之子公司\n其他说明\n5、关联交易情况\n（1）购销商品、提供和接受劳务的关联交易\n采购商品/接受劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 获批的交易额度 是否超过交易额度 上期发生额\n浙江高盛钢结构有\n工程建造 1,275,826.79\n限公司\n浙江荣兴活性炭有\n原材料 2,423,957.10 28,000,000.00否 3,914,565.88\n限公司\n江西华邦药业有限 原料药及医药中\n23,998,498.62 50,000,000.00否 809,858.52\n公司 间体\n台州市东港包装用\n原材料 4,393.37\n品有限公司\n187。",
      "chunk_type": "child",
      "parent_id": "2e75d2d7",
      "child_ids": [],
      "sibling_ids": [
        "982e5d57",
        "3e97a146",
        "13f6be1a",
        "80350609"
      ],
      "position": 1,
      "start_char": 976,
      "end_char": 1722,
      "page_number": 185,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.363553",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "间接通过东港投资公司",
        "industry": null,
        "char_count": 746,
        "word_count": 60,
        "sentence_count": 16,
        "chinese_char_count": 509,
        "readability_score": 0.0,
        "information_density": 0.10723860589812333,
        "coherence_score": 0.63064680210163,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8729222520107238,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "投资",
        "800万元"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "投资",
        "营业",
        "股份",
        "股东"
      ]
    },
    {
      "chunk_id": "3e97a146",
      "content": " 是否超过交易额度 上期发生额\n浙江高盛钢结构有\n工程建造 1,275,826.79\n限公司\n浙江荣兴活性炭有\n原材料 2,423,957.10 28,000,000.00否 3,914,565.88\n限公司\n江西华邦药业有限 原料药及医药中\n23,998,498.62 50,000,000.00否 809,858.52\n公司 间体\n台州市东港包装用\n原材料 4,393.37\n品有限公司\n187。\n\n出售商品/提供劳务情况表\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n苏州第四制药厂有限公司 原料药及医药中间体 261,061.95 504,310.34\n台州艾斐科技有限公司 电费 404,095.99 678,615.69\n江西华邦药业有限公司 设备销售 255,603.43\n江西华邦药业有限公司 原料药及医药中间体 44,247.79\n购销商品、提供和接受劳务的关联交易说明\n（2）关联受托管理/承包及委托管理/出包情况\n本公司受托管理/承包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名受托/承包资产类 托管收益/承包收 本期确认的托管\n受托/承包起始日受托/承包终止日\n称 称 型 益定价依据 收益/承包收益\n关联托管/承包情况说明\n本公司委托管理/出包情况表：\n单位： 元\n委托方/出包方名受托方/承包方名委托/出包资产类 托管费/出包费定 本期确认的托管\n委托/出包起始日委托/出包终止日\n称 称 型 价依据 费/出包费\n关联管理/出包情况说明\n（3）关联租赁情况\n本公司作为出租方：\n单位： 元\n承租方名称 租赁资产种类 本期确认的租赁收入 上期确认的租赁收入\n本公司作为承租方：\n单位： 元\n出租方名称 租赁资产种类 本期确认的租赁费 上期确认的租赁费\n关联租赁情况说明\n（4）关联担保情况\n本公司作为担保方\n单位： 元\n被担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n本公司作为被担保方\n单位： 元\n188。",
      "chunk_type": "child",
      "parent_id": "2e75d2d7",
      "child_ids": [],
      "sibling_ids": [
        "982e5d57",
        "476451fe",
        "13f6be1a",
        "80350609"
      ],
      "position": 2,
      "start_char": 1522,
      "end_char": 2360,
      "page_number": 185,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.363756",
        "report_type": "财务报表附注",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "台州艾斐科技有限公司",
        "industry": null,
        "char_count": 838,
        "word_count": 102,
        "sentence_count": 16,
        "chinese_char_count": 533,
        "readability_score": 0.0,
        "information_density": 0.0477326968973747,
        "coherence_score": 0.41999999999999993,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8544152744630071,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "收入"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "收入"
      ]
    },
    {
      "chunk_id": "13f6be1a",
      "content": "出包情况说明\n（3）关联租赁情况\n本公司作为出租方：\n单位： 元\n承租方名称 租赁资产种类 本期确认的租赁收入 上期确认的租赁收入\n本公司作为承租方：\n单位： 元\n出租方名称 租赁资产种类 本期确认的租赁费 上期确认的租赁费\n关联租赁情况说明\n（4）关联担保情况\n本公司作为担保方\n单位： 元\n被担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n本公司作为被担保方\n单位： 元\n188。\n\n担保方 担保金额 担保起始日 担保到期日 担保是否已经履行完毕\n关联担保情况说明\n（5）关联方资金拆借\n单位： 元\n关联方 拆借金额 起始日 到期日 说明\n拆入\n拆出\n（6）关联方资产转让、债务重组情况\n单位： 元\n关联方 关联交易内容 本期发生额 上期发生额\n（7）关键管理人员报酬\n单位： 元\n项目 本期发生额 上期发生额\n关键管理人员报酬 8,152,800.00 7,761,100.00\n（8）其他关联交易\n6、关联方应收应付款项\n（1）应收项目\n单位： 元\n期末余额 期初余额\n项目名称 关联方\n账面余额 坏账准备 账面余额 坏账准备\n台州艾斐科技有限\n应收账款 63,451.70 3,172.59\n公司\n江西华邦药业有限\n应收账款 9,682.64 2,904.79\n公司\n小 计 9,682.64 2,904.79 63,451.70 3,172.59\n（2）应付项目\n单位： 元\n项目名称 关联方 期末账面余额 期初账面余额\n189\n\n应付账款 浙江荣兴活性炭有限公司 171,167.79 816,333.28\n应付账款 浙江高盛钢结构有限公司 169,367.59 154,247.59\n应付账款 江西华邦药业有限公司 51,086.20\n台州市东港包装用品有限公\n应付账款 4,393.37\n司\n小 计 344,928.75 1,021,667.07\n7、关联方承诺\n8、其他\n十三、股份支付\n1、股份支付总体情况\n√ 适用 □ 不适用\n单位： 元\n公司本期授予的各项权益工具总额 0.00\n公司本期行权的各项权益工具总额 18,146,500.00\n公司本期失效的各项权益工具总额 105,000.00\n公司期末发行在外的股票期权行权价格的范围和合同剩余期限 0\n公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 0\n其他说明\n根据公司2015 年第一次临时股东大会审议通过的《浙江海翔药业股份有限公司限制性股票激励计划\n（草案）》及其摘要(以下简称激励计划)，公司首次授予激励对象限制性股票3,471.5万股，预留部分限制\n性股票380万股。根据公司2015年度股东大会决议审议通过的2015年度利润分配方案，上述限制性股票数\n量调整为7,703万股。",
      "chunk_type": "child",
      "parent_id": "2e75d2d7",
      "child_ids": [],
      "sibling_ids": [
        "982e5d57",
        "476451fe",
        "3e97a146",
        "80350609"
      ],
      "position": 3,
      "start_char": 2160,
      "end_char": 3308,
      "page_number": 185,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.363978",
        "report_type": "财务报表附注",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 1148,
        "word_count": 144,
        "sentence_count": 25,
        "chinese_char_count": 712,
        "readability_score": 0.0,
        "information_density": 0.12195121951219512,
        "coherence_score": 0.6877365129916881,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8480836236933798,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "收入",
        "利润"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "收入",
        "利润",
        "应收",
        "应付",
        "股份",
        "股东",
        "分配",
        "债务"
      ]
    },
    {
      "chunk_id": "80350609",
      "content": "公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限 0\n其他说明\n根据公司2015 年第一次临时股东大会审议通过的《浙江海翔药业股份有限公司限制性股票激励计划\n（草案）》及其摘要(以下简称激励计划)，公司首次授予激励对象限制性股票3,471.5万股，预留部分限制\n性股票380万股。根据公司2015年度股东大会决议审议通过的2015年度利润分配方案，上述限制性股票数\n量调整为7,703万股。截至2018年12月31日累计回购已获授但尚未解锁的限制性股票429.2万股，累计解锁\n限制性股票5,459.15万股。\n\n根据公司2019年3月13日第五届董事会第二十一次会议决议，公司2018年度绩效考核已满足行权条件，\n对首次及预留授予激励对象持有的限制性股票1,814.65万股予以解锁。2、以权益结算的股份支付情况\n√ 适用 □ 不适用\n单位： 元\n授予日权益工具公允价值的确定方法 根据布莱克-斯科尔模型来计算期权的理论价值\n可行权权益工具数量的确定依据 无\n本期估计与上期估计有重大差异的原因 无\n190。",
      "chunk_type": "child",
      "parent_id": "2e75d2d7",
      "child_ids": [],
      "sibling_ids": [
        "982e5d57",
        "476451fe",
        "3e97a146",
        "13f6be1a"
      ],
      "position": 4,
      "start_char": 3108,
      "end_char": 3568,
      "page_number": 185,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          185
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.364212",
        "report_type": "财务报表附注",
        "fiscal_year": 2015,
        "fiscal_quarter": null,
        "company_code": "浙江海翔药业股份有限公司",
        "industry": null,
        "char_count": 460,
        "word_count": 24,
        "sentence_count": 9,
        "chinese_char_count": 342,
        "readability_score": 0.0,
        "information_density": 0.2173913043478261,
        "coherence_score": 0.7190981432360743,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8733913043478261,
      "relevance_score": 1.0,
      "keywords": [
        "权益",
        "利润"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "权益",
        "利润",
        "股份",
        "股东",
        "分配",
        "回购",
        "公允价值",
        "价值"
      ]
    },
    {
      "chunk_id": "3aad9ac6",
      "content": "以权益结算的股份支付计入资本公积的累计金额 174,493,817.84\n本期以权益结算的股份支付确认的费用总额 7,113,749.53\n其他说明\n3、以现金结算的股份支付情况\n□ 适用 √ 不适用\n4、股份支付的修改、终止情况\n5、其他\n十四、承诺及或有事项\n1、重要承诺事项\n资产负债表日存在的重要承诺\n(一) 重要承诺事项\n1. 已签订的尚未履行或尚未完全履行的对外投资合同及有关财务支出\n根据公司2016年9月28日第四届董事会第三十次会议决议，公司拟使用自有资金投资医健战略投资基\n金上海佳添冠投资合伙企业(有限合伙)。上海佳添冠投资合伙企业(有限合伙)目标规模20亿元，公司拟以自\n有资金不超过2亿元人民币认购该基金，截至本财务报表批准报出日，公司尚未实际出资。2. 根据公司2019年2月14日第五届董事会第二十次会议决议，台州前进公司拟与内蒙古生力资源（集\n团）有限责任公司共同投资设立内蒙古科菲化工有限公司(以下简称科菲化工公司)，科菲化工公司一期计\n划投资总额为50,000.00万元，其中台州前进公司计划投资24,500.00万元，占科菲化工公司49.00%的股权。\n\n根据公司2020年1月22日第六届董事会第二次会议，公司决定终止对科菲化工公司的投资。(二) 前期承诺履行情况\n1. 根据2015年10月30日公司2015年第三次临时股东大会审议通过的《关于公司非公开发行 A 股股票\n方案（修订稿）的议案》，公司非公开发行人民币普通股(A股)股票99,890,023股，募集资金净额为\n1,014,403,606.71元，上述募集资金全部用于投资建设以下项目：\n项目名称 项目实施主体 总投资额 募集资金计划投\n(万元) 入(万元)\n原料药及中间体CMO中心扩建项目 川南药业公司 46,034.58 40,000.00\n年产30亿片（粒）固体制剂技改项目 本公司 35,852.00 35,000.00\n医药综合研发中心 川南药业公司 15,073.00 15,000.00\n医药中试车间技改项目 本公司 9,256.00 9,000.00\n环保设施改造项目 本公司及子公司 15,502.00 14,000.00\n合 计 121,717.58 113,000.00\n截至2019年12月31日，本公司已使用募集资金直接投入上述项目44,720.30万元，根据公司2019年3月\n11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资项目并将结余募集资金用于永\n久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目的市场环境已发生较大变化，公司\n终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。",
      "chunk_type": "child",
      "parent_id": "da2eda41",
      "child_ids": [],
      "sibling_ids": [
        "a9205a23"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1158,
      "page_number": 191,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.364718",
        "report_type": "财务报表附注",
        "fiscal_year": 2016,
        "fiscal_quarter": null,
        "company_code": "有限责任公司共同投资设立内蒙古科菲化工有限公司",
        "industry": null,
        "char_count": 1158,
        "word_count": 71,
        "sentence_count": 28,
        "chinese_char_count": 747,
        "readability_score": 0.0,
        "information_density": 0.16407599309153714,
        "coherence_score": 0.6813761093035704,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8580310880829016,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "财务",
        "报表",
        "20亿元",
        "2亿元",
        "000.00万元"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "费用",
        "现金",
        "投资",
        "资产负债表",
        "资本公积",
        "股权",
        "股份"
      ]
    },
    {
      "chunk_id": "a9205a23",
      "content": "2月31日，本公司已使用募集资金直接投入上述项目44,720.30万元，根据公司2019年3月\n11日2018 年度股东大会会议审议通过的《关于终止实施部分募集资金投资项目并将结余募集资金用于永\n久性补充流动资金的议案》，因年产30 亿片（粒）固体制剂技改项目的市场环境已发生较大变化，公司\n终止实施该项目并将结余募集资金 370,616,060.66 元转入公司普通账户，用于永久补充公司流动资金。2. 根据公司2018年第一次临时股东大会及第三次临时股东大会，公司拟以集中竞价交易方式回购公司\n191。",
      "chunk_type": "child",
      "parent_id": "da2eda41",
      "child_ids": [],
      "sibling_ids": [
        "3aad9ac6"
      ],
      "position": 1,
      "start_char": 958,
      "end_char": 1211,
      "page_number": 191,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          191
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.364922",
        "report_type": "财务报表附注",
        "fiscal_year": 2019,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 253,
        "word_count": 10,
        "sentence_count": 5,
        "chinese_char_count": 184,
        "readability_score": 0.0,
        "information_density": 0.19762845849802374,
        "coherence_score": 0.7133333333333334,
        "standards_profile_summary": {}
      },
      "quality_score": 0.742709090909091,
      "relevance_score": 1.0,
      "keywords": [
        "投资",
        "720.30万元"
      ],
      "entities": [],
      "topics": [
        "财务报表附注"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "投资",
        "股东",
        "回购"
      ]
    },
    {
      "chunk_id": "aee2dd2d",
      "content": "支付银行借款保证金 900,000.00\n合计 20,278,463.47 590,452,772.90\n支付的其他与筹资活动有关的现金说明：\n79、现金流量表补充资料\n（1）现金流量表补充资料\n单位： 元\n补充资料 本期金额 上期金额\n1．将净利润调节为经营活动现金流量： -- --\n净利润 770,782,185.09 605,003,820.78\n加：资产减值准备 14,240,855.70 18,867,903.52\n固定资产折旧、油气资产折耗、生产性生\n172,822,169.17 161,268,842.88\n物资产折旧\n无形资产摊销 30,277,923.13 31,103,003.79\n长期待摊费用摊销 223,651.32 162,421.24\n处置固定资产、无形资产和其他长期资产\n-244,580.94 -659,231.88\n的损失（收益以“－”号填列）\n固定资产报废损失（收益以“－”号填列） 4,395,355.91 761,505.33\n公允价值变动损失（收益以“－”号填列） -5,010,265.70\n财务费用（收益以“－”号填列） -7,552,032.06 -14,604,700.41\n投资损失（收益以“－”号填列） 15,240,062.55 9,359,378.55\n递延所得税资产减少（增加以“－”号填列） 5,147,540.13 -4,649,984.56\n递延所得税负债增加（减少以“－”号填列） 22,351,927.43 8,175,428.28\n存货的减少（增加以“－”号填列） 52,643,000.47 -99,308,067.53\n经营性应收项目的减少（增加以“－”号填\n-276,602,622.13 -71,443,627.33\n列）\n经营性应付项目的增加（减少以“－”号填\n-191,326,340.46 152,422,810.70\n列）\n经营活动产生的现金流量净额 612,399,095.31 791,449,237.66\n2．不涉及现金收支的重大投资和筹资活\n-- --\n动：\n3．现金及现金等价物净变动情况： -- --\n现金的期末余额 1,525,777,908.45 1,069,208,275.60\n减：现金的期初余额 1,069,208,275.60 2,245,777,296.21\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n172。",
      "chunk_type": "child",
      "parent_id": "61b29498",
      "child_ids": [],
      "sibling_ids": [
        "5cda9b24",
        "e0c05d21",
        "b06beb2d"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1041,
      "page_number": 172,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.365919",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1041,
        "word_count": 84,
        "sentence_count": 41,
        "chinese_char_count": 338,
        "readability_score": 0.0,
        "information_density": 0.1633045148895293,
        "coherence_score": 0.48,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7298751200768492,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "利润",
        "现金流",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "费用",
        "利润",
        "现金",
        "投资",
        "应收",
        "应付",
        "存货",
        "固定资产"
      ]
    },
    {
      "chunk_id": "5cda9b24",
      "content": "1,449,237.66\n2．不涉及现金收支的重大投资和筹资活\n-- --\n动：\n3．现金及现金等价物净变动情况： -- --\n现金的期末余额 1,525,777,908.45 1,069,208,275.60\n减：现金的期初余额 1,069,208,275.60 2,245,777,296.21\n现金及现金等价物净增加额 456,569,632.85 -1,176,569,020.61\n172。\n\n（2）本期支付的取得子公司的现金净额\n单位： 元\n金额\n其中： --\n其中： --\n其中： --\n其他说明：\n（3）本期收到的处置子公司的现金净额\n单位： 元\n金额\n其中： --\n其中： --\n其中： --\n其他说明：\n（4）现金和现金等价物的构成\n单位： 元\n项目 期末余额 期初余额\n一、现金 1,525,777,908.45 1,069,208,275.60\n其中：库存现金 131,545.99 195,522.60\n可随时用于支付的银行存款 1,525,298,726.49 1,068,623,694.25\n可随时用于支付的其他货币资金 347,635.97 389,058.75\n三、期末现金及现金等价物余额 1,525,777,908.45 1,069,208,275.60\n其他说明：\n(1) 不涉及现金收支的商业汇票背书转让金额\n项 目 本期数 上期数\n背书转让的商业汇票金额 1,203,398,004.56 1,019,486,370.21\n其中：支付货款 763,162,260.55 663,084,419.99\n支付固定资产等长期资产购置款 440,235,744.01 356,401,950.22\n(2) 不属于现金及现金等价物的货币资金情况的说明\n项 目 期末数 期初数\n质押的定期存款 34,316,000.00\n结构性存款 750,000,000.00\n银行承兑汇票保证金 30,797,464.00 102,564,848.73\n173。",
      "chunk_type": "child",
      "parent_id": "61b29498",
      "child_ids": [],
      "sibling_ids": [
        "aee2dd2d",
        "e0c05d21",
        "b06beb2d"
      ],
      "position": 1,
      "start_char": 841,
      "end_char": 1683,
      "page_number": 172,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.366154",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 842,
        "word_count": 91,
        "sentence_count": 29,
        "chinese_char_count": 300,
        "readability_score": 0.0,
        "information_density": 0.07125890736342043,
        "coherence_score": 0.26999999999999996,
        "standards_profile_summary": {}
      },
      "quality_score": 0.7425178147268408,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "投资"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "现金",
        "投资",
        "固定资产"
      ]
    },
    {
      "chunk_id": "e0c05d21",
      "content": " 763,162,260.55 663,084,419.99\n支付固定资产等长期资产购置款 440,235,744.01 356,401,950.22\n(2) 不属于现金及现金等价物的货币资金情况的说明\n项 目 期末数 期初数\n质押的定期存款 34,316,000.00\n结构性存款 750,000,000.00\n银行承兑汇票保证金 30,797,464.00 102,564,848.73\n173。\n\n小 计 30,797,464.00 886,880,848.73\n80、所有者权益变动表项目注释\n说明对上年期末余额进行调整的“其他”项目名称及调整金额等事项：\n81、所有权或使用权受到限制的资产\n单位： 元\n项目 期末账面价值 受限原因\n货币资金 30,797,464.00开立银行承兑汇票\n固定资产 22,554,937.46银行融资抵押\n无形资产 10,291,182.19银行融资抵押\n合计 63,643,583.65 --\n其他说明：\n82、外币货币性项目\n（1）外币货币性项目\n单位： 元\n项目 期末外币余额 折算汇率 期末折算人民币余额\n货币资金 -- -- 214,734,480.07\n其中：美元 30,636,838.136.9762 213,728,710.16\n欧元 40,660.307.8155 317,780.57\n港币\n英镑 75,189.279.1501 687,989.34\n应收账款 -- -- 146,207,835.41\n其中：美元 20,665,705.866.9762 144,168,097.22\n欧元 260,986.277.8155 2,039,738.19\n港币\n其他应收款 2,859.22\n其中：欧元 365.847.8155 2,859.22\n应付账款 5,296,661.70\n其中：美元 663,385.606.9762 4,627,910.62\n欧元 85,567.287.8155 668,751.08\n其他应付款 8,199,889.22\n174。\n\n其中：美元 789,910.036.9762 5,510,570.35\n欧元 342,262.847.8155 2,674,955.23\n英镑 1,569.789.1501 14,363.64\n长期借款 -- --\n其中：美元\n欧元\n港币\n其他说明：\n（2）境外经营实体说明，包括对于重要的境外经营实体，应披露其境外主要经营地、记账本位币及选择\n依据，记账本位币发生变化的还应披露原因。",
      "chunk_type": "child",
      "parent_id": "61b29498",
      "child_ids": [],
      "sibling_ids": [
        "aee2dd2d",
        "5cda9b24",
        "b06beb2d"
      ],
      "position": 2,
      "start_char": 1483,
      "end_char": 2539,
      "page_number": 172,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.366370",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1056,
        "word_count": 108,
        "sentence_count": 55,
        "chinese_char_count": 343,
        "readability_score": 0.0,
        "information_density": 0.13257575757575757,
        "coherence_score": 0.35760000000000003,
        "standards_profile_summary": {}
      },
      "quality_score": 0.728219696969697,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "权益",
        "融资",
        "经营"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "权益",
        "现金",
        "应收",
        "应付",
        "固定资产",
        "无形资产",
        "经营",
        "披露",
        "账面价值"
      ]
    },
    {
      "chunk_id": "b06beb2d",
      "content": "\n174。\n\n其中：美元 789,910.036.9762 5,510,570.35\n欧元 342,262.847.8155 2,674,955.23\n英镑 1,569.789.1501 14,363.64\n长期借款 -- --\n其中：美元\n欧元\n港币\n其他说明：\n（2）境外经营实体说明，包括对于重要的境外经营实体，应披露其境外主要经营地、记账本位币及选择\n依据，记账本位币发生变化的还应披露原因。√ 适用 □ 不适用\n子公司 子公司类型 境外主要经营地 记账 选择依据\n本位币\nGeneVida GmbH 全资子公司 德国 欧元 根据公司经营所处经济环境选择\nGANGXIANG（SINGAPORE） 全资子公司 新加坡 人民币 根据公司经营所处经济环境选择\n香港港翔公司 全资子公司 香港 人民币 根据公司经营所处经济环境选择\n83、套期\n按照套期类别披露套期项目及相关套期工具、被套期风险的定性和定量信息：\n84、政府补助\n（1）政府补助基本情况\n单位： 元\n种类 金额 列报项目 计入当期损益的金额\n（2）政府补助退回情况\n□ 适用 √ 不适用\n其他说明：\n(1) 明细情况\n1) 与资产相关的政府补助\n项 目 期初递延收益 本期新增补助 本期摊销 期末递延收益 本期摊销 说明\n列报项目\n175。",
      "chunk_type": "child",
      "parent_id": "61b29498",
      "child_ids": [],
      "sibling_ids": [
        "aee2dd2d",
        "5cda9b24",
        "e0c05d21"
      ],
      "position": 3,
      "start_char": 2339,
      "end_char": 2893,
      "page_number": 172,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          172
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.366587",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 554,
        "word_count": 74,
        "sentence_count": 12,
        "chinese_char_count": 320,
        "readability_score": 0.0,
        "information_density": 0.1263537906137184,
        "coherence_score": 0.42636363636363633,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8310469314079423,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "经营"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "经营",
        "披露",
        "摊销",
        "借款"
      ]
    },
    {
      "chunk_id": "b8ef424f",
      "content": "年产400吨碳青霉烯类抗生 5,695,281.12 1,423,820.28 4,271,460.84 其他收益\n素关键中间体4-AA项目\n年产1吨瑞格列奈、10吨卡洛 235,862.40 117,931.20 117,931.20 其他收益\n芬、10吨阿托伐醌、50吨\nT1620、300吨聚卡波菲钙、\n300吨4,4'-二氟二苯甲酮、100\n吨奈韦拉平产业化项目\n催化净化处理塔建设项目 140,000.00 30,000.00 110,000.00 其他收益\n年产50吨培南类产品及扩建 132,000.00 48,000.00 84,000.00 其他收益\n厂房技改项目\n企业技术中心创新能力建设 133,333.33 40,000.00 93,333.33 其他收益\n项目\n年产8亿元(粒)口服固体制剂 7,065,200.00 997,440.00 6,067,760.00 其他收益\n项目\n临海市创新驱动加快推进工 1,042,718.40 208,543.68 834,174.72 其他收益\n业经济转型升级政策\n省级工业与信息化专项资金 632,766.12 92,599.92 540,166.20 其他收益\n回收溶剂循环化技改项目\n省工业化和信息化深度融合 457,675.28 66,169.92 391,505.36 其他收益\n示范试点区财政补助\n浙江省化学原料药基地椒江 263,333.33 40,000.00 223,333.33 其他收益\n区块循环化改造项目补助资\n金\n年产2吨盐酸阿莫罗芬、20吨 2,090,683.87 281,889.96 1,808,793.91 其他收益\n阿特来马来酸盐、5吨多尼培\n南、20吨美罗培南、5吨比阿\n培南、60吨PHE产业化项目\n(续建)\n年产15000吨环保型活性艳 850,000.00 100,000.00 750,000.00 其他收益\n蓝KN-R商品染料技改项目\n大品种药物的生产技术改造- 860,416.67 2,000,000.00 291,265.91 2,569,150.76 其他收益\n美罗培南原料药绿色合成技\n术改造\n临海医化园区循环化改造项 490,000.00 105,000.00 385,000.00 其他收益\n目\n南洋涂—固废减量化处置项 2,286,832.98 246,999.96 2,039,833.02 其他收益\n目\n年产400吨MAP、100吨OA、 11,962,166.31 10,000,000.00 1,490,999.91 20,471,166.40 其他收益\n200吨DA、100吨甲砜霉素、\n10吨联苯双酯产业化新项目\n年产580吨柳氮磺胺吡啶产 2,115,735.00 248,910.00 1,866,825.00 其他收益\n业化项目\n176。",
      "chunk_type": "child",
      "parent_id": "33e91743",
      "child_ids": [],
      "sibling_ids": [
        "22233eaf",
        "6601f973",
        "65c8625b"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1195,
      "page_number": 176,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.367966",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1195,
        "word_count": 113,
        "sentence_count": 54,
        "chinese_char_count": 416,
        "readability_score": 0.0,
        "information_density": 0.01673640167364017,
        "coherence_score": 0.36,
        "standards_profile_summary": {}
      },
      "quality_score": 0.4517991631799163,
      "relevance_score": 1.0,
      "keywords": [
        "8亿元"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "金额数据"
      ]
    },
    {
      "chunk_id": "22233eaf",
      "content": "99.96 2,039,833.02 其他收益\n目\n年产400吨MAP、100吨OA、 11,962,166.31 10,000,000.00 1,490,999.91 20,471,166.40 其他收益\n200吨DA、100吨甲砜霉素、\n10吨联苯双酯产业化新项目\n年产580吨柳氮磺胺吡啶产 2,115,735.00 248,910.00 1,866,825.00 其他收益\n业化项目\n176。\n\n清洁生产循环利用及三废综 4,800,000.00 600,000.00 4,200,000.00 其他收益\n合治理提升项目\n年产15500吨活性染料产业 1,296,000.00 1,296,000.00 其他收益\n升级及配套项目\n孵化器车间技改项目 793,220.34 81,355.92 711,864.42 其他收益\n浙江省化学原料药基地椒江 400,000.00 10,000.00 390,000.00 其他收益\n区块循环化改造项目补助资\n金项目补助\n年产700吨M-562关键中间体 500,000.00 33,333.33 466,666.67 其他收益\n产业一体化项目\n小 计 43,343,225.15 12,900,000.00 6,554,259.99 49,688,965.16\n2) 与收益相关，且用于补偿公司已发生的相关成本费用或损失的政府补助\n项 目 金额 列报项目 说明\n税费返还 1,828,299.60 其他收益 临政办发〔2018〕166号\n财政专项基金 4,150,682.78 其他收益 台财企发〔2019〕34号、临财企〔2018〕\n55号、台财企发〔2018〕27号、椒区\n委发〔2019〕18号等\n政府奖励 14,486,841.50 其他收益 椒商务〔2018〕59号、椒商务〔2019〕\n51号、台政办函[2019]14号、椒江委\n发〔2019〕18号等\n科技补助 116,841.00 其他收益 台科〔2019〕87号等\n小 计 20,582,664.88\n(2) 本期计入当期损益的政府补助金额为27,136,924.87元。85、其他\n八、合并范围的变更\n1、非同一控制下企业合并\n（1）本期发生的非同一控制下企业合并\n单位： 元\n购买日至期 购买日至期\n被购买方名 股权取得时 股权取得成 股权取得比 股权取得方 购买日的确\n购买日 末被购买方 末被购买方\n称 点 本 例 式 定依据\n的收入 的净利润\n其他说明：\n（2）合并成本及商誉\n单位： 元\n177。",
      "chunk_type": "child",
      "parent_id": "33e91743",
      "child_ids": [],
      "sibling_ids": [
        "b8ef424f",
        "6601f973",
        "65c8625b"
      ],
      "position": 1,
      "start_char": 995,
      "end_char": 2058,
      "page_number": 176,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.368254",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1063,
        "word_count": 115,
        "sentence_count": 36,
        "chinese_char_count": 419,
        "readability_score": 0.0,
        "information_density": 0.12229539040451551,
        "coherence_score": 0.6367923945426969,
        "standards_profile_summary": {}
      },
      "quality_score": 0.6128880526810913,
      "relevance_score": 1.0,
      "keywords": [
        "收入",
        "成本",
        "利润",
        "924.87元"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "收入",
        "成本",
        "费用",
        "利润",
        "商誉",
        "净利润",
        "合并",
        "股权",
        "税费"
      ]
    },
    {
      "chunk_id": "6601f973",
      "content": " 本期计入当期损益的政府补助金额为27,136,924.87元。85、其他\n八、合并范围的变更\n1、非同一控制下企业合并\n（1）本期发生的非同一控制下企业合并\n单位： 元\n购买日至期 购买日至期\n被购买方名 股权取得时 股权取得成 股权取得比 股权取得方 购买日的确\n购买日 末被购买方 末被购买方\n称 点 本 例 式 定依据\n的收入 的净利润\n其他说明：\n（2）合并成本及商誉\n单位： 元\n177。\n\n合并成本\n合并成本公允价值的确定方法、或有对价及其变动的说明：\n大额商誉形成的主要原因：\n其他说明：\n（3）被购买方于购买日可辨认资产、负债\n单位： 元\n购买日公允价值 购买日账面价值\n可辨认资产、负债公允价值的确定方法：\n企业合并中承担的被购买方的或有负债：\n其他说明：\n（4）购买日之前持有的股权按照公允价值重新计量产生的利得或损失\n是否存在通过多次交易分步实现企业合并且在报告期内取得控制权的交易\n□ 是 √ 否\n（5）购买日或合并当期期末无法合理确定合并对价或被购买方可辨认资产、负债公允价值的相关说明\n（6）其他说明\n2、同一控制下企业合并\n（1）本期发生的同一控制下企业合并\n单位： 元\n合并当期期 合并当期期\n企业合并中 构成同一控 比较期间被 比较期间被\n被合并方名 合并日的确 初至合并日 初至合并日\n取得的权益 制下企业合 合并日 合并方的收 合并方的净\n称 定依据 被合并方的 被合并方的\n比例 并的依据 入 利润\n收入 净利润\n其他说明：\n（2）合并成本\n单位： 元\n合并成本\n或有对价及其变动的说明：\n其他说明：\n178\n\n（3）合并日被合并方资产、负债的账面价值\n单位： 元\n合并日 上期期末\n企业合并中承担的被合并方的或有负债：\n其他说明：\n3、反向购买\n交易基本信息、交易构成反向购买的依据、上市公司保留的资产、负债是否构成业务及其依据、合并成本的确定、按照权益\n性交易处理时调整权益的金额及其计算：\n4、处置子公司\n是否存在单次处置对子公司投资即丧失控制权的情形\n□ 是 √ 否\n是否存在通过多次交易分步处置对子公司投资且在本期丧失控制权的情形\n□ 是 √ 否\n5、其他原因的合并范围变动\n说明其他原因导致的合并范围变动（如，新设子公司、清算子公司等）及其相关情况：\n合并范围增加\n公司名称 股权取得方式 股权取得时点 出资额 出资比例\n盛嘉环保公司 设立 2019/4/29 100%\n6、其他\n九、在其他主体中的权益\n1、在子公司中的权益\n（1）企业集团的构成\n持股比例\n子公司名称 主要经营地 注册地 业务性质 取得方式\n直接 间接\n川南药业公司 台州市 台州市 医药制造 100.00% 设立\n海翔销售公司 台州市 台州市 医药销售 100.00% 设立\n上海海翔公司 上海市 上海市 技术研发 100.00% 设立\n179。",
      "chunk_type": "child",
      "parent_id": "33e91743",
      "child_ids": [],
      "sibling_ids": [
        "b8ef424f",
        "22233eaf",
        "65c8625b"
      ],
      "position": 2,
      "start_char": 1858,
      "end_char": 3044,
      "page_number": 176,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.368503",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1186,
        "word_count": 151,
        "sentence_count": 7,
        "chinese_char_count": 885,
        "readability_score": 0.0,
        "information_density": 0.16020236087689715,
        "coherence_score": 0.8252949133436663,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8984822934232715,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "经营",
        "924.87元"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "成本",
        "利润",
        "投资",
        "商誉",
        "净利润",
        "合并"
      ]
    },
    {
      "chunk_id": "65c8625b",
      "content": "例\n盛嘉环保公司 设立 2019/4/29 100%\n6、其他\n九、在其他主体中的权益\n1、在子公司中的权益\n（1）企业集团的构成\n持股比例\n子公司名称 主要经营地 注册地 业务性质 取得方式\n直接 间接\n川南药业公司 台州市 台州市 医药制造 100.00% 设立\n海翔销售公司 台州市 台州市 医药销售 100.00% 设立\n上海海翔公司 上海市 上海市 技术研发 100.00% 设立\n179。\n\n台州东旭公司 台州市 台州市 设备制造 100.00% 设立\nGeneVida GmbH 德国多特蒙德 德国多特蒙德 医药销售 100.00% 设立\nGANGXIANG\n新加坡 新加坡 贸易 100.00% 设立\n（SINGAPORE）\n港翔化工公司 台州市 台州市 化工销售 100.00% 设立\n瓯华环保公司 盐城市 盐城市 技术研发 100.00% 设立\n盛嘉环保公司 台州市 台州市 技术研发 100.00% 设立\n非同一控制下企\n香港港翔公司 香港 香港 贸易 100.00%\n业合并\n非同一控制下企\n港翔科技公司 台州市 台州市 化工销售 100.00%\n业合并\n非同一控制下企\n台州前进公司 台州市 台州市 化工制造 100.00%\n业合并\n非同一控制下企\n台州振港公司 台州市 台州市 化工制造 9.27% 90.73%\n业合并\n非同一控制下企\n盐城瓯华公司 盐城市 盐城市 化工制造 100.00%\n业合并\n非同一控制下企\n瓯华研究院 盐城市 盐城市 技术研发 100.00%\n业合并\n在子公司的持股比例不同于表决权比例的说明：\n持有半数或以下表决权但仍控制被投资单位、以及持有半数以上表决权但不控制被投资单位的依据：\n对于纳入合并范围的重要的结构化主体，控制的依据：\n确定公司是代理人还是委托人的依据：\n其他说明：\n（2）重要的非全资子公司\n单位： 元\n本期归属于少数股东的 本期向少数股东宣告分\n子公司名称 少数股东持股比例 期末少数股东权益余额\n损益 派的股利\n子公司少数股东的持股比例不同于表决权比例的说明：\n其他说明：\n（3）重要非全资子公司的主要财务信息\n单位： 元\n期末余额 期初余额\n子公司\n流动资 非流动 资产合 流动负 非流动 负债合 流动资 非流动 资产合 流动负 非流动 负债合\n名称\n产 资产 计 债 负债 计 产 资产 计 债 负债 计\n180。",
      "chunk_type": "child",
      "parent_id": "33e91743",
      "child_ids": [],
      "sibling_ids": [
        "b8ef424f",
        "22233eaf",
        "6601f973"
      ],
      "position": 3,
      "start_char": 2844,
      "end_char": 3842,
      "page_number": 176,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          176
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.368738",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": "港翔化工公司",
        "industry": null,
        "char_count": 998,
        "word_count": 166,
        "sentence_count": 18,
        "chinese_char_count": 645,
        "readability_score": 0.0,
        "information_density": 0.14028056112224446,
        "coherence_score": 0.5122300018821757,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8585170340681363,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "投资",
        "经营",
        "财务"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "投资",
        "股东权益",
        "合并",
        "经营",
        "股东"
      ]
    },
    {
      "chunk_id": "7ed84545",
      "content": "单位： 元\n本期发生额 上期发生额\n子公司名称 综合收益总 经营活动现 综合收益总 经营活动现\n营业收入 净利润 营业收入 净利润\n额 金流量 额 金流量\n其他说明：\n（4）使用企业集团资产和清偿企业集团债务的重大限制\n（5）向纳入合并财务报表范围的结构化主体提供的财务支持或其他支持\n其他说明：\n2、在子公司的所有者权益份额发生变化且仍控制子公司的交易\n（1）在子公司所有者权益份额发生变化的情况说明\n（2）交易对于少数股东权益及归属于母公司所有者权益的影响\n单位： 元\n其他说明\n3、在合营安排或联营企业中的权益\n（1）重要的合营企业或联营企业\n持股比例 对合营企业或联\n合营企业或联营\n主要经营地 注册地 业务性质 营企业投资的会\n企业名称 直接 间接\n计处理方法\n苏州第四制药厂\n常熟 常熟 医药制造 32.66% 权益法核算\n有限公司\n在合营企业或联营企业的持股比例不同于表决权比例的说明：\n持有20%以下表决权但具有重大影响，或者持有20%或以上表决权但不具有重大影响的依据：\n（2）重要合营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n其他说明\n181。\n\n（3）重要联营企业的主要财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n苏州第四制药厂有限公司 苏州第四制药厂有限公司\n流动资产 29,519,105.76 25,072,727.50\n非流动资产 84,757,893.18 93,352,602.90\n资产合计 114,276,998.94 118,425,330.40\n流动负债 36,442,141.82 25,462,418.24\n非流动负债 21,400,000.00 22,000,000.00\n负债合计 57,842,141.82 47,462,418.24\n归属于母公司股东权益 56,434,857.12 71,167,909.30\n按持股比例计算的净资产份额 18,431,624.34 23,243,439.18\n--其他 -297,151.93 -297,151.93\n对联营企业权益投资的账面价值 18,134,472.41 22,946,287.25\n营业收入 57,010,459.03 39,434,028.51\n净利润 -14,733,052.18 -10,672,428.70\n综合收益总额 -14,733,052.18 -10,672,428.70\n其他说明\n（4）不重要的合营企业和联营企业的汇总财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n合营企业： -- --\n投资账面价值合计 29,744,910.02 43,141,852.54\n下列各项按持股比例计算的合计数 -- --\n--净利润 -11,947,734.96 -3,438,323.",
      "chunk_type": "child",
      "parent_id": "5b871825",
      "child_ids": [],
      "sibling_ids": [
        "d553b711"
      ],
      "position": 0,
      "start_char": 0,
      "end_char": 1189,
      "page_number": 181,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.369502",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1189,
        "word_count": 120,
        "sentence_count": 32,
        "chinese_char_count": 605,
        "readability_score": 0.0,
        "information_density": 0.15979814970563497,
        "coherence_score": 0.4392613636363636,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8035323801513876,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "收入",
        "利润",
        "投资",
        "营业收入",
        "净利润",
        "净资产",
        "股东权益"
      ]
    },
    {
      "chunk_id": "d553b711",
      "content": "70\n综合收益总额 -14,733,052.18 -10,672,428.70\n其他说明\n（4）不重要的合营企业和联营企业的汇总财务信息\n单位： 元\n期末余额/本期发生额 期初余额/上期发生额\n合营企业： -- --\n投资账面价值合计 29,744,910.02 43,141,852.54\n下列各项按持股比例计算的合计数 -- --\n--净利润 -11,947,734.96 -3,438,323.72\n--综合收益总额 -11,947,734.96 -3,438,323.72\n联营企业： -- --\n下列各项按持股比例计算的合计数 -- --\n其他说明\n182。\n\n（5）合营企业或联营企业向本公司转移资金的能力存在重大限制的说明\n（6）合营企业或联营企业发生的超额亏损\n单位： 元\n累积未确认前期累计认的损 本期未确认的损失（或本期分\n合营企业或联营企业名称 本期末累积未确认的损失\n失 享的净利润）\n其他说明\n（7）与合营企业投资相关的未确认承诺\n（8）与合营企业或联营企业投资相关的或有负债\n4、重要的共同经营\n持股比例/享有的份额\n共同经营名称 主要经营地 注册地 业务性质\n直接 间接\n在共同经营中的持股比例或享有的份额不同于表决权比例的说明：\n共同经营为单独主体的，分类为共同经营的依据：\n其他说明\n5、在未纳入合并财务报表范围的结构化主体中的权益\n未纳入合并财务报表范围的结构化主体的相关说明：\n6、其他\n十、与金融工具相关的风险\n本公司从事风险管理的目标是在风险和收益之间取得平衡，将风险对本公司经营业绩的负面影响降至\n最低水平，使股东和其他权益投资者的利益最大化。基于该风险管理目标，本公司风险管理的基本策略是\n确认和分析本公司面临的各种风险，建立适当的风险承受底线和进行风险管理，并及时可靠地对各种风险\n进行监督，将风险控制在限定的范围内。本公司在日常活动中面临各种与金融工具相关的风险，主要包括信用风险、流动性风险及市场风险。\n\n管理层已审议并批准管理这些风险的政策，概括如下。(一) 信用风险\n信用风险，是指金融工具的一方不能履行义务，造成另一方发生财务损失的风险。1. 信用风险管理实务\n(1) 信用风险的评价方法\n公司在每个资产负债表日评估相关金融工具的信用风险自初始确认后是否已显著增加。\n\n在确定信用风\n险自初始确认后是否显著增加时，公司考虑在无须付出不必要的额外成本或努力即可获得合理且有依据的\n信息，包括基于历史数据的定性和定量分析、外部信用风险评级以及前瞻性信息。公司以单项金融工具或\n者具有相似信用风险特征的金融工具组合为基础，通过比较金融工具在资产负债表日发生违约的风险与在\n183。",
      "chunk_type": "child",
      "parent_id": "5b871825",
      "child_ids": [],
      "sibling_ids": [
        "7ed84545"
      ],
      "position": 1,
      "start_char": 989,
      "end_char": 2105,
      "page_number": 181,
      "bbox": null,
      "element_type": "text",
      "extraction_confidence": 0.7,
      "is_table": false,
      "table_structure_preserved": false,
      "table_metadata": null,
      "metadata": {
        "source_file": "/Users/skybay7/ZenParse/input/pdfs/2020-01-23__浙江海翔药业股份有限公司__002099__海翔药业__2019年__年度报告.pdf",
        "page_numbers": [
          181
        ],
        "extraction_method": "text_semantic",
        "processing_timestamp": "2025-11-26T15:26:54.369760",
        "report_type": "现金流量表",
        "fiscal_year": null,
        "fiscal_quarter": null,
        "company_code": null,
        "industry": null,
        "char_count": 1116,
        "word_count": 77,
        "sentence_count": 18,
        "chinese_char_count": 835,
        "readability_score": 0.0,
        "information_density": 0.17025089605734767,
        "coherence_score": 0.6795801301005322,
        "standards_profile_summary": {}
      },
      "quality_score": 0.8992831541218638,
      "relevance_score": 1.0,
      "keywords": [
        "资产",
        "负债",
        "权益",
        "成本",
        "利润",
        "投资",
        "经营",
        "财务",
        "报表"
      ],
      "entities": [],
      "topics": [
        "现金流量表"
      ],
      "contains_financial_data": true,
      "financial_indicators": [
        "资产",
        "负债",
        "权益",
        "成本",
        "利润",
        "投资",
        "净利润",
        "资产负债表",
        "合并",
        "营业"
      ]
    }
  ]
}